Page last updated: 2024-08-16

ribavirin and Chronic Hepatitis C

ribavirin has been researched along with Chronic Hepatitis C in 5975 studies

Research

Studies (5,975)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's113 (1.89)18.2507
2000's2339 (39.15)29.6817
2010's3306 (55.33)24.3611
2020's217 (3.63)2.80

Authors

AuthorsStudies
Elazar, M; Glenn, JS; Korba, BE; Lui, P; Rossignol, JF1
Cho, WJ; Han, J; Jin, Y; Khadka, DB; Kim, M; Lee, HW; Li, X; Yang, S; Yoon, YS1
Batey, R; Ferencz, S1
Ball, L; Brooks, L; Gish, R; Sulkowski, MS; Wasserman, R1
Kryczka, W1
Jasonek, J; Kacprzak-Bergman, I; Zaleska, I1
Ahmed, OA; Dabbous, H; Elsayed, MH; Elserafy, M; Elshafie, A; Ezzat, H; Farid, A; Hassan, M; Hassany, M; Naguib, GG; Safwat, E; Shaker, MK; Shazly, YE; Sherief, AF1
Hou, MC; Huang, YH; Lan, KH; Lee, WP; Wang, YW1
Al-Judaibi, B; Carleton, BC; Drögemöller, BI; Ford, JA; Kim, RB; Lee, SS; Lin, JJ; Loucks, CM; Ramji, A; Ross, CJ; Schwarz, UI; Tam, E; Trueman, JN; Wright, GEB; Yoshida, EM1
Álvares-DA-Silva, MR; Dihl, RR; Librelotto, CS; Simon, D; Souza, AP1
Calvaruso, V; Ceccherini-Silberstein, F; Craxì, A; Di Maio, VC; Di Marco, V; Ferraro, D; Gibilaro, G; La Mantia, C; Licata, A; Petta, S; Reina, G1
Chiappini, E; de Martino, M; Galli, L; Motisi, MA; Parigi, S; Tamborino, A1
Adianti, M; Aoki-Utsubo, C; Hafid, AF; Hotta, H; Permanasari, AA; Tumewu, L; Wahyuni, TS; Widyawaruyanti, A1
Beier, C; Cornberg, M; Kordecki, N; Maasoumy, B; Ohlendorf, V; Sandmann, L; Tergast, TL; Wedemeyer, H1
Li, X; Lou, L1
Abdel-Bary, HM; El Sayed, IET; Ghanm, SE; Othman Saad, W; Saad, BF; Shebl, NA1
Baré, PC; Cairo, FM; Cocco, PA; Massenzio, NE; Picchio, GR; Villamil, FG1
Christensen, PB; Søholm, J; Øvrehus, A1
Carrilho, FJ; Cunha-Silva, M; Lima, RGR; Lourenço, MS; Mazo, DF; Oliveira, AIN; Oliveira, CP; Pessoa, MG; Sevá-Pereira, T; Souza, EO; Zitelli, PMY1
Abd-Elsalam, S; AbdElrahman, M; Bader El Din, NG; Barakat, AZ; El Awady, MK; Elbatae, H; Farouk, S; Ibrahim, MK; Omran, D; Tawfik, S1
Jang, JY; Jun, DW; Jung, YK; Kim, MY; Kim, SG; Kwon, OS; Lee, JW; Lee, SH; Park, JY; Yoo, HW1
Nguyen, MH; Wong, YJ1
Chen, J; Gao, H; Guan, Y; Hua, R; Huang, Y; Jiang, Y; Kong, F; Li, C; Li, G; Ma, H; Mao, X; Meng, C; Niu, J; Tan, Y; Wang, J; Wang, Z; Wen, X; Wu, Q; Xin, Y; Xiong, Q; Xu, B; Zhang, X; Zhang, Y; Zhao, L1
Al-Judaibi, B; Carleton, BC; Chang, WC; Crotty, P; Drögemöller, BI; Farivar, JF; Ford, JA; Kim, RB; Lee, SS; Li, KH; Lin, JJ; Loucks, CM; Ramji, A; Ross, CJD; Schwarz, UI; Tam, E; Trueman, JN; Walston, LL; Wright, GEB; Yoshida, EM1
Bair, MJ; Chang, CC; Chang, TS; Chen, CH; Chen, CT; Chen, CY; Chen, GY; Cheng, PN; Chong, LW; Chuang, WL; Dai, CY; Hsieh, TY; Hsiung, CK; Hu, JT; Huang, CF; Huang, CS; Huang, JF; Huang, YH; Hung, CH; Kao, CN; Kao, JH; Kuo, HT; Lee, MH; Lee, PL; Lee, TH; Lin, CL; Lin, CW; Lin, CY; Lin, HC; Liu, CH; Liu, CJ; Lo, CC; Mo, LR; Peng, CY; Su, WW; Tai, CM; Tsai, PC; Tsai, WL; Tseng, KC; Wang, CC; Wang, SJ; Wu, WC; Yang, CC; Yang, SS; Yeh, ML; Yu, ML1
AlBayati, SM; Faraj, OA1
Boscarino, JA; Daida, YG; Gordon, SC; Lu, M; Moorman, AC; Rupp, LB; Schmidt, MA; Spradling, PR; Teshale, EH; Trudeau, S; Zhang, J1
Al-Karim, S; Bazarah, S; Hamed, MH; Pushparaj, PN; Qadri, I; Rehman, S1
Kao, JH; Liu, CH; Liu, CJ1
Christensen, PB; Dröse, S; Hansen, JF; Holm, DK; Madsen, LW; Røge, BT; Øvrehus, A1
Ahn, SB; An, J; Jun, DW; Ko, MJ; Lee, J; Park, DA; Yim, SY; Yoo, JJ1
Abd-Aal, MS; Abdel-Hafez, AS; Abdel-Hamid, TM; Abdel-Rahman, RZ; Abdelsalam, MFA; Elaatar, MB; Elgohary, MA; Elkady, AO; Elnagar, MT; Elnagdy, TR; Elsaied, MA; Emam, ME; Fatoh, AR; Hamada, MM; Hasan, EM; Helmy, S; Ibrahim, AA; Lotfy, HH; Mubark, MA; Nawar, OM; Sakr, MA; Seadawy, MG; Selem, MA; Shehata, MM; Zaki, AI1
Al-Dhamin, Z; An, J; Cui, L; Han, T; Hou, Y; Li, L; Li, W; Liang, J; Liu, L; Nan, Y; Xue, N; Zhang, L; Zhao, W1
A Wahsh, E; Ahmed, M; Ahmed, S; Elsayed, A; Esamat, G; Gomaa, A; Hassan, E; Ramadan, A1
Guo, M; Ke, L; Liu, J; You, R1
Azzari, C; Bartolini, E; Indolfi, G; Moriondo, M; Resti, M; Ricci, S; Rubino, C; Stinco, M; Trapani, S; Veronese, P1
Ebell, M; Elshafie, S; Trivedi-Kapoor, R1
Ar, C; Bozcan, S; Canbakan, B; Gültürk, İ; Hatemi, İ; Özdemir, S; Sonsuz, A; Yıldırım, S1
Rabarioely, SS; Rabenjanahary, TH; Rakotozafindrabe, ALR; Ramanampamonjy, RM; Randriamifidy, NH; Rasolonjatovo, AS; Razafimahefa, SH; Razafindrazoto, CI1
Chang, YL; Hou, MC; Huang, YH; Lan, KH; Lee, WP; Lu, CL; Wang, YK; Wang, YW1
Bacinschi, X; Gales, L; Haineala, B; Iliescu, L; Mercan, A; Popescu, GC; Rodica, A; Serban, D; Toma, L; Zgura, A1
Belyavtsev, AN; Dedova, AV; Kuprianov, VV; Nikolaeva, LI; Samokhvalov, EI; Sapronov, GV; Shastina, NS; Shevchenko, NG; Stuchinskaya, MD1
Akbulut, A; Akıncı, E; Bal, T; Barut, Ş; Batırel, A; Baykam, N; Çabalak, M; Can, G; Çelebi, G; Çuvalcı Öztoprak, N; Duygu, F; Erben, N; Esen Yıldız, İ; Esen, Ş; Gül, HC; Günal, Ö; Gündüz, A; Güner, R; Hızel, K; İnan, D; İnce, N; Karaali, R; Karabay, O; Karsen, H; Kaya, S; Köksal, İ; Kömür, S; Köse, Ş; Kumbasar Karaosmanoğlu, H; Kurtaran, B; Namıduru, M; Önlen, Y; Sarı, ND; Sarıgül Yıldırım, F; Şenateş, E; Şener, A; Sırmatel, F; Sünnetçioğlu, M; Tabak, F; Tosun, S; Türker, K; User, Ü; Yamazhan, T; Yörük, G; Zerdali, E1
Joshita, S; Okumura, T; Ota, M; Sugiura, A; Umemura, T1
Bishai, N; Fiki, ME; Garem, NE; Ibrahim, M; Nabawy, WE1
Aoki, K; Force, L; Ishizaki, A; Konishi, H; Liu, LJ; Mita, E; Mizutani, H; Nakamoto, D; Ng, LJ; Shing, D1
Bergersen, BM; Dalgard, O; Finbråten, AK; Hagen, K; Lagging, M; Leiva, RA; Mikkelsen, Y; Roberts, RS; Rosseland, CM; Sandvei, PK; Simonsen, Ø; Singh, R; Young, L1
Abdelghafour, R; AbdelRazek, W; Dabees, H; Said, M; Shousha, HI1
Biliotti, E; Calvani, R; Capuani, G; Giampaoli, O; Miccheli, A; Sciubba, F; Spagnoli, M; Taliani, G; Tomassini, A1
Abd El-Hameed, M; Dawood, RM; El Ray, AA; Mahmoud Diab, T; Mashaal, AR; Seyam, M; Shemis, MA1
Chang, CC; Chang, YS; Chen, JH; Chen, SC; Chou, SM; Hsu, HC; Kuo, TT; Lin, TM; Shen, YC; Yeh, HJ1
Gapon, MN; Grushko, IP; Romanova, EB; Tverdokhlebova, TI; Vodyanitskaya, SY1
Cordie, A; Esmat, G; Kamel, AM; Sabry, N1
Fujita, K; Manabe, T; Masaki, T; Morishita, A; Nakahara, M; Ogawa, C; Ohura, K; Tadokoro, T; Tani, J1
Gamil, AN; Hassuna, NA; Khairy, R; Mahmoud, MS; Mohamed, WK1
Ansari, MA; Barnes, E; Chau, NVV; Cooke, GS; Dang Trong, T; Day, JN; Flower, B; Hoglund, RM; Hung, LM; Kestelyn, E; Kingsley, C; Le Ngoc, C; Le Thi, T; Mccabe, L; Nguyen Bao, T; Nguyen Thi Ngoc, P; Pett, SL; Phuong, LT; Quang, VM; Rahman, M; Smith, D; Tarning, J; Thwaites, GE; Turner, H; van Doorn, R; Van Nuil, JI; Vo Thi, T; Vu Thi Kim, H; Walker, AS1
Poddar, U; Umesh Reddy, DV1
Amendola Pires, M; Barbosa, ENP; Brandão Mello, CE; Campos, LB; de Almeida, NAA; de Barros, JJF; de Paula, VS; de Santana, CG; Horta, MAP1
Abdel-Rahman, YO; Abdel-Razik, W; Dabbous, HM; Elakel, W; Elmakhzangy, H; Elshafaey, A; Esmat, G; Ismail, SA; Omar, H; Saeed, R; Salama, R; Waked, I; Ziada, DH1
Ammar, I; Doss, W; El Raziky, M; El-Sayed, M; Elakel, W; Elsaeed, K; Elserafy, M; Elshazly, Y; Fayad, T; Hassany, M; Korany, M; Mahrous, M; Mehrez, M; Saad, Y; Salama, R; Zaki, A1
Ahn, SH; Cho, SB; Chung, WJ; Jang, ES; Jeong, SH; Kim, IH; Kim, KA; Kim, S; Kim, YS; Lee, BS; Lee, S; Lee, YJ; Park, HJ1
Berak, H; Brzdęk, M; Citko, J; Dybowska, D; Flisiak, R; Garlicki, A; Janczewska, E; Jaroszewicz, J; Klapaczyński, J; Krygier, R; Lorenc, B; Mazur, W; Parfieniuk-Kowerda, A; Piekarska, A; Tomasiewicz, K; Tronina, O; Zarębska-Michaluk, D1
Congly, SE; El-Kassas, M; El-Raey, F; Emadeldeen, M; Esmat, G; Gomaa, AA; Hassany, M; Lee, SS; Liu, H1
Cheng, ML; Li, H; Qin, YJ; Zhou, XN1
El-Marakby, MG; Sabri, NA; Solayman, MH1
Kottilil, S; Lee, MH; O'Brien, TR; Wilson, E1
Bukh, J; Fahnøe, U; Filskov, J; Jenssen, H; Pedersen, MS; Schønning, K; Sølund, C; Weis, N1
Briones, C; de Ávila, AI; Domingo, E; Durán-Pastor, A; Gallego, I; García-Crespo, C; Gómez, J; Gregori, J; Martínez-González, B; Perales, C; Quer, J; Somovilla, P; Soria, ME1
Elmowafy, AY; Elrakaiby, MT; Mohamed Abdelnajid, D; Rostaing, L1
Hussain, N; Iqbal, M; Mahnoor, M; Maqsood, Q; Sumrin, A; Wajid, A; Younas, S1
Coppola, N; Devan, P; Mohan, BP; Neo, JE; Preda, CM; Tam, YCS; Tiong, KLA; Wijarnpreecha, K; Wong, YJ1
Dong, G; Jiang, J; Li, J; Li, X; Long, S; Su, M; Wei, Y; Zhou, Y1
Alsina, A; Borg, B; Chang, C; Charlton, M; Flamm, S; Hernandez, C; Hézode, C; Landis, C; Lawitz, E; Mercier, RC; Ravendhran, N; Reddy, KR; Samuel, D; Scherbakovsky, S; Shiffman, M1
Li, H; Liu, Z; Ma, C; Wang, J; Wang, X; Wang, Y; Xu, X1
Daryani, N; Imam, U; Mumtaz, F; Parkash, A1
Abdelmahmoud, MB; AlAlwan, AM; AlGhamdi, HS; AlHabobi, AA; Aljumah, AA; AlOun, AA; AlQahtani, RS; AlThiab, KM; AlTraif, IH; Ghomraoui, FA1
Fried, MW; Hassan, MA; Hinestrosa, F; Jacobson, IM; Kort, JJ; Larsen, L; Lok, AS; Lu, W; Michael, LC; Morelli, G; Nelson, DR; Pearlman, BL; Peter, JA; Reddy, KR; Shiffman, ML; Sulkowski, MS; Vainorius, M; Wang, GP; Willner, I1
Antón, JJ; Arenas, JI; Bernal, E; Casado, M; Chueca, N; Collado, A; De la Iglesia, A; Espinosa, MD; García, F; García-Bujalance, S; García-Deltoro, M; García-Herola, A; Hernández-Quero, J; Hidalgo-Tenorio, C; Lozano, AB; Macías, J; Martínez, O; Omar, M; Pascasio, JM; Pérez, AB; Pineda, JA; Rincón, P; Ríos, MJ; Rivero-Juárez, A; Rosales, JM; Salmerón, J; Santos, J; Selfa, A; Téllez, F; Vélez, M; Von-Wichmann, MÁ1
Merat, S1
Aguiar, BF; Bittar, C; Campos, GRF; Marques, NN; Martinelli, ALC; Molina, BF; Pereira, LRL; Rahal, P; Rodrigues, JPV; Souza, FF1
Darwish, NHE; Elbasiony, M; Mousa, SA; Shiha, G; Soliman, R1
Ahumada, A; Aldamiz-Echevarría, T; Baliellas, C; Barril, G; Benlloch, S; Bonet, L; Carmona, I; Castaño, MA; Castro, Á; de Álvaro, C; de Los Santos, I; Delgado, M; Devesa-Medina, MJ; García-Buey, L; García-Samaniego, J; Gea-Rodríguez, F; González-Parra, E; Gutiérrez, ML; Jiménez-Pérez, M; Laguno, M; Londoño, MC; Losa, JE; Mallolas, J; Manzanares, A; Martín-Granizo, I; Montero-Alonso, M; Montes, ML; Morán-Sánchez, S; Morano, L; Muñoz-Gómez, R; Navascués, CA; Polo-Lorduy, B; Riveiro-Barciela, M; Rivero, A; Roget, M; Serra, MÁ1
Abe-Chayama, H; Aikata, H; Chayama, K; Fujino, H; Hayes, CN; Imamura, M; Kawaoka, T; Miki, D; Murakami, E; Nakahara, T; Ono, A; Osawa, M; Saito, Y; Serikawa, M; Teraoka, Y; Tsuge, M; Uchida, T1
El-Shabrawi, M; Hassanin, F2
Berg, T; Boeker, KHW; Buggisch, P; C-Registry, GH; Günther, R; Hinrichsen, H; Klinker, H; Manns, MP; Mauss, S; Müller, T; Serfert, Y; Wiegand, J; Zeuzem, S1
Cescon, M; De Pace, V; Galli, S; Maggi, F; Morelli, MC; Pistello, M; Ravaioli, M; Re, MC; Vero, V1
Avram, L; Craciun, R; Crisan, D; Crisan, N; Epure, F; Grigorescu, M; Grigorescu, MD; Leach, N; Lupsor, M; Radu, C; Suciu, A1
Alvarez, M; Bartlett, S; Binka, M; Butt, ZA; Chong, M; Cook, D; Darvishian, M; Janjua, NZ; Krajden, M; Pearce, ME; Ramji, A; Rossi, C; Samji, H; Tyndall, M; Wong, J; Wong, S; Yoshida, EM; Yu, A1
Amin, J; Bruggmann, P; Bruneau, J; Conway, B; Cooper, C; Cunningham, EB; Dalgard, O; Dillon, JF; Dore, GJ; Feld, JJ; Fraser, C; Gane, E; Grebely, J; Hajarizadeh, B; Hellard, M; Lacombe, K; Litwin, AH; Marks, P; Matthews, GV; Powis, J; Read, P; Shaw, D1
Aimono, Y; Kamoshida, T; Kogo, M; Kohyama, N; Yamamoto, T1
Attia, D; Doss, W; Ebeid, B; El Raziky, M; El Serafy, M; El-Khayat, H; Esmat, G; Fouad, Y; Gomaa, A; Hasseb, A; Kamal, EM; Mahmoud, H; Sameh, Y1
Calil-Elias, S; Crisante, VC; Cursino, CN; de Almeida, RMVR; Duarte, GDS; Giordani, F; Monteiro, PGO; Vieira, TBQ; Xavier, AR1
Ahn, SB; Jeong, JY; Jeong, SW; Jun, DW; Kim, HS; Kim, MY; Kim, SG; Kim, W; Lee, SW; Park, SJ; Shim, JJ; Sohn, JH; Suk, KT1
Aguilar, P; Aldámiz-Echevarría, T; Andrade, RJ; Carnicer, F; Carrión, JA; Chimeno-Hernández, S; Delgado, M; Escarda, A; Espinosa, N; Estébanez, Á; Gallego, A; García-Buey, L; Hernández-Guerra, M; Hijona, L; Izquierdo, S; Jou, A; Lorente, S; Magaz, M; Manuel Sousa, J; Manzanares, A; Martín-Granizo, I; Mateos-Muñoz, B; Menéndez, F; Morán-Sánchez, S; Morano, L; Moreno-Planas, JM; Morillas, RM; Polo-Lorduy, B; Pulido, F; Rico, M; Rincón, D; Rodríguez, M; Rubín, Á; Salmerón, J; Sampedro, B; Sánchez Antolín, G; Vergara, M; Von-Wichmann, MÁ; Zozaya, JM1
Abd El-Wahab, EW; Helmy, SH; Nagaty, A1
Carvalho, L; Daniels, E; Eveson, L; Foxton, M; Nelson, M; Pillai, S; Sellers, P; Whyte, R1
Chang, PH; Chen, YT; Chien, CH; Chien, RN; Hu, CC; Hua, MC; Lin, CL; Lin, ST; Weng, CH1
Chayama, K; Gonzalez, YS; Kawaguchi, I; Kumada, H; Mitchell, D; Virabhak, S; Yuen, C1
Abdelkawy, KS; Ebaid, NF; El-Haggar, SM; El-Magd, MA; Elbarbry, FA; Ziada, DH1
Chaikledkaew, U; Due, OT; Genuino, AJM; Sobhonslidsuk, A; Thakkinstian, A1
Chen, CL; Chen, DS; Chen, PJ; Chou, SW; Kao, JH; Liu, CH; Liu, CJ; Su, TH; Tseng, TC; Yang, HC1
Abdel Haleem, H; Abdel-Razek, W; Anees, M; El-Sayed, MH; El-Serafy, M; El-Shazly, Y; Eletreby, R; Elkhouly, R; Elshenawy, M; Esmat, G; Hamdy, M; Hassany, M; Kamal, E; Kasem, G; Salama, M; Salama, R; Shafeek, A1
Abutidze, A; Averhoff, F; Butsashvili, M; Chkhartishvili, N; Ezugbaia, M; Gamkrelidze, A; Gvinjilia, L; Kerashvili, V; Kvaratskhelia, V; Metreveli, D; Morgan, J; Nasrullah, M; Shadaker, S; Sharvadze, L; Tsertsvadze, T1
Abdel Alem, S; Abdel Aziz, H; Abdellatif, Z; Al Askalany, M; Cordie, A; El Akel, W; Elsharkawy, A; Esmat, G; Kamal, W; Kamel, S; Kandeel, A; Meshaal, S1
Attia, FM; Badr, RE; Hassan, AA; Hassan, AM; Saleh, MH; Soliman, AB1
Cui, LY; Liu, LD; Nan, YM; Zhao, W1
Bonora, S; Cingolani, A; d'Arminio Monforte, A; Lo Caputo, S; Marinaro, L; Mussini, C; Puoti, M; Rossotti, R; Saracino, A; Soria, A; Tavelli, A; Uberti-Foppa, C1
Pawlotsky, JM10
Aghemo, A; Aimo, G; Baiguera, C; Bella, D; Bernasconi, DP; Bhoori, S; Boldizzoni, R; Bonfanti, P; Capretti, A; Carderi, I; Carriero, C; Centenaro, R; Ciaccio, A; Colella, E; Cologni, G; Colombo, A; Colombo, S; D'Ambrosio, R; d'Arminio Monforte, A; De Bona, A; Degasperi, E; Del Poggio, P; Di Marco, M; Dionigi, E; Fagiuoli, S; Fava, M; Gatti, F; Giglio, O; Giorgini, A; Graffeo, M; Grossi, PA; Hasson, H; Lampertico, P; Landonio, S; Lapadula, G; Lazzaroni, S; Liani, C; Lombardi, A; Menzaghi, B; Migliorino, GM; Molteni, C; Noventa, F; Pagnucco, L; Pan, A; Pasulo, L; Perini, P; Pigozzi, MG; Polo, S; Puoti, M; Rizzardini, G; Rossotti, R; Rumi, MG; Schiavini, M; Soria, A; Spinelli, O; Spinetti, A; Terreni, N; Uberti-Foppa, C; Valenti, L; Valsecchi, MG; Viganò, M; Viganò, P; Vinci, M1
Akhan, S; Ergun, NC; Köse, Ş; Onlen, Y; Tatar, B; Turken, M; Yılmaz, Y1
Chung, WJ; Jang, ES; Jeong, SH; Kim, IH; Kim, KA; Kim, YS; Lee, BS; Lee, YJ1
David, J; Delahooke, T; Dustan, S; Iliffe, M; Kurmoo, F; Lai, FY; May, S; Patel, A; Stephenson, I; Tang, JW; Wiselka, M1
Cazarim, MS; Chachá, SGF; Martinelli, ALC; Pereira, LRL; Rodrigues, JPV1
Aleman, S; Björkström, NK; Carlsson, T; Falconer, K; Gorin, JB; Malone, DFG; Sandberg, JK; Strunz, B1
Althoff, KN; Elion, RA; Eron, JJ; Gillman, J; Huhn, GD; Jayaweera, DT; Mills, A; Mounzer, K; Moyle, G; Patel, SV; Radtchenko, J; Santiago, S; Sax, PE1
Abbasy, M; Abdu Allah, AM; Elimam, H; Elnaidany, N; Essa, A; Mohamed Ibraheem, KI; Nada, A; Sabry, A; Shehab-Eldeen, S1
Allah-Kouadio, E; Allouka, KCE; Gnépéhi, OB; Kohi, DS; N'guessan-Irié, AG; Siransy-Kouakou, NG1
Sirinawasatien, A; Techasirioangkun, T1
Aghemo, A; Colapietro, F1
Bunchorntavakul, C; Charatcharoenwitthaya, P; Chonprasertsuk, S; Komolmit, P; Piratvisuth, T; Sanpajit, T; Sethasine, S; Siripipattanamongkol, C; Sobhonslidsuk, A; Sukeepaisarnjaroen, W; Sutthivana, C; Tangkijvanich, P; Tanwandee, T; Wongpaitoon, V1
Aghayeva, S; Asiller, ÖÖ; Balkan, A; Çalışkan Kartal, A; Demir, M; Erarslan, E; Gülşen, MT; Güner, R; Köksal, I; Örmeci, N; Sezgin, O; Yaraş, S1
Alston-Smith, B; Anthony, DD; Balagopal, A; Cohen, DE; Morse, GD; Quinn, J; Santana-Bagur, JL; Smeaton, LM; Sulkowski, MS; Talal, AH; Venuto, CS; Vu, V; Wyles, DL1
Bair, MJ; Chen, CJ; Chen, CY; Chen, JJ; Cheng, JS; Cheng, PN; Chien, RN; Chiu, YC; Chu, CH; Chuang, WL; Dai, CY; Hsu, WF; Huang, JF; Huang, YH; Hung, CH; Kao, JH; Kuo, HT; Lai, HC; Lee, PL; Lin, CW; Lin, CY; Lin, HC; Liu, CH; Liu, CJ; Lo, CC; Lo, GH; Peng, CY; Su, WW; Tai, CM; Tsai, PC; Tsai, WL; Tseng, KC; Tung, SY; Wang, CC; Wang, JH; Yan, SL; Yang, CC; Yu, ML1
Fan, XG; Ma, SJ; Xiong, YH; Zheng, YX1
Abou-Samra, AB; Butt, AA; Nasir, B; Rasool, S; Rubi, G; Tayyab, GUN1
Bartenschlager, R; Boldanova, T; Bracht, T; Broering, R; Brown, RJP; Brüggemann, Y; Engelmann, M; Friesland, M; Heim, MH; Kinast, V; Pietschmann, T; Plociennikowska, A; Sitek, B; Steinmann, E; Todt, D; Vieyres, G; Vondran, FWR; Zhang, Y1
Che, D; Lu, Y; Wu, B; Zhou, H1
Abd-Elsalam, SM; Abdulaziz, BA; El Attar, IH; El Kassas, M; Emadeldeen, M; Said, EM1
Abu Raya, M; Baruch, Y; Khoury, J; Klein, A; Saadi, T; Sabo, E; Yaccob, A1
Bernhard, B; Stickel, F1
Alhaddad, O; Elsabaawy, D; Elsabaawy, M; Elshazly, H; Khalil, F; Rady, M; Sabry, A; Shebl, N; Wahb, A1
Alston-Smith, BL; Anthony, DD; Balagopal, A; Bhattacharya, D; Cohen, DE; Damjanovska, S; Kowal, CM; Shive, CL; Smeaton, LM; Sulkowski, MS; Wyles, DL1
Asan, A; Aygen, B; Barut, Ş; Batırel, A; Bilgin, H; Çelen, MK; Çelik, İ; Demirtürk, N; Ersöz, G; Karakeçili, F; Kınıklı, S; Mıstık, R; Şimşek, F; Türker, N; Turkish Society Of Clinical Microbiology And Infectious Diseases, TSGFVHOT; Ural, O; Yıldız, O; Zararsız, G1
Chu, JN; Collins, J; Eweje, F; Faiz, MT; Gwynne, D; Hayward, A; Hess, K; Hua, T; Ishida, K; Katz, S; Koeppen, R; Langer, R; Lopes, A; McManus, R; Miller, JB; Salama, JAF; Slocum, AH; Soares, V; Steiger, C; Sulkowski, MS; Tamang, SM; Thomas, DL; Traverso, G; Verma, M1
Day, J; Le, HM; Le, PT; Nghiem, NM; Nguyen, DT; Rahman, M; Tran, TTT; Vo, QM1
Borgia, SM; Brown, RS; Carrat, F; Doucette, K; Fagiuoli, S; Khalili, M; Lampertico, P; Losappio, R; Mangia, A; Mertens, M; Milligan, S; Ntalla, I; Ouzan, D; Papatheodoridis, G; Pérez-Hernandez, F; Ramji, A; Ramroth, H; Shafran, SD; Turnes, J; Vanstraelen, K; Wedemeyer, H; Wick, N1
Hsu, EK; Jolley, CD; Jonas, MM; Leung, DH; Liu, L; Lobritto, SJ; Molleston, JP; Narkewicz, MR; Rosenthal, P; Wen, J; Yao, BB; Zha, J1
Altıntaş, E; Ateş, F; Özdoğan, O; Sezgin, O; Üçbilek, E; Yaraş, S1
Batista, AD; da Silva Sacerdote, AB; de Barros Barreto, S; Filgueira, NA; Lopes, EP2
Alhusseini, MM; Mohamed, GA; Salama, MM; Saleh, SA1
Jalota, A; Lerma, EV; Lindner, BK; Thomas, B1
Chen, DS; Chen, PJ; Kao, JH; Liu, CH; Liu, CJ; Su, TH1
Białkowska-Warzecha, J; Błaszczyk, J; Jabkowski, M; Jędrzejczak-Pospiech, K; Poliwczak, AR; Woźny, J1
Ahmed, H; Elsadek, HM; Elsayed, IA; Gendia, MA; Gouda, TM; Lbrahim, NF; Magdy, MM; Sadek, AMEM; Shafeik, H; Shendi, AM; Yousif, MM; Zahran, MH; Zaki, AM1
Abdurakhmanov, DT; Burnevich, EZ; Filatova, AL; Karpov, VV; Milovanova, SY; Moiseev, SV; Nikulkina, EN; Rozina, TP; Severov, MV; Tanashuk, EL1
Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Lai, WT; Lee, HC; Liang, PC; Lin, YH; Lin, ZY; Yeh, ML; Yu, ML1
Aikata, H; Chayama, K; Fukuhara, T; Hayes, CN; Imamura, M; Mori, N; Ohya, K; Takaki, S; Tsuji, K; Yamaguchi, S1
Nordien, R; Sonderup, MW; Spearman, CW1
Attia, A; Baudoin, M; Boyer, S; Kouanfack, C; Lacombe, K; Lemoine, M; Moh, R; Nishimwe, ML; Rouveau, N; Seydi, M; Sylla, B; Woode, ME1
Abdel Alem, S; Abdellatif, Z; Abdo, M; Moustafa, A; Rabiee, A1
Calise, SJ; Chan, EKL1
Fagundes, RN; Ferreira, LEVVC; Pace, FHL1
Colak Ergun, N; Kose, S; Tatar, B; Turken, M1
Abuelhassan, WB; Ally, R; Gasim, GI; Menezes, C1
Cázares-Cortazar, A; Chapararro-Sánchez, A; de la Luz Martínez-Rodríguez, M; Gaytán-Martínez, J; Mata-Marín, JA; Mauss, S; Ocaña-Mondragón, A; Uribe-Noguez, LA; Villavicencio-Ferrel, PE1
Chang, TT; Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC; Wu, CH; Wu, IC; Yang, EH1
Benfield, T; Bukh, J; Fahnøe, U; Galli, A; Mejer, N; Ramirez, S; Weiland, O1
Bellón, JM; Berenguer, J; Carrero, A; Esteban, H; Galindo, MJ; González-García, J; Guardiola, JM; Hernández-Quero, J; Hontañón, V; Jiménez-Sousa, MA; Martínez, E; Navarro, J; Pérez-Latorre, L; Quereda, C; Resino, S; Santos, I; Sanz, J; Téllez, MJ; von Wichmann, MA1
Anees, M; Doss, W; El Akel, W; Eletreby, R; Esmat, G; Hashem, A; Hassany, M; Helmy, A; Khalaf, N; Kobtan, A; Mansour, S; Naguib, M1
Berg, T; Heyne, R; John, C; Klinker, H; Naumann, U; Niederau, C; Serfert, Y; Stein, K; Stoehr, A; Teuber, G; Wiegand, J; Zeuzem, S1
Al-Attiyah, R; Al-Nakib, W; Essa, S; Siddique, I1
Gandjour, A1
Liu, Y1
Barrett, BK; Chan, J; Feld, JJ; Hamadeh, A; Kim, JJ; Wong, WWL1
Chien, RN; Chuang, WL; Hsu, CW; Hsu, SJ; Huang, YW; Kuo, HT; Lin, HH; Lo, GH; Peng, CY; Qin, A; Su, CW; Su, WW; Tseng, KC; Yang, SS; Yu, ML1
Aho, I; Amele, S; Bhagani, S; Chkhartisvili, N; Clarke, A; Domingo, P; Falconer, K; Fonquernie, L; Jabłonowska, E; Leen, C; Lundgren, J; Maltez, F; Matulionyte, R; Mocroft, A; Peters, L; Rockstroh, J; Rodger, A; Sarcletti, M; Stephan, C; Szlavik, J; Wandeler, G; Zaccarelli, M; Østergaard, L1
Abd-Elsalam, S; Abo-Amer, YE; Ahmed, R; Badawi, R; El-Abgeegy, M; Elguindy, AMA; Elkadeem, M; Elsergany, HF; Elshweikh, SA; Hawash, N; Mansour, L; Mohmed, AA; Soliman, MY; Soliman, S1
Chen, SC; Cheng, TS; Chuang, WL; Dai, CY; Hsieh, PH; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, ZY; Yeh, ML; Yu, ML1
Al-Tawashi, AS; Alaa, AM; Awwad, MA; El-Derany, MO; Eltobgy, MM; Gharib, MM; Kasem, MH; Mostafa, AM; Moubarak, AS; Omar, HM; Saafan, HA1
Chen, YM; Mei, YY; Wu, YK; Xu, WX; Zhang, XH1
Doretto, P; Ermacora, A; Fumagalli, S; Gattei, V; Mauro, E; Mazzaro, C; Toffolutti, F; Tonizzo, M1
Bebek-Ivankovic, H; Bevanda, M; Grgic, S; Nikolic, J; Soldo-Coric, L; Susak, B1
Abdelbaser, ES; Elsadek, HM; Emara, MH; Farag, AA; Soliman, HH1
Ang, TL; Fock, KM; Koh, J; Kumar, LS; Kumar, R; Kwek, A; Law, NM; Lee, ZC; Li, W; Tan, J; Tan, YB; Teo, EK; Thurairajah, PH; Wong, YJ1
Farooq, MO; Malik, K; Mengal, FUA; Salim, A1
Choi, IS; Kim, KM; Shim, SG1
Ali, M; Ali, S; Haque, S; Lougher, E; Nawaz, MS; Paudyal, V; Rasheed, F; Ur-Rehman, T1
Chang, YL; Hou, MC; Huang, YH; Lan, KH; Lee, WP; Wang, YK; Wang, YW1
Kottilil, S; Masur, H; Meissner, EG; Orr, C; Xu, W1
Balázs, I; Feldbacher, N; Horvath, A; Kollroser, M; Leber, B; Nusshold, C; Posch, A; Rechberger, GN; Sattler, W; Spindelböck, W; Stadlbauer, V; Stauber, RE; Stiegler, P; Streit, A1
Chang, CC; Chang, CH; Chang, CY; Chen, CY; Chen, JJ; Chen, PY; Fang, YJ; Hsieh, TY; Huang, CS; Huang, JJ; Huang, KJ; Huang, YJ; Kao, JH; Kao, WY; Lai, HC; Lee, FJ; Lee, PL; Liu, CH; Liu, CJ; Lo, CC; Peng, CY; Shih, YL; Su, PY; Su, WW; Tsai, MC; Tseng, CW; Tseng, KC; Yang, SS1
Aniszewska, M; Kowalik-Mikołajewska, B; Lewandowski, Z; Marczyńska, M; Pluta, M; Pokorska-Śpiewak, M1
Abdallah, OE; Abdel Hammed, OM; Elharrif, MG; Elwan, AW; Mahfouz, MK; Maksoud H A, A; Ragab AboZaid, OA1
Bugajska, J; Inglot, M; Janocha-Litwin, J; Malyszczak, K; Marciniak, D; Pawlak, D; Pawlowski, T; Zalewska, M1
Bourliere, M; Buti, M; Chokkalingam, A; Colombo, M; Esteban, R; Gaggar, A; Henry, L; Mangia, A; Manns, M; Muir, A; Nader, F; Papatheodoridis, GV; Racila, A; Stepanova, M; Younossi, I; Younossi, ZM; Zeuzem, S1
Atta, AM; Atta, MLBS; Isabel Schinoni, M; Jesus, LS; Oliveira, IS; Silva, JPCG1
Batista, AD; Carvalho, BT; Filgueira, NA; Lacerda, C; Lacerda, HR; Lima, K; Lima, MS; Lopes, EP; Medeiros, TB; Melo, CRL; Santos, JC; Silva, IPL1
Cole, JL; Stark, JE1
Peker, BO; Sarıtaş Yüksel, E; Şener, AG; Topal, F1
Han, QY; He, S; Liu, ZW; Wang, XY1
Adenugba, A; Geissler, EK; Hornung, M; Junger, H; Kupke, P; Lang, H; Marquardt, JU; Peschel, G; Schlitt, HJ; Weigand, K; Werner, JM; Zimmermann, T1
Abd El-Maksoud, E; Hegazy, MGA; Maher, AM; Salem, AM1
Bair, MJ; Chen, CJ; Chen, CY; Chen, JJ; Cheng, JS; Cheng, PN; Chien, RN; Chiu, YC; Chu, CH; Chuang, WL; Dai, CY; Hsieh, MH; Huang, CF; Huang, JF; Huang, YH; Hung, CH; Kao, JH; Kuo, HT; Lai, HC; Lee, PL; Lin, CW; Lin, CY; Lin, HC; Liu, CH; Liu, CJ; Lo, CC; Lo, GH; Peng, CY; Su, WW; Tai, CM; Tsai, PC; Tsai, WL; Tseng, KC; Tung, SY; Wang, CC; Wang, JH; Yan, SL; Yang, CC; Yeh, ML; Yu, ML1
Fedorchenko, SV; Klimenko, Z; Martynovych, T; Solianyk, I1
Sarrazin, C1
Chuma, M; Fukuda, H; Hara, K; Kondo, M; Maeda, S; Morimoto, M; Moriya, S; Nozaki, A; Numata, K; Sakamaki, K; Tanaka, K; Yamanaka, T1
Kamimura, H; Kamimura, K; Terai, S; Tsuchiya, A1
El-Sayed, EM; Hassanien, KS; Helal, GK; Ismail, RS; Zakarya, ZM1
Zarębska-Michaluk, D1
Huang, JC; Muo, CH; Su, FH; Wu, CM; Wu, MM; Yeh, CC1
Khedhiri, M; Triki, H1
Aldunate, F; Chiodi, D; Cristina, J; Echeverría, N; Hernández, N; López, P; Moratorio, G; Moreno, P; Sánchez-Cicerón, A; Soñora, M1
AbdAllah, M; Abdel-Razek, W; Alalfy, M; Alboraie, M; Ammar, I; Doss, W; El Akel, W; El-Bendary, M; El-Sayed, MH; El-Serafy, M; Elbaz, T; Esmat, G; Gomaa, A; Hassany, M; Hefny, Z; Kamal, E; Okasha, A; Shaaban, E1
Dehghan Manshadi, SA; Kalantari, S; Karimi, J; Malekzadeh, R; Malekzadeh, Z; Mardani, M; Merat, D; Merat, S; Mirminachi, B; Mohraz, M; Nikbin, M; Norouzi, A; Poustchi, H; Rasoolinejad, M; Sali, S; Sedghi, R; Sharifi, AH; Somi, MH; Tabarsi, P; Tayeri, K1
Akhan, S; Aktuğ Demir, N; Arslan Özel, S; Asan, A; Aygen, B; Barut, Ş; Batırel, A; Bilgin, H; Çağatay, A; Çelen, MK; Çelik, İ; Çetinkaya, RA; Demirtürk, N; Doğan, N; Ersöz, G; Gürbüz, Y; Hakyemez, İN; İnan, D; Kamalak Güzel, D; Karakeçili, F; Kınıklı, S; Konya, P; Korkmaz, P; Kuruüzüm, Z; Mıstık, R; Örmen, B; Öztürk, S; Saltoğlu, N; Şener, A; Şimşek, F; Şimşek, S; Suer, K; Tarakçı, H; Tülek, N; Tuna, N; Tuncer Ertem, G; Türker, N; Türkoğlu, E; Ural, O; Yıldız, O; Yıldız, U1
Amano, N; Genda, T; Ikeda, Y; Kabemura, D; Kita, Y; Murata, A; Sato, S; Shimada, Y; Tsuzura, H; Yatagai, N1
Bourlière, M; Meszaros, M; Ouzan, D; Pageaux, GP; Tran, A; Truchi, R1
Miyasaka, A; Suzuki, A; Takikawa, Y; Yoshida, Y1
Enomoto, M; Fujii, H; Hai, H; Kawada, N; Kozuka, R; Nonomura, A; Tamori, A; Uchida-Kobayashi, S1
Ahmed, M; Gomaa, AA; Mansey, AE; Rabea, HM; Wahsh, EA1
Baek, YH; Cho, HC; Heo, NY; Hong, Y; Kang, YW; Lee, SS; Lee, SW; Park, SJ; Seo, KI; Shin, JW; Yoon, JS; Yoon, KT1
Barbaliscia, S; Bruzzone, B; Cassol, C; Caudai, C; Ceccherini-Silberstein, F; Coppola, N; Cuomo, N; Di Maio, VC; Micheli, V; Monno, L; Montagnani, F; On Behalf Of The Hcv Virology Italian Resistance Network Vironet, C; Paglicci, L; Paolucci, S; Rossetti, B; Santantonio, T; Zanelli, G; Zazzi, M1
Chemych, MD; Lishnevska, AG1
Feng, K; Huang, P; Ke, L; Lin, C; Liu, J; Pan, S; Yang, X; Zeng, Y1
Andreone, P; Cusi, MG; De Luca, A; Di Donato, R; Furlini, G; Galli, C; Galli, S; Gandolfo, C; Grandini, E; Guarneri, V; Loggi, E; Margotti, M; Mercinelli, S; Raffaelli, CS; Re, MC; Rossetti, B; Savellini, GG; Vitale, G; Vukotic, R1
Bellan, M; Crobu, MG; D'Avolio, A; Gualerzi, A; Pirisi, M; Smirne, C1
Bukh, J; Christensen, PB; Fahnøe, U; Madsen, LW; Pedersen, MS; Øvrehus, A1
Baumert, TF; Berg, T; Brants, L; Buggisch, P; Discher, T; Friebe, A; Fromm, G; Kemper, J; Lieb, K; Link, R; Ockenga, J; Reimer, J; Rentrop, M; Sarkar, R; Sarkar, S; Schaefer, M; Schläpfer, T; Spengler, U; Weidenbach, H; Zeuzem, S1
Darling, JM; Di Bisceglie, A; Dong, M; Evon, DM; Fishbein, DA; Fried, MW; Hinestrosa, F; Horne, PM; Khalili, M; Kixmiller, S; Lok, AS; Michael, L; Moon, JS; Morelli, G; Muir, AJ; Nelson, DR; Pearlman, B; Peter, J; Rajender Reddy, K; Segal, JB; Sherman, KE; Shiffman, ML; Sloan, A; Stewart, PW; Sulkowski, MS; Vainorius, M; Wadsworth, S1
Chang, CC; Chang, CH; Chang, CY; Chen, CY; Chen, JJ; Chen, PY; Fang, YJ; Hsieh, TY; Huang, CS; Huang, KJ; Huang, YJ; Hwang, JJ; Kao, JH; Kao, WY; Lai, HC; Lee, FJ; Lee, PL; Liu, CH; Liu, CJ; Lo, CC; Peng, CY; Shih, YL; Su, PY; Su, WW; Tsai, MC; Tseng, CW; Tseng, KC; Wu, JH; Yang, SS1
Krzyzanski, W; Perez-Ruixo, JJ; Vermeulen, A; Woot de Trixhe, X1
Al Abosy, R; Allen, TM; Chung, RT; Comstock, DE; Fidler, S; Fox, J; Frater, J; Gerdemann, U; Haining, WN; Kim, AY; Lauer, GM; Martin, GE; Sen, DR; Tonnerre, P; Tully, DC; Weiss, SA; Wolski, D; Yates, KB1
Boglione, L; Cardellino, CS; Cariti, G; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G1
Furuya, K; Iio, E; Ito, J; Izumi, T; Katagiri, M; Kawagishi, N; Kimura, M; Konno, J; Kumagai, K; Morikawa, K; Nakai, M; Natsuizaka, M; Ogawa, K; Ohara, M; Sakamoto, N; Shimada, N; Sho, T; Suda, G; Tanaka, Y; Tsubota, A; Umemura, M; Yamamoto, Y1
Everson, GT; Kiser, JJ; Langness, JA; Nguyen, M; Wieland, A1
Baiguera, C; Garcia-Fraile Fraile, LJ; Puoti, M; Rossotti, R1
Bhamidimarri, KR; Burke, G; Chen, L; Ciancio, G; Guerra, G; Kupin, W; Ladino, M; Martin, P; Mattiazzi, A; Pedraza, F; Roth, D1
Baeg, JY; Cho, J; Chung, JW; Jang, ES; Jeong, SH; Jung, EU; Kim, IH; Kim, JW; Kim, YS; Seo, SY1
Hao, X; Li, H; Li, Y; Ma, Y; Wang, J; Xiao, Y; Xu, B; Yang, L1
Buzas, C; Ciobanu, L; Tantau, M1
Boglione, L; Cariti, G; Cusato, J; D'Avolio, A; Di Perri, G2
Arefiev, Y; Budhathoki, N; Gayam, V; Guss, D; Khalid, M; Khan, A; Mansour, M; Mohanty, SR; Mukhtar, O; Rangaraju, AM; Sherigar, JM; Siddiqui, I1
Cheng, K; Chevaliez, S; Cloherty, G; Cohen, DE; Dawson, GJ; Feld, JJ; Hackett, J; Herman, C; Maasoumy, B; Pawlotsky, JM; Rockstroh, JK; Sarrazin, C; Wedemeyer, H1
Bansal, A; Dutta, U; Goyal, O; Grover, R; Kishore, H; Malhi, NS; Nanda, V; Saluja, H; Sehgal, A; Sidhu, JS; Sidhu, S; Sidhu, SS; Singh, G; Singh, R1
El Sayed, MH; Giaquinto, C; Gonzalez-Peralta, RP; Indolfi, G; Thorne, C1
Fernández-Cuenca, F; López-Hernández, I; Paniagua-García, M; Ríos-Villegas, MJ1
Bider-Canfield, Z; Cheetham, TC; Gharibian, D; Latt, NL; Louie, V; Mittal, R; Sahota, A; Yanny, BT1
Chevaliez, S; Fourati, S; François, M; Hézode, C; Mallat, A; Pawlotsky, JM; Roudot-Thoraval, F; Ruiz, I; Scoazec, G; Soulier, A; Varaut, A1
Awni, W; DaSilva-Tillmann, B; Dutta, S; Lin, CW; Liu, W; Menon, R; Podsadecki, T; Shulman, N1
Angarano, G; Bruno, G; Milella, M; Saracino, A1
Chen, KY; Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Ko, YM; Liang, PC; Lin, CC; Lin, YH; Lin, ZY; Liu, TW; Tsai, PC; Tsai, YS; Wang, SC; Yeh, ML; Yu, ML1
Abraham, GM; Spooner, LM2
Almawi, WY; Ghazoueni, E; Loueslati, BY; Mouelhi, L; Rabia, NA; Sghaier, I1
Barocas, JA; Beiser, M; Gaeta, JM; León, C; Linas, BP; O'Connell, JJ1
Brown, RS; Charlton, M; Curry, MP; Hunt, S; O'Leary, JG; Stepanova, M; Younossi, ZM1
Asselah, T; ElKhashab, M; Feld, JJ; Ferenci, P; Hassanein, T; Hézode, C; Mobashery, N; Moreno, C; Papatheodoridis, G; Pilot-Matias, T; Qaqish, RB; Redman, R; Yu, Y; Zeuzem, S1
Allam, N; Asselah, T; Doss, W; Esmat, G; Hall, C; Hassany, M; Mobashery, N; Mohey, MA; Qaqish, RB; Redman, R; Shiha, G; Soliman, R; Waked, I; Yosry, A; Zayed, N1
Agarwal, K; Aguilar, H; Asatryan, A; Dore, GJ; Felizarta, F; Gane, E; Gordon, SC; Hassanein, T; Kort, J; Kwo, PY; Lin, CW; Liu, R; Lovell, SS; Maliakkal, B; Mensa, FJ; Muir, AJ; Ng, TI; Overcash, JS; Poordad, F; Sulkowski, MS; Wang, S; Wyles, DL1
Aghemo, A; Colombo, M; D'Ambrosio, R; Degasperi, E1
Gray, E; Norris, S; O'Leary, A; Pasta, DJ1
Alavian, SM; Behnava, B; Dolatimehr, F; Gholami-Fesharaki, M; Karimi-Sari, H; Rezaee-Zavareh, MS; Sharafi, H1
Bruno, S; Maisonneuve, P1
Akriviadis, E; Arvaniti, P; Bellou, A; Dalekos, GN; Goulis, I; Karatapanis, S; Kattamis, A; Koskinas, J; Kountouras, D; Kourakli, A; Maragkos, K; Papatheodoridis, GV; Petropoulou, F; Sinakos, E; Tampaki, M; Toli, B; Triantos, C; Tsiaoussis, G; Vassiliadis, T; Vlachaki, E; Zachou, K1
Álvarez, B; Benito, JM; Cabello, A; García, M; García-Samaniego, J; Górgolas, M; Madejón, A; Martín-Carbonero, L; Rallón, N1
Arai, M; Chiba, T; Haga, Y; Imazeki, F; Kanda, T; Kato, N; Maruyama, H; Nakamoto, S; Nakamura, M; Ogasawara, S; Ooka, Y; Saito, T; Sasaki, R; Suzuki, E; Takahashi, K; Tawada, A; Wu, S; Yasui, S; Yokosuka, O1
Carmona-Soria, I; Caunedo-Alvarez, A; Cordero-Ruiz, P; Flores-Cucho, A; Quezada-Pacheco, RH; Rodríguez-Téllez, M; Romero-Gómez, M; Vilches-Arenas, Á1
Chan, HL; Lo, AO; Wong, GL; Wong, VW1
El Raziky, M; Elakel, W; Eletreby, R; Esmat, G1
Darwish, NHE; Elberry, MH; Mousa, SA1
Enomoto, M; Hagihara, A; Hai, H; Kawada, N; Kawamura, E; Kozuka, R; Morikawa, H; Motoyama, H; Murakami, Y; Tamori, A; Teranishi, Y; Uchida-Kobayashi, S; Yoshida, K1
Everson, GT; Jackson, WE1
Ali, A; Idrees, M; Rafique, S; Saleem, K; Wahid, B1
Abdel Baki, A; El Raziky, M; Mansour, SA; Shahin, RMH; Zayed, NA1
Chen, LC; Xie, Q1
Aghemo, A; Alberti, A; Antinori, A; Ascione, A; Bruno, R; Bruno, S; Chirianni, A; Craxì, A; Gaeta, GB; Giannini, EG; Marzioni, M; Merli, M; Messina, V; Montilla, S; Pani, L; Perno, CF; Petta, S; Puoti, M; Raimondo, G; Rendina, M; Russo, P; Silberstein, FC; Villa, E; Zignego, AL1
Brainard, DM; Davis, MN; Dvory-Sobol, H; Etzkorn, K; Gane, EJ; Hinestrosa, F; Huang, KC; McHutchison, JG; McNally, J; Morelli, G; Osinusi, A; Shiffman, ML; Stedman, CAM; Sulkowski, MS; Thompson, AJ1
Abe, H; Arai, T; Atsukawa, M; Iio, E; Itokawa, N; Iwakiri, K; Kato, K; Kondo, C; Okubo, T; Shimada, N; Tanaka, Y; Tsubota, A1
Bailey, R; Borgia, S; Brainard, DM; Cooper, C; Elkhashab, M; Feld, JJ; Greenbloom, S; Huang, KC; Huchet, E; Hyland, RH; Marotta, P; Massetto, B; McHutchison, JG; Ramji, A; Shafran, SD; Svarovskaia, ES; Swain, MG; Tam, E; Vachon, ML; Willems, B; Yoshida, EM; Yun, C1
Arnon, R; Balistreri, WF; Brainard, DM; Gonzalez-Peralta, RP; Hardikar, W; Jonas, MM; Kanwar, B; Kersey, K; Kirby, B; Lin, CH; Massetto, B; Murray, KF; Rosenthal, P; Schwarz, KB; Shao, J; Svarovskaia, E; Wirth, S1
Abdelhafez, AT; Cusato, J; D'Avolio, A; De Nicolo, A; Di Perri, G; El Desoky, ES; Hussein, AM; Kamel, SI1
Fujikawa, T; Iwabuchi, S; Matsui, K; Nagata, M; Nakano, M; Nakazaki, H; Shimizu, H; Takatsuka, K; Tanemura, H; Watanabe, T1
Chen, KY; Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Ko, YM; Liang, PC; Lin, CC; Lin, YH; Lin, ZY; Liu, TW; Tsai, PC; Tsai, YS; Yeh, ML; Yu, ML1
De Meyer, S; Thys, K; Van Remoortere, P; Vandebosch, A; Verloes, R; Vijgen, L1
Czarny, P; Jabłkowski, M; Karwowski, B; Majchrzak, K; Merecz-Sadowska, A; Śliwiński, T; Szemraj, J1
Beumont, M; Bourgeois, S; Corbett, C; Da Silva, MH; DeJesus, E; Diago, M; Ferenci, P; Fevery, B; Gane, EJ; George, J; Hinrichsen, H; Janczewska, E; Jessner, W; Kalmeijer, R; Lenz, O; Nikitin, I; Reesink, H; Shukla, U1
Harada, S; Iida, T; Koshino, K; Masuda, K; Matsuyama, T; Nakamura, T; Nobori, S; Ushigome, H; Yoshimura, N1
Enomoto, M; Kawada, N; Murakami, Y1
Ahmad, W; Alam, SE; Asif, M; Hussain Jaffery, SS; Sajjad, SF1
Andriulli, A; Guarino, M; Morisco, F1
Alavian, SM; Rezaee-Zavareh, MS1
Caloska-Ivanova, V; Curakova, E; Dimitrova-Genadieva, M; Joksimovic, N; Kiprijanovska, S; Serafimoski, V; Todorovska, B; Trajkovska, M; Zafirova-Ivanovska, B1
Peterson, D; Van Ermen, A1
Chen, SC; Chen, YL; Chuang, WL; Dai, CY; Huang, CF; Huang, CI; Huang, JF; Lin, TY; Lin, ZY; Yeh, ML; Yu, ML1
Ashraf, M; Bukhsh, A; Gul, A; Khiljee, S; Omer, MO; Rafique, G1
Cho, NH; Choi, JY; Choi, MS; Kim, BG; Kim, DH; Kim, W; Kim, Y; Kwon, EK; Lee, JW; Lee, WW; Min, CK; Shin, HM1
Furusyo, N; Hayashi, T; Murata, M; Ogawa, E; Toyoda, K; Ura, K1
Amin, J; Applegate, TL; Backmund, M; Bourgeois, S; Bruggmann, P; Bruneau, J; Conway, B; Cunningham, EB; Dalgard, O; Dore, GJ; Dunlop, A; Foster, GR; Grebely, J; Hajarizadeh, B; Hellard, M; Marks, PS; Midgard, H; Quiene, S; Robaeys, G; Shaw, D; Staehelin, C; Swan, T; Weltman, M1
Kaabi, SA; Singh, R; Soofi, ME; Thandassery, RB; Tharian, B1
Cohen, DE; Cohen, E; Feld, JJ; Foster, GR; Fried, MW; Larsen, L; Mobashery, N; Nelson, DR; Poordad, F; Tatsch, F; Wedemeyer, H1
Burman, B; Edwards, AM; Kozarek, RA; Lee, H; Shin, HP; Siddique, A; Wang, C; Zehr, T; Zeigler, A1
Angarano, G; Bruno, G; Dell'Acqua, R; Fabrizio, C; Lo Caputo, S; Milano, E; Milella, M; Monno, L; Saracino, A; Scudeller, L1
Aggarwal, R; Bhargava, R; Goel, A; Rai, P1
Berry, K; Chang, M; Green, PK; Hettinger, BD; Hum, J; Ioannou, GN; Jou, JH; Lundblad, J1
Caruso, V; Cenderello, G; Copetti, M; Forni, G; Gamberini, R; Ganga, R; Mangia, A; Piazzolla, V; Piga, A; Quarta, A; Santoro, R; Sarli, R1
Chen, SC; Chen, YL; Chuang, WL; Dai, CY; Hsieh, MH; Huang, CF; Huang, CI; Huang, JF; Lin, KH; Lin, ZY; Yeh, ML; Yu, ML1
Bredi, E; Covini, G1
Abdel Alem, S; Abdellatif, Z; Adel, E; Elsharkawy, A; Esmat, G; Fouad, R; Hussein, MS; Musa, S; Nagy, A; Yosry, A1
Afdhal, NH; Curry, MP; Iriana, S1
Afdhal, NH; Bacon, B; Curry, MP; Dieterich, D; Flamm, SL; Guest, L; Kowdley, KV; Lee, Y; Milligan, S; Tapper, EB; Tsai, N; Younossi, Z1
Lin, HC; Su, CW; Yang, YY1
Balslev, U; Belard, E; Dalgard, O; Färkkilâ, M; Hallager, S; Heggelund, L; Karlsen, L; Krarup, H; Lagging, M; Lund Laursen, A; Madsen, LG; Noraberg, G; Skalshøi Kjær, M; Thorup Røge, B; Weiland, O; Weis, N; Øvrehus, A1
Donato, FM; Fabrizi, F; Messa, P1
Amrose, P; Anand, S; Kumar, MS; McFall, AM; Mehta, SH; Ramasamy, B; Solomon, SS; Srikrishnan, AK; Sulkowski, MS; Thomas, DL1
Guo, H; Li, Z; Liu, Z; Qi, W; Sun, D; Wang, H; Wang, J; Wang, S; Wang, X; Zhang, Y; Zhao, P; Zhou, C; Zhu, L1
Bhattacharjee, S; Bhushan, A; Chinnaswamy, S; Ghosh, S1
Antón, MD; Ferrando, I; Latorre, P; Moreno Osset, E; Pascual, A; Polanco, A1
Adlin Nadia, Z; Tan, SS1
Agrati, C; Bordoni, V; Casetti, R; Ciccosanti, F; Cimini, E; D'Offizi, G; Fimia, G; Lionetti, R; Martini, F; Montalbano, M; Refolo, G; Sacchi, A; Taibi, C; Tumino, N; Turchi, F1
Abdolrahimi, F; Davari, M; Dizaji, SP; Fateh, A; Fateh, R; Gharibzadeh, S; Ghazanfari, M; Jamnani, FR; Sakhaee, F; Siadat, SD; Vaziri, F1
Abdel-Razik, A; El-Wakeel, N; Eldars, W; Elgamal, A; Elkashef, W; Elzehery, R; Farag, R; Mousa, N; Shabana, W1
Chen, DS; Chen, PJ; Hong, CM; Kao, JH; Liu, CH; Liu, CJ; Su, TH; Tseng, TC; Yang, HC3
Asim, M; Jamil, A; Majeed, A; Rashid, A; Razak, S; Wahid, M1
Abdo, M; Abouelkhair, M; Doss, W; Elakel, W; Elbaz, T; Elgarem, N; Elsayed, MH; Elserafy, M; Elshazly, Y; Esmat, G; Gaballa, A; Hassany, M; Mahran, Z; Mehrez, M; Mohey, MA; Omar, A; Waked, I; Yosry, A1
Andriulli, A; Barone, M; Brancaccio, G; Conti, F; Di Leo, A; Francavilla, R; Gatti, P; Iannone, A; Ippolito, AM; Lauletta, G; Masetti, C; Messina, V; Milella, M; Morisco, F; Napoli, N; Pesce, F; Santantonio, T; Shahini, E; Smedile, A; Termite, AP; Tundo, P1
Aikata, H; Chayama, K; Daijo, K; Fujino, H; Hatooka, M; Hayes, CN; Hiramatsu, A; Honda, F; Imamura, M; Kan, H; Kawakami, Y; Kawaoka, T; Kobayashi, T; Masaki, K; Miki, D; Morio, K; Morio, R; Nagaoki, Y; Nakahara, T; Nakamura, Y; Ochi, H; Ono, A; Teraoka, Y; Tsuge, M1
Kim, HJ; Lee, HW; Oh, IS; Won, JW1
Carrai, P; Coppola, C; Cordone, G; Lenci, I; Lionetti, R; Martini, S; Melazzini, M; Montilla, S; Morelli, C; Pani, L; Petraglia, S; Piai, G; Pietrosi, G; Romano, A; Russo, FP; Russo, P; Tamé, M; Toniutto, P; Trotta, MP1
Almasio, PL; Barr, E; Bruno, S; Buti, M; Butterton, JR; Dutko, FJ; Fernsler, D; Gao, W; Grandhi, A; Hassanein, TI; Huang, HC; Jancoriene, L; Lawitz, E; Li, JJ; Liu, H; Muellhaupt, B; Nguyen, BT; Pearlman, B; Plank, RM; Robertson, MN; Ruane, PJ; Shepherd, A; Su, FH; Tannenbaum, B; Vierling, JM; Wahl, J; Wan, S; Yeh, WW; Yoshida, EM1
Ardévol, M; López, D; Masnou, H; Morillas, RM1
Asli, E; Davari, M; Fateh, A; Gharibzadeh, S; Jamnani, FR; Sadeghi, S; Siadat, SD; Vaziri, F1
Kim, HB; Lee, YJ; Myung, SK; Park, BJ1
Bian, DD; Chen, Y; Duan, C; Duan, ZP; Jiang, YY; Liu, M; Liu, S; Wang, T; Wang, Z; Zhang, JY; Zheng, SJ; Zhou, HY1
Alves, K; Beyer, J; Burroughs, M; Chayama, K; Collins, C; Dekhtyar, T; Irvin, M; Krishnan, P; Kumada, H; Pilot-Matias, T; Redman, R; Reisch, T; Rodrigues, L; Schnell, G; Setze, C; Tripathi, R1
Barnes, E; Brown, A; de Vree, JML; Klenerman, P; Kootstra, NA; Reesink, HW; Sinnige, MJ; Stelma, F; Swadling, L; van der Ree, MH; van der Valk, M; van Nuenen, AC; Willemse, SB1
Feld, JJ; Jacobson, I; Pawlotsky, JM; Poordad, F; Sulkowski, M; Tatsch, F1
Abutidze, A; Chkhartishvili, N; Dolmazashvili, E; Karchava, M; Sharvadze, L; Tsertsvadze, T1
Crisan, D; Grigorescu, M; Grigorescu, MD; Radu, C; Suciu, A1
Abdel-Daim, MM; Abushouk, AI; Ahmed, H; Loutfy, SA; Menshawy, A; Mohamed, A; Negida, A1
Kim, HJ; Lee, HW; Won, JW; Yoo, KY1
Larijani, MS; Mohajel, N; Nikbin, M; Sadat, SM1
Abaci, N; Akyuz, F; Akyuz, U; Besisik, F; Cakiris, A; Ciftci, S; Demir, K; Kaymakoglu, S; Keskin, F; Ustek, D1
Arends, JE; Bijmolen, M; Blokzijl, H; Burger, DM; de Kanter, CTMM; de Knegt, RJ; Dofferhoff, ASM; Drenth, JPH; Lieveld, FI; Maan, R; Smolders, EJ; van der Valk, M; van Erpecum, KJ; van Tilborg, M1
Kanda, T; Moriyama, M1
Bodeau, S; Brochot, E; Domange, B; Duverlie, G; Garçon, L; Handala, L; Helle, F; Nguyen-Khac, E; Ouled-Haddou, H1
Caraceni, P; Carrai, P; Donato, MF; Fagiuoli, S; Filì, D; Gianstefani, A; Martini, S; Mazzarelli, C; Melazzini, M; Montilla, S; Pani, L; Petraglia, S; Rendina, M; Russo, P; Trotta, MP; Visco-Comandini, U1
Huang, JW; Liao, HT; Tan, P; Yuan, KF1
Comstock, E; Kottilil, S; Kumar, NS; Mathur, P; McSweegan, E; Mercer, N1
Ballard, C; Cachay, ER; Colwell, B; Hicks, C; Mathews, WC; Torriani, F1
Li, T; Liu, F; Qu, YD; Wang, L; Xue, Y; Zhang, LX1
Bassiony, MAA; Hanafy, AS; Hussein, S; Mohamed, MS1
Azzari, C; Cananzi, M; D'Antiga, L; Indolfi, G; Nebbia, G; Resti, M; Ricci, S; Serranti, D; Stagi, S1
Abdalla, U; Abdel-Khalek, EE; Abdel-Wahab, M; Al-Refaey, AK; Al-Shobari, M; Ali, M; El-Gilany, AH; Elghawalby, AN; Elmorshedi, M; Sadani, M; Salah, T; Shiha, U; Sultan, AM; Yassen, AM1
Bair, MJ; Chen, HL; Cheng, CH; Lee, YK; Lin, CC; Lin, IT; Wong, MW; Wu, CH1
Feroz, F; Sajid, M; Talat, H; Wahid, Z1
Atta, AM; Cabral, MS; Oliveira, IS; Pereira, AB; Santos, PL; Santos, TPS; Schinoni, MI; Sousa-Atta, MLB1
Abd El-Wahab, EW; Nagaty, A1
Ardèvol, M; Carrión, JA; Gallego, A; González-Colominas, E; Lens, S; Londoño, MC; López, D; Mariño, Z; Mojal, S; Morillas, RM; Pagès, N; Solà, R; Torras, X1
Chen, M; Fan, H; Huang, P; Liu, M; Wang, J; Yao, Y; Yu, R; Yue, M; Zang, F1
Hayashi, Y; Imoto, S; Kato, A; Kim, CW; Kim, KI; Kim, SK; Kim, SR; Kobayashi, M; Kudo, M; Morimoto, E; Ohtani, A; Saijo, Y; Seo, K; Yano, Y1
Buechel, D; Choi, M; DeNardo, Z; Stiller, M1
Barner, A; Early, J; Gottfried, S; Gumpert, R; Libaridian, L; Morrison, V; Santamaria, A; Shipton, L; Sokol, R1
Aburawash, A; Elsisi, GH; Waked, E1
Alric, L; Bellissant, E; Bourlière, M; de Lédinghen, V; Gibowski, S; Hézode, C; Jézéquel, C; Laforest, C; Larrey, D; Métivier, S; Pailhé, A; Pawlotsky, JM; Pol, S; Renault, A; Samuel, D; Tran, A; Tual, C; Zoulim, F1
Kim, DY2
Cairó, M; Carrion, JA; Cifuentes, C; Crespo, M; Cucurull, J; Erice, E; Force, L; Guardiola, JM; Laguno, M; Marco, A; Navarro, J; Roget, M; Vilaró, J; Vilchez, HH1
Brown, RS; Camus, G; Copans, A; Ghali, P; Guyer, B; Haubrich, R; Kang, M; Luetkemeyer, AF; Mantry, PS; Ni, L; Rossaro, L; Satapathy, SK; Shen, X; Tam, E1
Chen, SC; Chiou, SS; Chuang, WL; Dai, CY; Hsieh, MY; Hsu, WY; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, PC; Lin, ZY; Yeh, ML; Yu, ML; Zeng, YS1
Arai, M; Chiba, T; Imazeki, F; Kanda, T; Mikata, R; Nakamoto, S; Nakamura, M; Shirasawa, H; Tawada, A; Wu, S; Yasui, S; Yokosuka, O1
Lagging, M; Waldenström, J1
Bhardwaj, N; Brainard, D; Chang, S; Chodavarapu, K; Feld, JJ; Mangia, A; Martin, R; McNally, J; Miller, MD; Mo, H; Murrell, B; Osinusi, A; Ragonnet-Cronin, M; Sulkowski, M; Svarovskaia, ES; Wertheim, JO1
Backhus, J; Dikopoulos, N; Groß, MJ; Härter, G; Ludwig, L; Seufferlein, T; Zizer, E1
Brandão-Mello, CE; Brito, JDU; Campos, AF; Ferreira, PRA; Gonzalez, MP; Grando, AV; Lopes, MIBF; Martinelli, ALC; Mazo, DFC; Mendes-Corrêa, MC; Nastri, ACS; Pessôa, MG; Reuter, T1
Figlerowicz, M; Kaczmarek, M; Kemnitz, P; Mania, A; Mazur-Melewska, K; Sikora, J; Służewski, W; Żeromski, J1
Ferenci, P; Gschwantler, M; Gutic, E; Haltmayer, H; Kozbial, K; Laferl, H; Lang, T; Luhn, J; Moser, S; Reiberger, T; Schleicher, M; Schubert, R; Schütz, A; Schwabl, P; Schwanke, C; Steindl-Munda, P1
Agudelo, EZ; Campos-Varela, I; Roberts, JP; Sarkar, M; Terrault, NA1
Abdo, AA; Al-Ashgar, HI; Alalwan, AA; AlBekairy, AM; Alblawi, MA; Alghamdi, A; Alghamdi, H; Alhamoudi, W; Aljumah, A; Alquaiz, M; Alsohaibani, F; Alswat, KA; AlTamimi, W; Altraif, IH; Altraif, S; Babatin, MA; Handoo, FA; Loustaud-Ratti, V; Marquett, P; Murtaza, S; Peedikayil, M; Sanai, F1
Al-Zoairy, R; Beinhardt, S; Datz, C; Ferenci, P; Graziadei, I; Gschwantler, M; Hofer, H; Kozbial, K; Laferl, H; Maieron, A; Moser, S; Schwarzer, R; Stättermayer, AF; Stauber, R; Steindl-Munda, P; Strasser, M; Trauner, M; Zoller, H1
Casado, J; Gila, A; Jiménez-Ruiz, SM; Muñoz de Rueda, P; Muñoz-Gámez, JA; Pavón-Castillero, EJ; Quiles, R; Ruiz-Extremera, A; Salmerón, J1
Andini, R; Atripaldi, L; Durante-Mangoni, E; Maiello, C; Mattucci, I; Vitrone, M; Zampino, R1
Ahmad, I; Anwar, A; Aziz, H; Irfan, J; Mukhtar, M; Ovais, M; Raza, A1
Clark, A; Dusheiko, G; Fathi, H; Hill, NR1
Badshah, C; Barr, E; Brown, A; Durkan, C; Foster, GR; Haber, B; Hézode, C; Lahser, F; Roberts, SK; Robertson, M; Wahl, J; Zekry, A; Zhang, B; Zuckerman, E1
Chang, KC; Chen, CH; Hu, TH; Hung, CH; Kuo, FY; Lin, JT; Lin, MT; Lu, SN; Tsai, MC; Tseng, PL; Wang, JH; Wu, CK; Yen, YH1
Anderson, R; Avellar, AM; Castro, R; Hyde, C; Jorge, MJ; Mujica-Mota, R; Perazzo, H; Romero, C; Silva, JC; Silva, PS; Veloso, VG1
Barbosa, MED; Carrilho, FJ; de Campos Mazo, DF; de Oliveira, CPMS; Farias, AQ; Pessoa, MG; Zaninotto, AL1
Abou-Samra, AB; Butt, AA; Shaikh, OS; Yan, P1
Hamano, G; Ito, T; Kawada, N; Kubo, S; Takemura, S; Tamori, A; Tanaka, S1
Cornberg, M; Deterding, K; Kirschner, J; Manns, MP; Mix, C; Port, K; Schlevogt, B; Siederdissen, CHZ; Sollik, L; Wedemeyer, H1
Abdulla, NA; Amin, MA; El Maksoud, NA; Halim, MH; Kamel, A; Moussa, SM; Ragab, HM1
AbdAllah, M; Doss, W; El Akel, W; El Kassas, M; El Shazly, H; El Shazly, Y; Elbaz, T; Elsaeed, K; Esmat, G; Gomaa, AA; Ismail, SA; Korany, M; Nasr, A; Omar, H; Said, M; Shaker, MK; Waked, I; Yousif, M1
Gonzalez-Peralta, R; Henry, L; Hunt, S; Murray, K; Rosenthal, P; Schwarz, KB; Stepanova, M; Wirth, S; Younossi, ZM1
Ahn, SH; Chan, HL; Chuang, WL; Han, KH; Henry, L; Kao, JH; Kinh, N; Lai, CL; Lai, W; Lim, YS; Stepanova, M; Younossi, ZM; Yuen, MF1
Al-Zoairy, R; Beinhardt, S; Ferenci, P; Graziadei, I; Hofer, H; Kozbial, K; Maieron, A; Rasoul-Rockenschaub, S; Stättermayer, AF; Stauber, R; Strasser, M; Trauner, M; Zoller, H1
Angus, PW; George, J; Gow, P; Jeffrey, G; Mason, S; McCaughan, GW; Mitchell, J; Morales, B; Parker, FC; Roberts, SK; Strasser, SI; Tallis, C; Thompson, AJ; Thwaites, PA; Wigg, A1
Chen, PC; King, YC; Lai, CH; Liu, CY; Yang, YH1
Birkemose, I; Christensen, PB; Ernst, A; Holm, DK; Krarup, H; Mössner, B; Øvrehus, ALH1
Fiel, MI; Putra, J; Schiano, TD1
Albillos, A; García González, M; Gea Rodríguez, F; Rodríguez de Santiago, E; Tavío Hernández, E; Téllez Villajos, L; Velázquez Kennedy, K1
Espinoza, MA; Giglio, A; Soza, A; Vargas, C1
Chang, KC; Hu, TH; Lin, MT; Tsai, MC; Tseng, PL; Wu, CK; Ye, YH1
Chen, C; Hartigan-O'Connor, DJ; Khalili, M; Lanier, LL; Lu, D; Manos, MM; McCune, JM; Méndez-Lagares, G; Monto, A; Ryan, JC; Segal, MR; Shen, H; Terrault, N1
Maughan, A; Ogbuagu, O1
Asselah, T; Bellissant, E; Bourlière, M; Bronowicki, JP; Canva, V; Diallo, A; Fontaine, H; Laforest, C; Leroy, V; Loustaud-Ratti, V; Ouzan, D; Petrov-Sanchez, V; Renault, A; Roulot, D; Rousseau, C; Schischmanoff, O; Serfaty, L; Thibault, V; Zoulim, F1
Afghani, AA; Alghamdi, AS; Alghamdi, MN; AlMousa, A; Alswat, K; AlZanbagi, A; Aseeri, M; Assiri, AM; Babatin, MA; Sanai, FM1
Alavi, M; Dore, GJ; Law, MG1
de Avila, L; Doyle, J; Stepanova, M; Thompson, A; Younossi, I; Younossi, ZM1
Bunchorntavakul, C; Palecki, J; Reddy, KR; Tan Dat, H; Thu Thuy, PT1
Akushevich, L; Ben-Ari, Z; Fried, MW; Gallant, J; Hassan, M; Kuo, A; Landis, CS; Liapakis, AM; Lim, JK; Lok, AS; Michael, L; Nelson, DR; Park, JS; Pockros, PJ; Shiffman, ML; Terrault, NA; Vainorius, M; Zeuzem, S1
Amador, C; Carmena, J; Flores, J; Galindo, MJ; García-Deltoro, M; Masiá, M; Mínguez, C; Montero, M; Ortega, E; Reus, S1
Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kominami, Y; Kumada, H; Ohya, K; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y1
Boglione, L; Cariti, G; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G; Pinna, SM1
Dohmen, K; Ichiki, Y; Ishibashi, H; Kawano, A; Miki, K; Morita, C; Nomura, H; Shigematsu, H; Shimoda, S; Takahashi, K; Yanagita, K1
Abd El Rehim, AY; Alamrani, MA; Alezzi, ZMM; Fathallah, WF; Othman, FH1
Lomonosova, E; Tavis, JE1
Aslam, R; Khaliq, S; Manzoor, S; Naeemi, H; Naz, S; Raza, SM; Shahzad, MA1
Chen, CY; Chen, MY; Chen, Q; Kao, JH; Peng, CY; Tang, H; Wu, JJ; Yu, ML1
Bessone, F; Borzi, SM; Cartier, M; D'Amico, C; Descalzi, VI; Fainboim, HA; Figueroa Escuti, S; Frías, S; Gadano, AC; Gaite, LA; Galdame, OA; Haddad, L; Longo, C; Marciano, S; Marino, M; Peralta, M; Perez Ravier, R; Reggiardo, MV; Vistarini, C1
Abd El Latif, Y; Alboraie, M; Doss, W; El Kassas, M; El Tahan, A; El-Serafy, M; Elakel, W; Elsaeed, K; ElShazly, Y; Esmat, G; Ezzat, S; Korany, M; Nabeel, MM; Omran, D1
Buggisch, P; Corbett, C; Fevery, B; Horban, A; Jessner, W; Lawitz, E; Lee, SS; Lenz, O; Moreno, C; Shukla, U; Verbinnen, T; Zoulim, F1
Scott, LJ1
Brainard, DM; Cheng, J; Dou, X; Duan, Z; Gao, ZL; German, P; Gong, G; Hou, JL; Hu, P; Jia, J; Jiang, D; Jiang, J; Kersey, K; Knox, SJ; Li, J; Li, L; Li, W; Lin, F; Massetto, B; Mo, H; Mou, Z; Nan, Y; Ning, Q; Niu, JQ; Tang, H; Wang, G; Wei, L; Wu, S; Xie, Q; Xu, M; Yang, JC; Yang, Y; Zhang, LL1
Bair, MJ; Chen, HL; Cheng, CH; Lee, YK; Lin, CC; Lin, IT; Wu, CH1
Bataga, S; Brisc, C; Caruntu, FA; Chiriac, S; Cijevschi Prelipcean, C; Curescu, M; Gheorghe, L; Girleanu, I; Goldis, A; Iacob, S; Miftode, E; Mihai, C; Preda, C; Rogoveanu, I; Singeap, AM; Sporea, I; Stanciu, C; Stefanescu, G; Trifan, A1
Iqbal, S; Raza, A; Yousaf, MI; Yousuf, MH1
Hoan, NX; Meyer, CG; Song, LH; Tong, HV; Velavan, TP1
Deng, XZ; Ding, WL; Li, GT; Wang, LJ; Xiao, W; Zhang, GQ; Zhang, JH; Zhou, ZX; Zhu, DY; Zhu, YM1
Álvarez, H; Castro-Iglesias, A; Delgado, M; Grandal, M; Mariño, A; Mena, A; Pérez, AB; Pernas, B; Poveda, E; Tabernilla, A; Valcarce, N1
Bittermann, T; Weinberg, E1
Borba, HHL; Ferreira, VL; Leonart, LP; Pontarolo, R; Tonin, FS1
Imnadze, T; Mikadze, I; Vashakidze, E1
Asante-Appiah, E; Asselah, T; Barr, E; de Ledinghen, V; Gerstoft, J; Hwang, P; Nguyen, BY; Pockros, PJ; Reesink, H; Robertson, M; Serfaty, L; Talwani, R; Wahl, J1
Agarwal, K; Asante-Appiah, E; Barclay, S; Barr, E; Brown, AS; Collier, J; Cramp, ME; Du, J; Forton, DM; Foster, GR; Fox, R; Gilbert, CL; Gordon, F; Haber, B; Moreea, S; Mutimer, DJ; Robertson, MN; Rosenberg, WM; Ryder, SD; Ustianowski, A; Wahl, J1
Aghemo, A; Baldanti, F; Borghi, M; D'Ambrosio, R; De Nicola, S; Degasperi, E; Lampertico, P; Lunghi, G; Novazzi, F; Paolucci, S; Perbellini, R1
Caroprese, M; Coppola, N; De Pascalis, S; Guerrera, B; Iovinella, V; Macera, M; Masarone, M; Minichini, C; Occhiello, L; Starace, M; Vitrone, M1
Mandorfer, M; Peck-Radosavljevic, M; Reiberger, T1
Anani, M; Attia, FM; F, GM; M, H; Saleh, RM1
Cheon, GJ; Cho, YS; Jang, JY; Jeong, SW; Jun, BG; Kim, BS; Kim, HS; Kim, SG; Kim, YD; Kim, YS; Lee, SH; Lee, WC; Lee, YN; Park, EJ1
Abdel-Gabbar, M; Abdel-Moneim, A; Aboud, A; Ramadan, M; Zanaty, M1
Kaplan, DE1
Berthillon, P; Bordes, I; Chemin, I; Crouy, S; Larrat, S; Leroy, V; Maynard, M; Petit, MA; Pradat, P; Scholtès, C; Trépo, C; Virlogeux, V; Zoulim, F1
El-Raziky, M; Elsharkawy, A; Fouad, A; Khairy, M; Salama, A; Tantawy, O1
Cherian, R; Driscoll, C; Genther, K; Goode, MB; Lee, H; Lewis, S; Luketic, VA; Martin, K; Matherly, S; Patel, V; Puri, P; Sanyal, AJ; Siddiqui, MS; Smith, P; Sterling, RK; Stravitz, RT1
Gonzales, GR; Gonzalez, SA; Modi, AA; Nazario, HE1
Otori, K; Tanaka, Y; Yokomori, H1
Aoufi-Rabih, S; Fabrizi, F; García-Agudo, R; González-Corvillo, C; Salgueira-Lazo, M1
Aghemo, A; Cresseri, D; Donato, FM; Fabrizi, F; Fraquelli, M; Lampertico, P; Messa, P; Moroni, G; Passerini, P1
Kanda, T; Matsuoka, S; Moriyama, M1
Abdel-Gabbar, M; Abdel-Moneim, A; Aboud, A; Ramadan, M; Zanaty, MI1
Masumoto, A; Miyazaki, M; Motomura, K; Tanaka, K; Yada, M1
Abergel, A; Besch, C; Botta-Fridlund, D; Cagnot, C; Canva, V; Chevaliez, S; Coilly, A; Conti, F; D'Alteroche, L; De Ledinghen, V; Debette-Gratien, M; Diallo, A; Duclos-Vallee, JC; Dumortier, J; Duvoux, C; Fougerou-Leurent, C; Francoz, C; Habersetzer, F; Houssel-Debry, P; Jezequel, C; Kamar, N; Lebray, P; Leroy, V; Martino, VD; Montialoux, H; Moreno, C; Pageaux, GP; Perre, P; Radenne, S; Rossignol, E; Silvain, C; Tran, A; Veislinger, A1
Chang, F; Duan, CA; Jin, X; Lu, Y1
Jang, H; Jin, YJ; Kim, CW; Kim, L; Yoon, CH1
Fan, H; Feng, Y; Huang, P; Liu, M; Xia, X; Yao, Y; Yu, R; Yue, M; Zang, F; Zhang, Y1
Alavian, SE; Alavian, SM; Behnava, B; Keshvari, M; Pouryasin, A; Pouryasin, M; Sharafi, H; Shirmast, P1
Hashimoto, S; Hayashi, K; Nakagawa, Y; Saito, K; Takahashi, K; Takamura, M; Takeuchi, S; Tanabe, Y; Tasaki, M; Terai, S; Tomita, Y; Yamagiwa, S; Yoshida, T1
ElBasiony, M; Hassan, AA; Mikhail, NNH; Shiha, G; Soliman, R1
Abdel-Razek, W; Brainard, DM; Doss, W; Elbasiony, M; Elsharkawy, A; Esmat, G; Fouad, R; Hammad, R; Hassany, M; Kersey, K; Lu, S; Massetto, B; McHutchison, JG; Osinusi, A; Shiha, G; Soliman, R; Waked, I; Zakareya, T1
Cheung, CYS; Cooper, SE; Liu, HY1
Gupta, E; Kataria, A; Nayak, SL; Sarin, SK1
Cervino, L; Hynicka, LM1
Furqan, S; Jabeen, S; Rashid, O1
Balart, L; Barr, E; Ghalib, R; Hanna, GJ; Hwang, P; Luketic, V; Nguyen, BY; Pearlman, B; Ravendhran, N; Robertson, M; Talwani, R; Vierling, J; Zamor, PJ1
Zeuzem, S16
Atsumi, T; Fujieda, Y; Nakai, M; Nakamura, H; Yasuda, S1
Aghemo, A; Aglitti, A; Andreone, P; Boccaccio, V; Bollani, S; Brunetto, MR; Bruno, S; Calvaruso, V; Ciancio, A; Coco, B; Conti, F; Degasperi, E; Di Leo, A; Di Marco, V; Giorgini, A; Lampertico, P; Lleo, A; Maisonneuve, P; Marzi, L; Persico, M; Rendina, M; Troshina, G; Villa, E; Zuin, M1
Fazylov, VC; Guryanova, SV; Manapova, ER1
Du, Y; Hou, W; Huo, Z; Qiao, K; Trieu, C1
Abdo, AA; Al-Hamoudi, WK; Alalwan, AM; Albenmousa, A; Albiladi, H; Alghamdi, AS; AlGhamdi, H; Aljawad, MS; Aljumah, AA; AlMousa, A; Almutairi, NH; Alothmani, HS; Alsahafi, A; AlSaleemi, MS; Alswat, K; Altraif, IH; AlZanbagi, A; Assiri, AM; Awny, A; Babatin, MA; Dahlan, Y; Mousa, WA; Sanai, FM1
Abdallah, F; El Tarabily, M; Ibrahim, M; Mohamed, G1
Abdel-Gabaar, M; Abdel-Moneim, A; Aboud, A; Ramadan, M; Zanaty, MI1
Bogomolov, PO; Chen, X; Enejosa, JV; Isakov, V; Maevskaya, MV; Ogurtsov, P; Paduta, D; Pasechnikov, V; Shulman, NS; Viani, RM; Znoyko, O1
Ananyan, S; Gemilyan, M; Hakobyan, G1
Boscarino, JA; Daida, YG; Gordon, SC; Holmberg, SD; Lu, M; Moorman, AC; Rupp, LB; Schmidt, MA; Spradling, PR; Teshale, EH; Xing, J; Zhong, Y1
Honma, T; Imai, M; Ishikawa, T; Iwanaga, A; Nozawa, Y; Owaki, T; Sano, T; Sato, H; Seki, K; Yoshida, T1
Agarwal, K; Cannon, MD; Carey, I; Childs, K; Considine, A; Dusheiko, G; Manini, MA; Mazzarelli, C; Suddle, A1
Zhang, DZ; Zhang, QF1
Zhang, DZ; Zhang, QY; Zhu, F1
Aghemo, A; Ascione, A; Bruno, S; Craxì, A; De Luca, M; Fontanella, L; Gasbarrini, A; Giannini, EG; Izzi, A; Marzioni, M; Melazzini, M; Messina, V; Montilla, S; Orlandini, A; Petta, S; Puoti, M; Sangiovanni, V; Trotta, MP; Villa, E; Zignego, AL1
Alavian, SM; Sharafi, H1
Kamiya, K; Komine, M; Maekawa, T; Murata, S; Ohtsuki, M; Waki, Y1
Chae, HB; Jang, JW; Kang, YW; Kim, HS; Kim, SB; Kim, SH; Kim, YM; Ko, SY; Lee, BS; Lee, JD; Lee, SH; Lee, TH; Song, IH; Song, MJ1
Hindi, NN; Saleh, MI1
Abd El Latif, Y; Doss, W; El Kassas, M; El Shazly, Y; El Tahan, A; Elbadry, M; Esmat, G; Farid, AM; Fontanet, A; Funk, AL; Sherief, A; Shimakawa, Y; Vasiliu, A; Youssef, N1
Höner Zu Siederdissen, C; Maasoumy, B1
Berak, H; Białkowska, J; Bolewska, B; Fleischer-Stępniewska, K; Flisiak, R; Garlicki, A; Janczewska, E; Karpińska, E; Karwowska, K; Nazzal, K; Piekarska, A; Simon, K; Tomasiewicz, K; Tronina, O; Tuchendler, E; Zarębska-Michaluk, D; Łucejko, M1
Auckle, R; Che, WL; Li, HL; Liu, L; Mohammed, AQ; Xu, SL; Zhao, DD1
Alami, NN; Allam, N; Esmat, G; Fouad, R; Hall, C; Hassany, M; Kopecky-Bromberg, S; Mobashery, N; Mohey, M; Qaqish, RB; Shiha, G; Soliman, R; Waked, I1
Bhamidimarri, KR; Chu, D; Han, SB; Hu, KQ; Lee, TP; Ma, X; Mohanty, SR; Pan, CQ; Park, J; Tiongson, BC; Tong, M; Wang, D; Xiao, PY1
Cerban, R; Ester, C; Gheorghe, C; Gheorghe, L; Iacob, R; Iacob, S; Pietrareanu, C; Popescu, I1
Alper, CJ; Clements, K; Greenwood, BC; Hydery, T; Jeffrey, PL; Kouris, G; Lavitas, P; Lenz, K; Price, M1
Kim, SM; Song, IH1
Blatt, CR; Carneiro, JMM; Chachá, SGF; Farias, MR; Feltrin, AA; Gomes, LO; Martinelli, ALC; Noblat, LACB; Pereira, LRL; Rodrigues, JPV; Rosa, JAD; Silveira, MPT; Teixeira, MR; Vecchi, MD1
Ahn, SH; Chan, HL; Chuang, WL; Han, KH; Henry, L; Kao, JH; Lai, CL; Lim, YS; Nguyen, KV; Stepanova, M; Wei, L; Younossi, ZM1
Barone, CR; Bonamigo, RR; Boza, JC; Oliveira, FB; Pires, GC; Rossi, SD; Silva, M1
But, DYK; Chan, CW; Chan, HLY; Chan, JMC; Cheung, WI; Chow, WH; Fan, TTT; Fung, JYY; Hui, AJ; Hui, YT; Kung, KN; Lai, KB; Lai, LSW; Lai, MS; Lam, BCY; Lam, JTW; Lam, K; Lao, WC; Lau, JYL; Leung, NWY; Li, MKK; Liu, K; Liu, SD; Loo, CK; Lui, TKL; Luk, WF; Ma, YK; Mak, WY; Ng, ACY; Shan, EHS; Tong, RKN; Tsang, OTY; Tsang, SWC; Wong, GLH; Wong, VWS; Yuen, MF1
Arand, M1
Andersen, ES; Bukh, J; Christensen, PB; Fahnøe, U; Gerstoft, J; Kjær, MS; Laursen, AL; Mössner, B; Pedersen, MS; Røge, BT; Schønning, K; Sølund, C; Weis, N1
Abdel Wahed, WY; Ahmed, EI; Ahmed, TI; Hassan, EA1
Al-Deen Abead, M; Baraka, MA; Gomaa, AA; Hussein, AK; Wahsh, EA1
Brainard, DM; Camus, G; Chayama, K; De-Oertel, S; Enomoto, H; Ide, T; Ikeda, F; Izumi, N; Jiang, D; Kakizaki, S; Kawakami, Y; Kurosaki, M; McHutchison, JG; McNabb, BL; Mizokami, M; Mochida, S; Stamm, LM; Takaguchi, K; Takehara, T; Tanaka, Y; Toyoda, H; Ueno, Y; Yatsuhashi, H1
Asante-Appiah, E; Barr, E; Black, T; Brunhofer, J; Galloway, A; Haber, B; Hwang, P; Lahser, F; Palcza, J; Robertson, M; Wahl, J1
Feng, L; Gong, F; Hu, S; Huang, H; Sun, B; Yuan, F; Zheng, F1
Gao, B; Su, Y; Tong, Z; Wang, W; Zhang, C; Zhang, H; Zhang, L; Zhong, J1
Brieva, T; Frias, M; Rivero, A; Rivero-Juarez, A1
Husic-Selimovic, A; Jahic, E; Merhemic, Z; Prohic, D; Sofic, A1
Bacca, D; Cenderello, G; Copetti, M; De Stefano, G; Losappio, R; Mangia, A; Mazzola, M; Minerva, N; Palmieri, V; Piazzola, V; Potenza, D; Santoro, R; Sogari, F; Terreni, N1
Arnon, R; Balistreri, WF; Bansal, S; Brainard, DM; Evans, HM; Garrison, KL; Gillis, LA; Gonzalez-Peralta, RP; Jonas, MM; Kersey, K; Lin, CH; Massetto, B; Murray, KF; Narkewicz, MR; Parhy, B; Rosenthal, P; Schwarz, K; Shao, J; Wen, J; Whitworth, S1
Feist, C; Galle, PR; Grambihler, A; Münzel, T; Ostad, MA; Schattenberg, JM; Schmidt, FP; Schnorbus, B; Sprinzl, MF; Wenz, T; Zimmermann, T1
Abdel-Ghafar, TS; Abdelkareem, M; Abdelsameea, E; Abozeid, M; Alsebaey, A; Elfayomy, M; Elhelbawy, M; Fekry, M; Othman, W; Rewisha, E; Rgab, A; Sabry, A; Shebl, N; Waked, I1
Abdellatif, Z; Anwar, I; Bekheet, N; El-Nahaas, SM; Elhossary, W; Elsharkawy, A; Esmat, G; Fouad, R; Khairy, M; Maher, RM1
Chakraborty, S; Garlapati, P; Gayam, V; Gill, A; Guss, D; Khalid, M; Mandal, AK; Mansour, M; Mohanty, S; Mukhtar, O; Sherigar, J; Shrestha, B; Tiongson, B1
Gandhi, M; Jhaveri, A; Merchant, R; Nagral, A; Nagral, N; Parikh, NS; Sawant, S1
Béguelin, C; Bernasconi, E; Böni, J; Braun, DL; Conen, A; Delaloye, J; Fehr, JS; Flepp, M; Günthard, HF; Hampel, B; Kouyos, R; Künzler-Heule, P; Nguyen, H; Nicca, D; Rauch, A; Rougemont, M; Schmid, P; Shah, C; Stöckle, M1
Keam, SJ; Markham, A1
Cabello, V; Juampérez, J; Julio, E; Mercadal-Hally, M; Quintero, J; Rodrigo, C; Segarra, Ó; Soler-Palacín, P1
Abdel-Samiee, M; Abdo, M; Elbaz, T; Esmat, G; Gamil, M; Hassan, EA; Moustafa, A; Omar, H; Qawzae, A; Zaghloul, AM1
Abid, S; Abraham, P; Abu Bakar, N; Ahmed, T; Arisar, FAQ; Bwa, AH; Chen, KP; Dan, YY; Dhore, P; Eapen, CE; Goh, KL; Hamid, S; Hj Md Said, RB; Ho, SH; Jafri, W; Kamat, M; Koshy, A; Lee, YM; Lim, SG; Madan, K; Mehta, R; Mohamed, R; Phyo, WW; Piratvisuth, T; Shah, SR; Shukla, A; Tan, SS; Tanwandee, T; Tee, HP; Tyagi, S; Wadhawan, M; Win, KM; Yang, WL; Yin, TP1
Bischoff, J; Rockstroh, JK1
Minowa, K; Suzuki, M; Tajiri, H1
Abdel-Aziz, EM; Abdel-Malek, MO; Hashim, AA; Hetta, HF; Mekky, MA; Morsy, KH; Osman, HA1
Gruenhage, F; Hahn, D; Kaiser, R; Lammert, F; Meyer, MR; Stokes, CS1
Aurora, R; Kanda, T; Kato, N; Meyer, K; Moriyama, M; Ray, R; Ray, RB; Sasaki, R; Yokosuka, O1
Yeon, JE1
Jacobson, IM2
Abd-Elsalam, S; Badawi, R; Elfert, A; Elkhouly, RA; Elnawasany, S; Hawash, N; Kobtan, A; Mansour, L; Selim, A; Soliman, S; Yousef, M1
Chang, Y; Cho, EJ; Cho, H; Cho, YY; Hwang, SG; Kim, HY; Kim, YJ; Lee, DH; Lee, JH; Lee, JM; Lee, YB; Nam, JY; Yoon, JH; Yu, SJ1
Chang, CH; Chen, DS; Chen, PJ; Hong, CM; Huang, YJ; Hung, CC; Kao, JH; Liu, CH; Liu, CJ; Liu, WC; Su, TH; Sun, HY; Tseng, TC; Yang, HC; Yang, SS1
Dhiman, RK; Duseja, A; Grover, GS; Premkumar, M; Rathi, S; Satsangi, S; Taneja, S1
Aggarwal, M; Bhari, N; Gupta, M1
Chen, DZ; Chen, KD; Li, LJ; Ou, HL; Su, JW; Wu, XX; Xu, XW; Yao, HP; Yu, HY1
Buonanno, P; Camera, S; Caporaso, N; Capuano, I; Donnarumma, L; Ferreri, L; Morisco, F; Sabbatini, M1
Abdelsameea, E; Essa, M; Sabry, A; Salama, M; Tharwa, ES1
Budimir, J; Dušek, D; Jugović, D; Krajcar, N; Kurelac, I; Papić, N; Vince, A1
Anton, MD; Badia, E; Bonacci, M; Calleja, JL; Carmona, I; Carrión, JA; Castellote, J; Castro Urda, JL; de la Vega, J; Diago, M; Fernández, I; Fernández-Bermejo, M; Fernández-Rodríguez, C; Figueruela, B; Gallego, A; García Buey, L; García, ND; García-Samaniego, J; Gea, F; Hernández-Conde, M; Llerena, S; Menéndez, F; Molina, E; Montoliu, S; Moreno-Palomares, JJ; Moreno-Planas, JM; Morillas, RM; Pascasio, JM; Perelló, C; Piqueras Alcol, B; Romero-Gómez, M; Rosales-Zabal, JM; Salmeron, FJ; Sánchez Ruano, JJ; Souto-Rodríguez, R1
El-Tantawy, WH; Temraz, A1
Chen, EQ; Deng, R; Lv, DD; Tang, H; Tao, YC; Wang, ML; Wang, YH; Yuan, M1
Lee, TY; Yang, SS1
Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC1
Fukaya, Y; Hirosawa, T; Imai, M; Isoda, N; Kurata, H; Miura, K; Morimoto, N; Murayama, K; Murohisa, T; Nomoto, H; Numao, N; Okamura, Y; Ozawa, I; Sato, T; Tahara, T; Takaoka, Y; Tano, S; Tsukui, M; Watanabe, S; Yamamoto, H; Yoshizumi, H1
Asaoka, Y; Enooku, K; Fujiwara, N; Koike, K; Minami, T; Nakagawa, H; Nakagomi, R; Nishibatake Kinoshita, M; Sato, M; Shiina, S; Tateishi, R; Uchino, K; Wake, T1
Cicchetti, A; De Solda, F; Drago, C; Kondili, LA; Nappi, C; Rolli, FR; Ruggeri, M1
Bair, MJ; Chen, CH; Chen, CK; Chen, CP; Cheng, CH; Cheng, CY; Cheng, SH; Zou, H1
Chen, B; Chen, EQ; Jiang, W; Tang, H; Tao, YC; Wang, ML; Wang, YH; Wu, DB1
Abhilash, VB; Asati, PK; Behera, MK; Dixit, VK; Jain, AK; Nath, P; Shukla, SK1
Ghesquiere, W; Huhn, GD; Linaberry, M; McPhee, F; Noviello, S; Poordad, F; Ramji, A; Shafran, SD; Shiffman, ML; Wong, A; Wong, F; Yang, R1
Ali, Q; Imran, M; Iqbal, K; Jamal, A; Kalam, I; Ullah, S; Waqar, AB1
Aartun, J; Kottilil, S; Masur, H; Meissner, EG; Orr, C1
Avril, E; Bouscaillou, J; Butsashvili, M; Etienne, A; Gamezardashvili, A; Inaridze, I; Kamkamidze, G; Kharshiladze, D; Kikvidze, T; Labartkava, K; Le Pluart, D; Luhmann, N1
Applegate, TL; Bruggmann, P; Bruneau, J; Castro, E; Conway, B; Cooper, C; Crawford, S; Cunningham, EB; Dalgard, O; Daulouede, JP; Dore, GJ; Dunlop, A; Erratt, A; Feld, JJ; Fraser, C; Gane, E; Grebely, J; Hajarizadeh, B; Hellard, M; Kronborg, I; Lacombe, K; Marks, P; Matthews, GV; Moriggia, A; Petoumenos, K; Powis, J; Schmid, P; Shaw, D; Stedman, C1
De Maria, C; Ghidotti, I; Giannini, EG; Grillo, F1
Agnieszka, P; Andrzej, H; Hanna, B; Iwona, BO; Kamila, CC; Karol, P; Kosińska, J; Marek, R; Pollak, A; Płoski, R; Tomasz, L1
Khaliq, S; Raza, SM1
Angelidakis, G; Blechacz, B; Economides, MP; Granwehr, BP; Hosry, J; Jiang, Y; Kaseb, A; Kyvernitakis, A; Mahale, P; Miller, E; Naing, A; Raad, II; Samaniego, F; Torres, HA1
Asim, M; Khan, A; Rashid, A1
Choe, WH; Kim, AR; Kim, JH; Kwon, SY; Park, SJ; Yoo, BC1
Bamberger, T; Graziadei, I; Gschwantler, M; Katalinic, N; Maieron, A; Stauber, R1
Ceccherini-Silberstein, F; Cento, V; Craxì, A; Di Maio, VC; Perno, CF1
Abou-Samra, AB; Butt, AA; Freiberg, MS; Shaikh, OS; Shuaib, A; Yan, P1
Acero, D; Alsius, M; Buxó, M; Ferri, MJ; López, C; Queralt, X; Serra, I1
Brooks-Rooney, C; Chen, CY; Chen, JJ; Cheng, PN; Hsieh, TY; Huang, YH; Kao, JH; Lin, CL; Liu, CH; Lo, CC; Ma, Q; Peng, CY; Su, WW; Yu, ML1
Choi, HY; Chung, W; Jang, ES; Jeong, SH; Ki, M; Kim, KA1
Cenderello, G; Di Biagio, A; Taramasso, L1
Bair, MJ; Chen, HL; Cheng, CH; Chu, CY; Lee, YK; Lin, IT; Wu, CH1
Back, DJ; Burger, DM; Colbers, A; de Knegt, RJ; Drenth, JPH; El-Sherif, O; Honkoop, P; Smolders, EJ; van Seyen, M; van Wijngaarden, P; Wouthuyzen-Bakker, M1
Fattehi, MR; Ghorbani, M; Hojati, SA; Maserat, E; Safarpour, A1
Chen, DS; Chen, PJ; Cheng, PN; Chien, RN; Chuang, WL; Hsu, SJ; Huang, CF; Huang, JF; Huang, YH; Hung, CH; Kao, JH; Lin, CY; Liu, CH; Liu, CJ; Peng, CY; Su, CW; Yu, ML1
Chang, KC; Chen, CH; Hu, TH; Hung, CH; Kee, KM; Lin, MT; Lu, SN; Sou, FM; Tsai, MC; Wang, JH; Wu, CK; Yen, YH1
Aguilar, H; Asatryan, A; Asselah, T; Baumgarten, A; Conway, B; Dore, GJ; Foster, GR; Grebely, J; Gschwantler, M; Hu, Y; Jackson, D; Mensa, FJ; Sherman, KE; Tomasiewicz, K; Wang, S1
Cho, HA; Cho, JY; Cho, SB; Choi, SK; Jun, CH; Kim, MW; Lim, SW; Seo, JH; Yoon, JH1
Aboufarrag, GA; Lashen, SA; Madkour, MA; Shamseya, MM1
Izumi, T; Kawagishi, N; Kimura, M; Kudo, Y; Maehara, O; Miyoshi, H; Morikawa, K; Nakai, M; Nakamura, A; Natsuizaka, M; Nishida, M; Ogawa, K; Ohara, M; Sakamoto, N; Sho, T; Suda, G; Suzuki, K; Umemura, M1
Chen, WT; Chen, YC; Hsieh, YC; Huang, CH; Jeng, WJ; Lin, CC; Lin, CY; Lin, SM; Sheen, IS; Teng, W1
Chen, CL; Chen, DS; Chen, PJ; Chou, SW; Kao, JH; Liu, CH; Liu, CJ; Su, TH; Tseng, TC; Wu, SJ; Yang, HC1
Affonso-de-Araújo, ES; Álvares-da-Silva, MR; Alves, K; Brandão-Mello, CE; Cheinquer, H; Coelho, HS; Cohen, DE; Ferraz, ML; Ferreira, PRA; Furtado, J; Lari, SA; Liu, L; Martinelli, A; Mendes-Correa, MC; Nunes, EP; Parana, R; Pessoa, MG; Pilot-Matias, T; Ramalho-Madruga, JV; Shulman, NS; Silva, G; Tripathi, R1
Abou El-Khier, NT; Abousamra, NK; Arafa, MM; Eladl, E; Elhammady, D; Esmael, ME; Shahin, D; Shaker, G; Sharaf-Eldeen, O1
Ibrahim, MM; Shahid, I1
Chen, CH; Hu, TH; Hung, CH; Kee, KM; Lu, SN; Wang, JH; Yen, YH1
Gani, RA; Hasan, I; Jasirwan, COM; Kalista, KF; Kurniawan, J; Lesmana, CRA; Nababan, SHH; Sulaiman, AS; Zulkifly, S1
Elgouhary, SM; Mowafy, MA; Said-Ahmed, KE1
Abushouk, AI; Al-Husseini, M; El-Raey, F; Johar, D; Mohammed, EG; Montasser, MF; Salaheldin, M; Zaky, S1
Alberti, A; Angeli, E; Angelico, M; Badia, L; Belli, L; Biolato, M; Borghi, V; Calvaruso, V; Carrai, P; Craxì, A; D'Offizi, G; Fagiuoli, S; Felder, M; Grieco, A; Guaraldi, G; Lionetti, R; Mancusi, RL; Mazzarelli, C; Milazzo, L; Montalbano, M; Pasulo, L; Persico, M; Piai, G; Puoti, M; Santantonio, T; Verucchi, G; Villa, E1
Dohi, T; Jain, A; Kadry, Z; Krok, KL; Miller, D; Riley, TR; Schreibman, I; Sharma, R1
Barker, L; Jiles, RB; White, JZ; Yin, S1
Chan, HL; Cheung, D; Chim, AM; Chung, C; Fung, JY; Hui, YT; Loo, CK; Wong, GL; Wong, VW1
El-Hamamsy, M; El-Meteini, M; Mansy, AE; Montasser, IF; Nabet, DE1
Boyacıoğlu, AS; Çolak, T; Dağlı, Ü; Haberal, M; Hilmioğlu, F; Öcal, S; Özer Etik, D; Selçuk, H; Suna, N1
Back, D; Bondin, M; Bourgeois, S; Buggisch, P; Charafeddine, M; Crown, E; Curescu, M; Dorr, P; Ferenci, P; Flisiak, R; Kleine, H; Larrey, D; Marra, F; Norris, S1
Akarca, US; Akdogan, M; Akhan, S; Aladag, M; Ataseven, H; Cakaloglu, Y; Cavus, B; Demir, M; Erol, C; Ersoz, G; Gunduz, F; Gunsar, F; Idilman, R; Iliaz, R; Karasu, Z; Kaymakoglu, S; Kiyici, M; Koklu, H; Koksal, AS; Koksal, İ; Ozgenel, M; Sahin, M; Tabak, F; Turan, İ1
Berger, F; Boesecke, C; Buendgens, L; Christensen, S; Hüppe, D; Ingiliz, P; Lutz, T; Mauss, S; Schewe, K; Simon, KG; Tacke, F1
Basha, MAA; Bassiony, MA; Hanafy, AS1
Brandão, ABM; Cantisani, GPC; Costabeber, AM; Fleck Junior, AM; Kiss, G; Leipnitz, I; Marroni, CA; Martini, J; Meine, MH; Mucenic, M; Rossato, G; Sacco, FKR; Schlindwein, ES; Zanotelli, ML1
Dabes, H; ElSaeed, K; ElSerafy, M; ElShazly, Y; Hamed, S; Omar, H; Saad, Y; Said, M; Soliman, Z1
Ferrentino, N; Lidofsky, SD; Strader, DB; VanOpdorp, JR1
Frydecka, D; Hadryś, T; Inglot, M; Małyszczak, K; Pawłowski, T1
Farias, MR; Foppa, AA; Gomes, LO; Rosa, JAD; Rover, MRM; Teixeira, MR1
Ding, X; Fan, Z; Liu, J; Liu, S; Wang, F1
Chen, J; Fang, Z; Li, M; Li, Y; Lin, Q1
Cho, M; Han, SY; Heo, J; Kim, DU; Kim, GH; Kim, HH; Park, SG; Park, YJ; Pyeon, SI; Song, GA; Woo, HY1
Cooper, CL; Crawley, A; Doyle, MA; Galanakis, C; Mulvihill, E1
Chu, CJ; Hou, MC; Huang, YH; Lee, FY; Lee, SD; Lin, CC; Su, CW; Wang, YJ; Wu, SH2
Atanasov, PK; Buggisch, P; Lee, J; Petersen, J; Stoehr, A; Supiot, R; Ting, J; Wursthorn, K1
Aldir, I; Bana E Costa, T; Carvalho, A; Chagas, C; Correia, JM; Falcão, F; Farinha, H; Lebre, L; Lopes, C; Mansinho, K; Marques, S; Miranda, AC; Mirco, A; Peixe, P; Perez, R; Viegas, E1
Afify, S; Alboraie, M; Algaber, MA; Doss, W; El Halwagy, H; El Kassas, M; El Latif, YA; El Tahan, A; Elsaeed, K; Elserafy, M; Omar, H1
Chang, YK; Chen, KH; Chen, KT; Tseng, YT1
Birerdinc, A; Curry, MP; de Avila, L; Escheik, C; Estep, JM; Gerber, L; Golabi, P; Stepanova, M; Weinstein, AA; Younossi, ZM1
Ahn, YH; Cho, E; Cho, SB; Choi, SK; Jun, CH; Kim, DH; Lee, MJ; Park, H1
Babudieri, S; Barbarini, G; Candilo, FD; Cariti, G; Dell'Isola, S; Distefano, M; Ettorre, GM; Fontanella, L; Giannelli, V; Iovinella, V; Ippolito, AM; Izzi, A; Marignani, M; Messina, V; Moretti, A; Palitti, VP; Pellicelli, A; Pompili, M; Scifo, G; Tarquini, P; Vennarecci, G; Vignally, P1
Cunningham, HE; Grgic, T; Lachiewicz, AM; Shea, TC1
Abou-Samra, AB; Aslam, S; Butt, AA; Shaikh, OS; Yan, P1
Bank, L; Bernstein, D; Epstein, M; Krishnan, P; Lucey, MR; Martinez, M; Nelson, DR; Pockros, PJ; Polepally, AR; Poordad, F; Ravendhran, N; Reindollar, R; Sedghi, S; Trinh, R; Unnebrink, K1
Cascio, A; Cervo, A; Colomba, C; Di Carlo, P; Firenze, A; Saporito, L; Tolomeo, M; Trizzino, M1
Graf, C; Herrmann, E; Mücke, MM; Mücke, VT; Vermehren, J; Zeuzem, S1
El-Kosasy, AM; Hussein, LA; Magdy, N; Youssef, AA1
Choi, JW; Ko, SY; Seo, HY; Seo, MS; Yoon, SY1
Chen, CH; Chien, RN; Hsieh, SY; Hu, TH; Hung, CH; Lin, CL; Lin, CY; Lu, SN; Sheen, IS; Tung, SY1
Bani Melhim, S; Saleh, MI1
Chen, SC; Hung, HC; Lee, YT; Liao, HH; Tsao, SM1
Skorokhodova, N; Tsarova, O; Zhyvytsia, D1
Bwa, AH; Hlaing, NKT; Kyaw, AMM; Lin, S; Loza, BL; Maung, MZ; Maung, ST; Myint, KT; Nangia, G; Reddy, KR; Sein Win, S; Tun, KT; Win, KM1
Barr, E; Burnevich, E; Buti, M; Feld, JJ; Foster, GR; Gane, E; Hanna, GJ; Jackson, B; Katchman, H; Klopfer, S; Lahser, F; Lawitz, E; Platt, HL; Rabinovitz, M; Robertson, MN; Shaughnessy, M; Tomasiewicz, K; Yeh, WW1
Borba, HHL; Ferreira, VL; Minowa, E; Pontarolo, R; Rochau, U; Siebert, U; Sroczynski, G; Wiens, A1
Bermúdez, C; Cheinquer, H; Coelho Borges, S; de Araujo, A; de Maman, Í; Fleck, A; Gadano, A; Garrastazul, P; Haddad, L; Kliemann, D; Marciano, S; Mendizabal, M; Nader, LA; Piñero, F; Ridruejo, E; Silva, M; Wolff, FH1
Ahmed, NS; Aref, AM; Helal, TEA; Mahmoud, HA; Radwan, NA; Wahib, AA; Zaki, AM1
Angelico, M; Antonucci, F; Armenia, D; Bellocchi, MC; Carioti, L; Ceccherini-Silberstein, F; Cento, V; Ciancio Manuelli, M; De Leonardis, F; Lenci, I; Manzia, TM; Milana, M; Perno, CF; Sforza, D; Sorbo, MC; Tisone, G1
Abdelrazik, M; Aboushady, M; Alwassief, A; Elbahrawy, A; Elmestikawy, A; Shahba, H; Ziada, D1
Chi, X; Gao, X; Li, Y; Lv, J; Niu, J; Sun, H; Wang, X; Wu, R; Yu, G1
Fukui, N; Kamimura, K; Kawai, H; Mizuno, K; Sakai, N; Sakamaki, A; Someya, T; Sugai, T; Takamura, M; Terai, S; Tominaga, K; Watanabe, H; Yamagiwa, S1
Boscarino, JA; Daida, YG; Gordon, SC; Li, J; Lu, M; Moorman, AC; Rupp, LB; Schmidt, MA; Spradling, PR; Teshale, EH; Trudeau, S; Wu, KH; Zhang, T1
Baicus, C; Constantinescu, I; Diculescu, M; Dumitru, R; Gavrila, D; Istratescu, D; Manuc, M; Manuc, T; Oproiu, A; Preda, CM; Sandra, I; Tieranu, C; Vasilescu, C; Voiosu, T1
Amiot, X; Arotcarena, R; Cadranel, JF; Causse, X; Garioud, A; Halfon, P; Heng, R; Lucidarme, D; Medmoun, M; Mokhtari, C; Ollivier-Hourmand, I; Pariente, A; Pulwermacher, P; Rémy, AJ; Renou, C; Rosa-Hézode, I; Zanditenas, D; Zougmoré, H1
Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Higashi, N; Igarashi, A; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K1
Balistreri, WF; Bansal, S; Brainard, DM; Davison, S; Feiterna-Sperling, C; Gillis, LA; Gonzalez-Peralta, RP; Hsueh, CH; Indolfi, G; Jonas, MM; Kelly, DA; Lin, CH; Massetto, B; Murray, KF; Nightingale, S; Parhy, B; Rosenthal, P; Schwarz, KB; Shao, J; Sokal, EM; Wirth, S1
Wahid, B1
Frosi, A; Frosi, G; Meloni, MF1
Chen, H; Gao, SS; Li, HW; Qiu, H; Sun, ZL; Wang, JM; Wang, ZR1
Amory, C; Gardenier, D; Weiss, JJ; Woody, A1
Amin, J; Artenie, AA; Bruggmann, P; Bruneau, J; Conway, B; Cooper, C; Cunningham, EB; Dalgard, O; Dore, GJ; Erratt, A; Feld, JJ; Grebely, J; Hajarizadeh, B; Hellard, M; Lacombe, K; Litwin, AH; Marks, P; Matthews, GV; Powis, J; Quiene, S; Read, P; Stedman, C1
Arora, S; Dhiman, RK; Duseja, A; Grover, GS; Premkumar, M; Rathi, S; Roy, A; Satsangi, S; Taneja, S1
Bourlière, M; Bronowicki, JP; Chimienti, F; Cleophax, S; Doffoel, M; Lang, JP; Pujol, JF; Salvetat, N; Schwan, R; Van der Laan, S; Vire, B; Weissmann, D1
A, M; Abd-Elsamie, E; Badawy, ER; ElMelegy, TT; Hassaballa, AE; Kamal-ElDin, TM; Mekky, MA; Zahran, AM1
Aldámiz-Echevarría, T; Bellón, JM; Berenguer, J; Carrero, A; Díez, C; Fanciulli, C; Garcia-Broncano, P; Jiménez-Sousa, MA; Medrano, LM; Miralles, P; Pérez-Latorre, L; Resino, S1
Gao, XH; Jing, P1
Chi, X; Gao, X; Jiang, J; Jiang, T; Niu, J; Pan, Y; Wang, M; Wang, X; Wu, R; Yan, H1
Gaballah, AH; Ghazy, AA; Mostafa, H; Osman, EM; Rashwan, EA; Tawfik, S1
Afendy, A; Gaggar, A; Jacobson, IM; Lalezari, J; Lawitz, EJ; Muir, AJ; Myers, RP; Nader, F; Racila, A; Reddy, KR; Ruane, PJ; Schwabe, C; Stepanova, M; Younossi, I; Younossi, ZM1
Djauzi, S; Gani, RA; Harimurti, K; Ibrahim, F; Imannuel, S; Kurniawan, J; Nafrialdi, N1
Campo-Cerecedo, F; Grueiro, MC; Monteagudo, B; Vilas-Sueiro, A1
Fazylov, VKh; Manapova, ÉR; Sozinova, IuM; Tkacheva, SV1
Albrecht, JK; Barnard, RJ; Brass, CA; Chaudhri, E; Davis, MN; Gordon, SC; Hazuda, DJ; Howe, AY; Howe, JA; Jacobson, IM; Kwo, PY; Lawitz, EJ; McCone, J; Ogert, RA; Pedicone, LD; Pound, D; Qiu, P; Ralston, R; Ravendhran, N; Rossaro, L; Schiff, ER; Vierling, JM1
Araújo Ramos, AL; Hoffmann, L; Ramos, JA; Rondinelli, E; Silva, R; Souza, EV; Tanuri, A; Urményi, TP; Villela-Nogueira, CA1
Blum, R; Kessebohm, K; Pfaundler, N; Stickel, F; Stieger, M1
Arisawa, T; George, J; Hayashi, N; Saito, T; Shiroeda, H; Toshikuni, N; Tsuchishima, M; Tsutsumi, M1
Al Meshari, K; Al-Ashgar, H; Al-Mdani, A; Al-Qahtani, A; Al-Shoail, G; Aleid, H; Bzeizi, KI; Mousa, D; Saadeh, M; Sanai, FM1
Gara, N; Ghany, MG1
Agarwal, K; Carey, I; Joshi, D1
Abe, H; Hirose, K; Honma, T; Ishikawa, T; Kamimura, T; Kubota, T; Nagashima, A; Seki, K; Togashi, T; Yoshida, T1
Bismuth, M; Blanc, P; Christophorou, D; Daurès, JP; Duny, Y; Flori, N; Funakoshi, N; Valats, JC1
Chou, R; Cottrell, EB; Fu, R; Hartung, D; Rahman, B; Wasson, N1
An, D; Barnard, RJ; Bhanja, S; Gane, EJ; Gress, J; Hwang, P; Lawitz, E; Mobashery, N; Rodriguez-Torres, M; Serfaty, L; Stoehr, A1
Bernstein, B; Cohen, DE; Koev, G; Kowdley, KV; Larsen, L; Lawitz, E; Menon, R; Pilot-Matias, T; Podsadecki, T; Poordad, F; Siggelkow, S; Tripathi, R1
Balistreri, WF; Barton, BA; Cheng, I; Gonzalez-Peralta, RP; Haber, BA; Jonas, MM; Lobritto, SJ; Mellman, W; Mohan, P; Molleston, JP; Murray, KF; Narkewicz, MR; Njoku, D; Rosenthal, P; Schwarz, KB; Talor, MV1
Box, T; Chen, J; Dejesus, E; Dubuc-Patrick, G; Godofsky, E; Kwo, P; Lalezari, J; Lawrence, S; Mayers, D; McCarville, J; Mehra, P; Nguyen, T; O'Riordan, W; Pietropaolo, K; Poordad, F; Sullivan-Bólyai, J; Zhou, XJ1
Corvino, SM; Grotto, RM; Padovani, JL; Pardini, MI; Silva, GF; Zeminian, LB1
Amaral, KM; Costi, C; da Fré, NN; da Silva, CM; Fiegenbaum, M; Grandi, T; Niel, C; Picon, PD; Rossetti, ML1
Ahmed, A; Doss, W; Saad, Y; Saleh, DA1
Andreone, P; Brandao-Mello, CE; Craxi, A; Di Bisceglie, AM; Freilich, B; Hooper, G; Jensen, DM; Marcellin, P; Messinger, D; Olveira Martín, A; Rajender Reddy, K; Tatsch, F; Teuber, G; Wat, C1
Ahn, SM; Byun, KS; Choi, DJ; Jung, YK; Kim, JH; Kim, JW; Kim, YS; Kwon, OS; Park, SJ; Yang, JW; Yeon, JE1
Heller, T; Tana, MM1
Cacoub, P; Saadoun, D; Terrier, B1
Feld, JJ; Ghany, MG; Hara, K; Haynes-Williams, V; Heller, T; Hoofnagle, JH; Kleiner, DE; Koh, C; Liang, TJ; Rotman, Y; Zhao, X1
Bani-Sadr, F; Carrieri, P; Dabis, F; Loko, MA; Marchou, B; Morlat, P; Neau, D; Pambrun, E; Salmon, D; Winnock, M1
Eshach Adiv, O; Kori, M; Rosen, I; Shaoul, R; Yerushalmi, B; Zion, N1
Abd-Eldaem, AA; Ahmad, YK; Azmy, MK; Badr, GA; El-Dahshan, T; Houssein, MA1
Al-Ahdal, MN; Al-Ashgar, HI; Al-Qahtani, A; Al-Thawadi, S; Helmy, A; Khalaf, N; Khan, MQ; Sanai, FM1
Cioe, PA; Friedmann, PD; Promrat, K; Stein, MD1
Mensa, FJ; Zeuzem, S1
Antón Ródenas, G; Martínez Pascual, C; Ortiz Sánchez, ML; Pons Miñano, JA1
Grudinin, M; Komissarov, A; Kozlov, V; Samusenko, I; Stelmakh, V1
Abdo, AA; Al-hamoudi, W; Alfaleh, A; Alfaleh, FZ; Ali, SM; Alswat, K; Bedewi, MA; El-sharkawy, M; Hadad, Q; Helmy, A; Omar, M; Shalaby, A1
Angulo, J; Biel, F; Labbé, P; López-Lastra, M; Miquel, JF; Pavez, C; Pino, K; Soza, A1
Andreone, P; Brown, KK; Cammarata, S; Chuang, WL; Feutren, G; Flisiak, R; Foster, GR; George, J; Gould, M; Jacobson, IM; Komolmit, P; Lee, CM; Messina, I; Pianko, S; Piratvisuth, T; Rasenack, J; Sarin, SK; Shah, S; Sola, R; Sood, A; Tanwandee, T; Thongsawat, S; Yin, Y; Zeuzem, S1
Anzai, K; Eguchi, Y; Hirai, M; Isoda, H; Iwane, S; Izumi, N; Kawaguchi, Y; Kimura, S; Kurose, K; Mizuta, T; Nakashita, S; Oeda, S; Ozaki, I; Takahashi, H1
Alshuth, U; Berger, F; Heyne, R; Hueppe, D; John, C; Mauss, S; Moog, G; Pape, S; Pfeiffer-Vornkahl, H; Schober, A1
Boonstra, A; de Bruijne, J; de Knegt, RJ; Hotho, DM; Janssen, HL; Reesink, HW; Spaan, M; Treitel, MA1
Arnholm, B; Björkman, P; Hellstrand, K; Lagging, M; Lindh, M; Nilsson, S; Norkrans, G; Wahlberg, T; Wallmark, E; Weiland, O; Wejstål, R; Westin, J; Widell, A1
Andreoletti, M; Borroni, G; Cazzaniga, M; Ceriani, R; Guerzoni, P; Omazzi, B; Pich, MG; Prada, A; Salerno, F; Spinzi, G; Terreni, N1
Colle, I; Degre, D; Moreno, C; Van Vlierberghe, H1
Jia, JD; Rakhda, MI; Wang, TI; Zhao, XY1
Cornberg, M; Manns, MP2
Abrams, GA; Afdhal, NH; Albanis, E; Bernstein, DE; Berrey, MM; Bzowej, NH; Darling, JM; Dejesus, E; Dieterich, DT; Freilich, B; Hassanein, T; Hindes, R; Hyland, RH; Jacobson, IM; Jensen, D; Kowdley, KV; Lalezari, JP; Lawitz, E; Lin, M; Mader, M; Mo, H; Muir, A; Nelson, DR; Poordad, FF; Reddy, KR; Rodriguez-Torres, M; Sheikh, AM; Sulkowski, MS; Symonds, WT1
Burney, T; Dusheiko, G2
Afdhal, N; Albanis, E; An, D; Anderson, JK; Bernstein, DE; Berrey, MM; Crespo, I; Davis, MN; DeMicco, M; Dvory-Sobol, H; Gordon, SC; Hassanein, T; Hindes, RG; Hyland, RH; Jacobson, IM; Kowdley, KV; Lawitz, E; Nelson, DR; Symonds, WT; Vierling, JM1
Aghemo, A; Colombo, M; Cremonesi, E; Degasperi, E; Mantovani, S; Mele, D; Mondelli, MU; Oliviero, B; Rumi, MG; Tinelli, C; Varchetta, S1
Jia, Z; Li, D; Liang, HJ; Ma, L; Wei, X; Yang, D1
Asselah, T; Böcher, WO; Bourlière, M; Bronowicki, JP; Datsenko, Y; Kukolj, G; Larrey, D; Mauss, S; Nehmiz, G; Pawlotsky, JM; Pol, S; Scherer, J; Shafran, SD; Steinmann, GG; Stern, JO; Sulkowski, MS1
Carifa, A; Eley, T; Falk, P; Fridell, R; Gardiner, D; Hernandez, D; McPhee, F; Monikowski, A; Ueland, J; Wang, C; Yu, F; Zhou, N1
Chan, CH; Gilliver, RS; Hansen, RD; Jones, BE1
Coffin, CS; Fritzler, MJ; Myers, RP; Stinton, LM1
Fernández-Rodríguez, A; Jiménez-Sousa, MÁ; Resino, S1
Al-Shamma, S; Allen, H; Hovell, C; Hydes, T; Sharer, NM; Williams, EJ1
Bruha, R; Dusek, L; Kreidlova, M; Marecek, Z; Petrtyl, J; Urbanek, P1
Fischer, L; Logge, C; Nashan, B; Sterneck, M; Vettorazzi, E1
Cao, H; Gao, ZL; Guo, XY; Xie, DY; Xie, JQ; Zhang, XH; Zhao, ZX1
Backus, LI; Belperio, PS; Cheung, RC; Hwang, EW; Mole, LA; Thomas, IC1
Akin, MS; Atabay, A; Dogan, UB; Yalaki, S1
Cacopardo, B; Nunnari, G; Pinzone, MR1
Hickman, M; Martin, NK; Miners, A; Vickerman, P1
Mazana, JS1
Bota, S; Neghină, AM; Popescu, A; Şirli, R; Sporea, I; Străin, M1
Berg, T; Däumer, M; Dietz, J; Fitting, D; Füller, C; Herrmann, E; Lengauer, T; Mihm, U; Sarrazin, C; Schelhorn, SE; Susser, S; Teuber, G; Wedemeyer, H; Welker, MW; Zeuzem, S1
Aboalam, H; Ahmed, WH; Eldin, AS; Furusyo, N; Hayashi, J; Murata, M; Ogawa, E; Zaky, S1
Arama, V; Popescu, C; Popescu, GA1
Abdel-Rahman, M; El-Akel, W; El-Beshlawy, M; El-Raziky, M; Esmat, G; Saad, Y; Said, M; Zayed, N1
Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kawano, A; Kotoh, K; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K; Tanabe, Y4
Aizawa, N; Enomoto, H; Higuchi, K; Hongo, Y; Jyomura, H; Kim, SR; Kudo, M; Nishida, N; Nishiguchi, S; Nishikawa, H; Okazaki, K; Osaki, Y; Seki, T; Tsuda, Y1
Cheng, J; Gao, YJ; Li, MH; Lu, Y; Qiu, GH; Shen, G; Wu, Y; Xie, Y; Xu, D; Yang, M; Zhang, L; Zhang, YL; Zhuang, LW1
Anty, R; Cardot-Leccia, N; Lacour, JP; Ortonne, JP; Passeron, T; Pop, S; Tran, A; Trucchi, R; Tsilika, K1
Cahn, P; Gun, A; Laufer, N; Ojeda, D; Quarleri, J; Sede, M1
Chuang, WL; Dai, CY; Yu, ML1
Angus, P; Arasteh, K; Asselah, T; Böcher, WO; Bronowicki, JP; Gane, E; Heim, M; Kukolj, G; Larrey, D; Lohse, AW; Mensa, FJ; Müllhaupt, B; Nehmiz, G; Pol, S; Roberts, S; Schuchmann, M; Stern, JO; Zarski, JP; Zeuzem, S; Zoulim, F1
Chen, SC; Chuang, WL; Dai, CY; Hsieh, MH; Hsieh, MY; Huang, CF; Huang, JF; Juo, SH; Lin, YC; Lin, ZY; Wang, LY; Yeh, ML; Yu, ML1
Benito, JM; Berenguer, J; Cosín, J; Fernández-Rodríguez, A; García-Álvarez, M; Guzmán-Fulgencio, M; Jiménez-Sousa, MA; López, JC; Miralles, P; Rallón, N; Resino, S; Restrepo, C; Soriano, V2
Alemán, R; Castellano, G; García-Samaniego, J; González-Portela, C; Granados, R; Jorge Juan, M; Pérez, R; Romero, M; Suárez, D1
Geng, JX; Zhang, JM; Zhang, Q1
Capuron, L; de la Torre, R; Giménez, D; Gratacòs, M; Langohr, K; Martín-Santos, R; Moreno-España, J; Navinés, R; Solà, R; Udina, M1
Bruggmann, P; Brunner, N; Falcato, L; Rosemann, T; Senn, O1
Casado, JL; Dronda, F; Hermida, JM; Moreno, A; Moreno, S; Navas, E; Pérez-Elías, MJ; Quereda, C; Royuela, A; Serrano-Villar, S1
Boonstra, A; De Knegt, RJ; Groothuismink, ZM; Janssen, HL; Koning, L; Roomer, R; Spaan, M1
de Jong, YP; Jacobson, IM; Jesudian, AB1
Dixit, V; Fabrizi, F; Messa, P1
Akuta, N; Arase, Y; Hara, T; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Seko, Y; Sezaki, H; Suzuki, F; Suzuki, Y1
Aoki, Y; Hiramine, S; Imamura, M; Ito, K; Kanto, T; Kimura, T; Kirikae, I; Korenaga, M; Masaki, N; Matsui, T; Mizokami, M; Murata, K; Saito, H; Sugiyama, M; Yoshio, S1
Jung, YK; Kim, JH1
Byun, KS; Han, KH; Heo, NY; Kim, KM; Lee, HC; Lee, KS; Lee, YS; Lim, YS; Paik, SW; Suh, DJ; Yoon, SK1
Aguilera, V; Berenguer, M; Vinaixa, C1
Apica, B; Chen, EY; Czul, F; Dubin, P; Lee, WM; Martin, P; Sclair, SN1
Chen, Y; Han, Q; Li, N; Liu, X; Liu, Z; Lv, Y; Yang, C; Zeng, X; Zhang, P; Zhu, Q1
Bazin-Karra, D; Blanc, F; Cacoub, P; Cazorla, C; Decaux, O; Karras, A; Lambotte, O; Longuet, M; Musset, L; Pialoux, G; Pol, S; Resche Rigon, M; Saadoun, D; Thibault, V; Vittecoq, D; Ziza, JM1
Abeleira, M; Diz, P; Eirea, M; Feijoo, J; Limeres, J; Ocampo, A; Ramos, I1
Drenth, JP2
Arterburn, S; Brainard, D; Davis, MN; Gane, EJ; Gordon, SC; Hassanein, T; Hyland, RH; Jacobson, IM; Jiang, D; Kayali, Z; Kowdley, KV; Lawitz, E; Mangia, A; McHutchison, JG; McNally, J; Nyberg, L; Reddy, KR; Rodriguez-Torres, M; Schultz, M; Sheikh, AM; Subramanian, GM; Symonds, WT; Wyles, D; Younossi, Z1
Al-Assi, MT; An, D; Bennett, M; Brainard, D; Everson, G; Feld, J; Gordon, SC; Jacobson, IM; Kowdley, KV; Lawitz, E; Lin, M; McHutchison, JG; McNally, J; Nelson, DR; Patel, K; Pianko, S; Rodriguez-Torres, M; Schiff, E; Shiffman, ML; Subramanian, GM; Sulkowski, MS; Symonds, WT; Yoshida, EM1
Idrees, M; Rehman, HU; Ullah, S1
Chen, CL; Chen, DS; Chen, PJ; Kao, JH; Liu, CH; Liu, CJ; Su, TH; Ting, TT; Tseng, TC1
Beckstead, S; Beking, D; Finch, S; Knorr, T; Lynch, C; MacKenzie, M; Mayer, D; Melles, B; Newman, AI; Shore, R1
Inglot, M; Malyszczak, K; Pawlowski, T; Radkowski, M; Szymczak, A; Zalewska, M1
Brass, CA; Bronowicki, JP; Chhatwal, J; El Khoury, AC; Elbasha, EH; Ferrante, SA; Poordad, F1
Gómez, S; Marcoval, J; Martín, C; Notario, J1
Aghemo, A; Colombo, M; Degasperi, E; Lampertico, P; Viganò, M1
Cheong, JY; Cho, SW; Han, S; Hwang, SG; Jang, JW; Jeong, SH; Jin, YJ; Kim, JH; Kim, YS; Lee, CK; Lee, JI; Lee, JS; Lee, JW; Park, CK; Park, SH; Park, YM; Rim, KS; Sohn, JH; Yang, JM; Yim, HJ1
Chang, B; Li, B; Sun, Y; Teng, G; Zhang, W; Zhao, J1
Bojovic, K; Delic, D; Jevtovic, DJ; Katanic, N; Milosevic, I; Pesic, I; Simonovic, J; Svirtlih, N1
Fontana, RJ; Rangnekar, AS1
Beumont, M; Ceulemans, H; De Meyer, S; Dierynck, I; Foster, GR; Ghys, A; Lin, TI; Picchio, G; Van Baelen, B1
Abbassi, MM; Ali-Eldin, ZA; Ibrahim, WA; Mohamed, AA; Sabry, NA1
Hsu, YA; Hung, DZ; Liao, WL; Lim, YP; Lin, CY; Peng, CY; Tien, N; Tsai, FJ; Tsai, KH; Wan, L1
Cooper, CL; Kelly, EM1
Baron, J; Biedroń-Machura, M; Błońska-Fajfrowska, B; Musialik, J; Pierzchała, W; Sozańska, E; Zbroszczyk, M1
Arena, U; Corti, G; Laffi, G; Leoncini, L; Marra, F; Milani, S; Monti, M; Pellegrini, E; Pinzani, M; Renzo, S; Stasi, C; Triboli, E; Zignego, AL1
Durantel, D; Levrero, M; Testoni, B1
Schmutz, JL; Trechot, P1
An, CM; Dai, EH; Jia, YH; Kong, L; Li, YS; Nan, YM; Su, SS; Sun, DX; Zhang, YG; Zhao, SX; Zheng, HW1
Gong, WJ; Ma, XH; Sun, YX; Teng, ZL; Zhang, SQ1
Coton, T; Diallo, I1
Akyuz, F; Badur, S; Baran, B; Demir, K; Ermis, F; Gulluoglu, M; Kaymakoglu, S; Simsek, BP; Uyanikoglu, A1
Christian, A; Gallimore, AM; Godkin, A; Hills, RK; Jones, E; Pembroke, T; Wang, EC1
Bukh, J; Carlsen, TH; Christensen, PB; Jensen, TB; Krarup, H; Laursen, AL; Pedersen, J; Schønning, K; Weis, N1
Abergel, A; Alric, L; Attali, P; Barthe, Y; Bernard, PH; Bourlière, M; Bronowicki, JP; Cacoub, P; Canva, V; Carrat, F; Causse, X; Dao, T; de Ledinghen, V; Di Martino, V; Dorival, C; Feray, C; Fontaine, H; Grando-Lemaire, V; Guyader, D; Hézode, C; Hillon, P; Larrey, D; Loustaud-Ratti, V; Lucidarme, D; Marcellin, P; Métivier, S; Pawlotsky, JM; Petrov-Sanchez, V; Pol, S; Poynard, T; Raabe, JJ; Riachi, G; Rosa, I; Samuel, D; Serfaty, L; Tran, A; Zarski, JP; Zoulim, F1
Hisanaga, Y; Kanamori, A; Kiriyama, S; Kitabatake, S; Kumada, T; Murakami, Y; Tada, T; Tanikawa, M; Toyoda, H1
Abdel-Rahman, M; El Raziky, M; El-Akel, W; El-Sayed, M; Elsharkawy, A; Esmat, G; Ghoneim, H; Khattab, H1
Chen, PJ; Chu, YT; Kuo, RN; Lai, MS; Liu, CJ; Shau, WY1
Aravena, E; González, MZ; Iturriaga, H; Pinto, A; Roblero, JP1
Akin, MS; Dogan, UB; Yalaki, S2
Eiraku, K; Furusyo, N; Harada, Y; Hayashi, J; Kainuma, M; Mitsumoto, F; Murata, M; Ogawa, E; Okada, K; Shimizu, M; Takayama, K; Toyoda, K1
Perelson, AS; Rong, L1
Adda, N; Adiwijaya, B; Bsharat, M; Dieterich, DT; Garg, V; Gharakhanian, S; Girard, PM; Henshaw, J; Mahnke, L; McCallister, S; Rockstroh, JK; Rubin, RA; Sherman, KE; Soriano, V; Sulkowski, MS1
Bukatman, R; Gordon, P; Kramer, D; Krug, P; Mermelstein, P1
Auriemma, F; Caporaso, N; Donnarumma, L; Gaeta, L; Gentile, I; Granata, R; Guarino, M; Loperto, I; Morisco, F; Stroffolini, T1
Hagiwara, H; Hayashi, N; Hijioka, T; Hiramatsu, N; Iio, S; Imai, Y; Inada, M; Inoue, A; Inui, Y; Kanto, T; Kasahara, A; Mita, E; Miyagi, T; Miyazaki, M; Oshita, M; Oze, T; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yoshida, Y; Yoshihara, H1
Bajaj, JS; Forton, DM1
Funk, EK; Heytens, L; Kohli, A; Kottilil, S; Kwan, R; Masur, H; Nelson, A; Polis, MA; Shaffer, A; Shivakumar, B; Sneller, M1
Chan, MW; Chou, JL; Huang, HB; Tseng, CW; Tseng, KC; Wu, SF1
Asch, SM; Chan, K; Clark, JA; Gifford, AL; Groessl, EJ; Hanchate, AD; Ho, SB; Lai, MN; Wong, JB1
Geier, A; Rau, M1
Calcagno, A; Cusato, J; D'Avolio, A; Di Perri, G1
Asselah, T6
Hsu, SH; Wang, SN; Yeh, ML1
Albrecht, JK; Bacon, BR; Brass, CA; Bronowicki, JP; Burroughs, MH; Davis, M; Deng, W; Dutko, FJ; Esteban, R; Gordon, SC; Lawitz, EJ; Poordad, F; Rajender Reddy, K; Sniukiene, V; Sulkowski, MS; Yoshida, EM1
Beinhardt, S; Dulic, M; Ferenci, P; Gschwantler, M; Hofer, H; Holzmann, H; Laferl, H; Maieron, A; Rutter, K; Scherzer, TM; Stättermayer, AF; Steindl-Munda, P; Strassl, R1
Abbas, SM; El-Feky, HM; Hegab, MF; Lashin, AH; Metwally, MA; Shaheen, YA1
Barreiro, P; Camacho, A; Caruz, A; Cifuentes, C; Di Lello, FA; García-Rey, S; Macias, J; Neukam, K; Pineda, JA; Rallon, NI; Rivero, A; Rivero-Juarez, A; Soriano, V1
Abdelli, N; Ben Abdallah, H; Bizid, S; Bouali, R; Kilani, I; Mohamed, G1
Akahane, T; Igarashi, T; Ishii, M; Iwata, T; Kakazu, E; Kato, T; Kimura, O; Kisara, N; Kobayashi, T; Kondo, Y; Miura, M; Miyazaki, Y; Morosawa, T; Nakayama, H; Ninomiya, M; Obara, N; Sasaki, K; Shimosegawa, T; Ueno, Y1
Cariti, G; Ceretto, S; Ciancio, A; Ciccone, G; Colletta, C; De Blasi, T; Giordanino, C; Grasso, A; Marenco, S; Mazzucco, D; Picciotto, A; Pirisi, M; Rizzetto, M; Sacco, M; Saracco, G; Simondi, D; Smedile, A; Smirne, C; Traverso, A1
Sharma, P1
Airoldi, A; Belli, LS; Bitetto, D; Burra, P; Cmet, S; Colpanij, M; Cussigh, A; De Feo, T; De Martin, E; Donato, MF; Fabris, C; Fagiuoli, S; Falleti, E; Gambato, M; Mantovani, M; Pasulo, L; Piccolo, G; Rigamonti, C; Toniutto, P; Viganò, R1
Aggarwal, J; Bayliss, M; Donepudi, M; Goss, T; Martin, M; Vera-Llonch, M; Younossi, Z1
Glavaš, S; Gornjaković, S; Mehmedović, A; Mesihović, R; Papović, V; Saray, A; Vanis, N; Vukobrat-Bijedić, Z1
Chan, JM; Fung, J; Lai, CL; Liu, K; Seto, WK; Tsang, OT; Wong, DK; Yuen, MF1
Aoki, K; Kumada, H; Ohtsuki, M; Sakurai, Y; Sueki, H; Torii, H; Yamada, I1
Belleli, D; Davis, AK; Kemp, W; McCarthy, P; Northcott, MJ; Ong, WL; Street, A; Tran, H; Walsh, M1
Baldo, V; Carlotto, A; Del Bianco, T; Fabris, P; Floreani, A; Giordani, MT; Grasso, A; Malfatti, F; Miotti, MA; Tramarin, A1
Annicchiarico, EB; D'Aversa, F; Gasbarrini, A; Pompili, M; Ponziani, FR; Siciliano, M1
Chang, KC; Chen, TC; Chien, YS; Hu, TH; Hung, CH; Lee, CT; Lin, MT; Shen, CH; Tsai, MC; Tseng, PL; Yen, YH1
Ahlén, G; Diepolder, H; Fons, M; Frelin, L; Jung, MC; Levander, S; Mathiesen, I; Sällberg, M; Sardesai, NY; Vahlne, A; Weiland, O1
Barnard, RJ; Cheney, CA; Dinubile, MJ; Graham, DJ; Hazuda, DJ; Himmelberger, AL; Hwang, PM; McHale, CM; Mobashery, N; Newhard, W; Nickle, D; Reeves, JD; Rivera, AA; Strizki, J1
Naggie, S; Osinusi, A1
Cooper, C; Fainboim, H; Greaves, W; Howe, AY; Mak, C; Mallolas, J; Pol, S; Rivero, A; Sklar, P; Slim, J; Sulkowski, M; Thompson, S; Wahl, J; Wenning, L1
Abe, H; Aida, Y; Aizawa, Y; Ika, M; Ishiguro, H; Itagaki, M; Kato, K; Miyazaki, T; Seki, N; Shimada, N; Sutoh, S; Tsubota, A; Yoshizawa, K1
Akuta, N; Arase, Y; Fukushima, T; Hara, T; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y1
Taylor, DR1
Christensen, P; Dalgard, O; Färkkilä, M; Hellstrand, K; Lagging, M; Langeland, N; Lindh, M; Norkrans, G; Rauning Buhl, M; Rembeck, K; Westin, J1
Benhamou, Y; Beumont, M; De Backer, K; De Meyer, S; Ghys, A; Lebray, P; Luo, D; Moussalli, J; Picchio, GR; Ratziu, V1
Kanda, T; Miyamura, T; Nakamoto, S; Nakamura, M; Wu, S; Yokosuka, O1
Barreiro, P; de Mendoza, C; Fernandez-Montero, JV; Labarga, P; Plaza, Z; Poveda, E; Soriano, V; Treviño, A; Vispo, E1
Abrams, GA; Ahmad, A; Bourlière, M; Bronowicki, JP; Cohen, D; Eley, T; Fried, MW; He, B; Hézode, C; Hindes, R; Hughes, E; Larrey, D; Martorell, CT; Massoud, O; McPhee, F; Mendez, P; Morris, DW; Pol, S; Ratziu, V; Reddy, KR; Reilly, B; Rustgi, VK; Thuluvath, PJ; Younes, Z1
Albrecht, JK; Bacon, B; Bárcena, R; Brass, CA; Deng, W; Esteban-Mur, R; Gordon, SC; Hadziyannis, SJ; Häussinger, D; Jacobson, IM; Manns, MP; Marcellin, P; Morgan, TR; Norkrans, G; Pedicone, LD; Pockros, PJ; Poynard, T; Schiff, ER; Schmidt, WN; Shaikh, OS; Shiffman, ML; Smith, CI1
Andrei, A; Füller, C; Köberle, V; Kronenberger, B; Perner, D; Piiper, A; Sarrazin, C; Susser, S; Waidmann, O; Zeuzem, S1
Bonner, JE; Esserman, DA; Evon, DM; Fried, MW; Golin, CE; Rao, T1
George, PM; Mitchell, JA1
Bregigeon, S; Colson, P; Poizot-Martin, I; Solas, C; Tamalet, C; Tourres, C1
Hsiao, CC; Hu, TH; Hung, CH; Kee, KM; Lee, CM; Lu, SN; Wang, JC; Wang, JH; Yen, YH1
Benito, JM; Berenguer, J; Cosín, J; Fernández-Rodríguez, A; García-Álvarez, M; Guzmán-Fulgencio, M; Jiménez-Sousa, MA; López, JC; Medrano, J; Miralles, P; Rallón, N; Resino, S; Soriano, V1
Abdel-Aziz, AO; Alam El-Din, HM; Bahnassy, AA; Eldahshan, DH; Mohamed, WS; Shousha, HI; Zayed, N; Zekri, AR1
Borovicka, J; Gerlach, TJ; Helbling, B; Moradpour, D; Pache, I; Stickel, F; Worni, M1
Amano, K; Arinaga, T; Fujimoto, Y; Ide, T; Ishii, K; Kuhara, K; Kumashiro, R; Kuwahara, R; Miyajima, I; Morita, Y; Murashima, S; Ogata, K; Sakai, K; Sata, M; Shirachi, M; Uchimura, N1
Bell, S; Holmes, J; Thompson, A1
Chen, DS; Chen, MY; Chen, PJ; Chen, TC; Kao, JH; Liu, CH; Liu, CJ; Su, TH1
Baumgarten, A; Boesecke, C; Grzeszczuk, A; Mandorfer, M; Meyer-Olson, D; Neukam, K; Payer, BA; Peck-Radosavljevic, M; Pineda, JA; Puoti, M; Reiberger, T; Rivero, A; Rockstroh, JK; Trauner, M; Zangerle, R1
Kang, EJ; Kweon, YO; Lee, HS; Lee, YL; Park, HW; Park, SY; Tak, WY; Yang, HM1
Brown, J; Paladino, JA; Turner, SJ1
Ballard, C; Cachay, ER; Colwell, B; Hill, L; Lin, JC; Mathews, WC; Torriani, FJ; Wyles, DL1
Kumada, T; Murakami, Y; Tada, T; Toyoda, H1
Chen, JY; Chen, WT; Huang, CH; Huang, CW; Jeng, WJ; Lin, CY; Sheen, IS1
Beinhardt, S; Datz, C; Ferenci, P; Hofer, H; Laferl, H; Maieron, A; Rutter, K; Scherzer, TM; Schwarzer, R; Stättermayer, AF; Stauber, R; Steindl-Munda, P; Strasser, M1
Han, H; Hoofnagle, JH; Liang, TJ; Noureddin, M; Park, YJ; Rotman, Y; Witthaus, M1
Kawada, A; Oiso, N; Sato, M1
Gwinn, M; Hu, DJ; Zhang, L1
Asahina, Y; Enomoto, N; Hosokawa, T; Itakura, J; Izumi, N; Kakinuma, S; Kurosaki, M; Muraoka, M; Nakagawa, M; Nakanishi, H; Nishimura, T; Suzuki, Y; Takahashi, Y; Tamaki, N; Tsuchiya, K; Ueda, K; Watanabe, M; Yasui, Y1
Akuta, N; Hara, T; Hosaka, T; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y1
Ahmed, Wu; Alam, SE; Arif, A; Sajjad, SF; Waquar, J1
Berenguer, M; Calleja, JL; Molina, E; Romero-Gómez, M1
Battegay, M; Beniowski, M; Grint, D; Jevtovic, D; Kirk, O; Lundgren, JD; Mocroft, A; Peters, L; Pradier, C; Rockstroh, JK; Schwarze-Zander, C; Soriano, V1
Ikeda, F; Iwasaki, Y; Matsushita, H; Miyake, Y; Moritou, Y; Nanba, S; Nouso, K; Onishi, H; Seki, H; Takaki, A; Takeuchi, Y; Yamamoto, K; Yasunaka, T1
Beinhardt, S; Ferenci, P; Hofer, H; Rutter, K; Scherzer, TM; Stättermayer, AF; Steindl-Munda, P; Strasser, M; Trauner, M; Wrba, F1
Ehleben, C; Pearlman, BL3
Amendola Pires, MM; Barcaui, HS; Barroso, PF; Brandão-Mello, CE; May, SB; Tavares, GC1
Berki, T; Halasz, M; Hegedus, G; Hunyady, B; Miseta, A; Palinkas, L; Par, A; Par, G; Szekeres-Bartho, J; Szereday, L; Vincze, A1
El Raziky, M; Nassar, YH; Nour, ZA; Shaker, OG1
Deraz, DM; Elbaz, TM; Shehab, HM1
Banerjee, S; Gakkhar, S; Keval, R1
Alraies, MC; Alraiyes, AH; Alsabbagh, ME; Eisa, N1
Abbasi, A; Bhutto, AR; Butt, N; Dhillo, AK; Munir, SM1
Beumont-Mauviel, M; Buti, M; De Smedt, G; Dore, GJ; Ferenci, P; Flisiak, R; Fried, MW; Gilles, L; Jacobson, I; Lenz, O; Manns, M; Marcellin, P; Nikitin, I; Peeters, M; Poordad, F; Scott, J; Sekar, V; Sherman, M; Zeuzem, S1
Amanzada, A; Mihm, S; Ramadori, G1
Everson, GT; Reddy, KR1
Blum, HE3
Everhart, JE; Wright, E1
Berki, T; Fehér, J; Fráter, E; Gervain, J; Haragh, A; Hunyady, B; Kisfali, P; Lengyel, G; Melegh, B; Nemes, Z; Pálinkás, L; Papp, M; Pár, A; Pár, G; Péterfi, Z; Schuller, J; Szalay, F; Szinku, Z; Tornai, I; Tusnádi, A; Varga, M; Várszegi, D; Vincze, A1
Cai, QX; Hong, CX; Lin, CS; Zhang, XH; Zhao, ZX1
Abe, H; Aida, Y; Aizawa, Y; Ika, M; Ishiguro, H; Shimada, N; Tsubota, A; Yoshizawa, K1
Brochot, E; Duverlie, G; Guillemard, C; Mathurin, P; Nguyen-Khac, E; Plantier, JC; Riachi, G; Vabret, A1
Chang, CY; Chang, SY; Chen, CY; Hung, DZ; Liao, WL; Lim, YP; Peng, CY; Tien, N; Tsai, FJ; Wan, L1
Aghemo, A; Colombo, M3
Ahmed, DS; Barua, R; Chowdhury, MS; Ishaque, SM; Masud, H; Parveen, S; Rahman, MA; Rahman, MZ1
Afdhal, NH; Albrecht, JK; Alves, K; Bacon, BR; Balart, L; Brass, CA; Brown, RS; Burroughs, MH; Calleja, JL; Craxi, A; Deng, W; Dutko, FJ; Flamm, SL; Hézode, C; Koury, KJ; Kowdley, KV; Lawitz, E; Lee, SS; Morgan, TR; Nelson, DR; Nyberg, L; Pedicone, LD; Poordad, F; Reddy, KR; Rossaro, L; Sulkowski, MS; Wahl, J; Wedemeyer, H; Zeuzem, S1
Aziz, S; Mirza, T; Sohail, S1
Boglione, L; Cariti, G; Caviglia, GP; Ciancio, A; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G; Rizzetto, M; Smedile, A; Strona, S; Troshina, G1
Dultz, G; Friedrich-Rust, M; Herrmann, E; Hofmann, WP; Kronenberger, B; Sarrazin, C; Seelhof, M; Teuber, G; Vermehren, J; von Wagner, M; Welker, MW; Zeuzem, S1
Aghemo, A; Lampertico, P1
Han, J; Hoop, RS; Jacobson, IM; Korner, EJ; Lafleur, J; Martin, P; Pandya, P; Talal, AH1
Mishra, A; Younossi, Z1
Ferenci, P; Rutter, K1
Cheng, G; Corsa, AC; Delaney, WE; Kim, CU; Krawczyk, S; Mo, H; Pakdaman, R; Peng, B; Qi, X; Robinson, M; Shen, M; Sheng, XC; Tay, C; Tian, Y; Wang, Y; Yang, C; Yang, H1
Halota, W; Pawłowska, M; Pilarczyk, M; Wiśniewska-Ligier, M; Woźniakowska-Gęsicka, T1
Andréjak, M; Bodeau, S; Brochot, E; Castelain, S; Durand-Maugard, C; Duverlie, G; François, C; Helle, F; Lemaire-Hurtel, AS; Nguyen-Khac, E1
Gane, EJ; Lawitz, E1
Hsu, CS1
Kuboki, M; Nishiguchi, S; Omata, M; Sakai, Y; Sakamoto, W; Steinmann, G; Tsuda, Y; Tsunematsu, S; Urano, Y1
Arakawa, Y; Higuchi, T; Matsumura, H; Moriyama, M; Nakamura, H; Nirei, K; Ogawa, M; Tanaka, N1
Arnaud, C; Berthillon, P; Chemin, I; Maynard, M; Petit, MA; Pradat, P; Spaziante, M; Taliani, G; Trépo, C1
Igarashi, K; Katsumi, T; Nishise, Y; Okumoto, K; Saito, K; Saito, T; Sato, C; Shao, L; Soga, T; Sugimoto, M; Tomita, K; Tomita, M; Ueno, Y; Watanabe, H1
Ahn, SM; Choi, DJ; Jung, YK; Kim, JH; Kim, JS; Kim, YS; Kwon, OS1
Gong, GZ; Jiang, YF; Liu, D; Liu, SF; Peng, ML; Xiao, XQ; Zhang, M1
Abate, ML; Andriulli, A; Andriulli, N; Angelico, M; Barone, M; Brancaccio, G; Calvaruso, V; Cozzolongo, R; Craxi, A; D'Andrea, G; Di Marco, V; Fasano, M; Fattovich, G; Felder, M; Gaeta, GB; Gatti, P; Gioffreda, D; Ippolito, AM; Margaglione, M; Mazzella, G; Milella, M; Morisco, F; Santantonio, T; Smedile, A; Tundo, P; Valvano, MR1
Enomoto, M; Fujii, H; Hagihara, A; Hai, H; Kawada, N; Kawamura, E; Morikawa, H; Tamori, A; Tanaka, Y; Thuy, le TT; Uchida-Kobayashi, S1
Flisiak, R; Jaroszewicz, J; Lapinski, TW; Panasiuk, A; Parfieniuk-Kowerda, A; Rogalska-Plonska, M; Swiderska, M1
Blázquez-Pérez, A; Mar, J; San Miguel, R1
Arakawa, T; Hige, S; Karino, T; Kimura, M; Kuwata, Y; Nakajima, T; Ohmura, T; Ozeki, I; Sato, T; Toyota, J1
Gerken, G; Herzer, K; Jochum, C; Papadopoulos-Köhn, A; Paul, A; Timm, J1
Goto, S; Hayashi, N; Kato, M; Komada, Y; Seto, C1
Cao, YG; Hou, HR; Jin, X; Kang, Y; Liang, SQ; Liu, JP; Shang, J1
Cai, RT; Shen, L; Yang, YF; Zhang, YC; Zhao, W1
Tacke, F; Zimmermann, HW1
Lee, TH; Patel, K; Tillmann, HL1
Chen, LY; Lei, XZ; Li, YX; Liu, K; Lu, JJ; Ma, YJ; Tang, H; Yang, M; Yang, YJ1
Bianic, F; Cure, S; Curtis, S; Dusheiko, G; Gavart, S; Lee, S2
Baur, K; Cerny, A; Dufour, JF; Frei, P; Geier, A; Gerlach, T; Heim, M; Held, U; Kofmehl, R; Leucht, AK; Manser, CN; Mertens, J; Moradpour, D; Müllhaupt, B; Negro, F; Rau, M; Schmitt, J1
Cai, Z; Deng, H; Ji, F1
Anderson, RT; Baran, RW; Dietz, B; Erickson, P; Gooch, K; Revicki, DA1
Boucher, CA; Broekman, MM; Brouwer, JT; Burger, DM; de Knegt, RJ; Drenth, JP; Hoepelman, AI; Lamers, MH; Reesink, HW; van Hoek, B1
Arends, JE; Dutilh, JC1
Feigelstock, DA; Mihalik, KB1
Chiba, M; Dohmen, T; Goto, T; Kamada, K; Kanata, R; Minami, S; Miura, K; Ohnishi, H; Ohshima, S; Sakai, T; Sato, W; Shibuya, T; Sugimoto, Y1
Hu, KQ; Zhang, YY1
Bau, S; Ferguson, J; Saab, S; Zhou, K1
Karasawa, T; Saito, T; Soga, T; Sugimoto, M; Ueno, Y1
Armienta-Sarabia, R; Cordero-Pérez, P; Hernández-Gómez, ME; Malé-Velázquez, R; Marín-López, E; Muñoz-Espinosa, LE; Núñez-Camarena, Jde J; Olivera-Martínez, MA; Sánchez-Avila, JF; Torres-González, L1
Akiyama, MJ; Chan, SM; Hong, LK; Huddleston, L; Piotrowski, JI; Roytman, MM; Trujillo, R; Tsai, NC1
Galle, PR; Knapstein, J; Zimmermann, T1
Harrison, SA; Torres, DM1
Alsaran, K; Molhem, A; Sabry, A1
Pol, S2
Albrecht, JK; Brass, CA; Clark, PJ; Gordon, SC; Jazwinski, AB; Lawitz, EJ; Muir, AJ; Noviello, S; Pedicone, LD; Sulkowski, MS; Thompson, AJ1
Cabezas, J; Crespo, J; Luis Calleja, J; Selmo, J1
Forns, X; Solà, R1
Planas, R; Tural, C1
Macías, J; Rivero, A1
García, F; Poveda, E1
Pineda, JA1
Aizawa, N; Enomoto, H; Iijima, H; Ikeda, N; Imanishi, H; Iwata, K; Iwata, Y; Nishiguchi, S; Saito, M; Sakai, Y; Takashima, T; Tanaka, H1
Camacho, A; López-Cortés, LF; Marquez, M; Merino, D; Mira, JA; Pineda, JA; Rivero, A; Rivero-Juarez, A; Téllez, F1
Fabri, M; Kiralj, K; Mikić, SS; Preveden, T; Ruzić, M; Vukadinov, T1
Brahm, J; Torres, C; Venegas, M1
Aparicio, E; Clotet, B; Franco, S; Martinez, MA; Parera, M; Tural, C1
Agúndez, JA; Fernández-Pérez, C; García-Martín, E; Ladero, JM; Maestro, ML; Martínez, C; Ortega, L; Suárez, A; Vidaurreta, M1
Wang, P; Wang, X; Xu, DH; Yan, SS; Yin, J; Zhang, PJ1
Bichoupan, K; Dieterich, DT; Shankar, H1
Ashraf, J; Azam, S; Imran, M; Khalid, M; Khaliq, HM; Manzoor, S; Tariq, M1
Baklan, Z; Kotar, T; Lesnicar, G; Maticic, M; Meglic Volkar, J; Poljak, M; Prah, J; Rajter, M; Selic Kurincic, T1
Blotner, S; Brennan, BJ; Grippo, JF; Magnusson, MO; Martin, P; Nieforth, K; Solsky, J; Wang, K; Wat, C; Wilkins, JJ1
Inao, M; Mochida, S; Nakayama, N; Sugawara, K1
Cao, ZH; Chen, XY; Du, XF; Guo, DD; Liu, YL; Lu, JF; Ma, LN; Zhang, YH1
Chang, SC; Chung, YC; Hung, CT; Lee, HM; Li, SF; Pai, LW; Yang, SS1
Hézode, C4
Agarwal, K; Barnabas, A1
Eiraku, K; Furusyo, N; Harada, Y; Hayashi, J; Kainuma, M; Mitsumoto, F; Murata, M; Ogawa, E; Ohnishi, H; Okada, K; Shimizu, M; Takayama, K; Toyoda, K1
Abdou, MM; Kishk, RM; Mandour, MF; Matsuura, K; Nemr, NA; Ragheb, MM; Tanaka, Y; Watanabe, T1
Adkison, K; Cutrell, A; Elko-Simms, C; Gardner, S; Hamatake, R; Hong, Z; Rodriguez-Torres, M; Walker, J1
Faheem, S; Kazmi, SY; Khalid, SR; Tanveer, A1
Brulotte, N; Hahn, H; Lee, M1
Ahmed, QL; Ashraf, J; Ashraf, W; Aziz, H; Imran, M; Khalid, M; Manzoor, S; Tariq, M1
Genda, T; Hirano, K; Ichida, T; Iijima, K; Ishikawa, S; Kanemitsu, Y; Kikuchi, T; Narita, Y; Sato, S; Tsuzura, H; Wada, R1
Albrecht, JK; Bacon, B; Balart, L; Bourliere, M; Brass, CA; Bronowicki, JP; Bruno, S; Burroughs, M; Davis, MN; Felizarta, F; Helmond, FA; Kwo, P; Manns, MP; McCone, J; Pedicone, LD; Poordad, F; Reddy, KR; Rossaro, L; Schiff, E; Shiffman, ML; Sings, HL; Sulkowski, MS; Vierling, JM1
Amanzada, A; Cameron, S; Goralczyk, AD1
Aghemo, A; Bitetto, D; Bruno, R; Caraceni, P; Ciancio, A; Coco, B; Marzioni, M; Petta, S; Rendina, M; Valenti, L1
Calleja, JL; Crespo, J; Diago, M; García-Samaniego, J; Planas, R; Romero-Gómez, M; Rubio-Terrés, C; Solà, R; Turnes, J; Ventayol, P1
Chen, XY; He, ZM; Hua, W; Ma, LN1
Barnard, RJ; Bhanja, S; Bourque, M; DiNubile, MJ; Gane, EJ; Hwang, PM; Lawitz, E; Mobashery, N; Rodriguez-Torres, M; Serfaty, L; Stoehr, A; Strizki, J; Zhou, A1
Galle, PR; Grambihler, A; Kittner, JM; Koch, S; Schattenberg, JM; Schuchmann, M; Thieringer, F; Weinmann, A; Weiss, NM; Wiltink, J; Zimmermann, T1
Afdhal, NH; Bakulin, I; Brainsky, A; Campbell, FM; Chen, PJ; Dusheiko, GM; Geib, J; Giannini, EG; Han, KH; Kamel, YM; Lawitz, E; Mohsin, A; Patwardhan, R; Poordad, F; Rodriguez-Torres, M; Rugina, S; Shiffman, ML; Tayyab, GU; Theodore, D; Vasey, SY1
Au, JS; Pockros, PJ1
Beste, LA; Green, PK; Ioannou, GN; Scott, JD; Yang, Y1
Ancuta, I; Aronsohn, A; Caruntu, F; Cheinquer, H; Coppola, C; Delic, D; Digiacomo, A; Dusheiko, GM; Korner, E; Lengyel, G; Marcellin, P; Orlandini, A; Pruthi, J; Schmitz, M; Silva, GF; Tallarico, L; Tatsch, F1
Pockros, PJ; You, DM1
Alessio, L; Capoluongo, N; Coppola, N; De Pascalis, S; Macera, M; Minichini, C; Paradiso, L; Pisaturo, M; Sagnelli, C; Sagnelli, E; Stanzione, M1
Lam, TT; Markov, PV; Pybus, OG; Rose, R1
Carpio-Pedroza, JC; Cruz-Rivera, M; Escobar-Gutiérrez, A; Fonseca-Coronado, S; Larouche, A; Martinez-Guarneros, A; Ruiz-Tovar, K; Soudeyns, H; Vazquez-Chacon, CA; Yamasaki, LH1
Castillo-Ferrando, JR; Espinosa, N; Gutierrez-Valencia, A; Lopez-Cortes, LF; Ruiz-Valderas, R; Torres-Cornejo, A; Viciana, P1
Chen, X; Guo, X; Ruan, P; Yang, G; Yuan, J; Zhang, M; Zhou, B1
Baronas, V; Haines, K; Klumpp, K; Le Pogam, S; Li, L; Nájera, I; Piso, K; So, SS; Tong, X; Yan, JM1
Grigorian, ÉG; Sarkisiants, NK1
Cao, Q; Ding, GQ; Kang, Y; Liu, JP; Shang, J; Wei, JF; Xiao, EH1
Deguchi, H; Higashi, K; Ichinose, M; Iguchi, M; Inoue, I; Kato, J; Kawaguchi, M; Kawashima, A; Maekita, T; Mori, Y; Moribata, K; Shingaki, N; Tamai, H; Tsukuda, H; Ueda, K1
Bon, D; Cai, SY; Haagmans, B; Herrmann, E; Kottilil, S; Lee, YJ; Lempicki, R; Masur, H; Nelson, A; Osinusi, A; Polis, M; Poonia, S; Shivakumar, B; Sneller, M; Wood, B1
Abdo, AA; Al-Ahdal, MN; Al-Ashgar, HI; Al-Qahtani, AA; Alhamlan, FS; Elhefnawi, M; Khalaf, NZ; Sanai, FM; Zaid, A1
Chang, KC; Chen, CH; Hu, TH; Huang, CM; Hung, CH; Kuo, YH; Lee, CM; Liang, CM; Lu, SN; Tsai, MC; Wang, JH; Yen, YH1
Bergmann, JF; de Bruijne, J; de Knegt, RJ; Hughes, E; Janssen, HL; Molenkamp, R; Rebers, SP; Reesink, HW; Schinkel, J; Thomas, XV; Treitel, MA; Weegink, CJ1
Ackefors, M; Gjertsen, H; Nyström, J; Sönnerborg, A; Weiland, O; Wernerson, A1
Alberti, A; Bruno, R; Calvaruso, V; Covolo, L; Craxì, A; Di Marco, V; Donato, F; Fattovich, G; Ferrari, C; Gaeta, GB; Levrero, M; Mondelli, M; Mussini, C; Puoti, M; Raimondo, G; Santantonio, T; Suter, F1
Benanti, F; Cacopardo, B; Nunnari, G; Pinzone, MR1
Chen, L; Chen, X; Liu, C; Lu, Y; Xu, Q; Yang, L; Yang, Z; Zhuang, L1
Mingote-Adán, C; Solís-Herruzo, JA; Solis-Muñoz, P1
Jiangrong, W; Jing, L; Yingying, L1
Berg, T; Beumont-Mauviel, M; De Smedt, G; Ferenci, P; Foster, GR; Fried, MW; Gane, E; Hezode, C; Hirschfield, GM; Jacobson, I; Lenz, O; Nikitin, I; Peeters, M; Pockros, PJ; Poordad, F; Scott, J; Sekar, V; Sinha, R; Zeuzem, S1
Bieber, B; Gillespie, B; Goodkin, DA; Jadoul, M; Robinson, BM1
Barreiro, P; de Mendoza, C; Fernández-Montero, JV; Labarga, P; Sánchez-Parra, C; Soriano, V; Treviño, A; Vispo, E1
Chayama, K; Karino, Y; Kawakami, Y; Kumada, H; Suzuki, F; Toyota, J1
Antinori, S; Cattaneo, D; Falvella, FS; Gervasoni, C; Magni, C; Milazzo, L; Peri, AM; Vidale, S1
Gong, G; Luo, H; Wang, H; Xiao, S; Zhou, H1
Abdurakhmanov, D; Colombo, M; DeMasi, R; Fernández, I; Ferreira, PA; Hill, A; Iraqi, W; Läuffer, JM; Lonjon-Domanec, I; Moreno, C; Strasser, SI; Streinu-Cercel, A; Urbanek, P; Verheyen, A; Wedemeyer, H1
Hou, XJ; Wang, J; Xu, JH; Yu, YY1
Beinhardt, S; Datz, C; Ferenci, P; Gschwantler, M; Hofer, H; Maieron, A; Rutter, K; Scherzer, TM; Stättermayer, AF; Stauber, R; Steindl-Munda, P; Strasser, M; Strassl, R; Trauner, M1
Aslam, S; Bremer, B; Cobb, B; Cornberg, M; Halfon, P; Luk, K; Maasoumy, B; Manns, MP; Wedemeyer, H1
Abdo, S; Attia, D; El Akel, W; El Raziky, M; Elsharkawy, A; Esmat, G; Khatab, H; Shaker, O1
Ding, X; Hyland, RH; Lawitz, E; McHutchison, JG; Membreno, FE; Mo, H; Pang, PS; Poordad, FF; Symonds, WT1
Doyle, JS; Hellard, ME1
Mahale, P; Okhuysen, PC; Torres, HA1
Abe-Sandes, K; Angelo, AL; Cavalcante, LN; Lemaire, DC; Lyra, AC; Lyra, LG; Machado, TB; Malta, F; Pinho, JR1
Rodríguez-Torres, M1
Anagnostou, O; Andreadis, I; Deutsch, M; Kalafateli, M; Ketikoglou, I; Manolakopoulos, S; Mela, M; Papatheodoridis, G; Pectasides, D; Schini, M; Striki, A; Triantos, C1
Chen, PJ; Chen, YC; Cheng, SN; Chu, HC; Hsieh, TY; Lin, JA; Shih, YL1
Chen, CY; Chien, RN; Fang, CC; Fang, YJ; Hsu, CW; Huang, YH; Hung, CH; Lee, CM; Lu, SN; Peng, CY; Tsai, TJ; Tseng, KC; Tung, SY; Yeh, CT1
Almerighi, C; Angelico, M; Bandiera, F; Biliotti, E; Di Candilo, F; Di Masi, F; Forte, P; Francioso, S; Gentile, S; Lionetti, R; Longo, MA; Montalbano, M; Nosotti, L; Parruti, G; Piccolo, P; Piras, MR; Ponti, ML; Renzi, S; Riccobelli, F; Salso, A; Santopaolo, F; Taliani, G; Zaru, S1
Al Badawy, N; El Zowalaty, M; Husseiny, MI; Ibrahim, S; Mohtady, H; Omar, AR; Sadeq, R1
Bitetto, D; Ceriani, E; Cmet, S; Cussigh, A; Dissegna, D; Fabris, C; Falleti, E; Fattovich, G; Ieluzzi, D; Lenisa, I; Pirisi, M; Rostello, A; Toniutto, P1
Baragli, F; Corti, G; Salomoni, E1
Gazdag, G; Horváth, G; Szabó, O; Takács, R; Ungvari, GS1
Ahmed, A; Nguyen, MH; Wantuck, JM1
Brandão-Mello, CE; de Araújo Ramos, AL; de França, PH; de Jesus Dominici, A; de Mattos, AA; de Souza Leite Pinho, M; Ferreira, LE; Garcia, CE; Garcia, RF; Moreira, S; Nader, LA; Ramos, JA; Rondinelli, E; Tovo, CV; Villela-Nogueira, CA1
Adler, M; Assene, C; de Galocsy, C; Delwaide, J; Lasser, L; Michielsen, P; Mulkay, JP; Nkuize, M1
Bansal, M; Bichoupan, K; Branch, AD; Dieterich, DT; Gaglio, PJ; Giannattasio, ER; Kalia, H; Liu, LU; Marfo, K; Martel-Laferriere, V; Odin, JA; Perumalswami, P; Reinus, JF; Schiano, TD; Schwartz, JM2
Brost, S; Ganten, TM; Koschny, R; Schirmacher, P; Stremmel, W; Sykora, J; Walczak, H; Zimmermann, A1
Alberti, A; Colombo, M; Craxì, A; Rizzetto, M1
Fernández-Alonso, R; González-Diéguez, ML; Junceda-Moreno, J; Pérez-Carro, G; Rodríguez-García, M1
Henry, L; Hunt, S; Mir, HM; Singer, ME; Younossi, ZM1
Barreiro, P; Camacho, A; Labarga, P; Macias, J; Neukam, K; Pineda, JA; Rivero, A; Rivero-Juarez, A; Soriano, V; Torre-Cisneros, J1
Applegate, T; Cherepanov, V; Dore, GJ; Feld, JJ; Grebely, J; Hellard, M; Kaldor, JM; Lloyd, AR; Matthews, GV; Petoumenos, K; Sherker, A; Yeung, B1
Chauhan, R; Chen, AY; Jacobson, IM; Michalak, TI; Talal, AH; Zeremski, M1
Ando, K; El-Shamy, A; Fujinami, A; Hasegawa, Y; Hayashi, Y; Hotta, H; Imoto, S; Kim, KI; Kim, SK; Kim, SR; Kudo, M; Ohta, M; Sugimoto, K; Takashi, H; Tanaka, Y; Yano, Y1
El-Shamy, A; Fujinami, A; Hasegawa, Y; Hatae, T; Hotta, H; Imoto, S; Kim, KI; Kim, SK; Kim, SR; Kudo, M; Ohta, M; Sugimoto, K; Tanaka, Y1
El-Shamy, A; Fujinami, A; Fujioka, H; Hasegawa, Y; Hatae, T; Hayashi, Y; Hotta, H; Imoto, S; Kim, KI; Kim, SK; Kim, SR; Kudo, M; Ohta, M; Sugimoto, K; Tanaka, Y; Yano, Y1
Hörl, WH; Schmidt, A1
Ide, T; Kato, K; Kondoh, M; Kumada, T; Matsuyama, K; Sata, M; Shimada, N; Takaguchi, K; Toyoda, H; Tsubota, A1
Alam, S; Alexander, GJ; Bargery, C; Dearden, J; Forton, D; Foster, GR; Freshwater, D; Mills, PR; Moreea, S; Ryder, S; Shoeb, D; Vila, X; Weatherall, A; White, E1
Coskun, A; Karaoglu, AO; Yukselen, O; Yukselen, V1
Brennan, BJ; Gane, EJ; Kulkarni, R; Larrey, DG; Le Pogam, S; Morcos, PN; Nájera, I; Petric, R; Rouzier, R; Shulman, NS; Smith, P; Tran, JQ; Wiercinska-Drapalo, A; Yetzer, ES; Zhang, Y1
Chen, DS; Chen, PJ; Chen, SI; Chuang, WL; Dai, CY; Huang, CF; Huang, JF; Hung, PH; Kao, JH; Liang, CC; Lin, JW; Liu, CH; Liu, CJ; Su, TH; Tsai, HB; Tsai, MK; Yang, HC; Yang, SS; Yu, ML1
Burroughs, AK; Davidson, BR; Gurusamy, KS; Toon, CD; Tsochatzis, E1
Casado, JL; Martí-Belda, P; Moreno, A; Moreno, S; Pérez-Elías, MJ; Quereda, C1
Furusyo, N; Hayashi, J; Hayashi, T; Ihara, T; Ikezaki, H; Kainuma, M; Kajiwara, E; Murata, M; Ogawa, E; Okada, K; Satoh, T; Takahashi, K; Toyoda, K1
Aghemo, A; Clark, PJ; Colombo, M; D'Ambrosio, R; Degasperi, E; Galmozzi, E; Muir, AJ; Patel, K; Rumi, MG; Thompson, AJ; Urban, TJ; Vock, DM1
Khokhar, N; Niazi, TK; Qureshi, MO1
Benini, F; Cinquegrana, A; Fasoli, M; Furba, P; Giacò, E; Lanzini, A; Pigozzi, MG; Zanini, B1
Bibert, S; Bochud, PY; Covolo, L; Donato, F; Fattovich, G; Lagging, M; Negro, F1
Gane, E; Gerber, L; Henry, L; Hunt, S; Jacobson, IM; Lawitz, E; Nader, F; Nelson, D; Stepanova, M; Younossi, ZM1
Agarwal, K; Bertelsen, K; Brown, RS; Buti, M; De Masi, R; De Meyer, S; Hézode, C; Horsmans, Y; Janczewska, E; Luo, D; Nyberg, L; Paraná, R; Rizzetto, M; Sievert, W; Witek, J; Zeuzem, S1
Aghemo, A; D'Ambrosio, R; Fabrizi, F; Martin, P; Messa, P; Moroni, G; Passerini, P1
Fukui, H; Hagiwara, H; Hamasaki, T; Hayashi, E; Hayashi, N; Hijioka, T; Hiramatsu, N; Imai, Y; Inada, M; Inoue, A; Inui, Y; Ito, T; Kasahara, A; Katayama, K; Kato, M; Mita, E; Miyagi, T; Miyazaki, M; Oshita, M; Oze, T; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yamada, A; Yoshida, Y; Yoshihara, H1
Alashinnawy, HA; Alwakeel, HR; Kandil, HM; Matarese, LE; Omar, NA; Rewisha, EA; Taha, AA; Zaghla, HE1
Chen, SC; Chuang, WL; Dai, CY; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Lin, ZY; Wang, LY; Yeh, ML; Yu, ML1
Matsuura, K; Tanaka, Y; Watanabe, T1
Goh, C1
Aichelburg, MC; Breitenecker, F; Mandorfer, M; Obermayer-Pietsch, B; Payer, BA; Peck-Radosavljevic, M; Puoti, M; Reiberger, T; Rieger, A; Trauner, M; Zangerle, R1
Alshuth, U; Berg, T; Böhm, S; Herrmann, E; Mihm, U; Sarrazin, C; Teuber, G; Wedemeyer, H; Welker, MW; Zeuzem, S1
Cai, WP; Hu, FY; Lan, Y; Liu, B; Tang, XP; Xu, M1
Gane, E; Henry, L; Hunt, S; Jacobson, IM; Lawitz, E; Nader, F; Nelson, D; Stepanova, M; Younossi, ZM1
Dusheiko, G; Ferenci, P1
Ahlenstiel, G; Booth, DR; Douglas, MW; George, J; Leung, R; Liddle, C; O'Connor, KS; Parnell, G; Patrick, E; Read, SA; Stewart, GJ; Suppiah, V; van der Poorten, D; Yang, JY1
Harada, N; Hayashi, N; Hiramatsu, N; Kanto, T; Miyagi, T; Miyazaki, M; Morishita, N; Oze, T; Takehara, T; Tatsumi, T; Yakushijin, T; Yamada, R; Yoshida, Y1
Doucette, K; Emokpare, D; Harris, P; Hawkins, K; Kaita, K; McHattie, J; Minuk, GY; O'Brien, M; Pinette, G; Uhanova, J; Wong, S; Worobetz, L1
Brew, IF; Butt, C; Wright, N1
Joshita, S; Katsuyama, Y; Kimura, T; Komatsu, M; Matsumoto, A; Morita, S; Nozawa, Y; Ota, M; Shibata, S; Tanaka, E; Umemura, T; Yoshizawa, K1
Girón-Gonzalez, JA; Lopez-Cortes, LF; Pineda, JA; Rivero, A; Rivero-Juarez, A1
Bonner, JE; Esserman, DA; Evon, DM; Golin, CE1
Enomoto, N; Maekawa, S3
Alonso, S; Bárcena, R; Calleja, JL; Casanovas, T; Fernández-Rodríguez, CM; González, JM; Jorquera, F; Martín-Martín, L; Masnou, H; Miquel-Planas, M; Morillas, RM; Navarro, JM; Planas, R; Poyato, A; Romero-Gomez, M; Salmerón, J; Solà, R1
Albrecht, J; Brass, C; Bronowicki, JP; Colvard, LY; Davis, M; Deng, W; Flamm, S; Galati, J; Gordon, SC; Helmond, FA; Howe, AY; Jacobson, I; Lawitz, E; Luketic, V; Marcellin, P; McCone, J; Muir, AJ; Pedicone, LD; Poordad, F; Treitel, M; Vierling, JM; Wahl, J; Yoshida, EM1
Abe, H; Aikata, H; Chayama, K; Fujino, H; Fukuhara, T; Hayes, CN; Hiraga, N; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Kan, H; Kawakami, Y; Kawaoka, T; Kobayashi, T; Masaki, K; Miki, D; Miyaki, D; Murakami, E; Naeshiro, N; Nagaoki, Y; Nakahara, T; Ochi, H; Ohishi, W; Ono, A; Takahashi, S; Tsuge, M; Urabe, A; Yokoyama, S1
Guner, R; Tufan, ZK1
Bon, D; Herrmann, E; Kottilil, S; Masur, H; Meissner, EG; O'Brien, TR; Osinusi, A; Prokunina-Olsson, L; Tang, W1
Benhamou, Y; Shiffman, ML1
Traynor, K2
Bani-Sadr, F; Cacoub, P; Carrat, F; Fromentin, D; Goujard, C; Hessamfar, M; Krastinova, E; Perronne, C; Pol, S; Yazdanpanah, Y1
Bayliss, MS; Crosby, RD; L'Italien, G; Mathias, S; Sapra, S1
Cybula, M; Szemraj, J1
Andreone, P; Coate, B; DeMasi, R; Diago, M; Focaccia, R; Foster, GR; Horban, A; Lawitz, EJ; Lonjon-Domanec, I; Negro, F; Picchio, G; Pol, S; Roberts, S; Serfaty, L; Witek, J; Younossi, Z; Zeuzem, S1
Ahadi-Barzoki, M; Dashti-Khavidaki, S; Karimzadeh, I; Khalili, H; Nasiri-Toosi, M; Ravi, S1
Koff, RS2
Djordjević, J; Kostić, V; Radović, J; Vujić, S1
Alavian, SM; Behnava, B; Hajarizadeh, B; Keshvari, M; Pouryasin, A; Sharafi, H1
Ferenci, P; Stättermayer, AF2
Fehér, J; Fráter, E; Gervain, J; Haragh, A; Hunyady, B; Kisfali, P; Lengyel, G; Melegh, B; Nemes, Z; Papp, M; Pár, A; Pár, G; Péterfi, Z; Schuller, J; Szalay, F; Szereday, L; Szinku, Z; Tornai, I; Tusnádi, A; Varga, M; Várszegi, D; Vincze, A1
Berry, L; Irving, W1
Iqbal, M; Nomani, AZ; Qureshi, MS; Rasheed, K1
Bodeau, S; Brochot, E; Duverlie, G; Nguyen-Khac, E1
Eder, E; Ferenci, P; Hofer, H; Scherzer, TM1
Gupta, AC; Hissar, S; Midha, V; Sarin, SK; Sood, A; Sukriti, S; Trehanpati, N1
Aguilar-Noriega, D; Alvarez-Lajonchere, L; Amador-Cañizares, Y; Armas, A; Castellanos, M; Cinza-Estévez, Z; Dausá, M; Dubuisson, J; Dueñas-Carrera, S; González, Y; Guerra, I; Martínez-Donato, G; Núñez, M; Pérez Aguiar, A; Raíces, I; Revé, I; Valenzuela, C; Vasallo, C; Wychowski, C1
Aghemo, A; Colombo, M; Falconer, K; Lunghi, G; Sarrazin, C; Susser, S; Vermehren, J; Weiland, O; Zeuzem, S1
Eley, T; Everson, GT; Gao, M; Gardiner, DF; Grasela, DM; Hassanein, T; Hernandez, D; Hindes, R; Hinestrosa, F; Huang, SP; Jacobson, I; Lawitz, E; Lok, AS; McPhee, F; Nelson, DR; Pasquinelli, C; Reddy, KR; Rodriguez-Torres, M; Schwartz, H; Sherman, D; Sulkowski, MS; Symonds, W; Thuluvath, PJ; Wind-Rotolo, M1
Bernstein, B; Cohen, DE; Everson, GT; Foster, GR; Khatri, A; Kowdley, KV; Kwo, P; Larsen, L; Lawitz, E; Liossis, G; Nelson, DR; Pilot-Matias, T; Podsadecki, T; Poordad, F; Sulkowski, MS; Xie, W; Zeuzem, S1
Abraham, GM; Gammal, RS; Spooner, LM1
Bakulin, IG; Kiseleva, AV1
Arora, SK; Chawla, Y; Rana, D1
Markulin, A; Morović, M; Patrk, I; Patrk, J1
Abad-Molina, C; Gutierrez-Valencia, A; Jimenez-Jimenez, L; Lopez-Cortes, LF; Ruiz-Valderas, R; Torres-Cornejo, A; Viciana, P1
Ahlén, G; Bode, JG; Brass, A; Brenndörfer, ED; Karthe, J; Sällberg, M1
Bourlière, M; Eley, T; Everson, GT; Gardiner, DF; Grasela, DM; Hézode, C; Huang, SP; Lawitz, EJ; Li, J; Lok, AS; Marcellin, P; McPhee, F; Pasquinelli, C; Pol, S; Rodriguez-Torres, M; Serfaty, L; Wind-Rotolo, M; Yu, F1
Chayama, K; Kawakami, Y; Yokoyama, S1
Chayama, K; Hernandez, D; Hughes, EA; Ishikawa, H; Izumi, N; Kawada, N; Kumada, H; McPhee, F; Monikowski, A; Osaki, Y; Toyota, J; Ueland, J; Watanabe, H; Yokosuka, O; Yu, F; Zhou, N1
Chayama, K; Hayashi, N; Hu, W; Hughes, EA; Ikeda, K; Ishikawa, H; Kumada, H; McPhee, F; Miyagoshi, H; Mochida, S; Suzuki, F; Toyota, J1
Hu, W; Hughes, EA; Ishikawa, H; Izumi, N; Kawada, N; Kumada, H; McPhee, F; Osaki, Y; Sata, M; Ueki, T; Yamamoto, K; Yokosuka, O1
Lebano, R; Masarone, M; Persico, M; Romano, M; Rosato, V1
Aggarwal, V; Cameron, BA; Lloyd, AR; Martinez, D; Nguyen, N; Palmer, C; Simar, D; Zekry, A1
Criado-Illana, MT; García-López, L; Hidalgo-Collazos, P; Marín-Ventura, L; Sánchez, R1
Abe, H; Aikata, H; Chayama, K; Hayes, CN; Hiraga, N; Honda, Y; Imamura, M; Inaba, T; Kanai, A; Kawaoka, T; Kosaka, K; Matsui, H; McPhee, F; Miki, D; Murakami, E; Ochi, H; Ono, A; Takahashi, S; Tsuge, M1
Baldini, A; Coate, B; DeMasi, R; Luo, D; Mrus, J; Witek, J; Zeuzem, S1
Dou, XG2
Alvarez, H; de la Llana, FG; Domingo, P; Genebat, M; Guardiola, JM; Hernández-Quero, J; Leal, M; Lluch, JF; Marín, J; Mariño, A; Martínez, L; Martínez-Madrid, O; Martínez-Pérez, MA; Ruiz-Mateos, E; Sánchez-Villegas, J; Vera, F1
Abdel-Hady, M; Bansal, S; Barnes, E; Brown, M; Davies, P; Davison, SM; Kelly, DA; Mieli-Vergani, G; Mulla, S; Tizzard, SA1
Dillon, JF; Heron, T; Miller, MH1
Galmozzi, E; Lampertico, P1
Aghemo, A; Galmozzi, E1
Brainard, DM; Habersetzer, F; Herring, RW; Kanwar, B; Lawitz, E; Massetto, B; McHutchison, JG; Mo, H; Pang, PS; Pol, S; Rodriguez-Torres, M; Shiffman, ML; Subramanian, GM; Sulkowski, MS; Trenkle, JD; Wyles, DL; Zhu, Y1
Adams-Huet, B; Bedimo, R; Holodniy, M; Jain, MK; Kushner, LE; Li, X; Terekhova, D1
Aspinall, E; Barclay, ST; Dillon, JF; Dusheiko, G; Goldberg, D; Hayes, P; Hutchinson, SJ; Innes, H; Mills, PR1
Carrion, AF; Gutierrez, J; Martin, P1
Honda, A; Ikegami, T; Kohjima, M; Matsuzaki, Y; Miyazaki, T; Nakamuta, M1
Alston-Smith, B; Andersen, J; Chung, RT; Glesby, MJ; Hadigan, C; Kitch, D; Luetkemeyer, A; Marks, KM; Tien, P1
Aggarwal, J; Donepudi, M; Goss, TF; Suthoff, E; Vera-Llonch, M; Younossi, Z1
Buccoliero, G; Massa, P; Pisconti, S; Resta, F; Urbano, T1
Thomas, DL1
Ridruejo, E2
Ascione, A; Ciancio, A; Craxì, A; Deodato, B; Golotta, C; Iannacone, C; Piccinino, F1
Enomoto, M; Fujii, H; Iwai, S; Kawada, N; Kobayashi, S; Morikawa, H; Nakaya, M; Sakaguchi, H; Tamori, A1
Fu, JJ; Jiang, D; Kong, WJ; Pan, XC; Wei, L1
Awad, T; Gluud, C; Hauser, G; Mabrouk, M; Štimac, D; Thorlund, K1
Awad, T; Brok, J; Gluud, C; Gluud, LL; Hauser, G; Mabrouk, M; Štimac, D; Thorlund, K1
Yang, HS; Zhang, CY; Zhang, HM; Zhang, Q1
Booth, CL; Bridge, SH; Dusheiko, G; Garcia-Diaz, A; Haque, T; Irish, D; Jacobs, M; Labbett, W; Macartney, MJ; McCormick, AL; Rosenberg, W; Smith, C; Tanwar, S; Trembling, P; Velazquez, C1
Boglione, L; Cariti, G; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G1
Arslan, F; Aslan, F; Ceylan, B; Fincanci, M; Özgüneş, N; Yardimci, C1
Aoki, T; Harada, N; Hasegawa, K; Ishizawa, T; Kaneko, J; Kokudo, N; Sakamoto, Y; Sugawara, Y; Tamura, S; Tanaka, T; Togashi, J; Yamashiki, N1
Ackrill, A; Badman, E; Bernaards, C; Chan, A; Chen, YC; Kulkarni, R; Moreira, S; Smith, PF; Thommes, J; Zhu, Y1
Brogan, AJ; Deniz, B; Miller, JD; Rubin, J; Talbird, SE; Thompson, JR1
Baranyi, A; Kapfhammer, HP; Meinitzer, A; Putz-Bankuti, C; Rothenhäusler, HB; Stauber, R1
Amiri, M; Bailly, F; Funingana, G; Gonçalves, F; Hartig-Lavie, K; Maynard, M; Pradat, P; Virlogeux, V; Zoulim, F1
Delang, L; Neyts, J; Verpaalen, B1
Chen, SC; Chuang, WL; Dai, CY; Hsieh, MH; Hsieh, MY; Huang, CF; Huang, JF; Lin, ZY; Tsai, PC; Wang, LY; Yang, HL; Yang, JF; Yeh, ML; Yu, ML1
Goyal, O; Hissar, S; Khanna, P; Midha, V; Sharma, SK; Sood, A1
Hidaka, H; Jiang, W; Kitagawa, H; Koizumi, W; Nakazawa, T1
Cong, X; Feng, B; Jin, Q; Kang, Y; Kong, FY; Liu, YY; Rao, HY; Shang, J; Wei, L; Xie, Q; Yang, RF; Zhang, HY1
Shiffman, ML11
Goto, S; Hayashi, N; Izumi, N; Kato, M; Ki, R; Komada, Y; Kumada, H; Okanoue, T; Seto, C; Tsubouchi, H; Yatsuhashi, H2
Angelico, M; Antonucci, G; Belli, L; Bertuzzo, V; Bitetto, D; Bringiotti, R; Burra, P; Colombo, M; Colpani, M; De Martin, E; De Ruvo, N; Di Benedetto, F; Di Leo, A; Di Paolo, D; Donato, MF; Ettorre, GM; Fagiuoli, S; Fornasiere, E; Gasbarrini, A; Gerunda, GE; Giannelli, V; Giusto, M; Iemmolo, RM; Lupo, L; Marino, M; Memeo, V; Merli, M; Miglioresi, L; Montalti, R; Morelli, MC; Pasulo, L; Pinna, AD; Pompili, M; Ponziani, FR; Rendina, M; Rigamonti, C; Rossi, G; Senzolo, M; Tisone, G; Toniutto, P; Vero, V; Viganò, R; Visco-Comandini, U; Zappimbulso, M1
Dong, RQ; Han, R; Zhao, CY; Zhen, Z; Zhou, DF; Zhou, JY1
Barin, B; Barnes, D; Curry, M; Dove, L; Johl, J; Millis, M; Peters, M; Poordad, F; Reddy, KR; Regenstein, F; Roland, M; Schiano, T; Schiff, E; Shaikh, O; Shetty, K; Stock, P; Terrault, N1
Chen, SC; Chou, WW; Chuang, WL; Dai, CY; Hsi, E; Huang, CF; Huang, JF; Juo, SH; Lin, ZY; Wang, LY; Yeh, ML; Yu, ML1
Mandorfer, M1
Choudhuri, G; Khan, AJ; Mohindra, S; Negi, TS; Parmar, D; Saraswat, VA1
Aziz, H; Gill, ML; Gill, U; Raza, A1
Liu, T; Liu, X; Sha, K; Wang, Y; Yang, F; Yang, L; Zhang, L1
Abe, H; Chayama, K; Hayashida, Y; Hayes, CN; Kubo, M; Miki, D; Ochi, H1
Azuma, T; Bai, F; Hatazawa, Y; Hayakumo, T; Hayashi, Y; Hirano, H; Hotta, H; Imoto, S; Kim, SR; Miki, A; Minami, A; Momose, K; Rinonce, HT; Saito, M; Seo, Y; Sugano, M; Tani, S; Widasari, DI; Yano, Y; Yoon, S1
Bailly, F; Chiarello, P; Gagnieu, MC; Hatu, G; Livrozet, JM; Maynard, M; Miailhes, P; Parant, F; Pourcelot, E; Pradat, P; Zoulim, F1
Canva, V; Deltenre, P; Deuffic-Burban, S; Dhumeaux, D; Larrey, D; Mallet, V; Mathurin, P; Obach, D; Pageaux, GP; Pol, S; Roudot-Thoraval, F; Schwarzinger, M; Yazdanpanah, Y1
Beinhardt, S; Ferenci, P; Hofer, H; Rutter, K; Scherzer, T; Stättermayer, AF1
Catalli, L; Chua, J; Manos, MM; Monto, A; Murphy, RC; Pauly, MP; Saxena, V; Shvachko, VA; Terrault, NA; Wayne, E; Yee, HS1
Agathon, D; Bataille, V; Carreno, V; Di Bisceglie, AM; Fich, A; Flisiak, R; Habersetzer, F; Hennequi, M; Honnet, G; Inchauspé, G; Janczweska-Kazek, E; Limacher, JM; Mazur, W; Romero-Gomez, M; Stanciu, C; Tanasescu, C; Toh, ML; Wedemeyer, H; Zerr, P1
de Almeida, PR; de Mattos, AA; Tovo, CV1
Chen, PJ; Liu, CJ1
Al-Bawardy, B; Canterbury, K; Charlton, MR; Colby, CL; Gross, JB; Kim, WR; Larson, JJ; Poterucha, JJ; Therneau, TM; Warner, J1
Sogni, P1
Boglione, L; D'Avolio, A; De Nicolò, A; Di Perri, G1
Assoumou, SA; Barter, DM; DiLorenzo, M; Freedberg, KA; Horsburgh, CR; Kim, AY; Leff, JA; Linas, BP; Salomon, JA; Schackman, BR; Weinstein, MC1
Appourchaux, K; Asselah, T; Bedossa, P; Bièche, I; Broët, P; De Muynck, S; Estrabaud, E; Lada, O; Lapalus, M; Marcellin, P; Martinot-Peignoux, M; Valla, D; Vidaud, M1
Brambilla, N; Bringiotti, RS; Castellaneta, A; Castellaneta, NM; D'Amato, M; Di Leo, A; Giacovelli, G; Rendina, M; Rizzi, SF; Rovati, L; Zappimbulso, M1
Andriulli, A; Cozzolongo, R; Fontana, R; Iacobellis, A; Ippolito, A; Minerva, N; Niro, GA; Palmieri, O; Valvano, MR1
Andriulli, A; Margaglione, M; Palmieri, O; Valvano, MR1
Casado-Caballero, F; Escobar-Jimenez, F; Gonzalez-Calvin, JL; Hernandez-Quero, J; Martin-Rodriguez, JL; Redondo-Cerezo, E1
Hagan, LM; Schinazi, RF; Sulkowski, MS1
Altincatal, A; Cho, K; Gagnon, DR; Grotzinger, KM; Hermos, JA; Lawler, EV; Quach, L; Weber, HC1
Bonfim Freitas, F; da Silva Conde, SR; da Silva Graça, E; de Almeida Lins, PA; Demachki, S; Ferreira de Araújo, MT; Fonseca Filgueiras, NK; Ishak, R; Rosário Vallinoto, AC; Silva Dos Santos, BT; Soares Monteiro, JC1
Alfaro, I; Lens, S1
Arama, V; Brisc, C; Caruntu, F; Gheorghe, L; Goldis, A; Iacob, S; Motoc, A; Preotescu, L; Rednic, N; Rugina, S; Simionov, I; Stefan, I1
Dulic, M; Dulic-Lakovic, E; Graninger, W; Gschwantler, M; Rieder, F; Schwarzer, R; Steininger, C1
Mano, S; Mizokami, M; Nishida, N; Nishino, J; Sugiyama, M; Tokunaga, K1
Amin, M; Hayashi, Y; Hendrayana, A; Hotta, H; Kurniawan, H; Lusida, MI; Mustika, S; Setiawan, PB; Utsumi, T; Wahyuni, RM; Wibawa, ID; Wibowo, BP; Yamani, LN; Yano, Y1
Druyts, E; Mills, EJ; Thorlund, K1
Aguilera, I; Gómez-Bravo, MA; Núñez-Roldán, A; Sousa, JM1
Abergel, A; Alric, L; Attali, P; Barthe, Y; Bernard, PH; Bourliere, M; Bronowicki, JP; Cacoub, P; Canva, V; Carrat, F; Causse, X; Chazouilleres, O; Dao, T; De Ledinghen, V; Di Martino, V; Dorival, C; Fontaine, H; Fontanges, T; Gournay, J; Grando-Lemaire, V; Guyader, D; Hézode, C; Hillon, P; Larrey, D; Loustaud-Ratti, V; Lucidarme, D; Marcellin, P; Metivier, S; Pawlotsky, JM; Petrov-Sanchez, V; Pol, S; Portal, I; Poynard, T; Raabe, JJ; Riachi, G; Rosa, I; Samuel, D; Tran, A; Zarski, JP; Zoulim, F1
Dusheiko, G; Esteban, R; Hezode, C; Hunt, SL; Nader, F; Reesink, HW; Stepanova, M; Weiland, O; Younossi, ZM; Zeuzem, S1
Müllhaupt, B; Rampini, SK; Schaffstein, S1
Aimitsu, S; Aisaka, Y; Chayama, K; Hayes, CN; Kawakami, H; Kawakami, Y; Kira, S; Kitamoto, M; Kohno, H; Moriya, T; Nakanishi, T; Nonaka, M; Takahashi, S; Tsuji, K; Yamashina, K; Yokoyama, S1
Hagiwara, H; Harada, N; Hayashi, N; Hikita, H; Hiramatsu, N; Imai, Y; Inoue, A; Inui, Y; Kanto, T; Kasahara, A; Katayama, K; Mita, E; Miyagi, T; Miyazaki, M; Morishita, N; Oshita, M; Oze, T; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yamada, R; Yoshida, Y; Yoshihara, H1
Baykal, T; Bernstein, B; Bourlière, M; DaSilva-Tillmann, B; Desmond, P; Di Bisceglie, AM; Hassanein, T; Jacobson, IM; Jensen, DM; Larsen, L; Marinho, RT; Pilot-Matias, T; Podsadecki, T; Poordad, F; Sulkowski, MS; Tam, E; Varunok, P; Wedemeyer, H; Xiong, J; Zeuzem, S1
An, D; Bernstein, DE; Chojkier, M; Di Bisceglie, AM; Fried, MW; Ghalib, R; Gordon, SC; Herring, R; Hyland, RH; Kowdley, KV; Lawitz, E; McHutchison, JG; Muir, AJ; Pang, PS; Pockros, PJ; Pound, D; Reddy, KR; Rossaro, L; Rustgi, V; Ryan, M; Schiff, E; Shiffman, ML; Subramanian, GM; Svarovskaia, E; Symonds, WT1
Aguilar, H; Bernstein, B; Coakley, E; Crawford, D; DaSilva-Tillmann, B; Feld, JJ; Kowdley, KV; Larsen, L; Nelson, DR; Pilot-Matias, T; Podsadecki, T; Sigal, S; Weiland, O; Xiong, J1
Arends, JE; Burger, DM; de Kanter, CT; de Knegt, RJ; Drenth, JP; Reesink, HW; van der Valk, M1
Agarwal, K; Berg, T; Bernstein, B; Campbell, AL; Collins, CA; Da Silva-Tillmann, B; Forns, X; Hezode, C; Kowdley, KV; Lovell, SS; Podsadecki, T; Poordad, F; Shiffman, ML; Trinh, R; Wedemeyer, H; Yoshida, EM; Zeuzem, S1
Afdhal, N; Agarwal, K; Bräu, N; Buggisch, P; Buti, M; Chojkier, M; Ding, X; Foster, GR; Gitlin, N; Jacobson, IM; Kwo, P; Mangia, A; Marcellin, P; McHutchison, JG; Mo, H; Muir, AJ; Pang, PS; Puoti, M; Romero-Gomez, M; Subramanian, GM; Symonds, WT; Yang, JC; Zarski, JP; Zeuzem, S1
Barrero Alor, F; Casado Monge, PG; Jiménez Macías, FM; Pujol de la Llave, E; Ramos Lora, M; Ruíz-Frutos, C1
Allegra, S; Boglione, L; Cariti, G; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G; Ghisetti, V1
Angelillo, IF; Coppola, N; Pisaturo, M; Sagnelli, C; Sagnelli, E1
Deraz, D; Elattar, I; Elbaz, T; Hafez, A; Shehab, H1
Akahoshi, T; Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kawano, A; Kotoh, K; Maehara, Y; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K; Tanabe, Y1
Muir, AJ2
Pavri, TM; Reddy, KR; Sinese, L; Wirjosemito, A1
Barrou, B; Lemoinne, S; Thabut, D1
Kao, JH; Liu, CH3
Dybowska, D; Halota, W; Kozielewicz, D2
Bacon, BR; Bronowicki, JP; Bruno, S; Deng, W; DiNubile, MJ; Dutko, FJ; Esteban, R; Flamm, SL; Helmond, FA; Koury, KJ; Kwo, PY; Manns, MP; Pedicone, LD; Poordad, F; Vierling, JM; Wahl, J; Zeuzem, S1
Chen, DS; Chen, PJ; Chen, SI; Chuang, WL; Dai, CY; Huang, CF; Huang, JF; Hung, PH; Kao, JH; Lee, CY; Liang, CC; Lin, JW; Liu, CH; Liu, CJ; Su, TH; Tsai, HB; Tsai, MK; Yang, HC; Yang, SS; Yu, ML1
Aghemo, A; Cappellini, MD; Colancecco, A; Colombo, M; Monico, S; Porretti, L; Prati, G; Ronzoni, L; Rumi, MG1
Abrignani, S; Almasio, P; Ascione, A; Bonino, F; Brunetto, MR; Colombatto, P; Houghton, M; Maina, AM; Mondelli, M; Muratori, L; Pinzello, G; Rappuoli, R; Romagnoli, V; Rosa, D; Rumi, MG1
Enomoto, N; Fujiwara, K; Izumi, N; Joh, T; Kurosaki, M; Kusakabe, A; Matsuura, K; Mizokami, M; Nojiri, S; Orito, E; Sakamoto, N; Shinkai, N; Tanaka, Y; Watanabe, T; Yatsuhashi, H1
Barreiro, P; de Mendoza, C; Fernandez-Montero, JV; Labarga, P; Pinilla, J; Plaza, Z; Soriano, V; Vispo, E1
Berg, T; Bremer, B; Cornberg, M; Filmann, N; Herrmann, E; Lunemann, S; Manns, MP; Markova, AA; Mihm, U; Sarrazin, C; Schlaphoff, V; Wedemeyer, H; Zeuzem, S1
Agarwal, K; Austin, A; Barclay, ST; Brown, A; Dillon, JF; Dundas, P; Dusheiko, GM; Foster, GR; Fox, R; Hayes, PC; Leen, C; Miller, MH; Millson, C; Ryder, SD; Tait, J; Ustianowski, A1
Jang, JY; Jeong, SW; Jung, HJ; Kim, BS; Kim, HS; Kim, SG; Kim, YS; Lee, SH; Lee, YN1
Bagnarelli, P; Capobianchi, MR; Ferreri, ML; Galli, C; Garbuglia, AR; Monachetti, A; Sabatini, R1
Bourgeois, S; De Galocsy, C; Horsmans, Y; Lasser, L; Mulkay, JP; Tomasovic, S; Van Vlierberghe, H1
Bair, MJ; Chen, HL; Chen, MJ; Lin, CC; Lin, IT; Shih, SC; Wang, HY; Wang, TE; Wu, CH1
Konstantinov, DIu; Konstantinova, EA; Popova, LL; Strebkova, EA; Suzdal'tsev, AA1
Coppola, N; Filippini, P; Martini, S; Pisaturo, M; Sagnelli, C; Sagnelli, E1
Ray, K2
Chusri, P; Kumthip, K; Maneekarn, N; Nelson, KE; O'Brien, A; Pantip, C; Thongsawat, S2
Grewal, P; Kim, B; Thung, SN; Trivedi, A1
Akkarathamrongsin, S; Payungporn, S; Poovorawan, K; Poovorawan, Y; Prapunwattana, P; Tangkijvanich, P; Thong, VD2
Abdel-Aty, EF; Abdel-Ghaffar, AY; Abdel-Ghaffar, TY; Allam, AA; Behairy, BE; Ehsan, NA; El Naghi, S; El-Araby, HA; El-Guindi, MA; El-Hennawy, AM; El-Karaksy, H; El-Raziky, MS; El-Sebaie, H; Helmy, H; Sira, MM1
Antón, J; de Juan, J; Faraco, I; García-Guerrero, J; Marco, A; Portilla, J; Pozo, E; Saiz de la Hoya, P1
Amaral, KM; Costi, C; Fiegenbaum, M; Fré, NN; Grandi, T; Gregianini, TS; Niel, C; Picon, PD; Rossetti, ML; Silva, CM1
Kashiwagi, Y; Kawashima, H; Nagao, R; Nishimata, S; Suzuki, S; Tsutsumi, N1
Broekman, M; Drenth, JP; Gluud, C; Lamers, MH2
Braddock, M; Chen, YP; He, JP; Li, LF; Lin, YQ; Shi, KQ; Wang, LR; Zheng, MH1
Ghany, MG; Liang, TJ1
Brainard, DM; Dusheiko, GM; Esteban, R; Ferenci, P; Flisiak, R; Hézode, C; Hyland, RH; Illeperuma, A; Mangia, A; McHutchison, JG; Reesink, HW; Salupere, R; Subramanian, GM; Svarovskaia, E; Symonds, WT; Weiland, O; Zeuzem, S1
Baruch, Y; Bernstein, D; Bhandari, BR; Box, TD; Caruntu, FA; Chulanov, V; Cohen, D; Cooper, C; Enayati, P; Ferenci, P; Gervain, J; Green, S; Hassanein, T; Janczewska, E; King, M; Lalezari, J; Luo, Y; Marinho, RT; Moreno, C; Nyberg, A; Planas, R; Podsadecki, T; Reddy, KR; Rizzardini, G; Sepe, T; Tam, E; Tsai, N; Xie, W; Younes, Z1
Chayama, K; Imamura, M3
Aichelburg, MC; Boesecke, C; Lang, G; Mandorfer, M; Niederecker, A; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A; Strassl, R; Trauner, M1
Francis, J; Gordon, CE1
Berg, T; Buggisch, P; Buslau, A; Hinrichsen, H; Maasoumy, B; Sarrazin, C; Schiefke, I; Wedemeyer, H; Wiegand, J1
Harada, N; Hayashi, N; Hiramatsu, N; Imai, Y; Inui, Y; Kaneko, A; Kasahara, A; Miyagi, T; Morishita, N; Oshita, M; Oze, T; Suzuki, K; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yamada, A; Yamada, R; Yoshida, Y; Yoshihara, H1
Chapman, R; Costella, A; De Angelis, D; Griffiths, J; Harris, HE; Harris, RJ; Ramsay, M; Thomas, B1
Linas, BP; Pho, MT1
Adda, N; Bengtsson, L; Bzowej, NH; DeMasi, R; Dusheiko, GM; Flamm, SL; Fried, MW; George, S; Kieffer, TL; Muir, AJ; Nelson, DR; Reddy, KR; Sullivan, JC; Wright, CI1
An, J; Deng, H; Feng, Y; Ji, F; Li, Z; Xiao, S; Zhang, Y1
Angeli, E; Caputo, A; Cattelan, AM; Iannacone, C; Maida, I; Nasta, P; Pontali, E; Puoti, M; Verucchi, G1
Dixit, NM; Garaigorta, U; Padmanabhan, P1
James, P; Win, LL; Wong, DK1
Borgia, G; Buonomo, AR; Coppola, N; Gentile, I; Zappulo, E1
Choi, YW; Huh, KC; Kang, YW; Kim, SM; Kim, YS; Lee, KO; Lee, TH1
Alavian, SM; Keshvari, M; Sharafi, H1
Barrett, L; Kottilil, S; Masur, H; Odigie, M; Osinusi, A; Polis, MA; Suffredini, AF; Townsend, K; Wang, H1
Miyagi, Y; Nomura, H; Tanimoto, H; Yamashita, N1
Ahmed, DS; Chowdhury, MS; Huda, MN; Mahmuduzzaman, M; Perveen, S; Rahman, MA; Rahman, MZ; Raihan, MA1
Mutimer, D1
Chan, J1
Alexander, P; James, A; Long, AG; Shiffman, ML1
Bel Hadj, N; Ben Nejma, H; Cheikh, M; Ennaifer, R; Hefaiedh, R; Romdhane, H1
Abe, H; Aizawa, Y; Atsukawa, M; Itokawa, N; Iwakiri, K; Kawamoto, C; Kondo, C; Nakagawa, A; Sakamoto, C; Shimada, N; Tsubota, A1
Takehara, T4
Degen, O; Eißing, F; Hennigs, A; Hertling, S; Hüfner, A; Jordan, S; Lohse, AW; Lüth, S; Röder, C; Schmiedel, S; Schulze zur Wiesch, J; Sterneck, M; van Lunzen, J; Wehmeyer, MH1
Beumont, M; De Meyer, S; Dierynck, I; Ghys, A; Luo, D; Picchio, G1
Alavian, SM; Bokharaei-Salim, F; Keyvani, H; Monavari, SH; Sadeghi, F; Salehi-Vaziri, M; Salimi, S; Vahabpour, R1
Alves, K; Asmal, M; DeSouza, C; Di Bisceglie, AM; Gane, E; George, S; Jacobson, IM; Kauffman, R; Kieffer, T; Koziel, MJ; Nelson, D; Sulkowski, M; Zhang, EZ1
Böcher, WO; Hennecke, N; Kayser, A; Kukolj, G; Lohmann, V; Martin, B; Neumann-Haefelin, C; Thimme, R1
Abdelsalam, MS; Althaf, MM; Nadri, Q; Rashwan, M1
Beumont-Mauviel, M; Buti, M; de Araujo, ES; De La Rosa, G; Horsmans, Y; Janczewska, E; Kalmeijer, R; Lenz, O; Manns, M; Marcellin, P; Ouwerkerk-Mahadevan, S; Peeters, M; Poordad, F; Scott, J; Sinha, R; Villamil, F1
Beumont-Mauviel, M; Craxi, A; De La Rosa, G; Dore, GJ; Foster, GR; Fried, MW; Jacobson, IM; Kalmeijer, R; Lenz, O; Moroz, L; Ouwerkerk-Mahadevan, S; Peeters, M; Radu, M; Rafalsky, VV; Scott, J; Sinha, R1
Enomoto, N; Ito, K; Izumi, N; Koike, K; Komatsu, M; Masaki, N; Masaki, T; Mizokami, M; Murata, K; Nakamuta, M; Shimada, N; Sugiyama, M; Tanaka, Y; Tsubota, A; Watanabe, S; Yoneda, M1
Cao, GW; Lin, J; Wu, JF; Zhang, HW; Zhang, Q1
Bukowska-Ośko, I; Cortes, KC; Laskus, T; Opoka-Kegler, J; Pawełczyk, A; Perlejewski, K; Radkowski, M1
Chernova, O; Ignatova, T; Moiseev, S; Novikov, P1
de la Vega, J; López-Larrea, C; López-Rodríguez, R; López-Vázquez, A; Martínez-Borra, J; Martínez-Camblor, P; Pérez-Álvarez, R; Pérez-López, R; Prieto, J; Rodrigo, L; Sanz-Cameno, P; Vidal-Castiñeira, JR1
Chen, TW; Chu, HC; Fan, HL; Hsieh, CB; Hsieh, TY; Hsu, KF1
Joshita, S; Kamijo, A; Katsuyama, Y; Kimura, T; Kiyosawa, K; Kobayashi, M; Komatsu, M; Maruyama, A; Matsumoto, A; Mori, H; Morita, S; Nozawa, Y; Ota, M; Shibata, S; Takamatsu, M; Tanaka, E; Umemura, T; Wada, S; Yoshizawa, K1
Abe, H; Akamatsu, S; Chayama, K; Hayes, CN; Hiraga, N; Imamura, M; Miki, D; Murakami, E; Ochi, H; Tsuge, M1
Duvic, M; Kyvernitakis, A; Mahale, P; Torres, HA1
Galati, G; Gallo, P; Menna, P; Minotti, G; Picardi, A; Salvatorelli, E; Vespasiani Gentilucci, U1
Einecke, D1
Furusyo, N; Harada, Y; Hayashi, J; Hayashi, T; Ihara, T; Murata, M; Ogawa, E; Shimizu, M; Toyoda, K1
Bernstein, B; Chevaliez, S; Cloherty, G; Cohen, D; Herman, C; Pawlotsky, JM; Sarrazin, C; Wedemeyer, H1
Atta, HA; Kamel, M; Kishk, R; Metwally, L; Nemr, N; Ragheb, M1
Abdurakmonov, D; Abrao Ferreira, P; Colombo, M; DeMasi, R; Fernández, I; Hill, A; Iraqi, W; Lonjon-Domanec, I; Moreno, C; Strasser, S; Streinu-Cercel, A; Urbanek, P; Verheyen, A; Wedemeyer, H1
Acero Fernández, D; Ferri Iglesias, MJ; Figa Francesch, M; Hombrados Verde, M; López Nuñez, C; Louvriex Freire, R; Virolés Torrent, S1
Boldrini, B; Caini, P; Fabbrizzi, A; Fognani, E; Gragnani, L; Laffi, G; Monti, M; Piluso, A; Ranieri, J; Triboli, E; Urraro, T; Zignego, AL1
Aghemo, A; Andriulli, A; Angelico, M; Brancaccio, G; Calvaruso, V; Craxi, A; Di Marco, V; Di Paolo, D; Gavrila, C; Grassi, E; Ippolito, AM; Nardi, A; Squadrito, G; Valvano, MR1
Abdi, AM; Boglione, L; Cardellino, CS; Cariti, G; Caviglia, GP; Ciancio, A; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G; Rizzetto, M; Smedile, A; Strona, S; Troshina, G1
Honda, M; Kaneko, S; Lemon, SM; Murai, K; Murakami, S; Okada, H; Sakai, Y; Shimakami, T; Shiomoto, T; Shirasaki, T; Takabatake, R; Tokumaru, A; Yamashita, T1
Hu, H; Liu, F; Ren, H; Wang, X; Wei, F1
Cacoub, P; Saadoun, D2
Chen, TH; Liao, WL; Lim, YP; Lin, WY; Peng, CY; Tsai, FJ; Wan, L1
Chen, DS; Hsu, CS; Hsu, SJ; Kao, JH; Lin, HH; Tseng, TC; Wang, CC1
Korr, M1
Bon, D; Fauci, AS; Herrmann, E; Hewitt, S; Kottilil, S; Masur, H; McHutchison, J; Meissner, EG; Osinusi, A; Polis, M; Porcella, S; Prokunina-Olsson, L; Sturdevant, D; Suffredini, AF; Virtaneva, K; Wang, H; Wu, D1
Kekez, AJ2
Duvnjak, M; Kurelac, I; Vince, A1
Hrstić, I; Ostojić, R1
Begovac, J2
Smolić, M; Smolić, R; Vcev, A1
Almasio, PL; Andreone, P; Azzola, E; Benedetti, A; Borghesio, E; Borgia, G; Carosi, G; Carrara, M; Coppola, C; Koch, M; Masocco, M; Mazzotta, F; Mele, A; Milella, M; Nardone, G; Rizzetto, M; Romano, M; Rosina, F; Sagnelli, E; Tosti, ME; Zignego, AL1
Cornberg, M; Deterding, K; Höner Zu Siederdissen, C; Maasoumy, B; Manns, MP; Markova, AA; Port, K; Rogalska-Taranta, M; Wedemeyer, H1
Ginba, H; Ide, T; Izumi, N; Kumada, T; Matsuyama, K; Sata, M; Shimada, N; Takaguchi, K; Toyoda, H2
Aroucha, DC; Cavalcanti, Mdo S; do Carmo, RF; Dutra, RA; Moura, P; Pereira, LB; Pereira, LM; Vasconcelos, LR1
Bharali, R; Chowdhury, SJ; Gumma, PK; Kar, P; Karra, VK1
Lin, JA; Shih, YL1
Lim, TH; Pearlman, BL1
Allen, TM; Park, SH; Rehermann, B; Tully, DC; Veerapu, NS1
Kared, H; Klein, MB; Saeed, S; Shoukry, NH1
Corchado, S; Girón-González, JA; López-Cortés, LF; Márquez-Coello, M; Rivero, A; Rivero-Juárez, A; Torres-Cornejo, A1
Berak, H; Bukowska-Ośko, I; Cortés, KC; Horban, A; Laskus, T; Maroszek, K; Pawełczyk, A; Perlejewski, K; Płoski, R; Radkowski, M; Zagordi, O1
An, J; Heo, NY; Kim, KM; Lee, D; Lee, HC; Lee, W; Lee, YS; Lim, YS; Oh, M; Shim, JH; Suh, DJ1
Jouan, L; Lamarre, D; Rigsby, H; Rodrigue-Gervais, IG; Willems, B1
Cornella, S; Shah, NL; Stine, JG1
Bessone, F; Bronowicki, JP; Cohen, D; Eley, T; Gadano, A; He, B; Hernandez, D; Hughes, E; Martorell, CT; McPhee, F; Mendez, P; Pol, S; Ratziu, V; Terg, R; Thuluvath, PJ; Younes, Z; Yu, F1
Bourhis, F; Cure, S; Hunt, S; Nader, F; Stepanova, M; Younossi, ZM1
Dixit, V; Fabrizi, F; Martin, P; Messa, P2
Aghemo, A; Colombo, M; Ferraris Fusarini, C; Garlaschi, MC; Lunghi, G; Maiavacca, R; Matinato, C; Novembrino, C; Ramondetta, M; Ronchi, M; Torresani, E1
Ahmad, A; Chan, P; Freeman, J; Hillson, J; Horga, MA; Hruska, M; Kansra, V; Lopez-Talavera, JC; Wang, X2
Galle, PR; Knapstein, J; Wörns, MA; Zimmermann, T1
Alavi, M; Baker, D; Balcomb, A; Doong, N; Dore, GJ; Erratt, A; Grebely, J; Hallinan, R; Hill, S; Keats, J; Marks, P; Richmond, D; Siriragavan, S; Smart, J1
Aherfi, S; Borentain, P; Botta-Fridlund, D; Bregigeon, S; Brouqui, P; Colson, P; Dhiver, C; Gérolami, R; Mokhtari, S; Moreau, J; Motte, A; Poizot-Martin, I; Portal, I; Ravaux, I; Ruiz, JM; Solas, C; Stein, A; Tamalet, C1
Ahmed, A; Assem, N; Doss, W; El Kassas, M; El Raziky, M; Elsharkawy, A; Esmat, G; Hassany, M; Sabry, D1
Arora, S; Everson, G; Flisiak, R; George, J; Ghalib, R; Gordon, SC; Gray, T; Greenbloom, S; Hassanein, T; Hillson, J; Horga, MA; Jacobson, IM; Jeffers, L; Kowdley, KV; Lawitz, E; Lopez-Talavera, JC; Lueth, S; Muir, AJ; Rodriguez-Torres, M; Rustgi, V; Shemanski, L; Shiffman, ML; Srinivasan, S; Vargas, HE; Vierling, JM; Xu, D; Zeuzem, S1
Ahmed, A; Gordon, SC; Park, H; Saab, S; Sulkowski, M; Younossi, Z1
Bruno, R; Bruno, S; Cabibbo, G; Cammà, C; Craxì, A; Enea, M; Gasbarrini, A; Macaluso, FS; Petta, S; Plaia, A1
Deguchi, H; Ichinose, M; Iguchi, M; Inoue, I; Kato, J; Kawaguchi, M; Kawashima, A; Maekita, T; Mori, Y; Moribata, K; Shingaki, N; Tamai, H; Ueda, K; Wada, Y1
Arotçarena, R; Causse, X; Denis, J; Hagège, H; Henrion, J; Lesgourgues, B; Nalet, B; Pariente, A; Rémy, AJ1
Berenguer, J; Cosín, J; Fernández-Rodríguez, A; García-Álvarez, M; Guzmán-Fulgencio, M; Jiménez-Sousa, MA; López, JC; Martínez, P; Miguel Benito, J; Miralles, P; Rallón, N; Resino, S; Soriano, V1
Andruszkiewicz, A; Bartoszewicz, K; Duczkowska, M; Jurczyk, K; Karpińska, E; Laurans, Ł; Parczewski, M; Socha, Ł; Sławiński, J; Wawrzynowicz-Syczewska, M; Zeair, S1
Antón, JJ; de la Hoya, PS; Faraco, I; Hoyos, C; Juan, Jd; Marco, A; Pozo, E; Yllobre, C1
Beumont, M; Callewaert, K; Corregidor, A; DeJesus, E; Fevery, B; Ghalib, R; Gitlin, N; Jacobson, IM; Lambrecht, T; Lawitz, E; Lim, JK; Lindsay, KL; Ouwerkerk-Mahadevan, S; Pearlman, B; Picchio, G; Pockros, PJ; Rabinovitz, M; Rodriguez-Torres, M; Scott, JD; Sulkowski, MS; Symonds, WT; Younossi, ZM1
Bourlière, M; Bräu, N; Brunetto, MR; Esmat, G; Everson, GT; Fried, MW; Ghesquiere, W; Hernandez, D; Hézode, C; Hirschfield, GM; Hughes, EA; Kwo, PY; Lawitz, EJ; Liu, Z; McPhee, F; Noviello, S; Pockros, PJ; Pol, S; Rodriguez-Torres, M; Rustgi, VK; Schnittman, S; Serfaty, L; Shafran, SD; Sievert, W; Sulkowski, M; Tatum, HA; Thuluvath, PJ; Vierling, JM; Waked, I; Weiland, O; Weis, N; Wind-Rotolo, M; Yin, PD; Zeuzem, S1
Harada, N; Hayashi, N; Hiramatsu, N; Imai, Y; Inada, M; Inui, Y; Ito, T; Kasahara, A; Kato, M; Mita, E; Miyagi, T; Morishita, N; Oshita, M; Oze, T; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yamada, R; Yoshida, Y; Yoshihara, H1
Devine, S; Kattan, M; Muir, A; Thompson, A1
Abbassi, MM; Aref, AM; EzzEl-Arab, MA; Hamed, WA; Mohamed, AA1
Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Itoh, A; Katano, Y; Kumada, T; Kuzuya, T; Masuda, H; Nakano, I; Toyoda, H; Urano, F; Yoshioka, K1
Aimitsu, S; Aisaka, Y; Chayama, K; Hayes, CN; Imamura, M; Kawakami, H; Kawakami, Y; Kira, S; Kitamoto, M; Kohno, H; Moriya, T; Nakanishi, T; Nonaka, M; Takahashi, S; Tsuji, K; Yamashina, K; Yokoyama, S1
Maldonado, AM; Martín-Álvarez, A; Muñoz-de-Rueda, P; Quer, J; Quiles-Pérez, R; Salmerón, J1
Deghedy, A; El-Fatah Fahmy Hanno, A; Mohiedeen, KM; Sayed, R1
Manos, MM; Murphy, RC; Pauly, MP; Price, JC; Shvachko, VA1
Berdeaux, G; Bianic, F; Cure, S; de Knegt, RJ; Lamotte, M; van Agthoven, M; van der Kolk, A; Vellopoulou, A1
Kraus, MR; Schäfer, A; Scheurlen, M1
Barreiro, P; de Mendoza, C; Fernández-Montero, JV; Labarga, P; Soriano, V1
Dan, YY; Elbasha, EH; Ferrante, SA; Hsu, TY1
Abd El Aziz, G; El Raziky, M; Rashad, A; Shaker, O1
Hayashi, N; Izumi, N; Mobashery, N1
Bertz, R; Bifano, M; Eley, T; Gardiner, D; Grasela, DM; He, B; Huang, SP; Kandoussi, H; Sevinsky, H; Zhu, K1
Bardadin, K; Berak, H; Horban, A; Kołakowska-Rządzka, A; Laskus, T; Stańczak, JJ; Walewska-Zielecka, B; Wasilewski, M1
Chang, KC; Chang, ML; Chen, TH; Cheng, ML; Chiu, CT; Hu, TH; Lin, CH; Lin, WR; Pang, JH; Shiao, MS; Sung, CM; Tsou, YK; Yeh, CT1
Abradelo, M; Agüero, F; Aguilera, V; Antela, A; Barcena, R; Bernal, C; Castells, L; de la Rosa, G; Del Campo, S; Esteban-Mur, JI; Fernandez, JR; González-García, J; Laguno, M; Manzardo, C; Miro, JM; Montero, JL; Olivares, S; Perez, I; Rimola, A; Rodriguez, M; Salcedo, M; Suarez, F; Valdivieso, A; Xiol, X1
Climente-Martí, M; Gómez-Álvarez, S; Guglieri-López, B; Ventura-Cerdá, JM1
Caro-Pérez, N; Coto-Llerena, M; Crespo, G; Fernández-Carrillo, C; Forns, X; Gambato, M; González, P; Mensa, L; Navasa, M; Pérez-del-Pulgar, S1
Al Bouzidi, A; El Baaj, M; Hadri, L; Moudden, MK; Ouarssani, A; Ziadi, T1
Abdou, AG; Asaad, NY; Ehsan, N; El-Sabaawy, MM; Elkholy, S; Elnaidany, NF; Eltahmody, M1
Adachi, K; Hayashi, M; Ishii, T; Kumano, R; Kumon, D; Sato, A; Yamada, T; Yamauchi, M1
Eslick, GD; Kitson, MT; Roberts, SK; Sarrazin, C; Toniutto, P1
Bazin-Kara, D; Blanc, F; Cacoub, P; Cazorla, C; Decaux, O; Karras, A; Lambotte, O; Musset, L; Peltier, J; Pialoux, G; Pol, S; Resche Rigon, M; Saadoun, D; Thibault, V; Vittecoq, D; Ziza, JM1
Aboulker, JP; Aumaitre, H; Batisse, D; Bertucci, I; Braun, J; Chevaliez, S; Cotte, L; de Truchis, P; Gervais, A; Lacombe, K; Lascoux-Combe, C; Michelet, C; Molina, JM; Morlat, P; Neau, D; Rosa, I; Sogni, P; Valantin, MA; Vincent, C; Vittecoq, D1
Rockstroh, JK2
Asselah, T; Bruno, S; Craxi, A1
Ebrahimi, M; Haqshenas, G; KayvanJoo, AH1
Bai, CH; Chong, LW; Lai, HW; Liao, CS; Lin, YM; Pu, CY; Su, HC; Tsai, PJ; Tsai, YS; Tsao, CW; Young, KC1
Alshuth, U; Hueppe, D; Jordan, S; Lohse, AW; Lueth, S; Mauss, S; Pfeiffer-Vornkahl, H; Roeder, C; Schulze Zur Wiesch, J; Stoll, S; Zehnter, E1
Andreone, P; Conti, F; Vitale, G1
Delaney, W; Dvory-Sobol, H; Lawitz, EJ; Mabery, E; McHutchison, J; Miller, MD; Mo, H; Skurnac, T; Svarovskaia, ES; Voitenleitner, C1
Aldámiz-Echevarría, T; Bellón, JM; Berenguer, J; Carrero, A; Crespo, M; Esteban, H; Galindo, MJ; González-García, J; Guardiola, JM; López-Aldeguer, J; Montes, M; Quereda, C; Santos, I; Sanz, J; Téllez, MJ; Von Wichmann, MA; Zamora, FX1
Cifuentes, C; Di Lello, FA; Gómez-Mateos, J; Guelfo, JR; Macías, J; Mira, JA; Neukam, K; Palomares, JC; Parra-Sánchez, M; Pineda, JA; Real, LM1
Beumont, M; Cerri, K; Evon, DM; Fu, M; Gilles, L; Peeters, M; Rosa, K; Scott, J; Zeuzem, S1
Lutchman, GA; Nguyen, MH; Nguyen, NH; Vutien, P; Wong, CR; Yee, BE; Zhang, B1
Jiang, D; Li, J; Li, XG; Li, Z; Liu, Y; Wang, M; Wu, S; Zhang, H; Zhang, Y; Zhang, Z; Zheng, W; Zhou, R1
Chiang, CH; Lai, FJ1
Bezemer, G; de Knegt, RJ; Hansen, BE; Hotho, DM; Janssen, HL; Van Gool, AR; Veldt, BJ1
Brussman, K; Nadir, A; Smith, ZM1
De La Rosa, G; Dieterich, D; Gutiérrez, F; Jenkins, A; Jessner, W; Klein, MB; Lenz, O; Orkin, C; Ouwerkerk-Mahadevan, S; Peeters, M; Reynes, J; Rockstroh, JK; Shukla, U; Tambuyzer, L1
Allen, S; Barclay, S; Bhattacharyya, D; Dillon, JF; Fox, R; Fraser, A; Goldberg, DJ; Hayes, PC; Hutchinson, SJ; Innes, HA; Kennedy, N; McDonald, SA; Mills, PR1
Brainard, D; Dvory-Sobol, H; Gao, B; Garrison, KL; Genda, T; Hino, K; Ide, T; Ikeda, F; Ishizaki, A; Izumi, N; Knox, S; McHutchison, JG; Mizokami, M; Mochizuki, H; Nakane, K; Nirei, K; Nishigaki, Y; Nishiguchi, S; Omata, M; Omote, M; Sakamoto, N; Symonds, WT; Takehara, T; Toda, N; Toyoda, H; Ueno, Y; Umemura, T; Yanase, M; Yatsuhashi, H; Yokosuka, O1
Jiao, J; Liu, W; Qu, C; Zheng, Z; Zhu, J1
Imran, M; Manzoor, S; Parvaiz, F1
Kang, Y; Shang, J; Zeng, Y1
Kottilil, S; Lee, YJ; Masur, H; McHutchison, J; Meissner, EG; Naggie, S; Osinusi, A; Patel, K; Qin, J; Remaley, AT; Sampson, M; Sims, Z; Sturdevant, D; Subramanian, M1
Du, S; Gong, Y; Kong, W; Li, C; Li, J; Mao, W; Qu, Y; Rao, H; Tian, S; Yang, J; Zhang, W1
Boghdadi, G; Seleem, WM1
Blanchard, E; Samaras, K; Vickers, CR1
Martel-Laferrière, V1
Aichelburg, MC; Grabmeier-Pfistershammer, K; Lang, G; Mandorfer, M; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Schwabl, P; Steiner, S; Trauner, M1
Aldámiz-Echevarria, T; Berenguer, J; Briz, V; Carrero, A; Diez, C; García-Álvarez, M; Guzmán-Fulgencio, M; Jiménez-Sousa, MA; Pineda-Tenor, D; Resino, S; Tejerina, F1
Cai, L; Chen, Y; Liao, R; Liu, X; Lu, Q; Wang, X; Yang, X; Yang, Z; Zhang, L1
Amanzada, A; Cameron, S; Goralczyk, AD; Mihm, S; Moriconi, F; Reinhardt, L1
Peltekian, KM1
Yau, AH; Yoshida, EM1
Congly, SE; Lee, SS1
Saab, S; Younossi, ZM1
Ahn, SH; Baatarkhuu, O; Han, KH; Jung, KS; Kim, BK; Kim, DY; Kim, SU; Moon, C; Park, JY1
Fabiani, F; Focà, A; Liberto, MC; Marascio, N; Nucara, S; Perrotti, N; Quirino, A; Strazzulla, A; Torti, C; Trapasso, F; Zicca, E1
Abu Shanab, A; Carr, MJ; Chin, JL; Collison, M; Connell, J; Coughlan, S; Hall, WW; Mac Nicholas, R; McCormick, PA; Merriman, RB; Segurado, R1
Berak, H; Eng, S; Feld, JJ; Foster, GR; Hooper, GJ; Jablkowski, M; Jacobson, IM; Jensen, DM; Kulkarni, R; Le Pogam, S; Lim, CY; Nájera, I; Navarro, MT; Perez-Gomez, HR; Pol, S; Scalori, A; Shahdad, S; Shulman, NS; Tam, E; Tavel, JA; Vierling, JM; Yetzer, ES; Yoshida, EM1
Druyts, E; Lorenzi, M; Mills, EJ; Thorlund, K; Toor, K1
Gonzalez-Peralta, R; Jonas, MM; Lobritto, S; Molleston, JP; Murray, KF; Pavlovic, V; Rosenthal, P; Schwarz, KB; Warne, C; Wat, C; Wen, J1
Badri, P; Bennett, M; Campbell, A; Hu, Y; Kapoor, M; Lawitz, E; Pilot-Matias, T; Poordad, F; Rodrigues, L; Rodriguez-Torres, M; Sullivan, G; Vilchez, RA1
Bock, JA; Fairley, KJ; Inverso, NA; Maeng, DD; Pitcavage, JM; Smith, RE; Williams, MS1
Broder, MS; Chang, E; L'Italien, G; Sapra, S1
Halota, W; Junik, R; Kozielewicz, D1
Böcher, W; Buti, M; Buynak, RJ; Dufour, JF; Gallivan, JP; Mantry, P; Mensa, FJ; Soriano, V; Stern, JO; Taunk, J; Vinisko, R; Zeuzem, S1
Balart, LA; Behorquez, HE; Bohorquez, HE; Bruce, D; Carmody, I; Chandra, PK; Cohen, AJ; Dash, S; Gunduz, F; Hazari, S; Kurt, R; Loss, G; Panigrahi, R; Poat, B; Wu, T1
Aikata, H; Chayama, K; Fujino, H; Fukuhara, T; Hiramatsu, A; Imamura, M; Kan, H; Kawaoka, T; Morio, R; Sasaki, T1
Baum, U; Böker, KH; Buggisch, P; Busch, HW; Cornberg, M; Hardtke, S; Heidrich, B; Hinrichsen, H; Klinker, H; Link, R; Maasoumy, B; Manns, MP; Möller, B; Naumann, U; Petersen, J; Teuber, G; Wedemeyer, H; Wiegand, SB; Zehnter, E1
De Silva, S; Foster, GR1
De Knegt, RJ; Hansen, B; Janssen, HL; Orlent, H1
Brunetto, MR; Cohen, D; Cooney, E; de Lédinghen, V; Dore, GJ; Fung, SK; George, J; Ghesquiere, W; Hagens, P; Harley, H; Hernandez, D; Hézode, C; Hughes, EA; Larrey, D; Lawitz, E; Lee, SS; McPhee, F; Noviello, S; Pol, S; Ramji, A; Shafran, SD; Strasser, SI; Taliani, G; Tatum, HA; Tran, A; Weis, N; Zaltron, S1
Arenas, J; Babudieri, S; Bollani, S; Bruno, S; Calleja, JL; Calvaruso, V; Caremani, M; Ceccherini Silberstein, F; Chemello, L; Ciancio, A; Colletta, C; Craxì, A; Crespo, J; Forns, X; Gea, F; Larrubia, JR; Magni, C; Maisonneuve, P; Mangia, A; Marenco, S; Moretti, A; Pascasio, JM; Perez-Alvarez, R; Piovesan, S; Zignego, AL1
Dong, ZX; Guo, SM; Xiang, XG; Xie, Q; Zhao, GD; Zhou, HJ; Zhuang, Y1
Dillon, JF; Miller, MH; Paterson, JC1
Brennan, B; Canini, L; Chatterjee, A; Guedj, J; Lemenuel-Diot, A; Perelson, AS; Smith, PF1
An, D; Brainard, DM; Dvory-Sobol, H; Hyland, RH; Lawitz, E; McHutchison, JG; Membreno, FE; Poordad, F; Symonds, WT1
Barakat, F; Cattie, JE; Cherner, M; Franklin, D; Grant, I; Hassanein, T; Heaton, RK; Letendre, SL; Perry, W; Umlauf, A; Woods, SP1
Goldhaber-Fiebert, JD; Holodniy, M; Liu, S; Watcha, D1
Ishihara, T; Kaneko, K; Mizushima, T1
Hazama, T; Hitobe, Y; Ikeda, F; Iwasaki, Y; Miyake, K; Namba, S; Nouso, K; Shiraha, H; Takaki, A; Yamamoto, K; Yamasaki, N1
Akamatsu, N; Aoki, T; Hasegawa, K; Izumi, N; Kaneko, J; Kokudo, N; Kurosaki, M; Sakamoto, Y; Sugawara, Y; Tamura, S; Tanaka, T1
Lagging, M; Nyström, K; Waldenström, J1
Rojas, Á; Romero-Gómez, M1
Stirnimann, G1
Baxter, L; Cooper, K; Frampton, GK; Hartwell, D; Loveman, E1
Abe, H; Aizawa, Y; Arai, T; Atsukawa, M; Fukuda, T; Hashimoto, S; Itokawa, N; Iwakiri, K; Kawamoto, C; Kondo, C; Matsushita, Y; Nakagawa, A; Nakatsuka, K; Sakamoto, C; Shimada, N; Tsubota, A1
Aghemo, A; Berardinelli, L; D'Ambrosio, R; Fabrizi, F; Martin, P; Messa, P; Pallotti, F1
Beumont-Mauviel, M; De La Rosa, G; Forns, X; Fried, MW; Fu, M; Jacobson, IM; Jessner, W; Kalmeijer, R; Lenz, O; Manns, MP; Ouwerkerk-Mahadevan, S; Peeters, M; Poordad, F; Scott, JA; Sinha, R; Zeuzem, S1
Fauci, AS; Kohli, A; Kottilil, S; Marti, MM; Masur, H; McHutchison, JG; Meissner, EG; Nelson, A; Osinusi, A; Pang, PS; Silk, R; Subramanian, GM; Townsend, K; Zhang, X1
Agarwal, K; Cohen, D; Podsadecki, T; Poordad, F; Xie, W; Younes, Z1
Aldámiz-Echevarria, T; Berenguer, J; Carrero, A; Diez, C; García-Alvarez, M; García-Broncano, P; Guzmán-Fulgencio, M; Jiménez-Sousa, MA; Pineda-Tenor, D; Resino, S; Tejerina, F; Vázquez-Morón, S1
Ghanbari, R; Heidari, Z; Shahzamani, K; Tahamsebifar, A1
Anan, A; Fukunaga, A; Hirano, G; Irie, M; Iwashita, H; Iwata, K; Kitamura, Y; Kunimoto, H; Kuno, S; Morihara, D; Nishizawa, S; Sakisaka, S; Sakurai, K; Shakado, S; Sohda, T; Takata, K; Takeyama, Y; Tanaka, T; Tsuchiya, N; Watanabe, H; Yokoyama, K; Yoshikane, M; Yotsumoto, K1
Bory, F; Broquetas, T; Cabrero, B; Cañete, N; Carrión, JA; Coll, S; García-Retortillo, M; Giménez, MD; González-Colominas, E; Knobel, H; Pellicer, R; Retamero, A; Salas, E; Solà, R1
Badri, P; Brown, R; Burton, JR; Coakley, E; Forns, X; Gordon, F; Kwo, PY; Levitsky, J; Mantry, PS; Pilot-Matias, T; Setze, C; Te, HS; Terrault, NA; Vargas, HE; Vilchez, RA; Xie, W1
Antonini, TM; Bonhomme-Faivre, L; Coilly, A; Duclos-Vallée, JC; Furlan, V; Haim-Boukobza, S; Roque-Afonso, AM; Samuel, D; Sebagh, M; Taburet, AM; Teicher, E; Vittecoq, D1
Chen, DS; Chen, PJ; Chung, CS; Kao, JH; Liang, CC; Lin, CK; Liu, CH; Liu, CJ; Su, TH; Yang, HC1
Cornberg, M; Höner zu Siederdissen, C1
Deroń, Z; Jabłonowska, E; Piekarska, A; Sidorkiewicz, M; Skubała, A; Wójcik, K1
Berg, T; Hamdi, N; Herrmann, E; Lange, C; Müller, T; Perner, D; Sarrazin, C; Susser, S; Zeuzem, S1
Kawano, A; Miyagi, Y; Nomura, H; Tanimoto, H; Yamashita, N1
Costa e Silva, FV; Jardim, FN; Mosegui, GB; Peregrino, AA; Rodrigues, MP; Vianna, CM1
Antolović-Požgain, A; Barbić, J; Bošnjak, Z; Perić, M; Roksandić-Križan, I; Ružman, N; Šarkanj, B; Vuković, D1
Alberti, A; Brass, C; Buti, M; Calistru, P; Chuang, WL; Davis, GL; Flisiak, R; Goeser, T; Horban, A; Kao, JH; Mazzella, G; Orsenigo, R; Pol, S; Rasenack, J; Streinu-Cercel, A; Tabak, F1
Asch, SM; Barnett, PG; Dally, SK; Gidwani, R; Goldhaber-Fiebert, JD; Lo, J; Owens, DK1
Feray, C; Hézode, C; Pawlotsky, JM; Ruiz, I1
Ferenci, P9
Arizumi, T; Chishina, H; Hagiwara, S; Inoue, T; Kitai, S; Kouno, M; Kudo, M; Minami, Y; Takita, M; Ueshima, K; Yada, N1
Arizumi, T; Hagiwara, S; Inoue, T; Kudo, M; Minami, T; Nishida, N; Sakurai, T; Takita, M; Ueshima, K; Yada, N1
Bielsa Marsol, I; Carrascosa Carrillo, JM; Ferrándiz Foraster, C; López Escartin, D; Masnou Ridaura, H; Morillas Cunill, R; Plana Pla, A; Planas Vilà, R; Toro Montecinos, M; Vilavella Rius, M1
Beumont, M; Buelens, A; Ceulemans, H; De Meyer, S; Fevery, B; Lenz, O; Peeters, M; Picchio, G; Tambuyzer, L; Verbinnen, T; Vijgen, L1
Bagaglio, S; Della Torre, L; Hasson, H; Lazzarin, A; Merli, M; Messina, E; Morsica, G; Uberti-Foppa, C1
Ain, D; Doehle, B; Jiang, D; Kersey, K; Kirby, BJ; Knox, SJ; Massetto, B; McHutchison, JG; Meshrekey, R; Mikhail, S; Riad, J; Ruane, PJ; Soliman, M; Stryker, R; Symonds, WT; Wolfe, PR1
Becerro González, I; Carrascosa de Lome, R; de Argila, D; García-Buey, L; Martín Domínguez, V; Villar, K1
Mangia, A; Piazzolla, V1
Chang, KC; Chen, CH; Chen, HH; Hu, TH; Huang, CC; Huang, CM; Hung, HC; Lee, CM; Lin, MT; Lu, SN; Tsai, MC; Tseng, PL; Wang, JH; Wu, CK; Wu, YY; Yen, YH1
Chen, X; Wei, L; Wu, H; Yan, H; Zhang, S; Zhang, Y; Zhao, Y1
Ali, K; Aziz, H; Gill, ML; Irfan, J; Khattak, JZ; Raza, A1
Barr, E; Bourliere, M; DeJesus, E; Dutko, F; Gerstoft, J; Haber, B; Hezode, C; Howe, AY; Hwang, P; Kugelmas, M; Mallolas, J; Murillo, A; Nahass, R; Pol, S; Robertson, M; Serfaty, L; Shaughnessy, M; Shibolet, O; Sulkowski, M; Vierling, JM; Wahl, J; Weis, N; Zuckerman, E1
Alric, L; Balart, L; Barr, E; Bronowicki, JP; Dutko, F; Gane, E; Ghalib, R; Ghesquiere, W; Guyader, D; Haber, B; Howe, AY; Hwang, P; Lagging, M; Lawitz, E; Lester, L; Pearlman, B; Robertson, M; Shaughnessy, M; Sievert, W; Sund, F; Tam, E; Wahl, J1
Bernabucci, V; Cammà, C; Cerami, C; Ciancio, A; Critelli, R; Karampatou, A; Petta, S; Rizzetto, M; Sagnelli, C; Strona, S; Todesca, P; Turco, L; Villa, E1
Maliakkal, B; Soota, K1
Andreone, P; Dammers, E; Fu, M; George, J; Horban, A; Jessner, W; Kurland, D; Lenz, O; Ouwerkerk-Mahadevan, S; Reddy, KR; Scott, J; Stanciu, C; Verbinnen, T; Villamil, FG; Weiland, O; Zeuzem, S; Zoulim, F1
Dusheiko, G1
Aihara, Y; Fukuba, R; Fukui, H; Kawaratani, H; Kaya, D; Kubo, T; Mitoro, A; Morioka, C; Noguchi, R; Yoshiji, H1
Andreone, P; Gamal, N; Vukotic, R1
Arbuckle, R; Beumont, M; Brohan, E; Fu, M; Gilles, L; Jessner, W; Panter, C; Scott, J1
Artuk, C; Eyigün, CP; Gül, HC; Kıratlı, K; Kozan, S; Oztuna, A; Tunca, Y1
Cohen, S; Cooney, E; DeMicco, M; Ghalib, R; Hanson, J; Hughes, E; Lawitz, E; Martorell, C; Ravendhran, N; Rustgi, V; Tatum, H; Thuluvath, PJ; Treitel, M; Zamparo, J; Zhao, J1
Guo, L; Han, Y; Zhu, J1
Jones, B; Warren, E; Wright, A1
Aoki, Y; Hashimoto, S; Imamura, M; Izumi, N; Kage, M; Kang, JH; Kanto, T; Kimura, T; Korenaga, M; Kurosaki, M; Masaki, N; Mizokami, M; Murata, K; Naito, S; Nomura, H; Sugiyama, M; Takeda, T; Yamagiwa, Y; Yatsuhashi, H; Yoshio, S1
Beste, LA; Green, PK; Ioannou, GN1
Chen, CH; Chiu, YC; Hu, TH; Hung, CH; Kuo, MT; Lee, CM; Lu, SN; Wang, JH1
Angus, P; Asselah, T; Böcher, W; Bourlière, M; Bronowicki, JP; Buti, M; Gallivan, JP; Gane, EJ; Lohse, AW; Manns, M; Mensa, FJ; Müllhaupt, B; Roberts, S; Sabo, JP; Schuchmann, M; Soriano, V; Stern, JO; Stickel, F; Voss, F; Zeuzem, S1
Benjamin, S; Botfield, MC; Dimova, RB; Penney, MS; Talal, AH; Zeremski, M1
Chan, J; Mohammad, RA; Smith, MA1
Burnevich, ÉZ; Tikhonova, NIu1
Chen, TC; Chen, YH; Lin, CY; Lin, SY; Lin, WR; Lu, PL; Yang, YH1
Bodeau, S; Brochot, E; Duverlie, G1
Bernstein, B; Chevaliez, S; Cloherty, G; Cohen, DE; Herman, C; Pawlotsky, JM; Sarrazin, C; Wedemeyer, H1
Jensen, DM; Welch, NM1
Ansaldi, C; Benali, S; Bourlière, M; Le Folgoc, G; Lecomte, L; Riso, A1
Abdel-Razek, W; Waked, I1
Bargach, T; Chatioui, S; Elasri, F; Iferkhass, S; Khoyaali, A; Oubaaz, A; Reda, K1
Benanti, F; Cacopardo, B; D'Agata, V; Nunnari, G; Pinzone, MR; Rapisarda, L; Spartà, D; Zanghì, AM1
Bennis, Y; Bodeau, S; Brochot, E; Capron, D; Duverlie, G; Nguyen-Khac, E; Solas, C1
Andreoni, M; Angelico, M; Antonucci, FP; Aragri, M; Babudieri, S; Ceccherini-Silberstein, F; Cento, V; De Leonardis, F; Di Biagio, A; Di Carlo, D; Di Maio, VC; Di Paolo, D; Gasbarrini, A; Landonio, S; Lenci, I; Magni, CF; Mancon, A; Manunta, A; Micheli, V; Mura, MS; Nicolini, LA; Nosotti, L; Parruti, G; Pellicelli, A; Perno, CF; Rizzardini, G; Sarrecchia, C; Siciliano, M; Taliani, G; Tontodonati, M; Vecchiet, J1
Kagawa, K; Katayama, Y; Kuniyoshi, T; Suzuki, K; Takada, H; Tamano, M1
Celik, B; Gumuslu, S; Kose, S; Seyman, D; Yalcin, AD; Yalcin, AN1
Abel, L; Albert, ML; Barthe, Y; Bronowicki, JP; Carrat, F; Casrouge, A; Dorival, C; Fontaine, H; Fontanet, A; Gayat, E; Hézode, C; Lagaye, S; Mallet, V; Mottez, E; Pol, S; Sultanik, P; Theodorou, I1
Cornberg, J; Cornberg, M; Deterding, K; Höner Zu Siederdissen, C; Kirschner, J; Maasoumy, B; Manns, MP; Mix, C; Port, K; Sollik, L; Wedemeyer, H1
Baumert, TF; Brainard, D; Brandt-Sarif, T; Castells, L; Chang, P; Charlton, M; Coilly, A; Denning, J; Fontana, RJ; Forns, X; Habersetzer, F; Kivett, V; Londoño, MC; McHutchison, JG; Prieto, M; Symonds, WT1
Ehleben, C; Pearlman, BL; Perrys, M1
An, J; Ni, W; Qiao, J1
Agarwal, K; Asselah, T; Bourlière, M; Calinas, F; Crespo, J; Datsenko, Y; Dufour, JF; Ferenci, P; Forton, D; Foster, GR; Garcia, M; Kukolj, G; Maevskaya, M; Morano, LE; Moreno, C; Nishiguchi, S; Omata, M; Ouzan, D; Quinson, AM; Sarrazin, C; Scherer, J; Schuchmann, M; Stern, JO; Zehnter, E; Zeuzem, S1
Aboulker, JP; Barrail-Tran, A; Chevaliez, S; Cotte, L; Fournier, I; Lacombe, K; Molina, JM; Taburet, AM; Valantin, MA; Vincent, C1
Kawasaki, Y; Masaki, N; Sato, I; Shimbo, T1
Ferenci, P; Ferenci-Förster, D; Hagmann, M; Kienbacher, C; Miehsler, W; Moser, G; Reichhold, D; Scherzer, TM; Staufer, K1
Diego, R; Giampaolo, Q; Marco, R; Sara, B; Vasilij Benatti, S1
Bonino, F; Brunetto, MR; Colombatto, P; Iannazzo, S; Oliveri, F; Ricco, G1
Bradrick, SS; Goldstein, DB; Lu, YF; Urban, TJ1
Andreone, P; Gamal, N; Vitale, G1
Modi, R; Saab, S1
Hunt, SL; Naggie, S; Orkin, C; Puoti, M; Stepanova, M; Sulkowski, M; Younossi, ZM1
Abd El-Wahab, EW; Mikheal, A; Shatat, HZ; Sidkey, F1
Feld, JJ; Krahn, M; Tu, HA; Wong, T; Wong, WWL1
Antinori, S; Calvi, E; Cheli, S; Clementi, E; D'Avolio, A; De Nicolò, A; Falvella, FS; Magni, C; Mazzali, C; Milazzo, L; Peri, AM1
Bernhardt, P; Duvoux, C; Firpi, RJ; Grazi, GL; Levy, G; Mulhaupt, B; Pageaux, G; Rauer, B; Renner, EL; Schirm, F; Villamil, F1
Foster, GR5
Abbott, S; Barrett, LL; Bon, D; Chavez, J; Diaz, G; Egerson, D; Fauci, AS; Gross, C; Herrmann, E; Jolley, TA; Kapoor, R; Kleiner, DE; Kohli, A; Kotb, C; Kottilil, S; Kwan, R; Marti, MM; Masur, H; McHutchison, J; Meissner, EG; Nelson, A; Osinusi, A; Pang, PS; Petersen, T; Polis, MA; Proschan, M; Sidharthan, S; Silk, R; Sims, Z; Sneller, M; Spurlin, E; Subramanian, GM; Symonds, WT; Talwani, R; Teferi, G; Townsend, K; Wood, BJ1
Devaki, P; Jencks, D; McCormack, SA; Nguyen, MH; Nguyen, NH; Vutien, P; Yee, BE1
Beumont, M; Bourgeois, S; Fevery, B; Francque, S; Grange, JD; Hezode, C; Jessner, W; Lenz, O; Marcellin, P; Moreno, C; Ouwerkerk-Mahadevan, S; Peeters, M; Samuel, D; Shukla, U; Zoulim, F1
Becker, B; Berden, FA; Burger, DM; Colbers, AP; de Kanter, CT; de Knegt, RJ; Dofferhoff, AS; Drenth, JP; Grintjes-Huisman, KJ; Koning, L; Rockstroh, JK; Roukens, MM; Wasmuth, JC1
Pawlowska, M1
Childs-Kean, LM; Hand, EO1
Araki, Y; Ikeda, F; Iwasaki, Y; Kobashi, H; Miyake, Y; Okamoto, R; Takaki, A; Taniguchi, H; Yamamoto, K1
Do, D; Nambudiri, V; Shuster, M1
Henry, L; Younossi, Z1
Ahmed, A; Dieterich, D; Gordon, SC; Park, H; Saab, S; Younossi, ZM2
Brainard, D; Gaggar, A; Gonzalez, M; Kirby, B; McHutchison, JG; Rodriguez-Orengo, J; Rodriguez-Torres, M; Shen, G; Svarovskaia, E; Symonds, WT1
Okubo, A; Tamaki, K1
Abraham, GM; Akushevich, L; Di Bisceglie, AM; El-Genaidi, H; Fenkel, JM; Fried, MW; Kuo, A; Mah'moud, MA; Nelson, DR; Rustgi, VK; Sterling, RK; Stewart, PW; Stewart, TG; Sulkowski, MS1
Afdhal, N; Hunt, SL; Kowdley, KV; Marcellin, P; Stepanova, M; Younossi, ZM; Zeuzem, S1
Alric, L; Bailly, F; Bourlière, M; Bronowicki, JP; Carrat, F; Dufour, C; Fontaine, H; Hézode, C; Larrey, D; Loustaud-Ratti, V; Métivier, S; Pradat, P; Samuel, D; Serfaty, L; Virlogeux, V; Zarski, JP; Zoulim, F1
Angelico, M; Antonucci, FP; Armenia, D; Babudieri, S; Bellocchi, MC; Bertoli, A; Cacciatore, P; Carioti, L; Ceccherini-Silberstein, F; Cento, V; Di Maio, VC; Fortuna, S; Manunta, A; Navarra, P; Neumann, AU; Parruti, G; Perno, CF; Tontodonati, M; Trave, F; Valenti, F; Vecchiet, J1
Badri, P; Chayama, K; Kumada, H; Kurosaki, M; Notsumata, K; Pilot-Matias, T; Rodrigues, L; Sato, K; Setze, C; Vilchez, RA1
Anderson, PL; Baouchi-Mokrane, F; Burton, JR; D'Argenio, DZ; Everson, GT; Hammond, KP; Kiser, JJ; Rower, JE; Urban, TJ; Wu, LS1
Ray, G1
Ackefors, M; Castedal, M; Dahlgard, O; Gjertsen, H; Verbaan, H; Weiland, O; Wernerson, A1
Arends, JE; Dabis, F; Fontaine, H; Gilbert, C; Lacombe, K; Loko, MA; Miailhes, P; Puoti, M; Rockstroh, JK; Rosenthal, E; Salmon, D; Sogni, P; Winnock, M; Wittkop, L1
Devrajani, BR; Hayat, AS; Rajput, MI; Shaikh, N; Shaikh, S; Waryah, AM1
Di Bisceglie, AM; Fan, X; Lin, J; Wang, W; Xu, Y1
Buti, M; Cloherty, G; De Meyer, S; Dierynck, I; Ghys, A; Janssen, K; Luo, D; Picchio, G; Sarrazin, C; Witek, J1
Akuta, N; Hosaka, T; Ikeda, K; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y1
Boglione, L; Cardellino, CS; Cariti, G; D'Avolio, A; De Nicolò, A; Di Perri, G; Ghisetti, V; Ruggiero, T1
Brainard, D; Gaggar, A; Iser, DM; Massetto, B; McHutchison, JG; Molina, JM; Nelson, M; Ni, L; Orkin, C; Puoti, M; Rockstroh, JK; Stephan, C; Subramanian, GM; Svarovskaia, E; Zamora, FX1
Kim, AY; Naggie, S1
Allegra, S; Boglione, L; Cariti, G; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G; Gatto, A1
Guo, Q; Islam, MS; Li, JS; Li, ZQ; Ping, Y; Wang, F; Wang, LP; Wang, M; Yue, DL; Zhang, TF; Zhang, Y; Zhang, Z1
Barreira, P; Cadinha, S; da Silva, JP; Malheiro, D1
Hisanaga, Y; Ito, T; Kanamori, A; Kiriyama, S; Kitabatake, S; Kumada, T; Tada, T; Tanikawa, M; Toyoda, H1
Gale, SE; Klibanov, OM; Santevecchi, B1
Adler, M; Bourgeois, S; Brixko, C; Deltenre, P; Delwaide, J; Henrion, J; Langlet, P; Moreno, C; Mulkay, JP; Nevens, F1
Angeli, E; Caputo, A; Carosi, G; Cattelan, AM; Giralda, M; Iannacone, C; Maida, I; Nasta, P; Pontali, E; Puoti, M; Verucchi, G1
Ahn, JH; Baek, YH; Han, SY; Jo, YM; Kim, SY; Kim, WJ; Lee, JY; Lee, SW1
Chen, J; Chen, Y; Ling, Q; Min, N; Shang, B; Ye, Q; Zhong, J; Zhou, H; Zhuo, Y1
Chen, MH; Chou, CT; Huang, DF; Huang, YH; Lin, HY; Tsai, CY1
Bernstein, D; Brunetto, M; de Ledinghen, V; Elkhashab, M; Everson, G; Hennicken, D; Heo, J; Hézode, C; Hughes, E; Jensen, D; Kugelmas, M; Luketic, V; Mauss, S; McPhee, F; Mendez, P; Noviello, S; Pol, S; Serfaty, L; Sherman, KE; Tran, A; Vierling, J; Younes, ZH; Zeuzem, S1
Azam, S; Imran, M; Manzoor, S; Resham, S1
Ghani, E; Hussain, AB; Rathore, MA1
Endo, M; Fujita, T; Fujiwara, K; Iijima, S; Iio, E; Ito, K; Joh, T; Kusakabe, A; Matsuura, K; Miyaki, T; Nojiri, S; Onomoto, K; Shinkai, N; Tanaka, Y; Watanabe, T1
Afzal, S; Idrees, M; Khubaib, B; Saleem, S; Wasim, M1
Arastéh, K; Bhagani, S; Dieterich, D; Guardiola, JM; Ingiliz, P; Jain, MK; Kort, J; Laguno, M; Manero, M; Nelson, M; Rockstroh, JK; Soriano, V; Stern, JO; Tural, C; Vinisko, R1
Burnevich, EZ1
Choi, DJ; Jung, YK; Kim, EJ; Kim, JH; Kim, YS; Kwon, OS; Lee, HN; Lee, JJ; Park, SY; Shin, SK1
Ali, FT; Ali, MA; Elgizawy, MM; Elsawy, AM1
Hedrick, KT; Just, SM; Kahn, DR1
Angarano, G; Bartolomeo, N; Bruno, G; Fasano, M; Ladisa, N; Maggi, P; Monno, L; Saracino, A; Volpe, A1
Abe, H; Aizawa, Y; Atsukawa, M; Fukuda, T; Itokawa, N; Iwakiri, K; Kawamoto, C; Kondo, C; Matsushita, Y; Nakagawa, A; Nakatsuka, K; Sakamoto, C; Shimada, N; Tsubota, A1
Füessl, HS2
Jäger-Becker, D1
Chida, T; Kageyama, F; Kawamura, K; Kawata, K; Kobayashi, Y; Nagasawa, M; Noritake, H; Sasada, Y; Suda, T; Watanabe, S1
Chepa-Lotrea, X; Fryzek, N; Ghany, M; Keane, M; Kim, YJ; Liang, TJ; Rehermann, B; Serti, E1
Cerri, K; Kuwabara, H; Mahlich, J; Treur, M; Westerhout, K; Yatsuhashi, H1
Fujinaiga, H; Koike, K1
Akuta, N; Kumada, H1
Hiramatsu, N; Oze, T; Takehara, T1
Izumi, N; Suzuki, S1
Mochida, S1
Joshita, S; Tanaka, E1
Benito, JM; Berenguer, J; Cosín, J; García-Álvarez, M; Guzmán-Fulgencio, M; Jiménez-Sousa, MA; López, JC; Miralles, P; Pineda-Tenor, D; Rallón, N; Resino, S; Retana, D; Soriano, V1
Chi, B; Li, M; Liu, DW; Wang, J; Wu, XX; Zheng, H1
Gaytán-Martínez, JE; Huerta García, G; Mata-Marín, JA; Sandoval-Ramirez, JL1
Harada, N; Hayashi, N; Hiramatsu, N; Oze, T; Takehara, T; Tatsumi, T1
Abergel, A; Alric, L; Bourlière, M; Bronowicki, JP; de Ledinghen, V; Doehle, B; Grangé, JD; Guyader, D; Habersetzer, F; Hézode, C; Hyland, RH; Jiang, D; Larrey, DG; Leroy, V; Loustaud-Ratti, V; Marcellin, P; Mathurin, P; McHutchison, JG; Metivier, S; Pang, PS; Pol, S; Ratziu, V; Serfaty, L; Subramanian, GM; Symonds, WT; Tran, A; Zoulim, F1
Aghasadeghi, MR; Fateh, A; Ghazanfari, M; Hadizade Tasbiti, AR; Keyvani, H; Mollaie, HR; Monavari, SH; Yari, S1
Arabzadeh, SA; Ebrahimi, S; Fazlalipour, M; Iranmanesh, Z; Mollaie, HR; Zahedi, MJ1
Andersson, K; Avorn, J; Brennan, T; Choudhry, NK; Krumme, AA; Matlin, OS; Najafzadeh, M; Shrank, WH1
Afdhal, NH; Campbell, FM; Dusheiko, GM; Elkashab, M; Giannini, EG; Iyengar, M; Muir, AJ; Reddy, KR; Romero-Gómez, M; Sigal, SH; Theodore, D; Vasey, SY; Vijayaraghavan, S1
Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kawano, A; Kotoh, K; Koyanagi, T; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K3
Asabe, S; Funyu, J; Hashimoto, Y; Hosoda, Y; Inao, M; Koshima, Y; Mochida, S; Nakayama, N; Nishikawa, K; Omori-Mizuno, Y; Tanaka, M; Tomita, K; Yakabi, K1
Liffmann, DK; Rein, DB; Smith, BD; Ward, JW; Wittenborn, JS1
Curto, J; Di Yacovo, S; Ferrer, E; Imaz, A; Podzamczer, D; Saumoy, M; Van den Eynde, E; Vila, A1
Häggblom, A; Nowak, P; Nyström, J; Stenkvist, J; Weiland, O1
Butterton, JR; Feng, HP; Hulskotte, EG; Khalilieh, S; Wenning, LA1
Andriulli, A; Angelico, M; Di Marco, V; Fasano, M; Fattovich, G; Felder, M; Gaeta, GB; Gatti, P; Granata, R; Ippolito, AM; Mazzella, G; Milella, M; Morisco, F; Santantonio, T; Smedile, A; Valvano, MR1
Deguchi, H; Ichinose, M; Iguchi, M; Inoue, I; Kato, J; Maeda, Y; Maekita, T; Mori, Y; Moribata, K; Muraki, Y; Nuta, J; Shimizu, R; Shingaki, N; Takifuji, K; Tamai, H; Yamaue, H1
Faisal, N; Lilly, LB; Marquez, M; Mumtaz, K; Renner, EL1
El-Maraghy, SA; Motawi, TK; Senousy, MA; Shaker, OG1
Ben-Marzouk-Hidalgo, OJ; Castillo-Ferrando, JR; Espinosa, N; Gutierrez-Valencia, A; Lopez-Cortes, LF; Ruiz-Valderas, R; Torres-Cornejo, A; Viciana, P1
Hirohashi, K; Kanazawa, A; Kubo, S; Tanaka, S; Uenishi, T; Yamamoto, T1
Enjoji, M; Fujimori, N; Fukuizumi, K; Fukushima, N; Harada, N; Haraguchi, K; Kato, M; Kawabe, K; Kohjima, M; Kotoh, K; Koyama, S; Kurokawa, M; Murata, Y; Nakamura, T; Nakamuta, M; Sasaki, Y; Shimonaka, Y; Sumida, Y; Yoshimoto, T1
Amemiya, F; Enomoto, N; Fukasawa, M; Inoue, T; Komatsu, N; Maekawa, S; Miura, M; Moriishi, K; Muraoka, M; Nakayama, Y; Sakamoto, M; Sato, M; Sato, T; Suzuki, Y; Takano, S; Tatsumi, A; Uetake, T; Yamaguchi, T; Yamashita, A1
Carlsson, T; Hörnfeld, E; Lindahl, K; Parke, Å; Schvarcz, R; Ståhle, L; Weiland, O1
Assoumou, SA; Barter, DM; Freedberg, KA; Horsburgh, CR; Kim, AY; Leff, JA; Linas, BP; Morgan, JR; Pho, MT; Salomon, JA; Schackman, BR; Weinstein, MC1
Coilly, A; Duclos-Vallée, JC; Roche, B; Samuel, D2
Akiyama, MJ; Cheung, R; Ha, NB; Li, J; Nguyen, MH; Piotrowski, JI; Roytman, MM; Tsai, N; Vo, KP; Vu, VD; Vutien, P; Wantuck, J1
Abd-Elaati, BM; Ehsan, NA; El-Araby, HA; Konsowa, HA; Sira, AM1
Cai, WP; Gao, QS; Gao, YQ; Jiao, YM; Li, HJ; Li, LH; Weng, WJ; Wu, H; Zhu, WJ1
Güneş, P; Yaşar, B; Yaşar, Ş1
Albandea Moreno, C; Bautista Galán, C; Ruiz Arredondo, J; Serrato, AR1
Oni, O; Pandya, P; Rzouq, F1
Chang, WY; Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MH; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, WY; Lin, YH; Lin, ZY; Tsai, PC; Yeh, ML; Yu, ML1
Wedemeyer, H1
Asselah, T; Berenguer, M; Fleischer-Stepniewska, K; Hall, C; Hassanein, T; Hézode, C; Marcellin, P; Mobashery, N; Pilot-Matias, T; Pol, S; Reddy, KR; Redman, R; Schnell, G; Vilchez, RA1
Aguilar, H; Cohen, DE; Felizarta, F; Galen, E; King, M; Kowdley, KV; Lalezari, J; McGovern, B; Polepally, AR; Rustgi, V; Sullivan, JG; Varunok, P1
Appourchaux, K; Asselah, T; Bièche, I; Boyer, N; Carrat, F; Estrabaud, E; Lada, O; Lapalus, M; Marcellin, P; Martinot-Peignoux, M; Vidaud, M1
Flamm, S; Lawitz, E; McHutchison, JG; Morelli, G; Pang, PS; Pockros, P; Svarovskaia, E; Wyles, D; Yang, JC; Younes, Z; Zhu, Y1
Afdhal, N; Bourlière, M; Ding, X; Dvory-Sobol, H; Feld, JJ; Gane, E; Hyland, R; Knox, S; Lawitz, E; Mangia, A; Marcellin, P; McHutchison, JG; Mizokami, M; Omata, M; Pang, P; Pol, S; Reddy, KR; Subramanian, GM; Sulkowski, M; Symonds, W; Welzel, TM; Yang, J; Zeuzem, S1
Demuth, D; Forssen, U; Grotzinger, K; Irving, WL; Rizzetto, M; Roughley, A; Theodore, D1
Bennett, M; Brainard, D; Doehle, B; Gane, EJ; Hassanein, T; Jacobson, IM; Kanwar, B; Liu, L; McHutchison, JG; Mo, H; Nahass, RG; Pol, S; Subramanian, GM; Sulkowski, MS; Symonds, WT1
Alter, HJ; Ascierto, ML; Bedognetti, D; Bozzano, F; De Maria, A; DeGiorgi, V; Marenco, S; Marincola, FM; Marras, F; Matsuura, K; Moretta, L; Picciotto, A; Schechterly, C; Sommariva, M; Wang, E; Zhao, Y1
Abe, H; Aida, Y; Aizawa, Y; Furihata, T; Ishiguro, H; Itagaki, M; Seki, N; Shimada, N; Sugita, T; Sutoh, S; Tsubota, A1
Chen, HB; Huang, P; Su, J; Wang, J; Xu, Y; Yu, RB; Zhang, Y; Zhang, YY1
Akgöllü, E; Akkız, H; Bekar, A; Kuran, S; Sandıkçı, M; Ülger, Y; Üsküdar, O; Yalınbaş Kaya, B; Yıldırım, S1
Betular, J; Enomoto, H; Gao, B; Garrison, K; Genda, T; Ide, T; Ikeda, F; Ishizaki, A; Izumi, N; Knox, SJ; Korenaga, M; McHutchison, JG; Mizokami, M; Mo, H; Mochizuki, H; Nakane, K; Nirei, K; Nishigaki, Y; Omata, M; Omote, M; Pang, PS; Sakamoto, N; Symonds, WT; Takehara, T; Toda, N; Toyoda, H; Ueno, Y; Umemura, T; Yanase, M; Yatsuhashi, H; Yokosuka, O1
Beinhardt, S; Ferenci, P; Hofer, H; Peck-Radosavljevic, M1
Bartolini, B; Capobianchi, MR; D'Offizi, G; Garbuglia, AR; Gianpiero, D; Giombini, E; Hughes, EA; Ippolito, G; Lionetti, R; McPhee, F; Montalbano, M; Sias, C; Taibi, C; Zhou, N1
Chi, X; Jiang, J; Liu, Y; Lv, J; Niu, J; Pan, Y; Sun, B; Sun, H; Tu, Z; Wang, X; Wu, R; Zhong, J1
Ahn, SB; Choe, WH; Chung, JI; Jun, DW; Jung, KS; Kim, DY; Kim, JK; Kim, SG; Kim, W; Lee, SH; Park, SY; Seo, YS; Shim, JJ; Shin, HP1
Chtioui, H; Decosterd, LA; Giostra, E; Majno, PE; Moradpour, D; Pascual, M; Vionnet, J1
Chang, LC; Chen, LW; Chien, CH; Chien, RN; Hu, CC; Lin, CL; Liu, CJ1
Gattei, V; Mauro, E; Mazzaro, C; Panarello, G; Pozzato, G1
Cammà, C; Carosi, G; Craxì, A; Cure, S; Guerra, I1
Harada, N; Harimoto, N; Ikegami, T; Itoh, S; Kawanaka, H; Kimura, Y; Maehara, Y; Oki, E; Saeki, H; Shirabe, K; Soejima, Y; Takeishi, K; Tsujita, E; Uchiyama, H; Yamashita, YI; Yoshizumi, T1
Barr, E; Buti, M; Calleja, JL; DiNubile, MJ; Forns, X; Gilbert, C; Gordon, SC; Hofer, H; Howe, AY; Lawitz, E; Palcza, J; Robertson, MN; Wahl, J; Zuckerman, E2
Kitson, MT; Roberts, SK; Sarrazin, C; Toniutto, P1
Belsey, J; Ladha, I; Mehnert, A; Pascoe, K; Treur, M; Westerhout, K1
El Sabaawy, D; El-Bahrawy, H; El-Haggar, S; El-Said, H; Waked, I1
Albillos, A; Hernández-Guerra, M; Luis Calleja, J; Molina, E; Planas, R; Romero-Gómez, M; Turnes, J1
Liu, C; Pang, Q; Qu, K; Zhang, JY1
Fazylov, VKh; Manapova, ÉR; Tkacheva, SV1
Abraldes, JG; Albillos, A; Bañares, R; Bosch, J; Calleja, JL; Forns, X; García-Pagán, JC; García-Retortillo, M; Lens, S; Rincón, D; Sanchez-Tapias, JM1
Brown, A; Habibi, MS; Selvapatt, N1
Furusyo, N; Hayashi, J; Ikezaki, H; Murata, M; Ogawa, E; Shimizu, M; Takayama, K1
Cariani, E; Ferrari, C; Missale, G; Roli, L; Trenti, T; Villa, E1
Bhagani, S; Collado, A; de Los Santos-Gil, I; Delgado, M; Fehr, J; Haberl, A; López-Cortés, LF; Lutz, T; Mandorfer, M; Márquez, M; Mauss, S; Munteanu, DI; Neukam, K; Pineda, JA; Rivero, A; Rivero-Juárez, A; Rockstroh, JK; Scholten, S; Stoeckle, M1
Ali, E; El Sherbini, A; Mostafa, S1
Abravanel, F; Alain, S; André-Garnier, E; Baazia, Y; Besse, B; Bouvet, D; Bouvier-Alias, M; Brochot, E; Caporossi, A; David-Tchouda, S; Duverlie, G; Fleury, H; Gaudy-Graffin, C; Gouriou, S; Gozlan, J; Guivarch, M; Haïm-Boukobza, S; Halfon, P; Hantz, S; Henquell, C; Lada, O; Lagathu, G; Larrat, S; LeGuillou-Guillemette, H; Mackiewicz, V; Margier, J; Maylin, S; Mirand, A; Mohamed, S; Morand, P; Mourez, T; Pawlotsky, JM; Pivert, A; Plantier, JC; Pronier, C; Ramière, C; Roque-Afonso, AM; Scholtes, C; Schvoerer, E; Thibault, V; Trimoulet, P; Vallet, S; Velay, A1
Ho, S; Mehnert, A; Pacou, M; Pettré, S; Pisini, M; Taieb, V; Ustianowski, A; Van Sanden, S1
Aksoz, S; Ay, N; Baysal, B; Danis, R; Kaya, S1
Abo Youssef, H; Darwish, RK; El-Karaksy, HM; Mandour, IA; Mogahed, EA; Rady, NH; Sharaf, SA1
Doehle, B; Doss, W; Esmat, G; Fouad, R; Hammad, R; Hassany, M; Jiang, D; Kersey, K; Khairy, M; Knox, SJ; Massetto, B; McHutchison, JG; Samir, W; Shiha, G; Soliman, R1
Colombo, M2
Al Marzooqi, SH; Feld, JJ1
Cozzolongo, R; Giannuzzi, V; Lanzilotta, E; Leandro, G; Porcelli, P1
Cooper, J; Dore, GJ; Everson, G; Freilich, B; Ghesquiere, W; Herring, R; Hézode, C; Hughes, EA; Kwo, P; Lalezari, J; McPhee, F; Muir, AJ; Pockros, PJ; Poordad, F; Ramji, A; Reau, N; Sheikh, A; Stuart, K; Swenson, ES; Thompson, AJ; Tran, A; Vierling, J; Yang, R; Yin, PD; Yozviak, J1
Hajiaghamohammadi, A; Kazemifar, AM; Miroliaee, A; Nazem, M; Samimi, R1
Broquetas, T; Calleja, JL; Campillo, A; Carrión, JA; de la Revilla, J; Forns, X; Lens, S; Londoño, MC; Mariño, Z; Perello, C; Sánchez-Tapias, JM; Urbano-Ispizua, Á1
Dzwonek, AB; Wiśniewska-Ligier, M; Woźniakowska-GĘsicka, T1
Elarbi, B; Hicham, E; Mimoun, Z; Nadia, K; Nadia, T; Reda, TM; Saâd, E; Saâd, M1
Egawa, H; Hashimoto, E; Kogiso, T; Kotera, Y; Omori, A; Shiratori, K; Taniai, M; Tokushige, K; Yamamoto, M1
Afdhal, N; Alqahtani, SA; Ding, X; Fried, M; Gordon, SC; Kowdley, KV; Kwo, P; Mangia, A; Marcellin, P; McHutchison, JG; Pang, PS; Pound, D; Reddy, KR; Sulkowski, M; Yang, JC; Zeuzem, S1
Abe, H; Aizawa, Y; Arai, T; Atsukawa, M; Itokawa, N; Iwakiri, K; Kondo, C; Nakagawa, A; Okubo, T; Shimada, N; Tsubota, A1
Chu, PS; Ebinuma, H; Hibi, T; Kanai, T; Nakamoto, N; Saito, H; Shiba, S; Sugiyama, K; Taniki, N; Usui, S; Wakayama, Y; Wakita, T; Yamagishi, Y; Yamaguchi, A1
Beebe, A; Gicquelais, RE; Haselow, DT; Patil, N; Quattlebaum, T; Smith, NH; Zohoori, N1
Buti, M; Esteban, R; Llaneras, J; Riveiro-Barciela, M1
Bushman, LR; Jimmerson, LC; Kiser, JJ; Kottilil, S; McHutchison, JG; Meissner, EG; Osinusi, A; Petersen, T; Rower, JE; Sims, Z; Wolfe, P1
Burridge, A; Fialho, R; File, A; Keller, M; Pereira, M; Tibble, J; Whale, R1
Abdelatty, S; El Akel, W; El Raziky, M; Elsharkawy, A; Gamal Eldeen, H; Mabrouk, M; Said, SE; Tantawy, O1
Bárcena, R; Berenguer, M; Buti, M; Calleja, JL; Crespo, J; Fernández, I; González, O; López, J; Pérez, F1
Afdhal, N; Arterburn, S; Brandt-Sarif, T; Brown, K; Brown, RS; Charlton, M; Denning, J; Dvory-Sobol, H; Everson, GT; Flamm, SL; Fontana, RJ; Fried, MW; Gilroy, R; Korenblat, KM; Kumar, P; Kuo, A; Kwo, P; Landis, C; McHutchison, JG; Muir, AJ; O'Leary, JG; Pang, PS; Pungpapong, S; Reddy, KR; Schiff, E; Sulkowski, MS; Teperman, L; Terrault, NA; Vargas, HE; Watt, KD1
Frankova, S; Hejda, V; Jirsa, M; Merta, D; Neroldova, M; Senkerikova, R; Sperl, J; Spicak, J; Viklicky, O; Volfova, M1
Asselah, T; Cacoub, P; Carrat, F; Lapidus, N; Pol, S; Ratziu, V; Serfaty, L; Souberbielle, JC; Terrier, B; Thibault, V1
Arenas, MD; Caramelo, C; Carnicer, F; Espinosa, M; Fabrizi, F; Hernàndez, J1
Ikeda, H; Kamijo-Ikemori, A; Kimura, K; Matsui, K; Okuse, C; Shibagaki, Y; Sugaya, T; Yasuda, T1
Achterfeld, A; Canbay, A; Gerken, G; Herzer, K; Papadopoulos-Köhn, A; Paul, A; Timm, J; Walker, A1
Abo Taleb, ME; Aref, WM; El Hawary, MS; Fathy, MM; Makhlouf, MM; Nabih, MI1
Araki, Y; Hashimoto, N; Ishii, Y; Iwasaki, Y; Okamoto, R; Yamamoto, K1
Afdhal, NH; Rourke, M; Sethi, N; Sethi, S; Tapper, EB; Vong, A1
Celikel, ÇA; Fincanci, M; Gucin, Z; Mert, A; Midilli, K; Osme, A; Ozaras, R; Ozbay, G; Ozturk, R; Senturk, H; Tabak, F; Tahan, V; Tozun, N; Yenice, N1
Abd Elalim, MH; Mohamed, NA; Motawae, IA; Nagib, AN; Zaky, DZ1
Bahnasy, K; El Gohary, E; Fouad, A; Ghoraba, D; Hafez, T; Hassan, H; Kamal, SM; Kassim, S; Nabegh, L1
Mondelli, MU1
Connelly, SM; Fleischer, R; Harrington, PR; Lewis, LL; Murray, J2
Feld, JJ; Shah, H; Sheehan, K; Sockalingam, S1
Athanasakis, K; Ferrante, SA; Hill, M; Kyriopoulos, II; Kyriopoulos, J; Petrakis, I; Retsa, MP1
Bell, SJ; Bonanzinga, S; Bowden, DS; Congiu, M; Desmond, PV; Holmes, JA; Iser, DM; Kia, YH; Nguyen, T; Sandhu, MK; Sievert, W; Thompson, AJ; Visvanathan, K1
Böker, KH; Cordes, HJ; Cornberg, M; Gonnermann, A; Hardtke, S; Heidrich, B; Klinker, H; Koch, A; Kraus, MR; Manns, MP; Möller, B; Naumann, U; Roggel, C; Rössle, M; Schuchmann, M; Stoehr, A; Trein, A; Wedemeyer, H1
Charlton, MR; Dhanasekaran, R; Mounajjed, T; Sanchez, W; Watt, KD; Wiesner, RH1
Hunt, S; Lam, B; Nader, F; Stepanova, M; Younossi, ZM1
Bourlière, M; Bronowicki, JP; Carrieri, MP; Pol, S; Stepanova, M; Younossi, ZM1
Allegra, S; Boglione, L; Cariti, G; Cusato, J; D'Avolio, A; Di Perri, G1
Brito, C; Pereira, T; Resende, C; Ventura, F1
Awni, WM; Bernstein, BM; Ding, B; Dutta, S; Khatri, A; Lawitz, EJ; Marbury, TC; Menon, RM; Mullally, VM; Podsadecki, TJ1
Alessandrini, A; Alicino, C; Bruzzone, B; Del Puente, F; Di Biagio, A; Icardi, G; Mazzarello, G; Prinapori, R; Signori, A; Sticchi, L; Viscoli, C1
Ampuero, J; Andrade, RJ; Buti, M; Cabezas, J; Calleja, JL; Crespo, J; Del Campo, JA; Fernández, I; Forns, X; Lens, S; Millán, R; Rojas, L; Romero-Gómez, M1
Donato, MF; Durantel, D; Fresquet, J; Helle, F; Lebossé, F; Levrero, M; Negro, F; Testoni, B; Zoulim, F1
Alavian, SM; Behnava, B; Keshvari, M; Mehrnoush, L; Salimi, S; Sharafi, H1
Kanto, T; Korenaga, M; Masaki, N; Mizokami, M; Murata, K; Shimbo, T; Yamagiwa, Y1
Buggisch, P; Eißing, C; Hartl, J; Jordan, S; Lohse, AW; Lüth, S; Petersen, J; Schulze Zur Wiesch, J; Stoehr, A; Wehmeyer, MH1
Chang, WT; Chen, SC; Chen, YL; Chuang, WL; Dai, CY; Hou, NJ; Huang, CF; Huang, CI; Huang, JF; Lin, PC; Lin, ZY; Tsai, PC; Yeh, ML; Yu, ML1
Abdel-Hamid, AH; Ghanem, HZ; Hassan, HA; Sadik, NA; Shaker, OG1
Bruneau, J; Deterding, K; Dore, GJ; Doyle, JS; Grebely, J; Hellard, ME; Kim, AY; Lloyd, AR; Manns, MP; Matthews, G; McGovern, BH; Morris, MD; Page, K; Rice, TM; Sacks-Davis, R; Spelman, T; Wedemeyer, H1
Burger, DM; de Kanter, CT; Deenen, MJ; Dofferhoff, AS; Drenth, JP; Fleuren, HW; Gisolf, EH; Grintjes-Huisman, KJ; Koopmans, PP; van der Ven, AJ1
Aziz, H; Irfan, J; Raza, A1
Alberti, A; De Franceschi, L; Dissegna, D; Donato, F; Fattovich, G; Ieluzzi, D; Iolascon, A; Lupo, F; Matté, A; Piovesan, S; Raffetti, E; Russo, R; Siciliano, A; Toniutto, P; Turrini, F; Zuliani, V1
Adinolfi, LE; Alessio, L; Boemio, A; Coppola, N; Grandone, A; Marrone, A; Minichini, C; Pisaturo, M; Sagnelli, E; Stanzione, M; Starace, M; Zampino, R1
Chen, W; Krahn, M1
Altman, RB; Gong, L; Klein, TE; Muir, AJ; Shuldiner, SR1
Kalsekar, A; Le, TK; Macaulay, D; Sorg, RA; Wei, J; Wu, EQ; Yuan, Y1
Calabrese, LH; Vassilopoulos, D1
Collado, A; de los Santos-Gil, I; Girón-González, JA; López-Cortés, LF; Macías, J; Merino, D; Mira, JA; Neukam, K; Ojeda-Burgos, G; Pérez-Pérez, M; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Rivero-Juárez, A; Téllez, F; Torres-Cornejo, A1
Eccles, J; Fialho, R; File, A; Haq, I; Keller, M; Pereira, M; Rolt, M; Tibble, J; Whale, R1
Avila, C; Chuang, WL; Flisiak, R; Foster, GR; Hézode, C; Li, B; Naoumov, NV; Pawlotsky, JM; Peng, CY; Piratvisuth, T; Rasenack, J; Sarin, SK; Shah, S; Wedemeyer, H; Wong, KA; Zhang, W1
Arain, A; Bastens, B; Bourgeois, S; Bruckers, L; Buntinx, F; d'Heygere, F; de Galocsy, C; Deltenre, P; Francque, S; George, C; Henrion, J; Janssens, F; Laleman, W; Mathei, C; Moreno, C; Nevens, F; Robaeys, G; Van Overbeke, L; Van Vlierberghe, H; Verrando, R1
Chen, DS; Chen, PJ; Chuang, WL; Dai, CY; Huang, CF; Huang, JF; Kao, JH; Liang, CC; Lin, CL; Lin, JW; Liu, CH; Liu, CJ; Su, TH; Yang, HC; Yang, SS; Yu, ML2
Song, ZZ1
Aristizabal, P; Carlin, AF; Paulson, MS; Schooley, RT; Song, Q; Stamm, LM; Wang, H; Wyles, DL1
Bau, S; Busuttil, RW; Durazo, F; El Kabany, M; Goo, T; Han, S; Jimenez, M; Kaldas, F; Saab, S; Tong, MJ; Zhao, D1
E Behairy, B; Hussein, ME; Khedr, MA; Marei, AM; Nage, SA; Zakaria, HM1
Almeida, AJ; Brandão-Mello, CE; Coelho, HS; Costa, MM; Costa, VD; Delvaux, N; Esberard, EB; Flores, PP; Lampe, E; Villar, LM; Villela-Nogueira, CA1
Castro-Iglesias, A; Cid, P; Macías, J; Martínez-Marcos, F; Mena, A; Merchante, N; Merino, MD; Monje-Agudo, P; Neukam, K; Ortega-González, E; Pernas, B; Pineda, JA; Real, LM; Rivero, A; Rivero-Juárez, A1
Dimovski, A; Dzekova-Vidimliski, P; Matevska-Geshkovska, N; Mena, S; Nikolov, IG; Rostaing, L; Sikole, A1
Lee, BS; Rou, WS1
Kim, HJ; Lee, HW; Lee, YJ; Park, SJ; Yang, SY; Yoo, KY1
Bailly, F; Pradat, P; Virlogeux, V; Zoulim, F1
Behl, AS; Betts, KA; Kalsekar, A; Li, J; Signorovitch, JE; Song, Y; Sorg, RA1
De Oliveira, JA; Martins, EC; Pereira, R; Reis, TM; Silva, MC1
Fraenkel, L; Garcia-Tsao, G; Lim, J; Monto, A; Reyna, V1
Carter, ME; Gundlapalli, AV; Haroldsen, C; LaFleur, J; Nelson, RE1
Anagnostopoulos, A; Aouri, M; Böni, J; Braun, DL; Decosterd, L; Durisch, N; Eberhard, N; Fehr, J; Ledergerber, B; Metzner, KJ; Müllhaupt, B; Rauch, A; Weber, R1
Azam, S; Imran, M; Manzoor, S; Naseem, S; Resham, S; Saalim, M1
Beinhardt, S; Ferenci, P; Ferlitsch, A; Freissmuth, C; Hofer, H; Kozbial, K; Mandorfer, M; Peck-Radosavljevic, M; Reiberger, T; Schwabl, P; Schwarzer, R; Stättermayer, AF; Trauner, M1
Albert, ML; Casrouge, A; Decalf, J; Duffy, D; Kottilil, S; Masur, H; Meissner, EG1
Fushimi, S; Igawa, T; Ikeda, F; Matsuo, R; Nakatsukasa, H; Nouso, K; Yoshino, T1
Almasio, PL; Boccaccio, V; Bruno, S; Giannini, EG; Russo, ML; Sewpaul, P1
Berger, KL; Kukolj, G; Quinson, AM; Ranga, M; Scherer, J; Sha, N; Stern, JO1
Bura, M; Kowala-Piaskowska, AE; Kuśnierczyk, P; Mozer-Lisewska, I; Pauli, A; Piasecki, E; Rozpłochowski, B; Żeromski, J; Zwolińska, K1
Capobianchi, MR; Castiglione, F; D'Offizi, G; Garbuglia, AR; Lapa, D; Lionetti, R; Montalbano, M; Paci, P; Taibi, C; Visco-Comandini, U2
Ballestri, S; Bertolotti, M; Lonardo, A; Marrazzo, A; Romagnoli, D1
Besma, YL; Brochot, E; Gazouani, E; Morel, V; Mouelhi, L; Sghaier, I1
Bae, SH; Jang, ES; Jeong, SH; Jung, EU; Kim, IH; Kim, YS; Lee, HC; Lee, SS; Lee, YJ1
El Agheb, MO; Grange, JD1
Alexander, PC; James, AM; Long, AG; Shiffman, ML1
Allam, S; Boursier, J; Bronowicki, JP; Canva, V; De Lédinghen, V; Ducancelle, A; Dufour, C; Fontaine, H; Hézode, C; Larrey, D; Moal, V; Poynard, T; Veillon, P; Vergniol, J; Zoulim, F1
Ambrosioni, J; Bernasconi, E; Bregenzer, A; Cavassini, M; Kovari, H; Ledergerber, B; Müller, D; Rauch, A; Rotger, M; Russmann, S; Speck, RF; Stöckle, M; Velli, P1
Aung, AT; Aung, K; Naing, C; Sitt, T1
Gissel, C; Götz, G; Mahlich, J; Repp, H1
Hagiwara, H; Hamasaki, T; Harada, N; Hayashi, N; Hijioka, T; Hikita, H; Hiramatsu, N; Imai, Y; Inada, M; Inoue, A; Irishio, K; Ito, T; Katayama, K; Kato, M; Mita, E; Miyagi, T; Morishita, N; Oze, T; Sakamori, R; Tahata, Y; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yamada, R; Yamada, Y; Yoshida, Y; Yoshihara, H1
Baskič, D; Djurdjevič, P; Jovanovič, D; Mijailovič, Z; Mitrovkič, S; Popovič, S; Vukovič, VR1
Altus, R; Colman, A; Dan, YY; Fragomelli, V; Galhenage, S; Guan, R; Jones, T; Lee, YM; Leembruggen, N; Lim, SG; Luman, W; Mason, S; Mollison, L; Morales, B; Nazareth, S; Pham, T; Piratvisuth, T; Sendall, C; Sukeepaisarnjaroen, W; Sutedja, D; Tan, SS; Tanwandee, T; Teo, EK; Than, YM; Totten, L; Wigg, A1
Alshuth, U; Baumgarten, A; Böker, K; Hofmann, WP; Hüppe, D; Lutz, T; Manns, MP; Mauss, S; Moog, G; Pfeiffer-Vornkahl, H; Schober, A; Schott, E; Wedemeyer, H1
Chen, G; Chen, H; Chen, X; Dou, X; Feng, Y; Gao, Z; Gong, G; Hou, J; Li, J; Niu, J; Rao, H; Shang, J; Wei, L; Wu, Y; Xie, Q; Xu, X; Yang, R; You, H; Zhang, D; Zhao, P1
Abdurakhmanov, D; Bao, W; Brass, C; Buggisch, P; Calistru, P; Flisiak, R; Gould, M; Griffel, LH; Heo, J; Hsu, SJ; Makara, M; Mazur, W; Mazzella, G; Merz, M; Mutimer, D; Naoumov, NV; Nault, B; Samuel, D; Stanciu, C; Thongsawat, S; Van Kính, N; Vierling, JM; Zeuzem, S1
Bastian, ND; Griffin, PM; Zhang, S1
Antoni, C; Eisenbach, C; Galle, PR; Pathil, A; Schattenberg, JM; Sprinzl, MF; Stein, K; Steinebrunner, N; Stremmel, W; Wörns, MA; Zimmerer, T; Zimmermann, T1
Escheik, C; Estep, M; Gerber, L; Stepanova, M; Weinstein, A; Younossi, ZM1
Ando, S; Imai, Y; Inao, M; Kouyama, J; Mochida, S; Motoya, D; Naiki, K; Nakao, M; Nakayama, N; Sugawara, K; Uchida, Y1
Agarwal, K; Barnes, E; Brainard, DM; Brown, A; Cooper, C; Forton, D; Foster, GR; George, J; Han, B; Lin, M; Massetto, B; McHutchison, JG; Nahass, RG; Pianko, S; Subramanian, GM1
Berenguer, M; Everson, G; Ferenci, P; Forns, X; Fried, MW; Lopez-Talavera, JC; Lovell, S; Pedrosa, M; Poordad, F; Shiffman, ML; Trinh, R; Wedemeyer, H1
Cornberg, J; Cornberg, M; Deterding, K; Höner Zu Siederdissen, C; Kirschner, J; Manns, MP; Mix, C; Mix, H; Port, K; Solbach, P; Sollik, L; Wedemeyer, H; Worzala, D1
Boor, PP; de Jonge, J; de Ruiter, PE; Ijzermans, JN; Kwekkeboom, J; Metselaar, HJ; Tilanus, HW; van der Laan, LJ1
An, D; Brainard, D; Gane, EJ; Hyland, RH; Pang, PS; Stedman, CA; Svarovskaia, E1
Fukushima, K; Ishido, M; Kobayashi, H; Komada, Y; Nakayama, M; Yoshizawa, K1
Chen, YC; Hwang, SJ; Li, CY; Lin, LC; Wu, CP1
Barcińska, D; Bereszyńska, I; Czubała, K; Dziechciowska, K; Januszkiewicz-Lewandowska, D; Kałużna, EM; Mozer-Lisewska, I; Nowak, JS; Rembowska, J; Świątek-Kościelna, B; Wysocka-Leszczyńska, J; Wysocki, J1
Faus, MJ; Gallego, A; Guardiola, JM; Mangues, MA; Masip, M; Pagès, N; Torras, X; Tuneu, L1
Haj-Sheykholeslami, A; Hemmati, K; Keshvari, M; Mohammadzadehparjikolaei, F; Pouryasin, A; Sharafi, H1
Birch, C; Clausen, MR; Gaardbo, JC; Gerstoft, J; Hartling, HJ; Hove, M; Nielsen, SD; Trøseid, M; Ullum, H1
Abdel-Hamid, M; Amr, KS; Esmail, MA; Ghazawy, ER; Hassuna, NA1
Brainard, DM; Elsheikh, E; Gerber, L; McHutchinson, JG; Nader, F; Stamm, LM; Stepanova, M; Younossi, ZM1
Gonzalez-Peralta, RP; Jonas, MM; Lobritto, SJ; Mogul, D; Molleston, JP; Murray, KF; Pavlovic, V; Rosenthal, P; Schwarz, KB; Thompson, B; Warne, C; Wat, C; Wen, J1
Antón, JJ; Caylà, JA; de Juan, J; Faraco, I; Marco, A; Saíz de la Hoya, P; Trujols, J1
Bartels, DJ; Garg, V; Haseltine, EL; Kieffer, TL; Kimko, H; Luo, H; Tolsma, J1
Araki, Y; Fujioka, S; Hashimoto, N; Ikeda, F; Iwasaki, Y; Nanba, S; Seki, H; Takaguchi, K; Takaki, A; Yamamoto, K1
Baba, N; Ikeda, F; Iwasaki, Y; Miyake, Y; Moritou, Y; Nagano, T; Nanba, S; Nouso, K; Ohnishi, H; Seki, H; Senoh, T; Takaguchi, K; Takaki, A; Takeuchi, Y; Yamamoto, K; Yasunaka, T1
Aghemo, A; Bruno, R1
Buti, M; Esteban, R; Riveiro-Barciela, M1
Feld, JJ3
Alavi, M; Day, R; Dore, GJ; Martinello, M; Matthews, GV; Schteinman, A; Williams, K1
Arends, JE; Brinkman, K; Hoepelman, AI; Kortmann, W; Posthouwer, D; Reiss, P; Richter, C; Schinkel, J; Smit, C; van Assen, S; van der Ende, M; van der Meer, JT; van der Valk, M1
Bjøro, K; Dalgard, O; Marcellin, P; Martinot-Peignoux, M; Ring-Larsen, H; Verbaan, H1
Craxì, A; Feld, JJ; Forton, D; Manns, MP; Negro, F; Sulkowski, MS1
Clemente-Ricote, G; García-González, X; Giménez-Manzorro, Á; Ochoa-Palominos, A; Rodríguez-González, CG; Sanjurjo-Sáez, M1
Hirashima, N; Imamura, J; Iwase, H; Shimada, M; Sugiura, W; Watanabe, T; Yokomaku, Y1
Bellanti, F; Lauletta, G; Lipsi, MR; Natalicchio, MI; Sansonno, D; Serviddio, G; Vendemiale, G; Villani, R1
Barnes, M; Gautam, M; Gonzalez, S; Habib, A; Mantry, P; McAfee, J; Modi, AA; Nazario, H; Teachenor, O; Trotter, JF; Tujague, L; Weinstein, J1
Braillon, A1
Komolmit, P; Poovorawan, Y; Sukeepaisarnjaroen, W; Suksawatamnuay, S; Tangkijvanich, P; Thaimai, P; Thanapirom, K; Treeprasertsuk, S; Wasitthankasem, R1
Cockerham-Colas, L; Heo, M; Litwin, AH; Reynoso, S; Roose, RJ; Soloway, IJ; Tenore, C1
Brainard, DM; Clark, PJ; Estep, M; Hunt, S; McHutchison, JG; Negro, F; Patel, K; Paulson, M; Song, Q; Stamm, LM; Stepanova, M; Subramanian, GM; Younossi, ZM1
Badshah, MB; Kwo, PY1
Buclin, T; Chtioui, H1
Ahn, SH; Chon, YE; Han, KH; Jung, KS; Kim, BK; Kim, DY; Kim, SU; Lee, HW; Park, JY; Park, YN1
Khatri, A; Menon, R1
Brown, A; Gendrano, IN; Howe, A; Hwang, P; Lagging, M; Mantry, PS; Mobashery, N; Ramji, A; Robertson, M; Vierling, JM; Wahl, J; Weilert, F; Zhang, B1
Huo, N; Li, MR; Shao, CP; Xi, HL; Xu, XY; Yu, M; Zhang, RW1
Boonstra, A; de Knegt, RJ; Janssen, HL; Spaan, M; van Oord, GW1
Chung, RT; Corey, KE; Friedman, LS; Hundemer, GL; Sise, ME; Ufere, N; Wisocky, J1
Cheng, PN; Hsu, SJ; Huang, CF; Lai, HC; Liu, CJ; Lo, CC; Mo, LR; Peng, CY; Su, CW; Su, WW; Tsai, WL; Tseng, KC; Wang, CH; Yang, CC; Yu, ML1
Farfour, E; Hillaire, S; Kahn, JE; Peytavin, G; Sené, T; Zucman, D1
Dimitrova, D; Fredlund, P; Gray, T; Hillson, J; Shemanski, L; Srinivasan, S1
Burger, DM; Buti, M; de Kanter, CT; DeMasi, R; Dofferhoff, AS; Drenth, JP; Ouwerkerk-Mahadevan, S; Witek, J; Zeuzem, S1
Asada, W; Hashimoto, S; Ichino, N; Kan, T; Kato, M; Kawabe, N; Kurashita, T; Murao, M; Nakano, T; Nakaoka, K; Nishikawa, T; Ohki, M; Osakabe, K; Shibata, A; Shimazaki, H; Sugiyama, H; Takagawa, Y; Takamura, T; Yoshioka, K1
Augustyniak, K; Berak, H; Dobracka, B; Dobracki, W; Dudziak, M; Flisiak, R; Horban, A; Janczewska, E; Jurczyk, K; Kozielewicz, D; Kryczka, W; Lapinski, T; Librant-Suska, M; Lojewski, W; Musialik, J; Olszok, I; Pisula, A; Postawa-Klosińska, B; Ruszala, A; Wroblewski, J; Zarebska-Michaluk, D1
Hayashi, N; Howe, AY; Kumada, H; Ludmerer, SW; Mobashery, N; Nakamuta, M; Takase, A; Takehara, T1
A, Y; E, F; GM, Sel-D; H, AG; M, A; MM, B; MM, el-S; U, Y1
Abrignani, S; Aghemo, A; Balistreri, F; Bianco, A; Cheroni, C; Colombo, M; D'Ambrosio, R; De Francesco, R; Donnici, L; Neddermann, P; Pagani, M; Rumi, MG; Soffredini, R; Zanoni, V1
Besheer, M; El-Karaksy, HM; El-Raziky, MS; Mogahed, EA; Mubarak, S; Saleh, D1
Bronowicki, JP; Hézode, C1
Alshuth, U; Bert, F; Hüppe, D; Krauth, C; Mauss, S; Pfeiffer-Vornkahl, H; Rossol, S; Stahmeyer, JT1
Kozlov, VK; Nekrasova, AN; Stelmah, VV1
Buti, M; Esteban, R5
Banhegyi, D; Bergin, C; Chernova, O; DeMasi, R; Doroana, M; Gori, A; Hadacek, B; Liu, C; Nelson, M; Rockstroh, JK; Verucchi, G1
Akpo, EI; Kleintjens, J; Sbarigia, U; Wan, G1
Alsiö, Å; Färkkilä, M; Holmström, L; Jungnelius, R; Lagging, M; Langeland, N; Lund, K; Mørch, K; Nieminen, U; Norkrans, G; Nuutinen, H; Pedersen, C; Rauning Buhl, M; Rembeck, K; Rubensson, A; Torell, E; Waldenström, J; Westin, J1
Cui, X; Jia, J; Kong, Y1
García-Álvarez, M; Jiménez-Sousa, MA; Pineda-Tenor, D; Resino, S; Vázquez-Morón, S1
Barrail-Tran, A; Cheret, A; Furlan, V; Molina, JM; Piroth, L; Rosa, I; Rosenthal, E; Taburet, AM; Vincent, C1
Cao, LL; Chen, DW; Dong, Y; Gan, Y; Han, J; Wang, FC; Wang, FS; Wang, LM; Wang, P; Xu, ZQ; Yan, JG; Zeng, QL; Zhang, HF; Zhang, XX; Zhang, Z; Zhu, SS1
Alavi, M; Balcomb, AC; Bath, N; Day, CA; Dore, GJ; Dunlop, AJ; Grebely, J; Haber, PS; Micallef, M; Phung, N; Treloar, C; Weltman, MD1
Al-Assi, MT; Banyai, T; Beumont-Mauviel, M; Bifano, M; Boparai, N; Bourlière, M; Bronowicki, JP; Buti, M; Cheung, K; Gadano, A; Gea, F; Hézode, C; Hughes, EA; Loustaud-Ratti, V; Makara, M; McPhee, F; Noviello, S; Olveira, A; Ouwerkerk-Mahadevan, S; Petersen, J; Picchio, G; Pol, S; Pruitt, R; Thabut, D; Zeuzem, S1
Gusev, DA; Kozlov, KV; Shakhmanov, DM; Shishkin, MK; Sukachev, VS; Zhabrov, SS; Zhdanov, KV1
Belsey, J; Duchesne, I; Mehnert, A; Pisini, M; Van Sanden, S1
Babudieri, S; Bonfanti, P; Celesia, BM; De Socio, GV; Di Biagio, A; Falasca, K; Maggi, P; Magni, C; Martinelli, C; Menzaghi, B; Nicolini, LA; Parruti, G; Quirino, T; Ricci, E; Salomoni, E; Vichi, F1
Akiyama, T; Eguchi, Y; Ide, Y; Iwane, S; Kawaguchi, Y; Kawazoe, S; Kumagai, T; Mizuta, T; Otsuka, T; Ozaki, I; Yanagita, K; Yasutake, T1
Aggarwal, A; Ahmed, A; Chao, DT; Jayasekera, CR; Perumpail, RB; Pham, EA; Wong, RJ1
Huo, N; Li, M; Shao, C; Xu, X; Zhang, R1
Ehsan, N; El-Fert, A; El-Said, H; Ezzat, S; Kohla, MA; Taha, H1
Desta, T; Eley, T; Everson, GT; Gardiner, DF; Gitlin, N; Grasela, DM; Hassanein, T; Hawkins, T; Hinestrosa, F; Huang, SP; Lawitz, E; Levin, JM; McPhee, F; Rodriguez-Torres, M; Rustgi, V; Schwartz, H; Sims, KD; Thuluvath, PJ; Webster, L; Younossi, Z1
Bloom, AK; Chung, RT; Gustafson, JL; Hashemi, N; Kim, AY; Lin, MV; Lundquist, AL; Sise, ME; Steele, D; Thadhani, R; Thiim, M; Williams, WW; Wisocky, J1
Bernstein, DE; Bourgeois, S; Elkhashab, M; Feld, JJ; Fu, B; Horsmans, Y; Howieson, K; Larsen, L; Moreno, C; Pangerl, A; Polepally, AR; Poordad, F; Reindollar, RW; Shulman, NS; Tam, E; Trinh, R; Younes, Z1
Cooper, C; Doyle, MA1
Durant, J; Girard, PM; González-García, J; Grinsztejn, B; Horban, A; Janssen, K; Lathouwers, E; Montes, ML; Nelson, M; Ortega-Gonzalez, E; Ouwerkerk-Mahadevan, S; Rivero, A; Sasadeusz, J; Witek, J; Zakharova, N1
Calabuig, M; Hernández-Boluda, JC; Navarro, D; Piñana, JL; Serra, MÁ; Solano, C1
Ahmadi, W; El Ghannam, MT; El Khashab, MN; El-Ahwany, EG; El-Refaiy, M; Nagy, FM; Shaker, ZA; Zada, SK; Zoheiry, MK1
Arizumi, T; Chishina, H; Hagiwara, S; Ida, H; Iwanishi, M; Kitai, S; Kitano, M; Kudo, M; Minami, T; Minami, Y; Nishida, N; Sakurai, T; Takita, M; Ueshima, K; Yada, N1
Algendy, D; Amin, M; Elbadry, A; Esmat, S; Fawzi, M; Foda, A; Gabal, S; Kamal, M; Naga, M; Rashed, L; Sabry, D1
Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MH; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, YH; Lin, ZY; Yeh, ML; Yu, ML1
Bedimo, R; Bhattacharya, D; Brown, TT; Evans, C; Hollabaugh, K; Kang, M; McComsey, G; Overton, ET; Taiwo, B; Tebas, P1
Aldámiz-Echevarria, T; Benito, JM; Berenguer, J; Diez, C; Fernández-Rodríguez, A; García-Álvarez, M; Jiménez-Sousa, MA; Pineda-Tenor, D; Rallón, N; Resino, S; Soriano, V1
Hasson, H; Lazzarin, A; Merli, M; Messina, E; Salpietro, S; Uberti-Foppa, C1
Clark, S; Cooke, GS; Gellissen, R; Irving, W; Main, J; Padam, P; Thomson, E1
Dybowska, D; Karwowska, K; Kozielewicz, D; Wietlicka-Piszcz, M1
Cloherty, G; De Locht, P; De Meyer, S; Fevery, B; Gilles, L; Lenz, O; Perner, D; Picchio, G; Sarrazin, C; Susser, S1
Kwon, JH1
Brunda, M; Chu, T; Elston, R; Gane, EJ; George, J; Glavini, K; Hammond, JM; Jensen, DM; Le Pogam, S; Nájera, I; Passe, S; Piekarska, A; Rodriguez, I; Zeuzem, S1
Ryder, SD; Thiagarajan, P1
Espinoza, MA; Giglio, A; Soza, A; Vargas, CL1
Ogawa, E1
Fu, J; Huang, Y; Wu, S; Yang, Y; Yin, S1
Brainard, DM; Doehle, B; Dore, GJ; Flamm, SL; Gane, EJ; Han, L; Kumar, S; McHutchison, JG; McNally, J; Mogalian, E; Pianko, S; Rabinovitz, M; Reddy, KR; Roberts, SK; Shiffman, ML; Stedman, CA; Strasser, SI; Towner, WJ1
Choe, WH; Hwang, Y; Kim, JH; Kim, W; Kwon, SY; Yu, HM1
Kattakuzhy, S; Kottilil, S; Tang, L; Ward, H; Wilson, E1
Kohli, A; Kottilil, S; Masur, H; Meissner, EG; Osinusi, A; Remaley, AT; Sampson, M; Sidharthan, S; Tang, L; Townsend, K1
Mantry, PS; Pathak, L1
An, D; Brainard, DM; Brown, RS; Bzowej, N; Charlton, M; Curry, MP; Doehle, B; Fenkel, JM; Flamm, SL; Fontana, R; Fried, M; Korenblat, KM; Lawitz, E; McHutchison, JG; McNally, J; Muir, AJ; O'Leary, JG; Osinusi, A; Reddy, KR; Schiano, T; Schiff, E; Teperman, L1
Asselah, T; Bourlière, M; Dufour, JF; Ferenci, P; Forton, D; Foster, GR; García-Samaniego, J; Maevskaya, M; Mantry, P; Oliveira, C; Quinson, AM; Sha, N; Stern, JO; Warner, N; Wright, D; Wright, M; Yoshida, EM1
Hatae, T; Hayashi, Y; Imoto, S; Kim, KI; Kim, SK; Kim, SR; Kudo, M; Ohtani, A; Sugimoto, K; Tohyama, M; Yano, Y1
Deguchi, H; Ichinose, M; Iguchi, M; Inoue, I; Kato, J; Kawashima, A; Maeda, Y; Maekita, T; Mori, Y; Moribata, K; Niwa, T; Shingaki, N; Tamai, H1
Bo, Q; Brass, C; Griffel, L; Orsenigo, R; Wang, J1
Antonov, K; Boyanova, Y; Caloska-Ivanova, V; Dimovski, A; Dumitrascu, D; Dzekova-Vidimliski, P; Joksimovic, N; Mateva, L; Matevska-Geshkovska, N; Nikolov, IG; Nikolova, N; Romanciuc, G; Rostaing, L; Sikole, A1
Butt, AA; Chung, RT; Shaikh, OS; Sherman, KE; Yan, P2
Daher, S; Shalit, M; Tal, Y; Toker, O1
Aabakken, L; Dalgard, O; Grimstad, T; Isaksen, K; Karlsen, L; Sandvei, PK1
Chen, H; Chen, M; Huang, P; Li, J; Peng, Z; Su, J; Wang, J; Xu, Y; Yu, R; Yue, M; Zhang, Y1
Bukowska-Ośko, I; Cortes, KC; Inglot, M; Jabłońska, J; Laskus, T; Osowska, S; Pawełczyk, A; Pawłowski, T; Perlejewski, K; Radkowski, M; Ząbek, P; Zalewska, M1
Furuta, N; Ishida, H; Ito, H; Katano, Y; Nakamura, M; Nakayama, J; Seishima, M; Shirakami, Y; Suetsugu, A; Tauchi, R1
Delgado, M; López-Cortés, LF; Macías, J; Ojeda-Burgos, G; Pineda, JA; Recio, E; Ríos, MJ; Rivero-Juárez, A; Téllez, F1
Busuttil, RW; Cheng, EY; Holt, CD; Saab, S1
Ahmed, II; Anand, N; Ilyas, F; Singh, H1
Gish, R; Kohli, A; Manch, R; Nafisi, S; Roy, S1
Farnik, H; Herrmann, E; Lange, CM; Luhne, S; Sarrazin, C; Vermehren, J; Welker, MW; Welzel, T; Zeuzem, S1
Akamatsu, N; Arita, J; Hasegawa, K; Kaneko, J; Kokudo, N; Maki, H; Sakamoto, Y; Sugawara, Y; Tamura, S; Tanaka, T; Tsukada, K1
Chen, TM; Huang, PT; Lin, CC; Wen, CF1
Anzai, K; Eguchi, Y; Fujimoto, K; Iwane, S; Kawaguchi, Y; Kawazoe, S; Kuwashiro, T; Mizuta, T; Nakashita, S; Oeda, S; Otsuka, T; Oza, N; Ozaki, I; Takahashi, H1
Burger, J; Dranitsaris, G; Fraser, I; Lubbe, M; Sonderup, M; Stander, T1
Husa, P1
Abenavoli, L; Camera, S; Claar, E; Coppola, C; Coppola, N; De Luna, A; Federico, A; Gentile, I; Granata, R; Masarone, M; Morisco, F; Persico, M; Precone, D; Rosato, V; Salomone-Megna, A; Tartaglione, MT1
Chen, G; Chen, H; Chen, X; Dou, X; Feng, Y; Gao, Z; Gong, G; Hou, J; Li, J; Niu, J; Rao, H; Shang, J; Wei, L; Xie, Q; Xu, X; Yang, R; You, H; Zhang, D1
Mahmoud, M; Morsy, KH; Zaghloul, A1
Fan, Z; Hu, Z; Jin, R; Liang, S; Liu, Y; Nie, W; Qiu, L1
Bijani, B; Ghanei, L; Kazemifar, AM1
Boyer-Darrigand, N; D'alteroche, L; Dao, MT; Ducancelle, A; Fouchard-Hubert, I; Larrey, D; Le Guillou-Guillemette, H; Loustaud-Ratti, V; Lunel-Fabiani, F; Picard, N; Saulnier, P; Veillon, P1
D'Ambrosio, R; Galmozzi, E1
Abuelhassan, W; Blackard, JT; Bowyer, SM; Mahlangu, J; Mahomed, A; Prabdial-Sing, N; Puren, AJ; Vermeulen, M1
Afdhal, NH; Eggleton, E; Knox, SJ; Kowdley, K; Mangia, A; Mizokami, M; Omata, M; Pang, P; Park, SH; Saab, S; Subramanian, M; Zhu, Y1
Adeyi, O; Chen, L; Cotler, SJ; Deneke, MG; Duarte-Rojo, A; Feld, JJ; Fischer, SE; Malespin, M; McGilvray, ID; Selzner, N; Zita, D1
Atta, AM; Atta, ML; Carvalho, LP; Oliveira, IS; Paraná, R; Schinoni, MI1
Artigas, F; Egmond, E; Gimenez, D; Gómez-Gil, E; Grande, I; Gratacós, M; Kapczinski, F; Langohr, K; Martín-Santos, R; Navinés, R; Oriolo, G; Solà, R; Udina, M; Valdés, M; Vieta, E1
Luo, R; Nong, J; Qing, J; Shao, Y; Sun, Y; Tang, R; Wang, Y; Wu, M; Yin, Z; Yu, X1
Chen, CH; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Wang, JH1
Calvaruso, V; Craxì, A1
Boccaccio, V; Bruno, S; Maisonneuve, P; Russo, ML1
Nelson, DR; Peter, J1
Serfaty, L2
Ghany, M; Keane, M; Liang, TJ; O'Keefe, AC; Park, H; Rehermann, B; Rivera, E; Serti, E1
Dore, GJ; Martinello, M1
Cope, R; Faulds, S; Glowa, T; McMahon, D; Prasad, R1
Chang, PW; Huynh, TT; Rosinski, AA; Tong, LT; Tong, MJ1
Chi, X; Gao, X; Jiang, J; Kong, F; Lv, J; Mei, R; Niu, J; Pan, Y; Sun, B; Sun, H; Wang, X; Wu, R; Xu, H; Yu, G; Zhong, J1
Forns, X; Hézode, C; Le Pogam, S; Lee, SS; Nájera, I; Scalori, A; Thommes, JA; Voulgari, A; Wedemeyer, H1
Andersohn, F; Claes, AK; Kulp, W; Mahlich, J; Rockstroh, JK1
Fontana, RJ; Hughes, EA; Landis, C; McPhee, F; Noviello, S; Poordad, F; Schiff, ER; Swenson, ES; Vierling, JM; Yang, R1
Craft, ZN; Kamal, KM; Koerner, PH; Miller, RT; Trombatt, WD1
Salman, AG1
Waltschew, A1
Cho, EJ; Cho, Y; Kim, YJ; Lee, JH; Yoon, JH; Yu, SJ1
Asatryan, A; Fu, B; Jackson, DF; Kort, J; Landis, CS; Lin, CW; Ng, TI; Poordad, F; Yao, B1
Chen, CH; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Wang, JH; Yen, YH2
Arleo, A; Copetti, M; Mangia, A; Miscio, M; Piazzolla, V; Santoro, R; Squillante, MM1
Cooke, GS; Hill, A; Riley, RD; Saleem, J; Simmons, B1
Akhan, S; Aynioglu, A; Sargin Altunok, E; Sayan, M1
Hoofnagle, JH3
Rivero, A; Rivero-Juárez, A1
Chi, X; Gao, X; Hua, R; Jiang, J; Kong, F; Lv, J; Niu, J; Pan, Y; Sun, B; Sun, H; Wang, X; Wu, R; Xu, H; Yu, G; Zhong, J1
Angus, P; Bhore, R; Bronowicki, JP; Dore, GJ; Hezode, C; Jimenez-Exposito, MJ; Leroy, V; McPhee, F; Pianko, S; Pol, S; Stuart, K; Thompson, AJ; Tse, E1
Henry, L; Nader, F; Stepanova, M; Younossi, ZM1
Brooks, S; Miyoshi, Y; Murakami, J; Shimizu, T; Suzuki, M; Tajiri, H; Takano, T; Tanaka, Y1
Cheng, N; Ford, R; Norvell, JP; Parekh, S; Pillai, AA; Spivey, JR; Wedd, J; Young, N1
Brainard, DM; Chang, TT; Chen, JJ; Chien, RN; Chu, CJ; Chuang, WL; Han, L; Hsu, YC; Hu, TH; Kao, JH; Knox, SJ; Lo, GH; Mathias, A; Mo, H; Peng, CY; Sheen, IS; Wang, HY; Yang, JC1
Aldamiz-Echevarria, T; Benito, JM; Berenguer, J; Carrero, A; García-Álvarez, M; Jiménez-Sousa, MA; Pineda-Tenor, D; Rallón, N; Resino, S; Restrepo, C; Soriano, V; Vazquez-Morón, S1
Ackerman, P; Kalsekar, A; Kelley, C; Mu, F; Peeples, M; Signorovitch, J; Song, J; Swallow, E; Yuan, Y1
Nishimura, T1
Hiramatsu, N; Oze, T1
Izumi, N; Kurosaki, M; Suzuki, S1
Bailey, R; Cooper, C; Drolet, M; Elkashab, M; Farley, J; Feinman, SV; Marotta, P; Peltekian, K; Poliquin, M; Rampakakis, E; Witt-Sullivan, H1
Dolar, E; Gülten, M; Gürel, S; Kiyici, M; Nak, SG; Pekgöz, M1
Glisic, S; Jovanovic-Cupic, S; Krajnovic, M; Mandusic, V; Nozic, D; Petrovic, N; Stanojevic, M1
Ahn, SH; Brainard, DM; Byun, KS; Han, KH; Han, L; Han, SY; Heo, J; Jeong, SH; Kim, JH; Kim, YJ; Kim, YS; Knox, SJ; Lee, KS; Lee, YJ; Lim, YS; Mathias, A; Mo, H; Paik, SW; Tak, WY; Yang, JC; Yim, HJ; Yoon, SK1
Applegate, T; Dore, GJ; Grebely, J; Haber, P; Hellard, M; Iser, D; Lloyd, A; Maire, L; Martinello, M; Matthews, GV; Petoumenos, K; Sasadeusz, J; Shaw, D; Thompson, A; Yeung, B1
Arends, JE; Burger, DM; Friederich, P; Koek, GH; Lieveld, FI; Siersema, PD; van Erpecum, KJ; van Meer, S; van Nieuwkerk, KM; van Vlerken, LG1
Blanchet, M; Labonté, P; Le, QT; Seidah, NG1
Andrade, A; Bushman, L; Fuchs, EJ; Hendrix, CW; Kiser, JJ; Radebaugh, C; Ray, ML; Sulkowski, M1
Abd-Ellah, MF; Gad, MA; Helal, GK; Mahgoup, EM1
Li, J; Li, Z; Ping, Y; Shi, X; Wang, M; Yu, Z; Yue, D; Zhang, B; Zhang, Y; Zhang, Z1
Andrade, LE; Calise, SJ; Chan, EK; Keppeke, GD1
Kishk, R; Mandour, M; Nemr, N1
Bahirwani, R; Berg, C; Brown, RS; Castells, L; Chacko, KR; Durand, CM; ElSharkawy, AM; Emond, B; Ferenci, P; Fontana, RJ; Herzer, K; Ionescu-Ittu, R; Jafri, SM; Joshi, S; Knop, V; Lionetti, R; Loiacono, L; Londoño, MC; Montalbano, M; Moreno-Zamora, A; Mubarak, A; Pellicelli, AM; Prieto, M; Reddy, KR; Stadler, B; Stauber, RE; Stenmark, S; Torti, C; Vekeman, F; Weiland, O1
Afdhal, N; Charlton, M; Denning, J; Everson, GT; Flamm, SL; Hyland, R; Lin, M; McHutchison, JG; Pang, PS; Reddy, KR; Welzel, TM; Zeuzem, S1
Adachi, K; Ishii, T; Kumon, D; Matsumoto, N; Noguchi, Y; Okuse, C; Sato, A; Tamura, T1
Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Kunimoto, H; Saitoh, S; Sezaki, H; Sorin, Y; Suzuki, F; Suzuki, Y1
Abd El-Maksoud, M; Amin, M; El-Bendary, M; Neamatallah, MA1
Agarwal, K; Angus, P; Arterburn, S; Brainard, D; Buti, M; Calleja, JL; Colombo, M; Denning, J; Dufour, JF; Dvory-Sobol, H; Forns, X; Gane, EJ; Manns, M; McCaughan, G; McHutchison, JG; Müllhaupt, B; Mutimer, D; Pang, PS; Peck-Radosavljevic, M; Prieto, M; Rizzetto, M; Samuel, D; van Hoek, B; Van Vlierberghe, H; Yoshida, EM1
Al-Ansari, NL; El-Derany, MO; El-Mesallamy, HO; Hamdy, NM1
Barve, A; Brock, G; Buchanan, LA; Cave, B; Cave, MC; Crittenden, NE; Davis, EG; Gedaly, R; Jones, CM; Kuns-Adkins, CB; Marsano, L; Marvin, MR; McClain, CJ; Pinkston, CM; Rosenau, J; Shah, MB1
Grigg, N; Purcell, D; Santiago-Rolón, A; Toro, DH1
Hellard, M; Higgs, P; Wright, C1
Stepanova, M; Younossi, Z1
D'Argenio, DZ; Jimmerson, LC; Kiser, JJ; MacBrayne, CE; Wu, LS1
Chayama, K; Fujimoto, G; Howe, AY; Karino, Y; Kumada, H; Ludmerer, SW; Mobashery, N; Mochida, S; Nakamura, K; Suzuki, F1
Horn, M; Horvath, A; Jurse, P; Leber, B; Lemesch, S; Posch, A; Schmerböck, B; Spindelboeck, W; Stadlbauer, V; Stauber, RE; Stiegler, P; Streit, A; Tawdrous, M; Wuensch, G; Zettel, G1
Bernard Chabert, B; Descamps, D; Desnoyer, A; Fontaine, H; Gervais, A; Harent, S; Heurgué-Berlot, A; Hillaire, S; Laradi, A; Larrouy, L; Lê, MP; Muret, P; Peytavin, G; Pinto, A; Pospai, D; Salmon, D; Simonpoli, AM; Yazdanpanah, Y; Zucman, D1
Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MH; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, YH; Lin, ZY; Lu, MY; Wang, SC; Yeh, ML; Yu, ML1
Benhaourech, S; Borentain, P; Bregigeon, S; Colson, P; Darque, A; Gaubert, MR; Habib, G; Laugier, D; Maille, B; Renard, S; Salaun, E1
Abe-Sandes, K; Carrilho, FJ; de Castro Lyra, A; de Mello Malta, F; de Seixas Santos Nastri, AC; Diniz, MA; Dos Santos, SE; Pinho, JR; Yoshino, A1
Amorosa, VK; Dou, D; Kang, M; Kottilil, S; Lee, YJ; Matining, R; Osinusi, A; Peters, MG; Petersen, T; Umbleja, T; Wang, C; Zhang, X1
Camacho, A; Cuenca, F; Frias, M; Gonzalez, R; Gordon, A; Manzanares-Martín, B; Peña, J; Perez-Camacho, I; Pineda, JA; Rivero, A; Rivero-Juarez, A; Rodriguez-Cano, D1
Abdel Aziz, RA; Ahmed, SH; Al Akel, W; Al Sayed Taha, A; El Kazaz, AY; Esmat, GE; Mostafa, A; Rashed, LA; Sabry, D1
Hagiwara, H; Hayashi, N; Hikita, H; Hiramatsu, N; Hosui, A; Imai, Y; Inada, M; Ito, T; Kaneko, A; Katayama, K; Mita, E; Morishita, N; Oshita, M; Oze, T; Sakamori, R; Tahata, Y; Takehara, T; Tamura, S; Tatsumi, T; Urabe, A; Yakushijin, T; Yamada, R; Yamada, Y; Yoshida, Y1
Asselah, T; Bakalos, G; Flisiak, R; Messinger, D; Romero-Gomez, M; Shiffman, ML; Thompson, AJ1
Brennan, BJ; Hill, G; Kao, JH; Le Pogam, S; Lee, Y; Li, H; Najera, I; Sheen, IS; Tanwandee, T; Thommes, JA; Thongsawat, S; Tung, SY; Wu, JJ; Zhou, J1
Bała, A; Białkowska-Warzecha, JE; Broncel, M; Jabłkowski, MS; Poliwczak, AR1
Bae, SH; Chen, X; Chuang, WL; Garimella, T; Gong, G; Jia, J; Jia, Z; Li, Y; Lin, S; Lu, W; McPhee, F; Mo, L; Niu, J; Torbeyns, A; Treitel, M; Wei, L; Xie, Q; Xie, W; Xu, M; Yang, YF; Yin, PD; Zhang, M1
Imaizumi, N; Kashiwagi, T; Kashiwamura, S; Kishida, Y; Tanimura, H1
Poovorawan, K; Poovorawan, Y; Tangkijvanich, P; Thong, VD; Vongpunsawad, S; Wasitthankasem, R1
Bronte, F; Calvaruso, V; D'Ambrosio, R; Di Marco, V; Forni, G; Lanza, AG; Poggiali, E; Saracco, G1
Kurmanova, GM; Kurmanova, KB; Sadykova, ShS1
Ahlers, S; Bakalos, G; Coppola, C; Derbala, M; Ferenci, P; Foster, GR; Hassanein, T; Orlandini, A; Reddy, KR; Shiffman, ML; Tallarico, L1
Henry, L; Hunt, S; Nader, F; Stepanova, M; Younossi, ZM1
Abdurakhmanov, D; Baruch, Y; Bruck, R; Diago, M; Ferenci, P; Flisiak, R; Gadano, A; Hughes, EA; Jacobson, I; Janczewska, E; Knysz, B; Kopit, J; Lueth, S; McPhee, F; Michener, T; Noviello, S; Safadi, R; Shafran, S; Thabut, D; Thompson, AJ; Yin, PD; Zarebska-Michaluk, D; Zeuzem, S; Zignego, AL1
Hong, L; Huddleston, L; Poerzgen, P; Ramkissoon, R; Roytman, M; Seto, T; Trujillo, R; Tsai, N; Wong, L; Wu, C1
Bruden, DJ; Gove, JE; Homan, CE; Livingston, SE; McMahon, BJ; Plotnik, JN; Simons, BC; Spradling, PR; Townshend-Bulson, LJ1
Banerjee, D; Reddy, KR1
Cannizzaro, M; Cottone, M; Madonia, G; Madonia, S; Orlando, E; Stagno, B1
Komiyama, T; Tamura, Y; Tanaka, Y; Yokomori, H1
Bo, Q; Chen, X; Duan, Z; Feng, B; Hou, J; Jia, J; Li, J; Li, R; Liu, Y; Niu, J; Ren, H; Shang, J; Wang, FS; Wang, G; Wei, L; Yang, X; Zhuang, H1
Bae, WK; Choi, JW; Kim, JG; Kim, JW; Kim, KA; Lee, JS; Paik, WH; Song, TJ1
Asselah, T; Bennett, M; Forns, X; Liu, L; Moller, J; Pedrosa, M; Planas Vila, R; Reau, N; Rustgi, V; Shiffman, ML1
Gilbert, J; Jha, LK1
Diago, M; Peño, L; Plana, L; Urquijo, JJ1
Boucher, CM; Forest, CP; Walsh, A1
Chang, TT; Hsieh, YH; Huang, HT; Hung, TH; Tseng, CW; Tseng, KC; Tzeng, SJ; Wu, SF1
Badia, E; Sáez-Royuela, F1
Johnson, S; Marx, SE; Misurski, D; Parisé, H; Saab, S; Sanchez Gonzalez, Y; Virabhak, S; Wang, A1
Arai, M; Haga, Y; Imazeki, F; Kanda, T; Mikami, S; Nakamoto, S; Nakamura, M; Ogasawara, S; Sasaki, R; Tawada, A; Yasui, S; Yokosuka, O1
Warpakowski, A1
Chen, XH; Gao, L; Geng, JB; Hao, KY; Li, P; Wang, J; Wang, M; Wang, MR; Wang, SM; Xie, F; Xiong, X; Yang, ZG; Zhang, X; Zheng, WK1
Cai, WP; Chen, XJ; He, Y; Hu, FY; Ke, YC; Lan, Y; Li, LH; Tang, XP1
Baños, I; Bellot, P; Bhamidimarri, KR; Brainard, DM; Campos-Varela, I; Castells, L; Grewal, P; Guaraldi, G; Hasson, H; McHutchison, JG; Morbey, A; Moreno, A; Terrault, NA1
Al-Ansari, NL; El-Mesallamy, HO; Hamdy, NM; Rizk, HH1
Albrecht, JK; Alonso, E; Ciocca, M; Gonzalez, T; Goodman, Z; Haber, B; Jackson, B; Lacaille, F; Lang, T; Noviello, S; Pedreira, A; Rodriguez-Baez, N; Yang, Z1
Ding, SX; Gao, GS; Hu, AR; Hu, YR; Ma, JB; Shen, Q1
Choi, HS; Chun, HJ; Jung, CH; Kim, TH; Seo, YS; Suh, SJ; Um, SH; Yim, HJ; Yim, SY1
Aschenbrenner, DS1
Goto, H; Hayashi, K; Hirai, T; Honda, T; Ishigami, M; Ishizu, Y; Kuzuya, T; Tachi, Y1
Abdelsalam, A; Hammad, L; Rashed, L; Sabry, D; Salman, T1
Angus, P; Böcher, W; Buti, M; Buynak, RJ; Dufour, JF; Kadus, W; Mantry, P; Mensa, FJ; Pockros, PJ; Soriano, V; Stern, JO; Vinisko, R; Wright, D; Zeuzem, S1
Feld, JJ; Götte, M1
Bulja, D; Husic-Selimovic, A; Huskic, J; Sofic, A1
Banjac, V; Miskovic, M; Zivlak-Radulovic, N1
Barrail-Tran, A; Bellissant, E; Bourlière, M; Cotte, L; Fournier, I; Garraffo, R; Kheloufi, F; Lacarelle, B; Molina, JM; Poizot-Martin, I; Quaranta, S; Renault, A; Solas, C1
Awni, W; Dutta, S; Khatri, A; Menon, R; Mensing, S; Podsadecki, T1
Botta, D; Gaudy-Marqueste, C; Grob, JJ; Lorcy, S; Mancini, J; Oulies, V; Portal, I; Quiles, N; Richard, MA1
Badri, PS; Eckert, D; Menon, RM; Mensing, S; Polepally, AR1
Christensen, P; Dalgard, O; Färkkilä, M; Krarup, H; Lagging, M; Lindahl, K; Nilsson, S; Norkrans, G; Norrgren, H; Nyström, K; Rauning Buhl, M; Stenmark, S; Waldenström, J; Westin, J1
Huy Ho, NA; Paparoupa, M; Schuppert, F1
Bocquier, A; Carrieri, MP; Dabis, F; Esterle, L; Marcellin, F; Miailhes, P; Poizot-Martin, I; Protopopescu, C; Salmon-Ceron, D; Spire, B; Wittkop, L1
Chen, YZ; Xie, X; Zhang, L1
Abd-Ellah, MF; Eid, MS; Gad, MA; Helal, GK1
Saleem, A1
Bane, A; Kassa, E; Kefene, H1
Choi, WS; Jeong, JY; Kim, OZ; Min, JH; Pyo, JY; Sohn, JH; Song, JS1
Ivanova, AL; Tarasova, LV1
Aghasadeghi, MR; Bahiraei, N; Daneshvar, M; Javadi, F; Larijani, MS; Nikbin, M; Rad, LN; Rahimi, P; Sadat, SM; Siadat, SD; Zabihollahi, R1
Cooper, C; Dieterich, D; Dvory-Sobol, H; Han, L; McHutchison, JG; Naggie, S; Pang, PS; Saag, M; Stamm, LM; Sulkowski, M; Yang, JC1
Baik, SJ; Kim, HI; Kim, TH; Rhie, JY1
Cammà, C; Damele, F; Marcellusi, A; Mennini, FS; Taliani, G; Viti, R1
Brainard, DM; Byrne, S; Copans, A; Dvory-Sobol, H; Fuchs, M; Guyer, W; Ho, SB; Kaplan, DE; Le, H; Monto, A; Moon, S; Morgan, TR; Peyton, A; Rossaro, L; Roy, A; Shaikh, O; Zhu, Y1
Cheng, Y; Ding, N; Jin, X; Qing, S; Wang, J; Xin, S; Yan, T; Zhao, P1
Dudina, KR; Kalininа, OV; Kozina, AN; Yushchuk, ND; Znoyko, OO1
Acharya, SK; Das, P; Gupta, SD; Kalra, N; Kavimandan, A; Nayak, B; Panda, SK; Thakur, B; Vasudevan, S1
Cotler, SJ; Dahari, H; Halfon, P1
Allegra, S; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G1
Ridler, C1
Almeida, PR; Barros, IC; Casagrande, L; Dresch, KF; Feltrin, AA; Mattos, AA; Onofrio, FQ; Tovo, CV1
Neumaier, J1
Flemming, JA; Lowe, CE1
Aggarwal, R; Bhadauria, DS; Goel, A; Gupta, A; Kaul, A; Prasad, N; Rai, P; Sharma, RK1
Baruch, Y; Ben Ari, Z; Bhanja, S; Bruck, R; Gane, E; Howe, AY; Hwang, P; Mollison, L; Robertson, MN; Wahl, J; Zhao, Y; Zuckerman, E1
Backus, LI; Belperio, PS; Loomis, TP; Mole, LA; Shahoumian, TA1
Arientová, S; Beran, O; Boštík, P; Chalupa, P; Davidová, A; Holub, M; Kapla, J; Kondělková, K; Plíšek, S1
Biasi, L; Casari, S; Castelli, F; Chirico, C; Festa, E; Izzo, I; Salemme, M; Villanacci, V; Zanotti, P1
Burger, D; Gevers, TJ; Kooistra, MP; Richter, C; Schipper-Reintjes, E1
Akushevich, L; Di Bisceglie, AM; Feld, JJ; Frazier, LM; Fried, MW; Kuo, A; Maan, R; Mailliard, M; Manns, MP; Nelson, DR; Schmidt, M; Sherman, K; Sterling, R; Vainorius, M; Zeuzem, S1
Assy, N; Dong, Y; Flisiak, R; Gadano, A; Kao, JH; Kawazoe, S; Kumada, H; Lee, KS; Portsmouth, S; Srinivasan, S; Xu, D; Znoyko, O; Zwirtes, R1
Abdul-Kareem, S; Eid, Y; El-Sayed, M; Hamza, I; Marzaban, R1
Gouttenoire, J; Moradpour, D; Szkolnicka, D1
Arain, SR; Umer, TP1
Bogomolov, P; Cooney, E; Critelli, L; Olveira, A; Pol, S; Reesink, HW; Santagostino, E; Srinivasan, S; van Erpecum, K; Xu, D1
Aguilera, A; Arias, A; Benítez-Gutiérrez, L; Cuervas-Mons, V; de Mendoza, C; Lledó, G; Navarro, D; Otero, E; Peña, JM; Soriano, V; Treviño, A1
Gonzalez, YS; Johnson, S; Juday, T; Misurski, D; Parisé, H; Saab, S; Virabhak, S; Wang, A1
Aquilante, CL; Baouchi-Mokrane, F; Hodara, A; Jimmerson, LC; Kiser, JJ; Kottilil, S; Langness, JA; Meissner, EG; Sims, Z; Truesdale, A; Urban, TJ1
Battimelli, C; Durante-Mangoni, E; Falco, E; Iossa, D; Molaro, R; Pafundi, PC; Parrella, A; Sodano, G; Utili, R1
Alem, SA; Asem, N; El-Sayed, M; Elsharkawy, A; Esmat, G; Fouad, R; Hassan, E; Ismail, A; Yosry, A1
Aarnoutse, RE; Burger, DM; de Kanter, CT; Kan, R; Smolders, EJ; Touw, DJ; van Luin, M1
Ross, JS; Sangaralingham, LR; Shah, ND; Talwalkar, JA; Yao, X1
Goncales, ES; Goncales, FL; Lazarini, MS; Mendes, LC; Miotto, N; Pedro, MN; Stucchi, RS; Vigani, AG; Zanaga, LP1
Ali, OE; Elagawy, WA; Mohamed, AA; Moustfa, Z; Sayed, GA; Sayed, O1
Bayer, J; Gardner, EM; Johnson, S; Langness, J; Rogers, M; Rowan, SE; Smith, L1
Cariani, E; Pecoraro, V; Trenti, T; Villa, E1
Bakulin, I; Chulanov, V; Isakov, V; Kersey, K; Knox, SJ; Massetto, B; Svarovskaia, E; Zhdanov, K; Zhu, Y1
Khoury, J; Saadi, T1
Akutagawa, M; Ide, K; Kawasaki, Y; Masaki, N; Yamada, H1
Ceccherini-Silberstein, F; Craxì, A; Perno, CF; Petta, S; Viganò, M1
Geier, A; Kuhn, S; Kuntzen, D; Kuntzen, T; Müllhaupt, B; Seifert, B1
Agarwal, K; Brown, A; Cheung, MCM; Foster, GR; Gelson, WTH; Hudson, BE; Irving, WL; MacDonald, DC; McLauchlan, J; Mutimer, DJ; Verma, S; Walker, AJ1
Arai, M; Haga, Y; Kanda, T; Katsuno, T; Nakamoto, S; Nakamura, M; Ohta, Y; Sasaki, R; Wu, S; Yasui, S; Yokosuka, O1
Kao, JT; Tsai, SM; Tsai, YF1
Amundsen, BM; Chandraker, A; Chung, RT; Chute, D; Curry, MP; Elias, N; Gabardi, S; Hanifi, JM; Heher, EC; Lin, MV; Pavlakis, M; Riella, LV; Rutherford, AE; Sise, ME1
Akushevich, L; Alqahtani, S; Darling, J; Di Bisceglie, A; Frazier, LM; Fried, MW; Galati, JS; Kuo, A; Lim, JK; Morelli, G; Nelson, DR; Pockros, P; Reddy, RK; Sulkowski, MS; Vainorius, M; Welzel, TM; Zeuzem, S1
Fagundes, RN; Ferreira, LE; Pace, FH1
Chamorro-de-Vega, E; Collado Borrell, R; Escudero-Vilaplana, V; Fernandez-Llamazares, CM; Gimenez-Manzorro, A; Herranz, A; Ibañez-Garcia, S; Lallana Sainz, E; Lobato Matilla, E; Lorenzo-Pinto, A; Manrique-Rodriguez, S; Marzal-Alfaro, M; Ribed, A; Rodriguez-Gonzalez, CG; Romero Jimenez, RM; Sanjurjo, M; Sarobe Gonzalez, C1
Pham, YH; Rosenthal, P1
Henry, L; Hunt, S; Nader, F; Stepanova, M; Younossi, Y; Younossi, ZM1
Buggisch, P; Cornberg, M; Günther, R; John, C; Klinker, H; Lutz, T; Mauss, S; Niederau, C; Pfeiffer-Vornkahl, H; Sarrazin, C; Schober, A; Tacke, F1
Fu, N; Meng, P; Nan, Y; Niu, X; Qiao, L; Su, S; Wang, R; Zhang, Y; Zhao, S1
Aghemo, A; Carrinola, R; Colombo, M; D'Ambrosio, R; Rossetti, V1
Chen, GF; Chen, J; Hu, JH; Ji, D; Lau, G; Li, B; Liu, JL; Lu, L; Niu, XX; Shao, Q; Wang, C; Wang, YD; Wu, V; You, SL; Zhao, J1
Bugianesi, E; Saracco, GM; Vanni, E1
Afdhal, N; Bräu, N; Foster, GR; Henry, L; Hunt, S; Mangia, A; Nader, F; Patel, K; Reau, N; Roberts, SK; Stepanova, M; Sulkowski, M; Younossi, ZM1
Aba Alkhail, F; Ajlan, A; Al-Hamoudi, W; Al-Jedai, A; Al-Sebayel, M; Alarieh, R; Alkortas, D; Broering, D; Elsiesy, H1
Hsu, YC; Kor, CT; Su, PY; Su, WW; Wu, SS; Yen, HH1
Chen, Y; Gao, F; Hu, C; Huang, Y; Liu, J; Qiu, R; Shi, K; Sun, L; Wang, X; Yuan, G; Zhou, Y1
Bannan, C; Bergin, C; Coghlan, M; De Gascun, CF; Dean, J; Farrell, G; Murray, C; Sevastianova, K1
Abenavoli, L; Brkic, S; Lendak, D; Pete, M; Preveden, T; Ruzic, M1
Maasoumy, B; Sarrazin, C; Vermehren, J; Wedemeyer, H1
D'Ambrosio, R; De Nicola, S; Degasperi, E; Rumi, M1
Choi, JW; Hong, SH; Jang, JW; Kim, DY; Kim, I; Kim, W; Lee, D; Lee, JI; Paik, YH; Yoon, KT1
Etschmaier, A; Ferenci, P; Ferlitsch, A; Ferlitsch, M; Hametner, S; Hofer, H; Horvatits, T; Maieron, A; Paternostro, R; Peck-Radosavljevic, M; Quehenberger, P; Reiberger, T; Rutter, K; Salzl, P; Trauner, M1
Fujikawa, H; Hasegawa, H; Matsuoka, S; Moriyama, M; Ochiai, T; Watanabe, Y1
De Almeida, PR; De Leon, LB; De Mattos, AA; Feltrin, AA; Kliemann, DA; Pacheco, LS; Tovo, CV1
Casato, M; Ceccotti, G; Colantuono, S; De Santis, A; Del Padre, M; Fiorilli, M; Fognani, E; Gianni, E; Gragnani, L; Mitrevski, M; Monti, M; Perez, M; Petraccia, L; Pulsoni, A; Stasi, C; Urraro, T; Visentini, M; Zignego, AL1
Bennett, M; Brainard, DM; Curry, M; Dvory-Sobol, H; Hawkins, T; Herring, R; Hinestrosa, F; Jacobson, I; Lawitz, E; Lu, S; McHutchison, JG; Nahass, R; Pearlman, B; Rabinovitz, M; Reau, N; Reddy, KR; Schiff, E; Sheikh, A; Shiffman, M; Stamm, LM; Tran, T; Yang, JC; Younes, Z1
Axten, D; Dalton, J; Foster, GR; Gardner, H; Kunkel, J; Lewis, H; Tippett, A; Wilkinson, M; Wynne, S1
Kapol, N; Lochid-Amnuay, S; Teerawattananon, Y1
Afdhal, NH; Buti, M; Curry, MP; Dufour, JF; Firdoos, S; Flamm, S; Hughes, MS; Tapper, EB1
Appolo, B; Bloom, R; Patel, N; Sawinski, D1
Bailly, F; Choupeaux, L; Gagnieu, MC; Maynard, M; Pradat, P; Scholtès, C; Virlogeux, V; Zoulim, F1
Ahn, SH; Han, KH; Kim, BK; Kim, do Y; Kim, HS; Kim, JK; Kim, MN; Kim, SU; Park, JY1
Asselah, T; Bakalos, G; Esmat, G; Goulis, I; Messinger, D; Sanai, FM; Waked, I1
Kukhareva, EI; Ogurtsov, PP1
Abdelli, N; Ben Abdallah, H; Bizid, S; Bouali, R; Ghazouani, E; Mrabet, A; Ouedrani, A1
Afdhal, NH; Bacon, BR; Curry, MP; Dieterich, DT; Flamm, SL; Guest, LE; Kowdley, KV; Lee, Y; Tapper, EB; Tsai, NC; Younossi, ZM2
Chang, TT; Hsieh, YH; Huang, HT; Hung, TH; Ng, KJ; Tseng, CW; Tseng, KC; Tzeng, SJ; Wu, SF1
Hunt, S; Mizokami, M; Omata, M; Stepanova, M; Walters, M; Younossi, ZM1
Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsi, E; Hsieh, MH; Hsieh, MY; Hsieh, TJ; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, CC; Lin, YH; Lin, ZY; Lu, MY; Tsai, PC; Tsai, YS; Yeh, ML; Yu, ML1
Asante-Appiah, E; Barr, E; Flisiak, R; Gerstoft, J; Halota, W; Horvath, G; Jancoriene, L; Kazenaite, E; Kileng, H; Koklu, S; Leiva, R; Nguyen, BY; Patel, S; Platt, HL; Prinzing, R; Qiu, J; Ruiz-Tapiador, JA; Sperl, J; Streinu-Cercel, A; Urbanek, P; Wahl, J; Werling, K1
Guo, P; Li, G; Sun, X; Wu, D1
Ahn, J; Branch, A; Gripshover, J; Hassan, MA; Kwok, RM; Lee Sang, M; Patel, N; Potosky, DR; Robertazzi, S; Rodigas, C; Satoskar, R; Schiano, TD; Smith, CI; Te, HS; Tierney, A; Wiegel, J1
Abdel-Hameed, EA; Abdelwahab, SF; Ahmed, SH; Daef, EA; El-Feky, MA; El-Mokhtar, MA; Hetta, HF; Hossain, M; Khalil, NK; Medhat, A; Mehta, M; Mekky, MA; Mohamed, WA; Rouster, SD; Shata, MT; Sherman, KE1
Keating, GM1
Brainard, DM; Bronowicki, JP; Brown, A; Carr, V; Dore, GJ; Grebely, J; Kreter, B; Mauss, S; Natha, M; Puoti, M; Wyles, D; Yang, J; Yun, C; Zhu, Y1
Aspinall, RJ; Brainard, DM; Dore, GJ; Feld, JJ; Foster, GR; Fox, R; Grebely, J; Han, L; Mangia, A; McNally, J; Natha, M; Osinusi, A; Subramanian, GM; Sulkowski, M; Zeuzem, S1
Alric, L; Anty, R; Beaulieux, F; Botta-Fridlund, D; Bouix, C; Canva, V; Carrieri, MP; Conti, F; D'Alteroche, L; Duclos-Vallée, JC; Durand, F; Duvoux, C; Fontaine, H; Lebray, P; Leroy, V; Maynard, M; Métivier, S; Pageaux, GP; Paul, C; Petrov-Sanchez, V; Pradat, P; Roche, B; Roque-Afonso, AM; Samuel, D; Vilotitch, A; Wellems, C1
Chen, DS; Hsu, CS; Hsu, SJ; Kao, JH; Liu, WL1
Akushevich, L; Ben Ari, Z; Di Bisceglie, AM; Frazier, LM; Fried, MW; Kuo, A; Lim, JK; Lok, AS; Nelson, DR; Pockros, PJ; Shiffman, ML; Sulkowski, MS; Terrault, NA; Vainorius, M; Zeuzem, S1
Drago, F; Gasparini, G; Marenco, S; Parodi, A; Picciotto, A1
Bae, SH; Cho, SB; Jang, ES; Jeong, SH; Kim, IH; Kim, YS; Lee, HC; Lee, YJ; Ok, KS1
Duguet, A; Ethgen, O; Jeanblanc, G; Juday, T; Misurski, D; Sanchez Gonzalez, Y1
Berden, FA; Blokzijl, H; de Knegt, RJ; den Hollander, J; Drenth, JP; Friederich, P; Kievit, W; Kuiken, SD; van Erpecum, KJ; van Hoek, B; van Nieuwkerk, CM; van Vonderen, MG; Willemse, SB1
Abdo, AM; Helmy, S; Yakoot, M; Yousry, A1
Boglione, L; Cusato, J; D'Avolio, A; Di Perri, G1
Berg, T; Ferenci, P; Gschwantler, M; Herzer, K; Jimenez-Exposito, MJ; Peck-Radosavljevic, M; Petersen, J; Rockstroh, J; Spengler, U; van der Valk, M; Wedemeyer, H; Weiland, O; Welzel, TM; Zeuzem, S; Zhao, Y1
Arns, CW; Bastos, JC; Caserta, LC; Miotto, N; Padilla, MA; Vigani, AG1
Berak, H; Bialkowska, J; Bolewska, B; Fleischer-Stępniewska, K; Flisiak, R; Garlicki, A; Halota, W; Horban, A; Jabłkowski, M; Janczewska, E; Jaroszewicz, J; Karpińska, E; Karwowska, K; Knysz, B; Kryczka, W; Lucejko, M; Madej, G; Mozer-Lisewska, I; Nazzal, K; Piekarska, A; Pisula, A; Rostkowska, K; Simon, K; Tomasiewicz, K; Tronina, O; Tudrujek, M; Wawrzynowicz-Syczewska, M; Wiercińska-Drapało, A; Zarębska-Michaluk, D1
He, QF; Zhang, DZ; Zhang, QF1
Chadwick, PW; Heymann, WR1
Alric, L; Billaud, E; Bourcier, V; Bourliere, M; Bronowicki, JP; Carrat, F; Causse, X; Chazouilleres, O; D'Alteroche, L; Diallo, A; Dorival, C; Fontaine, H; Fouchard-Hubert, I; Geist, C; Gournay, J; Guyader, D; Habersetzer, F; Hezode, C; Larrey, D; Ledinghen, VD; Loustaud-Ratti, V; Lucier, S; Marcellin, P; Mathurin, P; Metivier, S; Minello, A; Petrov-Sanchez, V; Pol, S; Riachi, G; Rosa, I; Saillard, E; Samuel, D; Thabut, D; Tran, A; Zarski, JP; Zoulim, F1
Chawla, Y; Dhiman, RK; Duseja, A; Mehta, M; Satsangi, S; Taneja, S1
Abou Mrad, R; Alkhouri, N; Carey, WD; Eghtesad, B; Elfeki, MA; Hanouneh, IA; Modaresi Esfeh, J; O'Shea, R; Zein, NN; Zervos, X1
Damrah, I; Eurich, D; Gül-Klein, S; Pratschke, J; Raschzok, N; Reutzel-Selke, A; Sauer, IM; Schott, E; Stockmann, M; Strücker, B1
Furusyo, N; Hayashi, J; Hotta, T; Murata, M; Ogawa, E; Shimizu, M; Toyoda, K; Uchiumi, T1
Azzari, C; Cananzi, M; D'Antiga, L; Grisotto, L; Indolfi, G; Maccabruni, A; Nebbia, G; Resti, M; Zaramella, M1
Carter, W; Connelly, S; Struble, K1
El-Karaksy, HM; El-Mougy, FA; Mandour, IA; Mogahed, EA; Rady, NH; Sharaf, SA1
Heger, E; Inden, S; Kaiser, R; Kalaghatgi, P; Knops, E; Neumann-Fraune, M; Schübel, N; Sierra, S1
Beck, R; Berg, CP; Egetemeyr, DP; Lauer, UM; Malek, NP; Schwarz, JM; Werner, CR1
Forton, DM1
Abagiu, AO; Aramă, V; Bădărău, IA; Barbu, EC; Bojincă, M; Chiţu-Tișu, CE; Ion, DA; Lazăr, M; Olariu, CM; Olteanu, D1
Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y1
De Meyer, S; Fevery, B; Janssen, K; Jessner, W; Lenz, O; Peeters, M; Verbinnen, T; Witek, J1
Colston, EM; Hruska, MW; Kishnani, N; Narasimhan, P; Srinivasan, S; Wind-Rotolo, MM; Xu, D; Zwirtes, R1
Aghasadeghi, M; Fateh, A; Irani, S; Jamnani, FR; Sadat, SM; Sakhaee, F; Sedighimehr, P; Siadat, SD; Vaziri, F1
Britnell, SR; Britt, RB; Vanderman, AJ; Willets, AE; Woodard, CL1
Alric, L; Kamar, N; Rostaing, L1
Barr, E; Black, S; Buti, M; Dutko, FJ; Gane, EJ; Gress, J; Haber, B; Kwo, P; Lin, L; Lupinacci, L; Pearlman, B; Peng, CY; Robertson, M; Serfaty, L; Shafran, S; Stryszak, P; Vierling, JM; Wahl, J1
Dinu, S; Oprea, C; Oprişan, G; Ruta, S; Sultana, C; Teleman, MD; Voiculescu, M1
Greig, SL1
Alavian, SM; Behnava, B; Craig, JC; Keshvari, M; Pouryasin, A; Sharafi, H1
Amrani, A; Dayal, S; Jain, VK; Verma, P1
Beck, KR; Khalili, M; Kim, N1
Brooks-Rooney, C; Dan, YY; Eguchi, Y; Kawada, N; Lim, YS; Mondelli, MU; Negro, F; Tanaka, A; Younossi, ZM; Yu, ML1
Arenas, J; Cheinquer, H; Dong, Y; Flisiak, R; Nikitin, I; Rana, K; Shiffman, M; Srinivasan, S1
Shi, KQ; Wang, BQ; Wang, YL1
Borba, HH; Fernandez-Llimos, F; Pedroso, ML; Perlin, CM; Pontarolo, R; Steimbach, LM; Tonin, FS; Wiens, A1
Chida, T; Ito, M; Nakashima, K; Suzuki, T1
Boyd, S; Harrington, PR; Komatsu, TE; Naeger, LK; O'Rear, JJ; Sherwat, A; Tracy, L1
Chen, H; Chen, X; Huang, P; Liu, J; Liu, Q; Wang, G; Wang, Y; Xu, T; Yao, Y; Yu, R; Zhang, Y; Zhou, H1
Berry, K; Green, PK; Ioannou, GN; Su, F1
Ascione, A; Barbarini, G; Ceccherini-Silberstein, F; D'Ambrosio, C; Ettorre, GM; Fondacaro, L; Giannelli, V; Ialongo, P; Izzi, A; Marignani, M; Messina, V; Moretti, A; Pace Palitti, V; Pellicelli, AM; Perno, CF; Sacco, R; Scifo, G; Siciliano, M; Tarquini, P; Vignally, P1
Mendes, LC; Miotto, N; Stucchi, RS; Vigani, AG; Zanaga, LP1
Assis Jarek, NA; Borba, HH; Ferreira, VL; Muzzillo, DA; Pontarolo, R; Tonin, FS; Wiens, A1
Kaur, K; Mahajan, R; Mehta, V; Midha, V; Narang, V; Sharma, S; Singh, D; Sood, A; Wander, P1
Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Higashi, N; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K1
Akuschevich, L; Brown, RS; Di Bisceglie, AM; Everson, GT; Fried, MW; Galati, JS; Kuo, A; Kwo, PY; Lim, JK; Lok, AS; Manns, MP; Morelli, G; Nelson, DR; Pockros, PJ; Reddy, KR; Sulkowski, MS; Terrault, NA; Vainorius, M1
Antosik, D; Barcińska, D; Bereszyńska, I; Januszkiewicz-Lewandowska, D; Kałużna, E; Mozer-Lisewska, I; Nowak, J; Rembowska, J; Strauss, E; Świątek-Kościelna, B; Wysocki, J1
Darwish, T; Ghoneum, M; Medhat, E; Salama, H; Shaheen, M; Zekri, AN1
Abdo, A; Al-Hamoudi, W; Albarrag, A; Alhetheel, A; Alswat, K; Shakoor, Z1
Bodeau, S; Brochot, E; Diouf, M; Duverlie, G; Lemouel, JP; Nguyen-Khac, E1
Gul, A; Mahmood, S; Saif, T1
Cao, Y; Huo, N; Lu, H; Wu, C; Xu, X; Zhang, R; Zhang, X; Zhang, Y1
Ashby, CR; Jankovich, RD; Jodlowski, TZ; Puglisi, GM; Smith, SM1
Aikata, H; Amano, H; Arataki, K; Chayama, K; Hayes, CN; Hiramatsu, A; Imamura, M; Ito, H; Kawakami, Y; Kawaoka, T; Kohno, H; Makokha, GN; Morio, K; Moriya, T; Nagaoki, Y; Nakahara, T; Nakamura, T; Ochi, H; Tamura, T; Tsuge, M; Tsuji, K; Waki, K1
Bhayani, V; Kabrawala, M; Mehta, R; Nandaniya, P; Nandwani, S; Shah, M; Tekriwal, R1
Albanes, D; Freedman, ND; Horst, R; Howell, CD; Loftfield, E; Morgan, TR; O'Brien, TR; Pfeiffer, RM; Prokunina-Olsson, L; Weinstein, SJ1
Alexandru, DO; Kamal, AM; Kamal, KC; MitruŢ, P; Niculescu, M; Tica, AA; Tica, OS1
Bang, BR; Chopra, S; Cook, L; Elmasry, S; Feng, Z; Harper, T; Jerome, KR; Kahn, JA; Kanel, G; Kim, B; Saito, T; Wadhwa, S1
Bertino, G; Caraci, F; Chisari, G; Drago, F; Greco, C; Malaguarnera, G; Malaguarnera, M; Motta, M; Nunnari, G; Vacante, M; Vecchio, M1
Ingiliz, P; Jimenez-Exposito, MJ; Peck-Radosavljevic, M; Petersen, J; Rockstroh, JK; Van der Valk, M; Welzel, TM; Zeuzem, S; Zhao, Y1
Charlton, M; Curry, MP; Feld, J; Foster, GR; Henry, L; Hunt, S; Mangia, A; Nader, F; O'Leary, JG; Stepanova, M; Sulkowski, M; Younossi, ZM; Zeuzem, S1
Brown, KA; Brown, RS; Fontana, RJ; Levitsky, J; Rubin, RA; Russo, MW; Vargas, H; Yoshida, EM1
Elsheikh, E; Estep, JM; Gerber, L; Golabi, P; Karrar, A; Stepanova, M; Younossi, I; Younossi, ZM1
But, DY; Chan, CK; Chan, HL; Chan, KH; Fung, J; Hui, YT; Lai, CL; Lai, MS; Lam, YS; Lao, WC; Li, C; Lui, GC; Seto, WK; Tsang, OT; Wong, GL; Wong, VW; Yuen, MF1
Chang, JJ; Chen, CK; Chen, LW; Chen, SW; Chien, RN; Lee, TS; Liu, CJ; Wang, LJ; Yen, CL1
Bräu, N; Dieterich, DT; Miller, TR; Rivera-Mindt, M; Stivala, A; Weiss, JJ1
Buti, M; Calleja, JL; Corbett, C; Crespo, J; Diago, M; Fevery, B; Jessner, W; Kalmeijer, R; Kurland, D; Lens, S; Ortega, E; Pascasio, JM; Planas, R; Rodríguez, FG; Romero-Gómez, M1
Kahn, JG; Lai, JC; Mehta, N; Roberts, JP; Salazar, J; Saxena, V; Volk, M1
Castells, L; Fernandez Vazquez, I; Herrero, JI; Londoño, M; Narvaez Rodriguez, I; Otero, A; Pascasio, JM; Prieto, M; Sanchez Antolin, G; Testillano, M1
Acharya, SK; Chowdhury, A; Doehle, B; Duseja, A; Jiang, D; Kanwar, B; Kapoor, D; Kersey, K; Koshy, A; Madan, K; Mehta, R; Nijhawan, S; Pawan, R; Prasad, M; Sarin, S; Shah, SR; Shukla, A; Sood, A; Subramanian, M; Sud, R; Svarovskaia, E1
Alonso, S; Ampuero, J; Badia, E; Baliellas, C; Buti, M; Carrión, JA; Castro, Á; Devesa, MJ; Esteban, R; Fernandez, I; Fernandez-Carrillo, C; Fernández-Rodríguez, CM; Gea, F; Gómez, A; Granados, R; Lens, S; Llerena, S; Montero, JL; Olveira, A; Pascasio, JM; Planas, JM; Polo, B; Real, Y; Rincón, D; Riveiro-Barciela, M; Rubín, A; Salmeron, J; Turnes, J1
Eurich, D; Globke, B; Pratschke, J; Raschzok, N; Schott, E; Teegen, EM1
Clayton, CW; Jimmerson, LC; Kiser, JJ; Kottilil, S; MaWhinney, S; Meissner, EG; Sims, Z1
Chen, W; Dang, P; Feng, J; Ma, Y; Wang, L; Xi, W; Yu, Y1
Agostinacchio, E; Arleo, A; Carraturo, I; Copetti, M; De Stefano, G; Losappio, R; Mangia, A; Miscio, M; Palmieri, V; Piazzolla, V; Potenza, D; Santoro, R; Sarrazin, C; Spinzi, G; Susser, S1
Elbasha, E; Greaves, W; Nwankwo, C; Roth, D1
Afzal, S; Ali, M; Hassan, A; Idrees, M; Khalil, AT; Ovais, M; Shinwari, ZK; Zia, A1
Baraldi, C; Barisani, A; Dika, E; Fanti, PA; Patrizi, A; Vaccari, S1
Hu, P; Ren, H1
Amano, N; Genda, T; Hirano, K; Ichida, T; Iijima, K; Kanemitsu, Y; Murata, A; Nagahara, A; Narita, Y; Sato, S; Shimada, Y; Tsuzura, H; Wada, R; Watanabe, S1
Hayashi, Y; Imoto, S; Kim, CW; Kim, SK; Kim, SR1
Alberti, A; Bonfanti, M; Croce, D; Lazzarin, A; Nappi, C; Restelli, U1
Berg, T; Ferenci, P; Herzer, K; Hinrichsen, H; Inderson, A; Jimenez-Exposito, MJ; Klinker, H; Peck-Radosavljevic, M; Spengler, U; Welzel, TM; Zeuzem, S; Zhao, Y1
Backstedt, D; Choi, M; Patel, A; Pedersen, MR; Seetharam, AB1
Bai, X; Calleja, JL; Forns, X; Garcia-Samaniego, J; Kaste, R; Manns, M; Sarrazin, C; Stern, JO; Wu, J1
Chen, PJ; Hong, CM; Liu, CJ; Yeh, SH1
Asahina, Y; Asano, Y; Azuma, S; Iijima, S; Itsui, Y; Izumi, N; Kakinuma, S; Kaneko, S; Kawai-Kitahata, F; Miyoshi, M; Murakawa, M; Nagata, H; Nakagawa, M; Nitta, S; Otani, S; Tanaka, Y; Tohda, S; Tsuchiya, K; Tsunoda, T; Watanabe, M1
Chen, Y; Jiang, X; Song, Y; Tao, T1
Flisiak, R; Flisiak-Jackiewicz, M; Pogorzelska, J1
Lange, CM; Mücke, MM; Mücke, VT; Zeuzem, S1
Alvares-Lajonchere, L; Amador, Y; Camacho, H; Campaña, JR; Dueñas, S; Estevez, ZC; Fernández, JR; Gao, Y; Guillen, IA; Han, J; Martinez-Donato, G; Novoa, LI; Palenzuela Gardón, D; Zhang, X; Zhang, Z1
Bucher, HC; Calleja, JL; Castells, L; Evans, D; Giostra, E; Hofer, H; Irving, W; Lefevre, C; Pascasio, JM; Postema, R; Prieto, M; Weiland, O; Weis, N; Young, J1
Abdelaziz, AO; Doss, W; El Akel, W; El Demerdash, T; El Raziky, M; El Serafy, M; El Shazly, Y; Elsharkawy, A; Esmat, G; Fouad, R; Gaballah, A; Hassany, M; Makhlouf, MA; Motawea, I; Said, M; Seif, S; Shiha, G; Thursz, M; Waked, I; Yosry, A1
Jin, YJ; Lee, JW; Lee, SH; Shin, JY1
Cammà, C; D'Offizi, G; DeMasi, R; Janssen, K; Lionetti, R; Palma, M; Schlag, M; Taibi, C; Weber, K; Witek, J1
Aherfi, S; Brouqui, P; Colson, P; Dhiver, C; Meddeb, L; Menard, A; Mokhtari, S; Ravaux, I; Stein, A; Tissot-Dupont, H1
Berg, T; Böker, KH; Cornberg, M; Günther, R; Hüppe, D; Link, R; Manns, MP; Mauss, S; Niederau, C; Petersen, J; Pfeiffer-Vornkahl, H; Sarrazin, C; Schober, A; Serfert, Y1
Beck, R; Berg, CP; Dietz, J; Klag, T; Lauer, UM; Malek, NP; Sarrazin, C; Schwarz, JM; Werner, CR1
Frydecka, D; Małyszczak, K; Pawlak, D; Pawłowski, T1
Chan, SF; Ho, LY; Lo, KC; Lo, KY; Lo, MW; Mak, SK; Sin, HK; Wong, AKM; Wong, PN; Wong, YY1
Cartabellotta, F; Di Marco, V1
Baldanti, F; Ludovisi, S; Mondelli, MU; Paolucci, S; Premoli, M1
Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MH; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, YH; Lin, ZY; Liu, TW; Tsai, PC; Yeh, ML; Yu, ML1
Boyd, SD; Harrington, PR; Komatsu, TE; Murray, J; Sherwat, A; Tracy, L; Viswanathan, P1
Miyoshi, Y; Suzuki, M; Tajiri, H; Takano, T1
Andreoni, M; Angelico, M; Antonucci, F; Aragri, M; Babudieri, S; Barbaliscia, S; Bellocchi, MC; Bertoli, A; Brancaccio, G; Calvaruso, V; Caporaso, N; Ceccherini-Silberstein, F; Cento, V; Cozzolongo, R; Craxì, A; Di Biagio, A; Di Maio, VC; Francioso, S; Gianserra, L; Grieco, A; Landonio, S; Lenci, I; Loggi, E; Magni, CF; Masetti, C; Mastroianni, CM; Melis, M; Merli, M; Micheli, V; Morisco, F; Pace Palitti, V; Paoloni, M; Parruti, G; Pasquazzi, C; Pellicelli, AM; Perno, CF; Picciotto, A; Puoti, M; Rizzardini, G; Romagnoli, D; Rossi, P; Santopaolo, F; Sarmati, L; Siciliano, M; Taliani, G; Tarquini, P; Teti, E; Vecchiet, J; Verucchi, G; Vullo, V1
Barros, C; Bellón, JM; Berenguer, J; Carrero, A; Crespo, M; Esteban, H; Galindo, MJ; Gaspar, G; González-García, J; Guardiola, JM; Jusdado, JJ; Mallolas, J; Montero, M; Montes, ML; Ortega, E; Pulido, F; Quereda, C; Rodríguez-Castellano, E; Rubio, R; Santos, I; Sanz, J; Téllez, MJ; Tural, C; Von Wichmann, MA1
Enomoto, M; Hagihara, A; Hai, H; Kawada, N; Kawamura, E; Kozuka, R; Morikawa, H; Motoyama, H; Murakami, Y; Tamori, A; Teranishi, Y; Uchida-Kobayashi, S1
Hmwe, SS; Ide, T; Inoue, T; Kato, K; Kumada, T; Shimada, N; Takaguchi, K; Tanaka, Y; Torimura, T; Toyoda, H; Tsubota, A; Wakita, T1
Balba, G; Bowlus, CL; Brainard, DM; Cohen, A; Fried, MW; Han, B; Hyland, RH; Kim, AY; Kouides, P; McHutchison, JG; Reddy, KR; Rhame, F; Sax, PE; Stamm, LM; Terrault, NA; von Drygalski, A; Walsh, CE; Wang, J; Workowski, K1
Bourgeois, S; de Galocsy, C; Degré, D; Delwaide, J; Geerts, A; Gustot, T; Laleman, W; Langlet, P; Lasser, L; Lepida, A; Moreno, C; Negrin Dastis, S; Orlent, H; Reynaert, H; Sersté, T; Starkel, P; Van Steenkiste, C; Vanwolleghem, T1
Asatryan, A; Bernstein, DE; Felizarta, F; Flamm, SL; Fried, MW; Gordon, SC; Kort, J; Landis, CS; Lin, CW; Liu, R; Lovell, SS; Mensa, FJ; Ng, TI; Poordad, F; Reindollar, RW; Sulkowski, MS1
Abdalla, AF; Alsayed, MAEL; Barakat, T; Fathy, A; Mabood, SAE; Megahed, A; Salem, N; Zalata, KR1
Alvarez, M; Butt, ZA; Chong, M; Cook, D; Darvishian, M; Islam, N; Janjua, NZ; Krajden, M; Ramji, A; Samji, H; Tyndall, M; Wong, J; Yoshida, EM1
Kumakawa, M; Matsumoto, N; Matsumura, H; Matsuoka, S; Moriyama, M; Nakamura, H; Nirei, K; Yamagami, H1
Akamatsu, N; Eguchi, S; Goto, R; Ikegami, T; Kitagawa, Y; Kokudo, N; Maehara, Y; Okajima, H; Shinoda, M; Soyama, A; Taketomi, A; Ueda, Y; Uemoto, S; Yoshizumi, T1
Hunt, S; Mizokami, M; Omata, M; Stepanova, M; Walters, M; Younossi, Z1
Economides, MP; Shigle, TL; Torres, HA1
Jiang, JF; Liu, X; Shi, J; Sun, J1
Angarano, G; Bruno, G; Buccoliero, G; Dell'Acqua, R; Fabrizio, C; Fasano, M; Giammario, A; Ladisa, N; Milano, E; Milella, M; Minniti, S; Saracino, A; Scudeller, L; Tartaglia, A1
Chen, H; Huang, P; Li, J; Liu, M; Wang, J; Yao, Y; Yu, R; Yue, M; Zang, F; Zhang, Y1
Abe, M; Hiasa, Y; Hirooka, M; Horiike, N; Joko, K; Kisaka, Y; Michitaka, K; Nakanishi, S; Nonaka, T; Tada, F; Tanaka, Y; Tokumoto, Y; Watanabe, T; Yamauchi, K1
Ascione, T; Borgia, G; Buonomo, AR; Calò, F; Coppola, N; De Pascalis, S; de Stefano, G; Di Caprio, G; Federico, A; Filippini, P; Gaeta, GB; Gentile, I; Martini, S; Messina, V; Minichini, C; Persico, M; Rinaldi, L; Sangiovanni, V; Stanzione, M; Starace, M; Stornaiuolo, G; Zampino, R1
Albillos, A; Arenas, J; Badia, E; Baliellas, C; Blé, M; Buti, M; Calleja, JL; Carrión, JA; Castells, L; Crespo, J; de la Mata, M; Fernández Bermejo, M; Fernández Carrillo, C; Fernández, I; Fernández-Rodriguez, C; García-Samaniego, J; Granados, R; Herrero, JI; Lens, S; Llop, E; Mariño, Z; Moreno-Palomares, JJ; Moreno-Planas, JM; Pascasio, JM; Pons, C; Prieto, M; Romero, M; Salcedo, M; Salmerón, J; Turnes, J1
Ariaudo, A; Boglione, L; Carcieri, C; Cariti, G; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G; Favata, F; Mornese Pinna, S1
Akremi, R; Bennai, Y; Botta-Fridlund, D; Bourliere, M; Boyer, N; Bronowicki, JP; D'Alteroche, L; De Ledinghen, V; Di Martino, V; Fedchuk, L; Filipovics, A; Fontaine, H; Guyader, D; Hézode, C; Hubert-Fouchard, I; Larrey, D; Lebray, P; Leroy, V; Nguyen-Khac, E; Rosa, I; Silvain, C; Zhao, Y; Zoulim, F1
Ide, K; Iketani, R; Kawasaki, Y; Masaki, N; Yamada, H1
Arastéh, K; Bourgeois, S; Buggisch, P; Francque, S; Hoeben, E; Horsmans, Y; Jacquemyn, B; Kakuda, TN; Luo, D; Moreno, C; Nevens, F; Orlent, H; Schattenberg, JM; Van Remoortere, P; Van Vlierberghe, H; Vandebosch, A; Verloes, R; Vijgen, L1
Albillos, A; Ampuero, J; Arenas, J; Bañares, R; Calleja, JL; Crespo, J; Diago, M; Fernandez, I; García-Eliz, M; García-Samaniego, J; Gea, F; Jorquera, F; Lens, S; Llaneras, J; Llerena, S; Mariño, Z; Morillas, RM; Muñoz, R; Navascues, CA; Pascasio, JM; Perelló, C; Rincón, D; Rodriguez, CF; Ruiz-Antorán, B; Sacristán, B; Serra, MA; Simon, MA; Torras, X; Turnes, J1
Li, CX; Li, W; Li, ZQ; Liang, HX; Xu, GH; Yu, ZJ; Zeng, QL; Zhang, DW; Zhang, JY1
Barr, E; Haber, BA; Hézode, C; Howe, AYM; Hwang, P; Jacobson, IM; Kwo, PY; Lawitz, E; Peng, CY; Robertson, M; Wahl, J1
Efinger, M; Herrmann, E; Lange, CM; von Wagner, M; Welsch, C; Welzel, TM; Zeuzem, S1
Arias, A; Benítez-Gutiérrez, L; Citores, MJ; Cuervas-Mons, V; de Mendoza, C; Esposito, I; Requena, S; Soriano, V; Treviño, A1
Ezzat, W; Fouad, R; Heiba, A; Khairy, M; Khorshied, M; Sheta, MM; Zachariah, K1
Afendy, M; Cable, R; Esteban, R; Henry, L; Hunt, S; Jacobson, I; Nader, F; Stepanova, M; Sulkowski, M; Younossi, ZM; Zeuzem, S1
Ackerman, P; Berenguer, J; Cheinquer, H; Côté, P; Dieterich, D; Eley, T; Fessel, WJ; Gadano, A; Hernandez, D; Hughes, E; Lazzarin, A; Liu, Z; Matthews, G; McPhee, F; Mendez, P; Molina, JM; Moreno, C; Noviello, S; Pineda, JA; Pulido, F; Rivero, A; Rockstroh, J; Sulkowski, MS; Zakharova, N1
Bach, TA; Zaiken, K1
Ide, K; Iketani, R; Kawasaki, Y; Masaki, N1
Brito-Zerón, P; Cacoub, P; Casato, M; Ferri, C; Lamprecht, P; Mangia, A; Ramos-Casals, M; Retamozo, S; Saadoun, D; Tzioufas, AG; Younossi, ZM; Zignego, AL1
Brainard, DM; Dvory-Sobol, H; Gutierrez, J; Hyland, RH; Landaverde, C; Lawitz, E; McHutchison, JG; Poordad, F; Stamm, LM; Wells, J; Yang, Y1
Chang, TT; Ho, YC; Hsieh, YH; Tseng, CW; Tseng, KC; Tseng, LH; Wu, SF1
Bui, E; di Biase, L; Fasano, A; Freitas, ME; Picillo, M1
Castedal, M; Cederberg, S; Segenmark, M; Skoglund, C; Weiland, O1
Akremi, R; Allegre, T; Antonini, T; Aumaitre, H; Batisse, D; Bennai, Y; Billaud, E; Chas, J; Dabis, F; De Ledinghen, V; De Truchis, P; Dhiver, C; Dominguez, S; Fedchuk, L; Filipovics, A; Fontaine, H; Harent, S; Lacombe, K; Lafeuillade, A; Leroy, V; Metivier, S; Miailhes, P; Pageaux, GP; Perre, P; Rosenthal, E; Salmon Ceron, D; Sogni, P; Valantin, MA; Zhao, Y1
Buzzetti, E; Davidson, BR; Gurusamy, KS; Kalafateli, M; Thorburn, D; Tsochatzis, E1
Almarzooqi, S; Emery, JS; Feld, JJ; Janssen, HLA; Kowgier, M; Kuczynski, M; La, D; Shah, H; Wong, D1
Andreone, P; Berenguer, M; Calleja, JL; Cieciura, T; Donato, MF; Durlik, M; Fagiuoli, S; Forns, X; Herzer, K; Janssen, K; Jessner, W; Kalmeijer, R; Lenz, O; Mariño, Z; Ouwerkerk-Mahadevan, S; Peeters, M; Shukla, U; Sterneck, M; Verbinnen, T1
Chuang, WL; Dai, CY; Hsieh, MY; Huang, JF; Yu, ML4
Goto, H; Hayashi, K; Honda, T; Ishigami, M; Katano, Y; Nakano, I; Takamatsu, J; Toyoda, H; Yamamoto, K1
Enquist, R; Glaumann, H; Hollander, A; Lindahl, K; Lindh, G; Mattsson, L; Quist, A; Schvarcz, R; Weiland, O1
Chang, WY; Chen, SC; Chiu, CF; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, JF; Lee, LP; Lin, ZY; Wang, LY; Yang, YH; Yu, ML1
Pol, S; Soriano, V1
Banasch, M; Ellrichmann, M; Emminghaus, R; Goetze, O; Schmidt, WE1
Niederau, C4
Kaden, T; Niederau, C1
Dev, A; Dinh, T; George, J; Guirgis, M; Lee, A; Yan, KK; Zekry, A1
Borkowska, A; Drózdz, W; Dybowska, D; Halota, W; Kozielewicz, D; Ziółkowska-Kochan, M1
Jendryczka, E; Pawłowska, M; Pilarczyk, M1
Pawłowska, M4
El-Shamy, A; Hotta, H; Imoto, S; Kim, SR; Nagano-Fujii, M; Sasase, N1
El-Shamy, A; Hayashi, Y; Hotta, H; Imoto, S; Kawada, N; Kim, KI; Kim, SR; Kudo, M; Mita, K; Sasase, N; Shouji, I; Taniguchi, M1
Cvetković, RS; Keam, SJ2
Akue-Goeh, P; Howaizi, M; Maurer-Chagrin, F1
Andriulli, A; Iacobellis, A; Ippolito, A; Leandro, G; Mangia, A; Zeuzem, S1
Andreone, P; Ballardini, G; Berardi, S; Bernardi, M; Bianchi, FB; Biselli, M; Bolondi, L; Cescon, M; Colecchia, A; D'Errico, A; Del Gaudio, M; Ercolani, G; Gramenzi, A; Grazi, GL; Grigioni, W; Lenzi, M; Lodato, F; Lorenzini, S; Mazzella, G; Morelli, MC; Pinna, AD; Piscaglia, F; Ravaioli, M; Roda, E; Sama, C; Tame, MR; Vivarelli, M1
Clemente, G; Del Rio, JM; Gisbert, JP; Marin, M; Moreno-Otero, R; Nunez, O; Pivel, JP; Trapero-Marugan, M1
Bodenheimer, HC; Joyce, MA; Kadam, JS; Lake-Bakaar, G; Leonard, J; Lin, A1
Mangini, C; Pereira, GH1
Genné, D; Golay, A; Negro, F; Overbeck, K1
Cheng, D; Chu, Y; Liu, E; Xue, X; Yang, H; Yu, H; Zhao, S1
Hauser, P; Huckans, M; Loftis, J; Mitchell, A; Ruimy, S1
Agreda, M; Cuenca, F; Devesa, MJ; Díaz-Rubio, M; Ladero, JM; López-Alonso, G; Ortega, L; Suárez, A2
Jensen, DM; Martin, P1
Pedersen, C; Pedersen, CR1
Collado, A; Crespo, M; Esteban, JI; Girón-González, JA; González-Serrano, M; López-Cortés, LF; Merino, D; Mira, JA; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Van den Eynde, E1
Becheanu, G; Gheorghe, L; Herlea, V; Hrehoret, D; Iacob, S; Popescu, I1
Berenguer, M1
Bolewska, B; Czajka, A; Juszczyk, J; Moczko, J1
Adamek, A; Adamek, J; Bereszyńska, I; Juszczyk, J1
Kiciak, SG; Krzowska-Firych, J; Modrzewska, R1
Barreiro, P; López-Cortes, LF; Maida, I; Martín-Carbonero, L; Merino, D; Mira, JA; Pineda, JA; Rivero, A; Rodríguez-Nóvoa, S; Santos, I; Soriano, V; Vispo, E1
Bani-Sadr, F; Cacoub, P; Carrat, F; Driss, H; Goderel, I; Lapidus, N; Lunel-Fabiani, F; Morand, P; Perronne, C; Pol, S; Rosenthal, E; Simon, A1
Chang, SC; Ko, WS; Peng, CY; Wu, SS; Yang, SS1
Laguno, M; Mallolas, J1
Pearlman, BL3
Paik, SW1
Benini, MC; Biagini, MR; Capanni, M; Colagrande, S; Lorefice, E; Milani, S; Salvadori, E; Surrenti, C; Tozzi, A1
Crosbie, O; Fanning, LJ; Kenny-Walsh, E; Levis, J; Moreau, I1
Bani-Sadr, F; Bedossa, P; Cacoub, P; Carrat, F; Lunel-Fabiani, F; Morand, P; Perronne, C; Pialoux, G; Piroth, L; Pol, S; Salmon-Céron, D1
Aleman, S; Birk, M; Carlsson, T; Davidsdottir, L; Hagen, K; Hultcrantz, R; Oksanen, A; Rahbin, N; Syed, E; Weiland, O1
Kami, M; Komatsu, T; Miura, Y; Toda, N; Yotsuya, R1
Fujita, N; Hayashi, H; Iwasa, M; Kaito, M; Kobayashi, Y; Motonishi, S; Sugimoto, R; Takei, Y; Takeo, M; Tanaka, H; Tomosugi, N1
Cacopardo, B; Cappellani, A; Cappello, E; La Medica, G; Nigro, L; Nunnari, G; Palermo, F; Russo, R1
Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H4
Akhan, SC; Kalender, B; Ruzgar, M1
Gambarin-Gelwan, M; Jacobson, IM2
Bruno, R; De Luca, A; García-Samaniego, J; González, M; Losada, E; Mariño, A; Martín-Carbonero, L; Núñez, M; Puoti, M; Quinzan, G; Soriano, V1
Bruggmann, P; Dober, S; Falcato, L; Helbling, B; Keiser, O; Meili, D; Negro, F1
Arakawa, T; Atsumi, H; Goto, H; Hayashi, K; Hisanaga, Y; Honda, T; Kanamori, A; Katano, Y; Kiriyama, S; Kumada, T; Nakano, S; Sone, Y; Tanikawa, M; Toyoda, H1
Andrade, LJ; Atta, AM; D'Almeida Junior, A; Paraná, R1
Burton, JR; Castelblanco, N; Golden-Mason, L; Im, K; Klarquist, J; Rosen, HR; Smyk-Pearson, S; Terrault, N1
Jiménez-Rivera, J; Marxuach-Cuétara, A; Ortiz-Lasanta, G; Purcell-Arevalo, D; Ríos-Bedoya, CF; Rodríguez-Torres, M1
Hwang, Y; Lin, E1
Cheng, C; Fung, J; Hung, I; Lai, CL; Wong, D; Young, J; Yuen, MF1
Bigard, MA; Bronowicki, JP; Cadranel, JF; Canva, V; Cortot, A; Gueant, JL; Nousbaum, JB; Oussalah, A; Peyrin-Biroulet, L; Roblin, X; Seddik, M; Sogni, P1
Enomoto, M; Hino, M; Kawada, N; Ohnishi, M; Tamori, A; Yamane, T1
Borelli, S; Borgia, F; Borgia, G; Borrelli, F; Cerini, R; de Caterina, M; Di Taranto, MD; Fortunato, G; Gentile, I; Reynaud, L; Sacchetti, L; Simone, M; Viola, C1
Bain, VG; Benhamou, Y; Cronin, PW; Flisiak, R; Grigorescu, M; Kaita, K; McHutchison, JG; Pianko, S; Pulkstenis, E; Rehak, V; Shouval, D; Subramanian, GM; Yoshida, EM; Zeuzem, S1
Alsiö, A; Buhl, MR; Christensen, P; Dhillon, AP; Färkkilä, M; Hellstrand, K; Lagging, M; Langeland, N; Leutscher, P; Mørch, K; Norkrans, G; Pedersen, C; Westin, J1
Al-Ansari, M; Dickson, G; Weilert, F1
Ferenci, P; Formann, E; Gschwantler, M; Gurguta, C; Jessner, W; Watkins-Riedel, T; Wrba, F1
Bojunga, J; Bücker, A; Herrmann, E; Hofmann, WP; Kronenberger, B; Mihm, U; Sarrazin, C; Stamm, B; von Wagner, M; Zeuzem, S1
Bronowicki, JP; Cadranel, JF; Denis, J; Larrey, D; Perronne, C; Tran, A; Trépo, C1
Marcellin, P; Pol, S1
De Lédinghen, V; Lang, JP; Poynard, T; Ratziu, V; Rosenthal, E; Wartelle-Bladou, C1
Angelico, F; Angelico, M; Bandiera, F; Barlattani, A; Demelia, L; Forlini, G; Francioso, S; Gentile, S; Grieco, A; Guarascio, P; Koehler-Horst, B; Piccolo, P; Pilleri, G; Ponti, L; Rossi, Z; Soccorsi, F; Sorbello, O; Tarquini, P; Vecchia, RD; Zaru, S1
de Aguiar, MC; do Carmo, MA; Grossmann, Sde M; Teixeira, R1
Chang, CY; Chang, FY; Chu, CJ; Hung, TH; Hwang, SJ; Lee, CY; Lee, FY; Lee, SD; Lin, HC; Lu, RH; Yang, PL; Yu, MI1
Kato, M; Miura, H; Ryu, T; Saito, T; Yamada, H1
Bodenheimer, HC; Bonkovsky, HL; Monto, A; Rossi, SJ; Sulkowski, MS; Tice, AD; Yapp, RG1
Anderson, F; Bailey, RJ; Bain, VG; Cooper, CL; Krajden, M; Marotta, P; Yoshida, EM1
Białkowska, J; Dworniak, D; Jabłkowski, M; Pawełczyk, A; Pawełczyk, T; Rabe-Jabłońska, J; Strzelecki, D2
Abate, ML; Bo, S; Bugianesi, E; Cassader, M; Ciancio, A; Ciccone, G; Gambino, R; Giordanino, C; Olivero, A; Pellicano, R; Rizzetto, M; Saracco, G; Smedile, A1
Gładysz, A; Inglot, M; Machaj, A; Molin, I; Rymer, W; Zalewska, M1
Correale, M; Cozzolongo, R; Frisullo, S; Guerra, V; Iacovazzi, PA; Lanzillotta, E1
Back-Madruga, C; Bieliauskas, LA; Fontana, RJ; Kronfol, Z; Lindsay, KL; Lok, AS; Padmanabhan, L; Stoddard, AM1
Jensen, DM; Mishra, P1
Jagodziński, PP; Juszczyk, J; Kmieciak, D; Migdalski, P; Trzeciak, WH1
Smith, JP1
Crawford, V; Dalton, J; Foster, GR; Hekker, M; Jolly, F; Marley, R; Sims, E; Tippet, A; Turton, J; Wilkinson, M1
Bani-Sadr, F; Cacoub, P; Carrat, F; Goderel, I; Larrat, S; Lunel-Fabiani, F; Martha, B; Morand, P; Payan, C; Perronne, C; Piroth, L; Pol, S1
Husa, P; Husová, L; Slesinger, P; Stroblová, H; Svobodník, A1
Kristian, P; Pellová, A; Porubcin, S; Schréter, I1
Cacoub, P; Klatzmann, D; Landau, DA; Rosenzwajg, M; Saadoun, D; Trébeden-Negre, H1
Baloch, GH; Ghori, R; Jaffri, M; Masood, N; Memon, A; Memon, I; Memon, KI; Memon, S1
Berg, T; Hinrichsen, H; Hueppe, D; Manns, MP; Mauss, S; Moeller, B; Sarrazin, C; Wedemeyer, H; Zehnter, E; Zeuzem, S1
DeVoss, A; Hart, J; Jensen, DM; Mishra, P; Pai, R1
Bellati, G; Bellia, V; Bruno, S; Ceriani, R; Colloredo, G; Corradi, C; Del Poggio, P; Fornaciari, G; Parravicini, P; Pioltelli, P; Pozzpi, M; Ramella, G; Roffi, L; Rossini, A1
Beinhardt, S; Ferenci, P; Hofer, H; Holzmann, H; Kerschner, H; Rutter, K; Scherzer, TM; Schöniger-Hekele, M; Steindl-Munda, P1
Calogero, A; Cammalleri, L; Di Fazio, I; Gargante, MP; Malaguarnera, M; Pennisi, G; Rampello, L; Ranno, S; Risino, C; Vicari, E1
Angarano, G; Di Tullio, R; Fazio, V; Fornabaio, C; Saracino, A; Scotto, G; Tartaglia, A2
Blanco, Cdel V; Federico, A; Loguercio, C; Masarone, M; Persico, M; Torella, R1
Raimondo, G; Saitta, C1
Gasiorowski, J; Inglot, M; Szymczak, A1
Cornberg, M; Hadem, J; Hauptmann, C; Manns, MP; Süttmann, U; Wedemeyer, H1
Choi, P; Jung, EU; Kang, MJ; Kim, JH; Lee, SH; Lee, YJ; Park, ET; Park, SJ; Park, SW; Seol, SY1
Kaya, S1
Akuta, N; Arase, Y; Hirakawa, M; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H4
Deutch, M; Dourakis, S; Ioannidou, P; Karafoulidou, A; Katsarou, O; Kouraba, A; Nomikou, E; Terpos, E; Theodosiades, G; Tsevrenis, B1
Castro, G; Figueiredo, JF; Martinelli, Ade L; Ramalho, LN; Zucoloto, S1
Marcellin, P; Nelson, DR; Zeuzem, S1
Khan, F; Peltekian, KM; Peterson, TC1
Berg, T; Buggisch, P; Gerken, G; Goeser, T; Herrmann, E; Hinrichsen, H; Hofmann, WP; Manns, M; Spengler, U; Teuber, G; von Wagner, M; Weidenbach, H; Zeuzem, S1
Bugawan, T; Erlich, H; Im, K; Li, J; Liang, TJ; Rhodes, SL; Rosen, HR; Wahed, AS; Yang, H; Yee, LJ1
Barreiro, P; Collado, A; de Los Santos Gil, I; González-Serrano, M; Hernández-Burruezo, JJ; López-Cortés, LF; López-Ruz, MA; Macías, J; Martín-Rico, P; Merino, D; Mira, JA; Muñoz, L; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Soriano, V; Torres-Tortosa, M; Tural, C; Viciana, P1
Azim, J; McCurdy, H; Moseley, RH1
Ichijo, T; Joshita, S; Kiyosawa, K; Komatsu, M; Matsumoto, A; Shirakawa, H; Tanaka, E; Tanaka, N; Umemura, T; Yoshizawa, K1
Jiménez-Nácher, I; Morello, J; Rodríguez-Novoa, S; Soriano, V1
Becheanu, G; Cotruta, B; Cotruta, C; Gheorghe, C; Gheorghe, L; Trifu, V1
Bacosi, D; Baldelli, F; Belfiori, B; Chiodera, A; Ciliegi, P; Francisci, D; Tosti, A1
Alsiö, A; Dhillon, AP; Ferrari, C; Hellstrand, K; Islam, S; Lagging, M; Neumann, AU; Pawlotsky, JM; Schalm, SW; Westin, J; Ydreborg, M; Zeuzem, S1
Farooqi, JI; Farooqi, RJ1
Anikina, OV; Kovalenko, SN; Romantsov, MG; Sologub, TV1
Araújo, FM; Oliveira, GC; Redondo, RA; Rodrigues, NB; Sonoda, IV; Teixeira, R1
Cortina, B; del Olmo, JA; Lluch, P; Lluch, S; Mauricio, MD; Rodrigo, JM; Segarra, G; Serra, MA; Vila, JM1
Chang, ML; Hsu, CW; Tsao, ML; Yeh, CT1
Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Katamura, Y; Kawamura, Y; Kobayashi, M; Kumada, H; Nomura, N; Saito, S; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H1
Hashemi, N; Herrine, SK; Navarro, VJ; Rossi, S1
Ishikawa, T1
Cacoub, P; Chousterman, M; Fontanges, T; Lang, JP; Marcellin, P; Melin, P; Ouzan, D; Rotily, M; Varastet, M1
Davison, SM; Kelly, DA1
Chang, CS; Chang, SC; Chen, CY; Chuang, JY; Hsieh, YY; Kao, JH; Lu, YT; Yang, SS; Yeh, HZ1
Fehér, J; Hagymási, K1
Ackermann, O; Grigorian, N; Herrmann, E; Hofmann, WP; Lengauer, T; Mihm, U; Sarrazin, C; Welker, MW; Welsch, C; Zeuzem, S1
Caturelli, E; Dell'Isola, S; Ghittoni, G; Ialungo, AM; Roselli, P; Starnini, G1
Broers, B; Frei, M; Fried, R; Herold, M; Huber, M; Isler, M; Kölliker, C; Monnat, M; Oppliger, R; Schmid, P; Schönbucher, P; Seidenberg, A1
Antonini, T; Canfora, ML; Castaing, D; Delvart, V; Duclos-Vallee, JC; Roche, B; Roque-Afonso, AM; Saliba, F; Samuel, D; Sebagh, M1
Boumis, E; Capone, A; Drapeau, CM; Noto, P; Petrosillo, N; Remotti, D1
Jones, TL; Reeves, GE; Tran, HA1
Bergmann, JF; De Knegt, RJ; Janssen, HL1
Deuter, C; Doycheva, D; Stuebiger, N; Zierhut, M1
Azhar, M; Jamall, IS; Jamall, S; Yusuf, S1
Arnsten, JH; Gourevitch, MN; Harris, KA; Kaswan, D; Litwin, AH; Nahvi, S; Soloway, IJ; Tenore, PL; Zamor, PJ1
Nerrienet, E; Njouom, R; Pasquier, C; Rousset, D; Sartre, MT; Tchendjou, P; Timba, I1
Kearney, KR; Navarro, VJ; Thornton, JJ1
Lin, CC; Yin, MC1
Dai, Y; Ishii, K; Mohri, K; Motegi, E; Uesawa, Y1
Bonet, L; Cifuentes, C; Gatell, JM; Laguno, M; Laufer, N; Mallolas, J; Murillas, J; Perez, I; Veloso, S; Vidal, F1
Galizio, C; Johnson, K; Sargent, LA; Ubogu, EE1
Bogomolov, BP; Gromova, NI2
Curto, TM; Desanto, JL; Everson, GT; Hoefs, JC; Morgan, TR; Shiffman, ML; Sterling, RK; Wagner, DA; Wright, EC1
Burke, V; Cheng, W; Connelly, C; Flexman, J; Jamil, KM; Kontorinis, N; Leedman, PJ; McInerney, M; Metcalf, C; Nazareth, S; Tarquinio, L1
Herrmann, E; Hofmann, WP; Sarrazin, C; Zeuzem, S1
Alvarez-Lajonchere, L; Amador-Cañizares, Y; Dueñas-Carrera, S; González-Horta, EE; Guerra, I; Martínez-Donato, G; Pérez, A; Rodríguez-Alonso, I; Triana, J1
Bonkovsky, HL; Dienstag, JL; Fontana, RJ; Lok, AS; Naishadham, D; Sterling, RK; Su, GL1
Couzigou, P; Kharlov, N; Mascarell, V; Payen, JL; Pillard, F; Rivière, D1
Agostinacchio, E; Andriulli, A; Bacca, D; Carretta, V; Cozzolongo, R; Mangia, A; Minerva, N; Petruzzellis, D; Ricci, GL; Romano, M; Scotto, G; Sogari, F; Vinelli, F1
Adams, O; Emmelkamp, J; Häussinger, D; Kupfer, B; Oette, M; Rockstroh, J; Sagir, A; Vogel, M1
Akahane, T; Fukushima, K; Inoue, J; Ishii, M; Iwasaki, T; Kakazu, E; Kobayashi, T; Kogure, T; Kondo, Y; Mano, Y; Matsuda, Y; Miyazaki, Y; Nagasaki, F; Okamoto, H; Onodera, H; Shimosegawa, T; Ueno, Y; Yamamoto, T1
Bassa, A; Blanco, JL; Bonet, L; Calvo, M; Cifuentes, C; Gatell, JM; Laguno, M; Larrousse, M; Mallolas, J; Martínez, E; Martínez-Rebollar, M; Milinkovic, A; Murillas, J; Payeras, A; Pérez, I; Sánchez-Tapias, JM; Tural, C; Veloso, S; Vidal, F; Villalonga, C1
Amorosa, VK; Dorey-Stein, Z; Gross, R; Kostman, JR; Lo Re, V; Localio, AR; O'Flynn, R; Teal, V1
Gervain, J; Horváth, G; Hunyady, B; Makara, M; Pár, A; Szalay, F; Telegdy, L; Tornai, I1
Diago, M2
Nelson, DR; Reddy, KR; Zeuzem, S1
Hasegawa, I; Joh, T; Kurbanov, F; Matsuura, K; Mizokami, M; Nojiri, S; Ohno, T; Sugauchi, F; Tanaka, Y; Tokuda, H1
Antaki, N; Marcellin, P1
Hino, T; Ide, T; Kuhara, K; Kuwahara, R; Miyajima, I; Ogata, K; Sata, M1
Hegedüs, G; Hunyady, B; Miseta, A; Pár, A; Pár, G; Roth, E; Vincze, A1
Chae, HB; Kang, YW; Kim, AN; Kim, HS; Kim, JI; Kim, SB; Kim, SH; Lee, BS; Lee, HIe; Lee, HY; Lee, TH; Nam, SW; Park, BC; Park, JY; Song, IH1
Chang, SH; Choe, WH; Han, HS; Kim, BK; Ko, SY; Kwon, SY; Lee, CH1
Aoki, C; Goforth, J; Martinez, F; Prosser, C; Rossaro, L; Yuk, J1
Hartwell, D; Shepherd, J1
Akuta, N; Arase, Y; Hirakawa, M; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H2
El-Gohary, Y; Elfert, A; Keeffe, EB; Rossignol, JF1
Chen, DS; Chen, JH; Chen, PJ; Chen, SI; Hsu, SJ; Hung, PH; Kao, JH; Lai, MY; Liang, CC; Lin, JW; Liu, CH; Liu, CJ; Tsai, HB1
Benanti, F; Cacopardo, B; Caltabiano, E; Cappellani, A; Nunnari, G; Onorante, A; Russo, R1
Afendy, A; Bakshi, A; Baranova, A; Chan, JP; Chang, SY; Collantes, R; Iverson, AA; Manyam, G; Santini, CD; Sigua, CL; Stepanova, M; Younossi, ZM1
Ando, M; Araki, Y; Ikeda, H; Iwasaki, Y; Kobashi, H; Osawa, T; Sakaguchi, K; Shiratori, Y; Tanioka, D; Yamamoto, K1
Florianu, AI; Makashova, VV1
Ankoma-Sey, V; Hamzeh, FM; Jeffers, LJ; Martin, P; Rodriguez-Torres, M; Rossaro, L; Sheikh, MY1
Ferenci, P; Hofer, H; Novacek, G; Scherzer, TM; Schumacher, S; Staufer, K; Steindl-Munda, P; Vogelsang, H1
Elgouhari, HM; Feldstein, AE; Hanouneh, I; Zein, CO; Zein, NN1
Idrees, M; Riazuddin, S1
Antonietti, CL; Brandão-Mello, CE; Campos-de-Magalhães, M; da Silva, ML; de Almeida, AJ; de Oliveira, RV; do Espírito-Santo, MP; Lampe, E; Yoshida, CF1
Lake-Bakaar, G1
McHutchison, JG; Patel, K; Tillmann, HL1
Kronenberger, B; Zeuzem, S2
Audin-Mamlouk, H; Bismuth, M; Garrigues, V; Hilleret, MN; Mourad, G; Pageaux, GP; Zarski, JP1
Benhamou, Y; Kaita, KD; McHutchison, JG; Patel, K; Pulkstenis, E; Subramanian, GM; Torbenson, M; Yoshida, EM; Zeuzem, S1
Bojunga, J; Friedrich-Rust, M; Theobald, J; Zeuzem, S1
Aghemo, A; Colombo, M; Prati, GM; Rumi, MG1
Guy, CS; MacParland, SA; Michalak, TI; Pham, TN1
Akiyama, T; Ario, K; Eguchi, Y; Hisatomi, A; Kawaguchi, Y; Kuwashiro, T; Mizuta, T; Otsuka, T; Oza, N; Ozaki, I; Takahashi, H; Yoshimura, T1
Macías, J; Mira, JA; Neukam, K; Pineda, JA1
Błoñska-Fajfrowska, B; Hartleb, M; Musialik, J; Petelenz, M1
Barreiro, P; Soriano, V; Tuma, P; Vispo, E1
Alicante, S; Amante, A; Amato, F; Caserta, C; Fiorillo, MT; Foti, G; Gutamo, G; Mariano, A; Marra, M; Mele, A; Messineo, A; Pendino, GM; Polito, I; Surace, M; Surace, P; Vacalebre, C1
Amrani, N; Benaïssa, A; Kabbaj, N; Mohammadi, M; Sentissi, S1
Alberti, A1
Craxì, A; Tarantino, G1
Heathcote, J2
Asselah, T; Benhamou, Y; Marcellin, P1
Aslam, M; Hussain, T; Khan, DA; Khan, SA; Nadeem, A1
Albrecht, J; Bedossa, P; Berg, T; Brass, C; Bruix, J; Burroughs, M; Carrilho, F; Colombo, M; Craxi, A; Diago, M; Flamm, S; Gonçales, F; Griffel, L; Heathcote, EJ; McGarrity, T; Moreno-Otero, R; Mukhopadhyay, P; Poynard, T; Schiff, E; Schmidt, W; Silva, M; Terg, R1
Abbati, G; Belussi, F; Bonetto, S; Boninsegna, S; Borghi, A; Carbonieri, A; Corradini, E; Fagiuoli, S; Fattovich, G; Felder, M; Ferrara, F; Ferrari, C; Guido, M; Massari, M; Minola, E; Orlandini, A; Pietrangelo, A; Pozzato, G; Rizzo, G; Rossi, E; Rovere, P; Sardini, C; Tagliazucchi, M; Toniutto, P; Vegetti, A; Ventura, P; Zeneroli, ML1
Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, JF; Lin, ZY; Wang, LY; Yang, JF; Yu, ML1
Arribas, JR; Fraile, JM; González, JJ; Montes, ML1
Bergamaschi, D; Focaccia, R; Patzina, R; Prado, K1
Ben-Ari, Z; Braun, M; Cohen, M; Cohen-Ezra, O; Katz, L; Manhaim, V; Rotman, Y; Tur-Kaspa, R1
Ishibashi, H; Miyagi, Y; Nomura, H; Tanimoto, H1
Kitagawa, C; Kiuchi, K; Miyashiro, M1
Chang, WY; Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, JF; Lin, ZY; Wang, LY; Yu, ML1
Cammà, C; Petta, S1
Borrego, L; Guillermo, N; Hernández Santana, J; Jorge, M1
Kreek, MJ; Piccolo, P; Talal, AH1
Chan, PK; Li, CS; Tang, JW1
Aikata, H; Chayama, K; Imamura, M; Kawakami, Y; Kawaoka, T; Mori, N; Saneto, H; Takahashi, S; Takaki, S1
Alberdi-Leniz, A; Alvarez-Rubio, L; Banos, F; Lastra, CF; Marino, EL; Miro, S; Modamio, P1
Aoyagi, Y; Enjoji, M; Fujino, T; Fukuizumi, K; Harada, N; Miyahara, T; Nakamuta, M; Nakashima, M; Sakai, H; Takemoto, R; Yoshimoto, T1
Comar, C; Dal Maso, L; De Re, V; Festini, G; Mazzaro, C; Pozzato, G; Spina, M; Tirelli, U1
Abruzzese, G; Alpert, S; Kaul, V; Mehta, N; Murthy, UK; Teitelbaum, C1
Cannon, NA; Di Bisceglie, AM; Donlin, MJ; Lyra, AC; Mayes, LM; Tavis, JE1
El-Shamy, A; Hayashi, Y; Hotta, H; Imoto, S; Kim, SR; Kitai, S; Kudo, M; Mita, K; Muramatsu, A; Sasase, N; Taniguchi, M1
Akuta, N; Arase, Y; Hirakawa, M; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saito, S; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H2
Caroleo, B; De Sarro, G; Gallelli, L; Guadagnino, V; Staltari, O1
De Clercq, E2
Higaki, K; Ide, T; Karashima, T; Maeyama, Y; Narita, K; Okamura, S; Sakai, T; Sata, M; Sumie, H; Yoshikai, H1
Guindi, M; Kirby, M; O'Connor, C; Roberts, EA; Yap, J1
Carbonell, J; Crespo, M; Curran, A; Esteban, JI; Esteban, R; Falco, V; Imaz, A; Jardi, R; Ocaña, I; Pahissa, A; Ribera, E; Rodríguez-Frias, F; Van den Eynde, E; Villar del Saz, S1
Higashi, M; Ishibashi, H; Miyagi, Y; Nomura, H; Tanimoto, H1
Belle, SH; Brown, RS; Hoofnagle, JH; Howell, CD; Wahed, AS1
Cotter, MA; Petersen, MJ; Squires, SM1
Bain, VG; Neumann, AU; Patel, K; Pulkstenis, E; Subramanian, GM; Yoshida, EM1
Bonkovsky, HL; Chung, RT; Di Bisceglie, AM; Everhart, JE; Everson, GT; Ghany, MG; Greenson, JK; Hoefs, JC; Kim, HY; Lee, WM; Lindsay, KL; Lok, AS; Morishima, C; Sterling, RK1
Bacon, BR; Ghalib, R; Gitlin, N; Hassanein, T; Joshi, S; Kwo, P; Mendes, F; Morelli, G; Rothstein, K; Shiffman, ML1
Allen, SA; Chew, KW; Feller, E; Rich, JD; Taylor, LE1
Bartalesi, F; Bartoloni, A; Biliotti, E; Camiciottoli, G; Corti, G; Maluccio, NM; Taliani, G1
Fujita, N; Hara, N; Iwasa, M; Kaito, M; Kobayashi, Y; Kojima, Y; Miyachi, H; Takei, Y; Takeo, M; Tanaka, H1
Chokshi, S; Cooksley, H; Farmakiotis, D; Michalak, TI; Naoumov, NV; Pachiadakis, I; Sarrazin, C; Zeuzem, S1
de Man, RA; Dietvorst, MH; van Wijngaarden, P1
Bailey, RJ; Bain, VG; Cooper, CL; Deschênes, M; Krajden, M; Lee, SS; Marotta, PJ; Peltekian, K; Sherman, M; Usaty, C; Witt-Sullivan, H; Yoshida, EM1
Archimandritis, A; Elefsiniotis, J; Koskinas, J; Kostopoulos, P; Kotsiou, S; Kountouras, D; Savvas, S; Schina, M; Sidiropoulos, J; Zacharakis, G1
Chen, CL; Chen, DS; Chen, PJ; Hsu, CS; Kao, JH; Lai, MY; Liu, CH; Liu, CJ1
De Angelis, D; Grieve, RD; Grishchenko, M; Irving, WL; Ryder, SD; Sweeting, MJ; Thomson, BJ1
Knight, V; Sievert, W1
Chuang, WL; Yu, ML1
Ishida, C; Kato-Motozaki, Y; Komai, K; Kusunoki, S; Takahashi, K; Ueda, M; Yamada, M1
Damian, D; Gheorghe, C; Gheorghe, L; Grigorescu, M; Iacob, R; Iacob, S; Sirli, R; Sporea, I1
Bellou, A; Bibashi, E; Gigi, E; Raptopoulou-Gigi, M; Sinakos, E; Sykia, A1
Alain, S; Denis, F; Loustaud-Ratti, V; Marquet, P; Rousseau, A1
Koike, K2
Enomoto, N; Sakamoto, M2
Jeong, S; Kim, CH; Kim, HG; Kim, YS; Kwon, KS; Lee, DH; Lee, JI; Lee, JW; Park, BD; Shin, YW1
Barraud, H; Bronowicki, JP; Nani, A1
Basso, M; Blanchi, S; Giannini, EG; Picciotto, A; Savarino, V; Torre, F1
Bortolotti, F1
Celiento, M; De Rosa, A; Ripa, C; Schiano, A; Tambaro, O; Tarantino, L1
Bellón, JM; Berenguer, J; Esteban, H; González-García, J; Hernando, A; López-Aldeguer, J; Mallolas, J; Miralles, P; Montes, ML; Ortega, E; Quereda, C; Santos, I; Sanz, J; Tural, C; Von-Wichmann, MA1
Nikolaou, A; Telakis, E1
Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kobayashi, M; Kumada, H; Miyakawa, Y; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H1
Bani-Sadr, F1
Andreone, P; Brandão-Mello, CE; Craxi, A; Di Bisceglie, A; Freilich, B; Jensen, DM; Marcellin, P; Martin, AO; Messinger, D; Reddy, KR; Teuber, G; Thommes, JA; Tietz, A1
de Carvalho Filho, RJ; Ferrari, MV; Ferraz, ML; Freire, FC; Narciso-Schiavon, JL; Scanhola, GQ; Schiavon, Lde L; Silva, AE; Suarez, MM1
Elefsiniotis, I; Konstantinou, E; Mihas, C; Saroglou, G; Vezali, E1
Chrissafidou, A; Musch, E1
Amorosa, VK; Kovarik, CL; Lin, J; Lott, JP1
Korobowicz, E; Modrzewska, R; Tomasiewicz, K1
Bassendine, MF; Donaldson, P; Neely, D; Price, DA; Schmid, ML; Sheridan, DA; Toms, GL1
Accadia, L; Andriulli, A; Annicchiarico, BE; Bombardieri, G; Caruso, N; Iacobellis, A; Niro, GA; Siciliano, M; Valvano, MR1
Fartoux, L; Poupon, R; Serfaty, L1
Ballardini, G; Bianchi, FB; Ferri, S; Granito, A; Lenzi, M; Menichella, R; Muratori, L; Muratori, P; Pappas, G; Quarneti, C1
Drenth, JP; Heijdra, YF; Slavenburg, S1
Asjø, B; Myrmel, H; Ulvestad, E1
Alam, J; Everson, GT; Gordon, SC; Jacobson, IM; Kauffman, R; McHutchison, JG; McNair, L; Muir, AJ; Sulkowski, M1
Alam, J; Bengtsson, L; Bourlière, M; Bronowicki, JP; Dusheiko, G; Ferenci, P; Forestier, N; George, S; Gharakhanian, S; Goeser, T; Hézode, C; Kauffman, RS; Kieffer, T; Kwong, A; McNair, L; Pawlotsky, JM; Pol, S; Zeuzem, S1
Malgarini, RB; Pimpinella, G1
Amiot, X; Ancel, D; Chaslin-Ferbus, D; Garioud, A; Girot, R; Grange, JD; Hagege, I; Pol, S1
Marks, K; Talal, AH; Wan, DW; Yantiss, RK1
Schildgen, O1
Danis, D; Fejdiova, K; Gazdik, F; Gazdikova, K; Kajaba, I; Kratky, A; Laktis, K; Okruhlica, L; Pijak, MR; Wsolova, L1
Babany, G; Gagnieu, MC; Jourdil, JF; Marquet, P; Sauvage, FL; Stanke-Labesque, F1
Dimitroulopoulos, D; Elefsiniotis, IS; Koutsounas, S; Mariolis-Sapsakos, T; Mihas, C; Paraskevas, E; Pavlidis, C; Saroglou, G; Vezali, E1
Bräu, N; Fishbein, D; Stivala, A; Swan, T; Weiss, JJ1
Abbas, FA; Ayyub, MA; El-Moursy, SA; Khazindar, AM1
Itha, S; Radha Krishna, Y1
Blanc, F; Clot, J; Corbeau, P; Perney, P; Portalès, P; Psomas, C; Rigole, H; Turriere, C1
Ferenci, P; Rizzetto, M; Shiffman, ML; Zeuzem, S1
Bédossa, P; Cacoub, P; Carrat, F; Halfon, P; Lambert, J; Pénaranda, G; Perronne, C; Pol, S1
Bashirova, A; Bonkovsky, HL; Carrington, M; Chanock, SJ; Chung, RT; Crenshaw, AT; Di Bisceglie, AM; Dotrang, M; Fontana, RJ; Ghany, MG; Gretch, DR; Hutchinson, AA; Lee, WM; Lindsay, KL; Morgan, TR; Naishadham, D; O'Brien, TR; Pfeiffer, RM; Sterling, RK; Welzel, TM; Wright, EC1
Arora, S; Douglass, JM; Dunkelberg, JC; Qualls, C; Yu, S1
Haruna, Y; Kashiwagi, T; Katayama, K; Kishida, Y; Naitoh, M1
Furusyo, N; Hayashi, J; Maeda, S; Ogawa, E; Takeoka, H; Toyoda, K1
Weiland, O2
Hueppe, D; Jacobson, I; Kwo, P; Marotta, P; Zehnter, E1
Aronsohn, A; Reau, N1
De Compadri, P; Garattini, L; Koleva, D; Mangia, A; Motterlini Stat Sci, N1
Berg, T; Böcker, U; Bugert, P; Gundt, J; Haas, SL; Singer, MV; Weiss, C; Witt, H1
Bocket, L; Canva, V; Castelain, S; Deltenre, P; Dharancy, S; Duverlie, G; El Nady, M; François, C; Henrion, J; Hollebecque, A; Lazrek, M; Louvet, A; Mathurin, P; Wartel, F1
Arends, JE; Baak, LC; Boland, GJ; Hoepelman, AI; Simons, CP; Stuart, JC; van Baarle, D; van der Ende, ME; van Erpecum, KJ1
Couzigou, VP; DeLedinghen, V; Foucher, J; Gaundong Mbéthé, GL1
Etani, Y; Fujisawa, T; Inui, A; Kagimoto, S; Kiyohara, Y; Shimizu, T; Suzuki, M; Tajiri, H1
Barbare, JC; Cadranel, JF; Capron, D; Cazier, A; Dumouchel, P; Jouannaud, V; Rochette, J1
Conti, CM; Dalessandro, M; Falasca, K; Mancino, P; Manzoli, L; Pizzigallo, E; Ucciferri, C; Vecchiet, J1
Aidelsburger, P; Manns, MP; McHutchison, JG; Rossol, S; Siebert, U; Sroczynski, G; Wasem, J; Wong, JB1
Reiser, M; Timm, J1
Coffin, CS; Terrault, NA1
Adler, M; Brenard, R; D'Heygere, F; Delwaide, J; Henrion, J; Horsmans, Y; Langlet, P; Lasser, L; Laureys, A; Michielsen, P; Mulkay, JP; Nevens, F; Van Vlierberghe, H1
Amano, K; Fujimoto, M; Katsumura, N; Kimura, K; Kojima, T; Moriwaki, H; Nagaki, M; Naiki, T; Ninomiya, M; Sakai, T; Sano, C; Shimizu, M; Sugihara, JI; Tomita, E1
Bukh, J; Christensen, PB; Clausen, MR; Hansen, N; Krarup, H; Kromann-Andersen, H; Laursen, AL; Lunding, S; Møller, A; Obel, N; Schlichting, P; Weis, N1
Hadziyannis, SJ; Messinger, D; Popescu, M; Reddy, KR1
Berg, T; Biermer, M1
Arakawa, T; Fujiwara, Y; Hosomi, S; Kamata, N; Morimoto, K; Ohira, M; Oshitani, N; Sogawa, M; Suekane, T; Tamori, A; Tominaga, K; Watanabe, K; Watanabe, T; Yamagami, H1
Angelico, F; Angelico, M; Carbone, M; Del Ben, M; Feole, K; Francioso, S; Pignatelli, P; Violi, F1
Gaglio, PJ1
Cheng, DX; Chu, YL; Liu, EQ; Xue, X; Zhao, SH1
Gluud, LL; Iorio, A; Marchesini, E1
Brodanová, M; Brůha, R; Dusek, L; Janousová, E; Marecek, Z; Petrtýl, J; Subhanová, I; Urbánek, P1
Akuta, N; Chayama, K; Hashimoto, H; Itoh, Y; Izumi, N; Kumada, H; Minami, M; Okanoue, T; Onji, M; Takehara, T; Tanaka, E; Toyota, J; Yasui, K; Yoshioka, K1
Halota, W; Juszczyk, J1
Jabłońska, J; Kozłowska, J1
Bressler, B; Grippo, JF; Heathcote, EJ; Wang, K1
Doizaki, M; Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishizu, Y; Itoh, A; Katano, Y; Kumada, T; Nakano, I; Shimizu, J; Toyoda, H; Urano, F; Yoshioka, K1
Breilh, D; Castéra, L; Couzigou, P; de Lédinghen, V; Djabarouti, S; Foucher, J; Merrouche, W; Saux, MC; Trimoulet, P1
Benito-Martínez, S; González-Mateos, F; Larrubia, JR; Miquel-Plaza, J; Parra, T; Sanz-de-Villalobos, E1
Belle, SH; Brown, RS; Dove, LM; Hoofnagle, JH; Ramcharran, D; Rosen, RC; Wahed, AS1
Bartkowiak, J; Ciechowicz, J; Durys, B; Józwiak, B; Kosciuk, N; Majda-Stanislawska, E; Majewska, E; Piekarska, A; Sidorkiewicz, M1
Armendáriz-Borunda, J; Bautista López, CA; Lugo-Baruqui, A1
Gilani, N; Panetta, JD1
Hagiwara, H; Hayashi, N; Hijioka, T; Hiramatsu, N; Igura, T; Imai, Y; Imanaka, K; Inoue, Y; Inui, Y; Ito, T; Kaneko, A; Kanto, T; Kasahara, A; Katayama, K; Kato, M; Kiso, S; Mita, E; Mochizuki, K; Nagase, T; Ohkawa, K; Oshita, M; Oze, T; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yoshida, Y; Yoshihara, H1
Hagiwara, H; Hayashi, E; Hayashi, N; Hijioka, T; Hiramatsu, N; Igura, T; Imai, Y; Imanaka, K; Inoue, A; Inui, Y; Ito, T; Kanto, T; Kasahara, A; Kato, M; Kiso, S; Kurokawa, M; Mita, E; Mochizuki, K; Ohkawa, K; Oshita, M; Oze, T; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yamada, A; Yoshida, Y; Yoshihara, H1
Firbas, C; Hinrichsen, H; Hofmann, WP; Jilma, B; Klade, CS; Manns, MP; Schiefke, I; Schlaphoff, V; Schuller, E; Stauber, RE; Tauber, E; Thursz, M; Wedemeyer, H; Wiegand, J; Zeuzem, S1
Andriulli, A; Iacobellis, A1
Akin, H; Atug, O; Sari, M; Tozun, N; Yilmaz, Y1
Alba, LM; Bulchandani, D; Nachnani, JS; Pandya, PK; Rao, GA1
Alvarez-Pellicer, J; Bellón, JM; Berenguer, J; González-García, J; López-Aldeguer, J; Mallolas, J; Martín, PM; Quereda, C; Sanz, J; Tural, C; Von-Wichmann, MA1
Asaka, M; Chuma, M; Hige, S; Nagasaka, A; Nakanishi, M; Ogawa, K; Yamamoto, Y1
Aghemo, A; Colombo, M; D'Ambrosio, R; Donato, MF; Monico, S; Prati, GM; Rumi, MG1
Alvarez-Uria, G; Day, JN; Nasir, AJ; Russell, SK; Vilar, FJ1
Hwang, JM; Jeong, SH; Kang, HM; Kim, JW; Park, MJ1
Jackson, D; O'Brien, L; Sgorbini, M1
Afdhal, NH; Benhamou, Y; Chun, E; Halliman, DG; Heise, J; Nelson, DR; Pockros, PJ; Shiffman, ML1
Gomes, R; Lee, C; Manka, C; Reviere, R1
Adinolfi, LE; Durante-Mangoni, E; Portella, G; Ruggiero, G; Utili, R; Zampino, R1
Bacin, F; Glatre, F; Viennet, A1
Gschwantler, M; Ordubadi, P1
Andreoni, M; Angeli, E; Carbone, R; Cargnel, A; Giorgi, R; Gubertini, G; Mainini, A; Orani, A; Rizzardini, G; Schiavini, M; Uberti-Foppa, C1
Elefsiniotis, IS; Mihas, C; Saroglou, G; Vezali, E1
Coppola, N; Iodice, V; Macera, M; Piccinino, F; Sagnelli, E; Stanzione, M; Tonsiello, G1
Albrecht, JK; Bacon, BR; Brass, CA; Davis, MN; Galati, JS; Galler, GW; Ghalib, RH; Koury, K; Lawitz, EJ; Lee, WM; McCone, J; McHutchison, JG; Muir, AJ; Mukhopadhyay, P; Noviello, S; Nyberg, LM; Pedicone, LD; Schiff, ER; Shiffman, ML; Sulkowski, MS1
Abdel-Hamid, M; Bedossa, P; El Makhzangy, H; Elraziky, M; Esmat, G; Fontanet, A; Gad, RR; Mohamed, MK; Pol, S; Refai, R; Rekacewicz, C; Said, M; Shouman, S; Vignier, N; Zalata, K1
Abellán Galiana, P; Aguilera Sancho-Tello, V; Berenguer Haym, M; Merino Torres, JF; Pérez-Lázaro, A; Piñón Sellés, F1
Forde, KA; Reddy, KR1
Mauss, S; Schaefer, M1
Chan, HL; Cheng, AY; Wong, VW1
Alavian, SM; Tabatabaei, SV2
Blanc, F; Buchler, M; Cacoub, P; Coppéré, B; Ghillani, P; Karras, A; Pérard, L; Plaisier, E; Rosenzwajg, M; Saadoun, D; Sellam, J; Sène, D; Terrier, B1
Kao, JH1
Adinolfi, LE; Durante-Mangoni, E; Marrone, A; Merola, A; Restivo, L; Ruggiero, G; Salzillo, M; Tripodi, MF; Zampino, R1
Tsantrizos, YS1
Durantel, D1
Khan, AA; Sarwar, S1
Behnam, SE; Fife, DJ; Hindiyeh, R; Jeffes, EW; Wu, JJ1
de Silva, K; Jones, BE; Napoli, J; Pang, SH1
Andriulli, A; Attanasio, M; Bronte, F; Cabibbo, G; Cammà, C; Craxì, A; Enea, M; Licata, A1
Alavian, SM; Ayyub, M; Tabatabaei, SV1
Bedossa, P; Boyer, N; Cardoso, AC; Marcellin, P; Martinot-Peignoux, M; Maylin, S; Moucari, R; Nicolas-Chanoine, MH; Ripault, MP; Stern, C; Valla, D; Vidaud, M; Voitot, H1
Chung, RT; Hamzeh, FM; Jensen, DM; Rodriguez-Torres, M; Sulkowski, MS1
Kato, M; Matsumoto, S; Yamaguchi, T; Yuki, N1
Cheng, WS; Crawford, DH; Depamphilis, JK; Desmond, PV; Dore, GJ; Marks, PS; McCaughan, GW; Rawlinson, W; Rizkalla, B; Roberts, SK; Sievert, W; Weltman, MD; Yoshihara, M1
Babany, G; Canva-Delcambre, V; Deltenre, P; Deuffic-Burban, S; Dharancy, S; Lonjon-Domanec, I; Louvet, A; Mathurin, P; Roudot-Thoraval, F1
Fukui, H; Hagiwara, H; Hayashi, E; Hayashi, N; Hiramatsu, N; Hohsui, A; Imai, Y; Inada, M; Inoue, A; Inoue, Y; Ishida, H; Kanto, T; Kasahara, A; Kato, M; Kiso, S; Mita, E; Miyagi, T; Mochizuki, K; Oshita, M; Oze, T; Takehara, T; Tamura, S; Yakushijin, T; Yoshihara, H1
Attia, JR; Gibson, R; Malcolm Reeves, GE; Tran, HA1
Gerner, P; Jenke, AC; Moser, S; Orth, V; Wirth, S; Zilbauer, M1
Hinokio, Y; Imai, J; Ishigaki, Y; Katagiri, H; Kudo, H; Ogihara, T; Oka, Y; Shimosegawa, T; Ueno, Y; Yamada, T; Yamagiwa, Y1
Akahoshi, T; Ikejiri, K; Korenaga, D; Saku, M; Takenaka, K; Tomikawa, M1
Cheng, DX; Chu, YL; Liu, EQ; Waqar, AB; Xue, X; Yang, HJ; Yang, PH; Yu, Q; Zhao, SH1
Folwaczny, C; Janssen, G; Loeschke, K; Lorenz, R; Martin, G; Schaefer, M; Schmidt, F; Soyka, M1
Anselmo, M; De Leo, P; Fabris, P; Grasso, A; Malfatti, F; Martines, H; Menardo, G; Toscanini, F1
Guadagnino, V1
Alaeus, A; Blom, KG; Falconer, K; Gonzalez, VD; Laursen, AL; Mørn, B; Reichard, O; Sandberg, JK; Weis, N1
Lo, GH1
Gallefoss, F; Kristensen, Ø; Opsal, A; Rysstad, O; Skeie, K; Sundøy, A; Vederhus, JK; Øye, I1
Bae, SH; Byun, KS; Choi, JY; Han, KH; Kwon, JH; Lee, HC; Lee, KS; Lim, YS; Paik, SW; Yoon, SK1
Chuang, WL; Dai, CY; Huang, CF; Huang, JF; Yu, ML3
Al-Saran, K; Sabry, A; Shaheen, N; Yehia, A1
Hayashi, M; Kataoka, Y; Koguchi, H; Tachikawa, K; Tanaka, H1
Davis, C; Olerud, J; Shinohara, MM1
Bonkovsky, HL; Di Bisceglie, AM; Dienstag, JL; Everson, GT; Ghany, MG; Hoefs, JC; Lee, WM; Lindsay, KL; Lok, AS; Morishima, C; Naishadham, D; Shiffman, ML; Wright, EC1
An, JW; Brady, DE; Harrison, SA; Lawitz, E; Torres, DM; Ward, JA1
O'Brien, TR1
Hiasa, Y; Hige, S; Hino, K; Honda, M; Imamura, M; Ito, K; Ito, Y; Izumi, N; Koike, A; Korenaga, M; Kurosaki, M; Masaki, N; Matsuura, K; Mita, E; Mizokami, M; Mochida, S; Murawaki, Y; Nakagawa, M; Nishida, N; Nishiguchi, S; Sakai, A; Sakaida, I; Sakamoto, N; Sugauchi, F; Sugiyama, M; Tanaka, E; Tanaka, Y; Tokunaga, K; Yano, K1
Abate, ML; Ahlenstiel, G; Bahlo, M; Bassendine, M; Berg, T; Booth, DR; Dore, GJ; Fragomeli, V; George, J; Moldovan, M; Müller, T; Powell, E; Riordan, S; Sheridan, D; Smedile, A; Spengler, U; Stewart, GJ; Suppiah, V; Weltman, M1
Arora, A; Kuzniar, TJ; Vargas, L1
Dinya, E; Schaff, Z; Tulassay, Z; Werling, K1
Battezzati, PM; Benetti, A; Capsoni, F; Gershwin, ME; Giorgini, A; Lleó, A; Malinverno, F; Ongari, AM; Podda, M; Rossaro, L; Selmi, C; Zuin, M1
Herrmann, E; Hofmann, WP; Lengauer, T; Mihm, U; Polta, A; Sarrazin, C; Welsch, C; Zeuzem, S1
Borgia, G; Borrelli, F; Cerini, R; D'Agostino, E; D'Onofrio, M; Gentile, I; Paesano, L; Piazza, M; Viola, C1
Lanford, RE; Lemon, SM; Shimakami, T1
Aghemo, A; Colombo, M; D'Ambrosio, R; Del Ninno, E; Donato, MF; Prati, GM; Rumi, MG; Russo, A; Soffredini, R1
Arponen, S; Collado, A; Delgado, M; Gil, Ide L; González-Serrano, M; Gutiérrez-Valencia, A; López-Ruz, MA; Macías, J; Merino, D; Mira, JA; Omar, M; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Torres-Tortosa, M1
Hung, CH; Lin, MC; Tsai, MC1
Ansaldi, F; Borro, P; Gentile, R; Icardi, G; Ravetti, G; Sumberaz, A; Testino, G1
Almasio, PL; Amoruso, DC; Caporaso, N; Medda, E; Morisco, F; Paris, B; Stanzione, M; Stroffolini, T; Villa, E; Zuin, M1
Ferrari, C; Freedman, LS; Gorfine, M; Lukasiewicz, E; Neumann, AU; Pawlotsky, JM; Schalm, SW; Zeuzem, S1
Dore, GJ; French, R; Grebely, J; Haber, PS; Hellard, M; Kaldor, JM; Lloyd, AR; Marks, P; Matthews, GV; McCaughan, G; Petoumenos, K; Rawlinson, W; van Beek, I; White, P; Yeung, B1
Bae, SH; Choi, JY; Jang, JW; Jeong, SW; Kim, JD; Lee, SW; Song, MJ; Woo, HY; Yoon, SK; You, CR1
Ha, CY; Ju, K; Jung, WT; Kim, TH; Lee, OJ; Min, HJ; Shin, MK1
Barlow, LL; Chung, RT; Corey, KE; Kane, E; Munroe, C; Zheng, H1
Babany, G; Gagnieu, MC; Loustaud-Ratti, V; Marquet, P; Stanke-Labesque, F1
Belle, SH; Evon, DM; Fontana, RJ; Fried, MW; Ramcharran, D; Terrault, NA1
Pradat, P; Trepo, C1
Berg, T; Boland, GJ; de Vries, RA; Drenth, JP; Halangk, J; Kok, KF; van Herwaarden, AE; van Oijen, MG; van Soest, H1
Aghemo, A; Colombo, M; Coppola, A; Mancuso, ME; Mannucci, PM; Puoti, M; Rumi, MG; Santagostino, E1
Aslan, V; Naz, H1
Aghemo, A; Colombo, M; Rumi, MG2
Alonso López, S; Fernández Rodríguez, CM1
Chaparro, M; Gisbert, JP; Moreno-Otero, R; Trapero-Marugán, M1
Angeletti, C; Antonucci, G; Girardi, E; Longo, MA; Vairo, F1
Iijima, M; Sato, M; Sueki, H1
Chang, JJ; Chen, LW; Chien, RN; Lin, CL; Liu, CJ; Yen, CL1
Almerighi, C; Angelico, M; Anselmo, A; De Luca, L; Lenci, I; Lionetti, R; Monaco, A; Palmieri, G; Tariciotti, L; Tisone, G1
Brok, J; Gluud, C; Gluud, LL6
Callender, ME; Cash, WJ; McDougall, NI; Patterson, K1
Chaudhari, S; Lingisetty, CS; Proper, S; Satapathy, SK; Williams, S1
Basso, M; Bazzica, M; Contini, P; Giannini, EG; Marenco, S; Picciotto, A; Savarino, V1
Aketa, H; Chiba, M; Ikezawa, K; Iwahashi, K; Kanno, T; Katayama, K; Kita, H; Maeda, K; Matsuura, T; Michida, T; Mizuno, T; Naito, M; Nishio, A; Onishi, Y; Ono, A; Yumiba, T1
Andrade, RJ; Calleja, JL; De la Mata, M; Diago, M; Durán, S; Fernández-Rodríguez, CM; García-Samaniego, J; Herrerías, JM; Moreno-Otero, R; Nuñez, O; Olveira, A; Planas, R; Romero-Gómez, M; Salmerón, J; Solà, R1
Alonso-Arias, R; Díaz-Peña, R; Fernández-Suárez, J; López-Larrea, C; López-Vázquez, A; Martínez-Borra, J; Melón, S; Pérez, R; Prieto, J; Rodrigo, L; Vidal-Castiñeira, JR1
Alaeus, A; Björkström, NK; Blom, KG; Falconer, K; Gonzalez, VD; Ljunggren, HG; Sandberg, JK; Weiland, O1
Basso, M; Giannini, EG; Picciotto, A; Savarino, V3
Aalyson, M; Afdhal, N; Alam, J; Bengtsson, L; Bonkovsky, HL; Chandorkar, G; Gharakhanian, S; Gordon, SC; Harding, M; Kauffman, R; Lawitz, E; Lee, WM; McHutchison, JG; McNair, L; Poordad, F; Rustgi, VK1
Ascione, A; De Luca, M; Di Costanzo, GG; Fontanella, L; Lampasi, F; Lanza, AG; Leandro, G; Marino-Marsilia, G; Picciotto, FP; Tartaglione, MT1
Alric, L; Baazia, Y; Bouviers-Alias, M; Chaix, ML; Colson, P; Coppere, H; D'Alteroche, L; Doffoël, M; Fontaine, H; Foucher, J; Gassin, M; Gaudy, C; Hézode, C; Izopet, J; Legrand-Abravanel, F; Leguillou-Guillemette, H; Lunel-Fabiani, F; Nousbaum, JB; Payan, C; Poinard, T; Poynard, T; Pozzetto, B; Ravaux, I; Roche, B; Roque-Afonso, AM; Roulot, D; Schvoerer, E; Thibault, V; Trimoulet, P; Vallet, S1
Ben Mami, N; Ben Yahia, A; Bouzgarrou, N; Chouchane, L; Gabbouj, S; Hassen, E; Mahfoudh, W; Schvoerer, E; Triki, H1
Dabrowska, MM; Flisiak, R; Panasiuk, A1
Hsu, CS; Kao, JH3
Broglio, KR; Hahn, KM; Hortobagyi, GN; Kau, SC; Morrow, PKH; Tarrand, JJ; Taylor, SH; Theriault, RL1
Angelico, M; Baiocchi, L; Carbone, M; Lenci, I1
Askar, M; Avery, R; Corey, R; Eghtesad, B; Fung, J; Lopez, R; Miller, C; Pidwell, D; Thomas, D; Zein, NN1
Alberti, A; Bonisegna, S; Bortoletto, G; Franceschini, L; Marcolongo, M; Martines, D; Mirandola, S; Noventa, F; Plebani, M; Realdon, S; Scribano, L1
Guturu, P; Jaganmohan, S; Kuo, YF; Mummadi, R; Singal, AK; Singh, A; Sood, GK1
Butt, AA; Justice, AC; McGinnis, KA; Skanderson, M1
Dieterich, DT; Manns, MP; Rizzetto, M1
Kumada, T; Toyoda, H1
Calvieri, S; Carboni, V; Carlomagno, V; Giancristoforo, S; Maiani, E; Mattozzi, C; Richetta, AG1
Keicher, C; Kraus, MR; Rieger, P; Schäfer, A; Scheurlen, M; Seufert, J; Weissbrich, B1
Chen, G; Dewar, RL; Ferenci, P; Haagmans, BL; Kottilil, S; Levy-Drummer, RS; Masur, H; McLaughlin, M; Neumann, AU; Polis, MA; Rozenberg, L; Silva, M; Viola, MS1
Aguilar Reina, J1
Cabanillas, M; de la Santa, E; Domper, F; Galván, MD; Hernández, A; León, A; López, B; Lorente, R; Olmedo, J; Patón, R; Rodríguez, E1
Anand, N; Borozan, I; Chen, L; Edwards, AM; Feld, J; Fischer, S; Guindi, M; Heathcote, J; McGilvray, ID; Sun, J1
Hofmann, WP; Peveling-Oberhag, J; Zeuzem, S1
Garcia, G; Garcia, RT; Keeffe, EB; Levitt, BS; Li, J; Nguyen, HA; Nguyen, KK; Nguyen, MH; Nguyen, NH; Trinh, HN; Vutien, P1
El Monaiery, M; El Naghy, S; El Sebaie, H; Ghaffar, AY; Ghaffar, TY1
Berezovskaya, S; Bini, EJ; Choy-Shan, A; Sedlis, SP; Zinn, A1
Wei, L1
Li, MH; Xie, Y2
Chen, XY; Zhang, YH1
Chen, LJ; Li, MH; Lu, Y; Qiu, GH; Xie, Y; Xu, DZ1
Chun, E; Gish, RG; Gitlin, N; Halliman, DG; Heise, J; Marcellin, P; Rodriguez-Torres, M1
Anagnostou, O; Dimitroulopoulos, D; Manolakopoulos, S; Paraskevas, E; Petroulaki, E; Tsaklakidou, D; Tsamakidis, K; Tzourmakliotis, D; Xinopoulos, D1
Abdelaleem, A; Atef, R; Emad, M; Eslam, M; Hamdy, L; Khattab, M; Shaker, Y1
Chan, AH; Ensom, MH; Partovi, N1
Capron, D; Castelain, S; Duverlie, G; François, C; Nguyen-Khac, E1
Chen, SC; Chu, PY; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, JF; Lin, YY; Lin, ZY; Wang, LY; Yu, ML1
Imeryuz, N; Yilmaz, Y; Yonal, O1
Jovanović, M; Konstantinović, L; Kostić, V; Popović, L; Vrbić, M1
Falasca, K; Gorgoretti, V; Mancino, P; Pizzigallo, E; Ucciferri, C; Vecchiet, J1
Higami, K; Ishii, K; Kogame, M; Morita, T; Sano, M; Sawa, M; Shinohara, M; Sumino, Y1
Banasch, M; Ellrichmann, M; Meier, JJ; Schmidt, WE; Schrader, H; Vollmer, K1
Borum, ML; Igiehon, E; Shafa, S1
Chirino, RA; Chung, RT; Corey, KE; Dehesa-Violante, M; Gorospe, EC; Juarez, JA; Méndez-Navarro, J; Morán, S; Zheng, H1
Atripaldi, L; D'Antonio, A; Esposito, C; Perrella, A; Perrella, O; Sbreglia, C1
Fischler, B; Friman, S; Gerdén, B; Josephson, F; Karlström, O; Lagging, M; Sangfelt, P; Schvarz, R; Uhnoo, I; Weiland, O; Wejstål, R1
Afendy, A; Baranova, A; Birerdinc, A; Manyam, G; Stepanova, M; Younossi, I; Younossi, ZM1
Garcia, RT; Levitt, B; Nguyen, H; Nguyen, K; Nguyen, MH; Nguyen, NH; Trinh, H; VuTien, P1
Fukuhara, T; Ikegami, T; Kato, M; Kotoh, K; Maehara, Y; Shimoda, S; Soejima, Y; Taketomi, A; Yoshizumi, T1
Chuang, WL; Wu, KT; Yang, JF; Yu, ML1
Bihl, F; Negro, F1
Andreone, P; Anticoli, S; Balsano, C; Bernardi, M; Cursaro, C; Furlini, G; Galli, S; Gramenzi, A; Loggi, E; Margotti, M; Salerno, M; Spaziani, A1
Parkinson, E1
Atluri, D; Iduru, S; Mullen, K; Veluru, C1
Berenguer, J; Catalán, P; Cosín, J; López, JC; Miralles, P; Resino, S; Vargas, A1
Boland, GJ; de Vries, RA; Drenth, JP; Houben, P; Koek, GH; Lieverse, RJ; Schipper, ME; Siersema, PD; van der Schaar, PJ; van der Sluys Veer, A; van Erpecum, KJ; van Hoek, B; van Ooteghem, NA; van Soest, H; Vrolijk, JM1
Chin, HS; Kim, ET; Kim, LH; Lee, JI1
Burke, JD; Fish, EN1
Kaneko, J; Kokudo, N; Makuuchi, M; Sugawara, Y; Tamura, S; Yamashiki, N1
Craxì, A2
Drenth, JP; Slavenburg, S; van Oijen, MG; Weggelaar, I1
Ahn, SH; Chon, CY; Han, KH; Kim, DY; Kim, MN; Park, JY; Yoon, KT1
Fan, Y; Mao, Q; Tan, WT; Wang, XH; Zhou, YQ; Zhu, Y1
Ebinuma, H; Hibi, T; Inoue, M; Ojiro, K; Saito, H; Tada, S; Wakabayashi, K1
Elfert, A; Keeffe, EB; Rossignol, JF1
Battegay, M; Beckmann, JS; Berg, T; Bergmann, S; Bernasconi, E; Bochud, M; Bochud, PY; Borovicka, J; Cai, T; Cerny, A; Colombo, S; Descombes, P; Di Iulio, J; Dufour, JF; Furrer, H; Günthard, HF; Heim, M; Hirschel, B; Kutalik, Z; Malinverni, R; Moradpour, D; Mueller, T; Müllhaupt, B; Negro, F; Rauch, A; Telenti, A; Witteck, A1
Hibi, T; Hokari, R; Ikeda, M; Kato, N; Miura, S; Nakamura, M; Saito, H1
El-Shamy, A; Hayashi, Y; Hotta, H; Imoto, S; Kim, KI; Kim, SR; Kudo, M; Mita, K; Nagai, T; Nagano-Fujii, M; Nagata, Y; Sasase, N; Shoji, I; Taniguchi, M1
El-Shamy, A; Hayashi, Y; Hotta, H; Imoto, S; Kim, KI; Kim, SR; Kudo, M; Mita, K; Sasase, N; Shoji, I; Taniguchi, M1
Chung, H; Hagiwara, S; Hayaishi, S; Inoue, T; Ishikawa, E; Kudo, M; Minami, Y; Tatsumi, C; Ueda, T; Ueshima, K; Yada, N1
Chung, H; Hagiwara, S; Hatanaka, K; Hayaishi, S; Inoue, T; Ishikawa, E; Kitai, S; Kudo, M; Takita, M; Tatsumi, C; Ueda, T; Ueshima, K; Yada, N1
Cho, EY; Choi, CS; Kim, DG; Kim, HC; Kim, IH; Kim, SH; Kim, SW; Lee, CS; Lee, S; Lee, SO; Lee, ST1
Akiyama, M; Ichikawa, T; Miuma, S; Miyaaki, H; Motoyoshi, Y; Nakao, K; Ozawa, E; Shibata, H; Takeshita, S; Taura, N1
Asselah, T; Boyer, N; Cardoso, AC; Castelnau, C; El Ray, A; Giuily, N; Leclere, L; Marcellin, P; Martinot-Peignoux, M; Maylin, S; Moucari, R; Ripault, MP; Stern, C1
Mallet, V; Pol, S; Vallet-Pichard, A1
Féray, C1
Awad, T; Gluud, LL; Iorio, A; Marchesini, E1
Duffin, RP; Ichim, TE; Joyce, JA; Levin, NW; Tullis, RH1
Barreiro, P; González-Lahoz, J; González-Pardo, G; Jiménez-Nácher, I; Madejón, A; Medrano, J; Morello, J; Rodríguez-Novoa, S; Soriano, V1
Barreiro, P; Labarga, P; Martín-Carbonero, L; Medrano, J; Morello, J; Pinilla, J; Rodríguez-Novoa, S; Soriano, V; Tuma, P; Vispo, E1
Chang, WY; Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, CF; Huang, JF; Lin, ZY; Wang, LY; Yang, JF; Yu, ML1
Azuma, S; Enomoto, N; Itsui, Y; Kakinuma, S; Mogushi, K; Nagaie, S; Nakagawa, M; Sakamoto, N; Tanaka, H; Ueyama, M; Watanabe, M1
Arakawa, T; Fujimori, M; Hiramatsu, T; Hisanaga, Y; Hosokawa, T; Kanamori, A; Kiriyama, S; Kumada, T; Tada, T; Takagi, M; Tanikawa, M; Toyoda, H2
Antinori, S; Caramma, I; Cesari, M; Galli, M; Mazzali, C; Milazzo, L; Olivetti, M1
Bortolotti, F; Brugiolo, A; Carli, M; Cesaro, S; Guido, M; Petris, MG1
Chu, CJ; Lee, SD1
Dessouki, O; Kamiya, Y; Nagahama, H; Okada, S; Sasaki, Y; Suzu, S; Tanaka, M1
Rockstroh, JK; Vogel, M1
Bjoro, K; Dalgard, O; Ring-Larsen, H; Verbaan, H1
Baumgarten, A; Dikopoulos, N; Goelz, J; Heyne, R; Hueppe, D; John, C; Mauss, S; Moeller, B; Moog, G; Simon, KG; Teuber, G; Witthoeft, T; Wollschlaeger, S1
Bono, A; Cabibi, D; Cammà, C; Craxí, A; Di Marco, V; Licata, G; Marchesini, G; Petta, S; Porcasi, R; Scazzone, C; Tripodo, C1
Jain, MK; Zoellner, C1
Borg, BB; Doo, E; Feld, JJ; Ghany, MG; Heller, T; Hoofnagle, JH; Liang, TJ; Loomba, R; Lutchman, G; Modi, AA; Neumann, AU; Rivera, E; Rotman, Y; Soza, A1
Cheng, W; Flexman, JP; Hammond, T; Lee, S; Price, P; Watson, MW1
Halevy, S; Horev, A1
Amorosa, VK; Bruno, C; Dorey-Stein, Z; Ferrara, T; Hoffman-Terry, M; Kostman, JR; Lo Re, V; Mounzer, K; Slim, J1
Andreoli, A; Arcuri, P; Barbarini, G; Barbaro, G; Barlattani, A; Bonaventura, ME; D'Ambrosio, C; Mazzoni, E; Mecenate, F; Nosotti, L; Paffetti, A; Pellicelli, AM; Picardi, A; Romano, M; Soccorsi, F1
Bouraoui, R; Chebil, A; El Matri, L; Kort, F; Youssef, NB1
Albrecht, J; Bertelsen, AH; Brass, C; Fellay, J; Ge, D; Goldstein, DB; Gumbs, CE; Little, LD; McHutchison, JG; Muir, AJ; Qiu, P; Shianna, KV; Sulkowski, M; Thompson, AJ; Urban, TJ; Warner, A; Watson, M1
Mac Nicholas, R; Norris, S1
Lao, XQ; Li, JH; McCarthy, JJ; McHutchison, JG; Muir, AJ; Patel, K; Suchindran, S; Thompson, A; Tillmann, HL1
Abdo, A; Abu El-Asrar, AM; Al Otaibi, M; Al-Muammar, AM; Al-Mudhaiyan, TM1
Bengsch, B; Thimme, R1
Alsiö, A; Askarieh, G; Ferrari, C; Hellstrand, K; Lagging, M; Negro, F; Neumann, AU; Norkrans, G; Pawlotsky, JM; Pugnale, P; Schalm, SW; Söderholm, J; Westin, J; Zeuzem, S1
Bailly, F; Trepo, C1
Albrecht, JK; Alonso, E; Bortolotti, F; Brass, C; Broue, P; Calzado, MA; Ciocca, M; Galoppo, M; Gonzalez, T; Goodman, Z; Huber, WD; Hunter, B; Jara, P; Kerkar, N; Kullmer, U; Lacaille, F; Lachaux, A; Lang, T; Neigut, D; Noviello, S; Pedreira, A; Pollack, H; Ramakrishna, J; Ribes-Koninckx, C; Rodriguez-Baez, N; Shelton, M; Sniukiene, V; Valle-Segarra, AD; Wirth, S; Xu, CR; Zancan, L; Zheng, H1
Bielawski, KP; Izycka-Swieszewska, E; Romanowski, T; Sikorska, K; Stalke, P1
Araújo, DV; Araújo, GT; Fonseca, MC1
Bronowicki, JP; Diago, M; Nelson, DR; Pappas, SC; Rodriguez-Torres, M; Shiffman, ML; Tietz, A; Zeuzem, S1
Heathcote, EJ; Mazzulli, T; Pattullo, V; Ravindran, NC; Wong, DK1
Hagen, K; Rosenberg, P1
Dhillon, AP; Hellstrand, K; Lagging, M; Westin, J1
Kao, JH; Wang, CC1
Hrstić, I; Ostojić, R; Vucelić, B1
Begovac, J; Romih, V1
Colić Cvrlje, V; Filipec Kanizaj, T; Mrzljak, A; Ostojić, R1
Jaklin Kekez, A1
Bartkowiak, J; Grek, M; Jozwiak, B; Majda-Stanislawska, E; Piekarska, A; Sidorkiewicz, M1
Azevedo, RS; Carrilho, FJ; Gonçalves, L; Malta, Fde M; Medeiros-Filho, JE; Pinho, JR; Silva, LC1
Perez, V1
Ciocca, M; Cuarterolo, M; Ramonet, M1
Colombato, L; Descalzi, V; Gadano, A1
Galdame, O; Manero, E; Reggiardo, V1
Galdame, O; Jorge, A; Sordá, J1
González Ballerga, E; Levi, D; Reggiardo, V1
Bain, VG; Balshaw, R; Cooper, CL; Deschênes, M; Krajden, M; Lee, SS; Marotta, PJ; Peltekian, KM; Sherman, M; Usaty, C; Yoshida, EM1
Broussolle, C; Faurie, P; Sève, P; Trepo, C; Zoulim, F1
Florholmen, J; Goll, R; Gutteberg, T; Konopski, Z; Kristiansen, MG; Kvamme, JM; Paulssen, EJ; Steigen, SE; Sørbye, SW1
Amer, A; Bener, A; Derbala, M; Rashid, A; Shebl, FM1
Andriulli, A; Bacca, D; Carretta, V; Copetti, M; Cozzolongo, R; Dalgard, O; Mangia, A; Minerva, N; Mottola, L; Piazzolla, V; Ring-Larsen, H; Verbaan, H1
Dai, Y; Ishii, K; Mohri, K; Motege, E; Uesawa, Y1
Negro, F1
Ali, A; Eslam, M; Hamdy, L; Khattab, M; Sharwae, MA; Shatat, M1
Chen, TM; Chen, YP; Chow, KC; Huang, PT; Tung, JN; Wen, CF1
Cañete, N; Crespo, M; Jou, A; Mira, JA; Pahissa, A; Pineda, JA; Podzamczer, D; Solà, R; Tiraboschi, JM; Tural, C; Van den Eynde, E1
Feld, JJ; Ghany, MG; Hara, K; Haynes-Williams, V; Heller, T; Hoofnagle, JH; Ko, M; Koh, C; Leff, RD; Liang, TJ; Lutchman, GA; Meek, C; Neumann, AU; Pfeiffer, JK; Rivera, M; Rotman, Y1
Cardona-Meléndez, GM; DebRoy, S; Diaz, E; Kang, M; Kribs-Zaleta, C; Medina-Rios, L; Mubayi, A1
de la Cruz-Lombardo, J; Jiménez-Pérez, M; Lozano-Rey, JM; Pérez-Daga, JA; Rodrigo-López, JM; Sáez-Gómez, AB1
Chironna, M; Conteduca, V; Dammacco, F; De Re, V; Gatti, P; Lauletta, G; Mariggiò, MA; Russi, S; Sansonno, D; Sansonno, S; Tucci, FA1
Bruggmann, P; Dampz, M; Falcato, L; Gerlach, T; Kravecz, L1
Cheveau, A; Larrat, S; Leroy, V; Levast, M; Morand, P; Nicod, S; Plages, A; Seigneurin, JM; Thelu, MA; Zarski, JP1
El-Azm, AR; El-Demellawy, M; Salem, ML1
Beld, MG; Gelderblom, HC1
Baysoy, G; Demir, H; Temizel, IN; Uslu, N; Yuce, A1
Cacoub, P; Chousterman, M; Fontanges, T; Lang, JP; Marcellin, P; Melin, P; Ouzan, D; Rotily, M1
Ackermann, G; Waizmann, M1
Dzyublyk, I; Humphries, JE; Kromminga, A; Miroshnichenko, V; Moroz, L; Popovych, O; van Hoogdalem, EJ; Wilkes, MM; Yegorova, T; Zaytsev, I1
Goto, H; Hayashi, K; Hirooka, Y; Ishigami, M; Itoh, A; Katano, Y; Kumada, T; Nakano, I; Toyoda, H; Urano, F; Yoshioka, K1
Adda, N; Afdhal, NH; Bsharat, M; Di Bisceglie, AM; Garg, J; George, S; Heathcote, EJ; Jacobson, IM; Kauffman, RS; Manns, MP; McHutchison, JG; Muir, AJ; Reesink, HW; Terrault, NA; Zeuzem, S1
Cheong, HR; Cho, M; Heo, J; Kang, DH; Kim, DU; Kim, GH; Song, GA; Woo, HY; Yoon, KT1
Aguirrebengoa, K; Barreiro, P; Guardiola, JM; Labarga, P; Miralles, C; Miralles, P; Morello, J; Portu, J; Rodriguez-Novoa, S; Rubio, R; Soriano, V; Vispo, E1
Flisiak, I; Flisiak, R; Jaroszewicz, J; Rogalska, M1
Alsiö, Å; Buhl, MR; Christensen, PB; Färkkilä, M; Lagging, M; Langeland, N; Mørch, K; Norkrans, G; Pedersen, C; Sangfelt, P; Westin, J1
Colucci, G; Hadziyannis, SJ; Ishida, H; Lin, A; Sarrazin, C; Shiffman, ML; Zeuzem, S1
Antonaci, S; Napoli, N; Simone, O; Tortorella, C; Zaccaro, B1
Shouval, D2
Furusyo, N; Hayashi, J; Kainuma, M; Murata, M; Ogawa, E; Otaguro, S; Sawayama, Y; Taniai, H; Toyoda, K1
Doo, EC; Jacobson, IM; Murray, JS; Perrillo, RP; Peters, MG; Ross, DB; Wong, JB1
Dejaco, C; Donnerer, J; Ferenci, P; Hofer, H; Kessler, H; Sator, K; Sator, M; Scherzer, TM; Staufer, K1
Bourgois, A; Fischler, B; Gardovska, D; Kelly, D; Porta, G; Silveira, T; Sokal, EM; Stéphenne, X1
Cheng, W; Fernandez, S; Flexman, JP; Hammond, T; Lee, S; Price, P; Watson, MW2
Bader, TF; Bird, PC; Fazili, J; Lackey, CL; Mallonee, S; Mesiya, SA; Sachdev, AK; Schmidt, RD; Tierney, WM1
Chang, HH; Chen, IM; Shih, CC; Wang, BY; Yang, AH1
Cross, TJ; Harrison, PM; Hughes, S; Nolan, J; Quaglia, A1
Elkady, A; Hasegawa, I; Khan, A; Kurbanov, F; Matsuura, K; Mizokami, M; Ohno, T; Sugauchi, F; Tanaka, Y; Tokuda, H1
Zucker, DM1
Bárcena, R; Blesa, C; Casado, JL; Fortún, J; Mateos, ML; Moreno, A; Moreno, S; Pérez-Elías, MJ; Quereda, C; Rodríguez-Sagrado, MA1
Honda, M; Horimoto, K; Kaneko, S; Mizokami, M; Mizukoshi, E; Nakamoto, Y; Nakamura, M; Sakai, A; Sakai, Y; Shirasaki, T; Tanaka, Y; Tokunaga, K; Yamashita, T1
Blanc, F; Cacoub, P; Coppéré, B; Karras, A; Musset, L; Perard, L; Piette, JC; Resche Rigon, M; Rosenzwajg, M; Saadoun, D; Schoindre, Y; Sene, D; Terrier, B1
Kaur, A; Kaushal, S; Midha, V; Mittal, R; Puri, S; Singla, D; Sobti, P; Sood, A; Sood, N1
Cozma, A; Orāşan, O; Pârvu, A; Petrov, L; Rednic, N; Sâmpelean, D1
Ahlenstiel, G; Baumgarten, A; Bickel, M; Buggisch, P; Fenske, S; Gölz, J; Hintsche, B; John, C; Khaykin, P; Klinker, H; Lutz, T; Mayr, C; Rockstroh, JK; Schürmann, D; Staszewski, S; Stephan, C; Trein, A; Vogel, M1
Imazeki, F; Omata, M; Yokosuka, O1
Angelo, AL; Bendicho, MT; Carneiro, VL; Cavalcante, LN; Freire, SM; Lemaire, DC; Lyra, AC; Lyra, LG; Mendes, CM; Santana, N; Souza, SL1
de Carvalho-Mello, IM; de Queiróz, AT; Jardim, AC; Maracaja-Coutinho, V; Matioli, SR; Rahal, P1
Corcoy, R; Enríquez, J; Rigla, M; Torras, X; Vinagre, I1
Chanu, P; Frey, N; Goggin, T; Grippo, J; Jacqmin, P; Jonsson, EN; Jorga, K; Jumbe, NL; Lavielle, M; Snoeck, E1
Herrine, SK; Santos, C1
Berg, J; Biesenbach, G; Bodlaj, G; Hubmann, R; Saleh, K; Stojakovic, T1
Poordad, F; Zeuzem, S1
Chao, YC; Chen, CH; Chen, CL; Chen, DS; Chen, PJ; Chuang, WL; Dai, CY; Hu, TH; Huang, JF; Hung, CH; Kao, JH; Kuo, HT; Lai, MY; Lee, CM; Liao, LY; Lin, ZY; Liu, CH; Liu, CJ; Lu, SN; Su, TH; Tung, SY; Wang, JH; Wu, SS; Yang, SS; Yu, ML1
Schwarz, KB1
Kremen', NV; Romantsov, MG; Sologub, TV1
Alonso, N; Martínez-Arconada, MJ; Martínez-Cáceres, EM; Morillas, RM; Planas, R; Sanmartí, AM; Soldevila, B1
Piccolo, P1
Alsaran, K; Sabry, A; Shaheen, N1
Berzsenyi, MD; Roberts, SK1
Chang, WY; Chen, SC; Chiu, CF; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, CF; Huang, JF; Lin, ZY; Wang, LY; Yang, JF; Yu, ML1
Chan, JM; Chan, KH; Cheung, KW; Chow, DA; Kan, YM; Kwan, WK; Lai, TS; Li, FT; Li, MK; Li, RS; Lo, FH; Ng, FH; Tsang, OT; Yeung, YW; Zee, JS1
Frampton, CM; Gane, EJ; Gibson, M; Keogh, GF; Lockhart, MM; Murphy, MP; Orr, DW; Smith, RA; Taylor, KM; Weilert, F1
Fuchsteiner, H; Hackl, F; Luger, C; Maieron, A; Metz-Gercek, S; Mittermayer, H; Schöfl, R; Ziachehabi, A1
Kabieszová, L; Kloudová, A; Kůrková, J; Mrázek, J; Orságová, I; Petrousová, L; Pospísek, M; Roznovský, L1
Behrens, R; Enninger, A; Gerner, P; Hilbich, J; Kliemann, G; Walther, F; Wenzl, TG; Wirth, S1
Bernardini, C; Di Biagio, A; Mikulska, M; Nicco, E; Rosso, R; Viscoli, C1
Molina, JM; Palmer, P; Rachline, A; Simon, F1
Boesecke, C; Rockstroh, JK; Vogel, M; Wasmuth, JC1
Akuta, N; Arase, Y; Hirakawa, M; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Matsumoto, N; Saito, S; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H1
Ciancio, A; Rizzetto, M1
Andreone, P; Bernardi, M; Cannoletta, F; Cursaro, C; Di Donato, R; Fortini, C; Gramenzi, A; Grandini, E; Loggi, E; Riili, A; Scuteri, A1
Cho, MS; Choi, MS; Gwak, GY; Koh, KC; Lee, JH; Paik, SW; Shin, SR; Sinn, DH; Yoo, BC1
Changchien, CS; Chen, CH; Hu, TH; Hung, CH; Kee, KM; Lee, CM; Lu, SN; Tung, WC; Wang, JH1
Arends, JE; Baak, BC; Boonstra, A; Claassen, MA; Hoepelman, AI; Nanlohy, NM; van Baarle, D; van den Berg, CH; van Erpecum, KJ1
Ettorre, A; Harrison, RJ; Khakoo, SI; Little, AM1
Rustgi, VK2
Candolo Martinelli, AL; Carneiro, FP; Carneiro, MV; Figueiredo, JF; Passos, AD; Ramalho, LN; Secaf, M; Souza, FF; Teixeira, AC; Villanova, MG; Zucoloto, S1
Ando, K; Fukuda, K; Hayashi, Y; Hong, HS; Hotta, H; Imoto, S; Kim, SR; Kudo, M; Lee, YH; Mita, K; Nagano-Fujii, M; Nakajima, T; Nakashima, K; Shoji, I1
Cooper, C2
Byrnes-Blake, K; de la Torre, A; Flamm, S; Fontana, D; Freeman, J; Gordon, SC; Gray, T; Hausman, D; Hunder, NN; Lawitz, E; Lopez-Talavera, JC; Marotta, P; Muir, AJ; Shiffman, ML; Vierling, JM; Yoffe, B; Zaman, A1
Bonkovsky, HL; De Santo, JL; Di Bisceglie, AM; Dienstag, JL; Ghany, MG; Kim, HY; Lee, WM; Lindsay, KL; Lok, AS; Morgan, TR; Morishima, C; Shiffman, ML; Snow, KK1
Aydin, I; Ferenci, P; Hofer, H; Mueller, C; Neumueller-Guber, S; Scherzer, TM; Staufer, K; Steindl-Munda, P; Wrba, F1
Albrecht, JK; Brass, CA; Dhaliwal, S; Goteti, VS; Harrison, SA; Hu, KQ; Koury, K; McHutchison, JG; Noviello, S; Patel, K; Rossaro, L; Sulkowski, MS; Tillmann, H; Torres, DM1
Deng, L; El-Shamy, A; Fukuda, K; Haga, H; Hotta, H; Imai, Y; Ishii, R; Ito, J; Kawata, S; Nishise, Y; Okumoto, K; Saito, K; Saito, T; Sanjo, M; Shoji, I; Togashi, H; Watanabe, H1
Díaz-García, F; Fernández-Gutiérrez-Del-Alamo, C; Girón-González, JA; Marín-Serrano, E; Martín-Herrera, L; Rodríguez-Ramos, C1
Angelico, M; Baiocchi, L; Carbone, M; Conti, RL; Cucchiarelli, S; De Leonardis, F; Delle Monache, M; Di Paolo, D; Lenci, I; Nosotti, L1
Fehér, J; Lengyel, G3
Caruntu, F; Ceausu, E; Csiki, IE; Gheorghe, L; Iacob, S; Pascu, O; Simionov, I; Vadan, R1
Arakawa, T; Goto, H; Hayashi, K; Honda, T; Katano, Y; Kumada, T; Tada, T; Toyoda, H1
Chan, HL; Farrell, GC; Teoh, NC1
Bate, JP; Colman, AJ; Frost, PJ; Harley, HA; Shaw, DR1
Bacon, BR; Cianciara, J; Cronin, PW; Grigorescu, M; Lawitz, EJ; Lurie, Y; McHutchison, JG; Muir, AJ; Pulkstenis, E; Rodriguez-Torres, M; Rustgi, VK; Subramanian, GM; Sulkowski, MS; Tice, AD; Zeuzem, S1
Bain, VG; Benhamou, Y; Chuang, WL; Cronin, PW; Flisiak, R; Kryczka, W; Lawitz, EJ; Lee, CM; McHutchison, JG; Nelson, DR; Patel, K; Pianko, S; Pulkstenis, E; Rasenack, JW; Rodriguez-Torres, M; Subramanian, GM1
Farnik, H; Herrmann, E; Kronenberger, B; Lange, CM; Sarrazin, C; Zeuzem, S1
Fan, YM; Li, TM; Liu, XQ; Zhou, BT1
Belkahla, N; Chaabouni, H; Chouaib, S; Hariz, FB; Kchir, H; Maamouri, N; Mami, NB; Ouerghi, H1
Chung, YH; Jeong, SH; Jin, YJ; Kim, GM; Lee, HC; Lee, YS; Lim, YS; Park, YK; Suh, DJ; Yun, GJ1
Jang, JY; Jeon, SR; Jeong, SW; Kim, BS; Kim, SK; Kim, YS; Lee, YN; Lim, JH; Roh, MO; Ryu, YS1
Hanson, B; Lambot, F; Sztern, B1
Carvalho Filho, RJ; Ferrari, MV; Ferraz, ML; Freire, FC; Narciso-Schiavon, JL; Scanhola, GQ; Schiavon, Lde L; Silva, AE; Suarez, MM1
Gómez-Domínguez, E; González-Moreno, L; Jones, EA; Mendoza, J; Moreno-Otero, R; Trapero-Marugán, M1
Abdo, AA; Alajlan, A; Binamer, Y; Hamadah, I; Sanai, FM1
Chan, PK; Tam, JS; Tully, DC; Zhang, T; Zhou, DX1
Mendes-Corrêa, M; Núñez, M1
Browne, JA; Crowe, J; Devitt, E; Lawless, MW; Sadlier, D; Walsh, C1
Asselah, T; Bieche, I; De Muynck, S; Estrabaud, E; Lapalus, M; Marcellin, P; Saadoun, D; Soumelis, V; Vidaud, M1
Abergel, A; Connell, EV; Cooksley, WG; Diago, M; Dieterich, DT; Lai, MY; Lin, A; Pessôa, MG; Shiffman, ML; Swain, MG; Tietz, A; Zeuzem, S1
Broering, R; Gerken, G; Jiang, M; Kottilil, S; Lu, M; Schlaak, JF; Trippler, M; Zhang, X1
Batista-Neves, S; de Oliveira, IR; Galvão-de Almeida, A; Guindalini, C; Lyra, AC; Miranda-Scippa, A; Paraná, R; Quarantini, LC1
Bianchi, C; Hernández, N; Mescia, G; Pollio, C; Quintana, L; Robaina, G1
Ramos, EL1
Angerami, AF; Gonçales, ES; Gonçales, FL; Gonçales, NS; Moma, CA; Pavan, MH; Tozzo, R; Vigani, AG1
Bernasconi, E; Borovicka, J; Cavassini, M; Cerny, A; Chave, JP; Chuard, C; Dufour, F; Dutoit, V; Genné, D; Gonvers, JJ; Heim, MH; Malinverni, R; Monnat, M; Müllhaupt, B; Negro, F; Oneta, C; Troilliet, N1
Akuta, N; Arase, Y; Chayama, K; Hirakawa, M; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Nakamura, Y; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H1
Bignulin, S; Bitetto, D; Cmet, S; Cussigh, A; Fabris, C; Falleti, E; Fontanini, E; Fornasiere, E; Fumolo, E; Martinella, R; Pipan, C; Pirisi, M; Toniutto, P1
Ardiri, A; Bertino, G; Boemi, PM; Boemi, R; Bruno, CM; Calvagno, GS; Ierna, D; Naimo, S; Neri, S; Ruggeri, IM; Santonocito, MM; Speranza, A; Valenti, M1
Fowell, AJ; Nash, KL1
El Diasty, A; Saudy, N; Zaki, Mel S1
Adams, S; Ostermeier, M1
Camacho, A; del Valle, J; Macías, J; Mata, R; Merchante, N; Mira, JA; Neukam, K; Pérez-Camacho, I; Pineda, JA; Rivero, A; Rivero-Juárez, A; Torre-Cisneros, J1
Benedan, L; Borroni, V; Del Menico, B; Dongiovanni, P; Fargion, S; Fracanzani, AL; Galmozzi, E; Maggioni, P; Rametta, R; Valenti, L1
Jung, EU; Kang, HG; Lee, SH; Lee, YJ; Moon, SS; Park, SJ; Seo, JA; Seol, SY1
Song, BC1
Kenis, G; Koek, GH; Prickaerts, J; Robaeys, G; Steinbusch, HW; van Os, J; Wichers, M1
Araújo, ES; Barone, AA; Campos, AF; Mello, ES; Takagaki, T; Yamashiro, J1
Bonkovsky, HL; Dienstag, JL; Fontana, RJ; Goodman, ZD; Lok, AS; Naishadham, D; Sterling, RK; Su, GL; Wright, EC1
Chary, A; Holodniy, M; Kottilil, S; Murphy, AA; Polis, MA; Winters, MA1
Balciuniene, L; Blokhina, NP; Buti, M; Esteban, R; Faruqi, R; Feinman, SV; Horban, A; Lurie, Y; Pedicone, LD; Sarrazin, C; Teuber, G; Zakharova, NG1
Bech, P; Buhl, MR; Färkkilä, M; Hellstrand, K; Hjerrild, S; Lagging, M; Langeland, N; Leutscher, PD; Mørch, K; Norkrans, G; Pedersen, C1
Burbelo, PD; Ching, KH; Iadarola, MJ; Issa, AT; Kottilil, S; Kovacs, JA; Masur, H; Murphy, AA; Polis, MA; Schlaak, JF1
McHutchison, J; Naggie, S; Patel, K1
Belle, SH; Conjeevaram, HS; Evans, RW; Ramcharran, D; Wahed, AS; Wang, T; Yee, LJ1
Beste, LA; Chapko, M; Dominitz, JA; Ioannou, GN; Larson, MS1
Albrecht, JK; Anderson, FH; Brass, CA; Chaudhri, E; Davis, MN; Galati, JS; Gordon, SC; Jacobson, IM; Koury, K; Kwo, PY; Lawitz, EJ; McCone, J; Pedicone, LD; Pound, D; Ravendhran, N; Rossaro, L; Rubin, R; Schiff, ER; Vierling, JM1
Asano, T; Hatakeyama, H; Hayashi, T; Iwashita, M; Maeda, T; Nishiwaki, S; Saito, K; Tagami, A; Takada, J; Watanabe, N1
Bondarenko, AN; Goriacheva, LG; Kovalenko, AL; Kovalenko, SN; Petrov, AIu; Romantsov, MG; Shul'diakov, AA; Sologub, TV; Sukhanov, DS1
Aydemir, S; Cakal, B; Engin, H; Gokmen, A; Kiran, S; Oztoprak, N; Tekin, IO; Ustundag, Y1
Ceccherini-Silberstein, F; Cento, V; Di Masi, F; Manzoli, L; Mazzotta, E; Mercurio, F; Parruti, G; Perno, CF; Pieri, A; Polilli, E; Sozio, F; Tontodonati, M1
Abe, T; Fukuhara, T; Maehara, Y; Matsuura, Y; Motomura, T; Ninomiya, A; Okano, S; Shirabe, K; Soejima, Y; Taketomi, A; Uchiyama, H1
Beinhardt, S; Ferenci, P; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rutter, K; Staettermayer, AF1
Brochot, E; Capron, D; Castelain, S; Duverlie, G; François, C; Nguyen-Khac, E1
Bani-Sadr, F; Cacoub, P; Carrat, F; Chavanet, P; Duong, M; Duvillard, L; Halfon, P; Petit, JM; Piroth, L1
Hattori, T; Inoue, Y; Kodama, EN; Li, S; Matsuura, Y; Tanaka, T; Tani, H; Zhang, J1
Archimandritis, AJ; Giannaris, M; Koskinas, J; Malaktari, S; Papakostas, N; Savvas, SP1
Nagao, Y; Sata, M1
Daruich, J1
Galoppo, C; Galoppo, M1
Fujishiro, T; Kato, H; Narita, M1
Bacon, BR; Chun, E; Halliman, D; Hammond, J; Hassanein, T; Heise, J; Lawitz, E; Muir, AJ; Poordad, F; Shiffman, ML1
Baur, K; Berg, T; Bibert, S; Bochud, PY; Braun, J; Frei, P; Geier, A; Goetze, O; Iwata, R; Martin, IV; Mertens, JC; Müller, T; Müllhaupt, B; Schmitt, J; Stieger, B; Vergopoulos, A1
Afdhal, NH; Albrecht, JK; Brass, CA; Deng, W; Harrison, SA; Herrine, SK; Koury, K; Lee, WM; McCone, J; McHutchison, JG; Noviello, S; Pedicone, LD; Poordad, FF; Reddy, KR; Shiffman, ML; Sulkowski, MS1
Beinhardt, S; Datz, C; Dulic-Lakovic, E; Ferenci, P; Hofer, H; Kessler, HH; Krall, C; Maieron, A; Rutter, K; Scherzer, TM; Stättermayer, AF; Stauber, R; Steindl-Munda, P; Strasser, M; Zinober, K1
Boland, GJ; Burger, DM; Drenth, JP; Janssen, MP; Siersema, PD; Van Erpecum, KJ; Van Soest, H; Van Vlerken, LG1
Berg, T; Bojunga, J; Farnik, H; Hassler, A; Herrmann, E; Lange, CM; Sarrazin, C; von Wagner, M; Zeuzem, S1
Bakulin, IG; Sharabanov, AS1
Bakulin, IG; Iakovleva, EV; Moliarenko, EV; Sharabanov, AS1
Arai, K; Honda, M; Kaneko, S; Nakamura, M; Sakai, A; Sakai, Y; Shimakami, T; Shirasaki, T; Tateno, M; Yamashita, T1
Cardot-Leccia, N; Lacour, JP; Montaudié, H; Passeron, T; Sebbag, N1
Badley, AD; Cummins, NW; Klein, MB; Rider, DN; Rizza, SA; Saeed, S1
Kaur, A; Mehta, V; Midha, V; Mittal, R; Sharma, S; Sood, A; Sood, N; Thara, A1
Kaur, A; Midha, V; Mittal, R; Puri, S; Sandhu, JS; Sood, A; Sood, N1
Camacho, A; Caruz, A; de la Torre, J; Macías, J; Martínez, A; Mira, JA; Neukam, K; Palomares, JC; Pineda, JA; Rivero, A; Roldán, C; Salas, I1
Aghemo, A; Colombo, M; De Nicola, S; Rumi, MG1
Barreiro, P; Cuenca, L; Jiménez-Nácher, I; Labarga, P; Madejón, A; Medrano, J; Morello, J; Rodríguez-Nóvoa, S; Soriano, V; Vispo, E1
Abdurakhmanov, D; Bakulin, I; Cheinquer, H; Geyvandova, N; Harrison, SA; McKenna, M; Morozov, V; Rabbia, M; Reddy, KR; Rodriguez-Torres, M; Shiffman, ML; Silva, GF; Stanciu, C; Thommes, JA1
Barreiro, P; González-Lahoz, J; Labarga, P; Martín-Carbonero, L; Medrano, J; Soriano, V; Tuma, P; Vispo, E1
Chen, WL; Chen, XF; Chen, XP; Huang, J; Luo, XD1
Bernard, I; Brochot, E; Canva, V; Castelain, S; Descamps, V; Duverlie, G; François, C; Mathurin, P1
Altomare, E; Antonaci, S; Batini, I; Capria, A; Giannelli, G; Grandi, B; Guarducci, I; Marsi, O; Moscato, GA; Pellegrini, G; Pieri, D; Sacco, R1
Hiramatsu, N; Iwasaki, M; Izumi, N; Kurosaki, M; Sakamoto, M; Sakamoto, N; Sugauchi, F; Suzuki, Y; Yatsuhashi, H1
de Knegt, RJ; Hansen, BE; Janssen, HL; Roomer, R1
Pandya, PK; Rao, GA1
Ferenci, P; Ferlitsch, A; Gangl, A; Homoncik, M; Peck-Radosavljevic, M; Pramhas, S; Scherzer, T1
Amador-Cañizares, Y; Dueñas-Carrera, S1
Abate, G; Bertino, G; Boemi, P; Calvagno, GS; Di Pino, A; Giancarlo, C; Ignaccolo, L; Judica, A; Maiorca, D; Mastrosimone, G; Mauceri, B; Misseri, M; Neri, S; Palermo, F; Petralia, A; Rizzotto, A; Vadalà, G1
Belotti, C; Brocco, G; Bruno, R; Covolo, L; Cristofori, C; Donato, F; Fattovich, G; Gaeta, GB; Guido, M; Minola, E; Negro, F; Pasino, M; Perini, E; Puoti, M; Raimondo, G; Rossi, L; Santantonio, T1
Alejska, M; Błażewicz, J; Figlerowicz, M; Formanowicz, P; Jackowiak, P; Kędziora, P; Malinowska, N1
Agostinacchio, E; Andriulli, A; Annicchiarico, B; Bacca, D; Bandiera, F; Barbarini, G; Carretta, V; Cela, M; Mangia, A; Minerva, N; Montalto, G; Mottola, L; Pellicelli, A; Piazzolla, V; Ricci, GL; Romano, M; Russello, M; Scotto, G1
Azuma, K; Furusyo, N; Hayashi, J; Kainuma, M; Kajiwara, E; Kotoh, K; Maruyama, T; Nakamuta, M; Nomura, H; Satoh, T; Shimoda, S; Shimono, J; Takahashi, K; Tanabe, Y1
Anagnostou, O; Archimandritis, AJ; Deutsch, MJ; Georgiou, E; Karatapanis, S; Manesis, E; Manolakopoulos, S; Papatheodoridis, GV; Tiniakou, E; Tzourmakliotis, D1
Fujioka, T; Honda, M; Koyama, K; Matsuno, H; Ogawa, M; Shimokawa, K; Yoshizaki, T1
Cottone, M; D'Amico, G; Fasola, S; Giannuoli, G; Graviano, D; Madonia, S; Malizia, G; Patti, S; Tinè, F1
Baumgarten, A; Dikopoulos, N; Goelz, J; Herrmann, A; Heyne, R; Hueppe, D; John, C; Link, R; Mauss, S; Moeller, B; Simon, KG; Spelter, M; Teuber, G; Witthoeft, T; Wollschlaeger, S1
Meléndez-Mena, D; Ramírez-Mata, A; Reyes-Leyva, J; Rocha-Gracia, RC; Santos-López, G; Sedeño-Monge, V; Vallejo-Ruiz, V1
Fukuhara, T; Gion, T; Ikegami, T; Maehara, Y; Morita, K; Nagata, S; Soejima, Y; Sugimachi, K; Takeishi, K; Taketomi, A; Toshima, T; Umeda, K1
Afeltra, A; D'Avola, D; Dicuonzo, G; Galati, G; Gallo, P; Mazzarelli, C; Pellicelli, A; Picardi, A; Rigon, A; Spataro, S; Vespasiani-Gentilucci, U1
Kwo, PY; Vinayek, R1
Chevaliez, S; Hézode, C1
Beyazit, Y; Efe, C; Ozaslan, E; Purnak, T1
Bota, S; Curescu, M; Gheorghe, L; Iacob, S; Popescu, A; Sirli, R; Sporea, I1
Donnini, D; Franceschi, L; Furlanut, M; Sechi, L; Soardo, G1
Clark, PJ; McHutchison, JG; Thompson, AJ1
Ghany, MG; Noureddin, M2
Ando, N; Arakawa, T; Fujimori, M; Hisanaga, Y; Kanamori, A; Kimura, J; Kiriyama, S; Kumada, T; Niinomi, T; Sakai, K; Tada, T; Tanikawa, M; Toyoda, H; Yasuda, S1
Ahmed, F; Albert, C; Brand, M; Brass, C; Brown, R; Fixelle, AM; Herrera, JL; Jacobson, IM; Rustgi, VK; Wasserman, RB1
Abdo, AA; Ahmed, LR; Al-hamoudi, W; Al-Husseini, H; Al-Otaibi, MM; Albenmousa, A; Ali, SM; AlQaraawi, AM; AlSheikh, A; Alswat, KA; Hersi, A; Sanai, FM; Syed, M1
Bernardinello, E; Bertazzo, A; Cavalletto, L; Chemello, L; Comai, S; Costa, CV; Ragazzi, E1
Berrey, M; Cammack, N; De La Rosa, A; Ewing, A; Kang, H; Kosaka, A; Le Pogam, S; Nájera, I; Seshaadri, A; Symonds, B; Yan, JM1
Parikh, M; Singh, A; Sood, G1
Ghany, MG; Seeff, LB1
Cadranel, JF; Denis, J; Duprat, C; Faroux, R; Lahmek, P; Morin, T; Nalet, B; Pariente, A; Renou, C1
Barreiro, P; Benito, JM; Calvino, A; Caruz, A; Macías, J; McHutchison, J; Medrano, J; Naggie, S; Neukam, K; Pineda, JA; Rallón, N; Resino, S; Rivero, A; Sánchez-Piedra, C; Soriano, V; Vispo, E1
Fais, V; Gonçales, ES; Gonçales, FL; Gonçales, NS; Macedo de Oliveira, A; Pavan, MH; Tozzo, R; Vigani, AG1
Chen, P; Cheng, D; Liu, E; Lu, S; Wang, Y; Wei, K; Yang, P; Yu, Q; Zhao, S1
Branch, AD; Bräu, N; Dieterich, DT; Factor, SH; Fiel, MI; Rodriguez-Torres, M; Slim, J; Sterling, RK; Sulkowski, MS; Talal, AH; Vachon, ML1
Dai, CY1
Benhamou, Y; Bourlière, M; Bronowicki, JP; Chêne, G; Couzigou, P; Foucher, J; Halfon, P; Leroy, V; Marcellin, P; Penaranda, G; Pérusat, S; Trimoulet, P1
Beumont, M; Carosi, G; De Backer, K; Drenth, JP; Ferenci, P; Forns, X; Goeser, T; Luo, D; Marcellin, P; Nevens, F; Picchio, G; Serfaty, L; Van Heeswijk, R1
Balistreri, WF; Barton, BA; Gonzalez-Peralta, RP; Goodman, Z; Haber, BA; Jonas, MM; Lobritto, SJ; Mohan, P; Molleston, JP; Murray, KF; Narkewicz, MR; Robuck, PR; Rosenthal, P; Rossi, S; Schwarz, KB; Smith, L; Valsamakis, A1
El-Ghannam, M; El-Ray, A; Mounir, B; Taha, AA1
Adán-Merino, L; Castillo-Grau, P; Gea-Rodríguez, F; Martín-Arranz, E; Olveira-Martín, A; Prados, C; Sáenz, JC; Segura-Cabral, JM1
Heller, T; Liang, TJ; Raghuraman, S; Rehermann, B; Veerapu, NS1
Casteelen, G; Coutinho, RA; Jansen, PL; Krol, A; Lambers, FA; Lindenburg, CE; Prins, M; Schinkel, J; Urbanus, AT; van den Berg, CH; van Santen, G; Weegink, CJ1
Albrecht, J; Berg, T; Boparai, N; Brass, C; Bruix, J; Burroughs, M; Carrilho, F; Colombo, M; Craxi, A; Diago, M; Flamm, S; Gonçales, F; Griffel, L; Heathcote, EJ; McGarrity, T; Moreno-Otero, R; Munteanu, M; Poynard, T; Schiff, E; Schmidt, W; Silva, M; Terg, R1
Chen, SC; Chiu, CF; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Lin, ZY; Wang, LY; Yang, JF; Yeh, ML; Yu, ML1
He, Q; Li, ZY1
Aggelopoulou-Tiga, P; Bassaris, H; Delis, V; Diamanti, H; Dimitroulopoulos, D; Dimopoulou, M; Giannoulis, G; Ionnidou, P; Kaligeros, K; Karatapanis, S; Kardasi, M; Ketikoglou, I; Kountouras, J; Kouroumalis, E; Koutsounas, S; Manolakopoulos, S; Mimidis, K; Nikolaou, A; Papaioannou, C; Perperas, A; Protopapas, A; Thomopoulos, K; Tsianos, E; Tzelas, G1
Deng, L; Hotta, H; Ide, Y; Kim, SR; Sasayama, M; Shoji, I1
Chung, RT; Di Bisceglie, AM; Hassanein, T; Lentz, E; Poordad, FF; Prabhakar, A; Zhou, X1
Abe, H; Akuta, N; Chayama, K; Hayes, CN; Imamura, M; Kamatani, N; Kobayashi, M; Kumada, H; Miki, D; Nakamura, Y; Ochi, H; Suzuki, F1
Di Lernia, V1
Abbey, SE; Links, PS; Sockalingam, S1
Afdhal, N; Conjeevaram, HS; Everhart, JE; Hoofnagle, JH; Howell, CD; Wahed, AS1
Andersen, ES; Christensen, PB; Kjær, M; Krarup, H; Lillevang, S; Moessner, BK; Weis, N1
Bernsmeier, C; Duong, FH; Filipowicz, M; Heim, MH; Terracciano, L1
Bruguera, M; Fernández-Varo, G; Forns, X; González, P; Jiménez, W; Martinez, SM; Navasa, M; Sampson, E; Sánchez-Tapias, JM1
Féray, C; Guillouche, P1
Bahgat, MM; El-Gammal, NE; Emara, MH; Mohamed, LA1
Hegarty, JE; Norris, S; O'Farrelly, C; Ryan, EJ; Tajuddin, T1
Andriulli, A; Caruso, N; Iacobellis, A; Niro, GA; Perri, F; Valvano, MR1
Brillanti, S; Mazzella, G; Roda, E1
Hong, GH; Hu, YJ; Mao, Q; Wang, XH; Zhang, XQ; Zhou, YQ; Zhu, Y1
Bereszyńska, I; Elikowski, W; Kurosz, J; Marszałek, A; Małek, M; Mozer-Lisewska, I; Zawilska, K1
Al Dweik, NZ; Alkaabi, SR; Almohanadi, M; Amer, AM; Amin, A; Butt, MT; Derbala, MF; John, A; Pasic, F; Sharma, M; Shebl, FM; Yaqoob, R1
Albrecht, JK; Boparai, N; Gordon, SC; Hu, KQ; Koury, K; McCone, J; Muir, AJ; Noviello, S; Sulkowski, MS1
Xing, WL; Zhao, CY; Zhen, Z; Zhou, DF; Zhou, JY1
Barbera, C; Bortolotti, F; Cammà, C; Giacchino, R; Guido, M; Indolfi, G; Marazzi, MG; Resti, M; Verucchi, G; Zancan, L1
Bibert, S; Bochud, PY; Dill, MT; Duong, FH; Heim, MH; Papassotiropoulos, A; Roth, V; Terracciano, L; Vogt, JE1
Berg, T; Doehring, A; Herrmann, E; Lange, CM; Lötsch, J; Müller, T; Sarrazin, C; Schlecker, C; Susser, S1
Abe, H; Chayama, K; Hayes, CN; Hiraga, N; Imamura, M; Kawaoka, T; Kubo, M; Kumada, H; Maekawa, T; Mitsui, F; Nakamura, Y; Ochi, H; Ohishi, W; Takahashi, S; Tsuge, M; Tsunoda, T1
Boland, GJ; Burger, DM; Drenth, JP; Huisman, EJ; Siersema, PD; van Erpecum, KJ; van Soest, H; van Vlerken, LG1
Halota, W; Pawłowska, M; Pilarczyk, M1
Chiba, T; Egawa, H; Haga, H; Hatano, E; Kaido, T; Marusawa, H; Miyagawa-Hayashino, A; Mori, A; Ogawa, K; Ogura, Y; Oike, F; Takada, Y; Ueda, Y; Uemoto, S; Yoshizawa, A1
Arai, M; Chiba, T; Fujiwara, K; Imazeki, F; Kanai, F; Kanda, T; Kato, K; Kurihara, T; Mikami, S; Mikata, R; Nakamoto, S; Nishino, T; Sugiura, N; Tada, M; Takada, N; Takashi, M; Tanaka, T; Tawada, A; Tsubota, A; Wu, S; Yokosuka, O; Yonemitsu, Y1
Asahina, Y; Enomoto, N; Honda, M; Ito, K; Izumi, N; Kaneko, S; Kurosaki, M; Maekawa, S; Masaki, N; Matsuura, K; Mizokami, M; Nakagawa, M; Nishida, N; Sakai, A; Sakamoto, M; Sakamoto, N; Sugauchi, F; Sugiyama, M; Tanaka, Y; Tokunaga, K; Watanabe, M1
Abbate, I; Agrati, C; Capobianchi, MR; D'Offizi, G; Martini, F; Rozera, G; Sacchi, A; Vlassi, C1
Mederacke, I; Meyer-Olson, D; Wedemeyer, H; Witte, T1
Akase, T; Eguchi, Y; Iizuka, T; Ishizuka, H; Yoshiyama, Y1
Abe, H; Chayama, K; Hayes, CN; Hiraga, N; Imamura, M; Kubo, M; Maekawa, T; Miki, D; Mitsui, F; Nakamura, Y; Ochi, H; Takahashi, S; Tsuge, M1
Beinhardt, S; Ferenci, P; Hofer, H; Kerschner, H; Kessler, HH; Rutter, K; Scherzer, TM; Staettermayer, AF; Steindl-Munda, P1
Blatt, L; Bradford, W; Forestier, N; Guyader, D; Larrey, D; Marcellin, P; Patat, A; Porter, S; Rouzier, R; Seiwert, SD; Smith, P; Zeuzem, S1
Fried, MW; Hadziyannis, SJ; Messinger, D; Shiffman, ML; Zeuzem, S1
Fukui, H; Hagiwara, H; Hayashi, N; Hijioka, T; Hiramatsu, N; Imai, Y; Inada, M; Inoue, A; Inui, Y; Ito, T; Kanto, T; Kasahara, A; Kato, M; Kaytayama, K; Kiso, S; Mita, E; Miyagi, T; Mochizuki, K; Oshita, M; Oze, T; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yoshida, Y; Yoshihara, H1
Antonino, AT; Bechstein, WO; Bibert, S; Bochud, PY; Doehring, A; Farnik, H; Hansmann, ML; Hofmann, WP; Lange, CM; Lehr, HA; Lötsch, J; Moench, C; Moradpour, D; Müllhaupt, B; Pascual, M; Sarrazin, C; Shi, Y; Zeuzem, S1
Burroughs, AK; Davidson, BR; Gurusamy, KS; Tsochatzis, E1
Barone, AA; Cotler, SJ; Dahari, H; de Araujo, ES; Layden, TJ; Melo, CE; Neumann, AU1
Browne, JA; Crowe, J; Devitt, EJ; Gallagher, WM; Gaora, PO; Lawless, MW; Power, KA1
Delgado-Borrego, A1
Borque, MJ; Chaparro, M; García-Buey, L; González-Moreno, L; Mendoza, J; Moreno Monteagudo, JA; Moreno-Otero, R; Trapero-Marugán, M1
Abd el-Meguid, M; Anany, MA; Bader el-Din, NG; Barakat, A; el-Awady, MK; el-Zayady, AR; Esmat, G; Helmy, A; Tabll, AA; Zayed, N1
Bucurică, S; Costache, R; Ioniţă-Radu, F; Nuţă, P; Stanciu, S1
Ferguson, MC1
Abdalla, MS; Abdalla, S; Anany, MA; Bader El Din, NG; El Akel, W; El Awady, MK; El Raziky, M; El Zayady, AR; Esmat, G; Helmy, A; Sharada, HM; Tabll, AA; Zayed, N1
Ahloulay, M; Albert, ML; Casrouge, A; Decalf, J; Fontanet, A; Lababidi, C; Mallet, V; Mansour, H; Mapes, J; Mottez, E; Pol, S; Vallet-Pichard, A1
Morgan, TR; O'Brien, TR1
Aleem, AA; El Hadad, H; Essawy, M; Fouad, YM; Gomaa, W; Ibrahim, M; Ibrahim, Y; Shatat, M1
Borro, P; Testino, G1
Burger, DM; Dofferhoff, TS; Drenth, JP; Huntjens-Fleuren, HW; Koopmans, PP; Richter, C; Slavenburg, S; Verwey-Van Wissen, CP1
Alberti, A; Bortoletto, G; Campagnolo, D; Comastri, G; Mirandola, S; Pulvirenti, FR; Severini, L1
Gonzalez, SA; Keeffe, EB1
Cirulli, ET; Fellay, J; Goldstein, DB; Gumbs, CE; Hitomi, Y; McHutchison, JG; Shianna, KV; Thompson, AJ; Urban, TJ1
Afendy, A; Baranova, A; Limongi, D; Liotta, L; Mehta, R; Petricoin, E; Pierobon, M; Stepanova, M; Younossi, ZM1
Barton, D; Dore, G; Kronborg, I; Sasadeusz, JJ; Weltman, M; Yoshihara, M1
Sanyal, AJ1
Asselah, T; Marcellin, P3
Al, KS; Derbala, M; John, A; John, AK; Singh, R1
Aqel, B; Bini, EJ; Boyd, W; DeComarmond, C; Dieperink, E; Falck-Ytter, Y; Ho, SB; Kulig, CC; Liu, S; McKee, DP; Pedrosa, MC; Smith, CI; Tetrick, L1
Kovacs, A; Operskalski, EA1
Blum, HE; Grimm, D; Thimme, R1
Abe, H; Aimitsu, S; Chayama, K; Hayashida, Y; Hayes, CN; Hiraga, N; Imamura, M; Kao, JH; Kawakami, Y; Kubo, M; Kumada, H; Maekawa, T; Nakamura, Y; Nakano, R; Ochi, H; Tsunoda, T1
Ikegami, T; Masuda, Y; Matsuda, K; Mita, A; Miwa, S; Miyagawa, S; Nakazawa, Y; Ohno, Y; Sano, K; Urata, K1
Abu-Mouch, S; Buggisch, P; Chen, R; Cornberg, M; Faruqi, R; Hinrichsen, H; Horban, A; Ilan, Y; Klinker, H; Lurie, Y; Manns, M; Mauss, S; Merican, I; Müller, TH; Pedicone, LD; Rössle, M; Sood, A; Wedemeyer, H; Welsch, C; Zeuzem, S1
Mangia, A2
Fourcade, L; Gil, JM; Heno, P; Kerebel, S; Paule, P; Roche, NC1
Clarke, C; Ferlic-Stark, L; Goodgame, R; Raghavan, R; Rungta, M1
Chayama, K; Hayes, CN; Hiasa, Y; Izumi, N; Kumada, H; Matsumoto, A; Moriwaki, H; Nomura, H; Okanoue, T; Oketani, M; Sakisaka, S; Seike, M; Takehara, T; Toyota, J; Ueno, Y; Yoshioka, K; Yotsuyanagi, H1
Akuta, N; Arase, Y; Chayama, K; Hirakawa, M; Hosaka, T; Ikeda, K; Kamatani, N; Kawamura, Y; Kobayashi, M; Kumada, H; Miyakawa, Y; Nakamura, Y; Saito, S; Sezaki, H; Suzuki, F; Suzuki, Y1
Khudyakov, Y; Lara, J; Purdy, M; Xia, G1
Chang, NC; Chang, WY; Chen, SC; Chuang, WL; Dai, CY; Hsieh, MY; Huang, CF; Huang, JF; Juo, SH; Li, YN; Lin, ZY; Wang, LY; Wu, MS; Yang, JF; Yu, ML1
Feld, JJ; Fried, MW; Hu, Z; Li, Q; Liang, TJ; Thomas, E1
Aerssens, J; Afdhal, NH; Bollekens, J; Darling, JM; De Wit, M; Fanning, G; Fried, MW; Goldstein, DB; Howell, CD; Hudson, ML; McHutchison, JG; Scholliers, A; Shianna, KV; Talloen, W; Thompson, AJ1
Afdhal, NH; Booth, DR; Goldstein, DB; Mangia, A; McHutchison, JG; Murray, JS; Pawlotsky, JM; Shianna, KV; Tanaka, Y; Thomas, DL; Zeuzem, S1
Alric, L; Barange, K; Barel, P; Castan, B; Chatelut, E; Combis, JM; Desmorat, H; Dramard, JM; Garipuy, D; Guerin, B; Imbert, Y; Izopet, J; Métivier, S; Meurisse, JJ; Morin, T; Nicot, F; Payen, JL; Peron, JM; Renou, C; Sauné, K; Sire, S; Thebault, S1
Hiramatsu, N; Iwasaki, M; Izumi, N; Kurosaki, M; Nakagawa, M; Sakamoto, M; Sakamoto, N; Sugauchi, F; Suzuki, Y; Tamori, A1
Jovanović, D; Kuljić-Kapulica, N; Nozić, D; Rajić, R; Ristanović, E; Savić, D1
Khoramnia, R; Lohmann, CP; Maier, MM; Salgado, JP; Winkler von Mohrenfels, C1
Chen, Y; Chen, Z; He, LL; Lei, BJ; Lei, XZ; Tang, H; Xu, H1
Fujise, K; Namiki, Y; Tada, N; Tsubota, A1
Borque, MJ; Chaparro, M; González-Moreno, L; Mendoza, J; Moreno-Monteagudo, JA; Moreno-Otero, R; Trapero-Marugán, M1
Jia, CH; Lan, L; Liu, BW; Yu, J; Yuan, Y; Zhang, H1
Malhotra, R; Morley, AM; O'Sullivan, E; Thaung, C1
Ahmed, A; Aziz, AA; El Gohary, I; Ghoraba, D; Hafez, T; Kamal, SM; Mahmoud, S; Metaoei, M; Nabegh, L; Obadan, I1
Jahan, S; Khaliq, S; Pervaiz, A1
Deng, L; El-Shamy, A; Hotta, H; Ide, YH; Imoto, S; Kim, SR; Sasase, N; Shoji, I1
Ciesek, S; Manns, MP1
Aoyagi, Y; Ikeda, H; Matsuda, Y; Morita, S; Nomoto, M; Ohkoshi, S; Takahashi, H; Takeuchi, M; Tanaka, Y; Yamagiwa, S; Yano, M1
De Vincentiis, L; Durante-Mangoni, E; Iossa, D; Pinto, D; Ragone, E; Utili, R1
Adeeb, U; Athar, MA; Aziz, H; Bilal, I; Gil, ML; Raza, A; Waheed, Y1
Abdo, AA; Almasio, PL; Cacoub, P; Colombo, M; Eslam, M; Esteban, R; Ferenci, P; Hadziyannis, SJ; Harrison, SA; Ibrahim, N; Khattab, MA; Lee, SS; Manns, MP1
Aghemo, A; Colombo, M; Vezali, E1
El-Serag, HB; Kanwal, F; Stepanova, M; Younossi, ZM1
Bob, F; Bozdog, G; Cioca, D; Curescu, M; Gadalean, F; Gluhovschi, C; Gluhovschi, G; Kaycsa, A; Petrica, L; Sporea, I; Velciov, S; Vernic, C1
Chen, DS; Chen, HC; Chen, PJ; Hsu, CS; Hsu, SJ; Jeng, J; Kao, JH; Lai, MY; Liu, CH; Liu, CJ; Niu, WF; Tseng, TC1
Almasio, PL; Calvaruso, V; Mazza, M1
Budimir, J; Čajić, V; Dušek, D; Kurelac, I; Papić, N; Vince, A; Židovec Lepej, S1
Choi, MS; Gwak, GY; Kil, JS; Kim, J; Koh, KC; Lee, JH; Paik, SW; Shin, SR; Sinn, DH; Yoo, BC1
Chen, SC; Chuang, WL; Dai, CY; Hsieh, MH; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Lin, ZY; Yang, JF; Yeh, ML; Yu, ML1
Batool, U; Burki, UF; Iqbal, M; Khan, NU; Qureshi, S1
Duarte-Rojo, A; Feld, JJ; Heathcote, EJ1
Cacoub, P; Carrat, F; Geri, G; Halfon, P; Piroth, L; Pol, S; Poynard, T; Souberbielle, JC; Terrier, B1
Abbacchi, A; Adewuyi, SA; Debold, C; Hong, BA; Lisker-Melman, M; North, CS; Pollio, DE1
Carmo, RA; Moura, AS; Rocha, MO; Teixeira, AL; Teixeira, MM1
Jordá, E; López, V; Molina, I; Monteagudo, C1
Goksugur, N; Karabay, O; Ogutlu, A1
Berg, T; Doehring, A; Geisslinger, G; Herrmann, E; Hofmann, WP; Lötsch, J; Müller, T; Sarrazin, C; Schlecker, C; Zeuzem, S1
Chang, SW; Chen, JY; Kuo, SN; Lin, CY; Lin, YT; Sheen, IS; Shiu, CF; Wang, CM; Wu, J1
Grotzinger, K; Poordad, F; Sullivan, J; Theodore, D1
Chang, L; Gane, EJ; Horban, A; Nájera, I; Rouzier, R; Sampeur, P; Shulman, NS; Smith, P; Stedman, C; Tran, JQ; Wiercinska-Drapalo, A; Zhang, Y1
Canva, V; Castel, H; Corouge, M; Deltenre, P; Dharancy, S; Henrion, J; Lazrek, M; Louvet, A; Mathurin, P; Moreno, C; Wartel, F1
Bibert, S; Bochud, PY; Ferrari, C; Haagmans, B; Hellstrand, K; Lagging, M; Missale, G; Negro, F; Neumann, AU; Pawlotsky, JM; Schalm, S; Soulier, A; Zeuzem, S1
Alagbe, O; Felger, JC; Hu, F; Miller, AH; Pace, TW; Raison, CL; Woolwine, BJ1
Azuma, S; Hiasa, Y; Hige, S; Itoh, Y; Itsui, Y; Izumi, N; Kakinuma, S; Kurosaki, M; Mizokami, M; Nakagawa, M; Nishida, N; Sakamoto, N; Sekine-Osajima, Y; Tamori, A; Tanaka, E; Tanaka, Y; Tokunaga, K; Ueyama, M; Watanabe, M; Yuki, NS1
Diago, M; Urquijo, JJ1
Casas Rodrigo, M; Cebollero Agustí, A; Dalmau Obrador, B; Gallach Montero, M; Gavarró Puig, A; Gil Prades, M; Miquel Planas, M; Puig Del Castillo, I; Sánchez Delgado, J; Tomás Tutusaus, R; Vergara Gómez, M1
Blacklaws, H; Gardner, A; Usher, K1
Chong, VH1
Bjøro, K; Dalgard, O; Melum, E; Moghaddam, A; Reinton, N; Ring-Larsen, H; Verbaan, H1
Curto, TM; Everhart, JE; Freedman, ND; Lindsay, KL; Sinha, R; Wright, EC1
Domínguez López, A; Martínez, RA; Sánchez-Ávila, JF; Sánchez-Muñoz, F; Sixtos-Alonso, MS; Uribe, M; Vargas Vorácková, F1
Biesiada, G; Dumnicka, P; Kuśnierz-Cabala, B; Mach, T; Solnica, B1
Adachi, H; Aoki, Y; Higami, K; Hige, S; Hino, K; Imamura, M; Ito, K; Kani, S; Masaki, N; Mizokami, M; Mukaide, M; Murata, K; Nomura, H; Orito, E; Saito, H; Sato, Y; Sugiyama, M; Tanaka, Y; Yatsuhashi, H1
Furusyo, N; Hayashi, J; Hayashi, T; Ihara, T; Ikezaki, H; Kainuma, M; Koga, T; Murata, M; Ogawa, E; Toyoda, K1
Beinhardt, S; Ferenci, P; Ferlitsch, A; Gangl, A; Hofer, H; Kundi, M; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rutter, K; Trauner, M1
Backus, LI; Belperio, P; Boothroyd, DB; Halloran, J; Mole, LA; Phillips, BR1
Ichijo, T; Joshita, S; Kamijo, A; Katsuyama, Y; Komatsu, M; Matsumoto, A; Ota, M; Tanaka, E; Umemura, T; Yoneda, S; Yoshizawa, K1
Cacoub, P; Resche-Rigon, M; Saadoun, D; Semoun, O; Sène, D; Terrier, B1
Abdurakhmanov, DT; Baĭzhanova, ZhZh; Ignatova, TM; Nekrasova, TP1
Fleischer, M; Fleischer-Stepniewska, K; Gladysz, A; Inglot, M; Staszek-Zurowska, B; Szymczak, A1
Adler, M; D'Heygere, F; Decaestecker, J; Delwaide, J; George, C; Laureys, A; Nakad, A; Nevens, F; Van Vlierberghe, H1
Barcelo de Brito, S; Campos-de-Magalhães, M; Cecília da Fonseca Salgado, M; Eduardo Brandão-Mello, C; José de Almeida, A; Lúcia Elias Pires, M1
Furman, PA; Lam, AM; Murakami, E1
Fujiwara, K; Yasui, S; Yokosuka, O1
Alric, L; Babany, G; Bouvier-Alias, M; Bronowicki, JP; Charaf-Eddine, M; Chevaliez, S; Costes, B; Couzigou, P; Foucher, J; Hézode, C; Leroy, V; Mallat, A; Mathurin, P; Pawlotsky, JM; Rosa, I; Rouanet, S; Soulier, A; Tran, A1
van Erpecum, KJ; van Oijen, MG; van Vlerken, LG1
Askarieh, G; Bibert, S; Bochud, PY; Bruno, R; Clément, S; Covolo, L; Donato, F; Fattovich, G; Gaeta, GB; Guido, M; Lagging, M; Malerba, G; Negro, F; Pasino, M; Puoti, M; Raimondo, G; Santantonio, T1
Baleriola, C; Chaverot, S; Cheng, W; Crawford, D; Dore, GJ; Dubois, D; McCaughan, G; Rawlinson, WD; Rizkalla, B; Roberts, S; Sievert, W; Stelzer-Braid, S; Thommes, J; Weltman, M; Yoshihara, M1
Costas, P; Iturrino, J; Ortiz, A; Romero, CJ; Sánchez, CJ; Torres, EA; Velázquez, V1
Albrecht, JK; Bacon, BR; Boparai, N; Brass, CA; Bronowicki, JP; Bruno, S; DiNubile, MJ; Goodman, ZD; Jacobson, IM; Manns, MP; McCone, J; Poordad, F; Reddy, KR; Sniukiene, V; Sulkowski, MS1
Albrecht, JK; Bacon, BR; Boparai, N; Brass, CA; Burroughs, M; Esteban, R; Goodman, ZD; Gordon, SC; Lawitz, E; Marcellin, P; Poordad, F; Sings, HL; Vierling, JM; Zeuzem, S1
Jensen, DM1
Boonstra, A; Claassen, MA; de Knegt, RJ; Janssen, HL1
Arama, V; Gliga, S; Popescu, C1
Honda, M; Kaneko, S; Lemon, SM; Mizukoshi, E; Muramatsu, T; Nakamoto, Y; Nakamura, M; Nishitani, S; Sakai, A; Sakai, Y; Shimakami, T; Shirasaki, T; Suzuki, T; Tagata, Y; Takehana, K; Wakita, T; Yamashita, T; Yi, M1
Kowala-Piaskowska, A; Michalak, TI; Mozer-Lisewska, I; Pham, TN1
Cielecka-Kuszyk, J; Godzik, P; Komorowski, M; Madaliński, K1
Baxter, L; Hartwell, D; Jones, J; Shepherd, J2
Chang, SW; Chen, JY; Huang, CH; Huang, CW; Jeng, WJ; Lin, CY; Lin, TN; Sheen, IS1
Bonkovsky, HL; Di Bisceglie, AM; Dienstag, JL; Fontana, RJ; Ghany, MG; Lee, WM; Morgan, TR; Morishima, C; Seeff, LB; Shiffman, ML; Snow, KK; Stoddard, AM; Wright, EC1
Bitetto, D; Ceriani, E; Cmet, S; Cussigh, A; Fabris, C; Falleti, E; Fattovich, G; Fornasiere, E; Ieluzzi, D; Pasino, M; Pirisi, M; Toniutto, P2
Cheng, W; Crawford, DH; Depamphilis, JK; Dore, GJ; McCaughan, GW; Rawlinson, W; Rizkalla, B; Roberts, SK; Sievert, W; Weltman, M; Yoshihara, M1
Janssen, HL; Pan, Q; Tilanus, HW; van der Laan, LJ1
Buggisch, P; Hoepner, L; Lohse, AW; Lüth, S; Pudelski, N; Schulze Zur Wiesch, J; Supplieth, M1
Chen, JJ; Gao, YQ; Nie, HM1
Jang, JY; Jeong, SW; Kim, HS; Kim, SG; Kim, YS; Lee, SH; Lee, YN; Lim, JH; Park, TK1
Afif, N; de Vernejoul, MC; Javier, RM; Kuntz, JL; Sibilia, J1
Husa, P; Ivanovski, L; Messinger, D; Oltman, M; Rehák, V; Tietz, A; Urbanek, P2
Abe, H; Chayama, K; Hashimoto, Y; Hayashida, Y; Hiraga, N; Imamura, M; Kamatani, N; Kubo, M; Mitsui, F; Nakamura, Y; Nelson Hayes, C; Ochi, H; Ohishi, W; Takahashi, S; Tsuge, M; Tsunoda, T1
Akuta, N; Arase, Y; Hirakawa, M; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y1
Abe, H; Akuta, N; Azakami, T; Chayama, K; Hayes, CN; Imamura, M; Kamatani, N; Kawakami, Y; Kobayashi, M; Kumada, H; Miki, D; Nakamura, Y; Ochi, H; Sezaki, H; Suzuki, F; Takahashi, S; Tsuge, M1
Benito, JM; Goldstein, D; McHutchison, J; Naggie, S; Rallón, NI; Restrepo, C; Soriano, V; Vispo, E1
Bae, SH; Choi, JY; Jeong, SW; Kim, JD; Kwon, JH; Lee, JE; Song, MJ; Yoon, NR; Yoon, SK1
Furusyo, N; Hayashi, J; Hayashi, T; Ihara, T; Ikezaki, H; Kainuma, M; Murata, M; Ogawa, E; Taniai, H; Toyoda, K1
Fakharzadeh, E; Jabbari, H; Merat, S; Sharifi, AH; Zamini, H1
Abiru, S; Hashimoto, S; Ishibashi, H; Izumi, Y; Komori, A; Migita, K; Miyashita, T; Yasunaga, Y; Yatsuhashi, H1
Garcia, GF; Garib, JR; Silva, Fd; Teixeira, R1
Barreiro, P; Benito, JM; Camacho, A; Caruz, A; Labarga, P; Mira, JA; Neukam, K; Pineda, JA; Pinilla, J; Rallón, N; Rivero, A; Rodriguez-Novoa, S; Soriano, V; Vispo, E1
Fukui, H; Hagiwara, H; Hayashi, E; Hayashi, N; Hijioka, T; Hiramatsu, N; Hosui, A; Imai, Y; Inoue, A; Inui, Y; Ishida, H; Ito, T; Kanto, T; Kasahara, A; Katayama, K; Kato, M; Kiso, S; Mita, E; Miyagi, T; Mochizuki, K; Oshita, M; Oze, T; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yoshida, Y; Yoshihara, H1
Lai, CL; Liu, K; Seto, WK; Tanaka, Y; Yuen, MF1
Dicpinigaitis, PV; Weiner, FR1
Abdullah, NA; Amr, KS; El-Batae, HE; Elhosary, YA; Ezzat, WM; Raslan, HM1
Chang, CS; Lin, HY; Tsai, CY; Yan, SL; Yu, FL1
Bergsma, TT; Chen, C; Corey, AE; Devalaraja, M; Gastonguay, MR; Riggs, MM; Rogers, JA; Stein, DS; Subramanian, GM; Sun, H; Yu, J1
Hagiwara, H; Hayashi, E; Hayashi, N; Hijioka, T; Hiramatsu, N; Hosui, A; Imai, Y; Imanaka, K; Inui, Y; Ishida, H; Ito, T; Kaneko, A; Kanto, T; Kasahara, A; Kato, M; Kiso, S; Mita, E; Miyagi, T; Mochizuki, K; Nagase, T; Oshita, M; Oze, T; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yamada, A; Yoshida, Y; Yoshihara, H1
Akbar, H; Awan, Z; Butt, S; Hussain, A; Idrees, M; Rehaman, Iu; Sabar, MF; Saleem, S1
Carvalho-Filho, RJ; Carvente, CT; El Batah, PN; Ferraz, ML; Narciso-Schiavon, JL; Sampaio, JP; Schiavon, LL; Silva, AE; Silva, GA1
Akaike, J; Arakawa, T; Chayama, K; Kamiya, N; Karino, Y; Kumada, H; Kuwata, Y; Ohmura, T; Ozeki, I; Sato, T; Toyota, J; Yamada, I1
Isakov, VA; Morozov, SV; Selivestrova, TR; Trufanova, IuM1
Risum, M1
Hunyady, B1
Chiang, BL; Kao, JH; Liang, CC; Lin, YL; Liu, CH; Liu, CJ1
Kawaguchi, T; Kumada, T; Matsuda, F; Murakami, Y; Tada, T; Toyoda, H1
Ackerman, Z; Ben-Dov, IZ; Pappo, O1
Del Santo, F; Maratea, D; Messori, A1
González, S; Velasco, J1
Afzal, S; Akram, M; Ali, M; Butt, A; Butt, S; Hussain, A; Idrees, M; Liaqat, A; Rehman, IU; Saleem, S; Zafar, S1
Abbasi, A; Bhutto, AR; Butt, N; Munir, SM1
Ahmed, AS; Fathy, A; Hassan, A; Metwally, L1
Antinori, S; Bestetti, G; Foschi, A; Galli, M; Longhi, E; Mazzali, C; Milazzo, L; Parravicini, C; Vago, T; Viola, A1
Arai, H; Hirokawa, T; Horiuchi, K; Kakizaki, S; Mori, M; Naganuma, A; Ohyama, T; Sato, K; Shimada, Y; Tahara, H; Takagi, H; Tojima, H1
Fujita, T; Kawaguchi, T; Kumada, T; Kuroda, M; Matsuda, F; Morimoto, S; Murakami, Y; Onomoto, K; Shimotohno, K; Tanaka, M; Toyoda, H; Uno, K1
Arai, M; Azemoto, R; Fujiwara, K; Fukai, K; Imazeki, F; Kanda, T; Kato, K; Kita, K; Koma, Y; Mikami, S; Nakamoto, S; Sunaga, M; Suzuki, N; Takashi, M; Tawada, A; Wu, S; Yokosuka, O; Yonemitsu, Y; Yoshida, Y1
Cao, H; Hong, XL; Li, G; Pan, XF; Xu, QH; Zhang, K; Zhao, F; Zhao, ZX1
Aftab, M; Afzal, S; Akram, M; Badar, S; Hussain, A; Idrees, M; Ilyas, M; Khubaib, B; Zafar, S1
Błońska-Fajfrowska, B; Hartman, M; Klimacka-Nawrot, E; Lichtański, P; Musialik, J; Petelenz, M; Suchecka, W1
Masarone, M; Persico, M1
Ali, I; Attaullah, S; Idrees, M; Iqbal, A; Khan, J; Khan, S; Khan, SN; Siraj, S; Swati, ZA1
Ji, HF1
Escolano, C; Gutiérrez, F; López, N; Masiá, M; Robledano, C1
Eun, HS; Goh, PG; Kim, ES; Kim, HJ; Kim, MJ; Kim, SH; Kim, YJ; Lee, BS; Lee, ES; Lee, HY; Lee, SY; Moon, HS1
Aparcero, R; Del Campo, JA; Eslam, M; Kawaguchi, T; Khattab, MA; Romero-Gomez, M; Sata, M1
Al-Ahdal, MN; Al-Qahtani, AA; Rubino, S1
Castellano Tortajada, G; Castellanos González, M; Muñoz Gómez, R; Pérez Carreras, M1
Anand, BS; Jampana, SC; Singal, AK1
Dougherty, KA; Fried, MW; McGowan, CE1
Horiguchi, N; Kakizaki, S; Mori, M; Namikawa, M; Sato, K; Takagi, H; Yamazaki, Y; Yata, Y1
Hara, K; Ohira, A; Tanito, M1
Antoniazzi, S; Baldo, V; Baldovin, T; Cazzagon, N; Egoue, J; Floreani, A; Furlan, P; Minola, E1
Enomoto, N; Hiasa, Y; Hige, S; Hino, K; Honda, M; Itoh, Y; Izumi, N; Kaneko, S; Koike, A; Kurosaki, M; Matsuura, K; Mizokami, M; Mochida, S; Nishida, N; Nishiguchi, S; Sakamoto, N; Sugauchi, F; Sugiyama, M; Tanaka, E; Tanaka, Y; Tokunaga, K; Yatsuhashi, H1
Carazo, A; Casado, J; de Rueda, PM; Diago, M; Gila, A; León, J; López-Nevot, MÁ; Martín-Casares, A; Moreno-Otero, R; Muñoz, JA; Palomares, P; Pavón, EJ; Quiles, R; Romero-Gómez, M; Ruiz-Extremera, A; Sáenz-López, P; Salmerón, J; Sanz-Cameno, P1
Buti, M; Cervoni, JP; Di Martino, V; Ferenci, P; Jensen, DM; Mangia, A; Richou, C; Sanchez-Tapias, JM; Sheppard, F; Thévenot, T1
Jabbari, H; Malboobi, MA; Merat, S; Mousavi-Fard, SH; Sabahi, F; Shahzamani, K; Sharifi, H; Yahoo, N1
Hiramatsu, N; Iwasaki, M; Izumi, N; Kakinnuma, S; Kurosaki, M; Matsuura, K; Sakamoto, M; Sakamoto, N; Sugauchi, F; Suzuki, Y; Tamori, A1
Canva, V; Castel, H; Colin, M; Deltenre, P; Dharancy, S; Glowacki, F; Hazzan, M; Henrion, J; Lazrek, M; Louvet, A; Mathurin, P; Moreno, C; Noel, C; Ollivier, I; Provôt, F; Stanke, F; Tran, A1
Arpurt, JP; Boulay, G; Boutet, O; Daures, JP; Hyrailles-Blanc, V; Karlova, N; Larrey, D; Niang, B; Pageaux, GP; Ribard, D; Salse, A; Vaucher, E1
Fischer, K; Fransen van de Putte, DE; Mauser-Bunschoten, EP; Posthouwer, D1
Ianna, EA; Jones, TL; Reeves, GE; Tran, HA1
Brown, A; Foster, GR; Freshwater, D; Marley, R; Moreea, S; Mutimer, D; Rowe, IA; Sabin, CA; Shoeb, D; Sood, R1
Benicky, M; Benova, B; Gombosova, L; Jarcuska, P; Lazurova, I1
Arnholm, B; Eilard, A; Hellstrand, K; Lagging, M; Lindh, M; Nilsson, S; Norkrans, G; Söderholm, J; Wahlberg, T; Wejstål, R; Westin, J1
Berg, T; Möller, B; Möller, JF; Schott, E; Wiedenmann, B1
Cabibi, D; Cammà, C; Craxì, A; Di Marco, V; Di Stefano, R; Marchesini, G; Petta, S1
Crouzet, J; Di Martino, V; Hillon, P; Minello, A; Monnet, E; Thévenot, T1
Bukh, J; Christensen, PB; Hansen, N; Kjær, M; Krarup, HB; Laursen, AL; Møller, A; Obel, N; Schlichting, P; Weis, N1
Bozzano, F; Costa, P; De Maria, A; Fazio, V; Hirsch, I; Marras, F; Moretta, L; Olive, D; Picciotto, A1
Andreone, P; Beumont, M; Boogaerts, G; De Meyer, S; Diago, M; Ferenci, P; Focaccia, R; Foster, GR; Horban, A; Lawitz, E; Luo, D; Müllhaupt, B; Nevens, F; Picchio, G; Pockros, P; Pol, S; Polo, R; Roberts, S; Shouval, D; Terg, R; Van Heeswijk, R; van Hoek, B; Weiland, O; Younossi, Z; Zeuzem, S1
Rosen, HR1
Beumont, M; Bronowicki, JP; Carosi, G; Foster, GR; Hézode, C; Picchio, G; van Baelen, B; van Heeswijk, R; Verlinden, L; Weiland, O1
Dienstag, JL; Goodman, ZD; Hoefs, JC; Kleiner, DE; Shiffman, ML; Stoddard, AM1
Chen, KC; Chen, SC; Chuang, WL; Dai, CY; Hsieh, MY; Huang, CF; Huang, JF; Juo, SH; Kuo, HT; Lin, ZY; Wang, LY; Yang, JF; Yu, ML1
Afdhal, NH; Albrecht, JK; Brass, CA; Clark, PJ; Esteban, R; Fellay, J; Galler, GW; Ge, D; Goldstein, DB; Jacobson, IM; King, JW; Kwo, PY; Lawitz, EJ; McCone, J; McHutchison, JG; Muir, AJ; Naggie, S; Noviello, S; Patel, K; Pedicone, LD; Poordad, F; Shianna, KV; Shiffman, ML; Singh, A; Sulkowski, MS; Thompson, AJ; Tillmann, HL; Urban, TJ; Zhu, M; Zhu, Q1
Deltenre, P; Fartoux, L; Henrion, J; Lemoine, M; Louvet, A; Mathurin, P; Moreno, C; Mourad, A; Serfaty, L1
Chawla, YK; Das, A; Dhiman, RK; Duseja, A; Ghosh, S; Sharma, BK; Taneja, S; Tohra, SK1
Abdel-Aziz, DH; El-Gazayerly, ON; El-Sayed, MH; Sabry, NA1
Beam, C; Bonafede, M; Chakravarti, P; Pan, K; Solomon, M; Spiegel, B; Wilson, K1
Masuzaki, R; Schuppan, D; Shimada, M; Yoshida, S1
Chainuvati, S; Charatcharoenwitthaya, P; Kachintorn, U; Leelakusolvong, S; Limwongse, C; Manatsathit, S; Nimanong, S; Pausawasdi, N; Pithukpakorn, M; Pongprasobchai, S; Prachayakul, V; Tanwandee, T; Udompunturak, S; Vipatakul, N1
Agúndez, JA; Carballo, M; Devesa, MJ; Díaz-Rubio, M; Fernández, C; Ladero, JM; Martin, EG; Martínez, C; Suárez, A1
Alcaide, N; Aller, R; Almansa, R; Bermejo-Martín, JF; Caro-Patón, A; de la Fuente, C; González, JM; Jiménez-Sousa, MÁ; Largo, P; Ortiz de Lejarazu, R; Ruiz, L; Sánchez-Antolín, G1
Bonardi, R; Ciancio, A; Manca, A; Pellicano, R; Rizzetto, M; Tabone, M1
Imazeki, F; Kanda, T; Nakamoto, S; Wu, S; Yokosuka, O1
Pazgan-Simon, M; Simon, K1
Izumi, N; Kurosaki, M2
Goto, H; Hayashi, K; Honda, T; Katano, Y; Kawaguchi, T; Kumada, T; Matsuda, F; Murakami, Y; Toyoda, H1
Abe, H; Chayama, K; Hayes, CN; Hiraga, N; Imamura, M; Kamatani, N; Kubo, M; Miki, D; Nakamura, Y; Ochi, H; Takahashi, S; Tsuge, M1
Athar, MA; Aziz, H; Bilal, I; Irfan, J; Murtaza, S; Raza, A; Waheed, Y1
Dillon, JF; El Wahed, Z; Jafferbhoy, H; Miller, MH1
Chen, CH; Chuang, TW; Hu, TH; Hung, CH; Kuo, YH; Lee, CM; Lu, SN; Wang, JH1
Asselah, T; Chevaliez, S1
Burgess, C; Coppel, E; Corey, L; Goldstein, D; Holte, S; McHutchison, J; Scott, J; Urban, T; Wang, C1
Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsiao, PJ; Huang, CF; Huang, CI; Huang, JF; Lin, ZY; Shin, SJ; Yang, JF; Yeh, ML; Yu, ML1
Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Itoh, A; Katano, Y; Kumada, T; Nakano, I; Toyoda, H; Yoshioka, K1
Da Silva, A; de Juan, J; del Pozo, E; Faraco, I; Marco, A; Saiz de la Hoya, P; Veiras, FM; Yllobre, C1
Cabrera, R; Draganov, PV; Limaye, AR1
Kandel, C; Kandel, G1
Bouvier-Alias, M; Castéra, L; Hézode, C; Leroy, V; Mallat, A; Pawlotsky, JM; Rosa, I; Roudot-Thoraval, F; Roulot, D1
Aghemo, A; Colombo, M; D'Ambrosio, R; De Nicola, S; Degasperi, E; Donato, MF; Prati, GM; Rumi, MG1
Brissot, P; Danielou, H; Deugnier, Y; Guillygomarc'h, A; Guyader, D; Lainé, F; Le Dréau, G; Le Lan, C; Moirand, R; Védeilhié, C1
El-Serag, HB; Kanwal, F; Kramer, JR; Mei, M; Richardson, P1
Chakravarti, A; Chawla, YK; Dogra, G; Kar, P1
Elewa, U; Fervenza, FC; Poterucha, JJ; Sandri, AM1
Bonkovsky, HL; Chung, RT; Dotrang, M; Everhart, JE; Lok, AS; Morgan, TR; O'Brien, TR; Pfeiffer, RM; Shao, Y; Shiffman, ML; Sninsky, JJ1
Aguilera, V; Berenguer, M; Giusto, M; López-Andujar, R; Navarro, L; Ortiz, C; Prieto, M; Rodriguez, M; Rubin, A; San-Juan, F1
Corouge, M; Pol, S1
Schiff, ER1
Burgueño-Montañés, C; Pérez-Álvarez, R1
Berg, T; Boecher, WO; Buggisch, P; Dikopoulos, N; Encke, J; Goeser, T; Herrmann, E; Klinker, H; Möller, B; Prinzing, R; Sarrazin, C; Schulte-Frohlinde, E; Schwendy, S; Teuber, G; Thimme, R; Zeuzem, S1
Jacobson, IM; Olson, M1
Arai, M; Fujiwara, K; Imazeki, F; Kanda, T; Maruoka, D; Yokosuka, O1
Kang, P; Sun, LJ; Yan, BZ; Yu, JW; Zhao, YH5
Zhang, YH1
Bagree, A; Tavakoli-Tabasi, S1
Aghemo, A; Colombo, M; D'Ambrosio, R; de Franchis, R; De Nicola, S; Dell'Era, A; Donato, MF; Lampertico, P; Prati, GM; Primignani, M; Rumi, MG1
Asahina, Y; Enomoto, N; Hoshioka, Y; Hosokawa, T; Itakura, J; Izumi, N; Kato, T; Kurosaki, M; Kuzuya, T; Matsuura, K; Mizokami, M; Nakanishi, H; Nishida, N; Sugauchi, F; Suzuki, Y; Takahashi, Y; Tamaki, N; Tanaka, K; Tanaka, Y; Tokunaga, K; Tsuchiya, K; Ueda, K; Yasui, Y1
Chung, TL; Herrmann, E; Hofmann, WP; Karey, U; Lötsch, J; Mihm, U; Osbahr, C; Sarrazin, C; Susser, S; Welsch, C; Zeuzem, S1
de Knegt, RJ; Heijens, A; Janssen, HL; Roomer, R; Schutten, M; van Vuuren, AJ1
Dickensheets, H; Donnelly, RP; O'Brien, TR1
Arai, M; Fujiwara, K; Fukai, K; Imazeki, F; Kanda, T; Kato, K; Kimura, M; Mikami, S; Miyauchi, T; Nishino, T; Shimada, N; Sugiura, N; Takada, N; Takashi, M; Tsubota, A; Yokosuka, O; Yonemitsu, Y1
Chayama, K; Hayashi, N; Kumada, H; Okanoue, T; Toyota, J; Tsubouchi, H2
Belliveau, PP; Foote, BS; Spooner, LM1
Brass, C; Brown, RS; Freilich, B; Hu, KQ; Jacobson, IM1
Aalaei-Andabili, SH; Alavian, SM1
Moreno, V; Valencia, ME1
Hagiwara, H; Hayashi, N; Hiramatsu, N; Imai, Y; Inoue, Y; Inui, Y; Kanto, T; Kasahara, A; Katayama, K; Kiso, S; Kurashige, N; Mita, E; Miyagi, T; Mochizuki, K; Oshita, M; Oze, T; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yoshihara, H1
Gutierrez-Reyes, G; Hevezi, PA; Kershenobich, D; Lambert, P; Tom, E; Wilson, K; Zlotnik, A1
Back, D; Dieterich, D; Peters, M; Rockstroh, J; Sherman, KE; Soriano, V; Sulkowski, M1
Ilyas, JA; Vierling, JM1
Atsukawa, M; Harimoto, H; Kobayashi, T; Nakatsuka, K; Sakamoto, C; Shimizu, M; Takahashi, H; Tamura, H1
Carnauba, D; Damas, C; Diaz, RS; Dos Santos, CV; El-Far, F; Ferraz, ML; Reis, A; Santos, C; Serra, F; Silva, MH; Viana, MV1
Aberg, JA; Aboulafia, D; Bonilla, H; Dimova, R; Doonquah, L; Dove, L; Galpin, J; Glesby, MJ; Hassanein, T; Jacobson, IM; Johnston, B; Liu, RC; Pearce, D; Rodriguez, J; Talal, AH; Zeremski, M1
Adinolfi, LE; Lonardo, A; Loria, P; Restivo, L; Zampino, R1
Higuchi, K; Hirose, S; Honma, T; Ishikawa, T; Kamimura, T; Kubota, T; Seki, K; Suzuki, Y; Tasaki, K; Yoshida, T1
Carrieri, MP; Cohen, J; Salmon-Ceron, D; Winnock, M1
Chen, X; Dong, T; Guo, D; Jin, Y; Ma, L; Wei, L; Wu, H; Yan, H; Zhang, Y; Zhao, Y1
Ikeda, N; Nishino, R; Unoura, M1
Asahina, Y; Enomoto, N; Hoshioka, Y; Hosokawa, T; Itakura, J; Izumi, N; Katoh, T; Kurosaki, M; Muraoka, M; Nakanishi, H; Nitta, S; Sakamoto, N; Suzuki, Y; Takahashi, Y; Tamaki, N; Tanaka, K; Tsuchiya, K; Ueda, K; Yasui, Y1
Ahlenstiel, G; Edlich, B; Feld, JJ; Liang, TJ; Noureddin, M; Rehermann, B; Rotman, Y; Serti, E; Stoltzfus, J; Zabaleta Azpiroz, A1
Foster, GR; Goldberg, DJ; Hickman, M; Hutchinson, SJ; Martin, NK; Miners, A; Vickerman, P1
Goldenberg, D; Kurtz, S; Moisseiev, E1
Argiro, L; Botta, D; Bourliere, M; Castellani, P; Dessein, A; Halfon, P; Maor, Y; Oules, V; Ouzan, D; Pénaranda, G; Portal, I; Renou, C; Tran, A; Wartelle, C1
Balshaw, R; Cooper, C; Elkashab, M; Harris, P; Lalonde, R; Marrotta, PJ; Myers, RP; Sherman, M; Usaty, C; Witt-Sullivan, H1
Berg, T; Bergk, A; Buggisch, P; Chung, TL; Gerlach, T; Herrmann, E; Hinrichsen, H; Klinker, H; Sarrazin, C; Spengler, U; Weich, V; Zeuzem, S1
Alekseeva, LA; Bessonova, TV; Goriacheva, LG; Kotiv, MIa; Romantsov, MG; Vasil'eva, DK1
Berak, H; Cortés, KC; Fic, M; Horban, A; Ośko, I; Pawełczyk, A; Radkowski, M1
Antoniazzi, S; Baldo, V; Baldovin, T; Boemo, DG; Cazzagon, N; Egoue, J; Floreani, A; Minola, E1
Clark, PJ; Thompson, AJ1
Macías, J; Pineda, JA; Soriano, V; Vispo, E1
Kohli, A; Kottilil, S; Masur, H; Migueles, S; Naggie, S; Polis, MA; Shivakumar, B; Sidique, N; Subramanian, GM1
Bella, R; Bertino, G; Bruno, CM; Chisari, G; Gargante, MP; Lupo, L; Malaguarnera, M; Motta, M; Neri, S; Pennisi, G; Vacante, M1
Angus, P; Arasteh, K; Asselah, T; Boecher, WO; Bronowicki, JP; Gane, E; Haefner, C; Heim, M; Kukolj, G; Larrey, D; Lohse, A; Müllhaupt, B; Nehmiz, G; Pol, S; Roberts, S; Schuchmann, M; Stern, JO; Zarski, JP; Zeuzem, S; Zoulim, F1
Desenclos, JC; Deuffic-Burban, S; Dhumeaux, D; Larsen, C; Mathurin, P; Pol, S; Roudot-Thoraval, F; Yazdanpanah, Y1
Abate, ML; Ahlenstiel, G; Armstrong, NJ; Bassendine, M; Berg, T; Bochud, PY; Booth, DR; Dore, GJ; Dunn, D; Gaudieri, S; George, J; Hammond, E; Hellard, M; Irving, WL; Mallal, S; Matthews, G; Müller, T; Nattermann, J; Negro, F; O'Connor, KS; Powell, E; Riordan, S; Sheridan, D; Smedile, A; Spengler, U; Stewart, GJ; Suppiah, V; Weltman, M1
Aghemo, A; Cheroni, C; Colombo, M; D'Ambrosio, R; De Francesco, R; De Nicola, S; Donato, MF; Galmozzi, E; Prati, GM; Rumi, MG; Soffredini, R; Valenti, L1
Kalpaka, A; Klonizakis, P; Paschos, P; Pasvanti, C; Perifanis, V; Sinakos, E; Vlachaki, E1
Flisiak, R; Lapiński, TW; Parfieniuk-Kowerda, A; Rogalska-Płońska, M1
Almeida, JR; França, AV; Júnior, LJ; Nogueira, JB; Quintans, Jde S; Sena, LC1
Hagiwara, H; Hayashi, N; Higashitani, K; Hiramatsu, N; Iio, S; Inoue, M; Kakita, N; Kanto, T; Kasahara, A; Katayama, K; Matsubara, T; Mita, E; Miyazaki, M; Oze, T; Sakakibara, M; Takehara, T1
Chawla, YK; Dhiman, RK; Duseja, A; Ghosh, S1
Asselah, T; Bedossa, P; Bièche, I; Blanluet, M; Boyer, N; Broët, P; De Muynck, S; El Ray, A; Estrabaud, E; Lada, O; Lapalus, M; Marcellin, P; Martinot-Peignoux, M; Masliah-Planchon, J; Ripault, MP; Valla, D; Vidaud, D; Vidaud, M; Zhang, Q1
Bota, S; Danila, M; Neghina, AM; Popescu, A; Sirli, R; Sporea, I; Strain, M1
Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Imai, N; Kawamura, Y; Kobayashi, M; Kumada, H; Matsumoto, N; Saito, S; Seko, Y; Sezaki, H; Suzuki, F; Suzuki, Y1
Alvarez-Pellicer, J; Arponen, S; Barquilla, E; Bellón, JM; Berenguer, J; Crespo, M; De Miguel, J; Galindo, MJ; González-García, J; Guardiola, JM; López-Aldeguer, J; Mallolas, J; Miralles, P; Quereda, C; Tellez, MJ; von Wichmann, MA1
Almeida, C; Cifuentes, C; Claro, E; García-Rey, S; Gilabert, I; Macías, J; Merchante, N; Mira, JA; Neukam, K; Pineda, JA; Vázquez, MJ1
Mizokami, M; Sugiyama, M1
Arends, JE; Fransen, JH; Hoepelman, AI; van Baarle, D1
Feng, IC; Koay, LB; Kuo, HT; Lin, CY; Lin, YM; Sheu, MJ; Sun, CS1
Al-Enzi, SA; Alsurayei, SA; Ismail, E; Ismail, WA1
Jain, S; Midha, V; Sood, A1
Brahm, J; González, K; Venegas, M; Villanueva, RA1
Stiefelhagen, P1
Abad-Santos, F; Borque, MJ; Hernandez-Bartolome, A; Lopez-Rodriguez, R; Martin-Vilchez, S; Moreno-Otero, R; Muñoz de Rueda, P; Rodrigo, L; Rodriguez-Muñoz, Y; Roman, M; Salmeron, J; Sanz-Cameno, P; Trapero-Marugan, M; Vidal-Castiñeira, JR1
Amanzada, A; Blaschke, M; Goralczyk, A; Mihm, S; Moriconi, F; Ramadori, G; Schaefer, IM; van Thiel, D1
Bezemer, G; de Knegt, RJ; Drenth, JP; Droogleever Fortuyn, HA; Hansen, BE; Hengeveld, MW; Janssen, HL; Van Gool, AR; Weegink, CJ1
Bonner, JE; Esserman, DA; Evon, DM; Fried, MW; Ramcharran, D1
Bhagani, S1
Chang, KC; Chen, CH; Hung, CH; Kee, KM; Lee, CM; Lin, CY; Lu, SN; Tseng, PL; Wang, JH; Yen, YH1
Aractingi, S; Bachmeyer, C; Gombeaud, T; Moguelet, P; Sbidian, E1
Datz, C; Dulic-Lakovic, E; Ferenci, P; Hofer, H; Laferl, H; Maieron, A; Scherzer, TM; Stättermayer, AF; Stauber, R; Steindl-Munda, P; Strasser, M1
Chammas, MC; Danilovic, DL; Marui, S; Mendes-Correa, MC; Zambrini, H1
Abe, K; Kumagai, I; Miyasaka, A; Suzuki, K1
Berg, T; Böhm, S; Buggisch, P; Gerlach, T; Hinrichsen, H; Klinker, H; Möller, B; Neumann, K; Rasenack, J; Sarrazin, C; Spengler, U; Teuber, G; Weich, V; Wiegand, J1
Abdallah, DM; Hashad, DI; Salem, PE1
Chen, CH; Hu, TH; Huang, CM; Hung, CH; Lee, CM; Lu, SN; Wang, JH1
Ichijo, T; Joshita, S; Katsuyama, Y; Matsumoto, A; Ota, M; Tanaka, E; Umemura, T; Yoneda, S; Yoshizawa, K1
Azuma, S; Funaoka, Y; Itsui, Y; Kakinuma, S; Kitazume, A; Kiyohashi, K; Murakawa, M; Nakagawa, M; Nishimura-Sakurai, Y; Nitta, S; Onozuka, I; Sakamoto, N; Sekine-Osajima, Y; Ueyama, M; Watanabe, M; Watanabe, T1
Hiramatsu, N; Iwasaki, M; Izumi, N; Kakinuma, S; Kurosaki, M; Matsuura, K; Nakagawa, M; Sakamoto, M; Sakamoto, N; Sugauchi, F; Suzuki, Y; Tamori, A1
Afdhal, NH; Alsop, D; Byrnes, V; Hill, E; Lenkinski, R; Lowry, D; Miller, A; Weinstein, C1
Afdhal, NH; Fried, M; Goldstein, DB; Gorden, A; Howell, CD; Ibrahim, C; McHutchison, JG; Mitchell, BD; Ryan, KA; Shianna, KV; Shuldiner, AR; Thompson, AJ1
Aguirrebengoa, K; Barreiro, P; Benito, JM; Castro, MÁ; Labarga, P; Miralles, C; Miralles, P; Morello, J; Ocampo, A; Pineda, JA; Portu, J; Rallón, NI; Rodríguez-Nóvoa, S; Soriano, V; Tellez, MJ; Vispo, E1
Curto, TM; Everson, GT; Hoefs, JC; Lauriski, S; Morgan, TR; Shiffman, ML; Sterling, RK; Stoddard, A; Wagner, DA; Wright, EC1
Bull, RA; Dore, GJ; Grebely, J; Hellard, M; Kaldor, J; Lloyd, A; Matthews, GV; Petoumenos, K; Pham, ST; Rawlinson, W; White, PA; Yeung, B1
Lok, AS; Sharma, P1
Hegarty, J; Iqbal, M; McCormick, PA; O'Farrelly, C; Ryan, EJ; Sarwar, S1
Gołabek, V; Kupś-Rzepecka, J; Woźniakowska-Gesicka, T1
Adda, N; Berg, T; Dusheiko, G; Ferenci, P; George, S; Heathcote, EJ; Kauffman, RS; Martin, EC; McHutchison, JG; Muir, AJ; Pawlotsky, JM; Poordad, FF; Reesink, HW; Shiffman, ML; Zeuzem, S1
Mizokami, M; Nakanishi, M; Sugiyama, M; Tanaka, Y; Wakita, T1
Balshaw, R; Elkashab, M; Greenbloom, S; Hilzenrat, N; Lee, SS; Myers, RP; Pluta, H; Ramji, A; Sherman, M; Usaty, C1
Brahm, J; Hola, K; Pizarro, C; Smok, G; Venegas, M1
Andoh, A; Aomatsu, T; Fujiyama, Y; Imaeda, H; Nishimura, T; Okumura, Y; Osaki, R; Shioya, M; Takeuchi, T1
Wang, JB; Xu, Y1
Lesesne, SB; Patel, N; Rein, DB; Roblin, DW; Smith, BD; Wagner, LD; Ward, JW; Weinbaum, CM; Wittenborn, JS1
Backus, LI; Cheung, R; Hwang, EW; Thomas, IC2
Hurter, P; Kauffman, RS; Kwong, AD; Mueller, P1
Ahmed, U; Anas, A; Attia, M; Beejay, N; El-Azab, G; Giguere, A; Hassan, MH; Khalowf, M; Khan, A; Nasser, T; Nouh, M; Saleh, A1
Delić, D; Jašović-Gašić, M; Marić, NP; Pavlović, Z; Vuković, O1
Emara, MH; Radwan, MI1
Ando, M; Hirohata, M; Imagawa, A; Miyake, Y; Miyatake, H; Nakatsu, M; Takahara, M; Yamamoto, K1
Boninsegna, S; Buda, A; Fabris, P; Fagiuoli, S; Lobello, S; Martines, D; Milan, M; Scribano, L1
Goto, H; Hayashi, K; Honda, T; Katano, Y; Kawaguchi, T; Kumada, T; Matsuda, F; Murakami, Y; Tada, T; Toyoda, H1
Bibert, S; Bochud, PY; Cerny, A; Dollenmaier, G; Dufour, JF; Gerlach, TJ; Heim, MH; Kutalik, Z; Lange, CM; Malinverni, R; Moradpour, D; Morikawa, K; Müllhaupt, B; Negro, F1
Arase, Y; Kumada, H1
Hayashi, N; Hiramatsu, N; Oze, T2
Arase, Y2
Hokari, A1
Ide, T1
Ikeda, F; Iwasaki, Y; Yamamoto, K2
Karino, Y; Ozeki, I; Toyota, J1
Hasegawa, K; Hirono, H; Shibasaki, K; Soga, K; Watanabe, T1
Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kotoh, K; Maruyama, T; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K; Tanabe, Y3
Chen, X; Dong, T; Liu, Y; Ma, L; Shi, L; Wei, L; Wu, H; Yan, H; Zhang, Y; Zhao, Y1
Abe-Sandes, K; Angelo, AL; Cavalcante, LN; Lemaire, DC; Lyra, AC; Lyra, LG; Machado, TM; Malta, F; Mendes, CM; Pinho, JR1
Angeletti, C; Antonucci, G; Ciccosanti, F; Corazzari, M; Daniele, N; Fimia, GM; Iacono, OL; Ippolito, G; Perdomo, AB; Piacentini, M; Pisa, R; Testa, A1
Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishizu, Y; Itoh, A; Katano, Y; Nakano, I1
Asselah, T; Bedossa, P; Laouénan, C; Lapalus, M; Marcellin, P; Martinot-Peignoux, M; Maylin, S; Nicolas-Chanoine, MH; Panhard, X1
Heo, J1
Choi, BJ; Choi, JS; Choi, SB; Jee, SR; Jung, EU; Kim, JH; Lee, JI; Lee, SH; Lee, YJ; Park, SJ; Seol, SY; Song, YJ1
Jeong, SH; Kim, BH; Kim, YJ; Kim, YS; Lee, CK; Lee, JW; Park, CK; Park, SH; Yim, HJ1
Chung, WJ; Hwang, JS; Jang, BK; Kim, KH; Kweon, YO; Lee, CH; Lee, HJ; Suh, JI; Tak, WY1
Bonkovsky, HL; Dienstag, JL; Fontana, RJ; Litman, HJ; Lok, AS; Sterling, RK; Su, G1
Andrade, R; Candel, JM; Carazo, A; Diago, M; Gila, A; León, J; Martín, AB; Muñoz-de-Rueda, P; Navarro, JM; Quiles, R; Quintero, D; Ruiz-Extremera, A; Salmerón, J1
Chiba, T; Eso, Y; Henmi, S; Kimura, T; Kita, R; Marusawa, H; Nakajima, J; Nishikawa, H; Osaki, Y; Saito, S; Sakamoto, A; Ueda, Y1
Doi, Y; Hagiwara, H; Hayashi, E; Hayashi, N; Hijioka, T; Hiramatsu, N; Hosui, A; Iio, S; Imai, Y; Inoue, A; Inui, Y; Ito, T; Kanto, T; Kasahara, A; Kato, M; Kiso, S; Mita, E; Miyagi, T; Miyazaki, M; Oshita, M; Oze, T; Song, C; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yoshida, Y; Yoshihara, H1
Bertino, G; Galvano, F; Giordano, M; Li Volti, G; Malaguarnera, M; Motta, M; Neri, S; Pennisi, M; Vacante, M1
Battyáni, Z; Hunyady, B; Kovács, B1
Alsiö, A; Buhl, MR; Färkkilä, M; Hellstrand, K; Jannesson, A; Lagging, M; Langeland, N; Mørch, K; Norkrans, G; Pedersen, C; Westin, J1
Fouad, YM; Helmy, AK; Ibraheem, H; Khalaf, H; Rady, H1
Aberle, J; Ferenci, P; Holzmann, H; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A1
Buti, M; Homs, M1
Baron, A; Brochot, E; Capron, D; Castelain, S; Coulouarn, C; Descamps, V; Duchaussoy, I; Duverlie, G; François, C; Nguyen-Khac, E1
Abe, H; Chayama, K; Hayashida, Y; Hayes, CN; Kamatani, N; Nakamura, Y; Ochi, H; Uchiyama, T1
Alexander, G; Amirthalingam, G; Andrews, N; Costella, A; Harris, HE; Ramsay, ME1
Aoyagi, Y; Enjoji, M; Fujino, T; Fukuda, M; Ishibashi, H; Kohjima, M; Nakamuta, M; Satoh, T; Yatsuhashi, H1
Boroń-Kaczmarska, A; Jurczyk, K; Karpińska, E; Laurans, L; Parczewski, M; Wawrzynowicz-Syczewska, M1
Botfield, M; de Bruijne, J; Kieffer, TL; Molenkamp, R; Reesink, H; Schinkel, J; Shames, B; Sullivan, JC; Weegink, C1
Aulakh, VS; Hoefs, JC; Ilagan, BJ1
Nehra, V; Rizza, SA; Talwani, R; Temesgen, Z1
Côrtes, R; Diaz, RS; Ferreira, PR; Reis, A; Santos, C; Silva, MH; Tenore, Sde B; Vilhena, C1
Kim, R; McEwan, P; Townsend, R; Yuan, Y1
Cole, SW; Doho, GH; Felger, JC; Hu, F; Miller, AH; Pace, TW; Raison, CL; Woolwine, BJ1
Xue, R1
Lei, H; Liu, J; Pu, D; Tao, J1
Ishibashi, S; Nagasaka, S; Okada, K; Okada, N; Osuga, J; Sato, S; Sugano, K; Yagyu, H; Yamashita, Y1
Ferenci, P; Reddy, KR1
Bergin, C; Hennessy, M; Hopkins, S; Kennedy, A; Mulcahy, F; Spiers, JP1
Di Martino, V; Kantelip, JP; Monnet, E; Montange, D; Muret, P; Piedoux, S; Piroth, L; Royer, B; Thevenot, T1
Beinhardt, S; Ferenci, P; Hofer, H; Kerschner, H; Popow-Kraupp, T; Rutter, K; Scherzer, TM; Stättermayer, AF; Steindl-Munda, P1
Altmeyer, R; Cheng, CW; Chopra, N; Lawitz, E; Lim, SG; McHutchison, JG; Patel, K; Randle, JC; Tillmann, HL1
Ando, K; Fujinami, A; Fukuda, K; Hasegawa, Y; Hayashi, Y; Hotta, H; Imoto, S; Kim, KI; Kim, SR; Komaki, T; Kudo, M; Maekawa, Y; Nagata, Y; Nakajima, T; Ohta, M; Ohtani, A; Otono, Y; Saito, J; Sugimoto, K1
El-Shamy, A; Fujinami, A; Hasegawa, Y; Hotta, H; Imoto, S; Kasugai, H; Kawada, T; Kim, KI; Kim, SR; Kimura, N; Komaki, T; Konishi, E; Kudo, M; Makino, T; Morikawa, T; Muramatsu, A; Nagata, Y; Nakajima, T; Nakamura, A; Ohta, M; Saito, J; Sakashita, M; Sasase, N; Sasatani, K; Sugano, M; Tanaka, Y; Tsuchida, S1
Lim, JK; Porto, AF; Tormey, L1
Cibor, D; Ciećko-Michalska, I; Cieśla, A; Janas-Skulina, U; Mach, TH; Owczarek, D; Warunek, W1
Benito, JM; Clark, PJ; Goldstein, DB; McHutchison, JG; Morello, J; Naggie, S; Rallon, NI; Rodriguez-Novoa, S; Shianna, KV; Soriano, V; Thompson, AJ; Vispo, E1
Jabłonowska, E; Kur, B; Lewkowicz, P; Nocuń, M; Wójcik, K1
Ebinuma, H; Hibi, T; Kanai, T; Ojiro, K; Saito, H; Tada, S; Takayama, T; Wakabayashi, K; Yamagishi, Y1
Golik, OO; Konstantinov, DIu; Popova, LL; Suzdal'tsev, AA; Vasil'ev, SIu1
Gemovic, B; Glisic, S; Jovanovic Cupic, S; Perovic, V; Prljic, J; Vasiljevic, N; Veljkovic, N; Veljkovic, V1
Goulis, I; Karatapanis, S; Ketikoglou, I; Lisgos, P; Papastergiou, V; Saitis, I; Skorda, L; Stampori, M; Tsitsopoulos, E; Tsoplou, P; Vasiageorgi, A1
Hidaka, H; Koizumi, W; Minamino, T; Nakazawa, T; Ogasawara, S; Okuwaki, Y; Shibuya, A; Takada, J; Takahashi, A; Tanaka, Y; Watanabe, M1
Febles, MH; Hernández, LO; López, MJ; Martínez, ER; Román, JL; Sánchez, CG; Suárez, JM; Vanegas, NO1
Fujiwara, K; Imazeki, F; Kanda, T; Miyamura, T; Nakamoto, S; Wu, S; Yokosuka, O1
Branch, AD; Gutierrez, JA; Parikh, N1
Angarano, G; Antonelli, G; Caporaso, N; Cozzolongo, R; Fasano, M; Gaeta, GB; Giannelli, G; Milella, M; Morisco, F; Santantonio, T; Scagnolari, C; Scotto, G; Soldà, A; Trombetti, S1
Alegre, SM; Fioravante, M; Lorena, SL; Marin, DM; Pereira, TS; Soares, EC1
Chuang, WL; Huang, CF; Yu, ML1
Andreone, P; Gitto, S; Karampatou, A; Villa, E1
Bihrer, V; Forestier, N; Kronenberger, B; Piiper, A; Waidmann, O; Zeuzem, S1
Calle Serrano, B; Cornberg, M; Manns, MP; Markova, AA1
Forestier, N; Zeuzem, S2
Kwo, PY3
Bacon, BR; Khalid, O1
Esteban, R; Shiffman, ML1
Lin, F; Reddy, KR; Zoulim, F1
Clark, V; Nelson, DR1
Adhoute, X; Benali, S; Bourlière, M; Castellani, P; Khaloun, A; Oules, V; Portal, I; Wartelle-Bladou, C1
Roche, B; Samuel, D2
Sulkowski, MS4
Mangia, A; Mottola, L1
Kumar, CK; Sarin, SK1
El Kassas, M; El Raziky, M; Esmat, G; Gamil, ME; Hassany, M2
Fried, MW; McGowan, CE1
Armstrong, MJ; Houlihan, DD; Rowe, IA1
Fujiwara, K; Funyu, J; Harada, Y; Koshima, Y; Matsui, A; Mochida, S; Nagoshi, S; Nakamura, I; Nishikawa, K; Saito, A; Sekine, C; Shiomi, M; Sotome, N; Takegoshi, S; Tanaka, M; Toshima, K; Yoshida, T1
Dorantes, B; Eslam, M; Gallego-Durán, R; García-Collado, C; Grande, L; Morillo, R; Paradas, C; Pardo-Yules, B; Romero-Gómez, M1
Antinori, S; Foschi, A; Galli, M; Mazzali, C; Milazzo, L; Ridolfo, A; Viola, A1
Abellán, JJ; Aguilera, V; Berenguer, M; López-Labrador, FX; Ortíz-Cantó, C; Prieto, M; Rubín, A1
Aghemo, A; Degasperi, E1
Buti, M; Esteban, R; Simón-Talero, M1
Bruno, R; Cima, S; Fagiuoli, S; Filice, G; Maiocchi, L; Novati, S; Sacchi, P1
Aghemo, A; Prati, GM; Rumi, M1
Andreone, P; Camerini, R; Ciancio, A; De Rosa, A; Kaiser, S; Mangia, A; McBeath, R; Milella, M; Pol, S; Rizzetto, M; Solà, R; Tsianos, E1
González-Escribano, MF; Jimenez-Jimenez, L; López-Cortés, LF; Marquez-Solero, M; Mata, R; Pineda, JA; Rivero, A; Ruiz-Valderas, R; Torres-Cornejo, A; Viciana, P1
De Gottardi, A; Geier, A; Gerlach, T; Heim, M; Helbling, B; Hirschi, C; Negro, F; Stickel, F; Terziroli, B; Wehr, K1
Alavian, SM; Behnava, B; Tabatabaei, SV1
Hamzeh, FM; Jensen, D; Lentz, E; Reau, N; Zhou, X1
Gerken, G; Katsounas, A; Kottilil, S; Lempicki, RA; Polis, M; Schlaak, JF; Trippler, M; Wang, B1
Chaudhri, E; Chemello, L; Craxi, A; Diago, M; Faruqi, R; Koutsounas, S; Maticic, M; Ogurtsov, P; Pedicone, LD; Tartaglione, MT; Torras, J; Witthoeft, T; Yu, X; Zuckerman, E1
Abe, H; Chayama, K; Hayes, CN; Imamura, M; Kamatani, N; Miki, D; Nakamura, Y; Ochi, H; Ohishi, W; Tsuge, M1
Chang, ML; Cheng, JC; Huang, YH; Liang, KH; Lin, CY; Yeh, CT; Yeh, YJ1
Barreiro, P; Labarga, P; Poveda, E; Soriano, V; Vispo, E1
Bali, D; Cullufi, P; Dervishi, E; Durro, V; Velmishi, V1
Ahmad, B; Ali, I; Ali, S; Azam, S; Bashir, S1
Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Itoh, A; Katano, Y; Kumada, T; Kuzuya, T; Nakano, I; Tachi, Y; Toyoda, H; Urano, F; Yoshioka, K1
Habalová, V; Kristian, P; Schréter, I; Válková, I1
Wirth, S1
Dimitrova, DI; Eley, T; Everson, GT; Gardiner, DF; Ghalib, R; Grasela, DM; Guo, T; Lawitz, E; Lok, AS; Martorell, C; McPhee, F; Pasquinelli, C; Persson, A; Reindollar, R; Rustgi, V; Wind-Rotolo, M; Zhu, K1
Chan, HH; Chen, WC; Hsu, PI; Lai, KH; Lin, CK; Lin, KH; Tsai, WL; Yu, HC1
Allende, H; Bes, M; Campos-Varela, I; Castells, L; Charco, R; Esteban, JI; Esteban, R; Rodríguez-Frías, F; Sapisochin, G1
Chien, CH; Chien, RN; Hu, CC; Kuo, YL; Lin, CL; Lin, CY; Tien, HC; Weng, CH; Yen, CL1
Bunchorntavakul, C; Rajender Reddy, K; Tan Dat, H; Thu Thuy, PT1
Hiramatsu, N; Iwasaki, M; Izumi, N; Kakinuma, S; Kurosaki, M; Matsuura, K; Nakagawa, M; Sakamoto, M; Sakamoto, N; Sugauchi, F; Suzuki, Y; Tamori, A; Yatsuhashi, H1
Bourlière, M; Doffoël, M; Fagnani, F; Marcellin, P; Ouzan, D; Pawlotsky, JM; Pinta, A; Rosenheim, M; Rouanet, S; Salomon, L; Vray, M1
Cabibi, D; Colombo, MP; Craxì, A; Guarnotta, C; Petta, S; Pipitone, R; Tripodo, C1
Bolcic, F; Laufer, N; Moretti, F; Quarleri, J; Sede, M; Vazquez, M; Westergaard, G1
Baroni, GS; Covolo, L; Faraci, MG; Fattovich, G; Guido, M; Ieluzzi, D; Negro, F; Pasino, M; Passigato, N; Pierantonelli, I; Tonon, A1
de Moraes, CF; De Pauli, DS; Grotto, RM; Marangon, AV; Moliterno, RA; Pardini, MC; Sell, AM; Silva, GF; Visentainer, JE1
Bezemer, G; de Knegt, RJ; Esteban, JI; Ferrari, C; Hansen, BE; Lagging, M; Lurie, Y; Negro, F; Neumann, AU; Pawlotsky, JM; Schalm, SW; Van Gool, AR; Verheij-Hart, E; Zeuzem, S1
Antoniazzi, S; Bergasa, NV; Floreani, A; Mescoli, C1
Bredi, E; Carcamo, WC; Chan, EK; Colombo, M; Covini, G; von Mühlen, CA1
Berenguer, J; Cosín, J; Fernández-Rodríguez, A; Guzmán-Fulgencio, M; Jiménez, JL; López, JC; Micheloud, D; Miralles, P; Muñoz-Fernández, MÁ; Resino, S1
Benito, JM; McHutchison, J; Naggie, S; Rallón, NI; Restrepo, C; Soriano, V; Vispo, E1
Agarwal, K; Austin, A; Brown, A; Dillon, JF; Foster, GR; Fox, R; Fraser, A; Hayes, PC; Leen, C; Mills, PR; Mutimer, DJ; Ramachandran, P; Ryder, SD1
Ali, A; Aparcero, R; Del Campo, JA; Eslam, M; Grande, L; Khattab, MA; Mousa, YI; Romero-Gomez, M; Shaker, Y1
Hézode, C; Pawlotsky, JM; Sarrazin, C; Zeuzem, S1
Bergmann, JF; Boonstra, A; de Knegt, RJ; Haagmans, BL; Hansen, BE; Janssen, HL; Kwadijk-de Gijsel, S; Roomer, R; van Vuuren, AJ1
Baur, K; Bischoff Ferrari, HA; Frei, P; Geier, A; Iwata, R; Mertens, JC; Müllhaupt, B; Schmitt, J; Seifert, B; Stieger, B; von Eckardstein, A1
Chen, DS; Chen, JH; Chen, PJ; Hsu, SJ; Kao, JH; Liang, CC; Lin, CL; Lin, JW; Liu, CH; Liu, CJ; Su, TH; Tseng, TC; Yang, SS1
Ceauşu, E; Gheorghe, L; Iliescu, L; Mateescu, B; Micu, L; Mocan, T; Pascu, O; Seicean, A; Voiculescu, M1
Ausina Ruiz, V; Martró Català, E; Saludes Montoro, V1
Arora, SK; Chawla, YK; Dhiman, R; Duseja, A; Rana, D1
Campistol, JM; Esforzado, N1
Chang, WY; Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, JF; Lee, LP; Lin, ZY; Wang, LY; Yu, ML4
Afendy, A; Baranova, A; Birerdinc, A; Estep, M; Stepanova, M; Younossi, ZM1
Clark, PJ; Kelley, RI; Kratz, LE; McHutchison, JG; Millington, DM; Muir, AJ; Patel, K; Subramanian, M; Thompson, AJ; Tolun, AA; Vock, DM1
Azuma, T; Deng, L; El-Shamy, A; Fujisawa, T; Hotta, H; Ide, Y; Imoto, S; Kim, SR; Seo, Y; Shoji, I; Tani, S; Yano, Y; Yoon, S1
Karatapanis, S; Lisgos, P; Papastergiou, V; Skorda, L1
Dalagiorgou, G; Hatzakis, A; Kakkanas, A; Karamitros, T; Katsoulidou, A; Mavromara, P; Sypsa, V1
Clark, PJ; Herrmann, E; Katsounas, A; Kottilil, S; Lempicki, R; Masur, H; McHutchison, JG; Muir, AJ; Naggie, S; Osinusi, A; Patel, K; Polis, MA; Schlaak, JF; Shivakumar, B; Thompson, AJ; Trippler, M1
Midena, E; Noventa, F; Sebastiani, G; Tempesta, D; Vujosevic, S1
Kang, P; Sun, LJ; Yan, BZ; Yu, JW; Zhao, YH; Zhu, PF1
Hamzeh, FM; Han, J; Harrison, SA; Pandya, PK; Sheikh, MY; Vierling, JM1
Barili, V; Fasano, M; Ferrari, C; Missale, G; Molinari, A; Orlandini, A; Penna, A; Pilli, M; Ravanetti, L; Santantonio, T; Zerbini, A1
Barnes, E; Brown, A; Christian, A; Collier, JD; Foster, GR; Hibbert, L; Humphreys, IS; Klenerman, P; Rahman, M; von Delft, A1
Crespo, G; Lens, S1
Aoun, O; Bricaire, F; Mellon, G; Stitou, H; Thibault, V; Tubiana, R; Valantin, MA1
Abe, H; Arihiro, K; Chayama, K; Hayes, CN; Hiraga, N; Hyogo, H; Imamura, M; Kimura, Y; Kohno, T; Miki, D; Ochi, H; Ohnishi, M; Takahashi, S; Tanaka, S; Tsuge, M; Zhang, Y1
Cipriano, LE; Goldhaber-Fiebert, JD; Holodniy, M; Liu, S; Owens, DK1
De Martin, E; Di Paolo, D; Donato, MF; Fagiuoli, S; Farcomeni, A; Giannelli, V; Giusto, M; Iemmolo, RM; Merli, M; Miglioresi, L; Morelli, MC; Pasulo, L; Pompili, M; Ponziani, FR; Rendina, M; Toniutto, P; Viganò, R1
Ahmad, J; Haider, SI1
Hayat, AS; Masood, N; Shaikh, N1
Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MH; Hsieh, MY; Huang, CF; Huang, JF; Juo, SH; Lin, ZY; Shin, SJ; Yang, JF; Yeh, ML; Yu, ML1
Barreiro, P; Benito, JM; Camacho, A; Caruz, A; Labarga, P; Neukam, K; Pineda, JA; Rallón, NI; Restrepo, C; Rivero, A; Soriano, V; Vispo, E1
Bai, F; Bellistrì, GM; Borghi, F; Carosi, G; Gatti, F; Marchetti, G; Monforte, Ad; Nasta, P; Puoti, M; Tincati, C1
Inage, E; Minowa, K; Naritaka, N; Ohtsuka, Y; Saito, N; Shimizu, T; Suzuki, M; Tokita, A; Tsubahara, M1
Dybowska, D; Halota, W; Karwowska, K; Kozielewicz, D1
Halota, W; Kozielewicz, D1
Fujiyama, S; Haraoka, K; Miyase, S; Morishita, Y; Ouchida, Y1
Balistreri, W; Barton, BA; Duggan, C; Gonzalez-Peralta, RP; Haber, B; Jonas, MM; Lobritto, S; Mitchell, PD; Mohan, P; Molleston, JP; Murray, KF; Narkewicz, MR; Rosenthal, P; Schwarz, KB; Shepherd, JA1
Beumont, M; Carosi, G; DeMasi, R; Drenth, JP; Ferenci, P; Forns, X; Goeser, T; Lonjon-Domanec, I; Marcellin, P; Nevens, F; Picchio, G; Serfaty, L1
La Mura, V; Persico, M1
Peck-Radosavljevic, M; Reiberger, T1
Aronson, SJ; de Bruijne, J; Reesink, HW; Schinkel, J; van der Valk, M; Weegink, CJ1
Dusheiko, GM; Tanwar, S; Trembling, PM2
Enomoto, M; Fujii, H; Hagihara, A; Iwai, S; Kawabe, J; Kawada, N; Kawamura, E; Kobayashi, S; Kotani, K; Morikawa, H; Shiomi, S; Tamori, A; Tominaga, K1
Bellis, L; Dell' Unto, O; Elmo, MG; Guarisco, R; Mitidieri Costanza, O; Puoti, C; Spilabotti, L1
Albrecht, JK; Deng, W; González-Peralta, RP; Haber, B; Jonas, MM; Kelly, DA; Lachaux, A; Lang, T; Molleston, JP; Murray, KF; Narkewicz, MR; Noviello, S; Pollack, H; Shelton, M; Sinatra, FR; Te, HS; Wirth, S1
Ako, S; Hatamaru, K; Henmi, S; Iguchi, E; Inuzuka, T; Ishikawa, T; Kimura, T; Kita, R; Koshikawa, Y; Matsuda, F; Nakajima, J; Nishikawa, H; Osaki, Y; Saito, S; Sakamoto, A; Takeda, H1
Fan, XH; Liu, LC; Lu, HY; Shan, Y; Wang, LF; Wei, L; Wu, CH; Xu, XY; Yao, Y1
Aichelburg, MC; Breitenecker, F; Ferenci, P; Heil, PM; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A; Scherzer, TM; Schuster, C1
Domínguez Muñoz, E; Fernández Castroagudín, J; Molina Pérez, E1
Abdallah, N; Arastéh, K; Berger, F; Böcher, W; Cerny, A; de Ledinghen, V; Dikopoulos, N; Gerken, G; Gerlach, T; Girlich, B; Heim, MH; Kukolj, G; Larrey, D; Lohse, AW; Marquis, M; Mathurin, P; Scherer, J; Schuchmann, M; Steffgen, J; Stern, JO; Thimme, R; Tran, A; Trautwein, C; Trepo, C; Wu, K; Zarski, JP1
Bang, SJ; Jeong, ID; Jung, SW; Kim, B; Kim, CJ; Lee, SJ; Park, BR; Park, NH; Shin, JW1
Petta, S1
Francque, S; Ho, E; Michielsen, P1
Hou, J; Li, J; Li, W; Liu, S; Wang, J; Wu, Y; Zeng, Y; Zhang, J; Zhou, B; Zhou, Y1
Baiget, M; Del Mar Gutierrez, M; Domingo, P; Fontanet, A; Guardiola, JM; Lamarca, K; Martin, J; Mateo, MG; Muñoz, J; Pacho, C; Salazar, J; Torres, F; Vidal, F1
Aikata, H; Chayama, K; Hiraga, N; Hiramatsu, A; Imamura, M; Kawakami, Y; Kawaoka, T; Miki, D; Ochi, H; Ohdan, H; Onoe, T; Takahashi, S; Takaki, S; Tashiro, H; Tsuge, M; Waki, K1
Allen, S; Bhattacharyya, D; Bramley, P; Carman, B; Delahooke, TE; Dillon, JF; Goldberg, DJ; Hayes, P; Hutchinson, SJ; Innes, HA; Kennedy, N; Mills, PR; Morris, J; Robertson, C; Stanley, AJ1
Gupta, R; Kim, S; Taylor, MW1
Akuta, N; Arase, Y; Chayama, K; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Miyakawa, Y; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y1
Perry, CM1
Dallmeier, K; Neyts, J; Paeshuyse, J1
Deng, L; El-Shamy, A; Hasegawa, Y; Hotta, H; Ide, YH; Imoto, S; Kim, KI; Kim, SR; Ota, M; Shoji, I; Tanaka, Y1
Coenen, M; Eisenhardt, M; Glässner, A; Körner, C; Krämer, B; Nattermann, J; Sauerbruch, T; Spengler, U1
Abd-Aalhalim, H; Aly, H; Eslam, M; Khattab, MA; Mousa, YI; Samir, F; Shaker, O; Shaker, Y; Shatat, M1
Băţagă, S; Boţianu, AM; Demian, S; Georgescu, D; Macarie, I; Oltean, G1
Asaka, M; Chuma, M; Hige, S; Horimoto, H; Kobayashi, T; Nakai, M; Nakanishi, M; Ogawa, K; Sakamoto, N; Sho, T; Terashita, K1
Daniš, D; Gazdík, F; Gazdíková, K; Hučková, D; Kajaba, I; Okruhlica, L1
Blotner, SD; Brennan, BJ; Grippo, JF; Hagedorn, CH; Marbury, TC; Morcos, PN; Morrison, R; Sulkowski, M; Wang, K1
Fazio, V; Giannini, EG; Marenco, S; Picciotto, A; Pieri, G; Savarino, V1
Altus, R; Gordon, DL; Muller, K; Rodgers, A; Waddell, V; Wigg, A; Wundke, R1
Barnard, RJ; Caro, L; Gane, E; Hwang, PM; Lee, AW; Manns, MP; Marcellin, P; Rodriguez-Torres, M; Stoehr, A; Wiedmann, RT; Yeh, CT1
Chen, XY; Guo, DD; Huang, YX; Ma, LN; Ren, S; Yin, JM; Zheng, YH1
Coppola, N; Pasquale, G; Piccinino, F; Pisaturo, MA; Sagnelli, C; Sagnelli, E1
Casey, LC; Lee, WM1
Saxena, V; Terrault, N1
Hino, K; Hoshino, H; Hosoya, N; Kajiyama, Y; Kikuchi, K; Miyakawa, H; Takai, A1
Amur, S; Birnkrant, D; Fleischer, R; Hammerstrom, T; Jadhav, PR; Lewis, L; Liu, J; Naeger, L; O'Rear, J; Pacanowski, M; Robertson, S; Seo, S; Soon, G1
Gao, SJ; Jia, YH; Nan, YM1
García-Ruiz, I; Gómez-Izquierdo, E; Muñoz-Yagüe, MT; Solís-Herruzo, JA; Solís-Muñoz, P; Valverde, AM1
Alshuth, U; Christensen, S; Heyne, R; Hüppe, D; Mauss, S; Möller, B; Niederau, C; Pfaff, R; Theilmeier, A; Zehnter, E1
Afdhal, N; Albrecht, JK; Clark, PJ; Esteban, R; Fellay, J; Ge, D; Goldstein, DB; Harrison, SA; Kwo, P; McHutchison, JG; Muir, AJ; Naggie, S; Noviello, S; Patel, K; Pedicone, LD; Shianna, K; Sulkowski, MS; Thompson, AJ; Tillmann, HL; Urban, TJ; Vock, DM; Zhu, M; Zhu, Q1
Alavian, SM; Nejad, MR1
Burnett, D; Cornett, DD; Lindstrom, MJ; Lucey, MR; Rice, JP; Sawyer, J; Striker, R; Tsotsis, H; Voermans, P1
Ford, JA; Greanya, E; Partovi, N; Wilby, KJ; Yoshida, EM1
Aleman, S; Duberg, AS; Josephson, F; Lagging, M; Lindh, M; Weiland, O; Wejstål, R1
Amrani, N; Barkat, A; Elmachad, M; Kabbaj, N; Laarabi, FZ; Sefiani, A; Tajir, M1
Guarascio, P; Pellicelli, AM; Romano, M; Vignally, P1
Afdhal, NH; Lai, M1
Bae, SH; Jun, DW; Lee, YJ; Tak, WY1
Kim, TY1
Cho, KB; Chung, WJ; Hwang, JS; Jang, BK; Kim, ES; Kim, YJ; Park, KS1
Adda, N; Adiwijaya, B; Bartels, DJ; Beumont, M; De Meyer, S; Dierynck, I; Dorrian, J; Ghys, A; Jacobson, IM; Jiang, M; Kauffman, RS; Kieffer, TL; Kwong, AD; Picchio, G; Sherman, KE; Spanks, J; Sullivan, JC; Tigges, A; Zeuzem, S; Zhang, EZ1
Durmaz, O1
Chang, MF; Lim, J; Monto, A; Morgan, TR; Pocha, C; Ross, D; Yee, HS1
Aghemo, A; Colombo, M; De Nicola, S; Dongiovanni, P; Fargion, S; Ferenci, P; Maggioni, P; Motta, BM; Rumi, MG; Stättermayer, AF; Valenti, L1
Inose, K; Kani, S; Matsuura, K; Mizokami, M; Motojuku, N; Orito, E; Tanaka, Y; Wakimoto, Y; Watanabe, T; Yatsuhashi, H1
Chevaliez, S; Pawlotsky, JM; Rodriguez, C1
Barritt, AS; Fried, MW1
Thompson, AJ1
Naggie, S; Sulkowski, MS1
Ito, K; Masaki, N; Miyagi, Y; Mizokami, M; Nomura, H; Tanimoto, H; Yamashita, N1
Bruguera, M; Esteban, R; Forns, X; Planas, R; Quer, JC; Solà, R; Vergara, M1
Badridze, N; Chkhartishvili, N; Dolmazashvili, E; Dvali, N; Dzigua, L; Gatserelia, L; Gochitashivli, N; Karchava, M; Nelson, K; Sharvadze, L; Tsertsvadze, T; Zhamutashvili, M1
Amur, S; Pacanowski, M; Zineh, I1
Afendy, A; Baranova, A; Birerdinc, A; Estep, M; Stepanova, M; Younossi, I; Younossi, ZM1
Akkarathamrongsin, S; Komolmit, P; Mahachai, V; Poovorawan, K; Poovorawan, Y; Tangkijvanich, P1
Bani-Sadr, F; Cacoub, P; Carrat, F; Fromentin, D; Krastinova, E; Perronne, C; Piroth, L; Pol, S; Quertainmont, Y; Rosenthal, E1
Heim, MH1
Amemiya, F; Enomoto, N; Inoue, T; Kadokura, M; Kanayama, A; Kitamura, T; Komase, K; Komatsu, N; Maekawa, S; Miura, M; Nakayama, Y; Ohmori, T; Okada, S; Sakamoto, M; Shindo, H; Shindo, K; Sueki, R; Takano, S; Yamaguchi, T1
Bjøro, K; Dalgard, O; Eskesen, AN; Melum, E; Moghaddam, A; Ring-Larsen, H; Verbaan, H1
Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Seko, Y; Sezaki, H; Suzuki, F; Suzuki, Y2
Fishbein, D; Funk, E; Hu, Z; Kottilil, S; Masur, H; Naggie, S; Osinusi, A; Polis, M; Poonia, S; Schlaak, J; Trippler, M1
Igarashi, T; Inoue, J; Kakazu, E; Kimura, O; Kobayashi, K; Kobayashi, T; Kondo, Y; Miura, M; Ninomiya, M; Shimosegawa, T; Tamai, K; Tanaka, Y; Ueno, Y; Yamamoto, T1
Amur, S; Ayala, R; Florian, J; Harrington, P; Jadhav, PR; Mishra, P; Murray, J; O'Rear, J; Pacanowski, M; Robertson, S; Singer, M; Soon, G; Zeng, W1
Benhamou, Y; Boyer, N; Carenco, C; Guyader, D; Larrey, D; Marcellin, P; Pageaux, GP; Rouzier, R1
Furusyo, N; Hayashi, J; Hayashi, T; Ihara, T; Ikezaki, H; Kainuma, M; Murata, M; Ogawa, E; Okada, K; Taniai, H; Toyoda, K1
Baldanti, F; Fiorina, L; Paolucci, S; Papadimitriou, S1
Albrecht, JK; Boparai, N; Brass, CA; Bronowicki, JP; Bruno, S; Burroughs, MH; Deng, W; DiNubile, MJ; Esteban, R; Gottesdiener, KM; Jacobson, IM; Marcellin, P; Pedicone, LD; Poordad, F; Sulkowski, MS; Zeuzem, S1
Aghemo, A; Colombo, M; D'Ambrosio, R; De Nicola, S; Degasperi, E; Grancini, V; Orsi, E; Prati, GM; Rumi, MG; Soffredini, R1
Berak, H; Dusheiko, GM; Ferenci, P; Gane, EJ; Hadziyannis, SJ; Han, KH; Harley, HA; Horsmans, YJ; Husa, P; Jenny Heathcote, E; Lee, SS; Messinger, D; Roberts, SK; Tatsch, F1
Dowling, TC; Fossler, MJ; Howell, CD; Jin, R; McHutchison, JG1
Erdem, H; Örmeci, N1
Blum, HE; Neumann-Haefelin, C; Thimme, R1
Alsiö, Å; Askarieh, G; Buhl, MR; Christensen, PB; Färkkilä, M; Haagmans, BL; Hellstrand, K; Lagging, M; Langeland, N; Mørch, K; Nasic, S; Norkrans, G; Pedersen, C; Rembeck, K; Westin, J1
Aziz, H; Gill, ML; Gill, U; Raza, A; Waheed, Y1
Künzler-Heule, P; Panfil, EM1
Bukh, J; Christensen, PB; Krarup, HB; Krogsgaard, K; Laursen, AL; Madsen, PH; Orholm, M; Pedersen, C; Ring-Larsen, H; Schlichting, P1
Dieterich, D; Poordad, F1
Bellia, C; Cabibi, D; Cammà, C; Caruso, A; Ciaccio, M; Craxì, A; Di Marco, V; Mazzola, A; Petta, S1
Bibert, S; Bochud, PY; Guedj, H; Guedj, J; Lagging, M; Negro, F; Neumann, AU; Westin, J1
McCaughan, GW1
Dore, GJ1
Gold, J; Hellard, ME; Hickman, M; Higgs, P; Jenkinson, R; Martin, NK; Sacks-Davis, R; Stoové, MA; Vickerman, P1
Amin, J; Dore, GJ; George, J; Gidding, HF; Haber, PA; Law, MG; Macdonald, GA; Ostapowicz, G; Sasadeusz, JJ; Weltman, M1
Baumert, TF; Dill, MT; Duong, FHT; Filipowicz, M; Heim, MH; Makowska, Z; Merkofer, F; Terracciano, L; Tornillo, L1
Barut, S; Erkorkmaz, U; Günal, O1
Bolcic, F; Cassino, L; Laufer, N; Quarleri, J; Reynoso, R; Torres, C1
Di Bisceglie, AM; Dienstag, JL; Everson, GT; Ghany, MG; Lindsay, KL; Lok, AS; Morgan, TR; Morishima, C; Naishadham, D; Shiffman, ML; Szabo, G; Wright, EC1
Alves, A; Cardoso, C; Freire, R; Oliveira, A1
Bashir, S; Hamid, S; Mirza, S; Siddiqui, AR; Umar, M1
Allwinn, R; Berger, A; Peiffer, KH; Perner, D; Sarrazin, C; Susser, S; Vermehren, J; Zeuzem, S1
Adamek, A; Bereszyńska, I; Bura, A; Bura, M; Czajka, A; Hryckiewicz, K; Kowala-Piaskowska, A; Mozer-Lisewska, I1
Cheinquer, H; Curescu, M; Dusheiko, GM; Ferenci, P; Horban, A; Jensen, D; Lengyel, G; Mangia, A; Marcellin, P; Ouzan, D; Puoti, M; Rizzetto, M; Rodriguez-Torres, M; Schmitz, M; Shiffman, ML; Tatsch, F1
Palmer, M; Rubin, R; Rustgi, V1
Amanzada, A; Lindhorst, A; Mihm, S; Moriconi, F; Ramadori, G; Schneider, S; Suermann, T; van Thiel, DH1
Dimitroulopoulos, D; Karatapanis, S; Ketikoglou, I; Kostas, N; Lisgos, P; Papastergiou, V; Skorda, L1
Cai, Q; Gao, Z; Guo, X; Peng, L; Xie, J; Zhang, X; Zhao, Z1
Abrams, GA; Bräu, N; Bronowicki, JP; Diva, U; Everson, GT; Ghalib, RH; Hernandez, D; Hézode, C; Hindes, R; Hughes, EA; Lim, JK; Martorell, C; McPhee, F; Morris, DW; Pol, S; Reindollar, RW; Rustgi, VK; Schnittman, S; Tatum, HA; Thuluvath, PJ; Wind-Rotolo, M; Yin, PD1
El Saadany, S; Enaba, M; Ghazy, M; Hasan, A; Ziada, DH1
Bailly, F; Zoulim, F1
Barreiro, P; Benito, JM; Labarga, P; Rallon, NI; Soriano, V; Vispo, E1
Katsounas, A; Kottilil, S; Lempicki, RA; Masur, H; Murphy, AA; Osinusi, A; Polis, M; Rasimas, J; Raza, H; Rosenstein, D; Yang, J1
Liu, GW; Ma, SP; Wang, CF; Zhao, WX1
Boyer, N; Castelnau, C; Marcellin, P; Martinot-Peignoux, M; Ripault, MP; Stern, C; Valla, D1
Fadda, V; Maratea, D; Messori, A; Trippoli, S1
Arakaki, RF; Sarasombath, O; Suwantarat, N; Tice, AD1
Dieterich, D; Ladd, AM; Martel-Laferriere, V1
Chen, YH; Chiou, YL; Ke, T; Ko, WS1
Evon, DM; Hoofnagle, JH; Jiang, Z; Sarkar, S; Wahed, AS1
Bourlière, M; Le Folgoc, G; Lecomte, L; Wartelle-Bladou, C1
Berg, T; Biermer, M; Brodzinski, A; Fülöp, B; Heyne, R; Keller, K; Sarrazin, C; Schlosser, B; van Bömmel, F1
Adinolfi, LE; Barillari, M; Costa, G; Marrone, A; Zampino, R1
Bani-Sadr, F; Dominguez, S; Garraffo, R; Izopet, J; Pambrun, E; Peytavin, G; Poizot-Martin, I; Salmon, D; Solas, C; Winnock, M1
Kishikawa, T; Koike, K; Minami, T; Sato, M; Tateishi, R; Yoshida, H1
Campbell, SA; Tirado, CF; Weinrieb, RM; Zickmund, SL; Zook, CL1
Fujisaki, S; Goto, H; Hibino, Y; Hirashima, N; Iwase, H; Kamiya, A; Ryuge, N; Saito, M; Shimada, M; Sugiura, W; Tamaki, D; Tsuzuki, T; Yokoi, M; Yokomaku, Y1
Barsic, B; Dusek, D; Gorenec, L; Grlgic, I; Kurelac, I; Lepej, SZ; Papic, N; Vince, A1
Bartels, DJ; Beumont, M; Daems, B; De Meyer, S; Dierynck, I; Ghys, A; Kieffer, TL; Picchio, G; Sullivan, JC; Van Baelen, B; Zeuzem, S1
Aguirrebengoa, K; Asensi, V; Barreiro, P; Castro, A; da Silva, A; Echeverría, S; Guardiola, JM; Hernández-Quero, J; Labarga, P; Mariño, A; Miralles, P; Morano, L; Pineda, JA; Portu, J; Ríos, MJ; Rubio, R; Soriano, V; Téllez, MJ; Terrón, A; Vispo, E1
Badenhoop, K; Berg, T; Bibert, S; Bochud, PY; Bojunga, J; Burgisser, P; Cerny, A; Dufour, JF; Geier, A; Gerlach, TJ; Heim, MH; Kutalik, Z; Lange, CM; Malinverni, R; Moradpour, D; Müller, T; Negro, F; Regenass, S; Sarrazin, C; Zeuzem, S1
Dixit, NM; Krishnan, SM1
Beyler, AR; Coban, S; Dökmeci, A; Ekiz, F; Erdem, H; Köklü, S; Ormeci, N; Ozkan, H; Palabıyıkoğlu, M1
Ito, K; Masaki, N; Miyagi, Y; Mizokami, M; Nomura, H; Shibuya, T; Tanimoto, H; Yamashita, N1
Al-Osaimi, AM; Brown, RS; Everhart, JE; Everson, GT; Gillespie, BW; Kulik, LM; Lok, AS; Rodrigo, del R; Saab, S; Shiffman, ML; Terrault, NA1
Aghemo, A; Colombo, M; Galmozzi, E1
El-Dessouki, A; Sadik, NA; Shaker, OG1
Chen, YP; Fan, YC; Lin, XF; Liu, WY; Shi, KQ; Zheng, MH1
Arndt, S; Braunschweiger, I; Langhans, B; Nattermann, J; Nischalke, HD; Sauerbruch, T; Spengler, U1
Atsukawa, M; Fukuda, T; Itokawa, N; Kanazawa, H; Kidokoro, H; Kobayashi, T; Kondo, C; Matsushita, Y; Nakatsuka, K; Narahara, Y; Sakamoto, C; Tsubota, A1
Antonaci, S; Antonelli, G; Carducci, A; Giannelli, G; Mazzarelli, C; Monteleone, K; Picardi, A; Pizzigallo, E; Riva, E; Scagnolari, C; Selvaggi, C; Vincenzi, B1
Bernabucci, V; Cammà, C; De Maria, N; Di Leo, A; Enea, M; Ferrari, A; Francavilla, A; Gitto, S; Karampatou, A; Lei, B; Losi, L; Rendina, M; Vignoli, P; Villa, E; Vukotic, R1
Buti, M; Deltenre, P; Deuffic-Burban, S; Hatzakis, A; Mathurin, P; Moreno, C; Mühlberger, N; Parkes, J; Rosenberg, W; Siebert, U; Stroffolini, T; Zeuzem, S1
Burton, MJ; McGuire, BM; Passarella, MJ1
Chikazawa, Y; Fujimoto, K; Imura, J; Kimura, S; Nakagawa, M; Okuyama, H; Yamaya, H; Yokoyama, H1
Liu, N; Liu, P; Sun, C; Wen, Y1
Aspinall, E; Doyle, JS; Hellard, ME; Liew, D; Thompson, AJ1
Gao, ZL; Guo, XY; Lin, BL; Wang, GS; Xie, DY; Xie, JQ; Zhang, XH; Zhao, ZX1
Fan, XH; Huo, N; Lu, HY; Tian, D; Wang, LF; Wei, L; Wu, CH; Xu, XY; Zheng, YY1
Furusyo, N; Hayashi, J; Hayashi, T; Hiramine, S; Ihara, T; Ikezaki, H; Kainuma, M; Kajiwara, E; Mukae, H; Murata, M; Ogawa, E; Okada, K; Sudoh, M; Taniai, H; Toyoda, K1
Naveau, S; Perlemuter, G; Voican, CS1
Bourlière, M; Bronowicki, JP; Delasalle, P; Leroy, V; Pageaux, GP; Pariente, A; Pol, S; Serfaty, L; Zoulim, F1
Chen, DS; Chen, JH; Chen, PJ; Kao, JH; Liang, CC; Lin, CL; Lin, JW; Liu, CH; Liu, CJ; Su, TH; Tseng, TC; Yang, SS1
Azuma, T; El-Shamy, A; Fujisawa, T; Hamano, K; Hayashi, Y; Hirohata, S; Hotta, H; Kato, H; Kawara, A; Kitagaki, K; Kitajima, N; Maeda, T; Miki, A; Nakashima, T; Ouchi, S; Oya, M; Saito, M; Seo, Y; Tani, S; Yamada, H; Yamashita, Y; Yano, Y; Yoon, S; Yu, H1
Chang, KC; Chen, CH; Hu, TH; Hung, CH; Lee, CM; Lin, SC; Lu, SN; Tsai, MC; Tseng, PL; Wang, JH; Yen, MF; Yen, YH1
Houlihan, DD; Mutimer, DJ; Rowe, IA1
Antonini, TM; Barau, C; Bonhomme-Faivre, L; Coilly, A; Duclos-Vallée, JC; Furlan, V; Noël, C; Roche, B; Roque-Afonso, AM; Samuel, D; Taburet, AM1
Grammatikos, G; Vermehren, J; Zeuzem, S1
Baik, SJ; Cho, MS; Kim, TH; Moon, IH; Yoo, K1
Jabłonowska, E; Koślińska-Berkan, E; Omulecka, A; Piekarska, A; Szymańska, B; Wójcik, K1
Hussain, S; Kazmi, AR; Malik, SA; Mustafa, M; Naeem, M; Qureshi, S1
Chary, A; Holodniy, M; Kottilil, S; Masur, H; Naggie, S; Osinusi, A; Polis, MA; Winters, MA1
Chang, CK; Hsieh, YH; Hung, TH; Lai, NS; Tseng, CW; Tseng, KC; Wu, SF1
Dusheiko, G; Wedemeyer, H1
Diago, M; Hadziyannis, S; Harrison, SA; Jensen, DM; Marcellin, P; Messinger, D; Reddy, KR; Rizzetto, M; Roberts, SK; Tatsch, F; Weltman, M1
Drexler, DM; Grace, JE; Wei, C; Zvyaga, TA1
Aichelburg, MC; Breitenecker, F; Ferlitsch, A; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A; Schmied, B; Sieghart, W; Trauner, M1
Brochot, E; Capron, D; Castelain, S; Duchaussoy, I; Duverlie, G; François, C; Helle, F; Nguyen-Khac, E; Van Nhien, AN1
Beaumont, M; Garg, V; Kauffman, RS; van Heeswijk, RP1
Azzouz, MM; El Bouchtili, S; Hamzaoui, L; Mahmoudi, M; Siai, K1
Haruna, Y; Imaizumi, N; Kashiwagi, T; Kashiwamura, S; Kishida, Y; Tanimura, H1
Brjalin, V; Kuznetsova, T; Priimägi, L; Salupere, R; Tallo, T; Tefanova, V1
Aizawa, N; Enomoto, H; Iijima, H; Imanishi, H; Iwata, Y; Kuga, C; Matsuda, F; Nakamura, H; Nishiguchi, S; Saito, M; Shimomura, S; Tanaka, H; Tanaka, Y; Torii, Y; Tsutsui, H1
Berak, H; Bukowska-Ośko, I; Caraballo Cortés, K; Fic, M; Horban, A; Laskus, T; Pawełczyk, A; Radkowski, M1
Hu, YJ; Li, QR; Tan, ZX; Wang, XH; Xiong, YL; Yuan, J; Zhang, CJ; Zhu, Y1
Li, MY; Yuan, XL; Zhang, DZ1
Gafter-Gvili, A; Goldvaser, H; Katz, LH; Tur-Kaspa, R1
Chang, MH; Fung, HB; Gordon, LA1
Hagiwara, H; Harada, N; Hayashi, N; Hiramatsu, N; Imai, Y; Inoue, A; Inui, Y; Kanto, T; Kasahara, A; Katayama, K; Kiso, S; Kurokawa, M; Mita, E; Miyagi, T; Miyazaki, M; Oshita, M; Oze, T; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yamada, R; Yoshihara, H1
Abdallah, el S; Ahmed, R; Ahmed, Sel-D; Darwish, T; Omar, D; Sabry, D; Salama, H1
Abe, M; Furukawa, S; Hiasa, Y; Hirooka, M; Kumagi, T; Matsuura, B; Miyake, T; Miyaoka, H; Onji, M; Tokumoto, Y; Ueda, T; Watanabe, T; Yamamoto, S1
Huang, P; Xiong, QF; Yang, YF; Zhong, YD1
Atsukawa, M; Fukuda, T; Hashimoto, S; Itokawa, N; Kanazawa, H; Kidokoro, H; Kobayashi, T; Kondo, C; Matsushita, Y; Nakatsuka, K; Narahara, Y; Sakamoto, C; Tsubota, A1
Araki, M; Kawazoe, T; Lin, Y; Murata, M; Ogawa, M; Okamoto, T; Wakakura, M; Yamamura, T1
Cattaneo, D; Cheli, S; Clementi, E; Colella, E; Ferraris, L; Gervasoni, C; Milazzo, L1
Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kobayashi, T; Kumada, H; Saito, S; Sezaki, H; Suzuki, F; Suzuki, Y1
Clotet, B; Franco, S; Martinez, MA; Tural, C1
Bilasy, SE; Deng, L; El-Akel, W; El-Raziky, M; El-Shamy, A; Esmat, G; Hotta, H; Jiang, DP; Shoji, I1
Cohen, J2
Frolov, VM; Sotskaia, IaA1
Chen, CH; Hung, CH; Kee, KM; Lee, CM; Lu, SN; Wang, JH1
Bociąga-Jasik, M; Cibor, D; Cieśla, A; Głowacki, MK; Mach, T; Owczarek, D; Sanak, M; Sobczyk-Krupiarz, I1
Alfaleh, FZ; Alghamdi, AS; Alghamdi, H; Alqutub, A; Alswat, K; Altraif, I; Ismail, M; Sanai, FM; Shah, H1
Irimia, E; Mogoantă, L; Predescu, O; Streba, L; Streba, LA1
Lilea, GC; Rogoveanu, I; Streba, CT; Vere, CC1
Arai, M; Fujiwara, K; Imazeki, F; Jiang, X; Kanda, T; Miyamura, T; Nakamoto, S; Wu, S; Yokosuka, O1
Fleckenstein, JF; Madey, MA; Mahmoudi, TM; Marion, TN; Schechtman, KB; Weintraub, SJ1
Sadik, NA; Shaker, OG1
Ouzan, D1
Andrade, LE; Chan, EK; Ferraz, ML; Granato, C; Keppeke, GD; Nunes, E; Silva, EA1
Ding, Y; Jia, Z; Jiang, J; Niu, J; Tian, S1
Abe, H; Chayama, K; Hayashida, Y; Kamatani, N; Kumada, H; Maekawa, T; Nakamura, Y; Nakano, R; Ochi, H; Tsunoda, T1
Arnsten, JH; Jefferson, KS; Litwin, AH; Roose, RJ; Soloway, IJ; Stein, MR1
Chiba, T; Haga, H; Kawabata, H; Nishida, N; Takahashi, K1
Alves, AL; Augusto, F; Cardoso, C; Freire, R; Gonçalves, M; Oliveira, AP; Quintana, C1
Kondo, Y; Shimosegawa, T; Ueno, Y1
Debbiche, A; Fenniche, S; Kerkeni, N; Marrak, H; Mlika, RB; Mokhtar, I1
Chandy, GM; Conjeevaram, H; Jothimani, D1
Aziz, S1
Devrajani, BR; Kalhoro, M; Shaikh, S1
Albrecht, JK; Bacon, BR; Barnard, RO; Bourlière, M; Brass, CA; Burroughs, MH; Flamm, SL; Goteti, V; Hezode, C; Howe, JA; Jacobson, I; Lawitz, E; Niederau, C; Pedicone, LD; Poordad, F; Sherman, M; Sings, HL; Vierling, JM1
Dou, XG; Han, F; Zhang, D; Zhang, L1
Adams-Huet, B; Attar, N; Jain, MK; Lee, WM; Petersen, T; Yuan, H1
Afdhal, NH; Albrecht, JK; Brass, CA; Bronowicki, JP; Burroughs, MH; Harrison, SA; Jacobson, IM; Koury, KJ; Manns, MP; Pedicone, LD; Poordad, F; Rajender Reddy, K; Sings, HL; Sniukiene, V; Sulkowski, MS1
Flemming, JA; Terrault, NA1
Afridi, MS; Slim, J1
Ahola, T; Kaukinen, P1
Tai, YK; Tsai, CY; Wu, CS1
Cai, L; Dowling, TC; Howell, CD; Jin, R; McHutchison, JG; Tan, M1
Jang, JY; Jeong, SW; Kim, BS; Kim, Hi; Kim, HS; Kim, SG; Kim, SH; Kim, YS; Lee, SW; Park, SS; Seo, YR; You, BC1
Chung, WJ1
Barreiro, P; Soriano, V; Vispo, E1
Bijedic, N; Husic-Selimovic, A; Huskic, J; Vukobrat-Bijedic, Z1
Aghemo, A; Colombo, M; Degasperi, E; Ferrari, B; Lotta, LA; Peyvandi, F1
Abdel-Aziz, A; Besheer, T; Elbendary, A; Gad, Y; Mokbel, T; Mousa, N1
Bartalesi, F; Bartoloni, A; Cavallo, A; Corti, G; Pimpinelli, N; Salomoni, E; Taliani, G1
Chen, SW; Chien, CH; Chien, RN; Hu, CC; Kuo, YL; Lin, CL; Lin, CY; Yen, CL1
Ampuero, J; Conde, M; Del Campo, JA; García-Lozano, JR; García-Valdecasas, M; González-Escribano, MF; Maraver, M; Millán, R; Rojas, A; Rojas, L; Romero-Gómez, M1
Hashimoto, K; Nagao, Y; Sata, M1
Iijima, S; Iio, E; Kakuni, M; Kohara, M; Matsuura, K; Mizokami, M; Murakami, S; Shimada, T; Sugauchi, F; Sugiyama, M; Tanaka, Y; Watanabe, T; Yatsuhashi, H1
Derbala, MF; Rizk, NM1
Abe, H; Agata, R; Aizawa, Y; Fujise, K; Ika, M; Matsudaira, H; Nagatsuma, K; Namiki, Y; Shimada, N; Tada, N; Tsubota, A; Yoshizawa, K; Yumoto, Y1
Awad, AB; Awad, T; Doss, W; El-Akel, W; Mabrouk, M; Radwan, A; Zayed, N1
Jin, C; Ling, Z; Luo, Y; Mou, X; Xiang, C; Zhang, Q1
Boonstra, A; Claassen, MA; de Knegt, RJ; Groothuismink, ZM; Janssen, HL; Turgut, D1
Akahoshi, T; Fukuhara, T; Furusyo, N; Hayashi, J; Ikegami, T; Maehara, Y; Motomura, T; Shirabe, K; Soejima, Y; Tomikawa, M; Yoshizumi, T1
Haroon, W; Husain, A; Khan, Z; Mirza, SA; Nazir, L; Shaikh, MI1
Coelho, HS; Hoffmann, L; Perez, Rde M; Ramos, AL; Ramos, JA; Rondinelli, E; Silva, R; Urményi, TP; Villela-Nogueira, CA1
Dumortier, J; Gagnieu, MC; Guillaud, O; Janbon, B; Juillard, L; Leroy, V; Morelon, E1
Brjalin, V; Jõeste, E; Lapidus, N; Prikk, K; Salupere, R; Tefanova, V1
Andreoli, A; Barbarini, G; Barbaro, G; Barlattani, A; Bonaventura, ME; D'Ambrosio, C; Furlan, C; Gentilucci, UV; Marignani, M; Mastropietro, C; Mazzoni, E; Mecenate, F; Miglioresi, L; Mitidieri, O; Monarca, R; Nosotti, L; Pellicelli, AM; Picardi, A; Puoti, C; Romano, M; Stroffolini, T; Vignally, P1
Fan, XH; Lu, HY; Wang, LF; Wei, L; Wu, CH; Xu, XY; Yao, Y; Zheng, YY1
Adda, N; Bartels, DJ; Bengtsson, L; Gritz, L; Jacobson, IM; Kauffman, RS; Kieffer, TL; Luo, D; Picchio, G; Tomaka, F1
Cooper, C; Druyts, E; El Khoury, AC; Lester, R; Mills, EJ; Thorlund, K; Yaya, S1
Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Itoh, A; Katano, Y; Kojima, T; Kumada, T; Kuzuya, T; Matsushita, T; Nakano, I; Takamatsu, J; Toyoda, H; Yamamoto, K1
Aoyagi, Y; Enjoji, M; Fujino, T; Fukuizumi, K; Fukushima, N; Harada, N; Kato, M; Kohjima, M; Kotoh, K; Nakamuta, M; Nakashima, M; Sakamoto, N; Tanaka, Y; Yada, M; Yada, R; Yoshimoto, T1
Bochud, PY; Clément, S; Conzelmann, S; Dill, MT; Lagging, M; Missale, G; Negro, F; Neumann, AU; Pascarella, S; Pawlotsky, JM; Rubbia-Brandt, L; Zeuzem, S1
Drago, F; Javor, S; Parodi, A1
Hung, DZ; Liao, WL; Lim, YP; Peng, CY; Tien, N; Tsai, FJ; Wan, L1
Choi, DJ; Ha, MS; Jung, YK; Kim, JH; Kim, JS; Kim, YS; Kwon, OS; Lee, JW; Park, SY; Rim, MY; Yo, IK1
Chen, JY; Huang, CH; Huang, CW; Jeng, WJ; Lin, CY; Sheen, IS1
Atsukawa, M; Fukuda, T; Hashimoto, S; Itokawa, N; Iwakiri, K; Kanazawa, H; Kidokoro, H; Kobayashi, T; Kondo, C; Matsushita, Y; Nakatsuka, K; Narahara, Y; Sakamoto, C; Tsubota, A1
Doyle, JS; Hellard, ME; Shiell, AM; Visconti, AJ; Weir, A1
Jacobson, IM; Jesudian, AB2
Burton, JR; Everson, GT1
Button, P; Cheng, WS; Crawford, DH; Dore, GJ; George, J; Kitson, MT; McCaughan, GW; Roberts, SK; Sievert, W; Weltman, MD1
Albanis, E; Berrey, MM; Cornpropst, MT; Dejesus, E; Hebner, CM; Jiang, D; Kowdley, KV; Lalezari, J; Lawitz, E; Mader, M; McHutchison, JG; Nelson, DR; Rodriguez-Torres, M; Symonds, WT1
Gane, E3
Andriulli, A; Bossa, F; Fontana, R; Iacobellis, A; Ippolito, A; Niro, G; Spirito, F; Terracciano, F; Valvano, MR1
Chayama, K; Hayes, CN; Kawakami, Y; Ohishi, W1
Li, XH; Xie, DY; Xie, JQ; Xu, QH; Zhang, XH1
Cheng, J; Li, MH; Lu, Y; Qiu, GH; Shen, G; Xie, Y; Xu, DZ; Yang, M; Zhang, L; Zhang, YL; Zhao, H1
Bourlière, M; Bronowicki, JP; Chêne, G; Couzigou, P; Foucher, J; Leroy, V; Marcellin, P; Pérusat, S; Poynard, T; Trimoulet, P1
Becker, PP; Dill, MT; Dufour, JF; Geier, A; Manser, CN; Moradpour, D; Müllhaupt, B; Rau, M; Russmann, S; Schmitt, J; Semela, D; Stickel, F; Weisskopf, M1
Benguria, A; Benito, JM; Fiorante, S; Garcia, MI; Lopez-Fernandez, LA; Rallon, NI; Soriano, V1
Doyle, JS; Hellard, ME; Thompson, AJ1
Sarrazin, C; Vermehren, J1
Terrault, N2
Aghemo, A; Degasperi, E; Facchetti, F; Galmozzi, E; Lampertico, P1
Kumada, T; Tada, T; Toyoda, H1
Cheng, ML; Liu, SD; Ren, H; Shu, DY; Yang, QK1
Furusyo, N; Hayashi, J; Ogawa, E1
Lago, P; Pedroto, I; Salgueiro, P1
Izumi, N; Kurosaki, M; Suzuki, S; Tamaki, N1
Burra, P; Cescon, M; Donato, MF; Fagiuoli, S; Gasbarrini, A; Iemmolo, RM; Merli, M; Miglioresi, L; Milani, A; Paolo, DD; Pasulo, L; Pompili, M; Ponziani, FR; Rendina, M; Toniutto, P; Viganò, R; Zaccaria, R1
Abboud, D; Alideeb, S; Antaki, N; Asaad, F; Baroudi, O; Bibert, S; Bochud, PY; Hadad, M; Kebbewar, K; Negro, F; Sabah, H1
Aichelburg, MC; Breitenecker, F; Ferlitsch, A; Mandorfer, M; Obermayer-Pietsch, B; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A; Trauner, M1
Almeida, C; Benito, JM; Camacho, A; Caruz, A; Di Lello, FA; Herrero, R; Macías, J; Neukam, K; Pineda, JA; Rallón, NI; Rivero, A; Rivero-Juárez, A; Soriano, V1
Cooper, CL; Druyts, E; Kanters, S; Mills, EJ; Thorlund, K; Wu, P; Yaya, S1
Berg, T; Böcher, WO; Ehrlich, A; Eisenbach, C; Galle, PR; Gösseringer, R; Günther, R; Kittner, JM; Klass, DM; Neumann, K; Schlaak, JF; Schuchmann, M; Sprinzl, MF; Trautwein, C; Wachtlin, D; Zeuzem, S; Zimmermann, T1
Chen, SC; Chuang, WL; Dai, CY; Huang, CF; Huang, JF; Juo, SH; Kao, JH; Lin, ZY; Liu, CH; Tseng, TC; Wang, LY; Yeh, ML; Yu, ML1
Albert, J; Bojunga, J; Dultz, G; Forestier, N; Friedrich-Rust, M; Gaus, A; Gerber, L; Herrmann, E; Poynard, T; Sarrazin, C; Schneider, MD; Zeuzem, S1
Enomoto, N; Hashimoto, S; Imazeki, F; Inao, M; Inoue, T; Izumi, N; Kaito, M; Kudo, M; Mochida, S; Nishiguchi, S; Tanaka, A; Tsuchiya, K; Ueda, T; Yatsuhashi, H; Yokosuka, O1
Everhart, JE; Wright, EC1
González Díaz, P; López Peláez, MV; Téllez Molina, MJ; Vergas García, J1
Lange, CM1
Hou, W; Lu, W; Ma, P; Song, SD; Wang, L; Yang, JM1
Amaral, KM; Artico, S; Gonçalves, CB; Picon, PD1
Mangia, A; Mottola, L; Piazzolla, V1
Chmura, A; Cieciura, T; Lisik, W; Pacholczyk, M; Tronina, O; Wasiak, D; Łągiewska, B1
Aghemo, A; Altamura, AC; Cavallaro, F; Colombo, M; Dell'Osso, B; Palazzo, MC; Prati, G; Rumi, MG1
Cresseri, D; Donato, MF; Fabrizi, F; Fogazzi, GB; Martin, P; Messa, P; Passerini, P1
Churchill, ND; King, D; Kowala-Piaskowska, A; Lin, DM; Machaj, A; Michalak, TI; Mozer-Lisewska, I; Mulrooney-Cousins, PM; Pazgan-Simon, M; Pham, TN; Reddy, SB; Simon, K; Zalewska, M1
Bernstein, B; Cohen, DE; Heckaman, M; Koev, G; Kowdley, KV; Larsen, L; Lawitz, E; Menon, R; Pilot-Matias, T; Podsadecki, T; Poordad, F; Siggelkow, S; Tripathi, R1
Berrey, MM; Ding, X; Gane, EJ; Hindes, RG; Hyland, RH; Stedman, CA; Svarovskaia, E; Symonds, WT1
Guo, Z; He, X; Kong, Y; Liang, W; Ling, X; Schroder, PM; Shang, Y; Wang, X1
Maasoumy, B; Manns, MP1
Chopra, A; Drinnan, T; Klein, PL; Lee, SS1
Aghemo, A; Grassi, E1
Bourlière, M; Bronowicki, JP; Fontaine, H; Hézode, C; Pol, S; Wendt, A1
Han, J; Hoop, R; Jacobson, I; Korner, EJ; LaFleur, J; Martin, P; Pandya, P; Talal, AH1
Cheng, ML; Liu, XF; Wang, J; Zeng, AP1
Boonstra, A; de Knegt, RJ; Groothuismink, ZM; Hotho, DM; Janssen, HL; Kreefft, K1
Asahina, Y; Enomoto, N; Izumi, N; Kurosaki, M; Maekawa, S; Matsuura, K; Mizokami, M; Nakagawa, M; Nishida, N; Sakamoto, M; Sakamoto, N; Tanaka, Y; Tokunaga, K; Watanabe, M1
Keicher, C; Kraus, MR; Porst, H; Schäfer, A; Scheurlen, M; Sprinzl, K; Teuber, G; Wollschläger, S1
Calvaruso, V; Craxì, A; Di Marco, V; Di Stefano, R; Ferraro, D; Grimaudo, S; Pipitone, RM1
Agrati, C; Bonnafous, C; Capobianchi, MR; Cimini, E; D'Offizi, G; Martini, F; Sicard, H; Vlassi, C1
Kim, KA1
Domagalski, K; Grzybowski, T; Halota, W; Linkowska, K; Pawłowska, M; Pilarczyk, M; Smukalska, E; Tretyn, A1
Chazouillères, O; Pascale, A; Serfaty, L1
Hige, S; Ikehara, Y; Ito, K; Kage, M; Kuno, A; Matsuda, A; Mizokami, M; Narimatsu, H; Sakamoto, M; Sekiya, S; Tanaka, Y1
Choi, DJ; Jeong, SH; Jung, YK; Kim, JH; Kim, JW; Kim, YS; Kwon, OS; Park, SJ; Yang, JW1
Kim, R; McEwan, P; Yuan, Y1
Hadziyannis, SJ; Sevastianos, V1
Chien, RN; Hu, CC1
Abdel Aziz, AO; Abdelhafez, TH; Bader El Din, NG; El Awady, MK; El Hosary, Y; El Khayat, H; Salama, M; Tabll, A1
Chen, Q; Chen, W; Gu, L; Liang, B; Su, L; Tan, J; Tang, N; Wu, G; Wu, P; Xie, J; Yan, Y1
Chuang, WL; Dai, CY; Huang, JF; Yu, ML1
Bzowej, N; Chen, YC; Ferenci, P; Herring, R; Ipe, D; Jensen, D; Ma, MM; Munson, ML; Najera, I; Pockros, P; Rodriguez-Torres, M; Thommes, J; Vierling, J; Wedemeyer, H; Zeuzem, S1
Cai, W; Fu, Y; Guo, P; Hu, F; Qin, A; Tang, X; Xu, M; Yan, D; Yang, Q; Zhou, J1
Chhatwal, J; El Khoury, AC; Elbasha, EH; Ferrante, SA; Laires, PA1
Chen, YC; Cooper, C; Dickson, R; Jensen, D; Kulkarni, R; Lou Munson, M; Najera, I; Pockros, PJ; Ramji, A; Taylor, R; Thommes, J; Tice, A; Tsai, N; Vierling, JM1
Asselah, T; Bessone, F; Böcher, WO; Datsenko, Y; Fainboim, H; Ferenci, P; Heo, J; Kukolj, G; Lalezari, J; Leggett, B; Mauss, S; Nehmiz, G; Scherer, J; Steinmann, GG; Stern, JO; Sulkowski, MS1
Ali, RM; Arafa, MM; El-Alfy, HA; El-Etreby, S; Eldeek, BS; Farag, RE; Goda, IF; Saudy, NS1
Naggie, S1
Comee, MK; Malloy, M; Silva, M; Sitole, M; Spooner, L1
Cabibi, D; Cammà, C; Craxì, A; Di Marco, V; Handberg, A; Macaluso, FS; Marchesini, G; Petta, S1
Sönnerborg, A; Stenkvist, J; Weiland, O1
Heil, EL; Hynicka, LM1
Chen, Y; Guo, LL; He, LL; Lei, BJ; Lei, XZ; Liu, K; Xu, H1
Alvarez-Pellicer, J; Barquilla, E; Barros, C; Bellón, JM; Berenguer, J; Carrero, A; Galindo, MJ; Gaspar, G; González-García, J; Guardiola, JM; Jusdado, JJ; López-Aldeguer, J; Mallolas, J; Montes, ML; Ortega, E; Pulido, F; Quereda, C; Rubio, R; Santos, I; Sanz, J; Téllez, MJ; Tural, C; Van Den Eynde, E; Von Wichmann, MA1
Deng, H; Ji, F; Li, Z; Zhang, S1
Szabó, A; Tusnádi, A1
Karatapanis, S; Lisgos, P; Papastergiou, V; Prodromidou, K; Pselas, C; Stampori, M1
Abdalla, A; Ahlenstiel, G; Dahari, H; Doo, E; Edlich, B; Feld, JJ; Gara, N; Ghany, MG; Guedj, J; Han, H; Heller, T; Hogdal, L; Hoofnagle, JH; Koh, C; Liang, TJ; Noureddin, M; Park, SH; Park, YJ; Perelson, AS; Rehermann, B; Rotman, Y; Sarkar, S; Thomas, E; Titerence, R; Witthaus, M1
El Raziky, M; El-Shehaby, A; Fayez, S; Marzouk, S; Shaker, O; Zahra, A1
Davis, GL6
Brochier, J; Flexman, J; French, MA; Jeffrey, GP; Keane, NM; Lee, S; Macquillan, GC; Price, P1
Barbui, A; Bobbio, A; David, E; Fadda, M; Franchello, A; Lavezzo, B; Ottobrelli, A; Rizzetto, M; Salizzoni, M; Smedile, A; Torrani, M; Zamboni, F1
Bizollon, T; Trepo, C1
Cano, Y; Guyader, D; Poinsignon, Y; Saout, L1
Bernard, N; Dupon, M; Fleury, H; Galperine, T; Houghton, M; Lacut, JY; Lafon, ME; Le Bail, B; Legrand, E; Moreau, JF; Neau, D; Pitard, V; Ragnaud, JM; Schvoerer, E; Trimoulet, P1
Bruno, R; Filice, G; Puoti, M; Sacchi, P; Soriano, V1
Akremi, R; Benhamou, JP; Bourliere, M; Ibrahim, A; Katz, GG; Malkiewicz, I; Marcellin, P; Martinot-Peignoux, M; Neuman, MG; Shear, NH; Spircu, T1
Gitlin, N1
Akbar, HO2
Perlemuter, G1
Lucidarme, D1
Gervais, A1
Boyer, N; Marcellin, P1
Bernard, O1
Cacoub, P1
Bronowicki, JP1
Zoulim, F1
Hilleret, MN; Leroy, V1
Bourlière, M; Halfon, P; Portal, I1
Couzigou, P1
Perronne, C1
Larrey, D1
Trépo, C1
Gournay, J; Richou, C1
Durand, F1
Bernard, D; Colle, I; De Vos, M; Delanghe, J; Leroux-Roels, G; Praet, M; Van Vlierberghe, H; Verdievel, H1
Süoglu, OD1
Butterfield, JH; Kalaaji, AN; Kelkar, PS1
Buti, M; Cabasés, JM; Guillén, F; San Miguel, R1
Chan, KA; Chang, CH; Chen, KY; Lai, MY1
Ascione, T; Bruno, R; Campanone, A; De Sena, R; Felaco, FM; Filice, G; Gaeta, GB; Piccinino, F; Precone, DF; Spadaro, A; Stanzione, M; Stornaiuolo, G1
Allan, JE; de Boer, WB; Jeffrey, GP; MacQuillan, GC; McCaul, KA; Platten, MA; Reed, WD1
Gola, J; Gonciarz, Z; Jurzak, M; Krysiak, R; Mazur, W; Mazurek, U; Szuścik, T; Wilczok, T1
Bode, JC; Rothfuss, KS1
Iñigo, P; Lasierra, P; Moros, M; Pérez-Calvo, J1
Bean, P1
Layden, JE; Layden, TJ; Levy-Drummer, RS; Neumann, AU; Poulakos, J; Reddy, KR1
Almasio, P; Cappello, M; Cino, N; Craxì, A; Di Marco, V; Di Stefano, R; Ferraro, D; Parisi, P; Vaccaro, A1
Andreoni, M; Biglino, A; Carenzi, S; Cariti, G; Ciancio, A; Ciccone, G; Croce, G; Manca, A; Olivero, A; Orsi, PG; Rizzetto, M; Roffi, L; Saracco, G; Smedile, A; Tabone, M; Tappero, G1
Carosi, G; Craxi, A; Dhumeaux, D; Diago, M; Fried, MW; Gonçales, FL; Häussinger, D; Hoffman, J; Lin, A; Marinos, G; Reddy, KR; Shiffman, ML; Smith, C; Yu, J1
Friedlander, L; Kondaveeti, K; Van Thiel, DH1
Albrecht, JK; Dienstag, J; Garaud, JJ; Lee, WM; Lindsay, KL; Mak, C; Manns, M; McHutchison, JG; Patel, K; Poynard, T; Trepo, C1
Fehr, J; Kamal, SM; Peters, T; Rasenack, JW; Roesler, B1
Samuel, D1
Carbone, A; Carella, C; Cioffi, M; Mazziotti, G; Morisco, F; Sorvillo, F1
Dupke, S; Gölz, J; Klausen, G; Lichterfeld, M; Mauss, S; Mudar, M; Nischalke, HD; Notheis, G; Rockstroh, JK; Stein, L1
Bassit, L; Carrilho, FJ; da Silva, LC; Madruga, CL; Nishiya, A; Ono-Nita, SK; Pinho, JR1
Affrime, MB; Chung, C; Glue, P; Gupta, SK; Hajian, G; Heft, S; Jen, J; Laughlin, M1
Angelico, M; Araco, A; Bergamini, A; Bolacchi, F; Cepparulo, M; Ombres, D; Rocchi, G; Tisone, G1
Blanco, F; Garcia-Benayas, T; Soriano, V1
Bowden, S; Dev, AT; McCaw, R; Sievert, W; Sundararajan, V1
Doo, E; Everhart, JE; Ghany, MG; Heller, T; Hoofnagle, JH; Liang, TJ; Park, Y; Promrat, K; Soza, A1
Gehring, S; Gerner, P; Lang, T; Wirth, S1
Christiansen, L; Der-Petrossian, M; Ferenci, P; Gangl, A; Jessner, W; Maier, H; Steindl-Munda, P1
Agesta, N; Díaz-Pérez, JL; Zabala, R1
Dorak, MT; Folayan, GO; Kaslow, RA; Niwas, S; Tang, J; van Leeuwen, DJ; Yee, LJ1
Bass, EB; Chander, G; Gebo, KA; Herlong, HF; Jenckes, MW; Sulkowski, MS; Torbenson, MS1
Aprili, G; Capra, F; de Maria, E; Franchini, M; Gandini, G; Pattacini, C; Rossetti, G; Tagliaferri, A; Veneri, D1
Changchien, CS; Chen, CH; Chen, TM; Hung, CH; Lee, CM; Lu, SN; Tung, HD; Wang, JH1
Alain, S; Denis, F; Karaaslan, H; Le Meur, Y; Liozon, E; Loustaud-Ratti, V; Paraf, F; Vidal, E1
Andreone, P; Andriulli, A; Bruno, S; Cammà, C; Caporaso, N; Chiesa, A; Cino, L; Craxì, A; Crosignani, A; Di Marco, V; Freni, M; Gramenzi, AG; Lo Iacono, O; Mangia, A; Morisco, F; Puoti, M; Rumi, MG; Saracco, G; Schepis, F; Spadaro, A1
Bürger, E; Meier, V; Mihm, S; Ramadori, G; Saile, B1
Hamidah, A; Jamal, R; Yong, JF; Zulkifli, HI1
Blanc, F; Dereure, O; Guilhou, JJ; Larrey, D; Raison-Peyron, N1
Avenhaus, W; Domschke, W; Menzel, J; Poremba, C; Ullerich, H1
Malfertheiner, P1
Benhamou, Y; Cacoub, P1
Poynard, T3
Cacoub, P; Duhaut, P; Ghillani, P; Leger, JM; Lidove, O; Maisonobe, T; Myers, RP; Piette, JC; Servan, J; Thibault, V1
Myaing, M; Stein, DF1
Bessard, G; Larrat, S; Plages, A; Souvignet, C; Stanke-Labesque, F; Zarski, JP1
Pár, A1
Emens, LA; Sulkowski, MS1
Golzman, G; Hallevy, C; Herishanu, Y; Medvedovsky, M; Vander, T1
De Lalla, F; Fabris, P; Giordani, MT; Tositti, G1
Yang, G; Yang, X; Zhang, H1
Morisada, A; Ogawa, M1
Rakov, NE1
Bacon, BR4
Dantzler, TE; Lawitz, EJ1
Dejica, D; Dejica, V; Grigorescu, M; Neculoiu, D; Radu, C1
Folwaczny, C; Grunze, H; Heldwein, W; Koenig, A; Loeschke, K; Lorenz, R; Martin, G; Schaefer, M; Schindlbeck, N; Schmidt, F; Soyka, M1
Chen, DS; Chen, PJ; Chen, W; Kao, JH; Lai, MY2
Allen, SA; Cabral, AM; Osei, AM; Rich, JD; Spaulding, AC; Taylor, LE1
Datz, C; Ferenci, P; Gangl, A; Hackl, F; Hofer, H; Jessner, W; Kessler, H; Stauber, R; Watkins-Riedel, T1
Boyd, DG; McHutchinson, J; Pockros, PJ; Reddy, R; Reindollar, R; Wilkes, LB; Wright, T1
Carenzi, S; Ciancio, A; Olivero, A; Rizzetto, M; Saracco, G1
Hadziyannis, S; Koskinas, J; Manesis, E; Merkouraki, P1
King, J; Kooragayala, LM; Liang, C; Schulman, JA1
Calvo, F; Córdoba, J; Garijo, R; Gobernado, M; Jaén, J; López, L; Martínez, F; Molina, JM; Olaso, V; Siles, MS1
Kurth, BM; Manns, MP; McHutchison, JG; Ravens-Sieberer, U; Rossol, S; Siebert, U; Sroczynski, G; Wasem, J; Wong, JB1
Adams, P1
Bau, I; Beltrán, B; Calvo, F; Córdoba, J; Gobernado, M; López, B; Martínez, B; Molina, JM; Monte, E; Olaso, V; Siles, MS1
Okai, T; Sawabu, N; Shirasaki, F1
Berg, T; Gerlach, T; Herrmann, E; Hinrichsen, H; Hopf, U; Sarrazin, C; Wiedenmann, B; Zachoval, R; Zeuzem, S1
Cheung, R; Cooper, S; Greenberg, HB; He, XS; Ji, X; Li, Q1
Ahmed, SN; Albrecht, JK; Baulieux, J; Bismuth, H; Bizollon, T; Chevallier, M; Cohard, M; Ducerf, C; Feray, C; Geffner, M; Lemonnier, C; Reynes, M; Roche, B; Samuel, D; Trepo, C1
Changchien, CS; Chen, TM; Chen, WJ; Hu, TH; Hung, CH; Lee, CM; Lee, JF; Lu, SN; Tung, HD; Wang, JH1
Myers, RP; Poynard, T; Thibault, V1
Abbati, G; Boccia, S; Castagnetti, E; Distasi, M; Fabris, P; Fattovich, G; Felder, M; Fornaciari, G; Giusti, M; Lomonaco, L; Minola, E; Montanari, R; Pantalena, M; Paternoster, C; Redaelli, A; Rizzo, C; Rovere, P; Scattolini, C; Suppressa, S; Tagger, A; Tonon, A; Tositti, G; Zagni, I1
Crespo, J; Diago, M; Muñoz-Sánchez, M; Pérez, R; Romero-Gómez, M; Sánchez-Tapias, JM1
Farrell, GC; George, J; Kumar, D; Liddle, C; Lin, R; Samarasinghe, D; Wallington-Beddoe, C1
Buti, M; Cabasés, JM; Guillén-Grima, F; Mar, J; San Miguel, R1
Buti, M; Casado, MA; Esteban, R; Fosbrook, L; Medina, M; Wong, JB1
Massoud, OI; Mullen, KD; Yousef, WI1
Chang, TT; Chen, CY; Cheng, PN; Chow, NH; Hu, SC; Jen, CM; Young, KC1
Kuzmic, P; Lake-Bakaar, G; Ruffini, L1
Baran, A; Cagatay, T; Guneylioglu, D; Mert, A; Ozaras, R; Ozseker, F; Senturk, H; Tahan, V; Ucisik, AC; Yilmazbayhan, D1
Alvarez Delgado, A; Carneros Martín, JA; Fuentes Coronel, A; González San Martín, F1
Delahooke, TE; Hayes, PC; Kilpatrick, DC; Koch, C; Turner, ML1
Curran, MP; Keating, GM1
Chan, AO; Hui, CK; Lai, CL; Sablon, E; Wong, BC; Yuen, MF1
Battezzati, PM; Bissoli, F; Borzio, M; Bruno, S; Ceriani, R; Chiesa, A; Crosignani, A; Fargion, S; Fiorelli, G; Fracanzani, AL; Maraschi, A; Morini, L; Orlandi, A; Podda, M1
Ivanikov, IO; Pomova, NI; Siutkin, VE1
Amaraa, R; Fucikova, T; Mareckova, H; Urbanek, P2
Hirose, Y; Izumi, N; Kumada, H; Tsubota, A1
Caini, P; Gentilini, P; Giannelli, F; Giannini, C; Gragnani, L; La Villa, G; Laffi, G; Monti, M; Moscarella, S; Romanelli, RG; Solazzo, V; Zignego, AL1
Chapman, WC; Crippin, J; Jaramillo, A; Lisker-Melman, M; Mohanakumar, T; Sreenarasimhaiah, J1
Adinolfi, LE; Ruggiero, G; Tonziello, A; Utili, R1
Horiike, N; Onji, M1
Kaslow, RA; Perez, KA; Tang, J; van Leeuwen, DJ; Yee, LJ1
Allan, JE; Jeffrey, GP; MacQuillan, GC; Mamotte, C; Reed, WD1
Arribas, JR; Barreiro, P; Castro, A; García-Samaniego, J; González, J; Jiménez-Nácher, I; Martín-Carbonero, L; Núñez, M; Pedreira, J; Pérez-Olmeda, M; Romero, M; Soriano, V1
Dupon, M; Fleury, H; Galpérine, T; Lafon, ME; Legrand, E; Moreau, JF; Neau, D; Neau-Cransac, M; Pitard, V; Ragnaud, JM1
Dehesa Violante, M1
Juárez Navarro, JA1
Del Vecchio, C; Durante Mangoni, E; Marrone, A; Ruggiero, G; Saviano, D; Utili, R1
Carducci, B; Caruso, A; Cavaliere, AF; De Santis, L; De Santis, M; Lucchese, A; Straface, G1
Buti, M; Esteban, R; Lurie, Y; Sánchez-Avila, F; Valdés, A1
Iino, S3
Forns, X; Martínez-Bauer, E1
Hino, T; Hisamochi, A; Ide, T; Koga, Y; Kumashiro, R; Kuwahara, R; Ogata, K; Okamura, T; Sata, M; Seki, R; Tanaka, K1
Aprosina, ZG; Ignatova, TM; Il'iankova, AA; Krel', PE; Sekamova, SM; Serov, VV; Tanashchuk, EL1
Capra, F; De Maria, E; Franchini, M; Marchiori, L; Thalheimer, U; Vantini, I1
Abbate, I; Antonucci, G; Capobianchi, MR; Cappiello, G; Craxi, A; Di Marco, V; Di Stefano, R; Ferraro, D; Ippolito, G; Lo Iacono, O; Longo, R; Solmone, M1
Flamm, SL1
Andrès, E; Geisler, F; Maloisel, F; Noel, E; Pflumio, F1
Benech, H; Bonnet, E; Bouvier-Alias, M; Chêne, G; Goujard, C; Lassalle, R; Morlat, P; Payan, C; Pérusat, S; Pruvost, A; Salmon-Céron, D; Sogni, P; Tréluyer, JM; Zoulim, F1
Bianca, S; Ettore, G1
Batey, R; Bhathal, P; Bowden, S; De Solom, R; Marinos, G; McDonald, J; Mollison, L; Pianko, S; Reed, W; Sievert, W; Warner, S1
Beld, MG; Dijkgraaf, MG; Reesink, HW; Sentjens, RE; Weegink, CJ1
Aggelis, P; Akriviadis, E; Avgerinos, A; Giannoulis, G; Goritsas, K; Hatzakis, A; Hatzis G, G; Kanatakis, S; Ketikoglou, I; Manolakopoulos, S; Paraskevas, E; Raptopoulou, M; Sypsa, V; Tassopoulos, NC; Thomopoulos, K; Tsantoulas, D; Tzathas, C; Vafiadis, I; Vassiliadis, T1
Beaugrand, M; Bedossa, P; Bissery, A; Brissot, P; Bronowicki, JP; Buffet, C; Chaumet-Riffaud, P; Daurat, V; Degos, F; Dhumeaux, D; Eugene, C; Gayno, S; Larrey, D; Marcellin, P; Moussalli, J; Myers, RP; Naveau, S; Pol, S; Poynard, T; Riachi, G; Samuel, D; Serfaty, L; Sogni, P1
Bekkering, FC; Brouwer, JT; Hansen, BE; Schalm, SW; Vrolijk, JM1
Abergel, A; Alleman, I; Arpurt, JP; Bailly, F; Bernard, PH; Blanc, F; Botta-Fridlund, D; Botti, G; Bourlière, M; Caroli-Bosc, F; Chazouillères, O; Couzigou, P; De Lédinghen, V; Debonne, JM; Doll, F; Ducloux, S; Eugène, C; Gauthier, AP; Gérolami, A; Gérolami, V; Gouvernet, J; Grimaud, JC; Halfon, P; Khiri, H; Larrey, D; Mathieu-Chandelier, C; Moreau, X; Ouzan, D; Picon, M; Pol, S; Portal, I; Sogni, P; Thiefin, G; Vetter, D; Zamora, C1
Maygers, J; Pande, H; Thuluvath, PJ1
Belli, L; Civardi, E; Leveri, M; Marinelli, D; Rossi, L; Silini, EM1
Blanco, M; García Flores, MA; Graus, J; Pérez Mota, A; Pérez-Muñoz, C; Rodero, R; Villalgordo, C1
Fried, MW; Russo, MW2
Aytaman, A; Bini, EJ; Bräu, N; Finch, DA; Stancic, S1
Adams, O; Behlen-Wilm, U; Donner, A; Erhardt, A; Häussinger, D; Heintges, T1
Berg, T; Buggisch, P; Gerlach, T; Goeser, T; Herrmann, E; Hinrichsen, H; Hopf, U; Kronenberger, B; Nasser, S; Pape, GR; Spengler, U; Wursthorn, K; Zeuzem, S2
Baker, DE1
Appleby, TC; Hong, Z; Lau, JY; Walker, MP; Zhong, W1
Boeri, E; De Bona, A; Galli, L; Gallotta, G; Lazzarin, A; Morsica, G; Uberti-Foppa, C1
Bartenschlager, R; Haagmans, BL; Hansen, BE; Kaul, A; Lohmann, V; Schalm, SW; Vrolijk, JM1
Bioulac-Sage, P; Chêne, G; Dupon, M; Lacoste, D; Lafon, ME; Le Bail, B; Neau, D; Ragnaud, JM; Rullier, A; Trimoulet, P; Winnock, M1
Cornberg, M; Felten, G; Hüppe, D; Manns, MP; Wedemeyer, H; Wiegand, J1
Hrachovec, J; Patel, P1
Barreiros, AP; Galle, PR; Gerken, G; Löhr, HF; Schlaak, JF1
Akdogan, M; Bozdayi, M; Bozkaya, H; Ersoz, G; Kaymakoglu, S; Mert, A; Ozaras, R; Ozbay, G; Senturk, H; Tabak, F; Yenice, N1
Bendtsen, F; Holten-Andersen, M; Johansen, JS; Krarup, HB; Møller, A; Nøjgaard, C1
Aucella, F; Bunnapradist, S; Fabrizi, F; Lunghi, G; Martin, P1
Dev, A; McHutchison, JG; Muir, AJ; Patel, K1
Doo, E; Everhart, JE; Ghany, MG; Heller, T; Herion, D; Hoofnagle, JH; Khokhar, F; Kleiner, DE; Liang, TJ; Ong, J; Park, Y; Promrat, K; Soza, A1
Hoofnagle, JH; Soza, A1
Cointault, O; Durand, D; Izopet, J; Kamar, N; Ribes, D; Rostaing, L; Sandres-Saune, K; Selves, J1
Smith, C1
Guntz, P; Lunel, F; Maniez-Montreuil, M; Payan, C; Picchio, G; Veillon, P1
Goldie, SJ; Hammitt, JK; Salomon, JA; Weinstein, MC1
Dejica, D; Grigorescu, M; Neculoiu, D; Radu, C; Zaharie, T1
Folwaczny, C; Glas, J; König, A; Martin, K; Schaefer, M; Schiemann, U; Schmidt, F; Simperl, C; Török, HP1
Juszczyk, J2
Arif, A; Bank, L; Gregory, DH; Levine, RA; Mahl, TC; Sanderson, SO; Shah, A; Velu, RP1
Aguilar-Reina, J; Barroso, N; González-Escribano, MF; Montes-Cano, MA; Núñez-Roldan, A; Romero-Gómez, M; Sánchez-Muñoz, D; Torres, B1
Ahlenstiel, G; Berg, T; Brackmann, HH; Grünhage, F; Hess, L; Iwan, A; Kupfer, B; Sauerbruch, T; Schernick, A; Spengler, U; Woitas, RP1
McHutchison, JG; Patel, K2
Zhang, F1
Desmet, VJ; Roskams, T1
Boucher, EJ; Brissot, P; Canva, V; Colimon, R; Deugnier, Y; Guyader, D; Jacquelinet, C; Jacquelinet, S; Turlin, B1
Brunner, H; Datz, C; Ferenci, P; Gangl, A; Gschwantler, M; Hackl, F; Hofer, H; Jessner, W; Nachbaur, K; Rosenbeiger, M; Stauber, R; Steindl-Munda, P; Vogel, W1
Shobokshi, OA2
Al-Jaser, NM; Serebour, FE; Shobokshi, OA; Skakni, LI1
Al-Kayyal, BM; Shobokshi, OA; Tantawe, AO1
Campanozzi, F; D'Adduzio, A; Fazio, V; Grimaldi, M; Scotto, G1
Dieterich, DT; Spivak, JL1
Cadranel, JF; Djilloul, A; Pariente, A1
Niaz, A1
Bagri, AS; Dural, AT; Khaoustov, VI; Shtenberg, KM; Tran, T; Yoffe, B1
Tsolakos, A; Zalatimo, N1
Keeffe, EB3
Dixit, NM; Golia, P; Perelson, AS; Powers, KA; Ribeiro, RM; Talal, AH1
Herrmann, E; Welsch, C; Zeuzem, S1
Craxi, A; Licata, A1
Ma, QY1
Bressler, BL; Guindi, M; Heathcote, J; Tomlinson, G1
Albrecht, J; Davis, GL; Harvey, J; Manns, MP; McHutchison, JG; Wong, JB1
Heathcote, EJ; Manoharan, P; Moskovitz, DN1
Heathcote, J; Liu, LW; Mazzulli, T; Murray, A; Tomlinson, G1
Adler, M; Brouwer, JT; Delwaide, J; Hansen, BE; Michielsen, P; Nevens, F; Schalm, SW; Veldt, BJ1
Folwaczny, C; Glas, J; König, A; Martin, K; Schaefer, M; Schiemann, U; Schmidt, F; Simperl, C; Török, P1
Berkowitz, D; Hartman, C; Rimon, N; Shamir, R1
Bourlière, M; Cacoub, P; Chadapaud, S; Halfon, P; Khiri, H; Neumann, AU; Ouzan, D; Rieu, A1
Anagnostopoulos, G; Hatzakis, A; Hatzis, G; Kanatakis, S; Ketikoglou, I; Raptopoulou, M; Sidiropoulos, L; Sypsa, V; Tassopoulos, NC; Tsantoulas, D; Vafiadis, I1
Kessel, A; Sabo, E; Slobodin, G; Toubi, E; Yeshurun, D; Zuckerman, E1
Arnold, R; Berg, T; Herrmann, E; Junge, U; Kullmann, F; Lafrenz, M; Musch, E; Pascu, M; Pausch, J; Ramadori, G; Teuber, G; Weidenbach, H; Wiedmann, KH; Zankel, M; Zeuzem, S1
Cadranel, JF; Dumouchel, P; Gouérou, H; Legrand, MC; Nousbaum, JB; Savary, O1
Allison, M; Carithers, RL; Elizaga, M; Gaba, K; Gretch, DR; McElrath, MJ; Morishima, C; Musey, L1
Courcambeck, J; Halfon, P; Joly, H; Khiri, H; Ouzan, D; Pénaranda, G; Tran, A1
Maier, KP2
Degertekin, H; Kilinc, N; Yalcin, K; Yildiz, F1
Rodés, J1
Berenguer, M; Wright, TL2
Fennerty, MB; Keeffe, EB; Zaman, A1
Kerl, K; Lübbe, J; Negro, F1
Alaeus, A; Fischler, B; Reichard, O; Uhnoo, I; Weiland, O; Wejstål, R1
Bajaj, JS; Jeffers, LJ; Molina, E; Regev, A; Schiff, ER1
Beckebaum, S; Broelsch, CE; Cicinnati, VR; Dirsch, O; Erim, Y; Frilling, A; Gerken, G; Karliova, M; Malago, M; Treichel, U1
Calleja, JL; Castillo, P; Erdozain, JC; Escartín, P; Olveira, A; Segura, JM; Serrano, C1
Cruz, CN; Ferraz, ML; Kirsztajn, GM; Lopes, EP; Silva, AE; Valente, LM1
Kaplan, AL; Sidhu-Malik, NK1
Fried, MW; Russo, MW; Zacks, SL1
Duncan, M; Younossi, Z1
García González, N; Prieto Valtueña, J1
Abergel, A; Bacq, Y; Blanchi, A; Causse, X; Fouchard-Hubert, I; Loustaud-Ratti, V; Lunel, F; Payan, C; Rifflet, H; Silvain, C; Veillon, P1
Benedetti, P; Bertin, T; Boccia, S; Capanni, M; Carlotto, A; Costa, P; Fattovich, G; Felder, M; Ferrara, C; Giusti, M; Lisa Ribero, M; Lomonaco, L; Marin, R; Mazzella, G; Milani, S; Minola, E; Miracolo, A; Pantalena, M; Paternoster, C; Rizzo, C; Rossini, A; Rovere, P; Scattolini, C; Suppressa, S; Tagger, A; Zagni, I1
Belaye, T; Hui, CK; Lau, E; Monto, A; Wright, TL1
Jiao, J; Wang, JB2
del Mar Alcalde, M; Jiménez, C; Narváez, I; Pérez, B; Soria, A1
Barbakadze, G; Butsashvili, M; Jatchvliani, D; Kamkamidze, G; Kiladze, M1
Duvnjak, M; Hrabar, D; Pavić, T; Virović, L1
Sievert, W1
Busuttil, RW; Saab, S1
Annese, M; Babudieri, S; Bacca, D; Barbarini, G; Barbaro, G; Belloni, G; Francavilla, R; Fruttaldo, L; Grisorio, B; Hazra, C; Lucchini, A; Matarazzo, F; Rizzo, G; Torre, D1
Avataneo, T; Badalamenti, S; Framarin, L; Rosina, F; Salzedo, E; Tappero, G1
Buggisch, P; Grossmann, J; Koop, K; Reiser, M; Schmiegel, W; Wursthorn, K1
Haagmans, BL; Hansen, BE; Janssen, HL; Kwekkeboom, J; Osterhaus, AD; Schalm, SW; Vrolijk, JM; Zondervan, PE1
August-Jörg, BS; Borovicka, J; Dufour, JF; Gonvers, JJ; Henz, S; Hermann, R; Meyenberger, C; Renner, EL; Weitz, M1
Blanco, MI; Crespo, J; Diago, M; Enríquez, J; Jiménez, M; Melón, S; Olcoz, JL; Oña, M; Pérez, R; Rodrigo, L; Romero, M; Salmerón, J; Solá, R; Vaquero, P1
Adler, M; Bastens, B; Bourgeois, N; Brenard, R; Brouwer, J; Bruckers, L; Colle, I; de Galocsy, C; de Vries, RA; Delwaide, J; Henrion, J; Horsmans, Y; Leroux-Roels, G; Michielsen, P; Nevens, F; Robaeys, G; Van Vlierberghe, H1
Castéra, L; Couzigou, P; de Lédinghen, V; Fleury, H; Foucher, J; Trimoulet, P1
Dev, A; McHutchison, JG; Muir, A; Patel, K1
Albrecht, JK; Davis, GL; Manns, MP; McHutchison, JG; Wong, JB1
Bini, EJ; Bowers, PJ; Bräu, N; Dieterich, DT; Hassanein, TI; Sulkowski, MS; Wasserman, R1
García-Buey, L; Medina, J; Moreno-Monteagudo, JA; Moreno-Otero, R; Trapero-Marugán, M1
Arlt, AC; Dennin, RH; Gause, A; Gross, WL; Gutzeit, O; Lamprecht, P; Lerin-Lozano, C; Merz, H; Peters, SO; Solbach, W; Voswinkel, J1
Brillanti, S; Levantesi, F; Nigro, G; Roda, E; Vicari, S1
Rubin, RA1
Cheng, DM; Lagakos, SW1
Klinker, H1
Chapman, MD; Chester, BP; De Boer, B; Forster, E; Garas, G; Jeffrey, GP; Kontorinis, N; MacQuillan, GC; Speers, D; Young, J1
Nierengarten, MB1
Everson, GT; Forman, LM; Medeiros, BC; Seligman, PA1
Chengyu, P; Fujioka, S; Ikeda, F; Iwasaki, Y; Nakajima, H; Ohnishi, Y; Shimomura, H; Shiratori, Y; Takagi, SJ; Taniguchi, H; Umeoka, F1
Anania, FA; Black, M; Fairbanks, KD; Gelrud, LG; Lobis, IF; Maheshwari, A; Mehdi, J; Ryan, MJ; Thuluvath, PJ; Wu, LL1
Barcena, R; del Campo, S; Mateos, M; Moraleda, G; Moreno, J1
Lai, CL; Poynard, T; Ratziu, V; Yuen, MF1
Asensi, V; Blanch, J; García-Samaniego, J; Guardiola, J; Jiménez-Nácher, I; Morales, D; Núñez, M; Ochoa, A; Pérez-Olmeda, M; Romero, M; Sánchez-Montero, F; Santin, M; Soriano, V1
Haagsma, EB; Meijer, K; van der Meer, J1
Sánchez Tapias, JM1
Alfageme Michavila, I; Lara Lara, I; López Garrido, J; Merino Sánchez, M; Pérez Ronchel, J; Suárez García, E1
Dev, A; McHutchison, JG; Patel, K1
Primo Vera, J1
Bernstein, D1
Engler, S; Flechtenmacher, C; Gugler, R; Kallinowski, B; Stremmel, W; Wiedemann, KH1
Drouet, E; Hilleret, MN; Thelu, MA; Zarski, JP1
Funakoshi, S; Kiribayashi, Y; Maeda, Y; Maruhashi, A; Moriya, T; Murakami, T; Omoda, K; Takano, M1
Halota, W; Pawłowska, M4
Fehér, J; Fehérvári, I; Görög, D; Kóbori, L; Lengyel, G; Nemes, B; Patonai, A; Perner, F; Sárváry, E; Varga, M1
Khokhar, N3
Bevilacqua, P; Bozzola, L; Brown, D; de Lalla, F; Dusheiko, G; Fabris, P; Giordani, MT; Tositti, G; Webster, GJ1
Bauditz, J; Roske, AE; Schmidt, HH1
Carter, DJ; Elpern, DJ; Moore, MM1
Hayashi, N; Hiramatsu, N1
Goyal, A; Guptan, RC; Hashmi, AZ; Kumar, S; Malhotra, V; Sakhuja, P; Sarin, SK1
Alberti, A; Craxi, A; De Carli, C; Giuliani, G; Green, J; Patel, KK; Sullivan, SD; Wintfeld, N1
Andriulli, A; Giacobbe, A; Iacobellis, A; Leandro, G; Mangia, A; Minoli, G; Montalto, G; Pazienza, V; Piattelli, M; Piermanni, V; Spinzi, G; Vuturo, O1
Sette Júnior, H; Strauss, E1
Conca, P; Perrella, A; Perrella, O; Ragucci, P; Sorrentino, P; Tarantino, G1
Chen, DS; Chen, GH; Kao, JH; Lai, MY; Yang, SS1
Apolinario, A; Clemente, G; Diago, M; García-Monzón, C; Lo Iacono, O; Lorente, R; Majano, PL; Pérez, C1
Mascitelli, L; Pezzetta, F1
Castera, L; Dahari, H; Dhumeaux, D; Germanidis, G; Hezode, C; Lonjon, I; Neumann, AU; Pawlotsky, JM1
Ahmed, A; Keeffe, EB2
Figlerowicz, M; Kowala-Piaskowska, A; Mozer-Lisewska, I; Sluzewski, W1
Bonner, JO; Lyketsos, CG; Onyike, CU; Treisman, GJ1
Alam, I; Harb, G; Hu, S; Imperial, J; Klaskala, W; Perrillo, R; Rothstein, KD; Rubin, R1
Ackrill, AM; Balan, V; Bernstein, D; Bodenheimer, H; Diago, M; Hadziyannis, SJ; Lin, A; Marcellin, P; Morgan, TR; Pockros, PJ; Ramadori, G; Rizzetto, M; Sette, H; Zeuzem, S1
Benoni, G; Corrocher, R; Cuzzolin, L; Gabrielli, GB; Pasino, M; Perfetti, P; Stanzial, AM1
Chalupa, P; Husa, P; Husová, L; Penka, M; Smejkal, P1
Everson, GT; Fontana, RJ; Shiffman, ML; Tuteja, S; Vargas, HE1
Ball, L; Berggren, R; Dieterich, DT; Felizarta, F; Goodman, R; Khalili, M; Slim, J; Smith, C; Sulkowski, MS1
Ishida, F; Tanaka, E; Tanaka, N1
Baldini, V; Bardella, MT; Casella, G; Perego, D1
Boillot, O; Chevallier, P; Dumortier, J; Scoazec, JY1
Cooksley, G; Green, J; Hassanein, T; Horta E Vale, A; Lai, MY; Marinos, G; Pastore, G; Smith, C; Sulkowski, M; Trejo-Estrada, R; Wintfeld, N1
Bekkering, FC; Bourgeois, N; Brouwer, JT; Delwaide, J; Hansen, BE; Henrion, J; Lefebvre, V; Nevens, F; Schalm, SW; Van Hattum, J; Van Vlierberghe, H; Weegink, CJ1
Bahr, MJ; Manns, MP1
Rogers, CJ; Romagosa, R; Vincek, V1
Dietrich, CG; Gartung, C; Geier, A; Lammert, F; Lorenzen, J; Matern, S; Stolte, C; Wasmuth, HE1
Christensen, UB; Krogsgaard, K1
Bonkovsky, HL; Di Bisceglie, AM; Dienstag, JL; Everhart, JE; Everson, GT; Ghany, MG; Goodman, ZD; Lee, WM; Lindsay, KL; Lok, AS; Morgan, TR; Morishima, C; Shiffman, ML; Wright, EC1
Bonacini, M; Bräu, N; Frost, KR; Giffen, CA; Kostman, JR; Prokupek, D; Rodriguez-Torres, M; Smith, JJ1
Chi, CS; Chiu, CC; Fu, LS; Liao, YR; Lin, CC; Yen, CP1
Clavien, PA; Egger, HP; Fried, R; Giostra, E; Hadengue, A; Keller, W; Kraehenbuhl, S; Kullak-Ublick, GA; Locher, S; Mentha, G; Morel, P; Negro, F; Vanlemmens, C1
Cox, P; Jarrett, M1
Homma, M; Inoue, Y; Kohda, Y; Matsuzaki, Y; Mitamura, K; Shibata, M; Tanaka, N1
Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kobayashi, M; Kumada, H; Saitoh, S; Someya, T; Suzuki, F; Suzuki, Y; Tsubota, A2
Allan, JE; English, S; Garas, G; Harnett, GB; Jeffrey, GP; Macquillan, GC; Niu, X; Reed, WD; Speers, D1
Kobayashi, K; Niitsuma, H; Satoh, H; Shiina, M; Shimosegawa, T; Ueno, Y1
Antela, A; Bárcena, R; Casado, JL; Dronda, F; Mateos, ML; Moreno, A; Moreno, L; Moreno, S; Perez-Elías, MJ; Quereda, C1
Benhamou, Y; Bochet, M; Mehri, D; Myers, RP; Poynard, T; Thibault, V1
Alatrakchi, N; Autran, B; Benhamou, Y; Di Martino, V; Katlama, C; Poynard, T; Thibault, V1
Bottieau, E; Callens, S; Colebunders, R; Michielsen, P1
Abbate, I; Antonucci, G; Capobianchi, MR; Cappiello, G; Craxì, A; Di Marco, V; Di Stefano, R; Ferraro, D; Girardi, E; Ippolito, G; Lo Iacono, O; Longo, R; Solmone, M1
Borghi-Scoazec, G; Claudy, A; Merle, P; Scoazec, JY; Trepo, C1
Balestreri, L; Canzonieri, V; Cinelli, R; Dal Maso, L; Di Gennaro, G; Fedele, P; Nasti, G; Tedeschi, R; Tirelli, U1
Andreone, P; Bagaglio, S; Bruno, R; De Mitri, MS; Lazzarin, A; Morsica, G1
Hivnor, CM; Honig, PJ; Junkins-Hopkins, JM; Yan, AC1
Colombo, M; De Filippi, F; Mannucci, PM; Rivi, M; Rumi, MG; Santagostino, E1
Buffet, C2
Bain, C; Couzigou, P; Decullier, E; Epstein, A; Goutagny, N; Inchauspe, G; Ligeoix, B; Trepo, C; Vieux, C1
Bräu, N3
Lobos, IV; Marinho, RT; Moura, MC; Pinto, R; Santos, ML1
Ishii, H; Kinoshita, M; Kumagai, N; Saito, H; Takahashi, N; Tsuchimoto, K; Tsunematsu, S1
Fontana, RJ; Lok, AS; Marrero, JA; Oberhelman, K; Shehab, TM; Su, GL1
Dries, V; Goeser, T; Kasper, HU; Petersen-Benz, C1
Asnis, GM; De La Garza, R; Miller, AH; Raison, CL1
Bihl, F; Grattagliano, I; Jüni, P; Lauterburg, BH; Palasciano, G; Palmieri, VO; Portincasa, P; Russmann, S1
Buti, M; Esteban, R; Jardi, R; Mendez, C; Rodriguez-Frias, F; Sauleda, S; Schaper, M; Valdes, A1
Brechmann, T; Griga, T; Henke, H; Schmiegel, W; Voigt, E1
Contos, MJ; Hofmann, CM; Luketic, VA; Mills, AS; Sanyal, AJ; Shiffman, ML; Sterling, RK1
Denk, DM; Ferenci, P; Formann, E; Gangl, A; Jessner, W; Munda-Steindl, P; Stauber, R; Zollner, G1
Hrnicek, MJ; Mailliard, ME1
Arguedas, M1
Peters, T; Rasenack, J; Reincke, M; Schories, M1
Basso, M; Delfino, A; Pelli, N; Picciotto, A; Rossol, S; Torre, F1
Manjón-Haces, JA; Pérez-Alvarez, R; Pérez-Oliva, N; Vázquez-López, F1
Bielawski, KP; Lakomy, EA; Michalska, Z; Sikorska, K; Stalke, P; Witczak-Malinowska, K1
Chrapek, M; Kryczka, W; Zarebska-Michaluk, D1
Gonciarz, M; Gonciarz, Z; Jurzak, M; Kajdy, M; Mazur, W; Mazurek, U; Wilczok, T1
García-Samaniego, J; González-Lahoz, J; Núñez, M; Pérez-Olmeda, M; Ríos, P; Soriano, V1
Albrecht, J; Bourliere, M; Brass, C; Goeser, T; Harvey, J; Hultcrantz, R; Marcellin, P; Sanchez-Tapias, J; Sarrazin, C; Zeuzem, S1
Ferenci, P; Hofer, H; Jessner, W; Osterreicher, C; Penz, M; Steindl-Munda, P; Wrba, F1
Bornstein, JD; Killenberg, PG; Muir, AJ1
Lehmann, M; Manns, MP; Meyer, MF; Monazahian, M; Tillmann, HL; Wedemeyer, H1
Koff, JM; Younossi, Z1
Reddy, KR2
Bruno, R; Filice, G; Maiocchi, L; Sacchi, P; Zocchetti, C1
Fried, MW2
Keeffe, EB; Nguyen, MH1
Agarwal, K; Dieterich, DT; Kontorinis, N1
Everson, GT1
Cassidy, W; Howell, CD; Hu, S; Jeffers, LJ; Reddy, KR1
Chu, CM; Liaw, YF; Sheen, IS1
Breadmore, MC; Theurillat, R; Thormann, W1
Altman, RD; Concha, R; Herrera, I; Molina, EG; Schiff, ER1
Merican, I; Suresh, RL; Suryati, Y1
Gregor, M; Hass, HG; Kaiser, S; Kreysel, C; Nehls, O1
Asahina, Y; Hamano, K; Inoue, K; Itakura, J; Izumi, N; Kurosaki, M; Miyake, S; Nishimura, Y; Tsuchiya, K; Uchihara, M; Ueda, K1
Buti, M1
Bolognini, S; Careddu, GF; Cottoni, F; Deplano, A; Garrucciu, G; Lissia, A; Manzoni, NE; Montesu, MA; Solinas, A; Tocco, A1
Gudinaviciene, I; Jonaitis, L; Kupcinskas, L; Petrenkiene, V2
Han, KH; Yoon, YH1
Bonfissuto, G; Carroccio, A; Di Giovanni, G; Montalto, G; Riili, A; Sesti, R; Soresi, M; Tripi, S1
Ascione, A; Caporaso, N; Carbone, A; Fogliano, V; Marmo, R; Morisco, F; Scarpati, S; Stingo, S; Vitaglione, P1
Adams, O; Erhardt, A; Haussinger, D; Heintges, T; Kirschberg, O; Sagir, A1
Annicchiarico, BE; Siciliano, M1
Huang, SB; Liao, BM; Luo, GH1
Farrell, GC; Teoh, NC1
Husa, P; Husová, L; Penka, M; Smejkal, P1
Cholongitas, E; Papatheodoridis, GV2
Brouwer, JT; Haagmans, BL; Herscheid, AJ; Janssen, HL; Kusters, JG; Kwekkeboom, J; Schalm, SW; Tang, TJ; Vrolijk, JM1
Guardo, P; La Spina, M; Lo Nigro, L; Mirabile, E; Pisana, P; Schilirò, G1
Ammassari, A; Cauda, R; Cingolani, A; De Luca, A; Di Giambenedetto, S; Fantoni, M; Marasca, G; Tamburrini, E; Tumbarello, M1
Berger, F; Goelz, J; Jacob, B; Mauss, S; Schmutz, G1
Douglas, DD; Rodriguez-Luna, H1
Heathcote, J; Ramji, A1
Kottilil, S; Kovacs, JA; Polis, MA1
Bacq, Y; Barbereau, D; Corcia, P; de Toffol, B; Guennoc, AM1
Dowling, J; Gordon, A; Jenkins, P; Menahem, S; Mitchell, J; Roberts, SK1
Durantel, D; Khattab, E; Ottevaere, I; Sablon, E; Trepo, C; Vieux, C; Vuillermoz, I; Zoulim, F1
Hegenbarth, K; Ille, R; Krause, R; Lahousen, T; Lipp, RW; Little, RR; Schnedl, WJ1
Akbar, SM; Horiike, N; Murakami, H; Onji, M; Tsubouchi, E1
Cantu, NS; Hepburn, LM; Hepburn, MJ; Lapeer, MG; Lawitz, EJ1
Amati, L; Caccavo, D; Cozzolongo, R; Cuppone, R; Jirillo, E; Manghisi, OG; Pellegrino, NM1
Cozzolongo, R; Maiellaro, PA; Marino, P1
Barnes, E; De Lalla, F; Fabris, P; Giordani, MT; Grasso, A; Tositti, G1
Carosi, G; De Pamphilis, J; Dieterich, DT; Duff, F; Gonzalez-García, J; Katlama, C; Lazzarin, A; Lissen, E; Montaner, J; Passe, S; Rockstroh, JK; Rodriguez-Torres, M; Sasadeusz, J; Schrenk, UM; Sette, H; Torriani, FJ1
Alston, B; Andersen, J; Bhan, AK; Chung, RT; Colquhoun, D; Harb, G; Koziel, MJ; Liu, T; Nevin, T; Peters, MG; Robbins, GK; Sherman, KE; van der Horst, C; Volberding, P1
Artioli, S; Carosi, G; Maggiolo, F; Mignani, E; Paraninfo, G; Pastore, G; Puoti, M; Quinzan, GP; Raise, E; Ravasio, L; Resta, F; Rollo, A; Santantonio, T; Suter, F; Verucchi, G; Zaltron, S; Zanini, B1
Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kobayashi, M; Kumada, H; Saitoh, S; Someya, T; Suzuki, F; Suzuki, Y; Takaki, S; Tsubota, A1
Itoh, Y; Okanoue, T1
Acharya, SK; Batra, Y; Gupta, SD; Hazari, S; Panda, SK; Singh, R1
Baluch, MH; Dhillon, S; Farr, D; George, MM; Li, SD; Mindikoglu, AL; Van Thiel, DH1
Bernstein, DE; Cheinquer, H; Cooksley, G; Craxi, A; Foster, GR; Green, J; Hassanein, TI; Jensen, DM; Klaskala, W; Lee, SS; Patel, KK; Pettit, K; Sullivan, SD1
Anand, BS; Batash, S; Bini, EJ; Chaudhari, S; Dieterich, DT; Park, J; Pimstone, NR1
Cupelli, L; DePamphilis, J; Dieterich, D; Duff, F; Larrey, D; Mauss, S; Passe, S; Solsky, J; Torriani, FJ; Valenti, W1
Bargallo, X; Blanco, JL; de Lazzari, E; García-Criado, A; Gatell, JM; Laguno, M; Larrousse, M; León, A; Loncá, M; Mallolas, J; Martínez, E; Milinkovic, A; Miquel, R; Murillas, J; Sánchez-Tapias, JM1
Campbell, C; Farel, C; Koratich, C; Kottilil, S; Masur, H; McLaughlin, M; Metcalf, JA; Polis, MA; Robinson, MR; Suzman, DL1
Chamberlain, AJ; Poon, E1
Backmund, M; Heinz, A; Schaefer, M1
Aigner, ES1
Moriguchi, H; Sato, C1
Anwar, M; Hussain, AB; Hussain, S; Hussain, T; Karamat, KA; Kazmi, Y; Tariq, WU1
Khalili, M; Proietti, N1
Afdhal, NH; Oh, S1
Ahmed, F; Jacobson, IM1
Fontana, RJ2
Ahmed, F; Antignano, L; Bach, N; Brown, RS; Dieterich, DT; Esposito, SP; Gabbaizadeh, D; Geders, J; Jacobson, IM; Klion, F; Lebovics, E; Levendoglu, H; Russo, MW; Tobias, H1
Al-Ajmi, M; Al-Khaldi, J; Al-Nakib, B; Asker, H; Hasan, F; Owaid, S; Siddique, I; Varghese, R1
Colombo, M; Del Ninno, E; Parravicini, ML; Ronchi, G; Rumi, MG; Russo, A; Soffredini, R1
Canva, V; De Maeght, S; Deltenre, P; Dharancy, S; Henrion, J; Louvet, A; Mathurin, P; Paris, JC; Texier, F1
Bruno, S; Cammà, C; Camozzi, M; Colombo, M; Craxì, A; Di Bona, D; Di Marco, V; Mondelli, MU; Pinzello, G; Rebucci, C; Rumi, M; Vinci, M1
Fried, MW; Hadziyannis, SJ1
Fabrizi, F; Martin, P; Poordad, FF1
Sterling, RK; Sulkowski, MS1
Charlton, M; Wiesner, R1
Brillanti, S1
Caporaso, N; De Luise, G; Fogliano, V; Marmo, R; Morisco, F; Ritieni, A; Tuccillo, C; Verde, V1
Gazdik, F; Hrusovsky, S; Pijak, MR1
Brown, GR; Browning, JD; Getachew, Y; Prebis, M; Rogers, T1
Enomoto, M; Habu, D; Kohmoto, M; Nishiguchi, S; Seki, S; Shiomi, S; Takeda, T; Tamori, A1
Imperial, JC; Keeffe, EB; Lim, JK1
Asahina, Y; Izumi, N1
Kaneko, S; Nakamoto, Y1
Fukuda, A1
Hayashi, N; Iyoda, K; Kato, M; Yamamoto, K; Yuki, N1
Iyoda, K; Kato, M1
Kakumu, S2
Kondo, Y; Omata, M; Tateishi, R; Yoshida, H1
Izumi, N2
Imazeki, F1
Yamada, G1
Makuuchi, M; Sugawara, Y1
Hokari, A; Zeniya, M1
Nishiguchi, S; Tamori, A1
Apollonio, L; Avellini, C; Caldato, M; Fabris, C; Fumo, E; Mariuzzi, L; Minisini, R; Pirisi, M; Toniutto, P1
Cucurull, E; Espinoza, LR; Menon, Y; Reisin, E1
Mauss, S2
Santos Gil, I; Sanz Sanz, J1
Chebli, JM; Gaburri, AK; Gaburri, PD; Martins Junior, EV1
Alegría, S; Brahm, J; Buckel, E; Ceresa, S; Ferrario, M; Smok, G1
Rókusz, L1
Chaix, ML; Equi-Andrade, C; Fontaine, H; Kreis, H; Lebray, P; Nalpas, B; Pol, S; Serpaggi, J; Sobesky, R; Vallet-Pichard, A; Verkarre, V1
Chang, WY; Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Lee, LP; Lin, ZY; Wang, LY; Yu, ML4
Chang, TC; Chang, YC; Liao, SL; Su, DH1
Al-Ajmi, M; Al-Khaldi, J; Al-Nakib, B; Asker, H; Hasan, F; Owayed, S; Siddique, I; Varghese, R1
Barreiro, P; Camino, N; Garcia-Samaniego, J; González-Lahoz, J; Maida, I; Martin-Carbonero, L; Núñez, M; Romero, M; Soriano, V1
Antonini, MG; Babudieri, S; Baiguera, C; Carosi, G; Fenu, L; Maida, I; Mura, MS; Puoti, M; Putzolu, V; Rezza, G; Rossi, S; Sassu, S; Viale, P; Zanini, B1
Accogli, E; Azzaroli, F; Colecchia, A; Derenzini, M; Festi, D; Giovanelli, S; Lodato, F; Mazzella, G; Miracolo, A; Montagnani, M; Mwangemi, C; Nigro, G; Roda, E; Tamé, M; Trere, D1
Blum, HE; Moradpour, D3
Guthoff, R; Kirchhoff, A; Kirchhoff, U; Lafrenz, M1
Brodin, H; Cave, C; Gabbay, J; Price, A; Shepherd, J; Waugh, N1
Davis, GL; Saadeh, S1
Ong, JP; Younossi, ZM1
Gonzalez, SA; Jacobson, IM1
Collantes, R; Gujral, H; Viscomi, C1
Vogel, W2
Datz, C; Hackl, F; Hegenbarth, K; Hofer, H; Jessner, W; Peter, F; Schütze, K; Stauber, RE; Steindl-Munda, P1
de Moura, MC; Marinho, RT; Pinto, RM; Santos, ML1
Hayashi, J; Higashi, M; Ishibashi, H; Kajiwara, E; Kashiwagi, S; Maruyama, T; Matsui, Y; Mukai, T; Nagano, M; Nomura, H; Shimono, J; Tanimoto, H; Yamashita, N1
Blanco, JR; Metota, L; Oteo, JA; Rosel, L1
Altintas, E; Sezgin, O1
Berenguer, J; Berenguer, M; Calvo, F; Carrasco, D; Palau, A; Prieto, M; Rayón, JM1
Bogris, P; Elefsiniotis, IS; Magaziotou, I; Mavrogiannis, C; Pantazis, KD1
Andriulli, A; Bacca, D; Di Salvo, D; Iacobellis, A; Leandro, G; Maio, G; Mangia, A; Persico, M; Spadaccini, A; Ventrella, F1
Abbati, G; Boccia, S; Castagnetti, E; Distasi, M; Fabris, P; Fattovich, G; Felder, M; Fornaciari, G; Giusti, M; Lomonaco, L; Minola, E; Montanari, R; Noventa, F; Pantalena, M; Paternoster, C; Redaelli, A; Ribero, ML; Rizzo, C; Rovere, P; Scattolini, C; Suppressa, S; Tagger, A; Tomba, A; Tonon, A; Tositti, G; Zagni, I1
Białkowska, J; Bolewska, B; Boroń-Kaczmarska, A; Gładysz, A; Halota, W; Inglot, M; Jabłkowski, M; Jabłonska, J; Janas-Skulina, U; Jurczyk, K; Juszczyk, J; Kryczka, W; Kuydowicz, J; Lakomy, EA; Lyczak, A; Mach, T; Michalska, Z; Moczko, J; Modrzewska, R; Nazzal, K; Pabjan, P; Pawłowska, M; Piszko, P; Sikorska, K; Swiqtek, K; Tomasiewicz, K; Topczewska-Staubach, E; Wawrzynowicz-Syczewska, M; Zarqbska-Michaluk, D; Zejc-Bajsarowicz, M1
Aspinall, RJ; Pockros, PJ1
Dahab, ST; Khuroo, MS1
De Sarro, G; Ferraro, M; Gallelli, L; Mauro, GF1
Jan, MA; Muhammad, N; Rahman, N1
Alberti, A; Boccato, S; Bortoletto, G; Dal Pero, F; Ferrari, A; Gerotto, M; Realdon, S1
García-Samper, X; Gongora, J; Kershenobich, D; Poo, JL; Sánchez-Avila, F; Uribe, M2
Gładysz, A; Inglot, M1
Wawrzynowicz-Syczewska, M1
Bini, EJ; Mehandru, S1
Bell, H; Bjøro, K; Dalgard, O; Hellum, KB; Myrvang, B; Raknerud, N; Ritland, S; Skaug, K1
Keating, GM; Plosker, GL2
Rich, JD; Tashima, KT; Taylor, LE1
Herrmann, E; Kronenberger, B; Micol, F; von Wagner, M; Zeuzem, S1
Afdhal, NH; Bowers, PJ; Dieterich, DT; Goon, BL; Leitz, G; Mody, SH; Pockros, PJ; Schiff, ER; Shiffman, ML; Sulkowski, MS; Tang, KL; Wright, TL; Younossi, Z1
Al-Ahdal, MN; Alashgar, H; Alfaleh, FZ; Algamedi, A; Aljumah, A; Hadad, Q; Kessie, G; Khan, MQ; Khuroo, MS; Mayet, I1
Chang, WY; Chen, SC; Chuang, WL; Dai, CY; Hsieh, MY; Lee, LP; Lin, ZY; Wang, LY; Yu, ML2
Bajaj, JS; Daniel, J; Franco, J; Ho, S; Knox, JF; McKee, D; Peine, C; Saeian, K; Varma, RR1
Bozorg, B; Rifai, MA; Rosenstein, DL1
Asnis, GM; De La Garza, R; Henderson, MA; Rego, SA; Reinus, JF1
Wilson, MS1
Gholam, PM1
Brogna, A; Malaguarnera, M; Musumeci, S; Neri, S; Pistone, G; Romano, M1
Canepa, J1
Diago, M; Farci, P; Gane, E; Gitlin, N; Lamour, F; Lardelli, P; O'Brien, CB; Pockros, P; Prati, D; Reddy, KR; Shiffman, M; Zeuzem, S1
Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Someya, T; Suzuki, F; Suzuki, Y1
Kasahara, A2
Douglas, SD1
Borisov, AS; Broadwell, SD; Capuron, L; Jacobson, IM; Manatunga, AK; Miller, AH; Nemeroff, CB; Raison, CL; Woolwine, BJ1
Keeffe, EB; Kowdley, KV1
Fredrick, RT; Hassanein, TI1
Kowdley, KV1
Collantes, RS; Younossi, ZM1
Rossi, G1
González-Peralta, RP1
Bani-Sadr, F; Benzekri, A; Cacoub, P; Carrat, F; Degott, C; Goujard, C; Lunel-Fabiani, F; Morand, P; Perronne, C; Pialoux, G; Piroth, L; Pol, S; Rosenthal, E; Salmon-Céron, D1
Manns, MP; Wedemeyer, H1
Abad, MA; Gómez, G; Leal, M; Lissen, E; Molina-Pinelo, S; Sánchez-Quijano, A; Vallejo, A1
Arizcorreta, A; Brun, F; Fernández-Gutiérrez, C; García Juárez, R; Girón-González, JA; Guerrero, F; Pérez-Guzmán, E1
Hsieh, CH; Tasi, TN1
Goudeau, A; Gouriou, S; Legrand-Quillien, MC; Nousbaum, JB; Picard, B; Vallet, S1
Adair, D; Colby, TV; Gallegos-Orozco, JF; Jablonska, J; Kubicka, J; Laskus, T; Radkowski, M; Rakela, J; Walewska-Zielecka, B; Wilkinson, J1
Fujisaki, K; Ido, A; Kubozono, O; Sakashita, H; Sho, Y; Tahara, K; Tsubouchi, H; Yamaguchi, K1
Abbas, Z; Hamid, SS; Jafri, W; Tabassum, S1
Atsukawa, K; Higashimoto, M; Ishii, H; Saito, H; Takahashi, M1
Kraus, MR; Reimer, P; Schäfer, A; Scheurlen, M; Wissmann, S1
Altintas, E; Altiparmak, E; Cicek, B; Filik, L; Kilic, M; Odemis, B; Oguz, D; Zengin, N1
Ferenci, P; Ferlitsch, A; Formann, E; Gangl, A; Homoncik, M; Jilma, B; Panzer, S; Peck-Radosavljevic, M1
Crossey, M; D'Souza, R; Foster, GR; Hayward, C; Main, J; Murray-Lyon, IM; Rosenberg, W1
Almasio, PL1
Cutler, D; Grace, MJ1
Biglia, A; Blanch, J; Blanco, JL; de Pablo, J; García, F; Gatell, JM; Laguno, M; Larrousse, M; León, A; Lonca, M; Mallolas, J; Martinez, E; Miró, JM; Murillas, J1
Ballesteros, AL; Clotet, B; Côté, H; Fuster, D; Garrabou, G; López, S; Martínez, E; Miró, O; Planas, R; Rey-Joly, C; Salas, A; Tor, J; Tural, C; Videla, S1
Barreiro, P; García-Samaniego, J; González-Lahoz, J; Maida, I; Martín-Carbonero, L; Núñez, M; Soriano, V1
Arcos, P; Busteros, JI; de Dios García-Díaz, J; García-Sánchez, M1
Bassendine, M; Forton, D; Goldin, R; Grant, P; Main, J; Mills, PR; Millson, C; Naoumov, N; Tedder, R; Thomas, HC; Thursz, M; Torok, E; Wright, M1
Akriviadis, E; Hatzis, G; Kanatakis, S; Ketikoglou, I; Paraskevas, E; Raptopoulou, M; Sidiropoulos, L; Tsantoulas, D; Vafiadi, I; Vassiliadis, T1
Al-Taie, O; Kraus, MR; Schäfer, A; Scheurlen, M1
Hsu, S; Pielop, J; Shen, Y1
Barry, K; Cleare, AJ; Hotopf, M; Landau, S; Maddock, C; Maulayah, P; Norris, S; Pariante, CM1
Bessis, D; Blatìre, V; Girard, C; Guilhou, JJ; Guillot, B1
Ghany, M; Lutchman, G1
Bruchfeld, A; Lindahl, K; Schvarcz, R; Stahle, L1
Byun, KS; Chang, YJ1
Balan, V; Bowers, PJ; Burnett, A; Ghalib, R; Goon, BL; Jackson, J; Keeffe, EB; Leitz, GJ; Muir, AJ; Rossaro, L; Schwartz, D; Wu, GY1
Eng, SC; Gordon, SC; Kowdley, KV; McHutchison, JG; Patel, K; Rulyak, SJ1
Butt, MB; Gill, ML; Khokhar, N1
Cholewa, K; Gola, J; Gonciarz, Z; Jurzak, M; Mazur, W; Mazurek, U; Rozek-Kostórkiewicz, J; Sypniewski, D; Wilczok, T1
Egger, M; Furrer, H; Rauch, A; Reichen, J1
Alaric, L; Bureau, C; Péron, JM; Pey, F; Valmary, S; Vinel, JP; Zabraniechki, L1
Dimitropoulou, D; Gogos, CA; Labropoulou-Karatza, C; Siagris, D; Theocharis, GJ; Thomopoulos, KC; Tsamantas, AC1
Hu, SL; Jaber, BL1
Fujiyama, S; Hamada, A; Saito, H; Sasaki, Y; Uchida, M; Yamasaki, M1
Alston-Smith, B; Bassett, R; Brass, C; Fichtenbaum, C; Glesby, MJ; Jacobson, EL; Owens, S; Race, EM; Sherman, KE; Sulkowski, M1
Bonder, A; Fuentes, AP; Gallegos-Orozco, JF; García-Sandoval, M; Gutiérrez-Reyes, G; Gutiérrez-Ruíz, MC; Kershenobich, D; Loaeza-del Castillo, A; Olivera, MA; Rodríguez, R; Soto, L1
Molleston, JP; Rao, GS1
Afdhal, N; Kelleher, TB1
Blanco, JL; Forns, X; García, F; Gatell, JM; Laguno, M; Larrousse, M; León, A; Loncá, M; Mallolas, J; Martínez, E; Milinkovic, A; Miró, JM; Murillas, J; Sánchez-Tapias, JM1
Alain, S; Bezanahary, H; Doffoël-Hantz, V; Fauchais, AL; Liozon, E; Loustaud-Ratti, V; Ramos-Casals, M; Vidal, E1
Offner, F; Sagmeister, M; Sprenger, R1
Al-Jumah, A; Al-Nasser, M; Al-Traif, I; Handoo, FA1
Bianchi, FB; Granito, A; Guidi, M; Lenzi, M; Muratori, L; Muratori, P; Susca, M1
Bogdanos, DP; Mieli-Vergani, G; Vergani, D1
Asselah, T; Boyer, N; Marcellin, P; Ripault, MP1
Ffrench, RA; Freeman, AJ; Lloyd, AR; Marinos, G1
Bellis, L; Castellacci, R; Montagnese, F; Puoti, C1
Andrejczyn, M; Halota, W; Pawłowska, M1
Nitkiewicz, J1
Apale, P; Avolio, A; Bellia, V; Bordoni, T; Parravicini, P; Pioltelli, P; Pozzi, M; Redaelli, A; Roffi, L; Santamaria, G; Scalori, A1
Brodin, HF; Cave, CB; Gabbay, J; Price, A; Shepherd, J; Waugh, NR1
Siebert, U; Sroczynski, G1
de Knegt, RJ; Eijkemans, MJ; Habbema, JD; Hansen, BE; Schalm, SW; Stijnen, T; Veldt, BJ1
Daniel, S1
Mukherjee, S1
González-Lahoz, J; Soriano, V1
Bertisch, B; Huber, M; Meili, D; Oppliger, R; Renner, EL; Schmid, P; Schönbucher, P; Vernazza, P; Weber, R1
Barreiro, P; García-Samaniego, J; González-Lahoz, J; Martín-Carbonero, L; Núñez, M; Romero, M; Sánchez-Conde, M; Soriano, V1
Adamek, A; Adamek, J; Juszczyk, J1
Goto, H; Hayashi, K; Honda, T; Katano, Y; Nakano, I; Takamatsu, J; Toyoda, H; Yamamoto, K; Yano, M; Yoshioka, K1
Gross, JB1
Brito-Zerón, P; Cervera, R; Font, J; Mañá, J; Nardi, N; Ramos-Casals, M; Sánchez-Tapias, JM; Xaubet, A1
Karpov, SIu; Krel', PE1
Bachmeyer, C; Cadranel, JF; Ducamp-Posak, I; Dumouchel, P; Hammi, R; Thevenot, T1
Andrade, RJ; Castillo, J; Corpas, R; Cruz, M; Del Mar Viloria, M; Diago, M; Fernández-Rodríguez, CM; Gila, A; Grande, L; Gutiérrez, ML; López-Serrano, P; Muñoz-De-Rueda, P; Pérez, C; Romero-Gómez, M; Ruiz-Extremera, A; Salmerón, J; Suárez, E; Vázquez, L1
Alexander, GJ; Hoare, M; Woodall, T1
Chisholm, JA; Gavin, M; Keating, D; Mills, PR; Parks, S; Spence, E; Williams, G1
Lagging, M; Lindh, M; Norkrans, G; Wejstål, R; Westin, J1
Chung, HV; Farley, JD; Farley, TA; Lim, E; Walters, G; Wong, VK; Yoshida, EM1
Boulestin, A; Chatelut, E; Durand, D; Esposito, L; Izopet, J; Kamar, N; Rostaing, L; Sandres-Saune, K; Selves, J; Stébenet, M1
Antonaci, A; Antonaci, S; Giannelli, G; Maddalena, G; Napoli, N; Parisi, CV1
Angarano, G; Cibelli, DC; Fazio, V; Palumbo, E; Saracino, A; Scotto, G1
Ampurdanés, S; Forns, X; Franco, S; Furčić, I; Giménez-Barcons, M; Puig-Basagoiti, F; Saiz, JC; Sánchez-Tapias, JM1
Inoue, K; Izumi, N; Kurosaki, M; Miyake, S; Nakanishi, H; Nishimura, Y; Onuki, Y; Tsuchiya, K; Uchihara, M; Ueda, K; Yasuhiro, A1
Chang, JJ; Chang, LC; Chen, LW; Lee, TS; Liu, CJ; Yen, CL1
Antonaci, S; Giannelli, G; Simone, B; Vella, FS1
Zein, NN2
Ballauff, A; Gerner, P; Jenke, A; Kullmer, U; Lang, T; Pieper-Boustani, H; Wintermeyer, P; Wirth, S1
Anatol, P; Danuta, P; Robert, F1
Abergel, A; Bacq, Y; Causse, X; Giraudeau, B; Gros, J; Labarriere, D; Loustaud-Ratti, V; Si Ahmed, SN; Silvain, C; Veillon, P1
Desurmont, P; Filoche, B; Hamdan-Khalil, R; Khalil, A; Lucidarme, D1
Bernard, PH; Foucher, J; Lafon, ME; Ledinghen, VD; Legrand, E; Neau-Cransac, M1
Flisiak, R1
Jabłonowska, E1
Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Someya, T; Suzuki, F; Suzuki, Y; Tsubota, A1
Bouvier-Alias, M; Darthuy, F; Gourlain, K; Hézode, C; Pawlotsky, JM; Pellegrin, B; Rémiré, J; Soulier, A1
Castro, A; Castro, M; Diz Dios, P; Eirea, M; Hermida, M; Reforma, NG; Rodríguez, I1
Caizzi, M; Carniello, G; Di Gennaro, G; Donada, C; Maso, LD; Mazzaro, C; Pozzato, G; Tirelli, U; Virgolini, L; Zorat, F1
Bouton, V; Boyer, N; Farcy-Afif, M; Marcellin, P; Sinègre, M; Stocco, J; Tod, M1
Kumar, R; Kumar, S; Sarin, SK; Sharma, BC; Singh, J1
González-Gallego, J; Guerra, J; Jorquera, F; Marin, JJ; Merayo, JA; Monte, MJ; Olcóz, JL; Sanchez-Campos, S1
Bernstein, DE; Brown, RS; Herrine, SK; Lentz, E; Ondovik, MS; Te, H1
Butterfield, B; Drake, S; Holtzmuller, K; Howard, R; Sjogren, MH; Sjogren, R; Smith, M; Watts, A; Winston, B1
Akyuz, F; Besisik, F; Dincer, D; Karaca, C; Okten, A; Sever, MS1
Heathcote, J; Main, J1
Fukunaga, K; Hada, T; Hara, N; Hayashi, S; Ishikawa, T; Masaki, N; Ohnishi, K; Sawada, K; Takahashi, H; Toda, G; Yamamoto, T; Zeniya, M1
Chang, TT; Chang, WY; Chao, YC; Chen, DS; Cheng, PN; Hsieh, TY; Hwang, SJ; Lai, MY; Lee, SD; Liu, CJ; Yu, ML1
Andriulli, A; Annese, M; Bacca, D; Carretta, V; Cela, M; Conte, D; Festi, D; Guadagnino, V; Maio, G; Mangia, A; Minerva, N; Pazienza, V; Persico, M; Piattelli, M; Ricci, GL; Spirito, F1
Baldo, V; Bozzola, L; Carlotto, A; de Lalla, F; Fabris, P; Floreani, A; Giordani, MT; Negro, F; Rassu, M; Tramarin, A1
Karaman, G; Karaoğlu, AO; Savk, E; Sendur, N; Uslu, G1
Assor, P; Bacq, Y; d'Alteroche, L; Gaudy, C; Lefrou, L; Senecal, D1
Bruno, R; Ciappina, V; Filice, G; Maiocchi, L; Patruno, S; Sacchi, P; Zocchetti, C1
Angeli, E; Cargnel, A; Duca, P; Giorgi, R; Gubertini, G; Mainini, A; Schiavini, M1
Egashira, T; Fujiwara, K; Hashimoto, M; Inao, M; Ito, N; Matsui, A; Mishiro, S; Mochida, S; Nagano, M; Nagoshi, S; Naito, M1
Borgia, G; Borrelli, F; Cerini, R; Ciampi, R; Gentile, I; Piazza, M; Reynaud, L; Viola, C1
Escanhoela, CA; Gonçales, FL; Gonçales, NS; Pavan, MH; Pereira, JS; Silva, Cd1
Bruno, C; Cassidy, W; Howell, CD; Jeffers, L; Luo, S; Reddy, KR1
Tran, HA1
Berg, T; Garkisch, AS; Heinz, A; Hinzpeter, A; Pich, M; Schaefer, M; Schwaiger, M; Uebelhack, R; van Boemmel, F1
Colak, H; Kartal, ED; Ozgunes, I; Usluer, G1
Borozan, I; Chen, L; Coltescu, C; Edwards, AM; Feld, J; Heathcote, J; McGilvray, ID; Sun, J; Tannis, LL1
Aziz, AA; El Tawil, AA; Hakam, SA; He, Q; Ismail, A; Kamal, SM; Madwar, MA; Nakano, T; Rasenack, J; Saleh, WA1
Beniowski, M; Borgiel-Marek, H; Fila, A; Filipczyk, P; Janczewska-Kazek, E; Kajdaniuk, D; Kajdaniuk, J; Kos-Kudla, B; Marek, B; Mazurek, U; Niedziolka, D; Nowak, M; Ostrowska, Z; Pakula, D; Sieminska, L; Strzalka, B; Wilczok, T1
Aidelsburger, P; Bullinger, M; Greiner, W; Kurth, BM; Ravens-Sieberer, U; Rossol, S; Siebert, U; Sroczynski, G; von der Schulenburg, JM; Wasem, J; Wong, JB1
Anatol, P; Bozena, P; Danuta, P; Janusz, D1
Chiou, YL; Guo, CH; Hsu, GS; Ko, WS; Yaun, SR; Yeh, MS1
Barnes, DS; Bringman, D; Carey, WD; Farmer, D; Ferguson, R; Gramlich, T; Levinthal, G; Martin, LM; McCullough, AC; Mullen, KD; O'Shea, R; Ong, JP; Post, A; Tavill, AS; Younossi, ZM1
Chemin, I; Guillaud, O; Khattab, E; Mrani, S; Trepo, C; Vieux, C; Vuillermoz, I; Zoulim, F1
Furusyo, N; Hayashi, J; Kubo, N; Murata, M; Nabeshima, S; Nakamuta, M; Takeoka, H; Toyoda, K1
Germain, J; Ghany, M; Heller, T; Hoofnagle, JH; Hsu, HH; Jake Liang, T; Lutchman, G; Park, Y; Soza, A1
Chang, KM; Ikeda, F; Kaplan, DE; Reddy, KR; Shetty, K; Stadanlick, J; Sugimoto, K; Valiga, M1
Gwak, GY; Kang, GH; Kim, KA; Kim, TH; Lee, HS; Lim, YS; Yoon, JH1
Biliotti, E; Bresci, S; Capanni, M; Pimpinelli, N; Taliani, G; Tozzi, A1
Hauser, P; Loftis, JM; Rifai, MA2
Bouzas, E; Naoum, G; Papastathopoulos, K; Tsiodras, S; Vergados, I1
Datz, C; Ferenci, P; Gangl, A; Homoncik, M; Jessner, W; Kreil, A; Peck-Radosavljevic, M; Schmid, M1
Bacon, BR; Brunt, EM; Di Bisceglie, AM; Harrison, SA; Neuschwander-Tetri, BA; Oliver, DA; Qazi, RA1
Chang, TT; Huang, FC; Lin, SC; Shih, MH; Tseng, SH1
Andriulli, A; Annese, M; Bacca, D; Carretta, V; Mangia, A; Minerva, N; Persico, M; Ricci, GL; Romano, M; Santoro, R; Scotto, G; Sogari, F; Spirito, F; Vinelli, F; Zechini, F1
Fukunaga, K; Hirata, I; Kashiwamura, S; Ohnishi, K; Okamura, H; Saniabadi, A; Sawada, K1
D'Souza, R; Foster, GR; Sabin, CA1
Bertrand, JJ; Germain, S; Halfon, P; Harafa, A; Larroque, O; Martin, S; Muller, P; Renou, C1
Amer, A; Bener, A; Derbala, M; El Ghannam, M; Lopez, AC; Omar, M1
Boyer, N; Cazals-Hatem, D; Consigny, Y; Degott, C; Marcellin, P; Marrache, F; Martinot, M; Ripault, MP; Valla, D1
Carosi, G; Chaneac, M; Craxì, A; Dhumeaux, D; Diago, M; Ferenci, P; Fried, MW; Gonçales, FL; Häussinger, D; Marinos, G; Reddy, KR; Shiffman, ML; Smith, CI1
Bancila, I; Damian, D; Gheorghe, C; Gheorghe, L; Grigorescu, M; Iacob, R; Iacob, S; Parvulescu, I; Simionov, I; Vadan, R1
Bassendine, M; DeAngelis, D; Grieve, R; Main, J; Roberts, J; Rosenberg, W; Sweeting, M; Thomas, H; Wright, M1
Motoo, Y; Mouri, H; Ohtsubo, K; Sawabu, N; Watanabe, H; Yamaguchi, Y1
Adham, M; Baulieux, J; Bizollon, T; Chevallier, M; Ducerf, C; Mabrut, JY; Pradat, P; Radenne, S; Souquet, JC; Trepo, C; Zoulim, F1
Hohenberger, W; Meyer, T; Müller, V; Schellerer, V; Schuppan, D; Tannapfel, A; Yedibela, S1
Attia, M; Badran, HM; Barakat, E; El-Nakeeb, A; El-Tawil, A; El-Zayadi, AR; Saied, A; Selim, O; Zalata, K1
Carnicer, F; García, A; Gutiérrez, A; López, M; Ruiz, F; Zapater, P1
Alvarez Delgado, A; Fuertes Martín, A; Pérez García, ML1
Ikeda, S; Kaneko, K; Komastu, H; Nakamura, A; Takasu, K; Tojo, K1
Kizawa, H; Kondoh, R; Nagane, Y; Terayama, Y; Utsugisawa, K1
Sethi, A; Shiffman, ML1
Afdhal, NH; Curry, MP1
Biggins, SW; Terrault, NA1
Alam-Fotias, S; Bui, C; Mansberg, R; Nguyen, D; Shen, L1
Everson, GT; Fey, B; Forman, L; Halprin, A; Kugelmas, M; Ray, C; Trotter, J1
Carré, D; Coton, T; Delpy, R; Garnotel, E; Guisset, M1
Hurst, EA; Mauro, T1
Chen, DW; Dong, Y; Jia, WZ; Mao, YL; Tang, HM; Xu, ZQ; Yang, XJ; Zhang, HF; Zhu, SS1
Alric, L; Boulestin, A; Izopet, J; Legrand-Abravanel, F; Nicot, F; Sandres-Sauné, K; Vinel, JP1
Albrecht, J; Blatt, LM; Conrad, A; Dev, A; Heaton, S; McHutchison, JG; Owens, E; Patel, K; Pianko, S; Pockros, PJ1
Buitelaar, M; de Baar, MP; de Mendoza, C; Gonzalez-Lahoz, J; Sánchez-Conde, M; Soriano, V; Timmermans, E1
Aceti, A; Antonelli, M; Pasquazzi, C; Persechino, S; Pranteda, G; Teggi, A; Versace, I; Zechini, B1
Avci, A; Erhardt, A; Häussinger, D; Heintges, T; Lörke, J1
Alberti, A; Almasio, PL; Berrutti, M; Boccato, S; Cattaneo, C; Craxi, A; Demelia, L; Ideo, G; Pellicano, R; Picciotto, A; Rizzetto, M; Sorbello, O; Torre, F; Valenza, M; Venezia, G1
Hayashi, Y; Ishii, F; Izawa, S; Kim, KI; Kim, SR; Kimura, N; Kinoshita, K; Mita, K; Muramoto, Y; Nabeshima, S; Nakao, K; Ohtani, A; Sasase, N; Shikata, M; Tanaka, K; Taniguchi, M; Togitani, T1
Coelho, HS; de Segadas Soares, JA; Perez, RM; Villela-Nogueira, CA1
Casillas-Davila, L; Chirino-Sprung, R; Dehesa-Violante, M; Díaz-Hernandez, M; Juarez-Navarro, A; Navarro, JM; Vera-de-León, L1
Ashikaga, T; Ferrentino, N; Gordon, SR; Krawitt, EL; Lidofsky, SD; Ray, MA1
Esteban, JI; Ferrari, C; Gianfranco, E; Goulis, I; Hansen, B; Hezode, C; Lagging, M; Lukasiewicz, E; Lurie, Y; Negro, F; Neumann, AU; Pawlotsky, JM; Schalm, SW; Soulier, A; Tal, R; Verheij-Hart, E; von Wagner, M; Vrolijk, JM; Zeuzem, S1
Berg, T; Bergk, A; Bernsmeier, C; Häussinger, D; Heintges, T; Herrmann, E; Hinrichsen, H; Huber, M; Rasenack, J; von Wagner, M; Zeuzem, S1
Bárcena, R; Blesa, C; Fortún, J; García, M; García-Garzón, S; Martín-Dávila, P; Mateos, ML; Moreno, A; Moreno, L; Moreno, S; Muriel, A; Otón, E; Quereda, C1
Ahmad, J; Anand, BS; Awad, J; Aytaman, A; Bini, EJ; Bräu, N; Chang, KM; Cheung, R; Currie, S; Hagedorn, C; Ho, SB; Hu, KQ; Jeffers, L; Johnson, D; King, P; Mendenhall, C; Morgan, TR; Moseley, R; Pedrosa, M; Rossi, S; Sasaki, AW; Schmidt, WN; Shen, H; Simon, F; Strader, D; Waters, B; Wright, TL1
Akcan, Y; Kavak, A; Korkmaz, U1
Jensen, DM; Marcellin, P1
Aoun, E; Ghorra, S; Inati, A; Koussa, S; Sharara, AI; Taha, M; Taher, A1
Asahina, Y; Enomoto, N; Izumi, N; Kitamura, T; Kurosaki, M; Miyake, S; Nakanishi, H; Nishimura, Y; Onuki, Y; Tsuchiya, K; Uchihara, M; Ueda, K1
Perelson, AS; Ribeiro, RM1
Antonaci, S; Bergamini, C; Dentico, P; Fransvea, E; Giannelli, G; Marinosci, F; Maurel, P; Napoli, N1
Anderson, F; Friesenhahn, M; Gish, R; Gordon, S; Holodniy, M; Krajden, M; McHutchison, J; Pawlotsky, JM; Perrillo, R; Terrault, NA; Zitron, I1
Bläckberg, J; Carlsson, T; Norkrans, G; Reichard, O; Sangfelt, P; Wallmark, E; Weiland, O1
Diago, M; Giménez, MD; González, V; Matas, L; Montoliu, S; Morillas, RM; Padilla, E; Pérez, C; Planas, R; Solà, R1
Freshwater, DA; Mutimer, DJ; O'Donnell, K; Seyam, MS1
Azzaroli, F; Bacchi Reggiani, ML; Brillanti, S; Colecchia, A; Feletti, V; Giovanelli, S; Lodato, F; Mazzella, G; Montagnani, M; Muratori, R; Roda, E; Tamé, MR1
Ding, PP; He, Y; Huang, L; Li, H; Zhang, CY; Zheng, YH; Zhou, HY; Zou, W1
Diepolder, HM; Franz, M; Kashiwagi, N; Teuber, G; Ulsenheimer, A; Yokoyama, T; Zachoval, R1
Fukunaga, K; Morita, M; Murao, S; Nishumi, T; Shibutani, Y; Tani, S; Uchikoga, O; Yagi, N1
Kugelmas, M; Ward, RP1
Chokshi, S; Cooksley, H; Herrmann, E; Naoumov, NV; Tang, KH; Tatman, N; Williams, R; Zeuzem, S1
Fischinger, J; Hass, HG; Kaiser, S; Kreysel, C; Menzel, J1
Cheong-Lee, C; Ford, JA; Wong, VK; Yoshida, EM1
Castellano, G; Diago, M; Fernández, I; García-Monzón, C; García-Samaniego, J; Iacono, OL; Pérez, C; Romero, M1
Arazo, P; Barreiro, P; Berdún, MA; Camino, N; Echevarría, S; García-Samaniego, J; Losada, E; Martín-Carbonero, L; Miralles, C; Núnez, M; Ocampo, A; Ramos, B; Romero, M; Santos, I; Soriano, V1
Deutsch, M; Hadziyannis, S; Koskinas, J; Mailis, A; Tolis, G; Tzannos, K; Vassilopoulos, D1
Borg, BB; Hoofnagle, JH1
Kolor, B1
Jeong, SH; Suh, DJ1
Changchien, CS; Chen, CL; Chen, WJ; Huang, WS; Hung, CH; Lee, CM; Lu, SN; Tung, HD; Wang, JH1
Lai, MY2
Chang, WY; Chuang, WL; Dai, CY; Yu, ML1
Goto, H; Honda, T; Katano, Y; Kumada, T; Kuzuya, T; Nakano, I; Toyoda, H1
Henry, MJ1
Covino, M; Gasbarrini, G; Larocca, LM; Pizzolante, F; Pompili, M; Rapaccini, GL1
Chen, CH; Hung, CH; Lee, CM; Lu, SN; Tung, HD; Wang, JH1
Anand, BS; Bini, EJ; Bräu, N; Cheung, RC; Currie, S; Ho, SB; Shen, H; Wright, TL1
de Sola-Earle, C; Fernández-Moreno, N; Fernández-Pérez, F; García-Fernández, G; Méndez-Sánchez, I; Moreno-Mejías, P; Navarro-Jarabo, JM; Pérez-Aisa, A; Rivera-Irigoín, R; Sánchez-Cantos, A; Ubiña-Aznar, E; Vera-Rivero, F1
Alfonso, V; Campos, RH; Mbayed, VA; Sookoian, S1
Alex, P; Bader, T; Centola, M; Dozmorov, I; Gonzales, L; Gurakar, A; Naylor, M; Nguyen, T; Nour, B; Sebastian, A; Wallis, G; Wright, H1
Brouwer, JT; Mathot, RA; Orlent, H; Schalm, SW; Van Bommel, EF; Vulto, AG1
Adamski, M; Dziecioł, J; Panasiuk, A; Prokopowicz, D1
Czarnecki, M; Gładysz, A; Inglot, M; Jańczak, G; Małyszczak, K; Pawłowski, T; Rymer, W1
Jeleń, M; Piszko, P; Simon, K; Sulka, A1
Dworacki, G; Figlerowicz, M; Kaczmarek, E; Kaczmarek, M; Kowala-Piaskowska, A; Mozer-Lisewska, I; Słuzewski, W; Zeromski, J1
Figlerowicz, M; Kowala-Piaskowska, A; Mozer-Lisewska, I; Słuzewski, W3
Simon, K; Szymczak, A1
Gładysz, A; Inglot, M; Rymer, W1
Alejska, M; Błazewicz, J; Figlerowicz, M; Formanowicz, P; Jackowiak, P; Kedziora, P; Słuzewski, W1
Figlerowicz, M; Kowala-Piaskowska, A; Mozer-Lisewska, I; Słuzewska, M; Słuzewski, W1
Jankowska, I; Pawłowska, J; Rokitka, M; Socha, J; Sokal, E; Teisseyre, M1
Malone, DC; Poordad, FF; Tran, TT1
Black, M; Chang, A; Friedenberg, FK; Gautam, M; Horwitz, B; Schmutz, J; Skole, K; Thomas, R1
Bárcena, R; Blázquez, J; Foruny, JR; Gil-Grande, L; Moreno, A; Moreno, J; Moreno, S; Muriel, A; Pérez-Elías, MJ; Quereda, C; Rodriguez-Sagrado, MA; Sánchez, J1
de Franchis, R; Del Ninno, E; Ferrero Bogetto, S; Rumi, MG; Saibeni, S; Signorelli, C; Vecchi, M; Villa, F1
Aghemo, A; Colombo, M; Del Ninno, E; Donato, MF; Monti, V; Rumi, MG1
Broissand, C; Fontaine, H; Lebray, P; Nalpas, B; Pol, S; Serpaggi, J; Sobesky, R; Vallet-Pichard, A1
Gahr, S; Ganslmayer, M; Hahn, EG; Herold, C; Janson, C; Ocker, M; Zopf, S1
Conde-Taboada, A; Cruces, MJ; de la Torre, C; Feal, C; Gonzalez-Sixto, B; Mayo, E1
Kerl, K; Lübbe, J; Negro, F; Saurat, JH1
Bonkovsky, HL; Salek, J1
Chen, K; Chiou, CF; Robbins, S; Spiegel, BM; Younossi, ZM1
Brok, J; Gluud, C; Gluud, L1
Buti, M; Casado, MA; Esteban, R; Fosbrook, L1
Figlerowicz, M; Kowala-Piaskowska, A; Machowska, L; Mozer-Lisewska, I; Słuzewski, W1
Ding, PP; Gong, GZ; He, Y; Huang, L; Li, H; Yang, X; Zhang, CY; Zheng, YH; Zhou, HY; Zhou, W1
Baczkowski, A; Geffner, M; González-Peralta, RP; Gupta, S; Haber, B; Jonas, MM; Kelly, DA; Lang, T; Laughlin, M; Lurie, Y; Martin, S; Mieli-Vergani, G; Molleston, J; Murray, KF; Shelton, M1
Arapoglu, M; Gulec, SG; Nuhoğ, A; Urganci, N; Vural, S1
Garcia-Samaniego, J; Maida, I; Martin-Carbonero, L; Nuñez, M; Soriano, V1
Borque, MJ; García-Buey, L; Moreno-Monteagudo, JA; Moreno-Otero, R; Muñoz, C; Quintana, NE; Trapero, M; Vitón, M1
Altuna, L; Castiella, A; Fernández, J1
Danta, M; Dusheiko, G1
Bianchi, FB; Granito, A; Guidi, M; Lenzi, M; Muratori, L; Muratori, P; Pappas, G1
Goelz, J; Jessen, H; Klausen, G; Mauss, S; Mutz, A; Rockstroh, JK; Schmutz, G; Schranz, D; Schulz, C; Voigt, E; Weitner, L1
Attia, M; Badran, HM; Barakat, EM; El-Nakeeb, A; El-Tawil, A; El-Zayadi, AR; Hamdy, H; Saied, A; Selim, O1
Ahmed, F; Aytaman, A; Berman, DH; Bini, EJ; Bodenheimer, HC; Bräu, N; Brodsky, N; Brown, RS; Cerulli, MA; Chait, M; Edlin, BR; Ehrlich, J; Esposito, SP; Gardner, PW; Geders, JM; Gonzalez, SA; Jacobson, IM; Klion, FM; Lebovics, E; Min, AD; Rahmin, MG; Rovner, D; Russo, MW; Spivack, JE; Tobias, H1
Albrecht, J; Brass, C; Buti, M; Cianciara, J; Ferenci, P; Horsmans, Y; Ibranyi, E; Noviello, S; Sperl, J; Weiland, O; Zeuzem, S1
Gish, RG2
Bordens, RW; Cutler, DL; Grace, MJ1
Antinori, A; Carioti, J; Caroleo, B; Guadagnino, V; Trotta, MP1
Clouston, AD; Jonsson, JR; Lipka, GM; Powell, EE; Purdie, DM; Richardson, MM; Walsh, MJ1
Bodaghi, B; Cacoub, P; Cassoux, N; LeHoang, P; Rao, NA; Touitou, V; Tran, TH1
Andreone, P; Bernardi, M; Biselli, M; Bonvicini, F; Cursaro, C; Gramenzi, A; Loggi, E; Lorenzini, S1
Pialoux, G1
Gholam, PM; Rich, JD; Schwartzapfel, B; Taylor, LE1
Fukuoka, M; Hata, T; Kudo, M; Kuwano, H; Kuwao, H; Moriyama, K; Naitoh, S; Nomura, M; Tohda, Y1
Brunner, H; Datz, C; Ferenci, P; Formann, E; Gangl, A; Gschwantler, M; Hackl, F; Hubmann, R; Kessler, HH; Klingler, A; Laferl, H; Stauber, R; Steindl-Munda, P1
Butensky, E; Foote, D; Harmatz, P; Pakbaz, Z; Vichinsky, EP; Walters, MC1
Adachi, K; Akagi, S; Furuta, K; Ishihara, S; Kinoshita, Y; Kohge, N; Mishiro, T; Miyake, T; Rumi, MA; Sato, S; Uchida, Y1
Enomoto, M; Fujiwara, K; Jomura, H; Kawada, N; Mochida, S; Nishiguchi, S; Onishi, S; Saibara, T; Tamori, A1
Cornberg, M; Hadem, J; Herrmann, E; Manns, MP; Marschal, O; Reiser, M; Schmidt, HH; Schuppert, F; Steffen, M; Wedemeyer, H1
Fukui, K; Ichinose, M; Miyano, M; Tanaka, H; Ueda, H1
Kimu, M; Koike, N; Mitsutaka, M; Nakamura, T; Soda, M; Takahashi, H1
Hughes, CA; Shafran, SD1
Bourlière, M; Halfon, P; Khiri, H; Masseyeff, MF; Ouzan, D; Pénaranda, G1
Ando, M; Araki, Y; Hashimoto, N; Ikeda, H; Iwasaki, Y; Kawaguchi, M; Kita, K; Kobashi, H; Kobatake, T; Osawa, T; Sakaguchi, K; Shimoe, T; Shiratori, Y; Takaguchi, K; Tomita, M1
Crespo, J; Forns, X; Martínez-Bauer, E; Moreno-Otero, R; Pons, F; Romero-Gómez, M; Sánchez-Tapias, JM; Solá, R; Tesei, N1
Fraenkel, L; Garcia-Tsao, G; McGraw, S; Wongcharatrawee, S1
Ostojić, R1
Duvnjak, M; Lerotić, I; Pavić, T; Tomasić, V; Virović, L1
Weekley, D; Yuen, JC1
Barcena, R; Blesa, C; Foruny, JR; Garcia-Garzon, S; Garcia-Gonzalez, M; Moreno, A; Moreno-Zamora, A; Oton, E; Ruiz, P1
Bruckers, L; Buntinx, F; Matheï, C; Robaeys, G; Van Ranst, M; Van Vlierberghe, H1
Bertagnolli, M; Lewis, JH; Srivastava, S1
Berg, P; Bock, H; Frick, B; Friedrich-Rust, M; Herrmann, E; Hofmann, WP; Kellner, HU; Kihn, R; Moog, G; Pfaff, R; Rambow, A; Sarrazin, C; Schöfer, M; Tacke, W; Weber, C; Zeuzem, S1
Braga, EL; Freitas, LA; Lyra, AC; Lyra, LG; Moraes, CF; Souza, RM1
Bergholz, U; Ferenci, P; Formann, E; Gurguta, C; Kauer, C; Steindl-Munda, P1
Bankuti, C; Donnerer, J; Grahovac, M; Kessler, HH; Stadlbauer, V; Stauber, RE; Stelzl, E1
Cacciatore, P; Capani, F; Chincoli, C; Cosentino, L; D'Amico, E; di Pasqua, G; Palazzi, C; Pennese, E; Riario-Sforza, G1
Bastens, B; Bataille, C; Belaiche, J; Delwaide, J; Gerard, C; Hepatotropes, GL; Maes, B; Reenaers, C; Servais, B; Vaira, D1
Honda, T; Kojima, T; Matsushita, T; Takamatsu, J; Yamamoto, K1
Bailey, RJ; Bain, VG; Deschenes, M; Heathcote, J; Krajden, M; Lee, SS; Peltekian, K; Sherman, M; Simonyi, S; Yoshida, EM1
Abbas, Z; Hussainy, A; Jafri, W; Moatter, T1
Flisiak, I; Flisiak, R; Jaroszewicz, J; Lapinski, TW; Prokopowiczi, D1
Crone, C; Dan, AA; Farmer, DW; Martin, LM; Ong, JP; Robbins, SC; Wise, T; Younossi, ZM1
Kessler, CM1
Baka-Cwierz, B; Beniowski, M; Berak, H; Bolewska, B; Boroń-Kaczmarska, A; Cianciara, J; Cieśla, A; Dziambor, A; Gasiorowski, J; Gietka, A; Gliwińska, E; Gonciarz, Z; Gładysz, A; Halota, W; Horban, A; Inglot, M; Janas-Skulina, U; Janczewska-Kazek, E; Jaskowska, J; Jurczyk, K; Juszczyk, J; Knysz, B; Kryczka, W; Kuydowicz, J; Lakomy, EA; Logiewa-Bazger, B; Lyczak, A; Mach, T; Mazur, W; Michalska, Z; Modrzewska, R; Nazzal, K; Pabjan, P; Piekarska, A; Piszko, P; Sikorska, K; Sliwińska, M; Swietek, K; Szamotulska, K; Tomasiewicz, K; Topczewska-Staubach, E; Trocha, H; Wasilewski, M; Wawrzynowicz-Syczewska, M; Wrodycki, W; Zarebska-Michaluk, D; Zejc-Bajsarowicz, M1
Forestier, N; Friedrich-Rust, M; Zeuzem, S1
Elliott, RM; Granath, FN; Hamid, S; Lindström, H; Persson, MA; Siddiqui, AA; Yasmeen, A1
Alric, L; Balard, P; Izopet, J; Metivier, S; Peron, JM; Pipy, B; Thebault, S; Vinel, JP1
Andersen, J; Bhan, AK; Chung, RT; Graham, CS; Koziel, MJ; Liu, T; Peters, M; Sherman, KE; Wells, A1
Bergholz, U; Ferenci, P; Formann, E; Gurguta, C; Hofer, H; Jessner, W; Steindl-Munda, P1
Alter, H1
Gui Qiang, W; Jian Wu, Y; Shu Chen, L1
Hauser, P; Loftis, JM; Matthews, AM1
Biasin, M; Clerici, M; Galli, M; Gatti, N; Milazzo, L; Moroni, M; Niero, F; Piacentini, L; Riva, A; Zanone Poma, B1
Hara, Y; Hino, K; Kawakami, T; Kitase, A; Murakami, Y; Nagai, A; Okita, K; Okita, M; Okuda, M1
Abe, S; Narita, R; Oto, T; Otsuki, M; Tabaru, A1
Changchien, CS; Kee, KM; Lee, CM; Lu, SN; Tung, HD; Wang, JH; Wang, PW1
Asselah, T; Blazquez, M; Bonnet, J; Cohen, A; Condat, B; Estampes, B; Marcellin, P; Ngo, Y; O'Toole, D; Zanditenas, D1
Bowler, L; Coates, P; Singh, P; Tahrani, A1
Linde, R; Reichenbach, J; Strnad-Trojan, N; Trojan, J; Zeuzem, S; Zielen, S1
Adachi, Y; Fujita, N; Horiike, S; Kaito, M; Konishi, M; Sugimoto, R; Tanaka, H; Urawa, N; Watanabe, S1
Camacho, F; García-Bravo, B; Ruiz de Casas, A1
De Kaita, K; Minuk, GY; Renner, E; Wong, S1
Basso, M; Delfino, A; Pelli, N; Picciotto, A; Torre, F1
Blotner, S; Diago, M; Farci, P; Gane, E; Lardelli, P; O'Brien, CB; Pockros, P; Prati, D; Rajender Reddy, K; Shiffman, ML; Zeuzem, S1
Bianchi, FB; Granito, A; Guidi, M; Muratori, L; Muratori, P; Pappas, G1
Chiodo, F; Cristoni, L; Manfredi, R; Marinacci, G; Pavoni, M; Sabbatani, S1
Brosig, B; Gieler, U; Holthausen-Markou, S; Schreiber, M; Wölfelschneider, M1
Ibrányi, E; Nemes, L1
Arora, S; Diago, M; Gane, E; Green, J; O'Brien, C; Patel, K; Pockros, PJ; Reindollar, RW; Shiffman, ML; Tran, A; Wintfeld, N; Zeuzem, S1
Batisse, D; Chaix, ML; Dupont, C; Fontaine, H; Piketty, C; Pol, S; Rouveix, E; Rouzioux, C; Serpaggi, J; Vallet-Pichard, A; Viard, JP; Weiss, L1
Aghemo, A; D'Ambrosio, R; Rumi, MG1
Robert Ding, PH; Seow, EL1
Bruchfeld, A; Carlsson, T; Lindahl, K; Reichard, O; Schvarcz, R2
Chang, CH; Changchien, CS; Chen, WJ; Eng, HL; Hu, TH; Huang, CM; Hung, CH; Kee, KM; Lee, CM; Lu, SN; Wang, JH1
Azuma, K; Furusyo, N; Hayashi, J; Kajiwara, E; Katoh, M; Maruyama, T; Masumoto, A; Nakamuta, M; Nomura, H; Sakai, H; Shimoda, S; Shimono, J; Takahashi, K; Tanabe, Y1
Borgiel-Marek, H; Janczewska-Kazek, E; Kajdaniuk, D; Marek, B1
Kakibuchi, N; Kawakami, T; Kita, K; Murakami, Y; Okita, M; Takaguchi, K; Tomioka, K1
Godoy Guerrero, M; Manteca González, R; Palacios Rodríguez, S; Salgado Ordóñez, F1
Ariello, M; Conca, P; Mastrolia, M; Tarantino, G1
Kakizaki, S; Kanda, D; Mori, M; Sato, K; Sohara, N; Suzuki, H; Takagi, H1
Naoumov, NV; Paulon, E1
Lawson, A; Ryder, SD1
Hoepffner, N; Nikodem, AB; Paul, KA; Teuber, G1
Dieterich, DT; Mullen, MP; Patel, MR1
Anwar, W; Hussain, AB; Saif, M; Sarwar, M; Tariq, WU1
Stadlbauer, V; Stauber, RE1
Higashimoto, M; Jokyu, R; Saito, H; Takahashi, M1
Herrine, SK; Navarro, VJ; Rossi, S1
Baldo, V; Carderi, I; Ferrara, F; Floreani, A; Minola, E; Rizzotto, ER1
Choi, MS; Kim, DY; Kim, JH; Koh, KC; Lee, H; Lee, JH; Paik, SW; Rhee, JC; Song, SM; Yoo, BC1
Becker, MC; Bresson-Hadni, S; Bronowicki, JP; Di Martino, V; Lunel-Fabiani, F; Miguet, JP; Thevenot, T; Vanlemmens, C1
Chambers, T; Di Bisceglie, AM; Fan, X; Strinko, J1
Bonora, S; D'Avolio, A; de Requena, DG; Di Perri, G; Ibañez, A; Sciandra, M; Siccardi, M1
Böcher, WO; Galle, PR; Hillenbrand, H; Link, R; Löhr, HF; Mudter, J; Rahman, F; Schuchmann, M; Sprinzl, M1
Boroń-Kaczmarska, A; Jurczyk, K; Karpińska, E; Morańska, I; Urbanowicz, W; Wawrzynowicz-Syczewska, M1
Balestrieri, A; Balestrieri, C; Cauli, C; Chessa, L; Farci, P; Serra, G1
Montes-Ramírez, ML; Rodríguez-Zapata, M1
Díaz, F; Girón-González, JA; Marín-Serrano, E; Martín-Herrera, L; Rodríguez-Ramos, C1
Ahmad, J; Anand, BS; Awad, JA; Aytaman, A; Bini, EJ; Bräu, N; Chang, KM; Cheung, RC; Currie, S; Hagedorn, CH; Ho, SB; Hu, KQ; Jeffers, LJ; Johnson, DP; King, PD; Mendenhall, CL; Morgan, TR; Moseley, RH; Pedrosa, MC; Rossi, SJ; Schmidt, WN; Shen, H; Simon, FR; Waters, B; Wright, TL1
Herrmann, E; Mihm, U; Sarrazin, C; Zeuzem, S1
de Vries, RA; Kok, KF1
Everson, GT; Sieja, KS1
Alshuth, U; Berg, T; Buggisch, P; Gerlach, T; Goeser, T; Heintges, T; Kallinowski, B; Klinker, H; Martus, P; Nasser, S; Pape, GR; Rasenack, J; Sarrazin, C; Schmidt, WE; Spengler, U; von Wagner, M; Zeuzem, S1
Aceti, A; Bartolozzi, D; Blanc, PL; Capanni, M; Esperti, F; Ferrari, C; Forte, P; Gemignani, G; Guadagnino, V; Mari, T; Marino, N; Messerini, L; Milani, S; Pasquazzi, C; Rosina, F; Stroffolini, T; Tacconi, D; Taliani, G; Toti, M; Zignego, AL1
Husa, P; Slesinger, P; Stroblová, H; Svobodník, A2
Aiglová, K; Ehrmann, J; Kümpel, P; Palas, J1
Altés, J; Baguena, F; Casanova, A; de Castro, ER; Delejido, A; Garcia, MJ; Rota, R; Sala, M; Santin, M; Shaw, E; Valero, S1
Ackrill, AM; Ferenci, P; Hadziyannis, SJ; Jensen, DM; Marcellin, P; Morgan, TR; Pockros, PJ; Reddy, KR; Willems, B1
Brown, RS2
Juszczyk, J; Kmieciak, D; Kruszyna, Ł; Migdalski, P; Trzeciak, WH; Łaciński, M1
Asnis, GM; De La Garza, R1
Bilusic, M; Hrstic, I; Huic, D; Vucelic, B1
Main, J; Thomas, H1
Day, C; Desmond, CP; Dudley, F; Mitchell, J; Nguyen, S; Pianko, S; Roberts, SK1
Koksal, I1
Elefsiniotis, IS; Fotos, NV; Mavrogiannis, C; Moulakakis, A; Pantazis, KD1
Foster, GR; Hollander, A; Weiland, O1
McHutchison, JG; Muir, AJ; Patel, K1
Zoras, C1
Fukui, H; Matsumura, Y; Nishiofuku, M; Toyohara, M; Tsujimoto, T; Yamao, J; Yoshiji, H; Yoshikawa, M1
Dumitraşcu, DL; Grigorescu, M; Pascu, O; Pojoga, C1
Calonje, E; Perera, GK1
Fehér, J; Kiss, A; Lengyel, G; Podányi, B; Schaff, Z; Szakonyi, J1
Mathew, A; McGarrity, TJ; Peiffer, LP; Rhoades, K1
Anand, BS; Bini, EJ; Currie, S; Dieperink, E; Ho, SB; Shen, H; Wright, T1
Capelli, P; Corrocher, R; De Franceschi, L; Fattovich, G; Felder, M; Guido, M; Lanza, C; Leandro, G; Olivari, N; Pasino, M; Rugge, M1
Lin, F; Wang, HF1
Betterle, C; Cozzolongo, R; Fabris, P; Lanzilotta, E; Manghisi, OG; Paola Albergoni, M1
Christensen, AF; Mando, OG; Ridruejo, E1
Alessio, A; Buonsante, ME; Frider, B; Pellerano, G; Tiscornia, J1
Anderson, F; Bain, VG; Balshaw, R; Deschenes, M; Kaita, K; Krajden, M; Lee, SS; Peltekian, K; Sherman, M; Simonyi, S; Yoshida, EM1
Tulassay, Z; Werling, K1
García-Buey, L; Gómez-Domínguez, E; Moreno-Monteagudo, JA; Moreno-Otero, R; Trapero-Marugán, M1
Arakawa, Y; Moriyama, M1
Carnero-Fernández, M; Lite-Alvarez, JM; Pineda, JR1
Arpurt, JP; Bernard, P; Chousterman, M; Fischer, D; Glibert, A; Grasset, D; Lagier, E; Morin, T; Nalet, B; Pariente, A; Picon, M; Pillon, D; Ramdani, M; Renou, C; Rotily, M; Wartelle-Bladou, C1
Abud-Bastida, F; Constantino-Casas, P; García-Contreras, F; Garduño-Espinosa, J; Nevárez-Sida, A1
Grieve, R; Main, J; Roberts, J; Thomas, HC; Wright, M1
Ahern, M; Cai, FZ; Smith, M1
Bernal, Mdel C; Casado, J; De Rueda, PM; Huertas, C; Palacios, A; Rodríguez, L; Ruiz-Extremera, A; Salmerón, J1
Halota, W; Palewicz, E; Pawłowska, M1
Simon, K1
Ruiz-Sancho, A; Soriano, V1
Asselah, T; Bedossa, P; Boyer, N; Dargere, D; Marcellin, P; Martinot, M; Paradis, V; Ripault, MP; Valla, D1
Amorim, W; Cheinquer, H; Correa, E; Cotrim, H; Crespo, D; Fonseca, J; Gallizi, J; Lacet, C; Martinelli, A; Meirelles, A; Paraná, R; Parise, E; Pessoa, M; Sette, H; Silva, R; Spinelli, V; Tatsch, F1
Sette, H; Tatsch, FF; Vianna, D1
Ashikaga, T; Gordon, SR; Grace, ND; Krawitt, EL; Moskowitz, S; Palmer, M; Ray, MA; Yarze, JC1
Di Martino, V; Le Calvez, S; Massard, J; Munteanu, M; Poynard, T; Ratziu, V; Thabut, D; Thibault, V1
Iino, S; Itoh, F; Kobayashi, Y; Koike, K; Nagase, Y; Okuse, C; Suzuki, M; Yasuda, K; Yotsuyanagi, H1
Andreoni, M; Biglino, A; Calleri, G; Cariti, G; Ciancio, A; Ciccone, G; Colletta, C; Croce, G; Di Napoli, A; Giordanino, C; Macor, A; Manca, A; Orsi, PG; Pozzi, M; Prandi, G; Rizzetto, M; Saracco, G; Smedile, A; Tappero, GF1
Bordens, R; Cullen, C; Cutler, D; Grace, M; Harvey, J; Jackson, M; Laughlin, M; Poo, J; Silva, M; Wagner, F1
Balestrieri, C; Cauli, C; Chessa, L; Farci, P; Lai, ME; Scioscia, R; Serra, G1
Kupś, J; Wiśniewska-Ligier, M; Woźniakowska-Gesicka, T1
Barreiro, P; Garcia-Samaniego, J; Labarga, P; Martín-Carbonero, L; Nuñez, M; Ramos, B; Romero, M; Simarro, N; Soriano, V1
Berg, C; Bernstein, DE; Cooksley, G; Diago, M; Goncales, FL; Graham, P; Jensen, DM; Rasenack, J; Sette, H1
Adachi, Y; Fujita, N; Horiike, S; Iwasa, M; Kai, M; Kaito, M; Konishi, M; Sugimoto, R; Tanaka, H; Watanabe, S1
Arn, M; Borovicka, J; Criblez, D; Egger, H; Gonvers, JJ; Helbling, B; Meyenberger, C; Meyer-Wyss, B; Müllhaupt, B; Oneta, C; Rammert, C; Renner, EL; Rich, P; Rossi, L1
Bernfort, L; Reichard, O; Sennfält, K1
Blatt, LM; Seiwert, SD; Wang, T1
Baditoiu, L; Danila, M; Laza, A; Popescu, A; Sirli, R; Sporea, I1
Borque, MJ; Fernández, MJ; García-Buey, L; Medina, J; Moreno-Monteagudo, JA; Moreno-Otero, R; Muñoz, C; Quintana, NE; Salvanés, FR; Trapero-Marugán, M1
Bagheri, H; Barange, K; Bonnet, E; Claeyssens, S; Guitton, E; Massip, P; Montastruc, JL; Vinel, JP1
Alves, VA; Correa-Giannella, ML; Giannella-Neto, D; Machado, MC; Massarollo, PC; Ribeiro, CM; Stefano, JT1
Ito, S; Taguchi, N1
Abe, H; Aizawa, R; Aizawa, Y; Chuganji, Y; Endou, H; Fujimoto, T; Fujita, Y; Higuchi, T; Iga, D; Ishizuka, H; Itou, Y; Kuroda, H; Matsuda, T; Nakanishi, H; Ohta, K; Tomimatsu, M; Ushiyama, H1
Ahmad, I; Alam, A; Butt, AK; Dilshad, A; Khan, AA; Sarwar, S1
Arican, N; Gümrah, M; Mehtap, O; Yenice, N1
Di Liberto, G; Ducoulombier, D; Fallot, G; Feray, C; Kara, R; Roque-Afonso, AM; Samuel, D1
Cassidy, W; Howell, CD; Hu, S; Jeffers, LS; Lee, JS; Reddy, KR1
Farci, P; Green, J; Hornberger, J; Patel, KK; Prati, D; Zeuzem, S1
Chang, WY; Chen, SC; Chuang, WL; Dai, CY; Hsieh, MY; Huang, JF; Lee, LP; Lee, PL; Lin, ZY; Wang, LY; Yu, ML1
Chen, CH; Eng, HL; Hu, TH; Hung, CH; Kuo, FY; Lee, CM; Lu, SN; Wang, JH1
Andrade, RJ; Camargo, R; Cilvetti, A; Clavijo, E; García-Cortés, M; González, FJ; Lucena, MI; Martos-VanDussen, JV; Rosón, P; Vázquez, L1
Bahra, M; Berg, T; Langrehr, JM; Neuhaus, P; Neuhaus, R; Neumann, U; Puhl, G1
Daruich, J; Fainboim, H; Frider, B1
Elefsiniotis, IS; Kamposioras, K; Ketikoglou, I; Moulakakis, A; Pantazis, KD; Saroglou, G; Tontorova, R; Vezali, E1
Berenguer, M; Terrault, NA1
Bang, CT; Bodenheimer, HC; Clain, DJ; Gopal, K; Gopal, S; Johnson, TC; Min, AD; Pena-Sahdala, HN; Suwandhi, P; Walfish, A1
Bonkovsky, HL; Di Bisceglie, AM; Dienstag, JL; Everhart, JE; Everson, GT; Ghany, MG; Gretch, DR; Lee, WM; Lindsay, KL; Lok, AS; Morgan, TR; Morishima, C; Shiffman, ML; Wright, EC1
Furutani, T; Hara, Y; Hino, K; Kitase, A; Murakami, Y; Nagai, A; Okita, K; Okita, M; Okuda, M; Ren, F; Yamaguchi, Y; Yamashita, S; Yutoku, K1
Ariello, M; Conca, P; Sorrentino, P; Tarantino, G1
Carrilho, FJ; D'Amico, EA; Farias, AQ; Goncalves, LL; Gonçalves, PL1
Fireman, M; Hauser, P; Matthews, AM; Sobel, M; Zucker, B1
Amaral, AC; Conceição, RD; de Oliveira, AC; Leite, K; Parise, ER1
Stribling, R; Sussman, N; Vierling, JM1
Gisbert, JP; Maté, J; Medina, J; Moreno-Otero, R; Nam Cha, SJ; Salcedo-Mora, X1
Chao, YC; Chen, DS; Chen, EY; Chen, PJ; Chuang, WL; Dai, CY; Gu, ZJ; Hwang, Y; Lai, MY; Lee, CM; Liao, YT; Shian-Jy Bey, M; Wang, JH; Yu, ML1
Cotler, SJ; Layden, TJ; Layden-Almer, JE1
Chiba, T; Egawa, H; Ikeda, K; Iwai, A; Marusawa, H; Nabeshima, M; Takada, Y; Uemoto, S1
Boillot, O; Chevallier, P; Ducos, E; Dumortier, J; Gagnieu, MC; Scoazec, JY1
Carrión, JA; Costa, J; Feliu, A; Forns, X; García-Retortillo, M; González, P; Martínez-Bauer, E; Massaguer, A; Sánchez-Tapias, JM1
Barone, A; Brandão, C; Caramori, C; Carrilho, F; Focaccia, R; Patelli, M; Pedroso, M; Pereira, L; Pessoa, M; Silva, A; Tatsch, F1
Cornberg, M; Manns, MP; Wedemeyer, H4
Dudley, T; Haydon, G; Mutimer, D; O'Donnell, K1
Bräu, N; Eldeiry, LS; Greenberg, PD; Naqvi, Z; Rosman, AS1
Chung, DJ; Jin, HM; Kim, JH; Kim, K; Kim, N; Lee, J; Lee, KB1
Coupoulou, AA; Dimitropoulou, D; Gogos, CA; Karatza, C; Liava, A; Petsas, T; Siagris, D; Syrokosta, I; Thomopoulos, K; Tsamandas, AC; Zolota, V1
Fischer, K; Makris, M; Mauser-Bunschoten, EP; Posthouwer, D1
Bhagani, S; Johnson, M; Killingley, B; Slapak, G; Yee, TT1
Hayashi, K; Hirashima, N; Kato, H; Kato, T; Lau, JY; Mizokami, M; Mizuno, Y; Ogino, M; Ohno, T; Orito, E; Sakakibara, K; Sugihara, K; Suzuki, S; Tanaka, Y; Ueda, R1
Arataki, K; Chayama, K; Kumada, H; Ohishi, W; Takahashi, S; Tazuma, S; Toyota, K1
Aimitsu, S; Aisaka, Y; Chayama, K; Kawakami, H; Kitamoto, M; Kohno, H1
de Filippo, FR; Focareta, R; Forte, G; Piai, G; Scalice, E; Terracciano, F1
Aslan, V; Aykin, N; Cevik, F; Demirdal, T; Demirturk, N1
Costas, P; Ortiz, A; Torres, EA; Velázquez, V1
Aponte, N; Arroyo, J; Chinea, B; De Jesus-Monge, WE; González, H; Guzmán, A; Muñoz, H; Rivera, C; Rodríguez, F; Toro, DH; Torres, EA1
Antúnez, I; Aponte, N; Fernández-Carbia, A; Rodríguez-Perez, F; Toro, DH1
Müller, C1
Arora, N; Goyal, A; Kumar, GT; Sarin, SK; Shukla, DK; Suneetha, PV1
Adenwalla, M; Cheong-Lee, C; Ma, PE; Yoshida, EM; Zandieh, I1
Chang, WY; Chen, SC; Chuang, WL; Dai, CY; Hsieh, MY; Kuo, HT; Lee, LP; Lin, ZY; Tsai, SL; Wang, LY; Yu, ML1
Ansaldi, F; Gentile, R; Icardi, G; Ravetti, G; Sumberaz, A; Testino, G1
Antela, A; Bárcena, R; Celma, ML; Fernández-Muñoz, R; García-Martos, M; López-San Román, A; Moreno, A; Moreno, L; Moreno, S; Pérez-Elías, MJ; Quereda, C1
Funada, R; Harada, K; Hasegawa, K; Homma, N; Inoue, M; Ogata, N; Shibasaki, K; Soga, K; Uchida, M; Watanabe, T2
Arora, N; Blum, HE; Goyal, A; Hermann, E; Hissar, SS; Hofmann, WP; Sarin, SK; Sarrazin, C; Traver, S; Zeuzem, S1
Chang, WY; Chen, SC; Chiu, CF; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, JF; Lee, LP; Lin, ZY; Wang, LY; Yu, ML1
Clements, BJ; Malibu, Y; Sylvestre, DL1
Akimoto, Y; Harada, S; Hirai, M; Hirooka, T; Hotta, H; Ishii, F; Izawa, S; Kim, KI; Kim, SH; Kim, SR; Kimura, N; Kinoshita, K; Kinoshita, M; Motojima, M; Nabeshima, S; Nakao, K; Ohtani, A; Ohzu, M; Sasase, N; Shikata, M; Tanaka, K; Taniguchi, M1
Dhillon, AP; Dustin, LB; Ferrari, C; Haagmans, BL; Hellstrand, K; Lagging, M; Missale, G; Negro, F; Neumann, AU; Pawlotsky, JM; Romero, AI; Schalm, SW; Verheij-Hart, E; Westin, J; Zeuzem, S1
Battistin, L; Bernardinello, E; Briani, C; Cavalletto, L; Chemello, L; Ermani, M; Gatta, A; Ruggero, S; Toffanin, E; Zara, G1
Cua, IH; George, J; Henriquez, M; Kench, J; Kwan, V1
Bottari, S; Hilleret, MN; Leroy, V; Morel, F; Sturm, N; Trocme, C; Zarski, JP1
Alvarez, D; Ball, L; Brau, N; Dieterich, DT; Moorehead, L; Sulkowski, MS1
Boyer, N; Castelnau, C; Comanor, L; Giuily, N; Hendricks, D; Marcellin, P; Martinot-Peignoux, M; Minor, JM; Pham, BN; Ripault, MP1
Dolmazashvili, E; Gochitashvili, N; Kakabadze, T; Sharvadze, L; Tsertsvadze, T1
Andreoni, M; Anselmo, M; Basso, M; Calleri, G; Cariti, G; Ciancio, A; Ciccone, G; Cusumano, S; Gallo, M; Garbagnoli, P; Giordanino, C; Grasso, A; Manca, A; Marenco, G; Percario, G; Picciotto, A; Rizzetto, M; Rizzi, R; Saracco, G; Sartori, M; Smedile, A; Tabone, M1
Kobayashi, K; Kobayashi, T; Kondo, Y; Shiina, M; Shimosegawa, T; Ueno, Y1
Takahashi, H; Zeniya, M1
Elefsiniotis, IS; Ketikoglou, I; Pantazis, KD; Petrocheilou, A; Scarmeas, N; Toutouza, M; Tsianos, EV1
Cho, H; Kim, YM; Lee, JS; Lee, MY1
Araújo, C; Braga, H; Cruz, M; Cruz, T; Cunha, S; Mello, V; Ney-Oliveira, F; Nuñez, G; Parana, R; Schinoni, MI; Simões, MT1
Deschênes, M; Hilzenrat, N; Nudo, CG; Wong, P1
Mathew, A; McGarrity, T; Peiffer, LP; Rhoades, K1
Banerjee, R; Gupta, R; Lakhtakia, S; Ramakrishna, CH; Reddy, DN; Tandan, M1
Gehring, S; Gerner, P; Koeppelmann, S; Kullmer, U; Wintermeyer, P; Wirth, S1
Chrysagis, D; Dalekos, GN; Elefsiniotis, I; Gigi, E; Kanatakis, S; Kartalis, G; Ketikoglou, I; Koliouskas, D; Mimidis, K; Papadopoulos, VP; Paraskevas, E; Protopapas, A; Tsianos, E; Tzathas, C1
Alberti, A; Diago, M; Marcellin, P; Negro, F; Prati, D; Puoti, C; Roberts, SK; Rosenberg, W; Shiffman, ML; Zeuzem, S1
Bernard, PH; Castera, L; Champbenoit, P; Constant, A; Couzigou, P; De Ledinghen, V; Demotes-Mainard, J; Henry, C1
Colombo, M; Coppola, A; Linari, S; Mancuso, ME; Mannucci, PM; Rumi, MG; Santagostino, E1
Fabris, C; Pirisi, M; Toniutto, P1
Ebinuma, H; Hibi, T; Ishii, H; Kashiwazaki, K; Nishida, J; Saito, H; Shiozaki, H; Tada, S; Takahashi, M; Tanaka, S; Tsukada, N1
Asselah, T; Bourlière, M; Bouvier-Alias, M; Bronowicki, JP; Chevalier, M; Chevaliez, S; Desmorat, H; Foucher, J; Hézode, C; Lonjon-Domanec, I; Melin, P; Montestruc, F; Ouzan, D; Pawlotsky, JM; Renou, C; Tran, A; Zarski, JP1
Rustgi, VK; Shiffman, ML1
Alvarez, E; Bañares, R; Catalina, MV; Clemente, G; Lo Iacono, O; Matilla, AM; Nuñez, O; Rincon, D; Ripoll, C; Salcedo, M1
Ferenci, P; Formann, E; Gangl, A; Homoncik, M; Jilma, B; Peck-Radosavljevic, M; Schmid, M; Sieghart, W1
Chang, KC; Changchien, CS; Chen, CH; Hu, TH; Hung, CH; Kee, KM; Lee, CM; Lu, SN; Tseng, PL; Wang, JH; Yen, YH1
Durante Mangoni, E; Graham, CS; He, Q; Koziel, MJ1
Alessandri, A; Franco, V; Giannitrapani, L; Montalto, G; Rappa, F; Soresi, M; Tripi, S; Vuturo, O1
Arizcorreta, A; Brun, F; Fernández-Gutiérrez, C; Girón-González, JA; Guzmán, EP; Márquez, M; Rodríguez-Iglesias, M1
Hagiwara, H; Haruna, Y; Hayashi, N; Hijioka, T; Hiramatsu, N; Ishibashi, K; Kanto, T; Kasahara, A; Katayama, K; Kato, M; Kubota, S; Kurashige, N; Mita, E; Oshita, M; Oze, T; Takehara, T; Tamura, S; Tsuda, N; Yakushijin, T; Yoshihara, H1
Bodenheimer, HC; Clain, DJ; Homel, P; Kalakuntla, R; Min, AD; Narasimhan, G; Sargios, TN; Theise, ND1
Chen, EY; Gu, ZJ; Hwang, Y; Lin, E; Wang, SC1
Chang, WY; Chen, SC; Chuang, WL; Dai, CY; Hsieh, MY; Lee, CM; Lee, LP; Liaw, YF; Lin, SM; Lin, ZY; Wang, LY; Yu, ML1
Fernández-Carbia, A; González-Lassalle, E; Marxuach-Cuétara, AM; Ríos-Bedoya, CF; Rodríguez-Orengo, JF; Rodríguez-Torres, M; Salgado-Mercado, R1
Leung, Y; Myers, RP; Schindel, L; Urbanski, SJ1
Alexander, J; Kowdley, KV1
Agho, K; Byrne, A; Dore, GJ; Hallinan, R1
Etani, Y; Hasegawa, Y; Mushiake, S; Ozono, K; Tajiri, H1
Chang, CS; Chen, GH; Fu, LS; Kao, JH; Yang, SS; Yeh, HZ1
Cacoub, P; Piette, JC; Resche-Rigon, M; Saadoun, D; Thibault, V1
Artioli, S; Azzola, E; Basso, M; Blanchi, S; Grasso, A; Pelli, N; Percario, G; Picciotto, A; Torre, F1
Dixit, V; Fabrizi, F; Lunghi, G; Martin, P1
Lin, WA; Tang, SL; Tarn, YH1
Buggisch, P; Clumeck, N; DePamphilis, J; Dieterich, D; Lissen, E; Main, J; Mendes-Correa, M; Montaner, J; Nelson, M; Pessôa, M; Sola, R1
Barreiro, P; Garcia-Samaniego, J; Labarga, P; Ruiz-Sancho, A; Soriano, V1
Aguilera Sancho-Tell, V; Berenguer Haym, M; Iborra Colomino, M1
Dalekos, GN; Gatselis, NK; Georgiadou, SP; Hatzakis, A; Koukoulis, GK; Liaskos, C; Tassopoulos, N; Zachou, K1
Alves Couto, C; Costa Faria, L; de Abreu Ferrari, TC; de Melo Couto, OF; de Paula Farah, K; Dias Ribeiro, D1
Alaimo, G; Almasio, PL; Calvaruso, V; Craxì, A; D'Angelo, F; Di Marco, V; Di Stefano, R; Ferraro, D; Porrovecchio, S1
Civolani, A; Demelia, L; Murgia, D; Murru, A; Rizzetto, M; Sorbello, O1
Abergel, A; Alric, L; Barange, K; Bernard, PH; Bommelaer, G; Bonny, C; Bronowicki, JP; Castera, L; Chevallier, M; Darcha, C; Dhumeaux, D; Dubost, S; Henquell, C; Hezode, C; Lafeuille, H; Leroy, V; Martineau, N; Randl, K; Tran, A; Ughetto, S1
Carulli, N1
Balzola, F; Bellati, G; Benetti, G; Borzio, M; Colombo, A; Croce, G; Fargion, S; Iamoletti, C; Ramella, G; Rizzetto, M1
Duff, F; Jorga, K; Lamb, M; Snoeck, E; Wade, JR2
Fan, YM; Li, DM; Li, TS; Li, ZR; Liao, GX; Ma, XJ1
Boix-Martínez, V; Clemente-Ricote, G; Marco-Mouriño, A; Núñez-Martínez, O; Portilla-Sogorb, J; Reus-Bañuls, S; Saiz de la Hoya-Zamácola, P; Teixidó i Pérez, N1
Accadia, L; Andriulli, A; Annicchiarico, BE; Bombardieri, G; Caruso, N; Iacobellis, A; Leandro, G; Perri, F; Siciliano, M1
Ballesteros, AL; Clotet, B; Ferrer, MJ; Fumaz, CR; Fuster, D; Gómez, G; Masmitjà, E; Muñoz-Moreno, JA; Paredes, R; Pérez-Alvarez, N; Salas, A; Tural, C1
Romero-Gómez, M1
McHutchison, JG; Muir, AJ1
Dhillon, AP; Ferrari, C; Haagmans, BL; Hellstrand, K; Lagging, M; Missale, G; Negro, F; Neumann, AU; Norkrans, G; Pawlotsky, JM; Romero, AI; Schalm, SW; Verheij-Hart, E; von Wagner, M; Westin, J; Zeuzem, S1
Del Rio, RA; Post, AB; Singer, ME1
Bonkovsky, HL; Di Bisceglie, AM; Dienstag, JL; Everson, GT; Ghany, MG; Hoefs, JC; Kahn, JA; Lee, WM; Lok, AS; Morishima, C; Naishadham, D; Seeff, LB; Shiffman, ML1
Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Itoh, A; Katano, Y; Murayama, M; Nakano, I1
Bergholz, U; Ferenci, P; Gurguta, C; Hofer, H; Steindl-Munda, P1
Carrilho, FJ; da Silva, LC; de Carvalho Mello, IM; de Mello Malta, F; Medeiros-Filho, JE; Neumann, AU; Pinho, JR1
Buenestado-García, J; Egido-García, R; Piñol-Felis, C; Reñé-Espinet, JM; Rubio-Caballero, M; Rubio-Rivas, M1
Tural i Llàcher, C1
Laursen, AL; Vilstrup, H1
Berg, T; Bergk, A; Halangk, J; Hinrichsen, H; Müller, T; Neuhaus, P; Neumann, K; Puhl, G; Schott, E; Tinjala, S; Weich, V; Wiedenmann, B; Witt, H1
Hoofnagle, JH; Seeff, LB1
Deibler, P; Haasen, C; Reimer, J1
Darling, JM; Fried, MW1
Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kobayashi, M; Koyama, R; Kumada, H; Saitoh, S; Sezaki, H; Someya, T; Suzuki, F; Suzuki, Y1
Bonte, D; Capron, D; Castelain, S; Dedeurwaerder, S; Duverlie, G; François, C; Morel, V; Penin, F; Wychowski, C; Zawadzki, P1
Asselah, T; Belghiti, J; Boudjema, H; Durand, F; Francoz, C; Marcellin, P; Sobesky, R; Valla, D1
Afdhal, NH; Conjeevaram, HS; Everhart, JE; Hoofnagle, JH; Kleiner, DE; Wahed, AS; Zacks, S1
Honda, H; Honda, M; Kaneko, S; Kawamura, T; Tateno, M1
Ahn, SH; Chon, CY; Han, KH; Kim, JH; Lee, KS; Moon, YM; Park, YN1
Jiang, HC; Li, SC; Liu, BR; Yang, XH1
Back-Madruga, C; Bonkovsky, HL; Di Bisceglie, AM; Dienstag, JL; Fontana, RJ; Ghany, MG; Gretch, DR; Kulig, CC; Malet, PF; Morgan, TR; Snow, KK; Sterling, RK1
Fried, M; Hadziyannis, S; Hamzeh, FM; Morgan, TR; Reddy, KR; Shiffman, ML; Wright, TL; Zeuzem, S1
Baker, RD; Baker, SS; Dee, D1
Aikaterini, T; Barbara, M; Claudio, I; Daniela, C; Danila, C; Davide, P; Gaetano, B; Giuseppe, A; Luca, I; Luciano, C; Massimo, L; Salvatore, T; Sergio, N; Stefano, C1
Ide, T; Kage, M; Maruyama, T; Okamura, T; Sata, M; Seki, R; Uyesaka, N1
Manns, MP; Tillmann, H; Trebst, C; Wedemeyer, H; Windhagen, A1
Abbott, WG; Naoumov, NV; Rigopoulou, EI; Williams, R1
Adachi, Y; Fujita, N; Hasegawa, K; Horiike, S; Iwasa, M; Kaito, M; Kawanishi, S; Kobayashi, Y; Ma, N; Sugimoto, R; Tanaka, H1
Dhillon, AP; Hellstrand, K; Lagging, M; Missale, G; Negro, F; Neumann, AU; Norkrans, G; Pawlotsky, JM; Romero, AI; Schalm, SW; Verheij-Hart, E; Westin, J; Zeuzem, S1
Akamatsu, T; Ichijo, T; Kiyosawa, K; Matsumoto, A; Muto, H; Tanaka, E; Umemura, T; Yoshizawa, K1
De Heusden, N; Fischer, K; Mauser-Bunschoten, EP; Posthouwer, D1
Asselah, T; Bourlière, M; Boyer, N; Cazals-Hatem, D; El Ray, A; Marcellin, P; Martinot-Peignoux, M; Moucari, R; Oulès, V; Ripault, MP; Valla, D; Vidaud, D1
Conde, A; Cruces, M; De La Torre, C; García-Doval, I; González-Sixto, B; Mayo, E; Pardavila, R1
Bini, EJ; Bräu, N; Cheung, RC; Currie, SL; Ho, SB; Hu, KQ; Jeffers, L; McCracken, JD; Morgan, T; Schmidt, WN; Shen, H; Wright, TL1
Mallet, VO; Pol, S1
Bonkovsky, HL; Di Bisceglie, AM; Dienstag, JL; Everson, GT; Ghany, MG; Gretch, DR; Lee, WM; Lindsay, KL; Lok, AS; Morgan, TR; Shiffman, ML; Wright, EC1
Andrade, R; de la Mata, M; Diago, M; Granados, R; Muñoz de Rueda, P; Pérez, R; Romero, M; Ruiz-Extremera, A; Salmerón, J; Solá, R1
Colledan, M; Montalbano, M; Pasulo, L; Remuzzi, G; Sonzogni, A; Strazzabosco, M1
Bardadin, K; Berak, H; Horban, A; Paprocka, H; Stańczak, JJ; Wasilewski, M1
Balan, V; Cheruvattath, R; Gautam, M; Rakela, J; Rosati, MJ; Vargas, HE1
Bani-Sadr, F; Chakvetadze, C; Lamontagne, F; Le Pendeven, C; Pialoux, G; Vincensini, JP1
Bowers, P; Henry, DH; Lamarca, A; Leitz, G; Slim, J1
Belle, SH; Brodsky, L; Edenberg, HJ; Howell, C; Li, L; McClintick, JN; Sanda, C; Schaley, J; Stephens, MJ; Tavis, JE; Taylor, MW; Tsukahara, T1
Fuchs, M; Ludwig, D; Witthoeft, T1
Adachi, K; Iino, S; Ishii, T; Itoh, F; Katakura, Y; Matsumoto, N; Matsunaga, K; Okuse, C; Suzuki, M; Yotsuyanagi, H1
Giuliani, R; Manfredi, R; Sabbatani, S1
Araújo, E; Barone, AA; Borges, A; Coelho, HS; Corrêa-Giannella, ML; Ferraz, ML; Focaccia, R; Gonçales, FL; Gonçales, N; Lobato, C; Oliveira, U; Paixao, J; Perez, R; Rosa, H; Vigani, A; Vila, R; Weirich, J1
Bahra, M; Berg, T; Jacob, D; Langrehr, JM; Neuhaus, P; Neuhaus, R; Neumann, UP1
Antinori, A; Armignacco, O; Babudieri, S; Carioti, J; Caroleo, B; Guadagnino, V; Maio, G; Monarca, R; Montesano, F; Trotta, MP1
Adams, PC; Bain, VG; Chatterjee, A; Croitoru, K; Heathcote, EJ; Kaita, K; Lee, SS; Peltekian, K; Swain, MG; Teitel, J1
Bahnassy, AA; El-Awady, M; El-Din, HM; El-Hefnewi, M; Fouad, I; Khaled, MM; Omar, A; Thakeb, F; Zekri, AR1
Buti, M; Crespo, M; Esteban, JI; Esteban, R; Falco, V; Guardia, J; Ocaña, I; Pahissa, A; Ribera, E; Sauleda, S1
Brunetto, MR; Fargion, S; Gaeta, GB; Niro, GA; Picciotto, A; Pontisso, P; Raimondo, G; Saitta, C; Smedile, A; Squadrito, G1
Bourlière, M; Pol, S1
Chang, WY; Chuang, WL; Dai, CY; Lee, CM; Liaw, YF; Lin, SM; Lu, SN; Sheen, IS; Wang, JH; Yu, ML1
Delgado-Jimenez, Y; Fernandez-Herrera, J; Fraga, J; Garcia-Diez, A; Goiriz, R; Perez-Gala, S1
Aghemo, A; Colombo, M; D'Ambrosio, R; Del Ninno, E; Gallus, S; Ronchi, G; Rumi, MG; Soffredini, R1
Gra Oramas, B; Llanio Navarro, R; Ruenes Domech, C; Soler, E; Vilar Gomez, E1
Januszkiewicz-Lewandowska, D; Lewandowski, K; Mańkowski, P; Nowak, J; Nowicka, K; Pernak, M; Rembowska, J; Wysocki, J; Zawada, M1
Barreiro, P; Benito, JM; de Baar, M; de Mendoza, C; González-Lahoz, J; Martin-Carbonero, L; Rodriguez-Novoa, S; Soriano, V; Zahonero, N1
Brok, J; Gluud, C; Gong, Y; Koretz, RL1
Luketic, VA; Mihas, AA; Millwala, F; Sanyal, AJ; Shiffman, ML; Sterling, RK; Stravitz, RT1
Berenson, CS; Bhatti, Z1
Amore, M; Baldini, A; Beverini, E; Bonino, F; Brunetto, M; Carlini, M; Del Debbio, A; Dell'Osso, L; Ferrari, G; Maggi, L; Maj, M; Manca, E; Pini, S; Rucci, P; Scarallo, V; Semeraro, Q1
Kallman, J; Kincaid, J; Younossi, Z1
Foster, GR; Freivogel, K; Fried, MW; Hadziyannis, SJ; Messinger, D; Weiland, O1
Aszalós, Z; Lengyel, G; Tulassay, Z1
Davidson, P; Hartwell, D; Jones, J; Price, A; Shepherd, J; Waugh, N1
Campos, NG; Freedberg, KA; Goldie, SJ; Nunes, DP; Salomon, JA; Samet, JH; Servoss, JC1
Dong, MH; Kaunitz, JD; Smith, JP1
Christodoulou, D; Christou, L; Economou, MS; Filis, S; Tsianos, EV; Vienna, H1
Archimandritis, AJ; Hadziyannis, E; Karandreas, N; Kilidireas, C; Koskinas, J; Kountouras, D; Savvas, S1
Sallie, R1
Cacoub, P; Carrat, F; Fafi-Kremer, S; Lunel, F; Morand, P; Payan, C; Perronne, C; Pivert, A; Pol, S1
Honsová, E; Sperl, J; Sticová, E1
Attia, JR; Batey, RG; Jones, TL; Tran, HA1
Duggan, AE; Duggan, JM1
Abramowicz, M1
Dalmi, L; Gervain, J; Hunyady, B; Ibrányi, E; Makara, M; Pár, A; Szalay, F; Telegdy, L; Tornai, I1
Han, DS; Jeon, YC; Kim, TY; Park, YK; Sohn, JH; Son, BK1
Evoli, A; Servidei, S1
Assy, N; Embon, O1
Leiner, S1
Ben Salem, C; Bouraoui, K; Hmouda, H1
Andreu, AL; Buti, M; Crespo, M; Esteban, JI; Esteban, R; Falco, V; Guardia, J; Juarez, A; Ocaña, I; Pahissa, A; Quer, J; Ribera, E; Ruiz, I; Sauleda, S1
Amoruso, AC; Castellaneta, NM; Di Leo, A; Francavilla, A; Losito, F; Rendina, M; Schena, A; Schena, FP; Stallone, G1
Herrmann, E; Hofmann, WP; Kronenberger, B; Lohmann, V; Mihm, U; Polta, A; Sarrazin, C; Schönberger, B; Sonntag, T; Zeuzem, S1
Hayashi, N; Hiramatsu, N; Inoue, M; Itose, I; Kanto, T; Kasahara, A; Katayama, K; Kato, M; Miyatake, H; Miyazaki, M; Oze, T; Sakakibara, M; Takehara, T; Yakushijin, T1
Aberle, JH; Ferenci, P; Gurguta, C; Holzmann, H; Kundi, M; Perstinger, G; Popow-Kraupp, T; Sinzinger, U; Steindl-Munda, P; Weseslindtner, L1
Brown, RS; Manns, MP; McHutchison, JG; Reddy, KR; Shiffman, ML; Wong, JB1
García-Morán, S; Muñoz Fernández-Lomana, C; Sáez-Royuela, F1
Riley, TR; Taheri, MR1
Antón, M; Barniol, R; Benítez, A; Casanovas, T; Dalmau, B; Del Olmo, J; Diago, M; Díaz, F; Domínguez, A; Enríquez, J; Eraña, L; Garijo, JM; Gavilán, JC; Huarte, M; Jiménez, E; Montoro, M; Moreno-Otero, R; Muñoz-Sánchez, M; Olcoz, JL; Olveira, A; Orive, M; Pamplona, X; Pérez, R; Planas, R; Portu, J; Romero-Gómez, M; Roset, M; Rota, R; Salmerón, J; Sánchez-Galdón, S; Sánchez-Ruano, J; Sillero, C; Solá, R; Uribarrena, R1
Angeletti, C; Antonucci, G; Boumis, E; Capobianchi, MR; Comandini, UV; Girardi, E; Longo, MA; Noto, P; Oliva, A; Solmone, MC; Tocci, G; Vairo, F1
Bonkovsky, H; Faris-Young, S; Huntley, B; Lyons, MF; Reddy, KR; Ryan, M; Santoro, J; Sjogren, MH; Sjogren, R; Smith, C1
Ahmed, F; Gonzalez, SA; Jacobson, IM; Kadam, JS; Menezes, A1
Amaki, S; Arakawa, Y; Kaneko, M; Matsumura, H; Matsuoka, S; Moriyama, M; Nirei, K; Ogawa, M; Tanaka, N; Yamagami, H1
Lv, H; Wang, YZ; Yu, SL; Zhang, QG; Zhang, ZH1
Brunette, MF; Iber, M; Luckoor, R; Mistler, LA; Rosenberg, SD; Vidaver, RM1
Cuadrado Pastor, JM; Jover Díaz, FM; Wikman Jorgensen, PE1
Ambühl, PM; Calanca, LN; Fehr, T; Fischer-Vetter, J; Jochum, W; Müllhaupt, B; Wüthrich, RP1
Fleckenstein, J; Krushkal, J; Li, R; Mason, BC; Park, VM; Riely, C1
Dahari, H; Haller, I; Licholai, T; Markatou, M; Perelson, AS; Ribeiro, RM; Talal, AH; Zeremski, M1
Janssen, HL; Schalm, SW; Veldt, BJ1
Asselah, T; Boyer, N; Marcellin, P; Martinot, M; Ripault, MP1
Ivashkin, VT; Maevskaia, MV; Pablov, ChS; Vedernikova, AV; Zolotarevskiĭ, VB1
Batista-Neves, SC; Bressan, RA; Cruz, SC; Miranda-Scippa, A; Paraná, R; Quarantini, LC1
Cacayorin, E; Cedron, H; Kato, T; Levi, D; Moon, J; Nishida, S; Pyrsopoulos, N; Schiff, E; Selvaggi, G; Taffaro, M; Tzakis, A; Weppler, D1
Fucci, JC; Gleason, OC; Philipsen, MA; Yates, WR1
Bachmatov, L; Ben-Ari, Z; Cohen, M; Rotman, Y; Tur-Kaspa, R; Zemel, R1
Fischer, J; Metzler, G; Schaller, M1
Annicchiarico, BE; Avolio, AW; Bombardieri, G; Grillo, RL; Siciliano, M1
Karandikar, NJ; Lee, WM; Pillai, V; Thiele, DL1
Behler, CM; Chung, RT; Lin, F; Peters, MG; Robbins, GK; Vittinghoff, E; Volberding, PA1
Hayashi, N; Iino, S; Kiyosawa, K; Kuboki, M; Kumada, H; Okuno, T; Omata, M; Sakai, T1
Chao, PL; Chen, TM; Ho, KS; Huang, PT; Lin, LF; Liu, CC; Siauw, CP; Tsai, MH; Tung, JN1
El-Shamy, A; Hotta, H; Imoto, S; Kim, SR; Nagano-Fujii, M; Sasase, N; Sasayama, M1
Cincin, A; Imeryuz, N; Ozdogan, O; Tahan, V; Tozun, N1
Anderson, GD; Goharkhay, N; Hankins, GD; Jain, S; Saade, G1
Gaudy, C; Le Guillou-Guillemette, H; Lunel, F; Payan, C; Veillon, P1
Brok, J; Gluud, C; Gluud, LL; Simin, M; Stimac, D1
Asnis, GM; Borisov, AS; Bruno, CJ; Demetrashvili, MF; Evans, DL; Henderson, MA; Miller, AH; Raison, CL; Reinus, JF; Staab, JP; Weinreib, R; Woolwine, BJ; Zajecka, JM1
Almasio, PL; Amato, M; Craxí, A; De Lisi, S; Di Marco, V; Ferraro, D; Giordano, C; Lo Iacono, O; Mineo, C; Petta, S; Rodolico, V; Venezia, G1
Bartolomé, J; Carreño, V; Castellanos, ME; Castillo, I; López-Alcorocho, JM; Pardo, M; Quiroga, JA; Rodríguez-Iñigo, E1
Carreño, V; Desombere, I; Hultgren, C; Leroux-Roels, G; Quiroga, J; Sällberg, M; Van Vlierberghe, H; Weiland, O1
Encke, J; Stremmel, W; Weigand, K1
Alsiö, A; Ferrari, C; Hellstrand, K; Lagging, M; Neumann, AU; Pawlotsky, JM; Schalm, SW; Verhey-Hart, E; Westin, J; Ydreborg, M; Zeuzem, S1
Back-Madruga, C; Bieliauskas, LA; Fontana, RJ; Kronfol, Z; Lindsay, KL; Lok, AS; Padmanabhan, L; Snow, KK; Wright, EC1
Pár, A; Szalay, F; Tornai, I1
Barreiro, P; Berdún, MA; Galindo, MJ; Hernandez-Burruezo, JJ; Mariño, A; Martin-Carbonero, L; Miralles, C; Núñez, M; Sola, J; Soriano, V1
Arora, S; Gish, RG; Murphy, B; Nelson, DR; O'Brien, C; Rajender Reddy, K; Xu, Y1
Bramlage, C; Groene, HJ; Koziolek, MJ; Mueller, GA; Scheel, A; Strutz, F1
Danehower, S; Ghany, MG; Hoofnagle, JH; Liang, TJ; Lutchman, G; Song, BC; Thomson, M1
Farkas, A; Halász, T; Horváth, G; Tolvaj, G1
Córdoba López, A; Monterrubio Villar, J1
Kraus, MR; Schäfer, A; Scheurlen, M; Schöttker, K; Weissbrich, B1
Asahina, Y; Doi, F; Higaki, M; Hosokawa, T; Izumi, N; Kitamura, T; Kurosaki, M; Matsunaga, K; Miyake, S; Nakanishi, H; Tsuchiya, K; Uchihara, M; Ueda, K; Umeda, N1
Hayashi, N; Hiramatsu, N; Inoue, M; Itose, I; Kaimori, A; Kanto, T; Kasahara, A; Kuzushita, N; Miyatake, H; Miyazaki, M; Sakakibara, M; Takehara, T; Yakushijin, T1
Benhamou, Y; Bräu, N; Cargnel, A; Hatzakis, A; Mauss, S; Peters, M; Pol, S; Puoti, M; Rockstroh, J; Soriano, V; Sulkowski, M1
Forţofoiu, C; Genunche, A; Gofiţă, E; Streba, LA; Vere, CC1
Hubscher, S; Lai, WK; Mutimer, D; O'Donnell, K; Thorburn, D; Thurairajah, PH; White, A1
Gagnieu, MC; Maynard, M; Souvignet, C; Trepo, C1
Buntinx, F; De Bie, J; Robaeys, G; Van Ranst, M1
Arraes, LC; Crovella, S; Montenegro de Melo, F; Moura, P; Santos Silva, B; Segat, L; Silva Vasconcelos, LR1
Andreone, P; Attard, L; Bernardi, M; Biselli, M; Boccia, S; Bonvicini, F; Cursaro, C; Furlini, G; Galli, S; Giacomoni, PL; Gramenzi, A; Lorenzini, S; Verucchi, G1
Abdelmalek, MF; Liu, C; Valentine, JF1
Arduino, RC; Barnett, BJ; Bull, L; Torres, HA1
Bethanis, S; Christidou, A; Katsanika, A; Liapi, C; Manolakopoulos, S; Margeli, A; Sklavos, P; Stripeli, F; Theocharis, S; Tzourmakliotis, D; Vogiatzakis, E1
Armstrong, EP; Malone, DC; Skrepnek, GH; Yeh, WS1
Angus, P; Bowden, S; Gordon, A; McLean, C; Pedersen, J; Roberts, S; Thomson, K1
Goldmann, G; Kalff, JC; Oldenburg, J; Rockstroh, JK; Sauerbruch, T; Speidel, N; Spengler, U; Vogel, M; Voigt, E; Wojcik, K1
Biliotti, E; Taliani, G1
Fukumoto, K; Kanemasa, K; Sakai, K; Sumida, Y; Yoshida, N1
Hollander, A; Jönsson, B; Lidgren, M; Weiland, O1
Hubbard, S; Luketic, VA; Price, A; Salvatore, J; Sanyal, AJ; Shiffman, ML; Sterling, RK; Stravitz, RT1
Alston, B; Aweeka, FT; Chung, RT; Kang, M; Lizak, P; Yu, JY1
Bouajram, R; Dorn, A; Kim, AI; Saab, S1
Asselah, T; Auray-Cartier, V; Denis, J; Herbert, S; Lambare, B; Rautou, PE1
Li, SC; Li, XG; Sun, LJ; Wang, GQ; Yu, JW1
Bharadwaj, M; Boo, I; Bowden, S; Chin, R; Drummer, H; Fischer, AE; Giourouki, M; Johnson, D; Torresi, J1
Karkar, A1
Baazia, Y; Bailly, F; Bourcier, V; Bourlière, M; Castera, L; De Ledinghen, V; Deny, P; Fontaine, H; Grando, V; Marcellin, P; Poupon, R; Roudot-Thoraval, F; Roulot, D; Zarski, JP1
Bahnassy, AA; El-Din, HM; Esmat, GE; Hafez, MM; Haleem, HA; Sharaby, AF; Sharaf, H; Zakaria, MS; Zekri, AR1
Alestig, E; Arnholm, B; Eilard, A; Hellstrand, K; Lagging, M; Lindh, M; Norkrans, G; Wahlberg, T; Wejstål, R; Westin, J1
Bodaghi, B; Cacoub, P; Cassoux, N; Hoang, PL; Perlemuter, G; Piette, JC; Saadoun, D; Sene, D; Touitou, V1
Bárcena, R; del Campo, S; García, M; Garrido, E; Mateos, ML; Moreno, A; Moreno, S; Muriel, A; Quereda, C1
Arjal, RR; Burton, JR; Rosen, HR; Villamil, F1
Borghi, G; Chemin, I; Chevallier, M; Chevallier, P; Guillaud, O; Menouar, K; Mrani, S; Pradat, P; Trabaud, MA; Trépo, C; Zoulim, F1
Camerini, R; Ciancio, A; DE Rosa, A; Rizzetto, M1
Chang, WY; Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, JF; Lee, LP; Lin, ZY; Wang, LY; Yang, JF; Yu, ML1
Goto, H; Hayashi, K; Honda, T; Ishigami, M; Katano, Y; Kumada, T; Murayama, M; Nakano, I; Toyoda, H; Urano, F; Yoshioka, K1
Chang, KO; George, DW1
Kalia, H; Lopez, PM; Martin, P1
Chen, DS; Chen, PJ; Hsu, CS; Kao, JH; Lai, MY; Liu, CJ1
Araújo, ES; Barone, AA; Courtouké, C1
Alam, J; Bengtsson, L; Bronowicki, JP; Garg, V; Grange, JD; Horsmans, Y; Marcellin, P; McNair, L; Nevens, F; Purdy, S; Vetter, D1
Bräu, N; Clumeck, N; Cooper, DA; Dieterich, DT; Dore, GJ; Godofsky, EW; Lamoglia, RS; Lissen, E; Mendes-Correa, MC; Nelson, MR; Rodriguez-Torres, M; Sulkowski, M; Torriani, FJ; Tural, C; Yetzer, E1
Gluud, C; Gluud, LL; Krogsgaard, K1
Arenovich, T; Heathcote, J; Khan, K; Missiha, S1
Bansal, M; Hissar, S; Kumar, M; Midha, V; Sakhuja, P; Sarin, SK; Sood, A; Sood, N; Suneetha, PV1
Annemans, L; Beguin, C; Gerkens, S; Horsmans, Y; Mouchart, M; Nechelput, M; Peraux, B1
Ahmed, R; Antonishyn, N; Chui, L; Doucette, K; McDonald, RR; Obarianyk, A; Tandon, P; Webster, D1
Chan, HL; Chow, WC; Ren, H; Wee, T1
Bolokadze, N; Gochitashvili, N; Sharvadze, L; Tophuria, A; Tsertsvadze, T1
Berg, T; Bergk, A; Krüger, D; Plöckinger, U; Weich, V; Wiedenmann, B1
Fischer, K; Griffioen, A; Makris, M; Mauser-Bunschoten, EP; Posthouwer, D; Van Veen, JJ; Yee, TT1
Brindani, F; Gemignani, F; Marbini, A1
Agarwal, K; Emre, S; Fiel, MI; Kontorinis, N; Schiano, TD; Stanca, CM1
Benito, JM; Capa, L; Cascajero, A; de Mendoza, C; García-Samaniego, J; González-Lahoz, J; Muñoz, F; Nuñez, M; Romero, M; Soriano, V1
Aguirrebengoa, K; Arazo, P; Asensi, V; Barreiro, P; Berdún, MA; Blanco, F; Cervantes, M; de los Santos, I; Echeverria, S; Galindo, MJ; García-Samaniego, J; Guardiola, J; Hernandez-Burruezo, JJ; Losada, E; Martin-Carbonero, L; Miralles, C; Nuñez, M; Ocampo, A; San Joaquín, I; Sola, J; Soriano, V1
Arizcorreta-Yarza, A; Girón-González, JA; González-Serrano, M; Gutiérrez-Valencia, A; López-Cortés, LF; Macías, J; Mira, JA; Pineda, JA; Santos, I; Torre-Cisneros, J; Valera-Bestard, B; Vergara, S1
Capasso, M; Crocè, L; Iolascon, A; La Mura, V; Masutti, F; Moschella, F; Persico, E; Persico, M; Russo, R; Spano, D; Svelto, M; Tiribelli, C; Torella, R1
Berg, T; Friebe, A; Gutsche, J; Halangk, J; Heinz, A; Hinzpeter, A; Janssen, G; Kluschke, M; Mohmand, A; Pich, M; Sarkar, R; Schaefer, M; Schwaiger, M; Weich, V; Ziemer, M1
Barreiro, P; Casado, R; Castellares, C; Garcia-Gasco, P; Labarga, P; Maida, I; Martin-Carbonero, L; Pinilla, J; Soriano, V; Vispo, ME1
Berkan, E; Jozefowicz-Korczynska, M; Piekarska, A; Wojcik, K1
Dworacki, G; Figlerowicz, M; Kaczmarek, M; Kowala-Piaskowska, A; Mozer-Lisewska, I; Słuzewski, W; Zeromski, J1
Berak, H; Horban, A; Kołakowska-Rzadzka, A; Krzysztof, B; Stańczak, JJ; Walewska-Zielecka, B; Wasilewski, M1
Hashimoto, Y; Itoh, M; Kanto, H1
Altiparmak, E; Biyikoglu, I; Cicek, B; Filik, L; Oguz, D; Yilmaz, B1
Halász, T; Horváth, G; Stotz, G; Tolvaj, G1
Allegri, L; Buzio, C; Garini, G; Lannuzzella, F; Vaglio, A1
Alaimo, G; Almasio, PL; Calvaruso, V; Craxì, A; Di Marco, V; Di Stefano, R; Ferraro, D; Peralta, S1
Craxì, A; Heathcote, EJ; Marcellin, P1
Akyazi, Z; Erhardt, A; Häussinger, D; Heintges, T; Oette, M; Sagir, A1
Bani-Sadr, F; Billaud, E; Cacoub, P; Carrat, F; Doll, J; Goderel, I; Penalba, C; Perronne, C; Pol, S; Welker, Y1
Buti, M; Casado, MA; Esteban, R1
Akazawa, K; Aoyagi, Y; Kobayashi, K; Nakamura, J; Toyabe, S1
Clements, BJ; Sylvestre, DL1
Akgun, H; Baskol, M; Gursoy, S; Guven, K; Ozbakir, O; Torun, E; Yucesoy, M; Yurci, A1
Alpat, SN; Kartal, ED; Ozgunes, I; Usluer, G1
Dybowska, D; Halota, W1
Herrmann, E; Hofmann, WP; Kronenberger, B; Mihm, U; Piiper, A; Sarrazin, C; von Wagner, M; Zeuzem, S1
Abdel-Hamid, M; Abobakr, H; Anwar, M; Bedossa, P; El Hoseiny, M; Esmat, G; Fontanet, A; Gad, RR; Males, S; Mohamed, MK; Pol, S; Rekacewicz, C; Zalata, K1
Aguirrebengoa, K; Arazo, P; Asensi, V; Barreiro, P; Berdún, MA; Cervantes, M; de Los Santos, I; Echeverría, S; Galindo, MJ; García-Samaniego, J; Guardiola, JM; Hernandez-Burruezo, JJ; Losada, E; Miralles, C; Núñez, M; Ocampo, A; Romero, M; San Joaquín, I; Sola, J; Soriano, V1
Janczewska-Kazek, E; Kajdaniuk, D; Magiera, M; Marek, B; Pisula, A; Witor, A1
Chamuleau, RA1
de Messias-Reason, IJ; Kremsner, PG; Kun, JF; Pedroso, ML; Tena-Tomás, C1
Puoti, C1
Basile, V; Capone, D; Conca, P; Cuocolo, A; Di Minno, MN; Gentile, A; Tarantino, G; Tarantino, M1
Bzowej, N; Carr, C; Gish, RG; Hollinger, FB; Leung, J; Mirro, K; Moore, DH; Phillips, J; Poordad, F; Wakil, A; Yoffe, B1
Heger, B; Krook, AL; Nygaard, E; Stokka, D1
Deterding, K; Manns, MP; Potthoff, A; Rifai, K; Trautwein, C; Wedemeyer, H1
Kakibuchi, N; Kawakami, T; Kawashima, A; Kita, K; Koyabu, T; Murakami, Y; Okita, M; Takaguchi, K1
Berenguer, J; Clotet, B; Montes-Ramírez, M; Planas, R; Quereda, C; Rubio, R; Santín, M; Solà, R; Tural, C1
Di Bisceglie, AM; Ghalib, RH; Hamzeh, FM; Rustgi, VK1
Alberti, A; Boccato, S; Ferrari, A; Pistis, R; Sebastiani, G1
Bergin, C; Farrell, G; Hopkins, S; Kevans, D; Mahmud, N; Norris, S; White, B1
Capasso, M; Crocè, L; Iolascon, A; Persico, E; Persico, M; Russo, R; Tiribelli, C1
Bárcena, R; Crespo, J; Diago, M; Muñoz-Sánchez, M; Olveira, A; Pérez, R; Romero-Gómez, M; Sánchez-Tapias, JM1
Asselah, T; Bieche, I; Boyer, N; Laurendeau, I; Marcellin, P; Martinot-Peignoux, M; Narguet, S; Ripault, MP; Sabbagh, A; Valla, D; Vidaud, M1
Jeong, SH1
Jee, SR; Jung, EU; Kang, SW; Lee, SH; Lee, YJ; Pae, KI; Park, ET; Park, JH; Park, SJ; Seol, SY1
Byun, KS; Choi, DW; Han, WS; Kim, YH; Lee, SJ; Oh, SN; Yeon, JE1
Andreone, P; Bernardi, M; Biselli, M; Cursaro, C; Gramenzi, A; Scuteri, A; Serra, C; Vitale, G; Vukotic, R1
Ali, S; Cheema, HA; Memon, I; Mirza, R; Shah, U; Thobani, S1
Angelico, M; Di Paolo, D; Francioso, S; Galante, A; Lenci, I; Piccolo, P1
Bassett, ML1
Adachi, Y; Araki, J; Fujita, N; Horiike, S; Iwasa, M; Kaito, M; Kobayashi, Y; Mifuji, R; Sugimoto, R; Tanaka, H; Urawa, N; Yamamoto, M1
Adachi, Y; Fujita, N; Hamano, H; Ikoma, J; Imoto, I; Iwasa, M; Kaito, M; Kobayashi, Y; Kojima, Y; Yamauchi, K1
Haga, H; Ishii, R; Ito, J; Kawata, S; Misawa, K; Nishise, Y; Okumoto, K; Saito, K; Saito, T; Sanjo, M; Sugahara, K; Suzuki, A; Togashi, H; Watanabe, H1
Bergmann, JF; Brouwer, JT; de Knegt, RJ; de Vries, RA; Hansen, BE; Janssen, HL; Schalm, SW; van der Schaar, P; van der Sluys Veer, A; van Hoek, B; Verhey, E; Vrolijk, JM; Vroom, B1
Adamski, A; Blessman, D; Gandotra, SD; Htwe, TH; Khardori, NM; Koirala, J; Mushtaq, A; Rao, S; Sangwan, G1
Alshuth, U; Gelbmann, CM; Hüppe, D; Lafrenz, M; Link, R; Lohmeyer, J; Mauss, S; Möller, B; Niederau, C; Wiedmann, KH; Witthöft, T1
Cam, M; Chen, W; Feld, JJ; Fried, MW; Huang, Y; Liang, TJ; Nanda, S; Pusek, SN; Schweigler, LM; Theodore, D; Zacks, SL1
Altan, M; Bektas, H; Bektas, M; Cetinkaya, H; Gören, D1
Asim, M; Chakravarti, A; Das, RH; Kar, P; Kumar, D; Malik, A1
Baragiotta, AM; Biscontin, MG; Mazzaro, C; Pozzato, G; Spina, M; Tirelli, U; Zorat, F1
Aldinucci, A; Biagioli, T; Carpenedo, R; Cozzi, A; Giannini, C; Laffi, G; Moroni, F; Rosselli, M; Zignego, AL1
Gatti, P; Lauletta, G; Montrone, M; Sansonno, D; Sansonno, L; Troiani, L; Tucci, FA1
Almasio, PL; Cottone, C; D'Angelo, F1
Coppola, N; Piccinino, F1
Cammalleri, L; Colonna, V; Cristaldi, E; Gargante, MP; Malaguarnera, M; Romano, M; Vacante, M1
Abdelaziz, M; Ahmed, IN; El Kamary, SS; Hakem, SA; Hashem, M; Ibrahiem, A; Kamal, SM; Mansour, H; Moniem, M; Moustafa, A; Muhammadi, M; Sayed, K; Shardell, MD1
Brew, BJ; Dore, GJ; Kaldor, JM; Koorey, DJ; Krahn, MD; Maruff, P; Thein, HH1
Highleyman, L1
Benito, JM; Rallón, NI; Soriano, V1
Heathcote, EJ1
McCaughan, GW; Shackel, NA1
Dainichi, T; Enjoji, M; Gondo, H; Urabe, K1
Brandt, LR; Cua, IH; George, J; Hui, J; Kench, JG; Negro, F; Poustchi, H1
Hino, T; Hisamochi, A; Ide, T; Kawano, H; Korekoda, H; Kuhara, K; Kumashiro, R; Sata, M; Toubaru, T; Tsuruta, O1
Buti, M; Esteban, R; Majó, J; Segarra, A; Tovar, JL1
Ardevol, M; Castellví, P; Díez-Quevedo, C; Galeras, JA; García, F; Martín-Santos, R; Masnou, H; Miquel, M; Navinés, R; Planas, R; Solà, R; Soler, A1
Buzatu, E; Cooper, CL; Dudas, J; Esguerra, R; Gorrell, MD; Haber, PS; Hilzenrat, N; Ionescu, C; Leo, MA; Lieber, CS; McCaughan, GW; Neuman, MG; Ramadori, G; Saile, B; Seth, D; Sha, K; Voiculescu, M; Winkler, RE; Wyse, J; Zakhari, S1
Llopis González, A; Márquez Peiró, JF; Morales Suárez-Varela, M; Pérez Peiró, C; Valero Alcocer, VE1
Aghemo, A; Colombo, M; D'Ambrosio, R; Del Ninno, E; Gallus, S; Ronchi, G; Rumi, MG1
Hansen, BE; Heathcote, EJ; Hofmann, WP; Janssen, HL; Manns, MP; Reichen, J; Schalm, SW; Veldt, BJ; Wedemeyer, H; Zeuzem, S1
Devries, JH; Gelderblom, HC; Hamann, D; Hoekstra, JB; Jansen, PL; Reesink, HW; Schreuder, TC; Weegink, CJ1
Barton, BA; González-Peralta, RP; Murray, KF; Robuck, PR; Rodrigue, JR; Schwarz, KB; Shepherd, J1
Adang, RP; Cnossen, TT; de Vries, RA; Konings, CJ; Schalm, SW; Tan, AC; van Leusen, R1
Cantillano, AL; González-Pardo, G; Jiménez, I; Morello, J; Rodríguez-Nóvoa, S; Soriano, V1
Ehleben, C; Pearlman, BL; Saifee, S1
Cervello, M; Florena, AM; Giannitrapani, L; Ingrao, S; La Spada, E; Montalto, G; Soresi, M; Vuturo, O1
Battegay, E; Mettler, J; Zimmerli, L1
Castera, L; Couzigou, P; De Ledinghen, V; Foucher, J1
Kryczka, W; Lebensztejn, DM; Zarebska-Michaluk, D1
Baik, SK; Chang, SJ; Choi, JW; Kim, HW; Lee, HW; Lee, JI; Lee, KH; Namkung, J; Sohn, JH; Yeh, BI; Yoon, J1
Han, Q; Kang, W; Li, H; Liu, Z; Zhang, L; Zhang, N1
Lee, WM; Yuan, HJ1
Esposito, S; Hamzeh, FM; Rustgi, VK; Shiffman, ML1
Abdo, N; Antaki, F; Antaki, N; Ftayeh, M; Hadad, M; Hermes, A; Kebbewar, K1
De Angelis, D; Grieve, R; Irving, WL; Kwong, G; Ratib, S; Ryder, SD; Sweeting, M; Thomson, BJ1
Deutsch, M; Hadziyannis, SJ1
Bain, VG; Balshaw, RF; Cooper, C; Deschenes, M; Heathcote, EJ; Krajden, M; Lee, SS; Peltekian, KM; Powis, J; Sherman, M; Yoshida, EM1
Bonura, C; Craxì, A; Di Marco, V; Di Stefano, R; Ferraro, D; Giglio, M; Mondelli, MU1
Afdhal, NH; Brinkley, SC; de Oca, RM; Higgins, Y; Mehta, SH; Moore, RD; Sulkowski, MS; Thomas, DL; Torbenson, MS1
Alcocer, F; Bonet, L; Cordero, M; García-Samaniego, J; López-Serrano, P; Mariño, A; Martin-Carbonero, L; Nuñez, M; Portu, J; Soriano, V1
Ansari, S; Bateni, F; Vossogh, P1
Bacon, BR; McHutchison, JG1
Bacon, BR; McHutchison, JG; Owens, GS1
Blanc, D; Carrieri, MP; Dellamonica, P; Marcellin, F; Préau, M; Ravaux, I; Spire, B1
Chu, PL; Chung, GB; Liu, CH; Wu, KD; Yang, WS1
Gotoh, T; Hiramatsu, K; Joh, T; Kani, S; Matsuura, K; Mizokami, M; Takagi, K; Tanaka, Y; Wakimoto, Y1
Kim, HJ1
Ahn, CS; Choi, KM; Chung, YH; Hwang, S; Kim, KH; Lee, SG; Lee, YS; Moon, DB; Park, JI; Suh, DJ1
Chung, RT; Gale, M; Hoofnagle, JH; Lemon, SM; Liang, TJ; Polyak, SJ1
Aucejo, F; Hanouneh, IA; Lopez, R; Miller, C; Quinn, MK; Zein, NN1
Martin, P; Poordad, F; Reddy, KR1
Cho, BM; Cho, M; Heo, J; Hwang, SY; Kang, DH; Kim, GH; Kim, KY; Kim, TO; Lee, HJ; Lee, SM; Park, CW; Park, KT; Song, GA1
Camarena, C; de Guevara, CL; de la Vega, A; Díaz, C; Díez-Dorado, R; Frauca, E; Hierro, L; Jara, P; Larrauri, J; Miños-Bartolo, G; Rueda, M1
Abad, FJ; Borrás-Blasco, J; Casterá, E; Jiménez, I; Primo, J; Rosique-Robles, JD1
Casassus-Buihle, D; Chauveau, E; Fraudin, A; Oddes, B; Reffet, A; Terrier, F1
Cacoub, P; Karras, A; Perard, L; Resche-Rigon, M; Saadoun, D; Sene, D1
Aguirrebengoa, K; Asensi, V; Barreiro, P; Cervantes, M; Echeverria, S; Garcia-Samaniego, J; Núñez, M; Ocampo, A; Pascual, A; Soriano, V1
Ackrill, A; Bernstein, D; Bodenheimer, H; Dienstag, JL; Govindarajan, S; Hadziyannis, SJ; Marcellin, P; Messinger, D; Rakela, J; Reddy, KR; Schmidt, G1
Bemba, G; Kautz, A; Niederau, C1
Dalekos, GN; Germenis, A; Liaskos, C; Makaritsis, K; Rigopoulou, EI; Togousidis, E; Zografos, TA1
Bai, C; Collantes, R; Fang, Y; Farmer, D; Gujral, H; Gurung, C; Nader, FH; Ong, JP; Ramsey, L; Sjogren, M; Sjogren, R; Srishord, M; Terra, K; Younossi, ZM1
Dalmi, L; Gervain, J; Horváth, G; Hunyady, B; Ibrányi, E; Makara, M; Pár, A; Szalay, F; Telegdy, L; Tornai, I1
Clemente Ricote, G; Díaz Sánchez, A; Matilla Peña, A; Merino Rodríguez, B; Núñez Martínez, O1
Leevy, CB1
Iushchuk, ND; Ivanova, LM; Kravchenko, AV; Maksimova, SL; Morgunova, NM; Ol'shanskiĭ, AIa; Serebrovskaia, LV1
Dammacco, F; Sansonno, D; Sansonno, L; Troiani, L; Tucci, FA1
Herrmann, E; Naoumov, NV; Pachiadakis, I; Paulon, E; Tang, KH; Tatman, N; Zeuzem, S1
Carrozzo, M1
Casado, J; Diago, M; Gila, A; Lafuente, V; León, J; Palacios, A; Quiles, R; Rodriguez, L; Romero-Gómez, M; Rueda, PM; Ruiz-Extremera, A; Salmerón, J1
Gourineni, N; Pothula, VR; Punnam, A; Punnam, SR; Ranganathan, V1
Bonkovsky, HL; Dienstag, JL; Everson, GT; Ghany, MG; Lee, WM; Lindsay, KL; Lok, AS; Morgan, TR; Morishima, C; Shiffman, ML; Wright, EC1
Cacoub, P; Fois, E; Halfon, P; Landau, DA; Marcellin, P; Martinot-Peignoux, M; Saadoun, D1
Arizcorreta-Yarza, A; Collado, A; Fernández-Fuertes, E; Girón-González, JA; González-Serrano, M; López-Cortés, LF; Lozano, F; Macías, J; Merino, D; Mira, JA; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Torres-Tortoso, M; Valera-Bestard, B1
Bani-Sadr, F; Bedossa, P; Cacoub, P; Carrat, F; De Boever, CM; Halfon, P; Lapidus, N; Perronne, C; Pol, S1
Endo, H; Fujimoto, T; Iga, D; Otsuka, K; Tomimatsu, M1
Azuma, K; Enjoji, M; Furusyo, N; Hayashi, J; Kajiwara, E; Maruyama, T; Masumoto, A; Nakamuta, M; Nomura, H; Sakai, H; Shimoda, S; Shimono, J; Takahashi, K; Tanabe, Y1
Karino, Y; Toyota, J1
Enjoji, M; Higuchi, N; Horikawa, Y; Kato, M; Kinukawa, N; Kotoh, K; Nakamuta, M; Tajiri, H; Takayanagi, R; Ueda, A; Yamashita, N1
Aikata, H; Aimitsu, S; Chayama, K; Imamura, M; Ishihara, H; Kawakami, H; Kawakami, Y; Kitamoto, M; Moriya, T; Nakanishi, T; Satoh, K; Takahashi, S; Takaki, S; Tsuji, K1
Capuron, L; Majer, M; Miller, AH; Pagnoni, G; Raison, CL; Welberg, LA1
Buggisch, P; Cornberg, M; Steffen, M1
Dougherty, KA; Evon, DM; Fried, MW; Galanko, JA; Simpson, K; Verma, A1
Chen, PJ; Hwang, Y; Lin, CG; Wu, LS; Wu, YJ1
Cacoub, P; Delluc, A; Piette, JC; Saadoun, D1
Baldo, V; Baldovin, T; Carderi, I; Floreani, A; Minola, E; Rizzotto, ER1
Barreales, M; Castellano, G; Fernández, I; Manzano, M; Muñoz, R; Solís Herruzo, JA1
Amoruso, D; Caporaso, N; Morisco, F; Stroffolini, T1
Abate, ML; Baldi, I; Balzola, F; Ciancio, A; Ciccone, G; Pellicano, R; Puglisi, G; Rizzetto, M; Saracco, G; Smedile, A1
Hibi, T; Ikeda, M; Kato, N; Kumagai, N; Nakamura, M; Saito, H; Shimotohno, K; Tada, S1
Bilalović, N; Gogov, B; Gornjaković, S; Husić-Selimović, A; Koluder, N; Radović, S; Vukobrat-Bijedić, Z; Zubcević, N1
Andreoletti, M; Borroni, G; Casiraghi, MA; Ceriani, R; Guerzoni, P; Omazzi, B; Salerno, F; Terreni, N1
Deschênes, M; Hilzenrat, N; Soulellis, C; Turbide, C1
Antonaci, A; Antonaci, S; Giannelli, G; Napoli, N1
Alonso, S; Andrade, RJ; Barcena, R; Carmona, I; Diago, M; Durán, S; Fernández-Rodríguez, CM; Perez, R; Planas, R; Pons, JA; Romero-Gómez, M; Salmerón, J; Solá, R1
Robertson, M1
Borque, MJ; Chaparro-Sánchez, M; González-Moreno, L; Moreno-Monteagudo, JA; Moreno-Otero, R; Trapero-Marugan, M1
Kakibuchi, N; Kawakami, T; Kawashima, A; Kita, K; Koyabu, T; Murakami, Y; Okita, M; Takaguchi, K; Tsukamoto, I1
Adla, M; Ahmad, J; Downey, KK1
Coelho, KI; Corvino, SM; Henriques, RM; Pardini, MI; Peres, MN; Polônio, RJ; Silva, GF; Silveira, LV1
Ferenci, P; Staufer, K1
Agud, JM; Apraiz, L; Portu, J; Tarabini-Castellani, P1
Bal, C; Doyuk Kartal, E; Erben, N; Nayman Alpat, S; Ozgunes, I; Usluer, G; Yavuz, H1
Bolewska, B; Juszczyk, J; Wojtacha, A1
Chen, HY; Li, J; Rao, HY; Sun, Y; Wang, H; Wei, L; Zhang, LF; Zhu, LM1
Fernández, A; Rodríguez-González, L; Vázquez, S1
Cruciani, M; Franchini, M; Lippi, G; Mazzi, R; Mengoli, C; Veneri, D1
Carlsson, T; Quist, A; Weiland, O1
Hiramatsu, N1
Dev, A; McHutchison, JG; Patel, K; Pawlotsky, JM; Rigby, S; Symonds, WT; Ward, CL; Zekry, A1
McHutchison, J; Sulkowski, M1
Baek, YH; Han, SY; Jang, JS; Kim, JH; Kim, KT; Kim, MJ; Lee, JH; Lee, SW; Roh, MH; Yoon, HA1
Choi, JW; Eun, JR; Kim, KO; Lee, HJ; Moon, HJ1
Amrani, N; Benaïssa, A; Guedira, MM; Kabbaj, N; Mohammadi, M; Sentissi, S1
Arakawa, T; Atsumi, H; Hisanaga, Y; Kanamori, A; Kiriyama, S; Kumada, T; Nakano, S; Sone, Y; Tanikawa, M; Toyoda, H1
Bonino, F; Brunetto, MR; Ciccorossi, P; Civitano, L; Coco, B; Colombatto, P; Maina, AM; Oliveri, F; Romagnoli, V1
Schafer, DF1
Abdel-Hamid, M; Attala, M; El Hoseiny, M; El Makhzangy, H; Esmat, G; Fontanet, A; Gad, RR; Hasan, A; Males, S; Mohamed, MK; Shouman, S; Zalata, K1
Bailey, R; Bain, VG; Balshaw, R; Deschênes, M; Krajden, M; Lee, SS; Peltekian, K; Sherman, M; Witt-Sullivan, H; Yoshida, EM1
Coriat, R; Podevin, P1
Drenth, JP; Slavenburg, S1
Abe, S; Matsuhashi, T; Narita, R; Oto, T; Otsuki, M; Tabaru, A1
Dowling, TC; Hoofnagle, JH; Howell, CD; Jeffers, L; Paul, M; Taylor, M; Terrault, NA; Wahed, AS1
Lopukhova, NL1
Hsu, EK; Murray, KF1
Cooper, CL; Costiniuk, CT; Mills, E1
Bugawan, T; Erlich, H; Im, KA; Jeffers, L; Li, J; Liang, TJ; Rhodes, SL; Rosen, HR; Su, X; Tong, X; Wang, J; Yang, H; Yee, LJ1
Lübbe, J1
Beppu, T; Fuke, H; Ito, K; Shiraki, K; Sugimoto, K; Takei, Y; Tanaka, J; Yamamoto, N; Yoneda, K1
Del Olmo, JA; Escudero, A; Montes, F; Rodrigo, JM; Rodríguez, F; Serra, MA1
Fan, R; He, J; Jiang, TJ; Xie, YX; Zhang, X; Zhao, M; Zhao, P; Zhou, ZP1
Antoniades, CG; Cross, TJ; Harrison, PM1
Bergamaschi, V; Borghi, F; Carosi, G; Cologni, G; Gatti, F; Matti, A; Nasta, P; Puoti, M; Ricci, A1
Karlström, O; Sönnerborg, A; Weiland, O1
Chang, TT; Chen, JS; Cheng, PN; Wei, YL; Young, KC1
Foster, G; Mathurin, P1
Marcellin, P; Rizzetto, M1
Ferenci, P; Lee, SS1
Berg, T; Carosi, G1
Dusheiko, G; Nelson, D; Reddy, KR1
Carriero, D; Dieterich, DT; Fabrizi, F; Martin, P; Park, J; Uriel, AJ1
Alain, S; Calès, P; Denis, F; Fauchais, AL; Hubert, IF; Lefebvre, A; Liozon, E; Loustaud-Ratti, V; Lunel, F; Marquet, P; Rousseau, A; Sauvage, FL; Vidal, E1
Moreno-Monteagudo, JA; Moreno-Otero, R; Trapero, M1
Cebollero, A; Dalmau, B; Gallach, M; Gavarro, A; Gil, M; Masip, M; Miquel, M; Real, J; Rudi, N; Vergara, M1
Collado, A; de los Santos, I; del Valle, J; García-García, JA; Girón, JA; González-Serrano, M; López-Cortés, LF; Merino, D; Mira, JA; Pineda, JA; Ríos-Villegas, MJ; Rivero, A1
Alsiö, A; Buhl, MR; Dhillon, AP; Färkkilä, M; Hellstrand, K; Lagging, M; Langeland, N; Mørch, K; Norkrans, G; Pedersen, C; Westin, J1
Aitchison, KJ; Alexander, N; Binder, EB; Bull, SJ; Cassidy, E; Cleare, AJ; Cubells, JF; Hotopf, M; Huezo-Diaz, P; Maddock, C; Miller, AH; Miyazaki, C; Norris, S; Pariante, CM; Ranjith, G1
Antonini, MG; Babudieri, S; Baiguera, C; Carosi, G; Dettori, G; Fenu, L; Maida, I; Manno, D; Mura, MS; Puoti, M; Zanini, B1
Bracho, MA; Carnicer, F; Cuevas, JM; García-Robles, I; González-Candelas, F; Jiménez-Hernández, N; Moya, A; Olmo, JD; Ortega, E; Torres-Puente, M1
Bailey, RJ; Bain, VG; Cronin, PW; Kaita, KD; Marotta, P; McHutchison, JG; Patel, K; Pulkstenis, E; Subramanian, GM; Swain, MG; Yoshida, EM1
Asahina, Y; Enomoto, N; Hirayama, I; Hosokawa, T; Itakura, J; Izumi, N; Komatsu, N; Kurosaki, M; Miyake, S; Nakanishi, H; Sakamoto, N; Sato, M; Tanaka, T; Tasaka, M; Tsuchiya, K; Ueda, K; Umeda, N; Yasui, Y1
Elefsiniotis, IS; Ketikoglou, I; Koutsounas, S; Moulakakis, A; Pantazis, KD; Pavlidis, C; Scarmeas, N; Tsianos, EV1
Garcia, R; Keeffe, EB; Lam, KD; Nguyen, G; Nguyen, MH; Trinh, HN1
Caetano, J; Luxo, C; Martinho, A; Pais, B; Paiva, A; Valente, C1
Carson, S; Chan, BK; Chou, R1
Al Kaabi, SR; Al Khinji, MA; Al Mohanadi, M; Al-Marri, AD; Amer, AM; Bener, AB; Butt, MT; Derbala, MF; El Dweik, NZ; John, A; Pasic, F; Shebl, FM; Yakoob, R1
Bourliere, M1
Khunvichai, A; Kieffer, TL; Lawitz, E; McHutchison, JG; McNair, L; Muir, AJ; Rodriguez-Torres, M1
Ferenci, P; Gangl, A; Peck-Radosavljevic, M; Rasoul-Rockenschaub, S; Reiberger, T; Rieger, A1
Arnold, J; Berg, T; Bergk, A; Boecher, WO; Deterding, K; Forestier, N; Gruengreiff, K; Kaeser, T; Manns, MP; Potthoff, A; Schuchmann, M; Spengler, U; Trautwein, C; Wedemeyer, H; Zeuzem, S1
Canbakan, B; Mert, A; Ozaras, R; Ozbay, G; Senturk, H; Tabak, F; Tahan, V; Ulger, Y; Uraz, S1
Alaeus, A; Falconer, K; Gonzalez, VD; Michaëlsson, J; Moll, M; Reichard, O; Sandberg, JK1
Coppola, N; Filippini, P; Imparato, M; Martini, S; Piai, G; Piccinino, F; Pisapia, R; Sagnelli, C; Sagnelli, E; Stanzione, M; Tonziello, G1
Brown, JL1
Braconier, JH; Frydén, A; Norkrans, G; Reichard, O; Sönnerborg, A; Weiland, O2
Renner, EL2
Bresters, D; Damen, M1
Moussalli, J; Opolon, P; Poynard, T1
Bordessoule, D; Jaccard, A; Loustaud, V; Rogez, S; Turlure, P1
Córdoba Cortijo, J; López Viedma, B; Olaso Peiró, V1
Bletry, O; Cacoub, P; Cosserat, J; Cretel, E; Durand, JM; Frances, C; Godeau, P; Kaplanski, G; Lunel-Fabiani, F; Soubeyrand, J1
Ahmed, SS; Bailly, F; Chevallier, M; Chossegros, P; Habersetzer, F; Haem, J; Trépo, C; Zoulim, F1
Emslander, HP; Gössl, C; Hoffmann, RM; Jung, MC; Motz, R; Pape, GR; Zachoval, R1
Borghesio, E; Ghisetti, V; Marchiaro, G; Pittaluga, F; Rizzetto, M; Rocca, G; Saracco, G; Sostegni, R1
Lee, JH; Roth, WK; Sarrazin, C; Teuber, G; von Wagner, M; Zeuzem, S1
Nightingale, SL1
Carreño, V; Martín, J; Navas, S; Pardo, M; Quiroga, JA1
Borque, MJ; Fernández-Bermejo, M; García-Buey, L; García-Monzón, C; Iacono, LO; Moreno-Monteagudo, JA; Moreno-Otero, R; Sanz, P1
Alberti, A; Chemello, L; Crucitti, A; Donada, C; Donadon, V1
Frank, H; Jäckel, E; Manns, MP; Schüler, A; Trautwein, C; Wedemeyer, H; Wedemeyer, J1
Albrecht, J; Bain, V; Heathcote, J; Ideo, G; Lee, SS; Marcellin, P; Minuk, GS; Niederau, C; Poynard, T; Trepo, C; Zeuzem, S1
Albrecht, JK; Cort, S; Goodman, ZD; Gordon, SC; Lee, WM; Ling, MH; McHutchison, JG; Rustgi, VK; Schiff, ER; Shiffman, ML1
Albrecht, J; Craxi, A; Davis, GL; Esteban-Mur, R; Gordon, SC; Hoefs, J; Ling, MH; Rustgi, V; Shiffman, ML; Trepo, C; Zeuzem, S1
Liang, TJ1
Schalm, SW1
Hermann, R1
Annese, M; Bacca, D; Barbarini, G; Barbaro, G; Bellomo, G; Belloni, G; Di Lorenzo, G; Francavilla, R; Giancaspro, G; Grisorio, B; Rizzo, G; Soldini, M1
Bell, A; Dash, C; Dusheiko, GM; Flannery, B; Glue, P; Grellier, L; Khakoo, S; Lypnyj, D; Murray-Lyon, I; Walters, K; Wells, B1
Caselmann, WH; Manns, MP; Wedemeyer, H1
Ballaré, M; Farina, M; Negro, F; Tappero, G1
Pol, S; Zylberberg, H1
Ansaldi, F; Icardi, GC; Perasso, A; Testino, G; Venturino, V1
Bergmann, JF1
Brouwer, JT; Hansen, BE; Niesters, HG; Schalm, SW1
Averett, DR; Bard, J; Lim, C; Milovanovic, T; Pai, B; Phan, UT; Tam, RC1
Bell, H; Bjøro, K; Gutigard, BG; Harthug, S; Hellum, K; Maeland, A; Myrvang, B; Raknerud, N; Ritland, S; Simmonds, P; Skaug, K; von der Lippe, B1
Koretz, RL2
Al Ashgar, H; Cattral, MS; Greig, PD; Hemming, AW; Krajden, M; Levy, GA; Lilly, L; Wanless, IR1
Glue, P1
McHutchison, JG; Poynard, T1
Maddrey, WC1
Bayliss, MS; Cort, S; Neary, MP; Ware, JE1
Dieterich, DT; Purow, JM; Rajapaksa, R1
Marcellin, P1
Bolondi, L; Brillanti, S; Di Tomaso, M; Foli, M; Gramantieri, L; Masci, C1
Ochsendorf, F; Röder, C; Stryjek-Kaminska, D; Wolter, M; Zeuzem, S1
Andreone, P; Bernardi, M; Cursaro, C; D'Errico, A; Di Giammarino, L; Fiorino, S; Gasbarrini, G; Gramenzi, A; Miniero, R; Sbolli, G1
Martin, P; Saab, S1
Albrecht, J; Conrad, A; Elliot, M; Gianelli, G; Glue, P; McHutchison, J; Nyberg, L; Zambas, D1
Casalino, C; Genchi, C; Mariano, N; Maselli, R; Milella, M; Pastore, G; Pietromatera, G; Santantonio, T1
Chapman, RW; Christie, JM1
Begemann, F; Jablonowski, H1
Berg, T; Dietrich, CF; Lee, JH; Roth, WK; Sarrazin, C; Teuber, G; Zeuzem, S1
Fontaine, H; Pol, S1
Bellobuono, A; Brouwer, JT; Chemello, L; Chen, DS; Hansen, BE; Hollander, A; Lai, MY; Michielsen, PP; Milella, M; Pastore, G; Schalm, SW; Weiland, O1
Bayliss, MS; Davis, GL; Mannocchia, M; Ware, JE1
Abergel, A; Berthelot, P; Bourlière, M; Bréchot, C; Combis, JM; Couzigou, P; Larrey, D; Moussalli, J; Pol, S; Poupon, R; Tran, A1
Alberti, A; Cavalletto, L; Chemello, L; Gerotto, M; Gretch, DR; Polyak, SJ; Pontisso, P; Sullivan, DG1
Frossard, JL1
Castaño, G; Chohuela, E; Frider, B; Kien, MC; Neglia, V; Sookoian, S1
Sarrazin, C; Zeuzem, S1
Lavín, I; Palacios, A; Quintero, D; Rodríguez-Ramos, L; Ruiz-Extremera, A; Salmerón, J; Torres, C1
Annese, M; Bacca, D; Barbarini, G; Barbaro, G; Barelli, A; Belloni, G; Calleri, G; Del Poggio, P; Di Lorenzo, G; Ferrari, L; Francavilla, R; Fruttaldo, L; Grisorio, B; Gualandi, G; Mongiò, F; Paiano, A; Poltronieri, I; Rizzo, G; Rocchetto, P; Scotto, G1
Silvain, C1
García-Buey, L; García-Monzón, C; Ibarrola, N; Lo Iacono, O; Martínez-Salas, E; Moreno-Monteagudo, JA; Moreno-Otero, R; Sáiz, M; Sobrino, F1
Berg, T; Hoffmann, RM; Hopf, U; Jung, MC; Leifeld, L; Pape, GR; Prümmer, O; Spengler, U; Teuber, G; Zeuzem, S1
Macedo, G; Ribeiro, T1
Barbarini, G; Barbaro, G; Di Lorenzo, G; Giancaspro, G; Grisorio, B; Pellicelli, A; Soldini, M2
Castro, A; Hermida, M; López Calvo, S; Pedreira, J; Vega, P1
McHutchison, JG; Shermock, KM; Singer, ME; Younossi, ZM1
Henrion, J1
Fischler, B; Glaumann, H; Norkrans, G; Reichard, O; Sönnerborg, A; Uhnoo, I; Weiland, O; Wejstål, R1
Glaumann, H; Reichard, O; Schvarcz, R; Weiland, O1
Rizzetto, M; Saracco, G1
Goebel, FD; Jablonowski, H1
Albrecht, J; Goodman, Z; Ling, MH; McHutchison, J; Poynard, T1
Emmett, C; Gurakar, A; Hulagu, S; Jazzar, A; Karasu, Z; McMillon, G; Wright, H1
Forton, DM; Taylor-Robinson, SD; Thomas, HC; Török, ME1
Bekkering, FC; Brouwer, JT; Schalm, SW; van Rossum, TG1
Civeira, MP; Prieto, J1
Barnes, E; Dusheiko, G; Jacobs, R; Webster, G1
Bjøro, K; Frøland, SS; Haaland, T; Skaug, K1
Bodenheimer, HC; Davis, GL; Fiel, MI; Guido, M; Lewis, JH; Lindsay, KL; Schiano, TD; Seeff, LB; Thung, SN1
Lawrence, SP1
Böker, KH; Manns, MP1
Carucci, P; Chokshi, S; Cramp, ME; Naoumov, NV; Rossol, S; Williams, R1
McHutchison, J1
Jacobson, I1
Dieterich, DT1
Berg, T; Kronenberger, B; Lee, JH; Roth, WK; Rüster, B; Sarrazin, C; Zeuzem, S1
Moberg, L; Schvarcz, R; Sönnerborg, A1
Gordon, SC2
Caspary, WF; Dietrich, CF; Lee, JH; Stryjek-Kaminska, D; Teuber, G; Zeuzem, S1
Berg, T; Hoffmann, RM; Hopf, U; Lafrenz, M; Leifeld, L; Pape, GR; Spengler, U; Teuber, G; Zeuzem, S1
Albrecht, JK; Goodman, Z; Hong, Z; Kato, T; Lai, VC; Lau, JY; Mizokami, M; Orito, E1
Fimmel, CJ1
Batisse, D; Kazatchkine, MD; Landau, A; Piketty, C1
Bode, JC; Steimann, RU1
Bertoni, M; Bresci, G; Capria, A; Parisi, G; Scatena, F1
Greving, I; Griga, T; Hüppe, D; Mankel, K; Tromm, A1
Gross, JB; Kim, WR; Poterucha, JJ1
Bérets, O; Cointet, F; Debourdeau, P; Rault, A; Romand, F; Stoll, L; Védrine, L1
Gretch, DR; Pawlotsky, JM1
Andreone, P; Bernardi, M; Cursaro, C; D'Errico, A; Di Giammarino, L; Fiorino, S; Gasbarrini, G; Gramenzi, A; Grigioni, WF; Miniero, R1
Ayi, K; Brugnara, C; Corrocher, R; De Franceschi, L; Fattovich, G; Manzato, F; Noventa, F; Solero, P; Stanzial, AM; Turrini, F1
Cotrim, H; Lyra, L; Paraná, R; Portugal, M; Trepo, C; Vitvitski, L1
Bain, VG; Gutfreund, KS1
Sterneck, M1
Criblez, DH1
Davis, GL; Pauker, SG; Wong, JB1
Buti, M; Esteban, R; Guardi, J; Olive, G; Stalgis, C1
Borque, MJ; Carbonell, P; Castro, A; Diago, M; Fernandez-Bermejo, M; García, V; García-Buey, L; García-Monzón, C; Lo Iacono, O; Moreno, JA; Moreno-Otero, R; Pedreira, J; Sanz, P; Vega, P1
Datz, C; Ferenci, P; Fickert, P; Gschwantler, M; Hackl, F; Lin, W; Müller, C; Rainer, W; Stauber, R; Steindl-Munda, P; Watkins-Riedel, T1
Cacoub, P; Lunel, F1
Bacosi, M; Miglioresi, L; Ricci, GL; Russo, F1
Arribas, JR; García-Samaniego, J; González, J; Peña, JM; Pérez-Olmeda, M; Soriano, V1
Battaglia, AM; Hagmeyer, KO1
Paul, A1
Denham, C; Khalili, M; Perrillo, R1
Burns, DA; Taylor, C; Wiselka, MJ1
Abergel, A; Berthelot, P; Bourlière, M; Bréchot, C; Couzigou, P; Nalpas, B; Pol, S; Tran, A; Zarski, JP1
Batisse, D; Belec, L; Bloch, F; Duong Van Huyen, JP; Kazatchkine, MD; Landau, A; Petite, JP; Pialoux, G; Piketty, C; Weiss, L1
Carmona, I; Herrerías-Esteban, JM; Herrerías-Gutiérrez, JM; Jiménez-Sáenz, M; Piñar, A; Rebollo, J; Rojas, M; Salas, E1
Hoepelman, AI1
Baum, I; Berenguer, J; Córdoba, J; Gobernado, M; Lòpez Viedma, B; Molina, JM; Olaso, V; Prieto, M; Siles, MS1
Al-Faleh, FZ; Al-Humayed, S; Al-Juhani, M; Al-Karawi, M; Al-Otaibi, M; Alahdal, M; Aljumah, A; George, K; Mayet, I; Rezeig, M; Sbeih, F1
Foster, GR; Thomas, HC1
Chang, MH1
Dhumeaux, D; Hezode, C1
Albrecht, JK; Ling, MH; Pauker, SG; Poynard, T; Wong, JB1
Burroughs, AK; Papatheodoridis, GV; Pastacaldi, S; Teixeira, R1
McHutchison, JG; Younossi, Z1
Rasenack, JW1
Benhamou, Y; Poynard, T; Ratziu, V; Regimbeau, C1
Alberti, A; Belussi, F; Bernardinello, E; Casarin, P; Cavalletto, L; Chemello, L; Donada, C; Gatta, A; Marino, F; Pontisso, P1
Colucci, G1
Albrecht, JK; Fang, JW; Gordon, SC; McHutchison, JG; Silverman, AL1
Chutaputti, A1
McHutchison, JG; Pianko, S1
Koshy, A; Madda, JP; Marcellin, P; Martinot, M2
Bolondi, L; Brillanti, S; Foli, M; Levantesi, F; Masi, L1
Clement, RP; Glue, P; Gupta, SK; Jacobs, S; Raffanel, C; Rouzier-Panis, R; Sabo, R; Salfi, M1
Cruz, M; Cruz, T; Lyra, L; Paraná, R1
Herrmann, E; Neumann, AU; Schmidt, JM; Zeuzem, S1
De Bona, A; Finazzi, R; Foppa, CU; Lazzarin, A; Morsica, G; Sitia, G1
Bonkovsky, HL; Katz, E; Szabo, G1
Herrera, JL; Smith, JR1
Cuccorese, G; Miglietta, A; Modeo, ME; Spinazzola, AM; Tursi, A1
Cruz, CN; Felipe, M; Ferraz, LG; Figueiredo, VM; Granero, L; Lanzoni, V; Lopes, EP; Oliveira, PM; Silva, AE1
Benesch, M; Deutsch, J; Dornbusch, HJ; Kerbl, R; Kessler, HH; Lackner, H; Moser, A; Preisegger, KH; Schwinger, W; Urban, C1
Almasio, P; Cataldo, MG; Craxì, A; Di Marco, V; Di Stefano, R; Ferraro, D; Parisi, P; Vaccaro, A1
Bellobuono, A; Chiodo, F; Furione, L; Idéo, G; Magliano, E; Mondazzi, L; Tempini, S1
Chapman, R; Foster, GR1
Glue, P; Gupta, S; Hajian, G; Jen, JF; Zambas, D1
Benhamou, Y; Bochet, M; Bréchot, C; Chaix, ML; Fontaine, H; Katlama, C; Lagneaux, JL; Landau, A; Pialoux, G; Pol, S; Poynard, T; Zylberberg, H1
Albrecht, J; Bedossa, P; Davis, GL; Esteban-Mur, R; Goodman, Z; McHutchison, J; Poynard, T1
Contos, MJ; Gabbay, J; Hofmann, CM; Luketic, VA; Rustgi, V; Ryan, MJ; Sanyal, AJ; Shiffman, ML; Sterling, RK; Yoshida, C1
Albrecht, J; Dienstag, J; Gordon, SC; McHutchison, JG; Morgan, T; Pianko, S; Poynard, T; Reid, AE; Yao, R1
Hoofnagle, JH; Howell, C; Jeffers, L1
Fischler, B; Glaumann, H; Norkrans, G; Reichard, O; Sönnerbor, A; Uhnoo, I; Weiland, O; Wejstål, R1
Grob, PJ; Negro, F; Renner, EL1
García-Samaniego, J; Pérez-Olmeda, M; Rodríguez-Rosado, R; Romero, M; Soriano, V1
Amann, B; Grunze, H; Loeschke, K; Schäfer, M; Schlösser, S; Schmidt, F1
Glaser, D1
Castellano, G; Fernández, I; Hawkins, F; Muñoz, R; Solís-Herruzo, JA1
Diago, M; Enríquez, J; Gallego, A; García-Samaniego, J; Luján, MS; Pérez-Olmeda, T; Soriano, V; Torras, X1
Carlsson, T; Lindahl, K; Reichard, O; Schvarcz, R; Shev, S; Uhnoo, I; Wejstal, R1
Braun, F; Ramadori, G; Ringe, B; Wietzke, P1
Bonis, PA; Cheng, SJ; Lau, J; Pham, NQ; Wong, JB1
Schalm, SW; Vrolijk, JM1
Colantoni, A; De Maria, N; Harig, J; Idilman, R; Van Thiel, DH1
Berg, T; Hopf, U; Kaul, T; Naumann, U; Wiedenmann, B1
Hewitson, P; Shepherd, J; Waugh, N1
Amati, L; Caradonna, L; Cozzolongo, R; Cuppone, R; Giannuzzi, V; Jirillo, E; Manghisi, OG; Tamborrino, V1
Bertoni, M; Bresci, G; Capria, A; Parisi, G1
Albillos, A; Calleja, JL; Domper, F; Escartín, P; Martínez, JL; Moreno, R; Rossi, I1
Fattovich, G; Krampera, M; Pizzolo, G; Scupoli, MT1
Keeffe, EB; Lin, OS1
Balija, M; Bingulac-Popovic, J; Drazic, V; Grahovac, B; Grgicevic, D; Hrstic, I; Ostojic, R; Vucelic, B1
Baumgarten, R; Berg, T; Hoffmann, RM; Hopf, U; Lafrenz, M; Leifeld, L; Pape, GR; Spengler, U; Teuber, G; Zeuzem, S1
Aoki, Y; Cid-Ruzafa, J; Cummings, KJ; Fein, SG; Goodman, SN; Lee, SM; Sulkowski, MS; West, ES1
Koff, R1
Brown, RS; Russo, MW1
Bastani, B; Philipneri, M1
Castéra, L; Roulot, D1
Kallinowski, B; Pohl, J; Stremmel, W1
Ahmed, A; Cheung, R1
Brenci, S; Brizzolara, R; Campo, N; Contini, P; Ghio, M; Indiveri, F; Picciotto, A; Puppo, F; Sinelli, N; Torre, F1
Brouwer, JT; de Vries, RA; Glue, P; Kauffmann, RH; Schalm, SW; Tan, AC; van Leusen, R; Vroom, B1
Barnes, DS; Boparai, N; Brand, E; Carey, WD; Easley, K; Gramlich, T; Hodnick, S; McCullough, AC; Mullen, KD; Younossi, ZM; Zakko, W1
Albrecht, JK; Bayliss, MS; Cort, S; McHutchison, JG; Neary, MP; Pianko, S; Ware, JE; Yang, I1
Boudjema, H; Cadranel, JF; Caron, C; Cazier, A; Coutarel, P; Delacour, T; Di Martino, V; Dumouchel, P1
Bacon, BR; Brunt, EM; Di Bisceglie, AM; Smith-Wilkaitis, N; Thompson, J1
Gibson, AW; Kaslow, RA; Kimberly, R; Tang, J; Van Leeuwen, DJ; Yee, LJ1
Bhatti, A; Gabbay, R; McGarrity, TJ1
Adinolfi, LE; Andreana, A; Durante Mangoni, E1
Lagging, LM; Lindh, M; Nenonen, N; Norkrans, G; Wejstål, R; Westin, J1
Attias, D; Rowe, JM; Sabo, E; Sahar, D; Streichman, S; Yeshurun, D; Zuckerman, E; Zuckerman, T1
Cadorin, L; di Gennaro, G; Nasti, G; Rizzardini, G; Tirelli, U1
Berg, T; Hopf, U; Naumann, U; Wiedenmann, B1
Agarwal, K; Bassendine, DR; Bassendine, MF; Burt, AD; Craig, W; Gilvarry, E; Hewett, M; Jowett, SL; Smith, BC1
Hillon, P1
Billaud, G; Maertens, G; Querenghi, F; Trépo, C; Yu, Q; Zoulim, F1
Gómez, M; Otero, A; Souto, J; Suárez, FJ; Vázquez-Iglesias, JL1
Lam, NP; Layden, TJ; Wiley, TE1
Eibl, MM; Eibl, N; Ferenci, P; Gschwantler, M; Schernthaner, G; Weiss, W1
Angelico, F; Angelico, M; Bergamini, A; Bolacchi, F; Bongiovanni, B; Carvelli, C; Cepparulo, M; Cerasari, G; Demin, F; Francioso, S; Hurtova, M; Liuti, A; Ombres, D; Rocchi, G; Uccella, I1
Bodenheimer, HC; Bodian, C; Esposito, S; Geders, JM; Goldman, IS; Jacobson, IM; Jones, JL; Klion, FM; Lebovics, E; Min, AD; Tobias, H1
Bekkering, FC; Brouwer, JT; Hansen, BE; Schalm, SW1
Andriulli, A; Attino, V; Bacca, D; Carretta, V; Cela, M; Giangaspero, A; Leandro, G; Mangi, A; Minerva, N; Ventrella, F; Villani, MR1
Goeser, T; Kallinowski, B; Liehr, H; Moeller, B; Stremmel, W; Wechsler, JG; Wiese, M1
Arnold, JC; Stremmel, W1
Campos, R; Castaño, G; Cello, J; Flichman, D; Frider, B; Sookoian, S1
Barni, MC; Cadeo, GP; Carosi, G; Cristini, G; Forleo, MA; Gargiulo, F; Paraninfo, G; Puoti, M; Putzolu, V; Quiros-Roldan, E; Rossi, S; Spinetti, A; Zaltron, S; Zanini, B1
Bartlett, SE; Chapman, BA; Edgar, CL; Frampton, CM; Jennings, LC; Scahill, SL; Stace, NH1
James, JS1
Roehr, B1
Lee, SS; Sherman, M1
McHutchison, JG; Shad, JA1
Elez, R; Kronenberger, B; Lee, JH; Piiper, A; Roth, WK; Rüster, B; Weber, S; Zeuzem, S1
Meier, V; Ramadori, G1
Mullhaupt, B; Renner, EL; Sagmeister, M; Wong, JB1
Hayashi, N; Takehara, T1
Akremi, R; Asselah, T; Benhamou, JP; Boyer, N; Ibrahim, A; Jacobson-Brown, P; Katz, GG; Le Breton, V; Le Guludec, G; Malkiewicz, IM; Marcellin, P; Martinot-Peignoux, M; Neuman, MG; Shear, NH; Suneja, A1
Blendis, LM; Brill, S; Halpern, Z; Ibrahim, A; Katz, GG; Konikoff, FM; Magazinik, S; Malkiewicz, IM; Neuman, MG; Peretz, H; Sapir, D; Shear, NH1
Alaimo, G; Almasio, PL; Craxì, A; Di Marco, V; Di Stefano, R; Ferraro, D; Parisi, P; Peralta, S; Rodolico, V; Vaccaro, A1
Andreoni, M; Biglino, A; Calleri, G; Cariti, G; Ciancio, A; Ciccone, G; Colletta, C; Croce, G; Di Napoli, A; Macor, A; Maggi, G; Olivero, A; Orsi, PG; Rinaldi, E; Rizzetto, M; Roffi, L; Saracco, G; Smedile, A; Tappero, GF; Terreni, N1
Capra, F; De Maria, E; Franchini, M; Gandini, G1
Datz, C; Ferenci, P; Fickert, P; Gangl, A; Gschwantler, M; Hackl, F; Krejs, GJ; Lin, W; Müller, C; Rainer, W; Stauber, R; Steindl-Munda, P; Watkins-Riedel, T1
Chapman, R; Collier, J1
Rivero, A; Torre-Cisneros, J1
Couzigou, P; De Ledinghen, V; Foucher, J1
De Vos, M; Delanghe, JR; Leroux-Roel, G; Van Vlierbergh, H1
Carmona-Soria, I; González-Vilches, J; Herreriás-Gutiérrez, JM; Jiménez-Sáenz, M1
Andersson, J; Bruchfeld, A; Schvarcz, R; Ståhle, L2
Deschênes, M; Mishkin, D1
Fickert, P; Hegenbarth, K; Kroisel, PM; Maurer, U; Stauber, RE; Trauner, M1
Balestra, V; Brizzolara, R; Campo, N; Giusto, R; Grasso, A; Picciotto, A; Sinelli, N; Torre, F1
Contos, MJ; Hofmann, CM; Luketic, VA; Sanyal, AJ; Shiffman, ML; Sterling, RK1
Asahina, Y; Hamano, K; Itakura, J; Izumi, N; Kanazawa, N; Miyake, S; Noguchi, O; Sakai, T; Tsuchiya, K; Uchihara, M1
Carbonell, P; Cors, R; Diago, M; García, V; Luján, M; Marcaida, G; Tuset, C; Valeros, D1
Kato, N; Omata, M; Otsuka, M1
Kawabe, T; Toda, G1
Tanikawa, K1
Hultkrantz, R; Jonsson, D; Reichard, O; Sennfält, K; Wong, JB1
Azara, V; Branca, B; Deplano, A; Garrucciu, G; Manzoni, NE; Ogana, G; Solinas, A; Tocco, A1
Almar, M; Díaz-Golpe, V; García-Fernández, A; González-Gallego, J; Jorquera, F; Olcóz, JL1
Bacon, BR; Britton, RS; Di Bisceglie, AM; Mistry, B; Naeem, M1
Ashur, Y; Bishara, A; Eid, A; Galun, E; Ilan, Y; Israeli, E; Jurim, O; Safadi, R1
Anagnostopoulos, G; Aroni, K; Kontochristopoulos, GJ; Nakopoulou, L; Tassopoulos, NC1
Heathcote, J; Jain, K; Lam, WC; Thai, Q; Waheeb, S1
Kiyosawa, K; Sodeyama, T1
Bowlus, CL; Leigh, JP; Leistikow, BN; Schenker, M1
Cadorin, L; Carbone, A; Di Gennaro, G; Nasti, G; Talamini, R; Tavio, M; Tedeschi, RM; Tirelli, U1
Albrecht, JK; Goodman, ZD; Gordon, SC; Koury, K; Ling, M; Manns, MP; McHutchison, JG; Reindollar, R; Rustgi, VK; Shiffman, M1
Mert, A; Ozaras, R; Ozbay, G; Senturk, H; Tabak, F; Tahan, V1
García-Samaniego, J; Pérez-Olmeda, M; Rodríguez-Rosado, R; Soriano, V1
Ferenci, P; Gangl, A; Gschwantler, M; Hofer, H; Jessner, W; Mueller, C; Steindl-Munda, P; Watkins-Riedel, T; Wrba, F1
Blum, HE; Cerny, A; Heim, MH; Moradpour, D; Wölk, B1
Ahmed, S; Karim, A; Khan, A; Mattana, J; Steinberg, H1
Brunner, H; Datz, C; Ferenci, P; Gangl, A; Gschwantler, M; Hackl, F; Hegenbarth, K; Hofer, H; Jessner, W; Munda-Steindl, P; Nachbaur, K; Rosenbeiger, M; Stauber, R; Vogel, W1
Altisent, C; Esteban, JI; Esteban, R; Guardia, J; Juárez, A; Puig, L; Ruiz, I; Sauleda, S1
Ahmad, J; Demetris, AJ; Dodson, SF; Fung, JJ; Shakil, AO1
Airoldi, A; Alberti, AB; Belli, LS; Cernuschi, A; D'Amico, M; de Carlis, L; Forti, D; Minola, E; Pinzello, G; Rondinara, G; Vangeli, M1
Csef, H; Faller, H; Kraus, MR; Mörk, H; Schäfer, A; Scheurlen, M1
Banner, BF; Bonkovsky, HL; Colker, J; Israel, J; Liu, Q; McNeal, K; Stagias, J; Stefancyk, D; Zucker, GM1
Batisse, D; Belec, L; Bloch, F; Bruneval, P; Duong Van Huyen, JP; Jian, R; Kazatchkine, MD; Landau, A; Piketty, C; Weiss, L1
Chamuleau, RA; Molenaar, DS; Reesink, HW; Weegink, CJ1
Albrecht, JK; Dienstag, JL; Garaud, JJ; Gordon, SC; Ling, MH; McHutchison, JG; Morgan, TR; Shad, JA1
Gluud, C; Kjaergard, LL; Krogsgaard, K3
Gow, PJ; Mutimer, D1
Buti, M; Esteban, R; Martell, M; Morral, S; Sanchez, F; Stalgis, C1
Edelstein, MA; Martin, P1
Husa, P; Husova, L1
Attuil, V; Brengel-Pesce, K; Drouet, E; Leroy, V; Seigneurin, JM; Thelu, MA; Zarski, JP1
Di Bisceglie, AM1
Donahue, P; Hasan, I; Lebovics, E; Rehman, R; Rigas, B; Wittkowski, KM1
Ashur, Y; Granot, E; Shouval, D1
Addesa, JA; Navarro, VJ1
van Hattum, J; van Soest, H1
Adamek, B; Biskupska-Karasińska, M; Bolewska, B; Boroń-Kaczmarska, A; Cianciara, J; Daniluk, J; Dudziak, M; Dziambor, AP; Flieger, J; Gonciarz, Z; Gładysz, A; Juszczyk, J; Kozłowska, J; Kryczka, W; Kuydowicz, J; Lakomy, E; Machniak, M; Mazur, W; Niwicka-Michałowska, A; Piszko, P; Swietek, K; Słomka, M; Trocha, H; Wawrzynowicz-Syczewska, M; Witczak-Malinowska, K; Zaborowski, P; Zarebska-Michaluk, D1
Fontana, RJ; Klein, S; Lok, AS; Moyer, CA; Walsh, J; Webster, S1
Rosenberg, W; Stein, K; Wong, J1
Himelhoch, S1
Besancenot, JF; Bielefeld, P; Champigneulle, B; de Boulard, A; Gabreau, T; Hillon, P; Lévêque, L; Makki, H; Sgro, C1
Chen, DS; Chen, PJ; Kao, JH; Lai, MY1
Kumada, H1
Santin, M; Shaw, E1
Beltrame, A; Costa, AF; Kuchenbecker, R; Picon, PD1
Cecil, BD1
Braun, F; Meier, V; Ramadori, G; Wietzkebetaraun, P1
Koczorek, M1
Hwang, SJ1
Perry, CM; Scott, LJ1
Tossing, G1
Germer, JJ; Vidigal, PG; Zein, NN1
García-Samaniego, J; Núñez, M; Pérez-Olmeda, M; Ríos, P; Romero, M; Soriano, V1
Laurence, J1
Elkabes, B; Saner, G; Sökücü, S; Süoğlu D, OD1
Bell, H; Bjøro, K; Døskeland, B; Hellum, KB; Lund-Tønnesen, S; Maeland, A; Myrvang, B; Raknerud, N; Sandvei, P; Skaug, K1
Barange, K; Hrycewycz, N; Izopet, J; Pascal, JP; Payen, JL; Sandres, K1
Amarapurkar, A; Amarapurkar, D; Dhorda, M; Kankonkar, S; Kirpalani, A1
Lombraña, JL; Pérez-Alvarez, R; Pérez-López, R; Rodrigo, L; Rodríguez, M1
Skrivánková, J; Stránský, J1
Borque, MJ; Castro, A; De Pedro, A; Fernández-Bermejo, M; García-Buey, L; Lopez, S; Lorenzo, JA; Moreno-Monteagudo, JA; Moreno-Otero, R; Pedreira, JD1
Langner, RG; van Leeuwen, DJ; Yee, LJ1
Albrecht, JK; Davis, GL; Dienstag, JL; Esteban-Mur, R; Garaud, JJ; Goodman, ZD; Harvey, J; Ling, MH; McHutchison, JG; Morgan, T; Patel, K; Poynard, T1
Bica, I; McGovern, B1
Adams, G; Jones, A; Kumar, KS; Lee, WM; Malet, PF; Malik, AH; Ostapowicz, G; Wood, M; Yarbrough, K1
Colomb, MG; Drouet, C; Dumestre-Perard, C; Dutertre, N; Leroy, V; Ponard, D; Zarski, JP1
Akremi, R; Asselah, T; Benali, S; Benhamou, JP; Bourliere, M; Boyer, N; Ibrahim, A; Katz, GG; Le Breton, V; Le Guludec, G; Lecomte, L; Malkiewicz, I; Marcellin, P; Martinot-Peignoux, M; Neuman, MG; Shear, NH1
Hong, Z; Lau, JY; Tam, RC1
Beylot, C; Beylot-Barry, M; Cogrel, O; Couzigou, P; Doutre, MS; Marlière, V1
Häussinger, D; Heintges, T; Sagir, A; Wettstein, M1
Chou, S; Conrad, AJ; Lentz, JJ; Marousek, G; McHutchison, JG; Rose, SL; Rosen, HR; Taylor, K; Zaman, A1
Pockros, PJ1
Siboni, A1
Blackwell, J1
Mollison, L; Olynyk, J; Totten, L; Yusoff, IF1
Akuta, N; Arase, Y; Ikeda, K; Kobayashi, M; Kumada, H; Saitoh, S; Someya, T; Suzuki, F; Suzuki, Y; Tsubota, A1
Belaich, S; Crickx, B; Descamps, V; Grossin, M; Le Bozec, P; Marcellin, P; Wendling, J1
Cozzolongo, R; Cuppone, R; Manghisi, OG1
Bellobuono, A; Idéo, G1
Carreño, V1
Kinnman, N; Lindmarker, P; Schulman, S; von Sydow, M1
Forns Bernhardt, X1
Buti, M; Esteban-Mur, R; Guardia, J; Olivé, G1
García Buey, L; Moreno Monteagudo, JA; Moreno Otero, R1
Fukuda, Y; Hayashi, K; Nakano, I; Takamatsu, J; Toyoda, H1
Kimura, S; Makuuchi, M; Morisawa, Y; Oka, S; Sugawara, Y; Tachikawa, N1
Matsushima, T1
Baldini, C; Bombardieri, S; Della Rossa, A; Tavoni, A1
Hong, Z; Lau, JY; Liang, TJ; Tam, RC1
Fouchard-Hubert, I; Gergely, AE; Lafarge, P; Lunel-Fabiani, F1
Bernard, PH; Bourlière, M; Canva, V; Capron, D; Chêne, G; Couzigou, P; de Lédinghen, V; Desmorat, H; Fleury, H; Foucher, J; Lévy, S; Mannant, PR; Mion, F; Trimoulet, P; Winnock, M1
Haydon, GH; Mutimer, DJ1
Barbarini, G; Barbaro, G1
Albrecht, J; Goodman, Z; Lindsay, K; Ling, MH; Manns, M; McHutchison, J; Poynard, T; Trepo, C1
Arthur, MJ1
Brinkley-Laughton, S; Hudson, M; Reindollar, R; Sulkowski, M; Thomas, DL; Yu, J1
Esteban, JI; Juárez, A; Sauleda, S1
García Buey, L; Moreno Monteagudo, JA; Moreno Otero, R; Trapero Marugán, M1
Forns, X1
Duncan, D; Sharieff, KA; Younossi, Z1
Allende, H; Castro, FJ; Esteban, JI; Esteban, R; Guardia, J; Juárez, A; Martell, M; Moreno, F; Sauleda, S; Viladomiu, L1
Desch, S; Klinker, H; Langmann, P; Lingenauber, C; Väth, T; Zilly, M1
Herrine, SK1
Al-Khalid, J; Al-Mekhaizeem, K; Al-Nakib, B; Al-Shamali, M; Asker, H; Hasan, F; Siddique, I1
Chan, PK; Ha, SY; Li, CK; Ling, SC1
Bacon, BR; Blatt, LM; Brunt, EM; Cortese, CM; Goodman, ZD; Gordon, SC; Heaton, S; McHutchison, JG; Patel, K; Pianko, S1
Amato, G; Caporaso, N; Carella, C; Cioffi, M; Mazziotti, G; Morisco, F; Rotondi, M; Sorvillo, F; Tuccillo, C1
Abergel, A; Bernard, PH; Bourlière, M; Chêne, G; Couzigou, P; de Lédinghen, V; Fleury, H; Lévy, S; Portal, I; Rémy, AJ; Szostak, N; Tran, A; Trimoulet, P; Winnock, M1
Naoumov, NV1
Enomoto, M; Nishiguchi, S1
Bausch, J; Bordens, R; Grace, M; Wang, YS; Wyss, DF; Youngster, S1
Chou, S; Marousek, GI; Murphy, MD; Rosen, HR1
Bondeson, TL; Lindgren, SC; Verbaan, HP; Widell, HE1
Andriulli, A; Annese, M; Bacca, D; Carretta, V; Cela, M; Leandro, G; Mangia, A; Minerva, N; Piattelli, M; Santoro, R; Spirito, F; Ventrella, F1
Burtscheidt, W; Gaebel, W; Kornischka, J1
Willson, RA1
Changchien, CS; Chen, TM; Huang, WS; Hung, CH; Lee, CM; Lu, SN; Tung, HD; Wang, JH1
Bell, H; Bjøro, K; Dalgard, O; Hellum, KB; Myrvang, B1
Abbas, Z; Hamid, S; Tabassum, S1
Giostra, E; Mentha, G; Negro, F; Rizzoli, R; Trombetti, A1
Becquemont, L; Broly, F; Chazouilleres, O; Funck-Brentano, C; Jaillon, P; Poirier, JM; Poupon, R; Serfaty, L1
Burgart, LJ; Charlton, M; El-Amin, OM; Kremers, WK; Narayanan Menon, KV; Poterucha, JJ; Rosen, CB; Wiesner, RH1
Ashton-Prolla, P; Cheinquer, H; Cheinquer, N; Coelho-Borges, S; Krug, L1
Nĕmecek, V; Rýzlová, M; Stránský, J; Stríteský, J1
Bell, H; Berg, JP; Bjøro, K; Distante, S; Hellum, KB; Myrvang, B; Raknerud, N; Skaug, K1

Reviews

987 review(s) available for ribavirin and Chronic Hepatitis C

ArticleYear
Effect of sofosbuvir-based DAAs on changes in lower-density lipoprotein in HCV patients: a systematic review and meta-analysis.
    BMC infectious diseases, 2021, Sep-21, Volume: 21, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lipoproteins, LDL; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2021
[From treating in the dark towards eliminating hepatitis C].
    Ugeskrift for laeger, 2021, 11-15, Volume: 183, Issue:46

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin

2021
Efficacy and safety of direct-acting antiviral therapy for hepatitis C virus in elderly patients (≥65 years old): A systematic review and meta-analysis.
    Journal of viral hepatitis, 2022, Volume: 29, Issue:7

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Middle Aged; Ribavirin; Treatment Outcome

2022
Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review.
    Frontiers in public health, 2022, Volume: 10

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides

2022
Safety and efficacy of sofosbuvir-based medication regimens with and without ribavirin in hepatitis C patients: A systematic review and meta-analysis.
    Journal of clinical pharmacy and therapeutics, 2022, Volume: 47, Issue:8

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome

2022
Daclatasvir as a hepatitis C infection treatment option: an up-to-date evaluation.
    Expert opinion on pharmacotherapy, 2023, Volume: 24, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome

2023
Management of Hepatitis C in Children - A New Paradigm.
    Indian pediatrics, 2023, 01-15, Volume: 60, Issue:1

    Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Infant; Infant, Newborn; Interferons; Ribavirin; Treatment Outcome

2023
Evaluation of the Safety Profile of Direct-Acting Antivirals on Patients with Hepatitis C Virus: A Pharmacovigilance Study.
    Therapeutic innovation & regulatory science, 2023, Volume: 57, Issue:5

    Topics: Anilides; Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Pharmacovigilance; Recurrence; Ribavirin; Ritonavir; Sofosbuvir; Sustained Virologic Response

2023
Hepatitis C virus/Hepatitis B virus coinfection: Current prospectives.
    Antiviral therapy, 2023, Volume: 28, Issue:4

    Topics: Antiviral Agents; Coinfection; Hepacivirus; Hepatitis B virus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Ribavirin

2023
Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis.
    Viruses, 2023, 06-30, Volume: 15, Issue:7

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Neoplasms; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2023
Paediatric hepatitis C virus infection and its treatment: Present, past, and future.
    Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology, 2019, Volume: 20, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Nucleic Acid Synthesis Inhibitors; Protease Inhibitors; Ribavirin; Viral Nonstructural Proteins

2019
Systematic Review with Meta-Analysis: Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C Genotypes 5 and 6.
    BioMed research international, 2019, Volume: 2019

    Topics: Antiviral Agents; Benzimidazoles; Databases, Factual; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Sofosbuvir; Uridine Monophosphate

2019
Interferon-Free Hepatitis C Virus Therapy.
    Cold Spring Harbor perspectives in medicine, 2020, 11-02, Volume: 10, Issue:11

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Practice Guidelines as Topic; Ribavirin; Sustained Virologic Response

2020
Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus co-infection: systematic review and network meta-analysis.
    Journal of gastroenterology and hepatology, 2020, Volume: 35, Issue:9

    Topics: Administration, Oral; Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Ribavirin; Safety; Sulfonamides; Sustained Virologic Response; Treatment Outcome

2020
Hepatitis C and Treatment in Patients with Chronic Kidney Disease.
    Disease-a-month : DM, 2021, Volume: 67, Issue:2

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Kidney Transplantation; Patient Selection; Renal Dialysis; Renal Insufficiency, Chronic; Ribavirin

2021
Anti-rods/rings autoantibody and IMPDH filaments: an update after fifteen years of discovery.
    Autoimmunity reviews, 2020, Volume: 19, Issue:10

    Topics: Aged; Antiviral Agents; Autoantibodies; Female; Hepatitis C, Chronic; Humans; Male; Ribavirin

2020
Hepatitis C virus-related cryoglobulinemic vasculitis.
    Minerva medica, 2021, Volume: 112, Issue:2

    Topics: Antiviral Agents; Blood Component Removal; Colchicine; Cryoglobulinemia; Female; Glucocorticoids; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Rituximab; Vasculitis

2021
Treatment failure with DAA therapy: Importance of resistance.
    Journal of hepatology, 2021, Volume: 74, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Combinations; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Macrocyclic Compounds; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure

2021
Genotype 3-hepatitis C virus' last line of defense.
    World journal of gastroenterology, 2021, Mar-21, Volume: 27, Issue:11

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Treatment Outcome

2021
Hepatitis C in Tunisia from 1991 to 2019: A systematic review.
    La Tunisie medicale, 2021, Volume: 99, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Tunisia

2021
The Challenge of Treating Children With Hepatitis C Virus Infection.
    Journal of pediatric gastroenterology and nutrition, 2017, Volume: 64, Issue:6

    Topics: Administration, Oral; Adolescent; Antiviral Agents; Benzimidazoles; Child; Drug Therapy, Combination; Fluorenes; Hepatitis C, Chronic; Humans; Interferon Type I; Ribavirin; Sofosbuvir; Uridine Monophosphate

2017
Direct-acting antivirals: the endgame for hepatitis C?
    Current opinion in virology, 2017, Volume: 24

    Topics: Antiviral Agents; Disease Eradication; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Protease Inhibitors; Ribavirin; Viral Nonstructural Proteins; Virus Replication

2017
Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis.
    Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2017, Apr-20, Volume: 25, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Sofosbuvir

2017
Hepatitis C virus management: potential impact of nanotechnology.
    Virology journal, 2017, 05-02, Volume: 14, Issue:1

    Topics: Antiviral Agents; Drug Delivery Systems; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; MicroRNAs; Nanoparticles; Nanotechnology; Ribavirin; Viral Vaccines

2017
Sofosbuvir and velpatasvir for the treatment of hepatitis C.
    Expert review of gastroenterology & hepatology, 2017, Volume: 11, Issue:6

    Topics: Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Combinations; Drug Interactions; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Risk Factors; Sofosbuvir; Sustained Virologic Response; Viral Load

2017
Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis.
    Journal of hepatology, 2017, Volume: 67, Issue:4

    Topics: 2-Naphthylamine; Administration, Oral; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Young Adult

2017
Neurologic Manifestations of Hepatitis C Virus Infection.
    Clinics in liver disease, 2017, Volume: 21, Issue:3

    Topics: Antiviral Agents; Cerebrovascular Disorders; Electroencephalography; Hepatitis C, Chronic; Humans; Interferons; Magnetic Resonance Imaging; Mental Disorders; Neurocognitive Disorders; Ribavirin

2017
Impact of etiological treatment on prognosis.
    Hepatology international, 2018, Volume: 12, Issue:Suppl 1

    Topics: Alcohol Abstinence; Antiviral Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Hypertension, Portal; Interferon-alpha; Kidney Failure, Chronic; Liver Cirrhosis; Liver Diseases, Alcoholic; Liver Neoplasms; Liver Transplantation; Portal Pressure; Prognosis; Ribavirin

2018
Direct-acting antivirals for hepatitis C virus in patients on maintenance dialysis.
    The International journal of artificial organs, 2017, Oct-13, Volume: 40, Issue:10

    Topics: Antiviral Agents; Drug Combinations; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Renal Dialysis; Renal Insufficiency, Chronic; Ribavirin

2017
Role of ribavirin in interferon-free therapy for the treatment of hepatitisC virus.
    Gastroenterologia y hepatologia, 2017, Volume: 40, Issue:10

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Ribavirin

2017
Efficacy of vitamin D supplementation in combination with conventional antiviral therapy in patients with chronic hepatitis C infection: a meta-analysis of randomised controlled trials.
    Journal of human nutrition and dietetics : the official journal of the British Dietetic Association, 2018, Volume: 31, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Child; Dietary Supplements; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Vitamin D; Vitamins

2018
Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis.
    Clinical drug investigation, 2017, Volume: 37, Issue:11

    Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine

2017
Ledipasvir + Sofosbuvir for Liver Transplant Recipients With Recurrent Hepatitis C: A Systematic Review and Meta-analysis.
    Transplantation proceedings, 2017, Volume: 49, Issue:8

    Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepatitis C, Chronic; Humans; Recurrence; Ribavirin; Sofosbuvir; Uridine Monophosphate

2017
Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review.
    BMC infectious diseases, 2017, 11-16, Volume: 17, Issue:1

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine

2017
Micro-costing analysis of guideline-based treatment by direct-acting agents: the real-life case of hepatitis C management in Brazil.
    BMC gastroenterology, 2017, Nov-23, Volume: 17, Issue:1

    Topics: Antiviral Agents; Brazil; Carbamates; Costs and Cost Analysis; Drug Costs; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Proline; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Valine

2017
Pegylated interferon alpha 2a for the treatment of hepatitis C virus infection.
    Expert opinion on drug metabolism & toxicology, 2018, Volume: 14, Issue:2

    Topics: Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Failure, Chronic; Patient Selection; Pharmacogenetics; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2018
Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C.
    Drugs, 2018, Volume: 78, Issue:2

    Topics: Antiviral Agents; Benzimidazoles; Coinfection; Drug Combinations; Drug Therapy, Combination; Fluorenes; Genotype; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2018
Vitamin D deficiency and hepatitis viruses-associated liver diseases: A literature review.
    World journal of gastroenterology, 2018, Jan-28, Volume: 24, Issue:4

    Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Sustained Virologic Response; Viral Load; Vitamin D; Vitamin D Deficiency

2018
Sustained Virological Response in Special Populations with Chronic Hepatitis C Using Interferon-Free Treatments: A Systematic Review and Meta-analysis of Observational Cohort Studies.
    Clinical drug investigation, 2018, Volume: 38, Issue:5

    Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine

2018
[Chronic hepatitis C : Standard treatment and remaining challenges].
    Der Internist, 2018, Volume: 59, Issue:6

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Quality of Life; Ribavirin; Treatment Outcome

2018
Long-Term Liver Disease, Treatment, and Mortality Outcomes Among 17,000 Persons Diagnosed with Chronic Hepatitis C Virus Infection: Current Chronic Hepatitis Cohort Study Status and Review of Findings.
    Infectious disease clinics of North America, 2018, Volume: 32, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Observational Studies as Topic; Patient Reported Outcome Measures; Ribavirin; Time Factors; Young Adult

2018
Hepatitis C virus infection in chronic kidney disease: paradigm shift in management.
    The Korean journal of internal medicine, 2018, Volume: 33, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Renal Insufficiency, Chronic; Ribavirin

2018
Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C.
    Expert opinion on drug metabolism & toxicology, 2018, Volume: 14, Issue:9

    Topics: Antiviral Agents; Carbamates; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Valine

2018
Danoprevir: First Global Approval.
    Drugs, 2018, Volume: 78, Issue:12

    Topics: Antiviral Agents; China; Cyclopropanes; Dose-Response Relationship, Drug; Drug Approval; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Viral Nonstructural Proteins

2018
Are there any challenges left in hepatitis C virus therapy of HIV-infected patients?
    International journal of antimicrobial agents, 2020, Volume: 56, Issue:1

    Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Benzimidazoles; Carbamates; Coinfection; Drug Interactions; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sexual and Gender Minorities; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2020
Natural products for the management of the hepatitis C virus: a biochemical review.
    Archives of physiology and biochemistry, 2020, Volume: 126, Issue:2

    Topics: Antiviral Agents; Aquatic Organisms; Biological Products; Clinical Trials as Topic; Drug Therapy, Combination; Flavonoids; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Plant Extracts; Ribavirin

2020
Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan.
    Medicina (Kaunas, Lithuania), 2018, Nov-05, Volume: 54, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Pakistan; Prevalence; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response

2018
Viral resistance in HCV infection.
    Current opinion in virology, 2018, Volume: 32

    Topics: Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Failure

2018
Treatment of hepatitis C virus genotype 4 in the DAA era.
    Virology journal, 2018, 11-22, Volume: 15, Issue:1

    Topics: Aminoisobutyric Acids; Anilides; Antiviral Agents; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Interferons; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine

2018
All Oral Interferon-free Direct-acting Antivirals as Combination Therapies to Cure Hepatitis C.
    Current molecular medicine, 2018, Volume: 18, Issue:7

    Topics: Administration, Oral; Animals; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Ribavirin; Time Factors; Viral Load

2018
Sofosbuvir, ribavirin and pegylated interferon for a daclatasvir-resistent genotype 3 hepatitis C virus: case report and review.
    Revista do Instituto de Medicina Tropical de Sao Paulo, 2019, Feb-14, Volume: 61

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Viral Load

2019
Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4-5 chronic kidney disease: a systematic review and meta-analysis.
    Virology journal, 2019, 03-14, Volume: 16, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Prospective Studies; Renal Insufficiency, Chronic; Ribavirin; Sofosbuvir; Sustained Virologic Response

2019
Efficacy and safety of direct-acting antivirals for hepatitis C in the elderly: A systematic review and meta-analysis.
    Liver international : official journal of the International Association for the Study of the Liver, 2019, Volume: 39, Issue:9

    Topics: Age Factors; Aged; Anemia; Antiviral Agents; Hepatitis C, Chronic; Humans; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome

2019
Retreatment of Hepatitis C Virus-Infected Patients with Direct-Acting Antiviral Failures.
    Seminars in liver disease, 2019, Volume: 39, Issue:3

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Macrocyclic Compounds; Pyrrolidines; Quinoxalines; Retreatment; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure

2019
Maintenance interferon therapy in chronic hepatitis C patients who failed initial antiviral therapy: A meta-analysis.
    Medicine, 2019, Volume: 98, Issue:19

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferons; Polyethylene Glycols; Retreatment; Ribavirin

2019
What the infectious disease physician needs to know about pegylated interferon and ribavirin.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013, Volume: 56, Issue:11

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Infectious Disease Medicine; Interferons; Polyethylene Glycols; Ribavirin

2013
Review article: the treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients.
    Alimentary pharmacology & therapeutics, 2013, Volume: 37, Issue:7

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2013
Pegylated interferon-α2a and ribavirin versus pegylated interferon-α2b and ribavirin in chronic hepatitis C : a meta-analysis.
    Drugs, 2013, Volume: 73, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Odds Ratio; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2013
Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review.
    Annals of internal medicine, 2013, Jan-15, Volume: 158, Issue:2

    Topics: Adult; Antiviral Agents; Comparative Effectiveness Research; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2013
L11. Hepatitis C virus mixed cryoglobulinemia vasculitis: therapeutic options.
    Presse medicale (Paris, France : 1983), 2013, Volume: 42, Issue:4 Pt 2

    Topics: Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; B-Lymphocytes; Blood Component Removal; Combined Modality Therapy; Cryoglobulinemia; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Immunologic Factors; Immunosuppressive Agents; Interferon-alpha; Plasmapheresis; Polyethylene Glycols; Protease Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Rituximab

2013
Immunoglobulin G4-associated de novo autoimmune hepatitis after liver transplantation for chronic hepatitis B- and C-related cirrhosis and hepatocellular carcinoma: a case report with literature review.
    Transplantation proceedings, 2013, Volume: 45, Issue:2

    Topics: Antiviral Agents; Azathioprine; Carcinoma, Hepatocellular; Coinfection; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis, Autoimmune; Humans; Immunoglobulin G; Immunosuppressive Agents; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Prednisone; Recombinant Proteins; Recurrence; Ribavirin; Time Factors; Treatment Outcome

2013
The efficacy and safety of telaprevir-based regimens for treating chronic hepatitis C virus genotype 1 infection: a meta-analysis of randomized trials.
    Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:6

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Odds Ratio; Oligopeptides; Polyethylene Glycols; Publication Bias; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Ribavirin; Risk; RNA, Viral; Serine Proteinase Inhibitors; Treatment Outcome; Viral Load; Viremia

2013
[Development of sarcoidosis during treatment for chronic hepatitis C with pegylated interferon alfa-2a and ribavirin: case report and literature review].
    Le infezioni in medicina, 2013, Volume: 21, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Glucocorticoids; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Prednisone; Recombinant Proteins; Ribavirin; Sarcoidosis

2013
[Interferon treatment of chronic hepatitis C: basic immunobiology and immunopathology of the liver].
    Revista espanola de sanidad penitenciaria, 2013, Volume: 15, Issue:1

    Topics: Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Elasticity Imaging Techniques; Genetic Predisposition to Disease; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Spain; Treatment Outcome

2013
Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis.
    Clinical drug investigation, 2013, Volume: 33, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Gene Frequency; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Linear Models; Odds Ratio; Oligopeptides; Pharmacogenetics; Phenotype; Polyethylene Glycols; Polymorphism, Single Nucleotide; Proline; Recombinant Proteins; Ribavirin; Treatment Outcome

2013
[Inosine triphosphatase gene polymorphism and ribavirin-related anemia in chronic hepatitis C patients].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2012, Volume: 20, Issue:12

    Topics: Anemia; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Polymorphism, Genetic; Pyrophosphatases; Ribavirin

2012
Emerging therapeutic targets for hepatitis C virus infection.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2013, Volume: 11, Issue:6

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Discovery; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Proline; Ribavirin

2013
Antiviral therapy of symptomatic HCV-associated mixed cryoglobulinemia: meta-analysis of clinical studies.
    Journal of medical virology, 2013, Volume: 85, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Statistical; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2013
[Progress in hepatitis C treatment].
    Medicina clinica, 2013, Nov-16, Volume: 141, Issue:10

    Topics: Anemia; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Eruptions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Multicenter Studies as Topic; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Pruritus; Randomized Controlled Trials as Topic; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia

2013
Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C: a systematic review and meta-analysis.
    Antiviral research, 2013, Volume: 98, Issue:3

    Topics: Adjuvants, Immunologic; Antiviral Agents; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Interferon-alpha; Odds Ratio; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome; Viral Load

2013
PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history.
    Expert review of anti-infective therapy, 2013, Volume: 11, Issue:5

    Topics: Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2013
IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: a meta-analysis.
    Journal of viral hepatitis, 2013, Volume: 20, Issue:6

    Topics: Antiviral Agents; Asian People; Genetic Predisposition to Disease; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Odds Ratio; Polyethylene Glycols; Polymorphism, Single Nucleotide; Publication Bias; Ribavirin; Time Factors; Treatment Outcome; White People

2013
[Telaprevir-induced pityriasis rubra pilaris].
    Annales de dermatologie et de venereologie, 2013, Volume: 140, Issue:5

    Topics: Adrenal Cortex Hormones; Adult; Antiviral Agents; Biopsy; Drug Eruptions; Drug Therapy, Combination; Eosinophilia; Eosinophils; Hepacivirus; Hepatitis C, Chronic; Histamine Antagonists; Humans; Interferon-alpha; Keratinocytes; Lymphocytes; Middle Aged; Oligopeptides; Pityriasis Rubra Pilaris; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Skin; Viral Nonstructural Proteins

2013
New insights in recurrent HCV infection after liver transplantation.
    Clinical & developmental immunology, 2013, Volume: 2013

    Topics: Antibodies, Neutralizing; Antiviral Agents; Glucocorticoids; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Failure; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; Viral Envelope Proteins; Virus Internalization

2013
Evolution of cell culture systems for HCV.
    Antiviral therapy, 2013, Volume: 18, Issue:3 Pt B

    Topics: Antiviral Agents; Cell Culture Techniques; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Replicon; Ribavirin; RNA, Viral; Virus Cultivation; Virus Replication

2013
Protease inhibitors for hepatitis C: economic implications.
    PharmacoEconomics, 2013, Volume: 31, Issue:9

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Quality of Life; Recombinant Proteins; Ribavirin

2013
Viral hepatitis C gets personal--the value of human genomics to public health.
    Public health genomics, 2013, Volume: 16, Issue:4

    Topics: Antiviral Agents; Genomics; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Pharmacogenetics; Public Health; Ribavirin

2013
Management of anemia induced by triple therapy in patients with chronic hepatitis C: challenges, opportunities and recommendations.
    Journal of hepatology, 2013, Volume: 59, Issue:6

    Topics: Anemia; Drug Therapy, Combination; Erythrocyte Transfusion; Erythropoietin; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin

2013
Hepatitis C virus: standard-of-care treatment.
    Advances in pharmacology (San Diego, Calif.), 2013, Volume: 67

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin

2013
Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy.
    Molecular diagnosis & therapy, 2014, Volume: 18, Issue:1

    Topics: Anemia, Hemolytic; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Genetic Markers; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Polymorphism, Single Nucleotide; Precision Medicine; Protease Inhibitors; Pyrophosphatases; Ribavirin

2014
[Telaprevir in treatment-naïve patients with HCV monoinfection].
    Enfermedades infecciosas y microbiologia clinica, 2013, Volume: 31 Suppl 3

    Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Randomized Controlled Trials as Topic; Ribavirin; Young Adult

2013
[Telaprevir in HCV-monoinfected patients with failure to prior treatment].
    Enfermedades infecciosas y microbiologia clinica, 2013, Volume: 31 Suppl 3

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Multicenter Studies as Topic; Oligopeptides; Patient Selection; Polyethylene Glycols; Protease Inhibitors; Recurrence; Ribavirin; Treatment Failure; Treatment Outcome

2013
[Clinical use of telaprevir: stopping rules, predicting response, treatment length, and management of adverse effects].
    Enfermedades infecciosas y microbiologia clinica, 2013, Volume: 31 Suppl 3

    Topics: Anemia; Antiviral Agents; Clinical Trials as Topic; Drug Eruptions; Exanthema; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Liver Cirrhosis; Medical Futility; Multicenter Studies as Topic; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Ribavirin; RNA, Viral; Stevens-Johnson Syndrome; Viral Load

2013
[Safety and efficacy of telaprevir in patients with HIV and hepatitis C virus coinfection].
    Enfermedades infecciosas y microbiologia clinica, 2013, Volume: 31 Suppl 3

    Topics: Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Drug Eruptions; Drug Therapy, Combination; Gastrointestinal Diseases; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Severity of Illness Index

2013
[Telaprevir resistance].
    Enfermedades infecciosas y microbiologia clinica, 2013, Volume: 31 Suppl 3

    Topics: Antiviral Agents; Drug Resistance, Viral; Drug Synergism; Drug Therapy, Combination; Genes, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Mutation; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Ribavirin; Viral Nonstructural Proteins; Virus Replication

2013
[Meta-analysis of the efficacy and safety of telaprevir combined with peginterferon alfa plus ribavirin in patients with chronic hepatitis C].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2013, Volume: 21, Issue:7

    Topics: Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Ribavirin; Treatment Outcome

2013
The pharmacokinetic evaluation of boceprevir for treatment of hepatitis C virus.
    Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:12

    Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Interactions; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Proline; Ribavirin

2013
Role of viral and host factors in interferon based therapy of hepatitis C virus infection.
    Virology journal, 2013, Oct-01, Volume: 10

    Topics: Antiviral Agents; Genetic Markers; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Prognosis; Ribavirin; Treatment Outcome

2013
Management of anaemia and other treatment complications.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2013, Sep-30, Volume: 45 Suppl 5

    Topics: Anemia; Antiviral Agents; Contraindications; Drug Eruptions; Drug Therapy, Combination; Dysgeusia; Hemorrhoids; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Patient Selection; Platelet Count; Polyethylene Glycols; Proline; Pruritus Ani; Ribavirin; Serum Albumin

2013
Treatment of chronic hepatitis C virus infection after liver transplantation.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2013, Sep-30, Volume: 45 Suppl 5

    Topics: Antiviral Agents; Drug Interactions; End Stage Liver Disease; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Oligopeptides; Proline; Ribavirin; Secondary Prevention

2013
Treatment of chronic HCV genotype 1 infection with telaprevir: a Bayesian mixed treatment comparison of fixed-length and response-guided treatment regimens in treatment-naïve and -experienced patients.
    BMC gastroenterology, 2013, Oct-14, Volume: 13

    Topics: Antiviral Agents; Bayes Theorem; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2013
Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF).
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Volume: 46, Issue:1

    Topics: Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin

2014
Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.
    Gastroenterologia y hepatologia, 2013, Volume: 36, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cost of Illness; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Markov Chains; Middle Aged; Models, Economic; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Spain

2013
Novel therapeutic approaches for hepatitis C.
    Clinical pharmacology and therapeutics, 2014, Volume: 95, Issue:1

    Topics: Animals; Antiviral Agents; Clinical Trials as Topic; Drug Discovery; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin

2014
Simeprevir for the treatment of chronic hepatitis C.
    Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:18

    Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Simeprevir; Sulfonamides

2013
Efficacy and safety of peginterferon plus ribavirin for patients aged ≥ 65 years with chronic hepatitis C: a systematic review and meta-analysis.
    Clinics and research in hepatology and gastroenterology, 2014, Volume: 38, Issue:4

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2014
Predictors for dose reduction of antiviral therapy in older patients infected with hepatitis C virus: a meta-regression analysis.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2014, Volume: 33, Issue:4

    Topics: Age Factors; Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Regression Analysis; Ribavirin

2014
Can antidepressants prevent pegylated interferon-α/ribavirin-associated depression in patients with chronic hepatitis C: meta-analysis of randomized, double-blind, placebo-controlled trials?
    PloS one, 2013, Volume: 8, Issue:10

    Topics: Antidepressive Agents; Antiviral Agents; Citalopram; Depression; Double-Blind Method; Hepatitis C, Chronic; Humans; Interferon-alpha; Paroxetine; Polyethylene Glycols; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome

2013
Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection.
    Expert review of anti-infective therapy, 2013, Volume: 11, Issue:12

    Topics: Antiviral Agents; Biomarkers, Pharmacological; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2013
Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6.
    Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Ribavirin

2014
Lacrimal gland marginal zone lymphoma: regression after treatment of chronic hepatitis C virus infection: case report and review of the literature.
    Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:23

    Topics: Adult; Antiviral Agents; Eye Neoplasms; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lacrimal Apparatus; Lymphoma, B-Cell, Marginal Zone; Polyethylene Glycols; Recombinant Proteins; Remission Induction; Ribavirin; Tomography, X-Ray Computed

2013
Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantation.
    The Cochrane database of systematic reviews, 2013, Dec-02, Issue:12

    Topics: Antiviral Agents; Genotype; Graft Rejection; Graft Survival; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Secondary Prevention

2013
De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis C (case study and literature review).
    Digestive diseases and sciences, 2014, Volume: 59, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Glomerulonephritis, Membranoproliferative; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2014
Role of IL28B for chronic hepatitis C treatment toward personalized medicine.
    Journal of gastroenterology and hepatology, 2014, Volume: 29, Issue:2

    Topics: Antiviral Agents; Genome-Wide Association Study; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Genetic; Precision Medicine; Recombinant Proteins; Ribavirin; Treatment Outcome

2014
Can antiviral treatment for hepatitis C be safely and effectively delivered in primary care?: a narrative systematic review of the evidence base.
    The British journal of general practice : the journal of the Royal College of General Practitioners, 2013, Volume: 63, Issue:617

    Topics: Antiviral Agents; Delivery of Health Care; Epidemiologic Methods; General Practice; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Primary Health Care; Prisoners; Recombinant Proteins; Ribavirin

2013
HCV F1/F2 patients: treat now or continue to wait.
    Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34 Suppl 1

    Topics: Aminoisobutyric Acids; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Leucine; Oligopeptides; Proline; Quinolines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Treatment Outcome; Uridine Monophosphate

2014
[The role of hepcidin and polymorphisms in the regulatory region of the IL-28B gene in HCV infections].
    Postepy higieny i medycyny doswiadczalnej (Online), 2013, Dec-11, Volume: 67

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Hepcidins; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polymorphism, Genetic; Prognosis; Proline; Protease Inhibitors; Regulatory Sequences, Nucleic Acid; Ribavirin; Treatment Outcome

2013
Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection.
    Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Enzyme Inhibitors; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins

2014
Predictors of hepatitis C treatment response: what's new?
    Expert review of anti-infective therapy, 2014, Volume: 12, Issue:2

    Topics: Age Factors; Antiviral Agents; Biomarkers, Pharmacological; Clinical Trials as Topic; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Protease Inhibitors; Ribavirin; Viral Load

2014
[Triple therapy for chronic hepatitis C: practical aspects].
    Terapevticheskii arkhiv, 2013, Volume: 85, Issue:11

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Polyethylene Glycols; Ribavirin

2013
Success of antiviral therapy in chronic hepatitis C infection relates to functional status of myeloid dendritic cells.
    The Indian journal of medical research, 2013, Volume: 138, Issue:5

    Topics: Antiviral Agents; Dendritic Cells; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Myeloid Cells; Ribavirin; Treatment Outcome; Viral Load

2013
New antiviral agents for the treatment of hepatitis C: ABT-450.
    Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:5

    Topics: Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Viral Nonstructural Proteins

2014
Cure of hepatitis C virus infection without interferon alfa: scientific basis and current clinical evidence.
    Topics in antiviral medicine, 2014, Volume: 21, Issue:5

    Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Treatment Outcome

2014
Safety of direct-acting antivirals in the treatment of chronic hepatitis C.
    Expert opinion on drug safety, 2014, Volume: 13, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Hepatitis C, Chronic; Humans; Interferon-alpha; Protease Inhibitors; Ribavirin

2014
Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C.
    The Cochrane database of systematic reviews, 2014, Feb-28, Issue:2

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin

2014
Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C.
    The Cochrane database of systematic reviews, 2014, Feb-28, Issue:2

    Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin

2014
Hepatitis C virus therapy in the direct acting antiviral era.
    Current opinion in gastroenterology, 2014, Volume: 30, Issue:3

    Topics: Aminoisobutyric Acids; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Leucine; Oligopeptides; Proline; Quinolines; Ribavirin; Sofosbuvir; Thiazoles; Uridine Monophosphate

2014
IL-28B polymorphisms correlated with treatment response in HCV-4 mono-infected patients: a meta-analysis.
    PloS one, 2014, Volume: 9, Issue:3

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prognosis; Recombinant Proteins; Ribavirin; Treatment Outcome

2014
Review article: genetic factors that modify the outcome of viral hepatitis.
    Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:10

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis B, Chronic; Hepatitis C, Chronic; HLA-DP alpha-Chains; HLA-DP beta-Chains; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Treatment Outcome

2014
Chronic hepatitis C genotype 1 virus: who should wait for treatment?
    World journal of gastroenterology, 2014, Mar-21, Volume: 20, Issue:11

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Watchful Waiting

2014
Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection.
    World journal of gastroenterology, 2014, Mar-21, Volume: 20, Issue:11

    Topics: Antiviral Agents; Coinfection; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Ribavirin; Treatment Outcome

2014
[Future prospects for hepatitis C treatment: without interferon and ribavirin?].
    Gastroenterologia y hepatologia, 2014, Volume: 37, Issue:5

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin

2014
[Therapy of chronic hepatitis C].
    Praxis, 2014, Apr-09, Volume: 103, Issue:8

    Topics: Adult; Algorithms; Antiviral Agents; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Male; Polyethylene Glycols; Prognosis; Protease Inhibitors; Recombinant Proteins; Ribavirin

2014
Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations.
    Clinical pharmacokinetics, 2014, Volume: 53, Issue:5

    Topics: Antiviral Agents; Drug Interactions; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate

2014
Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors.
    PloS one, 2014, Volume: 9, Issue:4

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2014
The rapid evolution of treatment strategies for hepatitis C.
    The American journal of gastroenterology, 2014, Volume: 109, Issue:5

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate

2014
Preparation of HCV infected patients to the triple therapy with first generation protease inhibitors.
    Przeglad epidemiologiczny, 2013, Volume: 67, Issue:4

    Topics: Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Poland; Practice Guidelines as Topic; Proline; Protease Inhibitors; Ribavirin

2013
Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials.
    Journal of hepatology, 2014, Volume: 61, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral

2014
Sofosbuvir in the treatment of chronic hepatitis C: new dog, new tricks.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Aug-01, Volume: 59, Issue:3

    Topics: Administration, Oral; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Sofosbuvir; Viral Nonstructural Proteins

2014
Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection.
    Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:10

    Topics: Adenine; Antiviral Agents; Coinfection; DNA, Viral; Drug Therapy, Combination; Guanine; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Organophosphonates; Ribavirin; RNA, Viral; Tenofovir; Virus Replication

2014
Aminoadamantanes for chronic hepatitis C.
    The Cochrane database of systematic reviews, 2014, May-03, Issue:5

    Topics: Adult; Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome

2014
Factors associated with efficacy of pegylated interferon-α plus ribavirin for chronic hepatitis C after renal transplantation.
    Gene, 2014, Jul-10, Volume: 544, Issue:2

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Interferon alpha-2; Interferon-alpha; Kidney Transplantation; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult

2014
[Programs for continuing medical education: a session; 2. Current therapy for chronic hepatitis C].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2014, Mar-10, Volume: 103, Issue:3

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Education, Medical, Continuing; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Neoplasms; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Simeprevir; Sulfonamides

2014
Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus.
    Expert opinion on investigational drugs, 2014, Volume: 23, Issue:9

    Topics: Animals; Antiviral Agents; Disease Progression; Drug Design; Drug Therapy, Combination; Enzyme Inhibitors; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Uridine Monophosphate

2014
Hepatitis C.
    Disease-a-month : DM, 2014, Volume: 60, Issue:5

    Topics: Adult; Age Distribution; Anti-HIV Agents; Communicable Disease Control; Disease Management; Female; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Incidence; Liver Cirrhosis; Male; Middle Aged; Needs Assessment; Prisoners; Prisons; Ribavirin; Risk Assessment; Sex Distribution; Simeprevir; Sofosbuvir; Sulfonamides; Telemedicine; Treatment Outcome; United States; Uridine Monophosphate; Young Adult

2014
Simeprevir for the treatment of chronic hepatitis C genotype 1 infection.
    Expert review of anti-infective therapy, 2014, Volume: 12, Issue:8

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Design; Drug Evaluation, Preclinical; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Molecular Structure; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Simeprevir; Sulfonamides; Treatment Outcome

2014
Virus-related liver cirrhosis: molecular basis and therapeutic options.
    World journal of gastroenterology, 2014, Jun-07, Volume: 20, Issue:21

    Topics: Animals; Antiviral Agents; CD8-Positive T-Lymphocytes; Genotype; Hepacivirus; Hepatic Stellate Cells; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Inflammation; Interferon-alpha; Interferons; Interleukins; Killer Cells, Natural; Liver Cirrhosis; Mutation; Regeneration; Ribavirin; Stem Cells; Virus Replication

2014
Aminoadamantanes versus other antiviral drugs for chronic hepatitis C.
    The Cochrane database of systematic reviews, 2014, Jun-17, Issue:6

    Topics: Amantadine; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-gamma; Mycophenolic Acid; Randomized Controlled Trials as Topic; Ribavirin

2014
Efficacy and safety of pegylated interferon plus ribavirin therapy for chronic hepatitis C genotype 6: a meta-analysis.
    PloS one, 2014, Volume: 9, Issue:6

    Topics: Genotype; Hepatitis C, Chronic; Humans; Interferons; Polyethylene Glycols; Ribavirin; Safety

2014
[Treatment of viral hepatitis in children].
    Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti, 2013, Volume: 67, Issue:4

    Topics: Adenine; Adolescent; Antiviral Agents; Child; Child Welfare; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tenofovir

2013
[Treatment guidelines for patients with genotype 1 chronic hepatitis C infection].
    Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti, 2013, Volume: 67, Issue:4

    Topics: Adult; Antiviral Agents; Croatia; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; National Health Programs; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin

2013
[Treatment of non-1 genotype chronic hepatitis C patients].
    Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti, 2013, Volume: 67, Issue:4

    Topics: Adult; Age Factors; Antiviral Agents; Croatia; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; National Health Programs; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin

2013
Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients: meta-analysis of clinical studies.
    Journal of viral hepatitis, 2014, Volume: 21, Issue:10

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Renal Dialysis; Ribavirin; Treatment Outcome; Viral Load

2014
Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: a systematic review and meta-analysis.
    Journal of hepatology, 2014, Volume: 61, Issue:6

    Topics: Dietary Supplements; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Outcome Assessment, Health Care; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Vitamin D

2014
Treating hepatitis C in the elderly: the future is near?
    Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:14

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Medication Adherence; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin

2014
Meta-analysis: influence of host and viral factors in patients with chronic hepatitis C genotype 4 treated with pegylated interferon and ribavirin.
    European journal of gastroenterology & hepatology, 2014, Volume: 26, Issue:11

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Interferons; Liver Cirrhosis; Polymorphism, Genetic; Research Design; Ribavirin; Viral Load

2014
Association of rs12979860 and rs8099917 polymorphisms near IL28B with SVR in hepatic allograft recipients with HCV recurrence undergoing PEG-IFN/RBV therapy: a meta-analysis.
    Human immunology, 2014, Volume: 75, Issue:12

    Topics: Antiviral Agents; Graft Survival; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver; Liver Transplantation; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Recurrence; Ribavirin; Transplantation, Homologous

2014
Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review.
    Canadian journal of gastroenterology & hepatology, 2014, Volume: 28, Issue:8

    Topics: Administration, Oral; Antiviral Agents; Drug Approval; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin

2014
Network meta-analysis of direct-acting antivirals in combination with peginterferon-ribavirin for previously untreated patients with hepatitis C genotype 1 infection.
    QJM : monthly journal of the Association of Physicians, 2015, Volume: 108, Issue:4

    Topics: Antiviral Agents; Bayes Theorem; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin

2015
Treatment of hepatitis B and C in children.
    Minerva pediatrica, 2014, Volume: 66, Issue:5

    Topics: Adolescent; Antiviral Agents; Child; Drug Therapy, Combination; Egypt; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Infant; Interferon-alpha; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Treatment Outcome

2014
Hepatitis C genotype 1.
    Current opinion in infectious diseases, 2014, Volume: 27, Issue:6

    Topics: Antiviral Agents; Cost-Benefit Analysis; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate; Viral Load

2014
Update on the treatment of hepatitis C genotypes 2-6.
    Current opinion in infectious diseases, 2014, Volume: 27, Issue:6

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Global Health; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate; Viral Load

2014
Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C.
    Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:17

    Topics: Anilides; Animals; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Proline; Ribavirin; Valine; Viral Nonstructural Proteins

2014
The clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people: a systematic review and economic evaluation.
    Health technology assessment (Winchester, England), 2014, Volume: 18, Issue:65

    Topics: Adolescent; Antiviral Agents; Biomarkers; Child; Child Development; Child, Preschool; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Markov Chains; Models, Econometric; Polyethylene Glycols; Quality of Life; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load

2014
[All-oral, interferon-free therapies for patients with chronic genotype 1 hepatitis C virus infection].
    Deutsche medizinische Wochenschrift (1946), 2014, Volume: 139, Issue:47

    Topics: 2-Naphthylamine; Administration, Oral; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Drug Combinations; Fluorenes; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine

2014
Overall efficacy and safety results of sofosbuvir-based therapies in phase II and III studies.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Dec-15, Volume: 46 Suppl 5

    Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2014
Ribavirin induced hemolysis: a novel mechanism of action against chronic hepatitis C virus infection.
    World journal of gastroenterology, 2014, Nov-21, Volume: 20, Issue:43

    Topics: Anemia, Hemolytic; Animals; Antiviral Agents; Drug Synergism; Drug Therapy, Combination; Heme Oxygenase-1; Hemolysis; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Inflammation Mediators; Ribavirin; Treatment Outcome

2014
Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection.
    The Annals of pharmacotherapy, 2015, Volume: 49, Issue:3

    Topics: Adult; Animals; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Nausea; Ribavirin; Sofosbuvir; Uridine Monophosphate

2015
Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Viral Nonstructural Proteins

2015
Optimal therapy of genotype-2 chronic hepatitis C: what's new?
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35 Suppl 1

    Topics: Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Prevalence; Ribavirin; Sofosbuvir; Uridine Monophosphate

2015
Optimal therapy in genotype 4 chronic hepatitis C: finally cured?
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35 Suppl 1

    Topics: Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine; Viral Nonstructural Proteins

2015
[Bilateral non-arteritic ischemic optic neuropathy during treatment of viral hepatitis C with pegylated interferon and Ribavirin].
    Journal francais d'ophtalmologie, 2015, Volume: 38, Issue:1

    Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Fluorescein Angiography; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Optic Atrophy; Optic Neuropathy, Ischemic; Papilledema; Polyethylene Glycols; Radiography; Ribavirin

2015
ABT-450: a novel agent for the treatment of CHC genotype 1: focus on treatment-experienced patients.
    Expert review of anti-infective therapy, 2015, Volume: 13, Issue:3

    Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Neoplasms; Macrocyclic Compounds; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Uracil; Valine

2015
Meta-analysis: superior treatment response in Asian patients with hepatitis C virus genotype 6 versus genotype 1 with pegylated interferon and ribavirin.
    Intervirology, 2015, Volume: 58, Issue:1

    Topics: Adult; Antiviral Agents; Asian People; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Treatment Outcome

2015
Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection.
    Clinical therapeutics, 2015, Feb-01, Volume: 37, Issue:2

    Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Genotype; Headache; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Nausea; Polyethylene Glycols; Protease Inhibitors; Ribavirin; Simeprevir; Sofosbuvir

2015
Systematic review: patient-reported outcomes in chronic hepatitis C--the impact of liver disease and new treatment regimens.
    Alimentary pharmacology & therapeutics, 2015, Volume: 41, Issue:6

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Patient Outcome Assessment; Quality of Life; Ribavirin; Treatment Outcome

2015
Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.
    The Annals of pharmacotherapy, 2015, Volume: 49, Issue:5

    Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Tablets; Uracil; Valine

2015
[Outline of HCV treatment].
    Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:2

    Topics: Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Protease Inhibitors; Ribavirin

2015
IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: A systematic review and meta-analysis.
    Clinics and research in hepatology and gastroenterology, 2015, Volume: 39, Issue:5

    Topics: Antiviral Agents; Biomarkers; Disease Progression; Drug Therapy, Combination; Gene Expression Regulation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Treatment Outcome; Viral Load

2015
Clinical pharmacology profile of boceprevir, a hepatitis C virus NS3 protease inhibitor: focus on drug-drug interactions.
    Clinical pharmacokinetics, 2015, Volume: 54, Issue:6

    Topics: Animals; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome; Viral Load; Viral Nonstructural Proteins

2015
Management of post transplant hepatitis C in the direct antiviral agents era.
    Hepatology international, 2015, Volume: 9, Issue:2

    Topics: Antiviral Agents; Carbamates; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Liver Transplantation; Oligopeptides; Postoperative Complications; Proline; Protease Inhibitors; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Valine; Viral Nonstructural Proteins

2015
Interferon-free antiviral treatment of chronic hepatitis C in the transplant setting.
    Transplant international : official journal of the European Society for Organ Transplantation, 2015, Volume: 28, Issue:9

    Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cholestasis, Intrahepatic; Clinical Trials as Topic; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Fibrosis; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferons; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Valine

2015
[Triple therapy in cirrhotic patients and those with advanced fibrosis: relevant aspects in clinical practice].
    Gastroenterologia y hepatologia, 2014, Volume: 37 Suppl 1

    Topics: Anemia; Antiviral Agents; Clinical Trials as Topic; Cohort Studies; Comorbidity; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hypertension, Portal; Interferon-alpha; Liver Cirrhosis; Medication Adherence; Metabolic Syndrome; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Risk Factors

2014
Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis.
    The pharmacogenomics journal, 2016, Volume: 16, Issue:1

    Topics: Antiviral Agents; Asian People; Drug Therapy, Combination; Genetic Association Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Odds Ratio; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Viral Load; White People

2016
Systematic review with meta-analysis: comparison between therapeutic regimens for paediatric chronic hepatitis C.
    Alimentary pharmacology & therapeutics, 2015, Volume: 42, Issue:1

    Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Young Adult

2015
A network meta-analysis to compare simeprevir with boceprevir and telaprevir in combination with peginterferon-α and ribavirin in patients infected with genotype 1 Hepatitis C virus.
    Journal of medical economics, 2015, Volume: 18, Issue:10

    Topics: Antiviral Agents; Clinical Trials as Topic; Databases, Bibliographic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Oligopeptides; Proline; Protease Inhibitors; Ribavirin; Simeprevir; Viral Load

2015
Interferon-free therapy for hepatitis C: The hurdles amid a golden era.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2015, Volume: 47, Issue:9

    Topics: 2-Naphthylamine; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil

2015
Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:8

    Topics: Antiviral Agents; Disease Progression; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Prognosis; Ribavirin; Risk Assessment; Survival Analysis; Treatment Failure

2015
Therapy for hepatitis C genotype 3: moving forward.
    Journal of viral hepatitis, 2015, Volume: 22, Issue:9

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Health Care Costs; Health Services Accessibility; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine; Viral Load

2015
HCV Treatments and Their Integration Into Rheumatology.
    Current rheumatology reports, 2015, Volume: 17, Issue:8

    Topics: Antirheumatic Agents; Antiviral Agents; Arthritis; Cryoglobulinemia; Hepatitis C, Chronic; Humans; Interferon-alpha; Protease Inhibitors; Rheumatic Diseases; Ribavirin; Sialadenitis; Vasculitis

2015
Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection.
    Journal of comparative effectiveness research, 2015, Volume: 4, Issue:6

    Topics: Antiviral Agents; Carbamates; Comparative Effectiveness Research; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Isoquinolines; Male; Pyrrolidines; Ribavirin; Sulfonamides; Valine

2015
Management of direct-acting antiviral agent failures.
    Journal of hepatology, 2015, Volume: 63, Issue:6

    Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Protease Inhibitors; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Failure; Uracil; Uridine Monophosphate; Valine

2015
Direct-Acting Antivirals for Hepatitis C Virus (HCV): The Progress Continues.
    Current drug targets, 2017, Volume: 18, Issue:7

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Nucleic Acid Synthesis Inhibitors; Protease Inhibitors; Ribavirin; Treatment Outcome; Viral Nonstructural Proteins

2017
Extrahepatic morbidity and mortality of chronic hepatitis C.
    Gastroenterology, 2015, Volume: 149, Issue:6

    Topics: Antiviral Agents; Cryoglobulinemia; Glomerulonephritis; Glucose Metabolism Disorders; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Lymphoma; Morbidity; Ribavirin; Vasculitis

2015
Treatment of HCV in Patients who Failed First-Generation PI Therapy: a Review of Current Literature.
    Current gastroenterology reports, 2015, Volume: 17, Issue:10

    Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Failure

2015
Ideal oral combinations to eradicate HCV: The role of ribavirin.
    Journal of hepatology, 2016, Volume: 64, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Valine

2016
Efficacy and safety of simeprevir in combination with peginterferon and ribavirin for patients with hepatitis C genotype 1 infection: a meta-analysis of randomized trials.
    Revista espanola de enfermedades digestivas, 2015, Volume: 107, Issue:10

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Randomized Controlled Trials as Topic; Ribavirin; Simeprevir

2015
Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis.
    Journal of translational medicine, 2015, Oct-06, Volume: 13

    Topics: Aged; Anemia, Hemolytic; Antiviral Agents; Female; Genetic Variation; Genotype; Haplotypes; Hemoglobins; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Metabolism, Inborn Errors; Middle Aged; Odds Ratio; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Regression Analysis; Ribavirin; Treatment Outcome

2015
The hepatitis C revolution part 1: antiviral treatment options.
    Current opinion in infectious diseases, 2015, Volume: 28, Issue:6

    Topics: Antiviral Agents; Comorbidity; Drug Therapy, Combination; Evidence-Based Medicine; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome

2015
[Clinical Implication of Insulin Resistance in Chronic Hepatitis C Patients].
    Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases, 2015, Volume: 89, Issue:1

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferons; Ribavirin; Treatment Outcome

2015
[Diabetic retinopathy induced by PEG-IFN-alpha2a plus ribavirin in chronic hepatitis C: a literature review].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2015, Volume: 23, Issue:8

    Topics: Antiviral Agents; Diabetic Retinopathy; Drug Combinations; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2015
Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection.
    Expert review of gastroenterology & hepatology, 2016, Volume: 10, Issue:1

    Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Failure; Liver Transplantation; Recurrence; Renal Insufficiency; Ribavirin; Sofosbuvir

2016
Dasabuvir (ABT333) for the treatment of chronic HCV genotype I: a new face of cure, an expert review.
    Expert review of anti-infective therapy, 2016, Volume: 14, Issue:2

    Topics: 2-Naphthylamine; Antiviral Agents; Drug Combinations; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Macrocyclic Compounds; Ribavirin; Ritonavir; Sulfonamides; Uracil

2016
Defining the possibilities: is short duration treatment of chronic hepatitis C genotype 1 with sofosbuvir-containing regimens likely to be as effective as current regimens?
    Expert review of anti-infective therapy, 2016, Volume: 14, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Disease Management; Drug Administration Schedule; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load

2016
[Possibilities of IFN-free therapy of hepatitis C].
    Vnitrni lekarstvi, 2015, Volume: 61 Suppl 4

    Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine

2015
Why do I treat my patients with mild hepatitis C?
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36 Suppl 1

    Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Ribavirin; Treatment Outcome

2016
Why I do not treat patients for mild disease.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36 Suppl 1

    Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Ribavirin

2016
Is the benefit of treating patients with cirrhosis proven?
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; End Stage Liver Disease; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Ribavirin

2016
News and challenges in the treatment of hepatitis C in liver transplantation.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; End Stage Liver Disease; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Recurrence; Ribavirin

2016
Hepatitis C virus: how to provide the best treatment with what I have.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36 Suppl 1

    Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Protease Inhibitors; Quinoxalines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Young Adult

2016
Follow-up of patients with chronic hepatitis C and a sustained viral response.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36 Suppl 1

    Topics: Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Comorbidity; Disease Progression; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Ribavirin; Risk Factors; RNA, Viral; Treatment Outcome

2016
Simeprevir with pegylated interferon alfa 2a plus ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a meta-analysis and historical comparison.
    BMC infectious diseases, 2016, Jan-11, Volume: 16

    Topics: Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir; Treatment Outcome

2016
Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, Mar-15, Volume: 62, Issue:6

    Topics: Adolescent; Adult; Antiviral Agents; Coinfection; Drug Users; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Male; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Sustained Virologic Response; Viral Load; Young Adult

2016
Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison.
    Clinical therapeutics, 2016, Volume: 38, Issue:2

    Topics: Antiviral Agents; Carbamates; Clinical Trials, Phase III as Topic; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Valine

2016
Anti-rods/rings autoantibody generation in hepatitis C patients during interferon-α/ribavirin therapy.
    World journal of gastroenterology, 2016, Feb-14, Volume: 22, Issue:6

    Topics: Antibodies, Antinuclear; Antiviral Agents; Autoimmunity; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Immunity, Humoral; IMP Dehydrogenase; Interferon-alpha; Protein Conformation; Ribavirin; Self Tolerance; Time Factors; Treatment Outcome

2016
Influence of Host and Viral Factors on Patients with Chronic Hepatitis C Virus Genotype 6 Treated with Pegylated Interferon and Ribavirin: A Systematic Review and Meta-Analysis.
    Intervirology, 2015, Volume: 58, Issue:6

    Topics: Antiviral Agents; Coinfection; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Polyethylene Glycols; Polymorphism, Genetic; Ribavirin; Treatment Outcome

2015
Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights.
    Nature reviews. Gastroenterology & hepatology, 2016, Volume: 13, Issue:6

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Nucleotides; Protease Inhibitors; Ribavirin; Viral Nonstructural Proteins

2016
Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV Infection.
    European journal of drug metabolism and pharmacokinetics, 2017, Volume: 42, Issue:2

    Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Area Under Curve; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Function Tests; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Models, Biological; Proline; Renal Insufficiency; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine; Young Adult

2017
Association between IFNL4 rs368234815 polymorphism and sustained virological response in chronic hepatitis C patients undergoing PEGylated interferon/ribavirin therapy: A meta-analysis.
    Human immunology, 2016, Volume: 77, Issue:7

    Topics: Antigens, Viral; Genetic Predisposition to Disease; Hepatitis C, Chronic; Humans; Immunity; Interferon-alpha; Interleukins; Polyethylene Glycols; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome

2016
Meta-Analysis of Combination Therapy of Chinese Herbs Plus Interferon and Ribavirin in Patients with Chronic Hepatitis C.
    Medical science monitor : international medical journal of experimental and clinical research, 2016, May-30, Volume: 22

    Topics: Antiviral Agents; Chronic Disease; Complementary Therapies; Drug Therapy, Combination; Drugs, Chinese Herbal; Hepatitis C, Chronic; Humans; Interferons; Medicine, Chinese Traditional; Ribavirin; Treatment Outcome

2016
Pharmacogenetics of ribavirin-induced anemia in HCV patients.
    Pharmacogenomics, 2016, Volume: 17, Issue:8

    Topics: Anemia, Hemolytic; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Pharmacogenetics; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin

2016
Optimisation of triple therapy for patients with chronic hepatitis C: a systematic review.
    European journal of clinical investigation, 2016, Volume: 46, Issue:8

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Treatment Outcome

2016
Chronic Hepatitis C Infection in Children.
    Advances in pediatrics, 2016, Volume: 63, Issue:1

    Topics: Antiviral Agents; Child; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2016
Sofosbuvir-based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: case series and review of the literature.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:11

    Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Lung Transplantation; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome

2016
Influence of IL10 Gene polymorphisms on the sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy.
    Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 2016, Volume: 45

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukin-10; Polyethylene Glycols; Polymorphism, Single Nucleotide; Ribavirin

2016
Daclatasvir: A Review in Chronic Hepatitis C.
    Drugs, 2016, Volume: 76, Issue:14

    Topics: Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Pyrrolidines; Ribavirin; Sofosbuvir; Valine

2016
Hepatitis C virus: Promising discoveries and new treatments.
    World journal of gastroenterology, 2016, Jul-28, Volume: 22, Issue:28

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Protease Inhibitors; Ribavirin; RNA, Viral; Sustained Virologic Response; Viral Load

2016
Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis.
    Digestive diseases and sciences, 2016, Volume: 61, Issue:11

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2016
Reinventing HCV Treatment: Past and Future Perspectives.
    Journal of clinical pharmacology, 2017, Volume: 57, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Phosphoproteins; Protease Inhibitors; Randomized Controlled Trials as Topic; Ribavirin; Serine Proteases; Sustained Virologic Response; Viral Nonstructural Proteins

2017
How much of a problem is resistance in treating hepatitis C?
    Current opinion in infectious diseases, 2016, Volume: 29, Issue:6

    Topics: Antiviral Agents; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Treatment Failure; Viral Nonstructural Proteins

2016
Use of direct-acting agents for hepatitis C virus-positive kidney transplant candidates and kidney transplant recipients.
    Transplant international : official journal of the European Society for Organ Transplantation, 2016, Volume: 29, Issue:12

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Interferon-alpha; Kidney; Kidney Failure, Chronic; Kidney Transplantation; Polyethylene Glycols; Quinoxalines; Ribavirin; Sulfonamides; Transplant Recipients

2016
Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C.
    Drugs, 2016, Volume: 76, Issue:16

    Topics: Adult; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome

2016
The impact of hepatitis C virus outside the liver: Evidence from Asia.
    Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37, Issue:2

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Costs and Cost Analysis; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Japan; Liver Cirrhosis; Liver Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Ribavirin; Sustained Virologic Response; Treatment Failure

2017
Network meta-analysis of first- and second-generation protease inhibitors for chronic hepatitis C genotype 1: efficacy based on RVR and SVR 24.
    European journal of clinical pharmacology, 2017, Volume: 73, Issue:1

    Topics: Antiviral Agents; Genotype; Hepatitis C, Chronic; Humans; Interferons; Network Meta-Analysis; Polyethylene Glycols; Protease Inhibitors; Ribavirin; Sustained Virologic Response

2017
Advances in drug development for hepatitis C.
    Uirusu, 2015, Volume: 65, Issue:2

    Topics: Antiviral Agents; Drug Discovery; Drug Evaluation, Preclinical; Drug Therapy, Combination; Enzyme Inhibitors; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Ribavirin; Viral Nonstructural Proteins

2015
Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents.
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2016, Oct-24, Volume: 49, Issue:11

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Liver Cirrhosis; Pyrrolidines; Ribavirin; Sofosbuvir; Valine

2016
Ledipasvir/sofosbuvir with or without ribavirin for the treatment of chronic hepatitis C genotype 1: A pairwise meta-analysis.
    Journal of gastroenterology and hepatology, 2017, Volume: 32, Issue:4

    Topics: Antiviral Agents; Benzimidazoles; Databases, Bibliographic; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Randomized Controlled Trials as Topic; Ribavirin; Sofosbuvir; Treatment Outcome

2017
A systematic review of treatment response rates in Pakistani hepatitis C virus patients; current prospects and future challenges.
    Medicine, 2016, Volume: 95, Issue:50

    Topics: Adult; Antiviral Agents; Disease Management; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Pakistan; Prevalence; Ribavirin; Treatment Outcome

2016
[Current status of treatment of chronic hepatitis C and related challenges in the "Pre-DAA Era" in China].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2016, Nov-20, Volume: 24, Issue:11

    Topics: Antiviral Agents; China; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin

2016
Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2017, Volume: 55

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome

2017
Hepatitis C: efficacy and safety in real life.
    Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37 Suppl 1

    Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Pyrrolidines; Ribavirin; Risk Factors; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine

2017
Special populations: treating hepatitis C in patients with decompensated cirrhosis and/or advanced renal impairment.
    Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Randomized Controlled Trials as Topic; Renal Insufficiency; Ribavirin; Sofosbuvir; Sustained Virologic Response

2017
Management of direct antiviral agent failures.
    Clinical and molecular hepatology, 2016, Volume: 22, Issue:4

    Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Recurrence; Ribavirin; Sofosbuvir

2016
Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection.
    Journal of hepatology, 2017, Volume: 66, Issue:6

    Topics: Antiviral Agents; Autoimmune Diseases; Cryoglobulinemia; Evidence-Based Medicine; Hepatitis C, Chronic; Humans; Interferons; Lymphoma, B-Cell; Ribavirin; Rituximab; Vasculitis

2017
Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis.
    The Cochrane database of systematic reviews, 2017, 03-13, Volume: 3

    Topics: Acute Disease; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Network Meta-Analysis; Polyethylene Glycols; Quality of Life; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Viral Hepatitis Vaccines

2017
Management of chronic hepatitis C virus infection in HIV-infected patients.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, Jul-01, Volume: 47, Issue:1

    Topics: Antiviral Agents; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin

2008
[Therapy of chronic Hepatitis C in 2008].
    MMW Fortschritte der Medizin, 2008, Mar-27, Volume: 150, Issue:13

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2008
[The role of ribavirin in the treatment of chronic hepatitis C].
    Przeglad epidemiologiczny, 2008, Volume: 62, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Treatment Outcome; Virus Replication

2008
Peginterferon-alpha-2a (40 kD) plus ribavirin: a review of its use in the management of chronic hepatitis C mono-infection.
    Drugs, 2008, Volume: 68, Issue:9

    Topics: Administration, Oral; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2008
Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis.
    Alimentary pharmacology & therapeutics, 2008, Aug-15, Volume: 28, Issue:4

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2008
Peginterferon vs. interferon in the treatment of different HCV genotype infections in HIV patients.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2008, Volume: 27, Issue:12

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Middle Aged; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome

2008
Ribavirin in the treatment of chronic hepatitis C.
    Journal of gastroenterology and hepatology, 2008, Volume: 23, Issue:6

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Medicine; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Mutation; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome

2008
Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin.
    Journal of hepatology, 2008, Volume: 49, Issue:2

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Secondary Prevention

2008
[Thrombocytopenia in HCV infection. Natural interferon as an alternative therapy].
    Przeglad epidemiologiczny, 2007, Volume: 61, Issue:4

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Thrombocytopenia

2007
Pegylated IFN-alpha2b plus ribavirin for treatment-naive patients coinfected with HCV and HIV.
    Expert review of anti-infective therapy, 2008, Volume: 6, Issue:3

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome

2008
Extended-therapy duration for chronic hepatitis C, genotype 1: the long and the short of it.
    World journal of gastroenterology, 2008, Jun-21, Volume: 14, Issue:23

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2008
[Goals of treatment, indication, and treatment for chronic hepatitis C].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2008, Volume: 51, Issue:6

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2008
Optimizing the current therapy for chronic hepatitis C virus: peginterferon and ribavirin dosing and the utility of growth factors.
    Clinics in liver disease, 2008, Volume: 12, Issue:3

    Topics: Antiviral Agents; Drug Carriers; Hepatitis C, Chronic; Humans; Intercellular Signaling Peptides and Proteins; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2008
Optimal dose of peginterferon and ribavirin for treatment of chronic hepatitis C.
    Journal of viral hepatitis, 2008, Volume: 15, Issue:9

    Topics: Antiviral Agents; Clinical Trials as Topic; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; United States

2008
Thyroid dysfunction in hepatitis C individuals treated with interferon-alpha and ribavirin--a review.
    The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2008, Volume: 12, Issue:2

    Topics: Antiviral Agents; Autoantibodies; Hepatitis C, Chronic; Humans; Interferon-alpha; Iodide Peroxidase; Ribavirin; Thyroid Gland; Thyroiditis

2008
[Hepatitis C: which strategy in case of treatment failure ?].
    Gastroenterologie clinique et biologique, 2008, Volume: 32, Issue:3 Pt 2

    Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure

2008
[Adherence to pegylated combination therapy in patients with chronic hepatitis C. Importance of the hepatologist, general practitioner, and nurse].
    Gastroenterologie clinique et biologique, 2008, Volume: 32, Issue:3 Pt 2

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Patient Care Team; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2008
Hepatitis C: current and future therapies.
    The Mount Sinai journal of medicine, New York, 2008, Volume: 75, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Protease Inhibitors; Ribavirin; United States; United States Food and Drug Administration

2008
Treatment options for patients with hepatitis C: role of pharmacists in optimizing treatment response and managing adverse events.
    Pharmacotherapy, 2008, Volume: 28, Issue:9

    Topics: Antiviral Agents; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon Type I; Pharmacists; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin

2008
Expert opinion on the treatment of patients with chronic hepatitis C.
    Journal of viral hepatitis, 2009, Volume: 16, Issue:2

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2009
Treatment of the hepatitis B virus and hepatitis C virus co-infection: still a challenge for the hepatologist.
    Journal of hepatology, 2008, Volume: 49, Issue:5

    Topics: Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2008
[Current opportunities for treatment of chronic hepatitis C in patients with HIV co-infection].
    Przeglad epidemiologiczny, 2008, Volume: 62, Issue:2

    Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Comorbidity; Evidence-Based Medicine; Hepatitis C, Chronic; Humans; Interferons; Poland; Primary Health Care; Randomized Controlled Trials as Topic; Ribavirin; Risk Assessment

2008
[Treatment of chronic hepatitis C virus infection in hemodialysis patients].
    Mikrobiyoloji bulteni, 2008, Volume: 42, Issue:3

    Topics: Antiviral Agents; Contraindications; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Polyethylene Glycols; Prevalence; Recombinant Proteins; Renal Dialysis; Ribavirin; Turkey

2008
Interferon-based therapy for chronic hepatitis C: current and future perspectives.
    Nature clinical practice. Gastroenterology & hepatology, 2008, Volume: 5, Issue:11

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2008
Dynamic evolution of therapy for chronic hepatitis C: how will novel agents be incorporated into the standard of care?
    Antiviral therapy, 2008, Volume: 13, Issue:6

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Virus Replication

2008
Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C.
    The Journal of antimicrobial chemotherapy, 2008, Volume: 62, Issue:6

    Topics: Drug Monitoring; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Plasma; Ribavirin; Treatment Outcome

2008
Safety of peginterferon in the treatment of chronic hepatitis C.
    Expert opinion on drug safety, 2008, Volume: 7, Issue:6

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Medication Adherence; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2008
Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients.
    World journal of gastroenterology, 2008, Oct-28, Volume: 14, Issue:40

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Catheter Ablation; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Liver Neoplasms; Neoplasm Recurrence, Local; Ribavirin; Secondary Prevention; Treatment Outcome

2008
Management strategies for hepatitis C virus infection in children.
    Paediatric drugs, 2008, Volume: 10, Issue:6

    Topics: Adult; Anemia; Antiviral Agents; Child; Comorbidity; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin

2008
What is on the horizon for treatment of chronic hepatitis C?
    Minerva medica, 2008, Volume: 99, Issue:6

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Hepatitis Vaccines; Viral Load

2008
Is pegylated interferon superior to interferon, with ribavarin, in chronic hepatitis C genotypes 2/3?
    World journal of gastroenterology, 2008, Nov-21, Volume: 14, Issue:43

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2008
Taribavirin for the treatment of chronic hepatitis C.
    Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:18

    Topics: Anemia; Animals; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Hepatitis C, Chronic; Humans; Prodrugs; Ribavirin; Treatment Outcome

2008
Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms.
    Liver international : official journal of the International Association for the Study of the Liver, 2008, Volume: 28, Issue:10

    Topics: DNA-Directed RNA Polymerases; Gene Expression Regulation; Hepatitis C, Chronic; Humans; IMP Dehydrogenase; Interferon alpha-2; Interferon-alpha; Models, Biological; Mutation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins

2008
[Treatment of hepatitis C virus infection: current status and perspectives].
    Gastroenterologia y hepatologia, 2008, Volume: 31, Issue:9

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure; Viral Load; Viremia

2008
Ribavirin: current role in the optimal clinical management of chronic hepatitis C.
    Journal of hepatology, 2009, Volume: 50, Issue:2

    Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2009
Pegylated and non-pegylated interferon-alfa and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and meta-analysis.
    International journal of technology assessment in health care, 2009, Volume: 25, Issue:1

    Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome

2009
Peginterferon and ribavirin in HCV: improvement of sustained viral response.
    Best practice & research. Clinical gastroenterology, 2008, Volume: 22, Issue:6

    Topics: Anemia; Antiviral Agents; Clinical Trials as Topic; Depression; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Medication Adherence; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Thrombocytopenia; Treatment Outcome

2008
Future treatment options for HCV: double, triple, what is the optimal combination?
    Best practice & research. Clinical gastroenterology, 2008, Volume: 22, Issue:6

    Topics: Antiviral Agents; Cytidine; DNA-Directed RNA Polymerases; Drug Delivery Systems; Drug Resistance, Viral; Drug Therapy, Combination; Forecasting; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Nucleosides; Oligopeptides; Polyethylene Glycols; Prodrugs; Proline; Protease Inhibitors; Pyrimidine Nucleosides; Recombinant Proteins; Ribavirin

2008
A review of current anti-HCV treatment regimens and possible future strategies.
    Expert opinion on pharmacotherapy, 2009, Volume: 10, Issue:3

    Topics: Antiviral Agents; Clinical Trials as Topic; DNA-Directed RNA Polymerases; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Ribavirin

2009
[Role of tenofovir in HIV and hepatitis C virus coinfection].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 8

    Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Hypersensitivity; Drug Interactions; Drug Therapy, Combination; Fatty Liver; Glucose Metabolism Disorders; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver; Liver Cirrhosis; Organophosphonates; Reverse Transcriptase Inhibitors; Ribavirin; Tenofovir

2008
What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C?
    Liver international : official journal of the International Association for the Study of the Liver, 2009, Volume: 29 Suppl 1

    Topics: Alcoholism; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Hepatitis B; Hepatitis C, Chronic; HIV Infections; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Metabolic Syndrome; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2009
Optimizing the treatment of chronic hepatitis due to hepatitis C virus genotypes 2 and 3: a review.
    Liver international : official journal of the International Association for the Study of the Liver, 2009, Volume: 29 Suppl 1

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2009
Retreatment of chronic hepatitis C: who and how?
    Liver international : official journal of the International Association for the Study of the Liver, 2009, Volume: 29 Suppl 1

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Retreatment; Ribavirin; Time Factors

2009
Protease and polymerase inhibitors for the treatment of hepatitis C.
    Liver international : official journal of the International Association for the Study of the Liver, 2009, Volume: 29 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins

2009
What future for ribavirin?
    Liver international : official journal of the International Association for the Study of the Liver, 2009, Volume: 29 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Protease Inhibitors; Ribavirin; Viral Nonstructural Proteins

2009
[Serious loss of vision in bilateral anterior ischemic optic neuropathy caused by interferon].
    Nippon Ganka Gakkai zasshi, 2009, Volume: 113, Issue:1

    Topics: Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Optic Neuropathy, Ischemic; Polyethylene Glycols; Prednisolone; Recombinant Proteins; Ribavirin; Visual Acuity; Visual Fields

2009
Another ten stories in antiviral drug discovery (part C): "Old" and "new" antivirals, strategies, and perspectives.
    Medicinal research reviews, 2009, Volume: 29, Issue:4

    Topics: Antiviral Agents; Drug Discovery; Hepatitis C, Chronic; HIV Protease Inhibitors; IMP Dehydrogenase; Ribavirin

2009
Treatment of chronic hepatitis C in Asia: when East meets West.
    Journal of gastroenterology and hepatology, 2009, Volume: 24, Issue:3

    Topics: Antiviral Agents; Asia; Asian People; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; White People

2009
Spotlight on peginterferon-alpha-2a (40 kD) plus ribavirin in the management of chronic hepatitis C mono-infection.
    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2009, Volume: 23, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome

2009
[Cutting edge anti-viral therapy for hepatitis C].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2009, Volume: 106, Issue:4

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin

2009
[Chronic hepatitis C in children: natural history and prognosis].
    Recenti progressi in medicina, 2009, Volume: 100, Issue:2

    Topics: Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Evidence-Based Medicine; Hepatitis C, Chronic; Humans; Incidence; Interferons; Italy; Prevalence; Prognosis; Ribavirin; Risk Factors; Treatment Outcome; Viremia

2009
Treatment options for patients with chronic hepatitis C not responding to initial antiviral therapy.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2009, Volume: 7, Issue:9

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure; Viral Load

2009
Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature.
    Digestive diseases and sciences, 2010, Volume: 55, Issue:3

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lung Diseases, Interstitial; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2010
The hepatitis C virus enigma.
    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2009, Volume: 117, Issue:5-6

    Topics: Antigens, CD; Antiviral Agents; Biological Evolution; Disease Progression; Drug Synergism; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Receptors, Virus; Recombinant Proteins; Ribavirin; T-Lymphocyte Subsets; Tetraspanin 28; Viral Hepatitis Vaccines; Viremia; Virus Replication

2009
Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research.
    Alimentary pharmacology & therapeutics, 2009, Volume: 30, Issue:1

    Topics: Anti-HIV Agents; Antiviral Agents; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Medication Adherence; Ribavirin

2009
Management of hepatitis C virus genotype 2 or 3 infection: treatment optimization on the basis of virological response.
    Antiviral therapy, 2009, Volume: 14, Issue:2

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Viral Load

2009
Efficacy of chronic hepatitis C therapy in community-based trials.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2009, Volume: 7, Issue:10

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome

2009
Long-term outcomes after treatment with interferon and ribavirin in HCV patients.
    Journal of clinical gastroenterology, 2009, Volume: 43, Issue:7

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2009
Serine protease inhibitors as anti-hepatitis C virus agents.
    Expert review of anti-infective therapy, 2009, Volume: 7, Issue:5

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Discovery; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Recombinant Proteins; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors

2009
Management of patients co-infected with HBV and HCV.
    Expert review of anti-infective therapy, 2009, Volume: 7, Issue:5

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Carrier State; DNA, Viral; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Cirrhosis; Liver Neoplasms; Recombinant Proteins; Ribavirin; Risk Factors; RNA, Viral; Superinfection; Treatment Outcome

2009
Treatment of chronic hepatitis C in a slow responder: a case for extended therapy.
    Nature reviews. Gastroenterology & hepatology, 2009, Volume: 6, Issue:6

    Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2009
[Meta-analysis on peginterferon plus ribavirin in treatment of hepatitis C virus genotype 1 or 4 infection in HIV patients].
    Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2009, Volume: 38, Issue:3

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin

2009
Peginterferon plus ribavirin for chronic hepatitis C in patients with human immunodeficiency virus.
    The American journal of gastroenterology, 2009, Volume: 104, Issue:9

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2009
[Difficulties in treatment of kidney diseases related to HCV infection].
    Przeglad epidemiologiczny, 2009, Volume: 63, Issue:1

    Topics: Antiviral Agents; Cryoglobulinemia; Diet Therapy; Glomerulonephritis, Membranoproliferative; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Treatment Outcome

2009
Cytokines - their pathogenic and therapeutic role in chronic viral hepatitis.
    Revista espanola de enfermedades digestivas, 2009, Volume: 101, Issue:5

    Topics: Antiviral Agents; Apoptosis; Cytokines; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatocytes; Humans; Interferon-alpha; Liver; Lymphocyte Subsets; Models, Biological; Receptors, Cytokine; Ribavirin; Virus Replication

2009
[Novel treatments for hepatitis C viral infection and the hepatic fibrosis].
    Revista medica de Chile, 2009, Volume: 137, Issue:2

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2009
Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection.
    Expert opinion on pharmacotherapy, 2009, Volume: 10, Issue:12

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2009
Treatment options for hepatitis C and the rationale for low response rates in African Americans.
    Journal of the National Medical Association, 2009, Volume: 101, Issue:6

    Topics: Antiviral Agents; Black or African American; Disease Progression; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Ribavirin; Treatment Outcome; United States; White People

2009
Hepatitis C virus infection and immunomodulatory therapies.
    Clinics in liver disease, 2009, Volume: 13, Issue:3

    Topics: Antibodies, Monoclonal; Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Immunoglobulins; Immunologic Factors; Immunotherapy; Interferons; Nitro Compounds; Ribavirin; Thiazoles; Toll-Like Receptors; Viral Hepatitis Vaccines

2009
Hepatitis C treatment in patients with drug addiction: clinical management of interferon-alpha-associated psychiatric side effects.
    Current drug abuse reviews, 2008, Volume: 1, Issue:2

    Topics: Alcoholism; Antidepressive Agents; Antiviral Agents; Anxiety Disorders; Depressive Disorder; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Illicit Drugs; Interferon alpha-2; Interferon-alpha; Methadone; Narcotics; Patient Dropouts; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Substance Abuse, Intravenous

2008
Treatment of chronic hepatitis C in polytransfused thalassaemic patients: a meta-analysis.
    Journal of viral hepatitis, 2010, Volume: 17, Issue:4

    Topics: Adolescent; Adult; Animals; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Thalassemia; Treatment Outcome; Young Adult

2010
TMC-435, an NS3/4A protease inhibitor for the treatment of HCV infection.
    Current opinion in investigational drugs (London, England : 2000), 2009, Volume: 10, Issue:8

    Topics: Animals; Antiviral Agents; Carrier Proteins; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Simeprevir; Sulfonamides; Viral Nonstructural Proteins; Viral Proteins

2009
Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection.
    Current opinion in investigational drugs (London, England : 2000), 2009, Volume: 10, Issue:8

    Topics: alpha-Glucosidases; Animals; Antiviral Agents; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Glycoside Hydrolase Inhibitors; Hepacivirus; Hepatitis C, Chronic; Humans; Indolizines; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Prodrugs; Recombinant Proteins; Ribavirin

2009
Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: a meta-analysis.
    Journal of hepatology, 2009, Volume: 51, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2009
Development of thyroid diseases in the treatment of chronic hepatitis C with alpha-interferon may be a good prognosticator in achieving a sustained virological response: a meta-analysis.
    Journal of gastroenterology and hepatology, 2009, Volume: 24, Issue:7

    Topics: Adult; Antiviral Agents; Clinical Audit; Drug Therapy, Combination; Evidence-Based Medicine; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Odds Ratio; Prospective Studies; Ribavirin; Risk Assessment; RNA, Viral; Thyroid Diseases; Time Factors; Treatment Outcome; Viral Load

2009
Treatment with peginterferon plus ribavirin vs. interferon plus ribavirin for 48 weeks in Chinese patients with chronic hepatitis C.
    International journal of clinical practice, 2009, Volume: 63, Issue:9

    Topics: Adolescent; Adult; Antiviral Agents; Asian People; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult

2009
Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C.
    Journal of gastroenterology, 2009, Volume: 44, Issue:10

    Topics: Antiviral Agents; Drug Therapy, Combination; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Virulence Factors

2009
Hepatitis C: recent successes and continuing challenges in the development of improved treatment modalities.
    Current opinion in pharmacology, 2009, Volume: 9, Issue:5

    Topics: Antiviral Agents; Drug Design; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Polyethylene Glycols; Ribavirin; Treatment Outcome; Virus Replication

2009
Ribavirin therapeutic drug monitoring: why, when and how?
    Fundamental & clinical pharmacology, 2010, Volume: 24, Issue:4

    Topics: Antiviral Agents; Biological Availability; Dose-Response Relationship, Drug; Drug Monitoring; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Viral Load

2010
Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C.
    Expert review of anti-infective therapy, 2009, Volume: 7, Issue:8

    Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2009
[Treatment optimization in chronic hepatitis C virus infection].
    Gastroenterologia y hepatologia, 2010, Volume: 33, Issue:2

    Topics: Adult; Algorithms; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome; Viral Load; Viremia

2010
Ribavirin monotherapy for chronic hepatitis C.
    The Cochrane database of systematic reviews, 2009, Oct-07, Issue:4

    Topics: Anemia; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Randomized Controlled Trials as Topic; Ribavirin; Viral Load

2009
[HCV entry as a new therapeutic target in chronic hepatitis C].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2009, Volume: 27, Issue:158

    Topics: Animals; Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Virus Attachment; Virus Internalization

2009
Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2010, Volume: 8, Issue:2

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Fibrosis; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Risk Assessment

2010
Management of chronic hepatitis C patients who have relapsed or not responded to pegylated interferon alfa plus ribavirin.
    Journal of viral hepatitis, 2009, Volume: 16, Issue:12

    Topics: Antiviral Agents; Case Management; Controlled Clinical Trials as Topic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure

2009
Pharmacotherapy of chronic hepatitis C virus infection - the IDEAL trial: '2b or not 2b (= 2a), that is the question'.
    Expert opinion on pharmacotherapy, 2009, Volume: 10, Issue:17

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2009
Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation.
    Medical microbiology and immunology, 2010, Volume: 199, Issue:1

    Topics: Antiviral Agents; Chemoprevention; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Liver Transplantation; Ribavirin; Secondary Prevention; Treatment Outcome

2010
The utility of therapeutic drug monitoring for ribavirin in patients with chronic hepatitis C--a critical review.
    The Annals of pharmacotherapy, 2009, Volume: 43, Issue:12

    Topics: Adult; Algorithms; Antiviral Agents; Clinical Trials as Topic; Decision Making; Drug Monitoring; Hepatitis C, Chronic; Humans; Ribavirin; Treatment Outcome

2009
Optimizing the treatment of chronic viral hepatitis C.
    Expert review of gastroenterology & hepatology, 2009, Volume: 3, Issue:6

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2009
Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations.
    Scandinavian journal of infectious diseases, 2009, Volume: 41, Issue:6-7

    Topics: Acute Disease; Adult; Antiviral Agents; Child; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sweden

2009
Treatment of chronic hepatitis C.
    Minerva medica, 2009, Volume: 100, Issue:6

    Topics: Antiviral Agents; Biopsy, Needle; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Virus Replication

2009
Antiviral strategies: the present and beyond.
    Current molecular pharmacology, 2009, Volume: 2, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Influenza, Human; Interferon-alpha; Oseltamivir; Ribavirin; Structure-Activity Relationship

2009
Reducing treatment duration in patients infected with hepatitis C genotype 1: any need for further studies?
    Antiviral therapy, 2009, Volume: 14, Issue:8

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2009
Optimal length of antiviral therapy in patients with hepatitis C virus genotypes 2 and 3: a meta-analysis.
    Antiviral therapy, 2009, Volume: 14, Issue:8

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Middle Aged; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome

2009
New trends in hepatitis C management.
    Presse medicale (Paris, France : 1983), 2010, Volume: 39, Issue:4

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Carriers; Global Health; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin

2010
Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus.
    The Cochrane database of systematic reviews, 2010, Jan-20, Issue:1

    Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin

2010
Ribavirin plus interferon versus interferon for chronic hepatitis C.
    The Cochrane database of systematic reviews, 2010, Jan-20, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Randomized Controlled Trials as Topic; Ribavirin

2010
Modeling hepatitis C virus therapies combining drugs and lectin affinity plasmapheresis.
    Blood purification, 2010, Volume: 29, Issue:2

    Topics: Antiviral Agents; Clinical Trials as Topic; Combined Modality Therapy; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Mannose-Binding Lectins; Models, Biological; Plant Lectins; Plasmapheresis; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin; Sorption Detoxification; Treatment Outcome; Viral Load; Viremia

2010
Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b.
    Drugs, 2010, Volume: 70, Issue:2

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Treatment Outcome

2010
[Antiviral therapy for chronic hepatitis C: current status and perspectives].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2010, Volume: 130, Issue:2

    Topics: Antiviral Agents; DNA-Directed RNA Polymerases; Drug Administration Schedule; Drug Discovery; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Nitro Compounds; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Pyrimidine Nucleosides; Recombinant Proteins; Ribavirin; Thiazoles

2010
The treatment of chronic hepatitis C virus infection in HIV co-infection.
    European journal of medical research, 2009, Volume: 14

    Topics: Antiretroviral Therapy, Highly Active; Coinfection; Europe; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Ribavirin

2009
Role of ribavirin in HCV treatment response: now and in the future.
    Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:4

    Topics: Administration, Oral; Anemia, Hemolytic; Antiviral Agents; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2010
Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV - the role of epoetin, G-CSF and novel agents.
    Alimentary pharmacology & therapeutics, 2010, Volume: 31, Issue:9

    Topics: Anemia; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia; Viral Load

2010
Adverse effects of drugs in the treatment of viral hepatitis.
    Best practice & research. Clinical gastroenterology, 2010, Volume: 24, Issue:2

    Topics: Antiviral Agents; Drugs, Investigational; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Risk Assessment; Risk Factors

2010
The potential use of Toll-like receptor agonists to restore the dysfunctional immunity induced by hepatitis C virus.
    Cellular immunology, 2010, Volume: 262, Issue:2

    Topics: Adjuvants, Immunologic; Antiviral Agents; Dendritic Cells; Enzyme Inhibitors; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Innate; Indoleamine-Pyrrole 2,3,-Dioxygenase; Interferon-alpha; Killer Cells, Natural; Protein-Tyrosine Kinases; Ribavirin; T-Lymphocytes, Regulatory; Toll-Like Receptors

2010
Treatment of hepatitis C in 2011: what can we expect?
    Current gastroenterology reports, 2010, Volume: 12, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Forecasting; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin

2010
Anemia--a complication of antiviral treatment in chronic viral hepatitis C.
    Romanian journal of internal medicine = Revue roumaine de medecine interne, 2009, Volume: 47, Issue:3

    Topics: Anemia; Antiviral Agents; Erythropoietin; Hepatitis C, Chronic; Humans; Interferon-alpha; Recombinant Proteins; Ribavirin

2009
Impact of IL-28B SNPs on control of hepatitis C virus infection: a genome-wide association study.
    Expert review of anti-infective therapy, 2010, Volume: 8, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Genome-Wide Association Study; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome

2010
Pegylated-interferon plus ribavirin therapy in the treatment of CHC: individualization of treatment duration according to on-treatment virologic response.
    Current medical research and opinion, 2010, Volume: 26, Issue:7

    Topics: Algorithms; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Precision Medicine; Recombinant Proteins; Ribavirin; Viral Load

2010
[HIV and hepatitis C co-infection].
    Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:23

    Topics: AIDS-Related Opportunistic Infections; Algorithms; Antiretroviral Therapy, Highly Active; Antiviral Agents; Cross-Sectional Studies; Evidence-Based Medicine; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin

2010
Thymalfasin in the treatment of hepatitis B and C.
    Annals of the New York Academy of Sciences, 2010, Volume: 1194

    Topics: Adjuvants, Immunologic; Antiviral Agents; Europe; Hepacivirus; Hepatitis B; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferons; Polyethylene Glycols; Polymerase Chain Reaction; Ribavirin; Thymalfasin; Thymosin; Viral Vaccines

2010
Safety of small molecules in combination with interferon-based therapy for hepatitis C virus.
    Expert opinion on drug safety, 2010, Volume: 9, Issue:6

    Topics: Antiviral Agents; Clinical Trials as Topic; Comorbidity; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Molecular Targeted Therapy; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Standard of Care; Treatment Outcome

2010
Viral response to specifically targeted antiviral therapy for hepatitis C and the implications for treatment success.
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2010, Volume: 24, Issue:6

    Topics: Animals; Antiviral Agents; Carboxylic Acids; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Protease Inhibitors; Remission Induction; Ribavirin; Thiophenes; Treatment Outcome

2010
[Combined interferon, ribavirin treatment and the occurrence of hepatocellular carcinoma].
    Orvosi hetilap, 2010, Jul-18, Volume: 151, Issue:29

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Incidence; Interferons; Liver Neoplasms; Ribavirin

2010
Individualisation of antiviral therapy for chronic hepatitis C.
    Journal of gastroenterology and hepatology, 2010, Volume: 25, Issue:7

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Patient Care Team; Precision Medicine; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2010
Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2010, Volume: 8, Issue:10

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2010
Management of HIV and hepatitis virus coinfection.
    Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:15

    Topics: Animals; Antiretroviral Therapy, Highly Active; Disease Management; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2010
Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin.
    Liver international : official journal of the International Association for the Study of the Liver, 2010, Volume: 30, Issue:9

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Immunity, Humoral; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure; Viral Load

2010
Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C.
    Nature reviews. Gastroenterology & hepatology, 2010, Volume: 7, Issue:9

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2010
Telaprevir: a new hope in the treatment of chronic hepatitis C?
    Advances in therapy, 2010, Volume: 27, Issue:8

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Synergism; Genetic Predisposition to Disease; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Ribavirin; Serine Proteinase Inhibitors; Treatment Outcome

2010
Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors.
    The Journal of antimicrobial chemotherapy, 2010, Volume: 65, Issue:10

    Topics: Antiviral Agents; Carrier Proteins; Clinical Trials as Topic; Drug Resistance, Viral; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Serpins; Viral Nonstructural Proteins; Viral Proteins; Viruses

2010
[A case of cardiac sarcoidosis occurring during combination therapy by IFN alpha and ribavirin for chronic hepatitis C].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2010, Volume: 107, Issue:8

    Topics: Aged; Antiviral Agents; Cardiomyopathies; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Sarcoidosis

2010
Ribavirin monitoring in chronic hepatitis C therapy: anaemia versus efficacy.
    Antiviral therapy, 2010, Volume: 15, Issue:5

    Topics: Anemia, Hemolytic; Antiviral Agents; Dose-Response Relationship, Drug; Drug Monitoring; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Treatment Outcome

2010
[Thrombocytopenia in patients with chronic hepatitis C].
    Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, 2010, Issue:5

    Topics: Antiviral Agents; Biomarkers; Disease Progression; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia

2010
Early interferon-based treatment after detection of persistent hepatitis C virus infection: a critical decision.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2010, Volume: 30, Issue:11

    Topics: Animals; Cost-Benefit Analysis; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity; Interferons; Precision Medicine; Ribavirin; RNA, Viral

2010
Meta-analysis: ribavirin plus interferon vs. interferon monotherapy for chronic hepatitic C - an updated Cochrane review.
    Alimentary pharmacology & therapeutics, 2010, Volume: 32, Issue:7

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Randomized Controlled Trials as Topic; Ribavirin; Statistics as Topic; Treatment Outcome

2010
IL28B polymorphisms and chronic hepatitis C.
    Gastroenterologie clinique et biologique, 2010, Volume: 34, Issue:11

    Topics: Antiviral Agents; Biomarkers; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Viral Load

2010
IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies.
    The American journal of gastroenterology, 2011, Volume: 106, Issue:1

    Topics: Antiviral Agents; Female; Follow-Up Studies; Forecasting; Gene Expression Regulation, Viral; Genetic Predisposition to Disease; Genome-Wide Association Study; Genotype; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Polymorphism, Genetic; Precision Medicine; Randomized Controlled Trials as Topic; Ribavirin; Risk Assessment; Severity of Illness Index; Treatment Outcome

2011
Extended treatment duration for treatment naïve chronic hepatitis C genotype 1 late viral responders: a meta-analysis comparing 48 weeks vs 72 weeks of pegylated interferon and ribavirin.
    Journal of viral hepatitis, 2011, Volume: 18, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Time Factors; Treatment Outcome

2011
Pharmacokinetics and pharmacodynamics of peginterferon and ribavirin: implications for clinical efficacy in the treatment of chronic hepatitis C.
    Gastroenterology clinics of North America, 2010, Volume: 39, Issue:3

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2010
Management of untreated and nonresponder patients with chronic hepatitis C.
    Seminars in liver disease, 2010, Volume: 30, Issue:4

    Topics: Alcohol Drinking; Antiviral Agents; Biopsy; Decision Making; Deoxycytidine; Disease Management; Disease Progression; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Obesity; Polyethylene Glycols; Practice Patterns, Physicians'; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Treatment Failure; Viral Load; Virus Replication

2010
A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials.
    Clinical therapeutics, 2010, Volume: 32, Issue:9

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome

2010
Suicide risk in hepatitis C and during interferon-alpha therapy: a review and clinical update.
    Journal of viral hepatitis, 2011, Volume: 18, Issue:3

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon Type I; Recombinant Proteins; Ribavirin; Risk Factors; Suicide

2011
Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantation.
    Alimentary pharmacology & therapeutics, 2011, Volume: 33, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Transplantation; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome

2011
Ribavirin for chronic hepatitis C: and the mystery goes on.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2011, Volume: 43, Issue:6

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Off-Label Use; Ribavirin

2011
Combined antiviral therapy of hepatitis C virus in dialysis patients: meta-analysis of clinical trials.
    Journal of viral hepatitis, 2011, Volume: 18, Issue:7

    Topics: Adult; Aged; Anemia; Antiviral Agents; Clinical Trials as Topic; Cohort Studies; Drug Therapy, Combination; Female; Heart Failure; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-beta; Interferons; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Renal Insufficiency; Ribavirin; Treatment Outcome

2011
[Primary care enlightenment to local inhabitants--cooperation of medical institution and community pharmacy in treatment of chronic hepatitis C].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2010, Volume: 130, Issue:12

    Topics: Antiviral Agents; Community Networks; Community Pharmacy Services; Critical Pathways; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Nonprescription Drugs; Pharmacies; Polyethylene Glycols; Primary Health Care; Recombinant Proteins; Ribavirin

2010
Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients.
    Expert review of anti-infective therapy, 2011, Volume: 9, Issue:2

    Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome

2011
Antiviral prophylactic intervention for chronic hepatitis C virus in patients undergoing liver transplantation.
    The Cochrane database of systematic reviews, 2010, Dec-08, Issue:12

    Topics: Antiviral Agents; Genotype; Graft Rejection; Graft Survival; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Secondary Prevention

2010
Current therapies for chronic hepatitis C.
    Pharmacotherapy, 2011, Volume: 31, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Kidney Failure, Chronic; Liver Cirrhosis; Male; Pregnancy; Pregnancy Complications, Infectious; Ribavirin; Treatment Outcome

2011
Chronic viral hepatitis: epidemiology, molecular biology, and antiviral therapy.
    Frontiers in bioscience (Landmark edition), 2011, 01-01, Volume: 16, Issue:1

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis D, Chronic; Hepatitis Delta Virus; Hepatitis, Chronic; Hepatitis, Viral, Human; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2011
New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
    Liver international : official journal of the International Association for the Study of the Liver, 2011, Volume: 31 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Signal Transduction; Standard of Care; Virus Replication

2011
HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies.
    Current HIV/AIDS reports, 2011, Volume: 8, Issue:1

    Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Prevalence; Randomized Controlled Trials as Topic; Ribavirin

2011
[Genome-wide association studies].
    Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:3

    Topics: Antiviral Agents; Chromosomes, Human, Pair 19; Genetic Markers; Genetic Predisposition to Disease; Genome-Wide Association Study; Genotype; Haplotypes; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Phenotype; Polyethylene Glycols; Polymorphism, Single Nucleotide; Quantitative Trait Loci; Recombinant Proteins; Ribavirin

2011
Hepatitis C pharmacogenetics: state of the art in 2010.
    Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:1

    Topics: Antiviral Agents; Clinical Trials as Topic; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Pharmacogenetics; Polyethylene Glycols; Recombinant Proteins; Ribavirin; United States; United States Food and Drug Administration; Viral Load

2011
Treatment of hepatitis C virus infection in patients with end-stage renal disease.
    Journal of gastroenterology and hepatology, 2011, Volume: 26, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Kidney Failure, Chronic; Kidney Transplantation; Renal Dialysis; Ribavirin; Treatment Outcome; Viral Load

2011
Peginterferon and ribavirin treatment for hepatitis C virus infection.
    World journal of gastroenterology, 2011, Jan-28, Volume: 17, Issue:4

    Topics: Antiviral Agents; Disease Progression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2011
Sequence variability of HCV Core region: important predictors of HCV induced pathogenesis and viral production.
    Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 2011, Volume: 11, Issue:3

    Topics: Carcinoma, Hepatocellular; Cell Cycle; Drug Therapy, Combination; Fatty Liver; Genetic Variation; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferons; Liver Neoplasms; Ribavirin; Viral Core Proteins; Virus Replication

2011
Hepatitis in 2010: the dawn of a new era in HCV therapy.
    Nature reviews. Gastroenterology & hepatology, 2011, Volume: 8, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin

2011
Management of hepatitis C virus genotype 4: recommendations of an international expert panel.
    Journal of hepatology, 2011, Volume: 54, Issue:6

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Interferons; Interleukins; Liver Neoplasms; Liver Transplantation; Polymorphism, Single Nucleotide; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin

2011
A review of the treatment of chronic hepatitis C virus infection in cirrhosis.
    Clinical therapeutics, 2010, Volume: 32, Issue:13

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2010
Pegylated-interferon-α(2a) in clinical practice: how to manage patients suffering from side effects.
    Expert opinion on drug safety, 2011, Volume: 10, Issue:3

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Medication Therapy Management; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2011
'Easy to treat' genotypes were not created equal: can rapid virological response (RVR) level the playing field?
    Journal of hepatology, 2011, Volume: 55, Issue:2

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Fatty Liver; Genotype; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Insulin Resistance; Interferon Type I; Ribavirin; RNA, Viral; Treatment Outcome

2011
Cutaneous sarcoidosis developing after treatment with pegylated interferon and ribavirin: a new case and review of the literature.
    International journal of dermatology, 2011, Volume: 50, Issue:3

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sarcoidosis; Skin Diseases

2011
Irritability: an underappreciated side effect of interferon treatment for chronic hepatitis C?
    Journal of clinical nursing, 2011, Volume: 20, Issue:9-10

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Mood Disorders; Ribavirin

2011
Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus.
    Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:5

    Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Failure

2011
Efficacy of interferon-based antiviral therapy in patients with chronic hepatitis C infected with genotype 5: a meta-analysis of two large prospective clinical trials.
    Journal of medical virology, 2011, Volume: 83, Issue:5

    Topics: Adult; Animals; Antiviral Agents; Belgium; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome

2011
Nucleoside analog inhibitors of hepatitis C viral replication: recent advances, challenges and trends.
    Future medicinal chemistry, 2009, Volume: 1, Issue:8

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Models, Molecular; Molecular Structure; Nucleosides; Ribavirin; Viral Nonstructural Proteins; Virus Replication

2009
[Chronic hepatitis and occult HCV infection].
    Postepy biochemii, 2010, Volume: 56, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Immune Tolerance; Interferon-alpha; Ribavirin; Virus Replication

2010
Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
    Health technology assessment (Winchester, England), 2011, Volume: 15, Issue:17

    Topics: Antiviral Agents; Confidence Intervals; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Probability; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Risk Assessment; State Medicine; Treatment Outcome; Uncertainty; United Kingdom

2011
[New therapeutic options in chronic hepatitis C virus infection].
    Orvosi hetilap, 2011, May-29, Volume: 152, Issue:22

    Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2011
Antiviral therapy: why does it fail in HCV-related chronic hepatitis?
    Expert review of anti-infective therapy, 2011, Volume: 9, Issue:5

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Cryoglobulinemia; Disease Progression; Drug Resistance, Viral; Female; Glomerulonephritis; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Lymphoma, Non-Hodgkin; Male; Ribavirin; RNA, Viral; Sex Factors; Treatment Outcome; Viral Load

2011
Meta-analysis: insulin resistance and sustained virological response in hepatitis C.
    Alimentary pharmacology & therapeutics, 2011, Volume: 34, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Homeostasis; Humans; Insulin Resistance; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Statistics as Topic; Treatment Outcome; Viral Load

2011
Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naïve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials.
    Digestive diseases and sciences, 2011, Volume: 56, Issue:8

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2011
Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future.
    Hepatology (Baltimore, Md.), 2011, Sep-02, Volume: 54, Issue:3

    Topics: Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Viral Load

2011
Clinical practice. Chronic hepatitis C infection.
    The New England journal of medicine, 2011, Jun-23, Volume: 364, Issue:25

    Topics: Antiviral Agents; Hepacivirus; Hepatitis B Antibodies; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Practice Guidelines as Topic; Protease Inhibitors; Recombinant Proteins; Ribavirin; Viral Load

2011
Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis.
    Journal of hepatology, 2011, Volume: 55, Issue:6

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon-alpha; Polyethylene Glycols; Ribavirin; Treatment Outcome; Viral Load

2011
[Attempts to treat chronic hepatitis C with HCV protease inhibitor].
    Przeglad epidemiologiczny, 2011, Volume: 65, Issue:1

    Topics: Antiviral Agents; Drug Discovery; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2011
[Prediction of response to peg-interferon plus ribavirin therapy for chronic hepatitis C].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2011, Volume: 108, Issue:7

    Topics: Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2011
Mechanisms of non-response to antiviral treatment in chronic hepatitis C.
    Clinics and research in hepatology and gastroenterology, 2011, Volume: 35 Suppl 1

    Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Consensus Development Conferences as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Failure; Viral Load

2011
Treatment of hepatitis C-mediated glomerular disease.
    Nephron. Clinical practice, 2011, Volume: 119, Issue:2

    Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Rituximab

2011
New treatments for chronic hepatitis C virus infection.
    Medecine et maladies infectieuses, 2011, Volume: 41, Issue:11

    Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Compassionate Use Trials; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Molecular Targeted Therapy; Oligopeptides; Polyethylene Glycols; Proline; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA-Dependent RNA Polymerase; Serine Proteinase Inhibitors; Therapies, Investigational

2011
Role of the nurse practitioner in the management of patients with chronic hepatitis C.
    Journal of the American Academy of Nurse Practitioners, 2011, Volume: 23, Issue:8

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Nurse Practitioners; Nurse's Role; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors

2011
Interferon-lambda and therapy for chronic hepatitis C virus infection.
    Trends in immunology, 2011, Volume: 32, Issue:9

    Topics: Animals; Antiviral Agents; Chromosomes, Human, Pair 19; Drug Therapy, Combination; Gene Expression Regulation; Hepacivirus; Hepatitis C, Chronic; Humans; Immunotherapy; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Mice; Polyethylene Glycols; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Recombinant Proteins; Ribavirin; Transcription Factors; Treatment Outcome; Viral Load

2011
Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C.
    The Annals of pharmacotherapy, 2011, Volume: 45, Issue:9

    Topics: Animals; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins

2011
Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients.
    AIDS (London, England), 2011, Nov-28, Volume: 25, Issue:18

    Topics: Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; Coinfection; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin

2011
1990-2010: two decades of interferon-based therapy.
    Clinics in liver disease, 2011, Volume: 15, Issue:3

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors

2011
An overview of emerging therapies for the treatment of chronic hepatitis C.
    Clinics in liver disease, 2011, Volume: 15, Issue:3

    Topics: Antiviral Agents; Clinical Trials as Topic; Cyclophilins; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins

2011
Metabolic alterations and chronic hepatitis C: treatment strategies.
    Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:14

    Topics: Antiviral Agents; Body Weight; Cholesterol; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-alpha; Metabolic Syndrome; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2011
[Autoimmune hemolytic anemia in a case of chronic hepatitis type C 56 weeks after initiation of second line treatment with pegylated interferon alpha2b/ribavirin combination therapy].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2011, Volume: 108, Issue:9

    Topics: Anemia, Hemolytic, Autoimmune; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2011
Host genomics and HCV treatment response.
    Journal of gastroenterology and hepatology, 2012, Volume: 27, Issue:2

    Topics: Animals; Antiviral Agents; Coinfection; Drug Therapy, Combination; Genome-Wide Association Study; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Phenotype; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recurrence; Ribavirin; Treatment Outcome

2012
Host genetics.
    Current opinion in HIV and AIDS, 2011, Volume: 6, Issue:6

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome

2011
Response to standard of care antiviral treatment in patients with HCV liver cirrhosis - a systematic review.
    Journal of gastrointestinal and liver diseases : JGLD, 2011, Volume: 20, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin

2011
[Genome-wide association study on and the clinical application to chronic hepatitis C].
    Uirusu, 2011, Volume: 61, Issue:1

    Topics: Anemia, Hemolytic; Antiviral Agents; Genome-Wide Association Study; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Single Nucleotide; Precision Medicine; Pyrophosphatases; Racial Groups; Recombinant Proteins; Ribavirin

2011
Current treatment for chronic hepatitis C virus/HIV-infected individuals: the role of pegylated interferon-alpha and ribavirin.
    Current opinion in HIV and AIDS, 2011, Volume: 6, Issue:6

    Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Multicenter Studies as Topic; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2011
[Treatment strategy for chronic hepatitis C in Japan].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 4

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-beta; Japan; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin

2011
[Development of anti viral therapy for chronic hepatitis type C].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 4

    Topics: Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2011
[Combination therapy of PEG-interferon and ribavirin for chronic hepatitis C in Japan].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 4

    Topics: Aged; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2011
[Improved virologic response in chronic hepatitis C treated with peginterferon, ribavirin and add-on drug].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 4

    Topics: Antiviral Agents; Cyclosporine; Diterpenes; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fatty Alcohols; Female; Fluvastatin; Hepatitis C, Chronic; Humans; Indoles; Interferon-alpha; Male; Metformin; Nitro Compounds; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Silybin; Silymarin; Thiazoles

2011
[Re-treatment for patients with chronic hepatitis C who previously failed to peginterferon/ribavirin therapy].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 4

    Topics: Antiviral Agents; Drug Combinations; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure

2011
[Side effects of interferon-based therapy for chronic hepatitis C virus infection and clinical management of them].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 4

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2011
Literature review in cases with exacerbation of ulcerative colitis induced by treatment with interferon and/or ribavirin.
    Journal of gastroenterology and hepatology, 2011, Volume: 26, Issue:12

    Topics: Antiviral Agents; Colitis, Ulcerative; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferons; Prognosis; Ribavirin; Th1-Th2 Balance

2011
[Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
    Orvosi hetilap, 2011, Dec-11, Volume: 152, Issue:50

    Topics: Affect; Anemia, Hypochromic; Antiviral Agents; Autoimmune Diseases; Autoimmunity; Cardiovascular System; Clinical Trials as Topic; Drug Eruptions; Drug Synergism; Drug Therapy, Combination; Endocrine System Diseases; Eye; Hepatitis C, Chronic; Humans; Infections; Interferon alpha-2; Interferon-alpha; Neutropenia; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Respiratory System; Ribavirin; Risk Factors; Thrombocytopenia

2011
Telaprevir for the treatment of chronic hepatitis C infection.
    Expert review of anti-infective therapy, 2011, Volume: 9, Issue:12

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Mutation; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins

2011
[New agents for the treatment of hepatitis C].
    Enfermedades infecciosas y microbiologia clinica, 2012, Volume: 30, Issue:3

    Topics: Anemia; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Discovery; Drug Eruptions; Drugs, Investigational; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Molecular Targeted Therapy; Multicenter Studies as Topic; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Spain; Viral Nonstructural Proteins

2012
Telaprevir: looking for a sustained virologic response in hepatitis C virus infection.
    Drugs of today (Barcelona, Spain : 1998), 2011, Volume: 47, Issue:11

    Topics: Animals; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2011
Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C.
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2011, Volume: 14, Issue:8

    Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Costs; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Models, Economic; Quality-Adjusted Life Years; Ribavirin

2011
Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
    Antiviral therapy, 2011, Volume: 16, Issue:8

    Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2011
Management of chronic hepatitis C infection in children.
    Current opinion in pediatrics, 2012, Volume: 24, Issue:1

    Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2012
Classical and emerging roles of vitamin D in hepatitis C virus infection.
    Seminars in liver disease, 2011, Volume: 31, Issue:4

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Neoplasms; Osteoporosis; Ribavirin; Vitamin D; Vitamin D Deficiency; Vitamins

2011
Chronic hepatitis C infection in the elderly.
    The Kaohsiung journal of medical sciences, 2011, Volume: 27, Issue:12

    Topics: Age Factors; Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Prevalence; Ribavirin

2011
2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines.
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Standard of Care

2012
Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1

    Topics: Anemia; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Proline; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors; Treatment Outcome

2012
Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice.
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1

    Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Skin Diseases; Withholding Treatment

2012
Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders.
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1

    Topics: Adult; Aged; Anemia; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Serine Proteinase Inhibitors; Skin Diseases; Treatment Failure; Treatment Outcome; Virus Replication; Young Adult

2012
Phase III results in Genotype 1 naïve patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin.
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1

    Topics: Adult; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Ethnicity; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Indiana; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Polymorphism, Genetic; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome; Viral Load

2012
Triple therapy with boceprevir for HCV genotype 1 infection: phase III results in relapsers and nonresponders.
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1

    Topics: Anemia; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Substitution; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Serine Proteinase Inhibitors; Skin Diseases; Standard of Care; Treatment Failure

2012
Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1

    Topics: Algorithms; Anemia; Antiviral Agents; Clinical Protocols; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Skin Diseases; Time Factors; Viral Load

2012
Response-guided and -unguided treatment of chronic hepatitis C.
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1

    Topics: Antiviral Agents; Black People; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Patient Selection; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome

2012
Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow.
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1

    Topics: Antiviral Agents; Disease Eradication; Drug Administration Schedule; Drug Resistance, Viral; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome

2012
The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C.
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Recurrence; Ribavirin; Serine Proteinase Inhibitors; Viral Load

2012
Future treatment of patients with HCV cirrhosis.
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Serine Proteinase Inhibitors; Viral Load

2012
Hepatitis C virus treatment pre- and post-liver transplantation.
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1

    Topics: Antiviral Agents; Disease Progression; Drug Administration Schedule; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Postoperative Complications; Proline; Recombinant Proteins; Recurrence; Ribavirin; Serine Proteinase Inhibitors; Time Factors; Viral Load

2012
Hepatitis C virus-human immunodeficiency virus coinfection.
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1

    Topics: Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Oligopeptides; Patient Selection; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Treatment Failure; Treatment Outcome; Viral Load

2012
What's new in HCV genotype 2 treatment.
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load

2012
Treatment of patients with genotype 3 chronic hepatitis C--current and future therapies.
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Polymorphism, Genetic; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Time Factors; Viral Load

2012
The future for the treatment of genotype 4 chronic hepatitis C.
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1

    Topics: Albumins; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Nitro Compounds; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Thiazoles; Time Factors; Viral Load; Vitamin D

2012
Barriers to hepatitis C treatment.
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Health Services Accessibility; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Treatment Refusal; Viral Load

2012
Comparison of peginterferon pharmacokinetic and pharmacodynamic profiles.
    Journal of viral hepatitis, 2012, Volume: 19 Suppl 1

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Half-Life; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2012
Comparative trials of peginterferon α2a and peginterferon α2b for chronic hepatitis C.
    Journal of viral hepatitis, 2012, Volume: 19 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Half-Life; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome

2012
Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C.
    Journal of viral hepatitis, 2012, Volume: 19, Issue:2

    Topics: Anemia; Antiviral Agents; Erythropoietin; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Outcome

2012
Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: a systematic review and meta-analysis.
    Journal of viral hepatitis, 2012, Volume: 19, Issue:2

    Topics: Anemia; Antiviral Agents; Erythropoietin; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Outcome

2012
Treatment failure with new hepatitis C drugs.
    Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:3

    Topics: Antiviral Agents; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Phenotype; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Treatment Failure

2012
[Genetic polymorphisms as new predictive factors for successful treatment of chronic hepatitis C].
    Klinicka mikrobiologie a infekcni lekarstvi, 2011, Volume: 17, Issue:6

    Topics: Antiviral Agents; Drug Therapy, Combination; Genome-Wide Association Study; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome

2011
Antiviral strategies in hepatitis C virus infection.
    Journal of hepatology, 2012, Volume: 56 Suppl 1

    Topics: Antiviral Agents; Cyclophilins; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA-Dependent RNA Polymerase; Viral Nonstructural Proteins

2012
[Current options for predicting therapeutic response in chronically infected patients with hepatitis C virus genotype 1].
    Enfermedades infecciosas y microbiologia clinica, 2011, Volume: 29 Suppl 5

    Topics: Algorithms; Antiviral Agents; Drug Resistance, Viral; Forecasting; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Models, Biological; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prognosis; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Proteins

2011
Treatment of hepatitis C in dialysis patients.
    Contributions to nephrology, 2012, Volume: 176

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin

2012
Telaprevir for the treatment of hepatitis C.
    Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:4

    Topics: Antiviral Agents; Clinical Trials as Topic; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Randomized Controlled Trials as Topic; Ribavirin

2012
Update of old and emerging therapies in chronic hepatitis C.
    JPMA. The Journal of the Pakistan Medical Association, 2011, Volume: 61, Issue:12

    Topics: Antiviral Agents; Drug Evaluation, Preclinical; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Immunotherapy; Interferon-alpha; Recombinant Proteins; Ribavirin

2011
[New class of medicines for chronic hepatitis C].
    Nederlands tijdschrift voor geneeskunde, 2012, Volume: 156, Issue:10

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Outcome

2012
Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection.
    Expert review of anti-infective therapy, 2012, Volume: 10, Issue:3

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome

2012
Should we treat HCV carriers with normal ALT levels? The '5Ws' dilemma.
    Journal of viral hepatitis, 2012, Volume: 19, Issue:4

    Topics: Alanine Transaminase; Antiviral Agents; Carrier State; Hepatitis C, Chronic; Humans; Interferons; Liver; Ribavirin

2012
Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C?
    Minerva gastroenterologica e dietologica, 2012, Volume: 58, Issue:1

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Europe; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Japan; Liver Neoplasms; North America; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Risk Assessment; Treatment Outcome; Viral Load

2012
Ranking predictors of a sustained viral response for patients with chronic hepatitis C treated with pegylated interferon and ribavirin in Scotland.
    European journal of gastroenterology & hepatology, 2012, Volume: 24, Issue:6

    Topics: Acyltransferases; Adult; Age Distribution; Alanine Transaminase; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Retrospective Studies; Ribavirin; Sex Distribution; Treatment Outcome

2012
Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.
    Drugs, 2012, Mar-26, Volume: 72, Issue:5

    Topics: Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load

2012
Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action.
    Current opinion in virology, 2011, Volume: 1, Issue:6

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Pharmacogenetics; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2011
Hepatitis C therapy update.
    Current opinion in gastroenterology, 2012, Volume: 28, Issue:3

    Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Risk Factors

2012
Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies.
    Current opinion in organ transplantation, 2012, Volume: 17, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin

2012
Review of boceprevir and telaprevir for the treatment of chronic hepatitis C.
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2012, Volume: 26, Issue:4

    Topics: Antiviral Agents; Disease Management; Disease Progression; Drug Interactions; Drug Therapy, Combination; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Standard of Care; Treatment Outcome; Viral Load

2012
Treatment of hepatitis C virus infection in adults and children: updated Swedish consensus recommendations.
    Scandinavian journal of infectious diseases, 2012, Volume: 44, Issue:7

    Topics: Adult; Antiviral Agents; Child; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Time Factors

2012
Clinical utility of interleukin-28B testing in patients with genotype 1.
    Hepatology (Baltimore, Md.), 2012, Volume: 56, Issue:1

    Topics: Antiviral Agents; Confidence Intervals; Ethnicity; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Odds Ratio; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prognosis; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome; Viral Load

2012
Recent trends in the treatment of chronic hepatitis C.
    The Korean journal of hepatology, 2012, Volume: 18, Issue:1

    Topics: Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Precision Medicine; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Viral

2012
New virologic tools for management of chronic hepatitis B and C.
    Gastroenterology, 2012, Volume: 142, Issue:6

    Topics: Antiviral Agents; Clinical Trials as Topic; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Genome, Viral; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Point-of-Care Systems; Polyethylene Glycols; Proline; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome

2012
Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus.
    Gastroenterology, 2012, Volume: 142, Issue:6

    Topics: Anemia, Hypochromic; Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Eruptions; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Tract; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Treatment Outcome

2012
Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.
    Gastroenterology, 2012, Volume: 142, Issue:6

    Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Deoxycytidine; Dideoxynucleosides; Disease Progression; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Hepatitis C, Chronic; HIV Infections; Homosexuality, Male; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Diseases; Male; Oligopeptides; Organophosphonates; Polyethylene Glycols; Proline; Pyrrolidinones; Raltegravir Potassium; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Substance Abuse, Intravenous; Tenofovir; Treatment Outcome

2012
Interferons and hepatitis C virus.
    Swiss medical weekly, 2012, Volume: 142

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Janus Kinases; Ribavirin; Signal Transduction; STAT Transcription Factors

2012
TMC435 for the treatment of chronic hepatitis C.
    Expert opinion on investigational drugs, 2012, Volume: 21, Issue:8

    Topics: Animals; Antiviral Agents; Clinical Trials as Topic; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferons; Ribavirin; Simeprevir; Sulfonamides

2012
Basic answers to complicated questions for the course of chronic hepatitis C treatment.
    Expert review of gastroenterology & hepatology, 2012, Volume: 6, Issue:3

    Topics: Antiviral Agents; Disease Management; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2012
Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care.
    The Lancet. Infectious diseases, 2012, Volume: 12, Issue:9

    Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Standard of Care; United States

2012
[Direct antiviral treatment strategies in chronic hepatitis C].
    Deutsche medizinische Wochenschrift (1946), 2012, Volume: 137, Issue:25-26

    Topics: Hepatitis C, Chronic; Humans; Interferon-alpha; Protease Inhibitors; Ribavirin; Treatment Outcome

2012
[Hepatitis C! Experience in diagnosis and medical treatment. A literature review].
    Pflege, 2012, Volume: 25, Issue:3

    Topics: Adult; Ambulatory Care; Antiviral Agents; Child; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Long-Term Care; Male; Middle Aged; Patient-Centered Care; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Self Care; Sick Role

2012
Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents.
    Journal of viral hepatitis, 2012, Volume: 19, Issue:7

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Standard of Care; Treatment Outcome

2012
The changing therapeutic landscape for hepatitis C.
    The Medical journal of Australia, 2012, Jun-04, Volume: 196, Issue:10

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Patient Selection; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin

2012
[Efficacy of triple therapy in patients with chronic hepatitis C not treated and patients previously treated ineffectively].
    Przeglad epidemiologiczny, 2012, Volume: 66, Issue:1

    Topics: Antiviral Agents; Carrier Proteins; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Europe; Hepacivirus; Hepatitis C, Chronic; Humans; Intracellular Signaling Peptides and Proteins; Oligopeptides; Poland; Proline; Ribavirin; Serine Proteinase Inhibitors; Treatment Outcome; Viral Nonstructural Proteins

2012
Hepatitis C therapy in non-genotype 1 patients: the near future.
    Journal of viral hepatitis, 2012, Volume: 19, Issue:8

    Topics: Antioxidants; Antiviral Agents; Clinical Trials as Topic; Cyclophilins; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Protease Inhibitors; Ribavirin; Silybin; Silymarin

2012
Meta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C.
    Journal of gastroenterology, 2013, Volume: 48, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2013
Interleukin-28B polymorphisms on the SVR in the treatment of naïve chronic hepatitis C with pegylated interferon-α plus ribavirin: a meta-analysis.
    Gene, 2012, Oct-01, Volume: 507, Issue:1

    Topics: Antiviral Agents; Asian People; Black or African American; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Polyethylene Glycols; Polymorphism, Single Nucleotide; Ribavirin; RNA, Viral; Viral Load; White People

2012
Current and emerging antiviral treatments for hepatitis C infection.
    British journal of clinical pharmacology, 2013, Volume: 75, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Drugs, Investigational; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Models, Biological; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2013
Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver.
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32, Issue:10

    Topics: Antiviral Agents; Drug Combinations; France; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Time Factors

2012
[Chronic hepatitis C: improved cure rates with new approved medications].
    MMW Fortschritte der Medizin, 2012, Jun-21, Volume: O 154 Suppl 2

    Topics: Antiviral Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Drugs, Investigational; Genotype; Guideline Adherence; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin

2012
Ischemic colitis during interferon-ribavirin therapy for chronic hepatitis C: a case report.
    World journal of gastroenterology, 2012, Aug-21, Volume: 18, Issue:31

    Topics: Abdominal Pain; Antiviral Agents; Colitis, Ischemic; Colonoscopy; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Withholding Treatment

2012
Genomic variation-guided management in chronic hepatitis C.
    Expert review of gastroenterology & hepatology, 2012, Volume: 6, Issue:4

    Topics: Antiviral Agents; Genome-Wide Association Study; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Pharmacogenetics; Polyethylene Glycols; Precision Medicine; Pyrophosphatases; Recombinant Proteins; Ribavirin

2012
The race for interferon-free HCV therapies: a snapshot by the spring of 2012.
    Reviews in medical virology, 2012, Volume: 22, Issue:6

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin

2012
Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies.
    Expert opinion on drug safety, 2012, Volume: 11, Issue:6

    Topics: Age Factors; Antiviral Agents; Dose-Response Relationship, Drug; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Risk Factors; Sex Factors

2012
Telaprevir: pharmacokinetics and drug interactions.
    Antiviral therapy, 2012, Volume: 17, Issue:7

    Topics: Animals; Antiviral Agents; Clinical Trials as Topic; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ketoconazole; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Ribavirin; Viral Nonstructural Proteins

2012
[Efficacy and safety of a protease inhibitor with pegylated interferon and ribavirin in patients with untreated chronic hepatitis C: a meta analysis].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2012, Volume: 20, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Ribavirin; Treatment Outcome

2012
Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.
    The Cochrane database of systematic reviews, 2012, Sep-12, Issue:9

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Time Factors; Viral Load

2012
Boceprevir: a protease inhibitor for the treatment of hepatitis C.
    Clinical therapeutics, 2012, Volume: 34, Issue:10

    Topics: Animals; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin

2012
[Boceprevir (Victrelis), oral administration].
    Journal de pharmacie de Belgique, 2012, Issue:2

    Topics: Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Proline; Ribavirin

2012
New-onset type 1 diabetes mellitus and anti-aquaporin-4 antibody positive optic neuritis associated with type 1 interferon therapy for chronic hepatitis C.
    Internal medicine (Tokyo, Japan), 2012, Volume: 51, Issue:18

    Topics: Antibodies, Anti-Idiotypic; Antiviral Agents; Aquaporin 4; Diabetes Mellitus, Type 1; Drug Synergism; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon Type I; Interferon-alpha; Interferon-beta; Middle Aged; Optic Neuritis; Ribavirin

2012
Shortened peginterferon and ribavirin treatment for chronic hepatitis C.
    International journal of technology assessment in health care, 2012, Volume: 28, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Markov Chains; Polyethylene Glycols; Quality-Adjusted Life Years; Ribavirin; United Kingdom

2012
Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis.
    PloS one, 2012, Volume: 7, Issue:9

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin

2012
Tongue hyperpigmentation during PEG-interferon-alfa/ribavirin therapy in a non-Caucasian patient with chronic hepatitis C: a case report and review of the literature.
    International journal of dermatology, 2013, Volume: 52, Issue:5

    Topics: Adult; Antiviral Agents; Black People; Drug Eruptions; Hepatitis C, Chronic; Humans; Hyperpigmentation; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tongue

2013
A new era in the treatment of chronic hepatitis C infection.
    Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2013, Volume: 32, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin

2013
Managing adverse effects of interferon-alfa and ribavirin in combination therapy for HCV.
    Infectious disease clinics of North America, 2012, Volume: 26, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2012
[Treatment of hepatitis C infection: towards eradication of chronic virus].
    Duodecim; laaketieteellinen aikakauskirja, 2012, Volume: 128, Issue:18

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin

2012
Pharmacokinetics of new oral hepatitis C antiviral drugs.
    Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:1

    Topics: Administration, Oral; Animals; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin

2013
Association study of IL28B: rs12979860 and rs8099917 polymorphisms with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy using systematic meta-analysis.
    Gene, 2013, Jan-25, Volume: 513, Issue:2

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Pharmacogenetics; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome

2013
Interferon stimulated genes and hepatitis C virus infection.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2012, Volume: 32, Issue:12

    Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Fibrosis; Gene Expression Regulation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Viral Nonstructural Proteins

2012
Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis.
    QJM : monthly journal of the Association of Physicians, 2013, Volume: 106, Issue:2

    Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Comparative Effectiveness Research; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Proline; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome

2013
[Efficacy of peginterferon and ribavirin combination therapy of chronic hepatitis C: a pooled analysis].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2012, Volume: 60, Issue:5

    Topics: Antiviral Agents; Databases, Factual; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2012
Telaprevir for chronic hepatitis C virus infection.
    Clinics in liver disease, 2013, Volume: 17, Issue:1

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors

2013
Boceprevir and treatment of chronic hepatitis C.
    Clinics in liver disease, 2013, Volume: 17, Issue:1

    Topics: Anemia; Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors

2013
Management of the transplant recipient with chronic hepatitis C.
    Clinics in liver disease, 2013, Volume: 17, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Immunocompromised Host; Immunosuppressive Agents; Interferons; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Postoperative Care; Preoperative Care; Proline; Ribavirin; Serine Proteinase Inhibitors

2013
Future perspectives: towards interferon-free regimens for HCV.
    Antiviral therapy, 2012, Volume: 17, Issue:6 Pt B

    Topics: Administration, Oral; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Proline; Ribavirin; Treatment Outcome

2012
Estimates of HCV-1 patients attaining RVR following dual therapy with peg-interferon and ribavirin.
    Digestive diseases and sciences, 2013, Volume: 58, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2013
Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines.
    Journal of gastroenterology, 2013, Volume: 48, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Oligopeptides; Patient Selection; Polyethylene Glycols; Practice Guidelines as Topic; Protease Inhibitors; Recombinant Proteins; Ribavirin

2013
The role of viral and host genetics in natural history and treatment of chronic HCV infection.
    Best practice & research. Clinical gastroenterology, 2012, Volume: 26, Issue:4

    Topics: Antiviral Agents; Drug Resistance, Viral; Genome-Wide Association Study; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Remission, Spontaneous; Ribavirin; Treatment Outcome

2012
Treatment indication and response to standard of care with peginterferon and ribavirin in acute and chronic HCV infection.
    Best practice & research. Clinical gastroenterology, 2012, Volume: 26, Issue:4

    Topics: Acute Disease; Antiviral Agents; Contraindications; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Remission, Spontaneous; Ribavirin

2012
Triple therapy with boceprevir or telaprevir for treatment naïve HCV patients.
    Best practice & research. Clinical gastroenterology, 2012, Volume: 26, Issue:4

    Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin

2012
Response guided therapy in patients with chronic hepatitis C - yesterday, today and tomorrow.
    Best practice & research. Clinical gastroenterology, 2012, Volume: 26, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Induction Chemotherapy; Interferon-alpha; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2012
The role of resistance in HCV treatment.
    Best practice & research. Clinical gastroenterology, 2012, Volume: 26, Issue:4

    Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Microbial Sensitivity Tests; Molecular Targeted Therapy; Mutation; Oligopeptides; Proline; Protease Inhibitors; Ribavirin

2012
Liver transplantation in the setting of chronic HCV.
    Best practice & research. Clinical gastroenterology, 2012, Volume: 26, Issue:4

    Topics: Age Factors; Antiviral Agents; Cytomegalovirus Infections; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Protease Inhibitors; Ribavirin; Risk Factors; Secondary Prevention; Tissue Donors

2012
Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013, Volume: 56, Issue:7

    Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Clinical Trials as Topic; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2013
Update on the treatment of patients with non-genotype 1 hepatitis C virus infection.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013, Volume: 56, Issue:9

    Topics: Antiviral Agents; Drug Therapy, Combination; Europe; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Ribavirin; Time Factors; Treatment Outcome; United States; Viral Load

2013
Remission of HCV-associated glomerulonephritis with pegylated ifn and ribavirin therapy after liver transplantation: case report and literature review.
    The International journal of artificial organs, 2013, Volume: 36, Issue:1

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Administration Schedule; Drug Therapy, Combination; Glomerulonephritis, Membranous; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Remission Induction; Ribavirin; Treatment Outcome

2013
Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis.
    PloS one, 2012, Volume: 7, Issue:12

    Topics: Antiviral Agents; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Ribavirin

2012
Optimal treatment with telaprevir for chronic HCV infection.
    Liver international : official journal of the International Association for the Study of the Liver, 2013, Volume: 33 Suppl 1

    Topics: Antiviral Agents; Carrier Proteins; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Oligopeptides; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome; Viral Load; Viral Nonstructural Proteins

2013
Optimal treatment with boceprevir for chronic HCV infection.
    Liver international : official journal of the International Association for the Study of the Liver, 2013, Volume: 33 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Patient Selection; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Risk Factors; Serine Proteinase Inhibitors; Treatment Outcome; Viral Nonstructural Proteins

2013
How to optimize HCV therapy in genotype 1 patients: management of side-effects.
    Liver international : official journal of the International Association for the Study of the Liver, 2013, Volume: 33 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Serine Proteinase Inhibitors; Treatment Outcome

2013
How to optimize HCV therapy in genotype 2 patients.
    Liver international : official journal of the International Association for the Study of the Liver, 2013, Volume: 33 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome; Viral Load

2013
How to optimize HCV therapy in genotype 4 patients.
    Liver international : official journal of the International Association for the Study of the Liver, 2013, Volume: 33 Suppl 1

    Topics: Antiviral Agents; Comorbidity; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Serine Proteinase Inhibitors; Treatment Outcome; Viral Load

2013
How to optimize HCV therapy in genotype 1 patients with cirrhosis.
    Liver international : official journal of the International Association for the Study of the Liver, 2013, Volume: 33 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Serine Proteinase Inhibitors; Treatment Outcome

2013
Interferon free therapy with direct acting antivirals for HCV.
    Liver international : official journal of the International Association for the Study of the Liver, 2013, Volume: 33 Suppl 1

    Topics: Antiviral Agents; Drug Design; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Models, Molecular; Molecular Structure; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Treatment Outcome; Viral Nonstructural Proteins

2013
Treatment of hepatitis C: how will we use viral kinetics, response-guided therapy?
    Current gastroenterology reports, 2013, Volume: 15, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Kinetics; Models, Biological; Polyethylene Glycols; Protease Inhibitors; Ribavirin; RNA, Viral

2013
Telaprevir for genotype 1 chronic hepatitis C: a systematic review and meta-analysis.
    Die Pharmazie, 2012, Volume: 67, Issue:12

    Topics: Adult; Aged; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Publication Bias; Randomized Controlled Trials as Topic; Research Design; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult

2012
Glucose abnormalities in hepatitis C virus infection.
    The Kaohsiung journal of medical sciences, 2013, Volume: 29, Issue:2

    Topics: Adult; Antiviral Agents; Diabetes Mellitus, Type 2; Disease Progression; Female; Glucose; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin; Insulin Resistance; Interferon-alpha; Male; Middle Aged; Ribavirin

2013
Management of hepatitis C virus infection: the basics.
    Topics in antiviral medicine, 2012, Volume: 20, Issue:5

    Topics: Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Treatment Outcome; United States

2012
Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials.
    Clinical therapeutics, 2013, Volume: 35, Issue:2

    Topics: Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin

2013
Anemia management in patients with chronic viral hepatitis C.
    The Annals of pharmacotherapy, 2013, Volume: 47, Issue:2

    Topics: Anemia; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Erythropoietin; Hematinics; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Ribavirin; Risk Factors; Serine Proteinase Inhibitors; Viral Nonstructural Proteins

2013
Current treatment for chronic hepatitis C.
    Reviews in gastroenterological disorders, 2001, Volume: 1, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin

2001
Ribavirin and interferon combination for recurrent post-transplant hepatitis C: which benefit beyond 6 months?
    Journal of hepatology, 2002, Volume: 37, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Liver Transplantation; Postoperative Complications; Recurrence; Ribavirin

2002
HCV chronic hepatitis in patients with HIV: clinical management issues.
    The American journal of gastroenterology, 2002, Volume: 97, Issue:7

    Topics: Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Drug Interactions; Hepatitis C, Chronic; HIV Infections; Humans; Liver Transplantation; Ribavirin; Time Factors

2002
[Hepatitis C and alcohol].
    Gastroenterologie clinique et biologique, 2002, Volume: 26 Spec No 2

    Topics: Alanine Transaminase; Alcoholism; Antiviral Agents; Apoptosis; Biopsy; Carcinoma, Hepatocellular; Clinical Enzyme Tests; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Odds Ratio; Prevalence; Ribavirin; Risk Factors; Time Factors; Viral Load

2002
[Hepatitis C and drug use: epidemiology, screening, natural history and treatment].
    Gastroenterologie clinique et biologique, 2002, Volume: 26 Spec No 2

    Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Follow-Up Studies; France; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heroin Dependence; Humans; Interferons; Prevalence; Prisons; Prognosis; Prospective Studies; Recurrence; Ribavirin; Risk Factors; Substance Abuse, Intravenous; Substance-Related Disorders; Time Factors

2002
[Chronic hepatitis C in HIV-HCV coinfected patients].
    Gastroenterologie clinique et biologique, 2002, Volume: 26 Spec No 2

    Topics: Adult; Age Factors; Amantadine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Carcinoma, Hepatocellular; Child; Clinical Trials as Topic; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Meta-Analysis as Topic; Pilot Projects; Prevalence; Ribavirin; Risk Factors

2002
[Management of patients with hepatitis C virus infection. Virological tests].
    Gastroenterologie clinique et biologique, 2002, Volume: 26 Spec No 2

    Topics: Acute Disease; Adult; Algorithms; Antibodies, Viral; Antigens, Viral; Antiviral Agents; Biomarkers; Capsid; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Interferons; Male; Monitoring, Physiologic; Polymerase Chain Reaction; Prognosis; Ribavirin; RNA, Viral; Time Factors; Viral Load

2002
[Treatment of patients with chronic hepatitis C who have not been previously treated].
    Gastroenterologie clinique et biologique, 2002, Volume: 26 Spec No 2

    Topics: Antiviral Agents; Controlled Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Placebos; Polyethylene Glycols; Prognosis; Ribavirin; RNA, Viral; Time Factors

2002
[Treatment of patients with chronic hepatitis C virus infection and normal transaminases].
    Gastroenterologie clinique et biologique, 2002, Volume: 26 Spec No 2

    Topics: Antiviral Agents; Clinical Enzyme Tests; Clinical Trials as Topic; Drug Therapy, Combination; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Time Factors; Transaminases; Viral Load

2002
[Treatment of chronic hepatitis C in children].
    Gastroenterologie clinique et biologique, 2002, Volume: 26 Spec No 2

    Topics: Adolescent; Adult; Age Factors; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Infant; Infant, Newborn; Interferons; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Time Factors

2002
[Treatment of extrahepatic manifestations associated with hepatitis C virus infection].
    Gastroenterologie clinique et biologique, 2002, Volume: 26 Spec No 2

    Topics: Antiviral Agents; Autoantibodies; Cryoglobulinemia; Drug Therapy, Combination; Fatigue; Female; Glomerulonephritis, Membranoproliferative; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Lymphoproliferative Disorders; Male; Middle Aged; Odds Ratio; Porphyria Cutanea Tarda; Pruritus; Ribavirin; Sjogren's Syndrome; Surveys and Questionnaires; Thrombocytopenia; Time Factors; Vascular Diseases

2002
[Treatment of hepatitis C virus-related cirrhosis].
    Gastroenterologie clinique et biologique, 2002, Volume: 26 Spec No 2

    Topics: Antiviral Agents; Biopsy; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Fibrosis; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Meta-Analysis as Topic; Middle Aged; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Ribavirin; Time Factors

2002
[Treatment of patients with chronic hepatitis C who relapsed or did not respond to a previous treatment].
    Gastroenterologie clinique et biologique, 2002, Volume: 26 Spec No 2

    Topics: Amantadine; Antiviral Agents; Clinical Enzyme Tests; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Transaminases; Treatment Failure; Viral Load

2002
[Evaluation of response to treatment in chronic hepatitis C].
    Gastroenterologie clinique et biologique, 2002, Volume: 26 Spec No 2

    Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Biopsy; Carcinoma, Hepatocellular; Clinical Enzyme Tests; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferons; Liver; Liver Neoplasms; Meta-Analysis as Topic; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Transaminases; Viremia

2002
[Treatment of chronic hepatitis C in special groups].
    Gastroenterologie clinique et biologique, 2002, Volume: 26 Spec No 2

    Topics: Acute Disease; Adult; Antiviral Agents; Bone Marrow Transplantation; Child; Drug Therapy, Combination; Follow-Up Studies; Hemophilia A; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Transplantation; Liver Transplantation; Mental Disorders; Renal Dialysis; Ribavirin; Thalassemia; Time Factors

2002
[Quality of life of patients with chronic hepatitis C: effect of treatments].
    Gastroenterologie clinique et biologique, 2002, Volume: 26 Spec No 2

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Psychometrics; Quality of Life; Randomized Controlled Trials as Topic; Ribavirin; Surveys and Questionnaires; Time Factors; Viral Load

2002
[Treatment of chronic hepatitis C in patients with HIV coinfection: efficacy and tolerance].
    Gastroenterologie clinique et biologique, 2002, Volume: 26 Spec No 2

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Clinical Enzyme Tests; Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C; Hepatitis C, Chronic; HIV Infections; HIV Seronegativity; HIV Seropositivity; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Interferons; Liver Transplantation; Male; Multicenter Studies as Topic; Pregnancy; Pregnancy Complications, Infectious; Ribavirin; Time Factors; Transaminases

2002
[Treatment of chronic hepatitis C in patients coinfected with HIV: tolerability, drug interactions, therapeutic indications].
    Gastroenterologie clinique et biologique, 2002, Volume: 26 Spec No 2

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Didanosine; Drug Interactions; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Life Style; Mitochondria; Monitoring, Physiologic; Multicenter Studies as Topic; Patient Selection; Randomized Controlled Trials as Topic; Retrospective Studies; Reverse Transcriptase Inhibitors; Ribavirin; Stavudine; Time Factors; Viral Load; Zidovudine

2002
[Chronic hepatitis C: apart from antiviral treatment what other measures should be recommended?].
    Gastroenterologie clinique et biologique, 2002, Volume: 26 Spec No 2

    Topics: Adult; Alcoholism; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Iron Deficiencies; Liver Transplantation; Male; Obesity; Patient Education as Topic; Ribavirin; Risk Factors; Smoking; Smoking Prevention; Time Factors

2002
[Hepatitis C: therapeutic perspectives].
    Gastroenterologie clinique et biologique, 2002, Volume: 26 Spec No 2

    Topics: Antigens, Viral; Antiviral Agents; Cells, Cultured; Clinical Trials, Phase III as Topic; Cytokines; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Forecasting; Hepacivirus; Hepatitis C, Chronic; Humans; Immunotherapy; Interferon-alpha; Interferon-beta; Interferons; Multicenter Studies as Topic; Protease Inhibitors; Randomized Controlled Trials as Topic; Ribavirin; RNA, Viral; Viral Load

2002
Consensus conference. Treatment of hepatitis C.
    Gastroenterologie clinique et biologique, 2002, Volume: 26 Spec No 2

    Topics: Adult; Aged; Alcoholism; Amantadine; Antiviral Agents; Body Weight; Child; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Graft Rejection; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Mental Disorders; Middle Aged; Monitoring, Physiologic; Quality of Life; Recurrence; Ribavirin; Risk Factors; Substance-Related Disorders; Time Factors

2002
[Treatment of patients with chronic hepatitis C who never had been treated].
    Gastroenterologie clinique et biologique, 2002, Volume: 26 Spec No 2

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Biopsy; Body Weight; Clinical Enzyme Tests; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukin-2; Liver; Liver Cirrhosis; Meta-Analysis as Topic; Placebos; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Time Factors; Transaminases; Viral Load

2002
[Chronic hepatitis C: what to do if the first treatment failed?].
    Gastroenterologie clinique et biologique, 2002, Volume: 26 Spec No 2

    Topics: Amantadine; Animals; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Ethanol; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Mice; Mice, Transgenic; Multicenter Studies as Topic; Obesity; Randomized Controlled Trials as Topic; Recurrence; Ribavirin; Risk Factors; Smoking; Time Factors

2002
[Treatment of chronic hepatitis C: side effects, tolerability and quality of life].
    Gastroenterologie clinique et biologique, 2002, Volume: 26 Spec No 2

    Topics: Anemia, Hemolytic; Antiviral Agents; Blood Cell Count; Clinical Trials as Topic; Controlled Clinical Trials as Topic; Depressive Disorder; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Transplantation; Liver Transplantation; Mental Disorders; Neutropenia; Prospective Studies; Quality of Life; Retrospective Studies; Ribavirin; Risk Factors; Thrombocytopenia; Time Factors

2002
[Hepatitis C and liver transplantation].
    Gastroenterologie clinique et biologique, 2002, Volume: 26 Spec No 2

    Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Clinical Enzyme Tests; Clinical Trials as Topic; Drug Therapy, Combination; Follow-Up Studies; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Interferons; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Pilot Projects; Randomized Controlled Trials as Topic; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Tissue Donors; Transaminases

2002
Meta-analysis: combination therapy with interferon-alpha 2a/2b and ribavirin for patients with chronic hepatitis C previously non-responsive to interferon.
    Alimentary pharmacology & therapeutics, 2002, Volume: 16, Issue:9

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin

2002
Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C.
    Alimentary pharmacology & therapeutics, 2002, Volume: 16, Issue:9

    Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Ribavirin

2002
Treatment of chronic hepatitis C: a systematic review.
    Hepatology (Baltimore, Md.), 2002, Volume: 36, Issue:5 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2002
Motion - the available treatments for hepatitis C are cost effective: arguments for the motion.
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2002, Volume: 16, Issue:10

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Health Care Costs; Hepatitis C, Chronic; Humans; Interferons; Male; Ontario; Prognosis; Randomized Controlled Trials as Topic; Ribavirin; Severity of Illness Index; Treatment Outcome

2002
Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data.
    Gut, 2002, Volume: 51, Issue:6

    Topics: Adult; Antiviral Agents; Chi-Square Distribution; Drug Administration Schedule; Drug Therapy, Combination; Female; gamma-Glutamyltransferase; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Logistic Models; Male; Middle Aged; Ribavirin; Treatment Failure

2002
[Role of interferons in the treatment of hepatitis B and hepatitis C virus infections].
    La Revue de medecine interne, 2002, Volume: 23 Suppl 4

    Topics: Antiviral Agents; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin

2002
[Do the interferons have an antifibrotic action? The hepatologist's point of view].
    La Revue de medecine interne, 2002, Volume: 23 Suppl 4

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2002
[Hepatitis C virus infection--after 12 years. Advances in the management of chronic hepatitis C].
    Orvosi hetilap, 2002, Dec-01, Volume: 143, Issue:48

    Topics: Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Heterozygote; Humans; Hungary; Interferon alpha-2; Interferon-alpha; Interferons; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2002
[Novel mode of action of ribavirin (Rebetol), a drug for the treatment of chronic hepatitis C: inducting the mutation of RNA viruses].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2002, Volume: 120, Issue:6

    Topics: Animals; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; IMP Dehydrogenase; Interferon alpha-2; Interferon-alpha; Mutation; Recombinant Proteins; Ribavirin; RNA Viruses; RNA-Dependent RNA Polymerase

2002
Treatment of chronic hepatitis C in nonresponders to previous therapy.
    Current gastroenterology reports, 2003, Volume: 5, Issue:1

    Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2003
Therapy of chronic hepatitis C: a critical review.
    Current drug targets. Infectious disorders, 2003, Volume: 3, Issue:1

    Topics: Age Factors; Alanine Transaminase; Animals; Blood Coagulation Disorders, Inherited; Depressive Disorder; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Pregnancy; Recurrence; Renal Insufficiency; Ribavirin; Treatment Outcome

2003
[Combination therapy for chronic viral hepatitis C].
    Deutsche medizinische Wochenschrift (1946), 2003, Feb-21, Volume: 128, Issue:8

    Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2003
[Treatment of hepatitis C. Paris 27-28 February 2002].
    Annales de medecine interne, 2002, Volume: 153, Issue:7

    Topics: Adult; Aged; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferons; Paris; Practice Guidelines as Topic; Ribavirin; Transaminases; Treatment Outcome

2002
Sarcoidosis after use of interferon for chronic hepatitis C: report of a case and review of the literature.
    Digestive diseases and sciences, 2003, Volume: 48, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Sarcoidosis, Pulmonary

2003
Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C.
    Drugs, 2003, Volume: 63, Issue:7

    Topics: Adsorption; Antiviral Agents; Black People; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Treatment Outcome

2003
[Treatment of chronic hepatitis C in patients without previous treatment].
    Revista de gastroenterologia de Mexico, 2002, Volume: 67 Suppl 2

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Ribavirin

2002
[Treatment of chronic hepatitis C in patients coinfected with HIV-HCV/HBV].
    Revista de gastroenterologia de Mexico, 2002, Volume: 67 Suppl 2

    Topics: Antiviral Agents; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Ribavirin

2002
[Antiviral therapy for chronic viral hepatitis B and C].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 2

    Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-beta; Lamivudine; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2003
Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus.
    Expert opinion on pharmacotherapy, 2003, Volume: 4, Issue:5

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Half-Life; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2003
Chronic hepatitis C virus infection.
    JAMA, 2003, May-14, Volume: 289, Issue:18

    Topics: Antiviral Agents; Contraindications; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load

2003
Side effects of therapy for chronic hepatitis C.
    Gastroenterology, 2003, Volume: 124, Issue:6

    Topics: Antiviral Agents; Drug Therapy, Combination; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lung Diseases; Mental Disorders; Nervous System Diseases; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thyroid Diseases

2003
Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C.
    Reviews in gastroenterological disorders, 2003,Spring, Volume: 3, Issue:2

    Topics: Adult; Biological Availability; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome; Viral Load

2003
Hepatitis C virus therapies: current treatments, targets and future perspectives.
    Antiviral chemistry & chemotherapy, 2003, Volume: 14, Issue:1

    Topics: Animals; Antiviral Agents; Clinical Trials as Topic; Disease Models, Animal; Drug Design; Drug Therapy, Combination; Enzyme Inhibitors; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Recombinant Proteins; Ribavirin

2003
Treatment of HCV-related liver diseases after renal transplantation: modern views.
    The International journal of artificial organs, 2003, Volume: 26, Issue:5

    Topics: Antiviral Agents; Graft Survival; Hepatitis C, Chronic; Humans; Interferon Type I; Kidney Transplantation; Recombinant Proteins; Renal Dialysis; Ribavirin

2003
Ribavirin as maintenance therapy for hepatitis C patients: an interim peacekeeper?
    Hepatology (Baltimore, Md.), 2003, Volume: 38, Issue:1

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Ribavirin

2003
Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C.
    Antiviral research, 2003, Volume: 59, Issue:1

    Topics: Animals; Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Treatment Failure

2003
Current therapies for chronic hepatitis C. Drug combination achieves sustained response in more than half of patients.
    Postgraduate medicine, 2003, Volume: 114, Issue:1

    Topics: Alanine Transaminase; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Patient Compliance; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2003
Pegylated interferons in the treatment of chronic hepatitis C.
    Chinese medical journal, 2003, Volume: 116, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2003
The role of the laboratory in the diagnosis and management of chronic hepatitis C patients.
    Saudi medical journal, 2003, Volume: 24 Suppl 2

    Topics: Acute Disease; Biopsy, Needle; Clinical Laboratory Techniques; Enzyme-Linked Immunosorbent Assay; Female; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Saudi Arabia; Sensitivity and Specificity

2003
Chronic hepatitis C treatment. Side effects and their management.
    Saudi medical journal, 2003, Volume: 24 Suppl 2

    Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Maximum Tolerated Dose; Recombinant Proteins; Ribavirin; Risk Assessment; Saudi Arabia; Severity of Illness Index; Treatment Outcome

2003
Hepatis C virus genotype 4.
    Saudi medical journal, 2003, Volume: 24 Suppl 2

    Topics: Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Genome, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Prognosis; Recombinant Proteins; Ribavirin; Saudi Arabia; Treatment Outcome

2003
Pharmacokinetics of peginterferons.
    Seminars in liver disease, 2003, Volume: 23 Suppl 1

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Carriers; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Serum Albumin; Serum Albumin, Human

2003
Clinical trial results of peginterferons in combination with ribavirin.
    Seminars in liver disease, 2003, Volume: 23 Suppl 1

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Carriers; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2003
[Therapeutic progresses of hepatitis C].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2003, Volume: 11, Issue:8

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Treatment Outcome

2003
[Hepatitis: associated diseases. Risk groups -- prevention -- treatment].
    Praxis, 2003, Aug-13, Volume: 92, Issue:33

    Topics: Adenine; Adult; Antiviral Agents; Child; DNA, Viral; Female; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C; Hepatitis C, Chronic; Humans; Infant; Infant, Newborn; Interferons; Lamivudine; Liver Cirrhosis; Male; Mutation; Organophosphonates; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Time Factors

2003
Treatment strategies for hepatitis C: intervention prior to liver transplant, pre-emptively or after established disease.
    Clinics in liver disease, 2003, Volume: 7, Issue:3

    Topics: Antiviral Agents; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Preoperative Care; Recombinant Proteins; Ribavirin; Secondary Prevention; Time Factors

2003
Systematic review: peginterferon vs. standard interferon in the treatment of chronic hepatitis C.
    Alimentary pharmacology & therapeutics, 2003, Oct-01, Volume: 18, Issue:7

    Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin

2003
Chronic hepatitis C: updated Swedish consensus.
    Scandinavian journal of infectious diseases, 2003, Volume: 35, Issue:8

    Topics: Adult; Aged; Antiviral Agents; Consensus; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Practice Guidelines as Topic; Prognosis; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Survival Rate; Sweden; Treatment Outcome

2003
Peginterferon alfa-2a (40KD) (Pegasys) for the treatment of patients with chronic hepatitis C.
    International journal of clinical practice, 2003, Volume: 57, Issue:7

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Quality of Life; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome

2003
Management of newly diagnosed hepatitis C virus infection.
    Cleveland Clinic journal of medicine, 2003, Volume: 70 Suppl 4

    Topics: Antiviral Agents; Clinical Trials as Topic; Contraindications; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Patient Compliance; Patient Selection; Prognosis; Recombinant Proteins; Ribavirin

2003
Treatment options for nonresponders and relapsers to initial therapy for hepatitis C.
    Cleveland Clinic journal of medicine, 2003, Volume: 70 Suppl 4

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Neoplasms; Recurrence; Retreatment; Ribavirin

2003
Practical management of liver transplant recipients for hepatitis C.
    Minerva chirurgica, 2003, Volume: 58, Issue:4

    Topics: Antiviral Agents; Combined Modality Therapy; Disease Progression; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Reoperation; Ribavirin; Treatment Outcome

2003
Combined antiviral options for the treatment of chronic hepatitis C.
    Antiviral research, 2003, Volume: 60, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2003
Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies.
    The Journal of antimicrobial chemotherapy, 2004, Volume: 53, Issue:1

    Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Load

2004
Viral hepatitis C.
    Lancet (London, England), 2003, Dec-20, Volume: 362, Issue:9401

    Topics: Adult; Antiviral Agents; Comorbidity; Disease Progression; Enzyme-Linked Immunosorbent Assay; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Serotyping; Severity of Illness Index

2003
[Sarcoidosis following combined ribavirin and interferon therapy: a case report and review of the literature].
    Archivos de bronconeumologia, 2004, Volume: 40, Issue:1

    Topics: Antiviral Agents; Biopsy, Needle; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Sarcoidosis, Pulmonary; Tomography, X-Ray Computed

2004
Guidelines for stopping therapy in chronic hepatitis C.
    Current gastroenterology reports, 2004, Volume: 6, Issue:1

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Guidelines as Topic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Time Factors; Treatment Outcome; Viral Load

2004
New therapies for chronic hepatitis C virus infection.
    Current gastroenterology reports, 2004, Volume: 6, Issue:1

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Survival Analysis; Treatment Outcome

2004
[Peginterferon alpha and ribavirin therapy for difficult-to-treat chronic hepatitis C patients].
    Przeglad epidemiologiczny, 2002, Volume: 56 Suppl 4

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Load; Virus Replication

2002
[New therapeutic agents for chronic hepatitis C].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2004, Jan-10, Volume: 93, Issue:1

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Time Factors

2004
Update on chronic hepatitis C.
    Comprehensive therapy, 2003,Winter, Volume: 29, Issue:4

    Topics: Antiviral Agents; Biopsy; Contraindications; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Immunologic Tests; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Terminology as Topic; Treatment Outcome

2003
Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?
    Annals of internal medicine, 2004, Mar-02, Volume: 140, Issue:5

    Topics: Antiviral Agents; Confounding Factors, Epidemiologic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure; Viral Load

2004
Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2004, Volume: 2, Issue:3

    Topics: Antiviral Agents; Comorbidity; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Prognosis; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Survival Rate; Treatment Outcome

2004
Changing faces-natural course and treatment of hepatitis C after liver transplantation.
    Journal of hepatology, 2004, Volume: 40, Issue:4

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin

2004
Hepatitis C virus.
    The Nursing clinics of North America, 2004, Volume: 39, Issue:1

    Topics: Antiviral Agents; Complementary Therapies; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Nurse's Role; Prevalence; Quality of Life; Ribavirin; Risk Factors; Sex Characteristics; Sex Distribution; Sex Factors; United States; Women's Health

2004
Necrolytic acral erythema: response to combination therapy with interferon and ribavirin.
    Journal of the American Academy of Dermatology, 2004, Volume: 50, Issue:5 Suppl

    Topics: Acrodermatitis; Antiviral Agents; Child; Drug Therapy, Combination; Erythema; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Necrosis; Parenteral Nutrition; Recombinant Proteins; Ribavirin; Skin

2004
Epoetin alfa treatment for acute anaemia during interferon plus ribavirin combination therapy for chronic hepatitis C.
    Journal of viral hepatitis, 2004, Volume: 11, Issue:3

    Topics: Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Hematinics; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2004
Hepatitis C with normal liver enzymes: to treat or not to treat. Pro: most patients should be treated.
    The American journal of gastroenterology, 2004, Volume: 99, Issue:6

    Topics: Alanine Transaminase; Antiviral Agents; Decision Making; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Prognosis; Recombinant Proteins; Reference Values; Ribavirin; Risk Assessment; Severity of Illness Index; United States

2004
Hepatitis C with normal liver enzymes: to treat or not to treat. Con: most patients should not be treated.
    The American journal of gastroenterology, 2004, Volume: 99, Issue:6

    Topics: Alanine Transaminase; Antiviral Agents; Decision Making; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Recombinant Proteins; Reference Values; Ribavirin; Risk Assessment; Severity of Illness Index

2004
Host factors affecting the outcome of treatment of hepatitis C.
    Reviews in gastroenterological disorders, 2004, Volume: 4 Suppl 1

    Topics: Antiviral Agents; Biological Availability; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Integration Host Factors; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Patient Compliance; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Tissue Distribution; Treatment Outcome; Viral Load

2004
Viral factors affecting the outcome of therapy for chronic hepatitis C.
    Reviews in gastroenterological disorders, 2004, Volume: 4 Suppl 1

    Topics: Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Pharmacogenetics; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; RNA, Viral; Sensitivity and Specificity; Severity of Illness Index; Treatment Outcome; Viral Load

2004
Epidemiology and treatment outcomes of patients with chronic hepatitis C and genotypes 4 to 9.
    Reviews in gastroenterological disorders, 2004, Volume: 4 Suppl 1

    Topics: Africa; Antiviral Agents; Asia; Clinical Trials as Topic; Drug Therapy, Combination; Europe; Female; Follow-Up Studies; Genotype; Global Health; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Molecular Epidemiology; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Treatment Outcome; United States

2004
Management of patients with chronic hepatitis C virus infection and previous nonresponse.
    Reviews in gastroenterological disorders, 2004, Volume: 4 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Risk Assessment; RNA, Viral; Salvage Therapy; Severity of Illness Index; Treatment Failure; Treatment Outcome; Viral Load

2004
Current status of the use of growth factors and other adjuvant medications in patients receiving peginterferon and ribavirin.
    Reviews in gastroenterological disorders, 2004, Volume: 4 Suppl 1

    Topics: Antiviral Agents; Chemotherapy, Adjuvant; Drug Therapy, Combination; Erythropoietin; Female; Hepacivirus; Hepatitis C, Chronic; Hepatocyte Growth Factor; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Treatment Outcome; Viral Load

2004
Treatment of chronic hepatitis C in patients with decompensated cirrhosis.
    Reviews in gastroenterological disorders, 2004, Volume: 4 Suppl 1

    Topics: Antiviral Agents; Comorbidity; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Treatment Outcome; Viral Load

2004
Relapsing polychondritis, chronic hepatitis C virus infection, and mixed cryoglobulemia.
    Seminars in arthritis and rheumatism, 2004, Volume: 33, Issue:6

    Topics: Aged; Anti-Inflammatory Agents; Antiviral Agents; Cryoglobulinemia; Female; Hepatitis C, Chronic; Humans; Interferons; Leukemia, Myeloid, Acute; Polychondritis, Relapsing; Prednisone; Ribavirin

2004
[Current and future applications of viral clearance kinetics in the treatment of hepatitis C].
    Gastroenterologia y hepatologia, 2004, Volume: 27 Suppl 1

    Topics: Acute Disease; Antiviral Agents; Forecasting; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Kinetics; Remission, Spontaneous; Ribavirin; RNA, Viral; Viral Load; Viremia

2004
[Treatment of chronic hepatitis C].
    Orvosi hetilap, 2004, May-16, Volume: 145, Issue:20

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2004
[Peginterferon-alpha and ribavirin combination therapy in chronic hepatitis C].
    The Korean journal of hepatology, 2004, Volume: 10, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2004
Management of chronic hepatitis C virus infection: a new era of disease control.
    Internal medicine journal, 2004, Volume: 34, Issue:6

    Topics: Hepatitis C, Chronic; Humans; Interferons; Ribavirin

2004
Chronic hepatitis C and no response to antiviral therapy: potential current and future therapeutic options.
    Journal of viral hepatitis, 2004, Volume: 11, Issue:4

    Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Recurrence; Ribavirin

2004
Natural history of hepatitis C following liver transplantation.
    Current opinion in infectious diseases, 2004, Volume: 17, Issue:4

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Immunocompromised Host; Interferons; Liver Transplantation; Ribavirin

2004
When to treat patients with chronic hepatitis C.
    Current gastroenterology reports, 2004, Volume: 6, Issue:4

    Topics: Antiviral Agents; Comorbidity; Hepatitis C, Chronic; Humans; Interferons; Patient Selection; Ribavirin

2004
The immune responsiveness in hepatitis C virus infected patients: effects of interferon-alfa/ribavirin combined treatment on the lymphocyte response with special reference to B cells.
    Current pharmaceutical design, 2004, Volume: 10, Issue:17

    Topics: Antigens, CD19; Antiviral Agents; B-Lymphocytes; Clinical Trials as Topic; Drug Therapy, Combination; Endotoxins; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin

2004
Therapy of chronic hepatitis C virus infection in HIV co-infected people.
    Current pharmaceutical design, 2004, Volume: 10, Issue:17

    Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Ribavirin

2004
Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?
    Addiction (Abingdon, England), 2004, Volume: 99, Issue:9

    Topics: Antiviral Agents; Clinical Trials as Topic; Contraindications; Drug Therapy, Combination; Hepatitis C, Chronic; Heroin Dependence; Humans; Interferon-alpha; Mental Disorders; Research Design; Ribavirin; Substance-Related Disorders

2004
Treatment of the hepatitis C virus in patients coinfected with HIV.
    Gastroenterology clinics of North America, 2004, Volume: 33, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2004
Antiviral therapy for treatment naïve patients with hepatitis C virus.
    Gastroenterology clinics of North America, 2004, Volume: 33, Issue:3

    Topics: Antiviral Agents; Contraindications; Cost-Benefit Analysis; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Patient Compliance; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2004
Treatment of relapsers after combination therapy for chronic hepatitis C.
    Gastroenterology clinics of North America, 2004, Volume: 33, Issue:3

    Topics: Adjuvants, Pharmaceutic; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; Secondary Prevention

2004
Nonresponders to hepatitis C virus antiviral therapy: pegylated interferons and beyond.
    Gastroenterology clinics of North America, 2004, Volume: 33, Issue:3

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Patient Selection; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Retreatment; Ribavirin; Treatment Failure

2004
Evaluation of amantadine in chronic hepatitis C: a meta-analysis.
    Journal of hepatology, 2004, Volume: 41, Issue:3

    Topics: Amantadine; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon Type I; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin

2004
Treatment of hepatitis C virus: the first decade.
    Seminars in liver disease, 2004, Volume: 24 Suppl 2

    Topics: Age Factors; Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Prognosis; Ribavirin; Risk Factors; Viral Load

2004
Predictors of response to therapy for chronic hepatitis C.
    Seminars in liver disease, 2004, Volume: 24 Suppl 2

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Kinetics; Predictive Value of Tests; Prognosis; Ribavirin; Treatment Outcome; Viral Load

2004
Treatment of chronic hepatitis C infection with peginterferons plus ribavirin.
    Seminars in liver disease, 2004, Volume: 24 Suppl 2

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Treatment Outcome

2004
Hepatitis C virus in the setting of HIV or hepatitis B virus coinfection.
    Seminars in liver disease, 2004, Volume: 24 Suppl 2

    Topics: Adenine; Antiviral Agents; Comorbidity; Hepacivirus; Hepatitis B virus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Organophosphonates; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Risk Factors

2004
Natural history and management of hepatitis C infection after liver transplantation.
    Seminars in liver disease, 2004, Volume: 24 Suppl 2

    Topics: Disease Progression; Hepacivirus; Hepatitis C, Chronic; Humans; Immunoglobulins; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin

2004
Role of amantadine and other adjuvant therapies in the treatment of hepatitis C.
    Seminars in liver disease, 2004, Volume: 24 Suppl 2

    Topics: Adjuvants, Immunologic; Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin

2004
Retreatment of chronic hepatitis C virus infection.
    Reviews in gastroenterological disorders, 2004,Summer, Volume: 4, Issue:3

    Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Remission Induction; Retreatment; Ribavirin; RNA, Viral; Treatment Failure

2004
[Combination therapy of interferon plus ribavirin for chronic hepatitis C].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 7, Issue:Pt 1

    Topics: Antiviral Agents; Biomarkers; Drug Resistance; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome

2004
[Differential effects of interferon-based treatments in chronic hepatitis C].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 7, Issue:Pt 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome

2004
[Therapeutic effects of interferon on chronic hepatitis C from the aspect of dosage and method of administration].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 7, Issue:Pt 1

    Topics: Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Neoplasms; Randomized Controlled Trials as Topic; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome

2004
[Two-step interferon rebound therapy].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 7, Issue:Pt 1

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Cytokines; Drug Administration Schedule; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome

2004
[Efficacy of and indications for IFN retreatment of patients with chronic hepatitis C].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 7, Issue:Pt 1

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insurance, Health, Reimbursement; Interferons; Japan; Randomized Controlled Trials as Topic; Recurrence; Ribavirin; Treatment Outcome

2004
[Clinical significance of measuring HCV-RNA levels in patients with chronic hepatitis C by IFN treatment, including combination therapy with ribavirin].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 7, Issue:Pt 1

    Topics: Antiviral Agents; Biomarkers; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; RNA, Viral; Secondary Prevention; Time Factors; Treatment Outcome

2004
[Effectiveness of long-acting interferon (peginterferon)].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 7, Issue:Pt 1

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome

2004
[Prevention of adverse effects in ribavirin and interferon combination therapy].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 7, Issue:Pt 1

    Topics: Abnormalities, Drug-Induced; Anemia; Animals; Antiviral Agents; Cerebral Hemorrhage; Drug Eruptions; Drug Therapy, Combination; Feeding and Eating Disorders; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Tissue Distribution

2004
[Alternative measures for patients with chronic hepatitis C unresponsive to interferon therapy].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 7, Issue:Pt 1

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Cysteine; Drug Combinations; Drug Therapy, Combination; Genotype; Glycine; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Iron, Dietary; Liver Neoplasms; Oleanolic Acid; Phlebotomy; Prognosis; Ribavirin; Time Factors

2004
[Clinical aspects of type-C cirrhosis of liver--diagnosis, clinical course, treatment and prognosis].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 7, Issue:Pt 1

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cysteine; Disease Progression; Drug Combinations; Drug Therapy, Combination; Fibrosis; Glycine; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Liver Neoplasms; Oleanolic Acid; Prognosis; Ribavirin; Risk; Ursodeoxycholic Acid

2004
[Liver transplantation for hepatitis C virus cirrhosis--present status and future prospects].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 7, Issue:Pt 1

    Topics: Antiviral Agents; Brain Death; Combined Modality Therapy; Drug Therapy, Combination; Graft Survival; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Liver Cirrhosis; Liver Transplantation; Living Donors; Prognosis; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors

2004
[Difference between autoimmune hepatitis (AIH) with and without hepatitis C virus (HCV)].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 7, Issue:Pt 1

    Topics: Adrenal Cortex Hormones; Antiviral Agents; Autoantibodies; Azathioprine; Disease Susceptibility; Drug Therapy, Combination; Hepatitis C, Chronic; Hepatitis, Autoimmune; HLA-DR4 Antigen; Humans; Immunosuppressive Agents; Interferons; Ribavirin

2004
[Prevalence and clinical course in HBV and HCV dual chronic infection].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 7, Issue:Pt 1

    Topics: Adult; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferons; Lamivudine; Male; Prevalence; Ribavirin; Superinfection

2004
[Treatment of chronic hepatitis C].
    Orvosi hetilap, 2004, Aug-08, Volume: 145, Issue:32

    Topics: Antiviral Agents; Drug Therapy, Combination; Enzyme Inhibitors; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Hungary; IMP Dehydrogenase; Interferons; Liver Cirrhosis; Liver Transplantation; Nucleosides; Ribavirin; Risk Factors

2004
[Hepatitis C].
    Therapeutische Umschau. Revue therapeutique, 2004, Volume: 61, Issue:8

    Topics: Acute Disease; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Time Factors

2004
Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
    Health technology assessment (Winchester, England), 2004, Volume: 8, Issue:39

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin

2004
The evolving treatment of chronic hepatitis C: where we stand a decade out.
    Cleveland Clinic journal of medicine, 2004, Volume: 71 Suppl 3

    Topics: Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Forecasting; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Virus Replication

2004
Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration.
    Cleveland Clinic journal of medicine, 2004, Volume: 71 Suppl 3

    Topics: Administration, Oral; Algorithms; Antiviral Agents; Clinical Trials as Topic; Drug Carriers; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Patient Compliance; Patient Selection; Polyethylene Glycols; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors

2004
Retreatment of patients who do not respond to initial therapy for chronic hepatitis C.
    Cleveland Clinic journal of medicine, 2004, Volume: 71 Suppl 3

    Topics: Adjuvants, Immunologic; Alcoholism; Amantadine; Antiviral Agents; Black or African American; Clinical Trials as Topic; Counseling; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Infusions, Intravenous; Injections, Subcutaneous; Interferons; Liver Cirrhosis; Meta-Analysis as Topic; Oligonucleotides, Antisense; Patient Compliance; Ribavirin; RNA, Viral; Thymalfasin; Thymosin; Time Factors; White People

2004
Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia.
    Cleveland Clinic journal of medicine, 2004, Volume: 71 Suppl 3

    Topics: Anemia; Antiviral Agents; Clinical Trials as Topic; Darbepoetin alfa; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Filgrastim; Granulocyte Colony-Stimulating Factor; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukin-11; Neutropenia; Patient Compliance; Polyethylene Glycols; Quality of Life; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Thrombocytopenia

2004
The role of hematopoietic growth factors in special populations with chronic hepatitis C: patients with HIV coinfection, end-stage renal disease, or liver transplantation.
    Cleveland Clinic journal of medicine, 2004, Volume: 71 Suppl 3

    Topics: Anemia; Antiviral Agents; Clinical Trials as Topic; Comorbidity; Drug Therapy, Combination; Erythropoietin; Forecasting; Granulocyte Colony-Stimulating Factor; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Kidney Failure, Chronic; Liver Transplantation; Neutropenia; Patient Compliance; Recombinant Proteins; Recurrence; Renal Dialysis; Ribavirin

2004
The role of physician extenders in managing patients with chronic hepatitis C.
    Cleveland Clinic journal of medicine, 2004, Volume: 71 Suppl 3

    Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Neutropenia; Nurse Practitioners; Patient Compliance; Patient Education as Topic; Physician Assistants; Quality of Health Care; Ribavirin; Risk Factors; Social Support; Thrombocytopenia

2004
Peginterferon-alpha 2a (40 kDa)/ribavirin combination for the treatment of chronic hepatitis C infection.
    Expert review of anti-infective therapy, 2003, Volume: 1, Issue:3

    Topics: Animals; Clinical Trials as Topic; Drug Combinations; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2003
The management of side-effects during therapy for hepatitis C.
    Alimentary pharmacology & therapeutics, 2004, Nov-01, Volume: 20, Issue:9

    Topics: Antiviral Agents; Depressive Disorder; Drug Carriers; Drug Therapy, Combination; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2004
Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4.
    Alimentary pharmacology & therapeutics, 2004, Nov-01, Volume: 20, Issue:9

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome

2004
[Treatment strategies of acute and chronic hepatitis C].
    Przeglad epidemiologiczny, 2002, Volume: 56 Suppl 5

    Topics: Acute Disease; Antiviral Agents; Drug Administration Schedule; Drug Carriers; Drug Therapy, Combination; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin

2002
[Ribavirin--pharmacological features, antiviral effects against hepatitis C virus (HCV) and other viruses and side effects during treatment].
    Przeglad epidemiologiczny, 2002, Volume: 56 Suppl 5

    Topics: Antiviral Agents; Drug Therapy, Combination; Hemorrhagic Fevers, Viral; Hepatitis C, Chronic; Humans; Respiratory Tract Infections; Ribavirin; RNA Viruses; Virus Replication

2002
Treatment of acute and chronic hepatitis C.
    Clinics in liver disease, 1997, Volume: 1, Issue:3

    Topics: Amantadine; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Recurrence; Ribavirin

1997
Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in hepatitis C Virus And HIV co-infection.
    Drugs, 2004, Volume: 64, Issue:24

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Molecular Weight; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2004
Role of growth factors in the treatment of patients with HIV/HCV coinfection and patients with recurrent hepatitis C following liver transplantation.
    Journal of clinical gastroenterology, 2005, Volume: 39, Issue:1 Suppl

    Topics: Antiviral Agents; Growth Substances; Hematologic Diseases; Hematopoiesis; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Transplantation; Postoperative Complications; Recurrence; Ribavirin; United States

2005
Hematologic side effects of interferon and ribavirin therapy.
    Journal of clinical gastroenterology, 2005, Volume: 39, Issue:1 Suppl

    Topics: Anemia, Hypochromic; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Erythropoietin; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia

2005
The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin.
    Journal of clinical gastroenterology, 2005, Volume: 39, Issue:1 Suppl

    Topics: Anemia, Hypochromic; Antiviral Agents; Darbepoetin alfa; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Granulocyte Colony-Stimulating Factor; Growth Substances; Hematinics; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia

2005
Weight-based dosing: which impact on efficacy and safety of therapy?
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2004, Volume: 36 Suppl 3

    Topics: Antiviral Agents; Body Mass Index; Body Weight; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2004
Pegylating IFNs at his-34 improves the in vitro antiviral activity through the JAK/STAT pathway.
    Antiviral chemistry & chemotherapy, 2004, Volume: 15, Issue:6

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Histidine; Humans; Interferon alpha-2; Interferon-alpha; Isomerism; Models, Molecular; Molecular Weight; Polyethylene Glycols; Protein-Tyrosine Kinases; Recombinant Proteins; Ribavirin; Signal Transduction

2004
Pushing the treatment envelope for chronic hepatitis C--is more necessarily better?
    Hepatology (Baltimore, Md.), 2005, Volume: 41, Issue:2

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2005
[Treatment of chronic hepatitis C].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2004, Volume: 44, Issue:6

    Topics: Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2004
Children with hepatitis C.
    Current gastroenterology reports, 2005, Volume: 7, Issue:1

    Topics: Age Distribution; Antiviral Agents; Child; Child, Preschool; Disease Progression; Disease Transmission, Infectious; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Infant; Infectious Disease Transmission, Vertical; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Prognosis; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Sex Distribution

2005
Maintenance therapy for chronic hepatitis C.
    Current gastroenterology reports, 2005, Volume: 7, Issue:1

    Topics: Antiviral Agents; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Long-Term Care; Male; Prognosis; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Survival Analysis; Viral Load

2005
[Advances in the diagnosis and treatment of hepatitis C virus infection in patients with and without HIV infection].
    Enfermedades infecciosas y microbiologia clinica, 2005, Volume: 23, Issue:1

    Topics: Abnormalities, Drug-Induced; Antiviral Agents; Biopsy; Comorbidity; Disease Progression; Female; Hematologic Diseases; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Liver; Male; Ribavirin

2005
Treatment of chronic hepatitis c.
    Minerva gastroenterologica e dietologica, 2004, Volume: 50, Issue:1

    Topics: Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin

2004
Retreatment of chronic hepatitis C virus infection in patients who failed to achieve sustained virologic response.
    Minerva gastroenterologica e dietologica, 2004, Volume: 50, Issue:1

    Topics: Hepatitis C, Chronic; Humans; Interferons; Retreatment; Ribavirin; Treatment Failure

2004
[Interferons alpha in the treatment of chronic HCV infections].
    Przeglad epidemiologiczny, 2004, Volume: 58, Issue:3

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Carriers; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2004
[Chronic hepatitis C infection--mechanisms of virus "immune escape"].
    Przeglad epidemiologiczny, 2004, Volume: 58, Issue:3

    Topics: Antibody Formation; Antiviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Drug Resistance, Viral; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Cellular; Interferon-alpha; Ribavirin; Risk Factors; Treatment Outcome; Viral Proteins

2004
Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirin.
    Seminars in liver disease, 2005, Volume: 25, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2005
Peginterferon alpha-2a (40KD) plus ribavirin: a review of its use in the management of patients with chronic hepatitis C and persistently 'normal' ALT levels.
    Drugs, 2005, Volume: 65, Issue:4

    Topics: Alanine Transaminase; Antiviral Agents; Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin

2005
Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
    International journal of technology assessment in health care, 2005,Winter, Volume: 21, Issue:1

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Markov Chains; Polyethylene Glycols; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Technology Assessment, Biomedical

2005
Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Soci
    International journal of technology assessment in health care, 2005,Winter, Volume: 21, Issue:1

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Germany; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Markov Chains; Polyethylene Glycols; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Technology Assessment, Biomedical

2005
Dynamic decision analysis to determine optimal treatment duration in chronic hepatitis C.
    Alimentary pharmacology & therapeutics, 2005, Mar-01, Volume: 21, Issue:5

    Topics: Adult; Age Factors; Aged; Alanine Transaminase; Antiviral Agents; Clinical Enzyme Tests; Cohort Studies; Cost-Benefit Analysis; Decision Support Techniques; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Randomized Controlled Trials as Topic; Ribavirin; Sex Factors

2005
Chronic hepatitis C treatment patterns in African American patients: an update.
    The American journal of gastroenterology, 2005, Volume: 100, Issue:3

    Topics: Antiviral Agents; Black or African American; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2005
Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases.
    Medicine, 2005, Volume: 84, Issue:2

    Topics: Adult; Antiviral Agents; Female; Glucocorticoids; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prednisone; Ribavirin; Sarcoidosis; Skin Diseases

2005
[Clinical characterization and peculiarities of the clinical course of low-activity hepatitis C].
    Klinicheskaia meditsina, 2005, Volume: 83, Issue:1

    Topics: Adult; Antiviral Agents; Biopsy; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prognosis; Recombinant Proteins; Ribavirin

2005
[Syndrome of overlap: Chronic hepatitis C/autoimmune hepatitis: fact or fancy?].
    Recenti progressi in medicina, 2005, Volume: 96, Issue:1

    Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antiviral Agents; Diagnosis, Differential; Hepatitis C, Chronic; Hepatitis, Autoimmune; Humans; Interferons; Ribavirin; Syndrome

2005
[Crohn's disease associated with interferon and ribavirin treatment for chronic hepatitis C].
    Gastroenterologie clinique et biologique, 2005, Volume: 29, Issue:2

    Topics: Adult; Antiviral Agents; Crohn Disease; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Ribavirin

2005
[Chance of hepatic fibrosis treatment in chronic hepatitis C].
    Przeglad epidemiologiczny, 2004, Volume: 58 Suppl 1

    Topics: Anti-Inflammatory Agents; Antiviral Agents; Caspase Inhibitors; Cell Death; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-gamma; Interleukin-10; Liver Cirrhosis; Polyethylene Glycols; Ribavirin

2004
[Coinfection with HIV and HCV--epidemiologic, diagnostic, clinical and therapeutic implications].
    Przeglad epidemiologiczny, 2004, Volume: 58, Issue:4

    Topics: AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Ribavirin; Risk Factors

2004
Treatment of hepatitis C.
    Journal of viral hepatitis, 2005, Volume: 12, Issue:3

    Topics: Acute Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Maximum Tolerated Dose; Polyethylene Glycols; Prognosis; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Treatment Outcome; Viral Load

2005
[Treatment of hepatitis C virus infection].
    Praxis, 2005, May-04, Volume: 94, Issue:18

    Topics: Acute Disease; AIDS-Related Opportunistic Infections; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Longitudinal Studies; Meta-Analysis as Topic; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Viral Load

2005
[Treatment of chronic hepatitis C virus infection in human immunodeficiency virus (HIV) infected patients].
    Anales de medicina interna (Madrid, Spain : 1984), 2005, Volume: 22, Issue:6

    Topics: Antiviral Agents; Disease Progression; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Spain

2005
Approach to the management of patients with chronic hepatitis C who failed to achieve sustained virologic response.
    Clinics in liver disease, 2005, Volume: 9, Issue:3

    Topics: Amantadine; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon Type I; Interferon-alpha; Life Style; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Refusal; Viral Load

2005
Use of growth factors with antiviral therapy for chronic hepatitis C.
    Clinics in liver disease, 2005, Volume: 9, Issue:3

    Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon Type I; Neutropenia; Patient Compliance; Quality of Life; Recombinant Proteins; Ribavirin; Thrombocytopenia

2005
Treatment of recurrent hepatitis C after liver transplantation.
    Clinics in liver disease, 2005, Volume: 9, Issue:3

    Topics: Antiviral Agents; Graft Rejection; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Transplantation; Recombinant Proteins; Ribavirin; Secondary Prevention; Severity of Illness Index

2005
Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C: a case report and review of the literature.
    Archives of dermatology, 2005, Volume: 141, Issue:7

    Topics: Biopsy, Needle; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Risk Assessment; Sarcoidosis; Skin Diseases

2005
Ribavirin plus interferon versus interferon for chronic hepatitis C.
    The Cochrane database of systematic reviews, 2005, Jul-20, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Randomized Controlled Trials as Topic; Ribavirin

2005
[Current treatment of hepatitis C virus infection].
    Deutsche medizinische Wochenschrift (1946), 2005, Jul-29, Volume: 130, Issue:30

    Topics: Acute Disease; Amantadine; Animals; Antiviral Agents; Hepacivirus; Hepatitis B; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Recurrence; Ribavirin; Transaminases; Treatment Failure; Viral Envelope Proteins; Viral Hepatitis Vaccines

2005
Treatment of chronic hepatitis C in patients with renal disease.
    The Medical journal of Malaysia, 2005, Volume: 60 Suppl B

    Topics: Algorithms; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Kidney Failure, Chronic; Kidney Transplantation; Renal Dialysis; Ribavirin

2005
Using pegylated interferon and ribavirin to treat patients with chronic hepatitis C.
    American family physician, 2005, Aug-15, Volume: 72, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2005
[The adherence in the treatment of chronic hepatitis C].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2005, Volume: 18, Issue:106

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Quality of Life; Ribavirin; Treatment Outcome

2005
Current status of hepatitis C virus infection in Korea.
    Intervirology, 2006, Volume: 49, Issue:1-2

    Topics: Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; Child; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis B; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Korea; Liver Cirrhosis; Liver Neoplasms; Middle Aged; Prevalence; Ribavirin; Risk Factors; RNA, Viral; Species Specificity

2006
Viral etiology of hepatocellular carcinoma and HCV genotypes in Taiwan.
    Intervirology, 2006, Volume: 49, Issue:1-2

    Topics: Age Factors; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Neoplasms; Multivariate Analysis; Mutation; Ribavirin; RNA, Viral; Species Specificity; Taiwan; Treatment Outcome; Viral Nonstructural Proteins; Viremia

2006
Combined interferon and ribavirin therapy for chronic hepatitis C in Taiwan.
    Intervirology, 2006, Volume: 49, Issue:1-2

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis C Antibodies; Hepatitis C, Chronic; Hospitals, University; Humans; Incidence; Interferon-alpha; Liver Neoplasms; Male; Ribavirin; Seroepidemiologic Studies; Taiwan

2006
Treatment of chronic hepatitis C in southern Taiwan.
    Intervirology, 2006, Volume: 49, Issue:1-2

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Species Specificity; Taiwan; Viral Load

2006
[Molecular virology and treatment of patients with chronic hepatitis C].
    Przeglad epidemiologiczny, 2005, Volume: 59, Issue:2

    Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Carriers; Drug Therapy, Combination; Female; Fibrosis; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Failure; Liver Neoplasms; Male; Middle Aged; Poland; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome

2005
[HCV: immune response and its modifiers in clinical development].
    Przeglad epidemiologiczny, 2005, Volume: 59, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Immunotherapy; Interferon Type I; Interferon-alpha; Interferons; Recombinant Proteins; Ribavirin; T-Lymphocytes

2005
[Experimental therapy in HCV infection].
    Przeglad epidemiologiczny, 2005, Volume: 59, Issue:2

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Pyrones; Recombinant Proteins; Ribavirin; RNA-Dependent RNA Polymerase; RNA, Catalytic; RNA, Small Interfering; RNA, Viral; Treatment Outcome; Viral Nonstructural Proteins

2005
[The clinical consequences of changes occurring in HCV population during the first weeks of chronic hepatitis C treatment with interferon and ribavirin].
    Przeglad epidemiologiczny, 2005, Volume: 59, Issue:2

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polymorphism, Genetic; Prognosis; Recombinant Proteins; Ribavirin

2005
[Retreatment strategies for the patients with HCV infection].
    Przeglad epidemiologiczny, 2005, Volume: 59, Issue:2

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; Treatment Outcome

2005
[Current trends and first clinical studies of therapy for chronic hepatitis C in children using pegylated interferon alpha and ribavirin].
    Przeglad epidemiologiczny, 2005, Volume: 59, Issue:2

    Topics: Antiviral Agents; Child; Child Welfare; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Longitudinal Studies; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2005
Management of the hematologic complications of hepatitis C therapy.
    Clinics in liver disease, 2005, Volume: 9, Issue:4

    Topics: Anemia; Antiviral Agents; Bone Marrow; Epoetin Alfa; Erythropoietin; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferon Type I; Neutropenia; Recombinant Proteins; Ribavirin; Thrombocytopenia

2005
Clinical and immunological features of hepatitis C treatment-associated dermatitis in 36 prospective cases.
    The British journal of dermatology, 2005, Volume: 153, Issue:5

    Topics: Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin

2005
Chronic hepatitis C: management of treatment failures.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2005, Volume: 3, Issue:10 Suppl 2

    Topics: Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; Treatment Failure; Viral Load

2005
Ribavirin monotherapy for chronic hepatitis C.
    The Cochrane database of systematic reviews, 2005, Oct-19, Issue:4

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Randomized Controlled Trials as Topic; Ribavirin

2005
Financial impact of two different ways of evaluating early virological response to peginterferon-alpha-2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1.
    PharmacoEconomics, 2005, Volume: 23, Issue:10

    Topics: Antiviral Agents; Decision Trees; Drug Therapy, Combination; Economics, Pharmaceutical; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Multicenter Studies as Topic; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Spain

2005
Effects of adding ribavirin to interferon to treat chronic hepatitis C infection: a systematic review and meta-analysis of randomized trials.
    Archives of internal medicine, 2005, Oct-24, Volume: 165, Issue:19

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome

2005
New paradigms in the management of HIV and hepatitis C virus coinfection.
    Current opinion in infectious diseases, 2005, Volume: 18, Issue:6

    Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Clinical Trials as Topic; Disease Progression; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Multicenter Studies as Topic; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2005
Treating HCV with ribavirin analogues and ribavirin-like molecules.
    The Journal of antimicrobial chemotherapy, 2006, Volume: 57, Issue:1

    Topics: Antiviral Agents; Clinical Trials as Topic; Hepacivirus; Hepatitis C, Chronic; Humans; IMP Dehydrogenase; Molecular Structure; Ribavirin; Structure-Activity Relationship; Virus Replication

2006
Pegylated IFNs for chronic hepatitis C: an update.
    Expert opinion on drug delivery, 2005, Volume: 2, Issue:2

    Topics: Animals; Antiviral Agents; Drug Therapy; Drug Therapy, Combination; Forecasting; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Therapeutic Equivalency

2005
[Drug therapy in chronic liver disease].
    Praxis, 2005, Nov-30, Volume: 94, Issue:48

    Topics: Adenine; Administration, Oral; Anti-HIV Agents; Antiviral Agents; Azathioprine; Cholangitis, Sclerosing; Chronic Disease; Drug Therapy, Combination; Fatty Liver; Hemochromatosis; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis, Autoimmune; Hepatolenticular Degeneration; Humans; Immunosuppression Therapy; Interferons; Lamivudine; Liver Cirrhosis, Biliary; Liver Diseases; Organophosphonates; Prednisolone; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ribavirin; Time Factors

2005
Chronic hepatitis C virus management: 2000-2005 update.
    The Annals of pharmacotherapy, 2006, Volume: 40, Issue:1

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Randomized Controlled Trials as Topic; Ribavirin; Time Factors; Treatment Outcome

2006
Management of hepatitis C/HIV coinfection.
    Current opinion in infectious diseases, 2006, Volume: 19, Issue:1

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin

2006
[Hepatitis C--treatment of untreated (naive) patients].
    Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti, 2005, Volume: 59, Issue:5

    Topics: Acute Disease; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2005
Update on liver disease in hemophilia patients.
    Seminars in hematology, 2006, Volume: 43, Issue:1 Suppl 1

    Topics: Antiviral Agents; Factor VII; Factor VIIa; Hemophilia A; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Recombinant Proteins; Ribavirin

2006
Therapy of hepatitis C: from empiricism to eradication.
    Hepatology (Baltimore, Md.), 2006, Volume: 43, Issue:2 Suppl 1

    Topics: Antiviral Agents; Biopsy; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Transplantation; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin

2006
Viral hepatitis.
    Hepatology (Baltimore, Md.), 2006, Volume: 43, Issue:2 Suppl 1

    Topics: Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2006
Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management.
    Drugs, 2006, Volume: 66, Issue:2

    Topics: Antiviral Agents; Comorbidity; Hepatitis C, Chronic; Humans; Interferons; Mental Disorders; Ribavirin; Substance-Related Disorders

2006
Fatal cardiomyopathy associated with pegylated interferon/ribavirin in a patient with chronic hepatitis C.
    European journal of gastroenterology & hepatology, 2006, Volume: 18, Issue:3

    Topics: Antiviral Agents; Cardiomyopathy, Dilated; Drug Administration Schedule; Drug Therapy, Combination; Fatal Outcome; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2006
Resolution of diabetes in type 2 diabetic patient treated with IFN-alpha and ribavirin for hepatitis C.
    European journal of gastroenterology & hepatology, 2006, Volume: 18, Issue:3

    Topics: Adult; Antiviral Agents; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Remission Induction; Ribavirin; Treatment Failure; Weight Loss

2006
Ribavirin monotherapy for chronic hepatitis C infection: a Cochrane Hepato-Biliary Group systematic review and meta-analysis of randomized trials.
    The American journal of gastroenterology, 2006, Volume: 101, Issue:4

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Randomized Controlled Trials as Topic; Ribavirin

2006
[Significance of non-organ-specific autoantibodies in HCV-related chronic hepatitis].
    Recenti progressi in medicina, 2005, Volume: 96, Issue:12

    Topics: Antiviral Agents; Autoantibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2005
Chronic hepatitis C: treatment of pegylated interferon/ribavirin nonresponders.
    Current gastroenterology reports, 2006, Volume: 8, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Prognosis; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Failure; Viral Load

2006
Aspects of hepatitis C virus infection relating to liver transplantation.
    European journal of gastroenterology & hepatology, 2006, Volume: 18, Issue:4

    Topics: Antiviral Agents; Graft Survival; Hepatitis C, Chronic; Humans; Interferons; Liver Transplantation; Postoperative Complications; Ribavirin; Secondary Prevention

2006
Individualization of antiviral treatment regimens for chronic hepatitis C.
    European journal of gastroenterology & hepatology, 2006, Volume: 18, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Outcome

2006
Progression of hepatic fibrosis in chronic hepatitis C and the need for treatment in mild disease.
    European journal of gastroenterology & hepatology, 2006, Volume: 18, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Disease Progression; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Risk Factors

2006
[High dose repeat therapy in previously treated patients with chronic hepatitis C].
    Deutsche medizinische Wochenschrift (1946), 2006, Mar-17, Volume: 131, Issue:11

    Topics: Amantadine; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Time Factors; Treatment Outcome; Viral Load

2006
Novel approaches for therapy of chronic hepatitis C.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2006, Volume: 36, Issue:2

    Topics: Antidepressive Agents; Antiviral Agents; Clinical Trials as Topic; Erythropoietin; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Protease Inhibitors; Purine-Nucleoside Phosphorylase; Pyrimidine Nucleosides; Ribavirin; Viral Hepatitis Vaccines

2006
Management of patients with chronic hepatitis C infection.
    Clinical and experimental medicine, 2006, Volume: 6, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2006
Pegylated interferon plus ribavirin for chronic hepatitis C: the role of combination therapy today, tomorrow and in the future.
    Minerva gastroenterologica e dietologica, 2006, Volume: 52, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Forecasting; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2006
[Complementary treatments of chronic viral hepatitis C].
    Gastroenterologie clinique et biologique, 2006, Volume: 30, Issue:2

    Topics: Anemia; Antidepressive Agents; Antioxidants; Antiviral Agents; Erythropoietin; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia

2006
[Individualised treatment of chronic hepatitis C].
    Der Internist, 2006, Volume: 47 Suppl 1

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Germany; Hepatitis C, Chronic; Humans; Interferon-alpha; Practice Guidelines as Topic; Practice Patterns, Physicians'; Ribavirin

2006
Review article: predicting response in hepatitis C virus therapy.
    Alimentary pharmacology & therapeutics, 2006, Apr-15, Volume: 23, Issue:8

    Topics: Antiviral Agents; Fibrosis; Genes, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Prognosis; Ribavirin; Time Factors; Treatment Outcome; Viral Load

2006
Assessing evidence from clinical trials in chronic hepatitis C.
    Journal of viral hepatitis, 2006, Volume: 13 Suppl 1

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin

2006
Evaluating the evidence from clinical trials in chronic hepatitis C.
    Journal of viral hepatitis, 2006, Volume: 13 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome

2006
Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches.
    Journal of clinical gastroenterology, 2006, Volume: 40, Issue:4

    Topics: Anemia; Antiviral Agents; Depressive Disorder, Major; Hepatitis C, Chronic; Humans; Intercellular Adhesion Molecule-1; Interferon alpha-2; Interferon Type I; Interferon-alpha; Nitric Oxide; Paroxetine; Peptide Hydrolases; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Risk Factors; Selective Serotonin Reuptake Inhibitors; Thyroid Diseases

2006
Diagnosis and treatment of chronic hepatitis C infection.
    BMJ (Clinical research ed.), 2006, Apr-29, Volume: 332, Issue:7548

    Topics: Antibodies, Viral; Antiviral Agents; Biopsy; Drug Combinations; Hepatitis C, Chronic; Humans; Immunologic Tests; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Virology

2006
Systemic sarcoidosis presenting in a tattooed man undergoing treatment for hepatitis C.
    Clinical and experimental dermatology, 2006, Volume: 31, Issue:3

    Topics: Antiviral Agents; Combined Modality Therapy; Hepatitis C, Chronic; Histiocytes; Humans; Immunotherapy; Interferon-alpha; Male; Middle Aged; Paint; Ribavirin; Sarcoidosis; Skin; Skin Diseases; Tattooing

2006
[New trend in treatment in patients with chronic hepatitis C].
    Orvosi hetilap, 2006, Apr-09, Volume: 147, Issue:14

    Topics: Alanine Transaminase; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Lymphokines; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2006
Is interferon-beta an alternative treatment for chronic hepatitis C?
    World journal of gastroenterology, 2006, May-07, Volume: 12, Issue:17

    Topics: Antiviral Agents; Drug Therapy, Combination; Drug Tolerance; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-beta; Randomized Controlled Trials as Topic; Ribavirin

2006
Treatment of interferon-alpha for chronic hepatitis C.
    Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:9

    Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Failure; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2006
[Chronic hepatitis C--patients "difficult to treat"].
    Przeglad epidemiologiczny, 2006, Volume: 60, Issue:1

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2006
[The expectations for results of clinical trial "IDEAL"].
    Przeglad epidemiologiczny, 2006, Volume: 60, Issue:1

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome

2006
[HIV and HCV coinfection].
    Enfermedades infecciosas y microbiologia clinica, 2006, Volume: 24, Issue:5

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Carcinoma, Hepatocellular; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Contraindications; Disease Progression; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Multicenter Studies as Topic; Patient Selection; Polyethylene Glycols; Ribavirin; Risk Factors; Treatment Outcome; Viral Load

2006
Pharmacoeconomics applied to chronic hepatitis C.
    The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2006, Volume: 10, Issue:1

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Markov Chains; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin

2006
Chronic hepatitis C in HIV-infected patients: those who more need therapy are those who respond less.
    Infectious disorders drug targets, 2006, Volume: 6, Issue:1

    Topics: Antiviral Agents; CD4 Lymphocyte Count; Drug Interactions; Drug Monitoring; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Patient Selection; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Failure

2006
Paternal use of ribavirin-interferon alpha 2B combination therapy before conception.
    Canadian family physician Medecin de famille canadien, 2005, Volume: 51

    Topics: Antiviral Agents; Drug Combinations; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Paternal Exposure; Pregnancy; Recombinant Proteins; Ribavirin; Spermatozoa

2005
[HCV-HBV infection].
    Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64, Issue:7

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk

2006
[Side effects of interferon therapy for chronic hepatitis C].
    Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64, Issue:7

    Topics: Antiviral Agents; Drug Therapy, Combination; Fatigue; Hepatitis C, Chronic; Humans; Interferons; Leukopenia; Mental Disorders; Ribavirin; Thrombocytopenia

2006
Chronic hepatitis C therapy: changing the rules of duration.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2006, Volume: 4, Issue:8

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load

2006
Treating hepatitis C infection in liver transplant recipients.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2006, Volume: 12, Issue:8

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Transplantation; Reoperation; Ribavirin

2006
Treatment of hepatitis C infection.
    Gastroenterology clinics of North America, 2006, Volume: 35, Issue:2

    Topics: Antiviral Agents; Contraindications; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2006
Viral kinetics in the treatment of chronic hepatitis C.
    Journal of viral hepatitis, 2006, Volume: 13, Issue:8

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load

2006
Treating viral hepatitis C: efficacy, side effects, and complications.
    Gut, 2006, Volume: 55, Issue:9

    Topics: Amantadine; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Treatment Outcome

2006
Treatment of chronic hepatitis C in patients with haemophilia: a review of the literature.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2006, Volume: 12, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Hemophilia A; Hepatitis C, Chronic; HIV Seronegativity; HIV Seropositivity; Humans; Interferons; Ribavirin; RNA, Viral; Treatment Outcome

2006
Chronic Hepatitis B and C--current treatment and future therapeutic prospects.
    Wiener medizinische Wochenschrift (1946), 2006, Volume: 156, Issue:13-14

    Topics: Adenine; Antiviral Agents; DNA-Directed RNA Polymerases; Hepatitis B e Antigens; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Organophosphonates; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin

2006
[Optimization of the method of treatment of chronic viral hepatitis C with pegylated interferon-alfa and ribavirin].
    Przeglad epidemiologiczny, 2006, Volume: 60, Issue:2

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Carriers; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; Secondary Prevention; Treatment Outcome

2006
[Acute hepatitis. Biological hepatic anomalies in asymptomatic persons].
    La Revue du praticien, 2006, Sep-15, Volume: 56, Issue:13

    Topics: Acute Disease; Adult; Antiviral Agents; Cholestasis; Chronic Disease; Clinical Enzyme Tests; Diagnosis, Differential; France; Hepatitis A; Hepatitis B; Hepatitis B, Chronic; Hepatitis C; Hepatitis C, Chronic; Hepatitis D; Hepatitis D, Chronic; Hepatitis, Viral, Human; Humans; Infectious Disease Transmission, Vertical; Interferon-alpha; Phosphoric Monoester Hydrolases; Prevalence; Ribavirin; Transaminases

2006
Review article: management of patients with chronic hepatitis C virus infection and "normal" alanine aminotransferase activity.
    Alimentary pharmacology & therapeutics, 2006, Oct-15, Volume: 24, Issue:8

    Topics: Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Genotype; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Motivation; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin

2006
Antiviral treatment of hepatitis C.
    Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:15

    Topics: Adult; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors

2006
[Therapy of chronic hepatitis C].
    Praxis, 2006, Sep-20, Volume: 95, Issue:38

    Topics: Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2006
[Difficult-to-treat patients with chronic hepatitis C].
    Praxis, 2006, Sep-20, Volume: 95, Issue:38

    Topics: Antiviral Agents; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load

2006
Meta-analysis: anti-viral therapy of hepatitis C virus-related liver disease in renal transplant patients.
    Alimentary pharmacology & therapeutics, 2006, Nov-15, Volume: 24, Issue:10

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Kidney Transplantation; Postoperative Complications; Ribavirin; Treatment Outcome

2006
Antiviral treatment of hepatitis C: present status and future prospects.
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2006, Volume: 12, Issue:5

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2006
Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin.
    British journal of clinical pharmacology, 2006, Volume: 62, Issue:6

    Topics: Adult; Aged; Anemia; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Biological; Multicenter Studies as Topic; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Treatment Outcome; Viral Load

2006
Pharmacokinetics of ribavirin in patients with hepatitis C virus.
    British journal of clinical pharmacology, 2006, Volume: 62, Issue:6

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Cross-Over Studies; Drug Combinations; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Biological; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2006
[Treatment of chronic hepatitis C--ribavirin plus interferon versus interferon. An analysis of a systematic Cochrane review].
    Ugeskrift for laeger, 2006, Nov-27, Volume: 168, Issue:48

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Meta-Analysis as Topic; Ribavirin; Treatment Outcome

2006
Peginterferon and ribavirin for chronic hepatitis C.
    The New England journal of medicine, 2006, Dec-07, Volume: 355, Issue:23

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; RNA, Viral

2006
Optimizing treatment regimens in hepatitis C.
    Clinics in liver disease, 2006, Volume: 10, Issue:4

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Virus Replication

2006
[Hepatitis C and liver transplantation: fibrosis progression and treatment. Or how to improve management].
    Gastroenterologie clinique et biologique, 2006, Volume: 30, Issue:11

    Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Graft Rejection; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Postoperative Complications; Ribavirin; Secondary Prevention; Treatment Outcome

2006
Improving anti-HCV therapy.
    Discovery medicine, 2006, Volume: 6, Issue:35

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon Type I; Recombinant Proteins; Ribavirin

2006
Customizing treatment to patient populations.
    Nature clinical practice. Gastroenterology & hepatology, 2007, Volume: 4 Suppl 1

    Topics: Antiviral Agents; Body Weight; Dose-Response Relationship, Drug; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Virus Replication

2007
Optimizing treatment outcomes in chronic hepatitis C: management of non-response.
    Antiviral therapy, 2006, Volume: 11, Issue:8

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Outcome

2006
Hepatology may have problems with putative surrogate outcome measures.
    Journal of hepatology, 2007, Volume: 46, Issue:4

    Topics: Antiviral Agents; Bilirubin; Biomarkers; Cholagogues and Choleretics; Gastroenterology; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferons; Liver Cirrhosis, Biliary; Liver Diseases; Outcome Assessment, Health Care; Reproducibility of Results; Ribavirin; Ursodeoxycholic Acid; Viral Load

2007
The effects of HCV infection and management on health-related quality of life.
    Hepatology (Baltimore, Md.), 2007, Volume: 45, Issue:3

    Topics: Antiviral Agents; Chronic Disease; Depression; Fatigue; Health Status; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Diseases; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin

2007
[Hepatitis C viral infection and depression].
    Orvosi hetilap, 2007, Jan-07, Volume: 148, Issue:1

    Topics: Antidepressive Agents; Antiviral Agents; Depressive Disorder, Major; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin

2007
Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation.
    Health technology assessment (Winchester, England), 2007, Volume: 11, Issue:11

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Markov Chains; Multicenter Studies as Topic; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin

2007
Pegylated interferon-alpha2beta in combination with ribavirin does not aggravate thyroid dysfunction in comparison to regular interferon-alpha2beta in a hepatitis C population: meta-analysis.
    Journal of gastroenterology and hepatology, 2007, Volume: 22, Issue:4

    Topics: Adult; Drug Combinations; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thyroid Diseases

2007
Short-duration therapy for hepatitis C: suitable for all?
    Journal of viral hepatitis, 2007, Volume: 14, Issue:4

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2007
Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy.
    The American journal of gastroenterology, 2007, Volume: 102, Issue:4

    Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Quality of Life; Recombinant Proteins; Ribavirin

2007
Management of chronic hepatitis C.
    Minerva gastroenterologica e dietologica, 2007, Volume: 53, Issue:1

    Topics: Antiviral Agents; Decision Trees; Disease Progression; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Ribavirin

2007
Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C.
    Alimentary pharmacology & therapeutics, 2007, May-15, Volume: 25, Issue:10

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome

2007
Treatment of hepatitis C virus infection.
    World journal of gastroenterology, 2007, Apr-07, Volume: 13, Issue:13

    Topics: Acute Disease; Amantadine; Antiviral Agents; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2007
Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel.
    AIDS (London, England), 2007, May-31, Volume: 21, Issue:9

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Antiviral Agents; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Drug Interactions; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Ribavirin; Transaminases

2007
[Retreatment of chronic hepatitis C patients non responder to a previous antiviral treatment].
    Recenti progressi in medicina, 2007, Volume: 98, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; Risk Factors; Time Factors; Treatment Failure; Treatment Outcome

2007
The treatment of chronic hepatitis C in HIV-infected patients: a meta-analysis.
    HIV medicine, 2007, Volume: 8, Issue:5

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2007
Hepatitis C in dialysis units: the Saudi experience.
    Hemodialysis international. International Symposium on Home Hemodialysis, 2007, Volume: 11, Issue:3

    Topics: Antiviral Agents; Education, Nursing, Continuing; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Infection Control; Interferon-alpha; Kidney Failure, Chronic; Prevalence; Renal Dialysis; Ribavirin; Saudi Arabia

2007
Management and therapy of chronic hepatitis C virus infection in HIV-infected individuals.
    Journal of HIV therapy, 2007, Volume: 12, Issue:1

    Topics: Antiviral Agents; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Patient Compliance; Ribavirin; Treatment Outcome

2007
Review article: the treatment of hepatitis C virus recurrence after liver transplantation.
    Alimentary pharmacology & therapeutics, 2007, Jul-15, Volume: 26, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Transplantation; Male; Randomized Controlled Trials as Topic; Recurrence; Ribavirin; Risk Factors; Treatment Outcome

2007
Treatment of HCV in patients with renal failure.
    Archives of medical research, 2007, Volume: 38, Issue:6

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Kidney Failure, Chronic; Kidney Transplantation; Renal Dialysis; Ribavirin

2007
Hepatitis C treatment: shorter and better?
    The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2007, Volume: 11, Issue:1

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load

2007
WITHDRAWN: Ribavirin with or without alpha interferon for chronic hepatitis C.
    The Cochrane database of systematic reviews, 2007, Jul-18, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Randomized Controlled Trials as Topic; Ribavirin

2007
[Interferon in the treatment of viral hepatitis. The interferon was discovered 50 years ago].
    Orvosi hetilap, 2007, Aug-19, Volume: 148, Issue:33

    Topics: Animals; Antineoplastic Agents; Antiviral Agents; Drug Therapy, Combination; Fibroblasts; Hepatitis B, Chronic; Hepatitis C, Chronic; History, 20th Century; History, 21st Century; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Interferon-beta; Interferon-gamma; Interferons; Leukocytes; Lymphocytes; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Terminology as Topic

2007
[PEG IFN alpha-2a in the treatment of chronic hepatitis C in patients with treatment failure].
    Przeglad epidemiologiczny, 2007, Volume: 61, Issue:1

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure

2007
[Recent developments in the treatment of chronic hepatitis B and C].
    Nederlands tijdschrift voor tandheelkunde, 2007, Volume: 114, Issue:8

    Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Nucleosides; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2007
[Adaptive cell immune response against the hepatitis C virus infection].
    Medicina clinica, 2007, Oct-06, Volume: 129, Issue:12

    Topics: Acute Disease; Animals; Antiviral Agents; CD8-Positive T-Lymphocytes; Cells, Cultured; Disease Models, Animal; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Immunity, Cellular; Interferon-alpha; Killer Cells, Natural; Mutation; Pan troglodytes; Ribavirin; T-Lymphocytes; T-Lymphocytes, Helper-Inducer; Time Factors; Virus Replication

2007
Antiviral therapy: chronic hepatitis C.
    Journal of viral hepatitis, 2007, Volume: 14 Suppl 1

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Ribavirin

2007
Inflammation and repair in viral hepatitis C.
    Digestive diseases and sciences, 2008, Volume: 53, Issue:6

    Topics: Alcoholism; Antiviral Agents; Carcinoma, Hepatocellular; Cytokines; Disease Progression; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Inflammation; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Ribavirin; Risk Factors

2008
Future treatment of chronic hepatitis C.
    Antiviral therapy, 2007, Volume: 12, Issue:7

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Protease Inhibitors; Ribavirin

2007
Nonresponse to treatment for hepatitis C: current management strategies.
    Drugs, 2008, Volume: 68, Issue:1

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Viral; Drugs, Investigational; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Patient Compliance; Polyethylene Glycols; Ribavirin; Treatment Failure

2008
Long-term effects of interferon-based therapy for chronic hepatitis C.
    Oncology, 2007, Volume: 72 Suppl 1

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Survival Rate; Treatment Outcome; Viral Load

2007
Old and emerging therapies in chronic hepatitis C: an update.
    Journal of viral hepatitis, 2008, Volume: 15, Issue:1

    Topics: Antiviral Agents; Drug Evaluation, Preclinical; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Immunotherapy; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin

2008
Into the light: strategies for battling hepatitis C.
    The American journal of managed care, 2007, Volume: 13 Suppl 12

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2007
Making it happen: managed care considerations in vanquishing hepatitis C.
    The American journal of managed care, 2007, Volume: 13 Suppl 12

    Topics: Antiviral Agents; Cost-Benefit Analysis; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Managed Care Programs; Patient Education as Topic; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2007
[Review: clinical outcome after living donor liver transplantation in patients with hepatitis C virus-associated cirrhosis].
    The Korean journal of hepatology, 2007, Volume: 13, Issue:4

    Topics: Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Living Donors; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome

2007
Rapid virologic response: a new milestone in the management of chronic hepatitis C.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, Jan-01, Volume: 46, Issue:1

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2008
Current and emerging therapeutic approaches in HCV-related mixed cryoglobulinemia.
    Current medicinal chemistry, 2008, Volume: 15, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; B-Lymphocytes; Cryoglobulinemia; Enzyme Inhibitors; Hepacivirus; Hepatitis C, Chronic; Humans; Immunoglobulin M; Interferons; Oligonucleotides, Antisense; Rheumatoid Factor; Ribavirin; Rituximab; Signal Transduction

2008
Oral diseases associated with hepatitis C virus infection. Part 2: lichen planus and other diseases.
    Oral diseases, 2008, Volume: 14, Issue:3

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon Type I; Japan; Lichen Planus, Oral; Mediterranean Region; Mouth Mucosa; Mouth Neoplasms; Recombinant Proteins; Ribavirin; T-Lymphocytes

2008
[Development of antiviral therapy for patients with chronic hepatitis C].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2008, Volume: 105, Issue:2

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins

2008
[Treatment of the old patients with chronic hepatitis C].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2008, Volume: 105, Issue:2

    Topics: Aged; Anti-Infective Agents; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin

2008
Treatment of chronic hepatitis C with consensus interferon in relapsers and non-responders to interferon-based therapy.
    Hepato-gastroenterology, 2007, Volume: 54, Issue:80

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Recurrence; Ribavirin; Treatment Failure

2007
Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis.
    Current opinion in rheumatology, 2008, Volume: 20, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; B-Lymphocytes; Cryoglobulinemia; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Rituximab; Vasculitis

2008
Review article: novel therapeutic options for chronic hepatitis C.
    Alimentary pharmacology & therapeutics, 2008, Volume: 27, Issue:10

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Oligonucleotides, Antisense; Recombinant Proteins; Ribavirin; Thionucleotides; Treatment Outcome

2008
Treatment regimens for patients with chronic hepatitis C.
    Minerva gastroenterologica e dietologica, 2008, Volume: 54, Issue:2

    Topics: Algorithms; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2008
Hepatic sarcoidosis associated with pegylated interferon alfa therapy for chronic hepatitis C: case report and review of literature.
    Digestive diseases and sciences, 2008, Volume: 53, Issue:10

    Topics: Adult; Antiviral Agents; Biopsy; Chemical and Drug Induced Liver Injury; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Diseases; Male; Peptidyl-Dipeptidase A; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sarcoidosis

2008
Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin: a meta-analysis.
    The Journal of antimicrobial chemotherapy, 2008, Volume: 61, Issue:6

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Outcome; Viremia

2008
[Anti-viral therapy of type C chronic hepatitis. 3. New development in anti-viral therapy of type C chronic hepatitis--Peg-IFN/ribavirin combination therapy and a new anti-viral treatment].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2008, Jan-10, Volume: 97, Issue:1

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2008
Hepatitis B and C in children.
    Nature clinical practice. Gastroenterology & hepatology, 2008, Volume: 5, Issue:6

    Topics: Antiviral Agents; Child; Disease Transmission, Infectious; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Infectious Disease Transmission, Vertical; Interferon-alpha; Lamivudine; Ribavirin; Treatment Outcome

2008
Current and future management of chronic hepatitis C infection.
    Postgraduate medical journal, 2008, Volume: 84, Issue:990

    Topics: Antiviral Agents; Forecasting; Hepatitis C, Chronic; Humans; Interferons; Nucleic Acid Synthesis Inhibitors; Protease Inhibitors; Ribavirin

2008
Hepatitis C virus therapy to date.
    Antiviral therapy, 2008, Volume: 13 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2008
Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4.
    Antiviral therapy, 2008, Volume: 13 Suppl 1

    Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Predictive Value of Tests; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2008
Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3.
    Antiviral therapy, 2008, Volume: 13 Suppl 1

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2008
Ribavirin considerations in treatment optimization.
    Antiviral therapy, 2008, Volume: 13 Suppl 1

    Topics: Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Time Factors; Viral Load

2008
Pegylated interferons for chronic hepatitis C virus infection: an indirect analysis of randomized trials.
    Journal of viral hepatitis, 2008, Volume: 15, Issue:8

    Topics: Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2008
[Therapy of chronic hepatitis C: facing a breakthrough?].
    Schweizerische medizinische Wochenschrift, 1998, Jan-06, Volume: 128, Issue:1-2

    Topics: Amantadine; Clinical Trials as Topic; Combined Modality Therapy; Hepatitis C, Chronic; Humans; Interferon Type I; Recombinant Proteins; Recurrence; Ribavirin; Viral Load

1998
Hepatitis C treatment.
    Current studies in hematology and blood transfusion, 1998, Issue:62

    Topics: Alanine Transaminase; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Liver Transplantation; Retreatment; Ribavirin

1998
Management of hepatitis C.
    Journal of viral hepatitis, 1998, Volume: 5, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin

1998
[New antiviral agents in the treatment of chronic hepatitis B and C].
    Revista espanola de enfermedades digestivas, 1998, Volume: 90, Issue:4

    Topics: 2-Aminopurine; Antimetabolites; Antiviral Agents; Clinical Trials as Topic; Famciclovir; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Lamivudine; Prodrugs; Reverse Transcriptase Inhibitors; Ribavirin

1998
[Is combination therapy of chronic hepatitis C with interferon alpha and ribavirin in primary interferon nonresponders indicated?--An analysis of personal experiences and review of the literature].
    Zeitschrift fur Gastroenterologie, 1998, Volume: 36, Issue:9

    Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Randomized Controlled Trials as Topic; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

1998
[Chronic hepatitis C--therapeutic modalities for interferon failure].
    Praxis, 1998, Oct-14, Volume: 87, Issue:42

    Topics: Amantadine; Antiviral Agents; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Treatment Failure

1998
[Interactions between the human immunodeficiency virus and hepatitis C virus].
    La Revue de medecine interne, 1998, Volume: 19, Issue:12

    Topics: Anti-HIV Agents; Antiviral Agents; Comorbidity; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Prevalence; Ribavirin; Virus Replication

1998
[Ribavirin/interferon-alpha combination in treatment of chronic hepatitis C: what is the status today?].
    Schweizerische medizinische Wochenschrift, 1999, Jan-12, Volume: 129, Issue:1-2

    Topics: Antiviral Agents; Combined Modality Therapy; Hepatitis C, Chronic; Humans; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome

1999
The clinical pharmacology of ribavirin.
    Seminars in liver disease, 1999, Volume: 19 Suppl 1

    Topics: Absorption; Administration, Oral; Antiviral Agents; Biological Availability; Biological Transport; Drug Interactions; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Intestine, Small; Recombinant Proteins; Ribavirin

1999
Use of high-dose interferon in the treatment of chronic hepatitis C.
    Seminars in liver disease, 1999, Volume: 19 Suppl 1

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome

1999
Standards of treatment in chronic hepatitis C.
    Seminars in liver disease, 1999, Volume: 19 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

1999
Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C.
    Seminars in liver disease, 1999, Volume: 19 Suppl 1

    Topics: Antiviral Agents; Drug Administration Routes; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome

1999
Activity of combination therapy with interferon alfa-2b plus ribavirin in chronic hepatitis C patients co-infected with HIV.
    Seminars in liver disease, 1999, Volume: 19 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

1999
[Interferon-alpha and ribavirin: advances in the therapy of chronic hepatitis C].
    Deutsche medizinische Wochenschrift (1946), 1999, May-21, Volume: 124, Issue:20

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Immunocompromised Host; Interferon-alpha; Recurrence; Ribavirin

1999
Combination therapy for chronic hepatitis C: interferon and ribavirin.
    Hospital medicine (London, England : 1998), 1999, Volume: 60, Issue:5

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Recombinant Proteins; Recurrence; Ribavirin

1999
[Antiviral treatment of hepatitis C virus infection].
    La Revue de medecine interne, 1999, Volume: 20 Suppl 3

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Protease Inhibitors; Ribavirin; Risk Factors; RNA, Viral; Viral Load

1999
Treatment of chronic viral hepatitis.
    Acta clinica Belgica, 1999, Volume: 54, Issue:5

    Topics: Antiviral Agents; Glucocorticoids; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Patient Selection; Prednisone; Reverse Transcriptase Inhibitors; Ribavirin

1999
[Chronic viral hepatitis caused by B and C virus: diagnostic and therapeutic trends].
    Recenti progressi in medicina, 1999, Volume: 90, Issue:11

    Topics: Antiviral Agents; DNA, Viral; Genotype; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferons; Lamivudine; Polymerase Chain Reaction; Recurrence; Ribavirin; RNA, Viral

1999
Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C.
    Journal of hepatology, 1999, Volume: 31 Suppl 1

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Models, Theoretical; Ribavirin; Treatment Failure; Virus Replication

1999
Treatment of naive patients with chronic hepatitis C.
    Journal of hepatology, 1999, Volume: 31 Suppl 1

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Randomized Controlled Trials as Topic; Remission Induction; Ribavirin; Viral Load

1999
Retreatment of interferon relapse patients with chronic hepatitis C.
    Journal of hepatology, 1999, Volume: 31 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Recurrence; Ribavirin

1999
New treatment strategies in non-responder patients with chronic hepatitis C.
    Journal of hepatology, 1999, Volume: 31 Suppl 1

    Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Failure

1999
Early predictors of response to treatment in patients with chronic hepatitis C.
    Journal of hepatology, 1999, Volume: 31 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Prognosis; Remission Induction; Ribavirin; RNA, Viral; Time Factors; Viremia

1999
Long-term efficacy of treatment of chronic hepatitis C with alpha interferon or alpha interferon and ribavirin.
    Journal of hepatology, 1999, Volume: 31 Suppl 1

    Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Time Factors

1999
Advances in the treatment of hepatitis C.
    Advances in internal medicine, 2000, Volume: 45

    Topics: Antiviral Agents; Biopsy; Clinical Protocols; Disease Progression; Drug Therapy, Combination; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Cirrhosis; Liver Failure; Ribavirin

2000
[Therapy of chronic viral hepatitis].
    Der Internist, 1999, Volume: 40, Issue:12

    Topics: Antiviral Agents; Germany; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis D, Chronic; Hepatitis, Viral, Human; Humans; Interferons; Liver Transplantation; Prognosis; Renal Dialysis; Ribavirin; Risk Factors

1999
Antiviral therapy for chronic hepatitis B and C. Which patients are likely to benefit from which agents?
    Postgraduate medicine, 2000, Volume: 107, Issue:2

    Topics: Antiviral Agents; Contraindications; Drug Combinations; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Recombinant Proteins; Ribavirin

2000
Molecular tools for the treatment of hepatitis C.
    Antiviral therapy, 1998, Volume: 3, Issue:Suppl 3

    Topics: Antiviral Agents; Biomarkers; Drug Resistance, Microbial; Genetic Techniques; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; RNA, Viral; Time Factors; Viral Load; Viremia; Virus Replication

1998
Hepatitis C virus in the transplant setting.
    Antiviral therapy, 1998, Volume: 3, Issue:Suppl 3

    Topics: Antiviral Agents; Combined Modality Therapy; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Interferons; Liver Failure; Liver Transplantation; Recurrence; Ribavirin; RNA, Viral; Survival Rate; Time Factors; Tissue Donors

1998
Chronic viral hepatitis C: management update.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2000, Mar-21, Volume: 162, Issue:6

    Topics: Antiviral Agents; Canada; Drug Approval; Drug Monitoring; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Recombinant Proteins; Ribavirin

2000
[Etiology of hepatocellular carcinoma. The problem of the primary disease].
    Der Internist, 2000, Volume: 41, Issue:2 Pt 2

    Topics: Carcinoma, Hepatocellular; Cross-Cultural Comparison; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis, Alcoholic; Liver Neoplasms; Ribavirin; Risk Factors

2000
[New therapeutic possibilities in chronic hepatitis C].
    Praxis, 2000, Mar-09, Volume: 89, Issue:11

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin

2000
Treatment of autoimmune and extra-hepatic manifestations of HCV infection.
    Annales de medecine interne, 2000, Volume: 151, Issue:1

    Topics: Antiviral Agents; Autoantibodies; Autoimmune Diseases; Cryoglobulinemia; Hepacivirus; Hepatitis C, Chronic; Humans; Immune Complex Diseases; Interferon-alpha; Kidney; Lichen Planus; Microsomes; Microsomes, Liver; Ribavirin; Sialadenitis; Thyroiditis, Autoimmune

2000
Combination therapy with interferon and ribavirin in the treatment of chronic hepatitis C infection.
    The Annals of pharmacotherapy, 2000, Volume: 34, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Outcome

2000
Treatment strategies for chronic hepatitis C virus infection.
    Journal of gastroenterology, 2000, Volume: 35, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Carcinoma, Hepatocellular; Drugs, Chinese Herbal; Glycyrrhizic Acid; Hepatitis C, Chronic; Humans; Interferons; Iron Overload; Liver Neoplasms; Ribavirin; Treatment Outcome; Ursodeoxycholic Acid

2000
Current therapy for chronic hepatitis C.
    Gastroenterology, 2000, Volume: 118, Issue:2 Suppl 1

    Topics: Antiviral Agents; Drug Resistance; Hepatitis C, Chronic; Humans; Interferons; Monitoring, Physiologic; Recurrence; Ribavirin

2000
Therapeutic options for HCV--management of the infected individual.
    Bailliere's best practice & research. Clinical gastroenterology, 2000, Volume: 14, Issue:2

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Patient Selection; Practice Guidelines as Topic; Ribavirin; Treatment Outcome

2000
Treatment of chronic hepatitis C virus infection in children.
    Bailliere's best practice & research. Clinical gastroenterology, 2000, Volume: 14, Issue:2

    Topics: Antiviral Agents; Child; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; RNA, Viral; Treatment Outcome

2000
[Treatment of chronic hepatitis C: present and future].
    Gastroenterologie clinique et biologique, 2000, Volume: 24, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin

2000
Recurrent hepatitis C after liver transplantation.
    Journal of medical virology, 2000, Volume: 61, Issue:4

    Topics: Antiviral Agents; Cytomegalovirus; Drug Therapy, Combination; Flaviviridae; Hepacivirus; Hepatitis B virus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferons; Liver Cirrhosis; Liver Transplantation; Ribavirin; RNA, Viral

2000
Treatment strategies for hepatitis C: making the best of limited options.
    Cleveland Clinic journal of medicine, 2000, Volume: 67, Issue:7

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Predictive Value of Tests; Prognosis; Ribavirin

2000
[Hepatitis C--standard therapy].
    Praxis, 2000, Jun-15, Volume: 89, Issue:24

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Survival Rate; Treatment Outcome

2000
Adverse effects and other safety aspects of the hepatitis C antivirals.
    Journal of gastroenterology and hepatology, 2000, Volume: 15 Suppl

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Ribavirin

2000
Pre- and post-transplant treatment of hepatitis C.
    Journal of gastroenterology and hepatology, 2000, Volume: 15 Suppl

    Topics: Antiviral Agents; Drug Therapy, Combination; Graft Rejection; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Recurrence; Ribavirin

2000
Treatment of hepatitis C with interferon and ribavirin.
    Journal of gastroenterology and hepatology, 2000, Volume: 15, Issue:6

    Topics: Acute Disease; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Recurrence; Ribavirin

2000
Antiviral therapy for patients with chronic hepatitis C.
    Seminars in liver disease, 2000, Volume: 20, Issue:2

    Topics: Antiviral Agents; Clinical Trials as Topic; Comorbidity; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Patient Selection; Prognosis; Recombinant Proteins; Ribavirin; Treatment Outcome

2000
Treatment of chronic hepatitis C virus infection in patients with cirrhosis.
    Journal of viral hepatitis, 2000, Volume: 7, Issue:5

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Middle Aged; Ribavirin

2000
Hepatitis C virus kinetics.
    Antiviral therapy, 2000, Volume: 5, Issue:2

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Kinetics; Mathematical Computing; Models, Biological; Models, Statistical; Ribavirin; RNA, Viral

2000
Treatment of chronic hepatitis C in nonresponders to interferon monotherapy.
    Current gastroenterology reports, 2000, Volume: 2, Issue:1

    Topics: Alanine Transaminase; Antiviral Agents; Black or African American; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Iron; Liver; Recurrence; Ribavirin; RNA, Viral

2000
Management of recurrent hepatitis C after liver transplantation: a concise review.
    The American journal of gastroenterology, 2000, Volume: 95, Issue:9

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Prognosis; Ribavirin; RNA, Viral; Secondary Prevention

2000
Further evolution of hepatitis C treatment: individualized therapy.
    The American journal of gastroenterology, 2000, Volume: 95, Issue:9

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2000
Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2000, Volume: 32, Issue:5

    Topics: Adult; Antiviral Agents; Disease Progression; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin

2000
Hepatitis C in African Americans: summary of a workshop.
    Gastroenterology, 2000, Volume: 119, Issue:5

    Topics: Antiviral Agents; Black or African American; Carcinoma, Hepatocellular; Hepatitis C, Chronic; Humans; Incidence; Interferons; Liver Neoplasms; Liver Transplantation; Prevalence; Ribavirin; Substance Abuse, Intravenous; United States; Veterans

2000
[Hepatitis C virus infection. Overview. SEVHEP (Swiss Experts on Viral Hepatitis)].
    Praxis, 2000, Oct-05, Volume: 89, Issue:40

    Topics: Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon-alpha; Polymorphism, Genetic; Ribavirin; RNA, Viral

2000
Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials.
    Hepatology (Baltimore, Md.), 2001, Volume: 33, Issue:1

    Topics: Adult; Antiviral Agents; Clinical Trials as Topic; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Liver; Male; Middle Aged; Randomized Controlled Trials as Topic; Retreatment; Ribavirin

2001
Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review.
    Health technology assessment (Winchester, England), 2000, Volume: 4, Issue:33

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Prognosis; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome; United Kingdom

2000
Current treatment strategies for chronic hepatitis B and C.
    Annual review of medicine, 2001, Volume: 52

    Topics: Antiviral Agents; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Life Style; Recombinant Proteins; Ribavirin; Treatment Outcome; Vaccination

2001
Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials.
    JAMA, 2001, Jan-10, Volume: 285, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Randomized Controlled Trials as Topic; Ribavirin; Treatment Failure

2001
Should patients with chronic hepatitis C who have normal ALT levels be treated?
    Current gastroenterology reports, 2001, Volume: 3, Issue:1

    Topics: Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Endpoint Determination; Female; Hepatitis C, Chronic; Humans; Interferons; Middle Aged; Ribavirin; Treatment Outcome

2001
Pegylated interferons: what role will they play in the treatment of chronic hepatitis C?
    Current gastroenterology reports, 2001, Volume: 3, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2001
Kidney disease in patients with chronic hepatitis C.
    Current gastroenterology reports, 2001, Volume: 3, Issue:1

    Topics: Antigen-Antibody Complex; Antiviral Agents; Disease Progression; Glomerulonephritis; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Diseases; Kidney Transplantation; Postoperative Complications; Recurrence; Ribavirin; Treatment Outcome

2001
[Therapy of chronic hepatitis C].
    Wiener medizinische Wochenschrift (1946), 2000, Volume: 150, Issue:23-24

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Treatment Outcome

2000
[Treatment of pretransplant and posttransplant viral cirrhosis].
    Gastroenterologia y hepatologia, 2001, Volume: 24 Suppl 1

    Topics: Antiviral Agents; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Ribavirin; Secondary Prevention; Virus Replication

2001
Overview of interferon therapy for chronic hepatitis C.
    Clinics in liver disease, 1999, Volume: 3, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin

1999
Hepatitis C viral dynamics.
    Clinics in liver disease, 1999, Volume: 3, Issue:4

    Topics: Hepacivirus; Hepatitis B virus; Hepatitis C, Chronic; HIV; Humans; Interferons; Ribavirin

1999
Combination treatment with interferon and ribavirin for chronic hepatitis C.
    Clinics in liver disease, 1999, Volume: 3, Issue:4

    Topics: Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Liver Transplantation; Recurrence; Ribavirin

1999
Cost-effectiveness of combined interferon and ribavirin versus interferon alone.
    Clinics in liver disease, 1999, Volume: 3, Issue:4

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin

1999
Current and future treatment of hepatitis C.
    Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2001, Volume: 20 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Immunoglobulins; Immunotherapy; Interferon alpha-2; Interferon-alpha; Oligonucleotides, Antisense; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Catalytic; Virus Replication

2001
Transplantation for chronic hepatitis B and C: strategies for prevention and treatment of recurrent disease.
    Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2001, Volume: 20 Suppl 1

    Topics: Antiviral Agents; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Immunoglobulins; Interferon-alpha; Liver Transplantation; Recurrence; Ribavirin

2001
[Chronic hepatitis--new therapeutic options].
    Der Internist, 2001, Volume: 42, Issue:4

    Topics: Antiviral Agents; Contraindications; Drug Therapy, Combination; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Lamivudine; Polyethylene Glycols; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin

2001
Current and future therapies of hepatitis C.
    Clinics in liver disease, 2001, Volume: 5, Issue:2

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Hepacivirus; Hepatitis C, Chronic; Humans; Immunization, Passive; Immunologic Factors; IMP Dehydrogenase; Interferon-alpha; Phenylurea Compounds; Ribavirin; RNA, Viral

2001
Hepatitis C virus infection: 10 years after the discovery of the virus.
    European journal of gastroenterology & hepatology, 2001, Volume: 13, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Prevalence; Ribavirin; Risk Factors

2001
What is (cost) effective in patients with chronic hepatitis C virus infection?
    European journal of gastroenterology & hepatology, 2001, Volume: 13, Issue:5

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Europe; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin

2001
A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C.
    European journal of gastroenterology & hepatology, 2001, Volume: 13, Issue:5

    Topics: Adult; Antiviral Agents; Computer Simulation; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Markov Chains; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Switzerland; Treatment Outcome

2001
[Antiviral therapy for patients with chronic hepatitis C].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2001, Volume: 98, Issue:5

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-beta; Recombinant Proteins; Ribavirin; RNA, Viral

2001
Combination therapy with interferon-alpha and ribavirin for hepatitis C: practical treatment issues.
    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2001, Volume: 15, Issue:4

    Topics: Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA

2001
[Chronic viral hepatitis C: current therapy and perspectives].
    Gastroenterologie clinique et biologique, 2001, Volume: 25, Issue:4 Suppl

    Topics: Antiviral Agents; Cytokines; Drug Therapy, Combination; Hepatitis C, Chronic; Interferons; Recurrence; Ribavirin

2001
[PEG-interferons: significance for the treatment of viral hepatitis B and C].
    Deutsche medizinische Wochenschrift (1946), 2001, Jun-01, Volume: 126 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2001
[Recent progress and prospective view of chronic hepatitis C research].
    Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59, Issue:7

    Topics: Animals; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Neoplasms; Ribavirin

2001
[Treatment of chronic hepatitis C patients complicated with the other disease].
    Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59, Issue:7

    Topics: Collagen Diseases; Drug Therapy, Combination; Hematologic Diseases; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Ribavirin

2001
[Combination therapy of IFN and ribavirin].
    Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59, Issue:7

    Topics: Animals; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome

2001
[Present status of clinical trials on long-acting IFNs preparations (PEG-IFN alpha 2a, alpha 2b, IFN alpha-minipellet)].
    Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59, Issue:7

    Topics: Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2001
[Future outlook for treatment of chronic hepatitis C: IFN + ribavirin combination therapy].
    Rinsho byori. The Japanese journal of clinical pathology, 2001, Volume: 49, Issue:8

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin

2001
[Prognosis of chronic hepatitis C with regard to the aim of treatment].
    Rinsho byori. The Japanese journal of clinical pathology, 2001, Volume: 49, Issue:8

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Prognosis; Ribavirin

2001
Treatment of viral hepatitis--2001.
    Annals of medicine, 2001, Volume: 33, Issue:6

    Topics: Antiviral Agents; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2001
Hepatic granulomas in chronic hepatitis C.
    Journal of clinical gastroenterology, 2001, Volume: 33, Issue:4

    Topics: Biopsy, Needle; Drug Therapy, Combination; Female; Follow-Up Studies; Granuloma; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Diseases; Liver Function Tests; Middle Aged; Ribavirin; Risk Assessment; Treatment Outcome

2001
Management of hepatitis C in HIV-infected persons.
    Antiviral research, 2001, Volume: 52, Issue:2

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Carcinoma, Hepatocellular; Disease Management; Disease Transmission, Infectious; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Liver Neoplasms; Recurrence; Ribavirin

2001
Hepatitis C: a concise review.
    Minerva medica, 2001, Volume: 92, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Child; Clinical Trials as Topic; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Prognosis; Ribavirin; Viral Vaccines

2001
Advances in therapy for chronic hepatitis C.
    Clinics in liver disease, 2001, Volume: 5, Issue:4

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Patient Compliance; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin

2001
Management of interferon therapy nonresponders.
    Clinics in liver disease, 2001, Volume: 5, Issue:4

    Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukin-10; Ribavirin; RNA, Viral; Ursodeoxycholic Acid

2001
Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials.
    BMJ (Clinical research ed.), 2001, Nov-17, Volume: 323, Issue:7322

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Morbidity; Randomized Controlled Trials as Topic; Recurrence; Ribavirin; Risk

2001
Treatment of chronic hepatitis.
    BMJ (Clinical research ed.), 2001, Nov-17, Volume: 323, Issue:7322

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Lamivudine; Ribavirin

2001
[Diagnosis and treatment of chronic hepatitis C. Practical recommendations and new developments].
    Medizinische Klinik (Munich, Germany : 1983), 2001, Oct-15, Volume: 96, Issue:10

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Contraindications; Cost-Benefit Analysis; Diagnosis, Differential; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load

2001
Chronic hepatitis C: current status and rationale for antiviral therapy.
    The European journal of surgery. Supplement. : = Acta chirurgica. Supplement, 2001, Issue:586

    Topics: Hepatitis C, Chronic; Humans; Interferons; Ribavirin

2001
Treatment of chronic hepatitis C patients with combination of alpha-interferon and ribavirin, consensus and pegylated interferons.
    Bratislavske lekarske listy, 2001, Volume: 102, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2001
Concise review of the management of hepatitis C.
    Comprehensive therapy, 2001,Winter, Volume: 27, Issue:4

    Topics: Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Risk Factors

2001
Treatment of chronic hepatitis C: lessons from human immunodeficiency virus dynamics.
    Scandinavian journal of gastroenterology. Supplement, 2001, Issue:234

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; HIV-1; Humans; Interferon-alpha; Ribavirin

2001
Experimental and emerging therapies for chronic hepatitis C virus infection.
    Expert opinion on investigational drugs, 2001, Volume: 10, Issue:8

    Topics: Animals; Antiviral Agents; Hepatitis C, Chronic; Humans; Immunotherapy; Interferon Type I; Recombinant Proteins; Ribavirin; RNA, Viral

2001
[Chronic hepatitis C].
    Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60, Issue:1

    Topics: Drug Design; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Neoplasms; Neoplasm Recurrence, Local; Ribavirin

2002
Hepatitis C virus infection: an overview.
    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2001, Volume: 34, Issue:4

    Topics: Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Models, Genetic; Ribavirin; RNA, Viral

2001
Treatment of chronic hepatitis C with PEGylated interferon and ribavirin.
    Current gastroenterology reports, 2002, Volume: 4, Issue:1

    Topics: Antiviral Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2002
Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.
    Drugs, 2002, Volume: 62, Issue:3

    Topics: Adjuvants, Immunologic; Amino Acid Sequence; Anemia, Hemolytic; Antiviral Agents; Clinical Trials as Topic; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Molecular Sequence Data; Mood Disorders; Recombinant Proteins; Ribavirin

2002
Bullet points: new topics in HIV/AIDS.
    AIDS patient care and STDs, 2002, Volume: 16, Issue:1

    Topics: AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antiviral Agents; Hepatitis C, Chronic; HIV Infections; Humans; Lipids; Protease Inhibitors; Ribavirin

2002
Ribavirin with or without alpha interferon versus no intervention, placebo or alpha interferon for chronic hepatitis C.
    The Cochrane database of systematic reviews, 2002, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Randomized Controlled Trials as Topic; Ribavirin

2002
[Treatment of chronic hepatitis C with pegylated alpha-interferons].
    Deutsche medizinische Wochenschrift (1946), 2002, Mar-15, Volume: 127, Issue:11

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Patient Compliance; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Time Factors

2002
Mechanisms of action of ribavirin in antiviral therapies.
    Antiviral chemistry & chemotherapy, 2001, Volume: 12, Issue:5

    Topics: Animals; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Mutagenesis; Ribavirin; RNA Viruses; T-Lymphocytes; Virus Replication

2001
Developments in the treatment of chronic hepatitis C.
    Expert opinion on investigational drugs, 2002, Volume: 11, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2002
Sarcoidosis during combined interferon alfa and ribavirin therapy in 2 patients with chronic hepatitis C.
    Archives of dermatology, 2002, Volume: 138, Issue:4

    Topics: Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Sarcoidosis

2002
The treatment of chronic hepatitis C not responding to interferon.
    Current pharmaceutical design, 2002, Volume: 8, Issue:11

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin

2002
New therapies for the treatment of chronic hepatitis C.
    Current pharmaceutical design, 2002, Volume: 8, Issue:11

    Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligonucleotides, Antisense; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Catalytic

2002
Present treatment expectations and risks of chronic hepatitis C.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2002, Volume: 8, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure

2002
[Treatment of chronic hepatitis C. Combined treatment in naive patients].
    Gastroenterologia y hepatologia, 2000, Volume: 23 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin

2000
[Treatment of chronic hepatitis C relapse].
    Gastroenterologia y hepatologia, 2000, Volume: 23 Suppl 1

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon Type I; Interferon-alpha; Interferons; Recombinant Proteins; Recurrence; Ribavirin

2000
[Treatment of chronic hepatitis C in patients not responding to interferon].
    Gastroenterologia y hepatologia, 2000, Volume: 23 Suppl 1

    Topics: Amantadine; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Failure

2000
[Impact of HIV on HCV, GBV-C/HGV, and HBV infection].
    Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60, Issue:4

    Topics: Anti-HIV Agents; Antibiosis; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Flaviviridae Infections; GB virus C; Hemophilia A; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis, Viral, Human; HIV Infections; HIV-1; Humans; Interferons; Lamivudine; Liver Neoplasms; Liver Transplantation; Prognosis; Ribavirin

2002
[Treatment strategies for viral hepatitis].
    [Hokkaido igaku zasshi] The Hokkaido journal of medical science, 2002, Volume: 77, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferons; Lamivudine; Reverse Transcriptase Inhibitors; Ribavirin

2002
Treatment of chronic hepatitis C infection with cryoglobulinemia.
    Current opinion in rheumatology, 2002, Volume: 14, Issue:3

    Topics: Antiviral Agents; Cryoglobulinemia; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-beta; Interferons; Ribavirin

2002
Mechanism of action of ribavirin in the combination treatment of chronic HCV infection.
    Hepatology (Baltimore, Md.), 2002, Volume: 35, Issue:5

    Topics: Animals; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin

2002
Genetically modified interferon: is there a consensus yet?
    European journal of gastroenterology & hepatology, 2002, Volume: 14, Issue:5

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon Type I; Interferon-alpha; Recombinant Proteins; Ribavirin

2002
[Treatment of chronic hepatitis C in patients with HIV-coinfection].
    Gastroenterologia y hepatologia, 2002, Volume: 25, Issue:5

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Ribavirin

2002
[Antiviral treatment of chronic hepatitis C in interferon nonresponders].
    Gastroenterologia y hepatologia, 2002, Volume: 25, Issue:5

    Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Treatment Failure

2002
[Chronic hepatitis C: initial treatment in patients without previous treatment].
    Gastroenterologia y hepatologia, 2002, Volume: 25, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2002
[Treatment of chronic hepatitis C in cirrhosis of the liver].
    Gastroenterologia y hepatologia, 2002, Volume: 25, Issue:5

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Ribavirin

2002
Advances in treatment of chronic hepatitis C: 'pegylated' interferons.
    Cleveland Clinic journal of medicine, 2002, Volume: 69, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2002
Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications.
    Advanced drug delivery reviews, 2002, Jun-17, Volume: 54, Issue:4

    Topics: Animals; Antiviral Agents; Circular Dichroism; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Isomerism; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2002
Ribavirin with or without alpha interferon for chronic hepatitis C.
    The Cochrane database of systematic reviews, 2002, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Randomized Controlled Trials as Topic; Ribavirin

2002
[Interferon-induced paranoid psychosis. Review of the literature and case report].
    Der Nervenarzt, 2002, Volume: 73, Issue:5

    Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Paranoid Disorders; Recombinant Proteins; Ribavirin

2002
Nephrotoxicity of interferon alfa-ribavirin therapy for chronic hepatitis C.
    Journal of clinical gastroenterology, 2002, Volume: 35, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Nephrotic Syndrome; Ribavirin

2002
[Therapy of hepatitis C].
    Praxis, 2002, May-29, Volume: 91, Issue:22

    Topics: Antiviral Agents; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2002

Trials

1239 trial(s) available for ribavirin and Chronic Hepatitis C

ArticleYear
Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection.
    Journal of viral hepatitis, 2004, Volume: 11, Issue:3

    Topics: Anemia, Hemolytic; Antiviral Agents; Drug Combinations; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Risk Factors; Sex Factors

2004
Efficacy and safety of alfosbuvir plus daclatasvir in Chinese patients with hepatitis C virus genotypes 1, 2, 3, and 6 infection: An open-label, phase 2 study.
    Journal of viral hepatitis, 2022, Volume: 29, Issue:6

    Topics: Antiviral Agents; Carbamates; China; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Ribavirin; Treatment Outcome; Valine

2022
Four Weeks Treatment with Glecaprevir/Pibrentasvir + Ribavirin-A Randomized Controlled Clinical Trial.
    Viruses, 2022, 03-16, Volume: 14, Issue:3

    Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; COVID-19; Cyclopropanes; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Pandemics; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sulfonamides

2022
Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial.
    Journal of medicine and life, 2022, Volume: 15, Issue:3

    Topics: Antiviral Agents; Benzimidazoles; COVID-19 Drug Treatment; Drug Therapy, Combination; Egypt; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; SARS-CoV-2; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2022
Comparative Real Life Egyptian Experience of the Combination of Sofosbuvir Plus Daclatasvir or Simeprevir for 12 Weeks in Naïve Cirrhotic Patients Infected with HCV Genotype 4.
    Current drug safety, 2023, Volume: 18, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Egypt; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome

2023
A randomized-controlled trial of SOF/VEL/VOX with or without ribavirin for retreatment of chronic hepatitis C.
    Journal of hepatology, 2023, Volume: 79, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Retreatment; Ribavirin; Sofosbuvir; Treatment Outcome

2023
Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy.
    Gastroenterology, 2019, Volume: 157, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Combinations; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure; Viral Nonstructural Proteins

2019
SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 05-06, Volume: 70, Issue:10

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Iran; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Tablets; Treatment Outcome; Valine

2020
Addition of Epigallocatechin Gallate 400 mg to Sofosbuvir 400 mg + Daclatisvir 60 mg With or Without Ribavirin in Treatment of Patients with Chronic Hepatitis C Improves the Safety Profile: A Pilot Study.
    Scientific reports, 2019, 09-19, Volume: 9, Issue:1

    Topics: Adult; Catechin; Daclizumab; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Pilot Projects; Random Allocation; Ribavirin; Sofosbuvir; Standard of Care; Sustained Virologic Response; Tablets; Treatment Outcome; Viral Load

2019
Effects of vitamin D supplements in patients with chronic hepatitis C: a randomized, multi-center, open label study.
    The Korean journal of internal medicine, 2020, Volume: 35, Issue:5

    Topics: Antiviral Agents; Dietary Supplements; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load; Vitamin D

2020
Intrahepatic Viral Kinetics During Direct-Acting Antivirals for Hepatitis C in Human Immunodeficiency Virus Coinfection: The AIDS Clinical Trials Group A5335S Substudy.
    The Journal of infectious diseases, 2020, 07-23, Volume: 222, Issue:4

    Topics: 2-Naphthylamine; Acquired Immunodeficiency Syndrome; Adult; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Female; Hepatitis C, Chronic; Humans; Kinetics; Lactams, Macrocyclic; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; United States; Uracil; Valine; Viral Load

2020
High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life exp
    Archives of virology, 2020, Volume: 165, Issue:7

    Topics: Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Ribavirin; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine

2020
Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation.
    The Journal of infectious diseases, 2020, 09-14, Volume: 222, Issue:8

    Topics: 2-Naphthylamine; Adult; Anilides; Anti-HIV Agents; Antiviral Agents; Biomarkers; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Immunologic Factors; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine

2020
Mutations Identified in the Hepatitis C Virus (HCV) Polymerase of Patients with Chronic HCV Treated with Ribavirin Cause Resistance and Affect Viral Replication Fidelity.
    Antimicrobial agents and chemotherapy, 2020, 11-17, Volume: 64, Issue:12

    Topics: Antiviral Agents; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Mutation; Ribavirin; Viral Nonstructural Proteins; Virus Replication

2020
Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2021, Volume: 120, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Taiwan

2021
Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection.
    BMC infectious diseases, 2020, Dec-04, Volume: 20, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Killer Cells, Natural; Longitudinal Studies; Male; Neutrophils; Recurrence; Ribavirin; Sofosbuvir; T-Lymphocytes; Transcriptome; Treatment Outcome

2020
Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2022, Volume: 20, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Patient-Centered Care; Ribavirin; Sofosbuvir; Sustained Virologic Response

2022
Inferior cure rate in pilot study of 4-week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C.
    Liver international : official journal of the International Association for the Study of the Liver, 2021, Volume: 41, Issue:11

    Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Pilot Projects; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response

2021
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study.
    Hepatology (Baltimore, Md.), 2021, Volume: 74, Issue:6

    Topics: 2-Naphthylamine; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Genotyping Techniques; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Male; Middle Aged; Proline; Quinoxalines; Ribavirin; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine; Young Adult

2021
Epigenetic scars of CD8
    Nature immunology, 2021, Volume: 22, Issue:8

    Topics: 2-Naphthylamine; Anilides; Antigens, Viral; Antiviral Agents; CD8-Positive T-Lymphocytes; Chromatin; Cyclopropanes; Epigenesis, Genetic; Hepacivirus; Hepatitis C, Chronic; High Mobility Group Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunologic Memory; Lactams, Macrocyclic; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine

2021
HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients.
    Journal of virological methods, 2017, Volume: 245

    Topics: 2-Naphthylamine; Administration, Oral; Adult; Aged; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Retrospective Studies; Ribavirin; Ritonavir; RNA, Viral; Sensitivity and Specificity; Sulfonamides; Uracil; Viral Load

2017
Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:2

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Intention to Treat Analysis; Liver Cirrhosis; Male; Middle Aged; Patient Reported Outcome Measures; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Young Adult

2016
Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult

2016
Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:1

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Egypt; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult

2016
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.
    Journal of hepatology, 2017, Volume: 67, Issue:2

    Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Polymorphism, Genetic; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response; Treatment Failure

2017
Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen.
    Hepatology (Baltimore, Md.), 2017, Volume: 66, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir

2017
Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017, Jul-01, Volume: 65, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate

2017
Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection.
    Hepatology (Baltimore, Md.), 2017, Volume: 66, Issue:4

    Topics: Adolescent; Antiviral Agents; Child; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Ribavirin; Sofosbuvir; Sustained Virologic Response

2017
Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study.
    BMC infectious diseases, 2017, 06-02, Volume: 17, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir; Treatment Outcome

2017
Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.
    The International journal on drug policy, 2017, Volume: 47

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Drug Users; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Opiate Substitution Treatment; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Self Administration; Substance Abuse, Intravenous; Viral Load

2017
Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection.
    Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:4

    Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Thalassemia; Treatment Failure; Uridine Monophosphate

2017
Directly observed therapy of sofosbuvir/ribavirin +/- peginterferon with minimal monitoring for the treatment of chronic hepatitis C in people with a history of drug use in Chennai, India (C-DOT).
    Journal of viral hepatitis, 2018, Volume: 25, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Directly Observed Therapy; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; India; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sofosbuvir; Substance-Related Disorders; Sustained Virologic Response; Treatment Outcome; Viral Load; Young Adult

2018
Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2,
    The lancet. Gastroenterology & hepatology, 2017, Volume: 2, Issue:11

    Topics: Adult; Amides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Female; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response; Thiazoles; Uridine

2017
Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir.
    Journal of medical virology, 2018, Volume: 90, Issue:1

    Topics: Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Polymorphism, Genetic; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Failure; Treatment Outcome; Valine

2018
Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 03-19, Volume: 66, Issue:7

    Topics: Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Quinoxalines; Retreatment; Ribavirin; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure

2018
Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.
    Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; Fatigue; Female; Fluorenes; Headache; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Pregnancy; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate

2018
Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens.
    Journal of viral hepatitis, 2018, Volume: 25, Issue:4

    Topics: Antiviral Agents; Carbamates; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins

2018
Pharmacokinetics-Based Adjusted Versus Standard Dose of Ribavirin Does Not Improve Virologic Response Rates in Chronic Hepatitis C Genotype 4 Patients: A Randomized Controlled Trial.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2017, Volume: 37, Issue:11

    Topics: Darbepoetin alfa; Dose-Response Relationship, Drug; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Treatment Outcome

2017
Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study.
    Journal of viral hepatitis, 2018, Volume: 25, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Young Adult

2018
IL-21 as a Predictor of Sustained Virologic Response in Patients with Chronic Hepatitis C Virus Infection.
    Applied biochemistry and biotechnology, 2018, Volume: 185, Issue:2

    Topics: Adult; Aged; Egypt; Female; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Middle Aged; Ribavirin

2018
Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirin.
    Journal of viral hepatitis, 2018, Volume: 25, Issue:4

    Topics: Adolescent; Antiviral Agents; Child; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Male; Quality of Life; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Treatment Outcome

2018
The effect of interferon-free regimens on health-related quality of life in East Asian patients with chronic hepatitis C.
    Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:7

    Topics: Adult; Antiviral Agents; Asia, Eastern; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Linear Models; Liver Cirrhosis; Male; Middle Aged; Quality of Life; Ribavirin; Severity of Illness Index; Sofosbuvir; Sustained Virologic Response; Time Factors

2018
Four weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial.
    Journal of hepatology, 2018, Volume: 68, Issue:4

    Topics: Adult; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate

2018
Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study.
    European journal of gastroenterology & hepatology, 2018, Volume: 30, Issue:3

    Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Liver Cirrhosis; Male; Middle Aged; Pilot Projects; Pyrrolidines; Recombinant Proteins; Ribavirin; RNA, Viral; Sulfonamides; Sustained Virologic Response; Treatment Failure; Treatment Outcome; Valine; Viral Load

2018
Twelve-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study.
    Journal of gastroenterology and hepatology, 2018, Volume: 33, Issue:8

    Topics: Administration, Ophthalmic; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian People; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Isoindoles; Lactams; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Time Factors; Treatment Outcome

2018
Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: Results from a phase 3b study in China.
    Journal of gastroenterology and hepatology, 2018, Volume: 33, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Asian People; China; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; Young Adult

2018
Sofosbuvir Adverse Events Profile in a Subset of Pakistani Population.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2018, Volume: 28, Issue:2

    Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Neutropenia; Pancytopenia; Ribavirin; Sofosbuvir; Thrombocytopenia; Treatment Outcome

2018
Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis.
    Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:9

    Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Internationality; Liver Cirrhosis; Male; Middle Aged; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response; Young Adult

2018
Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial.
    Hepatology (Baltimore, Md.), 2018, Volume: 67, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Benzofurans; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Quinoxalines; Ribavirin; Sofosbuvir

2018
Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients.
    Digestive diseases and sciences, 2018, Volume: 63, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Retreatment; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult

2018
A sofosbuvir-based quadruple regimen is highly effective in HCV type 4-infected Egyptian patients with DAA treatment failure.
    Journal of hepatology, 2018, Volume: 68, Issue:6

    Topics: Adult; Antiviral Agents; Carbamates; Cohort Studies; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Treatment Outcome; Valine

2018
12 Weeks of a Ribavirin-Free Sofosbuvir and Nonstructural Protein 5A Inhibitor Regimen Is Enough to Treat Recurrence of Hepatitis C After Liver Transplantation.
    Hepatology (Baltimore, Md.), 2018, Volume: 68, Issue:4

    Topics: Adult; Aged; Belgium; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; France; Graft Survival; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prognosis; Prospective Studies; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins

2018
Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt.
    Gut, 2019, Volume: 68, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Egypt; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2019
Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV).
    European journal of gastroenterology & hepatology, 2018, Volume: 30, Issue:9

    Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Republic of Belarus; Ribavirin; Ritonavir; Russia; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Uracil; Valine

2018
A population pharmacodynamic model characterizing neutropenia associated with pegylated interferon alpha 2-a therapy in patients with chronic hepatitis C viral infection.
    Naunyn-Schmiedeberg's archives of pharmacology, 2018, Volume: 391, Issue:9

    Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocyte Count; Male; Middle Aged; Models, Biological; Neutropenia; Neutrophils; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2018
Change in the hepatic profile of hepatitis C virus genotype 4-infected patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: A subanalysis of the AGATE-II study.
    Journal of medical virology, 2018, Volume: 90, Issue:11

    Topics: Adult; Aged; Alanine Transaminase; Anilides; Antiviral Agents; Aspartate Aminotransferases; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine

2018
Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir.
    Revista do Instituto de Medicina Tropical de Sao Paulo, 2018, Volume: 60

    Topics: Antiviral Agents; Clinical Protocols; Decision Making; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Retrospective Studies; Ribavirin

2018
Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection.
    Journal of viral hepatitis, 2018, Volume: 25, Issue:12

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; China; Female; Fluorenes; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Quality of Life; Republic of Korea; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Sustained Virologic Response; Taiwan; Treatment Outcome

2018
[In process].
    Medizinische Monatsschrift fur Pharmazeuten, 2016, Volume: 39, Issue:8

    Topics: Benzofurans; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Ribavirin

2016
Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: a clinical randomized study.
    European journal of gastroenterology & hepatology, 2018, Volume: 30, Issue:10

    Topics: 2-Naphthylamine; Adult; Anemia; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fatigue; Female; Fluorenes; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil; Valine; Viral Load

2018
Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals.
    Hepatology international, 2018, Volume: 12, Issue:4

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Japan; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Young Adult

2018
Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11.
    Hepatology (Baltimore, Md.), 2018, Volume: 68, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; Child; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate

2018
Sofosbuvir, Pegylated Interferon and Ribavirin in the Treatment of an Egyptian Cohort with Hepatitis C Virus Infection in Real-Life Clinical Practice.
    Infectious disorders drug targets, 2019, Volume: 19, Issue:2

    Topics: Adolescent; Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult

2019
Characterization of changes in intrahepatic immune cell populations during HCV treatment with sofosbuvir and ribavirin.
    Journal of viral hepatitis, 2019, Volume: 26, Issue:3

    Topics: Antiviral Agents; Biopsy; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Kupffer Cells; Liver; Parenchymal Tissue; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2019
Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2019, Volume: 118, Issue:2

    Topics: Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; RNA, Viral; Sulfonamides; Sustained Virologic Response; Taiwan; Valine; Viral Nonstructural Proteins

2019
Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies.
    Drug and alcohol dependence, 2019, 01-01, Volume: 194

    Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Drug Users; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Young Adult

2019
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis.
    Annals of hepatology, 2018, Oct-16, Volume: 17, Issue:6

    Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Brazil; Carbamates; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Uracil; Valine; Viral Load

2018
Hepatitis C Direct Acting Antivirals and Ribavirin Modify Lipid but not Glucose Parameters.
    Cells, 2019, 03-15, Volume: 8, Issue:3

    Topics: Antiviral Agents; Apolipoproteins; Fatty Liver; Female; Glucose; Hepacivirus; Hepatitis C, Chronic; Homeostasis; Humans; Insulin Resistance; Lipids; Liver; Male; Middle Aged; Ribavirin; Treatment Outcome

2019
Cytokine balance is restored as patient-reported outcomes improve in patients recovering from chronic hepatitis C.
    Liver international : official journal of the International Association for the Study of the Liver, 2019, Volume: 39, Issue:9

    Topics: Adult; Antiviral Agents; Benzimidazoles; Biomarkers; Cytokines; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Prospective Studies; Ribavirin; Severity of Illness Index; Sofosbuvir; Surveys and Questionnaires; Sustained Virologic Response; Uridine Monophosphate

2019
Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis.
    Journal of viral hepatitis, 2019, Volume: 26, Issue:8

    Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine

2019
A time-to-event analysis describing virologic response in patients with chronic hepatitis C infection.
    Journal of chemotherapy (Florence, Italy), 2019, Volume: 31, Issue:5

    Topics: Adult; Aged; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Young Adult

2019
Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6.
    Journal of viral hepatitis, 2019, Volume: 26, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Interferons; Male; Middle Aged; Pyrrolidines; Ribavirin; RNA, Viral; Sustained Virologic Response; Thiazoles; Uridine; Young Adult

2019
Efficacy and safety of treatment of chronic hepatitis C with sofosbuvir and ribavirin with or without peginterferon: a French prospective real-life cohort study of unselected 211 patients.
    European journal of gastroenterology & hepatology, 2019, Volume: 31, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; France; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Load

2019
Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting.
    Journal of hepatology, 2019, Volume: 71, Issue:6

    Topics: Adult; Antiviral Agents; Benzimidazoles; Clinical Protocols; Delivery of Health Care; Disease Eradication; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; India; Liver Cirrhosis; Male; Public Health; Ribavirin; Sofosbuvir; Sustained Virologic Response; Telemedicine

2019
RNA editing blood biomarkers for predicting mood alterations in HCV patients.
    Journal of neurovirology, 2019, Volume: 25, Issue:6

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenosine Deaminase; Adult; Aged; Antiviral Agents; Biomarkers; Depression; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA Editing

2019
Long-term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients With Chronic Hepatitis C Virus Infection.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2020, Volume: 18, Issue:2

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2020
Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial.
    Antiviral therapy, 2013, Volume: 18, Issue:3

    Topics: Amino Acid Substitution; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome

2013
A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment.
    Journal of hepatology, 2013, Volume: 59, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Interferon-alpha; Isoindoles; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Sulfonamides; Viral Load; Viral Nonstructural Proteins; Young Adult

2013
A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1.
    Journal of hepatology, 2013, Volume: 59, Issue:1

    Topics: Aged; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Protease Inhibitors; Ribavirin; Ritonavir; Sulfonamides; Viral Nonstructural Proteins

2013
Autoantibodies and autoimmune disease during treatment of children with chronic hepatitis C.
    Journal of pediatric gastroenterology and nutrition, 2013, Volume: 56, Issue:3

    Topics: Adolescent; Antiviral Agents; Autoantibodies; Autoimmune Diseases; Child; Child, Preschool; Cohort Studies; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Longitudinal Studies; Male; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; United States

2013
IDX184 in combination with pegylated interferon-α2a and ribavirin for 2 weeks in treatment-naive patients with chronic hepatitis C.
    Antiviral therapy, 2013, Volume: 18, Issue:6

    Topics: Adult; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Female; Genotype; Guanosine Monophosphate; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2013
Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment.
    Journal of clinical gastroenterology, 2013, Volume: 47, Issue:9

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Randomized Controlled Trials as Topic; Recombinant Proteins; Retreatment; Ribavirin; Time Factors; Treatment Outcome

2013
Role of statins in the treatment of chronic hepatitis C virus infection.
    Journal of the Egyptian Society of Parasitology, 2012, Volume: 42, Issue:3

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Hepacivirus; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load; Virus Replication

2012
Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin.
    Journal of viral hepatitis, 2013, Volume: 20, Issue:4

    Topics: Adult; Albumins; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Lung; Lung Diseases, Interstitial; Male; Middle Aged; Polyethylene Glycols; Pulmonary Diffusing Capacity; Radiography, Thoracic; Recombinant Proteins; Ribavirin; Spirometry

2013
Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long-term follow-up.
    Journal of viral hepatitis, 2013, Volume: 20, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leucine; Male; Middle Aged; Placebos; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Sulfones; Treatment Outcome; Urea; Viral Load

2013
Dynamic tailoring of treatment durations improves efficiency of hepatitis C treatment with pegylated interferon and ribavirin.
    Journal of viral hepatitis, 2013, Volume: 20, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult

2013
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
    The Lancet. Infectious diseases, 2013, Volume: 13, Issue:5

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Nausea; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Secondary Prevention; Sofosbuvir; Time Factors; Treatment Outcome; Uridine Monophosphate; Young Adult

2013
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Puerto Rico; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; United States; Uridine Monophosphate

2013
Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial.
    Hepatology (Baltimore, Md.), 2013, Volume: 57, Issue:6

    Topics: Adult; Antiviral Agents; Carrier Proteins; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure; Viral Nonstructural Proteins

2013
Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir.
    Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:3

    Topics: Adult; Antiviral Agents; Carbamates; Dose-Response Relationship, Drug; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Interferons; Interleukins; Isoquinolines; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; RNA, Viral; Sulfonamides; Treatment Failure; Treatment Outcome; Valine; Viral Nonstructural Proteins

2013
The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis C patients with genotype 1.
    European journal of gastroenterology & hepatology, 2013, Volume: 25, Issue:9

    Topics: Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Turkey; Viral Load

2013
Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients.
    Journal of virology, 2013, Volume: 87, Issue:11

    Topics: Antiviral Agents; Base Sequence; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Male; Molecular Sequence Data; Mutation; Prospective Studies; Ribavirin

2013
Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
    Journal of hepatology, 2013, Volume: 59, Issue:2

    Topics: Adult; Age Factors; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2013
Relevance of the Core 70 and IL-28B polymorphism and response-guided therapy of peginterferon alfa-2a ± ribavirin for chronic hepatitis C of Genotype 1b: a multicenter randomized trial, ReGIT-J study.
    Journal of gastroenterology, 2014, Volume: 49, Issue:3

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Mutation; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2014
Secondary hyperpigmentation during interferon alfa treatment for chronic hepatitis C virus infection.
    JAMA dermatology, 2013, Volume: 149, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Hyperpigmentation; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mucous Membrane; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Skin Pigmentation

2013
Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results.
    Antiviral therapy, 2013, Volume: 18, Issue:8

    Topics: Acrylates; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Interferon-alpha; Leucine; Oligopeptides; Polyethylene Glycols; Proline; Quinolines; Recombinant Proteins; Ribavirin; Thiazoles; Treatment Outcome; Viral Load

2013
High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice.
    Clinical and molecular hepatology, 2013, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Asian People; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Republic of Korea; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult

2013
Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24.
    Annals of the rheumatic diseases, 2014, Volume: 73, Issue:5

    Topics: Aged; Antiviral Agents; Cohort Studies; Cryoglobulinemia; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Outcome; Vasculitis

2014
Sofosbuvir for previously untreated chronic hepatitis C infection.
    The New England journal of medicine, 2013, May-16, Volume: 368, Issue:20

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Young Adult

2013
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.
    The New England journal of medicine, 2013, May-16, Volume: 368, Issue:20

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Young Adult

2013
Treatment of chronic hepatitis C infection among current and former injection drug users within a multidisciplinary treatment model at a community health centre.
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2013, Volume: 27, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Community Health Centers; Community Health Services; Delivery of Health Care; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Mental Disorders; Middle Aged; Ontario; Patient Care Team; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Substance-Related Disorders; Treatment Outcome; Young Adult

2013
Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study.
    BMC infectious diseases, 2013, Apr-27, Volume: 13

    Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Double-Blind Method; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Markov Chains; Middle Aged; Models, Economic; Polyethylene Glycols; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin

2013
Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes.
    Journal of viral hepatitis, 2013, Volume: 20, Issue:6

    Topics: Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Mutation; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Analysis, Protein; Treatment Outcome; Viral Nonstructural Proteins

2013
Vitamin D levels in Egyptian HCV patients (genotype 4) treated with pegylated interferon.
    Acta gastro-enterologica Belgica, 2013, Volume: 76, Issue:1

    Topics: Adolescent; Adult; Antiviral Agents; Drug Monitoring; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Vitamin D; Young Adult

2013
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.
    Journal of hepatology, 2013, Volume: 59, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; France; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Proline; Prospective Studies; Ribavirin; Serine Proteinase Inhibitors; Treatment Outcome; Viral Load

2013
Sustained virological response based on the week 4 response in hepatitis C virus genotype 1 patients treated with peginterferons α-2a and α-2b, plus ribavirin.
    European journal of gastroenterology & hepatology, 2013, Volume: 25, Issue:11

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2013
Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial.
    Annals of internal medicine, 2013, Jul-16, Volume: 159, Issue:2

    Topics: Adult; Anti-HIV Agents; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2013
Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy.
    Journal of hepatology, 2013, Volume: 59, Issue:4

    Topics: Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Pyrophosphatases; Recombinant Proteins; Ribavirin; Risk Factors

2013
Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin.
    Alimentary pharmacology & therapeutics, 2013, Volume: 38, Issue:1

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2013
1(OH) vitamin D3 supplementation improves the sensitivity of the immune-response during Peg-IFN/RBV therapy in chronic hepatitis C patients-case controlled trial.
    PloS one, 2013, Volume: 8, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Calcifediol; Cell Line, Tumor; Cytokines; Dietary Supplements; Drug Synergism; Drug Therapy, Combination; Female; Gene Expression; Hepatitis C, Chronic; Hepatocytes; Humans; Immunity, Cellular; Immunologic Factors; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Ribavirin; T-Lymphocytes, Regulatory; Th1 Cells; Treatment Outcome

2013
Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study.
    Alimentary pharmacology & therapeutics, 2013, Volume: 38, Issue:2

    Topics: Adult; Antiviral Agents; Area Under Curve; Drug Therapy, Combination; Female; Genotype; Health Status; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prospective Studies; Quality of Life; Recombinant Proteins; Ribavirin; Surveys and Questionnaires; Time Factors; Viral Load

2013
Dermatological side-effects of telaprevir-based triple therapy for chronic hepatitis C in phase III trials in Japan.
    The Journal of dermatology, 2013, Volume: 40, Issue:8

    Topics: Adult; Aged; Antiviral Agents; Drug Eruptions; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Young Adult

2013
Therapy of chronic hepatitis C with PEG-IFN α-2b plus ribavirin in patients with genotype 2 or 3: 16 versus 24 weeks, clinical outcome and direct cost analyses.
    European journal of gastroenterology & hepatology, 2013, Volume: 25, Issue:12

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Female; Genotype; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Viral Load

2013
Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2013, Volume: 62, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Renal Dialysis; Ribavirin

2013
Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2013, Volume: 21, Issue:9

    Topics: Adult; Antiviral Agents; Combined Modality Therapy; Electroporation; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Lymphocyte Activation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Standard of Care; T-Lymphocytes; Vaccines, DNA; Viral Hepatitis Vaccines; Viral Load

2013
Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis.
    Virology, 2013, Sep-01, Volume: 443, Issue:2

    Topics: Adolescent; Adult; Aged; Amino Acid Substitution; Antiviral Agents; Cyclopropanes; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Isoindoles; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Peptide Hydrolases; Polyethylene Glycols; Proline; Ribavirin; RNA, Viral; Sulfonamides; Treatment Failure; Treatment Outcome; Viremia; Young Adult

2013
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.
    The Lancet. Infectious diseases, 2013, Volume: 13, Issue:7

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Placebos; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Young Adult

2013
Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse.
    Scandinavian journal of gastroenterology, 2013, Volume: 48, Issue:7

    Topics: Adult; Antiviral Agents; Biomarkers; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Genotyping Techniques; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2013
Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial.
    The Journal of infectious diseases, 2013, Volume: 208, Issue:6

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load; Young Adult

2013
Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C.
    Antiviral therapy, 2013, Volume: 18, Issue:7

    Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Isoquinolines; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Sulfonamides; Treatment Outcome; Viral Load

2013
Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin.
    Journal of viral hepatitis, 2013, Volume: 20, Issue:8

    Topics: Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome

2013
Optimizing ribavirin exposure by therapeutic drug monitoring improves treatment response in patients with chronic hepatitis C genotype 1.
    The American journal of gastroenterology, 2013, Volume: 108, Issue:7

    Topics: Adult; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2013
Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin.
    Journal of gastroenterology and hepatology, 2014, Volume: 29, Issue:1

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Genetic; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Taiwan; Time Factors; Treatment Outcome

2014
Impact of hepatitis B virus integration into liver tissue on the efficacy of peginterferon and ribavirin therapy in hepatitis B virus-negative chronic hepatitis C patients.
    Journal of clinical gastroenterology, 2014, Volume: 48, Issue:1

    Topics: Aged; Antiviral Agents; Biopsy, Needle; DNA, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis B virus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Virus Integration

2014
Temperature rise after peginterferon alfa-2a injection in patients with chronic hepatitis C is associated with virological response and is modulated by IL28B genotype.
    Journal of hepatology, 2013, Volume: 59, Issue:5

    Topics: Adult; Antiviral Agents; Body Temperature; Chemokine CXCL10; Female; Fever; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome

2013
Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor.
    Hepatology (Baltimore, Md.), 2014, Volume: 59, Issue:1

    Topics: Antiviral Agents; Contraindications; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2014
Nitazoxanide plus pegylated interferon and ribavirin in the treatment of genotype 4 chronic hepatitis C, a randomized controlled trial.
    Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34, Issue:2

    Topics: Drug Therapy, Combination; Egypt; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Nitro Compounds; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Statistics, Nonparametric; Thiazoles

2014
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study.
    Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:6

    Topics: Adolescent; Adult; Aged; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Simeprevir; Sulfonamides; Treatment Outcome; Viral Load

2013
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial.
    Gastroenterology, 2013, Volume: 145, Issue:5

    Topics: Algorithms; Anemia; Antiviral Agents; Disease Management; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythropoietin; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Treatment Outcome

2013
Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection.
    Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34, Issue:1

    Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Asian People; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Japan; Leucine; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Quinolines; Recombinant Proteins; Ribavirin; Thiazoles; Time Factors; Treatment Outcome

2014
Dynamics of serum metabolites in patients with chronic hepatitis C receiving pegylated interferon plus ribavirin: a metabolomics analysis.
    Metabolism: clinical and experimental, 2013, Volume: 62, Issue:11

    Topics: Adult; Aged; Antiviral Agents; Area Under Curve; Betaine; Carnitine; Chromatography, Liquid; Drug Therapy, Combination; Female; Glycine; Hepatitis C, Chronic; Humans; Interferons; Male; Metabolomics; Middle Aged; Polyethylene Glycols; Principal Component Analysis; Ribavirin; Tandem Mass Spectrometry; Treatment Outcome; Tryptophan; Viral Load

2013
Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study.
    Journal of gastroenterology, 2014, Volume: 49, Issue:1

    Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Simeprevir; Sulfonamides; Treatment Outcome; Viral Load; Young Adult

2014
[Efficacy of combination therapy with pegylated-interferon alfa-2a plus ribavirin in autoantibody-positive chronic hepatitis C patients].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2013, Volume: 21, Issue:5

    Topics: Adult; Antiviral Agents; Autoantibodies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2013
Psychometric evaluation of the hepatitis C virus patient-reported outcomes (HCV-PRO) instrument: validity, responsiveness, and identification of the minimally important difference in a phase 2 clinical trial.
    Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2014, Volume: 23, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Anxiety; Data Interpretation, Statistical; Depression; Drug Therapy, Combination; Female; Health Status Indicators; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Male; Middle Aged; Patient Outcome Assessment; Placebos; Psychometrics; Quality of Life; Reproducibility of Results; Ribavirin; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome; Young Adult

2014
Treatment of chronic hepatitis C with peginterferon alfa-2b, plus ribavirin in end stage renal disease patients treated by hemodialysis: single Saudi center experience.
    Renal failure, 2013, Volume: 35, Issue:10

    Topics: Adult; Antiviral Agents; Erythropoietin; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Renal Dialysis; Ribavirin; Saudi Arabia

2013
Predictors of consent to pharmacogenomics testing in the IDEAL study.
    Pharmacogenetics and genomics, 2013, Volume: 23, Issue:11

    Topics: Adolescent; Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genetic Testing; Genetic Variation; Genome-Wide Association Study; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Informed Consent; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Pharmacogenetics; Polyethylene Glycols; Polymorphism, Genetic; Precision Medicine; Pyrophosphatases; Racial Groups; Recombinant Proteins; Ribavirin; Sex Characteristics; Treatment Outcome; Young Adult

2013
Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C.
    Journal of gastroenterology, 2014, Volume: 49, Issue:8

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Embolization, Therapeutic; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Spleen; Splenectomy; Thrombocytopenia; Treatment Outcome

2014
Impact of added fluvastatin to standard-of-care treatment on sustained virological response in naïve chronic hepatitis C Patients infected with genotypes 1 and 3.
    Intervirology, 2014, Volume: 57, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome

2014
Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:12

    Topics: Adult; Aged; Antiviral Agents; Area Under Curve; Drug Administration Schedule; Drug Dosage Calculations; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Metabolic Clearance Rate; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Renal Insufficiency; Ribavirin; Severity of Illness Index

2013
Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response.
    The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:2

    Topics: Aged; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2014
Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study.
    Alimentary pharmacology & therapeutics, 2013, Volume: 38, Issue:9

    Topics: Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome

2013
A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected
    Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Biomarkers; Carbamates; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Phenotype; Polyethylene Glycols; Puerto Rico; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; United States; Valine; Viral Load; Viral Nonstructural Proteins

2014
Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials.
    Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34, Issue:5

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Young Adult

2014
Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2014, Volume: 12, Issue:6

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Interferon-alpha; Isoindoles; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Placebos; Proline; Ribavirin; Sulfonamides; Treatment Outcome; Viral Load; Young Adult

2014
Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
    Gastroenterology, 2014, Volume: 146, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzoates; Drug Administration Schedule; Female; Follow-Up Studies; Hematologic Agents; Hepatitis C, Chronic; Humans; Hydrazines; Induction Chemotherapy; Intention to Treat Analysis; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Maintenance Chemotherapy; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Pyrazoles; Recombinant Proteins; Ribavirin; Thrombocytopenia; Treatment Outcome; Young Adult

2014
Impact of age on viral kinetics of peginterferon alfa-2a/ribavirin in chronic hepatitis C: final analysis from the PROPHESYS cohort.
    Journal of viral hepatitis, 2014, Volume: 21, Issue:5

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Viral Load

2014
Role of ritonavir in the drug interactions between telaprevir and ritonavir-boosted atazanavir.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Volume: 58, Issue:2

    Topics: Adult; Antiviral Agents; Atazanavir Sulfate; Chromatography, Liquid; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Mass Spectrometry; Middle Aged; Oligopeptides; Plasma; Pyridines; Ribavirin; Ritonavir

2014
In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir.
    The Journal of infectious diseases, 2014, Mar-01, Volume: 209, Issue:5

    Topics: Antiviral Agents; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Mutation; Polyethylene Glycols; Recombinant Proteins; Replicon; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins

2014
[Predicting side effects of the treatment of chronic hepatitis with peginterferon alpha-2A with ribaverin].
    Klinicheskaia meditsina, 2013, Volume: 91, Issue:5

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Outcome

2013
Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor.
    Journal of viral hepatitis, 2013, Volume: 20, Issue:11

    Topics: Adult; Antiviral Agents; Cyclopropanes; Dipeptides; Drug Therapy, Combination; Evolution, Molecular; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leucine; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Sulfones; Urea; Viral Load; Viral Nonstructural Proteins

2013
Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial.
    Gastroenterology, 2014, Volume: 146, Issue:2

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir; Sulfonamides; Treatment Outcome; Viral Load; Young Adult

2014
Telaprevir is effective given every 12 h at 750 mg with pegylated interferon-α2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT.
    Antiviral therapy, 2014, Volume: 19, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2014
Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C.
    Gut, 2014, Volume: 63, Issue:7

    Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Linear Models; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome

2014
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.
    Lancet (London, England), 2014, Feb-08, Volume: 383, Issue:9916

    Topics: Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Combinations; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Male; Middle Aged; Protease Inhibitors; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins

2014
A double-blind randomized controlled study to evaluate the efficacy of low-dose oral interferon-alpha in preventing hepatitis C relapse.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2014, Volume: 34, Issue:3

    Topics: Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Secondary Prevention; Thrombocytopenia; Treatment Outcome

2014
A simple rule to personalize standard dual therapy across all genotypes in naive chronic hepatitis C patients: the TT4 randomized trial.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Volume: 46, Issue:2

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Precision Medicine; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2014
Response of Black African patients with hepatitis C virus genotype 4 to treatment with peg-interferon and ribavirin.
    Acta gastro-enterologica Belgica, 2013, Volume: 76, Issue:3

    Topics: Adult; Africa, Central; Aged; Antiviral Agents; Belgium; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Young Adult

2013
Factors of response to pegylated interferon/ribavirin combination therapy and mechanism of viral clearance.
    Digestive diseases (Basel, Switzerland), 2013, Volume: 31, Issue:5-6

    Topics: Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Ribavirin; Risk Factors; Treatment Outcome

2013
Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotypes 2a and 2b and high viral load.
    Digestive diseases (Basel, Switzerland), 2013, Volume: 31, Issue:5-6

    Topics: Amino Acid Sequence; Base Sequence; Demography; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Kinetics; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Ribavirin; Risk Factors; Sequence Analysis, DNA; Treatment Outcome; Viral Load; Viral Nonstructural Proteins

2013
Outcome of double-filtration plasmapheresis plus interferon treatment in nonresponders to pegylated interferon plus ribavirin combination therapy.
    Digestive diseases (Basel, Switzerland), 2013, Volume: 31, Issue:5-6

    Topics: Drug Therapy, Combination; Female; Filtration; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Middle Aged; Plasmapheresis; Polyethylene Glycols; Ribavirin; Risk Factors; Treatment Outcome

2013
Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study.
    Journal of gastroenterology, 2014, Volume: 49, Issue:11

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genetic Markers; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Japan; Logistic Models; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult

2014
Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trial.
    Journal of hepatology, 2014, Volume: 60, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2014
Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:2

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Cyclopropanes; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; Mutation; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load; Viral Nonstructural Proteins

2014
Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.
    Annals of internal medicine, 2013, Dec-03, Volume: 159, Issue:11

    Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Failure, Chronic; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin; Viral Load

2013
Addicts with chronic hepatitis C: difficult to reach, manage or treat?
    World journal of gastroenterology, 2013, Nov-28, Volume: 19, Issue:44

    Topics: Adult; Antiviral Agents; Cooperative Behavior; Drug Therapy, Combination; Drug Users; Female; Health Services Accessibility; Hepatitis C, Chronic; Humans; Interdisciplinary Communication; Interferon alpha-2; Interferon-alpha; Italy; Male; Medication Adherence; Middle Aged; Patient Care Team; Patient Dropouts; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors; Substance Abuse, Intravenous; Time Factors; Treatment Outcome

2013
Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.
    Gastroenterology, 2014, Volume: 146, Issue:3

    Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Fatigue; Female; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Male; Middle Aged; Nausea; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2014
Revisiting predictors of virologic response to PEGIFN + RBV therapy in HIV-/HCV-coinfected patients: the role of metabolic factors and elevated GGT levels.
    Journal of viral hepatitis, 2014, Volume: 21, Issue:1

    Topics: Adult; Drug Therapy, Combination; Female; gamma-Glutamyltransferase; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Failure

2014
Impact of ribavirin priming on viral kinetics and treatment response in chronic hepatitis C genotype 1 infection.
    Journal of viral hepatitis, 2014, Volume: 21, Issue:1

    Topics: Adult; Aged; Double-Blind Method; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Placebos; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Young Adult

2014
Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C).
    Journal of hepatology, 2014, Volume: 60, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Mental Health; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate

2014
Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study.
    Gastroenterologia y hepatologia, 2014, Volume: 37, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythropoietin; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Viremia

2014
Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response.
    Journal of hepatology, 2014, Volume: 60, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome; Viral Load

2014
Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C.
    Journal of gastroenterology, 2014, Volume: 49, Issue:12

    Topics: Adult; Age Factors; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interleukins; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recombinant Proteins; Regression Analysis; Ribavirin; Treatment Outcome; Young Adult

2014
IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin.
    The Journal of infectious diseases, 2014, Jun-01, Volume: 209, Issue:11

    Topics: Antiviral Agents; Gene Expression Regulation; Genetic Predisposition to Disease; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interleukins; Ribavirin; Sofosbuvir; Uridine Monophosphate

2014
Re-treatment of chronic HCV infection in HIV co-infected patients and predictors of sustained viral response.
    The Journal of infection, 2014, Volume: 68, Issue:5

    Topics: Adult; Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Recurrence; Ribavirin; Treatment Outcome

2014
Measurement properties of the flu-like symptom index from the hepatitis physical symptom severity diary.
    Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2014, Volume: 23, Issue:5

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Cohort Studies; Depression; Drug Therapy, Combination; Factor Analysis, Statistical; Fatigue; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Minnesota; Musculoskeletal Pain; Psychiatric Status Rating Scales; Reproducibility of Results; Ribavirin; Self Report; Severity of Illness Index; Sickness Impact Profile; Surveys and Questionnaires; Treatment Outcome; Virginia; Young Adult

2014
Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial.
    Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:6

    Topics: Adult; Aged; Female; Hepatitis C, Chronic; Homeostasis; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Biological; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Regression Analysis; Ribavirin; RNA, Viral; Treatment Failure; Treatment Outcome

2013
Hepatitis C viral infection among prisoners.
    Vojnosanitetski pregled, 2013, Volume: 70, Issue:11

    Topics: Adult; Age Distribution; Comorbidity; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Polyethylene Glycols; Prisoners; Recombinant Proteins; Ribavirin; RNA, Viral; Substance Abuse, Intravenous; Tattooing; Treatment Outcome

2013
HCV-specific immune responses induced by CIGB-230 in combination with IFN-α plus ribavirin.
    World journal of gastroenterology, 2014, Jan-07, Volume: 20, Issue:1

    Topics: Adult; Antiviral Agents; Biomarkers; Cells, Cultured; Cuba; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Immunity, Cellular; Immunity, Humoral; Immunization Schedule; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Leukocytes, Mononuclear; Male; Middle Aged; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Vaccines, DNA; Viral Hepatitis Vaccines

2014
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
    The New England journal of medicine, 2014, Jan-16, Volume: 370, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Protease Inhibitors; Pyrrolidines; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Valine; Viral Nonstructural Proteins; Young Adult

2014
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
    The New England journal of medicine, 2014, Jan-16, Volume: 370, Issue:3

    Topics: Administration, Oral; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Protease Inhibitors; Ribavirin; RNA, Viral; Sulfonamides; Valine; Viral Nonstructural Proteins; Young Adult

2014
Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders.
    Journal of hepatology, 2014, Volume: 60, Issue:3

    Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Sulfonamides; Valine

2014
A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection.
    Antiviral therapy, 2014, Volume: 19, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome; Valine; Viral Load; Young Adult

2014
Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1.
    Antiviral therapy, 2014, Volume: 19, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome; Valine; Viral Load

2014
Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Valine

2014
Risk factors predictive of anemia development during telaprevir plus peginterferon/ribavirin therapy in treatment-experienced patients.
    Journal of hepatology, 2014, Volume: 60, Issue:6

    Topics: Adult; Aged; Anemia; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome; Young Adult

2014
All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection.
    Hepatology (Baltimore, Md.), 2014, Volume: 60, Issue:1

    Topics: Administration, Oral; Adolescent; Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Purines; Pyridazines; Quinolines; Ribavirin; Treatment Outcome; Viral Nonstructural Proteins; Young Adult

2014
Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239.
    Journal of acquired immune deficiency syndromes (1999), 2014, Mar-01, Volume: 65, Issue:3

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Pilot Projects; Pioglitazone; Retreatment; Ribavirin; RNA, Viral; Thiazolidinediones; Treatment Failure; Treatment Outcome; Viral Load

2014
Work productivity among treatment-naïve patients with genotype 1 chronic hepatitis C infection receiving telaprevir combination treatment.
    Journal of viral hepatitis, 2015, Volume: 22, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Efficiency; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Surveys and Questionnaires; Treatment Outcome

2015
Treatment of chronic hepatitis C with pegylated interferon plus ribavirin in treatment-naïve 'real-life' patients in India.
    Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2014, Volume: 33, Issue:4

    Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; India; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2014
Hepatitis C virus core antigen, an earlier and stronger predictor on sustained virological response in patients with genotype 1 HCV infection.
    BMC gastroenterology, 2014, Mar-13, Volume: 14

    Topics: Adult; Antiviral Agents; Area Under Curve; Biomarkers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; ROC Curve; Time Factors; Viral Core Proteins

2014
Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies.
    Journal of gastroenterology, 2014, Volume: 49, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Japan; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Simeprevir; Sulfonamides; Young Adult

2014
Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection.
    Gastroenterology, 2014, Volume: 147, Issue:1

    Topics: Adult; Aged; Antibodies, Anti-Idiotypic; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunotherapy; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Vaccines, DNA; Viral Vaccines

2014
The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients.
    AIDS (London, England), 2014, Jan-28, Volume: 28, Issue:3

    Topics: Adult; Antiviral Agents; Cohort Studies; Coinfection; Cost-Benefit Analysis; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Oligopeptides; Ribavirin; Treatment Outcome; United States

2014
Antiviral activity and safety profile of silibinin in HCV patients with advanced fibrosis after liver transplantation: a randomized clinical trial.
    Transplant international : official journal of the European Society for Organ Transplantation, 2014, Volume: 27, Issue:7

    Topics: Antiviral Agents; Double-Blind Method; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Prospective Studies; Ribavirin; Silybin; Silymarin

2014
A real life boceprevir use in treatment-experienced HCV genotype 1 patients with advanced fibrosis.
    Journal of gastrointestinal and liver diseases : JGLD, 2014, Volume: 23, Issue:1

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Prognosis; Proline; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Young Adult

2014
Increased levels of serum amyloid A during the early phase of hepatitis C treatment with interferon are associated with sustained virologic response - a pilot study.
    Journal of gastrointestinal and liver diseases : JGLD, 2014, Volume: 23, Issue:1

    Topics: Adult; Antiviral Agents; Biomarkers; Drug Monitoring; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Pilot Projects; Prognosis; Ribavirin; Serum Amyloid A Protein; Treatment Outcome; Young Adult

2014
Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study.
    Journal of hepatology, 2014, Volume: 61, Issue:2

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Patient Outcome Assessment; Ribavirin; Sofosbuvir; Uridine Monophosphate

2014
Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial.
    Journal of viral hepatitis, 2014, Volume: 21, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Ribavirin; Treatment Outcome; Viral Load; Vitamin D; Vitamins

2014
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
    The New England journal of medicine, 2014, Apr-24, Volume: 370, Issue:17

    Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Double-Blind Method; Drug Combinations; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Retreatment; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Uracil; Valine; Viral Load; Young Adult

2014
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
    The New England journal of medicine, 2014, May-15, Volume: 370, Issue:20

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load; Young Adult

2014
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
    The New England journal of medicine, 2014, Apr-24, Volume: 370, Issue:17

    Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Double-Blind Method; Drug Combinations; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine; Viral Load; Young Adult

2014
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.
    The New England journal of medicine, 2014, May-22, Volume: 370, Issue:21

    Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Logistic Models; Macrocyclic Compounds; Male; Middle Aged; Proline; Recurrence; Ribavirin; Sulfonamides; Valine

2014
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
    The New England journal of medicine, 2014, May-15, Volume: 370, Issue:20

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load; Young Adult

2014
Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial.
    Journal of hepatology, 2014, Volume: 61, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Simeprevir; Sulfonamides; Treatment Failure

2014
Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis C patients with thrombocytopenia and advanced fibrosis.
    Journal of gastroenterology and hepatology, 2014, Volume: 29, Issue:9

    Topics: Adult; Aged; Alleles; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Platelet Count; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Severity of Illness Index; Splenectomy; Thrombocytopenia; Treatment Outcome; Young Adult

2014
Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial.
    Gut, 2015, Volume: 64, Issue:2

    Topics: Adult; Aged; Anemia; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythropoietin; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin; Treatment Outcome; Viral Load; Young Adult

2015
HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFNα2a and Ribavirin: a randomized controlled trial.
    Journal of viral hepatitis, 2014, Volume: 21, Issue:7

    Topics: Adjuvants, Immunologic; Antibodies, Neutralizing; Antiviral Agents; CD4-Positive T-Lymphocytes; Cell Proliferation; Combined Modality Therapy; Drug-Related Side Effects and Adverse Reactions; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Injections, Intramuscular; Interferon-alpha; Polyethylene Glycols; Polysorbates; Recombinant Proteins; Ribavirin; RNA, Viral; Squalene; Treatment Outcome; Vaccines, Synthetic; Viral Hepatitis Vaccines; Viral Load

2014
PEG-IFN alpha but not ribavirin alters NK cell phenotype and function in patients with chronic hepatitis C.
    PloS one, 2014, Volume: 9, Issue:4

    Topics: Antiviral Agents; Cell Count; Cell Degranulation; Cell Differentiation; Cytokines; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Killer Cells, Natural; Lymphocyte Activation; Middle Aged; Phenotype; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load

2014
[Individualization of antiviral treatment of chronic hepatitis].
    Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, 2013, Issue:6

    Topics: Adolescent; Adult; Antibodies, Viral; Antiviral Agents; Caproates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Precision Medicine; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Virus Replication; Young Adult

2013
Safety and efficacy of Hansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children.
    World journal of gastroenterology, 2014, Apr-28, Volume: 20, Issue:16

    Topics: Administration, Oral; Adolescent; Age Factors; Antiviral Agents; Biomarkers; Child; Child, Preschool; Drug Administration Schedule; Drug Therapy, Combination; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon-alpha; Male; Pichia; Polyethylene Glycols; Recombinant Proteins; Recurrence; Remission Induction; Ribavirin; RNA, Viral; Tertiary Care Centers; Time Factors; Treatment Outcome; Viral Load; Young Adult

2014
Directly observed therapy for chronic hepatitis C: a randomized clinical trial in the prison setting.
    Gastroenterologia y hepatologia, 2014, Volume: 37, Issue:8

    Topics: Adult; Antiviral Agents; Directly Observed Therapy; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Prisons; Recombinant Proteins; Ribavirin

2014
Sofosbuvir and ribavirin in HCV genotypes 2 and 3.
    The New England journal of medicine, 2014, May-22, Volume: 370, Issue:21

    Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load

2014
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
    The New England journal of medicine, 2014, May-22, Volume: 370, Issue:21

    Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Recurrence; Ribavirin; RNA, Viral; Sulfonamides; Valine

2014
The prospective randomized study on telaprevir at 1500 or 2250 mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1.
    Journal of gastroenterology, 2015, Volume: 50, Issue:3

    Topics: Aged; Anemia; Antiviral Agents; Dose-Response Relationship, Drug; Drug Eruptions; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2015
Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study.
    Antiviral therapy, 2015, Volume: 20, Issue:1

    Topics: Adult; Anemia; Antiviral Agents; Cell Count; Coinfection; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia; Viral Load

2015
Peginterferon α-2a and rivabirin in the treatment of chronic hepatitis C.
    Mymensingh medical journal : MMJ, 2014, Volume: 23, Issue:2

    Topics: Adult; Antiviral Agents; Bangladesh; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2014
Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir.
    Virology journal, 2014, May-16, Volume: 11

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Mutation; Oligopeptides; Ribavirin; Treatment Failure; Young Adult

2014
VX-222, a non-nucleoside NS5B polymerase inhibitor, in telaprevir-based regimens for genotype 1 hepatitis C virus infection.
    European journal of gastroenterology & hepatology, 2014, Volume: 26, Issue:7

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Cyclohexanols; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thiophenes; Treatment Outcome; Viral Nonstructural Proteins; Young Adult

2014
Restoration of HCV-specific CD8+ T cell function by interferon-free therapy.
    Journal of hepatology, 2014, Volume: 61, Issue:3

    Topics: Acrylates; Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; CD8-Positive T-Lymphocytes; Cell Proliferation; Cells, Cultured; Contraindications; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; In Vitro Techniques; Interferon alpha-2; Interferon-alpha; Leucine; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Quinolines; Recombinant Proteins; Ribavirin; Thiazoles; Treatment Outcome; Virus Replication

2014
Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2014, Aug-02, Volume: 384, Issue:9941

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir; Sulfonamides; Treatment Outcome

2014
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
    Lancet (London, England), 2014, Aug-02, Volume: 384, Issue:9941

    Topics: Adult; Antiviral Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir; Sulfonamides; Treatment Outcome

2014
HCV RNA assay sensitivity impacts the management of patients treated with direct-acting antivirals.
    Antiviral therapy, 2015, Volume: 20, Issue:2

    Topics: 2-Naphthylamine; Antiviral Agents; Biological Assay; Cyclopropanes; Drug Monitoring; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Lactams, Macrocyclic; Macrocyclic Compounds; Oligopeptides; Polyethylene Glycols; Proline; Reagent Kits, Diagnostic; Recombinant Proteins; Ribavirin; RNA, Viral; Sensitivity and Specificity; Sulfonamides; Treatment Outcome; Uracil; Viral Load

2015
Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program.
    Journal of hepatology, 2014, Volume: 61, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult

2014
Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Volume: 46, Issue:9

    Topics: Adult; Aged; Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Proline; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2014
Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner.
    Antiviral research, 2014, Volume: 109

    Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Isomerism; Male; Middle Aged; Oligopeptides; Ribavirin

2014
A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2014, Volume: 113, Issue:10

    Topics: Acarbose; Adult; Aged; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Metformin; Middle Aged; Pilot Projects; Pioglitazone; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Sex Factors; Thiazolidinediones; Viral Load

2014
Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome.
    The Journal of clinical investigation, 2014, Volume: 124, Issue:8

    Topics: Antiviral Agents; Chemokine CXCL10; Drug Therapy, Combination; Endopeptidases; Gene Expression; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver; Recurrence; Ribavirin; RNA, Messenger; Sofosbuvir; Treatment Outcome; Ubiquitin Thiolesterase; Uridine Monophosphate

2014
Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: a multicentre independent study supported by the Italian Drug Agency.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Volume: 46, Issue:9

    Topics: Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Hepatitis Viruses; Humans; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Registries; Ribavirin; RNA, Viral; Treatment Outcome

2014
Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease.
    European journal of gastroenterology & hepatology, 2014, Volume: 26, Issue:8

    Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Protease Inhibitors; Ribavirin; Risk Assessment; Severity of Illness Index; Treatment Outcome; Young Adult

2014
Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C.
    Journal of hepatology, 2014, Volume: 61, Issue:6

    Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Isoquinolines; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sulfonamides; Treatment Outcome; Young Adult

2014
Patients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens.
    Alimentary pharmacology & therapeutics, 2014, Volume: 40, Issue:6

    Topics: Adolescent; Antiviral Agents; Drug Therapy, Combination; Female; Health Surveys; Hepatitis C, Chronic; Humans; Interferons; Male; Patient Preference; Quality of Life; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Uridine Monophosphate

2014
Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 2: Exposure-response analyses for efficacy and safety variables.
    Journal of clinical pharmacology, 2015, Volume: 55, Issue:1

    Topics: Adult; Antiviral Agents; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Models, Biological; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2015
Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 1: Modeling optimal treatment duration and sustained virologic response rates.
    Journal of clinical pharmacology, 2015, Volume: 55, Issue:1

    Topics: Adult; Antiviral Agents; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Models, Biological; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load

2015
Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2015, Volume: 35, Issue:1

    Topics: Adolescent; Adult; Antiviral Agents; Cholecalciferol; Dietary Supplements; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Young Adult

2015
A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection.
    Journal of hepatology, 2014, Volume: 61, Issue:6

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2014
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.
    Lancet (London, England), 2014, Nov-15, Volume: 384, Issue:9956

    Topics: Adult; Antiviral Agents; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reference Values; Ribavirin; Risk Assessment; Severity of Illness Index; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate

2014
Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study.
    Gut, 2015, Volume: 64, Issue:6

    Topics: Adolescent; Adult; Aged; Carbamates; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Remission Induction; Ribavirin; Treatment Outcome; Valine; Viral Load; Young Adult

2015
Cost-effectiveness of boceprevir co-administration versus pegylated interferon-α2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore.
    Antiviral therapy, 2015, Volume: 20, Issue:2

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Markov Chains; Middle Aged; Polyethylene Glycols; Prognosis; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Singapore; Treatment Outcome; Viral Load

2015
Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study.
    Journal of gastroenterology, 2015, Volume: 50, Issue:2

    Topics: Adult; Antiviral Agents; Cyclopropanes; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Interferon-alpha; Isoindoles; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Sulfonamides; Viral Load; Young Adult

2015
The pharmacokinetics of daclatasvir and asunaprevir administered in combination in studies in healthy subjects and patients infected with hepatitis C virus.
    Clinical drug investigation, 2014, Volume: 34, Issue:9

    Topics: Adult; Antiviral Agents; Area Under Curve; Carbamates; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Sulfonamides; Valine; Young Adult

2014
Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study.
    Advances in medical sciences, 2014, Volume: 59, Issue:2

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Poland; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load; Young Adult

2014
Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Dec-15, Volume: 59, Issue:12

    Topics: Antiviral Agents; Coinfection; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2014
Clinical and in vitro resistance to GS-9669, a thumb site II nonnucleoside inhibitor of the hepatitis C virus NS5B polymerase.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:11

    Topics: Adult; Antiviral Agents; Base Sequence; Benzimidazoles; Cell Line; Drug Resistance, Viral; Female; Fluorenes; Furans; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Microbial Sensitivity Tests; Molecular Sequence Data; Protein Binding; Quinolines; Ribavirin; Sequence Analysis, RNA; Sofosbuvir; Thiophenes; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins

2014
Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection.
    BMC infectious diseases, 2014, Aug-26, Volume: 14

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Fatigue; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Male; Middle Aged; Quality of Life; Ribavirin; Self Report; Simeprevir; Sulfonamides; Surveys and Questionnaires; Treatment Outcome; Young Adult

2014
Effects of escitalopram prophylaxis during antiviral treatment for chronic hepatitis C in patients with a history of intravenous drug use and depression.
    The Journal of clinical psychiatry, 2014, Volume: 75, Issue:10

    Topics: Aged; Antiviral Agents; Citalopram; Comorbidity; Depression; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Placebos; Ribavirin; Selective Serotonin Reuptake Inhibitors; Substance Abuse, Intravenous; Treatment Outcome; Young Adult

2014
Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Dec-01, Volume: 59, Issue:11

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir; Sulfonamides; Treatment Outcome; Young Adult

2014
Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial.
    Journal of viral hepatitis, 2014, Volume: 21, Issue:11

    Topics: Adult; Aged; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Young Adult

2014
Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients.
    Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:3

    Topics: Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lipid Metabolism; Lipoproteins, LDL; Male; Middle Aged; Ribavirin; Sofosbuvir; Uridine Monophosphate; Virus Replication

2015
Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin.
    Journal of hepatology, 2015, Volume: 62, Issue:2

    Topics: Cyclopropanes; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Retrospective Studies; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome

2015
Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection.
    The Journal of infection, 2015, Volume: 70, Issue:2

    Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Sulfonamides; Treatment Outcome; Valine; Viral Load

2015
Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:2

    Topics: Acrylates; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Leucine; Oligopeptides; Proline; Quinolines; Ribavirin; RNA, Viral; Thiazoles; Treatment Outcome

2015
Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.
    Gastroenterology, 2015, Volume: 148, Issue:2

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; RNA, Viral; Valine

2015
A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV.
    Antiviral therapy, 2015, Volume: 20, Issue:5

    Topics: Antiviral Agents; Cyclopropanes; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Models, Theoretical; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Sulfonamides; Treatment Outcome; Viral Load; Viral Nonstructural Proteins

2015
Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis.
    Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate

2015
Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study.
    Annals of internal medicine, 2014, Nov-04, Volume: 161, Issue:9

    Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Mutation; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate

2014
An interferon-free antiviral regimen for HCV after liver transplantation.
    The New England journal of medicine, 2014, Dec-18, Volume: 371, Issue:25

    Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Calcineurin Inhibitors; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Uracil; Valine; Viral Nonstructural Proteins; Young Adult

2014
Ribavirin priming has no beneficial effects for chronic hepatitis C patients.
    Przeglad epidemiologiczny, 2014, Volume: 68, Issue:3

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Premedication; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult

2014
Weight loss during telaprevir-based triple therapy due to telaprevir-induced appetite loss.
    Internal medicine (Tokyo, Japan), 2014, Volume: 53, Issue:22

    Topics: Antiviral Agents; Appetite; Body Weight; Depression; Drug Therapy, Combination; Female; Genotype; Ghrelin; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-beta; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Ribavirin; Treatment Outcome; Weight Loss

2014
Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial.
    Journal of viral hepatitis, 2015, Volume: 22, Issue:7

    Topics: Adult; Aged; Antiviral Agents; Cyclosporine; Double-Blind Method; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Placebos; Ribavirin; Salvage Therapy; Treatment Outcome; Viral Load; Young Adult

2015
Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies.
    Journal of hepatology, 2015, Volume: 62, Issue:5

    Topics: Antiviral Agents; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Simeprevir; Time Factors; Treatment Failure; Viral Nonstructural Proteins

2015
Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry.
    Journal of hepatology, 2015, Volume: 62, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; RNA-Dependent RNA Polymerase; RNA, Viral; Sofosbuvir; Treatment Outcome; United States; Viral Load; Viral Nonstructural Proteins

2015
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a rando
    Lancet (London, England), 2015, Mar-21, Volume: 385, Issue:9973

    Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Ribavirin; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load; Young Adult

2015
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous
    Lancet (London, England), 2015, Mar-21, Volume: 385, Issue:9973

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Quinoxalines; Ribavirin; RNA, Viral; Sulfonamides; Treatment Failure; Treatment Outcome; Viral Load; Young Adult

2015
Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
    World journal of gastroenterology, 2014, Nov-28, Volume: 20, Issue:44

    Topics: Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Italy; Logistic Models; Menopause; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2014
Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.
    The Lancet. Infectious diseases, 2015, Volume: 15, Issue:1

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Placebos; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir; Sulfonamides; Treatment Outcome; Young Adult

2015
Prospective, observational real-life study on eligibility for and outcomes of antiviral treatment with peginterferon α plus ribavirin in chronic hepatitis C.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2015, Volume: 47, Issue:2

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Cardiovascular Diseases; Comorbidity; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Mental Disorders; Middle Aged; Patient Selection; Polyethylene Glycols; Prospective Studies; Ribavirin; Young Adult

2015
Simeprevir added to peginterferon and ribavirin lessens time with fatigue, depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST-1, QUEST-2 an
    Journal of viral hepatitis, 2015, Volume: 22, Issue:8

    Topics: Adolescent; Adult; Aged; Anemia; Depression; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Fatigue; Female; Hepatitis C, Chronic; Humans; Incidence; Interferons; Liver; Male; Middle Aged; Placebos; Ribavirin; Simeprevir; Treatment Outcome; Viral Load; Young Adult

2015
A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1.
    Journal of viral hepatitis, 2015, Volume: 22, Issue:8

    Topics: Adult; Antiviral Agents; Benzazepines; Double-Blind Method; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Interferon-alpha; Male; Middle Aged; Placebos; Ribavirin; Treatment Outcome; Viral Load; Viral Nonstructural Proteins; Young Adult

2015
Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:2

    Topics: Acrylates; Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Female; Hepatitis C, Chronic; Humans; Leucine; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Proline; Quinolines; Ribavirin; Thiazoles; Young Adult

2015
Intrahepatic and Peripheral CXCL10 Expression in Hepatitis C Virus-Infected Patients Treated With Telaprevir, Pegylated Interferon, and Ribavirin.
    The Journal of infectious diseases, 2015, Jun-01, Volume: 211, Issue:11

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Chemokine CXCL10; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load; Young Adult

2015
Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy.
    Journal of virological methods, 2015, Volume: 214

    Topics: Administration, Oral; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Pilot Projects; Prognosis; Proline; Ribavirin; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load

2015
Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:7

    Topics: Aged; Antiviral Agents; Area Under Curve; beta 2-Glycoprotein I; Biomarkers; Drug Therapy, Combination; Female; France; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Molecular Targeted Therapy; Oligopeptides; Polyethylene Glycols; Predictive Value of Tests; Proline; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Viral; ROC Curve; Time Factors; Treatment Outcome; Viral Load; Viral Nonstructural Proteins; Virus Replication

2015
Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation.
    Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:5

    Topics: Antiviral Agents; Compassionate Use Trials; Female; Hepatitis C, Chronic; Humans; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; Severity of Illness Index; Sofosbuvir; Treatment Failure; Uridine Monophosphate

2015
The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.
    Gastroenterology, 2015, Volume: 148, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate; Viral Load

2015
STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection.
    Journal of hepatology, 2015, Volume: 62, Issue:6

    Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Leucine; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Quinolines; Recombinant Proteins; Ribavirin; RNA, Viral; Thiazoles

2015
Telaprevir enhances ribavirin-induced anaemia through renal function impairment.
    Antiviral therapy, 2015, Volume: 20, Issue:5

    Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Kidney; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Renal Insufficiency; Ribavirin

2015
Interferon-λ4 is a cell-autonomous type III interferon associated with pre-treatment hepatitis C virus burden.
    Virology, 2015, Volume: 476

    Topics: Antiviral Agents; Cohort Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Interleukins; Male; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome; Viral Load

2015
Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes.
    The Journal of infectious diseases, 2015, Aug-01, Volume: 212, Issue:3

    Topics: Antiviral Agents; Coinfection; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Quality of Life; Ribavirin; Self Report; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2015
Sustained virological response to antiviral therapy in a randomized trial of cyclosporine versus tacrolimus in liver transplant patients with recurrent hepatitis C infection.
    Annals of transplantation, 2015, Jan-15, Volume: 20

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Calcineurin Inhibitors; Cyclosporine; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tacrolimus; Treatment Outcome; Young Adult

2015
Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study.
    Lancet (London, England), 2015, Mar-21, Volume: 385, Issue:9973

    Topics: Aged; Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Furans; Hepacivirus; Hepatitis C, Chronic; Humans; Intention to Treat Analysis; Male; Middle Aged; Quinolines; Ribavirin; RNA, Viral; Sofosbuvir; Thiophenes; Treatment Outcome; Uridine Monophosphate; Viral Load

2015
Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4.
    Journal of hepatology, 2015, Volume: 62, Issue:5

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Secondary Prevention; Simeprevir; Treatment Outcome; Viral Load

2015
The ARRIBA concept: adequate resorption of ribavirin.
    Antiviral therapy, 2015, Volume: 20, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Area Under Curve; Coinfection; Dose-Response Relationship, Drug; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Ribavirin; Treatment Outcome; Viral Load; Young Adult

2015
Randomized trial of peginterferon alpha-2b plus low and escalating dose of ribavirin in patients with chronic hepatitis C with high viral load genotype 1.
    Journal of medical virology, 2015, Volume: 87, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome; Viral Load

2015
Sofosbuvir for chronic hepatitis C virus infection genotype 1-4 in patients coinfected with HIV.
    Journal of acquired immune deficiency syndromes (1999), 2015, Apr-15, Volume: 68, Issue:5

    Topics: Adult; Aged; Animals; Anti-Retroviral Agents; Antiviral Agents; Cohort Studies; Drug Interactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load

2015
Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir.
    Alimentary pharmacology & therapeutics, 2015, Volume: 41, Issue:7

    Topics: Adolescent; Adult; Age Factors; Aged; Algorithms; Antiviral Agents; Biomarkers; Comorbidity; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Young Adult

2015
Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials.
    Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:6

    Topics: Adult; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Quality of Life; Ribavirin; Sofosbuvir; Uridine Monophosphate

2015
Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients.
    Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:5

    Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Valine; Young Adult

2015
Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:4

    Topics: Adult; Antiviral Agents; Body Weight; Erythrocytes; Female; Half-Life; Hepatitis C, Chronic; Humans; Liver Function Tests; Male; Middle Aged; Models, Statistical; Oligopeptides; Phosphorylation; Population; Ribavirin; Sex Characteristics

2015
Factors affecting outcome of treatment of chronic hepatitis C: result of an open label study from eastern India.
    Tropical doctor, 2016, Volume: 46, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; India; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome

2016
Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
    Lancet (London, England), 2015, Mar-21, Volume: 385, Issue:9973

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load; Young Adult

2015
A non-interventional phase IV Belgian survey to assess the antiviral effectiveness of pegylated interferon-alpha-2b and ribavirin treatment according to the stage of liver fibrosis in previously untreated patients with genotype 1/4/5/6 chronic hepatitis C
    Acta gastro-enterologica Belgica, 2014, Volume: 77, Issue:4

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Data Collection; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Young Adult

2014
Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders.
    Journal of hepatology, 2015, Volume: 63, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Carbamates; DNA, Viral; Drug Administration Schedule; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Sulfonamides; Treatment Outcome; Valine; Viral Load; Young Adult

2015
Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV.
    AIDS (London, England), 2015, Mar-13, Volume: 29, Issue:5

    Topics: Adolescent; Adult; Aged; Aminoisobutyric Acids; Anti-Retroviral Agents; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Leucine; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Quinolines; Recombinant Proteins; Ribavirin; Thiazoles; Treatment Outcome; Viral Load; Viremia; Young Adult

2015
Real life experience in treatment of HIV-1/HCV-coinfected patients with pegylated interferon alpha and ribavirin: predictors of SVR.
    The new microbiologica, 2015, Volume: 38, Issue:1

    Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load; Young Adult

2015
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
    The Lancet. Infectious diseases, 2015, Volume: 15, Issue:4

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Benzimidazoles; Double-Blind Method; Female; Fluorenes; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Placebos; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load; Young Adult

2015
Randomized study comparing vitamin D3 and 1α-Hydroxyvitamin D3 in combination with pegylated interferon/ribavirin therapy for chronic hepatitis C.
    Journal of gastroenterology and hepatology, 2015, Volume: 30, Issue:9

    Topics: Administration, Ophthalmic; Aged; Antiviral Agents; Biomarkers; Calcifediol; Cholecalciferol; Drug Synergism; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hydroxycholecalciferols; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Up-Regulation

2015
Bacterial infection as an adverse effect of telaprevir-based triple therapy for chronic hepatitis C infection.
    Internal medicine (Tokyo, Japan), 2015, Volume: 54, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Bacterial Infections; Biomarkers; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2015
Telaprevir and ribavirin interaction: higher ribavirin levels are not only due to renal dysfunction during triple therapy.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:6

    Topics: Adult; Antiviral Agents; Coinfection; Creatinine; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Ribavirin; Tandem Mass Spectrometry

2015
Hepatitis C therapy with interferon-α and ribavirin reduces the CD4 cell count and the total, 2LTR circular and integrated HIV-1 DNA in HIV/HCV co-infected patients.
    Antiviral research, 2015, Volume: 118

    Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; DNA, Circular; DNA, Viral; Female; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Viral Load; Virus Integration; Virus Replication

2015
Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.
    Lancet (London, England), 2015, Jun-20, Volume: 385, Issue:9986

    Topics: Adolescent; Adult; Aged; Alanine Transaminase; Anilides; Antiviral Agents; Aspartate Aminotransferases; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Valine; Young Adult

2015
Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.
    Journal of hepatology, 2015, Volume: 63, Issue:2

    Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Analgesics, Opioid; Anilides; Antiviral Agents; Buprenorphine; Carbamates; Cyclopropanes; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Methadone; Middle Aged; Opioid-Related Disorders; Proline; Retrospective Studies; Ribavirin; Sulfonamides; Uracil; Valine; Young Adult

2015
Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens.
    Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Failure; Uridine Monophosphate

2015
Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis.
    Hepatology (Baltimore, Md.), 2015, Volume: 62, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Young Adult

2015
Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failed.
    Hepatology (Baltimore, Md.), 2015, Volume: 62, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Failure; Uridine Monophosphate; Young Adult

2015
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.
    The Lancet. Infectious diseases, 2015, Volume: 15, Issue:6

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian People; Benzimidazoles; Drug-Related Side Effects and Adverse Reactions; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Male; Middle Aged; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome; Uridine Monophosphate; Young Adult

2015
A comparative study of variants of pegylated interferon alpha in treatment of chronic HCV patients.
    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2015, Volume: 123, Issue:6

    Topics: Adult; Antibodies, Neutralizing; Cost-Benefit Analysis; Drug Combinations; Egypt; Female; Genotype; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Young Adult

2015
[Applying of recombinant interleukin-1β to treat chronic hepatitis C for patients non-response to the previous antiviral therapy].
    Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, 2014, Issue:10

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Interleukin-1beta; Liver Function Tests; Male; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome; Viral Load

2014
Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients.
    World journal of gastroenterology, 2015, Apr-21, Volume: 21, Issue:15

    Topics: Aged; Alanine Transaminase; alpha-Fetoproteins; Antiviral Agents; Biomarkers; Down-Regulation; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2015
Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4.
    Journal of hepatology, 2015, Volume: 63, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir

2015
The role of alexithymia in quality of life impairment in patients with chronic hepatitis C during antiviral treatment.
    Comprehensive psychiatry, 2015, Volume: 60

    Topics: Affective Symptoms; Antiviral Agents; Depressive Disorder, Major; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mood Disorders; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Stress, Psychological

2015
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis.
    JAMA, 2015, May-05, Volume: 313, Issue:17

    Topics: Adult; Aged; Antiviral Agents; Benzazepines; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Sulfonamides; Valine; Viral Load

2015
Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials.
    Hepatology (Baltimore, Md.), 2015, Volume: 62, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Uridine Monophosphate; Young Adult

2015
Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin.
    The Journal of antimicrobial chemotherapy, 2015, Volume: 70, Issue:8

    Topics: Adult; Aged; Anemia; Antiviral Agents; Erythrocytes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Serum; Sofosbuvir; Treatment Outcome; Viral Load

2015
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
    Gastroenterology, 2015, Volume: 149, Issue:3

    Topics: Antiviral Agents; Benzimidazoles; Cholestasis, Intrahepatic; Disease Progression; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome; United States; Uridine Monophosphate

2015
Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study.
    World journal of gastroenterology, 2015, May-14, Volume: 21, Issue:18

    Topics: Adult; Aged; Antiviral Agents; Biomarkers; Calcifediol; Cholecalciferol; Drug Therapy, Combination; Female; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Intention to Treat Analysis; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Vitamin D Deficiency; Vitamins

2015
Assessment of interleukin 28B genotype as a predictor of response to combined therapy with pegylated interferon plus ribavirin in HCV infected Egyptian patients.
    Cytokine, 2015, Volume: 74, Issue:2

    Topics: Adult; Aged; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Ribavirin

2015
Randomized trial of low-dose peginterferon α-2b plus low and escalating doses of ribavirin in older patients with chronic hepatitis C with high viral load genotype 1.
    Journal of medical virology, 2015, Volume: 87, Issue:12

    Topics: Aged, 80 and over; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Molecular Sequence Data; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome; Viral Load

2015
Interplay between vitamin D status and antiviral therapy among chronic hepatitis C Egyptian patients.
    Journal of the Egyptian Society of Parasitology, 2015, Volume: 45, Issue:1

    Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Egypt; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Vitamin D

2015
Ribavirin Reduces Absolute Lymphocyte Counts in Hepatitis C Virus-Infected Patients Treated With Interferon-Free, Direct-Acting Antiviral Regimens.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015, Sep-15, Volume: 61, Issue:6

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Lymphocyte Count; Lymphopenia; Ribavirin

2015
Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEX Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical Trial.
    PloS one, 2015, Volume: 10, Issue:6

    Topics: Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Recurrence; Ribavirin; Surveys and Questionnaires; Treatment Outcome

2015
The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:1

    Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Monitoring; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Patient Outcome Assessment; Ribavirin; RNA, Viral; Sofosbuvir

2016
Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment.
    Archives of virology, 2015, Volume: 160, Issue:8

    Topics: Adult; Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome

2015
Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment.
    Journal of hepatology, 2015, Volume: 63, Issue:4

    Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatic Insufficiency; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Function Tests; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine

2015
High Response Rate to Pegylated Interferon Alpha and Ribavirin Combination Therapy in Hemophilic Children with Chronic Hepatitis C; A Case-Control Study.
    Pediatric hematology and oncology, 2015, Volume: 32, Issue:6

    Topics: Adolescent; Adult; Case-Control Studies; Child; Drug Therapy, Combination; Female; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2015
The tertiary prevention of hepatocellular carcinoma in chronic hepatitis C patients.
    Journal of gastroenterology and hepatology, 2015, Volume: 30, Issue:12

    Topics: Aged; Antiviral Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Histocompatibility Antigens Class I; Humans; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Ribavirin; Tertiary Prevention; Treatment Outcome

2015
Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection.
    Hepatology (Baltimore, Md.), 2015, Volume: 62, Issue:4

    Topics: Adult; Antiviral Agents; Cyclosporine; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2015
Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial.
    Scientific reports, 2015, Jul-01, Volume: 5

    Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2015
Highly effective peginterferon α-2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea.
    Clinical and molecular hepatology, 2015, Volume: 21, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Fatigue; Female; Genotype; Headache; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Recurrence; Republic of Korea; Ribavirin; RNA, Viral; Treatment Outcome

2015
A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.
    PloS one, 2015, Volume: 10, Issue:7

    Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Drug Administration Schedule; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Injections, Intravenous; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Patient Safety; Polyethylene Glycols; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Viral; Silybin; Silymarin; Treatment Outcome; Viral Load

2015
Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy.
    PloS one, 2015, Volume: 10, Issue:7

    Topics: Adult; Antiviral Agents; Benzimidazoles; Chemokine CXCL10; Convalescence; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Protein Processing, Post-Translational; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Load; Virus Replication

2015
12 weeks of interferon-based therapy is feasible in patients with hepatitis C-related cirrhosis and thrombocytopenia: A post hoc analysis of eltrombopag studies.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2015, Volume: 47, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Albumins; Antiviral Agents; Benzoates; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hydrazines; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Pyrazoles; Ribavirin; Risk Factors; Severity of Illness Index; Thrombocytopenia; Treatment Outcome

2015
Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:10

    Topics: Amino Acid Substitution; Aminoisobutyric Acids; Antiviral Agents; Carrier Proteins; Double-Blind Method; Drug Resistance, Viral; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Leucine; Mutation; Oligopeptides; Polyethylene Glycols; Polymorphism, Genetic; Proline; Quinolines; Recombinant Proteins; Ribavirin; Thiazoles; Treatment Outcome; Viral Nonstructural Proteins

2015
The impact of an inosine triphosphate pyrophosphatase genotype on bilirubin increase in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin.
    Journal of gastroenterology, 2016, Volume: 51, Issue:3

    Topics: Aged; Antiviral Agents; Bilirubin; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepatitis C, Chronic; Humans; Hyperbilirubinemia; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Pyrophosphatases; Recombinant Proteins; Ribavirin; Risk Factors; Simeprevir; Treatment Outcome

2016
[High sustained virological response to optimized therapy for refractory chronic hepatitis C treatment-na(i)ve patients: a multicenter randomized study].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2015, Volume: 23, Issue:6

    Topics: Antiviral Agents; Asian People; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Ribavirin

2015
Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II).
    Alimentary pharmacology & therapeutics, 2015, Volume: 42, Issue:7

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Cyclosporine; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; United States; Young Adult

2015
Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection.
    Gastroenterology, 2015, Volume: 149, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Severity of Illness Index; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load

2015
Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:11

    Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hypertension, Portal; Hypoalbuminemia; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Sulfonamides; Thrombocytopenia; Treatment Outcome; Uracil; Valine; Young Adult

2015
Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
    Gastroenterology, 2015, Volume: 149, Issue:6

    Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; New Zealand; Random Allocation; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load

2015
Predictive factors for 24 weeks sustained virologic response (SVR24) and viral relapse in patients treated with simeprevir plus peginterferon and ribavirin.
    Hepatology international, 2016, Volume: 10, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Ribavirin; RNA, Viral; Simeprevir; Treatment Outcome; Viral Load; Young Adult

2016
Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels.
    Journal of viral hepatitis, 2015, Volume: 22, Issue:12

    Topics: Antiviral Agents; Apolipoproteins; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir

2015
Association of hepatic oxidative stress and iron dysregulation with HCC development after interferon therapy in chronic hepatitis C.
    Journal of clinical pathology, 2016, Volume: 69, Issue:3

    Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Deoxyguanosine; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Iron Metabolism Disorders; Leukocytes, Mononuclear; Liver; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Oxidative Stress; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome

2016
Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial.
    Journal of viral hepatitis, 2016, Volume: 23, Issue:2

    Topics: Adult; Aged; Amides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Quinoxalines; Recombinant Proteins; Ribavirin; RNA, Viral; Sulfonamides; Viral Load; Viral Nonstructural Proteins; Young Adult

2016
Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, Jan-01, Volume: 62, Issue:1

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Ribavirin; Salvage Therapy; Sulfonamides; Treatment Outcome

2016
Peginterferon Lambda-1a Is Associated with a Low Incidence of Autoimmune Thyroid Disease in Chronic Hepatitis C.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2015, Volume: 35, Issue:11

    Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Double-Blind Method; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukins; Middle Aged; Polyethylene Glycols; Retrospective Studies; Ribavirin; Thyroiditis, Autoimmune; Thyrotropin; Treatment Outcome; Young Adult

2015
Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study.
    Journal of gastroenterology, 2016, Volume: 51, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Isoindoles; Japan; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Sulfonamides; Treatment Outcome; Young Adult

2016
Major depressive disorder and generalized anxiety disorder and response to treatment in hepatitis C patients in Egypt.
    International journal of psychiatry in medicine, 2015, Volume: 50, Issue:2

    Topics: Adult; Antiviral Agents; Anxiety Disorders; Depressive Disorder, Major; Egypt; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult

2015
Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients: An early access programme.
    The Journal of infection, 2015, Volume: 71, Issue:6

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Bilirubin; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Oligopeptides; Ribavirin; RNA, Viral; Young Adult

2015
Determinant Factors of the Direct Medical Costs Associated with Genotype 1 Hepatitis C Infection in Treatment-Experienced Patients.
    Drugs in R&D, 2015, Volume: 15, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir

2015
Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience.
    Scandinavian journal of gastroenterology, 2016, Volume: 51, Issue:3

    Topics: Adult; Age Factors; Antiviral Agents; Chemokine CXCL10; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Middle Aged; Polyethylene Glycols; Pyrophosphatases; Recombinant Proteins; Ribavirin; RNA, Viral; Scandinavian and Nordic Countries; Treatment Outcome

2016
Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection.
    Journal of hepatology, 2016, Volume: 64, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Carbamates; DNA, Viral; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Simeprevir; Treatment Outcome; Valine

2016
Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial.
    Scientific reports, 2015, Oct-15, Volume: 5

    Topics: Adult; Aged; Antiviral Agents; Body Weight; Dose-Response Relationship, Drug; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2015
Impact of nitazoxanide on sustained virologic response in Egyptian patients with chronic hepatitis C genotype 4: a double-blind placebo-controlled trial.
    European journal of gastroenterology & hepatology, 2016, Volume: 28, Issue:1

    Topics: Adult; Antiparasitic Agents; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Nitro Compounds; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Thiazoles; Viral Load

2016
Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Benzazepines; Carbamates; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Ribavirin; Sulfonamides; Treatment Outcome; Valine; Viral Load

2016
Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.
    Journal of hepatology, 2016, Volume: 64, Issue:2

    Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine

2016
Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study.
    The Journal of antimicrobial chemotherapy, 2016, Volume: 71, Issue:1

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Coinfection; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult

2016
Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin: A Randomized Study.
    Medicine, 2015, Volume: 94, Issue:42

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Precision Medicine; Recombinant Proteins; Ribavirin

2015
Effects of Pegylated Interferon/Ribavirin on Bone Turnover Markers in HIV/Hepatitis C Virus-Coinfected Patients.
    AIDS research and human retroviruses, 2016, Volume: 32, Issue:4

    Topics: Adult; Antiviral Agents; Biomarkers; Bone Remodeling; Coinfection; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Treatment Outcome

2016
Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:4

    Topics: Adult; Antiviral Agents; Australia; Benzothiadiazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; New Zealand; Phenotype; Proline; Quinolones; Remission Induction; Ribavirin; RNA, Viral; Sulfonamides; Time Factors; Treatment Outcome; United States; Viral Load

2016
Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.
    Annals of internal medicine, 2015, Dec-01, Volume: 163, Issue:11

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Young Adult

2015
Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration.
    AIDS research and human retroviruses, 2016, Volume: 32, Issue:5

    Topics: Antiviral Agents; Benzimidazoles; Cardiovascular Diseases; Cholesterol, LDL; Coinfection; Drug Therapy, Combination; Dyslipidemias; Female; Fluorenes; Furans; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Quinolines; Ribavirin; Sofosbuvir; Thiophenes; Uridine Monophosphate

2016
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.
    The New England journal of medicine, 2015, Dec-31, Volume: 373, Issue:27

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Combinations; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins

2015
Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirin.
    Journal of viral hepatitis, 2016, Volume: 23, Issue:3

    Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Leucine; Male; Middle Aged; Oligopeptides; Placebos; Proline; Quinolines; Ribavirin; Salvage Therapy; Thiazoles; Treatment Outcome

2016
The correlation between pretreatment cytokine expression patterns in peripheral blood mononuclear cells with chronic hepatitis C outcome.
    BMC infectious diseases, 2015, Dec-04, Volume: 15

    Topics: Adult; Aged; Antiviral Agents; Cytokines; Female; Gene Expression Profiling; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukins; Leukocytes, Mononuclear; Male; Middle Aged; Ribavirin; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha

2015
Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
    PloS one, 2015, Volume: 10, Issue:12

    Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Nitro Compounds; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Thiazoles; Treatment Outcome

2015
Impact of Body Weight Reduction via Diet and Exercise on the Anti-Viral Effects of Pegylated Interferon Plus Ribavirin in Chronic Hepatitis C Patients with Insulin Resistance: A Randomized Controlled Pilot Trial.
    Internal medicine (Tokyo, Japan), 2015, Volume: 54, Issue:24

    Topics: Adult; Antiviral Agents; Body Weight; Diet; Directive Counseling; Drug Therapy, Combination; Exercise; Female; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon-alpha; Male; Middle Aged; Obesity; Pilot Projects; Prospective Studies; Ribavirin; Treatment Outcome; Viral Load; Weight Loss

2015
[The efficacy and prognostic predictors of different treatment courses with pegylated interferon α-2a and ribavirin combination in recurrent chronic hepatitis C patients].
    Zhonghua nei ke za zhi, 2015, Volume: 54, Issue:8

    Topics: Antiviral Agents; Combined Modality Therapy; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome

2015
Can eicosapentaenoic acid maintain the original ribavirin dose or affect the response during the treatment course of chronic hepatitis C virus (HCV) patients?
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2016, Volume: 27, Issue:1

    Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eicosapentaenoic Acid; Female; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult

2016
Does Epoetin Beta Still Have a Place in Peginterferon Alpha-2a Plus Ribavirin Treatment Strategies for Chronic Hepatitis C?
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2016, Volume: 36, Issue:3

    Topics: Adult; Alanine Transaminase; Anemia; Antiviral Agents; Aspartate Aminotransferases; Drug Therapy, Combination; Erythropoietin; Female; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2016
Peripheral lymphocyte subsets in chronic hepatitis C: Effects of 12 weeks of antiviral treatment with interferon-alpha plus ribavirin.
    Microbial pathogenesis, 2016, Volume: 91

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; T-Lymphocyte Subsets; Treatment Outcome

2016
Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies.
    PloS one, 2016, Volume: 11, Issue:1

    Topics: Adult; Antibodies, Viral; Antimetabolites; Antiviral Agents; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2016
Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence.
    Hepatology (Baltimore, Md.), 2016, Volume: 63, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prospective Studies; Pyrrolidines; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Valine

2016
Ocular Surface Changes With Sofosbuvir in Egyptian Patients With Hepatitis C Virus Infection.
    Cornea, 2016, Volume: 35, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Dry Eye Syndromes; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Sofosbuvir; Tears

2016
High antiviral activity of NS5A inhibitor ABT-530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:8

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Protease Inhibitors; Pyrrolidines; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; United States

2016
Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).
    Hepatology (Baltimore, Md.), 2016, Volume: 63, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Valine

2016
Patient-Reported Outcomes of Elderly Adults with Chronic Hepatitis C Treated with Interferon- and Ribavirin-Free Regimens.
    Journal of the American Geriatrics Society, 2016, Volume: 64, Issue:2

    Topics: Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Humans; Interferons; Male; Ribavirin; Sofosbuvir; Treatment Outcome

2016
Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience.
    The American journal of gastroenterology, 2016, Volume: 111, Issue:2

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Gastroenterology; Genotype; Graft vs Host Disease; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Logistic Models; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Treatment Outcome; Viral Load

2016
A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:8

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Taiwan; Treatment Outcome; Viral Load; Young Adult

2016
A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus.
    Journal of viral hepatitis, 2016, Volume: 23, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian People; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Load; Young Adult

2016
Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies.
    Antiviral therapy, 2016, Volume: 21, Issue:5

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Medication Adherence; Middle Aged; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Failure

2016
Adherence to ribavirin in chronic hepatitis C patients on antiviral treatment: Results from a randomized controlled trial using real-time medication monitoring.
    Clinics and research in hepatology and gastroenterology, 2016, Volume: 40, Issue:5

    Topics: Antiviral Agents; Drug Monitoring; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Medication Adherence; Middle Aged; Oligopeptides; Proline; Ribavirin

2016
Coadministration of ezetimibe with pegylated interferon plus ribavirin could improve early virological response in chronic hepatitis C obese Egyptian patients.
    European journal of gastroenterology & hepatology, 2016, Volume: 28, Issue:5

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Egypt; Ezetimibe; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Obesity; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Single-Blind Method; Time Factors; Treatment Outcome; Viral Load; Virus Internalization

2016
On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trial.
    Antiviral therapy, 2016, Volume: 21, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load

2016
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
    The Lancet. Infectious diseases, 2016, Volume: 16, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Global Health; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Uridine Monophosphate; Viral Load

2016
Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 (GT1b) infection: Phase 3 studies.
    Journal of gastroenterology and hepatology, 2016, Volume: 31, Issue:10

    Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Isoindoles; Lactams, Macrocyclic; Leucine; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Sulfonamides; Viral Load; Young Adult

2016
Triple Therapy with First Generation Protease Inhibitors for Hepatitis C Markedly Impairs Function of Neutrophil Granulocytes.
    PloS one, 2016, Volume: 11, Issue:3

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocyte Elastase; Male; Middle Aged; Neutrophils; Oligopeptides; Proline; Prospective Studies; Protease Inhibitors; Retrospective Studies; Ribavirin; Treatment Outcome

2016
Interferon Stimulated Gene Expression in HIV/HCV Coinfected Patients Treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin.
    AIDS research and human retroviruses, 2016, Volume: 32, Issue:7

    Topics: Adult; Antiviral Agents; Coinfection; Female; Gene Expression Profiling; Hepatitis C, Chronic; HIV Infections; Humans; Immunologic Factors; Interferon-alpha; Interferons; Leukocytes, Mononuclear; Male; Middle Aged; Nitro Compounds; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thiazoles

2016
Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis.
    Journal of gastroenterology and hepatology, 2016, Volume: 31, Issue:10

    Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Young Adult

2016
A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin.
    Journal of gastroenterology and hepatology, 2016, Volume: 31, Issue:11

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Male; Middle Aged; Pyrrolidines; Ribavirin; RNA, Viral; Sulfonamides; Sustained Virologic Response; Valine; Young Adult

2016
A Protease Inhibitor with Induction Therapy with Natural Interferon-β in Patients with HCV Genotype 1b Infection.
    International journal of molecular sciences, 2016, Mar-09, Volume: 17, Issue:3

    Topics: Aged; Antiviral Agents; Cyclopropanes; Drug Administration Schedule; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Interferon-beta; Isoindoles; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Simeprevir; Sulfonamides

2016
Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort.
    PloS one, 2016, Volume: 11, Issue:3

    Topics: Adult; Aged; Anemia; Antiviral Agents; Asthenia; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Outcome Assessment, Health Care; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Ribavirin; RNA, Viral; Withholding Treatment

2016
An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens.
    The American journal of gastroenterology, 2016, Volume: 111, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Patient Reported Outcome Measures; Retrospective Studies; Ribavirin; Sofosbuvir

2016
Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.
    World journal of gastroenterology, 2016, Mar-28, Volume: 22, Issue:12

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Polymorphism, Genetic; Pyrrolidines; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Valine; Viral Load; Viral Nonstructural Proteins; Young Adult

2016
Rapidity and Severity of Hemoglobin Decreasing Associated with Erythrocyte Inosine Triphosphatase Activity and ATP Concentration during Chronic Hepatitis C Treatment.
    Biological & pharmaceutical bulletin, 2016, Volume: 39, Issue:4

    Topics: Adenosine Triphosphate; Adult; Aged; Antiviral Agents; Erythrocytes; Female; Genotype; Hemoglobins; Hepatitis C, Chronic; Humans; Male; Middle Aged; Protease Inhibitors; Pyrophosphatases; Ribavirin; Simeprevir

2016
[Daclatasvir/sofosbuvir is effective also in advanced liver disease].
    MMW Fortschritte der Medizin, 2016, Mar-31, Volume: 158, Issue:6

    Topics: Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Pyrrolidines; Ribavirin; Sofosbuvir; Valine

2016
Long-Term Follow-Up of Children Treated With Peginterferon and Ribavirin for Hepatitis C Virus Infection.
    Journal of pediatric gastroenterology and nutrition, 2017, Volume: 64, Issue:1

    Topics: Adolescent; Antiviral Agents; Body Height; Body Mass Index; Body Weight; Child; Child, Preschool; Drug Therapy, Combination; Female; Follow-Up Studies; Growth Disorders; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2017
Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study.
    European journal of gastroenterology & hepatology, 2016, Volume: 28, Issue:8

    Topics: Acrylates; Adult; Aminoisobutyric Acids; Antiviral Agents; Australia; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Leucine; Male; Middle Aged; Oligopeptides; Phenotype; Proline; Protease Inhibitors; Quinolines; Ribavirin; RNA, Viral; Sustained Virologic Response; Thiazoles; Time Factors; Treatment Outcome; United States

2016
Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients.
    Clinical drug investigation, 2016, Volume: 36, Issue:8

    Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Double-Blind Method; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine; Young Adult

2016
Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection.
    PloS one, 2016, Volume: 11, Issue:5

    Topics: Adult; Alanine Transaminase; Anemia; Chemokine CXCL10; Dose-Response Relationship, Drug; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Kinetics; Male; Middle Aged; Ribavirin; RNA, Viral; Treatment Outcome

2016
Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2017, Volume: 15, Issue:2

    Topics: Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Veterans

2017
[In HIV-HCV co-infection check for drug interactions].
    MMW Fortschritte der Medizin, 2016, Jun-09, Volume: 158 Suppl 1

    Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Carbamates; Compassionate Use Trials; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Valine

2016
Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1 infection.
    Journal of viral hepatitis, 2016, Volume: 23, Issue:10

    Topics: Adult; Amides; Antiviral Agents; Carbamates; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Quinoxalines; Recurrence; Ribavirin; Sulfonamides; Sustained Virologic Response; Treatment Outcome

2016
Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2016, Volume: 36, Issue:11

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prospective Studies; Pyrrolidines; Recombinant Proteins; Ribavirin; Valine; Young Adult

2016
Daclatasvir/peginterferon lambda-1a/ribavirin in patients with chronic HCV infection and haemophilia who are treatment naïve or prior relapsers to peginterferon alfa-2a/ribavirin.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2016, Volume: 22, Issue:5

    Topics: Adult; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Interferons; Interleukins; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Valine; Young Adult

2016
Efficacy of sofosbuvir plus ribavirin in treatment-naive patients with genotype-1 and -3 HCV infection: results from a Russian Phase IIIb study.
    Antiviral therapy, 2016, Volume: 21, Issue:8

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir

2016
Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, 10-15, Volume: 63, Issue:8

    Topics: Adult; Carbamates; Comorbidity; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Load

2016
Sofosbuvir-Based Therapy for Genotype 4 HCV Recurrence Post-Liver Transplant Treatment-Experienced Patients.
    Canadian journal of gastroenterology & hepatology, 2016, Volume: 2016

    Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Postoperative Period; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome

2016
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.
    Gastroenterology, 2016, Volume: 151, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Ribavirin; Serine Proteases; Sofosbuvir; Sulfonamides; Treatment Outcome; Viral Nonstructural Proteins; Young Adult

2016
Community nurse-led initiation of antiviral therapy for chronic hepatitis C in people who inject drugs does not increase uptake of or adherence to treatment.
    European journal of gastroenterology & hepatology, 2016, Volume: 28, Issue:11

    Topics: Adult; Antiviral Agents; Community Health Nursing; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome

2016
Simple Predictive Model for Identifying Patients with Chronic Hepatitis C and Hepatitis C Virus Genotype 4 Infection with a High Probability of Sustained Virologic Response with Peginterferon Alfa-2a/Ribavirin: Pooled Analysis of Data from Two Large, Inte
    Advances in therapy, 2016, Volume: 33, Issue:10

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Ethnicity; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; International Cooperation; Male; Models, Theoretical; Outcome Assessment, Health Care; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Research Design; Ribavirin; Sustained Virologic Response

2016
Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial.
    Journal of hepatology, 2016, Volume: 65, Issue:6

    Topics: Antiviral Agents; Benzofurans; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Quinoxalines; Ribavirin; RNA, Viral; Sofosbuvir

2016
Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, Dec-01, Volume: 63, Issue:11

    Topics: Adult; Antiviral Agents; Benzimidazoles; Data Interpretation, Statistical; Drug Therapy, Combination; Drug Users; Enzyme-Linked Immunosorbent Assay; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Opiate Substitution Treatment; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Viral Load

2016
Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, Dec-01, Volume: 63, Issue:11

    Topics: Adult; Antiviral Agents; Carbamates; Data Interpretation, Statistical; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Medication Adherence; Middle Aged; Opiate Substitution Treatment; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2016
Association of SCARB1 Gene Polymorphisms with Virological Response in Chronic Hepatitis C Patients Receiving Pegylated Interferon plus Ribavirin Therapy.
    Scientific reports, 2016, 08-26, Volume: 6

    Topics: Adult; Aged; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; Scavenger Receptors, Class B

2016
Very rapid virologic response and early HCV response kinetics, as quick measures to compare efficacy and guide a personalized response-guided therapy.
    Drug design, development and therapy, 2016, Volume: 10

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Kinetics; Male; Middle Aged; Precision Medicine; Ribavirin; Structure-Activity Relationship; Tablets; Viral Load

2016
Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study.
    Alimentary pharmacology & therapeutics, 2016, Volume: 44, Issue:9

    Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Diarrhea; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine

2016
The impact of directly acting antivirals on the enzymatic liver function of liver transplant recipients with recurrent hepatitis C.
    Transplant infectious disease : an official journal of the Transplantation Society, 2016, Volume: 18, Issue:6

    Topics: Administration, Oral; Aged; Antiviral Agents; Biopsy; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Liver; Liver Cirrhosis; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Tacrolimus; Transaminases; Valine

2016
Virology analyses of HCV genotype 4 isolates from patients treated with simeprevir and peginterferon/ribavirin in the Phase III RESTORE study.
    Journal of viral hepatitis, 2017, Volume: 24, Issue:1

    Topics: Antiviral Agents; Carrier Proteins; DNA, Viral; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Mutation, Missense; Polymorphism, Genetic; Ribavirin; Sequence Analysis, DNA; Simeprevir; Sustained Virologic Response; Treatment Failure; Viral Nonstructural Proteins

2017
Mechanisms of Hyperbilirubinemia During Peginterferon Lambda-1a Therapy for Chronic Hepatitis C Infection: A Retrospective Investigation.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2016, Volume: 36, Issue:11

    Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Hyperbilirubinemia; Interferon-alpha; Interleukins; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin

2016
Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.
    Gastroenterology, 2017, Volume: 152, Issue:1

    Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Retreatment; Ribavirin; RNA, Viral; Sulfonamides; Sustained Virologic Response; Treatment Failure; Young Adult

2017
A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C.
    PloS one, 2016, Volume: 11, Issue:10

    Topics: Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hematologic Diseases; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Young Adult

2016
Results of sofosbuvir-based combination therapy for chronic hepatitis C cohort of Indian patients in real-life clinical practice.
    Journal of gastroenterology and hepatology, 2017, Volume: 32, Issue:4

    Topics: Adult; Antiviral Agents; Asian People; Cohort Studies; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; India; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome

2017
Arabinoxylan rice bran (Biobran) suppresses the viremia level in patients with chronic HCV infection: A randomized trial.
    International journal of immunopathology and pharmacology, 2016, Volume: 29, Issue:4

    Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-gamma; Male; Middle Aged; Oryza; Ribavirin; Viral Load; Viremia; Xylans

2016
Efficacy and safety of sofosbuvir-based therapy for chronic hepatitis C infection in "real-life" cohort.
    Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2016, Volume: 35, Issue:6

    Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome

2016
Vitamin D Status and Virologic Response to HCV Therapy in the HALT-C and VIRAHEP-C Trials.
    PloS one, 2016, Volume: 11, Issue:11

    Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Treatment Outcome; Vitamin D; Vitamins

2016
Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability.
    BMC psychiatry, 2016, Nov-15, Volume: 16, Issue:1

    Topics: Adult; Antioxidants; Antiviral Agents; Anxiety; Depression; Double-Blind Method; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Psychiatric Status Rating Scales; Ribavirin; Silybin; Silymarin; Treatment Outcome; Work Performance

2016
Twice-Daily Telaprevir for Posttransplant Genotype 1 Hepatitis C Virus: A Prospective Safety, Efficacy, and Pharmacokinetics Study.
    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2018, Volume: 16, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Calcineurin Inhibitors; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Male; Middle Aged; North America; Oligopeptides; Phenotype; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Sustained Virologic Response; Treatment Outcome

2018
Treatment-emergent depression and anxiety between peginterferon alpha-2a versus alpha-2b plus ribavirin for chronic hepatitis C.
    BMC psychiatry, 2016, Nov-25, Volume: 16, Issue:1

    Topics: Antiviral Agents; Anxiety; China; Depression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin

2016
Simeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO).
    Alimentary pharmacology & therapeutics, 2017, Volume: 45, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2017
Sofosbuvir plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 or 3 infection in India.
    Journal of viral hepatitis, 2017, Volume: 24, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; India; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult

2017
HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment.
    PloS one, 2016, Volume: 11, Issue:12

    Topics: Acrylates; Adolescent; Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Leucine; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Prognosis; Proline; Quinolines; Ribavirin; RNA, Viral; Thiazoles; Viral Load; Young Adult

2016
The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease.
    BMC infectious diseases, 2017, 01-07, Volume: 17, Issue:1

    Topics: Antiviral Agents; Bayes Theorem; Carbamates; Cohort Studies; Drug Therapy, Combination; Europe; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Valine

2017
Clinical and virological predictors of sustained response with an interferon-based simeprevir regimen for patients with chronic genotype 1 hepatitis C virus infection.
    The new microbiologica, 2017, Volume: 40, Issue:1

    Topics: Adolescent; Adult; Aged; Albumins; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Simeprevir; Young Adult

2017
Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy.
    PloS one, 2017, Volume: 12, Issue:1

    Topics: Aged; Antiviral Agents; Cell Line; Drug Synergism; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Sensitivity and Specificity; Transfection; Treatment Outcome; Viral Load; Viremia

2017
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.
    Hepatology (Baltimore, Md.), 2017, Volume: 66, Issue:2

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Confidence Intervals; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Lactams, Macrocyclic; Leucine; Liver Function Tests; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Retreatment; Ribavirin; Sulfonamides; Time Factors; Treatment Outcome; United States; Viral Load; Young Adult

2017
Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection.
    BMC gastroenterology, 2017, Feb-10, Volume: 17, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Ribavirin; Ritonavir; Simeprevir; Sulfonamides; Valine

2017
Superiority of Interferon-Free Regimens for Chronic Hepatitis C: The Effect on Health-Related Quality of Life and Work Productivity.
    Medicine, 2017, Volume: 96, Issue:7

    Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Quality of Life; Ribavirin; Sofosbuvir; Treatment Outcome; Work Performance

2017
Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.
    Hepatology international, 2017, Volume: 11, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Treatment Outcome; Valine; Young Adult

2017
Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus.
    Hepatology (Baltimore, Md.), 2017, Volume: 65, Issue:6

    Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Confidence Intervals; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Quinoxalines; Ribavirin; Severity of Illness Index; Sofosbuvir; Sulfonamides; Treatment Outcome; Young Adult

2017
Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study.
    Transplant infectious disease : an official journal of the Transplantation Society, 2017, Volume: 19, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Cyclosporine; Drug Therapy, Combination; Female; Genotype; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; RNA, Viral; Simeprevir; Tacrolimus; Treatment Outcome; Valine; Viral Load

2017
Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin.
    Journal of viral hepatitis, 2008, Volume: 15, Issue:9

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2008
Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.
    Hepatology (Baltimore, Md.), 2008, Volume: 47, Issue:6

    Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Viremia

2008
[Efficacy of retherapy of chronic hepatitis C in children--own observation].
    Przeglad epidemiologiczny, 2008, Volume: 62, Issue:1

    Topics: Adolescent; Age Factors; Antiviral Agents; Child; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Multivariate Analysis; Poland; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Secondary Prevention; Treatment Outcome; Viral Load

2008
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation.
    Alimentary pharmacology & therapeutics, 2008, Aug-15, Volume: 28, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Secondary Prevention; Treatment Outcome

2008
Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin.
    Journal of hepatology, 2008, Volume: 49, Issue:2

    Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pioglitazone; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thiazolidinediones

2008
Risk factors for bacterial infections in HIV/hepatitis C virus-coinfected patients treated with interferon plus ribavirin.
    AIDS (London, England), 2008, Jul-11, Volume: 22, Issue:11

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Opportunistic Infections; Recombinant Proteins; Ribavirin

2008
Serum alpha-fetoprotein predicts virologic response to hepatitis C treatment in HIV coinfected patients.
    AIDS (London, England), 2008, Jul-31, Volume: 22, Issue:12

    Topics: Adult; alpha-Fetoproteins; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2008
[Association between raised IL-8 serum levels and resistance to combined peg-interferon plus ribavirin therapy in HCV+ active chronic hepatitis].
    Le infezioni in medicina, 2008, Volume: 16, Issue:2

    Topics: Adult; Antiviral Agents; Biomarkers; Data Interpretation, Statistical; Drug Resistance; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-8; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome

2008
Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4.
    Journal of viral hepatitis, 2008, Volume: 15, Issue:10

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Italy; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Spain; Treatment Outcome

2008
Prospective analysis of effector and regulatory CD4+ T cells in chronic HCV patients undergoing combination antiviral therapy.
    Journal of hepatology, 2008, Volume: 49, Issue:3

    Topics: Antiviral Agents; CD4-Positive T-Lymphocytes; Cohort Studies; Drug Therapy, Combination; Female; Forkhead Transcription Factors; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; T-Lymphocytes, Regulatory; Th1 Cells; Treatment Outcome

2008
Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2008, Volume: 48, Issue:2

    Topics: Administration, Oral; Adult; Albumins; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Health Status; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Compliance; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2008
Very early viral kinetics on interferon treatment in chronic hepatitis C virus genotype 4 infection.
    Antiviral therapy, 2008, Volume: 13, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2008
Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponde
    European journal of gastroenterology & hepatology, 2008, Volume: 20, Issue:7

    Topics: Adult; Age Factors; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Failure; Treatment Outcome; Young Adult

2008
Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration.
    The American journal of gastroenterology, 2008, Volume: 103, Issue:11

    Topics: Adult; Antiviral Agents; Directly Observed Therapy; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Methadone; Middle Aged; Narcotics; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Self Administration; Substance Abuse, Intravenous; Treatment Outcome

2008
[Depressive disorders and symptoms accompanying pegylated interferon alpha and ribavirin treatment of chronic hepatitis C patients].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2008, Volume: 24, Issue:144

    Topics: Adult; Antiviral Agents; Depressive Disorder; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Ribavirin

2008
Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study.
    The American journal of gastroenterology, 2008, Volume: 103, Issue:10

    Topics: Adult; Antiviral Agents; Blood Glucose; Diabetes Mellitus, Type 2; Drug Carriers; Female; Follow-Up Studies; Glucose Intolerance; Glucose Tolerance Test; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Incidence; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Prognosis; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Time Factors

2008
Prevalence and impact of GBV-C, SEN-V and HBV occult infections in HIV-HCV co-infected patients on HCV therapy.
    Journal of hepatology, 2008, Volume: 49, Issue:6

    Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Comorbidity; DNA Virus Infections; Drug Therapy, Combination; Female; Flaviviridae Infections; GB virus C; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis, Viral, Human; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Torque teno virus; Virus Diseases

2008
Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis.
    Antiviral therapy, 2008, Volume: 13, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2008
Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy.
    Gastroenterology, 2008, Volume: 135, Issue:5

    Topics: Antioxidants; Antiviral Agents; Dose-Response Relationship, Drug; Drug Carriers; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Free Radical Scavengers; Hepacivirus; Hepatitis C, Chronic; Humans; Infusions, Intravenous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Silybin; Silybum marianum; Silymarin; Time Factors; Treatment Outcome; Viral Load

2008
Peg-interferon alpha-2a versus Peg-interferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2008, Volume: 28, Issue:10

    Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2008
The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV-related chronic hepatitis.
    The American journal of gastroenterology, 2008, Volume: 103, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Antiviral Agents; Diet; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Young Adult

2008
Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C in patients with congenital coagulation disorders.
    Acta haematologica, 2008, Volume: 120, Issue:2

    Topics: Adolescent; Adult; Aged; Antiretroviral Therapy, Highly Active; Blood Coagulation Disorders, Inherited; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult

2008
Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection.
    Hepatology (Baltimore, Md.), 2008, Volume: 48, Issue:5

    Topics: Adult; Alanine Transaminase; Amantadine; Antiviral Agents; Aspartate Aminotransferases; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Dropouts; Patient Selection; Placebos; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2008
Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone.
    The Journal of antimicrobial chemotherapy, 2008, Volume: 62, Issue:6

    Topics: Adenine; Adult; Anti-HIV Agents; Blood; Cohort Studies; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tenofovir; Treatment Outcome; Viral Load

2008
Conventional interferon alfa-2b and ribavirin for 12 versus 24 weeks in HCV genotype 2 or 3.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2008, Volume: 18, Issue:10

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2008
Swiss multicenter study evaluating the efficacy, feasibility and safety of peginterferon-alfa-2a and ribavirin in patients with chronic hepatitis C in official opiate substitution programs.
    Digestion, 2008, Volume: 78, Issue:2-3

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Drug Users; Feasibility Studies; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2008
Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT-C trial.
    Alimentary pharmacology & therapeutics, 2009, Mar-01, Volume: 29, Issue:5

    Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Function Tests; Male; Middle Aged; Ribavirin; Statistics as Topic

2009
Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan.
    World journal of gastroenterology, 2008, Dec-21, Volume: 14, Issue:47

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2008
Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients.
    Hepatology (Baltimore, Md.), 2009, Volume: 49, Issue:1

    Topics: Adult; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Leukopenia; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2009
A randomized study of extended treatment with peginterferon alpha-2b plus ribavirin based on time to HCV RNA negative-status in patients with genotype 1b chronic hepatitis C.
    The American journal of gastroenterology, 2009, Volume: 104, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Young Adult

2009
[Effects of supplementation with the antioxidant flavonoid, silymarin, in chronic hepatitis C patients treated with peg-interferon + ribavirin. A placebo-controlled double blind study].
    Orvosi hetilap, 2009, Jan-11, Volume: 150, Issue:2

    Topics: Adult; Aged; Alanine Transaminase; Antioxidants; Antiviral Agents; Double-Blind Method; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Peroxidase; Polyethylene Glycols; Protective Agents; Ribavirin; RNA, Viral; Silymarin; Superoxide Dismutase; Treatment Outcome

2009
[Attention abnormalities in patients with chronic hepatitis C after pegylated interferon alpha and ribavirin treatment].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2008, Volume: 25, Issue:147

    Topics: Antiviral Agents; Attention; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2008
Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin.
    Gastroenterology, 2009, Volume: 136, Issue:3

    Topics: Adult; Antiparasitic Agents; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Nitro Compounds; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thiazoles; Treatment Outcome; Young Adult

2009
Factors associated with adherence to combination therapy of interferon and ribavirin for patients with chronic hepatitis C: importance of patient's motivation and physician's treatment experience.
    Liver international : official journal of the International Association for the Study of the Liver, 2009, Volume: 29, Issue:5

    Topics: Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Logistic Models; Male; Middle Aged; Motivation; Patient Acceptance of Health Care; Practice Patterns, Physicians'; Prospective Studies; Ribavirin; Statistics, Nonparametric

2009
Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C.
    The New England journal of medicine, 2009, Jan-15, Volume: 360, Issue:3

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon alpha-2; Interferon-alpha; Liver; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Viral Load; White People; Young Adult

2009
An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C.
    Journal of viral hepatitis, 2009, Volume: 16, Issue:3

    Topics: Adult; Albumins; Antiviral Agents; Biomarkers; Biopsy; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Reagent Kits, Diagnostic; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Treatment Outcome

2009
Antiviral treatment for hepatitis C virus infection: effectiveness at general population level in a highly endemic area.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2009, Volume: 41, Issue:7

    Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Antiviral Agents; Child; Endemic Diseases; Female; Hepatitis C, Chronic; Humans; Interferons; Italy; Male; Mass Screening; Middle Aged; Prevalence; Ribavirin; Young Adult

2009
Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy.
    Gastroenterology, 2009, Volume: 136, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Failure

2009
Low weight predicts neutropenia and peginterferon alfa-2a dose reductions during treatment for chronic hepatitis C.
    Journal of viral hepatitis, 2009, Volume: 16, Issue:5

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Body Mass Index; Body Surface Area; Body Weight; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Young Adult

2009
Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy.
    Journal of medical virology, 2009, Volume: 81, Issue:4

    Topics: Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Core Proteins; Viral Load; Viral Nonstructural Proteins

2009
Pharmacist intervention in treatment of patients with genotype 1 chronic hepatitis C.
    Journal of managed care pharmacy : JMCP, 2009, Volume: 15, Issue:2

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Medication Adherence; Middle Aged; Pharmacists; Pharmacy Service, Hospital; Polyethylene Glycols; Professional Role; Prospective Studies; Recombinant Proteins; Ribavirin; Spain; Treatment Outcome

2009
Pegylated-interferon plus ribavirin for HCV-positive indolent non-Hodgkin lymphomas.
    British journal of haematology, 2009, Volume: 145, Issue:2

    Topics: Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lymphoma, Non-Hodgkin; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2009
Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Apr-15, Volume: 48, Issue:8

    Topics: Adult; Analysis of Variance; Antiviral Agents; Chi-Square Distribution; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Hospitals; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Statistics, Nonparametric; Treatment Outcome; Viral Load

2009
Effective prediction of outcome of combination therapy with pegylated interferon alpha 2b plus ribavirin in Japanese patients with genotype-1 chronic hepatitis C using early viral kinetics and new indices.
    Journal of gastroenterology, 2009, Volume: 44, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2009
Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection.
    The Journal of infectious diseases, 2009, Apr-15, Volume: 199, Issue:8

    Topics: Antiviral Agents; Black or African American; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; White People

2009
Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.
    Hepatology (Baltimore, Md.), 2009, Volume: 49, Issue:6

    Topics: Antiviral Agents; Disease Progression; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors

2009
Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results.
    Hepatology (Baltimore, Md.), 2009, Volume: 49, Issue:6

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; Treatment Failure

2009
Granulocyte colony stimulating factor in HCV genotype-1 patients who develop Peg-IFN-alpha2b related severe neutropenia: a preliminary report on treatment, safety and efficacy.
    Journal of medical virology, 2009, Volume: 81, Issue:5

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Granulocyte Colony-Stimulating Factor; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Male; Middle Aged; Neutropenia; Neutrophils; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome

2009
Lenograstim in the treatment of severe neutropenia in patients treated with Peg-IFN and ribavirin: the experience of a single hepatology unit.
    Le infezioni in medicina, 2009, Volume: 17, Issue:1

    Topics: Antiviral Agents; Biopsy; Drug Administration Schedule; Drug Therapy, Combination; Granulocyte Colony-Stimulating Factor; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lenograstim; Liver; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2009
Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
    The Journal of antimicrobial chemotherapy, 2009, Volume: 63, Issue:6

    Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2009
Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial.
    Annals of internal medicine, 2009, Apr-21, Volume: 150, Issue:8

    Topics: Antiviral Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Treatment Failure

2009
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
    The New England journal of medicine, 2009, Apr-30, Volume: 360, Issue:18

    Topics: Adult; Antiviral Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Viral Load; Young Adult

2009
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
    The New England journal of medicine, 2009, Apr-30, Volume: 360, Issue:18

    Topics: Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Viral Load; Young Adult

2009
High virologic sustained response for former young intravenous drug users with chronic hepatitis C treated by pegylated interferon-alpha plus ribavirin.
    Bratislavske lekarske listy, 2009, Volume: 110, Issue:2

    Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Substance Abuse, Intravenous; Young Adult

2009
CXCR3 expression on peripheral CD4+ T cells as a predictive marker of response to treatment in chronic hepatitis C.
    Clinical immunology (Orlando, Fla.), 2009, Volume: 132, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Aspartate Aminotransferases; Biomarkers; CD4-Positive T-Lymphocytes; Drug Therapy, Combination; Female; Fibrosis; Flow Cytometry; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Prognosis; Receptors, CCR5; Receptors, CXCR3; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult

2009
Peginterferon alpha-2b and ribavirin for the treatment of chronic hepatitis C in Japanese pediatric and young adult patients: a survey of the Japan Society of Pediatric Hepatology.
    European journal of gastroenterology & hepatology, 2009, Volume: 21, Issue:11

    Topics: Adolescent; Adult; Antiviral Agents; Child; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult

2009
Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines.
    PharmacoEconomics, 2009, Volume: 27, Issue:4

    Topics: Adult; Antiviral Agents; Cost of Illness; Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy, Combination; Female; Genotype; Germany; Guidelines as Topic; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Life Expectancy; Male; Markov Chains; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Sensitivity and Specificity

2009
Clinical trial: a randomized trial of pegylated-interferon-alpha-2a plus ribavirin with or without amantadine in treatment-naïve or relapsing chronic hepatitis C patients.
    Alimentary pharmacology & therapeutics, 2009, Aug-15, Volume: 30, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Regression Analysis; Ribavirin; Treatment Outcome; Young Adult

2009
Clinical trial: extended treatment duration of peginterferon-alpha2b plus ribavirin for 72 and 96 weeks in hepatitis C genotype 1-infected late responders.
    Alimentary pharmacology & therapeutics, 2009, Aug-15, Volume: 30, Issue:4

    Topics: Adult; Aged; Analysis of Variance; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome

2009
Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients.
    Journal of viral hepatitis, 2009, Volume: 16, Issue:10

    Topics: Age Factors; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Secondary Prevention; Treatment Outcome

2009
Clinical trial: low plasma cholesterol and oxidative stress predict rapid virological response to standard therapy with peginterferon and ribavirin in HCV patients.
    Alimentary pharmacology & therapeutics, 2009, Sep-01, Volume: 30, Issue:5

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Cholesterol, LDL; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oxidative Stress; Polyethylene Glycols; Predictive Value of Tests; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult

2009
Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG-IFN alpha-2a (40KD) (PEGASYS).
    British journal of clinical pharmacology, 2009, Volume: 67, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Obesity; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult

2009
Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C.
    Vaccine, 2009, Aug-13, Volume: 27, Issue:37

    Topics: Adult; Aged; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Proliferation; Cells, Cultured; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Recurrence; Ribavirin; Treatment Outcome; Vaccines, Subunit; Viral Hepatitis Vaccines; Young Adult

2009
Immunological and mutagenic actions of ribavirin monotherapy preceding combination therapy with interferon for patients with chronic hepatitis C.
    Antiviral therapy, 2009, Volume: 14, Issue:4

    Topics: Adult; Aged; Antiviral Agents; CD4-Positive T-Lymphocytes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Cellular; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral

2009
The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype.
    Antiviral therapy, 2009, Volume: 14, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Failure

2009
A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 results.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Adolescent; Adult; Aged; Double-Blind Method; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2009
Predictability of sustained virological response to pegylated interferon alpha-2b Plus ribavirin therapy by week-8 viral response in HIV-positive patients with chronic hepatitis C virus infection.
    Current HIV research, 2009, Volume: 7, Issue:4

    Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Nucleic Acid Amplification Techniques; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2009
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.
    The New England journal of medicine, 2009, Aug-06, Volume: 361, Issue:6

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral

2009
Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4.
    Journal of medical virology, 2009, Volume: 81, Issue:9

    Topics: Adult; Antiviral Agents; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2009
Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients.
    Arthritis and rheumatism, 2009, Volume: 60, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Rituximab; Treatment Outcome; Vasculitis

2009
Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population.
    Journal of viral hepatitis, 2010, Feb-01, Volume: 17, Issue:2

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Body Mass Index; Ethnicity; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load

2010
Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Asian People; Black People; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; White People

2009
Factors influencing long-term changes in mental health after interferon-alpha treatment of chronic hepatitis C.
    Alimentary pharmacology & therapeutics, 2009, Nov-15, Volume: 30, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Mental Disorders; Middle Aged; Prospective Studies; Psychiatric Status Rating Scales; Ribavirin; Risk Factors; Severity of Illness Index; Time; Treatment Outcome; Young Adult

2009
Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin.
    Journal of hepatology, 2009, Volume: 51, Issue:6

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult

2009
Treatment of a common problem in hemodialysis patients: is the juice worth the squeeze?
    Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2009, Volume: 20, Issue:5

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Renal Dialysis; Ribavirin; Saudi Arabia; Time Factors; Treatment Outcome

2009
Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.
    Gastroenterology, 2009, Volume: 137, Issue:6

    Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Failure; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Proportional Hazards Models; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Failure; Viral Load

2009
Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2010, Volume: 8, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; United States; Viral Load

2010
Effect of liver steatosis on therapeutic response in chronic hepatitis C virus genotype 1 infected patients in hungary.
    Pathology oncology research : POR, 2010, Volume: 16, Issue:2

    Topics: Antiviral Agents; Fatty Liver; Hepacivirus; Hepatitis C, Chronic; Humans; Hungary; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2010
Treatment with PEG-interferon and ribavirin for chronic hepatitis C increases neutrophil and monocyte chemotaxis.
    Annals of the New York Academy of Sciences, 2009, Volume: 1173

    Topics: Adult; Aged; Antiviral Agents; Bacterial Infections; CD11b Antigen; Chemotaxis, Leukocyte; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Macrophage-1 Antigen; Male; Middle Aged; Monocytes; Neutrophils; Phagocytosis; Polyethylene Glycols; Reactive Oxygen Species; Recombinant Proteins; Ribavirin; Time Factors

2009
Iron depletion before HCV antiviral therapy: a pilot, randomized, controlled trial.
    Journal of clinical apheresis, 2009, Volume: 24, Issue:5

    Topics: Antiviral Agents; Female; Ferritins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Iron; Male; Middle Aged; Phlebotomy; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Transferrin

2009
Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.
    Gastroenterology, 2010, Volume: 138, Issue:1

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Young Adult

2010
Pegylated interferon alfa-2a and ribavirin treatment for recurrent hepatitis C: role of steatosis and body mass index.
    Panminerva medica, 2009, Volume: 51, Issue:2

    Topics: Adult; Antiviral Agents; Biopsy; Body Mass Index; Drug Therapy, Combination; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Severity of Illness Index; Time Factors; Treatment Outcome; Viral Load

2009
Hepatitis C virus/human immunodeficiency virus coinfection in hemophiliacs: high rates of sustained virologic response to pegylated interferon and ribavirin therapy.
    Journal of thrombosis and haemostasis : JTH, 2009, Volume: 7, Issue:12

    Topics: Adult; Female; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferons; Liver Diseases; Male; Polyethylene Glycols; Ribavirin; Treatment Outcome

2009
Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:6

    Topics: Adult; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Metformin; Middle Aged; Polyethylene Glycols; PPAR gamma; Recombinant Proteins; Ribavirin

2009
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:6

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Double-Blind Method; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Phenylurea Compounds; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2009
Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.
    Gastroenterology, 2010, Volume: 138, Issue:1

    Topics: Adult; Antiviral Agents; Biopsy; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome

2010
Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naive hepatitis C patients.
    Journal of hepatology, 2010, Volume: 52, Issue:1

    Topics: Adult; Anemia; Antiviral Agents; Diarrhea; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Endpoint Determination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2010
Peginterferon/ribavirin treatment achieves a higher compliance rate than interferon/ribavirin combination in patients chronically infected with HCV on methadone maintenance.
    European journal of gastroenterology & hepatology, 2009, Volume: 21, Issue:12

    Topics: Adult; Antidepressive Agents; Antiviral Agents; Drug Therapy, Combination; Drug Utilization; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Methadone; Opiate Substitution Treatment; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome

2009
Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance.
    Liver international : official journal of the International Association for the Study of the Liver, 2010, Volume: 30, Issue:3

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pioglitazone; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Thiazolidinediones; Young Adult

2010
Use of epoetin beta during combination therapy of infection with hepatitis c virus with ribavirin improves a sustained viral response.
    Journal of medical virology, 2010, Volume: 82, Issue:1

    Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Female; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2010
A randomized controlled trial of double versus triple therapy with amantadine for genotype 1 chronic hepatitis C in Latino patients.
    Digestive diseases and sciences, 2010, Volume: 55, Issue:9

    Topics: Adult; Amantadine; Antiviral Agents; Biopsy; Chi-Square Distribution; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Logistic Models; Male; Mexico; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2010
Ketoprofen, peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C: a phase II study.
    World journal of gastroenterology, 2009, Dec-21, Volume: 15, Issue:47

    Topics: 2',5'-Oligoadenylate Synthetase; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Ketoprofen; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Signal Transduction; STAT1 Transcription Factor; Treatment Outcome; Young Adult

2009
No beneficial effects of amantadine in treatment of chronic hepatitis C patients.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2010, Volume: 42, Issue:7

    Topics: Adult; Amantadine; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Intention to Treat Analysis; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load

2010
On-treatment predictions of success in peg-interferon/ribavirin treatment using a novel formula.
    World journal of gastroenterology, 2010, Jan-07, Volume: 16, Issue:1

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Dosage Calculations; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Logistic Models; Male; Middle Aged; Patient Selection; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Reproducibility of Results; Ribavirin; RNA, Viral; ROC Curve; Treatment Outcome; Viral Load; Young Adult

2010
Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study.
    The Journal of antimicrobial chemotherapy, 2010, Volume: 65, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2010
Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial.
    BMC gastroenterology, 2010, Feb-19, Volume: 10

    Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Young Adult

2010
Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2010, Volume: 51, Issue:5

    Topics: Adult; Chemokine CXCL10; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral

2010
High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin.
    Journal of hepatology, 2010, Volume: 52, Issue:4

    Topics: Adolescent; Antiviral Agents; Body Height; Body Weight; Child; Child Development; Child, Preschool; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2010
The role of iron overload and HFE gene mutations in the era of pegylated interferon and ribavirin treatment of chronic hepatitis C.
    Medical science monitor : international medical journal of experimental and clinical research, 2010, Volume: 16, Issue:3

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Case-Control Studies; Demography; Female; Hemochromatosis Protein; Hepatitis C, Chronic; Histocompatibility Antigens Class I; Humans; Interferon alpha-2; Interferon-alpha; Iron; Iron Overload; Liver Cirrhosis; Male; Membrane Proteins; Middle Aged; Mutation; Poland; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Young Adult

2010
Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin.
    Hepatology (Baltimore, Md.), 2010, Volume: 51, Issue:6

    Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2010
Ribavirin improves early responses to peginterferon through improved interferon signaling.
    Gastroenterology, 2010, Volume: 139, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Chemokine CXCL10; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mutation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Signal Transduction; Treatment Outcome

2010
Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study.
    Blood, 2010, Jul-22, Volume: 116, Issue:3

    Topics: Aged; Amino Acid Sequence; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; B-Lymphocytes; Base Sequence; Cryoglobulinemia; DNA Primers; Drug Therapy, Combination; Female; Genes, Immunoglobulin Heavy Chain; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver; Longitudinal Studies; Male; Middle Aged; Molecular Sequence Data; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Remission Induction; Ribavirin; Rituximab; RNA, Viral; Treatment Outcome

2010
Controlled release recombinant human interferon-α2b for treating patients with chronic hepatitis C genotype 1: a phase 2a clinical trial.
    Journal of viral hepatitis, 2011, Volume: 18, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Delayed-Action Preparations; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult

2011
Telaprevir for previously treated chronic HCV infection.
    The New England journal of medicine, 2010, Apr-08, Volume: 362, Issue:14

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Exanthema; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors; Treatment Failure; Viral Load; Young Adult

2010
Preemptive erythropoietin plus high ribavirin doses to increase rapid virological responses in HIV patients treated for chronic hepatitis C.
    AIDS research and human retroviruses, 2010, Volume: 26, Issue:4

    Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Epoetin Alfa; Erythrocytes; Erythropoietin; Female; Hematinics; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2010
Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infection.
    Journal of viral hepatitis, 2011, Volume: 18, Issue:4

    Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Plasma; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2011
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents.
    Journal of hepatology, 2010, Volume: 52, Issue:6

    Topics: Adolescent; Antiviral Agents; Child; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Patient Dropouts; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2010
An intervention to prevent symptoms associated with hepatitis C: a pilot study.
    Applied nursing research : ANR, 2010, Volume: 23, Issue:2

    Topics: Antiviral Agents; Attitude to Health; Drug Therapy, Combination; Exercise Test; Exercise Therapy; Fatigue; Feasibility Studies; Female; Hepatitis C, Chronic; Home Care Services; Humans; Interferon-alpha; Male; Massachusetts; Middle Aged; Nursing Assessment; Nursing Evaluation Research; Pilot Projects; Quality of Life; Ribavirin; Surveys and Questionnaires; Treatment Outcome; Walking

2010
Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia.
    Blood, 2010, Jul-22, Volume: 116, Issue:3

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Cohort Studies; Cryoglobulinemia; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Remission Induction; Ribavirin; Rituximab; RNA, Viral; Treatment Outcome

2010
Efficacy and safety of pegylated IFN alfa 2b alone or in combination with ribavirin in thalassemia major with chronic hepatitis C.
    Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2010, Volume: 29, Issue:2

    Topics: Adolescent; Adult; Antiviral Agents; beta-Thalassemia; Child; Child, Preschool; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult

2010
The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive Individuals.
    European journal of medical research, 2010, Mar-30, Volume: 15, Issue:3

    Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Case-Control Studies; Drug Carriers; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Young Adult

2010
The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients.
    Liver international : official journal of the International Association for the Study of the Liver, 2010, Volume: 30, Issue:7

    Topics: Administration, Oral; Adult; Alanine Transaminase; Antioxidants; Antiviral Agents; Aspartate Aminotransferases; Biomarkers; Double-Blind Method; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Male; Middle Aged; Mitochondria, Liver; Organophosphorus Compounds; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Ubiquinone; Viral Load

2010
Re-treatment of children with chronic hepatitis C who did not respond to interferon-alpha treatment.
    Journal of pediatric gastroenterology and nutrition, 2010, Volume: 51, Issue:2

    Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis B; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Recurrence; Retreatment; Ribavirin; RNA, Viral; Viral Load

2010
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection.
    Hepatology (Baltimore, Md.), 2010, Volume: 52, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatigue; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Middle Aged; Nausea; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2010
Outcome of sustained virological responders with histologically advanced chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2010, Volume: 52, Issue:3

    Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Disease Progression; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; Severity of Illness Index; Survival Rate; Treatment Outcome; United States

2010
Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy.
    Hepatology (Baltimore, Md.), 2010, Volume: 52, Issue:3

    Topics: Adult; Antiviral Agents; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Regression Analysis; Retrospective Studies; Ribavirin; Treatment Outcome; United States; Virus Replication

2010
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1.
    Gastroenterology, 2010, Volume: 139, Issue:4

    Topics: Adult; Albumins; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2010
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3.
    Gastroenterology, 2010, Volume: 139, Issue:4

    Topics: Adult; Aged; Albumins; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2010
A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin.
    Gastroenterology, 2010, Volume: 139, Issue:5

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Carriers; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2010
Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study.
    Swiss medical weekly, 2010, Volume: 140

    Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Long-Term Care; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2010
Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis.
    European journal of clinical pharmacology, 2010, Volume: 66, Issue:10

    Topics: Adult; Anemia, Hypochromic; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Female; Ferritins; Hematinics; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Quality of Life; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2010
Depressive symptoms following interferon-α therapy: mediated by immune-induced reductions in brain-derived neurotrophic factor?
    The international journal of neuropsychopharmacology, 2011, Volume: 14, Issue:2

    Topics: Antiviral Agents; Brain-Derived Neurotrophic Factor; Cytokines; Depression; Depressive Disorder, Major; Female; Hepatitis C, Chronic; Humans; Hydrocortisone; Immunologic Factors; Interferon-alpha; Male; Psychiatric Status Rating Scales; Ribavirin; Time Factors

2011
Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C.
    Gut, 2010, Volume: 59, Issue:10

    Topics: Adult; Biomarkers; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Models, Statistical; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin

2010
Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response.
    Hepatology (Baltimore, Md.), 2010, Volume: 52, Issue:4

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2010
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Viral Load; Viral Nonstructural Proteins

2010
[Pathogenetically substantiated therapy of patients with virus hepatitis C, quality of life, and the disease outcome risk (clinical survey)].
    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2010, Volume: 55, Issue:3-4

    Topics: Acridines; Adolescent; Adult; Antioxidants; Antiviral Agents; DNA; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Luminol; Male; Phthalazines; Quality of Life; Ribavirin; Risk Assessment; Succinates; Young Adult

2010
Response to anti-HCV therapy in HIV-HCV-coinfected patients: does the lipid profile really have an effect?
    Antiviral therapy, 2010, Volume: 15, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Lipids; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2010
Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2010, Volume: 52, Issue:4

    Topics: Adolescent; Adult; Anemia, Hemolytic; Antiviral Agents; Body Weight; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2010
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate.
    Gastroenterology, 2010, Volume: 139, Issue:5

    Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load

2010
Suboptimal endogenous erythropoietin response in chronic hepatitis C patients during ribavirin and PEG interferon treatment.
    European journal of gastroenterology & hepatology, 2010, Volume: 22, Issue:11

    Topics: Adolescent; Adult; Age Factors; Aged; Anemia; Antiviral Agents; Biomarkers; Creatinine; Double-Blind Method; Drug Therapy, Combination; Erythropoietin; Female; Hematocrit; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Linear Models; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult

2010
Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-α-2a and ribavirin.
    European journal of gastroenterology & hepatology, 2010, Volume: 22, Issue:11

    Topics: Adult; Aged; Antiviral Agents; Biomarkers; Cholesterol; Double-Blind Method; Drug Therapy, Combination; Europe; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hypercholesterolemia; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Triglycerides; Viral Load; Young Adult

2010
[Clinical significance of leukopenia and neutropenia patients with chronic hepatitis "C" in the various regimes antiretroviral therapy].
    Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, 2010, Issue:5

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukopenia; Liver Cirrhosis; Male; Middle Aged; Moscow; Neutropenia; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome

2010
Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads.
    Gastroenterology, 2010, Volume: 139, Issue:6

    Topics: Adult; Antiviral Agents; Body Weight; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Obesity; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load

2010
[Individualized respond guidance treatment of chronic hepatitis C with combination of peginterferon α-2a and ribavirin].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2010, Volume: 18, Issue:8

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult

2010
von Willebrand factor antigen: a novel on-treatment predictor of response to antiviral therapy in chronic hepatitis C genotypes 1 and 4.
    Antiviral therapy, 2010, Volume: 15, Issue:6

    Topics: Administration, Oral; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Recurrence; Ribavirin; von Willebrand Factor

2010
A multidisciplinary therapeutic approach for reducing the risk of psychiatric side effects in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin.
    Journal of clinical gastroenterology, 2010, Volume: 44, Issue:9

    Topics: Antiviral Agents; Depression; Drug Monitoring; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Psychotherapy; Recombinant Proteins; Ribavirin; Severity of Illness Index

2010
Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3.
    Journal of hepatology, 2010, Volume: 53, Issue:6

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Precision Medicine; Recombinant Proteins; Ribavirin; RNA, Viral; Young Adult

2010
Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C.
    World journal of gastroenterology, 2010, Sep-21, Volume: 16, Issue:35

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2010
Seizures during pegylated interferon and ribavirin therapy for chronic Hepatitis C: observations from the WIN-R trial.
    Journal of clinical gastroenterology, 2011, Volume: 45, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Seizures; Treatment Outcome

2011
RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients.
    The Journal of infectious diseases, 2010, Nov-15, Volume: 202, Issue:10

    Topics: Amino Acid Substitution; Antiviral Agents; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; New Zealand; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Selection, Genetic; United States; Viral Load; Viral Nonstructural Proteins; Virus Replication

2010
Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-α-2a and ribavirin in HIV/HCV co-infected patients.
    Journal of hepatology, 2011, Volume: 54, Issue:1

    Topics: Adult; Antiviral Agents; Case-Control Studies; Female; Hepatitis C, Chronic; HIV Infections; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Failure

2011
Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy).
    Journal of medical virology, 2010, Volume: 82, Issue:12

    Topics: Adolescent; Adult; Aged; Antibodies, Neutralizing; Antiviral Agents; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Failure; Treatment Outcome; Viral Load; Young Adult

2010
Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.
    Gastroenterology, 2011, Volume: 140, Issue:2

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult

2011
The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C.
    Gastroenterology, 2011, Volume: 140, Issue:2

    Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2011
Efficacy and safety of a novel pegylated interferon alpha-2a in Egyptian patients with genotype 4 chronic hepatitis C.
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2010, Volume: 24, Issue:10

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Young Adult

2010
FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program.
    Journal of hepatology, 2011, Volume: 54, Issue:2

    Topics: Adult; Alanine Transaminase; Biopsy; Drug Therapy, Combination; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Ribavirin

2011
Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2010, Volume: 52, Issue:6

    Topics: Adolescent; Adult; Aged; Body Weight; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Male; Middle Aged; Neutrophils; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2010
S-adenosyl-methionine and betaine improve early virological response in chronic hepatitis C patients with previous nonresponse.
    PloS one, 2010, Nov-08, Volume: 5, Issue:11

    Topics: Adult; Antiviral Agents; Arthralgia; Betaine; Diarrhea; Drug Therapy, Combination; Fatigue; Female; Gastrointestinal Agents; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; S-Adenosylmethionine; Time Factors; Treatment Outcome

2010
Hepatitis C treatment among racial and ethnic groups in the IDEAL trial.
    Journal of viral hepatitis, 2011, Volume: 18, Issue:4

    Topics: Adult; Antiviral Agents; Ethnicity; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Racial Groups; Recombinant Proteins; Ribavirin; Treatment Outcome; United States; Viral Load

2011
[The virological response in prolonged therapy of chronic hepatitis C with low-dose peginterferon alpha-2a].
    Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology, 2010, Volume: 24, Issue:2

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Young Adult

2010
Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin.
    Journal of hepatology, 2011, Volume: 54, Issue:5

    Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2011
Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study.
    Journal of hepatology, 2011, Volume: 54, Issue:6

    Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Carrier Proteins; Cyclopropanes; Double-Blind Method; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors; Sulfonamides; Viral Load; Viral Nonstructural Proteins

2011
Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection.
    Journal of hepatology, 2011, Volume: 55, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2011
Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy.
    Journal of hepatology, 2011, Volume: 54, Issue:4

    Topics: Adult; Age Factors; Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome

2011
Early proteomic analysis may allow noninvasive identification of hepatitis C response to treatment with pegylated interferon α-2b and ribavirin.
    European journal of gastroenterology & hepatology, 2011, Volume: 23, Issue:2

    Topics: Adult; Antiviral Agents; Biomarkers; Drug Monitoring; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Proteomics; Recombinant Proteins; Ribavirin; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

2011
Current antiviral combination therapy for chronic hepatitis C patients who failed to interferon alfa-based treatment.
    Journal of clinical pharmacy and therapeutics, 2011, Volume: 36, Issue:6

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; Treatment Outcome

2011
Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy.
    Addiction (Abingdon, England), 2011, Volume: 106, Issue:5

    Topics: Adult; Analgesics, Opioid; Antiviral Agents; Australia; Depressive Disorder, Major; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Medication Adherence; Opiate Substitution Treatment; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Substance Abuse Detection; Substance Abuse, Intravenous; Treatment Outcome

2011
U.S. multicenter pilot study of daily consensus interferon (CIFN) plus ribavirin for "difficult-to-treat" HCV genotype 1 patients.
    Digestive diseases and sciences, 2011, Volume: 56, Issue:3

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Interferon-alpha; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Young Adult

2011
Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C.
    Journal of hepatology, 2011, Volume: 55, Issue:3

    Topics: Adult; Body Weight; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Intention to Treat Analysis; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors

2011
The role of patient religiosity in the evaluation and treatment outcomes for chronic HCV infection.
    Journal of religion and health, 2013, Volume: 52, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Comorbidity; Depressive Disorder; Double-Blind Method; Female; Hepatitis C, Chronic; Humans; Illness Behavior; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Observational Studies as Topic; Patient Acceptance of Health Care; Patient Satisfaction; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Religion and Medicine; Religion and Psychology; Retrospective Studies; Ribavirin; Sex Factors; Surveys and Questionnaires; Treatment Outcome; Viral Load

2013
Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy.
    Journal of medical virology, 2011, Volume: 83, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2011
[Association between the influential factors and the effectiveness of pegylated interferon alpha-2a plus ribavirin as a combination treatment for chronic hepatitis C patients].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2011, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult

2011
[Efficacy of peginterferon alpha-2a in combination with ribavirin in treatment of eldly patients with chronic hepatitis C].
    Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology, 2010, Volume: 24, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Young Adult

2010
Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
    Liver international : official journal of the International Association for the Study of the Liver, 2011, Volume: 31, Issue:3

    Topics: Activities of Daily Living; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Health Status; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load

2011
Evaluation of prognostic factors for Peg Interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan.
    Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 2011, Volume: 11, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Pakistan; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult

2011
Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy.
    Proceedings of the National Academy of Sciences of the United States of America, 2011, Mar-01, Volume: 108, Issue:9

    Topics: Antiviral Agents; Drug Therapy, Combination; Genetic Predisposition to Disease; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Kinetics; Models, Biological; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Time Factors; Viral Load

2011
Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis.
    Journal of hepatology, 2011, Volume: 55, Issue:4

    Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Biomarkers; Drug Monitoring; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Prevalence; Ribavirin; Severity of Illness Index; Vitamin D; Vitamin D Deficiency

2011
Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients.
    Journal of hepatology, 2011, Volume: 55, Issue:5

    Topics: Adult; Antiviral Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Time Factors

2011
Early activation of p38 mitogen activated protein kinase is associated with interferon-alpha-induced depression and fatigue.
    Brain, behavior, and immunity, 2011, Volume: 25, Issue:6

    Topics: Antiviral Agents; Depression; Drug Therapy, Combination; Fatigue; Hepatitis C, Chronic; Humans; Hydrocortisone; Immunity, Innate; Interferon alpha-2; Interferon-alpha; Interleukin-6; Lymphocytes; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Polyethylene Glycols; Protein Processing, Post-Translational; Recombinant Proteins; Ribavirin; Severity of Illness Index; Time Factors

2011
IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection.
    Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3

    Topics: Adolescent; Adult; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Viral Load

2011
Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C.
    Gastroenterology, 2011, Volume: 140, Issue:7

    Topics: Antiviral Agents; Biomarkers; Chi-Square Distribution; Coffee; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Propensity Score; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; United States; Viral Load

2011
High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial).
    Gastroenterology, 2011, Volume: 141, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Chi-Square Distribution; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Linear Models; Logistic Models; Male; Middle Aged; Odds Ratio; Phenotype; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2011
Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients.
    Antiviral therapy, 2011, Volume: 16, Issue:2

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Reagent Kits, Diagnostic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia; Young Adult

2011
Boceprevir for untreated chronic HCV genotype 1 infection.
    The New England journal of medicine, 2011, Mar-31, Volume: 364, Issue:13

    Topics: Adult; Anemia; Antiviral Agents; Black People; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors; Treatment Outcome; Viral Load

2011
Boceprevir for previously treated chronic HCV genotype 1 infection.
    The New England journal of medicine, 2011, Mar-31, Volume: 364, Issue:13

    Topics: Anemia; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors; Treatment Outcome; Viral Load

2011
Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon.
    Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cause of Death; Disease Progression; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2011
Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1.
    Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:4

    Topics: Adolescent; Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load

2011
Efficacy and safety of peginterferon α-2a (40 kD) plus ribavirin among patients with chronic hepatitis C and earlier treatment failure to interferon and ribavirin: an open-label study in central and Eastern Europe.
    European journal of gastroenterology & hepatology, 2011, Volume: 23, Issue:5

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Europe, Eastern; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Failure; Viral Load

2011
Population pharmacokinetics and exposure-response of albinterferon alfa-2b.
    Journal of clinical pharmacology, 2012, Volume: 52, Issue:4

    Topics: Adolescent; Adult; Aged; Albumins; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon-alpha; Logistic Models; Male; Middle Aged; Models, Biological; Ribavirin; Tissue Distribution; Young Adult

2012
The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan.
    Journal of gastroenterology, 2011, Volume: 46, Issue:7

    Topics: Aged; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2011
Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients.
    Journal of gastroenterology, 2011, Volume: 46, Issue:7

    Topics: Anemia; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genomic Structural Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2011
Dysregulation of IFN system can lead to poor response to pegylated interferon and ribavirin therapy in chronic hepatitis C.
    PloS one, 2011, Volume: 6, Issue:5

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Gene Expression Profiling; Gene Expression Regulation; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Pharmacogenetics; Polyethylene Glycols; Polymorphism, Genetic; Precision Medicine; Predictive Value of Tests; Prognosis; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome

2011
Retreatment of patients with chronic hepatitis C relapsers to a previous antiviral treatment.
    European journal of gastroenterology & hepatology, 2011, Volume: 23, Issue:8

    Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; Treatment Outcome

2011
Telaprevir for retreatment of HCV infection.
    The New England journal of medicine, 2011, Jun-23, Volume: 364, Issue:25

    Topics: Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Serine Proteinase Inhibitors; Viral Load; Young Adult

2011
Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections.
    Gastroenterology, 2011, Volume: 141, Issue:3

    Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Single-Blind Method; Treatment Outcome

2011
Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial.
    Gastroenterology, 2011, Volume: 141, Issue:3

    Topics: Adult; Antiviral Agents; Biopsy; Carcinoma, Hepatocellular; Disease Progression; Drug Therapy, Combination; Female; Fibrosis; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Prevalence; Prognosis; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome

2011
Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2011, Volume: 65, Issue:4

    Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Ribavirin; Time Factors; Treatment Outcome; Viral Load

2011
Predictors of response to antiviral therapy in patients with chronic hepatitis C from Pakistani population.
    Chinese medical journal, 2011, Volume: 124, Issue:9

    Topics: Adult; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Pakistan; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Treatment Outcome

2011
Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis.
    Journal of hepatology, 2012, Volume: 56, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2012
An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C.
    PloS one, 2011, Volume: 6, Issue:7

    Topics: Antiviral Agents; Area Under Curve; Demography; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Middle Aged; Models, Biological; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome

2011
Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks.
    Gastroenterology, 2011, Volume: 141, Issue:5

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Precision Medicine; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Young Adult

2011
Impact of sex on virologic response rates in genotype 1 chronic hepatitis C patients with peginterferon alpha-2a and ribavirin treatment.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2011, Volume: 15, Issue:11

    Topics: Adult; Age Factors; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Sex Factors; Treatment Outcome

2011
The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy.
    Antiviral therapy, 2011, Volume: 16, Issue:5

    Topics: Antiviral Agents; Disease Progression; Endoscopy, Gastrointestinal; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk; Time Factors; Treatment Outcome

2011
Occurrence of hepatocellular carcinoma was not a rare event during and immediately after antiviral treatment in Japanese HCV-positive patients.
    Oncology, 2011, Volume: 80, Issue:5-6

    Topics: Adult; Age Factors; Aged; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Japan; Liver Cirrhosis; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; RNA, Viral; Tomography, X-Ray Computed; Treatment Outcome

2011
Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan.
    Journal of hepatology, 2012, Volume: 56, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Eruptions; Drug Therapy, Combination; Female; Genotype; Hematologic Diseases; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult

2012
Impact of Hispanic or Asian ethnicity on the treatment outcomes of chronic hepatitis C: results from the WIN-R trial.
    Journal of clinical gastroenterology, 2011, Volume: 45, Issue:8

    Topics: Adult; Antiviral Agents; Asian; Chi-Square Distribution; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; White People

2011
Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin.
    Journal of acquired immune deficiency syndromes (1999), 2011, Nov-01, Volume: 58, Issue:3

    Topics: Adult; Aged; Anemia; Antiviral Agents; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hepatitis C, Chronic; HIV Infections; Humans; Intercellular Signaling Peptides and Proteins; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multicenter Studies as Topic; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2011
Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:1

    Topics: Adult; Antiviral Agents; Cell Polarity; Cohort Studies; Drug Resistance, Viral; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Killer Cells, Natural; Male; Middle Aged; Phosphorylation; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Signal Transduction; STAT1 Transcription Factor; STAT4 Transcription Factor; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha

2012
Efficacy and safety of peginterferon α-2a (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe.
    European journal of gastroenterology & hepatology, 2011, Volume: 23, Issue:11

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult

2011
Female patients in fertile age with chronic hepatitis C, easy genotype, and persistently normal transaminases have a 100% chance to reach a sustained virological response.
    European journal of gastroenterology & hepatology, 2011, Volume: 23, Issue:11

    Topics: Adult; Age Factors; Alanine Transaminase; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Epidemiologic Methods; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Sex Factors; Treatment Outcome; Viral Load

2011
The supplementation of acetyl-L-carnitine decreases fatigue and increases quality of life in patients with hepatitis C treated with pegylated interferon-α 2b plus ribavirin.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2011, Volume: 31, Issue:9

    Topics: Acetylcarnitine; Adult; Dietary Supplements; Fatigue; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin

2011
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection.
    Gastroenterology, 2011, Volume: 141, Issue:6

    Topics: Acrylates; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Leucine; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Quinolines; Ribavirin; RNA-Dependent RNA Polymerase; RNA, Viral; Thiazoles; Treatment Outcome; Viral Load; Viral Nonstructural Proteins

2011
Safety and efficacy of combination therapy with pegylated interferon alpha-2a and ribavirin in treating patients with chronic hepatitis C and beta-thalassaemia major: a Greek single-center experience.
    Acta haematologica, 2011, Volume: 126, Issue:4

    Topics: Adult; Antiviral Agents; beta-Thalassemia; Chelation Therapy; Drug Therapy, Combination; Female; Greece; Hepatitis C, Chronic; Homozygote; Humans; Interferon alpha-2; Interferon-alpha; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Transfusion Reaction; Treatment Outcome

2011
The early on-treatment perihepatic lymph node response predicts sustained viral response of anti-hepatitis C virus therapy.
    European journal of gastroenterology & hepatology, 2011, Volume: 23, Issue:11

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lymphatic Diseases; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Treatment Outcome; Ultrasonography; Viral Load; Young Adult

2011
Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C.
    Alimentary pharmacology & therapeutics, 2011, Volume: 34, Issue:11-12

    Topics: Adult; Antiviral Agents; Anxiety Disorders; Citalopram; Double-Blind Method; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Selective Serotonin Reuptake Inhibitors; Treatment Outcome

2011
Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition.
    Journal of hepatology, 2012, Volume: 56, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Aspartic Acid; Basal Ganglia; Choline; Cognition; Cognition Disorders; Creatine; Frontal Lobe; Hepatitis C, Chronic; Humans; Inositol; Interferons; Magnetic Resonance Spectroscopy; Middle Aged; Neuropsychological Tests; Polyethylene Glycols; Prospective Studies; Ribavirin; Surveys and Questionnaires

2012
Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Liver Function Tests; Longitudinal Studies; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Assessment; Severity of Illness Index; Treatment Outcome

2012
[Thyroid dysfunctions in children with chronic hepatitis C during interferon alpha-2b therapy].
    Przeglad lekarski, 2011, Volume: 68, Issue:6

    Topics: Adolescent; Antiviral Agents; Causality; Child; Child, Preschool; Comorbidity; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thyroid Diseases

2011
Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response.
    Hepatology (Baltimore, Md.), 2011, Volume: 54, Issue:5

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; Treatment Outcome; Young Adult

2011
Randomised clinical trial: the efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa-2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3.
    Alimentary pharmacology & therapeutics, 2012, Volume: 35, Issue:1

    Topics: Adult; Antiviral Agents; Canada; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome

2012
Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.
    Journal of gastroenterology and hepatology, 2012, Volume: 27, Issue:7

    Topics: Adult; Age Factors; Antiviral Agents; Drug Administration Schedule; Drug Eruptions; Drug Therapy, Combination; Female; Genotype; Hematologic Diseases; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Mental Disorders; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Sex Factors

2012
YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C.
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32, Issue:4

    Topics: Adipokines; Adult; Chitinase-3-Like Protein 1; Disease Progression; Female; Genetic Association Studies; Genetic Predisposition to Disease; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Lectins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Promoter Regions, Genetic; Recombinant Proteins; Ribavirin

2012
L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-α 2b plus ribavirin.
    World journal of gastroenterology, 2011, Oct-21, Volume: 17, Issue:39

    Topics: Adult; Antiviral Agents; Carnitine; Dietary Supplements; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2011
Dynamic changes in HCV RNA levels and viral quasispecies in a patient with chronic hepatitis C after telaprevir-based treatment.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2012, Volume: 53, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2012
Molecular signatures of peripheral blood mononuclear cells during chronic interferon-α treatment: relationship with depression and fatigue.
    Psychological medicine, 2012, Volume: 42, Issue:8

    Topics: 2',5'-Oligoadenylate Synthetase; Antiviral Agents; Computational Biology; Depression; Drug Therapy, Combination; Fatigue; Female; Gene Expression Profiling; Gene Expression Regulation; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocytes, Mononuclear; Longitudinal Studies; Male; Microarray Analysis; Middle Aged; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Messenger; Severity of Illness Index

2012
[Efficacy of interferon alpha with ribavirin for treatment of chronic Hepatitis C].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2011, Volume: 19, Issue:9

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral; Young Adult

2011
Open-label phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic hepatitis C patients.
    Antiviral therapy, 2011, Volume: 16, Issue:8

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hypolipidemic Agents; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Selective Serotonin Reuptake Inhibitors; Sertraline; Simvastatin; Singapore; United States

2011
Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b.
    Polskie Archiwum Medycyny Wewnetrznej, 2011, Volume: 121, Issue:12

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2011
Prediction of effect of pegylated interferon alpha-2b plus ribavirin combination therapy in patients with chronic hepatitis C infection.
    PloS one, 2011, Volume: 6, Issue:12

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Statistical; Neural Networks, Computer; Polyethylene Glycols; Recombinant Proteins; Regression Analysis; Reproducibility of Results; Ribavirin; ROC Curve; Sensitivity and Specificity

2011
A multicenter study to clarify the optimal HCV-RNA negative period during combined therapy with pegylated interferon plus ribavirin in patients with chronic hepatitis caused by HCV genotype 2.
    Internal medicine (Tokyo, Japan), 2012, Volume: 51, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2012
Thalidomide with peginterferon alfa-2b and ribavirin in the treatment of non-responders genotype 1 chronic hepatitis C patients: proof of concept.
    Revista espanola de enfermedades digestivas, 2011, Volume: 103, Issue:12

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genes, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Salvage Therapy; Thalidomide; Treatment Outcome; Viral Load; Viremia

2011
Hepatitis C virus viral kinetics during α-2a or α-2b pegylated interferon plus ribavirin therapy in liver transplant recipients with different immunosuppression regimes.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2012, Volume: 53, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Immunocompromised Host; Interferon alpha-2; Interferon-alpha; Kinetics; Liver Transplantation; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2012
Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role?
    Journal of viral hepatitis, 2012, Volume: 19 Suppl 1

    Topics: Adjuvants, Immunologic; Adult; Aged; Double-Blind Method; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thymalfasin; Thymosin; Treatment Outcome; Viral Load; Young Adult

2012
Influence of IL28B polymorphisms on response to a lower-than-standard dose peg-IFN-α 2a for genotype 3 chronic hepatitis C in HIV-coinfected patients.
    PloS one, 2012, Volume: 7, Issue:1

    Topics: Adult; Dose-Response Relationship, Drug; Female; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Safety; Treatment Outcome

2012
Peginterferon alfa-2b plus weight-based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral response.
    Journal of viral hepatitis, 2012, Volume: 19, Issue:2

    Topics: Adolescent; Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Time Factors; Treatment Outcome; Viral Load; Young Adult

2012
Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C.
    Journal of viral hepatitis, 2012, Volume: 19, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Skin Diseases; Treatment Outcome; Withholding Treatment

2012
Preliminary study of two antiviral agents for hepatitis C genotype 1.
    The New England journal of medicine, 2012, Jan-19, Volume: 366, Issue:3

    Topics: Adult; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Valine

2012
A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C.
    Journal of hepatology, 2012, Volume: 56, Issue:5

    Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Load

2012
Age and total ribavirin dose are independent predictors of relapse after interferon therapy in chronic hepatitis C revealed by data mining analysis.
    Antiviral therapy, 2012, Volume: 17, Issue:1

    Topics: Adult; Age Factors; Aged; Antiviral Agents; Biomarkers, Pharmacological; Cohort Studies; Data Mining; Drug Dosage Calculations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Recurrence; Reproducibility of Results; Ribavirin; RNA, Viral; Viral Load

2012
Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study.
    BMC gastroenterology, 2012, Jan-31, Volume: 12

    Topics: Adult; Age Factors; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Europe; Female; Health Surveys; Hepatitis C, Chronic; Humans; Interferon-alpha; International Cooperation; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Severity of Illness Index; Sex Characteristics; Treatment Outcome

2012
Insulin resistance impairs viral dynamics independently of ethnicity or genotypes.
    Journal of clinical gastroenterology, 2012, Volume: 46, Issue:3

    Topics: Adult; Antiviral Agents; Black People; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hospitals, University; Humans; Insulin Resistance; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Ribavirin; Spain; Treatment Outcome; Viral Load; White People

2012
Continuous interferon-α2b infusion in combination with ribavirin for chronic hepatitis C in treatment-experienced patients.
    Antiviral therapy, 2012, Volume: 17, Issue:3

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Infusions, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome

2012
Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy.
    Antiviral therapy, 2012, Volume: 17, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Asian People; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Load

2012
Antinuclear antibody titer and treatment response to peginterferon plus ribavirin for chronic hepatitis C patients.
    The Kaohsiung journal of medical sciences, 2012, Volume: 28, Issue:2

    Topics: Adult; Aged; Antibodies, Antinuclear; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Young Adult

2012
Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner.
    Hepatology (Baltimore, Md.), 2012, Volume: 56, Issue:1

    Topics: Adult; Aged; Albumins; Antiviral Agents; Cholesterol; Chromatography, Gas; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Lanosterol; Lipid Metabolism; Male; Mass Spectrometry; Middle Aged; Oxidative Stress; Pilot Projects; Prognosis; Ribavirin; Risk Assessment; Severity of Illness Index; Signal Transduction; Statistics, Nonparametric; Treatment Outcome

2012
Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.
    Hepatology (Baltimore, Md.), 2012, Volume: 56, Issue:2

    Topics: Adult; Albumins; Antiviral Agents; Cohort Studies; Coinfection; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Immunity, Innate; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Middle Aged; Pharmacogenetics; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Ribavirin

2012
Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin.
    Hepatology (Baltimore, Md.), 2012, Volume: 56, Issue:2

    Topics: Adult; Antiviral Agents; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Insulin Resistance; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Pioglitazone; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Thiazolidinediones; Treatment Outcome

2012
Prophylaxis for ribavirin-related anemia using eicosapentaenoic acid in chronic hepatitis C patients.
    Pediatrics international : official journal of the Japan Pediatric Society, 2012, Volume: 54, Issue:4

    Topics: Adolescent; Anemia; Antiviral Agents; Child; Child, Preschool; Eicosapentaenoic Acid; Female; Hepatitis C, Chronic; Humans; Male; Ribavirin; Young Adult

2012
Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients.
    Journal of gastroenterology, 2012, Volume: 47, Issue:9

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2012
Pegylated interferon for chronic hepatitis C in children affects growth and body composition: results from the pediatric study of hepatitis C (PEDS-C) trial.
    Hepatology (Baltimore, Md.), 2012, Volume: 56, Issue:2

    Topics: Adolescent; Antiviral Agents; Body Composition; Body Height; Body Mass Index; Body Weight; Child; Child, Preschool; Cohort Studies; Drug Therapy, Combination; Eating; Fatty Liver; Female; Growth Disorders; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2012
Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1.
    Gut, 2012, Volume: 61, Issue:10

    Topics: Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Young Adult

2012
Effect of mosapride citrate on gastric emptying in interferon-induced gastroparesis.
    Digestive diseases and sciences, 2012, Volume: 57, Issue:6

    Topics: Adult; Aged; Benzamides; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gastric Emptying; Gastroparesis; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Morpholines; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Reference Values; Ribavirin; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome

2012
Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin.
    Journal of hepatology, 2012, Volume: 57, Issue:1

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Nonstructural Proteins; Young Adult

2012
Hepatitis C virus amino acid sequence diversity correlates with the outcome of combined interferon/ribavirin therapy in Chinese patients with chronic hepatitis C.
    Archives of virology, 2012, Volume: 157, Issue:6

    Topics: Adult; Amino Acid Sequence; Antiviral Agents; China; Drug Therapy, Combination; Female; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Molecular Sequence Data; Ribavirin; Treatment Outcome; Viral Proteins; Young Adult

2012
Changes in adipocytokines and insulin sensitivity during and after antiviral therapy for hepatitis C genotype 4.
    Journal of gastrointestinal and liver diseases : JGLD, 2012, Volume: 21, Issue:1

    Topics: Adipokines; Adult; Antiviral Agents; Biomarkers; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Tumor Necrosis Factor-alpha; Viral Load

2012
Anemia and thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C.
    Journal of gastroenterology, 2012, Volume: 47, Issue:11

    Topics: Adult; Aged; Anemia; Antiviral Agents; Erythropoietin; Female; Genotype; Hemoglobins; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Male; Middle Aged; Platelet Count; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Thrombocytosis

2012
Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II study.
    Hepatology (Baltimore, Md.), 2012, Volume: 56, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Indoles; Interferon-alpha; Isoindoles; Lactams, Macrocyclic; Leucine; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Sulfonamides; Young Adult

2012
The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2012, Volume: 16, Issue:6

    Topics: Adult; Antibodies, Viral; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Insulin Resistance; Interferon-alpha; Male; Metformin; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2012
Increase in platelet count based on inosine triphosphatase genotype during interferon beta plus ribavirin combination therapy.
    Journal of gastroenterology and hepatology, 2012, Volume: 27, Issue:9

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Interferon alpha-2; Interferon-alpha; Interferon-beta; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Multivariate Analysis; Platelet Count; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Ribavirin; Statistics, Nonparametric

2012
Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2012, Volume: 56, Issue:5

    Topics: Adult; Antiviral Agents; Body Mass Index; Confidence Intervals; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Homeostasis; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Models, Biological; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Failure; Viral Load

2012
Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients.
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32, Issue:8

    Topics: Adult; Anemia; Antiviral Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Internationality; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Thrombocytopenia; Treatment Outcome

2012
Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3.
    PloS one, 2012, Volume: 7, Issue:5

    Topics: Adult; Antiviral Agents; Biological Availability; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Obesity; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2012
Hepatitis C treatment outcomes in Australian clinics.
    The Medical journal of Australia, 2012, Jun-04, Volume: 196, Issue:10

    Topics: Adult; Antiviral Agents; Australia; Body Mass Index; Coinfection; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome

2012
Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C.
    The American journal of gastroenterology, 2012, Volume: 107, Issue:9

    Topics: Adult; Aged; Antiviral Agents; Biopsy; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Kaplan-Meier Estimate; Liver; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Ribavirin; Treatment Outcome

2012
High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials.
    Hepatology (Baltimore, Md.), 2012, Volume: 56, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Viral Load

2012
Randomised clinical trial: pre-dosing with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment-naïve patients with chronic hepatitis C genotype 1.
    Alimentary pharmacology & therapeutics, 2012, Volume: 36, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Purine-Nucleoside Phosphorylase; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2012
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.
    The Lancet. Infectious diseases, 2012, Volume: 12, Issue:9

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Double-Blind Method; Drug Therapy, Combination; Female; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Placebos; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; United States; Valine; Viral Load

2012
Perceived barriers to hepatitis C therapy for patients receiving opioid agonist treatment.
    Journal of addiction medicine, 2012, Volume: 6, Issue:3

    Topics: Adult; Antiviral Agents; Attitude to Health; Cohort Studies; Comorbidity; Comprehension; Health Services Accessibility; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interview, Psychological; Male; Middle Aged; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Education as Topic; Patient Selection; Recombinant Proteins; Ribavirin; Treatment Refusal

2012
Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial.
    Hepatology (Baltimore, Md.), 2012, Volume: 56, Issue:6

    Topics: Antiviral Agents; Chi-Square Distribution; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Inhibitory Concentration 50; Interferon-alpha; Kaplan-Meier Estimate; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Failure

2012
Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
    The Journal of infectious diseases, 2012, Sep-15, Volume: 206, Issue:6

    Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2012
Amantadine in non-responder patients with chronic hepatitis C: a randomized prospective study.
    Hepato-gastroenterology, 2012, Volume: 59, Issue:118

    Topics: Aged; Alanine Transaminase; Amantadine; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Turkey; Viral Load

2012
Estimation of two real-time RT-PCR assays for quantitation of hepatitis C virus RNA during PEG-IFN plus ribavirin therapy by HCV genotypes and IL28B genotype.
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2013, Volume: 19, Issue:1

    Topics: Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Treatment Outcome

2013
A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation.
    Hepatology (Baltimore, Md.), 2013, Volume: 57, Issue:5

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; End Stage Liver Disease; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Preoperative Care; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome

2013
An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin.
    Journal of viral hepatitis, 2012, Volume: 19, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Antiviral Agents; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Interferons; Interleukins; Male; Middle Aged; Ribavirin; Sex Factors; Treatment Outcome; Viral Load

2012
Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C.
    Journal of viral hepatitis, 2012, Volume: 19, Issue:9

    Topics: Adolescent; Adult; Age Factors; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Menopause; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sex Factors; Treatment Outcome; Young Adult

2012
Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: a randomized trial.
    Journal of hepatology, 2012, Volume: 57, Issue:6

    Topics: Adjuvants, Pharmaceutic; Aged; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Middle Aged; Polyethylene Glycols; Postmenopause; Prospective Studies; Raloxifene Hydrochloride; Recombinant Proteins; Ribavirin; RNA, Viral; Selective Estrogen Receptor Modulators

2012
Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin.
    Antiviral therapy, 2012, Volume: 17, Issue:6

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; RNA, Viral; Taiwan; Time Factors; Treatment Outcome

2012
Efficacy of peginterferon alpha-2A and ribavirin combination therapy in treatment-naive Estonian patients with chronic hepatitis C.
    Central European journal of public health, 2012, Volume: 20, Issue:2

    Topics: Adult; Age Factors; Antiviral Agents; Drug Therapy, Combination; Estonia; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Sex Factors; Viral Load

2012
Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b.
    Journal of gastroenterology and hepatology, 2013, Volume: 28, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Confidence Intervals; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Hepacivirus; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral

2013
[Efficacy of combined immunocorrection in the treatment of chronic viral hepatitis C].
    Terapevticheskii arkhiv, 2012, Volume: 84, Issue:6

    Topics: Acridines; Adult; Antigen-Antibody Complex; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Immunity, Cellular; Interferon Inducers; Interferon-alpha; Leukocytes, Mononuclear; Lymphocyte Count; Macrophages; Male; Meglumine; Middle Aged; Phagocytosis; Ribavirin; Succinates; T-Lymphocytes; Treatment Outcome; Young Adult

2012
Improvement of thrombocytopenia in hepatitis C-related advanced fibrosis patients after sustained virological response.
    Digestive diseases and sciences, 2013, Volume: 58, Issue:2

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Recombinant Proteins; Ribavirin; Severity of Illness Index; Thrombocytopenia; Time; Treatment Outcome

2013
Efficacy of PEG-interferon based treatment in patients with hepatitis C refractory to previous conventional interferon-based treatment.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2012, Volume: 22, Issue:10

    Topics: Antiviral Agents; Biopsy; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Hospitals, Teaching; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Pakistan; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Severity of Illness Index; Treatment Outcome; Viral Load

2012
Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2013, Volume: 11, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Double-Blind Method; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Placebos; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2013
Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial.
    Hepatology (Baltimore, Md.), 2013, Volume: 57, Issue:3

    Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Female; Hematinics; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Placebos; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Treatment Outcome

2013
Several factors including ITPA polymorphism influence ribavirin-induced anemia in chronic hepatitis C.
    World journal of gastroenterology, 2012, Nov-07, Volume: 18, Issue:41

    Topics: Aged; Anemia; Antiviral Agents; Biomarkers; Chi-Square Distribution; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Phenotype; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors

2012
HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b.
    BMC gastroenterology, 2012, Nov-16, Volume: 12

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2012
Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
    Journal of gastroenterology and hepatology, 2013, Volume: 28, Issue:3

    Topics: Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; Drug Administration Schedule; Drug Therapy, Combination; Female; Genetic Markers; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-beta; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2013
Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial.
    Journal of hepatology, 2013, Volume: 58, Issue:4

    Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome; Uridine Monophosphate; Young Adult

2013
[Study on retreatment of CHC patients with initial treatment failure].
    Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology, 2012, Volume: 26, Issue:4

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; Treatment Failure; Viral Load; Young Adult

2012
Interferon-gamma with peginterferon alpha-2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI).
    Journal of gastroenterology and hepatology, 2013, Volume: 28, Issue:2

    Topics: Adult; Antiviral Agents; Biomarkers; Chi-Square Distribution; Drug Therapy, Combination; Female; France; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-gamma; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2013
[Effect of interferon and ribavirin combination therapy in sixty-two patients with chronic hepatitis C originating from a single blood donor].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2012, Volume: 20, Issue:8

    Topics: Adolescent; Adult; Antiviral Agents; Blood Donors; Child; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Transfusion Reaction; Treatment Outcome; Viral Load; Young Adult

2012
No beneficial effect of all-trans retinoic acid in previous non-responder patients with chronic hepatitis C: the ATRACTION study, a phase II randomised trial.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2013, Volume: 45, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tretinoin; Viral Load

2013
Association of γ-glutamyl transferase (GGT) activity with treatment and clinical outcomes in chronic hepatitis C (HCV).
    Hepatology (Baltimore, Md.), 2013, Volume: 57, Issue:5

    Topics: Adult; Antiviral Agents; Biomarkers; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; gamma-Glutamyltransferase; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Predictive Value of Tests; Prognosis; Recombinant Proteins; Ribavirin; Treatment Outcome

2013
A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
    European journal of gastroenterology & hepatology, 2013, Volume: 25, Issue:5

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2013
Exploratory study of oral combination antiviral therapy for hepatitis C.
    The New England journal of medicine, 2013, Jan-03, Volume: 368, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Protease Inhibitors; Ribavirin; Ritonavir; RNA, Viral; Viral Load; Viral Nonstructural Proteins

2013
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.
    The New England journal of medicine, 2013, Jan-03, Volume: 368, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load; Viral Nonstructural Proteins

2013
In vivo interferon-alpha/ribavirin treatment modulates Vγ9Vδ2 T-cell function during chronic HCV infection.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2013, Volume: 33, Issue:3

    Topics: Adult; Antiviral Agents; Clonal Anergy; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-gamma; Male; Middle Aged; Receptors, Antigen, T-Cell, gamma-delta; Ribavirin; Time Factors

2013
PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients.
    Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:2

    Topics: Adolescent; Adult; Aged; Deoxycytidine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult

2013
JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients.
    Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:2

    Topics: Adolescent; Adult; Aged; Canada; Deoxycytidine; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; United States; Young Adult

2013
Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial.
    Hepatology (Baltimore, Md.), 2013, Volume: 57, Issue:6

    Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Carrier Proteins; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Leucine; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Quinolines; Recombinant Proteins; Ribavirin; Thiazoles; Viral Nonstructural Proteins

2013
Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C.
    Gut, 2014, Volume: 63, Issue:1

    Topics: Adult; Antiviral Agents; Biomarkers; Drug Administration Schedule; Drug Therapy, Combination; Female; Gene Expression Profiling; Hepatitis C, Chronic; Humans; Interferon Regulatory Factors; Interferon-alpha; Liver; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Transcriptome; Treatment Outcome; Viral Load

2014
Immunological markers predicting outcome in patients with hepatitis C treated with interferon-alpha and ribavirin.
    Immunology and cell biology, 2002, Volume: 80, Issue:4

    Topics: Adult; Antiviral Agents; Biomarkers; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Ki-1 Antigen; Liver Cirrhosis; Male; Middle Aged; Pilot Projects; Ribavirin; Treatment Failure; Treatment Outcome

2002
Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin.
    Journal of hepatology, 2002, Volume: 37, Issue:2

    Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Predictive Value of Tests; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome

2002
CD4 T lymphocyte proliferative responses to hepatitis C virus (HCV) antigens in patients coinfected with HCV and human immunodeficiency virus who responded to anti-HCV treatment.
    The Journal of infectious diseases, 2002, Aug-01, Volume: 186, Issue:3

    Topics: Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Female; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Lymphocyte Activation; Male; Middle Aged; Recombinant Proteins; Ribavirin; Statistics, Nonparametric; Tuberculin

2002
Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induction.
    Journal of viral hepatitis, 2002, Volume: 9, Issue:5

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral; Treatment Outcome; Viremia

2002
A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy.
    Hepatology (Baltimore, Md.), 2002, Volume: 36, Issue:4 Pt 1

    Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Multivariate Analysis; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2002
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    The New England journal of medicine, 2002, Sep-26, Volume: 347, Issue:13

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2002
Retreatment of high-dose interferon (5 MU daily) nonresponders with high-dose IFN + ribavirin.
    Digestive diseases and sciences, 2002, Volume: 47, Issue:9

    Topics: Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Retreatment; Ribavirin; Treatment Failure

2002
Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C.
    Gastroenterology, 2002, Volume: 123, Issue:4

    Topics: Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2002
High rate of sustained response to consensus interferon plus ribavirin in chronic hepatitis C patients resistant to alpha-interferon and ribavirin: a pilot study.
    Journal of gastroenterology, 2002, Volume: 37, Issue:9

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Interferon-alpha; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Ribavirin; Time Factors; Viral Load

2002
Ribavirin increases mitogen- and antigen-induced expression of CD40L on CD4+ T cells in vivo.
    Clinical and experimental immunology, 2002, Volume: 130, Issue:2

    Topics: Adjuvants, Immunologic; Antiviral Agents; CD4-Positive T-Lymphocytes; CD40 Ligand; Cells, Cultured; Cytokines; Female; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Lymphocyte Activation; Male; Middle Aged; Mitogens; Monocytes; Recurrence; Ribavirin; RNA, Viral; Viral Core Proteins

2002
Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2002, Volume: 36, Issue:5

    Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Male; Pilot Projects; Recombinant Proteins; Ribavirin; Transaminases; Treatment Outcome

2002
Interferon and ribavirin in HIV-negative haemophiliacs with chronic hepatitis C who were nonresponders to a previous interferon treatment.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2002, Volume: 8, Issue:6

    Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Failure

2002
High-dose interferon alpha-2a with ribavirin and amantadine in naïve chronic hepatitis C patients--results of a randomized, prospective, pilot study.
    Alimentary pharmacology & therapeutics, 2002, Volume: 16, Issue:12

    Topics: Adult; Amantadine; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2002
Serum levels of soluble intercellular-1 and vascular cell-1 adhesion molecules in chronic hepatitis C and the influence of interferon-alpha + ribavirin therapy.
    Romanian journal of gastroenterology, 2002, Volume: 11, Issue:4

    Topics: Adult; Antiviral Agents; Biomarkers; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C, Chronic; Humans; Intercellular Adhesion Molecule-1; Interferon-alpha; Male; Middle Aged; Prognosis; Ribavirin; Treatment Outcome; Vascular Cell Adhesion Molecule-1

2002
The safety and tolerability of daily infergen plus ribavirin in the treatment of naíïve chronic hepatitis C patients.
    Journal of viral hepatitis, 2003, Volume: 10, Issue:1

    Topics: Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Ribavirin; RNA, Viral; Safety; Treatment Outcome; Viral Load

2003
[Retreatment with interferon plus ribavirin in chronic hepatitis C patients with genotype 1 who had no response or a relapse with a previous interferon treatment. Long term follow-up].
    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2002, Volume: 15, Issue:3

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Time Factors

2002
Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.
    Gut, 2003, Volume: 52, Issue:3

    Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Female; Germany; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Life Expectancy; Male; Markov Chains; Middle Aged; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Survival Analysis

2003
Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.
    Gastroenterology, 2003, Volume: 124, Issue:3

    Topics: Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Postoperative Care; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Safety; Treatment Outcome

2003
Efficacy of prolonged 5 million units of interferon in combination with ribavirin for relapser patients with chronic hepatitis C.
    Journal of viral hepatitis, 2003, Volume: 10, Issue:2

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Recombinant Proteins; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Treatment Outcome

2003
Rationale and design of TeraViC-4 study: a phase III, randomized clinical trial to evaluate the effects of treatment duration with peginterferon alfa-2a (40-kDa) and ribavirin in naïve patients with chronic hepatitis C virus infection without early virolo
    Methods and findings in experimental and clinical pharmacology, 2002, Volume: 24, Issue:9

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Research Design; Ribavirin; Time Factors

2002
Clinical comparison of high-dose interferon-alpha2b with or without ribavirin for treatment of interferon-relapsed chronic hepatitis C.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2002, Volume: 34, Issue:12

    Topics: Adult; Antiviral Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral

2002
Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1.
    The Journal of infectious diseases, 2003, Apr-01, Volume: 187, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Genes, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin

2003
Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection.
    British journal of clinical pharmacology, 2003, Volume: 55, Issue:4

    Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2003
Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation.
    Blood, 2003, Aug-15, Volume: 102, Issue:4

    Topics: Alanine Transaminase; Antiviral Agents; B-Lymphocytes; Base Sequence; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 18; Drug Therapy, Combination; Female; Genes, bcl-2; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Molecular Sequence Data; Ribavirin; RNA, Viral; Translocation, Genetic; Treatment Outcome

2003
Effects of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon non-responsive chronic hepatitis C: a randomised trial.
    Gut, 2003, Volume: 52, Issue:5

    Topics: Adult; Alanine Transaminase; Amantadine; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; RNA, Viral; Treatment Outcome

2003
Association of CTLA4 polymorphisms with sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection.
    The Journal of infectious diseases, 2003, Apr-15, Volume: 187, Issue:8

    Topics: Abatacept; Adult; Antigens, CD; Antigens, Differentiation; Antiviral Agents; CTLA-4 Antigen; Female; Genetic Linkage; Hepacivirus; Hepatitis C, Chronic; Humans; Immunoconjugates; Interferon-alpha; Male; Pharmacogenetics; Polymorphism, Single Nucleotide; Ribavirin; Time Factors

2003
Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients.
    AIDS (London, England), 2003, May-02, Volume: 17, Issue:7

    Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load

2003
T-lymphocyte populations in hepatitis C and HIV co-infected patients treated with interferon-alfa-2a and ribavirin.
    HIV medicine, 2003, Volume: 4, Issue:2

    Topics: Adult; Antiviral Agents; Case-Control Studies; CD3 Complex; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Drug Administration Schedule; Female; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Lymphocyte Count; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; T-Lymphocyte Subsets; Viral Load

2003
Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases.
    Hepatology (Baltimore, Md.), 2003, Volume: 37, Issue:5

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2003
ISDR pattern and evolution in patients with chronic hepatitis C treated with standard or PEG-IFN plus ribavirin.
    Antiviral therapy, 2003, Volume: 8, Issue:2

    Topics: Amino Acid Sequence; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Mutation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sequence Alignment; Treatment Outcome; Viral Nonstructural Proteins

2003
Interferon-ribavirin in association with stavudine has no impact on plasma human immunodeficiency virus (HIV) type 1 level in patients coinfected with HIV and hepatitis C virus: a CORIST-ANRS HC1 trial.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003, May-15, Volume: 36, Issue:10

    Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferons; Male; Middle Aged; Ribavirin; RNA, Viral; Stavudine; Treatment Outcome; Viral Load

2003
Induction interferon and ribavirin for re-treatment of chronic hepatitis C patients unresponsive to interferon alone.
    Alimentary pharmacology & therapeutics, 2003, May-01, Volume: 17, Issue:9

    Topics: Adolescent; Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome

2003
Chronic hepatitis C patients with a post-treatment virological relapse re-treated with an induction dose of 18 MU interferon-alpha in combination with ribavirin and amantadine: a two-arm randomized pilot study.
    Journal of viral hepatitis, 2003, Volume: 10, Issue:3

    Topics: Adult; Aged; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome

2003
A randomized trial to assess the efficacy of interferon alpha in combination with ribavirin in the treatment of interferon alpha nonresponders with chronic hepatitis C: superior efficacy of high daily dosage of interferon alpha in genotype 1.
    Journal of viral hepatitis, 2003, Volume: 10, Issue:3

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2003
Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial.
    Journal of viral hepatitis, 2003, Volume: 10, Issue:3

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Treatment Outcome

2003
Retreatment with interferon and ribavirin vs interferon alone according to viraemia in interferon responder-relapser hepatitis C patients: a prospective multicentre randomized controlled study.
    Journal of viral hepatitis, 2003, Volume: 10, Issue:3

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia

2003
Combination therapy with interferon-alpha(2b), ribavirin, and amantadine in chronic hepatitis C nonresponders to interferon and ribavirin.
    Digestive diseases and sciences, 2003, Volume: 48, Issue:3

    Topics: Adult; Aged; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Pilot Projects; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Treatment Failure

2003
Combination treatment of IFNalpha2b and ribavirin in patients with chronic hepatitis C and persistently normal ALTs.
    Digestive diseases and sciences, 2003, Volume: 48, Issue:5

    Topics: Administration, Oral; Adult; Alanine Transaminase; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Pilot Projects; Prospective Studies; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome

2003
Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial.
    Hepatology (Baltimore, Md.), 2003, Volume: 37, Issue:6

    Topics: Adult; Aged; Alanine Transaminase; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Placebos; Recombinant Proteins; Ribavirin

2003
Pretreatment of chronic active hepatitis C in patients coinfected with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy.
    Journal of acquired immune deficiency syndromes (1999), 2003, Jun-01, Volume: 33, Issue:2

    Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Antiviral Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Prognosis; Prospective Studies; Ribavirin; Risk Factors; Treatment Outcome; Withholding Treatment

2003
A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C.
    Journal of virological methods, 2003, Jun-30, Volume: 110, Issue:2

    Topics: Antiviral Agents; Biological Assay; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Luciferases; Polyethylene Glycols; Recombinant Proteins; Replicon; Ribavirin; RNA, Viral; Tumor Cells, Cultured; Virus Replication

2003
Comparison of 2 regimens that include interferon-alpha-2a plus ribavirin for treatment of chronic hepatitis C in human immunodeficiency virus-coinfected patients.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003, Jun-15, Volume: 36, Issue:12

    Topics: Adolescent; Adult; Aged; Antiviral Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral

2003
Interferon-alpha2b induction treatment with or without ribavirin in chronic hepatitis C: a multicenter, randomized, controlled trial.
    Digestive diseases and sciences, 2003, Volume: 48, Issue:6

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin

2003
Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin.
    Hepatology (Baltimore, Md.), 2003, Volume: 38, Issue:1

    Topics: Antiviral Agents; Biopsy; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Ribavirin; RNA, Viral

2003
Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2003, Volume: 42, Issue:1

    Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Function Tests; Kidney Transplantation; Liver; Liver Function Tests; Male; Middle Aged; Necrosis; Pilot Projects; Proteinuria; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia

2003
Regression of fibrosis in chronic hepatitis C after therapy with interferon and ribavirin.
    Digestive diseases and sciences, 2003, Volume: 48, Issue:7

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Remission Induction; Ribavirin

2003
High rate of long-term virological response after a 1-year course of interferon +/- ribavirin in chronic hepatitis C relapsers. Results of a 191 patients randomized trial.
    Liver international : official journal of the International Association for the Study of the Liver, 2003, Volume: 23, Issue:4

    Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2003
Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy.
    Liver international : official journal of the International Association for the Study of the Liver, 2003, Volume: 23, Issue:4

    Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polymerase Chain Reaction; Prospective Studies; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2003
Interferon-alpha (IFN alpha) daily dose versus IFN alpha plus ribavirin for treatment-naive chronic hepatitis c patients infected by genotype 1b.
    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2003, Volume: 17, Issue:4

    Topics: Administration, Oral; Adult; Alanine Transaminase; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome

2003
[Treatment of chronic hepatitis C with interferon alpha and ribavirin. Results in "real life"].
    Gastroenterologie clinique et biologique, 2003, Volume: 27, Issue:6-7

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Ribavirin

2003
Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b.
    Seminars in liver disease, 2003, Volume: 23 Suppl 1

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Carriers; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Biological; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2003
Retreatment of hepatitis C non-responsive to interferon. A placebo controlled randomized trial of ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378].
    BMC gastroenterology, 2003, Aug-29, Volume: 3

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Failure

2003
A randomized trial to assess the efficacy of interferon-alpha daily in combination with ribavirin in the treatment of naïve patients with chronic hepatitis C.
    Journal of viral hepatitis, 2003, Volume: 10, Issue:5

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Time Factors; Treatment Outcome; Viral Load

2003
Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C.
    Journal of hepatology, 2003, Volume: 39, Issue:4

    Topics: Adult; Aged; Amantadine; Antiviral Agents; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome

2003
[Interferon, ribavirin and amantadine in prior nonresponders to interferon and ribavirin therapy with chronic hepatitis C (genotype 1)].
    Gastroenterologia y hepatologia, 2003, Volume: 26, Issue:8

    Topics: Adult; Aged; Amantadine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Prospective Studies; Recombinant Proteins; Retreatment; Ribavirin

2003
Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen.
    Journal of hepatology, 2003, Volume: 39, Issue:5

    Topics: Adult; Amantadine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Male; Middle Aged; Predictive Value of Tests; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Treatment Outcome; Viral Core Proteins; Viral Load

2003
A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C.
    Journal of hepatology, 2003, Volume: 39, Issue:5

    Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Interferon-alpha; Male; Middle Aged; Patient Compliance; Recombinant Proteins; Ribavirin

2003
Good safety profile and efficacy of leucocyte interferon-alpha in combination with oral ribavirin in treatment-naive patients with chronic hepatitis C: a multicentre, randomised, controlled study.
    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2003, Volume: 17, Issue:6

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin

2003
First-line therapy with daily versus thrice-weekly interferon alfa-2b plus ribavirin for chronic hepatitis C.
    European journal of gastroenterology & hepatology, 2003, Volume: 15, Issue:12

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2003
Twenty-four vs. forty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in interferon alpha monotherapy relapsers with chronic hepatitis C.
    Swiss medical weekly, 2003, Aug-23, Volume: 133, Issue:33-34

    Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Prospective Studies; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; Time Factors; Treatment Outcome

2003
Comparative study of the efficacy of an induction dose of interferon-alpha2b with ribavirin compared with standard combined treatment in naive patients with chronic hepatitis C.
    Journal of viral hepatitis, 2003, Volume: 10, Issue:6

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Spain

2003
Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naive chronic hepatitis C patients. A multicentre randomized controlled trial.
    Journal of viral hepatitis, 2003, Volume: 10, Issue:6

    Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Belgium; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Middle Aged; Netherlands; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load

2003
Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C.
    The American journal of gastroenterology, 2003, Volume: 98, Issue:11

    Topics: Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Polymerase Chain Reaction; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Survival Analysis; Treatment Outcome; Viral Load

2003
Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa.
    The American journal of gastroenterology, 2003, Volume: 98, Issue:11

    Topics: Adolescent; Adult; Aged; Analysis of Variance; Anemia; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Probability; Recombinant Proteins; Reference Values; Ribavirin; Treatment Outcome

2003
Anti-viral actions and viral dynamics in the early phase of three different regimens of interferon treatment for chronic hepatitis C: differences between the twice-daily administration of interferon-beta treatment and the combination therapy with interfer
    Acta medica Okayama, 2003, Volume: 57, Issue:5

    Topics: 2',5'-Oligoadenylate Synthetase; Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; eIF-2 Kinase; Female; Gene Expression; GTP-Binding Proteins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-beta; Kinetics; Male; Middle Aged; Monocytes; Myxovirus Resistance Proteins; Ribavirin; RNA, Viral; Time Factors

2003
Randomised, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naïve patients with chronic hepatitis C.
    Gut, 2004, Volume: 53, Issue:1

    Topics: Adult; Amantadine; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors; RNA, Viral; Treatment Outcome

2004
Response of TT virus to IFN plus ribavirin treatment in patients with chronic hepatitis C.
    World journal of gastroenterology, 2004, Volume: 10, Issue:1

    Topics: Adult; Antiviral Agents; DNA Virus Infections; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin; Torque teno virus; Treatment Outcome

2004
Treatment of chronic hepatitis C in HIV-infected patients with interferon alpha-2b plus ribavirin.
    AIDS research and human retroviruses, 2003, Volume: 19, Issue:12

    Topics: Adult; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; Treatment Outcome

2003
A randomized, double-blind, placebo-controlled clinical trial of high-dose interferon-alpha induction treatment combined with ribavirin for chronic hepatitis C in hemophilia.
    Journal of thrombosis and haemostasis : JTH, 2004, Volume: 2, Issue:1

    Topics: Adolescent; Adult; Antiviral Agents; Blood Coagulation Disorders; Double-Blind Method; Drug Therapy, Combination; Hemophilia A; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Recombinant Proteins; Ribavirin

2004
Interferon alfa2a induction therapy in combination with ribavirin and amantadine for the treatment of naive patients with chronic HCV infection.
    Journal of viral hepatitis, 2004, Volume: 11, Issue:1

    Topics: Adolescent; Adult; Aged; Alanine Transaminase; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Transaminases

2004
Dosage adjustment of ribavirin based on renal function in Japanese patients with chronic hepatitis C.
    Therapeutic drug monitoring, 2004, Volume: 26, Issue:1

    Topics: Adult; Aged; Algorithms; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Kidney; Kidney Function Tests; Male; Metabolic Clearance Rate; Middle Aged; Ribavirin

2004
A randomized trial of a 4- vs 12-week daily interferon dose regimen combined with ribavirin in treatment of patients with chronic hepatitis C.
    Hepatobiliary & pancreatic diseases international : HBPD INT, 2004, Volume: 3, Issue:1

    Topics: Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; India; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Probability; Recombinant Proteins; Recurrence; Reference Values; Ribavirin; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome

2004
Viral clearance in HCV viraemic patients with normal alanine aminotransferase after combination therapy: a controlled, open-labelled study.
    Alimentary pharmacology & therapeutics, 2004, Feb-01, Volume: 19, Issue:3

    Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Drug Combinations; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2004
Low daily dosage of interferon for 1 year after HCV-related end-therapy response. A randomized-controlled study.
    Liver international : official journal of the International Association for the Study of the Liver, 2003, Volume: 23, Issue:6

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2003
Interferon alpha and ribavirin in the treatment of children with chronic hepatitis C.
    European journal of pediatrics, 2004, Volume: 163, Issue:4-5

    Topics: Adolescent; Alanine Transaminase; Antiviral Agents; Child; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Ribavirin; RNA, Viral; Treatment Outcome

2004
Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C.
    Journal of viral hepatitis, 2004, Volume: 11, Issue:2

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Efficiency; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Surveys and Questionnaires; Treatment Outcome

2004
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.
    Annals of internal medicine, 2004, Mar-02, Volume: 140, Issue:5

    Topics: Adult; Antiviral Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2004
Daily versus thrice-weekly interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: a multicenter randomized controlled trial.
    Journal of acquired immune deficiency syndromes (1999), 2004, Apr-15, Volume: 35, Issue:5

    Topics: Adult; Antiviral Agents; Depression; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2004
The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C.
    Journal of hepatology, 2004, Volume: 40, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Fatigue; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin

2004
Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients.
    Journal of hepatology, 2004, Volume: 40, Issue:4

    Topics: Adult; Antiviral Agents; Double-Blind Method; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors

2004
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.
    Gastroenterology, 2004, Volume: 126, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Failure

2004
Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin.
    Hepatology (Baltimore, Md.), 2004, Volume: 39, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2004
Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation.
    Transplant international : official journal of the European Society for Organ Transplantation, 2004, Volume: 17, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Severity of Illness Index; Time Factors; Treatment Outcome; Viral Load

2004
High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load.
    Journal of gastroenterology, 2004, Volume: 39, Issue:2

    Topics: Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Load

2004
Efficacy and safety of combined treatment with pegylated-IFN-alpha 2b plus ribavirin in HIV-hepatitis C virus-co-infected patients.
    AIDS (London, England), 2004, Apr-30, Volume: 18, Issue:7

    Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2004
Comparison of IFN-alpha 2b with or without ribavirin for treatment of chronic hepatitis C in HIV-positive patients infected with hepatitis C virus genotype 3a.
    AIDS (London, England), 2004, Apr-30, Volume: 18, Issue:7

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin

2004
Sustained suppression of hepatitis C virus by high doses of interferon and ribavirin in adult hemophilic patients.
    Transfusion, 2004, Volume: 44, Issue:5

    Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin

2004
Quantification and functional analysis of plasmacytoid dendritic cells in patients with chronic hepatitis C virus infection.
    The Journal of infectious diseases, 2004, May-01, Volume: 189, Issue:9

    Topics: Adolescent; Adult; Antiviral Agents; Dendritic Cells; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocyte Count; Leukocytes, Mononuclear; Middle Aged; Ribavirin

2004
Low membrane protein sulfhydrils but not G6PD deficiency predict ribavirin-induced hemolysis in hepatitis C.
    Hepatology (Baltimore, Md.), 2004, Volume: 39, Issue:5

    Topics: Adult; Antiviral Agents; Cell Membrane; Dipyridamole; Erythrocytes; Female; Glutathione; Glutathione Disulfide; Glycogen Storage Disease Type I; Hemolysis; Hepatitis C, Chronic; Humans; In Vitro Techniques; Male; Maleates; Middle Aged; Predictive Value of Tests; Prospective Studies; Ribavirin; Sulfhydryl Compounds

2004
Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin.
    The American journal of gastroenterology, 2004, Volume: 99, Issue:5

    Topics: Adult; Amantadine; Audiometry; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hearing Loss, Sudden; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prognosis; Recombinant Proteins; Ribavirin; Risk Assessment; RNA, Viral; Sampling Studies; Severity of Illness Index

2004
[Autoantibodies against islet cell antigens and type 1 diabetes after treatment with interferon-alpha].
    Deutsche medizinische Wochenschrift (1946), 2004, May-14, Volume: 129, Issue:20

    Topics: Amantadine; Antiviral Agents; Autoantibodies; Diabetes Mellitus, Type 1; Double-Blind Method; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Islets of Langerhans; Male; Middle Aged; Randomized Controlled Trials as Topic; Retrospective Studies; Ribavirin; Treatment Failure

2004
Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3.
    Journal of hepatology, 2004, Volume: 40, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Drug Carriers; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2004
Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C.
    Journal of hepatology, 2004, Volume: 40, Issue:6

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Ferritins; Hepatitis C, Chronic; Humans; Interferons; Iron; Liver; Male; Middle Aged; Ribavirin; RNA, Viral; Viral Load

2004
Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites.
    The New England journal of medicine, 2004, May-27, Volume: 350, Issue:22

    Topics: Adult; Antiviral Agents; Black or African American; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Socioeconomic Factors; White People

2004
Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.
    Hepatology (Baltimore, Md.), 2004, Volume: 39, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Black or African American; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin

2004
Treatment of chronic hepatitis C in naive patients with high-dose interferon-alpha2a induction therapy and two different ribavirin doses.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2004, Volume: 36, Issue:5

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Pilot Projects; Recombinant Proteins; Ribavirin; Treatment Outcome

2004
A comparison of the exponential decay slope between PEG-IFN alfa-2b/ribavirin and IFN alfa-2b/ribavirin combination therapy in patients with chronic hepatitis C genotype 1b infection and a high viral load.
    Intervirology, 2004, Volume: 47, Issue:2

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia

2004
Skin reaction in antiviral therapy for chronic hepatitis C: a role for polyethylene glycol interferon?
    Acta dermato-venereologica, 2004, Volume: 84, Issue:2

    Topics: Adult; Amantadine; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Solvents; Treatment Outcome

2004
A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance.
    Hepatology (Baltimore, Md.), 2004, Volume: 40, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Methadone; Middle Aged; Narcotics; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Substance-Related Disorders; Treatment Outcome

2004
Differences in treatment outcome for hepatitis C among ethnic groups.
    The American journal of medicine, 2004, Aug-01, Volume: 117, Issue:3

    Topics: Adult; Asian; Black or African American; Ethnicity; Female; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferons; Male; Middle Aged; Ribavirin; Treatment Outcome; White People

2004
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
    The New England journal of medicine, 2004, Jul-29, Volume: 351, Issue:5

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2004
Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
    The New England journal of medicine, 2004, Jul-29, Volume: 351, Issue:5

    Topics: Adult; Analysis of Variance; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2004
A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients.
    Journal of hepatology, 2004, Volume: 41, Issue:2

    Topics: Adult; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Failure

2004
Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy.
    AIDS (London, England), 2004, Sep-03, Volume: 18, Issue:13

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Failure; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors

2004
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.
    AIDS (London, England), 2004, Sep-03, Volume: 18, Issue:13

    Topics: Adult; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome

2004
Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT.
    The American journal of gastroenterology, 2004, Volume: 99, Issue:9

    Topics: Administration, Oral; Adult; Alanine Transaminase; Biopsy, Needle; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Probability; Recombinant Proteins; Reference Values; Ribavirin; Risk Assessment; Severity of Illness Index; Treatment Outcome

2004
Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial.
    Journal of hepatology, 2004, Volume: 41, Issue:3

    Topics: Adult; Antiviral Agents; Drug Tolerance; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Safety

2004
Combination therapy for the treatment of hepatitis C in the veteran population: higher than expected rates of therapy discontinuation.
    Alimentary pharmacology & therapeutics, 2004, Sep-15, Volume: 20, Issue:6

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome; Veterans

2004
[Treatment with interferon and ribavirin of chronic hepatitis C in HIV-infected patients].
    Anales de medicina interna (Madrid, Spain : 1984), 2004, Volume: 21, Issue:8

    Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Treatment Outcome

2004
Peginterferon alpha-2b plus ribavirin with or without amantadine [correction of amantidine] for the treatment of non-responders to standard interferon and ribavirin.
    Antiviral therapy, 2004, Volume: 9, Issue:4

    Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Aged; Alanine Transaminase; Amantadine; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2004
Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
    Antiviral therapy, 2004, Volume: 9, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Predictive Value of Tests; Recurrence; Ribavirin; RNA, Viral

2004
Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis.
    World journal of gastroenterology, 2004, Nov-01, Volume: 10, Issue:21

    Topics: Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Nucleolus Organizer Region; Prospective Studies; Ribavirin; Silver Staining

2004
Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine.
    Wiener klinische Wochenschrift, 2004, Aug-31, Volume: 116, Issue:15-16

    Topics: Adult; Aged; Amantadine; Antiviral Agents; Austria; Dose-Response Relationship, Drug; Drug Combinations; Drug Tolerance; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Secondary Prevention; Treatment Failure; Treatment Outcome

2004
Treatment of patients with HCV infection with or without liver biopsy.
    Journal of viral hepatitis, 2004, Volume: 11, Issue:6

    Topics: Adult; Biopsy; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Male; Middle Aged; Ribavirin; Treatment Outcome

2004
A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone.
    Journal of viral hepatitis, 2004, Volume: 11, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Failure; Treatment Outcome

2004
[Peginterferon alpha-2b in patients with chronic hepatitis C].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2004, Volume: 16, Issue:94

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2004
Outcome of combined interferon-ribavirin in the treatment of chronic hepatitis C.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2004, Volume: 14, Issue:11

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin; Treatment Outcome

2004
Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
    Journal of medical virology, 2005, Volume: 75, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Sensitivity and Specificity; Treatment Outcome; Viral Load

2005
Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-week interim results of a pilot study.
    Journal of gastroenterology and hepatology, 2004, Volume: 19 Suppl 6

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Mexico; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Thymalfasin; Thymosin; Time Factors; Treatment Failure; Treatment Outcome; Viral Load; Virus Replication

2004
Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study.
    Hepatology (Baltimore, Md.), 2004, Volume: 40, Issue:6

    Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Pilot Projects; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome

2004
Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels.
    Hepatology (Baltimore, Md.), 2004, Volume: 40, Issue:6

    Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; gamma-Glutamyltransferase; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2004
Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy.
    Hepatology (Baltimore, Md.), 2004, Volume: 40, Issue:6

    Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Female; Hematinics; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Quality of Life; Recombinant Proteins; Ribavirin

2004
Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4.
    Liver international : official journal of the International Association for the Study of the Liver, 2004, Volume: 24, Issue:6

    Topics: Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Probability; Recombinant Proteins; Ribavirin; Risk Assessment; RNA, Viral; Saudi Arabia; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome

2004
Randomized trial of three different regimens for 24 weeks for re-treatment of chronic hepatitis C patients who failed to respond to interferon-alpha monotherapy in Taiwan.
    Liver international : official journal of the International Association for the Study of the Liver, 2004, Volume: 24, Issue:6

    Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Logistic Models; Male; Middle Aged; Probability; Recombinant Proteins; Ribavirin; Risk Assessment; Salvage Therapy; Severity of Illness Index; Statistics, Nonparametric; Taiwan; Treatment Outcome; Viral Load

2004
High-dose vitamin E supplementation does not diminish ribavirin-associated haemolysis in hepatitis C treatment with combination standard alpha-interferon and ribavirin.
    Alimentary pharmacology & therapeutics, 2004, Nov-15, Volume: 20, Issue:10

    Topics: Adult; Antioxidants; Antiviral Agents; Drug Therapy, Combination; Female; Hemolysis; Hepatitis C, Chronic; Humans; Male; Quality of Life; Ribavirin; Vitamin E

2004
Interleukin-2 plus ribavirin versus interferon-alpha-2b plus ribavirin in patients with chronic hepatitis C who did not respond to previous interferon-alpha-2b treatment.
    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2004, Volume: 18, Issue:6

    Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Interleukin-2; Liver; Liver Function Tests; Male; Patient Compliance; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Failure

2004
Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels.
    Gastroenterology, 2004, Volume: 127, Issue:6

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2004
Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
    JAMA, 2004, Dec-15, Volume: 292, Issue:23

    Topics: Adult; Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Viral Load

2004
Modifications of haematological series in patients co-infected with human immunodeficiency virus and hepatitis C virus during treatment with interferon and ribavirin: differences between pegylated and standard interferon.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2004, Volume: 10, Issue:12

    Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Blood Cell Count; Drug Therapy, Combination; Female; Hematologic Diseases; Hemorrhage; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin

2004
Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy.
    Journal of clinical microbiology, 2005, Volume: 43, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polymerase Chain Reaction; Predictive Value of Tests; Reagent Kits, Diagnostic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Core Proteins; Viral Load

2005
Effect of interferon and ribavirin combined with amantadine in interferon and ribavirin non-responder patients with chronic hepatitis C (genotype 1).
    World journal of gastroenterology, 2005, Jan-28, Volume: 11, Issue:4

    Topics: Adult; Amantadine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome

2005
Short- and long-term effects of therapy with interferon-alpha and pegylated interferon-alpha/ribavirin on platelet plug formation and von Willebrand factor release in patients with chronic hepatitis C.
    Alimentary pharmacology & therapeutics, 2005, Jan-01, Volume: 21, Issue:1

    Topics: Adult; Blood Platelets; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Platelet Adhesiveness; Platelet Aggregation; Platelet Count; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; von Willebrand Factor

2005
Discontinuation of pegylated interferon plus ribavirin in patients who are not responding to therapy -- patients' views of early cessation of therapy.
    Alimentary pharmacology & therapeutics, 2005, Jan-01, Volume: 21, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Attitude to Health; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure

2005
Mitochondrial effects of a 24-week course of pegylated-interferon plus ribavirin in asymptomatic HCV/HIV co-infected patients on long-term treatment with didanosine, stavudine or both.
    Antiviral therapy, 2004, Volume: 9, Issue:6

    Topics: Adult; Anti-HIV Agents; Antiviral Agents; Didanosine; DNA, Mitochondrial; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mitochondria; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin; Stavudine; Time Factors

2004
Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies.
    Antiviral therapy, 2004, Volume: 9, Issue:6

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome

2004
Treatment of histologically mild hepatitis C virus infection with interferon and ribavirin: a multicentre randomized controlled trial.
    Journal of viral hepatitis, 2005, Volume: 12, Issue:1

    Topics: Adult; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Quality of Life; Recombinant Proteins; Ribavirin

2005
Psychopathological symptoms during interferon-alpha and ribavirin treatment: effects on virologic response.
    Molecular psychiatry, 2005, Volume: 10, Issue:4

    Topics: Adult; Antiviral Agents; Anxiety; Depression; Drug Carriers; Drug Therapy, Combination; Fatigue; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index; Substance-Related Disorders; Time Factors; Treatment Outcome

2005
High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2005, Volume: 41, Issue:2

    Topics: Adult; Anemia; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2005
Changes in TNF-alpha mRNA levels in the peripheral blood of patients with chronic hepatitis C virus (HCV) infection during alpha-interferon and ribavirin therapy.
    Viral immunology, 2004, Volume: 17, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; RNA, Messenger; Treatment Outcome; Tumor Necrosis Factor-alpha

2004
Assessment of adverse reactions and pharmacokinetics of ribavirin in combination with interferon alpha-2b in patients with chronic hepatitis C.
    Drug metabolism and pharmacokinetics, 2004, Volume: 19, Issue:6

    Topics: Adult; Aged; Aging; Antiviral Agents; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Platelet Count; Recombinant Proteins; Ribavirin

2004
Pilot study of low-dose interleukin-2, pegylated interferon-alpha 2b, and ribavirin for the treatment of hepatitis C virus infection in patients with HIV infection.
    The Journal of infectious diseases, 2005, Mar-01, Volume: 191, Issue:5

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Middle Aged; Patient Dropouts; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; T-Lymphocyte Subsets

2005
Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon alpha-2b and ribavirin.
    Liver international : official journal of the International Association for the Study of the Liver, 2005, Volume: 25, Issue:1

    Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia

2005
Chronic hepatitis C. Genotypes and response to anti-viral therapy among Saudi patients.
    Saudi medical journal, 2004, Volume: 25, Issue:12

    Topics: Adult; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Saudi Arabia; Treatment Outcome

2004
Peds-C.
    Hepatology (Baltimore, Md.), 2005, Volume: 41, Issue:3

    Topics: Adolescent; Child; Child, Preschool; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2005
Interferon alpha-2a plus ribavirin 1,000/1,200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial.
    Infection, 2005, Volume: 33, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; Substance Abuse, Intravenous

2005
Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4.
    Antiviral therapy, 2005, Volume: 10, Issue:1

    Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon Type I; Male; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome

2005
Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
    The new microbiologica, 2005, Volume: 28, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Outcome and Process Assessment, Health Care; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Outcome; Viremia

2005
Treatment of genotype 1b HCV-related chronic hepatitis: efficacy and toxicity of three different interferon alfa-2b/ribavirin combined regimens in naive patients.
    The new microbiologica, 2005, Volume: 28, Issue:1

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2005
Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study.
    Journal of hepatology, 2005, Volume: 42, Issue:3

    Topics: Adult; Double-Blind Method; Drug Therapy, Combination; Etanercept; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunoglobulin G; Interferon alpha-2; Interferon-alpha; Male; Placebos; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2005
Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2005, Volume: 41, Issue:5

    Topics: Adolescent; Alanine Transaminase; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2005
Effect of interferon alpha2b plus ribavirin treatment on selected growth factors in respect to inflammation and fibrosis in chronic hepatitis C.
    World journal of gastroenterology, 2005, Mar-28, Volume: 11, Issue:12

    Topics: Adult; Antiviral Agents; Biomarkers; Epidermal Growth Factor; Female; Growth Substances; Hepatitis C, Chronic; Hepatocyte Growth Factor; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Platelet-Derived Growth Factor; Prognosis; Recombinant Proteins; Ribavirin

2005
Treatment of chronic hepatitis C in patients unresponsive to interferon. Interest of re-treatment combining interferon induction therapy and ribavirin (a multicenter pilot study).
    Gastroenterologie clinique et biologique, 2005, Volume: 29, Issue:2

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Prospective Studies; Recombinant Proteins; Retreatment; Ribavirin; Treatment Failure

2005
Modifications of T-lymphocyte subsets before and during interferon and ribavirin treatment for chronic hepatitis C infection.
    Viral immunology, 2005, Volume: 18, Issue:1

    Topics: Adult; Antigens, CD; Antiviral Agents; Female; Hepatitis C, Chronic; HLA-DR Antigens; Humans; Interferon Type I; Lymphocyte Count; Male; Middle Aged; Recombinant Proteins; Ribavirin; T-Lymphocytes; Time Factors

2005
Dynamic range of hepatitis C virus RNA quantification with the Cobas Ampliprep-Cobas Amplicor HCV Monitor v2.0 assay.
    Journal of clinical microbiology, 2005, Volume: 43, Issue:4

    Topics: Antiviral Agents; Automation; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Nucleic Acid Amplification Techniques; Reagent Kits, Diagnostic; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load

2005
Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study.
    Journal of hepatology, 2005, Volume: 42, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Compliance; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Vasculitis

2005
Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety.
    Digestive diseases and sciences, 2005, Volume: 50, Issue:4

    Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mycophenolic Acid; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; Treatment Outcome; Viral Load

2005
Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C.
    Digestive diseases and sciences, 2005, Volume: 50, Issue:4

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2005
Immunomodulatory effects of selective leucocytapheresis as a new adjunct to interferon-alpha2b plus ribavirin combination therapy: a prospective study in patients with high plasma HCV viraemia.
    Journal of viral hepatitis, 2005, Volume: 12, Issue:3

    Topics: Adjuvants, Immunologic; Biopsy, Needle; Combined Modality Therapy; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Interleukin-8; Leukapheresis; Male; Probability; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Assessment; RNA, Viral; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome; Tumor Necrosis Factor-alpha; Viral Load

2005
Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.
    Journal of viral hepatitis, 2005, Volume: 12, Issue:3

    Topics: Adolescent; Adult; Aged; Biopsy, Needle; Chi-Square Distribution; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Probability; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Single-Blind Method; Taiwan; Time Factors; Treatment Outcome

2005
A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
    Journal of viral hepatitis, 2005, Volume: 12, Issue:3

    Topics: Adolescent; Adult; Aged; Amantadine; Biopsy, Needle; Chi-Square Distribution; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Probability; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Single-Blind Method; Statistics, Nonparametric; Treatment Outcome; Viral Load

2005
Area-under-the-curve for peginterferon alpha-2a and peginterferon alpha-2b is not related to body weight in treatment-naive patients with chronic hepatitis C.
    Antiviral therapy, 2005, Volume: 10, Issue:2

    Topics: Antiviral Agents; Body Weight; Drug Carriers; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2005
Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
    Antiviral therapy, 2005, Volume: 10, Issue:2

    Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2005
Interferon-stimulated gene expression in black and white hepatitis C patients during peginterferon alfa-2a combination therapy.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2005, Volume: 3, Issue:5

    Topics: 2',5'-Oligoadenylate Synthetase; Adenosine Deaminase; Adult; Antiviral Agents; Black People; Drug Therapy, Combination; eIF-2 Kinase; Female; Gene Expression; Genotype; GTP-Binding Proteins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Myxovirus Resistance Proteins; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; White People

2005
Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C.
    Journal of hepatology, 2005, Volume: 42, Issue:6

    Topics: Adult; Antidepressive Agents, Second-Generation; Antiviral Agents; Citalopram; Depressive Disorder, Major; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Dropouts; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors

2005
Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response.
    Gut, 2005, Volume: 54, Issue:6

    Topics: Adult; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2005
The effect of zinc supplementation on the treatment of chronic hepatitis C patients with interferon and ribavirin.
    Clinical biochemistry, 2005, Volume: 38, Issue:7

    Topics: Adult; Drug Therapy, Combination; Female; Gluconates; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Zinc

2005
Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C.
    Digestive diseases and sciences, 2005, Volume: 50, Issue:5

    Topics: Adult; Amantadine; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Health Status; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Treatment Outcome; Viremia

2005
Helper T cell cytokine response to ribavirin priming before combined treatment with interferon alpha and ribavirin for patients with chronic hepatitis C.
    Antiviral research, 2005, Volume: 67, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Cytokines; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; T-Lymphocyte Subsets; T-Lymphocytes, Helper-Inducer; Treatment Outcome

2005
Prediction of treatment outcome in chronic hepatitis C patients based on early viral dynamics during high-dose induction interferon and ribavirin therapy.
    Intervirology, 2005, Volume: 48, Issue:4

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2005
Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.
    The New England journal of medicine, 2005, Jun-23, Volume: 352, Issue:25

    Topics: Adult; Analysis of Variance; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral

2005
Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis.
    Journal of viral hepatitis, 2005, Volume: 12, Issue:4

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2005
Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis.
    Journal of viral hepatitis, 2005, Volume: 12, Issue:4

    Topics: Adult; Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Follow-Up Studies; France; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2005
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.
    Journal of hepatology, 2005, Volume: 43, Issue:3

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis B virus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Probability; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2005
Effectiveness and tolerability of pegylated Interferon alpha-2a and ribavirin combination therapy in Romanian patients with chronic hepatitis C: from clinical trials to clinical practice.
    Romanian journal of gastroenterology, 2005, Volume: 14, Issue:2

    Topics: Alanine Transaminase; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Romania; Treatment Outcome

2005
Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C.
    Gut, 2006, Volume: 55, Issue:9

    Topics: Adult; Aged; Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Costs; Drug Therapy, Combination; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Models, Econometric; Polyethylene Glycols; Quality of Life; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Severity of Illness Index; United Kingdom

2006
Herbal medicine Ninjinyoeito ameliorates ribavirin-induced anemia in chronic hepatitis C: a randomized controlled trial.
    World journal of gastroenterology, 2005, Jul-14, Volume: 11, Issue:26

    Topics: Anemia; Antiviral Agents; Erythropoietin; Female; Hepatitis C, Chronic; Herbal Medicine; Humans; Liver Function Tests; Male; Middle Aged; Plant Extracts; Ribavirin; Th1 Cells; Th2 Cells; Viral Load

2005
Successful treatment of hepatitis C reinfection with interferon-alpha2b and ribavirin after liver transplantation.
    Liver international : official journal of the International Association for the Study of the Liver, 2005, Volume: 25, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Survival Rate; Time; Transaminases

2005
Non-interferon-based therapy: an option for amelioration of necro-inflammation in hepatitis C patients who cannot afford interferon therapy.
    Liver international : official journal of the International Association for the Study of the Liver, 2005, Volume: 25, Issue:4

    Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Male; Middle Aged; Necrosis; Protective Agents; Ribavirin; RNA, Viral; Silymarin; Treatment Outcome; Ursodeoxycholic Acid

2005
Co-infection of SENV-D among chronic hepatitis C patients treated with combination therapy with high-dose interferon-alfa and ribavirin.
    World journal of gastroenterology, 2005, Jul-21, Volume: 11, Issue:27

    Topics: Adult; Aged; Antiviral Agents; Circoviridae Infections; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin

2005
[An open-label pilot study evaluating the efficacy and safety of peginterferon alfa-2a combined with ribavirin in children with chronic hepatitis C].
    Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology, 2005, Volume: 19, Issue:2

    Topics: Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis B virus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2005
Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection.
    Journal of medical virology, 2005, Volume: 77, Issue:1

    Topics: Adult; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2005
Interferon beta-1a alone or in combination with ribavirin: a randomized trial to compare efficacy and safety in chronic hepatitis C.
    World journal of gastroenterology, 2005, Aug-07, Volume: 11, Issue:29

    Topics: Adjuvants, Immunologic; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon beta-1a; Interferon-beta; Male; Middle Aged; Ribavirin; Treatment Outcome

2005
Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C.
    Journal of hepatology, 2005, Volume: 43, Issue:2

    Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2005
International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C.
    Journal of hepatology, 2005, Volume: 43, Issue:2

    Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; International Cooperation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Safety; Treatment Outcome; Viral Load

2005
Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.
    Gastroenterology, 2005, Volume: 129, Issue:2

    Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Probability; Recombinant Proteins; Reference Values; Ribavirin; Risk Assessment; RNA, Viral; Severity of Illness Index; Treatment Outcome; Viral Load

2005
Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin.
    European journal of gastroenterology & hepatology, 2005, Volume: 17, Issue:9

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Research Design; Ribavirin; RNA, Viral; Sample Size; Treatment Failure; Treatment Outcome

2005
Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection.
    British journal of haematology, 2005, Volume: 130, Issue:4

    Topics: Adolescent; Adult; Antiviral Agents; beta-Thalassemia; Blood Transfusion; Child; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lebanon; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load

2005
Clinical role of serum and tissue matrix metalloprotease-9 expression in chronic HCV patients treated with pegylated IFN-alpha2b and ribavirin.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2005, Volume: 25, Issue:8

    Topics: Adult; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Matrix Metalloproteinase 9; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2005
Higher doses of peginterferon alpha-2b administered twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C: results of a pilot randomized study.
    Journal of viral hepatitis, 2005, Volume: 12, Issue:5

    Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2005
Leucocytapheresis with Adacolumn enhances HCV-specific proliferative responses in patients infected with hepatitis C virus genotype 1.
    Journal of medical virology, 2005, Volume: 77, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Cell Proliferation; Combined Modality Therapy; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukapheresis; Leukocytes, Mononuclear; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load

2005
High-dose interferon-alpha2b induction therapy in combination with ribavirin for treatment of chronic hepatitis C in patients with non-response or relapse after interferon-alpha monotherapy.
    World journal of gastroenterology, 2005, Sep-14, Volume: 11, Issue:34

    Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome

2005
Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C.
    Gut, 2006, Volume: 55, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Biomarkers; Chemokine CXCL10; Chemokines, CXC; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2006
Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C.
    Antiviral therapy, 2005, Volume: 10, Issue:5

    Topics: Administration, Oral; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; RNA, Viral; Spain; Treatment Outcome

2005
Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus.
    Journal of gastroenterology and hepatology, 2005, Volume: 20, Issue:10

    Topics: Aged; Alanine Transaminase; Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Recombinant Proteins; Ribavirin; RNA, Viral; Secondary Prevention; Survival Analysis; Treatment Outcome

2005
Multiplex cytokine profiling of initial therapeutic response in patients with chronic hepatitis C virus infection.
    Digestive diseases and sciences, 2005, Volume: 50, Issue:10

    Topics: Adult; Antiviral Agents; Cluster Analysis; Cytokines; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome

2005
The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies.
    Antiviral therapy, 2005, Volume: 10, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Autoantibodies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Treatment Outcome

2005
Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics.
    Hepatology (Baltimore, Md.), 2005, Volume: 42, Issue:5

    Topics: Adolescent; Antiviral Agents; Body Height; Body Weight; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2005
Can Peg-IFN alpha-2a plus ribavirin be used to treat patients with chronic hepatitis C and normal alanine aminotransferase levels?
    Nature clinical practice. Gastroenterology & hepatology, 2005, Volume: 2, Issue:3

    Topics: Adolescent; Alanine Transaminase; Antiviral Agents; Biomarkers; Drug Carriers; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome

2005
Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients.
    The Journal of infection, 2006, Volume: 53, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2006
Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
    The American journal of gastroenterology, 2005, Volume: 100, Issue:11

    Topics: Adult; Amantadine; Antiviral Agents; Drug Carriers; Drug Combinations; Drug Costs; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome

2005
A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C.
    The American journal of gastroenterology, 2005, Volume: 100, Issue:11

    Topics: Antiviral Agents; Black or African American; Drug Carriers; Drug Combinations; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; White People

2005
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.
    Journal of hepatology, 2006, Volume: 44, Issue:1

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viremia

2006
Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
    Journal of hepatology, 2006, Volume: 44, Issue:2

    Topics: Adult; Amantadine; Antiviral Agents; Disease Progression; Double-Blind Method; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2006
Interferon-beta plus ribavirin for patients with hepatitis C virus genotype 1: a randomised pilot trial.
    Gut, 2006, Volume: 55, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-beta; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Ribavirin; Treatment Outcome

2006
Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study.
    Journal of hepatology, 2006, Volume: 44, Issue:2

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Pilot Projects; Ribavirin; RNA, Viral; Treatment Outcome

2006
Assessment of early virological response to antiviral therapy by comparing four assays for HCV RNA quantitation using the international unit standard: implications for clinical management of patients with chronic hepatitis C virus infection.
    Journal of medical virology, 2006, Volume: 78, Issue:2

    Topics: Administration, Oral; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Polymerase Chain Reaction; Reagent Kits, Diagnostic; Recombinant Proteins; Reference Standards; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2006
Pegylated interferon and ribavirin for the recurrence of chronic hepatitis C genotype 1 in transplant patients.
    Transplantation proceedings, 2005, Volume: 37, Issue:9

    Topics: Adult; Antiviral Agents; Biopsy; Female; Hepatitis B; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome

2005
Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes.
    European journal of gastroenterology & hepatology, 2006, Volume: 18, Issue:2

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Compliance; Recombinant Proteins; Retrospective Studies; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome; Viral Load

2006
A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan.
    Liver international : official journal of the International Association for the Study of the Liver, 2006, Volume: 26, Issue:1

    Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Maximum Tolerated Dose; Middle Aged; Pilot Projects; Polyethylene Glycols; Probability; Recombinant Proteins; Reference Values; Ribavirin; Risk Assessment; ROC Curve; Severity of Illness Index; Single-Blind Method; Taiwan; Treatment Outcome

2006
[Pegylated interferon-alfa 2a with ribavirin in chronic viral hepatitis C (final report)].
    Przeglad epidemiologiczny, 2005, Volume: 59, Issue:3

    Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Carriers; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2005
Correlation between translation efficiency and outcome of combination therapy in chronic hepatitis C genotype 3.
    Journal of viral hepatitis, 2006, Volume: 13, Issue:2

    Topics: Adult; Animals; Antiviral Agents; Base Sequence; Cell Line; Down-Regulation; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Molecular Sequence Data; Nucleic Acid Conformation; Protein Biosynthesis; Ribavirin; RNA, Viral; Species Specificity; Treatment Outcome; Viral Proteins

2006
Pilot study of interferon-alpha-ribavirin-interleukin-2 for treatment of nonresponder patients with severe liver disease infected by hepatitis C virus genotype 1.
    Journal of viral hepatitis, 2006, Volume: 13, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; France; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Ribavirin; Species Specificity; Treatment Outcome; Viral Load

2006
Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection.
    AIDS (London, England), 2006, Feb-14, Volume: 20, Issue:3

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Disease-Free Survival; Hepatitis C, Chronic; HIV Infections; Humans; Immunity, Cellular; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2006
Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C.
    Liver international : official journal of the International Association for the Study of the Liver, 2006, Volume: 26, Issue:2

    Topics: Adult; Antiviral Agents; China; Drug Therapy, Combination; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Insulin; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Ultrasonography

2006
Vitamin E and C supplementation prevents decrease of eicosapentaenoic acid in mononuclear cells in chronic hepatitis C patients during combination therapy of interferon alpha-2b and ribavirin.
    Nutrition (Burbank, Los Angeles County, Calif.), 2006, Volume: 22, Issue:2

    Topics: Alanine Transaminase; Antiviral Agents; Ascorbic Acid; Dietary Supplements; Drug Synergism; Drug Therapy, Combination; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Vitamin E; Vitamins

2006
Effect of combination therapy with ribavirin and high-dose interferon-alpha2b for 24 weeks in chronic hepatitis C.
    Journal of gastroenterology and hepatology, 2006, Volume: 21, Issue:1 Pt 2

    Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin

2006
Hepatitis C virus free-virion and immune-complex dynamics during interferon therapy with and without ribavirin in genotype-1b chronic hepatitis C patients.
    Journal of viral hepatitis, 2006, Volume: 13, Issue:3

    Topics: Adult; Aged; Antigen-Antibody Complex; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunoprecipitation; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral

2006
Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C.
    Journal of hepatology, 2006, Volume: 44, Issue:4

    Topics: Alanine Transaminase; Antiviral Agents; Blood Glucose; Blood Pressure; Body Mass Index; Disease Progression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Linear Models; Male; Metabolic Syndrome; Metabolism; Polyethylene Glycols; Recombinant Proteins; Reference Values; Ribavirin; RNA, Viral; Sex Factors; Triglycerides

2006
Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life.
    Journal of gastroenterology and hepatology, 2006, Volume: 21, Issue:2

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Quality of Life; Recombinant Proteins; Ribavirin; Surveys and Questionnaires; Treatment Outcome

2006
Pegylated interferon alfa-2b (peg-intron) plus ribavirin (rebetol) in the treatment of chronic hepatitis C: a local experience.
    The Medical journal of Malaysia, 2005, Volume: 60, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Malaysia; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2005
Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2: a project of the Kyushu University Liver Disease Study Group.
    World journal of gastroenterology, 2006, Feb-07, Volume: 12, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral

2006
Effects of eicosapentaenoic acid supplementation in the treatment of chronic hepatitis C patients.
    Journal of nutritional science and vitaminology, 2005, Volume: 51, Issue:6

    Topics: 8-Hydroxy-2'-Deoxyguanosine; Alanine Transaminase; Deoxyguanosine; Dietary Supplements; Eicosapentaenoic Acid; Erythrocyte Membrane; Erythrocytes; Fatty Acids; Fatty Acids, Unsaturated; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lymphocyte Count; Male; Middle Aged; Phospholipids; Recombinant Proteins; Ribavirin

2005
Triple therapy of interferon and ribavirin with zinc supplementation for patients with chronic hepatitis C: a randomized controlled clinical trial.
    World journal of gastroenterology, 2006, Feb-28, Volume: 12, Issue:8

    Topics: Adult; Aged; Anti-Ulcer Agents; Antiviral Agents; Body Weight; Carnosine; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Organometallic Compounds; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Zinc; Zinc Compounds

2006
Pharmacokinetics, pharmacodynamics, and hepatitis C viral kinetics during antiviral therapy: the null responder.
    Journal of medical virology, 2006, Volume: 78, Issue:4

    Topics: 2',5'-Oligoadenylate Synthetase; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2006
Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy.
    Liver international : official journal of the International Association for the Study of the Liver, 2006, Volume: 26, Issue:3

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Male; Middle Aged; Prospective Studies; Research Design; Ribavirin; Time Factors; Treatment Outcome; Viral Load

2006
[Efficacy of combination therapy with interferon-alpha and ribavirin for chronic hepatitis C in relation to liver fibrosis and serum aminotransferase activity].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 2005, Volume: 58, Issue:11-12

    Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin

2005
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.
    Gastroenterology, 2006, Volume: 130, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viremia

2006
Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients.
    Gastroenterology, 2006, Volume: 130, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; gamma-Glutamyltransferase; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Time Factors; Treatment Failure; Treatment Outcome; Viral Load

2006
Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients.
    Journal of viral hepatitis, 2006, Volume: 13, Issue:5

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Retrospective Studies; Ribavirin; RNA, Viral

2006
Improvement in quality of life measures in patients with refractory hepatitis C, responding to re-treatment with Pegylated interferon alpha -2b and ribavirin.
    Health and quality of life outcomes, 2006, May-12, Volume: 4

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Sickness Impact Profile; Treatment Outcome

2006
Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy.
    Gut, 2006, Volume: 55, Issue:11

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Dropouts; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome

2006
High dose daily interferon-alpha induction and secondary adjunction of ribavirin in treatment-naive patients with chronic hepatitis C. A multicentric, randomised, controlled trial.
    Gastroenterologie clinique et biologique, 2006, Volume: 30, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2006
Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation.
    Health technology assessment (Winchester, England), 2006, Volume: 10, Issue:21

    Topics: Adult; Analysis of Variance; Antiviral Agents; Cost of Illness; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Quality of Life; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Surveys and Questionnaires; Treatment Outcome; United Kingdom; Viral Load

2006
[Early virologic response in retherapy with pegylated interferon alpha-2B plus ribavirin in children with chronic hepatitis C].
    Przeglad epidemiologiczny, 2006, Volume: 60, Issue:1

    Topics: Adolescent; Antiviral Agents; Child; Drug Administration Schedule; Drug Carriers; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2006
A study of low dose peginterferon alpha-2b with ribavirin for the initial treatment of chronic hepatitis C.
    The American journal of gastroenterology, 2006, Volume: 101, Issue:6

    Topics: Adult; Antiviral Agents; Chi-Square Distribution; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; New England; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2006
Risk factors for retinopathy associated with interferon alpha-2b and ribavirin combination therapy in patients with chronic hepatitis C.
    World journal of gastroenterology, 2006, Jun-21, Volume: 12, Issue:23

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Fundus Oculi; Hepatitis C, Chronic; Humans; Hypertension; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prevalence; Prospective Studies; Recombinant Proteins; Regression Analysis; Retinal Diseases; Retinal Hemorrhage; Ribavirin; Risk Factors; Time Factors

2006
Long-term follow-up of previous hepatitis C virus positive nonresponders to interferon monotherapy successfully retreated with combination therapy: are they really cured?
    The American journal of gastroenterology, 2006, Volume: 101, Issue:8

    Topics: Adult; Antiviral Agents; Chi-Square Distribution; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2006
A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).
    Journal of hepatology, 2006, Volume: 45, Issue:2

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2006
[Sustained virological response in children with chronic hepatitis C treated with interferon alpha and ribavirin].
    Przeglad lekarski, 2005, Volume: 62, Issue:12

    Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Ribavirin; RNA, Viral; Treatment Outcome

2005
Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin.
    Journal of viral hepatitis, 2006, Volume: 13, Issue:7

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin

2006
Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin.
    Journal of viral hepatitis, 2006, Volume: 13, Issue:7

    Topics: Adult; Aged; Antiviral Agents; Bezafibrate; Cholesterol, LDL; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hyperlipidemias; Hypolipidemic Agents; Interferons; Male; Middle Aged; Pilot Projects; Prospective Studies; Ribavirin; RNA, Viral; Viremia

2006
Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis.
    Journal of viral hepatitis, 2006, Volume: 13, Issue:7

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2006
Comparative study concerning the efficacy of Peg-IFN alpha-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in patients with chronic viral C hepatitis.
    Journal of gastrointestinal and liver diseases : JGLD, 2006, Volume: 15, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Matched-Pair Analysis; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Viral Load

2006
The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2006, Volume: 17, Issue:2

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2006
Peginterferon alfa-2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response.
    Journal of viral hepatitis, 2006, Volume: 13, Issue:6

    Topics: Antiviral Agents; Black or African American; Black People; Blood Cell Count; Drug Therapy, Combination; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2006
The economics of treating chronic hepatitis C patients with peginterferon alpha-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase.
    Journal of viral hepatitis, 2006, Volume: 13, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Markov Chains; Middle Aged; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin

2006
Impact of steatosis on long-term histological outcome in chronic hepatitis C after antiviral therapy.
    Antiviral therapy, 2006, Volume: 11, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Biopsy; Disease Progression; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral

2006
Vascular ophthalmological side effects associated with antiviral therapy for chronic hepatitis C are related to vascular endothelial growth factor levels.
    Antiviral therapy, 2006, Volume: 11, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Eye Diseases; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retinal Diseases; Retinal Neovascularization; Ribavirin; Vascular Endothelial Growth Factor A

2006
Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin.
    Transplantation, 2006, Jul-15, Volume: 82, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Graft Rejection; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome

2006
Immunogenicity of recombinant hepatitis B vaccine in treatment-naive and treatment-experienced chronic hepatitis C patients: the effect of pegylated interferon plus ribavirin treatment.
    World journal of gastroenterology, 2006, Jul-21, Volume: 12, Issue:27

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genes, MHC Class II; Hepacivirus; Hepatitis B Antibodies; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Immunization Schedule; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Retrospective Studies; Ribavirin; Vaccines, Synthetic

2006
HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial.
    Hepatology (Baltimore, Md.), 2006, Volume: 44, Issue:2

    Topics: Antiviral Agents; Biopsy; Drug Carriers; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Polymerase Chain Reaction; Predictive Value of Tests; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors

2006
Alpha-tocopherol [corrected] and ascorbic acid attenuates the ribavirin [corrected] induced decrease of eicosapentaenoic acid in erythrocyte membrane in chronic hepatitis C patients.
    Journal of gastroenterology and hepatology, 2006, Volume: 21, Issue:8

    Topics: alpha-Tocopherol; Ascorbic Acid; Drug Therapy, Combination; Eicosapentaenoic Acid; Erythrocyte Membrane; Female; Hepatitis C, Chronic; Humans; Liver Function Tests; Male; Middle Aged; Ribavirin; Treatment Outcome

2006
The results of a randomized trial looking at 24 weeks vs 48 weeks of treatment with peginterferon alpha-2a (40 kDa) and ribavirin combination therapy in patients with chronic hepatitis C genotype 1.
    Journal of viral hepatitis, 2006, Volume: 13, Issue:8

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral

2006
Prolonged negative HCV-RNA status led to a good outcome in chronic hepatitis C patients with genotype 1b and super-high viral load.
    Intervirology, 2006, Volume: 49, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-beta; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2006
Response to combination therapy of interferon alfa-2b plus ribavirin in Hispanics with chronic hepatitis C.
    Puerto Rico health sciences journal, 2004, Volume: 23, Issue:2 Suppl

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin

2004
A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C.
    Gut, 2007, Volume: 56, Issue:4

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome

2007
Cannabis use improves retention and virological outcomes in patients treated for hepatitis C.
    European journal of gastroenterology & hepatology, 2006, Volume: 18, Issue:10

    Topics: Adolescent; Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Marijuana Smoking; Middle Aged; Patient Compliance; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Substance-Related Disorders; Treatment Outcome; Viral Load

2006
Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection.
    The Journal of infectious diseases, 2006, Oct-01, Volume: 194, Issue:7

    Topics: Adult; Antiviral Agents; Chemokine CXCL10; Chemokines, CXC; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2006
Peripheral neurotoxicity of pegylated interferon alpha: a prospective study in patients with HCV.
    Neurology, 2006, Sep-12, Volume: 67, Issue:5

    Topics: Adolescent; Adult; Aged; Antibodies; Antiviral Agents; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Gangliosides; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neural Conduction; Neurologic Examination; Peripheral Nervous System Diseases; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Statistics, Nonparametric; Sulfoglycosphingolipids; Time Factors

2006
Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons.
    Journal of viral hepatitis, 2006, Volume: 13, Issue:10

    Topics: Adult; Anemia; Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Zidovudine

2006
Ifn/Rbv treatment induced anemia and its correction with epoetin alpha in patients with hepatitis C.
    Georgian medical news, 2006, Issue:137

    Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome

2006
A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin.
    Alimentary pharmacology & therapeutics, 2006, Oct-01, Volume: 24, Issue:7

    Topics: Adult; Amantadine; Antiviral Agents; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2006
Peripheral insulin resistance during treatment of chronic hepatitis C with peguilated interferon plus ribavirin.
    Journal of medical virology, 2006, Volume: 78, Issue:11

    Topics: Adult; Female; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2006
Sustained viral response to pegylated interferon alpha-2b and ribavirin in chronic hepatitis C refractory to prior treatment.
    Digestive diseases and sciences, 2006, Volume: 51, Issue:11

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure

2006
Efficacy of low dose peginterferon alpha-2b with ribavirin on chronic hepatitis C.
    World journal of gastroenterology, 2006, Sep-14, Volume: 12, Issue:34

    Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2006
Hepatitis C virus survival curve analysis in naïve patients treated with peginterferon alpha-2b plus ribavirin. A randomized controlled trial for induction with high doses of peginterferon and predictability of sustained viral response from early virologi
    Journal of gastrointestinal and liver diseases : JGLD, 2006, Volume: 15, Issue:3

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Survival Analysis

2006
High efficacy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C.
    Haematologica, 2006, Volume: 91, Issue:10

    Topics: Adult; Drug Therapy, Combination; Female; Hemophilia A; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin

2006
Role of erythrocytes as a reservoir for ribavirin and relationship with adverse reactions in the early phase of interferon combination therapy for chronic hepatitis C virus infections.
    Journal of clinical microbiology, 2006, Volume: 44, Issue:10

    Topics: Adult; Aged; Dose-Response Relationship, Drug; Erythrocytes; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin

2006
Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
    Gastroenterology, 2006, Volume: 131, Issue:4

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Fatigue; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2006
Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis.
    The American journal of gastroenterology, 2006, Volume: 101, Issue:10

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatic Veins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Portal Pressure; Prospective Studies; Recombinant Proteins; Ribavirin

2006
Erythropoietin treatment is associated with more severe thrombocytopenia in patients with chronic hepatitis C undergoing antiviral therapy.
    The American journal of gastroenterology, 2006, Volume: 101, Issue:10

    Topics: Adult; Antiviral Agents; Blood Cell Count; Double-Blind Method; Drug Therapy, Combination; Erythropoietin; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; P-Selectin; Polyethylene Glycols; Receptor, PAR-1; Recombinant Proteins; Ribavirin; Thrombocytopenia

2006
A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy.
    Hepatology (Baltimore, Md.), 2006, Volume: 44, Issue:5

    Topics: Antiviral Agents; Aspartate Aminotransferases; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Prognosis; Ribavirin; RNA, Viral; ROC Curve; Survival Rate; Treatment Outcome

2006
Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2007, Volume: 38, Issue:1

    Topics: Acute Disease; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Interferons; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2007
Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study.
    Arthritis and rheumatism, 2006, Volume: 54, Issue:11

    Topics: Aged; Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Remission Induction; Ribavirin; Treatment Outcome; Vasculitis

2006
Pegylated interferon and ribavirin in re-treatment of responder-relapser HCV patients.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2007, Volume: 39, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; RNA, Viral; Sensitivity and Specificity; Time Factors; Treatment Outcome; White People

2007
Histological response to pegIFNalpha-2a (40KD) plus ribavirin in HIV-hepatitis C virus co-infection.
    AIDS (London, England), 2006, Nov-14, Volume: 20, Issue:17

    Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Antiviral Agents; Biopsy; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2006
Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial.
    World journal of gastroenterology, 2006, Nov-14, Volume: 12, Issue:42

    Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Viral Load

2006
Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b.
    Journal of viral hepatitis, 2006, Volume: 13, Issue:12

    Topics: Adult; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2006
Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection: a randomised controlled study.
    Internal and emergency medicine, 2006, Volume: 1, Issue:2

    Topics: Adult; Antiviral Agents; Chi-Square Distribution; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2006
Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study.
    Journal of hepatology, 2007, Volume: 46, Issue:2

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Survival Analysis; Treatment Outcome

2007
IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection.
    Hepatology (Baltimore, Md.), 2006, Volume: 44, Issue:6

    Topics: Adult; Body Mass Index; Chemokine CXCL10; Chemokines, CXC; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Sensitivity and Specificity; Treatment Outcome

2006
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial.
    Hepatology (Baltimore, Md.), 2006, Volume: 44, Issue:6

    Topics: Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome

2006
Gender-dependent association of CTLA4 polymorphisms with resolution of hepatitis C virus infection.
    Journal of hepatology, 2007, Volume: 46, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, Differentiation; Antiviral Agents; CTLA-4 Antigen; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Sex Characteristics; T-Lymphocytes; Treatment Outcome

2007
Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.
    Intervirology, 2007, Volume: 50, Issue:1

    Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cause of Death; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Interferon-beta; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Ribavirin; Survival Analysis; Time Factors; Treatment Outcome

2007
Hepatitis C Virus p7 membrane protein quasispecies variability in chronically infected patients treated with interferon and ribavirin, with or without amantadine.
    Journal of medical virology, 2007, Volume: 79, Issue:2

    Topics: Adult; Aged; Amantadine; Amino Acid Sequence; Antiviral Agents; Drug Therapy, Combination; Female; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Treatment Outcome; Viral Proteins

2007
Expression profiling of peripheral-blood mononuclear cells from patients with chronic hepatitis C undergoing interferon therapy.
    The Journal of infectious diseases, 2007, Jan-15, Volume: 195, Issue:2

    Topics: Adult; Aged; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antiviral Agents; Down-Regulation; Drug Therapy, Combination; Female; Gene Expression Profiling; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lectins, C-Type; Leukocytes, Mononuclear; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Proteins; Receptors, Interleukin-7; Recombinant Proteins; Ribavirin; Treatment Outcome; Up-Regulation

2007
Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis.
    Journal of hepatology, 2007, Volume: 46, Issue:3

    Topics: Adult; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Health Status; Health Surveys; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Quality of Life; Recombinant Proteins; Ribavirin; Sexual Behavior; Sexual Dysfunctions, Psychological; Treatment Outcome

2007
Impaired filterability of erythrocytes from patients with chronic hepatitis C and effects of eicosapentaenoic acid on the filterability.
    The journal of physiological sciences : JPS, 2007, Volume: 57, Issue:1

    Topics: Adult; Aged; Anemia, Hemolytic; Antioxidants; Antiviral Agents; Drug Therapy, Combination; Eicosapentaenoic Acid; Erythrocyte Deformability; Erythrocyte Membrane; Erythrocytes; Hemorheology; Hepatitis C, Chronic; Humans; Interferon Type I; Japan; Middle Aged; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome

2007
Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection.
    Journal of viral hepatitis, 2007, Volume: 14, Issue:1

    Topics: Adult; Antiviral Agents; Biopsy; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Kinetics; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2007
Anti-Helicobacter pylori seropositivity: influence on severity and treatment response in patients with chronic hepatitis C.
    Journal of viral hepatitis, 2007, Volume: 14, Issue:1

    Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Platelet Count; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2007
Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans.
    Digestive diseases and sciences, 2007, Volume: 52, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Body Mass Index; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hospitals, Veterans; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Obesity; Prevalence; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Treatment Outcome; United States

2007
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.
    Gastroenterology, 2007, Volume: 132, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Time Factors

2007
Induction doses of interferon-alpha-2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non-responders to interferon monotherapy: a randomized trial.
    Journal of viral hepatitis, 2007, Volume: 14, Issue:2

    Topics: Adult; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin

2007
[Study of the efficacy of combined therapy with interferon alfacon-1 and ribavirin for chronic hepatitis C].
    Przeglad epidemiologiczny, 2006, Volume: 60, Issue:3

    Topics: Adult; Aged; Anemia; Depression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon Type I; Interferon-alpha; Leukocyte Count; Male; Middle Aged; Platelet Count; Recombinant Proteins; Ribavirin; Thyroiditis; Treatment Outcome; Viral Load

2006
Induction versus noninduction antiviral therapy for chronic hepatitis C virus in patients with congenital coagulation disorders: a Canadian multicentre trial.
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2007, Volume: 21, Issue:2

    Topics: Adult; Antiviral Agents; Blood Coagulation Disorders; Canada; Comorbidity; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral

2007
Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients.
    AIDS (London, England), 2007, Feb-19, Volume: 21, Issue:4

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2007
Virological profiles in hepatitis B virus/hepatitis C virus coinfected patients under interferon plus ribavirin therapy.
    Antiviral therapy, 2006, Volume: 11, Issue:7

    Topics: Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load; Virus Activation

2006
Outcome of chronic hepatitis C patients who required early termination of pegylated interferon-alpha plus ribavirin combination therapy.
    Antiviral therapy, 2006, Volume: 11, Issue:8

    Topics: Adult; Aged; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2006
Viusid, a nutritional supplement, in combination with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
    Liver international : official journal of the International Association for the Study of the Liver, 2007, Volume: 27, Issue:2

    Topics: Adult; Alanine Transaminase; Anemia; Antiviral Agents; Dietary Supplements; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome

2007
Subthreshold mania as predictor of depression during interferon treatment in HCV+ patients without current or lifetime psychiatric disorders.
    Journal of psychosomatic research, 2007, Volume: 62, Issue:3

    Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Bipolar Disorder; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Ribavirin; Risk Factors; Statistics as Topic

2007
Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin.
    Scandinavian journal of gastroenterology, 2007, Volume: 42, Issue:2

    Topics: Adolescent; Adult; Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2007
Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients.
    Journal of viral hepatitis, 2007, Volume: 14, Issue:4

    Topics: Adolescent; Adult; Antiviral Agents; Cell Nucleus; DNA; DNA, Mitochondrial; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin

2007
The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant.
    Journal of hepatology, 2007, Volume: 46, Issue:5

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Preoperative Care; Recombinant Proteins; Renal Dialysis; Ribavirin; RNA, Viral; Treatment Outcome

2007
Involvement of dendritic cell frequency and function in virological relapse in pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C patients.
    Journal of medical virology, 2007, Volume: 79, Issue:5

    Topics: Antiviral Agents; CD4-Positive T-Lymphocytes; Cell Count; Dendritic Cells; Drug Carriers; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lymphocyte Activation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2007
CD4+ T cell responses in patients with chronic hepatitis C undergoing peginterferon/ribavirin therapy correlate with faster, but not sustained, viral clearance.
    The Journal of infectious diseases, 2007, May-01, Volume: 195, Issue:9

    Topics: Adult; Antigens, Viral; Antiviral Agents; CD4-Positive T-Lymphocytes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2007
Treatment of chronic he1patitis C genotype 1 with peginterferon-alpha2a (40 kDa) plus ribavirin under routine clinical practice in Spain: early prediction of sustained virological response rate.
    Alimentary pharmacology & therapeutics, 2007, Apr-15, Volume: 25, Issue:8

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2007
Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin.
    Digestive diseases and sciences, 2007, Volume: 52, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Depression; Drug Therapy, Combination; Fatigue; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Viral Load

2007
[A 72 week follow-up study of chronic hepatitis C patients treated with peginterferon alfa-2b and ribavirin].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2007, Volume: 15, Issue:3

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Young Adult

2007
Combination therapy with ribavirin and amantadine in renal transplant patients with chronic hepatitis C virus infection is not superior to ribavirin alone.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2007, Volume: 39, Issue:1

    Topics: Adult; Amantadine; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Transplantation; Male; Middle Aged; Pilot Projects; Prospective Studies; Ribavirin

2007
Hepatitis C hypervariable region 1: association of reduced selection pressure in african americans with treatment failure.
    Digestive diseases and sciences, 2007, Volume: 52, Issue:10

    Topics: Adult; Antiviral Agents; Black or African American; Drug Carriers; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Selection, Genetic; Tennessee; Treatment Failure; Viral Proteins

2007
Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin.
    Journal of hepatology, 2007, Volume: 47, Issue:1

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2007
Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, May-15, Volume: 44, Issue:10

    Topics: Adult; Antiviral Agents; Hematologic Diseases; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Maximum Tolerated Dose; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2007
Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
    Journal of gastroenterology and hepatology, 2007, Volume: 22, Issue:5

    Topics: Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2007
Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C.
    Alimentary pharmacology & therapeutics, 2007, May-15, Volume: 25, Issue:10

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Depressive Disorder, Major; Double-Blind Method; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Paroxetine; Ribavirin

2007
Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2007, Volume: 45, Issue:5

    Topics: Adult; Affect; Antiviral Agents; Cognition; Cognition Disorders; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2007
Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients.
    Journal of acquired immune deficiency syndromes (1999), 2007, Aug-01, Volume: 45, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome

2007
Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study.
    Journal of hepatology, 2007, Volume: 47, Issue:1

    Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Thrombocytopenia; Treatment Outcome

2007
Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy.
    Gastroenterology, 2007, Volume: 132, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Cross-Over Studies; Disease Progression; DNA, Viral; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Mutagenesis; Ribavirin; Time Factors; Viral Nonstructural Proteins; Viral Proteins

2007
Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin.
    Journal of viral hepatitis, 2007, Volume: 14, Issue:6

    Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Cells, Cultured; Drug Therapy, Combination; eIF-2 Kinase; Female; Gene Expression Regulation; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Intramuscular; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Messenger; Treatment Outcome; Viral Load

2007
A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of nonresponder patients with chronic hepatitis C.
    Journal of gastroenterology, 2007, Volume: 42, Issue:5

    Topics: Adult; Aged; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin

2007
An assessment of serum leptin levels in patients with chronic viral hepatitis: a prospective study.
    BMC gastroenterology, 2007, May-31, Volume: 7

    Topics: Adolescent; Adult; Age Factors; Aged; Antiviral Agents; Biomarkers; Biopsy, Needle; Case-Control Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Lamivudine; Leptin; Liver Function Tests; Male; Middle Aged; Multivariate Analysis; Probability; Prospective Studies; Recombinant Proteins; Reference Values; Ribavirin; Risk Factors; Severity of Illness Index; Sex Factors; Treatment Outcome

2007
Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha.
    Hepatology (Baltimore, Md.), 2007, Volume: 46, Issue:2

    Topics: Adult; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2007
Early virological response in children with chronic hepatitis C treated with pegylated interferon and ribavirin.
    Infection, 2007, Volume: 35, Issue:3

    Topics: Adolescent; Antiviral Agents; Child; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load

2007
Immunomodulators, sFas and Fas-L as potential noninvasive predictors of IFN treatment in patients with HCV genotype-4.
    Journal of viral hepatitis, 2007, Volume: 14, Issue:7

    Topics: Adult; Antiviral Agents; Cytokines; Drug Therapy, Combination; Fas Ligand Protein; fas Receptor; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Receptors, Tumor Necrosis Factor, Type II; Recombinant Proteins; Ribavirin; Treatment Outcome

2007
Early viral kinetics during treatment of chronic hepatitis C virus infection with pegylated interferon alpha plus ribavirin in Taiwan.
    Intervirology, 2007, Volume: 50, Issue:4

    Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Asian People; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Taiwan; Treatment Outcome; Viral Load

2007
Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial.
    European journal of gastroenterology & hepatology, 2007, Volume: 19, Issue:8

    Topics: Adolescent; Adult; Aged; Amantadine; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Psychometrics; Quality of Life; Recombinant Proteins; Ribavirin; Treatment Outcome

2007
Phase 2 study of the combination of merimepodib with peginterferon-alpha2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C.
    Journal of hepatology, 2007, Volume: 47, Issue:4

    Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Phenylurea Compounds; Placebos; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2007
Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection.
    AIDS (London, England), 2007, Jul-31, Volume: 21, Issue:12

    Topics: Adult; Anti-HIV Agents; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2007
Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
    Journal of gastroenterology and hepatology, 2008, Volume: 23, Issue:2

    Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2008
Randomized trial of interferon beta-1a with or without ribavirin in Asian patients with chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2007, Volume: 46, Issue:2

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon beta-1a; Interferon-beta; Male; Middle Aged; Ribavirin; RNA, Viral

2007
IFN/RBV treatment induced neutropenia and its correction with neupogen in patients with hepatitis C.
    Georgian medical news, 2007, Issue:147

    Topics: Adult; Antiviral Agents; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Neutropenia; Recombinant Proteins; Ribavirin

2007
Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin.
    Antiviral therapy, 2007, Volume: 12, Issue:4

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2007
Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects.
    Hepatology (Baltimore, Md.), 2007, Volume: 46, Issue:4

    Topics: Adult; Antidepressive Agents; Antiviral Agents; Depression; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Mental Disorders; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors; Substance-Related Disorders; Treatment Outcome

2007
[The role and possibilities of natural interferon treatment in chronic hepatitis C: experience with natural interferon treatment for patients barred from combined antiviral therapy because of the STOP rule].
    Orvosi hetilap, 2007, Aug-19, Volume: 148, Issue:33

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Hungary; Interferon alpha-2; Interferon-alpha; Interferons; Leukopenia; Male; Middle Aged; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; Thrombocytopenia; Treatment Outcome; Viral Load

2007
Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial.
    Journal of hepatology, 2007, Volume: 47, Issue:4

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Hypertension, Portal; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2007
Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the 'accordion' regimen?
    Journal of hepatology, 2007, Volume: 47, Issue:4

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2007
Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin.
    Journal of viral hepatitis, 2007, Volume: 14, Issue:9

    Topics: Adult; Anemia; Anti-HIV Agents; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Zidovudine

2007
Adherence to hepatitis C treatment in recovering heroin users maintained on methadone.
    European journal of gastroenterology & hepatology, 2007, Volume: 19, Issue:9

    Topics: Adult; Antiviral Agents; Diagnosis, Dual (Psychiatry); Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Heroin Dependence; Humans; Interferon alpha-2; Interferon-alpha; Male; Mental Disorders; Methadone; Middle Aged; Patient Compliance; Prospective Studies; Recombinant Proteins; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome

2007
Dynamics of apoptotic activity during antiviral treatment of patients with chronic hepatitis C.
    Antiviral therapy, 2007, Volume: 12, Issue:5

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Apoptosis; Case-Control Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Keratin-18; Kinetics; Liver; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Virus Replication

2007
Serum alpha-foetoprotein level predicts treatment outcome in chronic hepatitis C.
    Antiviral therapy, 2007, Volume: 12, Issue:5

    Topics: Administration, Oral; Adult; alpha-Fetoproteins; Antiviral Agents; Biomarkers; Drug Administration Schedule; Drug Therapy, Combination; Egypt; Female; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Linear Models; Male; Middle Aged; Odds Ratio; Patient Selection; Polyethylene Glycols; Proteins; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Load; Virus Replication

2007
Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial.
    AIDS research and human retroviruses, 2007, Volume: 23, Issue:8

    Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin

2007
Does protracted antiviral therapy impact on HCV-related liver cirrhosis progression?
    World journal of gastroenterology, 2007, Sep-28, Volume: 13, Issue:36

    Topics: Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Ribavirin

2007
Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C.
    Liver international : official journal of the International Association for the Study of the Liver, 2007, Volume: 27, Issue:8

    Topics: Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver; Male; Middle Aged; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sex Factors; Time Factors; Treatment Failure; United States; Viral Load

2007
Hepatitis C treatment of opioid dependants receiving maintenance treatment: results of a Norwegian pilot study.
    European addiction research, 2007, Volume: 13, Issue:4

    Topics: Administration, Oral; Adult; Antiviral Agents; Buprenorphine; Comorbidity; Drug Therapy, Combination; Feasibility Studies; Female; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Methadone; Middle Aged; Narcotics; Norway; Opioid-Related Disorders; Patient Compliance; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Social Support; Substance Abuse, Intravenous

2007
Zinc supplementation prevents the increase of transaminase in chronic hepatitis C patients during combination therapy with pegylated interferon alpha-2b and ribavirin.
    Journal of nutritional science and vitaminology, 2007, Volume: 53, Issue:3

    Topics: Alanine Transaminase; Antiviral Agents; Ascorbic Acid; Carnosine; Dietary Supplements; Drug Therapy, Combination; Fatty Acids, Unsaturated; Female; Flow Cytometry; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Organometallic Compounds; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thiobarbituric Acid Reactive Substances; Time Factors; Transaminases; Treatment Outcome; Vitamin E; Vitamins; Zinc; Zinc Compounds

2007
Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study.
    Journal of viral hepatitis, 2007, Volume: 14, Issue:10

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Pilot Projects; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Safety; Spain; Treatment Outcome; Viral Load

2007
Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C.
    Journal of viral hepatitis, 2007, Volume: 14, Issue:10

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Viral Load

2007
Clinical trial: comparison of weekly once versus twice half-dose weekly administration of pegylated interferon alpha 2b in combination with ribavirin for the treatment of HCV-1 positive patients with chronic hepatitis C.
    Alimentary pharmacology & therapeutics, 2007, Oct-01, Volume: 26, Issue:7

    Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Injections; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Outcome

2007
Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients.
    Alimentary pharmacology & therapeutics, 2007, Oct-15, Volume: 26, Issue:8

    Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2007
Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C.
    Journal of gastroenterology and hepatology, 2007, Volume: 22, Issue:11

    Topics: Adult; Aged; Alcohol Drinking; Antiviral Agents; Disease Progression; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Iron; Iron Overload; Liver; Male; Middle Aged; Platelet Count; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Sex Factors; Transaminases; Treatment Outcome

2007
Effect of lactoferrin in patients with chronic hepatitis C: combination therapy with interferon and ribavirin.
    Journal of gastroenterology and hepatology, 2007, Volume: 22, Issue:11

    Topics: Adult; Antibodies; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lactoferrin; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viremia

2007
Gamma-glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-alpha-2b in chronic hepatitis C non-responders.
    Liver international : official journal of the International Association for the Study of the Liver, 2007, Volume: 27, Issue:9

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; gamma-Glutamyltransferase; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Quality of Life; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2007
Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial.
    Journal of viral hepatitis, 2007, Volume: 14, Issue:11

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Female; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2007
Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response.
    Hepatology (Baltimore, Md.), 2007, Volume: 46, Issue:5

    Topics: Adult; Antiviral Agents; Biopsy; Case-Control Studies; Cluster Analysis; Drug Therapy, Combination; Female; Gene Expression; Gene Expression Profiling; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Treatment Outcome

2007
L-carnitine treatment reduces steatosis in patients with chronic hepatitis C treated with alpha-interferon and ribavirin.
    Digestive diseases and sciences, 2008, Volume: 53, Issue:4

    Topics: Adult; Antiviral Agents; Carnitine; Drug Therapy, Combination; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Ribavirin; Vitamin B Complex

2008
Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response.
    Hepatology (Baltimore, Md.), 2007, Volume: 46, Issue:6

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load

2007
[Toxicity of the treatment of chronic hepatitis C with peginterferon alpha (2a or 2b) plus ribavirin in patients not previously treated].
    Medicina clinica, 2007, Nov-03, Volume: 129, Issue:16

    Topics: Alanine Transaminase; Antiviral Agents; Bilirubin; Cohort Studies; Drug Therapy, Combination; Fatigue; Fever; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Neutropenia; Patient Dropouts; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Viral Load

2007
Side effects of combination therapy of peginterferon and ribavirin for chronic hepatitis-C.
    Internal medicine (Tokyo, Japan), 2007, Volume: 46, Issue:22

    Topics: Adolescent; Adult; Age Factors; Aged; Diabetes Complications; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Hypertension; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Refusal; Viral Load

2007
Design of the PEDS-C trial: pegylated interferon +/- ribavirin for children with chronic hepatitis C viral infection.
    Clinical trials (London, England), 2007, Volume: 4, Issue:6

    Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Pediatrics; Placebos; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; United States

2007
Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders.
    Hepatology (Baltimore, Md.), 2007, Volume: 46, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2007
[Efficacy of combined antiviral therapy with interferon alfa and ribavirin in chronic hepatitis C patients with extrahepatic manifestations].
    Przeglad epidemiologiczny, 2007, Volume: 61, Issue:3

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prognosis; Ribavirin; Risk Factors; Surveys and Questionnaires; Treatment Outcome

2007
Interferon beta 1a versus interferon beta 1a plus ribavirin for the treatment of chronic hepatitis C in Chinese patients: a randomized, placebo-controlled trial.
    Digestive diseases and sciences, 2008, Volume: 53, Issue:8

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Asian People; China; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon beta-1a; Interferon-beta; Male; Middle Aged; Patient Compliance; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2008
Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin.
    Alimentary pharmacology & therapeutics, 2008, Mar-01, Volume: 27, Issue:5

    Topics: Adult; Anemia; Antiviral Agents; Depression; Drug Administration Schedule; Drug Therapy, Combination; Drug Tolerance; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multicenter Studies as Topic; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Surveys and Questionnaires; Thrombocytopenia; Time Factors; Viral Load

2008
Efficacy of interferon plus ribavirin in the treatment of hepatitis C virus genotype 5.
    Journal of viral hepatitis, 2008, Volume: 15, Issue:5

    Topics: Age Factors; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Syria; Treatment Outcome; Viral Load

2008
Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3.
    Journal of viral hepatitis, 2008, Volume: 15, Issue:1

    Topics: Adult; Antiviral Agents; Canada; DNA, Viral; Drug Administration Schedule; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Treatment Outcome

2008
Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection.
    The Pediatric infectious disease journal, 2008, Volume: 27, Issue:2

    Topics: Adolescent; Child; Child, Preschool; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2008
Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis.
    Annals of the rheumatic diseases, 2008, Volume: 67, Issue:10

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Rituximab; Treatment Outcome; Vasculitis

2008
Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.
    Journal of viral hepatitis, 2008, Volume: 15, Issue:5

    Topics: Adult; Anemia; Anti-HIV Agents; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; HIV Infections; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Multivariate Analysis; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Withholding Treatment; Zidovudine

2008
A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment.
    Journal of viral hepatitis, 2008, Volume: 15, Issue:5

    Topics: Adult; Anemia; Antiviral Agents; Darbepoetin alfa; Erythropoietin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematinics; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2008
Clinical trial: individualized treatment duration for hepatitis C virus genotype 1 with peginterferon-alpha 2a plus ribavirin.
    Alimentary pharmacology & therapeutics, 2008, Volume: 27, Issue:9

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Statistics as Topic; Viremia

2008
Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: project of the Kyushu University Liver Disease Study
    Journal of gastroenterology and hepatology, 2008, Volume: 23, Issue:7 Pt 1

    Topics: Adult; Aged; Antiviral Agents; Asian People; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2008
Eicosapentaenoic acid could permit maintenance of the original ribavirin dose in chronic hepatitis C virus patients during the first 12 weeks of combination therapy with pegylated interferon-alpha and ribavirin. A prospective randomized controlled trial.
    Intervirology, 2007, Volume: 50, Issue:6

    Topics: Adult; Aged; Anemia; Drug Therapy, Combination; Eicosapentaenoic Acid; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin

2007
Pegylated interferon alpha-2b plus ribavirin for naive patients with HCV-related cirrhosis.
    Journal of clinical gastroenterology, 2008, Volume: 42, Issue:6

    Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Viral Load

2008
The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
    Journal of viral hepatitis, 2008, Volume: 15, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia

2008
Efficacy in patients with dose reduction in combination therapy of peginterferon and ribavirin for chronic hepatitis C.
    Intervirology, 2008, Volume: 51, Issue:1

    Topics: Adult; Aged; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Viral Load

2008
Effect of pegylated interferon treatments for chronic active hepatitis C on quality of life.
    Journal of chemotherapy (Florence, Italy), 2008, Volume: 20, Issue:1

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin

2008
[Effect of pegylated interferon beta-1a therapy on the liver fibrosis in chronic hepatitis C: a semi-quantitative analysis].
    Zhonghua yi xue za zhi, 2008, Jan-08, Volume: 88, Issue:2

    Topics: Actins; Adult; Antiviral Agents; Collagen Type III; Female; Hepatitis C, Chronic; Humans; Interferon beta-1a; Interferon-beta; Liver; Liver Cirrhosis; Male; Middle Aged; Muscle, Smooth; Ribavirin; Treatment Outcome

2008
Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.
    Journal of viral hepatitis, 2008, Volume: 15, Issue:7

    Topics: Antiviral Agents; Designer Drugs; Dose-Response Relationship, Drug; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Research Design; Ribavirin

2008
Eight-week regimen of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C with hepatitis C virus genotype 2 and a rapid virological response.
    Liver international : official journal of the International Association for the Study of the Liver, 2009, Volume: 29, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Statistics, Nonparametric; Viremia

2009
Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alpha-2a plus ribavirin.
    Alimentary pharmacology & therapeutics, 2008, Volume: 28, Issue:1

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2008
Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus.
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2008, Volume: 22, Issue:4

    Topics: Adult; Anorexia; Antiviral Agents; Cannabinoids; Dose-Response Relationship, Drug; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Nausea; Retrospective Studies; Ribavirin; Treatment Outcome; Weight Loss

2008
Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b.
    Drugs, 2008, Volume: 68, Issue:6

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Kinetics; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Failure; Viral Load

2008
Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
    Journal of gastroenterology and hepatology, 2008, Volume: 23, Issue:6

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2008
Therapy with interferon-alpha and ribavirin for chronic hepatitis C virus infection upregulates membrane HLA-ABC, CD86, and CD28 on peripheral blood mononuclear cells.
    Journal of medical virology, 2008, Volume: 80, Issue:6

    Topics: Adult; Aged; Antigens, Surface; Antiviral Agents; Biomarkers; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Recombinant Proteins; Ribavirin; Time Factors; Up-Regulation

2008
Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin.
    The International journal of artificial organs, 2008, Volume: 31, Issue:4

    Topics: Adult; Aged; Anti-Retroviral Agents; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Dropouts; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Renal Dialysis; Renal Insufficiency; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2008
Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection.
    Hepatology (Baltimore, Md.), 2008, Volume: 47, Issue:6

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Sensitivity and Specificity; Treatment Outcome

2008
Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment.
    Molecular psychiatry, 2009, Volume: 14, Issue:12

    Topics: Adult; Antiviral Agents; Cohort Studies; Depression; Fatigue; Female; Gene Frequency; Genotype; Hepatitis C, Chronic; Humans; Interferon Type I; Interleukin-6; Male; Middle Aged; Polymorphism, Genetic; Psychiatric Status Rating Scales; Recombinant Proteins; Ribavirin; Serotonin Plasma Membrane Transport Proteins

2009
Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
    Infection, 2008, Volume: 36, Issue:3

    Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Infections; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Male; Middle Aged; Neutropenia; Neutrophils; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2008
Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2008, Volume: 6, Issue:6

    Topics: Administration, Oral; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2008
Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients.
    Journal of hepatology, 2008, Volume: 49, Issue:2

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2008
The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection.
    Journal of hepatology, 2008, Volume: 49, Issue:5

    Topics: Adult; Aged; Antiviral Agents; DNA, Viral; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral

2008
Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group.
    Lancet (London, England), 1998, Jan-10, Volume: 351, Issue:9096

    Topics: Adult; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome

1998
Ribavirin in hepatitis C related cryoglobulinemia.
    The Journal of rheumatology, 1998, Volume: 25, Issue:6

    Topics: Aged; Antiviral Agents; Cryoglobulinemia; DNA, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Transaminases; Treatment Outcome; Viral Load

1998
Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis C.
    Journal of hepatology, 1998, Volume: 28, Issue:6

    Topics: Adult; Antiviral Agents; Follow-Up Studies; Germany; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lung; Male; Middle Aged; Recombinant Proteins; Remission, Spontaneous; Ribavirin; Sarcoidosis, Pulmonary; Skin; Time Factors; Tomography, X-Ray Computed

1998
Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial.
    Hepatology (Baltimore, Md.), 1998, Volume: 28, Issue:2

    Topics: Adolescent; Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Forecasting; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Treatment Outcome

1998
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)
    Lancet (London, England), 1998, Oct-31, Volume: 352, Issue:9138

    Topics: Administration, Oral; Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral

1998
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.
    The New England journal of medicine, 1998, Nov-19, Volume: 339, Issue:21

    Topics: Adult; Antiviral Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

1998
Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
    The New England journal of medicine, 1998, Nov-19, Volume: 339, Issue:21

    Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral

1998
Adding ribavirin to interferon alpha-2b for chronic hepatitis C infection increased virological response and nausea.
    Gut, 1998, Volume: 43, Issue:5

    Topics: Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Nausea; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome

1998
Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study.
    The American journal of gastroenterology, 1998, Volume: 93, Issue:12

    Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Combinations; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Retreatment; Ribavirin; Treatment Outcome

1998
Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions.
    British journal of clinical pharmacology, 1998, Volume: 46, Issue:6

    Topics: Adolescent; Adult; Antiviral Agents; Drug Interactions; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin

1998
r-Interferon alfa-2b/ribavirin combined therapy followed by low-dose r-interferon alfa-2b in chronic hepatitis C interferon nonresponders.
    Hepatology (Baltimore, Md.), 1999, Volume: 29, Issue:1

    Topics: Antiviral Agents; Drug Resistance; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Injections, Intramuscular; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin

1999
[Opinion on interferon-ribavirin association in the primary treatment of chronic hepatitis C].
    Presse medicale (Paris, France : 1983), 1999, Jan-16, Volume: 28, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Evaluation Studies as Topic; Hepatitis C, Chronic; Humans; Interferon-alpha; Placebos; Ribavirin

1999
Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT.
    Journal of hepatology, 1999, Volume: 30, Issue:2

    Topics: Alanine Transaminase; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Forecasting; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome

1999
Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group.
    Scandinavian journal of gastroenterology, 1999, Volume: 34, Issue:2

    Topics: Adult; Antiviral Agents; Biopsy; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Viremia

1999
Outcome of long-term ribavirin therapy for recurrent hepatitis C after liver transplantation.
    Transplantation, 1999, May-15, Volume: 67, Issue:9

    Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Biopsy; Drug Administration Schedule; Female; Hepatitis C, Chronic; Humans; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Transplantation; Treatment Outcome

1999
Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C.
    Seminars in liver disease, 1999, Volume: 19 Suppl 1

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; RNA, Viral; Safety; Treatment Outcome

1999
Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients.
    Seminars in liver disease, 1999, Volume: 19 Suppl 1

    Topics: Adolescent; Alanine Transaminase; Antiviral Agents; Biopsy; Double-Blind Method; Drug Administration Routes; Drug Hypersensitivity; Drug Therapy, Combination; Female; Follow-Up Studies; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Male; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Safety; Treatment Outcome

1999
Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients.
    Seminars in liver disease, 1999, Volume: 19 Suppl 1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Quality of Life; Recombinant Proteins; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Surveys and Questionnaires; Treatment Outcome

1999
Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders.
    Italian journal of gastroenterology and hepatology, 1999, Volume: 31, Issue:2

    Topics: Adult; Alanine Transaminase; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Pilot Projects; Ribavirin; RNA, Viral; Statistics, Nonparametric

1999
Interferon-alpha plus ribavirin in chronic hepatitis C resistant to previous interferon-alpha course: results of a randomized multicenter trial.
    Journal of hepatology, 1999, Volume: 30, Issue:5

    Topics: Antiviral Agents; Biopsy; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Inflammation; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Necrosis; Ribavirin; Treatment Failure

1999
Changes in serum hepatitis C virus RNA in interferon nonresponders retreated with interferon plus ribavirin: a preliminary report.
    Journal of clinical gastroenterology, 1999, Volume: 28, Issue:4

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Pilot Projects; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Viremia

1999
Retreatment of non-responder or relapser chronic hepatitis C patients with interferon plus ribavirin vs interferon alone.
    Italian journal of gastroenterology and hepatology, 1999, Volume: 31, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Chi-Square Distribution; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Recurrence; Ribavirin; Statistics, Nonparametric; Treatment Failure; Treatment Outcome

1999
Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis.
    Gastroenterology, 1999, Volume: 117, Issue:2

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Ribavirin

1999
Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group.
    Hepatology (Baltimore, Md.), 1999, Volume: 30, Issue:2

    Topics: Female; Health Status; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Quality of Life; Recombinant Proteins; Ribavirin

1999
A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, France.
    Journal of hepatology, 1999, Volume: 31, Issue:1

    Topics: Antiviral Agents; Combined Modality Therapy; Female; France; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Failure; Viremia

1999
High prevalence of cutaneous reactions to interferon alfa plus ribavirin combination therapy in patients with chronic hepatitis C virus.
    Archives of dermatology, 1999, Volume: 135, Issue:8

    Topics: Adult; Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prevalence; Ribavirin

1999
[Interferon-alpha plus ribavirin combination therapy in chronic hepatitis C].
    Zeitschrift fur Gastroenterologie, 1999, Volume: 37, Issue:7

    Topics: Adult; Antiviral Agents; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome

1999
Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: a randomized trial.
    Liver, 1999, Volume: 19, Issue:4

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Biopsy; DNA Primers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Treatment Outcome

1999
Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial.
    The American journal of medicine, 1999, Volume: 107, Issue:2

    Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C, Chronic; Humans; Immunoblotting; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; Treatment Failure; Treatment Outcome

1999
Interferon-antibodies and the breakthrough phenomenon during ribavirin/interferon-alpha combination therapy and interferon-alpha monotherapy of patients with chronic hepatitis C.
    Zeitschrift fur Gastroenterologie, 1999, Volume: 37, Issue:8

    Topics: Adult; Antibodies; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome

1999
Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. Multicenter Interferon Beta Italian Group Investigators.
    Scandinavian journal of gastroenterology, 1999, Volume: 34, Issue:9

    Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-beta; Liver Function Tests; Male; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin

1999
Long-term re-treatment with interferon and ribavirin combination therapy in patients with chronic hepatitis C who are non-responders to interferon alone: a preliminary study.
    Scandinavian journal of infectious diseases, 1999, Volume: 31, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Long-Term Care; Male; Middle Aged; Prognosis; Prospective Studies; Retreatment; Ribavirin; Spain; Statistics, Nonparametric; Treatment Failure; Treatment Outcome

1999
Histological and virological long-term outcome in patients treated with interferon-alpha2b and ribavirin for chronic hepatitis C.
    Journal of viral hepatitis, 1999, Volume: 6, Issue:3

    Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome

1999
Therapy of special HIV-associated diseases: HCV-HIV-co-infection and AIDS-related Kaposi's sarcoma - official satellite to the 7th European Conference on Clinical Aspects and Treatment of HIV-infection, October 23, 1999 in Lisbon, Portugal.
    European journal of medical research, 1999, Dec-16, Volume: 4, Issue:12

    Topics: AIDS-Related Opportunistic Infections; Antibiotics, Antineoplastic; Antiviral Agents; Cost-Benefit Analysis; Daunorubicin; Doxorubicin; Hepatitis C, Chronic; Herpesvirus 8, Human; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Sarcoma, Kaposi

1999
Increased hepatic iron deposition resulting from treatment of chronic hepatitis C with ribavirin.
    American journal of clinical pathology, 2000, Volume: 113, Issue:1

    Topics: Alanine Transaminase; Double-Blind Method; Hemoglobins; Hepatitis C, Chronic; Humans; Iron; Liver; Ribavirin; Siderosis

2000
Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.
    Gastroenterology, 2000, Volume: 118, Issue:2

    Topics: Adult; Alanine Transaminase; Antiviral Agents; CD4-Positive T-Lymphocytes; Cohort Studies; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Interleukin-10; Lymphocyte Activation; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; T-Lymphocytes; Viral Load

2000
Perihepatic lymph nodes as a marker of antiviral response in patients with chronic hepatitis C infection.
    AJR. American journal of roentgenology, 2000, Volume: 174, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Lymph Nodes; Male; Middle Aged; Ribavirin; Treatment Outcome; Ultrasonography

2000
Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C.
    Digestion, 2000, Volume: 61, Issue:2

    Topics: Adolescent; Adult; Aged; Analysis of Variance; Antiviral Agents; Biopsy, Needle; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Probability; Prospective Studies; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Treatment Failure; Treatment Outcome

2000
TT virus infection in patients with chronic hepatitis C virus infection--effect of primers, prevalence, and clinical significance. Hepatitis Interventional Therapy Group.
    Journal of hepatology, 2000, Volume: 32, Issue:2

    Topics: Adult; Antiviral Agents; DNA Virus Infections; DNA Viruses; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Phylogeny; Polymerase Chain Reaction; Prevalence; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Retreatment; Ribavirin

2000
Effect of interferon and ribavirin on HIV viral load.
    AIDS (London, England), 2000, Jan-07, Volume: 14, Issue:1

    Topics: Adult; Antiviral Agents; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Ribavirin; Viral Load

2000
Interferon plus ribavirin in chronic hepatitis C non-responders to recombinant alpha-interferon.
    Journal of viral hepatitis, 2000, Volume: 7, Issue:1

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2000
Interferon-alpha-2b + ribavirin for the treatment of chronic hepatitis C in non-responders to interferon-alpha-monotherapy.
    Zeitschrift fur Gastroenterologie, 2000, Volume: 38, Issue:2

    Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome

2000
Interferon alpha plus ketoprofen or interferon alpha plus ribavirin in chronic hepatitis C non-responder to interferon alpha alone: results of a pilot study.
    Italian journal of gastroenterology and hepatology, 1999, Volume: 31, Issue:8

    Topics: Adolescent; Adult; Alanine Transaminase; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ketoprofen; Male; Middle Aged; Pilot Projects; Ribavirin; RNA, Viral

1999
Cost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C.
    The American journal of medicine, 2000, Apr-01, Volume: 108, Issue:5

    Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Life Expectancy; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; Survival Analysis; Treatment Outcome; United States

2000
Interim analysis of a randomized controlled trial of combination of ribavirin and high dose interferon-alpha in interferon nonresponders with chronic hepatitis C.
    Journal of viral hepatitis, 1999, Volume: 6 Suppl 1

    Topics: Adult; Aged; Alanine Transaminase; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Ribavirin; RNA, Viral

1999
Leucopenia is a side effect of combination therapy for hepatitis C infection.
    The American journal of gastroenterology, 2000, Volume: 95, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Leukopenia; Male; Recombinant Proteins; Ribavirin

2000
Interferon plus ribavirin in HIV-infected patients with chronic hepatitis C.
    Journal of acquired immune deficiency syndromes (1999), 1999, Nov-01, Volume: 22, Issue:3

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Pilot Projects; Recombinant Proteins; Ribavirin

1999
Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C.
    The American journal of gastroenterology, 2000, Volume: 95, Issue:5

    Topics: Adult; Alanine Transaminase; Amantadine; Clinical Enzyme Tests; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral

2000
Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b-related chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2000, Volume: 31, Issue:6

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral; Treatment Outcome

2000
Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients.
    AIDS (London, England), 2000, May-05, Volume: 14, Issue:7

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2000
Treatment of chronic hepatitis C genotype IV with interferon-ribavirin combination in Saudi Arabia: a multicentre study.
    Journal of viral hepatitis, 2000, Volume: 7, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Male; Middle Aged; Recombinant Proteins; Ribavirin; Saudi Arabia

2000
The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group.
    Journal of hepatology, 2000, Volume: 33, Issue:1

    Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Prognosis; Recurrence; Remission Induction; Retreatment; Ribavirin; Treatment Outcome

2000
Improved response to ribavirin interferon combination compared with interferon alone in patients with type 4 chronic hepatitis C without cirrhosis.
    Liver, 2000, Volume: 20, Issue:4

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2000
Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2000, Volume: 32, Issue:3

    Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Drug Resistance; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Prospective Studies; Ribavirin; RNA, Viral

2000
A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group.
    Hepatology (Baltimore, Md.), 2000, Volume: 32, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Blood Cell Count; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral

2000
Biochemical and virological changes in serum of nonresponder or relapser chronic hepatitis C patients retreated with interferon and ribavirin followed by interferon alone.
    The American journal of gastroenterology, 2000, Volume: 95, Issue:9

    Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Biomarkers; Drug Administration Routes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral

2000
A prospective and randomized study using ribavirin as monotherapy for the treatment of naïve patients with chronic hepatitis C.
    The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2000, Volume: 4, Issue:4

    Topics: Administration, Oral; Adult; Antiviral Agents; Double-Blind Method; Female; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prospective Studies; Ribavirin; RNA, Viral; Treatment Outcome

2000
Evaluation of long-term efficacy of interferon alpha-2b and ribavirin in combination in naive patients with chronic hepatitis C: an Italian multicenter experience. Ribavirin-Interferon in Chronic Hepatitis Italian Group Investigators.
    Journal of hepatology, 2000, Volume: 33, Issue:3

    Topics: Adult; Anti-Bacterial Agents; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome

2000
Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months.
    Journal of hepatology, 2000, Volume: 33, Issue:3

    Topics: Adult; Anti-Bacterial Agents; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome

2000
Early addition of ribavirin to interferon in chronic hepatitis C not responsive to interferon monotherapy.
    Journal of hepatology, 2000, Volume: 33, Issue:3

    Topics: Adult; Alanine Transaminase; Anti-Bacterial Agents; Antiviral Agents; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome

2000
Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group.
    The American journal of gastroenterology, 2000, Volume: 95, Issue:10

    Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Failure

2000
The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group.
    Gastroenterology, 2000, Volume: 119, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Black People; Drug Combinations; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Compliance; Recombinant Proteins; Ribavirin; RNA, Viral

2000
Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone.
    Journal of viral hepatitis, 2000, Volume: 7, Issue:6

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Failure; Treatment Outcome; Viral Load

2000
HCV RNA levels during therapy with amantadine in addition to interferon and ribavirin in chronic hepatitis C patients with previous nonresponse or response/relapse to interferon and ribavirin.
    Journal of viral hepatitis, 2000, Volume: 7, Issue:6

    Topics: Adult; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Failure; Treatment Outcome

2000
Interferon Alfa-2A and ribavirin therapy for hepatitis C recurrence after liver transplantation.
    Transplantation proceedings, 2000, Volume: 32, Issue:7

    Topics: Adult; Aged; Antiviral Agents; Cause of Death; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Failure; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recombinant Proteins; Recurrence; Ribavirin; Survival Rate; Time Factors; Treatment Outcome

2000
[Effect of ribavirin on dynamics of hepatitis C viremia in interferon alpha-treated patiens with response or no response].
    Zeitschrift fur Gastroenterologie, 2000, Volume: 38, Issue:11

    Topics: Adult; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viremia

2000
High-dose interferon plus ribavirin in chronic hepatitis C not responding to recombinant alpha-interferon.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2000, Volume: 32, Issue:8

    Topics: Alanine Transaminase; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon Type I; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Failure; Viral Load

2000
Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial.
    Liver, 2000, Volume: 20, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viremia

2000
Phase III Peg-Intron plus Rebetol results released.
    The AIDS reader, 2000, Volume: 10, Issue:12

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2000
Soluble beta2-mu-associated and beta2-mu-free HLA class I heavy chain serum levels in interferon-alpha nonresponder chronic hepatitis C patients. Markers of immune activation, and response to antiviral retreatment.
    Journal of clinical immunology, 2000, Volume: 20, Issue:6

    Topics: Adult; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Histocompatibility Antigens Class I; Humans; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Ribavirin; RNA, Viral

2000
A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy.
    Journal of hepatology, 2001, Volume: 34, Issue:1

    Topics: Adult; Aged; Amantadine; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Quality of Life; Recombinant Proteins; Ribavirin; Thyrotropin

2001
The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity.
    Journal of hepatology, 2001, Volume: 34, Issue:1

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Quality of Life; Recombinant Proteins; Recurrence; Ribavirin

2001
Treatment of chronic hepatitis C with amantadine hydrochloride in patients who had not responded to previous treatment with interferon-alpha and/or ribavirin.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2001, Mar-01, Volume: 32, Issue:5

    Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Treatment Outcome

2001
Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
    Hepatology (Baltimore, Md.), 2001, Volume: 33, Issue:3

    Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Drug Resistance; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Male; Middle Aged; Recurrence; Retreatment; Ribavirin; RNA, Viral

2001
[Hepatitis C. Chances for treatment increase].
    MMW Fortschritte der Medizin, 2001, Mar-08, Volume: 143, Issue:10

    Topics: Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2001
Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone.
    The American journal of gastroenterology, 2001, Volume: 96, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral

2001
Hepatitis C viral kinetics in difficult to treat patients receiving high dose interferon and ribavirin.
    Journal of hepatology, 2001, Volume: 34, Issue:3

    Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Kinetics; Male; Middle Aged; Ribavirin; Time Factors; Viral Load; Virus Replication

2001
Efficacy of 5 MU of interferon in combination with ribavirin for naïve patients with chronic hepatitis C virus: a randomized controlled trial.
    Journal of hepatology, 2001, Volume: 34, Issue:3

    Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Prognosis; Ribavirin; RNA, Viral

2001
Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2001, Volume: 33, Issue:2

    Topics: Adolescent; Adult; Analysis of Variance; Antiviral Agents; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Pilot Projects; Probability; Ribavirin; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome

2001
Interferon-alpha2a/ribaviran versus interferon-alpha2a alone for the retreatment of hepatitis C patients who relapse after a standard course of interferon.
    The New Zealand medical journal, 2001, Mar-23, Volume: 114, Issue:1128

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Recurrence; Retreatment; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral

2001
Pilot study of interferon-alpha and ribavirin treatment in patients with chronic hepatitis C and normal transaminase values.
    Journal of viral hepatitis, 2001, Volume: 8, Issue:3

    Topics: Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Biopsy; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Pilot Projects; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Viral Load

2001
Cytokine network in nonresponding chronic hepatitis C patients with genotype 1: role of triple therapy with interferon alpha, ribavirin, and ursodeoxycholate.
    Clinical biochemistry, 2001, Volume: 34, Issue:3

    Topics: Adult; Cytokines; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Ursodeoxycholic Acid

2001
High-dose prolonged combination therapy in non-responders to interferon monotherapy for chronic hepatitis C.
    Alimentary pharmacology & therapeutics, 2001, Volume: 15, Issue:7

    Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Female; Fibrosis; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral; Treatment Outcome

2001
A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone.
    Hepatology (Baltimore, Md.), 2001, Volume: 34, Issue:1

    Topics: Adult; Alanine Transaminase; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viremia

2001
Treatment of patients with chronic hepatitis C not responding to interferon with high-dose interferon alpha with or without ribavirin: final results of a prospective randomized trial. Austrian Hepatitis Study Group.
    European journal of gastroenterology & hepatology, 2001, Volume: 13, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Base Sequence; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Male; Middle Aged; Molecular Sequence Data; Organization and Administration; Polymerase Chain Reaction; Probability; Prospective Studies; Reference Values; Ribavirin; RNA, Viral; Treatment Failure; Treatment Outcome

2001
Factors influencing ribavirin-induced hemolysis.
    Journal of hepatology, 2001, Volume: 34, Issue:6

    Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Female; Haptoglobins; Hemoglobins; Hemolysis; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Phenotype; Platelet Count; Recombinant Proteins; Ribavirin; Risk Factors

2001
Clearance kinetics of hepatitis C virus under different antiviral therapies.
    Journal of medical virology, 2001, Volume: 64, Issue:4

    Topics: Adult; Aged; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral; Time Factors

2001
A randomized, controlled trial to determine whether continued ribavirin monotherapy in hepatitis C virus-infected patients who responded to interferon-ribavirin combination therapy will enhance sustained virologic response.
    The Journal of infectious diseases, 2001, Aug-15, Volume: 184, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Secondary Prevention; Treatment Outcome

2001
A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta.
    Hepatology (Baltimore, Md.), 2001, Volume: 34, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Blood; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Intravenous; Interferon-alpha; Interferon-beta; Male; Middle Aged; Monocytes; Ribavirin; RNA, Viral; Treatment Outcome

2001
Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa-2b and tribavirin.
    AIDS (London, England), 2001, Sep-28, Volume: 15, Issue:14

    Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2001
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
    Lancet (London, England), 2001, Sep-22, Volume: 358, Issue:9286

    Topics: Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2001
Combination of interferon induction therapy and ribavirin in chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2001, Volume: 34, Issue:5

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon Inducers; Male; Middle Aged; Patient Dropouts; Prospective Studies; Ribavirin; Treatment Outcome; Viral Load

2001
Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders.
    Hepatology (Baltimore, Md.), 2001, Volume: 34, Issue:5

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Blood Coagulation Disorders; Drug Therapy, Combination; Female; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome

2001
Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2001, Volume: 7, Issue:10

    Topics: Administration, Oral; Adult; Antiviral Agents; Chi-Square Distribution; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon-alpha; Liver Cirrhosis, Biliary; Liver Transplantation; Male; Middle Aged; Probability; Recurrence; Ribavirin; Treatment Outcome

2001
Comparative effects of different doses of ribavirin plus interferon-alpha2b for therapy of chronic hepatitis C: results of a controlled, randomized trial.
    Digestive diseases and sciences, 2001, Volume: 46, Issue:10

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Combinations; Female; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral

2001
Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients.
    AIDS (London, England), 2001, Nov-09, Volume: 15, Issue:16

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome

2001
Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy.
    Journal of viral hepatitis, 2001, Volume: 8, Issue:6

    Topics: Alanine Transaminase; Antiviral Agents; Chronic Disease; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Predictive Value of Tests; Ribavirin; RNA, Viral; Time Factors

2001
Cell adhesion molecules and hyaluronic acid as markers of inflammation, fibrosis and response to antiviral therapy in chronic hepatitis C patients.
    Mediators of inflammation, 2001, Volume: 10, Issue:5

    Topics: Adult; Antiviral Agents; Biomarkers; Female; Fibrosis; Hepatitis C, Chronic; Humans; Hyaluronic Acid; Inflammation Mediators; Intercellular Adhesion Molecule-1; Interferon Type I; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Failure; Vascular Cell Adhesion Molecule-1

2001
[Effectiveness of antiviral treatment of patients with chronic hepatitis C (a Polish multicenter study)].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2001, Volume: 11, Issue:64

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Poland; Ribavirin; Time Factors; Treatment Outcome

2001
High-dose interferon alfa-2b and ribavirin in patients previously treated with interferon: results of a prospective, randomized, controlled trial.
    Journal of clinical gastroenterology, 2002, Volume: 34, Issue:2

    Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Prospective Studies; Recombinant Proteins; Ribavirin

2002
Does interferon and ribavirin combination therapy increase the rate of treatment response in children with hepatitis C?
    Journal of pediatric gastroenterology and nutrition, 2002, Volume: 34, Issue:2

    Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Infant; Interferon-alpha; Male; Ribavirin; Transfusion Reaction; Treatment Outcome; Viral Load

2002
Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study.
    Scandinavian journal of gastroenterology, 2002, Volume: 37, Issue:2

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Recombinant Proteins; Ribavirin

2002
Sarcoidosis in two patients with chronic hepatitis C treated with interferon, ribavirin and amantadine.
    Journal of viral hepatitis, 2002, Volume: 9, Issue:1

    Topics: Adult; Amantadine; Antiviral Agents; Drug Synergism; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lung Diseases; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; Sarcoidosis

2002
Interferon-alpha plus ribavirin for 12 months increases the sustained response rates in chronic hepatitis C relapsers.
    Alimentary pharmacology & therapeutics, 2002, Volume: 16, Issue:2

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; gamma-Glutamyltransferase; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Recurrence; Ribavirin; Treatment Outcome

2002
A randomized trial of high-dose interferon alpha-2b, with or without ribavirin, in chronic hepatitis C patients who have not responded to standard dose interferon.
    Alimentary pharmacology & therapeutics, 2002, Volume: 16, Issue:3

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Failure

2002
Serum tumour necrosis factor-alpha and transforming growth factor-beta levels in chronic hepatitis C patients are immunomodulated by therapy.
    Cytokine, 2002, Jan-21, Volume: 17, Issue:2

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Transforming Growth Factor beta; Treatment Outcome; Tumor Necrosis Factor-alpha

2002
Treatment of patients with chronic hepatitis C with normal liver enzymes.
    Saudi medical journal, 2002, Volume: 23, Issue:3

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Viral Load

2002
A randomized study of alpha-interferon plus ribavirin for 6 months or 12 months for the treatment of chronic hepatitis C in patients with bleeding disorders.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2002, Volume: 8, Issue:2

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Blood Coagulation Disorders; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome

2002
Treatment of ribavirin/interferon-induced anemia with erythropoietin in patients with hepatitis C.
    Hepatology (Baltimore, Md.), 2002, Volume: 35, Issue:5

    Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin

2002
Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.
    Journal of hepatology, 2002, Volume: 36, Issue:5

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2002
Peginterferon-alpha-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open-label study.
    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2002, Volume: 16, Issue:2

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2002
Interferon-alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients with persistently normal aminotransferase levels.
    Digestion, 2002, Volume: 65, Issue:2

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Prospective Studies; Recombinant Proteins; Ribavirin

2002
Interferon and ribavirin as frontline treatment for chronic hepatitis C infection in thalassaemia major.
    British journal of haematology, 2002, Volume: 117, Issue:3

    Topics: Adolescent; Adult; Antiviral Agents; beta-Thalassemia; Child; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; Transfusion Reaction

2002
Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2002, Volume: 22, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Iron; Liver; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome

2002
Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone.
    Journal of hepatology, 2002, Volume: 36, Issue:6

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome

2002
High sustained response rate in patients with histologically mild (low grade and stage) chronic hepatitis C infection. A randomized, double blind, placebo controlled trial of interferon alpha-2b with and without ribavirin.
    European journal of gastroenterology & hepatology, 2002, Volume: 14, Issue:6

    Topics: Adult; Double-Blind Method; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral

2002
High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis.
    Journal of hepatology, 2002, Volume: 37, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; Treatment Outcome

2002
Effect of interferon alpha-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C.
    Clinical pharmacology and therapeutics, 2002, Volume: 71, Issue:6

    Topics: Acute Disease; Acyltransferases; Adult; Aged; Antimetabolites; Antiviral Agents; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Treatment Outcome

2002

Other Studies

3749 other study(ies) available for ribavirin and Chronic Hepatitis C

ArticleYear
Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.
    Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:11

    Topics: Antiviral Agents; Cell Line; Cytidine; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Nitro Compounds; Recombinant Proteins; Replicon; Ribavirin; Thiazoles; Virus Replication

2008
SAR study of bisamides as cyclophilin a inhibitors for the development of host-targeting therapy for hepatitis C virus infection.
    Bioorganic & medicinal chemistry, 2020, 10-01, Volume: 28, Issue:19

    Topics: Antiviral Agents; Cell Line, Tumor; Cyclophilin A; Diamide; Dose-Response Relationship, Drug; Drug Development; Enzyme Inhibitors; Hepacivirus; Hepatitis C, Chronic; Humans; Molecular Conformation; Molecular Docking Simulation; Molecular Targeted Therapy; Structure-Activity Relationship; Surface Plasmon Resonance

2020
Intracerebral haemorrhage and hepatitis C treatment.
    Journal of viral hepatitis, 2003, Volume: 10, Issue:5

    Topics: Adult; Antiviral Agents; Australia; Cerebral Hemorrhage; Drug Combinations; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Interferons; Male; Middle Aged; Retrospective Studies; Ribavirin

2003
[Acute hepatitis C].
    Przeglad epidemiologiczny, 2002, Volume: 56 Suppl 5

    Topics: Acute Disease; Adolescent; Adult; Aged; Antiviral Agents; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome

2002
[The treatment of HCV infection with interferon alpha and ribavirin in a child with diabetes I type].
    Przeglad epidemiologiczny, 2006, Volume: 60, Issue:2

    Topics: Adolescent; Antiviral Agents; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Treatment Outcome

2006
Direct-acting antiviral regimens in Egyptian patients with chronic hepatitis C virus infection: A real-world single-center experience.
    Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology, 2021, Volume: 22, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Egypt; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Retrospective Studies; Ribavirin; Treatment Outcome

2021
Novel variant in glycophorin c gene protects against ribavirin-induced anemia during chronic hepatitis C treatment.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 143

    Topics: Aged; Anemia, Hemolytic; Antiviral Agents; Canada; Case-Control Studies; Female; Genome-Wide Association Study; Glycophorins; Hepatitis C, Chronic; Humans; Male; Middle Aged; Pharmacogenetics; Pharmacogenomic Testing; Pharmacogenomic Variants; Prospective Studies; Pyrophosphatases; Receptors, Calcitriol; Ribavirin; Risk Assessment; Risk Factors

2021
Evaluation of the genetic toxicity of sofosbuvir and simeprevir with and without ribavirin in a human-derived liver cell line.
    Anais da Academia Brasileira de Ciencias, 2021, Volume: 93, Issue:4

    Topics: Antiviral Agents; Cell Line; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Simeprevir; Sofosbuvir

2021
Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with or without glucose abnormalities: Results of the EGG18 study.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2022, Volume: 54, Issue:8

    Topics: Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Glucose; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Ribavirin; RNA; Sulfonamides

2022
The use of antiviral drugs in children.
    Journal of chemotherapy (Florence, Italy), 2022, Volume: 34, Issue:2

    Topics: Adult; Antiviral Agents; Child; COVID-19; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Infant, Newborn; Ribavirin; SARS-CoV-2

2022
An in vitro study of an Artocarpus heterophyllus substance as a hepatitis C antiviral and its combination with current anti-HCV drugs.
    BMC complementary medicine and therapies, 2021, Oct-12, Volume: 21, Issue:1

    Topics: Antiviral Agents; Artocarpus; Cell Line; Cyclosporine; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Indonesia; Oligopeptides; Plant Extracts; Plant Leaves; Ribavirin

2021
[Glecaprevir/Pibrentasvir + Sofosbuvir + Ribavirin as a salvage regimen after Sofosbuvir + Velpatasvir + Voxilaprevir re-treatment failure].
    Zeitschrift fur Gastroenterologie, 2022, Volume: 60, Issue:6

    Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Child; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Failure; Treatment Outcome

2022
Comment on "Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience".
    Revista da Associacao Medica Brasileira (1992), 2021, Volume: 67, Issue:6

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Ribavirin

2021
Direct Relationship between Interleukin-10 Gene Polymorphism and Hepatocellular Carcinoma Complicated by Direct Acting Antiviral Treatment of Hepatitis C Virus.
    Asian Pacific journal of cancer prevention : APJCP, 2021, Oct-01, Volume: 22, Issue:10

    Topics: Adult; Aged; Antiviral Agents; Ascites; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interleukin-10; Liver Cirrhosis; Liver Neoplasms; Lymphadenitis; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Splenomegaly; Valine

2021
Twenty-year follow-up of an outbreak of hepatitis C in a small rural town of Argentina: The O'Brien Project.
    Annals of hepatology, 2022, Volume: 27 Suppl 1

    Topics: Aged; Antiviral Agents; Argentina; Carcinoma, Hepatocellular; Disease Outbreaks; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Neoplasms; Ribavirin

2022
Early liver function improvement following successful treatment of chronic hepatitis C in patients with decompensated cirrhosis: a real-life study.
    Clinics (Sao Paulo, Brazil), 2021, Volume: 76

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin; Sustained Virologic Response; Treatment Outcome

2021
The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients.
    Microbial pathogenesis, 2022, Volume: 162

    Topics: Antiviral Agents; Drug Therapy, Combination; Genetic Variation; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Immunity, Innate; Nerve Tissue Proteins; Ribavirin; Sofosbuvir; Treatment Outcome

2022
Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents.
    Scientific reports, 2022, 01-07, Volume: 12, Issue:1

    Topics: Administration, Oral; Aged; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Imidazoles; Incidence; Interferons; Isoquinolines; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Pyrrolidines; Retrospective Studies; Ribavirin; Seoul; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine

2022
Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAAs?
    Journal of hepatology, 2022, Volume: 77, Issue:1

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Sustained Virologic Response

2022
Patient-specific genetic factors predict treatment failure in sofosbuvir-treated patients with chronic hepatitis C.
    Liver international : official journal of the International Association for the Study of the Liver, 2022, Volume: 42, Issue:4

    Topics: Antiviral Agents; Canada; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interleukins; Ribavirin; Sofosbuvir; Treatment Failure; Treatment Outcome

2022
Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2022, Volume: 121, Issue:8

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Registries; Ribavirin; Sofosbuvir; Taiwan; Uridine Monophosphate

2022
Assessment of outcome for sample of Iraqi patients with chronic hepatitis C virus infection treated by Ledipasvir/sofosbuvir drug.
    JPMA. The Journal of the Pakistan Medical Association, 2021, Volume: 71(Suppl 8), Issue:12

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Pharmaceutical Preparations; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2021
Lower Rates of Emergency Department Visits and Hospitalizations Among Patients With Chronic Hepatitis C With Sustained Virological Response to Interferon-Free Direct-Acting Antiviral Therapy (2014-2018).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 10-12, Volume: 75, Issue:8

    Topics: Antiviral Agents; Emergency Service, Hospital; Hepacivirus; Hepatitis C, Chronic; Hospitalization; Humans; Interferons; Ribavirin; Sustained Virologic Response; Treatment Outcome

2022
Deciphering the Significance of Plasma Chemokines as Prognostic Biomarkers in Pegylated IFN-Α-2a /Ribavirin-Treated Chronic Hepatitis C Genotype 4 Patients.
    Infectious disorders drug targets, 2022, Volume: 22, Issue:5

    Topics: Antiviral Agents; Biomarkers; Chemokine CCL5; Chemokine CXCL10; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interleukin-8; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Treatment Outcome

2022
Sofosbuvir-based direct-acting antivirals for patients with decompensated hepatitis C virus-related cirrhosis.
    Journal of the Chinese Medical Association : JCMA, 2022, 05-01, Volume: 85, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome

2022
Geographic Distribution of HCV Genotypes and Efficacy of Direct-Acting Antivirals in Chronic HCV-Infected Patients in North and Northeast China: A Real-World Multicenter Study.
    Canadian journal of gastroenterology & hepatology, 2022, Volume: 2022

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2022
Epidemiology and Natural History of Childhood-Acquired Chronic Hepatitis C: A Single-Center Long-Term Prospective Study.
    Journal of pediatric gastroenterology and nutrition, 2022, 08-01, Volume: 75, Issue:2

    Topics: Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Prospective Studies; Ribavirin; Treatment Outcome

2022
Efficacy and Safety of Ombitasvir/Paritaprevir/ Ritonavir + Dasabuvir ± Ribavirin Combinations in Patients with Genotype 1 Hepatitis C and Inherited Bleeding Disorders.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2022, Volume: 33, Issue:5

    Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Child; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Retrospective Studies; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine

2022
[Efficacy and tolerance of direct-acting antiviral drugs for the treatment of hepatitis C in Joseph Raseta Befelatanana Teaching Hospital in Antananarivo, Madagascar].
    Medecine tropicale et sante internationale, 2021, 09-30, Volume: 1, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hospitals, Teaching; Humans; Madagascar; Retrospective Studies; Ribavirin; Sofosbuvir

2021
Sofosbuvir-based direct-acting antivirals and changes in cholesterol and low density lipoprotein-cholesterol.
    Scientific reports, 2022, 06-15, Volume: 12, Issue:1

    Topics: Antiviral Agents; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome

2022
A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania.
    Medical science monitor : international medical journal of experimental and clinical research, 2022, Jul-05, Volume: 28

    Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Prospective Studies; Ribavirin; Ritonavir; Romania; Sulfonamides; Uracil; Valine

2022
[The analysis of immunoreactivity of individual B-cell epitopes of hepatitis C virus (Flaviviridae: Hepacivirus: Hepatitis С virus) NS4a antigen].
    Voprosy virusologii, 2022, 07-14, Volume: 67, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Epitopes, B-Lymphocyte; Flaviviridae; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Nonstructural Proteins

2022
Efficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2022, Volume: 33, Issue:10

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Turkey

2022
Quantitative changes of lipoprotein(a) in chronic hepatitis C patients achieving a sustained virological response by direct-acting antivirals.
    Clinics and research in hepatology and gastroenterology, 2022, Volume: 46, Issue:8

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lipoprotein(a); Ribavirin; Sustained Virologic Response

2022
Dual versus triple therapy in treatment of hepatitis C virus (HCV).
    Irish journal of medical science, 2023, Volume: 192, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome

2023
Real-world Safety and Effectiveness of 24-week Sofosbuvir and Ribavirin Treatment in Patients Infected with Rare Chronic Hepatitis C Virus Genotypes 3, 4, 5, or 6 in Japan.
    Internal medicine (Tokyo, Japan), 2023, May-15, Volume: 62, Issue:10

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Japan; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome

2023
High real-world effectiveness of 12-week elbasvir/grazoprevir without resistance testing in the treatment of patients with HCV genotype 1a infection in Norway.
    Scandinavian journal of gastroenterology, 2023, Volume: 58, Issue:3

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin

2023
Three regimens for re-treatment failure of Sofosbuvir-based therapy for chronic hepatitis-C genotype-4: a cohort study.
    Revista do Instituto de Medicina Tropical de Sao Paulo, 2022, Volume: 64

    Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Failure; Treatment Outcome

2022
Precision Medicine: Determination of Ribavirin Urinary Metabolites in Relation to Drug Adverse Effects in HCV Patients.
    International journal of molecular sciences, 2022, Sep-02, Volume: 23, Issue:17

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Precision Medicine; Recombinant Proteins; Ribavirin; Treatment Outcome

2022
Detection of Occult Hepatitis C Virus Infection in Egyptian Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents.
    Asian Pacific journal of cancer prevention : APJCP, 2022, Sep-01, Volume: 23, Issue:9

    Topics: Aged; alpha-Fetoproteins; Antiviral Agents; Carbamates; Cross-Sectional Studies; Drug Therapy, Combination; Egypt; Fibrosis; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Leukocytes, Mononuclear; Pyrrolidines; Ribavirin; RNA; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2022
Association of interferon-based therapy with risk of autoimmune diseases in patients with chronic hepatitis C virus infection: A population-based Taiwanese cohort study.
    Frontiers in immunology, 2022, Volume: 13

    Topics: Cohort Studies; Graves Disease; Hashimoto Disease; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Retrospective Studies; Ribavirin; Risk Factors

2022
[Comparative evaluation of the effectiveness of narlaprevir in the composition of interferon and interferon-free treatment regimens for patients with chronic hepatitis C].
    Terapevticheskii arkhiv, 2022, Oct-12, Volume: 94, Issue:8

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Ritonavir; Treatment Outcome

2022
Ledipasvir/Sofosbuvir Is Effective for Relapsed Genotype 1b Hepatitis C Virus Patients after Achieving a Sustained Virological Response at Post-treatment Week 12 with Glecaprevir/Pibrentasvir.
    Internal medicine (Tokyo, Japan), 2023, Sep-01, Volume: 62, Issue:17

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Neoplasm Recurrence, Local; Ribavirin; Sofosbuvir

2023
Circulating microRNAs as predictors of response to sofosbuvir + daclatasvir + ribavirin in in HCV genotype-4 Egyptian patients.
    BMC gastroenterology, 2022, Dec-03, Volume: 22, Issue:1

    Topics: Antiviral Agents; Circulating MicroRNA; Egypt; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; MicroRNAs; Ribavirin; Sofosbuvir

2022
Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study.
    eLife, 2023, Jan-09, Volume: 12

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interleukins; Pilot Projects; Ribavirin; Sofosbuvir; Treatment Outcome

2023
Before Direct-Acting Antivirals for Hepatitis C Virus: Evaluation of Core Protein R70Q and L/C91M Substitutions in Chronically Infected Brazilian Patients Unresponsive to IFN and/or RBV.
    Viruses, 2023, 01-09, Volume: 15, Issue:1

    Topics: Antiviral Agents; Brazil; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2023
Evolution of liver fibrosis after interferon-based anti-hepatitis C virus therapy failure in 3,049 chronic hepatitis C patients without cirrhosis.
    Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology, 2023, Volume: 24, Issue:1

    Topics: Adult; Antiviral Agents; Female; Fibrosis; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Ribavirin

2023
Efficacy and safety of ombitasvir/paritaprevir/ritonavir-based therapy in HCV patients with chronic kidney disease.
    Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology, 2023, Volume: 24, Issue:1

    Topics: Anilides; Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Macrocyclic Compounds; Renal Insufficiency, Chronic; Ribavirin; Ritonavir; Treatment Outcome; Valine

2023
Next-generation sequencing analysis of hepatitis C virus resistance-associated substitutions in direct-acting antiviral failure in South Korea.
    Clinical and molecular hepatology, 2023, Volume: 29, Issue:2

    Topics: Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Ribavirin; Sofosbuvir; Viral Nonstructural Proteins

2023
Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens.
    Viruses, 2023, 03-04, Volume: 15, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Ribavirin; Treatment Outcome

2023
[A case of chronic hepatitis C treated with sofosbuvir/velpatasvir combined with ribavirin among 3-year-old children with low body weight].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2023, Feb-20, Volume: 31, Issue:2

    Topics: Antiviral Agents; Body Weight; Child, Preschool; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome

2023
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2023, Volume: 43, Issue:9

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interleukins; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome

2023
Pre-existing, treatment-specific resistance-associated substitutions in hepatitis C virus genotype 1 and 3 and viral RNA titers during treatment with direct-acting antivirals.
    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2023, Volume: 131, Issue:8

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response

2023
Fitness-Dependent, Mild Mutagenic Activity of Sofosbuvir for Hepatitis C Virus.
    Antimicrobial agents and chemotherapy, 2023, 07-18, Volume: 67, Issue:7

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Mutagens; Ribavirin; Sofosbuvir; Treatment Outcome

2023
Prediction of response to sofosbuvir-based therapy using serum interleukin-12 and single nucleotide polymorphism of the interleukin 28B gene as predictive factors in HCV positive genotype-4 patients.
    Medicine, 2023, Jul-14, Volume: 102, Issue:28

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukin-12; Interleukins; Polymorphism, Single Nucleotide; Ribavirin; Sofosbuvir; Treatment Outcome

2023
A Retrospective Study of Long-Term Clinical Outcomes in Patients with Chronic Hepatitis C Treated with Interferon and Ribavirin.
    Discovery medicine, 2023, Volume: 35, Issue:178

    Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome

2023
Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis.
    Viruses, 2023, 09-29, Volume: 15, Issue:10

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome

2023
Cytokine polymorphisms and genotypic susceptibility of HCV infection in ribavirin response to peg interferon.
    Tropical biomedicine, 2023, Sep-01, Volume: 40, Issue:3

    Topics: Antiviral Agents; Cytokines; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Interleukin-10; Interleukin-6; Interleukins; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Transforming Growth Factor beta1; Treatment Outcome; Tumor Necrosis Factor-alpha

2023
Associations of ITPA gene polymorphisms with outcomes among chronic hepatitis C patients treated with Peg-interferon/ribavirin: A 5-year follow-up study.
    Medicine, 2023, Oct-27, Volume: 102, Issue:43

    Topics: Antiviral Agents; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Interferons; Interleukins; Liver Cirrhosis; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Treatment Outcome

2023
Usefulness Of Sofosbuvir And Daclatasvir Combination In The Treatment Of HCV Infection In Childhood Cancer Patients: Experience From A Tertiary Care Hospital.
    JPMA. The Journal of the Pakistan Medical Association, 2023, Volume: 73, Issue:11

    Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Neoplasms; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Tertiary Care Centers; Treatment Outcome

2023
Effectiveness of generic sofosbuvir in the treatment of chronic hepatitis C virus infection in Saudi patients.
    Saudi medical journal, 2023, Volume: 44, Issue:12

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Drugs, Generic; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Saudi Arabia; Sofosbuvir; Treatment Outcome

2023
Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort.
    PloS one, 2019, Volume: 14, Issue:8

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Mutation; Quinoxalines; Ribavirin; Sofosbuvir; Spain; Sulfonamides; Sustained Virologic Response; Viral Nonstructural Proteins

2019
Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil.
    Clinics and research in hepatology and gastroenterology, 2020, Volume: 44, Issue:3

    Topics: Antiviral Agents; Brazil; Carbamates; Cohort Studies; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Mutation; Prospective Studies; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Valine

2020
Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study.
    PloS one, 2019, Volume: 14, Issue:9

    Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; Ribavirin; Ritonavir; Spain; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine

2019
Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy.
    Journal of medical virology, 2020, Volume: 92, Issue:2

    Topics: Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Cell Line; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Mutation; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Valine

2020
Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register).
    European journal of gastroenterology & hepatology, 2019, Volume: 31, Issue:11

    Topics: 2-Naphthylamine; Acute Disease; Adult; Aged; Anemia; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Female; Fluorenes; Germany; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Hypertension; Imidazoles; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Pleural Effusion; Proline; Pyrrolidines; Registries; Renal Insufficiency, Chronic; Ribavirin; Ritonavir; RNA, Viral; Severity of Illness Index; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Uridine Monophosphate; Valine

2019
Efficacy, Safety, and Predictors of Direct-acting antivirals in Hepatitis C Virus Patients with Heterogeneous Liver Diseases.
    The new microbiologica, 2019, Volume: 42, Issue:4

    Topics: 2-Naphthylamine; Antiviral Agents; Biomarkers, Pharmacological; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Middle Aged; Proline; Retrospective Studies; Ribavirin; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil

2019
Association between PNPLA3[G]/I148M variant, steatosis and fibrosis stage in hepatitis C virus - genetic matters.
    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2019, Volume: 70, Issue:4

    Topics: Antiviral Agents; Disease Progression; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lipase; Liver; Liver Cirrhosis; Male; Membrane Proteins; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral

2019
Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies.
    Journal of viral hepatitis, 2020, Volume: 27, Issue:3

    Topics: Age Factors; Antiviral Agents; Benzimidazoles; British Columbia; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Logistic Models; Lost to Follow-Up; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2020
Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 10-23, Volume: 71, Issue:7

    Topics: Analgesics, Opioid; Anilides; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Pharmaceutical Preparations; Ribavirin; Sustained Virologic Response

2020
[QOL Assessment in Chronic Hepatitis C Patients Receiving Ledipasvir/ Sofosbuvir or Simeprevir/Peginterferon/Ribavirin in Clinical Practice].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2019, Volume: 139, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Surveys and Questionnaires

2019
Retreatment of chronic hepatitis C virus genotype-4 patients after non-structural protein 5A inhibitors' failure: efficacy and safety of different regimens.
    European journal of gastroenterology & hepatology, 2020, Volume: 32, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Retreatment; Ribavirin; Sofosbuvir; Sustained Virologic Response

2020
Predictors of adverse drug reactions associated with ribavirin in direct-acting antiviral therapies for chronic hepatitis C.
    Pharmacoepidemiology and drug safety, 2019, Volume: 28, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antiviral Agents; Brazil; Carbamates; Drug Therapy, Combination; Fatigue; Female; Headache; Hepatitis C, Chronic; Humans; Imidazoles; Longitudinal Studies; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Pyrrolidines; Ribavirin; Risk Factors; Sofosbuvir; Valine

2019
Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain.
    PloS one, 2019, Volume: 14, Issue:11

    Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Lactams, Macrocyclic; Logistic Models; Macrocyclic Compounds; Male; Middle Aged; Multivariate Analysis; Proline; Ribavirin; Spain; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine

2019
Sofosbuvir-/Daclatasvir-based therapy for chronic HCV and HCV/hepatitis B virus coinfected patients in Egypt.
    Transactions of the Royal Society of Tropical Medicine and Hygiene, 2020, 02-07, Volume: 114, Issue:3

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Egypt; Genotype; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine

2020
Higher sustained virological response rates at 12 weeks in HIV-HCV co-infection; a tertiary centre experience.
    The Journal of infection, 2020, Volume: 80, Issue:2

    Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Retrospective Studies; Ribavirin; Treatment Outcome

2020
New Scoring Method to Predict Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C After Pegylated Interferon and Ribavirin Therapy.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2020, Volume: 40, Issue:2

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Regression Analysis; Retrospective Studies; Ribavirin; Risk Factors

2020
A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan.
    Advances in therapy, 2020, Volume: 37, Issue:1

    Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Japan; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Uridine Monophosphate

2020
The effect of genetic variations on ribavirin pharmacokinetics and treatment response in HCV-4 Egyptian patients receiving sofosbuvir/daclatasvir and ribavirin.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020, Volume: 121

    Topics: Carbamates; Drug Therapy, Combination; Egypt; Endpoint Determination; Gene Frequency; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Logistic Models; Middle Aged; Polymorphism, Single Nucleotide; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine

2020
Antiviral therapy against chronic hepatitis C is associated with a reduced risk of oral cancer.
    International journal of cancer, 2020, 08-01, Volume: 147, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Case-Control Studies; Confounding Factors, Epidemiologic; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Mouth Neoplasms; Ribavirin; Taiwan

2020
Sofosbuvir-containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Egypt; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2020
Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
    BMC infectious diseases, 2020, Jan-10, Volume: 20, Issue:1

    Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Georgia (Republic); Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Lost to Follow-Up; Male; Middle Aged; National Health Programs; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Young Adult

2020
Sustained virologic response and changes in liver fibrosis parameters following 12-wk administration of generic sofosbuvir and daclatasvir in HIV/HCV-coinfected patients with HCV genotype 4 infection.
    Transactions of the Royal Society of Tropical Medicine and Hygiene, 2020, 04-08, Volume: 114, Issue:4

    Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2020
Inducible Nitric Oxide Synthase Polymorphism In Hepatitis C Patients Treated With Interferon Based-Treatment As A Predictor of Early Virological Response.
    The Egyptian journal of immunology, 2019, Volume: 26, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Egypt; Haplotypes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Nitric Oxide Synthase Type II; Polyethylene Glycols; Ribavirin; Treatment Outcome

2019
[Progress of antiviral therapy for hepatitis C virus-related decompensated cirrhosis].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2019, Dec-20, Volume: 27, Issue:12

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Failure; Ribavirin; Sofosbuvir; Treatment Outcome

2019
Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohorts.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2020, Volume: 52, Issue:4

    Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Italy; Male; Middle Aged; Pyrrolidines; Regression Analysis; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine

2020
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Ribavirin; Sofosbuvir; Treatment Outcome

2020
Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience.
    Revista da Associacao Medica Brasileira (1992), 2019, Volume: 65, Issue:12

    Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Statistics, Nonparametric; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Uracil; Valine; Young Adult

2019
Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose.
    Gut and liver, 2020, 11-15, Volume: 14, Issue:6

    Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Republic of Korea; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2020
Comparative hepatitis C genotype 1-3 viral load kinetics in response to directly-acting antiviral therapy.
    The Journal of infection, 2020, Volume: 80, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Kinetics; Ribavirin; Viral Load

2020
Cost-effectiveness analysis is a mandatory strategy for health systems: evidence from a study involving therapies for hepatitis C.
    Cadernos de saude publica, 2020, Volume: 36, Issue:2

    Topics: Antiviral Agents; Brazil; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin

2020
Plasma FABP4 is associated with liver disease recovery during treatment-induced clearance of chronic HCV infection.
    Scientific reports, 2020, 02-07, Volume: 10, Issue:1

    Topics: Antiviral Agents; Cytokines; Fatty Acid-Binding Proteins; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Ribavirin

2020
Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV.
    PloS one, 2020, Volume: 15, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Coinfection; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; United States; Uridine Monophosphate; Viral Load

2020
Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir.
    Canadian journal of gastroenterology & hepatology, 2020, Volume: 2020

    Topics: Acute Kidney Injury; Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Egypt; Female; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney; Lipocalin-2; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Valine

2020
Pharmacological management of adverse events during treatment of chronic viral hepatitis in three Ivorian university hospitals
.
    International journal of clinical pharmacology and therapeutics, 2020, Volume: 58, Issue:5

    Topics: Antiviral Agents; Carbamates; Cote d'Ivoire; Cross-Sectional Studies; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Hospitals, University; Humans; Imidazoles; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Valine

2020
Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand.
    PloS one, 2020, Volume: 15, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Thailand; Time Factors; Treatment Outcome; Uridine Monophosphate

2020
Do gamma-glutamyltransferase levels identify HCV patients who require lifelong post-SVR follow-up?
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:3

    Topics: Follow-Up Studies; gamma-Glutamyltransferase; Hepatitis C, Chronic; Humans; Ribavirin; Risk Factors

2020
Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study.
    BMC gastroenterology, 2020, Mar-05, Volume: 20, Issue:1

    Topics: Adiponectin; Aged; Alanine Transaminase; Benzimidazoles; Blood Glucose; Carbamates; Cholesterol; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Insulin; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine; Viral Nonstructural Proteins

2020
Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2020, Volume: 31, Issue:2

    Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Azerbaijan; Cyclopropanes; Drug Therapy, Combination; Female; Genes, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Turkey; Uracil; Valine

2020
Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis.
    Scientific reports, 2020, 03-25, Volume: 10, Issue:1

    Topics: Adult; Antiviral Agents; Arthritis, Rheumatoid; Autoimmune Diseases; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Lupus Erythematosus, Systemic; Male; Middle Aged; Polyethylene Glycols; Proportional Hazards Models; Ribavirin; Sustained Virologic Response; Taiwan; Viral Load

2020
Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens.
    BMC gastroenterology, 2020, Apr-06, Volume: 20, Issue:1

    Topics: Adult; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Pakistan; Polyethylene Glycols; Proportional Hazards Models; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Tomography, X-Ray Computed; Valine

2020
C19orf66 is an interferon-induced inhibitor of HCV replication that restricts formation of the viral replication organelle.
    Journal of hepatology, 2020, Volume: 73, Issue:3

    Topics: Adult; Antiviral Agents; Cell Line, Tumor; Female; Gene Knockout Techniques; Genotype; HEK293 Cells; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Interferons; Liver; Male; Middle Aged; Organelles; Replicon; Ribavirin; RNA-Binding Proteins; RNA, Viral; Treatment Outcome; Viral Replication Compartments; Virus Replication

2020
Cost-effectiveness of Oral Regimens for Adolescents With Chronic Hepatitis C Virus Infection.
    The Pediatric infectious disease journal, 2020, Volume: 39, Issue:6

    Topics: Administration, Oral; Adolescent; Antiviral Agents; Benzimidazoles; Child; China; Cost-Benefit Analysis; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Markov Chains; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; United States

2020
Histomorphometric Findings May Help Predicting Response in Patients with Chronic Liver Disease.
    The Israel Medical Association journal : IMAJ, 2020, Volume: 22, Issue:5

    Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Predictive Value of Tests; Retrospective Studies; Ribavirin; Treatment Outcome

2020
Successful fourth line treatment of a relapse patient with chronic hepatitis C virus infection genotype 3a using sofosbuvir, glecaprevir/pibrentasvir, and ribavirin: a case report.
    Zeitschrift fur Gastroenterologie, 2020, Volume: 58, Issue:5

    Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Middle Aged; Neoplasm Recurrence, Local; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome

2020
Role of Ribavirin in the Era of Direct-Acting Antiviral Therapies of Chronic Hepatitis C.
    Expert review of anti-infective therapy, 2020, Volume: 18, Issue:8

    Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Egypt; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Ribavirin

2020
Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2020, Volume: 31, Issue:4

    Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Cyclopropanes; Databases, Factual; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Turkey; Uracil; Valine; Young Adult

2020
Development of a long-acting direct-acting antiviral system for hepatitis C virus treatment in swine.
    Proceedings of the National Academy of Sciences of the United States of America, 2020, 06-02, Volume: 117, Issue:22

    Topics: Animals; Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Imidazoles; Liver Cirrhosis; Models, Animal; Pyrrolidines; Ribavirin; Sofosbuvir; Swine; Valine

2020
Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam.
    PloS one, 2020, Volume: 15, Issue:5

    Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Vietnam; Viral Load

2020
Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:8

    Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2020
Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3-11 Years with Hepatitis C Genotype 1a.
    Advances in therapy, 2020, Volume: 37, Issue:7

    Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Child; Child, Preschool; Cyclopropanes; Cytochrome P-450 CYP3A Inhibitors; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Male; Proline; Ribavirin; Ritonavir; Sulfonamides; Tablets; Uracil; Valine

2020
The impact of direct-acting antiviral treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients: temporary? permanent?
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2020, Volume: 31, Issue:5

    Topics: Aged; Anilides; Antiviral Agents; Benzimidazoles; Blood Glucose; Cholesterol; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Lactams, Macrocyclic; Lipid Metabolism; Lipoproteins, LDL; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Triglycerides; Valine

2020
Anti-rod and ring antibodies in patients with chronic hepatitis C using direct-acting antivirals.
    Immunologic research, 2020, Volume: 68, Issue:3

    Topics: Aged; Antibodies, Antinuclear; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Fluorescent Antibody Technique, Indirect; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine

2020
M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals.
    World journal of gastroenterology, 2020, Jun-07, Volume: 26, Issue:21

    Topics: Adult; Antigens, Neoplasm; Antiviral Agents; Biomarkers; Biomarkers, Tumor; Carbamates; Drug Combinations; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Follow-Up Studies; Glycosylation; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; ROC Curve; Severity of Illness Index; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2020
Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2020, Volume: 119, Issue:12

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Taiwan

2020
Safety assessment of chronic hepatitis C treatment using h-FABP and 24-hour ECG Holter monitoring.
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2020, Jun-17, Volume: 48, Issue:285

    Topics: Antiviral Agents; Biomarkers; Electrocardiography, Ambulatory; Fatty Acid Binding Protein 3; Heart Rate; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2020
Real-world safety and effectiveness of retreatment of Egyptian chronic hepatitis C patients not responding to NS5A inhibitor-based therapies.
    Journal of viral hepatitis, 2020, Volume: 27, Issue:11

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Neoplasms; Prospective Studies; Retreatment; Ribavirin; Sofosbuvir; Treatment Outcome

2020
[Antiviral therapy of chronic hepatitis C: 30 years success story].
    Terapevticheskii arkhiv, 2019, Nov-15, Volume: 91, Issue:11

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Russia

2019
Cure or curd: Modification of lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication.
    The Kaohsiung journal of medical sciences, 2020, Volume: 36, Issue:11

    Topics: Aged; Antiviral Agents; Carbamates; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Dyslipidemias; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Risk; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Triglycerides; Valine

2020
Real-word efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection.
    Clinical journal of gastroenterology, 2020, Volume: 13, Issue:6

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Sofosbuvir; Treatment Outcome

2020
A decade of hepatitis C at the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa, in the pre-direct-acting antivirals era.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2020, Jan-29, Volume: 110, Issue:2

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Oligopeptides; Patient Selection; Polyethylene Glycols; Retrospective Studies; Ribavirin; South Africa; Treatment Outcome

2020
Long-term clinical benefits of Sofosbuvir-based direct antiviral regimens for patients with chronic hepatitis C in Central and West Africa.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:11

    Topics: Africa South of the Sahara; Antiviral Agents; Cote d'Ivoire; Hepatitis C, Chronic; Humans; Liver Neoplasms; Ribavirin; Sofosbuvir

2020
Impact of sustained virological response on metabolic disorders in diabetic chronic hepatitis C virus patients after treatment with generic sofosbuvir and daclatasvir.
    European journal of gastroenterology & hepatology, 2021, 12-01, Volume: 33, Issue:12

    Topics: Antiviral Agents; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Valine

2021
Health-related quality of life and fatigue in patients with chronic hepatitis C with therapy with direct-acting antivirals agents interferon-free.
    PloS one, 2020, Volume: 15, Issue:8

    Topics: Aged; Antiviral Agents; Brazil; Cohort Studies; Fatigue; Female; Hepatitis C, Chronic; Humans; Interferons; Linear Models; Male; Middle Aged; Patient Reported Outcome Measures; Prospective Studies; Quality of Life; Ribavirin; Sustained Virologic Response

2020
Rapid virologic response in chronic hepatitis C genotype 1: Evaluation of pretreatment factors in patients.
    Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology, 2020, Volume: 21, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Recombinant Proteins; Ribavirin; Treatment Outcome

2020
Hepatitis C infection at a tertiary hospital in South Africa: Clinical presentation, non-invasive assessment of liver fibrosis, and response to therapy.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2020, Aug-31, Volume: 110, Issue:9

    Topics: Adult; Aged; Antiviral Agents; Area Under Curve; Aspartate Aminotransferases; Comorbidity; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; ROC Curve; South Africa; Sustained Virologic Response; Tertiary Care Centers

2020
A decrease in hepatitis C virus RNA to undetectable levels in chronic hepatitis C patients after PegIFNα + RVB or sofosbuvir + NS5A inhibitor treatment is associated with decreased insulin resistance and persistent oxidative stress.
    Archives of virology, 2020, Volume: 165, Issue:12

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon-alpha; Male; Middle Aged; Oxidative Stress; Pilot Projects; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Viral Nonstructural Proteins

2020
Effectiveness and safety of ledipasvir/sofosbuvir for genotype 2 chronic hepatitis C infection: Real-world experience from Taiwan.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2021, Volume: 120, Issue:3

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Taiwan; Treatment Outcome

2021
Effects of Hepatitis C Virus (HCV) Eradication on Bone Mineral Density in Human Immunodeficiency Virus/HCV-Coinfected Patients.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021, 10-05, Volume: 73, Issue:7

    Topics: Antiviral Agents; Bone Density; Coinfection; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2021
The interrelation between lipid profile in chronic HCV patients and their response to antiviral agents.
    Expert review of gastroenterology & hepatology, 2021, Volume: 15, Issue:1

    Topics: Adult; Antiviral Agents; Carbamates; Female; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Lipid Metabolism; Lipids; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Pyrrolidines; Recombinant Proteins; Ribavirin; Sofosbuvir; Valine

2021
Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).
    European journal of gastroenterology & hepatology, 2022, 01-01, Volume: 34, Issue:1

    Topics: Amides; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; Registries; Renal Insufficiency, Chronic; Ribavirin; Sulfonamides; Sustained Virologic Response

2022
Modulation of Immune Cell Subsets by Hepatitis C Virus and Antiviral Therapy in Early Virological Response HCV Genotype 4-Infected Patients with Compensated Liver Disease.
    Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2021, Volume: 30, Issue:2

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Flow Cytometry; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; T-Lymphocytes

2021
Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results.
    PloS one, 2020, Volume: 15, Issue:10

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir

2020
Some concerns about "PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virus-related diseases".
    Liver international : official journal of the International Association for the Study of the Liver, 2021, Volume: 41, Issue:5

    Topics: Hepacivirus; Hepatitis C, Chronic; Humans; Interleukins; Programmed Cell Death 1 Receptor; Ribavirin

2021
Cost-effectiveness analysis of sofosbuvir and velpatasvir in chronic hepatitis C patients with decompensated cirrhosis.
    Journal of viral hepatitis, 2021, Volume: 28, Issue:2

    Topics: Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Infant, Newborn; Liver Cirrhosis; Liver Neoplasms; Ribavirin; Sofosbuvir; Treatment Outcome

2021
Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study.
    Journal of acquired immune deficiency syndromes (1999), 2021, 02-01, Volume: 86, Issue:2

    Topics: Anilides; Antiviral Agents; Benzimidazoles; Coinfection; Cyclopropanes; Female; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Lactams, Macrocyclic; Male; Middle Aged; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine

2021
Efficacy and safety of ombitasvir/paritaprevir/ritonavir/ribavirin in management of Egyptian chronic hepatitis C virus patients with chronic kidney disease: A real-life experience.
    Medicine, 2020, Oct-16, Volume: 99, Issue:42

    Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Egypt; Female; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Valine

2020
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
    The Kaohsiung journal of medical sciences, 2021, Volume: 37, Issue:4

    Topics: Age Factors; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Pyrrolidines; Quinoxalines; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides; Taiwan; Treatment Outcome; Valine

2021
Interleukin-17 haplotyping predicts hepatocellular carcinoma in sofosbuvir, pegylated interferon-alpha-2a & ribavirin treated chronic hepatitis C patients.
    Virus research, 2021, 01-15, Volume: 292

    Topics: alpha-Fetoproteins; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Haplotypes; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukin-17; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Receptors, Interleukin-17; Recombinant Proteins; Ribavirin; Sofosbuvir

2021
Efficacy and Safety of Sofosbuvir-Based Direct-Acting Antiviral Agents Treatment for Patients with Genotype 3/6 Hepatitis C Virus Infection.
    Canadian journal of gastroenterology & hepatology, 2020, Volume: 2020

    Topics: Antiviral Agents; Child; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Pharmaceutical Preparations; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome

2020
Depression Disorders in Patients with Chronic Hepatitis C.
    Psychiatria Danubina, 2020, Volume: 32, Issue:Suppl 4

    Topics: Antiviral Agents; Bosnia and Herzegovina; Buprenorphine; Depression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Methadone; Ribavirin

2020
Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients.
    European journal of gastroenterology & hepatology, 2020, Volume: 32, Issue:8

    Topics: Antiviral Agents; Carbamates; Child; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Liver Neoplasms; Male; Morbidity; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine

2020
Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort.
    Journal of gastroenterology and hepatology, 2021, Volume: 36, Issue:5

    Topics: Adult; Carbamates; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2021
Sofosbuvir-based Treatment for HCV: A Safe Option in Patients Undergoing Hemodialysis.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2020, Volume: 30, Issue:11

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Renal Dialysis; Ribavirin; Sofosbuvir; Treatment Outcome

2020
Combination treatment with sofosbuvir and ribavirin for patients diagnosed with hepatitis C genotype 2: A real-world, single-center study.
    Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology, 2021, Volume: 22, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome

2021
Improving access to the treatment of hepatitis C in low- and middle-income countries: evaluation of a patient assistance programme.
    International journal of clinical pharmacy, 2021, Volume: 43, Issue:4

    Topics: Antiviral Agents; Developing Countries; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir

2021
Precipitating factors causing hyperbilirubinemia during chronic hepatitis C treatment with paritaprevir/ritonavir/ombitasvir and dasabuvir.
    Journal of the Chinese Medical Association : JCMA, 2020, Volume: 83, Issue:12

    Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Cyclopropanes; Female; Hepatitis C, Chronic; Humans; Hyperbilirubinemia; Lactams, Macrocyclic; Male; Middle Aged; Precipitating Factors; Proline; Retrospective Studies; Ribavirin; Ritonavir; Sulfonamides; Taiwan; Uracil; Valine

2020
Direct acting antiviral therapy rescues neutrophil dysfunction and reduces hemolysis in hepatitis C infection.
    Translational research : the journal of laboratory and clinical medicine, 2021, Volume: 232

    Topics: Aged; Antiviral Agents; Female; Hemolysis; Hepatitis C, Chronic; Humans; Liver; Male; Middle Aged; Neutrophils; Phagocytosis; Prospective Studies; Ribavirin

2021
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment.
    Gut, 2022, Volume: 71, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Combinations; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Young Adult

2022
Pegylated interferon and ribavirin gone but not forgotten in the era of direct-acting antivirals.
    Minerva pediatrics, 2022, Volume: 74, Issue:1

    Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin; Treatment Outcome

2022
Sofosbuvir plus ribavirin combination regimen boost liver functions and antioxidant profile in hepatitis C virus patients.
    Microbial pathogenesis, 2021, Volume: 150

    Topics: Antioxidants; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome

2021
The role of anthranilic acid in the increase of depressive symptoms and major depressive disorder during treatment for hepatitis C with pegylated interferon-α2a and oral ribavirin.
    Journal of psychiatry & neuroscience : JPN, 2021, 01-18, Volume: 46, Issue:1

    Topics: Adult; Antiviral Agents; Cross-Sectional Studies; Depression; Depressive Disorder, Major; Female; Hepatitis C, Chronic; Humans; Immunologic Factors; Indoleamine-Pyrrole 2,3,-Dioxygenase; Interferon-alpha; Kynurenic Acid; Kynurenine; Longitudinal Studies; Male; Middle Aged; ortho-Aminobenzoates; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tryptophan

2021
IgE antibodies to hepatitis C virus core and nonstructural antigens in chronic hepatitis C patients before and after antiviral treatment.
    International immunopharmacology, 2021, Volume: 93

    Topics: Adult; Aged; Antibodies, Viral; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunoglobulin E; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Core Proteins; Viral Nonstructural Proteins

2021
A real-life study on the impact of direct-acting antivirals in the treatment of chronic hepatitis C in liver transplant recipients at two university centers in Northeastern Brazil.
    Revista do Instituto de Medicina Tropical de Sao Paulo, 2021, Volume: 63

    Topics: Aged; Antiviral Agents; Brazil; DNA, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Ribavirin; Transplant Recipients; Treatment Outcome

2021
Deinduction of P-glycoprotein resulting in delayed viral response during hepatitis C treatment.
    Journal of clinical pharmacy and therapeutics, 2021, Volume: 46, Issue:5

    Topics: Anti-Retroviral Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carbamates; Carbamazepine; Cell Membrane; Drug Combinations; Drug Interactions; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir

2021
The relevance between anti-rods/rings antibody and different treatment regimens in chronic hepatitis C virus infection.
    Microbiology and immunology, 2021, Volume: 65, Issue:4

    Topics: Antibodies, Antinuclear; Antiviral Agents; Genotype; Hepacivirus; Hepatitis Antibodies; Hepatitis C, Chronic; Humans; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2021
[Use of sofosbuvir-based regimens in the treatment of adolescents and children with chronic hepatitis C].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2021, Jan-20, Volume: 29, Issue:1

    Topics: Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; China; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome

2021
Ribavirin Improves NK Cell IFNγ Response During Sofosbuvir-based DAA Therapy in HCV-infected Liver Transplant Recipients.
    Transplantation, 2021, 10-01, Volume: 105, Issue:10

    Topics: Antiviral Agents; Case-Control Studies; Cell Degranulation; Cells, Cultured; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-gamma; Killer Cells, Natural; Liver Transplantation; Phosphorylation; Ribavirin; Sofosbuvir; STAT1 Transcription Factor; STAT4 Transcription Factor; Time Factors; Treatment Outcome

2021
Interferon-γ inducible protein-10 and interleukin 28B gene polymorphism as predictive markers for genotype 4 hepatitis C virus treatment response.
    Tropical biomedicine, 2020, Dec-01, Volume: 37, Issue:4

    Topics: Adult; Aged; Chemokine CXCL10; Cross-Sectional Studies; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; Sustained Virologic Response; Young Adult

2020
Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan.
    Journal of gastroenterology and hepatology, 2021, Volume: 36, Issue:8

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Renal Dialysis; Ribavirin; Taiwan; Treatment Outcome

2021
Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first- and second-generation NS5A inhibitors.
    Journal of medical virology, 2021, Volume: 93, Issue:8

    Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Mutation; Proline; Retreatment; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Viral Nonstructural Proteins

2021
Sofosbuvir-based therapies associated with regression of liver fibrosis in patients with hepatitis C virus infection: A prospective observational study.
    Medicine, 2021, Mar-26, Volume: 100, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2021
Successful treatment of positive-sense RNA virus coinfection with autoimmune hepatitis using double filtration plasmapheresis.
    BMJ case reports, 2021, Mar-25, Volume: 14, Issue:3

    Topics: Antiviral Agents; Coinfection; COVID-19; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Hepatitis, Autoimmune; Humans; Interferon alpha-2; Middle Aged; Plasmapheresis; Polyethylene Glycols; Positive-Strand RNA Viruses; Ribavirin; SARS-CoV-2; Treatment Outcome; Viral Load

2021
Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patients.
    Journal of clinical pharmacy and therapeutics, 2021, Volume: 46, Issue:4

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Black People; Carbamates; Drug Therapy, Combination; Egypt; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Male; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine; Young Adult

2021
Analysis of Different Types of Interferon-Associated Retinopathy in Patients with Chronic Hepatitis C Virus Infection Treated with Pegylated Interferon Plus Ribavirin.
    Viruses, 2021, 03-14, Volume: 13, Issue:3

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Male; Middle Aged; Retinal Diseases; Retrospective Studies; Ribavirin

2021
Resistance-associated substitutions and response to treatment in a chronic hepatitis C virus infected-patient: an unusual virological response case report.
    BMC infectious diseases, 2021, Apr-26, Volume: 21, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response

2021
Pregnancy outcome of anti-HCV direct-acting antivirals: Real-life data from an Egyptian cohort.
    Liver international : official journal of the International Association for the Study of the Liver, 2021, Volume: 41, Issue:7

    Topics: Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Infant, Newborn; Pregnancy; Pregnancy Outcome; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2021
Single-pill sofosbuvir and daclatasvir for treating hepatis C in patients co-infected with human immunodeficiency virus.
    International journal of clinical practice, 2021, Volume: 75, Issue:8

    Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine

2021
Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2021, Volume: 32, Issue:2

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome; Turkey

2021
Hepatitis B Surface Antigen Decline during Sofosbuvir and Ribavirin Therapy in Hepatitis B Inactive Carriers Who Were Co-infected with Hepatitis C.
    Internal medicine (Tokyo, Japan), 2021, Nov-15, Volume: 60, Issue:22

    Topics: Antiviral Agents; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Hepatitis C, Chronic; Humans; Retrospective Studies; Ribavirin; Sofosbuvir

2021
Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult-to-Treat HCV Patients.
    Hepatology (Baltimore, Md.), 2021, Volume: 74, Issue:4

    Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Monitoring; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Medication Therapy Management; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome

2021
Health-related quality of life in patients with chronic hepatitis C treated with sofosbuvir-based treatment at 1-year post-sustained virological response.
    Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2021, Volume: 30, Issue:12

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Infant; Quality of Life; Ribavirin; Sofosbuvir; Treatment Outcome

2021
Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed.
    Internal medicine (Tokyo, Japan), 2021, Nov-01, Volume: 60, Issue:21

    Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome

2021
Efficacy and Safety of Ombitasvir plus Paritaprevir, Ritonavir and Ribavirin in Non-cirrhotic Treatment-naïve and Treatment-experienced Egyptians with Chronic HCV Genotype-4 Infection.
    Current medical science, 2021, Volume: 41, Issue:3

    Topics: Adult; Anilides; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Male; Proline; Ribavirin; Ritonavir; Sulfonamides; Valine

2021
Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter Study.
    Journal of Korean medical science, 2021, May-31, Volume: 36, Issue:21

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Quinoxalines; Republic of Korea; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome

2021
Prevalence of resistance-associated substitutions to NS3, NS5A and NS5B inhibitors at DAA-failure in hepatitis C virus in Italy from 2015 to 2019.
    Le infezioni in medicina, 2021, Jun-01, Volume: 29, Issue:2

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Combinations; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Italy; Macrocyclic Compounds; Prevalence; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides

2021
THE ROLE OF GALECTIN-9 IN PATIENTS WITH CHRONIC VIRAL HEPATITIS C AND ITS CONNECTION WITH THE TYPE OF THERAPY, THE DEGREE OF FIBROSIS, CLINICAL, LABORATORY, AUTOIMMUNE AND INTEGRATIVE INDICATORS.
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 2021, Volume: 74, Issue:5

    Topics: Galectins; Hepatitis C, Chronic; Humans; Laboratories; Liver Cirrhosis; Ribavirin

2021
Efficacy and safety of danoprevir plus sofosbuvir in GT 1, 2, 3, or 6 chronic hepatitis C patients with or without cirrhosis in China.
    Medicine, 2021, Jun-18, Volume: 100, Issue:24

    Topics: Adult; Antiviral Agents; China; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Isoindoles; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response

2021
Hepatitis C Virus Core Antigen (HCVAg): an affordable assay to monitor the efficacy of treatment in DAAs era.
    The new microbiologica, 2021, Volume: 44, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Ribavirin; RNA, Viral; Treatment Outcome

2021
Sofosbuvir-based therapies in genotype 2 hepatitis C virus cirrhosis: A real-life experience with focus on ribavirin dose.
    Pharmacology research & perspectives, 2021, Volume: 9, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Valine

2021
Influence of gender on cytokine induced depression and treatment: Gender aspects of IFN-α-induced depression.
    Journal of affective disorders, 2021, 09-01, Volume: 292

    Topics: Antiviral Agents; Cytokines; Depression; Depressive Disorder, Major; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Ribavirin

2021
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis.
    Clinical and molecular hepatology, 2021, Volume: 27, Issue:4

    Topics: Antiviral Agents; Carbamates; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome

2021
Multiscale model of hepatitis C virus dynamics in plasma and liver following combination therapy.
    CPT: pharmacometrics & systems pharmacology, 2021, Volume: 10, Issue:8

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Models, Theoretical; Nonlinear Dynamics; Oligopeptides; Polyethylene Glycols; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2021
Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study.
    Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 2017, Volume: 51

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2017
Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy.
    Journal of gastroenterology, 2017, Volume: 52, Issue:10

    Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Prospective Studies; Pyrrolidines; Retreatment; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine

2017
Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions.
    World journal of gastroenterology, 2017, Mar-07, Volume: 23, Issue:9

    Topics: Analgesics; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Pharmacists; Pharmacy; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome

2017
Letter: sustained virological response and liver healing.
    Alimentary pharmacology & therapeutics, 2017, Volume: 45, Issue:8

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Recombinant Proteins; Ribavirin; RNA, Viral; Sustained Virologic Response

2017
Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study.
    Transplant international : official journal of the European Society for Organ Transplantation, 2017, Volume: 30, Issue:9

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Donor Selection; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Postoperative Care; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Tissue Donors; Treatment Outcome; Valine

2017
Prevalence and Incidence of Depression during Interferon-Based Antiviral Therapy in Chronic Hepatitis C Patients in the Republic of Korea.
    Gut and liver, 2017, May-15, Volume: 11, Issue:3

    Topics: Antiviral Agents; Depression; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Male; Middle Aged; Prevalence; Prospective Studies; Psychiatric Status Rating Scales; Republic of Korea; Ribavirin; Sustained Virologic Response

2017
SVR Rates of HCV-infected population under PEG-IFN-α/R treatment in Northwest China.
    Virology journal, 2017, 03-23, Volume: 14, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; China; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Ribavirin; Sustained Virologic Response; Treatment Outcome; Young Adult

2017
Fatal acute liver failure during Ritonavir-boosted Paritaprevir, Ombitasvir and Dasabuvir plus Ribavirin therapy.
    Journal of gastrointestinal and liver diseases : JGLD, 2017, Volume: 26, Issue:1

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Liver Failure, Acute; Ribavirin; Ritonavir

2017
Reasons to wait or to treat naive patients affected by chronic hepatitis C with low fibrosis stage and genotypes 2 or 3.
    European journal of public health, 2017, 10-01, Volume: 27, Issue:5

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferons; Italy; Male; Middle Aged; Patient Preference; Prospective Studies; Ribavirin; Sex Factors; Surveys and Questionnaires; Time Factors; Treatment Refusal

2017
Clinical efficacy and tolerability of direct-acting antivirals in elderly patients with chronic hepatitis C.
    European journal of gastroenterology & hepatology, 2017, Volume: 29, Issue:7

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Medical Records; Middle Aged; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Retrospective Studies; Ribavirin; Sustained Virologic Response; Time Factors; Treatment Outcome; Young Adult

2017
Treatment of chronic hepatitis C genotype 3 with Sofosbuvir-based therpy: a real-life study.
    Hepatology international, 2017, Volume: 11, Issue:3

    Topics: Adult; Antiviral Agents; Asia; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; India; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA Viruses; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Viral Load

2017
Acute fulminant hepatitis B during hepatitis C virus therapy with direct-acting antivirals in a patient co-infected with HIV.
    Enfermedades infecciosas y microbiologia clinica, 2017, Volume: 35, Issue:10

    Topics: Anti-HIV Agents; Antiviral Agents; Benzimidazoles; Coinfection; Drug Substitution; Fatal Outcome; Fluorenes; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Liver Failure, Acute; Male; Middle Aged; Oligopeptides; Ribavirin; Sofosbuvir; Virus Activation

2017
Real-World Experiences With a Direct-Acting Antiviral Agent for Patients With Hepatitis C Virus Infection.
    The Permanente journal, 2017, Volume: 21

    Topics: Aged; Anemia; Antiviral Agents; California; Drug Therapy, Combination; Fatigue; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Patient Selection; Retrospective Studies; Ribavirin; Sex Factors; Sofosbuvir; Viral Load

2017
Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017, Jun-01, Volume: 64, Issue:11

    Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine

2017
Exposure-Safety Response Relationship for Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Data from Five Phase II and Six Phase III Studies.
    Clinical drug investigation, 2017, Volume: 37, Issue:7

    Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine; Young Adult

2017
Sofosbuvir-based regimens against an "easy" villain: HCV genotype 2.
    Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37, Issue:8

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome

2017
Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2018, Volume: 117, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Sustained Virologic Response; Taiwan; Viral Load

2018
Sustained virological response in a treatment-experienced patient with hepatitis C virus genotype 6 infection: Follow-up on a reported case.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2017, 04-15, Volume: 74, Issue:8

    Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Ribavirin; Sofosbuvir; Sustained Virologic Response; Viral Load

2017
IL-10 and IL-28B gene variants as predictors of sustained response to peginterferon and ribavirin therapy in chronic HCV infection.
    Cytokine, 2022, Volume: 151

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Interleukin-10; Interleukins; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome

2022
Experience and Outcomes of Hepatitis C Treatment in a Cohort of Homeless and Marginally Housed Adults.
    JAMA internal medicine, 2017, 06-01, Volume: 177, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ill-Housed Persons; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Viral Load

2017
Effectiveness of triple therapy with direct-acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV treatment registry.
    BMC health services research, 2017, 04-19, Volume: 17, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ireland; Male; Middle Aged; Oligopeptides; Proline; Propensity Score; Prospective Studies; Registries; Ribavirin; Treatment Outcome; Uncertainty

2017
Reply to: "Methodological considerations when calculating person-time at risk for patients with chronic hepatitis C undergoing antiviral treatment".
    Journal of hepatology, 2017, Volume: 67, Issue:2

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin

2017
Treatment of chronic hepatitis C with direct-acting antivirals in patients with β-thalassaemia major and advanced liver disease.
    British journal of haematology, 2017, Volume: 178, Issue:1

    Topics: Adult; Antiviral Agents; beta-Thalassemia; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Severity of Illness Index; Simeprevir; Sofosbuvir; Valine

2017
Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2017, Volume: 37, Issue:6

    Topics: Adaptive Immunity; Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Coinfection; Female; Gene Expression Regulation; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Immunity, Innate; Interferon-alpha; Interferons; Interleukins; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2017
Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4
    International journal of molecular sciences, 2017, Apr-25, Volume: 18, Issue:5

    Topics: Aged; Antiviral Agents; Asian People; Benzimidazoles; Carrier Proteins; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Intracellular Signaling Peptides and Proteins; Japan; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins

2017
Long-term follow-up of patients with chronic hepatitis C treated with α-interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response.
    European journal of gastroenterology & hepatology, 2017, Volume: 29, Issue:7

    Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Sustained Virologic Response; Time Factors; Treatment Outcome

2017
Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong.
    Journal of gastroenterology and hepatology, 2017, Volume: 32, Issue:5

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Hong Kong; Humans; Interferon-alpha; Markov Chains; Middle Aged; Polyethylene Glycols; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome

2017
Response to Real life Egyptian experience of efficacy / safety of Simeprevir\\ Sofosbuvir in HCV genotype IV.
    Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Egypt; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome

2017
Long-Term Follow-Up of Resistance-Associated Substitutions in Hepatitis C Virus in Patients in Which Direct Acting Antiviral-Based Therapy Failed.
    International journal of molecular sciences, 2017, May-03, Volume: 18, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Male; Middle Aged; Polyethylene Glycols; Protease Inhibitors; Pyrrolidines; Recombinant Proteins; Ribavirin; Serine Proteases; Simeprevir; Sulfonamides; Time Factors; Treatment Failure; Valine; Viral Nonstructural Proteins

2017
Rising relapse rate in hepatitis C virus type 3a-infected patients against sofosbuvir and ribavirin combination therapy: a Pakistani experience.
    European journal of gastroenterology & hepatology, 2017, Volume: 29, Issue:8

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Recurrence; Ribavirin; Sofosbuvir; Treatment Failure

2017
ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C.
    Journal of medical virology, 2017, Volume: 89, Issue:10

    Topics: Adult; Alleles; Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Real-Time Polymerase Chain Reaction; Ribavirin; Treatment Outcome

2017
[Clinical timing and benefit of antiviral treatment for hepatitis C].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2017, Mar-20, Volume: 25, Issue:3

    Topics: Antiviral Agents; China; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Time Factors; Treatment Outcome

2017
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.
    The lancet. Gastroenterology & hepatology, 2017, Volume: 2, Issue:6

    Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Compassionate Use Trials; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Longitudinal Studies; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine

2017
Effectiveness and safety of community-based treatment with sofosbuvir plus ribavirin for elderly patients with genotype 2 chronic hepatitis C.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2017, Volume: 49, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response

2017
The role of ITPA and ribavirin transporter genes polymorphisms in prediction of ribavirin-induced anaemia in chronic hepatitis C Egyptian patients.
    Clinical and experimental pharmacology & physiology, 2017, Volume: 44, Issue:9

    Topics: Adult; Anemia; Egypt; Female; Genotype; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Male; Membrane Transport Proteins; Polymorphism, Single Nucleotide; Prognosis; Pyrophosphatases; Ribavirin

2017
Relationship of hepatitis B virus infection to the recurrence of hepatocellular carcinoma after direct acting antivirals.
    Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2017, Volume: 36, Issue:3

    Topics: Aged; Aged, 80 and over; Antibodies, Viral; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepatitis B Core Antigens; Hepatitis C, Chronic; Humans; Imidazoles; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Pyrrolidines; Retrospective Studies; Ribavirin; Risk Factors; Sofosbuvir; Valine

2017
Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and database.
    Medicine, 2017, Volume: 96, Issue:22

    Topics: Adult; Ambulatory Care; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Databases, Factual; Drug Therapy, Combination; Female; Health Care Costs; Hepatitis C, Chronic; Hospitalization; Humans; Interferons; Male; Middle Aged; National Health Programs; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Taiwan; Treatment Outcome; Viral Load

2017
Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845.
    Virology journal, 2017, 05-31, Volume: 14, Issue:1

    Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Genotype; Genotyping Techniques; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Ritonavir; Sequence Analysis, DNA; Simeprevir; Sulfonamides; Treatment Failure; Valine

2017
The Influence of Hepatitis C Virus Therapy on the DNA Base Excision Repair System of Peripheral Blood Mononuclear Cells.
    DNA and cell biology, 2017, Volume: 36, Issue:7

    Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cell Nucleus; Cyclopropanes; Deoxyuridine; DNA; DNA Breaks, Double-Stranded; DNA Glycosylases; DNA Repair; DNA-(Apurinic or Apyrimidinic Site) Lyase; Drug Therapy, Combination; Endonucleases; Gene Expression; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Lactams, Macrocyclic; Leukocytes, Mononuclear; Macrocyclic Compounds; Mitochondria; Molecular Mimicry; Primary Cell Culture; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine

2017
Effective Treatment With Daclatasvir and Asunaprevir in Kidney Transplant Patients Infected With Hepatitis C Virus: A Report of Two Cases.
    Transplantation proceedings, 2017, Volume: 49, Issue:5

    Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Interferons; Isoquinolines; Kidney Transplantation; Male; Middle Aged; Prednisolone; Prospective Studies; Pyrrolidines; Ribavirin; Sulfonamides; Treatment Outcome; Valine

2017
Detection of HCV RNA in Sustained Virologic Response to Direct-Acting Antiviral Agents: Occult or Science Fiction?
    Gastroenterology, 2017, Volume: 153, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; RNA; RNA, Viral; Sustained Virologic Response; Treatment Outcome

2017
Treatment of chronic Hepatitis C in Thalassemia major patients.
    JPMA. The Journal of the Pakistan Medical Association, 2017, Volume: 67, Issue:6

    Topics: Adolescent; Adult; Anemia; Antiviral Agents; beta-Thalassemia; Child; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Pilot Projects; Ribavirin; RNA, Viral; Sustained Virologic Response; Young Adult

2017
Letter: the efficacy of interferon-free regimens in HCV-related Child C cirrhosis needs careful interpretation-Authors' reply.
    Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:1

    Topics: Antiviral Agents; Child; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Ribavirin

2017
Letter: the efficacy of interferon-free regimens in HCV-related Child C cirrhosis needs careful interpretation.
    Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:1

    Topics: Antiviral Agents; Child; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Ribavirin

2017
Factors That Influence the Virological Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon and Ribavirin.
    Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki), 2017, Mar-01, Volume: 38, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Sustained Virologic Response; Time Factors; Treatment Outcome; Viral Load

2017
Increased warfarin requirements in a patient with chronic hepatitis C infection receiving sofosbuvir and ribavirin.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2017, Jun-15, Volume: 74, Issue:12

    Topics: Anticoagulants; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; International Normalized Ratio; Male; Middle Aged; Ribavirin; Sofosbuvir; Warfarin

2017
Pegylated interferon plus ribavirin combination therapy in postliver transplant recipients with recurrent hepatitis C virus infection.
    The Kaohsiung journal of medical sciences, 2017, Volume: 33, Issue:6

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Secondary Prevention; Transplant Recipients; Treatment Outcome

2017
Hematologic adverse effects and efficacy monitoring in chronic Hepatitis C patients treated with interferon and ribavirin combination therapy.
    Pakistan journal of pharmaceutical sciences, 2017, Volume: 30, Issue:1

    Topics: Adult; Age Factors; Anemia; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Incidence; Interferons; Male; Middle Aged; Pakistan; Ribavirin; Risk Factors; Sex Factors; Sustained Virologic Response; Time Factors; Treatment Outcome

2017
Immunological dynamics associated with rapid virological response during the early phase of type I interferon therapy in patients with chronic hepatitis C.
    PloS one, 2017, Volume: 12, Issue:6

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Gene Expression Regulation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Interleukins; Male; Middle Aged; Prospective Studies; Republic of Korea; Ribavirin; Treatment Outcome; Viral Load

2017
Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct-acting antiviral treatment for HCV.
    Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:1

    Topics: Aged; Antiviral Agents; Benzimidazoles; DNA, Viral; Female; Fluorenes; Hepacivirus; Hepatitis B; Hepatitis B Antibodies; Hepatitis B virus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Risk Assessment; Risk Factors; Sofosbuvir; Time Factors; Treatment Outcome; Virus Activation

2018
Noninvasive serum models to predict significant liver related events in chronic hepatitis C.
    Hepatology international, 2017, Volume: 11, Issue:4

    Topics: Adult; Antiviral Agents; Area Under Curve; Carcinoma, Hepatocellular; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Ribavirin

2017
Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients.
    Gut and liver, 2017, Sep-15, Volume: 11, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fibrosis; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Republic of Korea; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate

2017
The elderly and direct antiviral agents: Constraint or challenge?
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2017, Volume: 49, Issue:9

    Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Interactions; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Italy; Logistic Models; Male; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine

2017
Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience.
    Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2017, Volume: 36, Issue:3

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; India; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Pyrrolidines; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; Valine; Young Adult

2017
Improvement in Glycemic Control of Type 2 Diabetes After Successful Treatment of Hepatitis C Virus.
    Diabetes care, 2017, Volume: 40, Issue:9

    Topics: Aged; Antiviral Agents; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Ribavirin; Sustained Virologic Response

2017
Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2018, Volume: 117, Issue:6

    Topics: 2-Naphthylamine; Aged; Alanine Transaminase; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Postoperative Period; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine

2018
Cytoplasmic rods and rings in ribavirin treatment.
    Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37, Issue:11

    Topics: Cytoplasm; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin

2017
Improvement of glycemic state among responders to Sofosbuvir-based treatment regimens: Single center experience.
    Journal of medical virology, 2017, Volume: 89, Issue:12

    Topics: Aged; Antiviral Agents; Blood Glucose; Diabetes Mellitus, Type 2; Egypt; Female; Glycated Hemoglobin; Glycemic Index; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir

2017
Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients.
    Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:5

    Topics: Aged; Antiviral Agents; Benzimidazoles; Cohort Studies; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome

2017
Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study.
    PloS one, 2017, Volume: 12, Issue:7

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Scandinavian and Nordic Countries; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2017
The relationship between ITPA rs1127354 polymorphisms and efficacy of antiviral treatment in Northeast Chinese CHC patients.
    Medicine, 2017, Volume: 96, Issue:29

    Topics: Anemia, Hemolytic; Antiviral Agents; China; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotyping Techniques; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Pharmacogenomic Testing; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Pyrophosphatases; Recombinant Proteins; Ribavirin; Treatment Outcome

2017
Confounding by Single Nucleotide Polymorphism rs117648444 (P70S) Affects the Association of Interferon Lambda Locus Variants with Response to Interferon-α-Ribavirin Therapy in Patients with Chronic Genotype 3 Hepatitis C Virus Infection.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2017, Volume: 37, Issue:8

    Topics: Alleles; Cohort Studies; Female; Genome-Wide Association Study; Genotype; Haplotypes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Linkage Disequilibrium; Male; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Ribavirin; Sustained Virologic Response

2017
Hepatitis B reactivation in a patient with chronic hepatitis C treated with direct-acting antivirals.
    Gastroenterologia y hepatologia, 2018, Volume: 41, Issue:5

    Topics: Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Protease Inhibitors; Ribavirin; Ritonavir; Sulfonamides; Valine; Viral Load; Viral Nonstructural Proteins; Viremia; Virus Activation

2018
The clinical features and treatment outcome of chronic hepatitis C with pegylated interferon and ribavirin in routine care.
    The Medical journal of Malaysia, 2017, Volume: 72, Issue:3

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult

2017
Dendritic cells activation is associated with sustained virological response to telaprevir treatment of HCV-infected patients.
    Clinical immunology (Orlando, Fla.), 2017, Volume: 183

    Topics: Aged; Antiviral Agents; B7-1 Antigen; B7-2 Antigen; Dendritic Cells; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sustained Virologic Response; Treatment Outcome; Up-Regulation; Virus Replication

2017
The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection.
    Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 2017, Volume: 54

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HLA Antigens; Humans; Interferon-alpha; Interferons; Interleukins; Iran; Logistic Models; Male; Middle Aged; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome; Viral Load

2017
Do we need to screen for de-novo diabetes mellitus in chronic hepatitis C patients after a sustained virological response?
    European journal of gastroenterology & hepatology, 2017, Volume: 29, Issue:9

    Topics: Adult; Antiviral Agents; Biomarkers; Blood Glucose; Body Mass Index; Diabetes Mellitus; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Insulin; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Leptin; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors; Sustained Virologic Response; Time Factors; Treatment Outcome

2017
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan.
    Journal of gastroenterology and hepatology, 2018, Volume: 33, Issue:3

    Topics: 2-Naphthylamine; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Retrospective Studies; Ribavirin; Ritonavir; Safety; Sulfonamides; Taiwan; Treatment Outcome; Uracil; Valine; Viral Load

2018
Association of Interferon Alpha Receptor 1 with sustained virological response in hepatitis C and B co-infected patients.
    JPMA. The Journal of the Pakistan Medical Association, 2017, Volume: 67, Issue:7

    Topics: Adult; Antiviral Agents; Coinfection; Cross-Sectional Studies; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Polyethylene Glycols; Prognosis; Receptor, Interferon alpha-beta; Recombinant Proteins; Ribavirin; RNA, Messenger; RNA, Viral; Sustained Virologic Response

2017
Serious Adverse Events with Sofosbuvir Combined with Interferon and Ribavirin: Real-Life Egyptian Experience.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2017, Volume: 37, Issue:8

    Topics: Drug Therapy, Combination; Egypt; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Sofosbuvir; Withholding Treatment

2017
A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study.
    Journal of viral hepatitis, 2018, Volume: 25, Issue:1

    Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2018
The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.
    PloS one, 2017, Volume: 12, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Incidence; Interferon-alpha; Isoquinolines; Kaplan-Meier Estimate; Liver Neoplasms; Middle Aged; Proportional Hazards Models; Pyrrolidines; Ribavirin; Risk Factors; Sulfonamides; Treatment Outcome; Valine; Viral Load; Young Adult

2017
Clinical implication of serum uric acid level in pegylated interferon and ribavirin combination therapy for chronic hepatitis C infection.
    The Korean journal of internal medicine, 2017, Volume: 32, Issue:6

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Sustained Virologic Response; Uric Acid

2017
The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes.
    Transplant international : official journal of the European Society for Organ Transplantation, 2017, Volume: 30, Issue:12

    Topics: Analysis of Variance; Antiviral Agents; Cohort Studies; Compassionate Use Trials; Confidence Intervals; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Italy; Liver Cirrhosis; Liver Function Tests; Logistic Models; Male; Multivariate Analysis; Prognosis; Recurrence; Ribavirin; Risk Assessment; Severity of Illness Index; Sofosbuvir; Treatment Outcome

2017
Effect of IL15 rs10833 and SCARB1 rs10846744 on virologic responses in chronic hepatitis C patients treated with pegylated interferon-α and ribavirin.
    Gene, 2017, Sep-30, Volume: 630

    Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukin-15; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Scavenger Receptors, Class B; Sustained Virologic Response

2017
Current treatment status and barriers for patients with chronic HCV infection in mainland China: A national multicenter cross-sectional survey in 56 hospitals.
    Medicine, 2017, Volume: 96, Issue:34

    Topics: Adult; Age Factors; Antiviral Agents; China; Cross-Sectional Studies; Drug Therapy, Combination; Drug Utilization; Fees, Pharmaceutical; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Middle Aged; Polyethylene Glycols; Ribavirin; Severity of Illness Index; Sex Factors; Socioeconomic Factors; Young Adult

2017
Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing.
    Antiviral research, 2017, Volume: 146

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Chemokine CXCL10; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Male; MicroRNAs; Middle Aged; Pyrrolidines; Ribavirin; RNA, Viral; Sofosbuvir; Valine; Young Adult

2017
Response to Cytoplasmic rods and rings in ribavirin and Cytoplasmic rods and rings in mycophenolic acid treatment.
    Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37, Issue:11

    Topics: Cytoplasm; Hepatitis C, Chronic; Humans; Interferon-alpha; Mycophenolic Acid; Ribavirin

2017
Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA exper
    European journal of gastroenterology & hepatology, 2017, Volume: 29, Issue:11

    Topics: Adult; Antiviral Agents; Benzimidazoles; Disease Eradication; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Fluorenes; Genotype; Georgia (Republic); Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2017
Interferon-γ-inducible protein-10 in chronic hepatitis C: Correlations with insulin resistance, histological features & sustained virological response.
    The Indian journal of medical research, 2017, Volume: 145, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Biopsy; Chemokine CXCL10; Enzyme-Linked Immunosorbent Assay; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon-gamma; Liver; Male; Middle Aged; Ribavirin; Treatment Outcome; Viral Load

2017
Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced.
    Gut and liver, 2017, Sep-15, Volume: 11, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Resistance, Viral; Female; Fluorenes; Genotype; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Republic of Korea; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uridine Monophosphate; Valine

2017
Interleukin 20 Gene Polymorphism (rs1518108) is not Associated with Sustained Virological Response in Iranian Patients with Hepatitis C Virus Infection.
    Clinical laboratory, 2017, Sep-01, Volume: 63, Issue:9

    Topics: Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukins; Iran; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin

2017
Analysis of Hepatitis C Virus NS5A Region in Patients with Cirrhosis Using an Ultra-Deep Pyrosequencing Method.
    Clinical laboratory, 2017, Sep-01, Volume: 63, Issue:9

    Topics: Aged; Amino Acid Sequence; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Liver Cirrhosis; Male; Middle Aged; Mutation; Ribavirin; Viral Nonstructural Proteins

2017
Ribavirin steady-state plasma level is a predictor of sustained virological response in hepatitis C-infected patients treated with direct-acting antivirals.
    Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:9

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response

2017
Direct-acting antiviral agents against hepatitis C virus and lipid metabolism.
    World journal of gastroenterology, 2017, Aug-21, Volume: 23, Issue:31

    Topics: Antiviral Agents; Cholesterol; Drug Therapy, Combination; Fatty Liver; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Lipid Metabolism; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Triglycerides

2017
DHEA prevents ribavirin-induced anemia via inhibition of glucose-6-phosphate dehydrogenase.
    Antiviral research, 2017, Volume: 146

    Topics: Adenosine Triphosphate; Anemia; Antiviral Agents; Dehydroepiandrosterone; Erythrocytes; Glucosephosphate Dehydrogenase; Hemolysis; Hepatitis C, Chronic; Humans; Pentose Phosphate Pathway; Ribavirin

2017
The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation: A national real-life experience.
    Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Compassionate Use Trials; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Waiting Lists

2018
A pilot study to expand treatment of chronic hepatitis C in resource-limited settings.
    Antiviral research, 2017, Volume: 146

    Topics: Antiviral Agents; Developing Countries; District of Columbia; Genotype; Health Resources; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; India; Pilot Projects; Poverty; Ribavirin

2017
Validation of a questionnaire to monitor symptoms in HIV-infected patients during hepatitis C treatment.
    AIDS research and therapy, 2017, Sep-20, Volume: 14, Issue:1

    Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Retrospective Studies; Ribavirin; Surveys and Questionnaires; Treatment Outcome

2017
Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection.
    World journal of gastroenterology, 2017, Aug-28, Volume: 23, Issue:32

    Topics: Adult; Antiviral Agents; Carbamates; China; Drug Therapy, Combination; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Transplantation; Liver Cirrhosis; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrrolidines; Ribavirin; RNA, Viral; Sofosbuvir; Transplant Recipients; Treatment Outcome; Valine

2017
Sofosbuvir and daclatasvir plus ribavirin treatment improve liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients.
    European journal of gastroenterology & hepatology, 2017, Volume: 29, Issue:12

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Bilirubin; Carbamates; Drug Therapy, Combination; Egypt; End Stage Liver Disease; Female; Hepatitis C, Chronic; Humans; Imidazoles; International Normalized Ratio; Male; Middle Aged; Platelet Count; Prospective Studies; Pyrrolidines; Ribavirin; Serum Albumin; Severity of Illness Index; Sofosbuvir; Sustained Virologic Response; Valine

2017
Transient Hypothyroidism and Autoimmune Thyroiditis in Children With Chronic Hepatitis C Treated With Pegylated-interferon-α-2b and Ribavirin.
    The Pediatric infectious disease journal, 2018, Volume: 37, Issue:4

    Topics: Adolescent; Antiviral Agents; Autoantibodies; Case-Control Studies; Child; Child, Preschool; Female; Hepatitis C, Chronic; Humans; Hypothyroidism; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Thyroiditis, Autoimmune; Thyrotropin; Thyroxine

2018
Predictors of hepatitis C virus recurrence after living donor liver transplantation: Mansoura experience.
    Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology, 2017, Volume: 18, Issue:3

    Topics: Adult; Age Factors; Antiviral Agents; Cold Ischemia; Drug Therapy, Combination; Female; Graft Survival; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Living Donors; Male; Polyethylene Glycols; Postoperative Period; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Warm Ischemia; Young Adult

2017
High frequencies of a favorable IL-28B rs8099917 polymorphism and the clinical implications in patients with HCV in one multiracial area of Taiwan.
    The Kaohsiung journal of medical sciences, 2017, Volume: 33, Issue:10

    Topics: Adult; Aged; Antiviral Agents; Body Mass Index; Female; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Single Nucleotide; Population Groups; Recombinant Proteins; Retrospective Studies; Ribavirin; Taiwan; Viral Load

2017
Erythrodermic Psoriasis and Hepatitis C Infection Treated with Pegylated Interferon and Anti-TNFα α(Etanercept) Therapy.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2017, Volume: 27, Issue:9

    Topics: Adult; Antiviral Agents; Etanercept; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Male; Psoriasis; Ribavirin; RNA, Viral; Treatment Outcome; Tumor Necrosis Factor-alpha

2017
Immune response of Th17-associated cytokines by peripheral blood mononuclear cells from patients with chronic hepatitis C virus infection.
    Cytokine, 2018, Volume: 102

    Topics: Adult; Aged; Antiviral Agents; Cytokines; Female; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Immunity, Cellular; Interferon-alpha; Interleukin-17; Interleukin-22; Interleukins; Leukocytes, Mononuclear; Male; Middle Aged; Protease Inhibitors; Ribavirin; Sustained Virologic Response; Th17 Cells

2018
Real-life results of sofosbuvir based therapy in chronic hepatitis C -naïve and -experienced patients in Egypt.
    PloS one, 2017, Volume: 12, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Young Adult

2017
Potential drug-drug interactions of OMBITASVIR, PARITAPREVIR/ritonavir ± DASABUVIR ± ribavirin in clinical practice.
    Journal of gastroenterology and hepatology, 2018, Volume: 33, Issue:5

    Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine

2018
The association of LMP7 and TAP2 gene polymorphisms with treatment response to interferon/ribavirin in patients with genotype 1 chronic hepatitis C.
    International journal of molecular medicine, 2017, Volume: 40, Issue:6

    Topics: Adult; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B, Member 3; Female; Genetic Association Studies; Genetic Predisposition to Disease; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polymorphism, Single Nucleotide; Proteasome Endopeptidase Complex; Ribavirin; Viral Load

2017
Comparison of Sofosbuvir Plus Ribavirin Treatment with Pegylated Interferon Plus Ribavirin Treatment for Chronic Hepatitis C Genotype 2.
    Digestive diseases (Basel, Switzerland), 2017, Volume: 35, Issue:6

    Topics: alpha-Fetoproteins; Antiviral Agents; Biomarkers, Tumor; Bone Morphogenetic Protein 7; Carcinoma, Hepatocellular; Connective Tissue Growth Factor; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Function Tests; Liver Neoplasms; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2017
Cost effectiveness of hepatitis C treatments: Need for a comprehensive evaluation.
    The Kaohsiung journal of medical sciences, 2017, Volume: 33, Issue:11

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2017
Implementation of a multidisciplinary, team-based model to treat chronic hepatitis C in the primary care setting: Lessons learned.
    Healthcare (Amsterdam, Netherlands), 2018, Volume: 6, Issue:3

    Topics: Antiviral Agents; Boston; Hepatitis C, Chronic; Humans; Interferon-alpha; Patient Care Team; Primary Health Care; Qualitative Research; Ribavirin

2018
Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non-Cirrhotic Patients: A Societal Perspective.
    Value in health regional issues, 2017, Volume: 13

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Drug Therapy, Combination; Egypt; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Models, Statistical; Pyrrolidines; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Ribavirin; Sofosbuvir; Uridine Monophosphate; Valine

2017
Estimation of Direct Medical Costs Related to Chronic Hepatitis C: A Rationale for Early Antiviral Therapy.
    Gut and liver, 2017, 11-15, Volume: 11, Issue:6

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Ribavirin

2017
Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients.
    The Journal of antimicrobial chemotherapy, 2017, 10-01, Volume: 72, Issue:10

    Topics: Antiviral Agents; Benzimidazoles; Cohort Studies; Coinfection; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Spain; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate

2017
The treatment outcome and impact on blood transfusion demand of Peg-interferon/ribavirin in thalassemic patients with chronic hepatitis C.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2018, Volume: 117, Issue:1

    Topics: Adolescent; Adult; Antiviral Agents; Blood Transfusion; Case-Control Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Retrospective Studies; Ribavirin; Sustained Virologic Response; Taiwan; Thalassemia; Viral Load; Young Adult

2018
Association of
    International journal of medical sciences, 2017, Volume: 14, Issue:11

    Topics: Adult; Aged; Antiviral Agents; Fatty Liver; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Retrospective Studies; Ribavirin

2017
Editorial: ribavirin continues to play a role in treatment with direct-acting antivirals for hepatitis C virus-infected patients with decompensated cirrhosis.
    Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:11-12

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin

2017
Direct-acting antiviral agents in the treatment of chronic Hepatitis C - "Real-life" experience from an academic centre and two specialized clinical practices.
    Zeitschrift fur Gastroenterologie, 2018, Volume: 56, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Treatment Outcome

2018
Peginterferon still has a place in the treatment of hepatitis C caused by genotype 3 virus.
    Revista do Instituto de Medicina Tropical de Sao Paulo, 2017, Nov-06, Volume: 59

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome

2017
Higher expression of inhibitory CD158b and CD158e NK cell receptor and age predicts treatment response in children with chronic hepatitis C.
    Medical microbiology and immunology, 2018, Volume: 207, Issue:1

    Topics: Adolescent; Age Factors; Antiviral Agents; Child; Child, Preschool; Female; Hepatitis C, Chronic; Humans; Infant; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prognosis; Receptors, KIR2DL3; Receptors, KIR3DL1; Recombinant Proteins; Ribavirin; Sustained Virologic Response; Treatment Outcome

2018
Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease.
    European journal of gastroenterology & hepatology, 2018, Volume: 30, Issue:3

    Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate

2018
Use of a hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA-negative liver transplant recipient.
    Transplant infectious disease : an official journal of the Transplantation Society, 2018, Volume: 20, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Tissue Donors; Transplant Recipients; Viral Load

2018
Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment.
    Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:6

    Topics: Aged; Antiviral Agents; Austria; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Male; Middle Aged; Ribavirin; Sustained Virologic Response

2018
The antigenic variability of HCV in viral HLA-Ag binding is related to the activation of the host immune response.
    Scientific reports, 2017, Nov-14, Volume: 7, Issue:1

    Topics: Amino Acid Sequence; Antigens, Viral; Antiviral Agents; Binding Sites; CD4-Positive T-Lymphocytes; Cell Proliferation; Gene Expression; Haplotypes; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; HLA-DQ beta-Chains; Humans; Immunity, Innate; Immunodominant Epitopes; Interferon-alpha; Lymphocyte Activation; Mutation; Polyethylene Glycols; Protein Binding; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins

2017
Direct antiviral treatment of chronic hepatitis C in heart transplant recipients.
    Transplant infectious disease : an official journal of the Transplantation Society, 2018, Volume: 20, Issue:1

    Topics: Antiviral Agents; Comorbidity; Drug Therapy, Combination; Female; Genotype; Heart Transplantation; Hepacivirus; Hepatitis C, Chronic; Humans; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2018
Evaluation of Temporal Virological Responses to Interferon-α-2b plus Ribavirin among Genotype 3a Hepatitis C Virus-Infected Patients.
    Intervirology, 2017, Volume: 60, Issue:3

    Topics: Adolescent; Adult; Aged; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunotherapy; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2017
The association between steatosis and diabetes with hepatocellular carcinoma in non-genotype 3 chronic hepatitis C patients.
    Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:6

    Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Diabetes Complications; Diabetes Mellitus; Fatty Liver; Female; Genotype; Hepatitis C, Chronic; Humans; Interferons; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Retrospective Studies; Ribavirin; Risk Factors; Sustained Virologic Response; Taiwan

2018
Hepatitis C virus eradication improves immediate and delayed episodic memory in patients treated with interferon and ribavirin.
    BMC gastroenterology, 2017, Nov-25, Volume: 17, Issue:1

    Topics: Adult; Affect; Aged; Antiviral Agents; Attention; Depression; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Memory, Episodic; Middle Aged; Prospective Studies; Ribavirin; Sustained Virologic Response; Treatment Outcome

2017
Hepatitis B reactivation and outcomes in persons treated with directly acting antiviral agents against hepatitis C virus: results from ERCHIVES.
    Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:3

    Topics: Aged; Antiviral Agents; Coinfection; Female; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Virus Activation

2018
Surgical Outcomes in Hepatitis C Virus-Related Hepatocellular Carcinoma: Special Reference to Sustained Virological Responses to Interferon Therapy.
    The American surgeon, 2017, Nov-01, Volume: 83, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Case-Control Studies; Disease-Free Survival; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Ribavirin; Treatment Outcome

2017
Interferon-free cure of chronic Hepatitis C is associated with weight gain during long-term follow-up.
    Zeitschrift fur Gastroenterologie, 2017, Volume: 55, Issue:9

    Topics: Adult; Aged; Antimetabolites; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Middle Aged; Obesity; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Weight Gain

2017
Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt.
    Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:3

    Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Drugs, Generic; Egypt; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2018
Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation.
    Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:7

    Topics: Aged; Antiviral Agents; Austria; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine

2018
Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (MELD ≥ 15).
    Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:3

    Topics: Antiviral Agents; Australia; Carbamates; Compassionate Use Trials; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Survival Analysis; Treatment Outcome; Valine

2018
Retinal vascular complications associated with interferon-ribavirin therapy for chronic hepatitis C: A population-based study.
    Pharmacoepidemiology and drug safety, 2018, Volume: 27, Issue:2

    Topics: Adult; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Hypertension; Incidence; Interferon-alpha; Male; Middle Aged; Retina; Retinal Diseases; Retinal Vessels; Retrospective Studies; Ribavirin; Risk Factors; Taiwan

2018
Histological assessment of the liver explant in transplanted hepatitis C virus patients achieving sustained virological response with direct-acting antiviral agents.
    Histopathology, 2018, Volume: 72, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Humans; Inflammation; Liver Transplantation; Male; Middle Aged; Ribavirin; Simeprevir; Sofosbuvir; Uridine Monophosphate

2018
HCV-positive lymphoma after sustained virological response with direct-acting antiviral agents: The game is not over after HCV eradication.
    Journal of viral hepatitis, 2018, Volume: 25, Issue:5

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lymphoma; Ribavirin; Sustained Virologic Response; Treatment Outcome

2018
Estudio de impacto presupuestal de Daclatasvir asociado a Asunaprevir desde la perspectiva del sistema de salud público chileno.
    Value in health regional issues, 2017, Volume: 14

    Topics: Antiviral Agents; Carbamates; Chile; Cohort Studies; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Polyethylene Glycols; Protease Inhibitors; Public Health; Pyrrolidines; Recombinant Proteins; Ribavirin; Sulfonamides; Valine

2017
Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2018, Volume: 117, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Aspartate Aminotransferases; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Platelet Count; Regression Analysis; Retrospective Studies; Ribavirin; Risk Factors; Sustained Virologic Response; Taiwan; Tomography, X-Ray Computed; Treatment Failure

2018
Memory T Cell Proliferation before Hepatitis C Virus Therapy Predicts Antiviral Immune Responses and Treatment Success.
    Journal of immunology (Baltimore, Md. : 1950), 2018, 02-01, Volume: 200, Issue:3

    Topics: Adaptive Immunity; Antibodies, Viral; Antiviral Agents; CD4-Positive T-Lymphocytes; Cell Proliferation; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Innate; Immunologic Memory; Interferon-alpha; Longitudinal Studies; Lymphocyte Activation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Recombinant Proteins; Ribavirin; T-Box Domain Proteins; Treatment Outcome

2018
High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease.
    Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:8

    Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Registries; Renal Insufficiency, Chronic; Ribavirin; Ritonavir; Saudi Arabia; Sulfonamides; Sustained Virologic Response; Uracil; Valine

2018
Reply to: "'Who killed JR': Chronic hepatitis C or alcohol use disorders?"
    Journal of hepatology, 2018, Volume: 68, Issue:5

    Topics: Alcoholism; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin

2018
Hepatitis C Virus-Infected Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment With Interferon-Free Regimens.
    The Journal of infectious diseases, 2018, 03-13, Volume: 217, Issue:7

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Opiate Substitution Treatment; Patient Reported Outcome Measures; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2018
Sofosbuvir-ledipasvir with or without ribavirin for chronic hepatitis C genotype-1 and 6: real-world experience in Vietnam.
    Antiviral therapy, 2018, Volume: 23, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Patient Safety; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Vietnam; Viral Load

2018
Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2018, Volume: 16, Issue:11

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; North America; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult

2018
Interferon-free therapy for treating hepatitis C virus in difficult-to-treat HIV-coinfected patients.
    AIDS (London, England), 2018, 01-28, Volume: 32, Issue:3

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiviral Agents; Coinfection; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; Ribavirin; Spain; Treatment Outcome; Young Adult

2018
Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2.
    Journal of medical virology, 2018, Volume: 90, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Drug Therapy, Combination; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Prognosis; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult

2018
Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens.
    Archives of virology, 2018, Volume: 163, Issue:4

    Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cryoglobulinemia; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil; Valine

2018
Diabetes Mellitus Prevents an Improvement in the Serum Albumin Level During Interferon-free Sofosbuvir-based Therapy for Chronic Hepatitis C Patients: A Multi-institutional Joint Study.
    Internal medicine (Tokyo, Japan), 2018, Jun-01, Volume: 57, Issue:11

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Diabetes Complications; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Retrospective Studies; Ribavirin; Serum Albumin; Sofosbuvir; Uridine Monophosphate

2018
Factors Affecting the Virological Response Among Chronic Hepatitis C Virus Patients in Yemen.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2018, Volume: 38, Issue:1

    Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Microbial Sensitivity Tests; Multivariate Analysis; Regression Analysis; Ribavirin; Yemen

2018
NVR 3-778 Plus Pegylated Interferon-α Treatment for Chronic Hepatitis B Viral Infections: Could 1 + 1 = 3?
    Gastroenterology, 2018, Volume: 154, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2018
Distribution of IL28B and IL10 polymorphisms as genetic predictors of treatment response in Pakistani HCV genotype 3 patients.
    Archives of virology, 2018, Volume: 163, Issue:4

    Topics: Adult; Alleles; Antiviral Agents; Biomarkers; Case-Control Studies; Drug Therapy, Combination; Female; Gene Expression; Gene Frequency; Haplotypes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukin-10; Interleukins; Male; Middle Aged; Pakistan; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prognosis; Recombinant Proteins; Ribavirin

2018
Effectiveness and safety of original and generic sofosbuvir for the treatment of chronic hepatitis C: A real world study.
    Journal of medical virology, 2018, Volume: 90, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Argentina; Carbamates; Drug-Related Side Effects and Adverse Reactions; Drugs, Generic; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult

2018
Spur-of-the-Moment Modification in National Treatment Policies Leads to a Surprising HCV Viral Suppression in All Treated Patients: Real-Life Egyptian Experience.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2018, Volume: 38, Issue:2

    Topics: Antiviral Agents; Carbamates; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Microbial Sensitivity Tests; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Valine

2018
A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection.
    Virology journal, 2018, 01-30, Volume: 15, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Mutation; Ribavirin; Simeprevir; Sustained Virologic Response; Treatment Outcome; Viral Load

2018
Genotype distribution and treatment response among incarcerated drug-dependent patients with chronic hepatitis C infection.
    PloS one, 2018, Volume: 13, Issue:2

    Topics: Adult; Antiviral Agents; Case-Control Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prisoners; Ribavirin; Substance-Related Disorders

2018
Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older.
    Medicine, 2017, Volume: 96, Issue:50

    Topics: 2-Naphthylamine; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Proline; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine

2017
Association of IL-28B, TBX21 gene polymorphisms and predictors of virological response for chronic hepatitis C.
    Archives of virology, 2018, Volume: 163, Issue:5

    Topics: Adolescent; Adult; Aged; Antibodies, Viral; Antiviral Agents; Asian People; China; Disease Susceptibility; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Ribavirin; Sustained Virologic Response; T-Box Domain Proteins; Viral Core Proteins; Young Adult

2018
Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies.
    Journal of medical virology, 2018, Volume: 90, Issue:6

    Topics: Adult; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Mutant Proteins; Mutation, Missense; Prevalence; Ribavirin; Sequence Analysis, DNA; Viral Nonstructural Proteins

2018
Complete Response of Diffuse Large B Cell Lymphoma After Direct-Acting Antiviral Therapy for Hepatitis C Virus.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2019, Volume: 17, Issue:5

    Topics: Aged; Antiviral Agents; Carbamates; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Neoplasms; Lymphoma, Large B-Cell, Diffuse; Magnetic Resonance Imaging; Male; Radiography, Abdominal; Ribavirin; Sofosbuvir; Treatment Outcome

2019
EFFECTIVE TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTIONS WITH DIRECT ACTING ANTIVIRALS IN PRISONS SYSTEM.
    Georgian medical news, 2018, Issue:274

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; gamma-Glutamyltransferase; Genotype; Georgia (Republic); Hepacivirus; Hepatitis C, Chronic; Humans; Liver Function Tests; Male; Middle Aged; Prisoners; Prisons; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2018
12 weeks ombitasvir/paritaprevir-ritonavir + ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2018, Volume: 50, Issue:7

    Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Lactams, Macrocyclic; Liver; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Valine

2018
HCV genotype-3h, a difficult-to-diagnose sub-genotype in the DAA era.
    Antiviral therapy, 2018, Volume: 23, Issue:7

    Topics: 2-Naphthylamine; Aged; Amino Acid Substitution; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Isoenzymes; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Polymorphism, Genetic; Proline; Recurrence; Ribavirin; Sulfonamides; Treatment Failure; Uracil; Valine; Viral Load; Viral Nonstructural Proteins

2018
Monitoring the Evolution of Portal Hypertension After Sustained Virologic Response.
    Gastroenterology, 2018, Volume: 154, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Hypertension, Portal; Interferon-alpha; Recombinant Proteins; Ribavirin; Sustained Virologic Response; Treatment Outcome

2018
Interleukin-22 and Chemokine Interferon γ -Inducible-10 (IP-10) Levels in Chronic Hepatitis C Patients and Treatment Response to Pegylated Interferon and Ribavirin Therapy.
    The Egyptian journal of immunology, 2017, Volume: 24, Issue:2

    Topics: Antiviral Agents; Chemokine CXCL10; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukin-22; Interleukins; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load

2017
Platelet count is associated with sustained virological response rates in treatments for chronic hepatitis C.
    The Korean journal of internal medicine, 2019, Volume: 34, Issue:5

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Blood Platelets; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Republic of Korea; Retrospective Studies; Ribavirin; RNA, Viral; Sustained Virologic Response; Time Factors; Treatment Outcome; Viral Load; Young Adult

2019
Cost/Benefit of Hepatitis C Treatment: It Does Not End with SVR.
    Digestive diseases and sciences, 2018, Volume: 63, Issue:6

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Ribavirin

2018
Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy.
    Clinics and research in hepatology and gastroenterology, 2018, Volume: 42, Issue:4

    Topics: Aged; Antibodies; Antiviral Agents; Biomarkers; Carbamates; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Peptides; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Retrospective Studies; Ribavirin; Seroepidemiologic Studies; Sofosbuvir; Valine; Viral Load

2018
Effect of Direct-Acting Agents on Fibrosis Regression in Chronic Hepatitis C Virus Patients' Treatment Compared with Interferon-Containing Regimens.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2018, Volume: 38, Issue:3

    Topics: Antiviral Agents; Female; Fibrosis; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Microbial Sensitivity Tests; Middle Aged; Ribavirin; Sofosbuvir

2018
Treatment of HCV in the Department of Corrections in the Era of Oral Medications.
    Journal of correctional health care : the official journal of the National Commission on Correctional Health Care, 2018, Volume: 24, Issue:2

    Topics: Administration, Oral; Adult; Age Factors; Aged; Antiviral Agents; Benzimidazoles; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prisons; Ribavirin; Sex Factors; Socioeconomic Factors; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate

2018
Safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in hepatitis C genotype 1 patients including those with decompensated cirrhosis who failed prior treatment with simeprevir/sofosbuvir.
    Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:10

    Topics: Abdominal Pain; Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Esophageal and Gastric Varices; Fatigue; Female; Fluorenes; Gastrointestinal Hemorrhage; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Nausea; Prospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate

2018
Induction of inosine triphosphatase activity during ribavirin treatment for chronic hepatitis C.
    Clinica chimica acta; international journal of clinical chemistry, 2018, Volume: 482

    Topics: Adult; Aged; Anemia; Antiviral Agents; Enzyme Induction; Female; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Male; Middle Aged; Pyrophosphatases; Ribavirin

2018
'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
    The International journal of artificial organs, 2018, Volume: 41, Issue:7

    Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Valine

2018
Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up.
    The International journal of artificial organs, 2018, Volume: 41, Issue:6

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Kidney Diseases; Male; Middle Aged; Recurrence; Ribavirin; Treatment Outcome

2018
Early occurrence and recurrence of hepatocellular carcinoma in hepatitis C virus-infected patients after sustained virological response.
    Hepatology international, 2018, Volume: 12, Issue:2

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatectomy; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Neoplasms; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Ribavirin; Survival Analysis; Sustained Virologic Response

2018
Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus.
    World journal of gastroenterology, 2018, Apr-07, Volume: 24, Issue:13

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Japan; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult

2018
Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China.
    PloS one, 2018, Volume: 13, Issue:4

    Topics: Adult; Antiviral Agents; Carbamates; China; Cohort Studies; Cost-Benefit Analysis; Disease Progression; Female; Genotype; Health Care Costs; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Male; Markov Chains; Middle Aged; Monte Carlo Method; Polyethylene Glycols; Probability; Pyrrolidines; Quality of Life; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Sulfonamides; Treatment Outcome; Valine

2018
Bullous pemphigoid associated with chronic hepatitis C virus infection in a hepatitis B virus endemic area: A case report.
    Medicine, 2018, Volume: 97, Issue:15

    Topics: Administration, Oral; Aged; Antibodies, Viral; Antiviral Agents; Diagnosis, Differential; DNA, Viral; Glucocorticoids; Hepacivirus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Male; Methylprednisolone; Pemphigoid, Bullous; Republic of Korea; Ribavirin; Sofosbuvir; Treatment Outcome

2018
Association between
    BMJ open, 2018, 04-12, Volume: 8, Issue:4

    Topics: Antiviral Agents; China; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HLA-D Antigens; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome

2018
A facile PCR-RFLP method for genotyping of ITPA rs1127354 and rs7270101 polymorphisms.
    Journal of clinical laboratory analysis, 2018, Volume: 32, Issue:7

    Topics: Antiviral Agents; Cohort Studies; Female; Genotyping Techniques; Hepatitis C, Chronic; Humans; Iran; Male; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin

2018
Ombitasvir-Paritaprevir-Ritonavir Therapy in a Kidney Transplant Recipient With Chronic Hepatitis C Virus Genotype 1 Infection: A Case Report on the Importance of Considering Drug-Drug Interactions and Monitoring Cyclosporine Levels.
    Transplantation proceedings, 2018, Volume: 50, Issue:3

    Topics: Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cyclosporine; Drug Interactions; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Kidney Transplantation; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Proline; Ribavirin; Ritonavir; Sulfonamides; Valine

2018
Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience.
    Hepatology international, 2018, Volume: 12, Issue:4

    Topics: Administration, Oral; Adult; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine

2018
Ribavirin-induced anaemia reduced tacrolimus level in a hepatitis C patient receiving haemodialysis.
    BMJ case reports, 2018, Apr-18, Volume: 2018

    Topics: Adult; Anemia; Darbepoetin alfa; Hematinics; Hemoglobins; Hepatitis C, Chronic; Humans; Male; Renal Dialysis; Ribavirin; Tacrolimus; Treatment Outcome

2018
Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
    Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Drugs, Generic; Female; Fluorenes; Genotype; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; India; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Renal Insufficiency, Chronic; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load; Young Adult

2018
Direct-Acting Antivirals to Prevent Vertical Transmission of Viral Hepatitis C: When Is the Optimal Time to Treat?
    The Annals of pharmacotherapy, 2018, Volume: 52, Issue:11

    Topics: Antiviral Agents; Drug Administration Schedule; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Male; Pregnancy; Ribavirin; Sofosbuvir; Time Factors

2018
Sofosbuvir Causing Diabetes Mellitus: Is there a Link?
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2018, Volume: 28, Issue:5

    Topics: Antiviral Agents; Benzimidazoles; Blood Glucose; Carbamates; Diabetes Mellitus; Drug Therapy, Combination; Female; Glycated Hemoglobin; Hepatitis C, Chronic; Humans; Imidazoles; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine

2018
Elbasvir/grazoprevir in black adults with hepatitis C virus infection: a pooled analysis of phase 2/3 clinical trials.
    The American journal of gastroenterology, 2018, Volume: 113, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzofurans; Black or African American; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Retrospective Studies; Ribavirin; RNA, Viral; Sustained Virologic Response; Treatment Failure; Young Adult

2018
Remission of Nephrotic Syndrome After Therapy for Chronic Hepatitis C Virus Infection in a Patient With Systemic Lupus Erythematosus.
    Annals of internal medicine, 2018, 09-04, Volume: 169, Issue:5

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Glucocorticoids; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Lupus Nephritis; Nephrotic Syndrome; Prednisolone; Remission Induction; Ribavirin; Sofosbuvir; Tacrolimus

2018
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma.
    Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:12

    Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatic Encephalopathy; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Italy; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Valine

2018
[Cytopenias and their correction during antiviral therapy of chronic hepatitis C in patients with genotype 1].
    Voprosy virusologii, 2017, Volume: 62, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia; Treatment Outcome

2017
Distribution of IL28B rs12979860 and rs8099917 Genotypes in Patients with Chronic Hepatitis C Virus Infection in Tianjin, China.
    Clinical laboratory, 2018, Apr-01, Volume: 64, Issue:4

    Topics: Adult; Alleles; Antiviral Agents; Asian People; China; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Male; Middle Aged; Polymorphism, Single Nucleotide; Prevalence; Ribavirin

2018
Real life efficacy of ledipasvir/sofosbuvir in hepatitis C genotype 4-infected patients with advanced liver fibrosis and decompensated cirrhosis.
    The Journal of infection, 2018, Volume: 76, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Cohort Studies; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate

2018
Effectiveness of Sofosbuvir, Ribavirin and PEG-IFNα-2a in the Treatment of Naïve Egyptian Patients With Chronic Hepatitis C Virus Genotype 4.
    The American journal of the medical sciences, 2018, Volume: 355, Issue:5

    Topics: Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response

2018
Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4.
    Hepatology international, 2018, Volume: 12, Issue:4

    Topics: Adult; Antiviral Agents; Carbamates; Cohort Studies; Dose-Response Relationship, Drug; Drug Monitoring; Drug Therapy, Combination; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Function Tests; Male; Middle Aged; Pyrrolidines; Registries; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2018
Long-term familial Mediterranean fever remission on successful hepatitis C virus treatment in a patient not responding to colchicine: a case report.
    Journal of medical case reports, 2018, May-18, Volume: 12, Issue:1

    Topics: Antiviral Agents; Colchicine; Drug Therapy, Combination; Familial Mediterranean Fever; Female; Helicobacter Infections; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tubulin Modulators; Young Adult

2018
Successful Ombitasvir/Paritaprevir/Ritonavir Plus Ribavirin Retreatment for a Chronic Hepatitis C Genotype 2a Patient Who Relapsed after Sofosbuvir Plus Ribavirin Treatment.
    Internal medicine (Tokyo, Japan), 2018, Oct-01, Volume: 57, Issue:19

    Topics: Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Retreatment; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine

2018
Efficacy and Tolerability of Direct-Acting Antivirals for Hepatitis C in Older Adults.
    Journal of the American Geriatrics Society, 2018, Volume: 66, Issue:7

    Topics: Aged; Aged, 80 and over; Anemia; Antiviral Agents; Fatigue; Female; Headache; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load

2018
[Potential application of sofosbuvir-based treatment for chronic hepatitis C in China].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2018, Mar-20, Volume: 26, Issue:3

    Topics: Adolescent; Aged; Antiviral Agents; China; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir

2018
[Clinical value of pegylated interferon-α plus ribavirin-based therapy in antiviral treatment of chronic hepatitis C in China].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2018, Mar-20, Volume: 26, Issue:3

    Topics: Antiviral Agents; China; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2018
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.
    Infection, 2018, Volume: 46, Issue:5

    Topics: 2-Naphthylamine; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Biomarkers; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine

2018
Comment on 'Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study'.
    European journal of gastroenterology & hepatology, 2018, Volume: 30, Issue:7

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sulfonamides; Treatment Outcome; Valine

2018
Localized scleroderma occurring after treatment of chronic hepatitis C with sofosbuvir and ribavirin.
    The Journal of dermatology, 2019, Volume: 46, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Scleroderma, Localized; Skin; Sofosbuvir; Treatment Outcome

2019
Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study.
    Clinical and molecular hepatology, 2018, Volume: 24, Issue:3

    Topics: Aged; Anemia; Antiviral Agents; Dizziness; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Protease Inhibitors; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response

2018
Letter: concordance of SVR4 and SVR12 following direct-acting anti-viral treatment in Egypt.
    Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:11

    Topics: Antiviral Agents; Carbamates; Egypt; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Valine

2018
Editorial: retreatment of DAA-failures-no problem at all?
    Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:11

    Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Retreatment; Ribavirin; Simeprevir; Sofosbuvir

2018
Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real-world experience study.
    Journal of viral hepatitis, 2018, Volume: 25, Issue:11

    Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropanes; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver; Liver Cirrhosis; Liver Neoplasms; Macrocyclic Compounds; Male; Middle Aged; Poland; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine; Viral Load

2018
Pegylated Interferon-α Plus Ribavirin Therapy Improves Left Ventricular Diastolic Dysfunction in Patients With Chronic Hepatitis C Attaining Sustained Virological Response.
    The American journal of the medical sciences, 2018, Volume: 355, Issue:6

    Topics: Adult; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Echocardiography; Female; Genotype; Heart Ventricles; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Pilot Projects; Polyethylene Glycols; Reproducibility of Results; Ribavirin; Sustained Virologic Response; Ventricular Dysfunction, Left

2018
Real-World Study on Sofosbuvir-based Therapies in Asian Americans With Chronic Hepatitis C.
    Journal of clinical gastroenterology, 2019, Volume: 53, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian; Benzimidazoles; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Young Adult

2019
100% sustained virological response and fibrosis improvement in real-life use of direct acting antivirals in genotype-1b recurrent hepatitis C following liver transplantation.
    Journal of gastrointestinal and liver diseases : JGLD, 2018, Volume: 27, Issue:2

    Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Uridine Monophosphate; Valine

2018
Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1 Infection: A Retrospective Cohort Study in a Medicaid Population.
    Journal of managed care & specialty pharmacy, 2018, Volume: 24, Issue:7

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Medicaid; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Treatment Failure; United States; Uridine Monophosphate; Viral Load

2018
Direct-acting antiviral drugs are triggers for psoriasis: report of three cases.
    International journal of dermatology, 2018, Volume: 57, Issue:10

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Psoriasis; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Symptom Flare Up; Valine

2018
Territory-wide population-based study of chronic hepatitis C infection and implications for hepatitis elimination in Hong Kong.
    Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:11

    Topics: Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hong Kong; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Mortality; Retrospective Studies; Ribavirin; Sustained Virologic Response

2018
Study of Adverse Drug Effects of Direct-Acting Antivirals for Chronic HCV Infection at Fayoum Governorate, Egypt - A Pharmacovigilance Study.
    Current drug safety, 2018, Volume: 13, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Incidence; Male; Middle Aged; Pharmacovigilance; Prospective Studies; Pyrrolidines; Ribavirin; Severity of Illness Index; Sofosbuvir; Valine

2018
Real Life Egyptian Experience of Daclatasvir Plus Sofosbuvir with Ribavirin in Naïve Difficult to Treat HCV Patients.
    Infectious disorders drug targets, 2020, Volume: 20, Issue:1

    Topics: Administration, Oral; Adult; Carbamates; Case-Control Studies; Drug Combinations; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load

2020
Interim analysis of a 3-year follow-up study of NS5A and NS3 resistance-associated substitutions after treatment with grazoprevir-containing regimens in participants with chronic HCV infection.
    Antiviral therapy, 2018, Volume: 23, Issue:7

    Topics: Adult; Amino Acid Substitution; Antiviral Agents; Benzofurans; Drug Administration Schedule; Drug Combinations; Drug Resistance, Viral; Female; Follow-Up Studies; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Polymorphism, Genetic; Quinoxalines; Recurrence; Ribavirin; Serine Proteases; Treatment Failure; Viral Load; Viral Nonstructural Proteins

2018
KIR2DL2/C1 is a Risk Factor for Chronic Infection and Associated with Non-response to PEG-IFN and RBV Combination Therapy in Hepatitis C Virus Genotype 1b Patients in China.
    Virologica Sinica, 2018, Volume: 33, Issue:4

    Topics: Adult; Antiviral Agents; China; Drug Therapy, Combination; Female; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Receptors, KIR2DL2; Ribavirin; Risk Factors; Treatment Outcome

2018
Identification of IL-10-secreting CD8
    Immunology letters, 2018, Volume: 202

    Topics: Adult; Antiviral Agents; Biomarkers; CD28 Antigens; CD8-Positive T-Lymphocytes; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interleukin-10; Lymphocyte Activation; Male; Programmed Cell Death 1 Receptor; Ribavirin; RNA, Viral; T-Lymphocytes, Regulatory

2018
Impact of Different Sources of Infection on Therapy Response in Chronic Hepatitis C.
    Medical archives (Sarajevo, Bosnia and Herzegovina), 2018, Volume: 72, Issue:3

    Topics: Adult; Antiviral Agents; Blood Transfusion; Bosnia and Herzegovina; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Iatrogenic Disease; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Transfusion Reaction; Treatment Outcome

2018
Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis.
    PloS one, 2018, Volume: 13, Issue:7

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Italy; Liver Cirrhosis; Polymorphism, Genetic; Prospective Studies; Pyrrolidines; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine

2018
Interferon- and ribavirin-free therapy with new direct acting antivirals (DAA) for chronic hepatitis C improves vascular endothelial function.
    International journal of cardiology, 2018, Nov-15, Volume: 271

    Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Endothelium, Vascular; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Pilot Projects; Ribavirin; Treatment Outcome

2018
High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2018, Volume: 75

    Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Drugs, Generic; Egypt; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2018
High sustained virologic response rate using generic directly acting antivirals in the treatment of chronic hepatitis C virus Egyptian patients: single-center experience.
    European journal of gastroenterology & hepatology, 2018, Volume: 30, Issue:10

    Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Drugs, Generic; Egypt; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine; Viral Load

2018
Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African-American patients: a community-based retrospective cohort study.
    European journal of gastroenterology & hepatology, 2018, Volume: 30, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Black or African American; Carbamates; Community Health Centers; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response

2018
Treatment of Chronic Hepatitis C Infection with Direct Acting Antivirals in Adolescents with Thalassemia Major.
    Indian journal of pediatrics, 2019, Volume: 86, Issue:2

    Topics: Adolescent; Antiviral Agents; Benzimidazoles; beta-Thalassemia; Carbamates; Child; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load

2019
High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Men Who Have Sex With Men.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019, 02-01, Volume: 68, Issue:4

    Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug-Related Side Effects and Adverse Reactions; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Homosexuality, Male; Humans; Imidazoles; Male; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response; Treatment Outcome

2019
[Ledipasvir/sofosbuvir combination for chronic hepatitis C infection in children and adolescents].
    Anales de pediatria, 2019, Volume: 90, Issue:3

    Topics: Adolescent; Antiviral Agents; Benzimidazoles; Child; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load

2019
Efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infection.
    Journal of medical virology, 2019, Volume: 91, Issue:2

    Topics: Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine

2019
Findings from a large Asian chronic hepatitis C real-life study.
    Journal of viral hepatitis, 2018, Volume: 25, Issue:12

    Topics: Adult; Antiviral Agents; Asia; Benzimidazoles; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2018
Interferon-based Simeprevir Therapy for Pediatric Patients with Chronic Hepatitis C Viral Infection.
    Annals of hepatology, 2018, Aug-24, Volume: 17, Issue:5

    Topics: Adolescent; Age Factors; Antiviral Agents; Child; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir; Sustained Virologic Response; Time Factors; Treatment Outcome; Viral Load

2018
Efficacy of ombitasvir/paritaprevir/ritonavir/ribavirin in management of HCV genotype 4 and end-stage kidney disease.
    Clinics and research in hepatology and gastroenterology, 2019, Volume: 43, Issue:1

    Topics: Adult; Aged, 80 and over; Algorithms; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Valine

2019
Antidepressant effects of direct-acting antivirals against hepatitis C virus-Results from a pilot study.
    European journal of clinical investigation, 2018, Volume: 48, Issue:12

    Topics: Actigraphy; Adult; Aged; Antiviral Agents; Depression; Exercise; Fatigue; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Pilot Projects; Ribavirin; Treatment Outcome; Tryptophan; Viral Load; Young Adult

2018
Rapid hepatitis C virus clearance by antivirals correlates with immune status of infected patients.
    Journal of medical virology, 2019, Volume: 91, Issue:3

    Topics: Aged; Antiviral Agents; Chemokines; Cytokines; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Immunity, Innate; Interferon-alpha; Male; Middle Aged; Neutralization Tests; Polyethylene Glycols; Ribavirin; RNA, Viral; T-Lymphocytes, Helper-Inducer; Treatment Outcome; Viral Load

2019
Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?
    Clinical and molecular hepatology, 2018, Volume: 24, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Retrospective Studies; Ribavirin; Sofosbuvir

2018
Does Ribavirin Still Have a Role in Sofosbuvir and Velpatasvir Therapy for Patients With HCV Genotype 3 Infection and Cirrhosis?
    Gastroenterology, 2018, Volume: 155, Issue:4

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome

2018
Differential Effect of HCV Eradication and Fibrosis Grade on Hepatocellular Carcinoma and All-cause Mortality.
    Scientific reports, 2018, 09-12, Volume: 8, Issue:1

    Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Fibrosis; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Sustained Virologic Response

2018
Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study.
    Scientific reports, 2018, 09-12, Volume: 8, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Taiwan

2018
Direct-acting antiviral Therapy Is Safe and Effective in Pediatric Chronic Hepatitis C: The Public Health Perspective.
    Journal of pediatric gastroenterology and nutrition, 2019, Volume: 68, Issue:1

    Topics: Adolescent; Antiviral Agents; Carbamates; Child; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; India; Male; Program Evaluation; Public Health; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine

2019
Long-term persistence of anti-rods and rings antibodies in patients with chronic hepatitis C after antiviral treatment.
    Immunologic research, 2018, Volume: 66, Issue:5

    Topics: Aged; Antiviral Agents; Autoantibodies; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; IMP Dehydrogenase; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2018
Acneiform eruptions: An unusual dermatological side effect of ribavirin.
    Dermatologic therapy, 2018, Volume: 31, Issue:5

    Topics: Acneiform Eruptions; Adult; Antiviral Agents; Drug Eruptions; Hepatitis C, Chronic; Humans; Male; Ribavirin

2018
Patients with chronic hepatitis C receiving sofosbuvir and ribavirin-based treatment, with or without interferon in Zhejiang, China: An observational study.
    Medicine, 2018, Volume: 97, Issue:38

    Topics: Adult; Antiviral Agents; China; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Viral Load; Young Adult

2018
Eradication of HCV in Renal Transplant Recipients and Its Effects on Quality of Life.
    BioMed research international, 2018, Volume: 2018

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Italy; Kidney Transplantation; Male; Middle Aged; Quality of Life; Ribavirin; Sofosbuvir; Treatment Outcome

2018
Impact of new direct-acting antiviral drugs on hepatitis C virus-related decompensated liver cirrhosis.
    European journal of gastroenterology & hepatology, 2019, Volume: 31, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Biomarkers; Carbamates; Case-Control Studies; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Prospective Studies; Prothrombin Time; Pyrrolidines; Quality of Life; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Sustained Virologic Response; Time Factors; Treatment Outcome; Uridine Monophosphate; Valine

2019
Treatment of Elderly Patients with Chronic Hepatitis C: A Retrospective Cohort Study.
    Acta clinica Croatica, 2018, Volume: 57, Issue:1

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome

2018
Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort.
    Journal of viral hepatitis, 2019, Volume: 26, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzofurans; Cohort Studies; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Quinoxalines; Registries; Retrospective Studies; Ribavirin; Spain; Sustained Virologic Response; Treatment Outcome

2019
Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study.
    Virology journal, 2018, 10-01, Volume: 15, Issue:1

    Topics: Adult; Antiviral Agents; Asian People; Carbamates; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2018
The choice of antiviral therapy for hepatitis C recurrence after liver transplantation in the real world.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2018, Volume: 117, Issue:11

    Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Transplantation; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine

2018
Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2019, Volume: 118, Issue:5

    Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Taiwan; Valine

2019
No Regional Disparities in Sofosbuvir Plus Ribavirin Therapy for HCV Genotype 2 Infection in Tochigi Prefecture and Its Vicinity.
    Internal medicine (Tokyo, Japan), 2019, Feb-15, Volume: 58, Issue:4

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Geography; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Japan; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response

2019
Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy.
    Journal of hepatology, 2019, Volume: 70, Issue:1

    Topics: Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Japan; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Tomography, X-Ray Computed; Treatment Outcome

2019
Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy.
    Expert review of pharmacoeconomics & outcomes research, 2019, Volume: 19, Issue:3

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Cost-Benefit Analysis; Drug Therapy, Combination; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Italy; Markov Chains; Pyrrolidines; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Sofosbuvir; Uridine Monophosphate; Valine

2019
Evaluation of cost-effectiveness of peginterferon plus ribavirin for chronic hepatitis C treatment and direct-acting antiviral agents among HIV-infected patients in the prison and community settings.
    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2019, Volume: 52, Issue:4

    Topics: Adult; Antiviral Agents; Coinfection; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Health Care Costs; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Prisons; Retrospective Studies; Ribavirin; Taiwan; Viral Load

2019
Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real-world experience of a retrospective study.
    Journal of viral hepatitis, 2019, Volume: 26, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Carbamates; China; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2019
Effect of vitamin D supplementation on sustained virological response in genotype 1/4 chronic hepatitis C treatment-naïve patients from India.
    The Indian journal of medical research, 2018, Volume: 148, Issue:2

    Topics: Adult; Dietary Supplements; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; India; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sustained Virologic Response; Treatment Outcome; Viral Load; Vitamin D

2018
Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: a Phase III study (ALLY-3C).
    Antiviral therapy, 2019, Volume: 24, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine

2019
Predictive value of IL-28B rs12979860 variants for peg-IFN, sofosbuvir plus ribavirin treatment of HCV infection in Pakistani population.
    Personalized medicine, 2018, Volume: 15, Issue:6

    Topics: Adult; Antiviral Agents; Biomarkers, Pharmacological; Cross-Sectional Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Pakistan; Polyethylene Glycols; Polymorphism, Single Nucleotide; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2018
Direct acting antiviral-based treatment of hepatitis C virus infection among people who inject drugs in Georgia: A prospective cohort study.
    The International journal on drug policy, 2018, Volume: 62

    Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Drug Users; Female; Genotype; Georgia; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Substance Abuse, Intravenous

2018
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy.
    The International journal on drug policy, 2018, Volume: 62

    Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Medication Adherence; Middle Aged; Opiate Substitution Treatment; Proline; Qualitative Research; Ribavirin; Ritonavir; RNA, Viral; Substance Abuse, Intravenous; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine

2018
Successful DAA Treatment and Global Improvement in a Cirrhotic Patient with Concomitant HCV Infection and Autoimmune Hepatitis.
    Digestive diseases and sciences, 2019, Volume: 64, Issue:2

    Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Bilirubin; Carbamates; Female; gamma-Globulins; Hepatitis C, Chronic; Hepatitis, Autoimmune; Humans; Imidazoles; Liver; Liver Cirrhosis; Middle Aged; Pyrrolidines; Ribavirin; RNA, Viral; Serum Albumin; Sofosbuvir; Valine; Viral Load

2019
Next-generation sequencing analysis of new genotypes appearing during antiviral treatment of chronic hepatitis C reveals that these are selected from pre-existing minor strains.
    The Journal of general virology, 2018, Volume: 99, Issue:12

    Topics: Adult; Antiviral Agents; Female; Genetic Variation; Genetics, Population; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Interferons; Longitudinal Studies; Male; Middle Aged; Quasispecies; Ribavirin; Selection, Genetic; Young Adult

2018
Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational Study.
    The American journal of gastroenterology, 2019, Volume: 114, Issue:2

    Topics: Aged; Antiviral Agents; Benzimidazoles; Breast Neoplasms; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Fluorenes; Head and Neck Neoplasms; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Interferons; Liver Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Neoplasms; Polyethylene Glycols; Prospective Studies; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine

2019
Interferon alpha receptors and STAT1 as therapy predictors of a sustained virological response in hepatitis C/B co-infection.
    JPMA. The Journal of the Pakistan Medical Association, 2018, Volume: 68, Issue:11

    Topics: Adult; Antibodies, Viral; Coinfection; Cross-Sectional Studies; DNA, Viral; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression Regulation; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Polymerase Chain Reaction; Receptor, Interferon alpha-beta; Recombinant Proteins; Retrospective Studies; Ribavirin; STAT1 Transcription Factor

2018
The Efficacy and Safety of Direct-acting Antiviral Treatment for Chronic Hepatitis C Patients: A Single Center Study.
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2018, Oct-25, Volume: 72, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Dyspepsia; Elasticity Imaging Techniques; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2018
Burden of disease in patients with chronic hepatitis C in the Austrian REAL study.
    Wiener klinische Wochenschrift, 2019, Volume: 131, Issue:1-2

    Topics: Antiviral Agents; Austria; Cost of Illness; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prospective Studies; Quality of Life; Ribavirin; Treatment Outcome

2019
Direct-Acting Antiviral Therapy for HCV Infection Is Associated With a Reduced Risk of Cardiovascular Disease Events.
    Gastroenterology, 2019, Volume: 156, Issue:4

    Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Antiviral Agents; Cardiovascular Diseases; Coronary Artery Bypass; Drug Therapy, Combination; Female; Heart Failure; Hepatitis C, Chronic; Humans; Incidence; Interferon Type I; Male; Middle Aged; Myocardial Infarction; Peripheral Vascular Diseases; Protective Factors; Ribavirin; Stroke; Sustained Virologic Response

2019
Autoantibodies to cytoplasmic rods and rings in patients with hepatitis C virus infection treated with direct-acting antivirals: The role of prior treatment with interferon plus ribavirin.
    Gastroenterologia y hepatologia, 2019, Volume: 42, Issue:2

    Topics: Antiviral Agents; Autoantibodies; Cohort Studies; Cytoskeleton; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin

2019
Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2019, Volume: 118, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Ribavirin; Taiwan; Treatment Failure; Viral Load

2019
Cost-effectiveness of sofosbuvir plus ribavirin therapy for hepatitis C virus genotype 2 infection in South Korea.
    Journal of gastroenterology and hepatology, 2019, Volume: 34, Issue:4

    Topics: Aged; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Republic of Korea; Ribavirin; Sofosbuvir; Treatment Outcome

2019
Long-term histological change in chronic hepatitis C patients who had received peginterferon plus ribavirin therapy with sustained virological response.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2019, Volume: 118, Issue:7

    Topics: Adult; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sustained Virologic Response; Taiwan; Viral Load

2019
Successful HCV treatment of patients on contraindicated anti-epileptic drugs: Role of drug level monitoring.
    Journal of hepatology, 2019, Volume: 70, Issue:3

    Topics: Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir

2019
Hepatitis C Treatment in Patients with Drug Addiction Is Effective or Not Effective?
    Medical archives (Sarajevo, Bosnia and Herzegovina), 2018, Volume: 72, Issue:5

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Drug Users; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Load

2018
Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2019, Volume: 118, Issue:1 Pt 3

    Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Ribavirin; Risk Factors; Survival Rate; Sustained Virologic Response; Taiwan

2019
Sofosbuvir plus ribavirin for the treatment of hepatitis C virus genotype 2 in Korea: What's the optimal dosage of ribavirin in real-world setting?
    Journal of digestive diseases, 2019, Volume: 20, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Republic of Korea; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult

2019
Tolerability and effectiveness of generic direct-acting antiviral drugs in eradication of hepatitis C genotype 4 among Egyptian patients.
    Liver international : official journal of the International Association for the Study of the Liver, 2019, Volume: 39, Issue:5

    Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Drugs, Generic; Egypt; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Valine

2019
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan.
    PloS one, 2018, Volume: 13, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Safety; Sofosbuvir; Sustained Virologic Response; Taiwan; Treatment Outcome; Uridine Monophosphate

2018
Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis.
    PloS one, 2018, Volume: 13, Issue:12

    Topics: Adult; Aged; Antiviral Agents; Atherosclerosis; Cholesterol, LDL; Dyslipidemias; Fatty Liver; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lipid Metabolism; Liver; Male; Middle Aged; Ribavirin; Risk Factors; Sustained Virologic Response

2018
Timely eradication of HCV viremia by PegIFN/RBV is crucial in prevention of post RFA recurrence in CHC-HCC patients.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2019, Volume: 118, Issue:8

    Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Polyethylene Glycols; Proportional Hazards Models; Retrospective Studies; Ribavirin; Secondary Prevention; Sustained Virologic Response; Taiwan; Tertiary Prevention; Viral Load; Viremia

2019
Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection.
    Alimentary pharmacology & therapeutics, 2019, Volume: 49, Issue:3

    Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Lymphoma; Male; Middle Aged; Polyethylene Glycols; Ribavirin; Taiwan

2019
Th17 and IL-17 as Predictors of Hepatic Inflammation in Patients with Chronic Hepatitis C Virus Infection and Treated With Direct Antiviral Therapy.
    The Egyptian journal of immunology, 2018, Volume: 25, Issue:2

    Topics: Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Inflammation; Interleukin-17; Ribavirin; Sofosbuvir; Sustained Virologic Response; Th17 Cells; Treatment Outcome

2018
Sustained virological response and metabolic risk factors are associated with mortality in patients with chronic hepatitis C.
    PloS one, 2019, Volume: 14, Issue:1

    Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Risk Factors; Sustained Virologic Response

2019
Comparative efficacy of sofosbuvir-ribavirin versus sofosbuvir-daclatasvir for treatment of chronic hepatitis C in an area with limited NS5A inhibitor availability.
    Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2018, Volume: 37, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Health Services Accessibility; Hepatitis C, Chronic; Humans; Imidazoles; Indonesia; Male; Medically Underserved Area; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Valine; Viral Nonstructural Proteins; Young Adult

2018
Anatomical and Functional Retinal Complications of Combined Sofosbuvir and Ribavirin Therapy in Patients With Chronic Hepatitis C Virus.
    Ophthalmic surgery, lasers & imaging retina, 2019, 01-01, Volume: 50, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Electroretinography; Female; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prospective Studies; Retina; Ribavirin; Sofosbuvir; Tomography, Optical Coherence; Treatment Outcome; Visual Acuity; Young Adult

2019
Fib-4 Predicts Early Hematological Adverse Events Induced by Interferon-Based Triple Therapy in Chronic Hepatitis C Virus Patients.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2019, Volume: 39, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome

2019
Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program.
    Scientific reports, 2019, 01-24, Volume: 9, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Italy; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine

2019
Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy?
    Hepatology international, 2019, Volume: 13, Issue:2

    Topics: Aged; Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response

2019
Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection.
    Journal of gastroenterology and hepatology, 2019, Volume: 34, Issue:9

    Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Comparative Effectiveness Research; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Taiwan; Time Factors; Treatment Outcome; Uridine Monophosphate; Valine

2019
Sofosbuvir-Based Regimens for Chronic Hepatitis C in a Well-Insured U.S. Population: Patient Characteristics, Treatment Adherence, Effectiveness, and Health Care Costs, 2013-2015.
    Journal of managed care & specialty pharmacy, 2019, Volume: 25, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Costs; Drug Therapy, Combination; Female; Fluorenes; Health Care Costs; Hepatitis C, Chronic; Humans; Insurance, Health; Interferon-alpha; Male; Medicare; Medication Adherence; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; United States; Uridine Monophosphate; Young Adult

2019
Change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of direct-acting antiviral therapy.
    Journal of gastroenterology and hepatology, 2019, Volume: 34, Issue:9

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Drug Users; Female; Hepatitis C Antibodies; Hepatitis C, Chronic; Hong Kong; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prevalence; Program Evaluation; Recombinant Proteins; Ribavirin; Risk Factors; Substance Abuse, Intravenous; Sustained Virologic Response; Time Factors; Treatment Outcome

2019
Effect of cyclosporine A versus tacrolimus on the response to antiviral therapy after hepatitis C genotype-4 recurrence post-liver transplantation: A prospective cohort trial.
    Journal of clinical pharmacy and therapeutics, 2019, Volume: 44, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Calcineurin Inhibitors; Cyclosporine; Drug Interactions; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Sofosbuvir; Tacrolimus; Young Adult

2019
Successful Treatment With Direct-Acting Antiviral Agents of Hepatitis C in Patients With End-Stage Renal Disease and Kidney Transplant Recipients.
    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2019, Volume: 17, Issue:1

    Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Retrospective Studies; Ribavirin; Risk Factors; Ritonavir; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Uracil; Valine

2019
Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studi
    Journal of viral hepatitis, 2019, Volume: 26, Issue:6

    Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Internationality; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Young Adult

2019
Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort.
    Journal of viral hepatitis, 2019, Volume: 26, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate

2019
Risk factors for remaining liver injury in patients with virological elimination of chronic hepatitis C.
    Zeitschrift fur Gastroenterologie, 2019, Volume: 57, Issue:2

    Topics: Alanine Transaminase; Antiviral Agents; Fatty Liver; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Obesity; Prospective Studies; Ribavirin; Risk Factors; Sex Factors

2019
Management of HCV-related decompensated cirrhosis with direct-acting antiviral agents: who should be treated?
    Hepatology international, 2019, Volume: 13, Issue:2

    Topics: Adult; Antiviral Agents; Ascites; Carbamates; Drug Therapy, Combination; Esophageal and Gastric Varices; Female; Hepatic Encephalopathy; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Patient Selection; Pyrrolidines; Quality of Life; Ribavirin; RNA, Viral; Severity of Illness Index; Sofosbuvir; Survival Rate; Sustained Virologic Response; Ultrasonography; Valine

2019
Ritonavir-boosted paritaprevir, ombitasvir plus ribavirin could improve eGFR in patients with renal impairment and HCV: an Egyptian cohort.
    Expert review of gastroenterology & hepatology, 2019, Volume: 13, Issue:1

    Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Egypt; Female; Genotype; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Recovery of Function; Renal Dialysis; Renal Insufficiency, Chronic; Ribavirin; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine; Viral Load; Young Adult

2019
Utility of laboratory monitoring during hepatitis C treatment with ribavirin-free direct-acting antiviral regimens.
    Journal of viral hepatitis, 2019, Volume: 26, Issue:6

    Topics: Aged; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Monitoring, Physiologic; Retrospective Studies; Ribavirin; RNA, Viral; Sustained Virologic Response

2019
Biological and psychological components of depression in patients receiving IFN-alpha therapy for hepatitis C.
    Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 2019, Volume: 28, Issue:9

    Topics: Antiviral Agents; Depression; Depressive Disorder, Major; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Prospective Studies; Psychiatric Status Rating Scales; Ribavirin

2019
The benefits of a public pharmacist service in chronic hepattis C treatment: The real-life results of sofosbuvir-based therapy.
    Research in social & administrative pharmacy : RSAP, 2020, Volume: 16, Issue:1

    Topics: Antiviral Agents; Carbamates; Community Pharmacy Services; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Medication Adherence; Middle Aged; Pharmacists; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Valine

2020
HCV core antigen is a useful predictor during pegylated-interferon/ribavirin therapy in patients with hepatitis C virus genotype 1b.
    Medicine, 2019, Volume: 98, Issue:10

    Topics: Adult; Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; ROC Curve; Sustained Virologic Response; Treatment Outcome

2019
The predictors of sustained virological response with sofosbuvir and ribavirin in patients with chronic hepatitis C genotype 2.
    The Korean journal of internal medicine, 2021, Volume: 36, Issue:3

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Neoplasm Recurrence, Local; Ribavirin; Sofosbuvir; Treatment Outcome

2021
A 12-week rescue therapy by PrOD-based regimen for advanced fibrotic genotype-1 CHC patients who failed to pegylated interferon plus ribavirin.
    Journal of the Chinese Medical Association : JCMA, 2019, Volume: 82, Issue:3

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Sustained Virologic Response

2019
Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
    PloS one, 2019, Volume: 14, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Drug Administration Schedule; Drug Combinations; Female; Fluorenes; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Safety; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Young Adult

2019
Experience of a Portuguese Center: Effectiveness of Direct-Acting Antiviral Therapy for Hepatitis C.
    Acta medica portuguesa, 2019, Mar-29, Volume: 32, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Portugal; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Young Adult

2019
High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naïve and experienced chronic hepatitis C genotype 4: Real world results.
    Journal of medical virology, 2022, Volume: 94, Issue:2

    Topics: Adult; Anemia; Anilides; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Fatigue; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine

2022
Long-term outcomes and risk factors of thyroid dysfunction during pegylated interferon and ribavirin treatment in patients with chronic hepatitis C infection in Taiwan.
    BMC endocrine disorders, 2019, Apr-05, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Risk Factors; Taiwan; Thyroid Diseases; Young Adult

2019
Comparison of the Clinical Characteristics and Outcomes between Leprosy-Affected Persons in Sorokdo and the General Population Affected by Chronic Hepatitis C in Korea.
    Gut and liver, 2019, 09-15, Volume: 13, Issue:5

    Topics: Aged; Anemia, Hemolytic; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Leprosy; Male; Prevalence; Republic of Korea; Retrospective Studies; Ribavirin; Sustained Virologic Response; Treatment Outcome

2019
High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients.
    Gut and liver, 2020, 05-15, Volume: 14, Issue:3

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2020
Successful treatment of hepatitis C virus infection with direct-acting antivirals during hematopoietic cell transplant.
    Transplant infectious disease : an official journal of the Transplantation Society, 2019, Volume: 21, Issue:3

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hematopoietic Stem Cell Transplantation; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Leukemia, Myeloid, Acute; Male; Ribavirin; Treatment Outcome

2019
Hepatitis C Virus (HCV) Treatment With Directly Acting Agents Reduces the Risk of Incident Diabetes: Results From Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 03-03, Volume: 70, Issue:6

    Topics: Antiviral Agents; Diabetes Mellitus; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Treatment Outcome; Veterans

2020
Direct-acting antivirals and visceral leishmaniasis: a case report.
    BMC infectious diseases, 2019, Apr-18, Volume: 19, Issue:1

    Topics: Aged; Amphotericin B; Antiprotozoal Agents; Antiviral Agents; Coinfection; Hepatitis C, Chronic; Humans; Leishmania infantum; Leishmaniasis, Visceral; Male; Ribavirin; Sofosbuvir

2019
Validated RP-HPLC Method for Simultaneous Determination of Ribavirin, Sofosbuvir and Daclatasvir in Human Plasma: A Treatment Protocol Administered to HCV Patients in Egypt.
    Journal of chromatographic science, 2019, Aug-01, Volume: 57, Issue:7

    Topics: Carbamates; Chromatography, High Pressure Liquid; Egypt; Hepatitis C, Chronic; Humans; Imidazoles; Limit of Detection; Linear Models; Pyrrolidines; Reproducibility of Results; Ribavirin; Sofosbuvir; Valine

2019
Full-dose sofosbuvir plus low-dose ribavirin for hepatitis C virus genotype 2-infected patients on hemodialysis.
    The Korean journal of internal medicine, 2020, Volume: 35, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Renal Dialysis; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome

2020
Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis.
    Scientific reports, 2019, 05-08, Volume: 9, Issue:1

    Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Retrospective Studies; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine

2019
[EFFICACY AND SAFETY OF OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR IN PATIENTS WITH HCV 1B GENOTYPE INFECTION: REAL WORLD DATA].
    Georgian medical news, 2019, Issue:288

    Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Ukraine; Uracil; Valine

2019
High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar.
    Journal of viral hepatitis, 2019, Volume: 26, Issue:10

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Male; Middle Aged; Myanmar; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine

2019
Effectiveness and Cost-Effectiveness of Triple Therapy With Telaprevir and Boceprevir for Chronic Hepatitis C: A Decision Analysis From the Brazilian Public Health System Perspective.
    Value in health regional issues, 2019, Volume: 20

    Topics: Antiviral Agents; Brazil; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Female; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Markov Chains; Middle Aged; Oligopeptides; Proline; Public Health Practice; Quality-Adjusted Life Years; Ribavirin; Treatment Outcome

2019
B.A.R.C.O.S. (Brazilian Argentine Hepatitis C Collaborative Observational Study): Effectiveness and clinical outcomes of HCV treatment with daclatasvir and sofosbuvir with or without ribavirin.
    Journal of viral hepatitis, 2019, Volume: 26, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Argentina; Brazil; Carbamates; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult

2019
The role of hepatic progenitor cells in predicting response to therapy in Egyptian patients with chronic hepatitis C, genotype 4.
    African health sciences, 2019, Volume: 19, Issue:1

    Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Retrospective Studies; Ribavirin; Young Adult

2019
HCV resistance compartmentalization within tumoral and non-tumoral liver in transplanted patients with hepatocellular carcinoma.
    Liver international : official journal of the International Association for the Study of the Liver, 2019, Volume: 39, Issue:10

    Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Coinfection; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Phylogeny; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Viral Nonstructural Proteins

2019
Retreatment of Egyptian Chronic Hepatitis C Patients Not Responding to Pegylated Interferon and Ribavirin Dual Therapy.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2019, Volume: 39, Issue:9

    Topics: Antiviral Agents; Carbamates; Egypt; Female; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Pyrrolidines; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Valine

2019
The association of hepatitis c virus infection status with serum glucose levels.
    BMC gastroenterology, 2019, Jun-13, Volume: 19, Issue:1

    Topics: Adult; Antiviral Agents; Blood Glucose; Drug Therapy, Combination; Fasting; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin; Insulin Resistance; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Sustained Virologic Response

2019
A case report of psychiatric symptoms following direct-acting antiviral and ribavirin combination therapy for chronic hepatitis C in a patient with innate anxiety.
    BMC gastroenterology, 2019, Jun-13, Volume: 19, Issue:1

    Topics: Antiviral Agents; Anxiety; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Middle Aged; Ribavirin

2019
Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure.
    Journal of viral hepatitis, 2019, Volume: 26, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Duration of Therapy; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Sustained Virologic Response; Treatment Outcome; Young Adult

2019
Recurrence rate of hepatocellular carcinoma in patients with treated hepatocellular carcinoma and hepatitis C virus-associated cirrhosis after ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin therapy.
    United European gastroenterology journal, 2019, Volume: 7, Issue:5

    Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cyclopropanes; Hepatectomy; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Neoplasms; Macrocyclic Compounds; Middle Aged; Neoplasm Recurrence, Local; Proline; Prospective Studies; Radiofrequency Ablation; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine

2019
Cost-effectiveness analysis of sofosbuvir plus ribavirin in patients with genotype 2 chronic hepatitis C: an analysis with real world outcomes from a multicentre cohort in Japan.
    BMJ open, 2019, 06-19, Volume: 9, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Japan; Male; Middle Aged; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; Sustained Virologic Response

2019
Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection.
    Hepatology (Baltimore, Md.), 2020, Volume: 71, Issue:1

    Topics: Antiviral Agents; Child; Child, Preschool; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2020
Successful treatment of HBV, HCV, & HEV, with 12-week long use of tenofovir, sofosbuvir, daclatasvir, and ribavirin: A case report.
    Journal of infection and public health, 2020, Volume: 13, Issue:1

    Topics: Aged; Antiviral Agents; Asthma; Carbamates; Coinfection; Diabetes Complications; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis B; Hepatitis C, Chronic; Hepatitis E; Humans; Imidazoles; Male; Pyrrolidines; Ribavirin; Sofosbuvir; Tenofovir; Treatment Outcome; Valine; Viral Load

2020
Cluster of hepatitis C in a family: a twenty-year follow-up.
    Central European journal of public health, 2019, Volume: 27, Issue:2

    Topics: Antiviral Agents; Child; Disease Transmission, Infectious; Family; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Needle Sharing; Ribavirin

2019
Implications of soluble E-cadherin level of antiviral treatment in patients with chronic hepatitis C virus infection.
    International immunopharmacology, 2019, Volume: 74

    Topics: Adult; Antiviral Agents; Biomarkers, Pharmacological; Cadherins; China; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunotherapy; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Ribavirin; Viral Load

2019
Interprofessional team-based approach to patients with chronic hepatitis C and personality disorder: Three case studies.
    Archives of psychiatric nursing, 2019, Volume: 33, Issue:4

    Topics: Adult; Anemia; Antiviral Agents; Comorbidity; Delivery of Health Care, Integrated; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Interprofessional Relations; Male; Middle Aged; Personality Disorders; Polyethylene Glycols; Primary Health Care; Recombinant Proteins; Ribavirin; Sofosbuvir; Substance-Related Disorders

2019
Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International St
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 05-23, Volume: 70, Issue:11

    Topics: Analgesics, Opioid; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Pharmaceutical Preparations; Ribavirin; Substance Abuse, Intravenous; Sustained Virologic Response

2020
Effect of Combined HCV Therapy on Natural Killer Cell Activity.
    The Egyptian journal of immunology, 2019, Volume: 26, Issue:1

    Topics: Adult; Antiviral Agents; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Killer Cells, Natural; Male; Middle Aged; Natural Cytotoxicity Triggering Receptor 3; Ribavirin; Sofosbuvir; Sustained Virologic Response

2019
European mitochondrial haplogroups predict liver-related outcomes in patients coinfected with HIV and HCV: a retrospective study.
    Journal of translational medicine, 2019, 07-26, Volume: 17, Issue:1

    Topics: Adult; Antiviral Agents; Biopsy; Carcinoma, Hepatocellular; Coinfection; Disease Progression; DNA, Mitochondrial; Europe; Female; Genotype; Haplotypes; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver; Liver Failure; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Ribavirin; Risk

2019
Daclatasvir plus sofosbuvir, with or without ribavirin, is highly effective for all kinds of genotype-2 chronic hepatitis-C infection in Taiwan.
    Journal of the Chinese Medical Association : JCMA, 2019, Volume: 82, Issue:9

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Valine

2019
[Effectiveness and safety of sofosbuvir+daclatasvir in the treatment of chronic hepatitis C virus infection in Yan'an, Shaanxi].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2019, 06-20, Volume: 27, Issue:6

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine

2019
Inosine triphosphate pyrophosphatase polymorphisms are predictors of anemia in Chinese patients with chronic hepatitis C during therapy with ribavirin and interferon.
    Journal of gastroenterology and hepatology, 2020, Volume: 35, Issue:1

    Topics: Anemia; Antiviral Agents; Asian People; Drug Combinations; Female; Forecasting; Hemoglobins; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Pyrophosphatases; Ribavirin

2020
Relation between microRNA-21, transforming growth factor β and response to treatment among chronic hepatitis C patients.
    Journal of medical virology, 2019, Volume: 91, Issue:12

    Topics: Adult; Antiviral Agents; Biomarkers; Carbamates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; MicroRNAs; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Transforming Growth Factor beta; Treatment Outcome; Valine; Viral Load

2019
The Role of Hepatitis C Virus NS5A Region Mutation and SNP IL-28B of Host to Support Successful Pegylated Interferon and Ribavirin Treatment in Patients with HCV-HIV Coinfection: A Prospective Cohort Study.
    Acta medica Indonesiana, 2019, Volume: 51, Issue:2

    Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Interferons; Male; Middle Aged; Mutation; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Ribavirin; Sustained Virologic Response; Viral Nonstructural Proteins

2019
Papular Sarcoidosis of the Knees Following Treatment with Interferon Alpha and Ribavirin in a Woman with Hepatitis C.
    Actas dermo-sifiliograficas, 2019, Volume: 110, Issue:10

    Topics: Antiviral Agents; Drug Eruptions; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Knee; Middle Aged; Ribavirin; Sarcoidosis; Skin Diseases

2019
[Pegylated intereferon hematological safety in comparison with standard].
    Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, 2012, Issue:6

    Topics: Adult; Antiviral Agents; Female; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2012
Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study.
    Virology journal, 2013, Feb-14, Volume: 10

    Topics: Antiviral Agents; Brazil; Cohort Studies; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferons; Longitudinal Studies; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Prospective Studies; Protease Inhibitors; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Viral Nonstructural Proteins

2013
Adding pancreatic panniculitis to the panel of skin lesions associated with triple therapy of chronic hepatitis C.
    Liver international : official journal of the International Association for the Study of the Liver, 2013, Volume: 33, Issue:4

    Topics: Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Middle Aged; Oligopeptides; Pancreatitis; Panniculitis; Ribavirin; Skin

2013
Irsogladine maleate for the treatment of recurrent aphthous stomatitis in hepatitis C virus patients on pegylated-interferon and ribavirin: a pilot study.
    Journal of gastroenterology and hepatology, 2013, Volume: 28, Issue:6

    Topics: Anti-Ulcer Agents; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Stomatitis, Aphthous; Triazines

2013
Safety and efficacy of peginterferon-α2a plus ribavirin treatment in renal transplant recipients with chronic hepatitis C.
    Journal of hepatology, 2013, Volume: 58, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Kidney Transplantation; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin

2013
Surfactant protein-D is more useful than Krebs von den Lungen 6 as a marker for the early diagnosis of interstitial pneumonitis during pegylated interferon treatment for chronic hepatitis C.
    Hepato-gastroenterology, 2012, Volume: 59, Issue:119

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Early Diagnosis; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lung Diseases, Interstitial; Male; Middle Aged; Mucin-1; Polyethylene Glycols; Predictive Value of Tests; Pulmonary Surfactant-Associated Protein D; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome

2012
Variability and resistance mutations in the hepatitis C virus NS3 protease in patients not treated with protease inhibitors.
    Memorias do Instituto Oswaldo Cruz, 2013, Volume: 108, Issue:1

    Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Mutation; Polymorphism, Genetic; Ribavirin; RNA, Viral; Viral Nonstructural Proteins

2013
Response to treatment in Brazilian patients with chronic hepatitis C is associated with a single-nucleotide polymorphism near the interleukin-28B gene.
    Memorias do Instituto Oswaldo Cruz, 2013, Volume: 108, Issue:1

    Topics: Adolescent; Adult; Aged; Alleles; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult

2013
Adipokines and insulin resistance, predictors of response to therapy in Egyptian patients with chronic hepatitis C virus genotype 4.
    European journal of gastroenterology & hepatology, 2013, Volume: 25, Issue:8

    Topics: Adipokines; Adiponectin; Adult; Antiviral Agents; Area Under Curve; Biomarkers; Biopsy; Body Mass Index; Chi-Square Distribution; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon-alpha; Leptin; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Phenotype; Predictive Value of Tests; Ribavirin; Risk Factors; RNA, Viral; ROC Curve; Treatment Outcome; Viral Load

2013
Role of interleukin 28B-related gene polymorphisms in chronic hepatitis C and the response to antiviral therapy in Koreans.
    Journal of clinical gastroenterology, 2013, Volume: 47, Issue:7

    Topics: Adult; Antiviral Agents; Asian People; Case-Control Studies; DNA Primers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prevalence; Recombinant Proteins; Retrospective Studies; Ribavirin; Viral Load

2013
Autoantibodies in hepatitis C: red flag or bystander effect?
    Journal of pediatric gastroenterology and nutrition, 2013, Volume: 56, Issue:3

    Topics: Antiviral Agents; Autoantibodies; Autoimmune Diseases; Female; Hepatitis C, Chronic; Humans; Male; Ribavirin

2013
Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy.
    Alimentary pharmacology & therapeutics, 2013, Volume: 37, Issue:9

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult

2013
Factors associated with guideline-based hepatitis C virus (HCV) treatment initiation in HIV/HCV-coinfected patients: role of comorbidities and physicians' perceptions.
    HIV medicine, 2013, Volume: 14, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiviral Agents; Cardiovascular Diseases; Coinfection; Comorbidity; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Patient Compliance; Practice Guidelines as Topic; Ribavirin; Young Adult

2013
Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.
    World journal of gastroenterology, 2013, Feb-21, Volume: 19, Issue:7

    Topics: Adolescent; Age Factors; Antiviral Agents; Biomarkers; Child; Child, Preschool; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2013
Relationship of interferon-γ-inducible protein-10 kDa with viral response in patients with various heterogeneities of hepatitis C virus genotype-4.
    European journal of gastroenterology & hepatology, 2013, Volume: 25, Issue:4

    Topics: Adult; Antiviral Agents; Biomarkers; Chemokine CXCL10; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2013
A comparison of modified directly observed therapy to standard care for chronic hepatitis C.
    Journal of community health, 2013, Volume: 38, Issue:4

    Topics: Adult; Antiviral Agents; Directly Observed Therapy; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load

2013
Concordance between sustained virologic response week 12 (SVR12) and SVR24 in genotype 1 hepatitis C virus patients receiving interferon-free treatment in the SOUND-C2 study.
    Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:4

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin; Viral Load

2013
[Acquired hemophilia A in a patient with chronic hepatitis C virus infection receiving treatment with peginterferon α-2a].
    Medicina clinica, 2013, Sep-07, Volume: 141, Issue:5

    Topics: Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Autoantibodies; Autoantigens; Cyclophosphamide; Factor VIII; Glucocorticoids; Hematoma; Hemophilia A; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Rituximab

2013
[Case report of the available of interhenotypic recombinant in chronic hepatitis C: the algorithm of individualization of the antiviral therapy].
    Georgian medical news, 2013, Issue:215

    Topics: 5' Untranslated Regions; Adult; Algorithms; Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Male; Mutation; Phylogeny; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Viral Nonstructural Proteins

2013
The natural history and long-term outcomes in patients with chronic hepatitis C genotype 4 after interferon-based therapy.
    Liver international : official journal of the International Association for the Study of the Liver, 2013, Volume: 33, Issue:6

    Topics: Adult; Antiviral Agents; Biomarkers; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Phenotype; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2013
Genetic variations in host IL28B links to the detection of peripheral blood mononuclear cells-associated hepatitis C virus RNA in chronically infected patients.
    Journal of viral hepatitis, 2013, Volume: 20, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Leukocytes, Mononuclear; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; RNA, Viral; Treatment Outcome

2013
An automated rapid detection system using the quenching probe method for detecting interleukin 28B and inosine triphosphatase single nucleotide polymorphisms in chronic hepatitis C.
    Journal of viral hepatitis, 2013, Volume: 20, Issue:4

    Topics: Antiviral Agents; Automation, Laboratory; Clinical Laboratory Techniques; Drug-Related Side Effects and Adverse Reactions; Genetic Testing; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Interferons; Interleukins; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin

2013
Screening for autoantibodies in chronic hepatitis C patients has no effect on treatment initiation or outcome.
    Journal of viral hepatitis, 2013, Volume: 20, Issue:4

    Topics: Adult; Antiviral Agents; Autoantibodies; Cohort Studies; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin; Treatment Outcome

2013
Low glomerular filtration rate is a risk factor for ribavirin-associated anaemia in old patients with chronic hepatitis C.
    Journal of viral hepatitis, 2013, Volume: 20, Issue:4

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anemia; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin; Risk Factors

2013
Boceprevir-based triple therapy for belgian liver transplant patients infected with hepatitis C virus: a preliminary experience.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2013, Volume: 19, Issue:6

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Ribavirin

2013
Sofosbuvir: the final nail in the coffin for hepatitis C?
    The Lancet. Infectious diseases, 2013, Volume: 13, Issue:5

    Topics: Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate

2013
Hepatitis C treatment: interferon free or interferon freer?
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate

2013
Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection.
    Journal of hepatology, 2013, Volume: 59, Issue:1

    Topics: Antibody-Dependent Cell Cytotoxicity; Antiviral Agents; Biomarkers; CD56 Antigen; GPI-Linked Proteins; Hepatitis C, Chronic; Humans; Immunity, Innate; Immunophenotyping; Interferon-alpha; Killer Cells, Natural; Natural Cytotoxicity Triggering Receptor 3; Perforin; Polyethylene Glycols; Pore Forming Cytotoxic Proteins; Prospective Studies; Receptors, IgG; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome

2013
Sustained virological response following chronic hepatitis C treatment is associated with improvement in insulin resistance.
    Internal medicine journal, 2013, Volume: 43, Issue:6

    Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon-alpha; Male; Middle Aged; Prospective Studies; Ribavirin; Treatment Outcome; Viral Load

2013
Clinical associations and potential novel antigenic targets of autoantibodies directed against rods and rings in chronic hepatitis C infection.
    BMC gastroenterology, 2013, Mar-19, Volume: 13

    Topics: Antiviral Agents; Autoantibodies; Carbon-Nitrogen Ligases; Case-Control Studies; Cohort Studies; Drug Therapy, Combination; Female; Fluorescent Antibody Technique, Indirect; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; IMP Dehydrogenase; Inclusion Bodies; Interferons; Liver Cirrhosis, Biliary; Lupus Erythematosus, Systemic; Male; Middle Aged; Retrospective Studies; Ribavirin; Staining and Labeling

2013
Comment on: 'interleukin-28 polymorphisms on the SVR in the treatment of naïve chronic hepatitis C with pegylated interferon-α plus ribavirin: a meta-analysis'.
    Gene, 2013, Jun-10, Volume: 522, Issue:1

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukins; Male; Polyethylene Glycols; Polymorphism, Single Nucleotide; Ribavirin

2013
District general hospital networks can provide safe and effective hepatitis C treatment: results of a 5-year audit.
    European journal of gastroenterology & hepatology, 2013, Volume: 25, Issue:8

    Topics: Adult; Antiviral Agents; Chi-Square Distribution; Delivery of Health Care; Drug Therapy, Combination; England; Female; Hepatitis C, Chronic; Hospitals, District; Hospitals, General; Humans; Interferon-alpha; Male; Medical Audit; Nurse Clinicians; Patient Care Team; Patient Safety; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Standard of Care; Time Factors; Treatment Outcome

2013
Anemia as a predictor of response to antiviral therapy in chronic hepatitis C.
    Bratislavske lekarske listy, 2013, Volume: 114, Issue:4

    Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2013
Cost-effectiveness analysis of antiviral treatment in liver transplant recipients with HCV infection.
    Transplant international : official journal of the European Society for Organ Transplantation, 2013, Volume: 26, Issue:5

    Topics: Antiviral Agents; Cost-Benefit Analysis; Decision Support Techniques; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Quality-Adjusted Life Years; Recurrence; Ribavirin; Treatment Outcome

2013
[Genetic polymorphisms of IL-28B are associated with sustained virologic response in patients with chronic hepatitis C].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2012, Volume: 20, Issue:12

    Topics: Adult; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; Viral Load

2012
Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2013, Volume: 11, Issue:8

    Topics: Aged; Anemia; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Prospective Studies; Ribavirin; Treatment Outcome; Veterans; Viral Load

2013
How cost-effective is hepatitis C virus treatment for people who inject drugs?
    Journal of gastroenterology and hepatology, 2013, Volume: 28, Issue:4

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Substance Abuse, Intravenous

2013
Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia in Egyptian hepatitis C virus patients.
    World journal of gastroenterology, 2013, Mar-07, Volume: 19, Issue:9

    Topics: Adult; Anemia; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Egypt; Female; Gene Frequency; Genetic Predisposition to Disease; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Multivariate Analysis; Odds Ratio; Phenotype; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Ribavirin; Risk Factors; Time Factors; Treatment Outcome

2013
Type 1 diabetes mellitus with dual autoimmune mechanism related to pegylated interferon and ribavirin treatment for chronic HCV hepatitis.
    Journal of gastrointestinal and liver diseases : JGLD, 2013, Volume: 22, Issue:1

    Topics: Antiviral Agents; Autoantibodies; Autoimmune Diseases; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Hashimoto Disease; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon-alpha; Islets of Langerhans; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Vitiligo; Young Adult

2013
Hepatitis C genotype 4 with normal transaminases: correlation with fibrosis and response to treatment, a cohort Egyptian study of 4277 patients.
    Clinics and research in hepatology and gastroenterology, 2013, Volume: 37, Issue:5

    Topics: Adult; Alanine Transaminase; alpha-Fetoproteins; Antiviral Agents; Aspartate Aminotransferases; Cohort Studies; Cross-Sectional Studies; Egypt; Female; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Multivariate Analysis; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Severity of Illness Index; Sex Factors; Viral Load

2013
[Study on effect of intensive treatment for refractory chronic hepatitis C patients].
    Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology, 2012, Volume: 26, Issue:5

    Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2012
Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin.
    Archives of virology, 2013, Volume: 158, Issue:9

    Topics: Amino Acid Sequence; Antiviral Agents; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Molecular Sequence Data; Nitro Compounds; Polyethylene Glycols; Ribavirin; Sequence Alignment; Sequence Analysis, DNA; Thiazoles; Treatment Failure; Viral Nonstructural Proteins

2013
Pegylated interferon and ribavirin: a therapeutic option in patients who fail to respond to telaprevir-based triple therapy?
    Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:4

    Topics: Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Ribavirin

2013
Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin.
    Journal of gastroenterology and hepatology, 2013, Volume: 28, Issue:9

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; Treatment Outcome

2013
Hepatitis C treatment options improving.
    Mayo Clinic health letter (English ed.), 2013, Volume: 31, Issue:1

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Hepatitis C, Chronic; Humans; Polyethylene Glycols; Ribavirin; United States

2013
IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus-/HCV-coinfected patients.
    Journal of viral hepatitis, 2013, Volume: 20, Issue:5

    Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Genetic; Receptors, Cytokine; Retrospective Studies; Ribavirin; Treatment Failure

2013
Factors associated with early virological response to peginterferon-α-2a/ribavirin in chronic hepatitis C.
    World journal of gastroenterology, 2013, Mar-28, Volume: 19, Issue:12

    Topics: Adult; Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Socioeconomic Factors; Treatment Outcome

2013
Serotonin and interleukin-6: the role of genetic polymorphisms in IFN-induced neuropsychiatric symptoms.
    Psychoneuroendocrinology, 2013, Volume: 38, Issue:9

    Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents; Antiviral Agents; Anxiety; Cohort Studies; Depression; Drug Therapy, Combination; Fatigue; Genetic Predisposition to Disease; Hepatitis C, Chronic; Humans; INDEL Mutation; Interferon-alpha; Interleukin-6; Middle Aged; Point Mutation; Polyethylene Glycols; Promoter Regions, Genetic; Prospective Studies; Recombinant Proteins; Ribavirin; Serotonin; Serotonin Plasma Membrane Transport Proteins; White People

2013
Hepatitis C treatment for multimorbid patients with substance use disorder in a primary care-based integrated treatment centre: a retrospective analysis.
    European journal of gastroenterology & hepatology, 2013, Volume: 25, Issue:11

    Topics: Adult; Antiviral Agents; Delivery of Health Care, Integrated; Drug Administration Schedule; Drug Therapy, Combination; Feasibility Studies; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Opiate Substitution Treatment; Primary Health Care; Recombinant Proteins; Retrospective Studies; Ribavirin; Socioeconomic Factors; Substance-Related Disorders; Switzerland; Treatment Failure; Treatment Outcome

2013
Neutropenia during therapy with peginterferon and ribavirin in HIV-infected subjects with chronic hepatitis C and the risk of infections.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013, Volume: 57, Issue:3

    Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Middle Aged; Neutropenia; Opportunistic Infections; Prospective Studies; Ribavirin; Risk Assessment

2013
Erythropoietin administration suppresses human monocyte function in vitro and during therapy-induced anemia in HCV patients.
    Antiviral research, 2013, Volume: 98, Issue:3

    Topics: Anemia; Erythropoietin; Escherichia coli; Hepacivirus; Hepatitis C, Chronic; Humans; Interleukin-6; Ligands; Lipopolysaccharides; Monocytes; Phagocytosis; Reactive Oxygen Species; Receptors, Erythropoietin; Ribavirin; RNA, Messenger; Toll-Like Receptor 4

2013
Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1.
    Journal of medical virology, 2013, Volume: 85, Issue:6

    Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Treatment Outcome

2013
Ex vivo induction of IFN-λ3 by a TLR7 agonist determines response to Peg-IFN/ribavirin therapy in chronic hepatitis C patients.
    Journal of gastroenterology, 2014, Volume: 49, Issue:1

    Topics: Aged; Aminoquinolines; Antiviral Agents; Cells, Cultured; Dendritic Cells; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Imiquimod; Interferon-alpha; Interferons; Interleukins; Leukocytes, Mononuclear; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Ribavirin; RNA, Messenger; Toll-Like Receptor 7; Treatment Outcome

2014
Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?
    Clinical and molecular hepatology, 2013, Volume: 19, Issue:1

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2013
A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2013, Volume: 11, Issue:8

    Topics: Aged; Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Drug Utilization; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Proline; Retrospective Studies; Ribavirin; United States

2013
HCV clearance from saliva of HIV-HCV-coinfected patients on treatment with interferon plus ribavirin.
    Oral diseases, 2014, Volume: 20, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Saliva; Viral Load

2014
HCV treatment--no more room for interferonologists?
    The New England journal of medicine, 2013, May-16, Volume: 368, Issue:20

    Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins

2013
Mutations in the NS5A gene are associated with response to interferon+ribavirin combination therapy in patients with chronic hepatitis C virus 3a infection.
    European journal of gastroenterology & hepatology, 2013, Volume: 25, Issue:10

    Topics: Adolescent; Adult; Age Factors; Aged; Antiviral Agents; DNA Mutational Analysis; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Mutation; Phylogeny; Recombinant Proteins; Retrospective Studies; Ribavirin; Sex Factors; Treatment Outcome; Viral Load; Viral Nonstructural Proteins; Young Adult

2013
Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C.
    Proceedings of the National Academy of Sciences of the United States of America, 2013, May-07, Volume: 110, Issue:19

    Topics: Adult; Aged; Antiviral Agents; Biopsy; Body Mass Index; Cohort Studies; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; MicroRNAs; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome

2013
Replication of hepatitis C virus in peripheral blood mononuclear cells in patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin.
    Postepy higieny i medycyny doswiadczalnej (Online), 2013, Mar-11, Volume: 67

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Polyethylene Glycols; Recurrence; Ribavirin; RNA, Viral; Young Adult

2013
Oral hyperpigmentation associated with interferon-alpha and ribavirin therapy for hepatitis C virus infection.
    Actas dermo-sifiliograficas, 2014, Volume: 105, Issue:2

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Hyperpigmentation; Interferon-alpha; Middle Aged; Mouth Diseases; Ribavirin

2014
Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population.
    BMC gastroenterology, 2013, Apr-29, Volume: 13

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Republic of Korea; Retrospective Studies; Ribavirin; Viral Load

2013
Combination therapy of low-dose of PegIFNa-2a and ribavirin for patients with HCV-infected decompensated cirrhosis.
    Hepato-gastroenterology, 2013, Volume: 60, Issue:126

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Embolization, Therapeutic; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Splenectomy

2013
The comparison of chronic hepatitis C treatment outcome between intravenous drug users and non-intravenous drug users.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2013, Volume: 67, Issue:6

    Topics: Adult; Antiviral Agents; Drug Combinations; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Substance Abuse, Intravenous; Treatment Outcome

2013
The impact of polymorphisms in STAT6 on treatment outcome in HCV infected Taiwanese Chinese.
    BMC immunology, 2013, May-08, Volume: 14

    Topics: Asian People; Drug Therapy, Combination; Female; Gene Frequency; Genetic Predisposition to Disease; Haplotypes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Linkage Disequilibrium; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; STAT6 Transcription Factor; Taiwan; Treatment Outcome

2013
Hepatitis C antiviral treatment outcomes are comparable between clinical trial participants and recipients of standard-of-care therapy: an analysis of trial effect.
    European journal of gastroenterology & hepatology, 2013, Volume: 25, Issue:10

    Topics: Adult; Antiviral Agents; Bias; Clinical Trials as Topic; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Patient Selection; Retrospective Studies; Ribavirin; Treatment Outcome

2013
[Respiratory function impairment during treatment of chronic hepatitis C with peginterferon alfa2 and ribavirin. Two cases presentation].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 2012, Volume: 65, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Lung Diseases, Interstitial; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sarcoidosis; Young Adult

2012
Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2013, Volume: 45, Issue:10

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Elasticity; Elasticity Imaging Techniques; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load

2013
Mechanism of action of ribavirin in anti-HCV regimens: new insights for an age-old question?
    Gut, 2014, Volume: 63, Issue:1

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Transcriptome; Viral Load

2014
[Study of using an individualized treatment strategy to treat patients with chronic hepatitis C].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2013, Volume: 21, Issue:1

    Topics: Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Prospective Studies; Ribavirin; Treatment Outcome

2013
[Clinical observation of Hashimoto thyroiditis in patients with chronic hepatitis C undergoing pegylated-interferon alpha-2a and ribavirin combination therapy].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2013, Volume: 21, Issue:2

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hashimoto Disease; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Young Adult

2013
Hepatitis B virus and hepatitis C virus co-infection: a therapeutic challenge.
    Clinics and research in hepatology and gastroenterology, 2013, Volume: 37, Issue:3

    Topics: Antiviral Agents; Guanine; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin

2013
Co-infection with hepatitis B does not alter treatment response in chronic hepatitis C.
    Clinics and research in hepatology and gastroenterology, 2013, Volume: 37, Issue:5

    Topics: Antiviral Agents; Cohort Studies; DNA, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Viral Load; Virus Replication

2013
The paradox of NKp46+ natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon α treatment.
    Gut, 2014, Volume: 63, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Biomarkers; Biopsy; Case-Control Studies; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Flow Cytometry; Hepatic Insufficiency; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon-alpha; Killer Cells, Natural; Linear Models; Liver; Lymphocyte Activation; Male; Middle Aged; Natural Cytotoxicity Triggering Receptor 1; Ribavirin; Severity of Illness Index; Treatment Failure; Viral Load

2014
Neutralizing antibodies in patients with chronic hepatitis C, genotype 1, against a panel of genotype 1 culture viruses: lack of correlation to treatment outcome.
    PloS one, 2013, Volume: 8, Issue:5

    Topics: Antibodies, Neutralizing; Culture Techniques; DNA, Recombinant; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Mutation; Ribavirin; Treatment Outcome; Viral Envelope Proteins

2013
Association between hepatic steatosis and hepatic expression of genes involved in innate immunity in patients with chronic hepatitis C.
    Cytokine, 2013, Volume: 63, Issue:2

    Topics: Adaptor Proteins, Signal Transducing; Antiviral Agents; DEAD Box Protein 58; DEAD-box RNA Helicases; Drug Resistance, Viral; Drug Therapy, Combination; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Innate; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Receptors, Immunologic; Recombinant Proteins; Ribavirin; RNA, Messenger; Ubiquitin-Protein Ligases

2013
Coinfection with hepatitis C virus and schistosomiasis: fibrosis and treatment response.
    World journal of gastroenterology, 2013, May-07, Volume: 19, Issue:17

    Topics: Adult; Antiviral Agents; Chi-Square Distribution; Coinfection; Drug Therapy, Combination; Egypt; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Praziquantel; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Schistosomiasis; Schistosomicides; Time Factors; Treatment Outcome

2013
Treatment of patients with dual hepatitis C and B by peginterferon α and ribavirin reduced risk of hepatocellular carcinoma and mortality.
    Gut, 2014, Volume: 63, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Coinfection; Databases, Factual; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Propensity Score; Recombinant Proteins; Registries; Retrospective Studies; Ribavirin; Survival Analysis; Treatment Outcome; Young Adult

2014
[Results of chronic hepatitis C treatment in a public hospital].
    Revista medica de Chile, 2012, Volume: 140, Issue:12

    Topics: Antiviral Agents; Body Mass Index; Chile; Clinical Protocols; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Hospitals, Public; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Ribavirin; Treatment Outcome; Viral Load

2012
Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: a comparison of two real-time PCR assays.
    Antiviral research, 2013, Volume: 99, Issue:2

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral

2013
Mathematical analysis of multiscale models for hepatitis C virus dynamics under therapy with direct-acting antiviral agents.
    Mathematical biosciences, 2013, Volume: 245, Issue:1

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Mathematical Concepts; Models, Biological; Ribavirin; RNA, Viral; Viral Load; Virus Replication

2013
Energy dialogue technique in healing and health: relieving side effects and thyroid dysfunction in a male with hemophilia receiving pegylated interferon and ribavirin treatment for hepatitis C virus--an anecdotal case study.
    Journal of holistic nursing : official journal of the American Holistic Nurses' Association, 2013, Volume: 31, Issue:3

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hemophilia A; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Mind-Body Relations, Metaphysical; Ribavirin; Thyroid Diseases; Thyroid Gland

2013
Sustained virological response: a milestone in the treatment of chronic hepatitis C.
    World journal of gastroenterology, 2013, May-14, Volume: 19, Issue:18

    Topics: Adult; Aged; Antiviral Agents; Biomarkers; Biopsy; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Hospitals, University; Humans; Interferon alpha-2; Interferon-alpha; Italy; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Remission Induction; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult

2013
Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1.
    Journal of gastroenterology, 2014, Volume: 49, Issue:4

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Viral Load

2014
Cognitive improvement after HCV eradication: Extending the benefits.
    Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:2

    Topics: Antiviral Agents; Cognition Disorders; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2013
Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients.
    AIDS research and human retroviruses, 2013, Volume: 29, Issue:9

    Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Hypophosphatemia; Interferons; Kidney Diseases; Male; Middle Aged; Organophosphonates; Retrospective Studies; Ribavirin; Risk Factors; Tenofovir

2013
SOCS-1 promoter methylation and treatment response in chronic hepatitis C patients receiving pegylated-interferon/ribavirin.
    Journal of clinical immunology, 2013, Volume: 33, Issue:6

    Topics: Adult; DNA Methylation; Drug Resistance, Viral; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Immunotherapy; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Promoter Regions, Genetic; Recombinant Proteins; Ribavirin; RNA, Viral; Suppressor of Cytokine Signaling 1 Protein; Suppressor of Cytokine Signaling Proteins

2013
Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2013, Volume: 11, Issue:11

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Life Expectancy; Male; Middle Aged; Oligopeptides; Proline; Quality of Life; Ribavirin; Survival Analysis; Treatment Outcome; United States; United States Department of Veterans Affairs; Veterans Health

2013
Reply to: "estimating ribavirin plasma exposure: genetics or therapeutic drug monitoring?".
    Journal of hepatology, 2013, Volume: 59, Issue:3

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Male; Membrane Transport Proteins; Pyrophosphatases; Ribavirin

2013
Estimating ribavirin plasma exposure: genetics or therapeutic drug monitoring?
    Journal of hepatology, 2013, Volume: 59, Issue:3

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Male; Membrane Transport Proteins; Pyrophosphatases; Ribavirin

2013
ABT-450 combined with ritonavir, in addition to ABT-333 and ribavirin: a race for an interferon-free regimen to cure HCV infection.
    Journal of hepatology, 2013, Volume: 59, Issue:4

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Male; Protease Inhibitors; Ribavirin

2013
Durability of SVR in chronic hepatitis C patients treated with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral.
    Alimentary pharmacology & therapeutics, 2013, Volume: 38, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Load

2013
Incidence and predictors of hematological side effects in chronic HCV Egyptian patients treated with PEGylated interferon and ribavirin.
    Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2013, Volume: 32, Issue:5

    Topics: Adolescent; Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocyte Count; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Neutrophils; Platelet Count; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Thrombocytopenia; Young Adult

2013
Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2013, Volume: 32, Issue:11

    Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Receptors, LDL; Ribavirin; Treatment Outcome

2013
[Predictive factors of response to peginterferon and ribavirin in Tunisians patients with chronic hepatitis C: report of 141 cases].
    La Tunisie medicale, 2013, Volume: 91, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sex Factors; Tunisia; Viral Load

2013
Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting.
    European journal of gastroenterology & hepatology, 2014, Volume: 26, Issue:1

    Topics: Adult; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Glucose Metabolism Disorders; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Proportional Hazards Models; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2014
Sofosbuvir-based antiviral therapy for treatment naïve hepatitis C genotypes 1, 2, and 3.
    Gastroenterology, 2013, Volume: 145, Issue:1

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Male; Ribavirin; Uridine Monophosphate; Viral Nonstructural Proteins

2013
Interaction between calcineurin inhibitors and IL-28B rs12979860 C>T polymorphism and response to treatment for post-transplant recurrent hepatitis C.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2013, Volume: 45, Issue:11

    Topics: Alleles; Antiviral Agents; Calcineurin Inhibitors; DNA; Drug Therapy, Combination; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Interferon-alpha; Interferons; Interleukins; Liver Transplantation; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2013
Impact of sustained virus elimination on natural anticoagulant activity in patients with chronic viral hepatitis C.
    Bosnian journal of basic medical sciences, 2013, Volume: 13, Issue:2

    Topics: Adult; Anticoagulants; Antithrombin III; Blood Coagulation Tests; Case-Control Studies; Female; Fibrinogen; Hemostasis; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Partial Thromboplastin Time; Polyethylene Glycols; Protein C; Protein S; Prothrombin Time; Recombinant Proteins; Ribavirin

2013
Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection.
    Journal of viral hepatitis, 2013, Volume: 20, Issue:7

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Gene Frequency; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Interferons; Interleukins; Male; Middle Aged; Platelet Count; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Treatment Outcome; Young Adult

2013
Prevalence of transfusion-acquired hepatitis C in an Australian bleeding disorders population.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2013, Volume: 19, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Australia; Blood Coagulation Disorders; Blood Transfusion; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Retrospective Studies; Ribavirin; Transfusion Reaction; Young Adult

2013
Treatment of hepatitis C in compensated cirrhotic patients is equally effective before and after liver transplantation.
    World journal of gastroenterology, 2013, Jun-07, Volume: 19, Issue:21

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome

2013
Boceprevir for HCV in patients with HIV: where next?
    The Lancet. Infectious diseases, 2013, Volume: 13, Issue:7

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin

2013
New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.
    Journal of medical virology, 2013, Volume: 85, Issue:9

    Topics: Adult; Aged; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2013
Prediction of treatment efficacy and telaprevir-resistant variants after triple therapy in patients infected with hepatitis C virus genotype 1.
    Journal of clinical microbiology, 2013, Volume: 51, Issue:9

    Topics: Adult; Aged; Antiviral Agents; Asian People; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Prognosis; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult

2013
Alanine aminotransferase elevation during peginterferon alpha-2a or alpha-2b plus ribavirin treatment.
    International journal of medical sciences, 2013, Volume: 10, Issue:8

    Topics: Adult; Aged; Alanine Transaminase; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2013
Very late relapse after discontinuation of antiviral therapy for chronic hepatitis C.
    Antiviral therapy, 2013, Volume: 18, Issue:8

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome

2013
Serum microRNA-122 kinetics in patients with chronic hepatitis C virus infection during antiviral therapy.
    Journal of viral hepatitis, 2013, Volume: 20, Issue:8

    Topics: Adult; Antiviral Agents; Biomarkers; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Liver; Male; MicroRNAs; Middle Aged; Real-Time Polymerase Chain Reaction; Ribavirin; RNA, Viral; Serum

2013
Adherence to PEG/ribavirin treatment for chronic hepatitis C: prevalence, patterns, and predictors of missed doses and nonpersistence.
    Journal of viral hepatitis, 2013, Volume: 20, Issue:8

    Topics: Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Medication Adherence; Ribavirin; Risk Factors; Time Factors

2013
Evidence that pulmonary vascular pathology explains the decline in lung function associated with interferon α based therapies for chronic hepatitis C virus.
    Journal of viral hepatitis, 2013, Volume: 20, Issue:8

    Topics: Albumins; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Lung; Lung Diseases, Interstitial; Male; Polyethylene Glycols; Ribavirin

2013
Relapse of hepatitis C virus after 14 months of sustained virological response following pegylated-interferon alpha plus ribavirin therapy in a human immunodeficiency virus type 1 infected patient.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2013, Volume: 58, Issue:1

    Topics: Antiviral Agents; Cluster Analysis; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Phylogeny; Recurrence; Ribavirin; RNA, Viral; Sequence Analysis, DNA

2013
Serum proteome predicts virological response in chronic hepatitis C genotype 1b patients treated with pegylated interferon plus ribavirin.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2015, Volume: 114, Issue:7

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Mass Spectrometry; Middle Aged; Multivariate Analysis; Proteome; Ribavirin; Sensitivity and Specificity; Taiwan; Treatment Outcome; Viral Load

2015
HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy.
    AIDS (London, England), 2013, May-15, Volume: 27, Issue:8

    Topics: Adult; Alleles; Antiviral Agents; Coinfection; Female; Follow-Up Studies; Genotyping Techniques; Hepatitis C, Chronic; Histocompatibility Antigens Class I; HIV Infections; HLA-E Antigens; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; Viral Load

2013
Dynamic interplay between CXCL levels in chronic hepatitis C patients treated by interferon.
    Virology journal, 2013, Jul-01, Volume: 10

    Topics: Adult; Antiviral Agents; Cadherins; Chemokines; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prognosis; Prospective Studies; Real-Time Polymerase Chain Reaction; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2013
The importance of a prior psychiatric examination in pegylated interferon and ribavirin combination treatment for chronic hepatitis C.
    The Kurume medical journal, 2012, Volume: 59, Issue:3-4

    Topics: Aged; Antiviral Agents; Depression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Medication Adherence; Mental Disorders; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome

2012
Hepatitis C--an update.
    Australian family physician, 2013, Volume: 42, Issue:7

    Topics: Antiviral Agents; Australia; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load

2013
The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients.
    AIDS (London, England), 2013, Nov-13, Volume: 27, Issue:17

    Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome

2013
Advanced fibrosis is not a negative pretreatment predictive factor for genotype 2 or 3 chronic hepatitis C patients.
    Clinical and molecular hepatology, 2013, Volume: 19, Issue:2

    Topics: Adult; Age Factors; Antiviral Agents; Blood Platelets; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Severity of Illness Index; Treatment Outcome

2013
High incidence of serious adverse events in HIV-infected patients treated with a telaprevir-based hepatitis C virus treatment regimen.
    AIDS (London, England), 2013, Nov-28, Volume: 27, Issue:18

    Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Incidence; Interferon-alpha; Male; Middle Aged; Oligopeptides; Retrospective Studies; Ribavirin; Severity of Illness Index; United States; Withholding Treatment

2013
Various predictors of sustained virologic response in different age groups of patients with genotype-1 chronic hepatitis C.
    Journal of clinical gastroenterology, 2013, Volume: 47, Issue:9

    Topics: Adult; Age Factors; Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome

2013
Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients.
    Journal of hepatology, 2013, Volume: 59, Issue:5

    Topics: Adult; Alleles; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Homozygote; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Premenopause; Pyrophosphatases; Recombinant Proteins; Ribavirin; Sex Factors

2013
Vitiligo after combination therapy of pegylated interferon-α-2a, ribavirin and vitamin D in a patient with chronic hepatitis C.
    The Journal of dermatology, 2013, Volume: 40, Issue:9

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Vitamin D; Vitamin D Deficiency; Vitiligo

2013
Genetic variation near interleukin 28B and the risk of hepatocellular carcinoma in patients with chronic hepatitis C.
    Journal of gastroenterology, 2014, Volume: 49, Issue:7

    Topics: Adult; Aged; Alanine Transaminase; alpha-Fetoproteins; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Disease Progression; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-beta; Interferons; Interleukins; Liver Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin

2014
A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C.
    Journal of medical virology, 2013, Volume: 85, Issue:10

    Topics: Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Japan; Male; Oligopeptides; Pilot Projects; Ribavirin; Treatment Outcome

2013
Weight loss with interferon and ribavirin therapy in chronic hepatitis C patients.
    JPMA. The Journal of the Pakistan Medical Association, 2012, Volume: 62, Issue:11

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Chi-Square Distribution; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Pakistan; Ribavirin; Treatment Outcome; Weight Loss

2012
Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA.
    HIV medicine, 2013, Volume: 14, Issue:10

    Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Cohort Studies; Coinfection; Drug Therapy, Combination; Europe; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Patient Acceptance of Health Care; Poisson Distribution; Prospective Studies; Ribavirin

2013
Assessment of health-related quality of life and how it predicts the outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C.
    Journal of gastroenterology and hepatology, 2014, Volume: 29, Issue:2

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Forecasting; Health Surveys; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Quality of Life; Recombinant Proteins; Ribavirin; Serotyping; Treatment Outcome

2014
Role of FDFT1 polymorphism for fibrosis progression in patients with chronic hepatitis C.
    Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34, Issue:3

    Topics: Adult; Alleles; Antiviral Agents; Disease Progression; Farnesyl-Diphosphate Farnesyltransferase; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Risk Factors; RNA, Viral

2014
Low rates of sustained virologic response with peginterferon plus ribavirin for chronic hepatitis C virus infection in HIV infected patients in Rio de Janeiro, Brazil.
    PloS one, 2013, Volume: 8, Issue:7

    Topics: Adult; Aged; Antiviral Agents; Brazil; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load; Young Adult

2013
Increased baseline proinflammatory cytokine production in chronic hepatitis C patients with rapid virological response to peginterferon plus ribavirin.
    PloS one, 2013, Volume: 8, Issue:7

    Topics: Adult; Aged; Antiviral Agents; Cytokines; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Inflammation Mediators; Interferon-alpha; Killer Cells, Natural; Leukocytes, Mononuclear; Lymphocyte Activation; Male; Middle Aged; Phenotype; Ribavirin; RNA, Viral; T-Lymphocyte Subsets; Toll-Like Receptor 4; Treatment Outcome; Viral Load

2013
Single-nucleotide polymorphisms of IL-10 and IL-28B as predictors of the response of IFN therapy in HCV genotype 4-infected children.
    Journal of pediatric gastroenterology and nutrition, 2013, Volume: 57, Issue:2

    Topics: Adolescent; Alleles; Antiviral Agents; Child; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukin-10; Interleukins; Male; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome

2013
Modeling the dynamics of hepatitis C virus with combined antiviral drug therapy: interferon and ribavirin.
    Mathematical biosciences, 2013, Volume: 245, Issue:2

    Topics: Antiviral Agents; Computational Biology; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Kinetics; Mathematical Concepts; Models, Biological; Ribavirin; Treatment Outcome; Viral Load

2013
Sofosbuvir-based interferon-free therapy for patients with HCV infection.
    Journal of hepatology, 2013, Volume: 59, Issue:6

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Male; Ribavirin; Uridine Monophosphate; Viral Nonstructural Proteins

2013
Chronic hepatitis C therapy: a rare complication revisited.
    BMJ case reports, 2013, Jul-26, Volume: 2013

    Topics: Administration, Cutaneous; Antiviral Agents; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Recombinant Proteins; Ribavirin

2013
Liver histology of chronic hepatitis C patients who relapsed or not responded to conventional interferon and ribavirin therapy.
    JPMA. The Journal of the Pakistan Medical Association, 2013, Volume: 63, Issue:2

    Topics: Adult; Antiviral Agents; Biopsy; Female; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Male; Middle Aged; Recurrence; Ribavirin; Treatment Failure

2013
Relating serum GGT to ALT activity enhances its predictability on treatment outcome in chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2014, Volume: 59, Issue:3

    Topics: Antiviral Agents; Female; gamma-Glutamyltransferase; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin

2014
Treatment of chronic hepatitis C with protease inhibitor-based therapy after liver transplantation.
    Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:3

    Topics: Antiviral Agents; Drug Interactions; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Postoperative Complications; Proline; Protease Inhibitors; Recombinant Proteins; Recurrence; Ribavirin; Tacrolimus; Treatment Outcome

2013
[Sofosbuvir: alternative in hepatitis C infection?].
    Deutsche medizinische Wochenschrift (1946), 2013, Volume: 138, Issue:33

    Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin; Uridine Monophosphate

2013
Reply: To PMID 23258530.
    Hepatology (Baltimore, Md.), 2014, Volume: 59, Issue:3

    Topics: Antiviral Agents; Female; gamma-Glutamyltransferase; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin

2014
[IL28B CC genotype: a protective factor and predictor of the response to interferon treatment in chronic hepatitis C virus infection].
    Orvosi hetilap, 2013, Aug-11, Volume: 154, Issue:32

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cytokines; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Lymphocytes; Male; Middle Aged; Monocytes; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Protective Agents; Ribavirin; Transcription Factors

2013
Prevalence of IL-28B and ITPA genotypes in Chinese Han population infected persistently with hepatitis C virus genotype 6 or HCV-1.
    Journal of medical virology, 2013, Volume: 85, Issue:7

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Asian People; China; Ethnicity; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Hemolysis; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Middle Aged; Pyrophosphatases; Ribavirin; Young Adult

2013
Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b.
    Journal of medical virology, 2013, Volume: 85, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Apolipoprotein B-100; Biomarkers; Cohort Studies; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Serum; Treatment Outcome; Young Adult

2013
Kinetics of relapse after pegylated interferon and ribavirin therapy for chronic hepatitis C.
    Journal of medical virology, 2013, Volume: 85, Issue:7

    Topics: Adult; Aged; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; Time Factors; Treatment Outcome; Viral Load

2013
Genetic variation in NOS2A is associated with a sustained virological response to peginterferon plus ribavirin therapy for chronic hepatitis C in Taiwanese Chinese.
    Journal of medical virology, 2013, Volume: 85, Issue:7

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Nitric Oxide Synthase Type II; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Taiwan; Treatment Outcome

2013
Treatment of patients with dual hepatitis B and C: a step in the right direction.
    Gut, 2014, Volume: 63, Issue:3

    Topics: Antiviral Agents; Coinfection; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2014
Sustained virological response after treatment in patients with chronic hepatitis C infection--a five year follow up.
    Bangladesh Medical Research Council bulletin, 2013, Volume: 39, Issue:1

    Topics: Adult; Antiviral Agents; Bangladesh; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin

2013
Ultrasound based evaluation of hepatic steatosis and fibrosis in hepatitis C non-responders.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2013, Volume: 23, Issue:8

    Topics: Adult; Aged; Biopsy; Cross-Sectional Studies; Fatty Liver; Female; Fibrosis; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Predictive Value of Tests; Ribavirin; Sensitivity and Specificity; Treatment Failure; Ultrasonography; Young Adult

2013
Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients.
    Antiviral research, 2013, Volume: 100, Issue:1

    Topics: Adult; Anemia; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Retrospective Studies; Ribavirin; Treatment Outcome

2013
Baseline MELD score predicts hepatic decompensation during antiviral therapy in patients with chronic hepatitis C and advanced cirrhosis.
    PloS one, 2013, Volume: 8, Issue:8

    Topics: Adult; Aged; Antiviral Agents; Ascites; Disease Progression; Female; Follow-Up Studies; Hemorrhage; Hepatitis C, Chronic; Hospitalization; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk; Withholding Treatment

2013
Commentary: absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C.
    Alimentary pharmacology & therapeutics, 2013, Volume: 38, Issue:5

    Topics: Antiviral Agents; Contraindications; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin

2013
Commentary: absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C--authors' reply.
    Alimentary pharmacology & therapeutics, 2013, Volume: 38, Issue:5

    Topics: Antiviral Agents; Contraindications; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin

2013
Commentary: durability of SVR in chronic hepatitis C patients treated with peginterferon-a2a/ribavirin in combination with a direct-acting anti-viral.
    Alimentary pharmacology & therapeutics, 2013, Volume: 38, Issue:5

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin

2013
Commentary: durability of SVR in chronic hepatitis C patients treated with peginterferon-a2a/ribavirin in combination with a direct-acting anti-viral--authors' reply.
    Alimentary pharmacology & therapeutics, 2013, Volume: 38, Issue:5

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin

2013
Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:2

    Topics: Animals; Antiviral Agents; Benzimidazoles; Dogs; Drug Evaluation, Preclinical; Drug Resistance, Viral; Drug Synergism; Drug Therapy, Combination; Fluorenes; Haplorhini; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Inhibitory Concentration 50; Interferon-alpha; Protease Inhibitors; Purines; Pyridazines; Quinolines; Rats; Replicon; Ribavirin; Viral Nonstructural Proteins

2014
Efficacy of pegylated interferon α-2b and ribavirin in chronic hepatitis C virus (genotypes 1 and 4) infection.
    Journal of pediatric gastroenterology and nutrition, 2013, Volume: 57, Issue:6

    Topics: Adolescent; Antiviral Agents; Child; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retreatment; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome

2013
The end-of-treatment ribavirin concentration predicts hepatitis C virus relapse.
    Therapeutic drug monitoring, 2013, Volume: 35, Issue:6

    Topics: Adult; Antiviral Agents; Area Under Curve; Chromatography, Liquid; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Sensitivity and Specificity; Tandem Mass Spectrometry; Time Factors; Treatment Outcome

2013
Sofosbuvir for previously untreated chronic hepatitis C infection.
    The New England journal of medicine, 2013, 08-15, Volume: 369, Issue:7

    Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin; Uridine Monophosphate

2013
Sofosbuvir for previously untreated chronic hepatitis C infection.
    The New England journal of medicine, 2013, 08-15, Volume: 369, Issue:7

    Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin; Uridine Monophosphate

2013
Histopathology of type C liver disease for determining hepatocellular carcinoma risk factors.
    World journal of gastroenterology, 2013, Aug-14, Volume: 19, Issue:30

    Topics: Adult; Antiviral Agents; Biopsy; Carcinoma, Hepatocellular; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Japan; Kaplan-Meier Estimate; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Ribavirin; Risk Assessment; Risk Factors; Time Factors

2013
Pretreatment predictive factors for hepatitis C therapy outcome: relevance of anti-E1E2 antibodies compared to IP-10 and IL28B genotypes.
    Antiviral therapy, 2013, Volume: 18, Issue:8

    Topics: Adult; Antibodies; Antiviral Agents; Chemokine CXCL10; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Peptides; Pilot Projects; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2013
The impact of inosine triphosphatase variants on hemoglobin level and sustained virologic response of chronic hepatitis C in Korean.
    Journal of Korean medical science, 2013, Volume: 28, Issue:8

    Topics: Adult; Alleles; Antiviral Agents; Asian People; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hemolysis; Hepacivirus; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Pyrophosphatases; Recombinant Proteins; Republic of Korea; Retrospective Studies; Ribavirin; Treatment Outcome

2013
[Dynamic changes in PD-1, TLR3, and TLR4 surface expression on peripheral blood mononuclear cells in chronic hepatitis C patients undergoing peg-IFNalpha-2a plus ribavirin combination therapy].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2013, Volume: 21, Issue:3

    Topics: Adult; Case-Control Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Programmed Cell Death 1 Receptor; Recombinant Proteins; Ribavirin; Toll-Like Receptor 3; Toll-Like Receptor 4; Treatment Outcome; Young Adult

2013
Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin.
    Journal of hepatology, 2014, Volume: 60, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2014
Relationship between inosine triphosphate genotype and outcome of extended therapy in hepatitis C virus patients with a late viral response to pegylated-interferon and ribavirin.
    Journal of gastroenterology and hepatology, 2014, Volume: 29, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Inosine Triphosphate; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Regression Analysis; Ribavirin; Time Factors; Treatment Outcome; Young Adult

2014
Serum cytochrome c and m30-neoepitope of cytokeratin-18 in chronic hepatitis C.
    Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34, Issue:4

    Topics: Adult; Aged; Analysis of Variance; Apoptosis; Cytochromes c; Enzyme-Linked Immunosorbent Assay; Epitopes; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Keratin-18; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Statistics, Nonparametric

2014
Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients.
    PharmacoEconomics, 2013, Volume: 31, Issue:10

    Topics: Age Factors; Antiviral Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Markov Chains; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Spain

2013
Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C.
    Journal of viral hepatitis, 2014, Volume: 21, Issue:5

    Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Renal Insufficiency; Ribavirin; Serum

2014
[HCV reinfection after liver transplantation - management and first experiences with telaprevir-based triple therapy].
    Deutsche medizinische Wochenschrift (1946), 2013, Volume: 138, Issue:36

    Topics: Adult; Antiviral Agents; Cyclosporine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Postoperative Complications; Recombinant Proteins; Recurrence; Ribavirin; Tacrolimus; Viral Load

2013
[Clinical features of antiviral therapy-induced thyroid disease in patients with chronic hepatitis C].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2013, Volume: 21, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Ribavirin; Thyroid Diseases

2013
[Effect of antiviral treatment on expression of programmed death 1 and programmed death ligand 1 on peripheral T lymphocytes in patients with chronic hepatitis C].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2013, Volume: 21, Issue:4

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Real-Time Polymerase Chain Reaction; Ribavirin

2013
[Sofosbuvir for hepatitis C - is brevity the soul of wit?].
    Zeitschrift fur Gastroenterologie, 2013, Volume: 51, Issue:9

    Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin; Uridine Monophosphate

2013
Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients.
    Journal of medical economics, 2014, Volume: 17, Issue:1

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Markov Chains; Oligopeptides; Polyethylene Glycols; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin

2014
Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon-α and ribavirin in chronic hepatitis C virus patients.
    Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34, Issue:4

    Topics: Age Factors; Aged; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Matched-Pair Analysis; Polyethylene Glycols; Recombinant Proteins; Regression Analysis; Ribavirin; Sex Factors; Treatment Outcome; Viral Load

2014
Relapse of hepatitis C in three immunocompetent patients achieved a sustained virological response following interferon-based antiviral therapy.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2013, Volume: 58, Issue:3

    Topics: Antiviral Agents; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Ribavirin

2013
Treatment of hepatitis C monoinfection in adults--Dutch national guidelines.
    The Netherlands journal of medicine, 2013, Volume: 71, Issue:7

    Topics: Adult; Antiviral Agents; Drug Interactions; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Netherlands; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin

2013
Successful treatment after short course of telaprevir-based therapy in chronic hepatitis C infected patient.
    The Netherlands journal of medicine, 2013, Volume: 71, Issue:7

    Topics: Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load; Withholding Treatment

2013
Sensitivity of a ribavirin resistant mutant of hepatitis C virus to other antiviral drugs.
    PloS one, 2013, Volume: 8, Issue:9

    Topics: Amino Acid Substitution; Antiviral Agents; Cell Line; Cytidine; Drug Resistance, Viral; Fluorouracil; Hepacivirus; Hepatitis C, Chronic; Humans; Kinetics; Microbial Sensitivity Tests; Mutation; Ribavirin; Viral Proteins; Virus Replication

2013
A chronic subdural hematoma in a patient receiving combination therapy with pegylated interferon alfa-2b and ribavirin for chronic hepatitis C.
    Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:18

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Hematoma, Subdural, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tomography, X-Ray Computed

2013
Impact of occult hepatitis B virus infection or hepatitis B virus DNA integration on efficacy of chronic hepatitis C treatment with peginterferon and ribavirin: where are we?
    Journal of clinical gastroenterology, 2014, Volume: 48, Issue:1

    Topics: Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2014
Viral breakthrough is associated with resistance using direct acting agents in patients treated for chronic hepatitis C infection.
    Journal of clinical gastroenterology, 2014, Volume: 48, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Time Factors

2014
Metabolome analysis of erythrocytes from patients with chronic hepatitis C reveals the etiology of ribavirin-induced hemolysis.
    International journal of medical sciences, 2013, Volume: 10, Issue:11

    Topics: Antiviral Agents; Erythrocytes; Glycolysis; Hemolysis; Hepatitis C, Chronic; Humans; Oxidative Stress; Pentose Phosphate Pathway; Ribavirin

2013
Re-treatment with highly purified nIFNα in Mexican nonresponder patients with chronic genotype 1 hepatitis C.
    Archives of medical research, 2013, Volume: 44, Issue:6

    Topics: Antiviral Agents; Asthenia; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Obesity; Pilot Projects; Prospective Studies; Recombinant Proteins; Retreatment; Ribavirin; Viral Load

2013
New triple therapy for chronic hepatitis C: real life clinical experience in a community setting.
    Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health, 2013, Volume: 72, Issue:9 Suppl 4

    Topics: Antiviral Agents; Community Health Services; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Retrospective Studies; Ribavirin; Viral Load

2013
Antiviral triple therapy with boceprevir in a chronic hepatitis C haemodialysis patient awaiting kidney re-transplantation.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Volume: 46, Issue:1

    Topics: Adult; Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Kidney Failure, Chronic; Kidney Transplantation; Male; Methylprednisolone; Polyethylene Glycols; Proline; Renal Dialysis; Ribavirin; Treatment Outcome; Viral Load

2014
Small steps toward a better treatment for chronic hepatitis C infection: mericitabine, pegylated interferon, and ribavirin in the PROPEL and JUMP-C trials.
    Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:2

    Topics: Deoxycytidine; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2013
HCV, ribavirin, and anemia: a new dawn.
    Gastroenterology, 2013, Volume: 145, Issue:5

    Topics: Anemia; Erythropoietin; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin

2013
[Conclusions].
    Enfermedades infecciosas y microbiologia clinica, 2013, Volume: 31 Suppl 3

    Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Ribavirin

2013
A 24-week treatment strategy with pegylated interferon/ribavirin in HIV/hepatitis C virus genotype 3-coinfected patients who achieved a rapid virologic response results in a high sustained virologic response rate.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Volume: 58, Issue:1

    Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2014
Treatment of chronic hepatitis C in injecting drug users--a 5-year follow-up.
    Vojnosanitetski pregled, 2013, Volume: 70, Issue:8

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Recombinant Proteins; Recurrence; Ribavirin; Serbia; Substance Abuse, Intravenous; Treatment Outcome

2013
Lambda interferon serum levels in patients with chronic hepatitis C virus infection according to their response to therapy with pegylated interferon and ribavirin.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2014, Volume: 34, Issue:2

    Topics: Adult; Biomarkers, Pharmacological; Disease Progression; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity; Immunotherapy; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; Viral Load

2014
IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients.
    AIDS (London, England), 2014, Jan-02, Volume: 28, Issue:1

    Topics: Adult; Antiviral Agents; Cohort Studies; Coinfection; Female; Genetic Predisposition to Disease; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Interleukins; Male; Polymorphism, Genetic; Ribavirin; Treatment Failure

2014
Influence of vitamin D-related gene polymorphisms (CYP27B and VDR) on the response to interferon/ribavirin therapy in chronic hepatitis C.
    PloS one, 2013, Volume: 8, Issue:9

    Topics: 25-Hydroxyvitamin D3 1-alpha-Hydroxylase; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Phenotype; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Receptors, Calcitriol; Ribavirin; ROC Curve; Viral Load; Young Adult

2013
Telaprevir-induced, but not pegylated interferon-associated, retinopathy as a noteworthy adverse effect during triple antiviral therapy in patients with chronic hepatitis C.
    Journal of gastroenterology, 2014, Volume: 49, Issue:2

    Topics: Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retinal Diseases; Ribavirin

2014
Bone marrow suppression or active proliferation? An analysis of neutropenia after pegylated interferon treatment of patients with chronic hepatitis C.
    Scandinavian journal of infectious diseases, 2013, Volume: 45, Issue:12

    Topics: Adult; Antiviral Agents; Bone Marrow Cells; Cytokines; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Statistics, Nonparametric; Young Adult

2013
Risk of nonpsychotic mental disorders development in antiviral-treated mentally healthy chronic hepatitis C patients: A population-based study.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2015, Volume: 114, Issue:9

    Topics: Adult; Antiviral Agents; Chi-Square Distribution; Databases, Factual; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Mental Disorders; Middle Aged; National Health Programs; Non-alcoholic Fatty Liver Disease; Psychiatric Status Rating Scales; Ribavirin; Risk Factors; Taiwan

2015
Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.
    Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34, Issue:6

    Topics: Adult; Antiviral Agents; Biomarkers; Chi-Square Distribution; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterozygote; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Patient Selection; Pharmacogenetics; Phenotype; Polyethylene Glycols; Polymorphism, Single Nucleotide; Precision Medicine; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult

2014
End of treatment response in chronic hepatitis C patients treated with interferon alpha and ribavirin.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2013, Volume: 23, Issue:10

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Polymerase Chain Reaction; Predictive Value of Tests; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2013
Sustained virological response after 4 weeks of telaprevir, peginterferon, and ribavirin in an Asian patient with genotype 1 chronic hepatitis C and IL28B genotype CC.
    Digestive diseases and sciences, 2014, Volume: 59, Issue:4

    Topics: Aged; Antiviral Agents; Body Mass Index; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Standard of Care; Treatment Outcome; Viral Load

2014
Transcript analysis of P2X receptors in PBMCs of chronic HCV patients: an insight into antiviral treatment response and HCV-induced pathogenesis.
    Viral immunology, 2013, Volume: 26, Issue:5

    Topics: Adult; Antiviral Agents; Cytokines; Female; Gene Expression; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocytes, Mononuclear; Male; Polyethylene Glycols; Protein Isoforms; Receptors, Purinergic P2X; Recombinant Proteins; Ribavirin

2013
Prediction of liver stiffness hepatocellular carcinoma in chronic hepatitis C patients on interferon-based anti-viral therapy.
    Journal of gastroenterology and hepatology, 2014, Volume: 29, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Elasticity Imaging Techniques; Female; Forecasting; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Neoplasms; Male; Middle Aged; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Young Adult

2014
[Clinical features of antiviral therapy in 12 patients with hepatitis C virus-related cirrhosis after splenectomy].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2013, Volume: 21, Issue:8

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Postoperative Period; Ribavirin; Splenectomy; Treatment Outcome

2013
Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Volume: 46, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Decision Making; Disease Progression; Drug Carriers; Drug Discovery; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Patient Preference; Polyethylene Glycols; Proline; Prospective Studies; Ribavirin; Severity of Illness Index; Time Factors; Watchful Waiting

2014
Rates and predictors of response to anti-viral treatment for hepatitis C virus in HIV/HCV co-infection in a nationwide study of 619 patients.
    Alimentary pharmacology & therapeutics, 2013, Volume: 38, Issue:11-12

    Topics: Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Erythropoietin; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2013
Sustained virological response to antiviral treatment in chronic hepatitis C patients may be predictable by HCV-RNA clearance in peripheral blood mononuclear cells.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2013, Volume: 58, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Virus Replication

2013
Viral evolution explains the associations among hepatitis C virus genotype, clinical outcomes, and human genetic variation.
    Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 2013, Volume: 20

    Topics: Antiviral Agents; Drug Resistance, Viral; Evolution, Molecular; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Polymorphism, Single Nucleotide; Ribavirin

2013
Vertical transmission of hepatitis C virus: a tale of multiple outcomes.
    Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 2013, Volume: 20

    Topics: Antiviral Agents; Child; Coinfection; Evolution, Molecular; Female; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV Seropositivity; HIV-1; Humans; Infectious Disease Transmission, Vertical; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Pregnancy; Pregnancy Complications, Infectious; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2013
Genetic variation in interleukin 28B and response to antiviral therapy in patients with dual chronic infection with hepatitis B and C viruses.
    PloS one, 2013, Volume: 8, Issue:10

    Topics: Adult; Antiviral Agents; Female; Genetic Variation; Genotype; Hepatitis B; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Retrospective Studies; Ribavirin

2013
Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients.
    Journal of medical economics, 2014, Volume: 17, Issue:1

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Health Resources; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Markov Chains; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Survival Analysis

2014
[Efficacy of standard antiviral therapy retreatment following interferon treatment failure in chronic hepatitis C patients].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2013, Volume: 21, Issue:9

    Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; Treatment Failure

2013
Low-dose pegylated interferon-α2a plus ribavirin therapy for elderly and/or cirrhotic patients with HCV genotype-1b and high viral load.
    Antiviral therapy, 2014, Volume: 19, Issue:1

    Topics: Aged; Aged, 80 and over; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome; Viral Load

2014
Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients.
    Journal of medical virology, 2014, Volume: 86, Issue:2

    Topics: Adult; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Gene Expression Profiling; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome

2014
Hepatitis C virus genotype 1: how genetic variability of the core protein affects the response to pegylated-interferon and ribavirin therapy.
    Journal of medical virology, 2014, Volume: 86, Issue:2

    Topics: Adult; Antiviral Agents; Computational Biology; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Point Mutation; Ribavirin; Saudi Arabia; Sequence Analysis, DNA; Treatment Outcome; Viral Core Proteins

2014
Role of hepatitis C virus substitutions and interleukin-28B polymorphism on response to peginterferon plus ribavirin in a prospective study of response-guided therapy.
    Journal of viral hepatitis, 2013, Volume: 20, Issue:11

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Genetic; Predictive Value of Tests; Prognosis; Prospective Studies; Ribavirin; Treatment Outcome; Viral Load; Viral Nonstructural Proteins

2013
Evolution of fibrosis during HCV recurrence after liver transplantation--influence of IL-28B SNP and response to peg-IFN and ribavirin treatment.
    Journal of viral hepatitis, 2013, Volume: 20, Issue:11

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Female; Genetic Predisposition to Disease; Genotype; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polymorphism, Single Nucleotide; Recurrence; Ribavirin; Severity of Illness Index; Young Adult

2013
Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis.
    Journal of viral hepatitis, 2013, Volume: 20, Issue:11

    Topics: Adult; Aged; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Prospective Studies; Ribavirin; Sex Factors; Treatment Outcome; Viral Load

2013
Rheumatoid arthritis following PEG-interferon-alfa-2a plus ribavirin treatment for chronic hepatitis C: a case report and review of the literature.
    BMC research notes, 2013, Oct-30, Volume: 6

    Topics: Antiviral Agents; Arthritis, Rheumatoid; Autoantibodies; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Peptides, Cyclic; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2013
Neurocognitive function and dysfunction after hepatitis C therapy.
    Hepatology (Baltimore, Md.), 2014, Volume: 60, Issue:1

    Topics: Antiviral Agents; Cognition Disorders; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin

2014
Characteristics of the cellular immune response in HIV/HCV patients with hemophilia during peginterferon/ribavirin therapy in southern China.
    Diagnostic microbiology and infectious disease, 2014, Volume: 78, Issue:1

    Topics: Adult; Antiviral Agents; China; Cytokines; Enzyme-Linked Immunospot Assay; Female; Hemophilia A; Hepatitis C, Chronic; HIV Infections; Humans; Immunity, Cellular; Interferons; Interleukins; Leukocytes, Mononuclear; Male; Polymorphism, Single Nucleotide; Ribavirin; Young Adult

2014
Hepatitis C infection is very rarely treated among hemodialysis patients.
    American journal of nephrology, 2013, Volume: 38, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferons; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Prevalence; Proportional Hazards Models; Renal Dialysis; Ribavirin; Time Factors; Treatment Outcome

2013
Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy.
    Antiviral therapy, 2014, Volume: 19, Issue:3

    Topics: Adult; Antiviral Agents; Disease Progression; Drug Interactions; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Viral Load

2014
Seizures in patients with chronic hepatitis C treated with NS3/4A protease inhibitors: does pharmacological interaction play a role?
    Pharmacology, 2013, Volume: 92, Issue:5-6

    Topics: Adult; Antiviral Agents; Carrier Proteins; Drug Interactions; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Seizures; Viral Nonstructural Proteins

2013
Polymorphisms of interferon-λ4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C.
    Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:1

    Topics: Adult; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome

2014
Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir.
    Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Failure; Viremia

2014
Hepatic fibrosis and serum alpha-fetoprotein (AFP) as predictors of response to HCV treatment and factors associated with serum AFP normalisation after treatment.
    Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology, 2013, Volume: 14, Issue:3

    Topics: Adult; alpha-Fetoproteins; Antiviral Agents; Body Mass Index; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; ROC Curve; Viral Load

2013
Interferon-free hepatitis C treatment: one pill to fit all?
    Lancet (London, England), 2014, Feb-08, Volume: 383, Issue:9916

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Male; Protease Inhibitors; Ribavirin; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins

2014
Does chemotherapy cause viral relapse in cancer patients with hepatitis C infection successfully treated with antivirals?
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2014, Volume: 12, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin

2014
Myxovirus resistance, osteopontin and suppressor of cytokine signaling 3 polymorphisms predict hepatitis C virus therapy response in an admixed patient population: comparison with IL28B.
    Clinics (Sao Paulo, Brazil), 2013, Volume: 68, Issue:10

    Topics: Adult; Antiviral Agents; Female; Gene Frequency; Genetic Markers; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Myxovirus Resistance Proteins; Osteopontin; Polyethylene Glycols; Polymorphism, Genetic; Predictive Value of Tests; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Treatment Outcome

2013
Cirrhosis but not neutropenia is associated with the development of infection in patients with chronic hepatitis C undergoing treatment with pegylated interferon-alpha and ribavirin.
    Journal of viral hepatitis, 2014, Volume: 21, Issue:9

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Bacterial Infections; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Retrospective Studies; Ribavirin; Young Adult

2014
Peginterferon alfa-2a plus ribavirin for hemophilic patients with chronic hepatitis C virus infection in Taiwan.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2014, Volume: 113, Issue:10

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Genotype; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Taiwan; Treatment Outcome; Viral Load

2014
Endogenous IFNγ in chronic HCV genotype 4 patients treated with PEG-IFNα and ribavirin.
    Journal of infection in developing countries, 2013, Nov-15, Volume: 7, Issue:11

    Topics: Alanine Transaminase; Antiviral Agents; Egypt; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-gamma; Leukocytes, Mononuclear; Myxovirus Resistance Proteins; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin

2013
Genetic polymorphisms of vitamin D pathway predict antiviral treatment outcome in slow responder naïve patients with chronic hepatitis C.
    PloS one, 2013, Volume: 8, Issue:11

    Topics: 25-Hydroxyvitamin D3 1-alpha-Hydroxylase; Adult; Antiviral Agents; Cholestanetriol 26-Monooxygenase; Cytochrome P450 Family 2; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome; Vitamin D

2013
Very short course of triple therapy including telaprevir for chronic hepatitis C: a possible strategy in selected patients.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2014, Volume: 19

    Topics: Administration, Oral; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome

2014
When do psychiatric side effects emerge during antiviral treatment of hepatitis C?
    Psychiatria Danubina, 2013, Volume: 25, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Mental Disorders; Middle Aged; Referral and Consultation; Retrospective Studies; Ribavirin; Time Factors

2013
Interleukin 28B-related polymorphisms: a pathway for understanding hepatitis C virus infection?
    World journal of gastroenterology, 2013, Nov-14, Volume: 19, Issue:42

    Topics: Adult; Aged; Antiviral Agents; Brazil; Case-Control Studies; Drug Therapy, Combination; Female; Gene Frequency; Genetic Predisposition to Disease; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Linkage Disequilibrium; Male; Middle Aged; Phenotype; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Young Adult

2013
Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir.
    Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:2

    Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2014
Hepatocyte expression of TRAIL pathway regulators correlates with histopathological and clinical parameters in chronic HCV infection.
    Pathology, research and practice, 2014, Volume: 210, Issue:2

    Topics: Adult; Antiviral Agents; Apoptosis; Caspase 8; Drug Therapy, Combination; Female; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Hepatitis C, Chronic; Hepatocytes; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor, Member 10c; Recombinant Proteins; Ribavirin; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor Decoy Receptors

2014
The dilemma for patients with chronic hepatitis C: treat now or warehouse?
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Volume: 46, Issue:1

    Topics: Antiviral Agents; Drug Carriers; Drug Discovery; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Time Factors; Watchful Waiting

2014
[Interferon-alpha toxicity and reversible bilateral optical neuropathy: a timely withdrawal of the drug].
    Archivos de la Sociedad Espanola de Oftalmologia, 2014, Volume: 89, Issue:4

    Topics: Adult; Evoked Potentials, Visual; Factor VII Deficiency; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Optic Neuritis; Polyethylene Glycols; Postoperative Complications; Reaction Time; Recombinant Proteins; Ribavirin; Vision Disorders

2014
Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients.
    Journal of hepatology, 2014, Volume: 60, Issue:3

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2014
Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy.
    The Journal of infection, 2014, Volume: 68, Issue:4

    Topics: Adult; Coinfection; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Prognosis; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome; Viral Load

2014
Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infection.
    PloS one, 2013, Volume: 8, Issue:11

    Topics: Acute Disease; Adult; Antiviral Agents; Biomarkers; Chemokine CXCL10; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2013
Persistence of hepatitis C virus during and after otherwise clinically successful treatment of chronic hepatitis C with standard pegylated interferon α-2b and ribavirin therapy.
    PloS one, 2013, Volume: 8, Issue:11

    Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Limit of Detection; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Virus Replication

2013
Low hepcidin triggers hepatic iron accumulation in patients with hepatitis C.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2014, Volume: 29, Issue:6

    Topics: Adult; Animals; Antimicrobial Cationic Peptides; Antiviral Agents; Epidermal Growth Factor; Female; Hepacivirus; Hepatitis C, Chronic; Hepatocyte Growth Factor; Hepcidins; Humans; Interferon-alpha; Iron; Iron Overload; Liver Cirrhosis; Male; Middle Aged; Phlebotomy; Renal Insufficiency, Chronic; Ribavirin; Virus Replication

2014
Summaries for patients. Pegylated interferon with or without ribavirin for patients with hepatitis C receiving hemodialysis.
    Annals of internal medicine, 2013, Dec-03, Volume: 159, Issue:11

    Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Failure, Chronic; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin

2013
Regression of liver fibrosis is progressive after sustained virological response to HCV therapy in patients with hepatitis C and HIV coinfection.
    Journal of viral hepatitis, 2013, Volume: 20, Issue:12

    Topics: Adult; Antiviral Agents; Cohort Studies; Coinfection; Elasticity Imaging Techniques; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Treatment Outcome; Viral Load

2013
Valuable antiviral therapeutic options for the treatment of chronic hepatitis C patients with thrombocytopenia.
    Journal of viral hepatitis, 2013, Volume: 20, Issue:12

    Topics: Aged; Antiviral Agents; Cohort Studies; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Pyrophosphatases; Recombinant Proteins; Ribavirin; Thrombocytopenia; Treatment Outcome; Viral Load

2013
Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy.
    Journal of viral hepatitis, 2013, Volume: 20, Issue:12

    Topics: Aged; Anemia; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Metabolism, Inborn Errors; Middle Aged; Pyrophosphatases; Ribavirin; Treatment Outcome

2013
Treatment of decompensated cirrhosis secondary to hepatitis C with antiviral therapy.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2013, Volume: 23, Issue:12

    Topics: Adult; Aged; Amantadine; Antiviral Agents; Drug Administration Schedule; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Pakistan; Ribavirin; RNA, Viral; Treatment Outcome

2013
The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection.
    Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:3

    Topics: Adult; Antiviral Agents; Chemokine CXCL10; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; White People

2014
Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2014, Volume: 12, Issue:8

    Topics: Antiviral Agents; Efficiency; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Quality of Life; Randomized Controlled Trials as Topic; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Treatment Outcome; Uridine Monophosphate

2014
Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2014, Volume: 12, Issue:7

    Topics: Adult; Aged; alpha-Fetoproteins; Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Japan; Liver Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Ribavirin; Risk Factors

2014
Spontaneous weight change during chronic hepatitis C treatment: association with virologic response rates.
    International journal of medical sciences, 2013, Volume: 10, Issue:13

    Topics: Adult; Aged; Antiviral Agents; Body Mass Index; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Viral Load; Weight Loss; Young Adult

2013
Treatment efficacy of pegylated interferon plus ribavirin therapy in chronic hepatitis C patients with mixed genotype 1/2 infection.
    Journal of gastroenterology and hepatology, 2014, Volume: 29, Issue:5

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2014
Hepatitis C treatment and alopecia totalis.
    The journal of investigative dermatology. Symposium proceedings, 2013, Volume: 16, Issue:1

    Topics: Alopecia; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Withholding Treatment

2013
[Differential response to pegylated interferon plus ribavirin combination therapy in chronic hepatitis C and HIV/HCV co-infected patients].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2013, Volume: 21, Issue:11

    Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Interferons; Interleukins; Male; Polyethylene Glycols; Ribavirin; Treatment Outcome

2013
Beyond phase 3 registration trials: defining safety for triple therapy with protease inhibitors in cirrhosis.
    Gut, 2014, Volume: 63, Issue:7

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2014
Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent.
    Genes and immunity, 2014, Volume: 15, Issue:2

    Topics: Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Regulatory Factors; Interferon-alpha; Interferons; Interleukins; Liver; Liver Cirrhosis; Metallothionein; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome; Up-Regulation; Viral Load

2014
Significance of liver stiffness measurement by acoustic radiation force impulse (ARFI) among hepatitis C patients.
    Journal of medical virology, 2014, Volume: 86, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Drug Monitoring; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Liver; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Treatment Outcome

2014
Treatment of chronic hepatitis C in a Canadian Aboriginal population: results from the PRAIRIE study.
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2013, Volume: 27, Issue:12

    Topics: Adult; Alanine Transaminase; Antibodies, Viral; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Inuit; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load; White People

2013
Genetic polymorphism in IFNL4 and response to pegylated interferon-α and ribavirin in Japanese chronic hepatitis C patients.
    Tissue antigens, 2014, Volume: 83, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukins; Japan; Male; Middle Aged; Polymorphism, Genetic; Ribavirin; Treatment Outcome; Young Adult

2014
Atazanavir-based therapy with pegylated interferon and ribavirin for patients with hepatitis C and HIV.
    The Lancet. Infectious diseases, 2014, Volume: 14, Issue:1

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Polyethylene Glycols; Proline; Ribavirin

2014
Self-efficacy and adherence to antiviral treatment for chronic hepatitis C.
    Journal of clinical gastroenterology, 2015, Volume: 49, Issue:1

    Topics: Antiviral Agents; Communication; Depression; Educational Status; Female; Hepatitis C, Chronic; Humans; Insurance, Health; Interferons; Interpersonal Relations; Male; Medication Adherence; Physician-Patient Relations; Polyethylene Glycols; Proportional Hazards Models; Prospective Studies; Ribavirin; Self Efficacy

2015
Once-daily simeprevir in combination with pegylated-interferon and ribavirin: a new horizon in the era of direct-acting antiviral agent therapy for chronic hepatitis C.
    Journal of gastroenterology, 2014, Volume: 49, Issue:1

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir; Sulfonamides

2014
Telaprevir use in a chronic hepatitis C patient with hemophilia.
    European journal of gastroenterology & hepatology, 2014, Volume: 26, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Hemophilia A; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Ribavirin; Treatment Outcome

2014
Sofosbuvir approved for chronic hepatitis C infection.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2014, Jan-15, Volume: 71, Issue:2

    Topics: Drug Approval; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Sofosbuvir; United States; United States Food and Drug Administration; Uridine Monophosphate

2014
Alanine aminotransferase normalization at week 8 predicts viral response during hepatitis C treatment.
    World journal of gastroenterology, 2013, Dec-14, Volume: 19, Issue:46

    Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Biomarkers; Clinical Enzyme Tests; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2013
Pattern and associated factors of anti-hepatitis C virus treatment-induced adverse reactions.
    Expert opinion on drug safety, 2014, Volume: 13, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Young Adult

2014
Letter: the rs12979860 and ss469415590 polymorphisms of IFNL4 gene are in strong linkage disequilibrium in Caucasian patients with chronic hepatitis C.
    Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:3

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Ribavirin

2014
Letter: the rs12979860 and ss469415590 polymorphisms of IFNL4 gene are in strong linkage disequilibrium in Caucasian patients with chronic hepatitis C--authors' reply.
    Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:3

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Ribavirin

2014
IL28B and IL10R -1087 polymorphisms are protective for chronic genotype 1 HCV infection and predictors of response to interferon-based therapy in an East-Central European cohort.
    BMC research notes, 2014, Jan-08, Volume: 7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hungary; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Patient Selection; Polyethylene Glycols; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Receptors, Interleukin-10; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult

2014
Time for change: conventional interferon regimes should not be the standard of care for management of Pakistani genotype-3 in chronic hepatitis C.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2014, Volume: 24, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Asian People; Body Mass Index; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Pakistan; Ribavirin; Treatment Outcome

2014
DHEA and progesterone have a protective effect on ribavirin-induced hemolysis.
    Journal of hepatology, 2014, Volume: 60, Issue:4

    Topics: Anemia; Female; Hepatitis C, Chronic; Humans; Male; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Sex Factors

2014
Reply to: "DHEA and progesterone have a protective effect on ribavirin-induced hemolysis".
    Journal of hepatology, 2014, Volume: 60, Issue:4

    Topics: Anemia; Female; Hepatitis C, Chronic; Humans; Male; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Sex Factors

2014
Interleukin-28b CC genotype predicts early treatment response and CT/TT genotypes predicts non-response in patients infected with HCV genotype 3.
    Journal of medical virology, 2014, Volume: 86, Issue:4

    Topics: Adult; Antiviral Agents; Base Sequence; Biomarkers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome; Viral Load

2014
Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection.
    Journal of hepatology, 2014, Volume: 60, Issue:5

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors; Time Factors; Viral Load; Viremia

2014
Failed triple therapy in a treatment-experienced patient with genotype 6 hepatitis C infection.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2014, Feb-01, Volume: 71, Issue:3

    Topics: Aged; Antiviral Agents; Diagnostic Errors; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Treatment Failure; United States; Vietnam; Viral Load

2014
Cutaneous reactions in patients with chronic hepatitis C treated with peginterferon and ribavirin.
    Dermatology (Basel, Switzerland), 2014, Volume: 228, Issue:1

    Topics: Adult; Age Factors; Alopecia Areata; Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Eczema; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Pruritus; Recombinant Proteins; Ribavirin; Time Factors

2014
Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes.
    Journal of viral hepatitis, 2014, Volume: 21, Issue:3

    Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome; Viral Load; Young Adult

2014
Cleavage of the T cell protein tyrosine phosphatase by the hepatitis C virus nonstructural 3/4A protease induces a Th1 to Th2 shift reversible by ribavirin therapy.
    Journal of immunology (Baltimore, Md. : 1950), 2014, Feb-15, Volume: 192, Issue:4

    Topics: Adaptor Proteins, Signal Transducing; Animals; Antiviral Agents; Cell Differentiation; Chemokine CCL17; Chemokine CCL22; Chemokine CCL3; Chemokine CXCL11; Chemokine CXCL9; Hepacivirus; Hepatitis C, Chronic; Interferon-gamma; Interleukin-10; Liver; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Transgenic; Protein Tyrosine Phosphatase, Non-Receptor Type 2; Ribavirin; Th1 Cells; Th2 Cells; Tumor Necrosis Factor-alpha; Viral Nonstructural Proteins

2014
Letter: Pitavastatin supplementation of PEG-IFN/ribavirin improves sustained virological response against HCV.
    Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:4

    Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin

2014
Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b.
    Antiviral therapy, 2014, Volume: 19, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Phenotype; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Treatment Outcome; Valine; Viral Load; Young Adult

2014
The effect of antiviral therapy on hepatitis C virus-related thrombocytopenia: a case report.
    BMC research notes, 2014, Jan-24, Volume: 7

    Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Platelet Count; Polyethylene Glycols; Prednisone; Purpura, Thrombocytopenic, Idiopathic; Recombinant Proteins; Remission Induction; Ribavirin

2014
Characterisation of the cytokine milieu associated with the up-regulation of IL-6 and suppressor of cytokine 3 in chronic hepatitis C treatment non-responders.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:2

    Topics: Blotting, Western; Body Mass Index; Cohort Studies; Cytokines; DNA Primers; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Enzyme-Linked Immunospot Assay; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-gamma; Interleukin-2; Interleukin-6; Leukocytes, Mononuclear; Polyethylene Glycols; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Statistics, Nonparametric; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins

2015
[Treatment of infection due to hepatitis C virus in haemodialysis].
    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2014, Volume: 34, Issue:1

    Topics: Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Failure, Chronic; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin

2014
[The relevant factors and strategies related efficacy with standard of care in chronic hepatitis C treatment naive patients].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2013, Volume: 21, Issue:6

    Topics: Antiviral Agents; DNA, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Standard of Care

2013
Efficacy and tolerability after 24 weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfected subjects.
    Antiviral research, 2014, Volume: 104

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Ribavirin; Time Factors; Treatment Outcome; Viral Load; Young Adult

2014
Treatment of chronic viral hepatitis C in children and adolescents: UK experience.
    Archives of disease in childhood, 2014, Volume: 99, Issue:6

    Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Polymorphism, Single Nucleotide; Quality of Life; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; United Kingdom

2014
Commentary: real-world triple therapy experience treating hepatitis C virus.
    Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:5

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Oligopeptides; Polyethylene Glycols; Ribavirin

2014
Commentary: real-world triple therapy experience treating hepatitis C virus - authors' reply.
    Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:5

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Oligopeptides; Polyethylene Glycols; Ribavirin

2014
Letter: does the IFNL4 gene discovery really provide a causal role for the IL28B haplotype blocks?
    Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:5

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Ribavirin

2014
Letter: does the IFNL4 gene discovery really provide a causal role for the IL28B haplotype blocks? Authors' reply.
    Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:5

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Ribavirin

2014
Nonsynonymous variant Pro70Ser (rs117648444) in IFNL4 gene identifies carriers of the rs368234815 ΔG allele with higher HCV RNA decline during the first 4 weeks of pegylated interferon and ribavirin therapy in HCV-1 patients.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2014, Volume: 59, Issue:4

    Topics: Alleles; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Polymorphism, Single Nucleotide; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2014
Acute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co-infected patients.
    Journal of viral hepatitis, 2015, Volume: 22, Issue:1

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; Female; Hepacivirus; Hepatitis C, Chronic; Histocytochemistry; HIV Infections; Humans; Interferon-alpha; Liver; Male; Middle Aged; Prospective Studies; Ribavirin; Viral Load; Young Adult

2015
Patient-important benefits of clearing the hepatitis C virus through treatment: a simulation model.
    Journal of hepatology, 2014, Volume: 60, Issue:6

    Topics: Adult; Antiviral Agents; Decision Support Techniques; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Markov Chains; Middle Aged; Models, Statistical; Prognosis; Ribavirin; Risk Assessment; Severity of Illness Index

2014
Increased serum oxysterol concentrations in patients with chronic hepatitis C virus infection.
    Biochemical and biophysical research communications, 2014, Apr-11, Volume: 446, Issue:3

    Topics: Antiviral Agents; Case-Control Studies; Female; Hepatitis C, Chronic; Humans; Hydroxycholesterols; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oxidative Stress; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry

2014
Romiplostim for severe thrombocytopenia in the treatment of chronic hepatitis C virus infection: a new option for clinicians?
    The new microbiologica, 2014, Volume: 37, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Platelet Count; Receptors, Fc; Recombinant Fusion Proteins; Ribavirin; Thrombocytopenia; Thrombopoietin; Treatment Outcome

2014
Hepatitis C genotype 3: a tough match for interferon-free regimens.
    Gastroenterology, 2014, Volume: 146, Issue:4

    Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Ribavirin; Uridine Monophosphate

2014
Real-world outcomes in patients with chronic hepatitis C: primary results of the PROBE study.
    European journal of gastroenterology & hepatology, 2014, Volume: 26, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Remission Induction; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult

2014
Real-time PCR assays for hepatitis C virus RNA (genotype 1) is useful for evaluating virological response to the treatment with peginterferon-alpha2b and ribavirin.
    Osaka city medical journal, 2013, Volume: 59, Issue:2

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral

2013
Amino acid sequence analysis in patients with chronic HCV genotype 1b infection during pegylated interferon-α2a and ribavirin therapy.
    Antiviral therapy, 2014, Volume: 19, Issue:7

    Topics: Amino Acid Substitution; Antiviral Agents; Drug Therapy, Combination; Female; Genes, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Mutation; Open Reading Frames; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Treatment Outcome

2014
3.0T 31P MR spectroscopy in assessment of response to antiviral therapy for chronic hepatitis C.
    World journal of gastroenterology, 2014, Feb-28, Volume: 20, Issue:8

    Topics: Aged; Antiviral Agents; Esters; Female; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Magnetic Resonance Spectroscopy; Male; Middle Aged; Phosphorus; Ribavirin; Time Factors; Treatment Outcome

2014
Telaprevir or boceprevir based therapy for chronic hepatitis C infection: development of resistance-associated variants in treatment failure.
    Antiviral research, 2014, Volume: 105

    Topics: Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Mutation, Missense; Oligopeptides; Proline; Ribavirin; RNA, Viral; Treatment Failure; Viral Load; Viral Nonstructural Proteins

2014
Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir.
    Journal of viral hepatitis, 2014, Volume: 21, Issue:4

    Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Polymorphism, Genetic; Pyrophosphatases; Ribavirin; Treatment Outcome

2014
Efficiency of second pegylated interferon and ribavirin combination treatment for the relapsed hepatitis C virus infection in low-income countries.
    European journal of gastroenterology & hepatology, 2014, Volume: 26, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Poverty; Recurrence; Retreatment; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Turkey; Viral Load

2014
Impact of donor and recipient single nucleotide polymorphisms of IL28B rs8099917 in living donor liver transplantation for hepatitis C.
    PloS one, 2014, Volume: 9, Issue:3

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Genetic Association Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Transplantation; Living Donors; Middle Aged; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; Sequence Analysis, DNA; Treatment Outcome; Young Adult

2014
Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP-C and PROPEL studies.
    British journal of clinical pharmacology, 2014, Volume: 78, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Young Adult

2014
Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C.
    PloS one, 2014, Volume: 9, Issue:3

    Topics: Anemia; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Drug Therapy, Combination; Fatigue; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Models, Economic; Multicenter Studies as Topic; Oligopeptides; Outcome Assessment, Health Care; Polyethylene Glycols; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin

2014
Asymmetric dimethylarginine responses during interferon-α-induced depression in patients with chronic hepatitis C infection.
    Psychosomatic medicine, 2014, Volume: 76, Issue:3

    Topics: Adult; Analysis of Variance; Antiviral Agents; Arginine; Cardiovascular Diseases; Chromatography, Liquid; Depression; Depressive Disorder; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Nitric Oxide Synthase; Prospective Studies; Psychiatric Status Rating Scales; Regression Analysis; Ribavirin; Risk Factors; Time Factors

2014
Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score.
    Journal of viral hepatitis, 2014, Volume: 21, Issue:9

    Topics: Adult; Aged; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; End Stage Liver Disease; Female; Genotype; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Kidney; Kidney Function Tests; Male; Middle Aged; Oligopeptides; Proline; Prospective Studies; Ribavirin; Severity of Illness Index; Treatment Outcome; Viral Load

2014
Are statins a viable option for the treatment of infections with the hepatitis C virus?
    Antiviral research, 2014, Volume: 105

    Topics: Anticholesteremic Agents; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Treatment Outcome; Virus Replication

2014
Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication.
    Journal of hepatology, 2014, Volume: 61, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Cohort Studies; Female; gamma-Glutamyltransferase; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Ribavirin; Risk Factors; Taiwan

2014
Severe thrombocytopenia in a patient with inosine triphosphatase (ITPA)-CC genotype caused by pegylated interferon (IFN)-α-2a with ribavirin therapy: a case report.
    BMC research notes, 2014, Mar-12, Volume: 7

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Glucocorticoids; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Interferon-alpha; Middle Aged; Platelet Count; Polyethylene Glycols; Prednisolone; Pyrophosphatases; Recombinant Proteins; Ribavirin; Thrombocytopenia; Treatment Outcome

2014
Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Volume: 46, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Graft Survival; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Transplantation; Maintenance Chemotherapy; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Survival Rate; Time Factors

2014
[Dynamic changes in programmed death-1 expression on the surface of T cells in chronic hepatitis C patients undergoing interferon therapy].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2013, Volume: 21, Issue:12

    Topics: Adolescent; Adult; Antiviral Agents; Case-Control Studies; CD4-CD8 Ratio; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Programmed Cell Death 1 Receptor; Recombinant Proteins; Ribavirin; T-Lymphocyte Subsets; Young Adult

2013
Peginterferon and ribavirin for treatment of recurrent hepatitis C disease in HCV-HIV coinfected liver transplant recipients.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2014, Volume: 14, Issue:5

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Liver Diseases; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Prognosis; Prospective Studies; Recombinant Proteins; Ribavirin; Survival Rate; Transplant Recipients; Treatment Outcome; Young Adult

2014
Peripheral blood mononuclear cells microRNA predicts treatment outcome of hepatitis C virus genotype 1 infection.
    Antiviral research, 2014, Volume: 105

    Topics: Adult; Antiviral Agents; Biomarkers; Female; Gene Expression Profiling; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocytes, Mononuclear; Male; MicroRNAs; Middle Aged; Prospective Studies; Real-Time Polymerase Chain Reaction; Ribavirin; Treatment Outcome

2014
[MUW researcher of the month].
    Wiener klinische Wochenschrift, 2014, Volume: 126, Issue:5-6

    Topics: Austria; Awards and Prizes; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; History, 21st Century; HIV Seropositivity; Humans; Interferons; Interleukins; Liver Cirrhosis; Precision Medicine; Ribavirin; Translational Research, Biomedical

2014
Association of interleukin-10 polymorphisms with chronic hepatitis C virus infection in a case-control study and its effect on the response to combined pegylated interferon/ribavirin therapy.
    Epidemiology and infection, 2015, Volume: 143, Issue:1

    Topics: Adult; Aged; Case-Control Studies; Female; Genetic Association Studies; Genetic Predisposition to Disease; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukin-10; Male; Middle Aged; Polymorphism, Genetic; Ribavirin; Treatment Outcome

2015
Metabolic syndrome is associated with poor treatment response to antiviral therapy in chronic hepatitis C genotype 3 patients.
    European journal of gastroenterology & hepatology, 2014, Volume: 26, Issue:5

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Metabolic Syndrome; Pakistan; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Risk Factors; Time Factors; Treatment Outcome

2014
IFNL4/IL-28B haplotype structure and its impact on susceptibility to hepatitis C virus and treatment response in the Japanese population.
    The Journal of general virology, 2014, Volume: 95, Issue:Pt 6

    Topics: Antiviral Agents; Asian People; Case-Control Studies; Drug Therapy, Combination; Gene Frequency; Genetic Predisposition to Disease; Haplotypes; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Japan; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome

2014
Mutational diversity of NS5A and NS3 during triple therapy (telaprevir, pegylated-interferon-α 2b and ribavirin) for genotype 1b chronic hepatitis C: The Kobe Hepatitis Therapeutic Group.
    International journal of molecular medicine, 2014, Volume: 33, Issue:6

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mutation; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins

2014
Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients.
    BMC infectious diseases, 2014, Mar-20, Volume: 14

    Topics: Adult; Aged; Antiviral Agents; Biological Availability; Coinfection; Female; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Ribavirin; Young Adult

2014
Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
    Journal of hepatology, 2014, Volume: 61, Issue:1

    Topics: Antiviral Agents; Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy, Combination; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Middle Aged; Models, Economic; Oligopeptides; Proline; Quality-Adjusted Life Years; Ribavirin; Treatment Outcome

2014
Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis.
    Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:10

    Topics: Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Retrospective Studies; Ribavirin; Severity of Illness Index

2014
Comparative effectiveness of telaprevir-based triple therapy in patients with chronic hepatitis C.
    Mayo Clinic proceedings, 2014, Volume: 89, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Prospective Studies; Ribavirin; Treatment Outcome

2014
[Treatment of hepatitis C infection. A revolution should not hide another].
    Presse medicale (Paris, France : 1983), 2014, Volume: 43, Issue:4 Pt 1

    Topics: Antiviral Agents; Drug Therapy, Combination; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Proline; Protease Inhibitors; Ribavirin; Risk Reduction Behavior

2014
Triple or dual therapy for HCV-1 naive patients? Optimizing selection tools.
    Journal of hepatology, 2014, Volume: 61, Issue:1

    Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin

2014
Reduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis C.
    Journal of virology, 2014, Volume: 88, Issue:11

    Topics: Alanine Transaminase; Aspartate Aminotransferases; Drug Therapy, Combination; Gene Expression Regulation; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Linear Models; Liver Cirrhosis; MicroRNAs; Polyethylene Glycols; Polymorphism, Single Nucleotide; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; Statistics, Nonparametric; Viral Load

2014
Feasibility of pegylated interferon and ribavirin in hepatitis C-related cirrhosis with neutropenia or thrombocytopenia.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Volume: 46, Issue:7

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Epistaxis; Esophageal and Gastric Varices; Feasibility Studies; Female; Gastrointestinal Hemorrhage; Gingival Hemorrhage; Hepatitis C, Chronic; Humans; Infections; Interferon-alpha; Leukocyte Count; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Neutrophils; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Thrombocytopenia

2014
Reply to "triple or dual therapy for HCV-1 naive patients? Optimizing selection tools".
    Journal of hepatology, 2014, Volume: 61, Issue:1

    Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin

2014
Bone mineral density and bone turnover in non-cirrhotic patients with chronic hepatitis C and sustained virological response to antiviral therapy with peginterferon-alfa and ribavirin.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2014, Volume: 25, Issue:6

    Topics: Absorptiometry, Photon; Adult; Antiviral Agents; Biomarkers; Bone Density; Bone Diseases, Metabolic; Bone Remodeling; Case-Control Studies; Drug Therapy, Combination; Female; Femur Neck; Hepatitis C, Chronic; Humans; Interferon-alpha; Lumbar Vertebrae; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Receptors, Tumor Necrosis Factor, Type I; Recombinant Proteins; Ribavirin; Tumor Necrosis Factor Decoy Receptors; Young Adult

2014
Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.
    Hepatology (Baltimore, Md.), 2014, Volume: 60, Issue:1

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferons; Liver Cirrhosis; Markov Chains; Middle Aged; Quality-Adjusted Life Years; Retreatment; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate

2014
Incident severe thrombocytopenia in veterans treated with pegylated interferon plus ribavirin for chronic hepatitis C infection.
    Pharmacoepidemiology and drug safety, 2014, Volume: 23, Issue:5

    Topics: Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Platelet Count; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Severity of Illness Index; Thrombocytopenia; United States; Veterans

2014
SNP rs8099917 in gene IL28B might be associated with risk of chronic infection by HCV but not with response to treatment.
    BioMed research international, 2014, Volume: 2014

    Topics: Case-Control Studies; Female; Follow-Up Studies; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; Risk Factors; Treatment Outcome

2014
The interaction of a single-nucleotide polymorphism with age on response to interferon-α and ribavirin therapy in female patients with hepatitis C infection.
    Journal of medical virology, 2014, Volume: 86, Issue:7

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome

2014
Interleukin-28B polymorphisms and response of chronic hepatitis C patients from Indonesia to pegylated interferon/ribavirin treatment.
    Journal of clinical microbiology, 2014, Volume: 52, Issue:6

    Topics: Adult; Aged; Female; Gene Frequency; Genotype; Hepatitis C, Chronic; Humans; Indonesia; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome

2014
Letter to the editor.
    Journal of medical economics, 2014, Volume: 17, Issue:7

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Ribavirin

2014
De novo autoimmune hepatitis after interferon treatment in a liver transplant recipient with common variable immunodeficiency.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Volume: 46, Issue:7

    Topics: Antiviral Agents; Common Variable Immunodeficiency; Female; Hepatitis C, Chronic; Hepatitis, Autoimmune; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Ribavirin; Young Adult

2014
Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
    Gastroenterology, 2014, Volume: 147, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Comorbidity; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome

2014
The price of good health.
    Nature medicine, 2014, Volume: 20, Issue:4

    Topics: Antiviral Agents; Drug Costs; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferons; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate

2014
Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin.
    Journal of viral hepatitis, 2014, Volume: 21, Issue:5

    Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors

2014
[Lipid kinetics during dual antiviral therapy in patients with chronic hepatitis C].
    Medicina clinica, 2015, Jun-22, Volume: 144, Issue:12

    Topics: Adult; Antiviral Agents; Chemokine CXCL10; Cholesterol; Drug Therapy, Combination; False Positive Reactions; Fatty Liver; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Hypertriglyceridemia; Interferon-alpha; Interferons; Interleukins; Lipids; Lipoproteins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Ribavirin; ROC Curve; Sensitivity and Specificity; Severity of Illness Index; Treatment Outcome; Viral Load; Viremia

2015
Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms.
    Antiviral research, 2014, Volume: 106

    Topics: Adult; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Polymorphism, Genetic; Retrospective Studies; Ribavirin; Treatment Outcome

2014
The efficacy of a Hansenula-derived 20 kDa pegylated interferon alpha-2a in the treatment of genotype 4 chronic hepatitis C.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2014, Volume: 34, Issue:9

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Pichia; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult

2014
HCV therapy with daclatasvir, PEG-IFN, and RBV after boceprevir-based therapy failure post-liver transplantation in hyper-IgM syndrome.
    Transplantation, 2014, Apr-27, Volume: 97, Issue:8

    Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Hyper-IgM Immunodeficiency Syndrome; Imidazoles; Immunoglobulin M; Interferon-alpha; Liver Transplantation; Male; Polyethylene Glycols; Proline; Pyrrolidines; Recombinant Proteins; Ribavirin; Valine

2014
Triple therapy for hepatitis C virus infection in patients receiving hemodialysis.
    Annals of internal medicine, 2014, Apr-15, Volume: 160, Issue:8

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Renal Dialysis; Ribavirin

2014
Triple therapy for hepatitis C virus infection in patients receiving hemodialysis.
    Annals of internal medicine, 2014, Apr-15, Volume: 160, Issue:8

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Renal Dialysis; Ribavirin

2014
Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients.
    Journal of viral hepatitis, 2014, Volume: 21, Issue:6

    Topics: Adolescent; Adult; Aged; Anemia; Antiviral Agents; Cell Differentiation; Cell Proliferation; Erythroid Cells; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Young Adult

2014
ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type.
    Journal of viral hepatitis, 2014, Volume: 21, Issue:7

    Topics: Adult; Aged; Anemia; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2014
Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy.
    Journal of viral hepatitis, 2014, Volume: 21, Issue:7

    Topics: Antiviral Agents; Cohort Studies; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Retrospective Studies; Ribavirin; Treatment Outcome

2014
Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy.
    Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:12

    Topics: Aminoisobutyric Acids; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Interferons; Leucine; Oligopeptides; Proline; Quinolines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Uridine Monophosphate

2014
The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients.
    Clinical and molecular hepatology, 2014, Volume: 20, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Cholesterol; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Lipid Metabolism; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Triglycerides

2014
HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes.
    BMC infectious diseases, 2014, Apr-23, Volume: 14

    Topics: Adult; Aged; Aged, 80 and over; Coinfection; Female; Genotype; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Ribavirin; RNA, Viral

2014
Characteristics, treatment, and virologic responses of chronic hepatitis C patients treated with peginterferon alfa-2a and ribavirin in belgium: a sub-analysis of the PROPHESYS study.
    Acta gastro-enterologica Belgica, 2014, Volume: 77, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Belgium; Cohort Studies; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2014
Hepatitis C treatment outcome in relation to alcohol consumption and racial differences in southeastern Taiwan.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2015, Volume: 114, Issue:11

    Topics: Adult; Aged; Alcohol Drinking; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Taiwan; Treatment Outcome; Viral Load

2015
Viral hepatitis: new hepatitis C therapies-a medical pick and mix.
    Nature reviews. Gastroenterology & hepatology, 2014, Volume: 11, Issue:6

    Topics: Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Macrocyclic Compounds; Male; Ribavirin; Ritonavir; Sulfonamides; Uracil; Uridine Monophosphate

2014
Hepatitis C virus genotypes circulating in patients with chronic hepatitis C in Thailand and their responses to combined PEG-IFN and RBV therapy.
    Journal of medical virology, 2014, Volume: 86, Issue:8

    Topics: Adult; Aged; Antiviral Agents; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Molecular Epidemiology; Prevalence; Recurrence; Ribavirin; Thailand; Treatment Outcome

2014
Case report of successful treatment of fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin after liver transplantation.
    Seminars in liver disease, 2014, Volume: 34, Issue:1

    Topics: Antiviral Agents; Biopsy; Cholestasis, Intrahepatic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2014
IFNL3 (IL28B) and IFNL4 polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6.
    Journal of medical virology, 2014, Volume: 86, Issue:9

    Topics: Adult; Antiviral Agents; Female; Genetic Association Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Thailand; Treatment Outcome

2014
Tumour necrosis factor -308 and -238 promoter polymorphisms are predictors of a null virological response in the treatment of Brazilian hepatitis C patients.
    Memorias do Instituto Oswaldo Cruz, 2014, Volume: 109, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukin-10; Male; Middle Aged; Myxovirus Resistance Proteins; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Ribavirin; Treatment Failure; Tumor Necrosis Factor-alpha; Viral Load

2014
Efficacy of re-treatment by peginterferon alpha-2a and ribavirin in a child with hepatitis C.
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2014, Volume: 20, Issue:7

    Topics: Antiviral Agents; Child; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Hepatitis C, Chronic; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2014
Therapy of hepatitis C--back to the future.
    The New England journal of medicine, 2014, May-22, Volume: 370, Issue:21

    Topics: Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Proline; Ribavirin; Sulfonamides; Valine

2014
Therapeutic potential of and treatment with boceprevir/telaprevir-based triple-therapy in HIV/chronic hepatitis C co-infected patients in a real-world setting.
    AIDS patient care and STDs, 2014, Volume: 28, Issue:5

    Topics: Adult; Antiviral Agents; Austria; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Proline; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult

2014
Hepatitis C treatment in dialysis patients: is a new dawn approaching?
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2014, Volume: 64, Issue:2

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Renal Dialysis; Ribavirin

2014
Letter: Telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis.
    Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:11

    Topics: Antiviral Agents; Female; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin

2014
Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios.
    Journal of hepatology, 2014, Volume: 61, Issue:3

    Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Cost of Illness; End Stage Liver Disease; England; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Middle Aged; Models, Statistical; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Treatment Outcome

2014
Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy.
    Hepatology (Baltimore, Md.), 2014, Volume: 60, Issue:1

    Topics: Drug Costs; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate

2014
Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity.
    Journal of clinical gastroenterology, 2015, Volume: 49, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Viral Load; Young Adult

2015
Predictive factors for adverse dermatological events during pegylated/interferon alpha and ribavirin treatment for hepatitis C.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2014, Volume: 60, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prognosis; Retrospective Studies; Ribavirin; Risk Factors; Skin Diseases; Treatment Outcome; Viral Load; Young Adult

2014
Emergent properties of the interferon-signalling network may underlie the success of hepatitis C treatment.
    Nature communications, 2014, May-16, Volume: 5

    Topics: Antiviral Agents; Computer Simulation; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Polyethylene Glycols; Ribavirin; Signal Transduction; Treatment Failure

2014
Response-guided therapy for hepatitis C genotype 2 and 3 in those with HIV coinfection.
    Digestive diseases and sciences, 2014, Volume: 59, Issue:8

    Topics: Adult; Antiviral Agents; Coinfection; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Retrospective Studies; Ribavirin

2014
Cryptococcal meningitis in a patient with chronic hepatitis C treated with pegylated-interferon and ribavirin.
    The Korean journal of internal medicine, 2014, Volume: 29, Issue:3

    Topics: Antifungal Agents; Antiviral Agents; Cryptococcus neoformans; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Immunocompromised Host; Interferon alpha-2; Interferon-alpha; Meningitis, Cryptococcal; Middle Aged; Opportunistic Infections; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome

2014
Alanine transaminase as a single marker is not reliable for selecting candidates of pegylated interferon and ribavirin treatment.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2015, Volume: 114, Issue:2

    Topics: Antiviral Agents; Hemophilia A; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin

2015
Inteleukin-23 promotes interferon-α responsiveness in hepatitis C virus/HIV-coinfected patients.
    AIDS research and human retroviruses, 2014, Volume: 30, Issue:8

    Topics: Adult; Aged; Antiviral Agents; Female; Gene Expression; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Interleukin-23; Leukocytes, Mononuclear; Male; Middle Aged; Receptor, Interferon alpha-beta; Ribavirin; Treatment Outcome; Viral Load

2014
Interferon-beta plus ribavirin therapy can be safely and effectively administered to elderly patients with chronic hepatitis C.
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2014, Volume: 20, Issue:8

    Topics: Aged; Antiviral Agents; Female; Glomerular Filtration Rate; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon-beta; Male; Ribavirin; Serum Albumin

2014
Ribavirin with interferon for hepatitis C in dialysis patients: efficacious and safe in the right patients in good hands.
    Gut, 2015, Volume: 64, Issue:2

    Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin

2015
My treatment approach to chronic hepatitis C virus.
    Mayo Clinic proceedings, 2014, Volume: 89, Issue:7

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate

2014
Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with Peg interferon alfa-2a and ribavirin.
    La Tunisie medicale, 2014, Volume: 92, Issue:1

    Topics: Anemia, Hemolytic, Autoimmune; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index

2014
Serum 25(OH)D3 levels affect treatment outcomes for telaprevir/peg-interferon/ribavirin combination therapy in genotype 1b chronic hepatitis C.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Volume: 46, Issue:8

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Calcifediol; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult

2014
Safety and efficacy of protease inhibitor based combination therapy in a single-center "real-life" cohort of 110 patients with chronic hepatitis C genotype 1 infection.
    BMC gastroenterology, 2014, May-05, Volume: 14

    Topics: Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Treatment Outcome; Viral Load

2014
Associations between human TRIM22 gene expression and the response to combination therapy with Peg-IFNα-2a and ribavirin in Iranian patients with chronic hepatitis C.
    Journal of medical virology, 2014, Volume: 86, Issue:9

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Iran; Leukocytes, Mononuclear; Male; Middle Aged; Minor Histocompatibility Antigens; Polyethylene Glycols; Recombinant Proteins; Repressor Proteins; Ribavirin; Treatment Outcome; Tripartite Motif Proteins; Young Adult

2014
Acute hepatitis C infection in a renal transplant recipient: primacy of the liver or kidney?
    BMJ case reports, 2014, Jun-06, Volume: 2014

    Topics: Adult; Antiviral Agents; Female; Graft Rejection; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Failure, Chronic; Kidney Transplantation; Medical Tourism; Nephrectomy; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin

2014
Pretreatment prediction of the outcome of response-guided peginterferon-α and ribavirin therapy for chronic hepatitis C.
    Journal of gastroenterology and hepatology, 2014, Volume: 29, Issue:12

    Topics: Aged; Antiviral Agents; Female; Forecasting; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2014
Evidence for immune activation in patients with residual hepatitis C virus RNA long after successful treatment with IFN and ribavirin.
    The Journal of general virology, 2014, Volume: 95, Issue:Pt 9

    Topics: Alanine Transaminase; Antiviral Agents; Chemokine CCL4; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukin-12 Subunit p35; Interleukin-6; Interleukin-8; Leukocytes, Mononuclear; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Tumor Necrosis Factor-alpha; Viral Load; Viral Nonstructural Proteins

2014
HCV-associated cryoglobulinaemic vasculitis: triple/dual antiviral treatment and/or rituximab?
    Annals of the rheumatic diseases, 2014, Volume: 73, Issue:9

    Topics: Antiviral Agents; Cryoglobulinemia; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Protease Inhibitors; Ribavirin

2014
Diversity of killer cell immunoglobulin-like receptor (KIR) genotypes and KIR2DL2/3 variants in HCV treatment outcome.
    PloS one, 2014, Volume: 9, Issue:6

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Haplotypes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Killer Cells, Natural; Logistic Models; Polymorphism, Single Nucleotide; Receptors, KIR2DL2; Receptors, KIR2DL3; Ribavirin; Treatment Outcome

2014
Simultaneous splenectomy during liver transplantation augments anti-viral therapy in patients infected with hepatitis C virus.
    American journal of surgery, 2015, Volume: 209, Issue:1

    Topics: Adult; Antiviral Agents; Combined Modality Therapy; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Hypersplenism; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Splenectomy; Treatment Outcome

2015
KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C.
    Human immunology, 2014, Volume: 75, Issue:8

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; HLA-B Antigens; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Polymorphism, Genetic; Prognosis; Receptors, KIR3DL1; Recombinant Proteins; Ribavirin; Viral Load

2014
Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism.
    Journal of viral hepatitis, 2015, Volume: 22, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Genotyping Techniques; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukins; Male; Middle Aged; Oligopeptides; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Treatment Outcome; Young Adult

2015
Interferon-based treatment for patients with mycosis fungoides and hepatitis C virus infection: a case series.
    American journal of clinical dermatology, 2014, Volume: 15, Issue:5

    Topics: Adult; Antineoplastic Agents; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Mycosis Fungoides; Remission Induction; Ribavirin; Skin Neoplasms; Treatment Outcome

2014
Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship.
    Journal of viral hepatitis, 2014, Volume: 21, Issue:10

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Male; Oligopeptides; Renal Insufficiency; Ribavirin

2014
[Naturopathy consultation. Soon all patients will be curable. Decisive breakthrough in therapy of hepatitis C ].
    MMW Fortschritte der Medizin, 2014, Feb-20, Volume: 156, Issue:3

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2014
Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C.
    Antiviral therapy, 2015, Volume: 20, Issue:2

    Topics: Aged; Antiviral Agents; Area Under Curve; Aspartate Aminotransferases; Biomarkers; Biopsy; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Platelet Count; Polyethylene Glycols; Predictive Value of Tests; Prognosis; Prospective Studies; Recombinant Proteins; Ribavirin; ROC Curve; Treatment Outcome; Viral Load

2015
Genotype characterization of occult hepatitis B virus strains among Egyptian chronic hepatitis C patients.
    Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit, 2014, Mar-13, Volume: 20, Issue:2

    Topics: Adult; Antiviral Agents; Coinfection; DNA, Viral; Egypt; Female; Genotype; Hepatitis B virus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load

2014
[Early interruption of triple therapy with telaprevir in chronic hepatitis C due to severe adverse effects does not necessarily lead to treatment failure].
    Gastroenterologia y hepatologia, 2015, Volume: 38, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Cellulitis; Drug Eruptions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Parotitis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sepsis; Staphylococcal Infections; Treatment Outcome; Withholding Treatment

2015
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Volume: 46, Issue:9

    Topics: Adult; Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Prognosis; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2014
Impaired interferon signaling in chronic hepatitis C patients with advanced fibrosis via the transforming growth factor beta signaling pathway.
    Hepatology (Baltimore, Md.), 2014, Volume: 60, Issue:5

    Topics: Adult; Aged; Amino Acids; Animals; Antiviral Agents; Cell Line, Tumor; Dietary Supplements; Drug Therapy, Combination; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Liver; Liver Cirrhosis; Male; Mechanistic Target of Rapamycin Complex 1; Mice; Middle Aged; Multiprotein Complexes; Nutritional Status; Proto-Oncogene Proteins c-jun; Ribavirin; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; TOR Serine-Threonine Kinases; Transforming Growth Factor beta

2014
HCV-associated cryoglobulinemic vasculitis: triple/dual antiviral treatment and/or rituximab? Reply to the comment by Ignatova et al.
    Annals of the rheumatic diseases, 2014, Volume: 73, Issue:9

    Topics: Antiviral Agents; Cryoglobulinemia; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Protease Inhibitors; Ribavirin

2014
Association of MRC-1 and IL-28B with the treatment outcome of hepatitis C: a case control study.
    BMC gastroenterology, 2014, Jun-26, Volume: 14

    Topics: Adult; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Membrane Glycoproteins; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Receptors, Immunologic; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2014
Q & A with Karen Tashima, MD new direct-acting antiviral agents offer therapeutic revolution for hepatitis C virus infection.
    Rhode Island medical journal (2013), 2014, Jul-01, Volume: 97, Issue:7

    Topics: Antiviral Agents; Clinical Competence; Clinical Protocols; Drug Costs; Drug Discovery; Hepatitis C, Chronic; Humans; Interferons; Prevalence; Ribavirin; Viral Hepatitis Vaccines

2014
[Treatment of chronic hepatitis C in human immunodeficiency virus infected patients].
    Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti, 2013, Volume: 67, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load

2013
[Management of side effects induced by antiviral therapy for chronic hepatitis infection].
    Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti, 2013, Volume: 67, Issue:4

    Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Hematinics; Hepatitis C, Chronic; Humans; Oligopeptides; Protease Inhibitors; Ribavirin; Treatment Outcome

2013
Characteristics and outcomes of HCV genotype-1-infected patients treated with peginterferon and ribavirin combination therapy with discordant HCV responses 4 and 12 weeks after starting therapy.
    Intervirology, 2014, Volume: 57, Issue:5

    Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2014
Low IL10 serum levels as key factor for predicting the sustained virological response to IFNα/ribavirin in Brazilian patients with HCV carrying IL28B CT/TT genotype.
    Human immunology, 2014, Volume: 75, Issue:8

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukin-10; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Prognosis; Recombinant Proteins; Ribavirin; Viral Load

2014
rs2230201 polymorphism may dictate complement C3 levels and response to treatment in chronic hepatitis C patients.
    Journal of viral hepatitis, 2015, Volume: 22, Issue:2

    Topics: Adult; Antiviral Agents; Complement C3; Enzyme-Linked Immunosorbent Assay; Female; Gene Frequency; Genotype; Genotyping Techniques; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prospective Studies; Ribavirin; Serum; Treatment Outcome; Young Adult

2015
Reply to "Alanine transaminase as a single marker is not reliable for selecting candidates of pegylated interferon and ribavirin treatment".
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2015, Volume: 114, Issue:2

    Topics: Antiviral Agents; Hemophilia A; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin

2015
You're not the one: treating subjects co-infected with hepatitis C genotypes 2 and 3 and human immunodeficiency virus.
    Digestive diseases and sciences, 2014, Volume: 59, Issue:8

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Ribavirin

2014
Trace amounts of sporadically reappearing HCV RNA can cause infection.
    The Journal of clinical investigation, 2014, Volume: 124, Issue:8

    Topics: Animals; Antiviral Agents; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Pan troglodytes; Phylogeny; Plasma; Ribavirin; RNA, Viral; T-Lymphocytes; Time Factors; Transfusion Reaction; Viremia

2014
CD127 expression, exhaustion status and antigen specific proliferation predict sustained virologic response to IFN in HCV/HIV co-infected individuals.
    PloS one, 2014, Volume: 9, Issue:7

    Topics: Adult; Anti-HIV Agents; Cell Proliferation; Coinfection; Female; Hepatitis A Virus Cellular Receptor 2; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-7 Receptor alpha Subunit; Male; Membrane Proteins; Middle Aged; Recombinant Proteins; Ribavirin; T-Lymphocytes; Treatment Outcome

2014
Liver fibrosis, host genetic and hepatitis C virus related parameters as predictive factors of response to therapy against hepatitis C virus in HIV/HCV coinfected patients.
    PloS one, 2014, Volume: 9, Issue:7

    Topics: Adult; Aged; CD4-Positive T-Lymphocytes; Coinfection; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Tumor Necrosis Factor-alpha; Young Adult

2014
Deep sequencing of hepatitis C virus hypervariable region 1 reveals no correlation between genetic heterogeneity and antiviral treatment outcome.
    BMC infectious diseases, 2014, Jul-13, Volume: 14

    Topics: Adult; Antiviral Agents; Base Sequence; Female; Genetic Heterogeneity; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Envelope Proteins

2014
[Therapy spectrum in hepatitis C extended. Newer NS3/4A protease inhibitor in chronic hepatitis C-GT1/4 infection].
    MMW Fortschritte der Medizin, 2014, Jun-12, Volume: 156 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferons; Protease Inhibitors; Randomized Controlled Trials as Topic; Ribavirin; Secondary Prevention; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate

2014
No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients.
    Clinical and molecular hepatology, 2014, Volume: 20, Issue:2

    Topics: Adult; Alleles; Antiviral Agents; Asian People; Cohort Studies; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Linkage Disequilibrium; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Republic of Korea; Retrospective Studies; Ribavirin

2014
Intact dendritic cell pathogen-recognition receptor functions associate with chronic hepatitis C treatment-induced viral clearance.
    PloS one, 2014, Volume: 9, Issue:7

    Topics: Adult; Antiviral Agents; CD8-Positive T-Lymphocytes; Dendritic Cells; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Innate; Interferon alpha-2; Interferon-alpha; Lymphocyte Activation; Male; Middle Aged; Myeloid Cells; Polyethylene Glycols; Receptors, Pattern Recognition; Recombinant Proteins; Ribavirin; Toll-Like Receptors; Virus Replication

2014
Treatment of chronic hepatitis C complicated by mixed cryoglobulinemia with new protease inhibitor, sofosbuvir.
    Annals of the rheumatic diseases, 2014, Volume: 73, Issue:10

    Topics: Antiviral Agents; Cryoglobulinemia; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Protease Inhibitors; Ribavirin

2014
Interferon-ribavirin therapy induces serum antibodies determining 'rods and rings' pattern in hepatitis C patients.
    Journal of viral hepatitis, 2014, Volume: 21, Issue:12

    Topics: Adult; Aged; Antiviral Agents; Autoantibodies; Female; Fluorescent Antibody Technique, Indirect; Hepatitis C, Chronic; Humans; IMP Dehydrogenase; Interferons; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; Ribavirin; Young Adult

2014
Combination therapy with silibinin, pegylated interferon and ribavirin in a patient with hepatitis C virus genotype 3 reinfection after liver transplantation: a case report.
    Journal of medical case reports, 2014, Jul-21, Volume: 8

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Silybin; Silymarin

2014
Delivery of treatment for hepatitis C virus infection in the primary care setting.
    European journal of gastroenterology & hepatology, 2014, Volume: 26, Issue:9

    Topics: Adult; Antiviral Agents; Delivery of Health Care; Drug Therapy, Combination; Feasibility Studies; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hospitalization; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; New South Wales; Pilot Projects; Polyethylene Glycols; Primary Health Care; Recombinant Proteins; Ribavirin; Treatment Outcome

2014
Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
    Journal of medical virology, 2014, Volume: 86, Issue:11

    Topics: Adult; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Hospitals, University; Humans; Interferon-alpha; Male; Middle Aged; Mutation, Missense; Oligopeptides; Plasma; Proline; Ribavirin; Treatment Failure; Viral Load; Viral Nonstructural Proteins; Young Adult

2014
Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.
    Alimentary pharmacology & therapeutics, 2014, Volume: 40, Issue:6

    Topics: Antiviral Agents; Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy, Combination; Genotype; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate

2014
Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Volume: 46, Issue:10

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Italy; Male; Markov Chains; Middle Aged; Models, Economic; Multivariate Analysis; National Health Programs; Polyethylene Glycols; Proline; Quality of Life; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Treatment Outcome

2014
Hepatitis C viral kinetics as a determinant of stopping pegylated interferon and ribavirin in genotype 1 infection.
    Gut and liver, 2014, Volume: 8, Issue:4

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2014
Prediction of a null response to pegylated interferon α-2b plus ribavirin in patients with high viral load genotype 1b hepatitis C.
    Gut and liver, 2014, Volume: 8, Issue:4

    Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Area Under Curve; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Medication Adherence; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Young Adult

2014
Renal dysfunction associated with telaprevir-containing triple therapy for chronic hepatitis C: is early prediction possible?
    European journal of gastroenterology & hepatology, 2014, Volume: 26, Issue:9

    Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Predictive Value of Tests; Prospective Studies; Renal Insufficiency; Retrospective Studies; Ribavirin; Risk Factors

2014
PPARγ2 Pro12Ala polymorphism is associated with sustained virological response in HIV/HCV-coinfected patients under HCV therapy.
    Journal of acquired immune deficiency syndromes (1999), 2014, Oct-01, Volume: 67, Issue:2

    Topics: Adult; Animals; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; PPAR gamma; Retrospective Studies; Ribavirin; RNA, Viral; Time; Treatment Outcome; Viral Load

2014
Impact of antiviral treatment on survival in HCV-positive liver recipients.
    Annals of transplantation, 2014, Jul-30, Volume: 19

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Cohort Studies; End Stage Liver Disease; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Liver Transplantation; Male; Middle Aged; Poland; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Retrospective Studies; Ribavirin; Young Adult

2014
Multicenter study on the discontinuation and efficacy of chronic hepatitis C treatment in the Spanish penitentiary population (EPIBAND study).
    European journal of gastroenterology & hepatology, 2014, Volume: 26, Issue:10

    Topics: Adult; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Genotype; Health Knowledge, Attitudes, Practice; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Medication Adherence; Motivation; Patient Education as Topic; Polyethylene Glycols; Prisoners; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors; RNA, Viral; Spain; Time Factors; Treatment Outcome; Viral Load

2014
The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1.
    Journal of viral hepatitis, 2015, Volume: 22, Issue:3

    Topics: Aged; Antiviral Agents; Biopsy; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Treatment Outcome; Viral Load

2015
Prediction of treatment week eight response & sustained virologic response in patients treated with boceprevir plus peginterferon alfa and ribavirin.
    PloS one, 2014, Volume: 9, Issue:8

    Topics: Adult; Aged; Antiviral Agents; Decision Trees; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Models, Statistical; Proline; Reproducibility of Results; Ribavirin; Risk Factors; Time Factors; Treatment Outcome; Viral Load; Young Adult

2014
Can zinc levels predict response to pegylated-interferon and ribavirin therapy in hepatitis C genotype 4 infected Egyptian patients?
    Acta gastro-enterologica Belgica, 2014, Volume: 77, Issue:2

    Topics: Adult; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Ribavirin; Young Adult; Zinc

2014
Effect of peginterferon alfa-2b and ribavirin on hepatocellular carcinoma prevention in older patients with chronic hepatitis C.
    Journal of gastroenterology and hepatology, 2015, Volume: 30, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Time Factors

2015
Effect of prolonged administration of pegylated interferon/ribavirin therapy in genotypes 2a and 2b: propensity score-matched analysis.
    Journal of gastroenterology and hepatology, 2015, Volume: 30, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Propensity Score; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Young Adult

2015
Effects of ribavirin monotherapy on the viral population in patients with chronic hepatitis C genotype 1: direct sequencing and pyrosequencing of the HCV regions.
    Journal of medical virology, 2014, Volume: 86, Issue:11

    Topics: Adult; Antiviral Agents; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Pilot Projects; Point Mutation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome; Viral Load; Viral Nonstructural Proteins

2014
Serum complements C3 and C4 in chronic HCV infection and their correlation with response to pegylated interferon and ribavirin treatment.
    Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology, 2014, Volume: 15, Issue:2

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Case-Control Studies; Complement C3; Complement C4; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon Type I; Male; Middle Aged; Polyethylene Glycols; Ribavirin

2014
Effectiveness of telaprevir and boceprevir triple therapy for patients with hepatitis C virus infection in a large integrated care setting.
    Digestive diseases and sciences, 2014, Volume: 59, Issue:12

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Proline; Retrospective Studies; Ribavirin; RNA, Viral; Young Adult

2014
Cost utility of telaprevir-PR (peginterferon-ribavirin) versus boceprevir-PR and versus PR alone in chronic hepatitis C in The Netherlands.
    Applied health economics and health policy, 2014, Volume: 12, Issue:6

    Topics: Adult; Antiviral Agents; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Markov Chains; Middle Aged; Netherlands; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Severity of Illness Index

2014
Reply: To PMID 23300053.
    Hepatology (Baltimore, Md.), 2014, Volume: 60, Issue:1

    Topics: Antiviral Agents; Cognition Disorders; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin

2014
Long-term survival and liver-related events after pegylated interferon/ribavirin therapy in HIV-infected patients with chronic hepatitis C.
    Antiviral therapy, 2015, Volume: 20, Issue:1

    Topics: Adult; Antiviral Agents; Coinfection; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Retrospective Studies; Ribavirin; Survival Analysis; Viral Load

2015
Is rs8099917 polymorphism of IL-28B gene a good predictor of response to therapy of HCV than rs12979860? An Egyptian study.
    Cell biochemistry and biophysics, 2015, Volume: 71, Issue:1

    Topics: Adult; Antiviral Agents; Case-Control Studies; Chromosomes, Human, Pair 19; Drug Therapy, Combination; Egypt; Female; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome

2015
Distinct patterns of the lipid alterations between genotype 1 and 2 chronic hepatitis C patients after viral clearance.
    PloS one, 2014, Volume: 9, Issue:8

    Topics: Adult; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lipid Metabolism; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral

2014
Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.
    Journal of hepatology, 2015, Volume: 62, Issue:1

    Topics: Adult; Antiviral Agents; Coinfection; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2015
[Incidence, management and costs of adverse effects in chronic hepatitis C patients on triple therapy with telaprevir or boceprevir: first 12 weeks of treatment].
    Enfermedades infecciosas y microbiologia clinica, 2015, Volume: 33, Issue:5

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Retrospective Studies; Ribavirin; Time Factors

2015
IFNL4 polymorphism predicts response to hepatitis C treatment after liver transplantation.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2014, Volume: 61, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Transplantation; Male; Middle Aged; Polymorphism, Genetic; Ribavirin; Treatment Outcome

2014
[Sarcoïdose in patient with chronic hepatitis C treated with pegylated interferon].
    Revue de pneumologie clinique, 2014, Volume: 70, Issue:6

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sarcoidosis; Tomography, X-Ray Computed

2014
The role of IL-28, IFN-γ, and TNF-α in predicting response to pegylated interferon/ribavirin in chronic HCV patients.
    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2015, Volume: 123, Issue:1

    Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon-alpha; Interferon-gamma; Interleukins; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Statistics, Nonparametric; Tumor Necrosis Factor-alpha; Young Adult

2015
Early viral kinetics during hepatitis C virus genotype 6 treatment according to IL28B polymorphisms.
    World journal of gastroenterology, 2014, Aug-14, Volume: 20, Issue:30

    Topics: Adult; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Kinetics; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2014
Successful natural interferon-β plus ribavirin therapy in a chronic hepatitis C patient after discontinuation of interferon-α treatment due to arrhythmia and interstitial pneumonia.
    Clinical journal of gastroenterology, 2014, Volume: 7, Issue:4

    Topics: Antiviral Agents; Arrhythmias, Cardiac; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-beta; Lung Diseases, Interstitial; Middle Aged; Remission Induction; Ribavirin

2014
PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis.
    Journal of hepatology, 2015, Volume: 62, Issue:1

    Topics: Aged; Antiviral Agents; Cryoglobulinemia; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Severity of Illness Index; Treatment Outcome; Vasculitis

2015
Does HIV remain a risk factor for achieving sustained virologic response under direct acting antiviral-based modern hepatitis C virus therapy?
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Dec-15, Volume: 59, Issue:12

    Topics: Antiviral Agents; Coinfection; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Ribavirin

2014
HCV cirrhosis at the edge of decompensation: will paritaprevir with ritonavir, ombitasvir, dasabuvir, and ribavirin solve the need for treatment?
    Journal of hepatology, 2014, Volume: 61, Issue:6

    Topics: Anilides; Antiviral Agents; Carbamates; Female; Hepatitis C, Chronic; Humans; Macrocyclic Compounds; Male; Ribavirin; Ritonavir; Sulfonamides; Uracil

2014
Prediction of hepatitis C virus interferon/ribavirin therapy outcome based on viral nucleotide attributes using machine learning algorithms.
    BMC research notes, 2014, Aug-23, Volume: 7

    Topics: Adenine Nucleotides; Algorithms; Antiviral Agents; Artificial Intelligence; Chi-Square Distribution; Computational Biology; Cytosine Nucleotides; Decision Support Techniques; Decision Trees; DNA, Viral; Drug Therapy, Combination; Genotype; Guanine Nucleotides; Hepacivirus; Hepatitis C, Chronic; Humans; Hydrogen; Interferons; Nucleotides; Oxygen; Patient Selection; Ribavirin; Treatment Outcome; Uracil Nucleotides

2014
Fluoxetine a novel anti-hepatitis C virus agent via ROS-, JNK-, and PPARβ/γ-dependent pathways.
    Antiviral research, 2014, Volume: 110

    Topics: Alanine Transaminase; Antiviral Agents; Cell Line; Cell Survival; Cohort Studies; Drug Therapy, Combination; Enzyme Activation; Fluoxetine; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Interferon alpha-2; Interferon-alpha; JNK Mitogen-Activated Protein Kinases; Microbial Sensitivity Tests; Polyethylene Glycols; PPAR gamma; PPAR-beta; Reactive Oxygen Species; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; STAT1 Transcription Factor

2014
Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection.
    World journal of gastroenterology, 2014, Aug-21, Volume: 20, Issue:31

    Topics: Age Factors; Antiviral Agents; Chi-Square Distribution; Drug Therapy, Combination; Female; Germany; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome

2014
Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis.
    Journal of acquired immune deficiency syndromes (1999), 2014, Jul-01, Volume: 66, Issue:3

    Topics: Adult; Alanine Transaminase; Antiviral Agents; CD4 Lymphocyte Count; Cohort Studies; Disease Progression; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Follow-Up Studies; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Logistic Models; Male; Predictive Value of Tests; Ribavirin; RNA, Viral; Viral Load

2014
Core amino acid variation at position 110 is associated with sustained virological response in Caucasian patients with chronic hepatitis C virus 1b infection.
    Archives of virology, 2014, Volume: 159, Issue:12

    Topics: Amino Acid Substitution; Amino Acids; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Treatment Outcome; Viral Core Proteins; White People

2014
[Short-term curative effect of ribavirin combination therapy with pegylated interferon alfa-2a vs. interferon alfa-2a in patients with chronic hepatitis C].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2014, Volume: 22, Issue:4

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Infant; Infant, Newborn; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Young Adult

2014
Sarcoidosis on the injection sites following treatment of interferon-alpha and ribavirin for hepatitis C.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2014, Volume: 113, Issue:12

    Topics: Aged; Antiviral Agents; Hepatitis C, Chronic; Humans; Injections; Interferon-alpha; Male; Ribavirin; Sarcoidosis; Sarcoidosis, Pulmonary; Skin Diseases

2014
Treatment of hepatitis C with the earliest protease inhibitor-based therapy.
    Mayo Clinic proceedings, 2014, Volume: 89, Issue:9

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Male; Oligopeptides; Ribavirin

2014
What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C?
    Journal of hepatology, 2015, Volume: 62, Issue:2

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2015
A case of chronic hepatitis C patient of myocardial ischemia accompanied with interstitial pneumonia induced by pegylated interferon alpha-2a.
    International journal of clinical and experimental pathology, 2014, Volume: 7, Issue:8

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Lung Diseases, Interstitial; Middle Aged; Myocardial Ischemia; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2014
Predictive potential of IL-18 -607 and osteopontin -442 polymorphism in interferon-based therapy of HCV infection in the Pakistani population.
    Viral immunology, 2014, Volume: 27, Issue:8

    Topics: Adolescent; Adult; Female; Genotype; Genotyping Techniques; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukin-18; Male; Middle Aged; Osteopontin; Pakistan; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome; Young Adult

2014
[Genomic diversity of the genotype 1b hepatitis C virus open reading frame is correlated with outcomes of combined pegylated-interferon/ribavirin therapy in patients with chronic hepatitis C from Henan Province].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2014, Volume: 22, Issue:6

    Topics: Adult; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Open Reading Frames; Ribavirin; Treatment Outcome

2014
[Cases of hepatitis C virus infection with 2i/2a recombination genotype in the Lanzhou area and effects of related genetic variations on interferon alpha response].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2014, Volume: 22, Issue:7

    Topics: Angiogenesis Inhibitors; Antiviral Agents; Drug Therapy, Combination; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Open Reading Frames; Polyethylene Glycols; Recombinant Proteins; Recombination, Genetic; Ribavirin; Treatment Outcome

2014
Differential expression of Toll-like receptors 7 & 8 mRNA in monocytes of patients with chronic hepatitis C infection: correlation with interferon and ribavirin treatment.
    The Egyptian journal of immunology, 2014, Volume: 21, Issue:1

    Topics: Adult; Antiviral Agents; Cells, Cultured; Female; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Profiling; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Monocytes; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Messenger; Toll-Like Receptor 7; Toll-Like Receptor 8; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult

2014
Not so sweet: autoimmune diabetes mellitus on triple therapy for chronic hepatitis C infection.
    Diabetic medicine : a journal of the British Diabetic Association, 2015, Volume: 32, Issue:2

    Topics: Adult; Antiviral Agents; Autoimmune Diseases; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Proline; Protease Inhibitors; Ribavirin; Young Adult

2015
ABT-450/r-ombitasvir and dasabuvir with ribavirin eliminates viraemia in most patients with HCV infection with cirrhosis.
    Evidence-based medicine, 2015, Volume: 20, Issue:1

    Topics: Anilides; Antiviral Agents; Carbamates; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Macrocyclic Compounds; Male; Ribavirin

2015
Response-guided boceprevir-based triple therapy in HIV/HCV-coinfected patients: the HIVCOBOC-RGT study.
    The Journal of infectious diseases, 2015, Mar-01, Volume: 211, Issue:5

    Topics: Adult; Antiviral Agents; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2015
CXCL9, CXCL10 and CXCL11 polymorphisms are associated with sustained virologic response in HIV/HCV-coinfected patients.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2014, Volume: 61, Issue:3

    Topics: Adult; Alleles; Chemokine CXCL10; Chemokine CXCL11; Chemokine CXCL9; Coinfection; Female; Genotype; Genotyping Techniques; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Polymorphism, Genetic; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load

2014
Erythropoietin rs1617640 G allele associates with an attenuated rise of serum erythropoietin and a marked decline of hemoglobin in hepatitis C patients undergoing antiviral therapy.
    BMC infectious diseases, 2014, Sep-17, Volume: 14

    Topics: Adult; Alleles; Antiviral Agents; Down-Regulation; Epoetin Alfa; Erythropoietin; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome

2014
With all the new treatment regimens, complete elimination of hepatitis C virus in Canada is a possibility! But when will Canadians have access these drugs?
    Canadian journal of gastroenterology & hepatology, 2014, Volume: 28, Issue:8

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Ribavirin

2014
Editorial: can we afford the new direct-acting antivirals for treatment of genotype 1 hepatitis C?
    Alimentary pharmacology & therapeutics, 2014, Volume: 40, Issue:8

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Ribavirin; Uridine Monophosphate

2014
Editorial: can we afford the new direct-acting anti-virals for treatment of genotype 1 hepatitis C? Authors' reply.
    Alimentary pharmacology & therapeutics, 2014, Volume: 40, Issue:8

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Ribavirin; Uridine Monophosphate

2014
Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin.
    Digestive diseases and sciences, 2015, Volume: 60, Issue:2

    Topics: Adult; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Protective Factors; Recombinant Proteins; Republic of Korea; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2015
Interleukin 27 polymorphisms in HCV RNA positive patients: is there an impact on response to interferon therapy?
    BMC infectious diseases, 2014, Volume: 14 Suppl 5

    Topics: Adult; Aged; Antiviral Agents; Base Sequence; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukin-27; Male; Middle Aged; Molecular Sequence Data; Polymorphism, Single Nucleotide; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome

2014
Homozygosity for HLA group 2 alleles predicts treatment failure with interferon-α and ribavirin in chronic hepatitis C virus genotype 1 infection.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2015, Volume: 35, Issue:2

    Topics: Alleles; Antiviral Agents; Female; Hepatitis C, Chronic; HLA-C Antigens; Homozygote; Humans; Interferon-alpha; Male; Polymorphism, Single Nucleotide; Ribavirin

2015
Long-term growth outcomes in children treated for chronic hepatitis C.
    The Journal of pediatrics, 2014, Volume: 165, Issue:6

    Topics: Antiviral Agents; Body Height; Child; Female; Follow-Up Studies; Growth; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2014
Cost-effectiveness of IL28Β genotype-guided protease inhibitor triple therapy versus standard of care treatment in patients with hepatitis C genotypes 2 or 3 infection.
    Public health genomics, 2014, Volume: 17, Issue:5-6

    Topics: Adult; Aged; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Standard of Care; Treatment Outcome

2014
Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study.
    BMC health services research, 2014, Sep-24, Volume: 14

    Topics: Antiviral Agents; Comorbidity; Female; Health Care Costs; Hepatitis C, Chronic; Humans; Incidence; Insurance, Health; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin

2014
[Thyrotoxicosis induced by interferonotherapy of chronic hepatitis C in a woman with Hashimoto's thyroiditis].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2014, Volume: 37, Issue:218

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hashimoto Disease; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Ribavirin; Thyrotoxicosis

2014
Impaired expression of type I and type II interferon receptors in HCV-associated chronic liver disease and liver cirrhosis.
    PloS one, 2014, Volume: 9, Issue:9

    Topics: Autophagy; Biological Transport; Biopsy; Cells, Cultured; Down-Regulation; Endoplasmic Reticulum Stress; Ethanol; Fatty Acids, Nonesterified; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Liver; Liver Cirrhosis; Receptor, Interferon alpha-beta; Receptors, Interferon; Ribavirin; Virus Replication

2014
[A case of chronic hepatitis C with pancreas divisum and acute pancreatitis during combination treatment with telaprevir/peginterferon/ribavirin].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2014, Volume: 111, Issue:10

    Topics: Acute Disease; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Pancreatitis; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2014
Treatment of naïve patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAA.
    PloS one, 2014, Volume: 9, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Ribavirin; Young Adult

2014
High-dose (peg)interferon therapy in treatment-naïve, interleukin-28B rs12979860 CT/TT genotype 1 chronic hepatitis C.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2015, Volume: 47, Issue:1

    Topics: Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2015
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program.
    Journal of viral hepatitis, 2015, Volume: 22, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Italy; Male; Middle Aged; Proline; Ribavirin; RNA, Viral; Spain; Treatment Outcome; Viral Load

2015
IL28B genetic variations are associated with treatment response of patients with chronic hepatitis C in a Chinese Han population.
    Journal of digestive diseases, 2015, Volume: 16, Issue:2

    Topics: Adult; Age Factors; Antiviral Agents; Asian People; Case-Control Studies; China; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome

2015
Persistent neurocognitive decline in a clinic sample of hepatitis C virus-infected persons receiving interferon and ribavirin treatment.
    Journal of neurovirology, 2014, Volume: 20, Issue:6

    Topics: Adult; Affect; Antiviral Agents; Cognition; Depression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Psychological Tests; Recombinant Proteins; Ribavirin; Viral Load

2014
Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis.
    Annals of internal medicine, 2014, Oct-21, Volume: 161, Issue:8

    Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Prisoners; Proline; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; United States; Uridine Monophosphate

2014
Development of biodegradable nanoparticles for liver-specific ribavirin delivery.
    Journal of pharmaceutical sciences, 2014, Volume: 103, Issue:12

    Topics: Animals; Antiviral Agents; Biocompatible Materials; Cell Line, Tumor; Delayed-Action Preparations; Drug Delivery Systems; Excipients; Female; Galactans; Hep G2 Cells; Hepatitis C, Chronic; Humans; Lactic Acid; Liver; Mice; Mice, Inbred C57BL; Nanoparticles; Polyesters; Polylysine; Polymers; Ribavirin

2014
Nursing support increases the efficacy of interferon therapy in patients with chronic hepatitis C.
    Acta medica Okayama, 2014, Volume: 68, Issue:5

    Topics: Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Nurses, Community Health; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Surveys and Questionnaires; Treatment Outcome

2014
Use of simeprevir following pre-emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12-week pilot study.
    Journal of hepato-biliary-pancreatic sciences, 2015, Volume: 22, Issue:2

    Topics: Aged; Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Living Donors; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Simeprevir; Time Factors; Transplant Recipients; Treatment Outcome

2015
Do variations in the ITPA gene determine the risk of hepatitis C virus relapse?
    Future microbiology, 2014, Volume: 9, Issue:9

    Topics: Hepacivirus; Hepatitis C, Chronic; Humans; Polymorphism, Genetic; Pyrophosphatases; Recurrence; Ribavirin

2014
Sofosbuvir modulates the intimate relationship between hepatitis C virus and lipids.
    Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:3

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Lipid Metabolism; Male; Ribavirin; Sofosbuvir; Uridine Monophosphate

2015
Relationship between HCV dynamics and sustained virological responses in chronic hepatitis C genotype 1b patients treated with telaprevir-based triple therapy.
    European journal of gastroenterology & hepatology, 2014, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Japan; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult

2014
Acute allograft rejection following interferon therapy for hepatitis C in recipients who have returned to dialysis after kidney transplant failure: case study.
    The International journal of artificial organs, 2014, Volume: 37, Issue:11

    Topics: Acute Disease; Allografts; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Graft Rejection; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Transplantation; Middle Aged; Nephrectomy; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Renal Insufficiency, Chronic; Reoperation; Ribavirin; Risk Factors; Therapeutics; Time Factors

2014
Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies.
    Journal of viral hepatitis, 2015, Volume: 22, Issue:4

    Topics: Anemia; Antiviral Agents; Bilirubin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Exanthema; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Neutropenia; Prevalence; Pruritus; Ribavirin; Simeprevir

2015
Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis C virus genotype 1 infect
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015, Feb-15, Volume: 60, Issue:4

    Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Proline; Recurrence; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Uracil; Valine; Viral Load

2015
FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients.
    BMC medicine, 2014, Nov-03, Volume: 12

    Topics: Adult; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Antiviral Agents; Body Mass Index; Coinfection; Cross-Sectional Studies; Female; Genetic Predisposition to Disease; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Obesity; Odds Ratio; Polymorphism, Single Nucleotide; Proteins; Ribavirin

2014
Association of SNPs in interferon receptor genes in chronic hepatitis C with response to combined therapy of interferon and ribavirin.
    Acta medica Iranica, 2014, Volume: 52, Issue:10

    Topics: Adult; Aged; Antiviral Agents; Case-Control Studies; DNA; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Real-Time Polymerase Chain Reaction; Receptors, Interferon; Ribavirin; Viral Load; Young Adult

2014
Adjusting the starting dose of telaprevir according to renal function decreases adverse effects and affects the sustained virological response rate.
    European journal of gastroenterology & hepatology, 2015, Volume: 27, Issue:1

    Topics: Acute Kidney Injury; Aged; Anemia; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Female; Genotype; Glomerular Filtration Rate; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin

2015
Drug-drug interactions of telaprevir and boceprevir in HCV-monoinfected and HIV/HCV-coinfected patients can modify the adherence.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin

2015
Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation.
    AIDS (London, England), 2015, Jan-02, Volume: 29, Issue:1

    Topics: Adult; Antiviral Agents; Coinfection; Cyclosporine; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Immunosuppression Therapy; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Tacrolimus; Viral Load

2015
Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy.
    The Journal of infectious diseases, 2015, May-01, Volume: 211, Issue:9

    Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Fatty Liver; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2015
Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C.
    PloS one, 2014, Volume: 9, Issue:11

    Topics: Antiviral Agents; Drug Monitoring; Gene Expression Regulation; Genotype; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prognosis; Proline; Recombinant Proteins; Ribavirin; Signal Transduction; Treatment Outcome

2014
[Cost-effectiveness of hepatitis C treatment in slow virologic responders coinfected with HIV].
    Cadernos de saude publica, 2013, Volume: 29 Suppl 1

    Topics: Adult; Antiviral Agents; Coinfection; Cost-Benefit Analysis; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2013
Polymorphisms of Toll-like receptors 2 and 4 in chronically infected hepatitis C patients from north-east Croatia.
    Archives of virology, 2015, Volume: 160, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Croatia; Female; Genotype; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Polymorphism, Genetic; Ribavirin; RNA, Viral; Toll-Like Receptor 2; Toll-Like Receptor 4; Viral Load; Young Adult

2015
Uptake and utilization of directly acting antiviral medications for hepatitis C infection in U.S. veterans.
    Journal of viral hepatitis, 2015, Volume: 22, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Drug Utilization; Genotyping Techniques; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Proline; Retrospective Studies; Ribavirin; United States; Veterans

2015
Patient with decompensated hepatitis C virus-related cirrhosis delisted for liver transplantation after successful sofosbuvir-based treatment.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2015, Volume: 21, Issue:3

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Remission Induction; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load; Waiting Lists

2015
Viral hepatitis: cure of chronic hepatitis C--required length of follow-up?
    Nature reviews. Gastroenterology & hepatology, 2015, Volume: 12, Issue:1

    Topics: Antiviral Agents; Continuity of Patient Care; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Remission Induction; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate

2015
Efficacy and safety of telaprevir-based antiviral treatment for elderly patients with hepatitis C virus.
    Oncology, 2014, Volume: 87 Suppl 1

    Topics: Adult; Aged; Anemia; Antiviral Agents; Biomarkers; Drug Eruptions; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Male; Middle Aged; Oligopeptides; Renal Insufficiency; Ribavirin; Time Factors; Treatment Outcome; Viral Load

2014
Ultrasound elastography correlates treatment response by antiviral therapy in patients with chronic hepatitis C.
    Oncology, 2014, Volume: 87 Suppl 1

    Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2014
Drug eruptions induced by telaprevir in patients with chronic hepatitis C virus genotype 1 infection: a prospective study.
    Actas dermo-sifiliograficas, 2015, Volume: 106, Issue:3

    Topics: Adult; Aged; Disease Progression; Drug Eruptions; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Prospective Studies; Ribavirin; Serine Proteinase Inhibitors; Severity of Illness Index

2015
Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2014, Volume: 29

    Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Oligopeptides; Protease Inhibitors; Ribavirin; RNA, Viral; Viral Load

2014
[Drug Rash with Eosinophilia and Systemic Symptoms syndrome induced by telaprevir in a patient with chronic hepatitis C virus infection].
    Gastroenterologia y hepatologia, 2015, Volume: 38, Issue:8

    Topics: Anti-Inflammatory Agents; Antiviral Agents; Drug Hypersensitivity Syndrome; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Male; Methylprednisolone; Middle Aged; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin

2015
A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2015, Volume: 13, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Female; Genetic Predisposition to Disease; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Retrospective Studies; Ribavirin; Risk Factors; Taiwan; Young Adult

2015
Pretreatment serum macrophage inflammatory protein (MIP)-1 levels predict sustained virological responses to re-treatment in patients with chronic hepatitis C virus infection.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2015, Volume: 33

    Topics: Adult; Antiviral Agents; Chemokine CCL4; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult

2015
Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2015, Volume: 30

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Pakistan; Polyethylene Glycols; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome; Viral Load

2015
New kids on the block--step by step to an ideal HCV therapy.
    Lancet (London, England), 2015, Mar-21, Volume: 385, Issue:9973

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Female; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Male; Quinoxalines; Ribavirin; RNA, Viral; Sulfonamides

2015
Controlling hepatitis C with simeprevir.
    The Lancet. Infectious diseases, 2015, Volume: 15, Issue:1

    Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir; Sulfonamides

2015
Tuberculous peritonitis during pegylated interferon plus ribavirin combination therapy in a patient with chronic hepatitis C.
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2014, Volume: 111, Issue:12

    Topics: Aged; Antitubercular Agents; Drug Combinations; Female; Hepatitis C, Chronic; Humans; Interferons; Multimodal Imaging; Peritonitis, Tuberculous; Positron-Emission Tomography; Ribavirin; Tomography, X-Ray Computed

2014
[Investigation of the association between paraoxonase-1 gene polymorphisms and response to therapy in chronic hepatitis C patients].
    Mikrobiyoloji bulteni, 2014, Volume: 48, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Aryldialkylphosphatase; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Ribavirin; RNA, Viral; Treatment Outcome

2014
[Research of relationship between antiviral efficacy on chronic hepatitis C and the application time and dose of ribavirin].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2014, Volume: 22, Issue:10

    Topics: Antiviral Agents; Female; Genotype; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Ribavirin; Treatment Outcome; Viral Load

2014
Cost-effectiveness of telaprevir in patients with genotype 1 hepatitis C in Australia.
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2014, Volume: 17, Issue:8

    Topics: Antiviral Agents; Australia; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferons; Markov Chains; Models, Economic; Oligopeptides; Polyethylene Glycols; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Ribavirin; Severity of Illness Index

2014
Association of serum IFN-λ3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection.
    Journal of gastroenterology, 2015, Volume: 50, Issue:8

    Topics: Adult; Aged; Antiviral Agents; Biomarkers; Case-Control Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Inflammation Mediators; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin

2015
Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfected patients.
    European journal of gastroenterology & hepatology, 2015, Volume: 27, Issue:2

    Topics: Aged; Antiviral Agents; Coinfection; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Ribavirin; Treatment Outcome; Veterans

2015
Neutrophil-to-lymphocyte ratio as a predictor of response to peginterferon plus ribavirin therapy for chronic hepatitis C.
    Disease markers, 2014, Volume: 2014

    Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lymphocyte Count; Male; Middle Aged; Neutrophils; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2014
[Ways of improving adherence on telaprevir-based therapy in patients with chronic HCV infection].
    Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, 2014, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Medication Adherence; Oligopeptides; Ribavirin

2014
Incidence rates of tuberculosis in chronic hepatitis C infected patients with or without interferon based therapy: a population-based cohort study in Taiwan.
    BMC infectious diseases, 2014, Dec-19, Volume: 14

    Topics: Adult; Aged; Antiviral Agents; Case-Control Studies; Cohort Studies; Coinfection; Databases, Factual; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Taiwan; Tuberculosis; Young Adult

2014
Does Therapeutic Drug Monitoring of Ribavirin in HCV Genotype 3 Treatment With Sofosbuvir and Ribavirin Still Have a Role?
    Therapeutic drug monitoring, 2015, Volume: 37, Issue:4

    Topics: Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir

2015
[Is more expensive always better?].
    Nederlands tijdschrift voor geneeskunde, 2014, Volume: 159

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Ribavirin; Sofosbuvir; Uridine Monophosphate

2014
Cirrhotic patients are still at risk of developing hepatocellular carcinoma despite Interferon-induced sustained virological response.
    European review for medical and pharmacological sciences, 2014, Volume: 18, Issue:2 Suppl

    Topics: Adult; Aged; alpha-Fetoproteins; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Ribavirin; Treatment Outcome

2014
Patients treated with first-generation HCV protease inhibitors exhibit high ribavirin concentrations.
    Journal of clinical pharmacology, 2015, Volume: 55, Issue:5

    Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Retrospective Studies; Ribavirin

2015
Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2015, Volume: 47, Issue:2

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prognosis; Proline; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2015
Study of pruritus in chronic hepatitis C patients.
    World journal of gastroenterology, 2014, Dec-21, Volume: 20, Issue:47

    Topics: Adult; Aged; Antiviral Agents; Biomarkers; Case-Control Studies; Chemokine CCL17; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Pruritus; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome; Young Adult

2014
Circulating Apo 2L levels decreased in genotype II hepatitis C with pegylated interferon-2 alpha treatment.
    Le infezioni in medicina, 2014, Volume: 22, Issue:4

    Topics: Antiviral Agents; Biomarkers; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; TNF-Related Apoptosis-Inducing Ligand; Treatment Outcome; Turkey; Viral Load

2014
Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:7

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Eligibility Determination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hospitalization; Humans; Interferon-alpha; Male; Middle Aged; Patient Selection; Polyethylene Glycols; Prospective Studies; Ribavirin; Risk Factors; Sofosbuvir; Time Factors; Treatment Outcome

2015
[Pegylated interferon α-2a and ribavirin antiviral therapy efficacy for treating chronic hepatitis C and its effects on psychological status of patients].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2014, Volume: 22, Issue:10

    Topics: Antiviral Agents; Drug Combinations; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2014
Comparison of peginterferon alfa-2a and alfa-2b for treatment of patients with chronic hepatitis C: a retrospective study using the Japanese Interferon Database.
    Drug design, development and therapy, 2015, Volume: 9

    Topics: Adolescent; Combined Modality Therapy; Databases, Factual; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome

2015
Self-reported need for psychotherapy predicts interferon-induced depression in hepatitis C: stratification for interferon-free treatment.
    Antiviral therapy, 2015, Volume: 20, Issue:5

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Depression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Psychotherapy; Recombinant Proteins; Ribavirin; Self Report; Surveys and Questionnaires; Young Adult

2015
Pulmonary complications associated with pegylated interferon and ribavirin in HIV/hepatitis C virus coinfected patients.
    AIDS (London, England), 2014, Nov-13, Volume: 28, Issue:17

    Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Hypertension, Pulmonary; Interferon-alpha; Lung Diseases, Interstitial; Male; Middle Aged; Ribavirin

2014
A cost-effectiveness model to personalize antiviral therapy in naive patients with genotype 1 chronic hepatitis C.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2015, Volume: 47, Issue:3

    Topics: Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Italy; Male; Middle Aged; Models, Economic; Models, Theoretical; Practice Guidelines as Topic; Precision Medicine; Quality-Adjusted Life Years; Ribavirin

2015
Hepatitis C Virus Infection Is Systemic: Meeting Additional Goals.
    The Journal of infectious diseases, 2015, Aug-01, Volume: 212, Issue:3

    Topics: Antiviral Agents; Coinfection; Hepatitis C, Chronic; HIV Infections; Humans; Ribavirin; Uridine Monophosphate

2015
Insulin resistance as a predictor of early virologic response to HCV therapy among chronic HCV Egyptian patients.
    Journal of medical virology, 2015, Volume: 87, Issue:3

    Topics: Adolescent; Adult; Antiviral Agents; Cross-Sectional Studies; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon-alpha; Male; Middle Aged; Prognosis; Prospective Studies; Real-Time Polymerase Chain Reaction; Ribavirin; Treatment Outcome; Viral Load; Young Adult

2015
Cost-effectiveness of screening for hepatitis C in Canada.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2015, Feb-17, Volume: 187, Issue:3

    Topics: Adult; Antiviral Agents; Canada; Cost-Benefit Analysis; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Mass Screening; Middle Aged; Quality-Adjusted Life Years; Ribavirin

2015
SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir.
    The Journal of antimicrobial chemotherapy, 2015, Volume: 70, Issue:4

    Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Equilibrative Nucleoside Transporter 1; Female; Genetic Predisposition to Disease; Genotype; Genotyping Techniques; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prospective Studies; Ribavirin

2015
Shorter treatments for hepatitis C: another step forward?
    Lancet (London, England), 2015, Mar-21, Volume: 385, Issue:9973

    Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Furans; Hepatitis C, Chronic; Humans; Male; Quinolines; Ribavirin; RNA, Viral; Sofosbuvir; Thiophenes; Uridine Monophosphate

2015
Pegylated IFN-α-2a and ribavirin in the treatment of hepatitis C infection in children.
    Expert opinion on drug safety, 2015, Volume: 14, Issue:3

    Topics: Adult; Age Factors; Antiviral Agents; Child; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2015
[Chronic hepatitis C. Interferon free therapy also in patients with liver cirrhosis].
    MMW Fortschritte der Medizin, 2014, Dec-15, Volume: 156, Issue:21-22

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Liver Cirrhosis; Randomized Controlled Trials as Topic; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate

2014
Severe cutaneous adverse reaction to telaprevir.
    Dermatology online journal, 2015, Jan-15, Volume: 21, Issue:1

    Topics: Anti-Inflammatory Agents; Clobetasol; Drug Hypersensitivity Syndrome; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Middle Aged; Oligopeptides; Ribavirin; Stevens-Johnson Syndrome

2015
Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection.
    Alimentary pharmacology & therapeutics, 2015, Volume: 41, Issue:6

    Topics: Adult; Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Drug Therapy, Combination; Fluorenes; Genotype; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2015
Simeprevir with peginterferon and ribavirin induced interstitial pneumonitis: first case report.
    World journal of gastroenterology, 2015, Jan-21, Volume: 21, Issue:3

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Glucocorticoids; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Lung Diseases, Interstitial; Polyethylene Glycols; Prednisolone; Recombinant Proteins; Ribavirin; Simeprevir; Sulfonamides; Time Factors; Tomography, X-Ray Computed; Treatment Outcome

2015
Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC study.
    Clinics and research in hepatology and gastroenterology, 2015, Volume: 39, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA; Viral Load

2015
Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2015, Volume: 47, Issue:3

    Topics: Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Linear Models; Male; Middle Aged; Mutation; Oligopeptides; Protease Inhibitors; Ribavirin; RNA Stability; RNA, Viral; Treatment Outcome; Viral Load; Virus Replication

2015
Peg-IFN and ribavirin treatment for recurrence of genotype 2 and 3 hepatitis C after liver transplantation.
    Infectious diseases (London, England), 2015, Volume: 47, Issue:4

    Topics: Adult; Aged; Analysis of Variance; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin

2015
Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:9

    Topics: Anemia; Antiviral Agents; Cohort Studies; Coinfection; Drug Therapy, Combination; Female; France; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Italy; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Proline; Ribavirin; RNA, Viral; Treatment Outcome

2015
IL28B rs12980275 polymorphism shows association with response to treatment in Pakistani patients with chronic hepatitis C.
    Journal of medical virology, 2015, Volume: 87, Issue:5

    Topics: Adult; Antiviral Agents; Female; Genetic Variation; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Pakistan; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Ribavirin; Treatment Outcome

2015
Patterns of longitudinal change in hepatitis C virus neutralization titers correlate with the outcome of peginterferon and ribavirin combination therapy.
    Journal of medical virology, 2015, Volume: 87, Issue:5

    Topics: Antibodies, Neutralizing; Cohort Studies; Drug Therapy, Combination; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon-alpha; Longitudinal Studies; Ribavirin; Treatment Outcome

2015
An OPTIMIZE study retrospective analysis for management of telaprevir-treated hepatitis C virus (HCV)-infected patients by use of the Abbott RealTime HCV RNA assay.
    Journal of clinical microbiology, 2015, Volume: 53, Issue:4

    Topics: Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Molecular Diagnostic Techniques; Oligopeptides; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2015
Evolution of simeprevir-resistant variants in virological non-responders infected with HCV genotype 1b.
    Journal of medical virology, 2015, Volume: 87, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Resistance, Viral; Evolution, Molecular; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; High-Throughput Nucleotide Sequencing; Humans; Interferon-alpha; Male; Middle Aged; Mutation, Missense; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Simeprevir; Sulfonamides; Time Factors; Treatment Failure; Viral Nonstructural Proteins

2015
Relationship between the early boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2015, Volume: 21, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Monitoring; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Mutation, Missense; Plasma; Proline; Prospective Studies; Ribavirin; Treatment Failure

2015
PHOTON-2: hope for patients with HIV and HCV co-infection?
    Lancet (London, England), 2015, Mar-21, Volume: 385, Issue:9973

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate

2015
Treatment optimization of naïve HCV-1 patients using IL28B, RVR and fibrosis stage.
    Antiviral research, 2015, Volume: 116

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load

2015
Role of pharmacogenetic in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2015, Volume: 69

    Topics: Adult; Cohort Studies; Female; Gene Frequency; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Linkage Disequilibrium; Logistic Models; Male; Membrane Transport Proteins; Middle Aged; Multivariate Analysis; Pharmacogenetics; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome

2015
The host HLA-A*02 allele is associated with the response to pegylated interferon and ribavirin in patients with chronic hepatitis C virus infection.
    Archives of virology, 2015, Volume: 160, Issue:4

    Topics: Adult; Alleles; Antiviral Agents; Asian People; China; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HLA-A Antigens; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome

2015
Delayed hypersensitivity to ribavirin confirmed by provocation test.
    Journal of investigational allergology & clinical immunology, 2014, Volume: 24, Issue:6

    Topics: Antiviral Agents; Drug Hypersensitivity; Female; Hepatitis C, Chronic; Humans; Hypersensitivity, Delayed; Middle Aged; Ribavirin

2014
Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection.
    Journal of gastroenterology and hepatology, 2015, Volume: 30, Issue:7

    Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Diabetes Complications; Female; Follow-Up Studies; Forecasting; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Time Factors

2015
Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
    Journal of women's health (2002), 2015, Volume: 24, Issue:2

    Topics: Adult; Aging; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Glucose; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Italy; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2015
Retreatment with peginterferon and ribavirin in chronic hepatitis C.
    World journal of gastroenterology, 2015, Feb-14, Volume: 21, Issue:6

    Topics: Adult; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retreatment; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2015
Baseline factors associated with treatment response in patients infected with hepatitis C virus 1b by stratification of IL28B polymorphisms.
    Archives of virology, 2015, Volume: 160, Issue:4

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Young Adult

2015
Incidence and antiviral response of hepatitis C virus reactivation in lupus patients undergoing immunosuppressive therapy.
    Lupus, 2015, Volume: 24, Issue:10

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Glucocorticoids; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Incidence; Interferon-alpha; Lupus Erythematosus, Systemic; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Viral Load; Virus Activation

2015
Genetic variant of IL28B rs12979860, as predictive marker of interferon-based therapy in Pakistani population.
    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2015, Volume: 123, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genetic Markers; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Pakistan; Polyethylene Glycols; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome

2015
End-of-Treatment-Response in patients treated for hepatitis C virus with standard interferon and ribavirin based on viral load.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2015, Volume: 25, Issue:2

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Young Adult

2015
Influence of genes suppressing interferon effects in peripheral blood mononuclear cells during triple antiviral therapy for chronic hepatitis C.
    PloS one, 2015, Volume: 10, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Leukocytes, Mononuclear; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Suppressor of Cytokine Signaling Proteins; Treatment Outcome

2015
The genotype CC of IL-28B SNP rs12979860 is significantly associated with a sustained virological response in chronic HCV-infected Pakistani patients.
    Journal of digestive diseases, 2015, Volume: 16, Issue:5

    Topics: Adult; Antiviral Agents; Asian People; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Pakistan; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Real-Time Polymerase Chain Reaction; Ribavirin; Treatment Outcome

2015
[Simeprevir in combination with pegylated interferon-α and ribavirin in the treatment of naïve patients with genotype 1 chronic hepatitis C].
    Terapevticheskii arkhiv, 2014, Volume: 86, Issue:11

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Russia; Simeprevir; Sulfonamides

2014
[Prevalence, risk factors and clinical characteristics in patients with genotype 6 chronic hepatitis C: a single institute experience].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2015, Volume: 65, Issue:2

    Topics: Acupuncture Therapy; Adult; Aged; Antiviral Agents; Blood Transfusion; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Republic of Korea; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Tattooing

2015
Secreted Phosphoprotein 1 Promoter Genetic Variants Are Associated with the Response to Pegylated Interferon α Plus Ribavirin Combination Therapy in Egyptian Patients with Chronic Hepatitis C Virus Infection.
    Gut and liver, 2015, Volume: 9, Issue:4

    Topics: Adult; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Osteopontin; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Promoter Regions, Genetic; Recombinant Proteins; Ribavirin; Treatment Outcome

2015
Probable boceprevir-induced hyponatremia in a patient with chronic hepatitis C.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2015, Mar-15, Volume: 72, Issue:6

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Hyponatremia; Interferon-alpha; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin

2015
Safety and efficacy of partial splenic embolization in telaprevir-based triple therapy for chronic hepatitis C.
    Internal medicine (Tokyo, Japan), 2015, Volume: 54, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Combined Modality Therapy; Drug Therapy, Combination; Embolization, Therapeutic; Female; Genotype; Hepatitis C, Chronic; Humans; Hypersplenism; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Platelet Count; Polyethylene Glycols; Pyrophosphatases; Ribavirin; Thrombocytopenia; Treatment Outcome

2015
[A new era in therapy of chronic hepatitis C].
    MMW Fortschritte der Medizin, 2015, Feb-05, Volume: 157, Issue:2

    Topics: Antiviral Agents; Cohort Studies; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Randomized Controlled Trials as Topic; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate

2015
[New combination therapy increases chances of recovery].
    MMW Fortschritte der Medizin, 2015, Feb-19, Volume: 157, Issue:3

    Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Liver Cirrhosis; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate

2015
Optimism for patients with genotype 4 HCV infection: clinical trials with direct-acting antivirals finally available.
    Journal of hepatology, 2015, Volume: 62, Issue:5

    Topics: Benzazepines; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Interferon-alpha; Isoquinolines; Male; Polyethylene Glycols; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides

2015
Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders.
    Internal medicine (Tokyo, Japan), 2015, Volume: 54, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Japan; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2015
Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function.
    Gastroenterology, 2015, Volume: 149, Issue:1

    Topics: Aged; Antiviral Agents; Chemokine CXCL10; Chemokine CXCL11; Cytokines; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Killer Cells, Natural; Male; Middle Aged; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome

2015
Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naïve chronic hepatitis C genotype 1 patients in Japan.
    Journal of medical economics, 2015, Volume: 18, Issue:7

    Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Japan; Male; Markov Chains; Meta-Analysis as Topic; Middle Aged; Models, Econometric; Phenotype; Randomized Controlled Trials as Topic; Ribavirin; Simeprevir

2015
[Development of antiviral treatments for chronic hepatitis C].
    Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:2

    Topics: Hepatitis C, Chronic; Humans; Interferons; Ribavirin

2015
[Pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C].
    Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Neoplasms; Ribavirin

2015
[A triple combination therapy of simeprevir, pegylated-interferon and ribavirin with chronic hepatitis C virus genotype 1 infection].
    Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Simeprevir; Sulfonamides

2015
[Combined telaprevir plus ribavirin and pegylated interferon therapy for patients with chronic hepatitis C].
    Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2015
[Natural human IFNβ and ribavirin combination therapy].
    Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:2

    Topics: Aged; Depression; Drug Therapy, Combination; Hemophilia A; Hepatitis C, Chronic; Humans; Interferon-beta; Ribavirin; Thrombocytopenia

2015
TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfected patients.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2015, Volume: 65

    Topics: Adult; Alleles; Antiviral Agents; Coinfection; Female; Genotype; Haplotypes; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Polymorphism, Single Nucleotide; Retrospective Studies; Ribavirin; Toll-Like Receptor 3

2015
Responses to peginterferon alfa-2a vs alfa-2b plus ribavirin in a Mexican population with chronic hepatitis C.
    Journal of infection in developing countries, 2015, Mar-15, Volume: 9, Issue:3

    Topics: Adult; Antiviral Agents; Blood Chemical Analysis; Cohort Studies; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Mexico; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2015
Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma--A retrospective multicenter study.
    Journal of medical virology, 2015, Volume: 87, Issue:7

    Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Treatment Outcome; Viral Load

2015
High resolution melting curve assay for detecting rs12979860 IL28B polymorphisms involved in response of Iranian patients to chronic hepatitis C treatment.
    Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:5

    Topics: Adult; Alleles; Antiviral Agents; Base Sequence; Drug Therapy, Combination; Female; Genome-Wide Association Study; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Iran; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Treatment Outcome

2015
Evaluation of the frequency of the IL-28 polymorphism (rs8099917) in patients with chronic hepatitis C using Zip nucleic acid probes, Kerman, Southeast of Iran.
    Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:5

    Topics: Adult; Alanine Transaminase; Anaplastic Lymphoma Kinase; Antibodies, Viral; Antiviral Agents; Aspartate Aminotransferases; Drug Therapy, Combination; Female; Gene Frequency; Hepacivirus; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukins; Iran; Male; Middle Aged; Nucleic Acid Probes; Polyethylene Glycols; Polymorphism, Single Nucleotide; Real-Time Polymerase Chain Reaction; Receptor Protein-Tyrosine Kinases; Recombinant Proteins; Retrospective Studies; Ribavirin; Viral Load

2015
Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
    Annals of internal medicine, 2015, Mar-17, Volume: 162, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Disease Progression; Drug Costs; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Patient-Specific Modeling; Pyrrolidines; Ribavirin; Sensitivity and Specificity; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine

2015
Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.
    Journal of gastroenterology and hepatology, 2015, Volume: 30, Issue:8

    Topics: Adult; Age Factors; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Sex Factors; Thrombocytopenia; Treatment Outcome

2015
Comparative safety study on severe anemia by simeprevir versus telaprevir-based triple therapy for chronic hepatitis C.
    Journal of gastroenterology and hepatology, 2015, Volume: 30, Issue:8

    Topics: Age Factors; Aged; Anemia; Drug Therapy, Combination; Enzyme Inhibitors; Female; Genotype; Glomerular Filtration Rate; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multicenter Studies as Topic; Oligopeptides; Pyrophosphatases; Retrospective Studies; Ribavirin; Risk; Severity of Illness Index; Simeprevir; Viral Nonstructural Proteins

2015
The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015, Jul-15, Volume: 61, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Markov Chains; Middle Aged; Polyethylene Glycols; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Sofosbuvir; United States; Uridine Monophosphate; Young Adult

2015
Telaprevir decreases estimated glomerular filtration rate in HIV-hepatitis C virus coinfected patients.
    AIDS (London, England), 2015, May-15, Volume: 29, Issue:8

    Topics: Antiviral Agents; Coinfection; Creatinine; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Retrospective Studies; Ribavirin; Spain; Tertiary Care Centers

2015
Low levels of microbial translocation marker LBP are associated with sustained viral response after anti-HCV treatment in HIV-1/HCV co-infected patients.
    PloS one, 2015, Volume: 10, Issue:3

    Topics: Acute-Phase Proteins; Adult; Anti-HIV Agents; Aspartate Aminotransferases; Biomarkers; Carrier Proteins; Coinfection; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Kinetics; Lipopolysaccharide Receptors; Lipopolysaccharides; Male; Membrane Glycoproteins; Middle Aged; Retrospective Studies; Ribavirin; Solubility; Time Factors; Treatment Outcome

2015
HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome.
    Hepatology international, 2015, Volume: 9, Issue:1

    Topics: Adult; Age Factors; Antiviral Agents; Diabetes Mellitus, Type 2; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sex Factors; Treatment Outcome

2015
Prognostic effect of response to interferon therapy after laparoscopic splenectomy among patients with marked thrombocytopenia and hepatitis C virus-related cirrhosis.
    Hepatology international, 2015, Volume: 9, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Therapy, Combination; Esophageal and Gastric Varices; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Laparoscopy; Leukocyte Count; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Splenectomy; Survival Rate; Thrombocytopenia; Viral Load

2015
High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.
    Hepatology international, 2015, Volume: 9, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Postoperative Period; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Survival Rate

2015
Serum interferon-related microRNAs as biomarkers to predict the response to interferon therapy in chronic hepatitis C genotype 4.
    PloS one, 2015, Volume: 10, Issue:3

    Topics: Adult; Antiviral Agents; Biomarkers; Case-Control Studies; Female; Gene Expression Regulation; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Logistic Models; Male; MicroRNAs; Polyethylene Glycols; Precision Medicine; Prognosis; Recombinant Proteins; Ribavirin; ROC Curve; Treatment Outcome

2015
Fibrosing cholestatic hepatitis after successful interferon and ribavirin therapy for recurrent hepatitis C post living related liver transplantation: a case report.
    Osaka city medical journal, 2014, Volume: 60, Issue:2

    Topics: Adult; Allografts; Antiviral Agents; Biopsy; Cholestasis, Intrahepatic; Disease Progression; Drug Therapy, Combination; Fatal Outcome; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferons; Liver Cirrhosis; Liver Transplantation; Living Donors; Male; Recurrence; Ribavirin; Severity of Illness Index; Time Factors; Treatment Outcome

2014
Hepcidin/ferroportin expression levels involve efficacy of pegylated-interferon plus ribavirin in hepatitis C virus-infected liver.
    World journal of gastroenterology, 2015, Mar-21, Volume: 21, Issue:11

    Topics: Antiviral Agents; Blotting, Western; Cation Transport Proteins; Chromatography, Liquid; Drug Therapy, Combination; Female; Gene Expression Profiling; Gene Expression Regulation; Hepatitis C, Chronic; Hepcidins; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Retrospective Studies; Ribavirin; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Time Factors; Treatment Outcome

2015
Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.
    Journal of virology, 2015, Volume: 89, Issue:11

    Topics: Adult; Aged; Antiviral Agents; Base Sequence; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Oligopeptides; Phylogeny; Protease Inhibitors; Ribavirin; Sequence Alignment; Viral Nonstructural Proteins

2015
High-Dose Ribavirin Enhances Early Virological Response in Hepatitis C Genotype 1-Infected Patients.
    Therapeutic drug monitoring, 2015, Volume: 37, Issue:6

    Topics: Adult; Antiviral Agents; Chromatography, High Pressure Liquid; Cohort Studies; Coinfection; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Polyethylene Glycols; Retrospective Studies; Ribavirin; Treatment Outcome

2015
The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.
    Annals of internal medicine, 2015, May-05, Volume: 162, Issue:9

    Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Markov Chains; Monte Carlo Method; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; United States; Uridine Monophosphate

2015
Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir.
    Digestive diseases and sciences, 2015, Volume: 60, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Medication Adherence; Middle Aged; Oligopeptides; Proline; Retrospective Studies; Ribavirin; Treatment Outcome; Young Adult

2015
Hepatic progenitor cells in children with chronic hepatitis C: correlation with histopathology, viremia, and treatment response.
    European journal of gastroenterology & hepatology, 2015, Volume: 27, Issue:5

    Topics: Adolescent; Antiviral Agents; Cell Count; Child; Child, Preschool; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index; Stem Cells; Treatment Outcome; Viral Load

2015
Face skin hyperpigmentation during pegylated interferon and ribavirin therapy.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2015, Volume: 26, Issue:2

    Topics: Antiviral Agents; Biopsy; Drug Combinations; Drug Therapy, Combination; Face; Hepatitis C, Chronic; Humans; Hyperpigmentation; Injections, Subcutaneous; Interferon-alpha; Male; Melanocytes; Middle Aged; Ribavirin; Skin; Treatment Outcome

2015
[Severe bone marrow aplasia due to triple therapy for hepatitis C virus infection: Apropos of a case].
    Gastroenterologia y hepatologia, 2015, Volume: 38, Issue:9

    Topics: Anemia, Aplastic; Anti-Bacterial Agents; Antiviral Agents; Blood Component Transfusion; Drug Therapy, Combination; Filgrastim; Folic Acid; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prednisone; Ribavirin; Viremia; Vitamin B 12

2015
Sustained virologic response and other potential genotype-specific roles of statins among patients with hepatitis C-related chronic liver diseases.
    Clinics and research in hepatology and gastroenterology, 2015, Volume: 39, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-alpha; Male; Middle Aged; Military Medicine; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome; United States; Veterans

2015
Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan.
    Medicine, 2015, Volume: 94, Issue:13

    Topics: Adult; Aged; Antiviral Agents; Female; Health Knowledge, Attitudes, Practice; Health Services Accessibility; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Prevalence; Prospective Studies; Recombinant Proteins; Ribavirin; Taiwan

2015
Towards interferon-free treatment for all HCV genotypes.
    Lancet (London, England), 2015, Jun-20, Volume: 385, Issue:9986

    Topics: Anilides; Carbamates; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Macrocyclic Compounds; Male; Ribavirin; Ritonavir

2015
IFI35, mir-99a and HCV genotype to predict sustained virological response to pegylated-interferon plus ribavirin in chronic hepatitis C.
    PloS one, 2015, Volume: 10, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Gene Expression Regulation; Genome, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Intracellular Signaling Peptides and Proteins; Liver; Male; MicroRNAs; Middle Aged; Ribavirin; Young Adult

2015
Antiviral treatment discontinuation among hepatitis C-infected individuals with thrombocytopenia.
    Journal of viral hepatitis, 2015, Volume: 22, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Thrombocytopenia; Withholding Treatment

2015
Inherent transcriptional signatures of NK cells are associated with response to IFNα + rivabirin therapy in patients with Hepatitis C Virus.
    Journal of translational medicine, 2015, Mar-01, Volume: 13

    Topics: Cohort Studies; Gene Expression Profiling; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Killer Cells, Natural; Natural Cytotoxicity Triggering Receptor 3; NK Cell Lectin-Like Receptor Subfamily K; Polymorphism, Single Nucleotide; Reproducibility of Results; Ribavirin; Transcription, Genetic; Treatment Outcome

2015
Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
    World journal of gastroenterology, 2015, Apr-07, Volume: 21, Issue:13

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Pharmacogenetics; Phenotype; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Risk Factors; Time Factors; Treatment Outcome; Young Adult

2015
Interferon-λ-related genes and therapeutic response in Chinese hepatitis C patients.
    World journal of gastroenterology, 2015, Apr-07, Volume: 21, Issue:13

    Topics: Antiviral Agents; Area Under Curve; Asian People; Biomarkers; Chi-Square Distribution; China; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukin-10 Receptor beta Subunit; Interleukins; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myxovirus Resistance Proteins; Odds Ratio; Pharmacogenetics; Phenotype; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Receptors, Cytokine; Receptors, Interferon; Recombinant Proteins; Ribavirin; RNA, Viral; ROC Curve; Time Factors; Treatment Outcome; Viral Load

2015
Relationship between IL28B gene rs8099917 polymorphism and SVR in Turkish patients with hepatitis C virus genotype 1.
    Clinics and research in hepatology and gastroenterology, 2015, Volume: 39, Issue:6

    Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Retrospective Studies; Ribavirin; Turkey

2015
Dynamics of HCV genotype 4 resistance-associated variants during virologic escape with pIFN/RBV+daclatasvir: a case study using ultra deep pyrosequencing.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2015, Volume: 66

    Topics: Adolescent; Adult; Antiviral Agents; Carbamates; Drug Resistance, Viral; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Middle Aged; Pyrrolidines; Ribavirin; Treatment Failure; Valine; Viral Load; Viral Nonstructural Proteins

2015
CD24 Ala57Val polymorphism is associated with spontaneous viral clearance in the HCV-infected Chinese population.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:3

    Topics: Adult; Antiviral Agents; CD24 Antigen; China; Drug Combinations; Drug Monitoring; Female; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Immunity, Innate; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Therapeutics; Transcriptome

2015
Efficacy and safety of pegylated interferon base treatment in patients with chronic hepatitis C on dialysis.
    European journal of internal medicine, 2015, Volume: 26, Issue:4

    Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Male; Middle Aged; Neutropenia; Patient Dropouts; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Republic of Korea; Retrospective Studies; Ribavirin; Treatment Outcome

2015
Sofosbuvir and ribavirin before liver re-transplantation for graft failure due to recurrent hepatitis C: a case report.
    BMC gastroenterology, 2015, Mar-26, Volume: 15

    Topics: Antiviral Agents; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Preoperative Care; Recurrence; Reoperation; Ribavirin; Sofosbuvir

2015
Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study.
    BMC infectious diseases, 2015, Mar-26, Volume: 15

    Topics: Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Failure; Viral Load

2015
Efficacy and safety of pegylated interferon plus ribavirin for the treatment of hepatitis C virus-positive cryoglobulinemic glomerulonephritis.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2015, Volume: 47, Issue:7

    Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Glomerulonephritis, Membranoproliferative; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome

2015
Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy.
    Journal of medical economics, 2015, Volume: 18, Issue:9

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Italy; Markov Chains; Patient Acceptance of Health Care; Polyethylene Glycols; Quality-Adjusted Life Years; Ribavirin; Severity of Illness Index; Sofosbuvir

2015
Triple therapy using direct-acting agents for recurrent hepatitis C after liver transplantation: a single-center experience.
    Transplantation proceedings, 2015, Volume: 47, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Combined Modality Therapy; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Simeprevir; Treatment Outcome

2015
Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent.
    Journal of hepatology, 2015, Volume: 63, Issue:3

    Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Ribavirin; Sulfonamides; Treatment Failure

2015
Therapy: Retreatment of HCV infection in DAA nonresponders.
    Nature reviews. Gastroenterology & hepatology, 2015, Volume: 12, Issue:5

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Ribavirin; Uridine Monophosphate

2015
Reply to: "Evidence supporting a beneficial role of vitamin D in chronic hepatitis C".
    Journal of hepatology, 2015, Volume: 63, Issue:2

    Topics: Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Ribavirin; Vitamin D

2015
A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service.
    Journal of medical economics, 2015, Volume: 18, Issue:10

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Markov Chains; Middle Aged; Outcome Assessment, Health Care; Protease Inhibitors; Quality-Adjusted Life Years; Ribavirin; Simeprevir; State Medicine; United Kingdom

2015
Evidence supporting a beneficial role of vitamin D in chronic hepatitis C.
    Journal of hepatology, 2015, Volume: 63, Issue:2

    Topics: Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Ribavirin; Vitamin D

2015
Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2015, Volume: 13, Issue:10

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatitis C, Chronic; Humans; Hypertension, Portal; Interferon-alpha; Liver Failure; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Spain; Survival Analysis; Treatment Outcome; Viral Load

2015
A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin.
    Journal of medical virology, 2015, Volume: 87, Issue:10

    Topics: Adolescent; Adult; Age Factors; Aged; Antiviral Agents; Child; Cohort Studies; Coinfection; Drug Therapy, Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; London; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult

2015
Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy.
    PloS one, 2015, Volume: 10, Issue:4

    Topics: Adult; Coinfection; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Proline; Ribavirin; Treatment Outcome

2015
Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin.
    Journal of clinical microbiology, 2015, Volume: 53, Issue:7

    Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Inhibitory Concentration 50; Interferon-alpha; Male; Middle Aged; Mutation, Missense; Oligopeptides; Proline; Protease Inhibitors; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Nonstructural Proteins

2015
Evaluation of telaprevir-containing triple therapy in the treatment of chronic hepatitis C in hemodialysed patients.
    Infectious diseases (London, England), 2015, Volume: 47, Issue:9

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin

2015
Potential genetic markers for prediction of treatment response in Egyptian children infected with HCV genotype 4.
    Cytokine, 2015, Volume: 75, Issue:2

    Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Egypt; Female; Gene Frequency; Genetic Markers; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukin-10; Interleukins; Male; Polyethylene Glycols; Polymorphism, Single Nucleotide; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2015
Treatment outcome in chronic hepatitis C infection: a four years survey among Iranian patients.
    Global journal of health science, 2014, Nov-17, Volume: 7, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Iran; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2014
Aplastic anemia and severe pancytopenia during treatment with peg-interferon, ribavirin and telaprevir for chronic hepatitis C.
    World journal of gastroenterology, 2015, May-07, Volume: 21, Issue:17

    Topics: Aged; Anemia, Aplastic; Antiviral Agents; Biopsy; Bone Marrow Examination; Drug Therapy, Combination; Fatal Outcome; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Pancytopenia; Polyethylene Glycols; Ribavirin; Risk Factors; Severity of Illness Index; Treatment Outcome

2015
Mannose-binding lectin in chronic hepatitis C in children.
    Scandinavian journal of gastroenterology, 2015, Volume: 50, Issue:10

    Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Cohort Studies; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression Regulation, Viral; Genetic Markers; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Mannose-Binding Lectin; Metabolism, Inborn Errors; Phenotype; Polymerase Chain Reaction; Polymorphism, Genetic; Prognosis; Prospective Studies; Ribavirin; Severity of Illness Index; Treatment Outcome; United Kingdom

2015
The complete title: The effect of interleukin-28B rs12979860 polymorphism on the therapeutic response of Moroccan patients with chronic hepatitis C.
    Gene, 2015, Aug-15, Volume: 568, Issue:1

    Topics: Aged; Antiviral Agents; Female; Genetic Association Studies; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Middle Aged; Morocco; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome

2015
Mycophenolate mofetil may induce prolonged severe anemia during pegylated-interferon/ribavirin/simeprevir therapy in liver transplant recipients.
    Clinical journal of gastroenterology, 2015, Volume: 8, Issue:3

    Topics: Aged; Anemia; Antiviral Agents; Erythrocyte Transfusion; Female; Hepatitis C, Chronic; Humans; Immunocompromised Host; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Middle Aged; Mycophenolic Acid; Recurrence; Ribavirin; Simeprevir; Tacrolimus

2015
Vitamin D-related gene polymorphisms do not influence the outcome and serum vitamin D level in pegylated interferon/ribavirin therapy combined with protease inhibitor for patients with genotype 1b chronic hepatitis C.
    Journal of medical virology, 2015, Volume: 87, Issue:11

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Calcifediol; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polymorphism, Genetic; Protease Inhibitors; Ribavirin; Treatment Outcome; Young Adult

2015
Genotype-Associated Differential NKG2D Expression on CD56+CD3+ Lymphocytes Predicts Response to Pegylated-Interferon/Ribavirin Therapy in Chronic Hepatitis C.
    PloS one, 2015, Volume: 10, Issue:5

    Topics: Aged; Antiviral Agents; CD3 Complex; CD56 Antigen; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Lymphocytes; Male; Middle Aged; NK Cell Lectin-Like Receptor Subfamily K; Polymorphism, Single Nucleotide; Ribavirin; RNA, Messenger; Treatment Outcome

2015
Hepatitis C in Arkansas: updates on epidemiology, testing and treatment.
    The Journal of the Arkansas Medical Society, 2015, Volume: 111, Issue:12

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Arkansas; Cross-Sectional Studies; Drug Costs; Female; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Male; Middle Aged; Predictive Value of Tests; Ribavirin; Risk Factors; Sofosbuvir; Uridine Monophosphate; Young Adult

2015
Norepinephrine-enhancing antidepressant exposure associated with reduced antiviral effect of interferon alpha on hepatitis C.
    Psychopharmacology, 2016, Volume: 233, Issue:9

    Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antiviral Agents; Cohort Studies; Depressive Disorder, Major; Drug Interactions; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Norepinephrine; Prospective Studies; Ribavirin; Selective Serotonin Reuptake Inhibitors; Young Adult

2016
IP-10 Serum Level in Chronic Hepatitis C Virus Patients: Relation to Fibrosis and Response to Combined Interferon/Ribavirin Therapy.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2015, Volume: 35, Issue:8

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Chemokine CXCL10; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Prospective Studies; Ribavirin; ROC Curve; Treatment Outcome; Viral Load; Young Adult

2015
[Lead-in period and week 8 as predictive tools for response to boceprevir therapy: a retrospective study of Spanish real clinical practice].
    Gastroenterologia y hepatologia, 2015, Volume: 38, Issue:9

    Topics: Antiviral Agents; Clinical Decision-Making; Drug Monitoring; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Severity of Illness Index; Spain; Treatment Outcome; Viral Load; Viremia

2015
Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection.
    World journal of gastroenterology, 2015, May-14, Volume: 21, Issue:18

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Chi-Square Distribution; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Kidney Failure, Chronic; Logistic Models; Male; Middle Aged; Multivariate Analysis; Phenotype; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Retrospective Studies; Ribavirin; Risk Factors; Treatment Outcome; Viral Load; Young Adult

2015
Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population.
    Kidney & blood pressure research, 2015, Volume: 40, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Renal Dialysis; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome

2015
Does elevation of serum creatinine in patients with chronic hepatitis C under therapy of telaprevir mean renal impairment?
    Nephrology (Carlton, Vic.), 2015, Volume: 20, Issue:11

    Topics: Acute Kidney Injury; Adult; Aged; Antiviral Agents; Biomarkers; Creatinine; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Interferon-alpha; Japan; Kidney; Male; Middle Aged; Oligopeptides; Predictive Value of Tests; Prospective Studies; Ribavirin; Risk Factors; Time Factors; Treatment Outcome; Up-Regulation

2015
Daclatasvir, Simeprevir and Ribavirin as a Promising Interferon-Free Triple Regimen for HCV Recurrence after Liver Transplant.
    Digestion, 2015, Volume: 91, Issue:4

    Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppression Therapy; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Valine; Viral Load; Viremia

2015
Direct costs of first-generation protease inhibitors for the treatment of genotype 1 chronic hepatitis C viral infection.
    Journal of viral hepatitis, 2015, Volume: 22, Issue:12

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Ribavirin; Tertiary Care Centers; Treatment Outcome; Viral Load

2015
Hepatic apoptotic markers are not predictors for the virological response to interferon-based therapy in chronic hepatitis C patients.
    European journal of gastroenterology & hepatology, 2015, Volume: 27, Issue:9

    Topics: Adult; Antiviral Agents; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Turkey; Viral Load

2015
The accuracy and cost-effectiveness of hepatitis C core antigen assay in the monitoring of anti-viral therapy in patients with chronic hepatitis C genotype 4.
    Alimentary pharmacology & therapeutics, 2015, Volume: 42, Issue:3

    Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Polymerase Chain Reaction; Ribavirin

2015
Direct-Acting Antivirals Cure Innate Immunity in Chronic Hepatitis C.
    Gastroenterology, 2015, Volume: 149, Issue:1

    Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Killer Cells, Natural; Male; Ribavirin

2015
Psychiatric care during hepatitis C treatment: the changing role of psychiatrists in the era of direct-acting antivirals.
    The American journal of psychiatry, 2015, Volume: 172, Issue:6

    Topics: Antidepressive Agents; Antiviral Agents; Citalopram; Comorbidity; Cooperative Behavior; Delirium; Depressive Disorder; Dose-Response Relationship, Drug; Drug Substitution; Drug Therapy, Combination; Forecasting; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interdisciplinary Communication; Interferon alpha-2; Interferon-alpha; Male; Mianserin; Middle Aged; Mirtazapine; Physician's Role; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate

2015
Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis.
    Clinical therapeutics, 2015, Jul-01, Volume: 37, Issue:7

    Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Costs; Drug Therapy, Combination; Genotype; Greece; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Life Expectancy; Markov Chains; Models, Econometric; Polyethylene Glycols; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Sensitivity and Specificity

2015
The relationships between IFNL4 genotype, intrahepatic interferon-stimulated gene expression and interferon treatment response differs in HCV-1 compared with HCV-3.
    Alimentary pharmacology & therapeutics, 2015, Volume: 42, Issue:3

    Topics: Adult; Antiviral Agents; Female; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Genetic; Retrospective Studies; Ribavirin; Treatment Outcome

2015
Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:11

    Topics: Adult; Antiviral Agents; Biopsy; Disease Progression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Survival Rate; Treatment Outcome; Viral Load

2015
The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life.
    Alimentary pharmacology & therapeutics, 2015, Volume: 42, Issue:3

    Topics: Adult; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Mental Health; Middle Aged; Prospective Studies; Quality of Life; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Withholding Treatment

2015
Leg ulcer as a manifestation of eosinophilic vasculitis in a patient with hepatitis C virus infection, medicated with pegylated interferon/ribavirin.
    BMJ case reports, 2015, Jun-11, Volume: 2015

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Eosinophilia; Hepatitis C, Chronic; Humans; Interferon-alpha; Leg Ulcer; Male; Ribavirin; Vasculitis

2015
Role of HCV-RNA decay and IP-10 levels after 48 hours of standard HCV therapy as predictors of rapid virological response.
    Clinics and research in hepatology and gastroenterology, 2015, Volume: 39, Issue:6

    Topics: Antiviral Agents; Chemokine CXCL10; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Ribavirin; RNA Stability; RNA, Viral; Time Factors; Treatment Outcome

2015
Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2015, Volume: 68

    Topics: Adolescent; Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Hepatitis C, Chronic; Humans; Incidence; Male; Membrane Transport Proteins; Middle Aged; Oligopeptides; Proline; Prospective Studies; Protease Inhibitors; Pyrophosphatases; Ribavirin; Risk Assessment; Young Adult

2015
Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure.
    Journal of viral hepatitis, 2015, Volume: 22, Issue:12

    Topics: Aged; Antiviral Agents; Carrier Proteins; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Japan; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Simeprevir; Treatment Failure; Viral Nonstructural Proteins

2015
Ribavirin restores IFNα responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes.
    Gut, 2016, Volume: 65, Issue:4

    Topics: Antiviral Agents; Blotting, Western; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Epigenomics; Gene Expression; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Histone-Lysine N-Methyltransferase; Humans; Immunoprecipitation; Interferon-alpha; Real-Time Polymerase Chain Reaction; Ribavirin; RNA, Messenger; Transfection; Viral Load; Virus Replication

2016
Regional disparities in interferon therapy for chronic hepatitis C in Japan: a nationwide retrospective cohort study.
    BMC public health, 2015, Jun-19, Volume: 15

    Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Healthcare Disparities; Hepacivirus; Hepatitis C, Chronic; Humans; Immunotherapy; Interferon-alpha; Japan; Male; Middle Aged; Polyethylene Glycols; Retrospective Studies; Ribavirin; Viral Load

2015
Efficacy and safety of sofosbuvir-based triple therapy in hepatitis C genotype 4 infection.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2015, Volume: 47, Issue:9

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Tertiary Care Centers; Treatment Outcome; Viral Load

2015
Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection.
    Journal of gastroenterology and hepatology, 2015, Volume: 30, Issue:12

    Topics: Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Oligopeptides; Pharmacogenetics; Polyethylene Glycols; Propensity Score; Protease Inhibitors; Recombinant Proteins; Ribavirin; Simeprevir; Treatment Outcome

2015
Single-nucleotide polymorphism of Toll-like receptor 4 and interleukin-10 in response to interferon-based therapy in Egyptian chronic hepatitis C patients.
    Archives of virology, 2015, Volume: 160, Issue:9

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Gene Frequency; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukin-10; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Ribavirin; Toll-Like Receptor 4; Treatment Outcome; Young Adult

2015
Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort.
    Journal of viral hepatitis, 2015, Volume: 22, Issue:12

    Topics: Adult; Antiviral Agents; Australia; Canada; Coinfection; Drug Therapy, Combination; Female; Germany; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interleukins; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; United States; Viral Load

2015
Lower Ribavirin Plasma Concentrations in HCV/HIV-Coinfected Patients Than in HCV-Monoinfected Patients Despite Similar Dosage.
    Therapeutic drug monitoring, 2015, Volume: 37, Issue:6

    Topics: Adult; Antiviral Agents; Chromatography, High Pressure Liquid; Cohort Studies; Coinfection; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Polyethylene Glycols; Retrospective Studies; Ribavirin; Time Factors

2015
Optimum predictors of therapeutic outcome in HCV patients in Pakistan.
    Journal of medical virology, 2016, Volume: 88, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Pakistan; Prognosis; Ribavirin; Treatment Outcome

2016
Protease inhibitors-based therapy induces acquired spherocytic-like anaemia and ineffective erythropoiesis in chronic hepatitis C virus patients.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:1

    Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Erythrocyte Indices; Erythrocyte Membrane; Erythropoiesis; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polymorphism, Single Nucleotide; Proline; Protease Inhibitors; Pyrophosphatases; Ribavirin; Treatment Outcome

2016
Role of ITPA and IL28B variants in the management of chronic hepatitis C treatment.
    Le infezioni in medicina, 2015, Volume: 23, Issue:2

    Topics: Adolescent; Adult; Aged; Anemia; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-beta; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Predictive Value of Tests; Pyrophosphatases; Ribavirin; Sensitivity and Specificity; Treatment Outcome

2015
Disease burden of chronic hepatitis C among immigrants in Canada.
    Journal of viral hepatitis, 2015, Volume: 22, Issue:12

    Topics: Antiviral Agents; Canada; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Drug Therapy, Combination; Emigrants and Immigrants; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Neoplasms; Markov Chains; Models, Theoretical; Polyethylene Glycols; Quality-Adjusted Life Years; Retrospective Studies; Ribavirin

2015
PharmGKB summary: peginterferon-α pathway.
    Pharmacogenetics and genomics, 2015, Volume: 25, Issue:9

    Topics: Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome

2015
Costs and Resource Utilization Associated With Anemia and Rash in Chronic Hepatitis C Patients Treated With Direct-Acting Antiviral Agents in the United States.
    Clinical therapeutics, 2015, Volume: 37, Issue:8

    Topics: Adult; Aged; Anemia; Antiviral Agents; Databases, Factual; Drug Costs; Drug Eruptions; Drug Therapy, Combination; Female; Health Care Costs; Health Resources; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oligopeptides; Proline; Ribavirin; United States

2015
Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2015, Volume: 34, Issue:9

    Topics: Adult; Antiviral Agents; Cohort Studies; Coinfection; Drug Therapy, Combination; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk; Spain; Thrombocytopenia; Treatment Outcome; Viral Load

2015
Psychomotor retardation and vulnerability to interferon alpha induced major depressive disorder: Prospective study of a chronic hepatitis C cohort.
    Journal of psychosomatic research, 2015, Volume: 79, Issue:6

    Topics: Adult; Aged; Antidepressive Agents; Antiviral Agents; Depression; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Psychiatric Status Rating Scales; Psychomotor Performance; Ribavirin

2015
Belgian experience with triple therapy with boceprevir and telaprevir in genotype 1 infected patients who inject drugs.
    Journal of medical virology, 2016, Volume: 88, Issue:1

    Topics: Adult; Antiviral Agents; Belgium; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Proline; Prospective Studies; Retrospective Studies; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome

2016
Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin.
    Journal of hepatology, 2015, Volume: 63, Issue:3

    Topics: Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Lactams; Male; Polyethylene Glycols; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides

2015
Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection.
    Hepatology (Baltimore, Md.), 2015, Volume: 62, Issue:4

    Topics: Antiviral Agents; Case-Control Studies; Chemokines; Cytokines; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Time Factors

2015
Treating fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin: a matched analysis.
    Clinical transplantation, 2015, Volume: 29, Issue:9

    Topics: Adult; Aged; Antiviral Agents; Case-Control Studies; Cholestasis, Intrahepatic; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Survival; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Matched-Pair Analysis; Middle Aged; Postoperative Complications; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome

2015
Monocyte-derived dendritic cells in children with chronic hepatitis C: correlation with interferon and ribavirin therapy.
    European journal of gastroenterology & hepatology, 2015, Volume: 27, Issue:10

    Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Dendritic Cells; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Immunity, Cellular; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Polymerase Chain Reaction; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; T-Lymphocytes; Treatment Outcome

2015
Inosine triphosphatase allele frequency and association with ribavirin-induced anaemia in Brazilian patients receiving antiviral therapy for chronic hepatitis C.
    Memorias do Instituto Oswaldo Cruz, 2015, Volume: 110, Issue:5

    Topics: Anemia; Antiviral Agents; Brazil; Case-Control Studies; Female; Gene Frequency; Genotype; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin

2015
Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2015, Volume: 34, Issue:10

    Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Ribavirin; Spain; Treatment Outcome

2015
Single nucleotide polymorphisms near IL28B gene and response to treatment of chronic hepatitis C in hemodialysis patients.
    Renal failure, 2015, Volume: 37, Issue:7

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Renal Dialysis; Ribavirin; Viral Load

2015
Hepatitis C virus infection in patients with hemophilia in Korea: Is antiviral therapy effective and safe?
    Clinical and molecular hepatology, 2015, Volume: 21, Issue:2

    Topics: Antiviral Agents; Female; Hemophilia A; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin

2015
Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
    Digestive diseases (Basel, Switzerland), 2015, Volume: 33, Issue:4

    Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Protease Inhibitors; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine

2015
Sleep disturbances in hepatitis C patients undergoing treatment: minisleep questionnaire as a screening tool.
    Minerva gastroenterologica e dietologica, 2015, Volume: 61, Issue:3

    Topics: Antiviral Agents; Case-Control Studies; Cross-Sectional Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Sleep Wake Disorders; Surveys and Questionnaires

2015
Examining Hepatitis C Virus Treatment Preference Heterogeneity Using Segmentation Analysis: Treat Now or Defer?
    Journal of clinical gastroenterology, 2016, Volume: 50, Issue:3

    Topics: Aged; Antiviral Agents; Black or African American; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Patient Preference; Polyethylene Glycols; Proline; Ribavirin; Surveys and Questionnaires; White People

2016
Correlates of Initiation of Treatment for Chronic Hepatitis C Infection in United States Veterans, 2004-2009.
    PloS one, 2015, Volume: 10, Issue:7

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Ill-Housed Persons; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prevalence; Proportional Hazards Models; Recombinant Proteins; Ribavirin; Risk Factors; United States; United States Department of Veterans Affairs; Veterans

2015
Interleukin- 28B: a prognostic marker in interferon based therapy of chronic HCV patients of the Pakistan with variable treatment response.
    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2015, Volume: 123, Issue:9

    Topics: Adolescent; Adult; Biomarkers; Case-Control Studies; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Pakistan; Polymorphism, Single Nucleotide; Prognosis; Ribavirin; Treatment Outcome; Young Adult

2015
Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses.
    Alimentary pharmacology & therapeutics, 2015, Volume: 42, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Hypertension, Portal; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Portal Pressure; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Valine

2015
Severe liver injury associated with simeprevir plus pegylated interferon/ribavirin therapy in a patient with treatment-naïve genotype 1b hepatitis C virus: a case report.
    Clinical journal of gastroenterology, 2014, Volume: 7, Issue:5

    Topics: Aged; Antiviral Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Ribavirin; Severity of Illness Index; Simeprevir

2014
Genetic (KIR, HLA-C) and Some Clinical Parameters Influencing the Level of Liver Enzymes and Early Virologic Response in Patients with Chronic Hepatitis C.
    Archivum immunologiae et therapiae experimentalis, 2016, Volume: 64, Issue:1

    Topics: Adult; Biomarkers, Pharmacological; Female; Genetic Association Studies; Genetic Predisposition to Disease; Hepacivirus; Hepatitis C, Chronic; HLA-C Antigens; Humans; Immunity, Innate; Immunotherapy; Interferon-alpha; Killer Cells, Natural; Liver; Male; Middle Aged; Mutation; Polymorphism, Genetic; Receptors, KIR; Ribavirin

2016
The clinical significance of HCV core antigen detection during Telaprevir/Peg-Interferon/Ribavirin therapy in patients with HCV 1 genotype infection.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2015, Volume: 69

    Topics: Aged; Antigens, Viral; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Predictive Value of Tests; Prospective Studies; Ribavirin; RNA, Viral; ROC Curve; Sensitivity and Specificity; Viral Core Proteins

2015
Sofosbuvir-based therapy cures hepatitis C virus infection after prior treatment failures in a patient with concurrent lymphoma.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2015, Volume: 69

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Recurrence; Ribavirin; Sofosbuvir; Time Factors; Treatment Failure; Treatment Outcome

2015
Roles of ITPA and IL28B genotypes in chronic Hepatitis C patients treated with peginterferon plus ribavirin in Tunisian population.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2015, Volume: 69

    Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interleukins; Male; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Ribavirin; Treatment Outcome; Tunisia; Viral Load

2015
Treatment rate and factors related to interferon-based treatment initiation for chronic hepatitis C in South Korea.
    Journal of medical virology, 2016, Volume: 88, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hospitals, University; Humans; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Republic of Korea; Ribavirin; Young Adult

2016
[Evaluation of tolerance and efficacy of the treatment of chronic viral hepatitis C in homozygous sickle cell patients].
    The Pan African medical journal, 2015, Volume: 20

    Topics: Adult; Anemia, Sickle Cell; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Ribavirin; Treatment Outcome

2015
Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin.
    The American journal of gastroenterology, 2015, Volume: 110, Issue:8

    Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Contraindications; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Hyperbilirubinemia; Intention to Treat Analysis; Interferons; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Sepsis; Simeprevir; Sofosbuvir; Sulfonamides; Time Factors; Uridine Monophosphate

2015
The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients.
    Journal of viral hepatitis, 2015, Volume: 22, Issue:12

    Topics: Algorithms; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Models, Theoretical; Oligopeptides; Polyethylene Glycols; Proline; Random Allocation; Ribavirin; Treatment Outcome; Viral Load

2015
Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study.
    PloS one, 2015, Volume: 10, Issue:7

    Topics: Adult; Antiviral Agents; Coinfection; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome

2015
Sustained Virologic Response to a Dual Peginterferon alfa-2a and Ribavirin in Treating Chronic hepatitis C Infection: A Retrospective Cohort Study.
    Medicine, 2015, Volume: 94, Issue:30

    Topics: Adult; Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2015
Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany--an application of the efficiency frontier approach.
    BMC infectious diseases, 2015, Jul-30, Volume: 15

    Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Costs; Drug Therapy, Combination; Female; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Proline; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome

2015
Association between risk factors, basal viral load, virus genotype and the degree of liver fibrosis with the response to the therapy in patients with chronic hepatitis C virus infection.
    Vojnosanitetski pregled, 2015, Volume: 72, Issue:6

    Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome; Viral Load

2015
Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-Pacific hepatitis C virus genotype 1 non-responders/relapsers.
    World journal of gastroenterology, 2015, Jul-28, Volume: 21, Issue:28

    Topics: Antiviral Agents; Asia; Asian People; Australia; Biomarkers; Chi-Square Distribution; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Proline; Proportional Hazards Models; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Failure; Viral Load; White People

2015
Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study.
    PloS one, 2015, Volume: 10, Issue:7

    Topics: Adult; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2015
Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.
    BMC gastroenterology, 2015, Aug-05, Volume: 15

    Topics: Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Macrocyclic Compounds; Male; Markov Chains; Middle Aged; Polyethylene Glycols; Quality-Adjusted Life Years; Ribavirin; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate

2015
Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort.
    BMC gastroenterology, 2015, Aug-04, Volume: 15

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retreatment; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load; Young Adult

2015
Effects of Viral Eradication With Ledipasvir and Sofosbuvir, With or Without Ribavirin, on Measures of Fatigue in Patients With Chronic Hepatitis C Virus Infection.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2016, Volume: 14, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Biomarkers; Blood Chemical Analysis; Cytokines; Enzyme-Linked Immunosorbent Assay; Fatigue; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome

2016
Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing.
    Journal of gastroenterology, 2016, Volume: 51, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Mutation; Polyethylene Glycols; Polymorphism, Genetic; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Simeprevir; Treatment Outcome; Viral Nonstructural Proteins; Young Adult

2016
Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies.
    Alimentary pharmacology & therapeutics, 2015, Volume: 42, Issue:7

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Ultrasonography; Uridine Monophosphate; Valine

2015
Prednisolone does not affect direct-acting antivirals against hepatitis C, but inhibits interferon-alpha production by plasmacytoid dendritic cells.
    Transplant infectious disease : an official journal of the Transplantation Society, 2015, Volume: 17, Issue:5

    Topics: Antiviral Agents; Biomarkers; Carbamates; Cell Line, Tumor; Dendritic Cells; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Interferon-alpha; Isoquinolines; Liver Transplantation; Prednisolone; Pyrrolidines; Ribavirin; Sulfonamides; Valine

2015
A Taiwanese Nationwide Cohort Study Shows Interferon-Based Therapy for Chronic Hepatitis C Reduces the Risk of Chronic Kidney Disease.
    Medicine, 2015, Volume: 94, Issue:32

    Topics: Adult; Antiviral Agents; Cohort Studies; Comorbidity; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Male; Middle Aged; Renal Insufficiency, Chronic; Ribavirin; Risk Factors; Taiwan

2015
HCV Infection and Interferon-Based Treatment Induce p53 Gene Transcription in Chronic Hepatitis C Patients.
    Viral immunology, 2015, Volume: 28, Issue:8

    Topics: Adult; Antiviral Agents; Female; Gene Expression Profiling; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Real-Time Polymerase Chain Reaction; Ribavirin; Transcription, Genetic; Tumor Suppressor Protein p53; Young Adult

2015
Prevalence and detection of neuropsychiatric adverse effects during hepatitis C treatment.
    International journal of clinical pharmacy, 2015, Volume: 37, Issue:6

    Topics: Adult; Age Factors; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Health Status; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Medication Adherence; Mental Disorders; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Severity of Illness Index; Sex Factors

2015
Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients.
    World journal of gastroenterology, 2015, Aug-07, Volume: 21, Issue:29

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Iran; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Pharmacogenetics; Phenotype; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2015
T-cell homeostasis in chronic HCV-infected patients treated with interferon and ribavirin or an interferon-free regimen.
    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2015, Volume: 123, Issue:10

    Topics: Adult; Aged; Amides; Antiviral Agents; Apoptosis; Benzofurans; Carbamates; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Interleukin-7 Receptor alpha Subunit; Lipopolysaccharides; Lymphocyte Count; Lymphopenia; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Quinoxalines; Recombinant Proteins; Ribavirin; Sulfonamides

2015
Polymorphisms at IL28B gene as predictors of viral relapse in genotype 4 Egyptian hepatitis C patients.
    Journal of medical virology, 2016, Volume: 88, Issue:3

    Topics: Adult; Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Young Adult

2016
Durability of Response in Children Treated With Pegylated Interferon alfa [corrected] 2a ± Ribavirin for Chronic Hepatitis C.
    Journal of pediatric gastroenterology and nutrition, 2016, Volume: 62, Issue:1

    Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viremia

2016
Personality disorders do not affect treatment outcomes for chronic HCV infection in Spanish prisoners: the Perseo study.
    BMC infectious diseases, 2015, Aug-19, Volume: 15

    Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Odds Ratio; Personality Disorders; Polyethylene Glycols; Prisoners; Prisons; Prospective Studies; Recombinant Proteins; Ribavirin; Spain; Treatment Outcome; Young Adult

2015
Modeling population heterogeneity in viral dynamics for chronic hepatitis C infection: Insights from Phase 3 telaprevir clinical studies.
    Journal of pharmacokinetics and pharmacodynamics, 2015, Volume: 42, Issue:6

    Topics: Antiviral Agents; Biomarkers; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Monitoring; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Models, Biological; Models, Statistical; Nonlinear Dynamics; Oligopeptides; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2015
Effectiveness of extending treatment duration in therapy with pegylated interferon and ribavirin for genotype 2 hepatitis C virus infection.
    Acta medica Okayama, 2015, Volume: 69, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome

2015
Hepatitis C virus post-exposure prophylaxis: A reasonable option in the era of pangenotypic direct-acting antivirals?
    Journal of hepatology, 2015, Volume: 63, Issue:5

    Topics: Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Ribavirin; Sofosbuvir

2015
The impact of ribavirin plasma concentration on the efficacy of the interferon-sparing regimen, sofosbuvir and ribavirin.
    Antiviral therapy, 2016, Volume: 21, Issue:2

    Topics: Antiviral Agents; Drug Inverse Agonism; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir

2016
Favourable SVR12 rates with boceprevir or telaprevir triple therapy in HIV/HCV coinfected patients.
    The Netherlands journal of medicine, 2015, Volume: 73, Issue:7

    Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Sustained Virologic Response

2015
The Usefulness of Defining Rapid Virological Response by a Very Sensitive Assay (TMA) during Treatment of HCV Genotype 2/3 Infection.
    PloS one, 2015, Volume: 10, Issue:8

    Topics: Adult; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recurrence; Ribavirin; RNA, Viral; Sensitivity and Specificity; Treatment Outcome; Young Adult

2015
[Cost-effectiveness and safety of telaprevir and boceprevir for chronic hepatitis C in real-world clinical practice].
    Gastroenterologia y hepatologia, 2015, Volume: 38, Issue:10

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Emergency Service, Hospital; Female; Hematologic Diseases; Hepatitis C, Chronic; Hospitalization; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Remission Induction; Retrospective Studies; Ribavirin; Spain

2015
An Hepatitis C Virus (HCV)/HIV Co-Infected Patient who Developed Severe Hepatitis during Chronic HCV Infection: Sustained Viral Response with Simeprevir Plus Peginterferon-Alpha and Ribavirin.
    Internal medicine (Tokyo, Japan), 2015, Volume: 54, Issue:17

    Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index; Simeprevir; Treatment Outcome

2015
Combined Effects of 2 Interleukin 28B Polymorphisms on the Therapeutic Outcome of Hepatitis C Patients With Circulating Cryoglobulins.
    Medicine, 2015, Volume: 94, Issue:35

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; Case-Control Studies; Cryoglobulins; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Pharmacogenetics; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Outcome

2015
Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2016, Volume: 22, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Hepatitis Viruses; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Texas; Time Factors; Treatment Outcome

2016
Interferon-free treatments against HCV are far from free.
    Lancet (London, England), 2015, Aug-29, Volume: 386, Issue:9996

    Topics: Anilides; Carbamates; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Macrocyclic Compounds; Male; Ribavirin; Ritonavir

2015
Association between CXCL10 and DPP4 Gene Polymorphisms and a Complementary Role for Unfavorable IL28B Genotype in Prediction of Treatment Response in Thai Patients with Chronic Hepatitis C Virus Infection.
    PloS one, 2015, Volume: 10, Issue:9

    Topics: Adult; Antiviral Agents; Chemokine CXCL10; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Female; Gene Expression Regulation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prognosis; Recombinant Proteins; Ribavirin; Signal Transduction; Thailand; Treatment Outcome

2015
Successful treatment of chronic hepatitis C with triple therapy in an opioid agonist treatment program.
    The International journal on drug policy, 2015, Volume: 26, Issue:10

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Opiate Substitution Treatment; Polyethylene Glycols; Proline; Recombinant Proteins; Retrospective Studies; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome

2015
Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin.
    Journal of hepatology, 2016, Volume: 64, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Cholesterol; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Recurrence; Ribavirin; Sofosbuvir

2016
Pharmacokinetics in hepatic impairment: Mind the protein binding.
    Journal of hepatology, 2015, Volume: 63, Issue:6

    Topics: Anilides; Carbamates; Female; Hepatic Insufficiency; Hepatitis C, Chronic; Humans; Macrocyclic Compounds; Male; Ribavirin; Ritonavir; Sulfonamides; Uracil

2015
Predicting Liver-Related Events Using Transient Elastography in Chronic Hepatitis C Patients with Sustained Virological Response.
    Gut and liver, 2016, 05-23, Volume: 10, Issue:3

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Pregnancy; Recombinant Proteins; Ribavirin; Risk Factors

2016
Reply to "Pharmacokinetics in hepatic impairment: Mind the protein binding".
    Journal of hepatology, 2015, Volume: 63, Issue:6

    Topics: Anilides; Carbamates; Female; Hepatic Insufficiency; Hepatitis C, Chronic; Humans; Macrocyclic Compounds; Male; Ribavirin; Ritonavir; Sulfonamides; Uracil

2015
Thyroid dysfunction in Chinese hepatitis C patients: Prevalence and correlation with TPOAb and CXCL10.
    World journal of gastroenterology, 2015, Sep-07, Volume: 21, Issue:33

    Topics: Adult; Antiviral Agents; Asian People; Autoantibodies; Autoantigens; Biomarkers; Chemokine CXCL10; China; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Iodide Peroxidase; Iron-Binding Proteins; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Sex Factors; Thyroid Diseases; Thyroid Gland; Time Factors; Treatment Outcome

2015
Longitudinal analysis of peripheral and intrahepatic NK cells in chronic HCV patients during antiviral therapy.
    Antiviral research, 2015, Volume: 123

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Blood; Flow Cytometry; Hepatitis C, Chronic; Humans; Immunophenotyping; Interferon-alpha; Killer Cells, Natural; Liver; Longitudinal Studies; Middle Aged; Oligopeptides; Ribavirin; Young Adult

2015
Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency.
    Infectious diseases (London, England), 2015, Volume: 47, Issue:12

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Failure, Chronic; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Viral Load

2015
Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients.
    PloS one, 2015, Volume: 10, Issue:9

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Medical Futility; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Taiwan; Treatment Outcome

2015
Antihepatitis C virus treatments for HIV-hepatitis C virus coinfected cirrhotic patients: a need to look beyond the sustained viral response.
    AIDS (London, England), 2015, Sep-10, Volume: 29, Issue:14

    Topics: Antiviral Agents; Coinfection; Fatal Outcome; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Viral Load

2015
Ribavirin concentration determines treatment success of first-generation DAA-based chronic HCV therapy.
    Antiviral therapy, 2016, Volume: 21, Issue:2

    Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Ribavirin

2016
Changes of shear-wave velocity by interferon-based therapy in chronic hepatitis C.
    World journal of gastroenterology, 2015, Sep-21, Volume: 21, Issue:35

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome

2015
Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis: A Multicenter Cohort Study.
    Medicine, 2015, Volume: 94, Issue:38

    Topics: Antiviral Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Carriers; Drug Monitoring; Drug Substitution; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Oligopeptides; Patient Acuity; Poland; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2015
Hepatitis C Virus Deletion Mutants Are Found in Individuals Chronically Infected with Genotype 1 Hepatitis C Virus in Association with Age, High Viral Load and Liver Inflammatory Activity.
    PloS one, 2015, Volume: 10, Issue:9

    Topics: Adult; Age Factors; Aged; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Recurrence; Ribavirin; Sequence Deletion; Viral Envelope Proteins; Viral Load; Viral Proteins

2015
Safety and Efficacy of Combined Treatment with Pegylated Interferon Alpha-2b and Ribavirin for HCV Genotype 4 in Children.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2016, Volume: 36, Issue:1

    Topics: Adolescent; Antiviral Agents; Body Height; Body Weight; Child; Child, Preschool; Drug Administration Schedule; Drug Therapy, Combination; Female; Fever; gamma-Glutamyltransferase; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Male; Neutropenia; Neutrophils; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Surveys and Questionnaires; Treatment Outcome; Viral Load

2016
Costs and outcomes of treating chronic hepatitis C patients in routine care - results from a nationwide multicenter trial.
    Journal of viral hepatitis, 2016, Volume: 23, Issue:2

    Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Germany; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Quality of Life; Recombinant Proteins; Ribavirin; Treatment Outcome

2016
[Kinetics of Virus Load HCV-RNA in Blood Serum and Peripheral Mononuclear Cells in a Patient with Hepatocirrhosis and Chronic Virus Hepatitis C Termination Treated According to Noninterferon Treatment Scheme (Cycloferon + Ribavirin)].
    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2015, Volume: 60, Issue:3-4

    Topics: Acridines; Antiviral Agents; Contraindications; Drug Substitution; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Inducers; Interferon-alpha; Interferons; Interleukins; Leukocytes, Mononuclear; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Remission Induction; Ribavirin; Viral Load

2015
Therapy with direct-acting antivirals for genotype 3 patients: interferon's last gasp?
    Gastroenterology, 2015, Volume: 149, Issue:6

    Topics: Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Ribavirin; RNA, Viral; Sofosbuvir

2015
Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:12

    Topics: Adult; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Raltegravir Potassium; Recombinant Proteins; Ribavirin; Sulfonamides; Valine

2015
Interferon-α plus ribavirin yields 98 % sustained virologic response in children aged 1-5 years with iatrogenic chronic hepatitis C.
    Hepatology international, 2015, Volume: 9, Issue:4

    Topics: Adolescent; Antiviral Agents; Biopsy; Child; Child, Preschool; China; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Iatrogenic Disease; Incidence; Infant; Interferon-alpha; Liver; Male; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome

2015
Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study.
    Addiction (Abingdon, England), 2016, Volume: 111, Issue:2

    Topics: Adult; Aged; Ambulatory Care; Antiviral Agents; Community Health Centers; Delivery of Health Care; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Medication Adherence; Middle Aged; New South Wales; Opiate Substitution Treatment; Opioid-Related Disorders; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Substance Abuse Treatment Centers; Substance Abuse, Intravenous; Treatment Outcome

2016
[Effectiveness and safety of antiviral therapy of military personnel suffering from chronic hepatitis C].
    Voenno-meditsinskii zhurnal, 2015, Volume: 336, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Military Medicine; Military Personnel; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2015
Indirect comparison of the antiviral efficacy of peginterferon alpha 2a plus ribavirin used with or without simeprevir in genotype 4 hepatitis C virus infection, where common comparator study arms are lacking: a special application of the matching adjuste
    Current medical research and opinion, 2016, Volume: 32, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir

2016
Effectiveness of first-generation HCV protease inhibitors: does HIV coinfection still play a role?
    European journal of gastroenterology & hepatology, 2016, Volume: 28, Issue:1

    Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Protease Inhibitors; Ribavirin; RNA, Viral; Viral Load

2016
Efficacy and safety of telaprevir, pegylated interferon α-2b and ribavirin triple therapy in Japanese patients infected with hepatitis C virus genotype 1b.
    Internal medicine (Tokyo, Japan), 2015, Volume: 54, Issue:20

    Topics: Adult; Aged; Antiviral Agents; Asian People; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Oligopeptides; Patient Safety; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2015
Task-Shifting: An Approach to Decentralized Hepatitis C Treatment in Medically Underserved Areas.
    Digestive diseases and sciences, 2015, Volume: 60, Issue:12

    Topics: Aged; Aged, 80 and over; Antiviral Agents; California; Female; Health Services Accessibility; Hepatitis C, Chronic; Humans; Male; Medically Underserved Area; Middle Aged; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir

2015
Association of IL28B Genotypes and Baseline Serum Interferon-γ-Inducible- Protein-10 Levels with Treatment Response in Hepatitis C Virus Patients in China.
    Gut and liver, 2016, May-23, Volume: 10, Issue:3

    Topics: Antiviral Agents; Chemokine CXCL10; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; ROC Curve; Treatment Outcome

2016
Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents.
    Hepatology (Baltimore, Md.), 2016, Volume: 63, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Cryoglobulinemia; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir

2016
[HCV Genotype Distribution in Southwest China and Its Influence on Patients' Response to Pegylated-interferon α-2a Plus Ribavirin Therapy].
    Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2015, Volume: 46, Issue:4

    Topics: Antiviral Agents; China; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2015
Successful Hepatitis C Antiviral Therapy Induces Remission of Type 2 Diabetes: A Case Report.
    The American journal of case reports, 2015, Oct-20, Volume: 16

    Topics: Antiviral Agents; Diabetes Mellitus, Type 2; Hepatitis C, Chronic; Humans; Male; Middle Aged; Remission Induction; Ribavirin

2015
Successful treatment of hepatitis C virus infection with sofosbuvir and simeprevir in the early phase of an allogeneic stem cell transplant.
    Transplant infectious disease : an official journal of the Transplantation Society, 2016, Volume: 18, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Middle Aged; Ribavirin; Simeprevir; Sofosbuvir; Stem Cell Transplantation; Transplant Recipients; Transplantation, Homologous; Viral Load; Virus Replication

2016
ROLE OF T REGULATORY CELLS IN CHRONIC HCV INFECTED EGYPTIAN PATIENTS AND THEIR IMPACT ON THE RESPONSE TO PEGYLATED INTERFERON THERAPY.
    Journal of the Egyptian Society of Parasitology, 2015, Volume: 45, Issue:2

    Topics: Antiviral Agents; Forkhead Transcription Factors; Gene Expression Regulation; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Polyethylene Glycols; Recombinant Proteins; Ribavirin; T-Lymphocytes, Regulatory

2015
Early Viral Response Predicts the Efficacy of Antiviral Triple Therapy with Simeprevir, Peg-Interferon and Ribavirin in Patients Infected with Hepatitis C Virus Genotype 1.
    Digestive diseases (Basel, Switzerland), 2015, Volume: 33, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Simeprevir; Treatment Outcome; Viral Load

2015
Low-density lipoprotein receptor genetic polymorphism in chronic hepatitis C virus Egyptian patients affects treatment response.
    World journal of gastroenterology, 2015, Oct-21, Volume: 21, Issue:39

    Topics: Adult; Antiviral Agents; Case-Control Studies; Disease Progression; Drug Therapy, Combination; Egypt; Exons; Female; Gene Frequency; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pharmacogenetics; Phenotype; Polyethylene Glycols; Polymorphism, Genetic; Receptors, LDL; Recombinant Proteins; Remission Induction; Ribavirin; Treatment Outcome

2015
Short Communication: CXCL12 rs1029153 Polymorphism Is Associated with the Sustained Virological Response in HIV/Hepatitis C Virus-Coinfected Patients on Hepatitis C Virus Therapy.
    AIDS research and human retroviruses, 2016, Volume: 32, Issue:3

    Topics: Adult; Antiviral Agents; Chemokine CXCL12; Coinfection; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polymorphism, Single Nucleotide; Retrospective Studies; Ribavirin; Treatment Outcome

2016
Reply to Merli et al.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, Feb-15, Volume: 62, Issue:4

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Lymphopenia; Ribavirin

2016
Marked Decrease in Lymphocyte Count in HIV/Hepatitis C Virus (HCV)-Coinfected Patients With Advanced Liver Disease During Anti-HCV Treatment With Direct-Acting Antiviral Regimens Including Ribavirin.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, Feb-15, Volume: 62, Issue:4

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Lymphopenia; Ribavirin

2016
Reduced healthcare utilization following successful hepatitis C virus treatment in HIV-co-infected patients with mild liver disease.
    Journal of viral hepatitis, 2016, Volume: 23, Issue:2

    Topics: Adult; Antiviral Agents; Cohort Studies; Coinfection; Delivery of Health Care; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Liver Diseases; Male; Middle Aged; Patient Acceptance of Health Care; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Viral Load

2016
Renal impairment in patients with chronic hepatitis C treated with first generation protease inhibitors.
    Expert opinion on drug safety, 2015, Volume: 14, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Renal Insufficiency; Retrospective Studies; Ribavirin; Risk Factors; Time Factors; Young Adult

2015
Comparison of three quantitative HCV RNA assays in samples from HCV genotype 1- or 4-infected patients treated with the NS3/4A protease inhibitor simeprevir.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2015, Volume: 72

    Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Monitoring; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Protease Inhibitors; Retrospective Studies; Ribavirin; RNA, Viral; Simeprevir; Viral Load

2015
[Hope for Cirrhosis Patients with Genotype 1 Hepatitis C Virus Who Failed the Previous Treatment].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2015, Volume: 66, Issue:2

    Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Ribavirin; Uridine Monophosphate

2015
Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naïve Patients in Chile.
    PloS one, 2015, Volume: 10, Issue:11

    Topics: Antiviral Agents; Carbamates; Chile; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Polyethylene Glycols; Probability; Protease Inhibitors; Pyrrolidines; Quality of Life; Recombinant Proteins; Ribavirin; Sulfonamides; Valine

2015
Incidence of and risk factors for thyroid dysfunction during peginterferon α and ribavirin treatment in patients with chronic hepatitis C.
    The Korean journal of internal medicine, 2015, Volume: 30, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Autoantibodies; Biomarkers; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Republic of Korea; Retrospective Studies; Ribavirin; Thyroid Diseases; Thyroid Gland; Time Factors; Treatment Outcome

2015
Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma.
    Oncology, 2015, Volume: 89 Suppl 2

    Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Japan; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oligopeptides; Polyethylene Glycols; Polymerase Chain Reaction; Prognosis; Pyrrolidines; Recombinant Proteins; Ribavirin; RNA, Viral; Simeprevir; Sulfonamides; Valine; Viral Load

2015
Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus.
    Gut and liver, 2016, Jul-16, Volume: 10, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; ROC Curve; Treatment Outcome

2016
Glucose abnormalities in Asian patients with chronic hepatitis C.
    Drug design, development and therapy, 2015, Volume: 9

    Topics: Adult; Age Factors; Antiviral Agents; Asian People; Blood Glucose; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclosporine; Diabetes Mellitus, Type 2; Female; Hepatitis C, Chronic; Humans; Interferons; Logistic Models; Male; Middle Aged; Randomized Controlled Trials as Topic; Retrospective Studies; Ribavirin; Risk Factors; Sex Factors; Treatment Outcome

2015
Genetic predictors of the response to the treatment of hepatitis C virus infection.
    Bosnian journal of basic medical sciences, 2015, Nov-12, Volume: 15, Issue:4

    Topics: Adult; Antiviral Agents; Female; Genome-Wide Association Study; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Predictive Value of Tests; Ribavirin; Treatment Outcome; Viremia

2015
Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:5

    Topics: Aged; Antiviral Agents; Benzimidazoles; Comorbidity; Databases, Factual; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; United States

2016
Ribavirin Desensitization in Chronic Hepatitis C.
    The Israel Medical Association journal : IMAJ, 2015, Volume: 17, Issue:9

    Topics: Adult; Antiviral Agents; Desensitization, Immunologic; Drug Hypersensitivity; Female; Hepatitis C, Chronic; Humans; Ribavirin

2015
Hepatitis C treatment at three Norwegian hospitals 2000-2011.
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2015, Dec-01, Volume: 135, Issue:22

    Topics: Adult; Age Factors; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hospitals; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Norway; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Sex Factors; Substance Abuse, Intravenous; Treatment Outcome; Viral Load

2015
A novel polymorphism near HLA class II region is associated with spontaneous clearance of HCV and response to interferon treatment in Chinese patients.
    Journal of human genetics, 2016, Volume: 61, Issue:4

    Topics: Aged; Asian People; Biomarkers, Pharmacological; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HLA Antigens; Humans; Interferon-alpha; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome; Viral Load

2016
[Change in Serum Levels of New Hepatic Fibrosis Marker "Mac-2 Binding Protein Glycosylation isomer (M2BPGi)" in Patients with Chronic Hepatitis C during the Treatment of Pegylated Interferon and Ribavirin].
    Rinsho byori. The Japanese journal of clinical pathology, 2015, Volume: 63, Issue:8

    Topics: Adult; Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Galectin 3; Glycosylation; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Protein Binding; Ribavirin

2015
Paritaprevir/ritonavir/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection.
    Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:18

    Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Coinfection; Cyclopropanes; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine

2015
Intraocular pressure rise in the course of peginterferon alpha-2a, ribavirin, and boceprevir therapy for hepatitis C.
    Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 2015, Volume: 50, Issue:6

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Glaucoma, Open-Angle; Gonioscopy; Hepatitis C, Chronic; Humans; Interferon-alpha; Intraocular Pressure; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Tonometry, Ocular; Viral Load; Visual Fields

2015
Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment.
    Journal of hepatology, 2016, Volume: 64, Issue:4

    Topics: Acidosis, Lactic; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir

2016
Interleukin-2 receptor antagonist immunosuppression and consecutive viral management in living-donor liver transplantation for human immunodeficiency virus/hepatitis C-co-infected patients: a report of 2 cases.
    Clinical journal of gastroenterology, 2016, Volume: 9, Issue:1

    Topics: Antiviral Agents; Coinfection; Combined Modality Therapy; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Receptors, Interleukin-2; Recombinant Proteins; Ribavirin

2016
High post-treatment absolute monocyte count predicted hepatocellular carcinoma risk in HCV patients who failed peginterferon/ribavirin therapy.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:6

    Topics: Antiviral Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Monocytes; Neoplasm Staging; Polyethylene Glycols; Prognosis; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Time Factors

2016
Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.
    PharmacoEconomics, 2016, Volume: 34, Issue:4

    Topics: Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Interferon-alpha; Markov Chains; Models, Statistical; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Sofosbuvir; South Africa; Uridine Monophosphate

2016
Impact of Telaprevir in HCV Patients with Cirrhosis and RVR: Real-Life Data from Boceprevir or Telaprevir based "Triple Therapy" Experience in Southern Italy.
    Reviews on recent clinical trials, 2016, Volume: 11, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Italy; Liver Cirrhosis; Oligopeptides; Retrospective Studies; Ribavirin; Treatment Outcome

2016
Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy.
    Virology journal, 2015, Dec-18, Volume: 12

    Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; Blood; China; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Selection, Genetic; Treatment Outcome; Viral Core Proteins; Viral Load; Young Adult

2015
A local experience of treatment response in chronic hepatitis C infection.
    Le infezioni in medicina, 2015, Volume: 23, Issue:4

    Topics: Adult; Antiviral Agents; Body Mass Index; Developing Countries; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Hospitals, University; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Risk Factors; Treatment Outcome; Viral Load

2015
Do ITPA gene variants provide insight to detecting patients infected with HCV 2/1 recombinant strains?
    Hepatology (Baltimore, Md.), 2016, Volume: 64, Issue:1

    Topics: Antiviral Agents; Genotype; Hepatitis C, Chronic; Humans; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin

2016
Naturally occurring resistance mutations within the core and NS5B regions in hepatitis C genotypes, particularly genotype 5a, in South Africa.
    Antiviral research, 2016, Volume: 127

    Topics: Antiviral Agents; Base Sequence; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Drug Resistance, Viral; Drug Therapy, Combination; Epitopes, T-Lymphocyte; Female; Gene Frequency; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HLA Antigens; Humans; Interferons; Male; Middle Aged; Molecular Sequence Data; Mutation; Ribavirin; RNA, Viral; Sequence Analysis, Protein; South Africa; Viral Core Proteins; Viral Nonstructural Proteins

2016
Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older.
    Hepatology (Baltimore, Md.), 2016, Volume: 63, Issue:4

    Topics: Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Clinical Trials, Phase III as Topic; Cohort Studies; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Patient Safety; Randomized Controlled Trials as Topic; Retrospective Studies; Ribavirin; Risk Assessment; Sex Factors; Sofosbuvir; Treatment Outcome

2016
Protease inhibitors partially overcome the interferon nonresponse phenotype in patients with chronic hepatitis C.
    Journal of viral hepatitis, 2016, Volume: 23, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Biopsy; Female; Gene Expression Profiling; Hepatitis C, Chronic; Hepatocytes; Humans; Interferon-alpha; Liver; Macrophages; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Ribavirin; Staining and Labeling

2016
Glucocorticoid Receptors, Brain-Derived Neurotrophic Factor, Serotonin and Dopamine Neurotransmission are Associated with Interferon-Induced Depression.
    The international journal of neuropsychopharmacology, 2016, Volume: 19, Issue:4

    Topics: Adult; Antiviral Agents; Brain-Derived Neurotrophic Factor; Catechol O-Methyltransferase; Depression; Female; Genetic Predisposition to Disease; Hepatitis C, Chronic; Humans; Incidence; Indoleamine-Pyrrole 2,3,-Dioxygenase; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Receptor, Serotonin, 5-HT1A; Receptors, Glucocorticoid; Ribavirin; Tacrolimus Binding Proteins; Treatment Outcome; White People

2016
Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.
    Antiviral research, 2016, Volume: 126

    Topics: Adenosine; Antiviral Agents; Cell Line; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Mutation; Oligopeptides; Protease Inhibitors; Replicon; Ribavirin; RNA, Viral; Sofosbuvir; Viral Nonstructural Proteins; Virus Replication

2016
Association of vitamin D receptor gene polymorphisms with response to peginterferon plus ribavirin in Asian patients with chronic hepatitis C.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2016, Volume: 115, Issue:4

    Topics: Antiviral Agents; Female; Genotype; Haplotypes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polymorphism, Single Nucleotide; Receptors, Calcitriol; Ribavirin; Taiwan; Treatment Outcome; Viral Load

2016
Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNα.
    Gut, 2017, Volume: 66, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Cell Degranulation; Cells, Cultured; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Killer Cells, Natural; Male; Middle Aged; Phosphorylation; Pyrrolidines; Retreatment; Ribavirin; Signal Transduction; STAT1 Transcription Factor; Sulfonamides; Sustained Virologic Response; TNF-Related Apoptosis-Inducing Ligand; Valine; Viral Load

2017
Editorial Commentary: Interferon-free Hepatitis C Treatment Efficacy From Clinical Trials Will Translate to "Real World" Outcomes.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, Apr-01, Volume: 62, Issue:7

    Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Ribavirin; Treatment Outcome

2016
Treating Hepatitis C in a Ryan White-Funded HIV Clinic: Has the Treatment Uptake Improved in the Interferon-Free Directly Active Antiviral Era?
    AIDS patient care and STDs, 2016, Volume: 30, Issue:2

    Topics: Adult; Aged; Ambulatory Care Facilities; Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Odds Ratio; Retrospective Studies; Ribavirin; Treatment Outcome; United States

2016
Adverse events associated with ribavirin in sofosbuvir-based therapies for patients with chronic hepatitis C: A community practice experience.
    Journal of digestive diseases, 2016, Volume: 17, Issue:2

    Topics: Aged; Antiviral Agents; Community Health Services; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Patient Dropouts; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2016
Sustained viral response and treatment-induced cytopenia correlate with SLCs and KLF12 genotypes in interferon/ribavirin-treated Chinese chronic hepatitis C patients.
    Journal of gastroenterology and hepatology, 2016, Volume: 31, Issue:8

    Topics: Adult; Anion Transport Proteins; Antiporters; Antiviral Agents; China; Drug Therapy, Combination; Equilibrative Nucleoside Transporter 1; Female; Genetic Predisposition to Disease; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kruppel-Like Transcription Factors; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Pharmacogenomic Variants; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Sustained Virologic Response; Thrombocytopenia; Time Factors; Treatment Outcome

2016
Retrospective Analysis of the Medication Utilization and Clinical Outcomes of Patients Treated with Various Regimens for Hepatitis C Infection.
    Journal of pharmacy practice, 2017, Volume: 30, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Drug Utilization; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Nausea; Polyethylene Glycols; Recombinant Proteins; Renal Insufficiency; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Young Adult

2017
[Cutaneous sarcoidosis after treatment with interferon for hepatitis C: A not entirely rare but often overlooked reaction].
    Der Pathologe, 2016, Volume: 37, Issue:2

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Injections, Intravenous; Injections, Subcutaneous; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sarcoidosis; Skin; Skin Diseases

2016
Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea.
    Clinical and molecular hepatology, 2015, Volume: 21, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Fatigue; Female; Genotype; Headache; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Republic of Korea; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome

2015
Suppressor of cytokine signaling 1 expression in peripheral blood mononuclear cells of hepatitis C genotype 1 patients.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2016, Volume: 115, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Janus Kinases; Leukocytes, Mononuclear; Logistic Models; Male; Middle Aged; Ribavirin; Signal Transduction; Suppressor of Cytokine Signaling 1 Protein; Taiwan; Up-Regulation

2016
The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:7

    Topics: Aged; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Fatigue; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Italy; Liver Cirrhosis; Male; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine; Viral Load

2016
A case report: antiviral triple therapy with telaprevir in a haemodialysed HCV patient in Turkey.
    Acta clinica Belgica, 2015, Volume: 70, Issue:6

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Failure, Chronic; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2015
Hepatic decompensation during direct-acting antiviral therapy of chronic hepatitis C.
    Journal of hepatology, 2016, Volume: 64, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Uridine Monophosphate

2016
Sustained virological response with sofosbuvir and ledipasvir for hepatitis C virus genotype 5.
    The Lancet. Infectious diseases, 2016, Volume: 16, Issue:4

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Uridine Monophosphate

2016
IFNL4 ss469415590 polymorphism contributes to treatment decisions in patients with chronic hepatitis C virus genotype 1b, but not 2a, infection.
    Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 2016, Volume: 39

    Topics: Adult; Antiviral Agents; Asian People; China; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load

2016
Peginterferon Therapy in Children With Chronic Hepatitis C: A Nationwide, Multicenter Study in Japan, 2004-2013.
    Journal of pediatric gastroenterology and nutrition, 2016, Volume: 63, Issue:1

    Topics: Adolescent; Antiviral Agents; Asian People; Child; Child Health Services; Child, Preschool; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Medical Records; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Survival Analysis; Treatment Outcome

2016
IL15 polymorphism is associated with advanced fibrosis, inflammation-related biomarkers and virological response in human immunodeficiency virus/hepatitis C virus coinfection.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:9

    Topics: Adult; Antiviral Agents; Biomarkers; Coinfection; Cross-Sectional Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Interferons; Interleukin-15; Interleukins; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Odds Ratio; Polymorphism, Single Nucleotide; Retrospective Studies; Ribavirin; Spain; Sustained Virologic Response; Viral Load

2016
[Telaprevir, PEG-IFNα-2b and ribavirin combination therapy for difficult to treat patients with genotype 2 chronic hepatitis C].
    Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73 Suppl 9

    Topics: Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2015
[Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C].
    Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73 Suppl 9

    Topics: Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Outcome

2015
[Telaprevir, peginterferon and ribavirin therapy for chronic hepatitis C].
    Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73 Suppl 9

    Topics: Anemia; Drug Combinations; Hepatitis C, Chronic; Humans; Interferons; Kidney Function Tests; Oligopeptides; Ribavirin

2015
[A triple combination therapy of simeprevir (SM), pegylated-interferon and ribavirin (PR) with chronic hepatitis C virus genotype 1 infection].
    Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73 Suppl 9

    Topics: Drug Combinations; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Ribavirin; Simeprevir

2015
[Vaniprevir with pegylated interferon and ribavirin in treatment for chronic hepatitis C].
    Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73 Suppl 9

    Topics: Clinical Trials as Topic; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Hepatitis C, Chronic; Humans; Indoles; Interferons; Isoindoles; Lactams, Macrocyclic; Leucine; Proline; Ribavirin; Sulfonamides

2015
Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2016, Volume: 35, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Canada; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Young Adult

2016
Retreatment of Chronic Hepatitis C Infection with Telaprevir : Turkey Experience.
    Acta gastro-enterologica Belgica, 2016, Volume: 79, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Treatment Outcome; Turkey; Viral Load; Young Adult

2016
The influence of host factors and sequence variability of the p7 region on the response to pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b in patients from Serbia.
    Archives of virology, 2016, Volume: 161, Issue:5

    Topics: Adult; Antiviral Agents; Base Sequence; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; Serbia; Treatment Outcome; Viral Proteins

2016
Statins can exert dual, concentration dependent effects on HCV entry in vitro.
    Antiviral research, 2016, Volume: 128

    Topics: Claudin-1; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-alpha; Membrane Proteins; Membrane Transport Proteins; Polyethylene Glycols; Pravastatin; Receptors, LDL; Ribavirin

2016
Plasma and intracellular ribavirin concentrations are not significantly altered by abacavir in hepatitis C virus-infected patients.
    The Journal of antimicrobial chemotherapy, 2016, Volume: 71, Issue:6

    Topics: Adolescent; Adult; Antiviral Agents; Cytosol; Dideoxynucleosides; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Plasma; Prospective Studies; Ribavirin; Time Factors; Young Adult

2016
Dynamic changes in CD45RA(-)Foxp3(high) regulatory T-cells in chronic hepatitis C patients during antiviral therapy.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2016, Volume: 45

    Topics: Adult; Antiviral Agents; Female; Forkhead Transcription Factors; Hepatitis C, Chronic; Humans; Immunophenotyping; Interferon-alpha; Leukocyte Common Antigens; Male; Middle Aged; Ribavirin; T-Lymphocytes, Regulatory

2016
Role of ITPA gene polymorphism in ribavirin-induced anemia and thrombocytopenia in Egyptian patients with chronic hepatitis C.
    Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2016, Volume: 35, Issue:1

    Topics: Adult; Anemia; Antiviral Agents; Egypt; Female; Genetic Association Studies; Genotyping Techniques; Hepatitis C, Chronic; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Real-Time Polymerase Chain Reaction; Ribavirin; Thrombocytopenia; Young Adult

2016
Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2016, Volume: 22, Issue:4

    Topics: Aged; Antiviral Agents; Carbamates; Compassionate Use Trials; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Diseases; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Valine

2016
Sustained virological response after a 17-day treatment with daclatasvir plus asunaprevir in a cirrhotic patient with hepatitis C virus genotype 1b and null response for peginterferon ribavirin therapy.
    Clinical journal of gastroenterology, 2016, Volume: 9, Issue:2

    Topics: Administration, Oral; Antiviral Agents; Carbamates; Drug Administration Schedule; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Isoquinolines; Middle Aged; Pyrrolidines; Ribavirin; Sulfonamides; Treatment Failure; Valine; Viral Load

2016
Long-Term Outcomes of Hepatitis-C-Infected Patients Achieving a Sustained Virological Response and Undergoing Radical Treatment for Hepatocellular Carcinoma.
    Oncology, 2016, Volume: 90, Issue:3

    Topics: Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatectomy; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Ribavirin; Viral Load

2016
Interleukin 28B Polymorphism Predicts Treatment Outcome Among Egyptian Patients Infected With HCV Genotype 4.
    Hepato-gastroenterology, 2015, Volume: 62, Issue:140

    Topics: Adult; Alleles; Antiviral Agents; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prognosis; Real-Time Polymerase Chain Reaction; Ribavirin; RNA, Viral; Treatment Outcome

2015
Integrative role of vitamin D related and Interleukin-28B genes polymorphism in predicting treatment outcomes of Chronic Hepatitis C.
    BMC gastroenterology, 2016, Feb-24, Volume: 16

    Topics: 2',5'-Oligoadenylate Synthetase; Adenosine Deaminase; Adult; Alleles; Antiviral Agents; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Real-Time Polymerase Chain Reaction; Receptors, Calcitriol; Ribavirin; RNA-Binding Proteins; Treatment Outcome; Viral Load; Vitamin D

2016
Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2016, Volume: 22, Issue:5

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Patient Safety; Polymorphism, Genetic; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Transplant Recipients; Treatment Outcome

2016
Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:9

    Topics: Aged; Antiviral Agents; Databases, Factual; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Logistic Models; Male; Medication Adherence; Middle Aged; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; United States; Veterans

2016
Chronic Hepatitis C: Treatment, Complications, and Long-term Outcomes in a Population of Latino Veterans.
    Puerto Rico health sciences journal, 2016, Volume: 35, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Puerto Rico; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Seroepidemiologic Studies; Treatment Outcome; Veterans

2016
Letter: new treatments for hepatitis C have implications for quality of life in people who inject drugs.
    Alimentary pharmacology & therapeutics, 2016, Volume: 43, Issue:7

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Ribavirin

2016
Letter: new treatments for hepatitis C have implications for quality of life in people who inject drug--authors' reply.
    Alimentary pharmacology & therapeutics, 2016, Volume: 43, Issue:7

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Ribavirin

2016
Modeling Ribavirin-Induced Anemia in Patients with Chronic Hepatitis C Virus.
    CPT: pharmacometrics & systems pharmacology, 2016, Volume: 5, Issue:2

    Topics: Anemia; Antiviral Agents; Computer Simulation; Dose-Response Relationship, Drug; Erythrocytes; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Models, Biological; Pyrophosphatases; Ribavirin

2016
Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C.
    Journal of hepatology, 2016, Volume: 65, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Prospective Studies; Renal Dialysis; Ribavirin; Simeprevir; Sofosbuvir

2016
Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C.
    Scientific reports, 2016, Mar-11, Volume: 6

    Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-gamma; Interferons; Interleukins; Male; Middle Aged; Ribavirin; Treatment Failure; Viral Load

2016
Severe Pulmonary Arterial Hypertension in Patients Treated for Hepatitis C With Sofosbuvir.
    Chest, 2016, Volume: 149, Issue:3

    Topics: Antiviral Agents; Carbamates; Comorbidity; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Hypertension, Portal; Hypertension, Pulmonary; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Valine

2016
Association of IFNL3 and IFNL4 polymorphisms with hepatitis C virus infection in a population from southeastern Brazil.
    Archives of virology, 2016, Volume: 161, Issue:6

    Topics: Adult; Antiviral Agents; Brazil; Female; Genome-Wide Association Study; Haplotypes; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome

2016
KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapy.
    The pharmacogenomics journal, 2017, Volume: 17, Issue:4

    Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Platelet Count; Receptors, KIR; Ribavirin; Thrombocytopenia

2017
Hepatitis C Viral Kinetic Changes in a Retrospective Cohort Study of Chronic Hepatitis C Virus Egyptian Patients on Pegylated Interferon and Ribavirin Therapy.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2016, Volume: 36, Issue:3

    Topics: Adult; Aged; Alanine Transaminase; alpha-Fetoproteins; Antiviral Agents; Aspartate Aminotransferases; Drug Administration Schedule; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Sex Factors; Treatment Outcome; Viral Load

2016
Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy.
    Journal of medical virology, 2016, Volume: 88, Issue:10

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Ribavirin; Simeprevir; Sustained Virologic Response; Treatment Outcome

2016
A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin.
    PloS one, 2016, Volume: 11, Issue:3

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Models, Theoretical; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Viral Load; Young Adult

2016
Non-sustained ventricular tachycardia during treatment of genotype 3 chronic hepatitis C - a case report.
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2016, Volume: 40, Issue:236

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Ribavirin; Tachycardia, Ventricular

2016
Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2016, Volume: 48, Issue:6

    Topics: Adult; Antiviral Agents; beta-Thalassemia; Drug Therapy, Combination; Female; Heart Diseases; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Italy; Liver Cirrhosis; Logistic Models; Male; Multivariate Analysis; Polymorphism, Single Nucleotide; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load

2016
[EFFECTS OF URSODEOXYCHOLIC ACID IN STANDART INTERFERONTHERAPY OF PATIENTS WITH CHRONIC HEPATITIS C AND B].
    Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, 2015, Issue:8

    Topics: Adult; Alkaline Phosphatase; Bilirubin; Female; gamma-Glutamyltransferase; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Ursodeoxycholic Acid

2015
No Time for Bullies in Hepatitis C Virus Therapy: Genotype 3 Conquered?
    Gastroenterology, 2016, Volume: 150, Issue:5

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin

2016
Examining the clinical course of genotype 1 chronic hepatitis C patients treated with the cosmos regimen: including patients with advanced liver disease and East Asian ancestry.
    Hepatology international, 2016, Volume: 10, Issue:4

    Topics: Aged; Antiviral Agents; Asian People; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Administration Routes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Simeprevir; Treatment Outcome

2016
Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C.
    International journal of circumpolar health, 2016, Volume: 75

    Topics: Adult; Aged; Alaska; Alaskan Natives; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Indians, North American; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Treatment Outcome

2016
Letter: should HCV cirrhotics with high bilirubin or Gilbert's syndrome be excluded from paritaprevir, ombitasvir, or dasabuvir? Authors' reply.
    Alimentary pharmacology & therapeutics, 2016, Volume: 43, Issue:9

    Topics: Bilirubin; Gilbert Disease; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin

2016
Letter: should HCV cirrhotics with high bilirubin or Gilbert's syndrome be excluded from paritaprevir, ombitasvir, or dasabuvir?
    Alimentary pharmacology & therapeutics, 2016, Volume: 43, Issue:9

    Topics: Bilirubin; Gilbert Disease; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin

2016
Nationwide survey of specialist knowledge on current standard of care (Peg-IFN/RBV) and barriers of care in chronic hepatitis C patients in China.
    Journal of gastroenterology and hepatology, 2016, Volume: 31, Issue:12

    Topics: Antiviral Agents; Attitude of Health Personnel; China; Clinical Competence; Drug Therapy, Combination; Health Care Surveys; Health Knowledge, Attitudes, Practice; Health Services Accessibility; Hepatitis C, Chronic; Humans; Interferons; Patient Education as Topic; Polyethylene Glycols; Practice Patterns, Physicians'; Ribavirin; Standard of Care; Treatment Outcome

2016
Acute pancreatitis associated with pegylated interferon-alpha-2a therapy in chronic hepatitis C.
    Clinical and molecular hepatology, 2016, Volume: 22, Issue:1

    Topics: Amylases; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Lipase; Middle Aged; Pancreatitis; Polyethylene Glycols; Recombinant Proteins; Republic of Korea; Ribavirin; Tomography, X-Ray Computed

2016
Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents.
    The American journal of gastroenterology, 2016, Volume: 111, Issue:6

    Topics: 2-Naphthylamine; Anilides; Antacids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Hydrogen-Ion Concentration; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine

2016
Treatment of Dual Genotype Chronic Hepatitis C: Case Series.
    Digestive diseases and sciences, 2016, Volume: 61, Issue:8

    Topics: Aged; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Treatment Outcome

2016
Difficult management of triple therapy for chronic hepatitis C in a patient on haemodialysis.
    Gastroenterologia y hepatologia, 2017, Volume: 40, Issue:5

    Topics: Anemia, Hemolytic; Antiviral Agents; Bacteremia; Blood Component Transfusion; Catheter-Related Infections; Drug Therapy, Combination; Glomerulonephritis; Graft Rejection; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Interferon-alpha; Kidney Failure, Chronic; Kidney Transplantation; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Postoperative Complications; Recombinant Proteins; Renal Dialysis; Ribavirin; Staphylococcal Infections; Thrombocytopenia

2017
Healing livers, saving lives: Hepatitis C screening in an era of cure.
    JAAPA : official journal of the American Academy of Physician Assistants, 2016, Volume: 29, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin

2016
Association of sustained virologic response with reduced progression to liver cirrhosis in elderly patients with chronic hepatitis C.
    Clinical interventions in aging, 2016, Volume: 11

    Topics: Aged; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Proportional Hazards Models; Retrospective Studies; Ribavirin; Taiwan; Treatment Outcome; Ultrasonography

2016
Sofosbuvir plus ribavirin in Asian patients with chronic genotype 2 hepatitis C virus infection: history of a success?
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:8

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir

2016
Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.
    Journal of medical economics, 2016, Volume: 19, Issue:8

    Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Cyclopropanes; Drug Therapy, Combination; Female; Fibrosis; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Neoplasms; Macrocyclic Compounds; Male; Markov Chains; Middle Aged; Models, Econometric; Proline; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Valine

2016
Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin.
    International journal of medical sciences, 2016, Volume: 13, Issue:4

    Topics: Adult; Aged; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oligopeptides; Protease Inhibitors; Ribavirin; RNA, Viral; Simeprevir; Sustained Virologic Response; Treatment Outcome; Viral Load

2016
[Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2016, Mar-20, Volume: 24, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Sensitivity and Specificity; Sustained Virologic Response; Tandem Mass Spectrometry; Treatment Outcome; Viral Load

2016
[Clinical efficacy of pegylated interferon in patients co-infected with HIV and HCV who failed standard interferon therapy].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2016, Mar-20, Volume: 24, Issue:3

    Topics: Anti-Retroviral Agents; Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Immunotherapy; Interferon-alpha; Male; Prospective Studies; Recurrence; Ribavirin; RNA, Viral; Standard of Care; Sustained Virologic Response; Treatment Outcome; Viral Load

2016
Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy.
    Alimentary pharmacology & therapeutics, 2016, Volume: 43, Issue:12

    Topics: Adult; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; End Stage Liver Disease; Female; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Transplant Recipients; Treatment Outcome; Valine

2016
Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4.
    PloS one, 2016, Volume: 11, Issue:4

    Topics: Adult; Antiviral Agents; Biomarkers; CTLA-4 Antigen; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Polyethylene Glycols; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Programmed Cell Death 1 Receptor; Recombinant Proteins; Ribavirin; ROC Curve; Treatment Outcome; Viral Load

2016
Outcomes of Interferon/Ribavirin Therapy in Patients with HCV Defined by Expression of Plasma Soluble Human Leukocyte Antigen-G but Not IL-37.
    Medical science monitor : international medical journal of experimental and clinical research, 2016, Apr-26, Volume: 22

    Topics: Adult; Case-Control Studies; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C, Chronic; HLA-G Antigens; Humans; Interferon-alpha; Interleukin-1; Male; Ribavirin; Solubility; Treatment Outcome

2016
Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C.
    Gut and liver, 2016, Sep-15, Volume: 10, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Republic of Korea; Ribavirin; Sustained Virologic Response; Time

2016
A New Treatment for Chronic Hepatitis C.
    The American journal of nursing, 2016, Volume: 116, Issue:5

    Topics: Antiviral Agents; Benzofurans; Drug Combinations; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Ribavirin

2016
α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response.
    Journal of gastroenterology and hepatology, 2016, Volume: 31, Issue:5

    Topics: Aged; alpha-Fetoproteins; Antiviral Agents; Area Under Curve; Biomarkers; Biopsy; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Predictive Value of Tests; Remission Induction; Retrospective Studies; Ribavirin; ROC Curve; Severity of Illness Index; Sustained Virologic Response; Time Factors; Treatment Outcome

2016
Molecular assessment of vitamin D receptor polymorphism as a valid predictor to the response of interferon/ribavirin-based therapy in Egyptian patients with chronic hepatitis C.
    Journal of digestive diseases, 2016, Volume: 17, Issue:8

    Topics: Adult; Antiviral Agents; Biomarkers; Case-Control Studies; Drug Combinations; Female; Gene Frequency; Haplotypes; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Polymorphism, Single Nucleotide; Receptors, Calcitriol; Ribavirin; Sustained Virologic Response; Vitamin D; Young Adult

2016
Effect of Antiviral Therapy on Serum Activity of Angiotensin Converting Enzyme in Patients with Chronic Hepatitis C.
    Medical archives (Sarajevo, Bosnia and Herzegovina), 2016, Volume: 70, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Peptidyl-Dipeptidase A; Predictive Value of Tests; Prognosis; Recombinant Proteins; Ribavirin; Young Adult

2016
The Effect of Combination Antiviral Therapy in the Treatment of Hepatitis C on the Occurrence of Depressive Disorder in Patients Treated for Hepatitis C in the Republic of Srpska.
    Medical archives (Sarajevo, Bosnia and Herzegovina), 2016, Volume: 70, Issue:2

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Bosnia and Herzegovina; Depressive Disorder; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Personality Inventory; Prospective Studies; Ribavirin; Risk Factors; Severity of Illness Index; Sex Distribution; Young Adult

2016
Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV-hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy.
    AIDS (London, England), 2016, 08-24, Volume: 30, Issue:13

    Topics: Anemia; Antiviral Agents; Coinfection; Decision Support Techniques; Drug Therapy, Combination; Female; Genotyping Techniques; Glomerular Filtration Rate; Hepatitis C, Chronic; HIV Infections; Humans; Male; Membrane Transport Proteins; Oligopeptides; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Proline; Ribavirin

2016
[Cutaneous adverse events of telaprevir/peginterferon/ribavirin therapy for chronic hepatitis C: A multicenter prospective cohort study].
    Annales de dermatologie et de venereologie, 2016, Volume: 143, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Eruptions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Young Adult

2016
[Autoimmune hepatitis and membranous glomerulonephritis under immune therapy in chronic hepatitis C].
    Deutsche medizinische Wochenschrift (1946), 2016, Volume: 141, Issue:10

    Topics: Antiviral Agents; Diagnosis, Differential; Drug Therapy, Combination; Glomerulonephritis, Membranous; Hepatitis C, Chronic; Hepatitis, Autoimmune; Humans; Interferon-alpha; Kidney Function Tests; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2016
Short article: Fatigue in the long term after HCV treatment in HIV-HCV-coinfected patients: functional limitations persist despite viral clearance in patients exposed to peg-interferon/ribavirin-containing regimens (ANRS CO13-HEPAVIH cohort).
    European journal of gastroenterology & hepatology, 2016, Volume: 28, Issue:9

    Topics: Adult; Antiviral Agents; Chi-Square Distribution; Coinfection; Drug Therapy, Combination; Fatigue; Female; France; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Linear Models; Male; Middle Aged; Multivariate Analysis; Recovery of Function; Ribavirin; Risk Factors; Surveys and Questionnaires; Time Factors; Treatment Outcome; Viral Load

2016
Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients.
    Journal of medical virology, 2016, Volume: 88, Issue:12

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hydroxychloroquine; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2016
Unmasking of myasthenia gravis during pegylated Alfa 2 a interferon and ribavirin therapy for chronic hepatitis C.
    JPMA. The Journal of the Pakistan Medical Association, 2016, Volume: 66, Issue:5

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Myasthenia Gravis; Ribavirin

2016
COMMON GENOTYPES AND TREATMENT OUTCOMES OF HCV INFECTION AMONG ETHIOPIAN PATIENTS: A PROSPECTIVE STUDY.
    Ethiopian medical journal, 2016, Volume: 54, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Ethiopia; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prevalence; Prospective Studies; Ribavirin; Treatment Outcome

2016
Repeated Panniculitis Induced by Pegylated Interferon Alpha 2a in a Patient with Chronic Hepatitis C.
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2016, May-25, Volume: 67, Issue:5

    Topics: Abdomen; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Panniculitis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Skin; Ultrasonography

2016
[THE USE OF COMBINATION ANTIVIRAL THERAPY IN LIVER CIRRHOSIS HCV ETIOLOGY].
    Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, 2015, Issue:11

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Ribavirin

2015
Impact of TGF-β1 Gene Polymorphism (rs1800469) on Treatment Response to Pegylated Interferon/Ribavirin in Iranian Patients with Hepatitis C.
    Clinical laboratory, 2016, Volume: 62, Issue:4

    Topics: Adult; Cross-Sectional Studies; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferons; Male; Polymorphism, Single Nucleotide; Ribavirin; Transforming Growth Factor beta1

2016
Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, 08-15, Volume: 63, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Middle Aged; Recurrence; Ribavirin; Salvage Therapy; Sofosbuvir; Treatment Failure

2016
Myasthenia Crisis Induced by Pegylated-Interferon in Patient With Chronic Hepatitis C: A Case Report.
    Medicine, 2016, Volume: 95, Issue:21

    Topics: Adrenal Cortex Hormones; Antiviral Agents; Cholinesterase Inhibitors; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Myasthenia Gravis; Polyethylene Glycols; Respiration, Artificial; Ribavirin; Thymoma; Thymus Neoplasms

2016
Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?
    Clinical drug investigation, 2016, Volume: 36, Issue:8

    Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Hepatitis C, Chronic; Humans; Interferons; Italy; Liver Cirrhosis; Markov Chains; Monte Carlo Method; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Treatment Outcome

2016
[Analysis of ineffective antiviral therapy with pegylated interferon and ribavirin in a patient with chronic hepatitis C infected with HCV genotype 2].
    Terapevticheskii arkhiv, 2016, Volume: 88, Issue:5

    Topics: Adult; Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin; Treatment Failure

2016
Demographic profile, host, disease & viral predictive factors of response in patients with chronic hepatitis C virus infection at a tertiary care hospital in north India.
    The Indian journal of medical research, 2016, Volume: 143, Issue:3

    Topics: Adult; Aged; Female; Hepacivirus; Hepatitis C, Chronic; Humans; India; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sustained Virologic Response; Tertiary Care Centers

2016
Resurrection of response-guided therapy for sofosbuvir combination therapies.
    Journal of hepatology, 2016, Volume: 65, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir

2016
Therapy: HCV drugs reduce transplantation need.
    Nature reviews. Gastroenterology & hepatology, 2016, Volume: 13, Issue:7

    Topics: Antiviral Agents; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Transplantation; Ribavirin

2016
IMPACT OF THE PEGYLATED-INTERFERON AND RIBAVIRIN THERAPY ON THE TREATMENT-RELATED MORTALITY OF PATIENTS WITH CIRRHOSIS DUE TO HEPATITIS C VIRUS.
    Revista do Instituto de Medicina Tropical de Sao Paulo, 2016, Volume: 58

    Topics: Aged; Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2016
Successful treatment of hepatitis C, genotype 3, with sofosbuvir/ledipasvir in decompensated cirrhosis complicated by mixed cryoglobulinaemia.
    BMJ case reports, 2016, Jun-09, Volume: 2016

    Topics: Benzimidazoles; Cryoglobulinemia; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate

2016
Safety and effectiveness of response-guided therapy using pegylated interferon and ribavirin for chronic hepatitis C virus infection in patients on maintenance dialysis.
    Nephrology (Carlton, Vic.), 2017, Volume: 22, Issue:9

    Topics: Adolescent; Adult; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Renal Dialysis; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult

2017
Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice.
    Alimentary pharmacology & therapeutics, 2016, Volume: 44, Issue:4

    Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Black or African American; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Young Adult

2016
Effect of antiviral treatment of chronic hepatitis C on the frequency of regulatory T cells, T-cell activation, and serum levels of TGF-beta.
    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2016, Volume: 124, Issue:8

    Topics: ADP-ribosyl Cyclase 1; Adult; Aged; Antiviral Agents; CD8-Positive T-Lymphocytes; Female; Flow Cytometry; Genotype; Hepacivirus; Hepatitis C, Chronic; HLA-DR Antigens; Humans; Immunophenotyping; Interferon-alpha; Lymphocyte Activation; Male; Membrane Glycoproteins; Middle Aged; Protease Inhibitors; Ribavirin; Serum; T-Lymphocytes, Regulatory; Transforming Growth Factor beta; Young Adult

2016
Colitis during new direct-acting antiviral agents (DAAs) therapy with sofosbuvir, simeprevir and ribavirin for genotype 1b hepatitis C.
    Infection, 2016, Volume: 44, Issue:6

    Topics: Aged; Antiviral Agents; Colitis; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Ribavirin; Simeprevir; Sofosbuvir

2016
Full-dose sofosbuvir and daclatasvir for chronic hepatitis C infection in haemodialysis patients.
    The Netherlands journal of medicine, 2016, Volume: 74, Issue:5

    Topics: Antiviral Agents; Carbamates; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Valine; Viral Load

2016
Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, 09-15, Volume: 63, Issue:6

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Young Adult

2016
Thyroid Dysfunction in Chronic Hepatitis C Patients Treated with the Combined Pegylated Interferon-Ribavirin Therapy.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2016, Volume: 36, Issue:9

    Topics: Adult; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Ribavirin; Thyroid Diseases; Thyroid Function Tests; Treatment Outcome; Viral Load; Young Adult

2016
Treatment of chronic hepatitis E with ribavirin: lessons from deep sequencing.
    Gut, 2016, Volume: 65, Issue:10

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Hepatitis E; Hepatitis, Chronic; High-Throughput Nucleotide Sequencing; Humans; Interferon-alpha; Recombinant Proteins; Ribavirin; Treatment Outcome

2016
Raynaud's phenomenon and bilateral olecranon bursitis co-existing in a patient with chronic hepatitis B and D treated with pegylated interferon.
    JPMA. The Journal of the Pakistan Medical Association, 2016, Volume: 66, Issue:6

    Topics: Antiviral Agents; Bursitis; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis D; Humans; Interferon-alpha; Olecranon Process; Raynaud Disease; Recombinant Proteins; Ribavirin

2016
Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials.
    Antiviral therapy, 2017, Volume: 22, Issue:4

    Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Prognosis; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Sofosbuvir; Treatment Failure; Uridine Monophosphate

2017
Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.
    Advances in therapy, 2016, Volume: 33, Issue:8

    Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Lactams, Macrocyclic; Liver Cirrhosis; Liver Neoplasms; Macrocyclic Compounds; Markov Chains; Middle Aged; Polyethylene Glycols; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; United States; Uracil; Valine

2016
Variant Inosine Triphosphatase Phenotypes Are Associated With Increased Ribavirin Triphosphate Levels.
    Journal of clinical pharmacology, 2017, Volume: 57, Issue:1

    Topics: Adult; Cohort Studies; Female; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Male; Middle Aged; Pharmacogenomic Variants; Phenotype; Pyrophosphatases; Ribavirin

2017
Viability of pegIFNα-RBV for CHC in the direct acting antiviral era: a practical algorithm between efficacy and cost containment.
    Journal of chemotherapy (Florence, Italy), 2017, Volume: 29, Issue:2

    Topics: Algorithms; Antiviral Agents; Cost Control; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome

2017
FibroScan, APRI, FIB4, and GUCI: Role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infection.
    Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology, 2016, Volume: 17, Issue:2

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Area Under Curve; Aspartate Aminotransferases; Drug Therapy, Combination; Egypt; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; International Normalized Ratio; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; ROC Curve

2016
Measuring Plasma Concentrations of Ribavirin: First Report From a Quality Control Program.
    Therapeutic drug monitoring, 2016, Volume: 38, Issue:5

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Quality Control; Ribavirin

2016
Adoption of new agents and changes in treatment patterns for hepatitis C: 2010-2014.
    The American journal of managed care, 2016, 06-01, Volume: 22, Issue:6

    Topics: Adult; Antiviral Agents; Databases, Factual; Drug Therapy, Combination; Female; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Insurance Claim Review; Interferons; Logistic Models; Male; Middle Aged; Oligopeptides; Predictive Value of Tests; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; United States

2016
Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors.
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2016, Jun-23, Volume: 49, Issue:7

    Topics: Adult; Aged; Anemia; Antiviral Agents; Female; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Statistics, Nonparametric; Sustained Virologic Response; Time Factors; Treatment Failure; Young Adult

2016
MONOCYTE CHEMOTACTIC PROTEIN AND RESPONSE TO PEGYLATED INTERFERON-ALPHA-2A TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C (CHC) GENOTYPE 4.
    Journal of the Egyptian Society of Parasitology, 2016, Volume: 46, Issue:1

    Topics: Adolescent; Adult; Antiviral Agents; Case-Control Studies; Chemokine CCL2; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Young Adult

2016
Treatment of Hepatitis C Virus in HIV-Coinfected Individuals in Real-world Clinical Settings: Results From 2 Large HIV Care Clinics.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, 10-01, Volume: 63, Issue:7

    Topics: Antiviral Agents; Coinfection; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Ribavirin

2016
Severe Elevation of Liver Enzymes Does Not Necessarily Require Treatment Interruption in Patients Treated With a Combination of Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir for HCV Infection.
    Journal of clinical gastroenterology, 2016, Volume: 50, Issue:9

    Topics: 2-Naphthylamine; Alanine Transaminase; Anilides; Antiviral Agents; Aspartate Aminotransferases; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine; Withholding Treatment

2016
Regional Differences in Hepatitis C Treatment with Peginterferon and Ribavirin in Japan in Both Genotype 1 and Genotype 2: A Retrospective Cohort Study.
    Biological & pharmaceutical bulletin, 2016, Sep-01, Volume: 39, Issue:9

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Drug Utilization; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Japan; Male; Middle Aged; Polyethylene Glycols; Retrospective Studies; Ribavirin

2016
From current status to optimization of HCV treatment: Recommendations from an expert panel.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2016, Volume: 48, Issue:9

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Italy; Liver Cirrhosis; Liver Neoplasms; Practice Guidelines as Topic; Ribavirin; Societies, Medical; Viral Load

2016
Influence of Ribavirin Serum Levels on Outcome of Antiviral Treatment and Anemia in Hepatitis C Virus Infection.
    PloS one, 2016, Volume: 11, Issue:7

    Topics: Adult; Aged; Anemia; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Interferons; Interleukins; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Genetic; Retrospective Studies; Ribavirin; RNA, Viral; ROC Curve; Treatment Outcome; Young Adult

2016
Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.
    Journal of hepatology, 2016, Volume: 65, Issue:4

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; England; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Prospective Studies; Ribavirin; Treatment Outcome

2016
Successful sofosbuvir treatment with ribavirin dose reduction for chronic hepatitis C virus genotype 2 infection in a patient with ulcerative colitis: a case report.
    BMC gastroenterology, 2016, Jul-11, Volume: 16, Issue:1

    Topics: Antiviral Agents; Colitis, Ulcerative; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir

2016
How hepatitis C patients manage the treatment process of pegylated interferon and ribavirin therapy: a qualitative study.
    BMC health services research, 2016, 07-11, Volume: 16

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prescription Fees; Qualitative Research; Quality of Life; Recombinant Proteins; Ribavirin; Socioeconomic Factors; Taiwan

2016
Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
    PloS one, 2016, Volume: 11, Issue:7

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Kidney Transplantation; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Transplant Recipients; Treatment Outcome

2016
Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study.
    Gut, 2017, Volume: 66, Issue:10

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Serum Albumin; Sofosbuvir; Sustained Virologic Response; Young Adult

2017
[Health-Related Quality of Life in patients with hepatitis C treated with dual and triple therapy].
    Revista da Escola de Enfermagem da U S P, 2015, Volume: 49, Issue:6

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin

2015
Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice.
    The Annals of pharmacotherapy, 2016, Volume: 50, Issue:11

    Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine

2016
Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens.
    Medicine, 2016, Volume: 95, Issue:28

    Topics: Antiviral Agents; Benzimidazoles; Clinical Trials, Phase III as Topic; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Interferons; Male; Medication Adherence; Middle Aged; Multicenter Studies as Topic; Patient Reported Outcome Measures; Ribavirin; Sofosbuvir

2016
Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials.
    Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Prospective Studies; Registries; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Young Adult

2017
Involvement of the Interleukin-23/Interleukin-17 Axis in Chronic Hepatitis C Virus Infection and Its Treatment Responses.
    International journal of molecular sciences, 2016, Jul-15, Volume: 17, Issue:7

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukin-17; Interleukin-23; Male; Middle Aged; Polyethylene Glycols; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Young Adult

2016
Oral therapy approved for chronic HCV infection of all genotypes.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2016, Aug-01, Volume: 73, Issue:15

    Topics: Administration, Oral; Antiviral Agents; Carbamates; Drug Approval; Drug Combinations; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Sofosbuvir

2016
Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients.
    Hepatology international, 2016, Volume: 10, Issue:5

    Topics: Adolescent; Adult; Aged; Antiviral Agents; China; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Treatment Outcome; Young Adult

2016
Reply to "Chronic hepatitis C and diabetes: More questions than answers with the new direct acting antiviral drugs?".
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2016, Volume: 48, Issue:9

    Topics: Antiviral Agents; Diabetes Mellitus; Hepatitis C, Chronic; Humans; Ribavirin

2016
Rapid virological response assessment by Abbott RealTime hepatitis C virus assay for predicting sustained virological responses in patients with hepatitis C virus genotype 1 treated with pegylated-interferon and ribavirin.
    The Kaohsiung journal of medical sciences, 2016, Volume: 32, Issue:7

    Topics: Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; ROC Curve; Treatment Outcome

2016
Ten-year follow-up analysis of chronic hepatitis C patients after getting sustained virological response to pegylated interferon-α and ribavirin therapy.
    Journal of viral hepatitis, 2016, Volume: 23, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Ribavirin; Sustained Virologic Response; Treatment Outcome; Young Adult

2016
NS5A resistance leading to failure of 24-week therapy with sofosbuvir/ledipasvir and ribavirin for the treatment of hepatitis C genotype 1a infection in a HIV-1 co-infected patient.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2016, Volume: 82

    Topics: Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Liver Cirrhosis; Male; Middle Aged; Mutation, Missense; Ribavirin; Sofosbuvir; Treatment Failure; Viral Nonstructural Proteins

2016
Chronic Hepatitis C and Alcohol Abuse: The Single Center Experience of Novi Sad - Serbia.
    Reviews on recent clinical trials, 2016, Volume: 11, Issue:3

    Topics: Adult; Alcoholism; Antiviral Agents; Cross-Sectional Studies; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Retrospective Studies; Ribavirin; Serbia; Sustained Virologic Response

2016
Peripheral blood toll-like receptor 4 correlates with rapid virological response to pegylated-interferon and ribavirin therapy in hepatitis C genotype 1 patients.
    BMC gastroenterology, 2016, Jul-25, Volume: 16, Issue:1

    Topics: Aged; Antiviral Agents; Female; Gene Expression; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Monocytes; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Messenger; Toll-Like Receptor 4; Viral Load

2016
Reply to: "HCV RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin".
    Journal of hepatology, 2016, Volume: 65, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Kinetics; Ribavirin; RNA; RNA, Viral; Sofosbuvir; Sustained Virologic Response

2016
HCV-RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin.
    Journal of hepatology, 2016, Volume: 65, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Kinetics; Ribavirin; RNA; RNA, Viral; Sofosbuvir; Sustained Virologic Response

2016
Estimation of direct medical cost related to the management of chronic hepatitis C and its complications in South Korea.
    Medicine, 2016, Volume: 95, Issue:30

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Republic of Korea; Retrospective Studies; Ribavirin; Sustained Virologic Response; Young Adult

2016
von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2016, Volume: 48, Issue:10

    Topics: Adult; Antiviral Agents; Austria; Biomarkers; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Regression Analysis; Retrospective Studies; Ribavirin; ROC Curve; von Willebrand Factor

2016
Onset of Tuberculosis from a Pulmonary Latent Tuberculosis Infection during Antiviral Triple Therapy for Chronic Hepatitis C.
    Internal medicine (Tokyo, Japan), 2016, Volume: 55, Issue:15

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Latent Tuberculosis; Male; Oligopeptides; Polyethylene Glycols; Ribavirin; Treatment Outcome

2016
Antiretroviral therapy does not affect response to chronic hepatitis C therapy in HIV-coinfected patients.
    Journal of infection in developing countries, 2016, Aug-02, Volume: 10, Issue:7

    Topics: Adult; Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Interactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Sustained Virologic Response; Treatment Outcome

2016
Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia.
    Hepatology (Baltimore, Md.), 2016, Volume: 64, Issue:5

    Topics: Aged; Antiviral Agents; B-Lymphocytes; Cryoglobulinemia; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Practice Guidelines as Topic; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Vasculitis

2016
Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6.
    BMC gastroenterology, 2016, Aug-05, Volume: 16, Issue:1

    Topics: Antiviral Agents; Cost Savings; Cost-Benefit Analysis; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Markov Chains; Palliative Care; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Thailand

2016
The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis: A Cost-Effectiveness Analysis.
    Transplantation, 2017, Volume: 101, Issue:5

    Topics: Antiviral Agents; Benzimidazoles; Combined Modality Therapy; Cost-Benefit Analysis; Decision Support Techniques; Drug Administration Schedule; Fluorenes; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Models, Economic; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; Treatment Outcome; United States; Uridine Monophosphate

2017
Use of HCV+ Donors Does Not Affect HCV Clearance With Directly Acting Antiviral Therapy But Shortens the Wait Time to Kidney Transplantation.
    Transplantation, 2017, Volume: 101, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Hepatitis C, Chronic; Humans; Kidney Transplantation; Male; Middle Aged; Postoperative Complications; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Time Factors; Tissue Donors; Treatment Outcome; Uridine Monophosphate

2017
Sofosbuvir plus daclatasvir with or without ribavirin for chronic hepatitis C infection: Impact of drug concentration on viral load decay.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2016, Volume: 48, Issue:11

    Topics: Aged; Antiviral Agents; Carbamates; Drug Monitoring; Drug Therapy, Combination; Female; France; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Linear Models; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Valine; Viral Load

2016
Clinical Utility of a New Automated Hepatitis C Virus Core Antigen Assay for Prediction of Treatment Response in Patients with Chronic Hepatitis C.
    Journal of Korean medical science, 2016, Volume: 31, Issue:9

    Topics: Antigens, Viral; Antiviral Agents; Automation; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunoassay; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Reagent Kits, Diagnostic; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome

2016
[PROGNOSTIC VALUE OF THE COMBINATION OF BLOOD GROUP SPECIFICITY AND INTERLEUKIN 28B GENE POLYMORPHISM FOR ESTIMATION OF EFFICIENCY OF THERAPY WITH THE USE OF PEGYLATED INTERFERON α-2 AND RIBAVARIN IN PATIENTS WITH CHRONIC GENOTYPE 1 HEPATITIS C].
    Klinicheskaia meditsina, 2016, Volume: 94, Issue:3

    Topics: Adult; Antiviral Agents; Blood Group Antigens; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Predictive Value of Tests; Prognosis; Recombinant Proteins; Reproducibility of Results; Ribavirin

2016
Genome-wide association of IL-28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C in a Tunisian population.
    La Tunisie medicale, 2016, Volume: 94, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genome-Wide Association Study; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Genetic; Prospective Studies; Ribavirin; Tunisia

2016
Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study.
    Hepatology (Baltimore, Md.), 2016, Volume: 64, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Interactions; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Proton Pump Inhibitors; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome

2016
Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
    Clinical interventions in aging, 2016, Volume: 11

    Topics: Aged; Antiviral Agents; Aspartate Aminotransferases; Blood Platelets; Carcinoma, Hepatocellular; Disease Progression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Retrospective Studies; Ribavirin; Risk Factors; Sustained Virologic Response; Taiwan

2016
Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir.
    Medicine, 2016, Volume: 95, Issue:33

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Japan; Male; Middle Aged; Quality of Life; Ribavirin; Sofosbuvir; Surveys and Questionnaires

2016
Dynamics of PBMC gene expression in hepatitis C virus genotype 1-infected patients during combined peginterferon/ribavirin therapy.
    Oncotarget, 2016, Sep-20, Volume: 7, Issue:38

    Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Gene Expression Profiling; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Polyethylene Glycols; Ribavirin; Sequence Analysis, RNA; Treatment Outcome

2016
Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2016, Volume: 22, Issue:11

    Topics: Aged; Antiviral Agents; Benzimidazoles; Calcineurin Inhibitors; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Liver Transplantation; Male; Middle Aged; Pragmatic Clinical Trials as Topic; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Uridine Monophosphate

2016
Association between IL28B rs12979860 single nucleotide polymorphism and the frequency of colonic Treg in chronically HCV-infected patients.
    Archives of virology, 2016, Volume: 161, Issue:11

    Topics: Adult; Antiviral Agents; Colon; Cross-Sectional Studies; Egypt; Female; Hepatitis C, Chronic; Histocytochemistry; Humans; Interferon-alpha; Interferons; Interleukins; Intestinal Mucosa; Liver; Male; Middle Aged; Plasma; Polymorphism, Single Nucleotide; Ribavirin; T-Lymphocytes, Regulatory; Treatment Outcome; Viral Load; Young Adult

2016
Efficacy and safety of boceprevir-based triple therapy in HCV cirrhotic patients awaiting liver transplantation (ANRS HC29 BOCEPRETRANSPLANT).
    Clinics and research in hepatology and gastroenterology, 2017, Volume: 41, Issue:1

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; France; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Proline; Quality of Life; Retrospective Studies; Ribavirin; Treatment Outcome

2017
Ultrasensitive HCV RNA Quantification in Antiviral Triple Therapy: New Insight on Viral Clearance Dynamics and Treatment Outcome Predictors.
    PloS one, 2016, Volume: 11, Issue:8

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Principal Component Analysis; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2016
Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.
    Gastroenterology, 2016, Volume: 151, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Bilirubin; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Ribavirin; Risk Factors; Serum Albumin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Failure; Uridine Monophosphate; Young Adult

2016
Porphyrin Elevation in a Patient on Treatment With Simeprevir: Could It Be a Possible Explanation for Simeprevir-Associated Photosensitivity?
    The American journal of gastroenterology, 2016, Volume: 111, Issue:9

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Graft Rejection; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Photosensitivity Disorders; Porphyrins; Recurrence; Ribavirin; Simeprevir; Sofosbuvir

2016
The clinical outcomes of chronic hepatitis C in South Korea: A prospective, multicenter cohort study.
    Medicine, 2016, Volume: 95, Issue:35

    Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Republic of Korea; Ribavirin; Risk Factors; Survival Rate; Sustained Virologic Response

2016
Public health impact of comprehensive hepatitis C screening and treatment in the French baby-boomer population.
    Journal of medical economics, 2017, Volume: 20, Issue:2

    Topics: Aged; Antiviral Agents; France; Hepacivirus; Hepatitis C, Chronic; Humans; Markov Chains; Mass Screening; Middle Aged; Public Health; Ribavirin

2017
Limited Generalizability of Registration Trials in Hepatitis C: A Nationwide Cohort Study.
    PloS one, 2016, Volume: 11, Issue:9

    Topics: Adult; Aged; Anemia; Antiviral Agents; Cardiovascular Diseases; Eligibility Determination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Neoplasms; Netherlands; Neutropenia; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Regression Analysis; Retrospective Studies; Ribavirin; Risk Factors

2016
The Role of IL28B Genotype in HCV-RNA Baseline Levels.
    Intervirology, 2016, Volume: 59, Issue:2

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Retrospective Studies; Ribavirin; RNA, Viral; Viremia

2016
Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.
    Gut, 2016, Volume: 65, Issue:11

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Compassionate Use Trials; Drug Monitoring; Drug Therapy, Combination; Europe; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Failure; Male; Middle Aged; Pyrrolidines; Ribavirin; Severity of Illness Index; Sofosbuvir; Treatment Outcome; Valine

2016
Eruptive seborrheic keratoses secondary to telaprevir-related dermatitis.
    Cutis, 2016, Volume: 98, Issue:2

    Topics: Aged; Antiviral Agents; Drug Eruptions; Facial Dermatoses; Female; Hepatitis C, Chronic; Humans; Interferons; Keratosis, Seborrheic; Oligopeptides; Ribavirin

2016
Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
    Journal of hepatology, 2017, Volume: 66, Issue:1

    Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; France; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2017
Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C.
    Journal of gastroenterology and hepatology, 2017, Volume: 32, Issue:4

    Topics: Administration, Oral; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome

2017
Sofosbuvir/Ledipasvir Without Ribavirin Achieved High Sustained Virologic Response for Hepatitis C Recurrence After Liver Transplantation: Two-Center Experience.
    Transplantation, 2017, Volume: 101, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Female; Fluorenes; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate

2017
Comparison of the Abbott RealTime HCV and Roche COBAS Ampliprep/COBAS TaqMan HCV assays for the monitoring of sofosbuvir-based therapy.
    Antiviral therapy, 2017, Volume: 22, Issue:1

    Topics: Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Kinetics; Male; Middle Aged; Real-Time Polymerase Chain Reaction; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load

2017
Kinetic of Virologic Response to Pegylated Interferon and Ribavirin in Children With Chronic Hepatitis C Predicts the Effect of Treatment.
    The Pediatric infectious disease journal, 2016, Volume: 35, Issue:12

    Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2016
Effect of interleukin-10 gene promoter polymorphisms -1082 G/A and -592 C/A on response to therapy in children and adolescents with chronic hepatitis C virus infection.
    Human immunology, 2016, Volume: 77, Issue:12

    Topics: Adolescent; Alleles; Antiviral Agents; Child; Drug Therapy, Combination; Female; Fibrosis; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-10; Liver; Male; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Ribavirin; Treatment Outcome; Viral Load

2016
HCV Resistance Profile Evolution in a GT1b, DAA-Naive Patient Before, On, and After Failing Triple DAA Therapy.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2017, Volume: 15, Issue:2

    Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Disease Progression; Drug Combinations; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Sustained Virologic Response; Treatment Failure; Uracil; Valine; Viral Nonstructural Proteins

2017
Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12.
    World journal of gastroenterology, 2016, Sep-21, Volume: 22, Issue:35

    Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Hypertension, Portal; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Valine

2016
Body Composition Changes in Patients with Chronic Hepatitis C.
    Journal of gastrointestinal and liver diseases : JGLD, 2016, Volume: 25, Issue:3

    Topics: Absorptiometry, Photon; Adiposity; Adult; Antiviral Agents; Body Mass Index; Bone Density; Case-Control Studies; Cross-Sectional Studies; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Lipodystrophy; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Sex Factors; Smoking

2016
Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals.
    Oncology, 2016, Volume: 91, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Body Mass Index; Carbamates; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon Type I; Isoquinolines; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Oligopeptides; Pyrrolidines; Ribavirin; Risk Factors; RNA, Viral; Sulfonamides; Sustained Virologic Response; Valine; Young Adult

2016
IL28B rs12980275 and HLA rs4273729 genotypes as a powerful predictor factor for rapid, early, and sustained virologic response in patients with chronic hepatitis C.
    Archives of virology, 2017, Volume: 162, Issue:1

    Topics: Adult; Antiviral Agents; Cross-Sectional Studies; Female; Genotyping Techniques; Hepatitis C, Chronic; HLA Antigens; Humans; Interferon-alpha; Interferons; Interleukins; Iran; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prognosis; Recombinant Proteins; Ribavirin; Sustained Virologic Response; Time Factors; Young Adult

2017
Influence of Successful Chronic Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir on Warfarin Dosing Requirements in Four Veterans.
    Pharmacotherapy, 2016, Volume: 36, Issue:11

    Topics: Aged; Anticoagulants; Antiviral Agents; Benzimidazoles; Dose-Response Relationship, Drug; Drug Interactions; Fluorenes; Hepatitis C, Chronic; Humans; International Normalized Ratio; Male; Middle Aged; Pharmaceutical Services; Pharmacists; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Veterans; Warfarin

2016
Impact of hepatitis C virus core mutations on the response to interferon-based treatment in chronic hepatitis C.
    World journal of gastroenterology, 2016, Oct-07, Volume: 22, Issue:37

    Topics: Adolescent; Adult; Aged; Alleles; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Mutation; Polyethylene Glycols; Polymorphism, Genetic; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Viral Core Proteins; White People; Young Adult

2016
Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study.
    Journal of viral hepatitis, 2017, Volume: 24, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Young Adult

2017
Impact of IFNL4 rs12979860 and rs8099917 polymorphisms on response to Peg-Interferon-α and Ribavirin in patients with congenital bleeding disorder and chronic hepatitis C.
    Journal of clinical laboratory analysis, 2017, Volume: 31, Issue:4

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Female; Genetic Association Studies; Hemophilia A; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; Sustained Virologic Response; Young Adult

2017
Alopecia universalis as a side effect of pegylated interferon α-ribavirin combination therapy for hepatitis C: a rare case report.
    Journal of chemotherapy (Florence, Italy), 2017, Volume: 29, Issue:6

    Topics: Adult; Alopecia; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2017
Sofosbuvir-Containing Regimens for Chronic Hepatitis C Are Successful in the Safety-Net Population: A Real-World Experience.
    Digestive diseases and sciences, 2016, Volume: 61, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Pyrrolidines; Retrospective Studies; Ribavirin; San Francisco; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Vulnerable Populations; Young Adult

2016
Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in HCV genotype IV infected patients.
    Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Egypt; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome

2017
Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir.
    Gastroenterology, 2017, Volume: 152, Issue:3

    Topics: Antiviral Agents; Benzofurans; Clinical Trials as Topic; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Polymorphism, Genetic; Quinoxalines; Ribavirin; RNA, Viral; Treatment Failure; Treatment Outcome; Viral Nonstructural Proteins

2017
Polymorphisms of HLA-DM on Treatment Response to Interferon/Ribavirin in Patients with Chronic Hepatitis C Virus Type 1 Infection.
    International journal of environmental research and public health, 2016, 10-20, Volume: 13, Issue:10

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Asian People; China; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; HLA-D Antigens; Humans; Interferon-alpha; Male; Middle Aged; Odds Ratio; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome; Young Adult

2016
The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection.
    Hepatology (Baltimore, Md.), 2017, Volume: 65, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Asian; Black People; Cohort Studies; Databases, Factual; Drug Therapy, Combination; Ethnicity; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Prognosis; Racial Groups; Ribavirin; Risk Assessment; Simeprevir; Sofosbuvir; Survival Rate; Treatment Outcome; United States; White People

2017
Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study.
    Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response

2017
Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis.
    Antiviral research, 2016, Volume: 136

    Topics: Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Failure; Treatment Outcome

2016
All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database.
    Alimentary pharmacology & therapeutics, 2017, Volume: 45, Issue:1

    Topics: Administration, Oral; Adult; Antiviral Agents; Databases, Factual; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Internationality; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Ribavirin; Simeprevir; Sofosbuvir

2017
Interleukin 10 gene single nucleotide polymorphisms in Polish patients with chronic hepatitis C: Analysis of association with severity of disease and treatment outcome.
    Human immunology, 2017, Volume: 78, Issue:2

    Topics: Adult; Disease Progression; Drug Therapy, Combination; Female; Fibrosis; Gene Frequency; Genotype; Hepatitis C, Chronic; Humans; Inflammation; Interferon-alpha; Interleukin-10; Liver; Male; Middle Aged; Poland; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult

2017
Assessment of pro-inflammatory cytokines in sera of patients with hepatitis C virus infection before and after anti-viral therapy.
    Journal of infection in developing countries, 2016, Oct-31, Volume: 10, Issue:10

    Topics: Adult; Aged; Antiviral Agents; Cytokines; Flow Cytometry; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Serum; Sustained Virologic Response; Young Adult

2016
The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all-oral regimens good value to society?
    Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37, Issue:5

    Topics: Administration, Oral; Antiviral Agents; Benzimidazoles; Decision Making; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Markov Chains; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; United States; Uridine Monophosphate

2017
Hemoglobin during ribavirin-based HCV therapy is closely related to circulating levels of DHEA.
    Journal of medical virology, 2017, Volume: 89, Issue:6

    Topics: Adult; Aged; Anemia; Antiviral Agents; Dehydroepiandrosterone; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Male; Middle Aged; Predictive Value of Tests; Retrospective Studies; Ribavirin; Sensitivity and Specificity; Young Adult

2017
Regression of hepatocellular carcinoma after treatment with Sofosbuvir - A case report.
    JPMA. The Journal of the Pakistan Medical Association, 2016, Volume: 66, Issue:11

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome

2016
Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients.
    PloS one, 2016, Volume: 11, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian People; Base Sequence; Carbamates; China; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; RNA Helicases; Sequence Analysis, DNA; Serine Endopeptidases; Sulfonamides; Valine; Viral Load; Viral Nonstructural Proteins; Young Adult

2016
Paritaprevir/ritonavir/ombitasvir+dasabuvir plus ribavirin therapy and inhibition of the anticoagulant effect of warfarin: a case report.
    Journal of clinical pharmacy and therapeutics, 2017, Volume: 42, Issue:1

    Topics: 2-Naphthylamine; Anilides; Anticoagulants; Antiviral Agents; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine; Warfarin

2017
ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C.
    Journal of gastroenterology, 2017, Volume: 52, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Sofosbuvir; Treatment Outcome

2017
Clinical importance of pharmacogenetics in the treatment of hepatitis C virus infection.
    Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie, 2016, Volume: 57, Issue:2 Suppl

    Topics: Antiviral Agents; Female; Genotype; Hemoglobins; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Pharmacogenetics; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Ribavirin

2016
Detection of Occult Hepatitis C Virus Infection in Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents for Recurrent Infection After Liver Transplantation.
    Gastroenterology, 2017, Volume: 152, Issue:3

    Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Limit of Detection; Liver Transplantation; Male; Middle Aged; Prospective Studies; Pyrrolidines; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine; Viral Load; Virus Replication

2017
Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.
    Antiviral therapy, 2017, Volume: 22, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Imidazoles; Liver Diseases; Liver Function Tests; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine; Viral Load

2017
Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2017, Volume: 15, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Patient Reported Outcome Measures; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Sustained Virologic Response; Treatment Outcome

2017
The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV).
    Medicine, 2016, Volume: 95, Issue:46

    Topics: Affective Symptoms; Antiviral Agents; Benzimidazoles; Biomarkers; Cytokines; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Mental Disorders; Middle Aged; Neurotransmitter Agents; Retrospective Studies; Ribavirin; Sofosbuvir

2016
Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong.
    Journal of gastroenterology and hepatology, 2017, Volume: 32, Issue:6

    Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Hong Kong; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Proline; Retrospective Studies; Ribavirin; Ritonavir; Sulfonamides; Time Factors; Treatment Outcome; Uracil; Valine

2017
Greater decline in memory and global neurocognitive function in HIV/hepatitis C co-infected than in hepatitis C mono-infected patients treated with pegylated interferon and ribavirin.
    Journal of neurovirology, 2017, Volume: 23, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Cognitive Dysfunction; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Neuropsychological Tests; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin

2017
Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma.
    Transplantation, 2017, Volume: 101, Issue:5

    Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Drug Administration Schedule; Drug Therapy, Combination; Fluorenes; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Middle Aged; Models, Economic; Postoperative Care; Preoperative Care; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; United States; Uridine Monophosphate

2017
Efficacy and Safety of Therapy With Simeprevir and Sofosbuvir in Liver Transplant Recipients Infected by Hepatitis C Virus Genotype 4: Cohort Spanish Society of Liver Transplantation Cohort.
    Transplantation proceedings, 2016, Volume: 48, Issue:9

    Topics: Antiviral Agents; Drug Combinations; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Patient Safety; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Spain; Treatment Outcome

2016
Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort.
    Journal of viral hepatitis, 2017, Volume: 24, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins; Young Adult

2017
Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
    Transplant infectious disease : an official journal of the Transplantation Society, 2017, Volume: 19, Issue:1

    Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Interactions; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Immunocompromised Host; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir

2017
Effects of ribavirin/sofosbuvir treatment and ITPA phenotype on endogenous purines.
    Antiviral research, 2017, Volume: 138

    Topics: Adenosine Triphosphate; Anemia, Hemolytic; Female; Guanosine Triphosphate; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Inosine Triphosphate; Male; Middle Aged; Nucleotides; Phenotype; Polymorphism, Single Nucleotide; Purines; Pyrophosphatases; Retrospective Studies; Ribavirin; Sofosbuvir

2017
Utility of enzyme-linked immunosorbent assays to test core antigen in the diagnosis and antiviral therapy management of hepatitis C virus infections.
    Journal of medical virology, 2017, Volume: 89, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Disease Management; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Hepacivirus; Hepatitis C; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon-alpha; Limit of Detection; Male; Middle Aged; Predictive Value of Tests; Ribavirin; RNA, Viral; Sensitivity and Specificity; Viral Core Proteins; Viral Load; Young Adult

2017
Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience.
    Journal of hepatology, 2017, Volume: 66, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Recombination, Genetic; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Young Adult

2017
Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States.
    Journal of viral hepatitis, 2017, Volume: 24, Issue:4

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Computer Simulation; Cost-Benefit Analysis; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Quinoxalines; Renal Insufficiency, Chronic; Ribavirin; Sulfonamides; United States

2017
Lichen Aureus associated with interferon-alfa plus ribavirin.
    Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2017, Volume: 152, Issue:1

    Topics: Antiviral Agents; Dermoscopy; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Lichenoid Eruptions; Male; Middle Aged; Ribavirin

2017
Prediction of Hepatocellular Carcinoma Development after Hepatitis C Virus Eradication Using Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein.
    International journal of molecular sciences, 2016, Dec-20, Volume: 17, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Neoplasms; Male; Membrane Glycoproteins; Middle Aged; Plant Lectins; Polyethylene Glycols; Protein Binding; Receptors, N-Acetylglucosamine; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Young Adult

2016
Is response to anti-hepatitis C virus treatment predictive of mortality in hepatitis C virus/HIV-positive patients?
    AIDS (London, England), 2017, 03-13, Volume: 31, Issue:5

    Topics: Adult; Antiviral Agents; Cohort Studies; Coinfection; Europe; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Mortality; Prognosis; Ribavirin; RNA, Viral; Survival Analysis; Sustained Virologic Response; Treatment Outcome; Viral Load

2017
Sudden-onset sarcoidosis with severe dyspnea developing during pegylated interferon and ribavirin combination therapy for chronic hepatitis C.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2017, Volume: 28, Issue:1

    Topics: Adult; Antiviral Agents; Dyspnea; Female; Hepatitis C, Chronic; Humans; Interferons; Polyethylene Glycols; Ribavirin; Sarcoidosis, Pulmonary

2017
Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy.
    The European journal of health economics : HEPAC : health economics in prevention and care, 2018, Volume: 19, Issue:1

    Topics: Antiviral Agents; Carbamates; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Italy; Liver Cirrhosis; Pyrrolidines; Ribavirin; Sofosbuvir; Valine

2018
Real-world experience with daclatasvir plus sofosbuvir ± ribavirin for post-liver transplant HCV recurrence and severe liver disease.
    Transplant international : official journal of the European Society for Organ Transplantation, 2017, Volume: 30, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; End Stage Liver Disease; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome; Valine

2017
Genotype specific peripheral lipid profile changes with hepatitis C therapy.
    World journal of gastroenterology, 2016, Dec-14, Volume: 22, Issue:46

    Topics: Aged; Alanine Transaminase; Antiviral Agents; Benzimidazoles; Cholesterol; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Triglycerides

2016
Addition of ribavirin to daclatasvir plus asunaprevir for chronic hepatitis C 1b patients with baseline NS5A resistance-associated variants improved response.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2017, Volume: 116, Issue:4

    Topics: Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Liver Cirrhosis; Male; Middle Aged; Polymorphism, Genetic; Pyrrolidines; Ribavirin; Sulfonamides; Taiwan; Valine; Viral Load; Viral Nonstructural Proteins

2017
Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients.
    Journal of medical virology, 2017, Volume: 89, Issue:7

    Topics: Adult; Aged; Cytokines; Drug Resistance, Viral; Female; Gene Expression Regulation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver; Male; Middle Aged; Myxovirus Resistance Proteins; Polymorphism, Single Nucleotide; Ribavirin; RNA, Messenger; Suppressor of Cytokine Signaling 1 Protein; Ubiquitins

2017
Assessment of IL-28: rs12979860 and rs8099917 Polymorphisms in a Cohort of Cuban Chronic HCV Genotype 1b Patients.
    Journal of biomolecular techniques : JBT, 2017, Volume: 28, Issue:2

    Topics: Adolescent; Adult; Antiviral Agents; Case-Control Studies; Cohort Studies; Cuba; Female; Gene Frequency; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome; Vaccines, DNA; Viral Hepatitis Vaccines

2017
Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt.
    Alimentary pharmacology & therapeutics, 2017, Volume: 45, Issue:5

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Sofosbuvir

2017
Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs.
    Medicine, 2017, Volume: 96, Issue:1

    Topics: Adult; Age Factors; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Republic of Korea; Retrospective Studies; Ribavirin; Risk Assessment; Risk Factors

2017
Toward chronic hepatitis C eradication in HIV-positive patients, including those cirrhotic and infected with genotype 3 viruses.
    Gut, 2017, Volume: 66, Issue:10

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Ribavirin; Treatment Outcome

2017
Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection.
    Alimentary pharmacology & therapeutics, 2017, Volume: 45, Issue:5

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Registries; Ribavirin

2017
Hepatitis C "true" late relapse beyond 48weeks of sustained virologic response after direct acting antiviral therapy.
    Journal of hepatology, 2017, Volume: 66, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Recurrence; Ribavirin; Sustained Virologic Response; Treatment Outcome

2017
Functional Polymorphism in the Interleukin 6 (IL6) Gene with Respect to Depression Induced in the Course of Interferon-α and Ribavirin Treatment in Chronic Hepatitis Patients.
    Archivum immunologiae et therapiae experimentalis, 2016, Volume: 64, Issue:Suppl 1

    Topics: Adult; Antiviral Agents; Cohort Studies; Depression; Female; Genetic Predisposition to Disease; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukin-6; Longitudinal Studies; Male; Middle Aged; Poland; Polyethylene Glycols; Polymorphism, Genetic; Prevalence; Recombinant Proteins; Ribavirin

2016
Treatment of HCV in renal transplant patients with peginterferon and ribavirin: long-term follow-up.
    Clinical and experimental nephrology, 2017, Volume: 21, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Graft Rejection; Graft Survival; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Kidney Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Sustained Virologic Response; Time Factors; Treatment Outcome; Young Adult

2017
The HCV Sicily Network: a web-based model for the management of HCV chronic liver diseases.
    European review for medical and pharmacological sciences, 2016, Volume: 20, Issue:1 Suppl

    Topics: Antiviral Agents; Community Networks; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Internet; Male; Middle Aged; Ribavirin; Sicily; Treatment Outcome

2016
HCV intergenotype 2k/1b recombinant detected in a DAA-treated patient in Italy.
    Antiviral therapy, 2017, Volume: 22, Issue:4

    Topics: Alanine Transaminase; Antiviral Agents; Drug Combinations; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Liver Cirrhosis; Middle Aged; Phylogeny; Reassortant Viruses; Ribavirin; Sequence Analysis, RNA; Sofosbuvir; Treatment Failure

2017
A real-world impact of cost-effectiveness of pegylated interferon/ribavarin regimens on treatment-naïve chronic hepatitis C patients in Taiwan.
    The Kaohsiung journal of medical sciences, 2017, Volume: 33, Issue:1

    Topics: Aged; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Decision Making; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insurance, Health, Reimbursement; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Taiwan; Treatment Outcome; Viral Load

2017
US FDA Perspective on Elbasvir/Grazoprevir Treatment for Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection.
    Clinical drug investigation, 2017, Volume: 37, Issue:4

    Topics: Antiviral Agents; Benzofurans; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Renal Insufficiency, Chronic; Ribavirin; Treatment Outcome

2017
Pegylated interferon for hepatitis C virus infection in Down syndrome.
    Pediatrics international : official journal of the Japan Pediatric Society, 2017, Volume: 59, Issue:1

    Topics: Antiviral Agents; Down Syndrome; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2017
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.
    Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37, Issue:4

    Topics: Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Italy; Male; Middle Aged; Mutation; Recurrence; Ribavirin; Sequence Analysis, DNA; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Viral Nonstructural Proteins

2017
Eradication of hepatitis C virus and non-liver-related non-acquired immune deficiency syndrome-related events in human immunodeficiency virus/hepatitis C virus coinfection.
    Hepatology (Baltimore, Md.), 2017, Volume: 66, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Adult; Cohort Studies; Coinfection; Comorbidity; Databases, Factual; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV; Humans; Incidence; Interferon-alpha; Male; Middle Aged; Regression Analysis; Retrospective Studies; Ribavirin; Risk Assessment; Spain; Survival Analysis; Time Factors; Treatment Outcome

2017
Correlation between polymorphism in the inosine triphosphatase and the reductions in hemoglobin concentration and ribavirin dose during sofosbuvir and ribavirin therapy.
    Journal of gastroenterology and hepatology, 2017, Volume: 32, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic; Antiviral Agents; Asian People; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Male; Middle Aged; Multivariate Analysis; Polymorphism, Genetic; Pyrophosphatases; Ribavirin; Sofosbuvir

2017
Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2017, Volume: 23, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Combinations; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Young Adult

2017
Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium.
    PloS one, 2017, Volume: 12, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Belgium; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Treatment Outcome

2017
Pegylated interferon α/ribavirin therapy enhances bone mineral density in children with chronic genotype 4 HCV infection.
    World journal of pediatrics : WJP, 2017, Volume: 13, Issue:4

    Topics: Absorptiometry, Photon; Adolescent; Age Factors; Bone Density; Child; Child, Preschool; Cohort Studies; Drug Therapy, Combination; Egypt; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Retrospective Studies; Ribavirin; Sex Factors; Treatment Outcome

2017
Shift in disparities in hepatitis C treatment from interferon to DAA era: A population-based cohort study.
    Journal of viral hepatitis, 2017, Volume: 24, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; British Columbia; Cohort Studies; Female; Healthcare Disparities; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Ribavirin; Young Adult

2017
Steatosis influences the clinical profiles and long-term outcomes of interferon-treated chronic hepatitis C and liver cirrhosis patients.
    International journal of medical sciences, 2017, Volume: 14, Issue:1

    Topics: Adult; Antiviral Agents; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Non-alcoholic Fatty Liver Disease; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2017
Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience.
    Journal of gastroenterology, 2017, Volume: 52, Issue:8

    Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Liver Transplantation; Living Donors; Male; Middle Aged; Postoperative Period; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Viral Nonstructural Proteins

2017
Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trials.
    Health and quality of life outcomes, 2017, Jan-31, Volume: 15, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Japan; Male; Middle Aged; Psychometrics; Quality of Life; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Treatment Outcome

2017
Letter: should direct-acting antiviral drugs be used concomitantly with chemotherapeutic drugs in hepatitis C virus-infected patients with cancer? Authors' reply.
    Alimentary pharmacology & therapeutics, 2017, Volume: 45, Issue:5

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Neoplasms; Ribavirin

2017
Letter: should direct-acting antiviral drugs be used concomitantly with chemotherapeutic drugs in hepatitis C virus-infected patients with cancer?
    Alimentary pharmacology & therapeutics, 2017, Volume: 45, Issue:5

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Neoplasms; Ribavirin

2017
Safety and effectiveness of a 12-week course of sofosbuvir and simeprevir ± ribavirin in HCV-infected patients with or without HIV infection: a multicentre observational study.
    International journal of antimicrobial agents, 2017, Volume: 49, Issue:3

    Topics: Aged; Aged, 80 and over; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Italy; Male; Middle Aged; Protease Inhibitors; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2017
Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis.
    Canadian journal of gastroenterology & hepatology, 2017, Volume: 2017

    Topics: Amides; Antiviral Agents; Asthenia; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fatigue; Female; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Nausea; Quinoxalines; Randomized Controlled Trials as Topic; Ribavirin; RNA, Viral; Sulfonamides; Sustained Virologic Response; Viral Load

2017
Predictors of treatment efficacy and ALT non-normalization with sofosbuvir/ribavirin therapy for patients with hepatitis C virus genotype 2.
    Journal of medical virology, 2017, Volume: 89, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antigens, Neoplasm; Antiviral Agents; Drug Monitoring; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Membrane Glycoproteins; Middle Aged; Prognosis; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Withholding Treatment

2017
ITPase activity modulates the severity of anaemia in HCV-related cirrhosis treated with ribavirin-containing interferon-free regimens.
    Antiviral therapy, 2017, Volume: 22, Issue:7

    Topics: Aged; Alleles; Anemia; Antiviral Agents; Disease Susceptibility; Drug Therapy, Combination; Enzyme Activation; Female; Gene Frequency; Genotype; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Liver Cirrhosis; Male; Middle Aged; Odds Ratio; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Risk Factors; Severity of Illness Index

2017
Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry.
    Hepatology (Baltimore, Md.), 2017, Volume: 65, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cause of Death; Cohort Studies; Disease Progression; End Stage Liver Disease; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Function Tests; Logistic Models; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Registries; Retrospective Studies; Ribavirin; Risk Assessment; Severity of Illness Index; Sofosbuvir; Spain; Survival Analysis; Treatment Outcome

2017
Role of simeprevir plasma concentrations in HCV treated patients with dermatological manifestations.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2017, Volume: 49, Issue:6

    Topics: Adult; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Prospective Studies; Ribavirin; Simeprevir; Skin Diseases; Treatment Outcome; Viral Load

2017
Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme.
    Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37, Issue:9

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine

2017
The Safety Profile of Telaprevir-Based Triple Therapy in Clinical Practice: A Retrospective Cohort Study.
    Biological & pharmaceutical bulletin, 2017, May-01, Volume: 40, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin

2017
Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
    Journal of hepatology, 2017, Volume: 66, Issue:6

    Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Neoplasms; Macrocyclic Compounds; Male; Middle Aged; Neoplasm Recurrence, Local; Proline; Retrospective Studies; Ribavirin; Ritonavir; Sofosbuvir; Spain; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Uridine Monophosphate; Valine; Young Adult

2017
Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study.
    Journal of hepatology, 2017, Volume: 66, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; China; Drug Costs; Drug Therapy, Combination; Drugs, Generic; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Medical Tourism; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Therapeutic Equivalency; Treatment Outcome; Uridine Monophosphate; Viral Load

2017
Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
    Gastroenterology, 2017, Volume: 152, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzofurans; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Quinoxalines; Randomized Controlled Trials as Topic; Retreatment; Retrospective Studies; Ribavirin; RNA, Viral; Sulfonamides; Sustained Virologic Response; Viral Nonstructural Proteins; Young Adult

2017
Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response.
    PloS one, 2017, Volume: 12, Issue:2

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Fatty Liver; Hepacivirus; Hepatitis; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Middle Aged; Multivariate Analysis; Outcome Assessment, Health Care; Polyethylene Glycols; Prospective Studies; Retrospective Studies; Ribavirin; Risk Factors; Sustained Virologic Response; Time Factors; Transaminases

2017
Impact of ITPA gene polymorphisms on the risk of ribavirin-induced haemolytic anaemia using interferon-free antivirals for chronic hepatitis C.
    Antiviral therapy, 2017, Volume: 22, Issue:7

    Topics: Adult; Aged; Alleles; Anemia, Hemolytic; Antiviral Agents; Disease Susceptibility; Female; Genotype; Hepatitis C, Chronic; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Retrospective Studies; Ribavirin

2017
Single Nucleotide rs760370 Polymorphism at the Main Ribavirin Transporter Gene Detection by PCR-RFLP Assay Compared with the TaqMan Assay and Its Relation to Sustained Virological Response in Chronic HCV Patients Treated with Pegylated Interferon-Ribaviri
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2017, Volume: 37, Issue:2

    Topics: Adult; Alleles; Drug Therapy, Combination; Equilibrative Nucleoside Transporter 1; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Real-Time Polymerase Chain Reaction; Ribavirin; Treatment Outcome

2017
Outcomes of treatment with direct-acting antivirals for infection with hepatitis C virus genotypes 1-4 in an ambulatory care setting.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2017, Mar-01, Volume: 74, Issue:5 Suppleme

    Topics: Aged; Ambulatory Care; Ambulatory Care Facilities; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Load

2017
Risk Factors for Treatment Discontinuation Caused by Adverse Events When Using Telaprevir, Peginterferon, and Ribavirin to Treat Chronic Hepatitis C: A Real-World Retrospective Cohort Study.
    Biological & pharmaceutical bulletin, 2017, May-01, Volume: 40, Issue:5

    Topics: Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors

2017
Decrease in regulatory T-cell function in chronic hepatitis C patients receiving pegylated-interferon plus ribavirin.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2017, Volume: 58

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Ribavirin; T-Lymphocytes, Regulatory

2017
Hepatitis C Virus-Related Hepatic Myelopathy After Treatment With Sofosbuvir and Ribavirin: A Case Report.
    Annals of internal medicine, 2017, 03-07, Volume: 166, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Ribavirin; Sofosbuvir; Spinal Cord Diseases; Viral Load

2017
INF-free sofosbuvir-based treatment of post-transplant hepatitis C relapse - a Swedish real life experience.
    Scandinavian journal of gastroenterology, 2017, Volume: 52, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; End Stage Liver Disease; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Sweden; Treatment Outcome; Valine

2017
Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort.
    Journal of acquired immune deficiency syndromes (1999), 2017, 05-01, Volume: 75, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Coinfection; Drug-Related Side Effects and Adverse Reactions; Female; France; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2017
Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia.
    The American journal of gastroenterology, 2017, Volume: 112, Issue:8

    Topics: Antiviral Agents; Cryoglobulinemia; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Treatment Outcome

2017
Possible determinants of rapid virological response suggesting shorter courses of combination therapy for hepatitis C virus genotype 2.
    Hepatology (Baltimore, Md.), 2008, Volume: 48, Issue:1

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors

2008
Effect of ribavirin, in combination with interferon in patients with hepatitis C, on the bleeding risk associated with selective serotonin reuptake inhibitors.
    The Journal of clinical psychiatry, 2008, Volume: 69, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Factor VII; Hemophilia A; Hemorrhage; Hepatitis C, Chronic; Humans; Interferon-alpha; Mental Disorders; Ribavirin; Risk Factors; Selective Serotonin Reuptake Inhibitors

2008
Longitudinal effects of hepatitis C virus treatment on hepatic mitochondrial dysfunction assessed by C-methionine breath test.
    Alimentary pharmacology & therapeutics, 2008, Aug-15, Volume: 28, Issue:4

    Topics: Adult; Antiviral Agents; Breath Tests; Case-Control Studies; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Longitudinal Studies; Male; Methionine; Middle Aged; Mitochondria, Liver; Mitochondrial Diseases; Oxidative Stress; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2008
[Hepatitis C is curable. Even slightly elevated liver enzymes need further examination].
    MMW Fortschritte der Medizin, 2008, Mar-27, Volume: 150, Issue:13

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Forecasting; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Function Tests; Prognosis; Protease Inhibitors; Ribavirin; RNA, Viral; Treatment Outcome

2008
Treatment responses in Asians and Caucasians with chronic hepatitis C infection.
    World journal of gastroenterology, 2008, Jun-07, Volume: 14, Issue:21

    Topics: Adult; Aged; Antiviral Agents; Asian People; Australia; Case-Control Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; White People

2008
[Neuropsychiatric adverse events in patients with chronic hepatitis C treated with pegylated or recombinant interferon-alpha].
    Przeglad epidemiologiczny, 2008, Volume: 62, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Psychoses, Substance-Induced; Recombinant Proteins; Ribavirin; Severity of Illness Index

2008
Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy.
    Hepatology (Baltimore, Md.), 2008, Volume: 48, Issue:1

    Topics: Aged; Antiviral Agents; Consensus Sequence; Drug Therapy, Combination; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mutation; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Nonstructural Proteins

2008
Usefulness of a new immunoradiometric assay of HCV core antigen to predict virological response during PEG-IFN/RBV combination therapy for chronic hepatitis with high viral load of serum HCV RNA genotype 1b.
    Intervirology, 2008, Volume: 51 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Immunoradiometric Assay; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Treatment Outcome; Viral Core Proteins; Viral Load

2008
Successful rescue therapy with only 4 weeks ribavirin monotherapy in end-stage cirrhosis due to genotype 2 chronic hepatitis C.
    Digestive diseases and sciences, 2009, Volume: 54, Issue:2

    Topics: Aged; Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Ribavirin; Treatment Outcome

2009
Predictive graphical model, network-based medical tool for the prognosis of chronic hepatitis C patients treated with peg-interferon plus ribavirin.
    Alimentary pharmacology & therapeutics, 2008, Aug-15, Volume: 28, Issue:4

    Topics: Algorithms; Antiviral Agents; Computational Biology; Decision Support Techniques; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Reproducibility of Results; Ribavirin; ROC Curve; Treatment Outcome

2008
Concomitant diffuse large B-cell lymphoma and hepatocellular carcinoma in chronic hepatitis C virus liver disease: a study of two cases.
    Journal of medical virology, 2008, Volume: 80, Issue:8

    Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Neoplasms; Lymphoma, Large B-Cell, Diffuse; Male; Ribavirin; Time Factors

2008
Treatment of chronic hepatitis C virus infection among Brazilian haemophiliacs.
    The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2008, Volume: 12, Issue:1

    Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult

2008
Telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in chronic hepatitis C patients.
    Journal of hepatology, 2008, Volume: 49, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2008
Antiviral therapy completion and response rates among hepatitis C patients with and without schizophrenia.
    Schizophrenia bulletin, 2010, Volume: 36, Issue:1

    Topics: Aged; Antipsychotic Agents; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Long-Term Care; Male; Mental Health Services; Middle Aged; Patient Care Team; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Schizophrenia; Schizophrenic Psychology

2010
[Results of the treatment of chronic hepatitis C genotype 4--a comparative analysis with genotype 1].
    Revista espanola de enfermedades digestivas, 2008, Volume: 100, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Spain; Treatment Outcome

2008
[Treatment of chronic viral hepatitis].
    Ugeskrift for laeger, 2008, Jun-09, Volume: 170, Issue:24

    Topics: Antibodies, Monoclonal; Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Ribavirin; Treatment Outcome

2008
Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen.
    The Journal of antimicrobial chemotherapy, 2008, Volume: 62, Issue:4

    Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2008
Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases.
    Journal of gastrointestinal and liver diseases : JGLD, 2008, Volume: 17, Issue:2

    Topics: Adult; Antiviral Agents; Biopsy; Dose-Response Relationship, Drug; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome

2008
[Interferon alpha, gamma, omega before and during treatment of chronic hepatitis C with pegylated interferon alpha and ribavirin].
    Przeglad epidemiologiczny, 2007, Volume: 61, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Interferon-beta; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2007
[Long-term viral response to interferon alpha 2b plus ribavirin in chronic hepatitis C patients during standard therapy].
    Przeglad epidemiologiczny, 2007, Volume: 61, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Secondary Prevention; Treatment Outcome; Viral Load

2007
Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir.
    Antiviral therapy, 2008, Volume: 13, Issue:3

    Topics: Adult; Antiviral Agents; Dideoxynucleosides; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Reverse Transcriptase Inhibitors; Ribavirin; Risk Assessment; RNA, Viral; Spain; Treatment Failure; Viral Load

2008
Factors associated with quality of life in chronic hepatitis C patients who received interferon plus ribavirin therapy.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2008, Volume: 107, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Quality of Life; Ribavirin

2008
Occurrence of diffuse, poorly differentiated hepatocellular carcinoma during pegylated interferon plus ribavirin combination therapy for chronic hepatitis C.
    Journal of chemotherapy (Florence, Italy), 2008, Volume: 20, Issue:3

    Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tomography, X-Ray Computed

2008
Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a.
    Virology journal, 2008, Jul-09, Volume: 5

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Evolution, Molecular; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Phylogeny; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; Sequence Analysis, DNA; Treatment Failure; Treatment Outcome; Viral Load; Virus Replication

2008
Pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection in patients with Child-Pugh Class A liver cirrhosis.
    Scandinavian journal of gastroenterology, 2008, Volume: 43, Issue:11

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Severity of Illness Index; Treatment Outcome

2008
Pure red-cell aplasia associated with pegylated interferon-alpha-2b plus ribavirin.
    American journal of hematology, 2008, Volume: 83, Issue:9

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Red-Cell Aplasia, Pure; Ribavirin

2008
Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion.
    Journal of hepatology, 2008, Volume: 49, Issue:5

    Topics: Adult; Aged; Antimicrobial Cationic Peptides; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Ferritins; Hepatitis C, Chronic; Hepcidins; Humans; Interferon alpha-2; Interferon-alpha; Iron Overload; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Messenger

2008
Suitable treatment period in patients with virological response during combination therapy of peginterferon and ribavirin for chronic hepatitis C.
    Internal medicine (Tokyo, Japan), 2008, Volume: 47, Issue:14

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Secondary Prevention

2008
The response to pegylated interferon alpha 2a in haemodialysis patients with hepatitis C virus infection.
    Infection, 2008, Volume: 36, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome

2008
Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients.
    Journal of viral hepatitis, 2008, Volume: 15, Issue:10

    Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Patient Compliance; Ribavirin; Substance Abuse, Intravenous; Switzerland; Treatment Outcome

2008
Correlation of serum ribavirin concentration with pretreatment renal function estimates in patients with chronic hepatitis C receiving combination antiviral therapy with peginterferon and ribavirin.
    Journal of viral hepatitis, 2008, Volume: 15, Issue:9

    Topics: Aged; Antiviral Agents; Asian People; Creatinine; Cystatin C; Cystatins; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Function Tests; Male; Metabolic Clearance Rate; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Serum; Statistics as Topic

2008
Weight affect relapse rates in latinos with genotype 2/3 chronic hepatitis C (CHC) treated with peg IFN alfa-2a (Pegasys) 180 mcg/week and 800 mg daily of ribavirin for 24 weeks.
    Journal of medical virology, 2008, Volume: 80, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Body Weight; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Statistical; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Factors; Treatment Outcome

2008
A support vector machine approach to assess drug efficacy of interferon-alpha and ribavirin combination therapy.
    Molecular diagnosis & therapy, 2008, Volume: 12, Issue:4

    Topics: Algorithms; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Neural Networks, Computer; Polymorphism, Single Nucleotide; Ribavirin; Viral Load

2008
Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin.
    The Journal of infectious diseases, 2008, Sep-15, Volume: 198, Issue:6

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2008
Interaction of ribavirin with azathioprine metabolism potentially induces myelosuppression.
    Alimentary pharmacology & therapeutics, 2008, Oct-15, Volume: 28, Issue:8

    Topics: Adult; Antiviral Agents; Azathioprine; Drug Interactions; Female; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Male; Middle Aged; Pancytopenia; Platelet Count; Retrospective Studies; Ribavirin; Risk Factors

2008
Platelet-associated IgG for the diagnosis of immune thrombocytopaenic purpura during peginterferon alpha and ribavirin treatment for chronic hepatitis C.
    Liver international : official journal of the International Association for the Study of the Liver, 2008, Volume: 28, Issue:9

    Topics: Aged; Antiviral Agents; Blood Platelets; Female; Hepatitis C, Chronic; Humans; Immunoglobulin G; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Purpura, Thrombocytopenic; Recombinant Proteins; Ribavirin

2008
Homocysteine levels and sustained virological response to pegylated-interferon alpha2b plus ribavirin therapy for chronic hepatitis C: a prospective study.
    Liver international : official journal of the International Association for the Study of the Liver, 2009, Volume: 29, Issue:2

    Topics: Antiviral Agents; Folic Acid; Hepacivirus; Hepatitis C, Chronic; Homocysteine; Humans; Interferon alpha-2; Interferon-alpha; Italy; Methylenetetrahydrofolate Dehydrogenase (NADP); Polyethylene Glycols; Polymorphism, Genetic; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; ROC Curve; Vitamin B 12

2009
Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection.
    Hepatology (Baltimore, Md.), 2008, Volume: 48, Issue:2

    Topics: Antiviral Agents; Body Weight; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors

2008
Rapid virological response in hepatitis C virus genotype 1 and early ribavirin exposure.
    Hepatology (Baltimore, Md.), 2008, Volume: 48, Issue:2

    Topics: Antiviral Agents; Drug Administration Schedule; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Time Factors; Viral Load

2008
Interferon-induced haemolytic anaemia in hepatitis C.
    The New Zealand medical journal, 2008, Jul-25, Volume: 121, Issue:1278

    Topics: Anemia, Hemolytic, Autoimmune; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Ribavirin

2008
Prospective study of bone mineral density and metabolism in patients with chronic hepatitis C during pegylated interferon alpha and ribavirin therapy.
    Journal of viral hepatitis, 2008, Volume: 15, Issue:11

    Topics: Absorptiometry, Photon; Adult; Antiviral Agents; Bone and Bones; Bone Density; Collagen Type I; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Osteocalcin; Osteoporosis; Prospective Studies; Recombinant Proteins; Ribavirin

2008
[Management of chronic hepatitis in 2008].
    Gastroenterologie clinique et biologique, 2008, Volume: 32, Issue:3 Pt 2

    Topics: Antiviral Agents; Consensus Development Conferences as Topic; Disease Management; Hepatitis C, Chronic; Humans; Patient Care Team; Ribavirin

2008
Exacerbation of oral lichen planus lesions during treatment of chronic hepatitis C with pegylated interferon and ribavirin.
    European journal of gastroenterology & hepatology, 2008, Volume: 20, Issue:7

    Topics: Aged; Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lichen Planus, Oral; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2008
Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus ribavirin.
    Alimentary pharmacology & therapeutics, 2009, Volume: 29, Issue:1

    Topics: Antiviral Agents; Asian People; Cross-Sectional Studies; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Taiwan; Treatment Outcome; Viral Load

2009
[Peginterferon alfa-2b and ribavirin-induced pure red cell aplasia during treatment of chronic hepatitis C treated by cyclosporin A with good response].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2008, Jul-10, Volume: 97, Issue:7

    Topics: Administration, Inhalation; Antiviral Agents; Cyclosporine; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Red-Cell Aplasia, Pure; Ribavirin

2008
Outcomes of peginterferon alpha-2a and ribavirin hepatitis C therapy in Aboriginal Canadians.
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2008, Volume: 22, Issue:8

    Topics: Adult; Antiviral Agents; Canada; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Indians, North American; Interferon alpha-2; Interferon-alpha; Inuit; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2008
[Cytokine assessment in untreated hepatitis C virus infected patients and during interferon alpha +ribavirine therapy].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 2008, Volume: 61, Issue:1-3

    Topics: Adult; Antiviral Agents; Cytokines; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-gamma; Interleukin-10; Interleukin-2; Interleukin-4; Male; Monitoring, Physiologic; Ribavirin

2008
Serum 90K/Mac-2 binding protein (Mac-2BP) as a response predictor to peginterferon and ribavirin combined treatment in HCV chronic patients.
    Immunopharmacology and immunotoxicology, 2008, Volume: 30, Issue:4

    Topics: Adult; Aged; Antigens, Neoplasm; Biomarkers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Membrane Glycoproteins; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin

2008
Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C.
    The American journal of gastroenterology, 2008, Volume: 103, Issue:11

    Topics: Affect; Antiviral Agents; Biomarkers; Depression; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2008
Identification of a hepatitis C virus mutant lacking the hypervariable region 1 in a chronically infected patient non-responding to PEG-interferon-alpha/ribavirin therapy.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2009, Volume: 28, Issue:2

    Topics: Amino Acid Sequence; Antiviral Agents; Drug Resistance, Multiple, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Mutation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sequence Alignment; Sequence Analysis, DNA; Treatment Failure; Viral Proteins

2009
Community-based treatment for chronic hepatitis C in drug users: high rates of compliance with therapy despite ongoing drug use.
    Alimentary pharmacology & therapeutics, 2009, Volume: 29, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Drug Users; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Patient Compliance; Ribavirin; Substance-Related Disorders; Treatment Outcome; Viral Load

2009
[Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics].
    Klinicka mikrobiologie a infekcni lekarstvi, 2008, Volume: 14, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viremia

2008
[Haematologic adverse effects of treatment of chronic viral hepatitis B and C].
    Klinicka mikrobiologie a infekcni lekarstvi, 2008, Volume: 14, Issue:2

    Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia

2008
Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis.
    Arthritis and rheumatism, 2008, Volume: 58, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cell Count; Cryoglobulinemia; Drug Therapy, Combination; Female; Flow Cytometry; Forkhead Transcription Factors; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Remission Induction; Ribavirin; Statistics, Nonparametric; T-Lymphocytes, Regulatory; Treatment Outcome; Vasculitis

2008
Frequency of thyroid disorders during interferon and ribavirin therapy in chronic hepatitis C infection.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2008, Volume: 18, Issue:6

    Topics: Adult; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; Thyroid Diseases

2008
Marked flare in hepatic aminotransferases during treatment with pegylated interferon for chronic hepatitis C, genotype 2: a case report.
    Digestive diseases and sciences, 2009, Volume: 54, Issue:6

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Transaminases; Viral Load

2009
Sexual dysfunction in chronic hepatitis C virus patients treated with interferon alpha and ribavirin.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2008, Volume: 28, Issue:10

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Erectile Dysfunction; Hepatitis C, Chronic; Humans; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Ribavirin; Surveys and Questionnaires

2008
Pneumococcal meningitis during antiviral treatment with interferon and ribavirin in a splenectomized patient with chronic hepatitis C - do not miss vaccination before starting therapy.
    Zeitschrift fur Gastroenterologie, 2008, Volume: 46, Issue:9

    Topics: Adult; Antiviral Agents; Bacterial Proteins; Cefotaxime; Dose-Response Relationship, Drug; Drug Therapy, Combination; Follow-Up Studies; Hearing Loss, Unilateral; Hepatitis C, Chronic; Humans; Infusions, Intravenous; Interferon Type I; Interferon-alpha; Male; Meningitis, Pneumococcal; Opportunistic Infections; Penicillin G; Pneumococcal Vaccines; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Risk Factors; Splenectomy

2008
[Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection].
    The Korean journal of hepatology, 2008, Volume: 14, Issue:3

    Topics: Adult; Antiviral Agents; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Korea; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2008
Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients.
    Internal medicine (Tokyo, Japan), 2008, Volume: 47, Issue:19

    Topics: Adolescent; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Ribavirin; Risk Factors; Sex Factors; Young Adult

2008
HCV virological response during treatment of chronic hepatitis C is associated with liver histological improvement in patients with HCV/HIV co-infection.
    The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2008, Volume: 12, Issue:3

    Topics: Adult; Antiviral Agents; Biopsy; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2008
Effect of interferon-alpha, ribavirin, pentoxifylline, and interleukin-18 antibody on hepatitis C sera-stimulated hepatic stellate cell proliferation.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2008, Volume: 28, Issue:11

    Topics: Animals; Antibodies, Monoclonal; Cell Proliferation; Cells, Cultured; Hepacivirus; Hepatic Stellate Cells; Hepatitis C, Chronic; Interferon-alpha; Interleukin-18; Pentoxifylline; Phosphorylation; Proto-Oncogene Proteins c-jun; Rats; Rats, Sprague-Dawley; Ribavirin; Serum; Signal Transduction

2008
Polymorphism in the human major histocompatibility complex and early viral decline during treatment of chronic hepatitis C.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:2

    Topics: Alleles; Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Ethnicity; Female; Genes, MHC Class I; Genes, MHC Class II; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Major Histocompatibility Complex; Male; Middle Aged; Models, Statistical; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Viral Load

2009
Porphyria cutanea tarda as a complication of therapy for chronic hepatitis C.
    World journal of gastroenterology, 2008, Oct-14, Volume: 14, Issue:38

    Topics: Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Hemochromatosis; Hemochromatosis Protein; Hepatitis C, Chronic; Histocompatibility Antigens Class I; Humans; Interferon alpha-2; Interferon-alpha; Iron Overload; Male; Membrane Proteins; Middle Aged; Mutation; Phlebotomy; Polyethylene Glycols; Porphyria Cutanea Tarda; Recombinant Proteins; Ribavirin

2008
Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors.
    Hepatology (Baltimore, Md.), 2008, Volume: 48, Issue:6

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Body Weight; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Mutation; Neutrophils; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Ribavirin; Th1 Cells; Th2 Cells; Treatment Outcome; Viral Load; Young Adult

2008
Drug-induced Sweet's syndrome secondary to hepatitis C antiviral therapy.
    International journal of dermatology, 2008, Volume: 47, Issue:9

    Topics: Administration, Oral; Biopsy, Needle; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Immunohistochemistry; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Middle Aged; Prednisone; Recombinant Proteins; Ribavirin; Risk Assessment; Sweet Syndrome; Treatment Outcome

2008
Peginterferon plus Ribavirin for chronic hepatitis C in opiate addicts on methadone/buprenorphine maintenance therapy.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2009, Volume: 41, Issue:4

    Topics: Adolescent; Adult; Antiviral Agents; Buprenorphine; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Methadone; Middle Aged; Narcotics; Patient Compliance; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Substance Abuse, Intravenous; Treatment Outcome; Young Adult

2009
A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection.
    Scandinavian journal of gastroenterology, 2008, Volume: 43, Issue:1

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome

2008
[Immunomodulators in the "gold standard" of the chronic viral hepatitis C therapy].
    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2008, Volume: 53, Issue:3-4

    Topics: Acridines; Antiviral Agents; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon Inducers; Interferon-alpha; Male; Quality of Life; Ribavirin; Surveys and Questionnaires

2008
Genetic variability in the 5' UTR and NS5A regions of hepatitis C virus RNA isolated from non-responding and responding patients with chronic HCV genotype 1 infection.
    Memorias do Instituto Oswaldo Cruz, 2008, Volume: 103, Issue:6

    Topics: 5' Untranslated Regions; Antiviral Agents; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Phylogeny; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Nonstructural Proteins

2008
Unchanged plasma levels of dimethylarginines and nitric oxide in chronic hepatitis C.
    Scandinavian journal of gastroenterology, 2009, Volume: 44, Issue:2

    Topics: Adult; Antiviral Agents; Arginine; Case-Control Studies; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Nitric Oxide; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2009
Impact of the novel hepatotropic viruslike agent NV-F during chronic hepatitis C virus infection.
    The Journal of infectious diseases, 2008, Dec-15, Volume: 198, Issue:12

    Topics: Adult; Antibodies, Viral; Antigens, Viral; Antiviral Agents; DNA, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hepatitis Viruses; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2008
Natural human interferon beta plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus and a high viral load.
    Internal medicine (Tokyo, Japan), 2008, Volume: 47, Issue:21

    Topics: Adult; Aged; Asian People; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-beta; Male; Mental Disorders; Middle Aged; Pilot Projects; Retrospective Studies; Ribavirin; Viral Load

2008
Patient education improves adherence to peg-interferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: a prospective, real-life, observational study.
    World journal of gastroenterology, 2008, Oct-28, Volume: 14, Issue:40

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; France; Genotype; Health Care Surveys; Health Knowledge, Attitudes, Practice; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Medication Adherence; Middle Aged; Odds Ratio; Patient Education as Topic; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Assessment; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2008
IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2009, Volume: 41, Issue:6

    Topics: Adult; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-10; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Recombinant Proteins; Ribavirin; Taiwan; Treatment Outcome; Young Adult

2009
[Influence of weight reduction on the effectiveness of combined peginterferon and ribavirin treatment in chronic HCV hepatitis].
    Orvosi hetilap, 2008, Nov-16, Volume: 149, Issue:46

    Topics: Amantadine; Antioxidants; Antiviral Agents; Drug Therapy, Combination; Fatty Liver; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Obesity; Polyethylene Glycols; Protective Agents; Recombinant Proteins; Ribavirin; Silymarin; Treatment Outcome; Weight Loss

2008
Clinical relevance of the 2'-5'-oligoadenylate synthetase/RNase L system for treatment response in chronic hepatitis C.
    Journal of hepatology, 2009, Volume: 50, Issue:1

    Topics: 2',5'-Oligoadenylate Synthetase; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Endoribonucleases; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; RNA, Viral; Sensitivity and Specificity

2009
A surprising hyperpigmentation of the gums and tongue.
    Gut, 2008, Volume: 57, Issue:12

    Topics: Adult; Antiviral Agents; Female; Gingival Diseases; Hepatitis C, Chronic; Humans; Hyperpigmentation; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tongue Diseases

2008
Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2008, Volume: 14, Issue:12

    Topics: Adult; Aged; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prognosis; Ribavirin; Secondary Prevention; Treatment Outcome; Young Adult

2008
Bone marrow toxicity in HCV genotype 5a-infected patient after peg-IFN alpha-2a and ribavirin therapy.
    Journal of chemotherapy (Florence, Italy), 2008, Volume: 20, Issue:5

    Topics: Antiviral Agents; Bone Marrow; Bone Marrow Diseases; Fibrosis; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pancytopenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2008
The natural history of interferon-alpha2b-induced thyroiditis and its exclusivity in a cohort of patients with chronic hepatitis C infection.
    QJM : monthly journal of the Association of Physicians, 2009, Volume: 102, Issue:2

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; Thyroiditis

2009
Interferon-alpha-associated presumed ocular sarcoidosis.
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2009, Volume: 247, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Choroid Diseases; Drug Therapy, Combination; Female; Glucocorticoids; Granuloma; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Panuveitis; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Sarcoidosis; Tomography, X-Ray Computed

2009
Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program.
    Journal of substance abuse treatment, 2009, Volume: 37, Issue:1

    Topics: Adult; Analgesics, Opioid; Antiviral Agents; Diagnosis, Dual (Psychiatry); Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Methadone; Opioid-Related Disorders; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome; United States

2009
Efficacy and safety of peginterferon alpha-2a/ribavirin in treatment-naive Cameroonian patients with chronic hepatitis C.
    Journal of medical virology, 2008, Volume: 80, Issue:12

    Topics: Adult; Antiviral Agents; Cameroon; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2008
Vitamins B depletion, lower iron status and decreased antioxidative defense in patients with chronic hepatitis C treated by pegylated interferon alfa and ribavirin.
    Clinical nutrition (Edinburgh, Scotland), 2009, Volume: 28, Issue:1

    Topics: Adult; Aged; Antioxidants; Antiviral Agents; Biomarkers; Case-Control Studies; Female; Folic Acid Deficiency; Hepatitis C, Chronic; Humans; Interferon-alpha; Iron; Iron Deficiencies; Lipid Peroxidation; Male; Middle Aged; Nutritional Status; Oxidation-Reduction; Oxidative Stress; Ribavirin; Vitamin B 6 Deficiency; Vitamin B Complex; Vitamin B Deficiency; Young Adult

2009
[Relationship between patient profile and feverishness developed during interferon-ribavirin combination therapy of chronic hepatitis C patients].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2008, Volume: 128, Issue:12

    Topics: Adult; Aged; Aging; Antiviral Agents; Drug Therapy, Combination; Female; Fever; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Severity of Illness Index; Sex Characteristics

2008
Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin.
    Antiviral therapy, 2008, Volume: 13, Issue:7

    Topics: Adult; Anti-HIV Agents; Antiviral Agents; Dideoxynucleosides; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin; Treatment Outcome

2008
Interferon-alpha-2b/ribavirin-induced vestibulocochlear toxicity with dysautonomia in a chronic hepatitis C patient.
    European journal of gastroenterology & hepatology, 2008, Volume: 20, Issue:11

    Topics: Antiviral Agents; Drug Therapy, Combination; Hearing Loss, Sudden; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tinnitus; Vertigo

2008
[Comparative efficiency and side effects of combined antiviral therapy of chronic hepatitis C].
    Klinicheskaia meditsina, 2008, Volume: 86, Issue:9

    Topics: Antiviral Agents; DNA, Viral; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult

2008
Interferon-induced thyroid dysfunction in chronic hepatitis C.
    Journal of gastroenterology and hepatology, 2009, Volume: 24, Issue:6

    Topics: Adult; Case-Control Studies; Chi-Square Distribution; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Sex Factors; Thyroid Diseases; Thyroid Function Tests; Western Australia

2009
Induction of IgA and sustained deficiency of cell proliferative response in chronic hepatitis C.
    World journal of gastroenterology, 2008, Nov-28, Volume: 14, Issue:44

    Topics: Adult; Antibody Formation; Antiviral Agents; Capsid Proteins; Cell Proliferation; Female; Hepacivirus; Hepatitis C Antibodies; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Immunoglobulin A; Interferon-alpha; Leukocytes, Mononuclear; Lymphocyte Activation; Male; Middle Aged; Ribavirin; T-Lymphocytes; Up-Regulation; Viral Envelope Proteins; Viral Nonstructural Proteins

2008
Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2009, Volume: 7, Issue:2

    Topics: Adult; Antiviral Agents; Biomarkers; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load

2009
Is physical activity possible and beneficial for patients with hepatitis C receiving pegylated interferon and ribavirin therapy?
    Gastroenterologie clinique et biologique, 2009, Volume: 33, Issue:1 Pt 1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Exercise; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin

2009
Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection.
    Hepatology (Baltimore, Md.), 2009, Volume: 49, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Time Factors; Viremia

2009
SEN Virus infection in HIV/HCV coinfected patients.
    European journal of medical research, 2008, Nov-24, Volume: 13, Issue:11

    Topics: Adult; Antiviral Agents; Comorbidity; DNA Virus Infections; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; RNA, Viral; Torque teno virus; Virus Replication

2008
"12 weeks' stopping rule" in the treatment of genotype 1 chronic hepatitis C: two prognostic categories under the same label?
    Scandinavian journal of gastroenterology, 2008, Volume: 43, Issue:8

    Topics: Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Time Factors

2008
Adherence to hepatitis C virus therapy and early virologic outcomes.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Jan-15, Volume: 48, Issue:2

    Topics: Antiviral Agents; Cohort Studies; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Regression Analysis; Ribavirin; Time Factors; Treatment Outcome; Viral Load

2009
[Protocol for the antiviral therapy of chronic hepatitis C].
    Orvosi hetilap, 2008, Dec-21, Volume: 149, Issue:52

    Topics: Algorithms; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin

2008
Abbott RealTime hepatitis C virus (HCV) and Roche Cobas AmpliPrep/Cobas TaqMan HCV assays for prediction of sustained virological response to pegylated interferon and ribavirin in chronic hepatitis C patients.
    Journal of clinical microbiology, 2009, Volume: 47, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Blood; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Time Factors

2009
What is the safe duration of therapy for patients infected with HCV genotype 6?
    Nature clinical practice. Gastroenterology & hepatology, 2009, Volume: 6, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome

2009
[Efficacy of initial treatment with peginterferon alpha-2a versus peginterferon alpha-2b in combination with ribavirin in naive chronic hepatitis C patients living in Daejeon and Chungcheong Province in Korea: a comparative study].
    The Korean journal of hepatology, 2008, Volume: 14, Issue:4

    Topics: Adult; Antiviral Agents; Combined Modality Therapy; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Korea; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors

2008
[Treatment with pegylated interferon and ribavirin in a patient with fibrosing cholestatic hepatitis due to recurrent hepatitis C after liver transplantation].
    The Korean journal of hepatology, 2008, Volume: 14, Issue:4

    Topics: Antiviral Agents; Cholestasis, Intrahepatic; Combined Modality Therapy; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Tomography, X-Ray Computed

2008
The evaluation of patients with hepatitis C living in rural California via telemedicine.
    Telemedicine journal and e-health : the official journal of the American Telemedicine Association, 2008, Volume: 14, Issue:10

    Topics: Antiviral Agents; California; Female; Health Services Accessibility; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Poverty; Retrospective Studies; Ribavirin; Rural Population; Telemedicine

2008
Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2009, Volume: 49, Issue:3

    Topics: Adult; Antiviral Agents; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Outcome Assessment, Health Care; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral

2009
Pegylated interferon alpha-2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy.
    Gut, 2009, Volume: 58, Issue:2

    Topics: Adult; Antiviral Agents; Dialysis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin

2009
Leukocyte interferon alpha early retreatment for Child A HCV genotype 1b-infected cirrhotics intolerant to pegylated interferons.
    Infection, 2009, Volume: 37, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2009
Early gene expression profiles of patients with chronic hepatitis C treated with pegylated interferon-alfa and ribavirin.
    Hepatology (Baltimore, Md.), 2009, Volume: 49, Issue:3

    Topics: Adult; Antiviral Agents; Chemokine CCL3; Drug Therapy, Combination; Female; Gene Expression Profiling; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Regulatory Factor-2; Interferon-alpha; Male; Middle Aged; Models, Biological; Models, Genetic; Pilot Projects; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Messenger; STAT5 Transcription Factor; STAT6 Transcription Factor; Tumor Suppressor Proteins

2009
[Anti-virus response and interferon, cytokine systems in patients with chronic hepatitis C].
    Terapevticheskii arkhiv, 2008, Volume: 80, Issue:11

    Topics: Adult; Antiviral Agents; Cytokines; Female; Hepatitis C, Chronic; Humans; Interferon-gamma; Male; Middle Aged; Peptide Fragments; Retrospective Studies; Ribavirin; Young Adult

2008
Efficacy and safety of antiviral therapy in patients with Crohn's disease and chronic hepatitis C.
    Alimentary pharmacology & therapeutics, 2008, Sep-15, Volume: 28, Issue:6

    Topics: Adult; Antiviral Agents; Comorbidity; Crohn Disease; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunocompromised Host; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome

2008
Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection.
    Digestive diseases and sciences, 2009, Volume: 54, Issue:12

    Topics: Adult; Antiviral Agents; Case-Control Studies; Diabetes Mellitus; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Odds Ratio; Ohio; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Severity of Illness Index; Time Factors; Treatment Failure; Viral Load

2009
A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response.
    Journal of medical virology, 2009, Volume: 81, Issue:3

    Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Mutation, Missense; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome

2009
A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients.
    BMC gastroenterology, 2009, Jan-20, Volume: 9

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Cohort Studies; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pakistan; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load; Young Adult

2009
Autoimmune thrombocytopenia related to chronic hepatitis C virus infection.
    Hematology (Amsterdam, Netherlands), 2009, Volume: 14, Issue:1

    Topics: Adult; Aged; Anemia, Hemolytic, Autoimmune; Antibodies; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Platelet Count; Platelet Membrane Glycoproteins; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin

2009
The effect of controlled therapy interruption in chronic HCV infection: enhanced host immune response? A hypothesis.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2009, Volume: 44, Issue:2

    Topics: Alanine Transaminase; Antiviral Agents; Bilirubin; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin; Viral Load; Withholding Treatment

2009
Role of growth factors and thrombopoietic agents in the treatment of chronic hepatitis C.
    Current gastroenterology reports, 2009, Volume: 11, Issue:1

    Topics: Antiviral Agents; Benzoates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Hydrazines; Intercellular Signaling Peptides and Proteins; Interferon alpha-2; Interferon-alpha; Platelet Count; Polyethylene Glycols; Pyrazoles; Recombinant Proteins; Ribavirin; Thrombocytopenia; Thrombopoiesis; Treatment Outcome

2009
Treatment of chronic hepatitis C: anticipated impact of resistance in patients treated with protease inhibitors.
    Current gastroenterology reports, 2009, Volume: 11, Issue:1

    Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Mutation; Oligopeptides; Phenotype; Proline; Protease Inhibitors; Ribavirin; Viral Nonstructural Proteins; Virus Replication

2009
Pegylated interferon-alpha-based treatment for chronic hepatitis C in renal transplant recipients: an open pilot study.
    Transplant international : official journal of the European Society for Organ Transplantation, 2009, Volume: 22, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Diseases; Kidney Transplantation; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2009
Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.
    Journal of viral hepatitis, 2009, Volume: 16, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Autoimmunity; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Thyroid Diseases; Thyroid Function Tests; Thyroid Gland; Ultrasonography; Young Adult

2009
The optimal ribavirin dose for patients infected with hepatitis C virus genotype 3: should we utilize more?
    Hepatology (Baltimore, Md.), 2009, Volume: 49, Issue:2

    Topics: Dose-Response Relationship, Drug; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin

2009
Hepatitis C virus persisting after clinically apparent sustained virological response to antiviral therapy retains infectivity in vitro.
    Hepatology (Baltimore, Md.), 2009, Volume: 49, Issue:5

    Topics: Adult; Antibodies, Monoclonal; Antigens, CD; Antiviral Agents; Cells, Cultured; Female; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Ribavirin; RNA, Viral; T-Lymphocytes; Tetraspanin 28; Viral Envelope Proteins; Viral Nonstructural Proteins

2009
Whole-body insulin sensitivity index is a highly specific predictive marker for virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients with genotype 1b and high viral load.
    Digestive diseases and sciences, 2010, Volume: 55, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Glucose Tolerance Test; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin; Insulin Resistance; Insulin Secretion; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Receptors, Tumor Necrosis Factor, Type II; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Viral Load

2010
Pernicious anemia during peginterferon-alpha2b plus ribavirin therapy for chronic hepatitis C.
    European journal of gastroenterology & hepatology, 2009, Volume: 21, Issue:5

    Topics: Anemia, Pernicious; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2009
Anterior ischemic optic neuropathy complicating interferon alpha and ribavirin therapy in patients with chronic hepatitisC.
    Gastroenterologie clinique et biologique, 2009, Volume: 33, Issue:2

    Topics: Aged; Antiviral Agents; Female; Fluorescein Angiography; Fundus Oculi; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Optic Neuropathy, Ischemic; Papilledema; Recombinant Proteins; Ribavirin; Visual Acuity

2009
Effects of combined interferon alpha and ribavirin therapy on thyroid functions in patients with chronic hepatitis C.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2009, Volume: 19, Issue:2

    Topics: Adolescent; Adult; Antiviral Agents; Case-Control Studies; Cohort Studies; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Risk; Thyroid Diseases; Thyroid Function Tests; Treatment Outcome; Young Adult

2009
Serum ferritin as a predictor of treatment outcome in patients with chronic hepatitis C.
    The American journal of gastroenterology, 2009, Volume: 104, Issue:3

    Topics: Adult; Antiviral Agents; Disease Progression; Female; Ferritins; Hemolysis; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Iron; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Transferrin; Treatment Outcome

2009
Bacterial infection and neutropenia during peginterferon plus ribavirin combination therapy in patients with chronic hepatitis C with and without baseline neutropenia in clinical practice.
    Alimentary pharmacology & therapeutics, 2009, May-01, Volume: 29, Issue:9

    Topics: Adult; Aged; Antiviral Agents; Bacterial Infections; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome; Young Adult

2009
[Chorea during treatment with pegylated interferon and ribavirin in HIV-HCV coinfected patient].
    Enfermedades infecciosas y microbiologia clinica, 2009, Volume: 27, Issue:1

    Topics: Adult; Anti-HIV Agents; Antidepressive Agents; Antiviral Agents; Anxiety Disorders; Chorea; Citalopram; Depressive Disorder; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Hypothyroidism; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Polypharmacy; Recombinant Proteins; Ribavirin; Sensation Disorders; Thyroiditis, Autoimmune; Thyroxine

2009
Histological response study of chronic viral hepatitis C patients treated with interferon alone or combined with ribavirin.
    The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2008, Volume: 12, Issue:5

    Topics: Adult; Antiviral Agents; Combined Modality Therapy; Disease Progression; Female; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Male; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome

2008
Impact of early viral kinetics on pegylated interferon alpha 2b plus ribavirin therapy in Japanese patients with genotype 2 chronic hepatitis C.
    Journal of viral hepatitis, 2009, Volume: 16, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Asian People; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2009
Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients.
    Journal of hepatology, 2009, Volume: 50, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Insulin Resistance; Insulin-Secreting Cells; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Regression Analysis; Ribavirin; RNA, Viral; Viral Load

2009
Insulin resistance in HCV mono-infected and in HIV/HCV co-infected patients: Looking to the future.
    Journal of hepatology, 2009, Volume: 50, Issue:4

    Topics: Antiviral Agents; Diabetes Mellitus; Hepatitis C, Chronic; HIV Infections; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome; Viral Load

2009
[Lichenoid eruption in a patient with chronic hepatitis C virus infection treated with interferon and ribavirin].
    Gastroenterologia y hepatologia, 2009, Volume: 32, Issue:2

    Topics: Drug Eruptions; Drug Therapy, Combination; Female; Hand Dermatoses; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lichenoid Eruptions; Middle Aged; Recombinant Proteins; Ribavirin

2009
Treating chronic hepatitis C in recovering opiate addicts: yes, we can.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2009, Volume: 41, Issue:4

    Topics: Antiviral Agents; Buprenorphine; Drug Therapy, Combination; Drug Users; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Italy; Methadone; Narcotics; Patient Compliance; Polyethylene Glycols; Practice Guidelines as Topic; Practice Patterns, Physicians'; Recombinant Proteins; Refusal to Treat; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome; United States

2009
Molecular epidemiology of hepatitis C genotype 6a from patients with chronic hepatitis C from Hong Kong.
    Journal of medical virology, 2009, Volume: 81, Issue:4

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Hong Kong; Humans; Interferon alpha-2; Interferon-alpha; Molecular Epidemiology; Molecular Sequence Data; Mutation; Phylogeny; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Treatment Outcome; Viral Nonstructural Proteins

2009
Early decline of the HCV core antigen can predict SVR in patients with HCV treated by Pegylated interferon plus ribavirin combination therapy.
    Journal of digestive diseases, 2009, Volume: 10, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Genotype; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Core Proteins; Viral Load

2009
Outcome of retinopathy in chronic hepatitis C patients treated with peginterferon and ribavirin.
    Digestive diseases and sciences, 2010, Volume: 55, Issue:2

    Topics: Antiviral Agents; Drug Carriers; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retinal Diseases; Ribavirin; Treatment Outcome

2010
Evidence for action of ribavirin through the hepatitis C virus RNA polymerase.
    Journal of viral hepatitis, 2009, Volume: 16, Issue:8

    Topics: Amino Acid Sequence; Antiviral Agents; DNA-Directed RNA Polymerases; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Models, Molecular; Molecular Sequence Data; Mutation, Missense; Protein Structure, Tertiary; Ribavirin; RNA, Viral; Sequence Alignment; Sequence Analysis, DNA; Viral Proteins

2009
Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum hepatitis C virus RNA, genotype 1b, discontinued on attaining sustained virological response at week 16 after onset of acute pancreatitis.
    Digestion, 2009, Volume: 79, Issue:1

    Topics: Acute Disease; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Pancreatitis; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load

2009
Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype 1b and low-virus load.
    Internal medicine (Tokyo, Japan), 2009, Volume: 48, Issue:5

    Topics: Adult; Antiviral Agents; Biopsy; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2009
Serum transaminase elevations during pegylated interferon treatment of chronic HCV hepatitis probably induced by polyethylene glycol.
    Intervirology, 2008, Volume: 51, Issue:6

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Drug Therapy, Combination; Gene Expression Regulation, Enzymologic; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2008
[Case of overwhelming postsplenectomy infection (OPSI) with chronic hepatitis type C during peginterferon/ribavirin combination therapy].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2009, Volume: 106, Issue:3

    Topics: Antiviral Agents; Fatal Outcome; Female; Hepatitis C, Chronic; Humans; Immunocompromised Host; Interferon alpha-2; Interferon-alpha; Middle Aged; Neutropenia; Pneumococcal Infections; Pneumococcal Vaccines; Polyethylene Glycols; Postoperative Complications; Recombinant Proteins; Ribavirin; Sepsis; Splenectomy

2009
Sequential antiviral and iron chelation treatment in a teenage boy with congenital anemia, chronic hepatitis C, and secondary hemosiderosis.
    Journal of pediatric gastroenterology and nutrition, 2009, Volume: 48, Issue:3

    Topics: Adolescent; Anemia; Antiviral Agents; Chelation Therapy; Deferoxamine; Ferritins; Hemoglobinopathies; Hemosiderosis; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Ribavirin; Siderophores

2009
Pruritic papules limited to tattooed skin.
    Archives of dermatology, 2009, Volume: 145, Issue:3

    Topics: Adult; Hepatitis C, Chronic; Humans; Interferons; Male; Ribavirin; Sarcoidosis; Skin; Skin Diseases; Tattooing

2009
Early prediction of sustained virological response at day 3 of treatment with albinterferon-alpha-2b in patients with genotype 2/3 chronic hepatitis C.
    Liver international : official journal of the International Association for the Study of the Liver, 2009, Volume: 29, Issue:9

    Topics: Adult; Albumins; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral

2009
Treatment outcomes with pegylated interferon and ribavirin for male prisoners with chronic hepatitis C.
    Journal of clinical gastroenterology, 2009, Volume: 43, Issue:7

    Topics: Adult; Antiviral Agents; Black or African American; Drug Therapy, Combination; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prisoners; Recombinant Proteins; Retrospective Studies; Rhode Island; Ribavirin; Treatment Outcome; White People; Young Adult

2009
Combination treatment for chronic HCV hepatitis in lymphangioleiomyomatosis: first case report.
    Journal of chemotherapy (Florence, Italy), 2009, Volume: 21, Issue:1

    Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lung Neoplasms; Lymphangioleiomyomatosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2009
Patients achieving clearance of HCV with interferon therapy recover from decreased retinol-binding protein 4 levels.
    Journal of viral hepatitis, 2009, Volume: 16, Issue:10

    Topics: Aged; Antiviral Agents; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Plasma; Polyethylene Glycols; Recombinant Proteins; Retinol-Binding Proteins, Plasma; Ribavirin; Severity of Illness Index; Viral Load

2009
Early viraemia clearance during antiviral therapy of chronic hepatitis C improves dendritic cell functions.
    Clinical immunology (Orlando, Fla.), 2009, Volume: 131, Issue:3

    Topics: Adult; Antigens, Viral; Antiviral Agents; CD4-Positive T-Lymphocytes; Cells, Cultured; Dendritic Cells; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-12; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viremia

2009
Autoimmune haemolytic anaemia due to chronic hepatitis C virus infection treated with prednisone, pegylated interferon and ribavirin.
    The Netherlands journal of medicine, 2009, Volume: 67, Issue:3

    Topics: Adult; Anemia, Hemolytic, Autoimmune; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prednisolone; Recombinant Proteins; Ribavirin

2009
Re-treatment with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy.
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2009, Volume: 23, Issue:3

    Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retreatment; Retrospective Studies; Ribavirin; Treatment Outcome; Young Adult

2009
Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy.
    Antiviral therapy, 2009, Volume: 14, Issue:1

    Topics: Alanine Transaminase; Antiviral Agents; Asian People; Body Mass Index; Cholesterol, HDL; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2009
Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice.
    International journal of technology assessment in health care, 2009, Volume: 25, Issue:2

    Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Decision Trees; Drug Therapy, Combination; Female; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Markov Chains; Middle Aged; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin

2009
When less may not be best--the challenge of individualising antiviral therapy for chronic hepatitis C infection.
    Journal of gastroenterology and hepatology, 2009, Volume: 24, Issue:3

    Topics: Antiviral Agents; Asian People; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; White People

2009
Polyethylene glycol interferon alpha-2b-induced immune-mediated polyradiculoneuropathy.
    Internal medicine (Tokyo, Japan), 2009, Volume: 48, Issue:7

    Topics: Antiviral Agents; Autoantibodies; Autoantigens; Autoimmune Diseases of the Nervous System; Drug Carriers; Drug Therapy, Combination; G(M1) Ganglioside; Gait Disorders, Neurologic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Muscle Weakness; Plasmapheresis; Polyethylene Glycols; Polyradiculoneuropathy; Recombinant Proteins; Ribavirin

2009
High sustained virological response rate to combination therapy in genotype 1 patients with histologically mild hepatitis C.
    Journal of gastrointestinal and liver diseases : JGLD, 2009, Volume: 18, Issue:1

    Topics: Adult; Age Factors; Antiviral Agents; Biomarkers; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Romania; Severity of Illness Index; Time Factors; Transaminases; Treatment Outcome; Viral Load

2009
Severe autoimmune hemolytic anemia complicated with liver decompensation and invasive aspergillosis in a patient with chronic hepatitis C during treatment with peg-interferon-a and ribavirin.
    Journal of gastrointestinal and liver diseases : JGLD, 2009, Volume: 18, Issue:1

    Topics: Adrenal Cortex Hormones; Anemia, Hemolytic, Autoimmune; Antifungal Agents; Antiviral Agents; Female; Hepatic Encephalopathy; Hepatitis C, Chronic; Humans; Hypothyroidism; Interferon alpha-2; Interferon-alpha; Invasive Pulmonary Aspergillosis; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tomography, X-Ray Computed

2009
Ribavirin in chronic hepatitis C: past and future.
    Expert review of anti-infective therapy, 2009, Volume: 7, Issue:3

    Topics: Antiviral Agents; Drug Monitoring; Drug Synergism; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Ribavirin; Treatment Outcome

2009
[Prediction of response to peginterferon and ribavirin combination therapy using mutations in the HCV genome].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2009, Volume: 106, Issue:4

    Topics: Amino Acid Sequence; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Mutation; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2009
[Durability of a sustained virologic response in combination therapy with interferon/peginterferon and ribavirin for chronic hepatitis C].
    The Korean journal of hepatology, 2009, Volume: 15, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Viremia

2009
[Management of chronic hepatitis C which failed to respond to previous treatment].
    Gastroenterologie clinique et biologique, 2009, Volume: 33, Issue:4

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; Treatment Failure

2009
Elevations in alanine aminotransferase levels late in the course of antiviral therapy in hepatitis C virus RNA-negative patients are associated with virological relapse.
    Hepatology (Baltimore, Md.), 2009, Volume: 49, Issue:5

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral

2009
Localized scleroderma (morphea) in a patient with chronic hepatitis C.
    European journal of gastroenterology & hepatology, 2009, Volume: 21, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Scleroderma, Localized

2009
An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads.
    Intervirology, 2009, Volume: 52, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2009
[Treatment of chronic hepatitis C in HIV-infected patients].
    Gastroenterologie clinique et biologique, 2009, Volume: 33 Suppl 2

    Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Clinical Trials as Topic; Congresses as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome

2009
Summaries for patients. Re-treating patients with chronic hepatitis C who have not responded to peginterferon-alpha2b.
    Annals of internal medicine, 2009, Apr-21, Volume: 150, Issue:8

    Topics: Antiviral Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Treatment Failure

2009
Antinuclear antibody positivity in patients with chronic hepatitis C: clinically relevant or an epiphenomenon?
    European journal of gastroenterology & hepatology, 2009, Volume: 21, Issue:4

    Topics: Adult; Alanine Transaminase; Antibodies, Antinuclear; Antiviral Agents; Biomarkers; Cross-Sectional Studies; Drug Therapy, Combination; Female; Fluorescent Antibody Technique, Indirect; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Treatment Failure; Treatment Outcome

2009
Thyroid dysfunction in patients with chronic hepatitis C: virus- or therapy-related?
    Journal of gastroenterology and hepatology, 2009, Volume: 24, Issue:6

    Topics: Adult; Antiviral Agents; Chi-Square Distribution; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Thyroid Diseases; Thyroid Function Tests

2009
[Peripheral polyneuropathy and bilateral optic neuropathy during treatment of chronic hepatitis C].
    Deutsche medizinische Wochenschrift (1946), 2009, Volume: 134, Issue:18

    Topics: Adrenal Cortex Hormones; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Optic Nerve Diseases; Papilledema; Peripheral Nervous System Diseases; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Vision Disorders

2009
Peginterferon alfa-2b and ribavirin in chronic hepatitis C relapse: new indication. For some patients.
    Prescrire international, 2009, Volume: 18, Issue:99

    Topics: Clinical Trials as Topic; Drug Approval; Drug Therapy, Combination; Europe; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Secondary Prevention; Viral Load

2009
Iatrogenic hyperpigmentation in chronically infected hepatitis C patients treated with pegylated interferon and ribavirin.
    Journal of the American Academy of Dermatology, 2009, Volume: 60, Issue:5

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Hyperpigmentation; Iatrogenic Disease; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2009
[Impact of pegylated interferon alpha and ribavirin therapy of chronic hepatitis C on peripheral blood and intrahepatic lymphocytes].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2009, Volume: 26, Issue:151

    Topics: Adult; Antiviral Agents; Biopsy; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Female; Flow Cytometry; Hepatitis C, Chronic; Humans; Immunity, Cellular; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; T-Lymphocyte Subsets; Young Adult

2009
Apolipoprotein B-associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti-viral agents interferon-alpha and ribavirin.
    Alimentary pharmacology & therapeutics, 2009, Jun-15, Volume: 29, Issue:12

    Topics: Adult; Antiviral Agents; Apolipoproteins B; Cholesterol; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Retrospective Studies; Ribavirin; Treatment Outcome

2009
Sustained virological responses following standard anti-viral therapy in decompensated HCV-infected cirrhotic patients.
    Alimentary pharmacology & therapeutics, 2009, Jul-01, Volume: 30, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult

2009
Pioglitazone as adjuvant therapy in chronic hepatitis C: sequential rather than concomitant administration with pegylated interferon and ribavirin?
    Journal of hepatology, 2009, Volume: 50, Issue:6

    Topics: Adult; Antiviral Agents; Chemotherapy, Adjuvant; Drug Administration Schedule; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Pioglitazone; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Thiazolidinediones

2009
Clinical features and effect of antiviral therapy on anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis C.
    Journal of hepatology, 2009, Volume: 50, Issue:6

    Topics: Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Autoantibodies; Autoimmunity; CD8-Positive T-Lymphocytes; Cohort Studies; Female; Hepatitis C, Chronic; Humans; Immunoglobulin G; Interferons; Kidney; Liver; Male; Microsomes; Middle Aged; Ribavirin; Young Adult

2009
A step forward in therapy for hepatitis C.
    The New England journal of medicine, 2009, Apr-30, Volume: 360, Issue:18

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load

2009
Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C.
    The New England journal of medicine, 2009, Apr-30, Volume: 360, Issue:18

    Topics: Antiviral Agents; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Viral Load; White People

2009
Treatment of chronic hepatitis C in sickle cell disease and thalassaemic patients with interferon and ribavirin.
    European journal of gastroenterology & hepatology, 2009, Volume: 21, Issue:7

    Topics: Adolescent; Adult; Anemia, Hemolytic; Anemia, Sickle Cell; Antiviral Agents; beta-Thalassemia; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Pilot Projects; Ribavirin; Treatment Outcome; Young Adult

2009
Autoimmune hepatitis in the HIV-infected patient: a therapeutic dilemma.
    AIDS patient care and STDs, 2009, Volume: 23, Issue:6

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Hepatitis, Autoimmune; HIV Infections; Humans; Interferons; Liver Failure, Acute; Liver Function Tests; Male; Middle Aged; Ribavirin; Treatment Outcome

2009
Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C.
    The New England journal of medicine, 2009, Apr-30, Volume: 360, Issue:18

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon alpha-2; Interferon-alpha; Mutation; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load; White People

2009
Feasibility of ribavirin therapeutic drug monitoring in hepatitis C.
    Therapeutic drug monitoring, 2009, Volume: 31, Issue:3

    Topics: Antiviral Agents; Chromatography, High Pressure Liquid; Drug Monitoring; Drug Stability; Feasibility Studies; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Spectrometry, Mass, Electrospray Ionization

2009
Differential viral kinetics in treated genotype 4 chronic hepatitis C patients according to ethnicity.
    Journal of viral hepatitis, 2009, Volume: 16, Issue:10

    Topics: Adult; Antiviral Agents; Ethnicity; Europe; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2009
Successful treatment of chronic hepatitis C virus infection with peginterferon alpha-2a and ribavirin in patients with sickle cell disease.
    Saudi medical journal, 2009, Volume: 30, Issue:5

    Topics: Adolescent; Adult; Anemia, Sickle Cell; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Young Adult

2009
What caused this lingual hyperpigmentation in a patient with chronic hepatitis C?
    Liver international : official journal of the International Association for the Study of the Liver, 2010, Volume: 30, Issue:3

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Hyperpigmentation; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tongue Diseases

2010
Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patients: the Fibrovic 2 Study - ANRS HC02.
    Antiviral therapy, 2009, Volume: 14, Issue:2

    Topics: Adult; Antiviral Agents; Biomarkers; Biopsy; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index

2009
Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial.
    Hepatology (Baltimore, Md.), 2009, Volume: 49, Issue:6

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Time Factors

2009
Response to therapy with pegylated interferon and ribavirin for chronic hepatitis C in hispanics compared to non-Hispanic whites.
    The American journal of gastroenterology, 2009, Volume: 104, Issue:7

    Topics: Adult; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Logistic Models; Male; Middle Aged; Multivariate Analysis; New Mexico; Polyethylene Glycols; Probability; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Severity of Illness Index; Treatment Outcome; White People

2009
Multiple cytokine profiling of the therapeutic responses to ribavirin and pegylated interferon-alpha2b using an "induction" approach with natural interferon-beta in difficult-to-treat chronic hepatitis C.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2009, Volume: 29, Issue:6

    Topics: Adult; Cytokines; Drug Resistance, Viral; Drug Therapy, Combination; Female; Gene Expression Profiling; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-beta; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Serologic Tests; Transcriptional Activation; Treatment Outcome; Viral Load; Virulence

2009
The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin.
    Antiviral research, 2009, Volume: 83, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Asian People; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2009
What offers the best prediction of sustained virologic response during combination therapy with interferon and ribavirin: viral dynamics, viral levels at certain time points, or a combination of both?
    Journal of hepatology, 2009, Volume: 51, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; RNA, Viral; Viral Load

2009
Cost minimisation analysis of 12 or 24 weeks of peginterferon alfa-2b + ribavirin for hepatitis C virus.
    Journal of medical economics, 2008, Volume: 11, Issue:1

    Topics: Antiviral Agents; Costs and Cost Analysis; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Multicenter Studies as Topic; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Reproducibility of Results; Ribavirin

2008
Interleukin 18 promoter variants (-137G>C and -607C>A) in patients with chronic hepatitis C: association with treatment response.
    Journal of clinical immunology, 2009, Volume: 29, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Disease Progression; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukin-18; Male; Middle Aged; Polymorphism, Genetic; Prognosis; Promoter Regions, Genetic; Ribavirin; RNA, Viral; Treatment Outcome

2009
A 2-log drop in viral load at 1 month is the best predictor of sustained response in HCV patients with normal ALT: a kinetic prospective study.
    Journal of viral hepatitis, 2009, Volume: 16, Issue:7

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2009
Plasma HCV-RNA decline in the first 48 h identifies hepatitis C virus mono-infected but not HCV/HIV-coinfected patients with an undetectable HCV viral load at week 4 of peginterferon-alfa-2a/ribavirin therapy.
    Journal of viral hepatitis, 2009, Volume: 16, Issue:12

    Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2009
[Eradication of hepatitis C virus after a 5-week treatment].
    La Revue de medecine interne, 2009, Volume: 30, Issue:10

    Topics: Antiviral Agents; DNA, Viral; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Medication Adherence; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2009
Marked iron overload related to ribavirin and iron sulfate treatment in a patient with active viral C cirrhosis.
    European journal of gastroenterology & hepatology, 2009, Volume: 21, Issue:11

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Ferritins; Ferrous Compounds; Hepatitis C, Chronic; Humans; Iron Overload; Middle Aged; Ribavirin

2009
Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in patients with chronic hepatitis C, using viral and host factors: some concerns.
    Hepatology (Baltimore, Md.), 2009, Volume: 49, Issue:6

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin

2009
Quality of life, depression, and cytokine patterns in patients with chronic hepatitis C treated with antiviral therapy.
    Clinical and investigative medicine. Medecine clinique et experimentale, 2009, Jun-01, Volume: 32, Issue:3

    Topics: Adult; Antiviral Agents; Cohort Studies; Cytokines; Depression; Female; Hepatitis C, Chronic; Humans; Interleukin-10; Interleukin-2; Interleukin-4; Interleukin-6; Male; Middle Aged; Quality of Life; Ribavirin; Tumor Necrosis Factor-alpha

2009
Predictors of antiviral treatment initiation in hepatitis C virus-infected patients: a Danish cohort study.
    Journal of viral hepatitis, 2009, Volume: 16, Issue:9

    Topics: Adult; Antiviral Agents; Biomarkers; Cohort Studies; Denmark; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Models, Statistical; Prognosis; Ribavirin; Young Adult

2009
Rapid suppression of hepatitis C viremia induced by intravenous silibinin plus ribavirin.
    Gastroenterology, 2009, Volume: 137, Issue:1

    Topics: Aged; Antiviral Agents; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Infusions, Intravenous; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Silybin; Silymarin; Treatment Outcome; Viral Load

2009
Development of pouchitis with combination therapy with peg-interferon alpha-2b and ribavirin for chronic hepatitis C in a patient with ulcerative colitis who underwent pouch surgery.
    The American journal of gastroenterology, 2009, Volume: 104, Issue:6

    Topics: Adult; Antiviral Agents; Colitis, Ulcerative; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Ileostomy; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Pouchitis; Recombinant Proteins; Ribavirin

2009
[Efficacy of combination treatment with pegylated interferon plus ribavirin in patients chronically infected with HCV].
    Vnitrni lekarstvi, 2009, Volume: 55, Issue:5

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viremia; Young Adult

2009
Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study.
    Journal of gastroenterology, 2009, Volume: 44, Issue:9

    Topics: Adolescent; Adult; Aged; Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Mutation; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Sex Factors; Viral Load; Viral Nonstructural Proteins; Young Adult

2009
[Standards of treatment of the hepatitis C (June 2008)].
    Przeglad epidemiologiczny, 2009, Volume: 63, Issue:1

    Topics: Antiviral Agents; Critical Pathways; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome

2009
Efficacy of peginterferon-alpha-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C.
    Liver international : official journal of the International Association for the Study of the Liver, 2010, Volume: 30, Issue:4

    Topics: Adult; Age Factors; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Probability; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome; Young Adult

2010
Impact of ribavirin plasma level on sustained virological response in patients treated with pegylated interferon and ribavirin for chronic hepatitis C.
    Alimentary pharmacology & therapeutics, 2009, Sep-01, Volume: 30, Issue:5

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Viral Load; Young Adult

2009
Decline in male sexual desire, function, and satisfaction during and after antiviral therapy for chronic hepatitis C.
    Gastroenterology, 2009, Volume: 137, Issue:3

    Topics: Adult; Antiviral Agents; Black People; Drug Therapy, Combination; Ejaculation; Erectile Dysfunction; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Libido; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Surveys and Questionnaires; White People

2009
Mevalonate pathway modulation is associated with hepatitis C virus RNA presence in peripheral blood mononuclear cells.
    Virus research, 2009, Volume: 145, Issue:1

    Topics: Adolescent; Antiviral Agents; Child; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Male; Metabolic Networks and Pathways; Mevalonic Acid; Recombinant Proteins; Ribavirin; RNA, Viral; Young Adult

2009
Interferon-induced retinopathy and its risk in patients with diabetes and hypertension undergoing treatment for chronic hepatitis C virus infection.
    Alimentary pharmacology & therapeutics, 2009, Sep-15, Volume: 30, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Diabetes Mellitus; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hypertension; Interferon alpha-2; Interferon-alpha; Interferons; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retinal Diseases; Retrospective Studies; Ribavirin; Risk Factors

2009
Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin.
    Journal of viral hepatitis, 2009, Volume: 16, Issue:8

    Topics: Aged; Antiviral Agents; Dose-Response Relationship, Drug; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome

2009
Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin.
    Journal of viral hepatitis, 2009, Volume: 16, Issue:8

    Topics: Aged; Antiviral Agents; Dose-Response Relationship, Drug; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2009
Pegylated interferon/ribavirin-induced sudden sensorineural hearing loss in a patient with chronic hepatitis C.
    Journal of gastrointestinal and liver diseases : JGLD, 2009, Volume: 18, Issue:2

    Topics: Antiviral Agents; Audiometry, Pure-Tone; Drug Therapy, Combination; Hearing Loss, Sensorineural; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2009
Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin.
    Annals of hematology, 2010, Volume: 89, Issue:2

    Topics: Adult; Anemia; Antiviral Agents; Female; Genotype; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Multivariate Analysis; Neutropenia; Ribavirin; Risk Factors; Thrombocytopenia

2010
Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:2

    Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Ribavirin; Treatment Outcome

2009
Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection.
    Liver international : official journal of the International Association for the Study of the Liver, 2009, Volume: 29, Issue:7

    Topics: Adult; Antidepressive Agents; Antiviral Agents; Cohort Studies; Depression; Drug Therapy, Combination; Drug Users; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Mental Disorders; Middle Aged; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Substance Abuse, Intravenous; Treatment Failure; Viral Load

2009
Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.
    The Korean journal of hepatology, 2009, Volume: 15, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Myasthenia Gravis; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2009
Living with hepatitis C and treatment: the personal experiences of patients.
    Journal of clinical nursing, 2009, Volume: 18, Issue:16

    Topics: Adaptation, Psychological; Adult; Antiviral Agents; Attitude to Health; Cost of Illness; Drug Therapy, Combination; Family; Health Services Needs and Demand; Hepatitis C, Chronic; Humans; Interferons; Middle Aged; New South Wales; Nursing Methodology Research; Qualitative Research; Quality of Life; Ribavirin; Self Disclosure; Social Isolation; Stereotyping; Surveys and Questionnaires

2009
Correlates and prognostic value of the first-phase hepatitis C virus RNA kinetics during treatment.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Aug-15, Volume: 49, Issue:4

    Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2009
[Interferon-related retinopathy in a man with chronic hepatitis C].
    Journal francais d'ophtalmologie, 2009, Volume: 32, Issue:7

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Retinal Diseases; Ribavirin

2009
Peginterferon plus ribavirin over two years may be successful in patients with chronic hepatitis C and a very slow virologic response.
    Scandinavian journal of gastroenterology, 2009, Volume: 44, Issue:9

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Viral Load

2009
Predictive value of complete and partial early virological response on sustained virological response rates of genotype-4 chronic hepatitis C patients treated with PEG-interferon plus ribavirin.
    Intervirology, 2009, Volume: 52, Issue:5

    Topics: Adult; Animals; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Rats; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2009
[Spontaneous and treatment-induced virological dynamic in the plasma, PBMC and liver tissue in a patient with chronic HBV and HCV coinfection].
    Le infezioni in medicina, 2009, Volume: 17, Issue:2

    Topics: Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Follow-Up Studies; Hepatitis B Antibodies; Hepatitis B Antigens; Hepatitis B, Chronic; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Liver; Liver Cirrhosis; Male; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load; Viremia

2009
[Pegylated-interferon alpha plus ribavirin-induced subacute thyroiditis in chronic hepatitis C].
    Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2009, Volume: 56, Issue:3

    Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thyroiditis, Autoimmune; Thyroiditis, Subacute; Viral Load

2009
Interferon-induced thyroid dysfunction--not always transient.
    Journal of gastroenterology and hepatology, 2009, Volume: 24, Issue:6

    Topics: Animals; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Thyroid Diseases; Time Factors

2009
Telaprevir for chronic HCV infection.
    The New England journal of medicine, 2009, Jul-30, Volume: 361, Issue:5

    Topics: Antiviral Agents; Asian People; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2009
Leukocyte interferon-alpha and ribavirin for treatment of chronic hepatitis C patients intolerant to pegylated-interferon.
    Internal and emergency medicine, 2009, Volume: 4, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Drug Tolerance; Female; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2009
Response to combination therapy in hepatitis virus C genotype 2 and 3.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2009, Volume: 19, Issue:8

    Topics: Adult; Antimetabolites; Antiviral Agents; Cohort Studies; Databases, Factual; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferons; Male; Retrospective Studies; Ribavirin; Treatment Outcome

2009
Forewarned is forearmed.
    Journal of hepatology, 2009, Volume: 51, Issue:4

    Topics: Antiviral Agents; Fibrosis; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2009
Etanercept as prophylactic psoriatic therapy before interferon-alpha and ribavirin treatment for active hepatitis C infection.
    Clinical and experimental dermatology, 2010, Volume: 35, Issue:4

    Topics: Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Etanercept; Hepatitis C, Chronic; Humans; Immunoglobulin G; Interferon-alpha; Male; Middle Aged; Psoriasis; Receptors, Tumor Necrosis Factor; Ribavirin

2010
A fatal case of phlegmonous colitis in chronic hepatitis C receiving combination interferon and ribavirin therapy.
    Internal medicine journal, 2009, Volume: 39, Issue:7

    Topics: Colitis; Drug Therapy, Combination; Fatal Outcome; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin

2009
Outcome of combination antiviral therapy in hepatitis C virus infected patients with sickle cell disease.
    Saudi medical journal, 2009, Volume: 30, Issue:8

    Topics: Anemia, Sickle Cell; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin

2009
Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4.
    Gut, 2009, Volume: 58, Issue:12

    Topics: Adult; Antiviral Agents; Black People; Egypt; Female; France; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2009
Hepatic Toll-Like Receptor 3 expression in chronic hepatitis C genotype 1 correlates with treatment response to peginterferon plus ribavirin.
    Journal of viral hepatitis, 2010, Feb-01, Volume: 17, Issue:2

    Topics: Adult; Aged; Animals; Antiviral Agents; Biomarkers; Female; Gene Expression Profiling; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Toll-Like Receptor 3; Treatment Outcome

2010
Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:5

    Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Child; Child, Preschool; Disease Progression; Drug Therapy, Combination; Female; France; Hepatitis C, Chronic; Humans; Infant; Infant, Newborn; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Sensitivity and Specificity; Young Adult

2009
Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses.
    Journal of viral hepatitis, 2010, Volume: 17, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2010
Mutation frequency of NS5A in patients vertically infected with HCV genotype 1 predicts sustained virological response to peginterferon alfa-2b and ribavirin combination therapy.
    Journal of viral hepatitis, 2009, Volume: 16, Issue:12

    Topics: Adolescent; Amino Acid Sequence; Antiviral Agents; Child; Child, Preschool; Disease Transmission, Infectious; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Infectious Disease Transmission, Vertical; Interferon alpha-2; Interferon-alpha; Male; Molecular Sequence Data; Mutation, Missense; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Treatment Outcome; Viral Envelope Proteins; Viral Nonstructural Proteins; Young Adult

2009
Peginterferon (PEG-IFN) plus ribavirin combination therapy, but neither interferon nor PGE-IFN alone, induced type 1 diabetes in a patient with chronic hepatitis C.
    Internal medicine (Tokyo, Japan), 2009, Volume: 48, Issue:16

    Topics: Blood Glucose; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2009
Laparoscopic splenectomy with peginterferon and ribavirin therapy for patients with hepatitis C virus cirrhosis and hypersplenism.
    Surgical endoscopy, 2010, Volume: 24, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Hypersplenism; Interferon alpha-2; Interferon-alpha; Laparoscopy; Length of Stay; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Splenectomy; Tomography, X-Ray Computed; Treatment Outcome; Viral Load

2010
Comment to "Treating chronic hepatitis C in recovering opiate addicts: yes, we can".
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2010, Volume: 42, Issue:4

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Opioid-Related Disorders; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2010
High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment.
    Journal of virology, 2009, Volume: 83, Issue:21

    Topics: ADP-ribosyl Cyclase 1; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Disease Progression; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Lymphocyte Activation; Male; Middle Aged; Ribavirin; T-Lymphocyte Subsets; T-Lymphocytes; Viral Load; Young Adult

2009
Re-treating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: really safe and effective?
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:3

    Topics: Antiviral Agents; Drug Resistance, Viral; Hepatitis C, Chronic; Humans; Interferon Type I; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2009
[Short-term treatment of Hepatitis C in heroin-dependent patients].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2009, Aug-27, Volume: 129, Issue:16

    Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heroin Dependence; Humans; Interferon alpha-2; Interferon-alpha; Male; Patient Care Team; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Substance Abuse, Intravenous; Time Factors; Treatment Outcome

2009
Assessment of the efficacy of reducing peginterferon alpha-2a and ribavirin dose on virologic response in Koreans with chronic hepatitis C.
    The Korean journal of internal medicine, 2009, Volume: 24, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2009
The substantial role of initial ribavirin dose on the response to peginterferon alpha/ribavirin therapy in patients with genotype 1b chronic hepatitis C.
    The American journal of gastroenterology, 2009, Volume: 104, Issue:9

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2009
Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 2a high viral load and virological response to interferon-ribavirin combination therapy.
    Intervirology, 2009, Volume: 52, Issue:6

    Topics: Adult; Aged; Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Core Proteins; Viral Load

2009
Dual onset of type 1 diabetes mellitus and Graves' disease during treatment with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.
    Diabetes research and clinical practice, 2009, Volume: 86, Issue:2

    Topics: Antiviral Agents; Autoimmune Diseases; Diabetes Mellitus, Type 1; Female; Graves Disease; Hepatitis C, Chronic; Histocompatibility Antigens Class I; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2009
Concurrent antiphospholipid syndrome and cutaneous [corrected] sarcoidosis due to interferon alfa and ribavirin treatment for hepatitis C.
    Journal of drugs in dermatology : JDD, 2009, Volume: 8, Issue:9

    Topics: Antiphospholipid Syndrome; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Polyethylene Glycols; Ribavirin; Sarcoidosis

2009
Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2010, Volume: 42, Issue:2

    Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis B, Chronic; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2010
Interferon-alfa, interferon-lambda and hepatitis C.
    Nature genetics, 2009, Volume: 41, Issue:10

    Topics: Antiviral Agents; Drug Therapy, Combination; Genome-Wide Association Study; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Polymorphism, Single Nucleotide; Ribavirin; Signal Transduction; Treatment Outcome

2009
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.
    Nature genetics, 2009, Volume: 41, Issue:10

    Topics: Alleles; Antiviral Agents; Asian People; Chromosomes, Human, Pair 19; Drug Combinations; Female; Genome-Wide Association Study; Genome, Human; Haplotypes; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome

2009
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.
    Nature genetics, 2009, Volume: 41, Issue:10

    Topics: Adult; Antiviral Agents; Australia; Drug Therapy, Combination; Female; Gene Expression Regulation; Genome-Wide Association Study; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome

2009
Pleural effusion associated with pegylated interferon alpha and ribavirin treatment for chronic hepatitis C.
    Journal of hospital medicine, 2009, Volume: 4, Issue:7

    Topics: Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Pleural Effusion; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tomography, X-Ray Computed

2009
Effect of ribavirin on the frequency of RNase L cleavage sites within the hepatitis C viral genome.
    Journal of viral hepatitis, 2010, Volume: 17, Issue:3

    Topics: Antiviral Agents; Binding Sites; Cell Line; Endoribonucleases; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Point Mutation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Selection, Genetic; Viral Nonstructural Proteins; Virus Cultivation

2010
Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Oct-15, Volume: 49, Issue:8

    Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Female; Hepatitis C, Chronic; HIV Infections; Humans; Immunocompromised Host; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2009
Successful antiviral and antituberculosis treatment with pegylated interferon-alfa and ribavirin in a chronic hepatitis C patient with pulmonary tuberculosis.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2009, Volume: 108, Issue:9

    Topics: Alanine Transaminase; Antitubercular Agents; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tuberculosis, Pulmonary

2009
Retrospective, observational, multicentre study on an Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combined therapy (PEG-IFN and ribavirin): NADIR study.
    Journal of viral hepatitis, 2010, Volume: 17, Issue:6

    Topics: Adult; Age Factors; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Italy; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Treatment Failure

2010
Prediction of nonSVR to therapy with pegylated interferon-alpha2a and ribavirin in chronic hepatitis C genotype 1 patients after 4, 8 and 12 weeks of treatment.
    Journal of viral hepatitis, 2010, Volume: 17, Issue:5

    Topics: Adult; Age Factors; Antiviral Agents; Body Mass Index; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Statistical; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Sex Factors; Time Factors; Treatment Failure; Viral Load

2010
Effective treatment of injecting drug users with recently acquired hepatitis C virus infection.
    Gastroenterology, 2010, Volume: 138, Issue:1

    Topics: Acute Disease; Adult; Antiviral Agents; Australia; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Ribavirin; RNA, Viral; Seroepidemiologic Studies; Substance-Related Disorders; Treatment Outcome

2010
Impact of adherence to peginterferon-ribavirin combination therapy in chronic hepatitis C patients on achieving a sustained virologic response.
    The Korean journal of hepatology, 2009, Volume: 15, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2009
[A case of sudden-onset hearing loss in a patient treated with peginterferon alpha-2b and ribavirin for chronic hepatitis C].
    The Korean journal of hepatology, 2009, Volume: 15, Issue:3

    Topics: Anti-Inflammatory Agents; Antiviral Agents; Audiometry, Pure-Tone; Drug Therapy, Combination; Hearing Loss, Sudden; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prednisone; Recombinant Proteins; Ribavirin

2009
Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Case-Control Studies; Cholesterol; Cholesterol, LDL; Cohort Studies; Cross-Sectional Studies; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lipid Metabolism; Lipids; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral

2009
Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study.
    The American journal of gastroenterology, 2009, Volume: 104, Issue:12

    Topics: Antiviral Agents; Chi-Square Distribution; Cross-Sectional Studies; Depression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Multicenter Studies as Topic; Prevalence; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; United States

2009
Hepatitis C: CIFN for re-treatment of PEG-IFN plus RBV nonresponders?
    Nature reviews. Gastroenterology & hepatology, 2009, Volume: 6, Issue:10

    Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2009
Influence of alpha-1 antitrypsin heterozygosity on treatment efficacy of HCV combination therapy.
    European journal of gastroenterology & hepatology, 2010, Volume: 22, Issue:7

    Topics: Adult; alpha 1-Antitrypsin; Amantadine; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Germany; Hepatitis C, Chronic; Heterozygote; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Multicenter Studies as Topic; Netherlands; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome

2010
Treatment of autoimmune thrombocytopenia in a case of chronic hepatitis C with ursodeoxycholic acid.
    Journal of infection in developing countries, 2009, Sep-15, Volume: 3, Issue:8

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Purpura, Thrombocytopenic, Idiopathic; Recombinant Proteins; Ribavirin; Treatment Outcome; Ursodeoxycholic Acid

2009
Azathioprine plus ribavirin treatment and pancytopenia.
    Alimentary pharmacology & therapeutics, 2009, Nov-01, Volume: 30, Issue:9

    Topics: Adult; Anti-Inflammatory Agents; Antiviral Agents; Azathioprine; Crohn Disease; Drug Interactions; Hepatitis C, Chronic; Humans; Male; Pancytopenia; Ribavirin

2009
Age and prediction of sustained virological response to hepatitis C virus (HCV) infection treatment based on 28-day decrease in HCV RNA levels.
    The Journal of infectious diseases, 2009, Nov-01, Volume: 200, Issue:9

    Topics: Adult; Age Factors; Aged; Antiviral Agents; Drug Administration Schedule; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2009
Repeated episodes of fixed eruption 3 months after discontinuing pegylated interferon-alpha-2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection.
    Clinical and experimental dermatology, 2009, Volume: 34, Issue:8

    Topics: Aged; Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin

2009
Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
    Journal of gastroenterology and hepatology, 2010, Volume: 25, Issue:2

    Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome

2010
Maintenance ribavirin monotherapy delays fibrosis progression in liver transplant recipients with recurrent hepatitis C at high risk of progression.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2010, Volume: 42, Issue:4

    Topics: Antiviral Agents; Disease Progression; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Prospective Studies; Recurrence; Ribavirin

2010
Adjuvant therapy used in conjunction with combination therapy for chronic hepatitis C improves sustained virus response rates in genotype 1 patients.
    Journal of viral hepatitis, 2010, Volume: 17, Issue:4

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Erythropoietin; Female; Genotype; Granulocyte Colony-Stimulating Factor; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult

2010
Equally poor outcomes to pegylated interferon-based therapy in African Americans and Hispanics with chronic hepatitis C infection.
    Journal of clinical gastroenterology, 2010, Volume: 44, Issue:2

    Topics: Adult; Antiviral Agents; Black or African American; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon alpha-2; Interferon-alpha; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load

2010
Successful antiviral therapy determines a significant decrease in squamous cell carcinoma antigen-associated (SCCA) variants' serum levels in anti-HCV positive cirrhotic patients.
    Journal of viral hepatitis, 2010, Volume: 17, Issue:8

    Topics: Antigens, Neoplasm; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Serpins; Statistics, Nonparametric

2010
Splenectomy and antiviral treatment for thrombocytopenic patients with chronic hepatitis C virus infection.
    Journal of viral hepatitis, 2010, Volume: 17, Issue:7

    Topics: Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Splenectomy; Splenomegaly; Thrombocytopenia; Treatment Outcome; Viral Load

2010
Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection.
    Journal of virology, 2010, Volume: 84, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HLA Antigens; Humans; Interferon-alpha; Male; Middle Aged; Pharmacogenetics; Receptors, KIR; Receptors, KIR2DL2; Receptors, KIR2DL3; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2010
Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment.
    Journal of immunology (Baltimore, Md. : 1950), 2009, Nov-15, Volume: 183, Issue:10

    Topics: Adult; Antiviral Agents; CD56 Antigen; CD57 Antigens; Cell Degranulation; Chemokine CCL4; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-gamma; Killer Cells, Natural; Lymphocyte Subsets; Lysosomal-Associated Membrane Protein 1; Male; Middle Aged; NK Cell Lectin-Like Receptor Subfamily K; Perforin; Receptors, Natural Killer Cell; Ribavirin; Tumor Necrosis Factor-alpha

2009
Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension.
    Journal of internal medicine, 2009, Volume: 266, Issue:6

    Topics: Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hypertension, Portal; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2009
Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy.
    Journal of medical virology, 2009, Volume: 81, Issue:12

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genetic Variation; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome

2009
NS5A(ISDR-V3) region genetic variability of Tunisian HCV-1b strains: Correlation with the response to the combined interferon/ribavirin therapy.
    Journal of medical virology, 2009, Volume: 81, Issue:12

    Topics: Adult; Amino Acid Sequence; Antiviral Agents; Drug Therapy, Combination; Female; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Ribavirin; Statistics as Topic; Treatment Outcome; Tunisia; Viral Nonstructural Proteins

2009
Peginterferon alfa-2b or alfa-2a with ribavirin for hepatitis C.
    The New England journal of medicine, 2009, Oct-29, Volume: 361, Issue:18

    Topics: Antiviral Agents; Asian People; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Recurrence; Ribavirin

2009
Effects of chronic hepatitis C infection on the treatment of breast cancer patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Hepatitis C, Chronic; Humans; Interferons; Middle Aged; Neoplasm Staging; Retrospective Studies; Ribavirin; Treatment Outcome; Young Adult

2010
Comment on the PROVE1 and PROVE2 clinical trials: "I was taking a picture of Rapid Virological Response with telaprevir, but the background is unfocused!".
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:5

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome

2009
Lack of killer immunoglobulin-like receptor 2DS2 (KIR2DS2) and KIR2DL2 is associated with poor responses to therapy of recurrent hepatitis C virus in liver transplant recipients.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2009, Volume: 15, Issue:11

    Topics: Antiviral Agents; Bacterial Infections; Drug Resistance, Viral; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Killer Cells, Natural; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Postoperative Complications; Receptors, KIR; Receptors, KIR2DL2; Recombinant Proteins; Recurrence; Ribavirin

2009
Hyperinsulinaemia reduces the 24-h virological response to PEG-interferon therapy in patients with chronic hepatitis C and insulin resistance.
    Journal of viral hepatitis, 2010, Volume: 17, Issue:7

    Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hyperinsulinism; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2010
Hepatitis C treatment completion rates in routine clinical care.
    Liver international : official journal of the International Association for the Study of the Liver, 2010, Volume: 30, Issue:2

    Topics: Antiviral Agents; Cohort Studies; Databases, Factual; Drug Therapy, Combination; Ethnicity; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Medication Adherence; Middle Aged; Patient Dropouts; Polyethylene Glycols; Recombinant Proteins; Ribavirin; United States; Veterans

2010
Treatment of erythrodermic psoriasis in HCV+ patient with adalimumab.
    Dermatologic therapy, 2009, Volume: 22 Suppl 1

    Topics: Adalimumab; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiviral Agents; Dermatitis, Exfoliative; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Psoriasis; Recombinant Proteins; Ribavirin

2009
Platelet serotonin (5-HT) levels in interferon-treated patients with hepatitis C and its possible association with interferon-induced depression.
    Journal of hepatology, 2010, Volume: 52, Issue:1

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; Blood Platelets; Citalopram; Depression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Selective Serotonin Reuptake Inhibitors; Serotonin; Time Factors; Young Adult

2010
Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics.
    AIDS (London, England), 2009, Nov-27, Volume: 23, Issue:18

    Topics: Adult; Antiviral Agents; Black or African American; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; White People

2009
Viral dynamics and prediction of response to treatment with pegylated interferon and ribavirin in patients with chronic hepatitis C.
    Revista espanola de enfermedades digestivas, 2009, Volume: 101, Issue:10

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Viral Load

2009
Viral kinetics during the first month of treatment in patients with genotype 1 chronic hepatitis C.
    Revista espanola de enfermedades digestivas, 2009, Volume: 101, Issue:10

    Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Time Factors; Viral Load; Viremia

2009
Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection.
    Gastroenterology, 2010, Volume: 138, Issue:3

    Topics: Adult; Antiviral Agents; Biopsy; Cluster Analysis; Cytokines; Drug Resistance, Viral; Drug Therapy, Combination; Female; Gene Expression Profiling; Genotype; Hepatitis C, Chronic; Hepatocytes; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Kupffer Cells; Liver; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Patient Selection; Phenotype; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Outcome; Ubiquitins; Viral Load

2010
Similar treatment response to peginterferon and ribavirin in Asian and Caucasian patients with chronic hepatitis C.
    The American journal of gastroenterology, 2010, Volume: 105, Issue:5

    Topics: Adult; Analysis of Variance; Antiviral Agents; Asian People; Cohort Studies; Confidence Intervals; Disease Susceptibility; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Patient Compliance; Polyethylene Glycols; Probability; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Assessment; Treatment Outcome; White People

2010
Pegylated alpha interferon 2B plus ribavirin in the treatment of HCV genotype 4 infection.
    Indian journal of pediatrics, 2009, Volume: 76, Issue:9

    Topics: Adolescent; Child; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Treatment Outcome

2009
Nonischemic cardiomyopathy related to pegylated interferon and ribavirin.
    European journal of gastroenterology & hepatology, 2009, Volume: 21, Issue:12

    Topics: Antiviral Agents; Drug Therapy, Combination; Heart Failure; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2009
[Treatment for chronic hepatitis C, more opportunity, more challenge].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2009, Volume: 17, Issue:7

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis B virus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Protease Inhibitors; Ribavirin; RNA, Viral; Treatment Outcome

2009
[Difficult-to-treat patient with chronic hepatitis C: a challenge in clinical practice].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2009, Volume: 17, Issue:7

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Ribavirin; RNA, Viral; Viral Load

2009
[Advance in the management of the difficult-to-treat patients with chronic hepatitis C].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2009, Volume: 17, Issue:7

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Virus Replication

2009
[The study of optimal treatment in patients with refractory chronic hepatitis C].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2009, Volume: 17, Issue:7

    Topics: Administration, Cutaneous; Administration, Oral; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Viral Load

2009
[Prediction of sustained viral response to combinational therapy with interferon and ribavirin in chronic hepatitis C by rapid viral response].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2009, Volume: 17, Issue:7

    Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Antiviral Agents; Child; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult

2009
Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients.
    Alimentary pharmacology & therapeutics, 2010, Feb-15, Volume: 31, Issue:4

    Topics: Adult; Antiviral Agents; Body Mass Index; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome

2010
Human leukocyte antigen alleles and the response to pegylated interferon/ribavirin therapy in chronic hepatitis C patients.
    Antiviral research, 2010, Volume: 85, Issue:2

    Topics: Adult; Antiviral Agents; Female; Gene Frequency; Haplotypes; Hepatitis C, Chronic; HLA Antigens; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index; Taiwan; Treatment Outcome; Viral Load

2010
Do differences in pegylation of interferon alfa matter?
    Gastroenterology, 2010, Volume: 138, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2010
Metformin, hepatitis C, and insulin resistance: sufficient evidence?
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:6

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Metformin; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2009
[Efficiency of a combined peginterferon alpha-2a and ribavarin therapy in intravenous opiate substances abusers with chronic hepatitis C].
    Vojnosanitetski pregled, 2009, Volume: 66, Issue:10

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Morphine Dependence; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Substance Abuse, Intravenous

2009
Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region.
    Intervirology, 2010, Volume: 53, Issue:2

    Topics: Adult; Aged; Amino Acid Substitution; Female; Flow Cytometry; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Monocytes; Polyethylene Glycols; Receptor, Interferon alpha-beta; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Core Proteins; Viral Load

2010
Sustained virological response during exenatide treatment in a patient with hepatitis C and nonalcoholic steatohepatitis.
    The American journal of gastroenterology, 2009, Volume: 104, Issue:12

    Topics: Antiviral Agents; Drug Therapy, Combination; Exenatide; Fatty Liver; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Peptides; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; Venoms; Viral Load

2009
A case of irreversible alopecia associated with ribavirin and peg-interferon therapy.
    European journal of gastroenterology & hepatology, 2010, Volume: 22, Issue:1

    Topics: Aged; Alopecia Areata; Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2010
Treatment outcome of chronic hepatitis C in sickle cell disease and thalassemic patients with interferon and ribavirin.
    European journal of gastroenterology & hepatology, 2010, Volume: 22, Issue:1

    Topics: Anemia, Sickle Cell; Antiviral Agents; beta-Thalassemia; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Outcome

2010
Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment
    Scandinavian journal of gastroenterology, 2010, Volume: 45, Issue:2

    Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Interleukin-4; Leukocytes, Mononuclear; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load

2010
Functional pathway analysis of genes associated with response to treatment for chronic hepatitis C.
    Journal of viral hepatitis, 2010, Volume: 17, Issue:10

    Topics: Adult; Antiviral Agents; Blood; Female; Gene Expression Profiling; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Metabolic Networks and Pathways; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Viremia

2010
Response to pegylated interferon and ribavirin in Asian American patients with chronic hepatitis C genotypes 1 vs 2/3 vs 6.
    Journal of viral hepatitis, 2010, Volume: 17, Issue:10

    Topics: Adult; Antiviral Agents; Asian; Blood; California; Cohort Studies; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Medication Adherence; Middle Aged; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load

2010
The benefits of interferon treatment in patients without sustained viral response after living donor liver transplantation for hepatitis C.
    Transplantation proceedings, 2009, Volume: 41, Issue:10

    Topics: Aged; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Female; Genotype; Graft Survival; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Living Donors; Male; Middle Aged; Polymerase Chain Reaction; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Survival Rate

2009
Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin: some issues.
    Journal of hepatology, 2010, Volume: 52, Issue:2

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin

2010
What now? Responding to relapse in hepatitis C.
    Advance for nurse practitioners, 2007, Volume: 15, Issue:12

    Topics: Alcohol Drinking; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Male; Nurse Practitioners; Patient Education as Topic; Polyethylene Glycols; Primary Health Care; Recombinant Proteins; Recurrence; Referral and Consultation; Ribavirin; Risk Factors; United States; Viral Load

2007
A levitating tattoo in a hepatitis C patient on treatment.
    Liver international : official journal of the International Association for the Study of the Liver, 2010, Volume: 30, Issue:4

    Topics: Antiviral Agents; Biopsy, Needle; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Pulmonary Disease, Chronic Obstructive; Recombinant Proteins; Ribavirin; Risk Assessment; Sarcoidosis; Skin Diseases; Steroids; Tattooing; Treatment Outcome

2010
Association between plasma levels of eotaxin (CCL-11) and treatment response to interferon-alpha and ribavirin in HIV/HCV co-infected patients.
    The Journal of antimicrobial chemotherapy, 2010, Volume: 65, Issue:2

    Topics: Adult; Antiviral Agents; Chemokine CCL11; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Plasma; Retrospective Studies; Ribavirin; Treatment Outcome

2010
Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.
    Japanese journal of ophthalmology, 2009, Volume: 53, Issue:6

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Fluorescein Angiography; Hepatitis C, Chronic; Humans; Hypertension; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Retinal Diseases; Ribavirin; Risk Factors; Visual Acuity

2009
Pre-emptive antiviral therapy in living donor liver transplantation for hepatitis C: observation based on a single-center experience.
    Transplant international : official journal of the European Society for Organ Transplantation, 2010, Volume: 23, Issue:6

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Living Donors; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral

2010
[A comparison of 24- vs. 48-week peginterferon plus ribavirin in patients with genotype 1 chronic hepatitis C].
    The Korean journal of hepatology, 2009, Volume: 15, Issue:4

    Topics: Adult; Age Factors; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2009
[Predictive value of virological response on sustained virological response in hepatitis C patients].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2009, Volume: 17, Issue:12

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult

2009
Treatment of chronic hepatitis C using a 4-week lead-in with nitazoxanide before peginterferon plus nitazoxanide.
    Journal of clinical gastroenterology, 2010, Volume: 44, Issue:7

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Nitro Compounds; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thiazoles; Time Factors; Treatment Outcome; Young Adult

2010
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study.
    Gastroenterology, 2010, Volume: 138, Issue:4

    Topics: Adult; Aged; Female; Genetic Variation; Genome-Wide Association Study; Genotype; Haplotypes; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Failure

2010
An antioxidant resveratrol significantly enhanced replication of hepatitis C virus.
    World journal of gastroenterology, 2010, Jan-14, Volume: 16, Issue:2

    Topics: Antioxidants; Antiviral Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Resveratrol; Ribavirin; RNA, Viral; Stilbenes; Virus Replication; Xanthophylls

2010
Double-filtration plasmapheresis plus IFN for HCV-1b patients with non-sustained virological response to previous combination therapy: early viral dynamics.
    Intervirology, 2010, Volume: 53, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Female; Filtration; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-beta; Japan; Male; Middle Aged; Plasmapheresis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome; Viral Load

2010
Outcome and early viral dynamics with viral mutation in PEG-IFN/RBV therapy for chronic hepatitis in patients with high viral loads of serum HCV RNA genotype 1b.
    Intervirology, 2010, Volume: 53, Issue:1

    Topics: Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mutation, Missense; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Serum; Treatment Outcome; Viral Load

2010
Prolonged PEG-IFN and RBV is effective in patients with HCV genotype 1 and high viral load who achieved virological response later than 24 weeks.
    Intervirology, 2010, Volume: 53, Issue:1

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2010
PEG-IFNalpha/RBV combination therapy for chronic hepatitis C patients increases serum ferritin level while it improves sustained viral response rate.
    Intervirology, 2010, Volume: 53, Issue:1

    Topics: Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Ferritins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Statistics as Topic; Treatment Outcome

2010
HCV genetic elements determining the early response to peginterferon and ribavirin therapy.
    Intervirology, 2010, Volume: 53, Issue:1

    Topics: Antiviral Agents; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Mutation, Missense; Ribavirin; RNA, Viral; Treatment Outcome; Viral Core Proteins; Viral Nonstructural Proteins

2010
Efficacy and tolerability of pegylated interferon-alpha2a plus ribavirin versus pegylated interferon-alpha2b plus ribavirin in treatment-naive chronic hepatitis C patients.
    Intervirology, 2010, Volume: 53, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2010
Relationship between regulatory T cells and the combination of pegylated interferon and ribavirin for the treatment of chronic hepatitis type C.
    Intervirology, 2010, Volume: 53, Issue:3

    Topics: Aged; Antigens, CD; Antiviral Agents; Biopsy; Female; Flow Cytometry; Forkhead Transcription Factors; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Leukocytes, Mononuclear; Liver; Male; Middle Aged; Ribavirin; Staining and Labeling; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory

2010
Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin.
    Hepatology (Baltimore, Md.), 2010, Volume: 51, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral

2010
Towards predicting the therapeutic response in patients with hepatitis C.
    Alimentary pharmacology & therapeutics, 2010, Jan-15, Volume: 31, Issue:2

    Topics: Hepacivirus; Hepatitis C, Chronic; Humans; Predictive Value of Tests; Ribavirin

2010
Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:4

    Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Secondary Prevention

2010
Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C Virus coinfected patients with prior nonresponse or relapse.
    Journal of acquired immune deficiency syndromes (1999), 2010, Volume: 53, Issue:3

    Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2010
Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C.
    The Journal of infectious diseases, 2010, Volume: 201, Issue:5

    Topics: Aged; Aged, 80 and over; Antiviral Agents; Case-Control Studies; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2010
Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection.
    Journal of gastroenterology, 2010, Volume: 45, Issue:6

    Topics: Adult; Aged; Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Medication Adherence; Middle Aged; Molecular Sequence Data; Multivariate Analysis; Mutation; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Young Adult

2010
Transient reappearance of serum hepatitis C virus RNA observed by real-time PCR during antiviral therapy with peginterferon and ribavirin in patients with HCV genotype 1b.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2010, Volume: 47, Issue:3

    Topics: Aged; Antiviral Agents; Drug Monitoring; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Serum

2010
An updated follow-up of chronic hepatitis C after three decades of observation in pediatric patients cured of malignancy.
    Pediatric blood & cancer, 2010, Jul-15, Volume: 55, Issue:1

    Topics: Adolescent; Adult; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Fibrosis; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Interferons; Male; Neoplasms; Ribavirin; RNA, Messenger; Survival Rate; Treatment Outcome; Young Adult

2010
Occult hepatitis B virus infection in patients with chronic hepatitis C: An actor behind the scene or just a bystander?
    Journal of gastroenterology and hepatology, 2010, Volume: 25, Issue:2

    Topics: Alanine Transaminase; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2010
Chronic hepatitis C viral infection reduces NK cell frequency and suppresses cytokine secretion: Reversion by anti-viral treatment.
    Biochemical and biophysical research communications, 2010, Mar-05, Volume: 393, Issue:2

    Topics: Antimicrobial Cationic Peptides; Antiviral Agents; Cell Degranulation; Cytokines; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Killer Cells, Natural; Lymphocyte Count; Peptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral

2010
In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks. Pooled analysis of two Scandinavian trials.
    European journal of gastroenterology & hepatology, 2010, Volume: 22, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Biopsy; Databases, Factual; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Scandinavian and Nordic Countries; Treatment Outcome; Young Adult

2010
Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: the PRACTICE study.
    Journal of viral hepatitis, 2010, Volume: 17, Issue:7

    Topics: Adult; Antiviral Agents; Cohort Studies; Female; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2010
Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2010, Volume: 51, Issue:4

    Topics: Adult; Aged; Cholestanetriol 26-Monooxygenase; Cytochrome P450 Family 2; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Risk Factors; Vitamin D

2010
Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response.
    Alimentary pharmacology & therapeutics, 2010, Volume: 31, Issue:9

    Topics: Adult; Aged; Antiviral Agents; Cytokines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Messenger; Treatment Outcome

2010
Increased proportion of the CD56(bright) NK cell subset in patients chronically infected with hepatitis C virus (HCV) receiving interferon-alpha and ribavirin therapy.
    Journal of medical virology, 2010, Volume: 82, Issue:4

    Topics: Adult; Aged; Antiviral Agents; CD3 Complex; CD56 Antigen; Female; Flow Cytometry; Hepatitis C, Chronic; Humans; Interferon-alpha; Killer Cells, Natural; Lymphocyte Subsets; Male; Middle Aged; Ribavirin; Young Adult

2010
New-onset psoriasis following treatment with pegylated interferon-alpha 2b and ribavirin for chronic hepatitis C.
    The Israel Medical Association journal : IMAJ, 2009, Volume: 11, Issue:12

    Topics: Adult; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Psoriasis; Recombinant Proteins; Ribavirin

2009
The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients.
    Antiviral therapy, 2010, Volume: 15, Issue:1

    Topics: Adult; Antiviral Agents; Cohort Studies; Dideoxynucleosides; Drug Interactions; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load

2010
[Vogt-Koyanagi-Harada disease associated with interferon-alpha and ribavirin therapy for chronic hepatitis C infection].
    Journal francais d'ophtalmologie, 2010, Volume: 33, Issue:3

    Topics: Adrenal Cortex Hormones; Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Male; Methylprednisolone; Recombinant Proteins; Ribavirin; Tropicamide; Uveomeningoencephalitic Syndrome

2010
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.
    Nature, 2010, Mar-18, Volume: 464, Issue:7287

    Topics: Alleles; Anemia, Hemolytic; Antiviral Agents; Chromosomes, Human, Pair 20; Europe; Genetic Variation; Genome-Wide Association Study; Hemoglobins; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Polymorphism, Single Nucleotide; Pyrophosphatases; Racial Groups; Ribavirin; United States

2010
Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin.
    Gastroenterology, 2010, Volume: 138, Issue:7

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load

2010
Vogt-Koyanagi-Harada disease occurring during interferon-alpha and ribavirin therapy for chronic hepatitis C virus infection.
    International ophthalmology, 2010, Volume: 30, Issue:5

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Fluorescein Angiography; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; Uveomeningoencephalitic Syndrome

2010
Ribavirin ante portas: uptake transporters into hepatocytes dissected.
    Journal of hepatology, 2010, Volume: 52, Issue:4

    Topics: Antiviral Agents; Equilibrative Nucleoside Transporter 1; Hepatitis C, Chronic; Hepatocytes; Humans; Ribavirin

2010
Maintenance ribavirin monotherapy: the case for post-transplantation recurrent hepatitis C.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2010, Volume: 42, Issue:4

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Immunocompromised Host; Liver Transplantation; Postoperative Complications; Recurrence; Ribavirin

2010
Cost effectiveness of peginterferon alfa-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil.
    The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2009, Volume: 13, Issue:3

    Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Markov Chains; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Treatment Outcome

2009
Pegylated interferon plus optimized weight-based ribavirin dosing negate the influence of weight and body mass index on early viral kinetics and sustained virological response in chronic hepatitis C.
    Journal of viral hepatitis, 2010, Volume: 17, Issue:12

    Topics: Antiviral Agents; Body Mass Index; Body Weight; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2010
Serum B12 levels predict response to treatment with interferon and ribavirin in patients with chronic HCV infection.
    Journal of viral hepatitis, 2011, Volume: 18, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Prognosis; Retrospective Studies; Ribavirin; Serum; Severity of Illness Index; Treatment Outcome; Vitamin B 12

2011
Are FoxP3(+) cells involved in hyporesponsiveness to interferon/ribavirin therapy in chronic hepatitis C?
    Journal of viral hepatitis, 2011, Volume: 18, Issue:2

    Topics: Antiviral Agents; Biopsy; Forkhead Transcription Factors; Hepacivirus; Hepatitis C, Chronic; Humans; Immune Tolerance; Interferons; Liver; Ribavirin; T-Lymphocyte Subsets; Treatment Outcome

2011
Extending combination therapy with peginterferon plus ribavirin for genotype 2 chronic hepatitis C virological responders: a pilot study of 7 cases.
    Intervirology, 2010, Volume: 53, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome

2010
Metformin improves sustained virologic response in difficult-to-cure hepatitis C: more questions than answers.
    Hepatology (Baltimore, Md.), 2010, Volume: 51, Issue:3

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Metformin; Ribavirin

2010
[Retreatment options for patients with chronic hepatitis C].
    Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti, 2009, Volume: 63, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; RNA, Viral

2009
[Treatment of chronic hepatitis C in human immunodeficiency virus infected patients].
    Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti, 2009, Volume: 63, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load

2009
[Treatment of recurrent hepatitis C infection after liver transplantation].
    Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti, 2009, Volume: 63, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin

2009
[Treatment of viral hepatitis in children].
    Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti, 2009, Volume: 63, Issue:5

    Topics: Antiviral Agents; Child; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Immunization; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2009
Expression of microRNA-155 precursor in peripheral blood mononuclear cells from Hepatitis C patients after antiviral treatment.
    Acta virologica, 2010, Volume: 54, Issue:1

    Topics: Adolescent; Antiviral Agents; Child; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; MicroRNAs; Recombinant Proteins; Ribavirin; RNA Precursors; RNA, Viral; Treatment Outcome; Young Adult

2010
Sequencing of E2 and NS5A regions of HCV genotype 3a in Brazilian patients with chronic hepatitis.
    Memorias do Instituto Oswaldo Cruz, 2010, Volume: 105, Issue:1

    Topics: Adult; Amino Acid Sequence; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Molecular Sequence Data; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Viral Envelope Proteins; Viral Nonstructural Proteins

2010
[Hepatitis C: 15 years of life].
    Acta gastroenterologica Latinoamericana, 2005, Volume: 35 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2005
[Treatment of hepatitis C in children].
    Acta gastroenterologica Latinoamericana, 2005, Volume: 35 Suppl 1

    Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin

2005
[Chronic hepatitis C. First treatment].
    Acta gastroenterologica Latinoamericana, 2005, Volume: 35 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2005
[Treatment of relapsers].
    Acta gastroenterologica Latinoamericana, 2005, Volume: 35 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin

2005
[Treatment of cirrhotics].
    Acta gastroenterologica Latinoamericana, 2005, Volume: 35 Suppl 1

    Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2005
[Treatment of patients with normal liver aminotransferases].
    Acta gastroenterologica Latinoamericana, 2005, Volume: 35 Suppl 1

    Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Reference Values; Ribavirin; Transaminases

2005
Identifying HCV genotype 1 patients at risk of relapse.
    European journal of gastroenterology & hepatology, 2010, Volume: 22, Issue:5

    Topics: Adult; Age Distribution; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; White People

2010
Sarcoidosis and hepatitis C: clinical description of 11 cases.
    European journal of gastroenterology & hepatology, 2010, Volume: 22, Issue:8

    Topics: Adrenal Cortex Hormones; Adult; Antiviral Agents; Arthritis; Cohort Studies; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Sarcoidosis; Treatment Outcome; Uveitis; Young Adult

2010
A rapid chemokine response of macrophage inflammatory protein (MIP)-1α, MIP-1β and the regulated on activation, normal T expressed and secreted chemokine is associated with a sustained virological response in the treatment of chronic hepatitis C.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2011, Volume: 17, Issue:2

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Chemokine CCL2; Chemokine CCL3; Chemokine CCL4; Chemokine CCL5; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Treatment Outcome; Viral Load

2011
Microalbuminuria in hepatitis C-genotype 4: effect of pegylated interferon and ribavirin.
    World journal of gastroenterology, 2010, Mar-14, Volume: 16, Issue:10

    Topics: Adult; Albumins; Albuminuria; Antiviral Agents; Case-Control Studies; Creatinine; Female; Genotype; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Renal Insufficiency, Chronic; Ribavirin; Viral Load

2010
Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha-2b and ribavirin.
    Alimentary pharmacology & therapeutics, 2010, Volume: 31, Issue:12

    Topics: Adult; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Hepatitis Viruses; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Statistics as Topic; Time Factors; Treatment Outcome; Viral Load; Young Adult

2010
Prediction models for feverishness developed during interferon therapy of chronic hepatitis C patients.
    Die Pharmazie, 2010, Volume: 65, Issue:2

    Topics: Adult; Aged; Algorithms; Antiviral Agents; Body Temperature; Data Interpretation, Statistical; Excipients; Female; Fever; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Models, Statistical; Polyethylene Glycols; Predictive Value of Tests; Ribavirin

2010
Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients.
    The American journal of gastroenterology, 2010, Volume: 105, Issue:9

    Topics: Adult; Antiviral Agents; Body Mass Index; Chi-Square Distribution; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Statistics, Nonparametric; Treatment Outcome

2010
Reappraisal of the importance of mutations in the NS5A-PKR-binding domain of hepatitis C-1b virus in the era of optimally individualized therapy.
    Journal of viral hepatitis, 2011, Volume: 18, Issue:2

    Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; eIF-2 Kinase; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Protein Binding; Protein Interaction Domains and Motifs; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome; Viral Load; Viral Nonstructural Proteins

2011
Ability of treatment week 12 viral response to predict long-term outcome in genotype 1 hepatitis C virus/HIV coinfected patients.
    AIDS (London, England), 2010, Apr-24, Volume: 24, Issue:7

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Regression Analysis; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2010
Evaluating treatment of hepatitis C for hemolytic anemia management.
    Mathematical biosciences, 2010, Volume: 225, Issue:2

    Topics: Anemia, Hemolytic; Antiviral Agents; Computer Simulation; Drug Therapy, Combination; Erythropoietin; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Models, Biological; Recombinant Proteins; Ribavirin

2010
Hepatitis C virus recurrence after liver transplantation: analysis of factors related to sustained viral response.
    Transplantation proceedings, 2010, Volume: 42, Issue:2

    Topics: Adult; Antiviral Agents; Drug Tolerance; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Viral Load

2010
Treatment outcome in relation to alcohol consumption during hepatitis C therapy: an analysis of the Swiss Hepatitis C Cohort Study.
    Drug and alcohol dependence, 2010, Jul-01, Volume: 110, Issue:1-2

    Topics: Adult; Alcohol Drinking; Antiviral Agents; Cohort Studies; Female; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Cirrhosis; Male; Middle Aged; Patient Compliance; Recombinant Proteins; Regression Analysis; Retrospective Studies; Ribavirin; RNA, Viral; Socioeconomic Factors; Switzerland; Treatment Outcome; Viral Load

2010
Prevalence and impact of occult hepatitis B infection in chronic hepatitis C patients treated with pegylated interferon and ribavirin.
    Journal of medical virology, 2010, Volume: 82, Issue:5

    Topics: Adult; Antiviral Agents; Blood; DNA, Viral; Female; France; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Prevalence; Reagent Kits, Diagnostic; Recombinant Proteins; Ribavirin

2010
Transient reappearance of serum hepatitis C virus RNA observed by real-time PCR during antiviral therapy with peginterferon and ribavirin: Reappearance of references published in 2005-2009.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2010, Volume: 48, Issue:2

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Serum

2010
Safety of ribavirin in adolescent thalassemic patients with chronic hepatitis C virus infection.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2010, Volume: 48, Issue:1

    Topics: Adolescent; Antiviral Agents; Female; Ferritins; Hepatitis C, Chronic; Humans; Male; Ribavirin; RNA, Viral; Thalassemia

2010
Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study.
    European journal of gastroenterology & hepatology, 2010, Volume: 22, Issue:9

    Topics: Analgesics, Opioid; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Hepatitis C, Chronic; Interferon alpha-2; Interferon-alpha; Medication Adherence; Polyethylene Glycols; Prospective Studies; Quality of Life; Recombinant Proteins; Ribavirin; Substance-Related Disorders; Surveys and Questionnaires; Treatment Outcome

2010
High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin.
    Journal of substance abuse treatment, 2010, Volume: 38, Issue:4

    Topics: Adult; Antidepressive Agents; Antiviral Agents; Buprenorphine; Citalopram; Depression; Directly Observed Therapy; Drug Administration Schedule; Female; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Methadone; Middle Aged; Narcotics; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Substance Abuse Treatment Centers; Substance Abuse, Intravenous; Treatment Outcome; Young Adult

2010
Mutations in the core and NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated-interferon-alpha 2b and ribavirin combination therapy.
    Journal of viral hepatitis, 2011, Volume: 18, Issue:4

    Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mutation, Missense; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Core Proteins; Viral Nonstructural Proteins

2011
[Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection].
    The Korean journal of hepatology, 2010, Volume: 16, Issue:1

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Severity of Illness Index; Treatment Outcome

2010
Successful antiviral therapy is associated with a decrease of serum prohepcidin in chronic hepatitis C.
    World journal of gastroenterology, 2010, Apr-14, Volume: 16, Issue:14

    Topics: Adult; Aged; Antimicrobial Cationic Peptides; Antiviral Agents; Female; Hepatitis C, Chronic; Hepcidins; Humans; Interferon alpha-2; Interferon-alpha; Iron; Male; Middle Aged; Polyethylene Glycols; Protein Precursors; Recombinant Proteins; Ribavirin; Young Adult

2010
Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy.
    Journal of hepatology, 2010, Volume: 52, Issue:6

    Topics: Antiviral Agents; Drug Monitoring; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Predictive Value of Tests; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Viral Load; Viremia

2010
Impairment of TLR7-dependent signaling in dendritic cells from chronic hepatitis C virus (HCV)-infected non-responders to interferon/ribavirin therapy.
    Journal of clinical immunology, 2010, Volume: 30, Issue:4

    Topics: Antiviral Agents; Cells, Cultured; Dendritic Cells; Drug Resistance, Viral; Hepatitis C, Chronic; Humans; Interferon Inducers; Interferons; Ribavirin; Signal Transduction; Toll-Like Receptor 7; Treatment Failure

2010
Focus. The impact of ribavirin treatment on spermatogenesis inpatients with chronic hepatitis C.
    Journal of hepatology, 2010, Volume: 52, Issue:6

    Topics: Adult; Antiviral Agents; Child; Hepatitis C, Chronic; Humans; Male; Ribavirin; Spermatogenesis; Spermatozoa

2010
Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment.
    BMC gastroenterology, 2010, Apr-16, Volume: 10

    Topics: Administration, Oral; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Liver; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Virulence

2010
Entering the new era of therapy for HBV and HCV infections.
    The Journal of family practice, 2010, Volume: 59, Issue:4 Suppl

    Topics: Administration, Oral; Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2010
Seminal fluid ribavirin level and functional semen parameters in patients with chronic hepatitis C on antiviral combination therapy.
    Journal of hepatology, 2010, Volume: 52, Issue:6

    Topics: Adult; Antiviral Agents; Asthenozoospermia; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligospermia; Recombinant Proteins; Ribavirin; RNA, Viral; Semen; Spermatogenesis; Spermatozoa

2010
Could a loss of memory T cells limit responses to hepatitis C virus (HCV) antigens in blood leucocytes from patients chronically infected with HCV before and during pegylated interferon-alpha and ribavirin therapy?
    Clinical and experimental immunology, 2010, Jul-01, Volume: 161, Issue:1

    Topics: Adult; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antigens, Viral; Antiviral Agents; Apoptosis Regulatory Proteins; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cytomegalovirus; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Immunologic Memory; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Leukocytes; Lymphocyte Activation; Lymphocyte Count; Male; Middle Aged; Polyethylene Glycols; Programmed Cell Death 1 Receptor; Recombinant Proteins; Ribavirin; RNA, Viral; T-Lymphocyte Subsets; Young Adult

2010
Outcome of a hepatitis C outbreak among patients in a pain management clinic.
    Digestive diseases and sciences, 2010, Volume: 55, Issue:6

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Biopsy; Chi-Square Distribution; Cross Infection; Disease Outbreaks; Female; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferons; Liver; Male; Middle Aged; Oklahoma; Pain Clinics; Retrospective Studies; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult

2010
Peginterferon alpha-2b and acute allograft failure in a heart transplant recipient.
    The Annals of thoracic surgery, 2010, Volume: 89, Issue:5

    Topics: Acute Disease; Antiviral Agents; Autopsy; Disease Progression; Fatal Outcome; Graft Rejection; Heart Transplantation; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Time Factors; Transplantation, Homologous

2010
Do steatosis and steatohepatitis impact on sustained virological response (SVR) rates in patients receiving pegylated interferon and ribavirin for chronic hepatitis C infection?
    Journal of medical virology, 2010, Volume: 82, Issue:6

    Topics: Adult; Antiviral Agents; Biopsy; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Histocytochemistry; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2010
Positive selection of core 70Q variant genotype 1b hepatitis C virus strains induced by pegylated interferon and ribavirin.
    The Journal of infectious diseases, 2010, Jun-01, Volume: 201, Issue:11

    Topics: Adult; Aged; Amino Acid Substitution; Animals; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Mice; Mice, Transgenic; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Selection, Genetic; Sequence Analysis, DNA; Treatment Failure; Viral Core Proteins

2010
Safe co-administration of raltegravir, pegylated-interferon and, ribavirin in HIV individuals with hepatitis C virus-related liver damage.
    AIDS (London, England), 2010, May-15, Volume: 24, Issue:8

    Topics: Adult; Antiviral Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2010
Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.
    Gastroenterology, 2010, Volume: 139, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Cluster Analysis; Drug Therapy, Combination; Female; Gene Expression Profiling; Gene Expression Regulation; Hepacivirus; Hepatitis C, Chronic; Heterozygote; Homozygote; Humans; Interferon alpha-2; Interferon Regulatory Factors; Interferon-alpha; Interferons; Interleukins; Liver; Logistic Models; Male; Middle Aged; Odds Ratio; Oligonucleotide Array Sequence Analysis; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2010
Natural killer cell receptor and HLA-C gene polymorphisms among patients with hepatitis C: a comparison between sustained virological responders and non-responders.
    Liver international : official journal of the International Association for the Study of the Liver, 2010, Volume: 30, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Female; Gene Frequency; Hepacivirus; Hepatitis C, Chronic; HLA-C Antigens; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Predictive Value of Tests; Probability; Prognosis; Receptors, KIR2DL5; Receptors, Natural Killer Cell; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; Statistics, Nonparametric; Treatment Failure; Treatment Outcome; Viral Load

2010
Relation of pretreatment sequence diversity in NS5A region of HCV genotype 1 with immune response between pegylated-INF/ribavirin therapy outcomes.
    Journal of viral hepatitis, 2011, Volume: 18, Issue:2

    Topics: Adult; Antiviral Agents; Epitopes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immune Evasion; Interferons; Male; Ribavirin; Treatment Outcome; Viral Nonstructural Proteins

2011
[Type 1 diabetes developing during alpha-interferon therapy: report of two cases].
    Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2010, Volume: 57, Issue:8

    Topics: Adult; Antiviral Agents; Autoantibodies; Autoimmune Diseases; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Glutamate Decarboxylase; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2010
A comprehensive hepatitis C viral kinetic model explaining cure.
    Clinical pharmacology and therapeutics, 2010, Volume: 87, Issue:6

    Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Models, Biological; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sensitivity and Specificity; Treatment Outcome; Viral Load

2010
Making the best of a bad situation: early chronic nosocomial HCV infection.
    Digestive diseases and sciences, 2010, Volume: 55, Issue:6

    Topics: Age Factors; Antiviral Agents; Biopsy; Cross Infection; Disease Outbreaks; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferons; Liver; Oklahoma; Pain Clinics; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2010
Alkaline phosphatase predicts relapse in chronic hepatitis C patients with end-of-treatment response.
    World journal of gastroenterology, 2010, May-21, Volume: 16, Issue:19

    Topics: Adolescent; Adult; Aged; Alkaline Phosphatase; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult

2010
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
    The Journal of infectious diseases, 2010, Jul-01, Volume: 202, Issue:1

    Topics: Adult; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Female; Genotype; Hepacivirus; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Virus Activation

2010
Hepatitis C: not so indolent in survivors of pediatric cancer?
    Pediatric blood & cancer, 2010, Jul-15, Volume: 55, Issue:1

    Topics: Adolescent; Adult; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Neoplasms; Ribavirin; RNA, Messenger; Young Adult

2010
[Use of immunomodulators in the therapy of chronic hepatitis C: improving standard approach].
    Eksperimental'naia i klinicheskaia farmakologiia, 2010, Volume: 73, Issue:4

    Topics: Acridines; Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Male; Quality of Life; Ribavirin

2010
A prospective study of T- and B-lymphocyte subpopulations, CD81 expression levels on B cells and regulatory CD4(+) CD25(+) CD127(low/-) FoxP3(+) T cells in patients with chronic HCV infection during pegylated interferon-alpha2a plus ribavirin treatment.
    Journal of viral hepatitis, 2011, Volume: 18, Issue:6

    Topics: Adult; Antigens, CD; Antigens, CD19; Antiviral Agents; B-Lymphocyte Subsets; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Tetraspanin 28

2011
Amantadine for treatment of hepatitis C: time to say "enough is enough"?
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2010, Volume: 42, Issue:7

    Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Evidence-Based Medicine; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure

2010
Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.
    International urology and nephrology, 2011, Volume: 43, Issue:3

    Topics: Adolescent; Adult; Alanine Transaminase; Anemia; Antiviral Agents; Aspartate Aminotransferases; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Failure, Chronic; Leukocyte Count; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin; RNA, Viral; Saudi Arabia

2011
Viral response guided therapy for hepatitis C in the approaching era of direct acting anti-viral agents.
    Journal of gastroenterology and hepatology, 2010, Volume: 25, Issue:4

    Topics: Antiviral Agents; Biomarkers; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Phenotype; Polyethylene Glycols; Precision Medicine; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2010
Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response.
    Journal of gastroenterology and hepatology, 2010, Volume: 25, Issue:4

    Topics: Adult; Antiviral Agents; Biomarkers; Chi-Square Distribution; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Phenotype; Polyethylene Glycols; Predictive Value of Tests; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Taiwan; Time Factors; Treatment Outcome; Viral Load

2010
Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1.
    Journal of gastroenterology and hepatology, 2010, Volume: 25, Issue:4

    Topics: Adolescent; Adult; Age Factors; Aged; Antiviral Agents; Biopsy; Chi-Square Distribution; Drug Therapy, Combination; Female; Genotype; Hepatitis B virus; Hepatitis C, Chronic; Hong Kong; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Phenotype; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult

2010
Antiviral treatment of chronic hepatitis C in clinical routine.
    Wiener klinische Wochenschrift, 2010, Volume: 122, Issue:7-8

    Topics: Adult; Antiviral Agents; Austria; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Selection; Polyethylene Glycols; Prognosis; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Ribavirin; Viral Load

2010
[Retreatment with peginterferon plus ribavirin in chronic hepatitis C patients: our own experiences].
    Klinicka mikrobiologie a infekcni lekarstvi, 2010, Volume: 16, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retreatment; Ribavirin

2010
Safety and efficacy of pegylated interferon and ribavirin in adolescents with human immunodeficiency virus and hepatitis C virus acquired perinatally.
    Journal of medical virology, 2010, Volume: 82, Issue:7

    Topics: Adolescent; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2010
Case report: Cure of chronic infection with hepatitis C virus after 6 weeks of peg-interferon and ribavirin in a patient co-infected with HIV.
    Journal of medical virology, 2010, Volume: 82, Issue:7

    Topics: Administration, Cutaneous; AIDS-Related Opportunistic Infections; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV-1; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2010
Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 1b and high virus load.
    Internal medicine (Tokyo, Japan), 2010, Volume: 49, Issue:11

    Topics: Adult; Cohort Studies; Drug Therapy, Combination; Exanthema; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-beta; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load

2010
Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 2 and high virus load.
    Internal medicine (Tokyo, Japan), 2010, Volume: 49, Issue:11

    Topics: Aged; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-beta; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load

2010
Immunological modifications during treatment with thymosin alpha1 plus antiviral therapy in chronic hepatitis C.
    Annals of the New York Academy of Sciences, 2010, Volume: 1194

    Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunomodulation; Male; Middle Aged; Polyethylene Glycols; Retreatment; Ribavirin; Thymalfasin; Thymosin

2010
Risk factors for relapse in chronic hepatitis C patients who have achieved end of treatment response.
    Journal of gastroenterology and hepatology, 2010, Volume: 25, Issue:5

    Topics: Adult; Age Factors; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Logistic Models; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Republic of Korea; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2010
Liver stiffness decrease after effective antiviral therapy in patients with chronic hepatitis C: Longitudinal study using FibroScan.
    Journal of gastroenterology and hepatology, 2010, Volume: 25, Issue:5

    Topics: Antiviral Agents; Body Mass Index; Drug Therapy, Combination; Elasticity; Elasticity Imaging Techniques; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Predictive Value of Tests; Ribavirin; RNA, Viral; Severity of Illness Index; Taiwan; Time Factors; Treatment Outcome; Viral Load

2010
T-cell responses at baseline and during therapy with peginterferon-alpha and ribavirin are not associated with outcome in chronic hepatitis C infected patients.
    Antiviral research, 2010, Volume: 87, Issue:3

    Topics: Adult; Antiviral Agents; Cell Proliferation; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; T-Lymphocytes; Treatment Outcome

2010
Association of NKG2A with treatment for chronic hepatitis C virus infection.
    Clinical and experimental immunology, 2010, Volume: 161, Issue:2

    Topics: Adult; Antiviral Agents; CD3 Complex; CD56 Antigen; Cell Count; Female; Hepatitis C, Chronic; HLA Antigens; Humans; Interferon alpha-2; Interferon-alpha; Killer Cells, Natural; Male; Middle Aged; Natural Cytotoxicity Triggering Receptor 1; Natural Cytotoxicity Triggering Receptor 3; NK Cell Lectin-Like Receptor Subfamily C; NK Cell Lectin-Like Receptor Subfamily K; Polyethylene Glycols; Receptors, KIR; Receptors, KIR2DL1; Receptors, KIR2DL3; Recombinant Proteins; Remission Induction; Ribavirin; RNA, Viral; T-Lymphocytes; Time Factors

2010
The H63D genetic variant of the HFE gene is independently associated with the virological response to interferon and ribavirin therapy in chronic hepatitis C.
    European journal of gastroenterology & hepatology, 2010, Volume: 22, Issue:10

    Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Female; Genetic Variation; Genotype; Hemochromatosis Protein; Hepatitis C, Chronic; Histocompatibility Antigens Class I; Humans; Interferon alpha-2; Interferon-alpha; Iron; Liver; Male; Membrane Proteins; Prevalence; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors

2010
Autoimmune thrombocytopenic purpura during pegylated interferon α treatment for chronic hepatitis C.
    Internal medicine (Tokyo, Japan), 2010, Volume: 49, Issue:12

    Topics: Aged; Drug Carriers; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Purpura, Thrombocytopenic, Idiopathic; Recombinant Proteins; Ribavirin; Treatment Outcome

2010
Prevalence and clinical significance of GB virus type C/hepatitis G virus coinfection in patients with chronic hepatitis C undergoing antiviral therapy.
    Journal of viral hepatitis, 2011, Volume: 18, Issue:7

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Coinfection; Female; Flaviviridae Infections; GB virus C; Hepatitis C, Chronic; Hepatitis, Viral, Human; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Prevalence; Recombinant Proteins; Ribavirin; Risk Factors; RNA, Viral; Substance Abuse, Intravenous; Treatment Outcome

2011
Secondary structure of the amino-terminal region of HCV NS3 and virological response to pegylated interferon plus ribavirin therapy for chronic hepatitis C.
    Journal of medical virology, 2010, Volume: 82, Issue:8

    Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Polyethylene Glycols; Polymorphism, Genetic; Protein Structure, Secondary; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome; Viral Load; Viral Nonstructural Proteins

2010
Hepatocyte growth factor and chronic hepatitis C.
    Revista espanola de enfermedades digestivas, 2010, Volume: 102, Issue:6

    Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Hepatocyte Growth Factor; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin

2010
Toll-like receptor (TLR) expression on CD4+ and CD8+ T-cells in patients chronically infected with hepatitis C virus.
    Cellular immunology, 2010, Volume: 264, Issue:2

    Topics: Adult; Aged; Antigens, CD; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Separation; DEAD Box Protein 58; DEAD-box RNA Helicases; Female; Flow Cytometry; Hepacivirus; Hepatitis C, Chronic; Humans; Immunologic Memory; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Receptors, Immunologic; Recombinant Proteins; Ribavirin; Toll-Like Receptors

2010
Plasma/erythrocyte ribavirin x100 ratio as an indicator of sustained virological response in HCV genotype 1 patients with early virological response.
    Antiviral therapy, 2010, Volume: 15, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Erythrocytes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Plasma; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Sensitivity and Specificity; Treatment Outcome; Young Adult

2010
Access to peginterferon plus ribavirin therapy for hepatitis C in Romania between 2002-2009.
    Journal of gastrointestinal and liver diseases : JGLD, 2010, Volume: 19, Issue:2

    Topics: Antiviral Agents; Awareness; Drug Costs; Drug Therapy, Combination; Health Knowledge, Attitudes, Practice; Health Promotion; Health Services Accessibility; Hepatitis C, Chronic; Humans; Insurance, Health, Reimbursement; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Practice Patterns, Physicians'; Recombinant Proteins; Referral and Consultation; Ribavirin; Romania; Time Factors

2010
Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load.
    Journal of gastroenterology and hepatology, 2010, Volume: 25, Issue:6

    Topics: Antiviral Agents; Biopsy; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Analysis, RNA; Treatment Outcome; Viral Load

2010
High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C.
    Journal of gastroenterology and hepatology, 2010, Volume: 25, Issue:7

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Drug Users; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Prevalence; Prisoners; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; South Australia; Substance Abuse, Intravenous; Time Factors; Treatment Outcome; Viral Load

2010
[Effectiveness of combined therapies using two types of peginterferon and ribavirin in treating chronic hepatitis C virus genotypes 1b/6a infections].
    Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, 2010, Volume: 32, Issue:3

    Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-gamma; Male; Middle Aged; Polyethylene Glycols; Retrospective Studies; Ribavirin; Treatment Outcome; Young Adult

2010
[Reactivation of tuberculosis during dual therapy with pegylated interferon and ribavirin for chronic hepatitis C].
    La Revue de medecine interne, 2010, Volume: 31, Issue:11

    Topics: Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Virus Activation

2010
[Mutations within the interferon sensitivity determining region in Korean patients infected with hepatitis C virus genotype 1b].
    The Korean journal of hepatology, 2010, Volume: 16, Issue:2

    Topics: Adult; Aged; Amino Acid Sequence; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Mutation; Polyethylene Glycols; Recombinant Proteins; Republic of Korea; Ribavirin

2010
[Occurrence of diabetic ketoacidosis and autoimmune thyroiditis in a patient treated with pegylated interferon-alpha 2b and ribavirin for chronic hepatitis C].
    The Korean journal of hepatology, 2010, Volume: 16, Issue:2

    Topics: Adult; Antiviral Agents; Diabetic Ketoacidosis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Insulin; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thyroiditis, Autoimmune; Thyroxine

2010
[Thrombotic thrombocytopenic purpura mediated by an ADAMTS13-inhibitor related to a treatment with pegylated-interferon alpha-2a and ribavirine in a patient with chronic hepatitis C].
    Presse medicale (Paris, France : 1983), 2010, Volume: 39, Issue:11

    Topics: ADAM Proteins; ADAMTS13 Protein; Adult; Antiviral Agents; Autoantibodies; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Purpura, Thrombotic Thrombocytopenic; Recombinant Proteins; Ribavirin

2010
Antinuclear antibody positivity in patients with chronic hepatitis C: clinically relevant or an epiphenomenon?
    European journal of gastroenterology & hepatology, 2009, Volume: 21, Issue:4

    Topics: Adult; Alanine Transaminase; Antibodies, Antinuclear; Antiviral Agents; Biopsy; Cross-Sectional Studies; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin

2009
Hepatic fibrosis in patients with chronic hepatitis C assessed by transient elastography: implications for determining the efficacy of antiviral therapy.
    Revista espanola de enfermedades digestivas, 2010, Volume: 102, Issue:7

    Topics: Adult; Antiviral Agents; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin

2010
Interferon-induced vitiligo in hepatitis C patients: a case series.
    International journal of dermatology, 2010, Volume: 49, Issue:7

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Vitiligo

2010
Sequence diversity of hepatitis C virus 6a within the extended interferon sensitivity-determining region correlates with interferon-alpha/ribavirin treatment outcomes.
    Virus research, 2010, Volume: 153, Issue:1

    Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Polymorphism, Genetic; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome; Viral Proteins

2010
Early viral and peripheral blood mononuclear cell responses to pegylated interferon and ribavirin treatment: the first 24 h.
    European journal of gastroenterology & hepatology, 2010, Volume: 22, Issue:10

    Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Female; Gene Expression Profiling; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Time Factors

2010
The interferon stimulated gene 15 functions as a proviral factor for the hepatitis C virus and as a regulator of the IFN response.
    Gut, 2010, Volume: 59, Issue:8

    Topics: Animals; Antiviral Agents; Carcinoma, Hepatocellular; Cells, Cultured; Cytokines; Drug Therapy, Combination; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Gene Silencing; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Neoplasms; Mice; Protease Inhibitors; Replicon; Ribavirin; RNA, Small Interfering; Ubiquitins; Viral Load; Virus Replication

2010
Is the interferon-α-triggered depressive episode a self-limited kind of depression? Four cases of persistent affective symptoms after antiviral treatment in HCV-infected individuals.
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2010, Volume: 11, Issue:7

    Topics: Antiviral Agents; Depressive Disorder, Major; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Hospitals, University; Humans; Interferon alpha-2; Interferon-alpha; Long-Term Care; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; Substance Withdrawal Syndrome

2010
[Effectiveness of pegylated interferon alfa 2a and ribavirin for chronic hepatitis C in clinical practice].
    Acta gastroenterologica Latinoamericana, 2010, Volume: 40, Issue:2

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load; Young Adult

2010
Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2010, Volume: 30, Issue:8

    Topics: Adult; Aged; Antiviral Agents; Bone Marrow; Clinical Trials, Phase I as Topic; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load

2010
Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
    BMC infectious diseases, 2010, Jul-20, Volume: 10

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2010
Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.
    Hepatology (Baltimore, Md.), 2010, Volume: 52, Issue:2

    Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; Female; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prognosis; Recombinant Proteins; Remission Induction; Ribavirin; Viral Core Proteins; Young Adult

2010
An early viral response to standard interferon-alpha identifies resistance to combination therapy with peginterferon and ribavirin in patients infected by HCV genotype 1.
    Journal of medical virology, 2010, Volume: 82, Issue:9

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Intramuscular; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2010
Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C.
    Transplant international : official journal of the European Society for Organ Transplantation, 2011, Volume: 24, Issue:1

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Cholecalciferol; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Vitamin D; Vitamin D Deficiency

2011
Study of nitric oxide in patients with chronic hepatitis C genotype 4: relationship to viremia and response to antiviral therapy.
    Immunological investigations, 2010, Volume: 39, Issue:6

    Topics: Adult; Antiviral Agents; Biomarkers, Pharmacological; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Nitric Oxide; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Viral Load; Viremia

2010
Retinopathy associated with pegylated interferon and ribavirin treatment for chronic hepatitis C.
    Optometry (St. Louis, Mo.), 2010, Volume: 81, Issue:11

    Topics: Administration, Oral; Antiviral Agents; Drug Administration Schedule; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Remission, Spontaneous; Retinal Hemorrhage; Ribavirin

2010
Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin.
    The Journal of antimicrobial chemotherapy, 2010, Volume: 65, Issue:10

    Topics: Adult; Antiviral Agents; Cohort Studies; Elasticity; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load

2010
A tetra-primer amplification refractory mutation system polymerase chain reaction for the evaluation of rs12979860 IL28B genotype.
    Journal of viral hepatitis, 2011, Volume: 18, Issue:9

    Topics: Adult; Aged; Alleles; Antiviral Agents; Female; Genetic Testing; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome; White People

2011
[24 weeks treatment with pegylated interferon alfa plus ribavirin may be possible in genotype 1 chronic hepatitis C patients with rapid virological response who have low pretreatment viremia].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2010, Volume: 56, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load; Viremia

2010
[Is 24 weeks of peginterferon and ribavirin combination therapy sufficient for the patients with genotype 1 chronic hepatitis C?].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2010, Volume: 56, Issue:1

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load

2010
Expectoration of large bronchial casts secondary to the treatment of chronic hepatitis C with pegylated interferon and ribavirin.
    Clinics (Sao Paulo, Brazil), 2010, Volume: 65, Issue:7

    Topics: Antiviral Agents; Bronchial Diseases; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2010
Impact of interferon-ribavirin treatment on hepatitis C virus (HCV) protease quasispecies diversity in HIV- and HCV-coinfected patients.
    The Journal of infectious diseases, 2010, Sep-15, Volume: 202, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Plasma; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Nonstructural Proteins

2010
Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2010, Volume: 52, Issue:2

    Topics: Adult; Antiviral Agents; Depressive Disorder, Major; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Failure

2010
Proteome-wide anti-hepatitis C virus (HCV) and anti-HIV antibody profiling for predicting and monitoring the response to HCV therapy in HIV-coinfected patients.
    The Journal of infectious diseases, 2010, Sep-15, Volume: 202, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Monitoring; Hepatitis C Antibodies; Hepatitis C, Chronic; HIV Antibodies; HIV Core Protein p24; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Core Proteins; Viral Envelope Proteins; Viral Nonstructural Proteins

2010
Associations between serum lipids and hepatitis C antiviral treatment efficacy.
    Hepatology (Baltimore, Md.), 2010, Volume: 52, Issue:3

    Topics: Adult; Antiviral Agents; Black or African American; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lipids; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Triglycerides; White People

2010
Predictors of early treatment discontinuation among patients with genotype 1 hepatitis C and implications for viral eradication.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2010, Volume: 8, Issue:11

    Topics: Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Intercellular Signaling Peptides and Proteins; Interferons; Male; Medication Adherence; Middle Aged; Retrospective Studies; Ribavirin; Risk Factors; Time Factors; Viremia

2010
Effects of pegylated interferon α on fibrinolytic parameters in patients with chronic hepatitis C.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2011, Volume: 17, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Carboxypeptidase B2; Female; Fibrin Fibrinogen Degradation Products; Fibrinolysis; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Ribavirin; Time Factors; Tissue Plasminogen Activator

2011
Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48h after the start of treatment with pegylated interferon and ribavirin.
    Antiviral research, 2010, Volume: 88, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA Stability; RNA, Viral; Treatment Outcome

2010
Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C.
    Gastroenterology, 2010, Volume: 139, Issue:5

    Topics: Adult; Antiviral Agents; Drug Carriers; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Polymorphism, Genetic; Recombinant Proteins; Recurrence; Ribavirin; RNA, Messenger; RNA, Viral; Tissue Donors; Treatment Outcome

2010
Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2010, Volume: 49, Issue:2

    Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Silybin; Silymarin; Treatment Outcome; Viral Load

2010
Procyanidin B1 purified from Cinnamomi cortex suppresses hepatitis C virus replication.
    Antiviral chemistry & chemotherapy, 2010, Aug-11, Volume: 20, Issue:6

    Topics: Antiviral Agents; Biflavonoids; Catechin; Cell Line, Tumor; Cinnamomum zeylanicum; Drugs, Chinese Herbal; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Proanthocyanidins; Recombinant Proteins; Replicon; Ribavirin; RNA, Viral; Virus Internalization; Virus Replication

2010
Interferon alpha-induced hashimoto thyroiditis followed by transient graves disease in a patient with chronic HCV infection.
    Southern medical journal, 2010, Volume: 103, Issue:6

    Topics: Adult; Antiviral Agents; Autoantibodies; Autoantigens; Disease Progression; Drug Therapy, Combination; Follow-Up Studies; Graves Disease; Hashimoto Disease; Hepatitis C, Chronic; Humans; Hypothyroidism; Interferon alpha-2; Interferon-alpha; Iodide Peroxidase; Iron-Binding Proteins; Male; Polyethylene Glycols; Receptors, Thyrotropin; Recombinant Proteins; Ribavirin; Th1 Cells; Th2 Cells

2010
Dental problems delaying the initiation of interferon therapy for HCV-infected patients.
    Virology journal, 2010, Aug-17, Volume: 7

    Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Stomatognathic Diseases

2010
Chronic hepatitis C treatment in näive patients.
    Annals of hepatology, 2010, Volume: 9 Suppl

    Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2010
Management of hepatitis C virus infection in childhood.
    Annals of hepatology, 2010, Volume: 9 Suppl

    Topics: Antiviral Agents; Asymptomatic Infections; Biopsy; Child; Child, Preschool; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Interferon-alpha; Ribavirin; Risk Factors; RNA, Viral; Treatment Outcome; Viral Load

2010
A case of severe thrombocytopenia in a patient with chronic hepatitis C caused by a single administration of pegylated interferon α 2a subsequent to 48 weeks of pegylated interferon α 2b plus ribavirin therapy.
    Internal medicine (Tokyo, Japan), 2010, Volume: 49, Issue:16

    Topics: Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index; Thrombocytopenia

2010
The role of bile acid retention and a common polymorphism in the ABCB11 gene as host factors affecting antiviral treatment response in chronic hepatitis C.
    Journal of viral hepatitis, 2011, Volume: 18, Issue:11

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome

2011
Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2011, Volume: 9, Issue:4

    Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2011
Differential interferon signaling in liver lobule and portal area cells under treatment for chronic hepatitis C.
    Journal of hepatology, 2010, Volume: 53, Issue:5

    Topics: Adult; Aged; Drug Therapy, Combination; Female; Gene Expression Profiling; Hepatitis C, Chronic; Humans; Immunity, Innate; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Signal Transduction

2010
Drug rash with eosinophilia and systemic symptoms due to telaprevir.
    Dermatology (Basel, Switzerland), 2010, Volume: 221, Issue:4

    Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antiviral Agents; Clinical Trials, Phase II as Topic; Drug Eruptions; Drug Therapy, Combination; Dyspnea; Eosinophilia; Exanthema; Female; Fever; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Transaminases; Treatment Outcome

2010
Polymorphism in tumor necrosis factor-related apoptosis-inducing ligand receptor 1 is associated with poor viral response to interferon-based hepatitis C virus therapy in HIV/hepatitis C virus-coinfected individuals.
    AIDS (London, England), 2010, Nov-13, Volume: 24, Issue:17

    Topics: Adult; Antiviral Agents; Canada; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Diseases; Male; Middle Aged; Polymorphism, Genetic; Receptors, Tumor Necrosis Factor, Member 25; Recombinant Proteins; Ribavirin; RNA, Viral

2010
How sustained is sustained viral response in patients with hepatitis C virus infection?
    Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2010, Volume: 29, Issue:3

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Life Tables; Liver Cirrhosis; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome

2010
Nephrotic syndrome with pegylated interferon alfa 2a and ribavirin for a patient with chronic hepatitis C.
    Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2010, Volume: 29, Issue:3

    Topics: Adult; Antiviral Agents; Diuretics; Glomerulosclerosis, Focal Segmental; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2010
Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Oct-01, Volume: 51, Issue:7

    Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Polyethylene Glycols; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2010
Twelve-week posttreatment follow-up predicts a sustained virological response to pegylated interferon and ribavirin therapy.
    Hepatology (Baltimore, Md.), 2010, Volume: 52, Issue:3

    Topics: Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Load

2010
Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection.
    The Journal of infectious diseases, 2010, Oct-15, Volume: 202, Issue:8

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Equilibrative Nucleoside Transporter 1; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin

2010
Treatment of chronic hepatitis C in HIV-infected patients with compensated liver cirrhosis.
    Journal of viral hepatitis, 2011, Volume: 18, Issue:8

    Topics: Adult; Drug Combinations; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome

2011
Relationship between the hepatitis C viral load and the serum interferon concentration during the first week of peginterferon-alpha-2b-ribavirin combination therapy.
    Journal of medical virology, 2010, Volume: 82, Issue:10

    Topics: Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Serum; Viral Load

2010
Quantitative determination of hepatitis C core antigen in therapy monitoring for chronic hepatitis C.
    Intervirology, 2011, Volume: 54, Issue:2

    Topics: Antigens, Viral; Antiviral Agents; Clinical Laboratory Techniques; Drug Monitoring; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; RNA, Viral; Sensitivity and Specificity; Viral Core Proteins

2011
Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis.
    Journal of gastroenterology, 2011, Volume: 46, Issue:3

    Topics: Adolescent; Adult; Age Factors; Aged; alpha-Fetoproteins; Antiviral Agents; Data Mining; Decision Trees; Drug Carriers; Female; gamma-Glutamyltransferase; Genotype; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Predictive Value of Tests; Retrospective Studies; Ribavirin; Sex Factors; Treatment Outcome; Young Adult

2011
Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2010, Volume: 52, Issue:4

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Bacterial Infections; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Infections; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors

2010
Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C.
    Gastroenterology, 2011, Volume: 140, Issue:1

    Topics: Antiviral Agents; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Interferon alpha-2; Interferon-alpha; Longitudinal Studies; Male; Metformin; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load

2011
The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients.
    Liver international : official journal of the International Association for the Study of the Liver, 2011, Volume: 31, Issue:1

    Topics: Adult; Antiviral Agents; Chi-Square Distribution; Drug Therapy, Combination; Female; Genotype; Health Status Indicators; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Italy; Logistic Models; Male; Middle Aged; Models, Biological; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; White People

2011
Hepatitis C virus quasispecies in chronically infected children subjected to interferon-ribavirin therapy.
    Archives of virology, 2010, Volume: 155, Issue:12

    Topics: Adolescent; Antiviral Agents; Child; Cluster Analysis; DNA, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Sequence Homology; Viral Envelope Proteins

2010
Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C.
    Liver international : official journal of the International Association for the Study of the Liver, 2010, Volume: 30, Issue:10

    Topics: Adolescent; Adult; Antiviral Agents; Chi-Square Distribution; Contraindications; Drug Therapy, Combination; Drug Users; Female; Genotype; Greece; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Logistic Models; Male; Medication Adherence; Middle Aged; Odds Ratio; Retrospective Studies; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Substance Abuse, Intravenous; Time Factors; Treatment Outcome; Viral Load; Young Adult

2010
A case of type 1 diabetes onset and recurrence of Graves' disease during pegylated interferon-α plus ribavirin treatment for chronic hepatitis C.
    Internal medicine (Tokyo, Japan), 2010, Volume: 49, Issue:18

    Topics: Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Graves Disease; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyendocrinopathies, Autoimmune; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Secondary Prevention; Treatment Outcome

2010
Predictive factors for response to peginterferon-alpha and ribavirin treatment of chronic HCV infection in patients aged 65 years and more.
    Digestive diseases and sciences, 2010, Volume: 55, Issue:11

    Topics: Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Intention to Treat Analysis; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2010
An open-safety study of dual antiviral therapy in real-world patients with chronic hepatitis C.
    Pharmacoepidemiology and drug safety, 2010, Volume: 19, Issue:11

    Topics: Adult; Age Factors; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Male; Medication Adherence; Middle Aged; Ribavirin

2010
Estimating the likelihood of sustained virological response in chronic hepatitis C therapy.
    Journal of viral hepatitis, 2011, Volume: 18, Issue:4

    Topics: Adult; Antiviral Agents; Cohort Studies; Female; Germany; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2011
Quantitative analysis of interferon alpha receptor subunit 1 and suppressor of cytokine signaling 1 gene transcription in blood cells of patients with chronic hepatitis C.
    Virology journal, 2010, Sep-18, Volume: 7

    Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Receptor, Interferon alpha-beta; Recombinant Proteins; Ribavirin; Suppressor of Cytokine Signaling 1 Protein; Suppressor of Cytokine Signaling Proteins; Transcription, Genetic

2010
Early diagnosis and treatment resolved cholestatic hepatitis C without fibrosis after living donor liver transplantation: report of a case.
    Surgery today, 2010, Volume: 40, Issue:10

    Topics: Antiviral Agents; Biopsy; Cholangiography; Cholestasis, Intrahepatic; Diagnosis, Differential; Drug Carriers; Early Diagnosis; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Postoperative Complications; Recombinant Proteins; Ribavirin; RNA, Viral; Ultrasonography, Doppler

2010
Angiogenic cytokines in patients undergoing antiviral treatment for chronic hepatitis C virus infection.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2011, Volume: 31, Issue:2

    Topics: Adult; Angiopoietin-2; Antiviral Agents; Case-Control Studies; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Vascular Endothelial Growth Factor A; Viral Load

2011
The next step for taribavirin.
    Hepatology (Baltimore, Md.), 2010, Volume: 52, Issue:4

    Topics: Anemia, Hemolytic; Antiviral Agents; Hepatitis C, Chronic; Humans; Ribavirin

2010
Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virological response.
    Hepatology (Baltimore, Md.), 2010, Volume: 52, Issue:4

    Topics: Antiviral Agents; Body Weight; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2010
Serum lipid profile and chronic hepatitis C virus.
    Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:2

    Topics: Antiviral Agents; Biomarkers; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Polyethylene Glycols; Polymorphism, Genetic; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Outcome

2011
Outcome of antiviral treatment in patients with chronic genotype 1 HCV hepatitis. A retrospective study in 507 patients.
    Journal of gastrointestinal and liver diseases : JGLD, 2010, Volume: 19, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Romania; Time Factors; Treatment Outcome; Viral Load; Young Adult

2010
Fluoxetine disposition in patients with chronic hepatitis C treated with interferon-α.
    Clinical pharmacokinetics, 2010, Volume: 49, Issue:11

    Topics: Adult; Antidepressive Agents, Second-Generation; Antiviral Agents; Area Under Curve; Drug Interactions; Drug Therapy, Combination; Female; Fluoxetine; Half-Life; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Phenotype; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Young Adult

2010
Editorial: Treatment of patients with HCV-related cirrhosis with peginterferon and ribavirin: Swinging the pendulum toward treatment.
    The American journal of gastroenterology, 2010, Volume: 105, Issue:10

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2010
High ability to predict the treatment outcome of peginterferon and ribavirin combination therapy based on the reduction in HCV RNA levels at 4 weeks after starting therapy and amino acid substitutions in the hepatitis C virus in patients infected with HCV
    Journal of gastroenterology, 2011, Volume: 46, Issue:4

    Topics: Aged; Amino Acid Substitution; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Nonstructural Proteins

2011
Prevalence and impact of hepatic steatosis on the response to antiviral therapy in Saudi patients with genotypes 1 and 4 chronic hepatitis C.
    Digestive diseases and sciences, 2011, Volume: 56, Issue:4

    Topics: Adult; Antiviral Agents; Biopsy; Body Mass Index; Diabetes Mellitus; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hyperlipidemias; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Retrospective Studies; Ribavirin; Saudi Arabia; Severity of Illness Index

2011
The smoldering epidemic. The number of new cases of hepatitis C is down, but millions are chronically infected and may not know it.
    Harvard health letter, 2010, Volume: 35, Issue:11

    Topics: Antiviral Agents; Disease Outbreaks; Drug Therapy, Combination; Hepatitis A; Hepatitis B; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Ribavirin

2010
Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C.
    Pharmacological research, 2011, Volume: 63, Issue:1

    Topics: Adult; Antiviral Agents; Case-Control Studies; Depression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Interferon alpha-2; Interferon-alpha; Italy; Kynurenine; Male; Middle Aged; Polyethylene Glycols; Psychiatric Status Rating Scales; Recombinant Proteins; Ribavirin; Serotonin; Time Factors; Treatment Outcome; Tryptophan

2011
Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy.
    Journal of viral hepatitis, 2011, Volume: 18, Issue:4

    Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Treatment Outcome; Viral Core Proteins; Viral Nonstructural Proteins

2011
Treatment of chronic hepatitis C with pegylated interferon and ribavirin in treatment-naive patients in 'true life': a plea in favor of independent postmarketing evaluations.
    European journal of gastroenterology & hepatology, 2010, Volume: 22, Issue:11

    Topics: Adult; Age Factors; Antiviral Agents; Biomarkers; Chi-Square Distribution; Drug Therapy, Combination; Evidence-Based Medicine; Female; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Hospitals, General; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Product Surveillance, Postmarketing; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Severity of Illness Index; Time Factors; Treatment Outcome; Viral Load

2010
Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Nov-15, Volume: 51, Issue:10

    Topics: Adult; Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon Type I; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Models, Statistical; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recombinant Proteins; Reproducibility of Results; Ribavirin; ROC Curve; Viral Load

2010
The association of cryoglobulinaemia with sustained virological response in patients with chronic hepatitis C.
    Journal of viral hepatitis, 2011, Volume: 18, Issue:4

    Topics: Adult; Antiviral Agents; Cryoglobulinemia; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Necrosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2011
Treatment uptake of patients with chronic hepatitis C: can we expect and do more?
    Digestive diseases and sciences, 2010, Volume: 55, Issue:12

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin

2010
Chronic hepatitis C treatment in a cystic fibrosis patient in the pulmonary pre-transplant stage.
    Revista espanola de enfermedades digestivas, 2010, Volume: 102, Issue:10

    Topics: Adult; Antiviral Agents; Cystic Fibrosis; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Liver; Lung Transplantation; Male; Portal System; Ribavirin

2010
Sporadic reappearance of minute amounts of hepatitis C virus RNA after successful therapy stimulates cellular immune responses.
    Gastroenterology, 2011, Volume: 140, Issue:2

    Topics: Adult; Aged; Cohort Studies; Cross-Sectional Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C Antibodies; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Immunity, Cellular; Interferons; Limit of Detection; Male; Middle Aged; Prospective Studies; Recurrence; Ribavirin; RNA, Viral; T-Lymphocytes

2011
Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project.
    European journal of gastroenterology & hepatology, 2011, Volume: 23, Issue:1

    Topics: Adult; Antibodies, Viral; Antiviral Agents; Cohort Studies; Comorbidity; Drug Users; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Mental Disorders; Middle Aged; Netherlands; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Substance-Related Disorders; Treatment Outcome

2011
The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis c patients with hepatocellular carcinoma post curative therapies - a multicenter prospective trial.
    Journal of hepatology, 2011, Volume: 54, Issue:2

    Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Case-Control Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Viral Load

2011
[Effect of peginterferon alpha-2a combinated with ribavirin in the treatment of rebound patient with chronic hepatitis C: a case report].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2010, Volume: 18, Issue:10

    Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2010
Pegylated interferon alfa-2b pen device and ribavirin treatment for patients with chronic hepatitis C: an evaluation of patient satisfaction.
    European journal of gastroenterology & hepatology, 2010, Volume: 22, Issue:9

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Equipment Design; Female; Hepatitis C, Chronic; Humans; Injections; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Patient Education as Topic; Patient Satisfaction; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Surveys and Questionnaires

2010
Analysis of neutralizing antibodies against hepatitis C virus in patients who were treated with pegylated-interferon plus ribavirin.
    The Kobe journal of medical sciences, 2010, Sep-28, Volume: 56, Issue:2

    Topics: Antibodies, Neutralizing; Antiviral Agents; Cell Line; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2010
HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.
    Gut, 2011, Volume: 60, Issue:2

    Topics: Aged; Amino Acid Substitution; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2011
Treatment of psoriasis in patients with hepatitis C virus infection.
    Clinical and experimental dermatology, 2011, Volume: 36, Issue:4

    Topics: Acitretin; Antiviral Agents; Cyclosporine; Drug Eruptions; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Methotrexate; Psoriasis; Ribavirin

2011
Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C.
    Gastroenterology, 2011, Volume: 140, Issue:2

    Topics: Adult; Age Factors; Antiviral Agents; Body Mass Index; Body Weight; Clinical Trials as Topic; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Multicenter Studies as Topic; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2011
Lower liver stiffness in patients with sustained virological response 4 years after treatment for chronic hepatitis C.
    European journal of gastroenterology & hepatology, 2011, Volume: 23, Issue:1

    Topics: Alanine Transaminase; Antiviral Agents; Cohort Studies; Denmark; Elasticity Imaging Techniques; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hyaluronic Acid; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2011
Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C.
    Alimentary pharmacology & therapeutics, 2011, Volume: 33, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; Epidemiologic Methods; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Recombinant Proteins; Ribavirin; Young Adult

2011
Occult hepatitis B infection in egyptian chronic hepatitis C patients: prevalence, impact on pegylated interferon/ribavirin therapy.
    Virology journal, 2010, Nov-17, Volume: 7

    Topics: Adult; Age Distribution; Comorbidity; DNA, Viral; Female; Hepacivirus; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2010
Interferon-α suppressed granulocyte colony stimulating factor production is reversed by CL097, a TLR7/8 agonist.
    Journal of gastroenterology and hepatology, 2010, Volume: 25, Issue:12

    Topics: Adult; Aged; Antiviral Agents; Case-Control Studies; Cells, Cultured; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Granulocyte Colony-Stimulating Factor; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Ireland; Leukocyte Count; Male; Middle Aged; Neutropenia; Neutrophils; Polyethylene Glycols; Prospective Studies; Quinolines; Recombinant Proteins; Ribavirin; Time Factors; Toll-Like Receptor 7; Toll-Like Receptor 8; Treatment Outcome

2010
Long-term outcome after antiviral therapy of patients with hepatitis C virus infection and decompensated cirrhosis.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2011, Volume: 9, Issue:3

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatic Insufficiency; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2011
Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a.
    Journal of viral hepatitis, 2011, Volume: 18, Issue:8

    Topics: Adult; Antiviral Agents; China; Drug Evaluation; Drug Therapy, Combination; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome

2011
[Pulmonary embolism in a 30 year-old man with chronic hepatitis C during therapy with pegylated interferon-α and ribavirin].
    Kardiologia polska, 2010, Volume: 68, Issue:11

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Pulmonary Embolism; Recombinant Proteins; Ribavirin; Treatment Outcome

2010
Hepatitis C virus genotype 4 with normal transaminases: histological changes, schistosomiasis and response to treatment.
    Journal of viral hepatitis, 2011, Volume: 18, Issue:7

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Cohort Studies; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Schistosomiasis; Transaminases; Treatment Outcome

2011
Management of chronic hepatitis C in childhood: the impact of therapy in the clinical practice during the first 2 decades.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2011, Volume: 43, Issue:4

    Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Infant; Interferon alpha-2; Interferon-alpha; Interferons; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral

2011
Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C.
    Gastroenterology, 2011, Volume: 140, Issue:3

    Topics: Acetyltransferases; Adult; Antiviral Agents; Biopsy; Cytokines; Decision Support Techniques; Decision Trees; Drug Therapy, Combination; Female; Gene Expression Regulation; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver; Logistic Models; Male; Membrane Proteins; Middle Aged; Oxidoreductases Acting on CH-CH Group Donors; Phenotype; Polyethylene Glycols; Proteins; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; RNA, Messenger; Switzerland; Transcription Factors; Treatment Outcome; Ubiquitins

2011
Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients.
    Journal of hepatology, 2011, Volume: 54, Issue:3

    Topics: Adult; Alanine Transaminase; Alleles; Antiviral Agents; Base Sequence; Case-Control Studies; DNA Primers; Female; Gene Frequency; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load

2011
Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b.
    Journal of hepatology, 2011, Volume: 54, Issue:3

    Topics: Aged; Alleles; Antiviral Agents; Drug Resistance, Viral; Female; Gene Frequency; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Interferons; Interleukins; Japan; Male; Middle Aged; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2011
Ribavirin rather than PEG-interferon pharmacodynamics predict nonresponse to antiviral therapy in naive chronic hepatitis C patients.
    Journal of viral hepatitis, 2012, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Failure; Viral Load; Young Adult

2012
Virologic response to treatment with Pegylated Interferon alfa-2b and Ribavirin for chronic hepatitis C in children.
    Medical science monitor : international medical journal of experimental and clinical research, 2010, Volume: 16, Issue:12

    Topics: Alanine Transaminase; Child; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Treatment Outcome

2010
Effect of maintenance therapy with low-dose peginterferon for recurrent hepatitis C after living donor liver transplantation.
    Journal of viral hepatitis, 2012, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Young Adult

2012
Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test.
    Journal of viral hepatitis, 2011, Volume: 18, Issue:7

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Molecular Diagnostic Techniques; Nucleic Acid Amplification Techniques; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; RNA, Messenger; RNA, Viral; Treatment Outcome

2011
Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.
    Journal of hepatology, 2011, Volume: 54, Issue:3

    Topics: Aged; Alleles; Antiviral Agents; Data Mining; Decision Trees; Drug Resistance, Viral; Female; Genes, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Interferons; Interleukins; Japan; Logistic Models; Male; Middle Aged; Models, Biological; Mutation; Polymorphism, Single Nucleotide; Prognosis; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Core Proteins; Viral Load

2011
The basal activation state of DC subsets correlates with anti-HCV treatment outcome in HCV/HIV co-infected patients.
    Clinical immunology (Orlando, Fla.), 2011, Volume: 138, Issue:2

    Topics: Antiviral Agents; Dendritic Cells; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load

2011
Successful clearance of hepatitis C virus with pegylated interferon α-2a and ribavirin in an etanercept-treated patient with psoriatic arthritis, hepatitis B virus coinfection and latent tuberculosis.
    Annals of the rheumatic diseases, 2011, Volume: 70, Issue:7

    Topics: Adult; Antiviral Agents; Arthritis, Psoriatic; Drug Therapy, Combination; Etanercept; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Immunoglobulin G; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Latent Tuberculosis; Male; Polyethylene Glycols; Receptors, Tumor Necrosis Factor; Recombinant Proteins; Ribavirin

2011
IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy.
    Journal of hepatology, 2011, Volume: 54, Issue:6

    Topics: 2',5'-Oligoadenylate Synthetase; Adult; Aged; Aged, 80 and over; Antiviral Agents; Cytokines; Drug Therapy, Combination; eIF-2 Kinase; Female; Gene Expression; GTP-Binding Proteins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Myxovirus Resistance Proteins; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Messenger; Treatment Outcome; Ubiquitins

2011
Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection.
    Journal of hepatology, 2011, Volume: 55, Issue:2

    Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Tissue Donors; Treatment Outcome

2011
Pharmacodynamics of PEG-IFN-[alpha]-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients.
    Journal of acquired immune deficiency syndromes (1999), 2011, Feb-01, Volume: 56, Issue:2

    Topics: Antiviral Agents; Black People; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Models, Theoretical; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral; Serum; South America; Viral Load; White People

2011
Treating hepatitis C: are children the same as adults?
    Gastroenterology, 2011, Volume: 140, Issue:2

    Topics: Adult; Antiviral Agents; Child; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Multicenter Studies as Topic; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin

2011
Human cytomegalovirus infection inhibits response of chronic hepatitis-C-virus-infected patients to interferon-based therapy.
    Journal of gastroenterology and hepatology, 2011, Volume: 26, Issue:1

    Topics: Adult; Antibodies, Viral; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Disease Progression; DNA, Viral; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Envelope Proteins; Viral Load; Virus Activation

2011
An adult case with onset of celiac disease during chronic hepatitis C antiviral treatment.
    Romanian journal of internal medicine = Revue roumaine de medecine interne, 2010, Volume: 48, Issue:1

    Topics: Adult; Antiviral Agents; Celiac Disease; Female; Hepatitis C, Chronic; Humans; Interferons; Ribavirin

2010
Single nucleotide polymorphism at exon 7 splice acceptor site of OAS1 gene determines response of hepatitis C virus patients to interferon therapy.
    Journal of gastroenterology and hepatology, 2011, Volume: 26, Issue:5

    Topics: 2',5'-Oligoadenylate Synthetase; Adult; Antiviral Agents; Case-Control Studies; Chi-Square Distribution; DNA Mutational Analysis; Drug Resistance, Viral; Drug Therapy, Combination; Egypt; Exons; Female; Gene Frequency; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Odds Ratio; Phenotype; Polyethylene Glycols; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; RNA Splice Sites; Treatment Outcome; Young Adult

2011
Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV.
    The Journal of clinical investigation, 2011, Volume: 121, Issue:1

    Topics: Antiviral Agents; Chemokine CXCL10; Dipeptidyl Peptidase 4; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Peptide Fragments; Polyethylene Glycols; Prognosis; Protein Array Analysis; Receptors, CXCR3; Recombinant Proteins; Ribavirin; T-Lymphocytes; Treatment Failure

2011
IL28B-genotype testing now and in the era of direct-acting antiviral agents.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2011, Volume: 9, Issue:4

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2011
Nitric oxide levels and sustained virological response to pegylated-interferon alpha2a plus ribavirin in chronic HCV genotype 4 hepatitis: A prospective study.
    Journal of gastrointestinal and liver diseases : JGLD, 2010, Volume: 19, Issue:4

    Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Egypt; Enzyme-Linked Immunosorbent Assay; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Liver; Logistic Models; Male; Middle Aged; Nitric Oxide; Nitric Oxide Synthase Type II; Odds Ratio; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2010
Hepatitis C recurrence: influence of serum cholesterol levels and liver steatosis on antiviral therapy.
    Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:4

    Topics: Antiviral Agents; Body Mass Index; Cholesterol; Fatty Liver; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Triglycerides; Viral Load

2011
Ribavirin plasma concentration measurements in patients with hepatitis C: early ribavirin concentrations predict steady-state concentrations.
    Therapeutic drug monitoring, 2011, Volume: 33, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Monitoring; Drug Therapy, Combination; Female; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin

2011
Comparable performance of TMA and Real-Time PCR in detecting minimal residual hepatitis C viraemia at the end of antiviral therapy.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2011, Volume: 50, Issue:3

    Topics: Antiviral Agents; Drug Monitoring; Hepatitis C, Chronic; Humans; Interferons; Molecular Diagnostic Techniques; Predictive Value of Tests; Prognosis; Ribavirin; RNA, Viral; Sensitivity and Specificity; Viremia; Virology

2011
Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function.
    Gastroenterology, 2011, Volume: 140, Issue:4

    Topics: Adenosine Triphosphate; Adenylosuccinate Synthase; Adolescent; Adult; Anemia; Antiviral Agents; Enzyme Activation; Erythrocytes; Genetic Variation; Genotype; Guanosine Triphosphate; Hepatitis C, Chronic; Humans; In Vitro Techniques; Inosine Triphosphatase; Inosine Triphosphate; Pyrophosphatases; Ribavirin; Young Adult

2011
Protein pathway activation associated with sustained virologic response in patients with chronic hepatitis C treated with pegylated interferon (PEG-IFN) and ribavirin (RBV).
    Journal of proteome research, 2011, Feb-04, Volume: 10, Issue:2

    Topics: Adult; Antiviral Agents; Area Under Curve; Female; Hepatitis C, Chronic; Humans; Intercellular Signaling Peptides and Proteins; Interferon Type I; Leukocytes, Mononuclear; Male; Middle Aged; Phosphoproteins; Polyethylene Glycols; Protein Array Analysis; Proteomics; Recombinant Proteins; Regression Analysis; Reproducibility of Results; Ribavirin; Sensitivity and Specificity; Signal Transduction; Statistics, Nonparametric

2011
Role of insulin resistance and hepatic steatosis in the progression of fibrosis and response to treatment in hepatitis C.
    Liver international : official journal of the International Association for the Study of the Liver, 2011, Volume: 31 Suppl 1

    Topics: Antiviral Agents; Fatty Liver; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; MicroRNAs; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2011
Audit of state-funded antiviral treatment for chronic hepatitis C in Qatar.
    Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit, 2010, Volume: 16, Issue:11

    Topics: Adult; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Qatar; Recombinant Proteins; Residence Characteristics; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2010
IL-28B predicts response to chronic hepatitis C therapy--fine-mapping and replication study in Asian populations.
    The Journal of general virology, 2011, Volume: 92, Issue:Pt 5

    Topics: Adult; Aged; Antiviral Agents; Asia; Asian People; Female; Gene Frequency; Genotype; Haplotypes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Genetic; Prognosis; Ribavirin; Treatment Outcome; Viral Load

2011
Treatment of chronic hepatitis C with pegylated interferon and ribavirin in treatment-naive patients in 'true life'.
    European journal of gastroenterology & hepatology, 2011, Volume: 23, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Patient Dropouts; Recombinant Proteins; Ribavirin

2011
Clinicopathological features of hepatitis C virus disease after living donor liver transplantation: relationship with in situ hybridisation data.
    Pathology, 2011, Volume: 43, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Biopsy; Drug Therapy, Combination; End Stage Liver Disease; Female; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Immunosuppressive Agents; In Situ Hybridization; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin

2011
IL28B: A new wager in the skyline of hepatitis C virus infection.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2011, Volume: 43, Issue:3

    Topics: Antiviral Agents; Genome-Wide Association Study; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome

2011
[Complete atrio-ventricular block: a rare complication of interferon alpha therapy].
    Presse medicale (Paris, France : 1983), 2011, Volume: 40, Issue:3

    Topics: Adult; Antiviral Agents; Atrioventricular Block; Cooperative Behavior; Drug Therapy, Combination; Electrocardiography; Electrocardiography, Ambulatory; Hepatitis C, Chronic; Humans; Interdisciplinary Communication; Interferon alpha-2; Interferon-alpha; Male; Pacemaker, Artificial; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Signal Processing, Computer-Assisted

2011
Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C.
    Journal of gastroenterology, 2011, Volume: 46, Issue:4

    Topics: Adult; Age Factors; Aged; Amino Acid Substitution; Antiviral Agents; Data Mining; Decision Trees; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Retrospective Studies; Ribavirin; Sensitivity and Specificity; Sex Factors; Time Factors; Viral Load; Viral Nonstructural Proteins

2011
Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.
    Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:2

    Topics: Adult; Aged; Anemia; Antiviral Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Retrospective Studies; Ribavirin

2011
Coevolution of the hepatitis C virus polyprotein sites in patients on combined pegylated interferon and ribavirin therapy.
    Journal of virology, 2011, Volume: 85, Issue:7

    Topics: Adaptation, Biological; Antiviral Agents; Drug Resistance, Viral; Evolution, Molecular; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Polyproteins; Ribavirin; Treatment Outcome

2011
Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients.
    Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:1

    Topics: Adult; Asian People; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2011
Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models.
    Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:1

    Topics: Drug Synergism; Guanosine; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Regulatory Factor-7; Interferon-alpha; Interferon-Stimulated Gene Factor 3, gamma Subunit; NF-kappa B; Oxidoreductases Acting on CH-CH Group Donors; Polyethylene Glycols; Proteins; Recombinant Proteins; Ribavirin; Tumor Cells, Cultured

2011
Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response.
    Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:1

    Topics: Adult; Black or African American; Chemokine CXCL10; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; White People

2011
Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis.
    Journal of medical virology, 2011, Volume: 83, Issue:3

    Topics: Antiviral Agents; Cohort Studies; Data Mining; Decision Trees; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Multivariate Analysis; Mutation; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Core Proteins

2011
[Therapy of chronic hepatitis C--virologic response monitoring].
    Vojnosanitetski pregled, 2010, Volume: 67, Issue:11

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load; Young Adult

2010
[Acute loss of vision during therapy of chronic hepatitis C].
    Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2011, Volume: 108, Issue:6

    Topics: Adult; Antibodies, Monoclonal, Humanized; Antiviral Agents; Bevacizumab; Drug Therapy, Combination; Fluorescein Angiography; Hepatitis C, Chronic; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Interferon-alpha; Intravitreal Injections; Macular Edema; Male; Polyethylene Glycols; Recombinant Proteins; Retinal Vein Occlusion; Ribavirin; Tomography, Optical Coherence; Vision, Low; Visual Acuity

2011
Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin.
    World journal of gastroenterology, 2011, Jan-28, Volume: 17, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Fibrosis; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2011
Sarcoid-related dacryoadenitis following treatment with interferon alpha and ribavarin for hepatitis C.
    Orbit (Amsterdam, Netherlands), 2011, Volume: 30, Issue:1

    Topics: Aged; Antiviral Agents; Biopsy; Dacryocystitis; Diagnosis, Differential; Female; Glucocorticoids; Hepatitis C, Chronic; Humans; Interferon-alpha; Prednisolone; Ribavirin; Sarcoidosis; Tomography, X-Ray Computed

2011
Polymorphisms of hepatitis C virus non-structural protein 5A and core protein and clinical outcome of pegylated-interferon/ribavirin combination therapy.
    Intervirology, 2012, Volume: 55, Issue:1

    Topics: Aged; Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome; Viral Core Proteins; Viral Nonstructural Proteins

2012
[A case with chronic hepatitis C who developed liver cirrhosis due to liver dysfunction caused by pegylated interferon plus ribavirin treatment despite negativity of serum HCV RNA, during therapy].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2011, Volume: 108, Issue:2

    Topics: Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2011
Safety and efficacy of peginterferon alpha plus ribavirin in patients with chronic hepatitis C and coexisting heart disease.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2011, Volume: 43, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Disease Progression; Echocardiography; Electrocardiography; Female; Genotype; Heart Diseases; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Troponin I

2011
Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States.
    Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:3

    Topics: Adolescent; Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Insurance Coverage; Insurance, Health; Interferon alpha-2; Interferon-alpha; Male; Medicaid; Medically Uninsured; Middle Aged; Nutrition Surveys; Polyethylene Glycols; Recombinant Proteins; Ribavirin; United States

2011
Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects?
    Immunopharmacology and immunotoxicology, 2011, Volume: 33, Issue:4

    Topics: Adenine; Adult; Albuminuria; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors

2011
Treatment of chronic hepatitis C in Croatian war veterans: experiences from Croatian reference center for viral hepatitis.
    Croatian medical journal, 2011, Volume: 52, Issue:1

    Topics: Adult; Comorbidity; Croatia; Dose-Response Relationship, Drug; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Ribavirin; Risk Factors; Severity of Illness Index; Stress Disorders, Post-Traumatic; Treatment Outcome; Veterans; Veterans Health; Warfare

2011
Efficacy of peg-interferon-α-2a plus ribavirin for patients aged 60 years and older with chronic hepatitis C in Korea.
    Journal of gastroenterology and hepatology, 2011, Volume: 26, Issue:3

    Topics: Age Factors; Antiviral Agents; Asian People; Aspartate Aminotransferases; Biomarkers; Chi-Square Distribution; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Korea; Logistic Models; Male; Middle Aged; Odds Ratio; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2011
Serum visfatin is correlated with disease severity and metabolic syndrome in chronic hepatitis C infection.
    Journal of gastroenterology and hepatology, 2011, Volume: 26, Issue:3

    Topics: Adult; Analysis of Variance; Antiviral Agents; Biomarkers; Biopsy; Case-Control Studies; Chi-Square Distribution; Cytokines; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Metabolic Syndrome; Middle Aged; Nicotinamide Phosphoribosyltransferase; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Severity of Illness Index; Taiwan; Treatment Outcome; Up-Regulation; Viral Load

2011
Pre-treatment predictors of response for assessing outcomes to standard treatment in infection with HCV genotype 3.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2011, Volume: 21, Issue:2

    Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Polymerase Chain Reaction; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Outcome

2011
The use of psychoeducation for a patient with hepatitis C and psychiatric illness in preparation for antiviral therapy: a case report and discussion.
    Journal of clinical psychology in medical settings, 2011, Volume: 18, Issue:1

    Topics: Adaptation, Psychological; Alcoholism; Antiviral Agents; Awareness; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Mental Disorders; Middle Aged; Patient Education as Topic; Problem Solving; Psychotherapy; Psychotherapy, Group; Recombinant Proteins; Recurrence; Ribavirin; Social Support; Substance Abuse, Intravenous; Suicidal Ideation

2011
Soluble inflammatory markers as predictors of virological response in patients with chronic hepatitis C virus infection treated with interferon-α plus ribavirin.
    Memorias do Instituto Oswaldo Cruz, 2011, Volume: 106, Issue:1

    Topics: Adult; Antiviral Agents; Biomarkers; Chemokines; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Predictive Value of Tests; Receptors, Tumor Necrosis Factor; Ribavirin; RNA, Viral; Severity of Illness Index; Treatment Outcome; Viral Load

2011
Tongue hyperpigmentation during interferon therapy.
    The Journal of dermatology, 2011, Volume: 38, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Hyperpigmentation; Interferon alpha-2; Interferon-alpha; Middle Aged; Recombinant Proteins; Ribavirin; Tongue Diseases

2011
Role of nucleoside transporters SLC28A2/3 and SLC29A1/2 genetics in ribavirin therapy: protection against anemia in patients with chronic hepatitis C.
    Pharmacogenetics and genomics, 2011, Volume: 21, Issue:5

    Topics: Adult; Aged; Anemia, Hemolytic; Antiviral Agents; Equilibrative Nucleoside Transporter 1; Equilibrative-Nucleoside Transporter 2; Female; Genetic Association Studies; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Membrane Transport Proteins; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin

2011
IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection.
    Genes and immunity, 2011, Volume: 12, Issue:4

    Topics: Adult; Aged; Alleles; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; Taiwan; Young Adult

2011
Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia.
    Journal of medical economics, 2011, Volume: 14, Issue:2

    Topics: Antiviral Agents; Blood Transfusion; Disease Progression; Female; Health Care Costs; Health Resources; Hepatitis C, Chronic; Humans; Inpatients; Insurance Claim Review; Interferons; Male; Middle Aged; Outpatients; Platelet Count; Regression Analysis; Retrospective Studies; Ribavirin; Thrombocytopenia; United States

2011
Usefulness of viral kinetics for early prediction of a sustained virological response in HCV-1 non-responders re-treated with pegylated interferon and ribavirin.
    Journal of hepatology, 2011, Volume: 55, Issue:5

    Topics: Antiviral Agents; Area Under Curve; Decision Support Techniques; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; ROC Curve; Time Factors; Treatment Failure; Viral Load

2011
IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C.
    Journal of hepatology, 2011, Volume: 55, Issue:5

    Topics: Adult; Alleles; Antiviral Agents; Female; Gene Frequency; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors

2011
Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b.
    Journal of medical virology, 2011, Volume: 83, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Female; Gene Frequency; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Leukocyte Count; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Treatment Outcome

2011
Hepatitis C virus: five-year follow-up of patients with sustained virological response.
    Revista espanola de enfermedades digestivas, 2011, Volume: 103, Issue:2

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Multicenter Studies as Topic; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2011
Five-year follow-up of patients with chronic C hepatitis and sustained virological response.
    Revista espanola de enfermedades digestivas, 2011, Volume: 103, Issue:2

    Topics: Adult; Antiviral Agents; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral

2011
Autoimmune thyroiditis and delayed onset psoriasis in association with combination therapy for chronic hepatitis C infection.
    Singapore medical journal, 2011, Volume: 52, Issue:2

    Topics: Antiviral Agents; Autoantibodies; Autoimmunity; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Polyethylene Glycols; Poverty; Psoriasis; Recombinant Proteins; Ribavirin; Thyroiditis, Autoimmune

2011
IFN-stimulated gene expression is a useful potential molecular marker of response to antiviral treatment with Peg-IFNα 2b and ribavirin in patients with hepatitis C virus genotype 1.
    Archives of medical research, 2011, Volume: 42, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Biomarkers, Pharmacological; Drug Therapy, Combination; Female; Gene Expression; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2011
[Evaluation of selected laboratory markers of liver fibrosis in patients with chronic hepatitis type C].
    Przeglad lekarski, 2010, Volume: 67, Issue:7

    Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Biopsy; Cholesterol; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Platelet Count; Ribavirin

2010
The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B
    Journal of clinical microbiology, 2011, Volume: 49, Issue:5

    Topics: Aged; Antiviral Agents; Asian People; Drug Therapy, Combination; Female; Genetic Testing; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Japan; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Ribavirin; Treatment Outcome

2011
Ribavirin concentration in the later stages of 48 week pegylated interferon-alpha2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological response.
    The Journal of antimicrobial chemotherapy, 2011, Volume: 66, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Chromatography, High Pressure Liquid; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Serum; Treatment Outcome; Viral Load

2011
Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2011, Volume: 9, Issue:7

    Topics: Adult; Antiviral Agents; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Portal Pressure; Predictive Value of Tests; Prognosis; Recombinant Proteins; Ribavirin; Thrombocytopenia; Treatment Outcome

2011
A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2011, Volume: 9, Issue:6

    Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin; Survival Analysis; Treatment Outcome; United States; Viral Load

2011
Association of serum cytokine levels with treatment response to pegylated interferon and ribavirin therapy in genotype 1 chronic hepatitis C patients.
    The Journal of infectious diseases, 2011, Apr-15, Volume: 203, Issue:8

    Topics: Amino Acid Substitution; Antiviral Agents; Biomarkers; Cytokines; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Viral Core Proteins

2011
Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis.
    Arthritis and rheumatism, 2011, Volume: 63, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Ribavirin; Severity of Illness Index; Systemic Vasculitis; Treatment Outcome

2011
[Metabolic syndrome in patients with chronic hepatitis C genotype 1].
    Vestnik Rossiiskoi akademii meditsinskikh nauk, 2011, Issue:1

    Topics: Adult; Antiviral Agents; Fatty Liver; Female; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Leptin; Liver Cirrhosis; Male; Metabolic Syndrome; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome

2011
Tubo-ovarian abscess during therapy of chronic hepatitis C with pegylated interferon and ribavirin.
    Neuro endocrinology letters, 2011, Volume: 32, Issue:1

    Topics: Abdominal Abscess; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Oophoritis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Salpingitis

2011
Factor VIII and IX deficiencies related to acquired inhibitors in a patient with chronic hepatitis C virus infection receiving treatment with pegylated interferon plus ribavirin.
    Hematology (Amsterdam, Netherlands), 2011, Volume: 16, Issue:2

    Topics: Antiviral Agents; Autoantibodies; Drug Therapy, Combination; Factor IX; Factor VIII; Hemophilia A; Hemophilia B; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2011
Autoimmune fulminant hepatic failure in chronic hepatitis C during Peg-interferon-alpha 2b plus ribavirin treatment showing histological heterogeneity.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2011, Volume: 43, Issue:8

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Hepatitis, Autoimmune; Humans; Interferon alpha-2; Interferon-alpha; Liver Failure, Acute; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2011
Ribavirin concentration is a more important predictor of sustained viral response than anemia in hepatitis C patients.
    Gastroenterology, 2011, Volume: 140, Issue:5

    Topics: Anemia; Antiviral Agents; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Treatment Outcome; Viral Load

2011
IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.
    Alimentary pharmacology & therapeutics, 2011, Volume: 33, Issue:10

    Topics: Adult; Antiviral Agents; Chemokine CXCL10; Cohort Studies; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load

2011
Outcomes of an underserved Hispanic population with chronic hepatitis C treated with pegylated-interferon and ribavirin in a government-sponsored clinic.
    Puerto Rico health sciences journal, 2011, Volume: 30, Issue:1

    Topics: Adolescent; Adult; Antiviral Agents; Female; Government Programs; Health Facilities; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon alpha-2; Interferon-alpha; Male; Medically Underserved Area; Middle Aged; Polyethylene Glycols; Puerto Rico; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Young Adult

2011
A new era of hepatitis C therapy begins.
    The New England journal of medicine, 2011, Mar-31, Volume: 364, Issue:13

    Topics: Anemia; Antiviral Agents; Black People; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors

2011
Retention of CD4+ CD25+ FoxP3+ regulatory T cells in the liver after therapy-induced hepatitis C virus eradication in humans.
    Journal of virology, 2011, Volume: 85, Issue:11

    Topics: Antiviral Agents; Biopsy; CD4 Antigens; Forkhead Transcription Factors; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukin-2 Receptor alpha Subunit; Liver; Ribavirin; T-Lymphocytes, Regulatory

2011
Acute pericarditis due to pegylated interferon alpha therapy for chronic HCV hepatitis - case report.
    BMC gastroenterology, 2011, Mar-31, Volume: 11

    Topics: Acute Disease; Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Ibuprofen; Interferon alpha-2; Interferon-alpha; Pericarditis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Withholding Treatment

2011
Malnutrition impairs interferon signaling through mTOR and FoxO pathways in patients with chronic hepatitis C.
    Gastroenterology, 2011, Volume: 141, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Base Sequence; Cell Line, Tumor; Drug Therapy, Combination; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Japan; Liver; Liver Cirrhosis; Male; Malnutrition; Mechanistic Target of Rapamycin Complex 1; Middle Aged; Molecular Sequence Data; Multiprotein Complexes; Nutritional Status; Odds Ratio; Polyethylene Glycols; Polymorphism, Genetic; Proteins; Recombinant Proteins; Regression Analysis; Ribavirin; RNA Interference; RNA, Viral; Severity of Illness Index; Signal Transduction; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; TOR Serine-Threonine Kinases; Transaminases; Transfection; Treatment Outcome; Viral Load; Virus Replication

2011
[Inhibitors of hepatitis C virus--current standards and status of investigations].
    Przeglad epidemiologiczny, 2010, Volume: 64, Issue:4

    Topics: Antiviral Agents; Clinical Trials as Topic; Drugs, Investigational; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2010
IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection.
    PloS one, 2011, Mar-30, Volume: 6, Issue:3

    Topics: Adult; Female; Genetic Predisposition to Disease; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Linkage Disequilibrium; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prognosis; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2011
Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:4

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Viral Load; Vitamin D; Vitamin D Deficiency

2011
Ribavirin enhances interferon-stimulated gene transcription by activation of the interferon-stimulated response element.
    Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:4

    Topics: Cell Line, Tumor; Drug Synergism; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Regulatory Factors; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Transcriptional Activation

2011
"Real-Life" comparison of pegylated-interferon 2a versus 2b combination therapy of chronic hepatitis C virus.
    Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:4

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin

2011
[Syndrome distribution among patients with chronic hepatitis C and interventions of integrated traditional Chinese and Western medicine: study protocol].
    Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine, 2011, Volume: 9, Issue:4

    Topics: Adolescent; Adult; Aged; Antiviral Agents; China; Drugs, Chinese Herbal; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Medicine, Chinese Traditional; Middle Aged; Multicenter Studies as Topic; Prospective Studies; Randomized Controlled Trials as Topic; Ribavirin; Social Planning; Young Adult

2011
Has genetics eradicated the good old predictors of hepatitis C treatment response?
    Clinics and research in hepatology and gastroenterology, 2011, Volume: 35, Issue:3

    Topics: Antiviral Agents; Genetic Markers; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Prognosis; Ribavirin

2011
Vogt-Koyanagi-Harada disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C.
    The Korean journal of hepatology, 2011, Volume: 17, Issue:1

    Topics: Anti-Inflammatory Agents; Antiviral Agents; Drug Therapy, Combination; Female; Fluorescein Angiography; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Magnetic Resonance Imaging; Middle Aged; Polyethylene Glycols; Prednisolone; Recombinant Proteins; Ribavirin; Tomography, X-Ray Computed; Uveomeningoencephalitic Syndrome

2011
Skeletal recovery from hepatitis C-associated osteosclerosis (HCAO) following antiviral treatment.
    Joint bone spine, 2011, Volume: 78, Issue:4

    Topics: Antiviral Agents; Bone and Bones; Female; Hepatitis C, Chronic; Humans; Interferons; Middle Aged; Osteosclerosis; Radiography; Recovery of Function; Ribavirin

2011
Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b.
    Journal of medical virology, 2011, Volume: 83, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Japan; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Core Proteins; Viral Load; Young Adult

2011
Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy.
    Journal of medical virology, 2011, Volume: 83, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferons; Liver; Liver Neoplasms; Male; Middle Aged; Ribavirin; RNA, Viral; Viral Core Proteins; Young Adult

2011
Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy.
    Journal of medical virology, 2011, Volume: 83, Issue:6

    Topics: Amino Acid Substitution; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Japan; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; RNA, Viral; Treatment Outcome; Viral Core Proteins

2011
IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.
    AIDS (London, England), 2011, May-15, Volume: 25, Issue:8

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral; Spain; Treatment Outcome; Viral Load

2011
[Durability of sustained virologic response in chronic hepatitis C: analysis of factors related to relapse after sustained virologic response with peginterferon plus ribavirin combination therapy].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2011, Volume: 57, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; RNA, Viral

2011
Association between virological response and decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in HCV genotype 1: another story.
    Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:5

    Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2011
Abbott RealTime PCR assay is useful for evaluating virological response to antiviral treatment for chronic hepatitis C.
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2011, Volume: 17, Issue:6

    Topics: Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Statistics, Nonparametric; Treatment Outcome; Viral Load

2011
Bell's palsy associated with chronic HCV infection before and during peginterferon alfa and ribavirin therapy.
    Archives of Iranian medicine, 2011, Volume: 14, Issue:3

    Topics: Adult; Antiviral Agents; Bell Palsy; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2011
Rheumatoid arthritis following a treatment with IFN-alpha/ribavirin against HCV infection.
    Internal medicine (Tokyo, Japan), 2011, Volume: 50, Issue:9

    Topics: Antiviral Agents; Arthritis, Rheumatoid; Autoantibodies; B-Cell Activating Factor; Cytokines; Hepatitis C, Chronic; Humans; Interferon Type I; Magnetic Resonance Imaging; Male; Middle Aged; Peptides, Cyclic; Recombinant Proteins; Ribavirin; Risk Factors

2011
Dyspnoea in patients with chronic hepatitis C treated with pegylated interferon and ribavirin.
    Scandinavian journal of infectious diseases, 2011, Volume: 43, Issue:8

    Topics: Adult; Aged; Analysis of Variance; Antiviral Agents; Body Mass Index; Dyspnea; Female; Follow-Up Studies; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Ribavirin; Spirometry; Young Adult

2011
Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapse.
    AIDS (London, England), 2011, May-15, Volume: 25, Issue:8

    Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Recurrence; Ribavirin

2011
Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan.
    Journal of gastroenterology, 2011, Volume: 46, Issue:8

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retreatment; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2011
The Effects of IL-28B and ITPA polymorphisms on treatment of hepatitis C virus genotype 6.
    The American journal of gastroenterology, 2011, Volume: 106, Issue:5

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Ribavirin; Young Adult

2011
Chronic cough associated with interferon/ribavirin therapy for hepatitis C.
    Journal of clinical pharmacy and therapeutics, 2011, Volume: 36, Issue:3

    Topics: Antiviral Agents; Capsaicin; Cough; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reflex; Ribavirin; Sensory System Agents

2011
Possible role of angiotensin-converting enzyme polymorphism on progression of hepatic fibrosis in chronic hepatitis C virus infection.
    Transactions of the Royal Society of Tropical Medicine and Hygiene, 2011, Volume: 105, Issue:7

    Topics: Adult; Antiviral Agents; Disease Progression; Female; Genetic Predisposition to Disease; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Peptidyl-Dipeptidase A; Polyethylene Glycols; Polymerase Chain Reaction; Polymorphism, Genetic; Recombinant Proteins; Ribavirin

2011
Pure red cell aplasia caused by pegylated interferon-α-2a plus ribavirin in the treatment of chronic hepatitis C.
    World journal of gastroenterology, 2011, Apr-28, Volume: 17, Issue:16

    Topics: Aged; Antiviral Agents; Bone Marrow Cells; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Red-Cell Aplasia, Pure; Ribavirin

2011
High baseline interleukine-8 level is an independent risk factor for the achievement of sustained virological response in chronic HCV patients.
    Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 2011, Volume: 11, Issue:6

    Topics: Adolescent; Adult; Aged; Analysis of Variance; Case-Control Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Interleukin-8; Male; Middle Aged; Pakistan; Reference Values; Ribavirin; Risk Factors; Treatment Failure; Viral Load; Young Adult

2011
Evidence of a significant role for Fas-mediated apoptosis in HCV clearance during pegylated interferon plus ribavirin combination therapy.
    Antiviral therapy, 2011, Volume: 16, Issue:3

    Topics: Adult; Antiviral Agents; Apoptosis; Cross-Sectional Studies; Drug Therapy, Combination; Fas Ligand Protein; fas Receptor; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Receptors, Tumor Necrosis Factor, Type I; Recombinant Proteins; Ribavirin; Treatment Outcome

2011
[Indicators of body composition as prognostic factors of efficiency of antiviral therapy for chronic hepatitis C].
    Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, 2011, Issue:1

    Topics: Adult; Antiviral Agents; Body Mass Index; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin

2011
[Extrahepatic manifestations in hepatitis C].
    Ugeskrift for laeger, 2011, May-09, Volume: 173, Issue:19

    Topics: Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2011
Functional impairment of dendritic cells in patients infected with hepatitis C virus genotype 1 who failed peginterferon plus ribavirin therapy.
    Journal of medical virology, 2011, Volume: 83, Issue:7

    Topics: Adult; Antigens, CD; Antiviral Agents; Biomarkers; Case-Control Studies; CD83 Antigen; China; Dendritic Cells; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunoglobulins; Interferon alpha-2; Interferon-alpha; Interleukin-10; Male; Membrane Glycoproteins; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2011
Impact of genetic polymorphisms near the IL28B gene and amino acid substitutions in the hepatitis C virus core region on interferon sensitivity/resistance in patients with chronic hepatitis C.
    Journal of medical virology, 2011, Volume: 83, Issue:7

    Topics: Antiviral Agents; Chromosomes, Human, Pair 19; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Core Proteins; Viral Load

2011
The prognostic value of changes in serum ferritin levels during therapy for hepatitis C virus infection.
    Journal of medical virology, 2011, Volume: 83, Issue:7

    Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Ferritins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load

2011
First-line treatments for hepatitis C.
    Alimentary pharmacology & therapeutics, 2011, Volume: 33, Issue:12

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Outcome

2011
[Tuberculous lymphadenitis after successful treatment of hepatitis C].
    Enfermedades infecciosas y microbiologia clinica, 2011, Volume: 29, Issue:8

    Topics: Adult; Antiviral Agents; Cytokines; Hepatitis C, Chronic; Humans; Immunocompromised Host; Interferon-alpha; Latent Tuberculosis; Male; Mycobacterium tuberculosis; Opportunistic Infections; Pakistan; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tuberculosis, Lymph Node

2011
Effects of host and virus related factors on interferon-α+ribavirin and pegylated-interferon+ribavirin treatment outcomes in chronic Hepatitis C patients.
    Virology journal, 2011, May-17, Volume: 8

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Pakistan; Ribavirin; RNA, Viral; Serum; Treatment Outcome; Viral Load; Young Adult

2011
Efficacy of interferon-ribavirin therapy in chronic hepatitis C patients.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2011, Volume: 21, Issue:5

    Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Young Adult

2011
T helper type 1/T helper type 17-related cytokines in chronic hepatitis C patients before and after interferon and ribavirin therapy.
    Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2011, Volume: 20, Issue:4

    Topics: Adult; Antiviral Agents; Cytokines; Drug Therapy, Combination; Female; Health Status Indicators; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Statistics as Topic; Th1 Cells; Th17 Cells; Time Factors; Viral Load; Young Adult

2011
Liver-related factors associated with low vitamin D levels in HIV and HIV/HCV coinfected patients and comparison to general population.
    Current HIV research, 2011, Volume: 9, Issue:3

    Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver; Male; Middle Aged; Retrospective Studies; Ribavirin; Vitamin D; Vitamin D Deficiency

2011
A retrospective cohort study of partial splenic embolization for antiviral therapy in chronic hepatitis C with thrombocytopenia.
    Journal of gastroenterology, 2011, Volume: 46, Issue:8

    Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Combined Modality Therapy; Embolization, Therapeutic; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Male; Medication Adherence; Middle Aged; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Splenic Artery; Thrombocytopenia; Treatment Outcome

2011
Chronic hepatitis C genotype 2 and 3: are we ready for personalized medicine?
    Journal of hepatology, 2011, Volume: 55, Issue:3

    Topics: Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2011
Response to peginterferon-alfa 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 2.
    Digestive diseases and sciences, 2011, Volume: 56, Issue:11

    Topics: Adult; Aged; Antiviral Agents; Asian People; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome

2011
[MiR-196a-2 gene polymorphism and the antiviral therapy of chronic hepatitis C].
    Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology, 2010, Volume: 24, Issue:6

    Topics: Adolescent; Adult; Aged; Alleles; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; MicroRNAs; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Young Adult

2010
Characterization of hepatitis C Virus genotype 3a hypervariable region 1 in patients achieved rapid virological response to alpha interferon and ribavirin combination therapy.
    Virology journal, 2011, May-23, Volume: 8

    Topics: Amino Acid Substitution; Antigens, Viral; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Molecular Sequence Data; Polymorphism, Genetic; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome; Viral Envelope Proteins; Viral Load

2011
Taste disturbances during therapy with pegylated interferon-alpha 2b and ribavirin in patients with chronic hepatitis C.
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 2010, Volume: 63, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Taste Disorders

2010
Response to combination therapy of HCV 3a infected Pakistani patients and the role of NS5A protein.
    Virology journal, 2011, May-25, Volume: 8

    Topics: Adult; Amino Acid Substitution; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Pakistan; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Viral Nonstructural Proteins

2011
Vitamin D levels may explain the racial differences in response rates to antiviral therapy for chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2011, Volume: 54, Issue:4

    Topics: Antiviral Agents; Biomarkers; Black or African American; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Treatment Outcome; Vitamin D; White People

2011
Treatment for hepatitis C virus with pegylated interferon-α plus ribavirin induces anti-atherogenic effects on cardiovascular risk biomarkers in HIV-infected and -uninfected patients.
    The Journal of antimicrobial chemotherapy, 2011, Volume: 66, Issue:8

    Topics: Adult; Antiviral Agents; Atherosclerosis; Biomarkers; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin

2011
[Importance of medication adherence to peginterferon-ribavirin combination therapy in patients with chronic hepatitis C].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2011, May-25, Volume: 57, Issue:5

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral

2011
Sequence variation of the HVR1 region of Hepatitis C virus in response to interferon-α and ribavirin treatment.
    Journal of infection in developing countries, 2011, May-28, Volume: 5, Issue:5

    Topics: Amino Acid Sequence; Antiviral Agents; Cluster Analysis; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Molecular Sequence Data; Polymorphism, Genetic; Ribavirin; RNA, Viral; Saudi Arabia; Sequence Analysis, DNA; Viral Proteins

2011
[Cutaneous necrosis due to injection of interferon-alpha 2b in a patient with chronic hepatitis C].
    Gastroenterologia y hepatologia, 2011, Volume: 34, Issue:8

    Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Antiviral Agents; Debridement; Drug Eruptions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Middle Aged; Necrosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Skin Ulcer

2011
Response-guided therapy for acute hepatitis C: applying concepts from chronic treatment.
    Liver international : official journal of the International Association for the Study of the Liver, 2011, Volume: 31, Issue:6

    Topics: Acute Disease; Antiviral Agents; Biomarkers; Drug Administration Schedule; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2011
Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin.
    Journal of gastroenterology and hepatology, 2012, Volume: 27, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination; False Negative Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Predictive Value of Tests; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2012
Retinal nerve fibre layer defects associated with cotton-wool spots in patients with interferon retinopathy.
    Acta ophthalmologica, 2012, Volume: 90, Issue:2

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Intraocular Pressure; Middle Aged; Nerve Fibers; Polyethylene Glycols; Recombinant Proteins; Retinal Diseases; Retinal Ganglion Cells; Ribavirin; Tomography, Optical Coherence; Visual Acuity; Visual Fields

2012
Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C.
    Human molecular genetics, 2011, Sep-01, Volume: 20, Issue:17

    Topics: Antiviral Agents; Genome-Wide Association Study; Genotype; Hepatitis C, Chronic; Humans; Interferons; Linkage Disequilibrium; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Thrombocytopenia

2011
Cyclosporine a-based immunosuppression reduces relapse rate after antiviral therapy in transplanted patients with hepatitis C virus infection: a large multicenter cohort study.
    Transplantation, 2011, Aug-15, Volume: 92, Issue:3

    Topics: Antiviral Agents; Cohort Studies; Cyclosporine; Female; Graft Rejection; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Postoperative Complications; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Secondary Prevention

2011
Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin.
    The American journal of gastroenterology, 2011, Volume: 106, Issue:7

    Topics: Adult; Alleles; Antiviral Agents; Area Under Curve; Drug Therapy, Combination; Female; Genes, MHC Class I; Genes, MHC Class II; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; ROC Curve; Viral Load

2011
Mutations in the E2 and NS5A regions in patients infected with hepatitis C virus genotype 1a and their correlation with response to treatment.
    Journal of medical virology, 2011, Volume: 83, Issue:8

    Topics: Adult; Amino Acid Substitution; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mutation, Missense; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Envelope Proteins; Viral Nonstructural Proteins

2011
Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis.
    Journal of gastroenterology, 2011, Volume: 46, Issue:9

    Topics: Adult; Aged; Anemia, Hemolytic; Antiviral Agents; Cohort Studies; Decision Trees; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reproducibility of Results; Retrospective Studies; Ribavirin; Severity of Illness Index

2011
Anti-viral therapy in haemodialysed HCV patients: efficacy, tolerance and treatment strategy.
    Alimentary pharmacology & therapeutics, 2011, Volume: 34, Issue:4

    Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin; Time Factors; Treatment Outcome; Viral Load

2011
Education by a nurse increases response of patients with chronic hepatitis C to therapy with peginterferon-α2a and ribavirin.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2011, Volume: 9, Issue:9

    Topics: Adult; Antiviral Agents; Education, Medical; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Medication Adherence; Middle Aged; Nurses; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome

2011
The burden of HCV treatment in patients with inherited bleeding disorders.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2011, Volume: 17, Issue:5

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Blood Coagulation Disorders, Inherited; Cost of Illness; Depressive Disorder; Drug Therapy, Combination; Fatigue; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Quality of Life; Ribavirin; Surveys and Questionnaires; Young Adult

2011
The adjuvant role of thyroxine in the treatment of chronic hepatitis C infection.
    QJM : monthly journal of the Association of Physicians, 2012, Volume: 105, Issue:7

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Ribavirin; Thyroid Diseases; Thyroxine

2012
Response to antiviral therapy in patients with genotype 3 chronic hepatitis C: fibrosis but not race encourages relapse.
    European journal of gastroenterology & hepatology, 2011, Volume: 23, Issue:9

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Asian People; Child; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Treatment Outcome; Young Adult

2011
Celiac disease manifested during the treatment of chronic hepatitis C by pegylated alpha interferon and ribavirin.
    Bratislavske lekarske listy, 2011, Volume: 112, Issue:6

    Topics: Adult; Celiac Disease; Hemophilia A; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2011
IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1.
    Journal of viral hepatitis, 2011, Volume: 18, Issue:7

    Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Kinetics; Linkage Disequilibrium; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prognosis; Recombinant Proteins; Ribavirin; Treatment Outcome

2011
CD154, a marker of antigen-specific stimulation of CD4 T cells, is associated with response to treatment in patients with chronic HCV infection.
    Journal of viral hepatitis, 2011, Volume: 18, Issue:7

    Topics: Adult; Aged; Antiviral Agents; Biomarkers; CD4-Positive T-Lymphocytes; CD40 Ligand; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Lymphocyte Activation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2011
TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1.
    Journal of viral hepatitis, 2011, Volume: 18, Issue:7

    Topics: Adult; Aged; Antiviral Agents; Blood Glucose; Body Mass Index; Drug Therapy, Combination; Fatty Liver; Female; Hepacivirus; Hepatitis C, Chronic; Homeostasis; Humans; Insulin Resistance; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Triglycerides; Viral Load

2011
Long-term outcome of chronic hepatitis C in a population-based cohort and impact of antiviral therapy: a propensity-adjusted analysis.
    Journal of viral hepatitis, 2011, Volume: 18, Issue:7

    Topics: Adolescent; Adult; Aged; Alcohol Drinking; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2011
Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: a Danish nationwide cohort study.
    BMC infectious diseases, 2011, Jun-21, Volume: 11

    Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Denmark; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2011
Activating NK cell receptor expression/function (NKp30, NKp46, DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment.
    European journal of immunology, 2011, Volume: 41, Issue:10

    Topics: Adult; Aged; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antiviral Agents; CD56 Antigen; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Killer Cells, Natural; Leukocyte Immunoglobulin-like Receptor B1; Male; Middle Aged; Natural Cytotoxicity Triggering Receptor 1; Natural Cytotoxicity Triggering Receptor 3; Polyethylene Glycols; Receptors, IgG; Receptors, Immunologic; Recombinant Proteins; Ribavirin; Treatment Outcome; Viremia

2011
Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin.
    Journal of hepatology, 2012, Volume: 56, Issue:1

    Topics: Adult; Antiviral Agents; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2012
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients.
    Journal of hepatology, 2012, Volume: 56, Issue:2

    Topics: Adult; Antiviral Agents; Female; Genome-Wide Association Study; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukopenia; Linkage Disequilibrium; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Ribavirin; Thrombocytopenia

2012
Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C.
    Digestive diseases and sciences, 2011, Volume: 56, Issue:8

    Topics: Adolescent; Adult; Age Factors; Aged; Alanine Transaminase; Alcohol Drinking; Antiviral Agents; Body Mass Index; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult

2011
Efficacy and safety of pegylated interferon in children and adolescents infected with chronic hepatitis C: a preliminary study.
    Journal of pharmacy practice, 2011, Volume: 24, Issue:2

    Topics: Adolescent; Antiviral Agents; Child; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome

2011
Direct medical care costs among pegylated interferon plus ribavirin-treated and untreated chronic hepatitis C patients.
    Digestive diseases and sciences, 2011, Volume: 56, Issue:10

    Topics: Adult; Antiviral Agents; Cost of Illness; Drug Therapy, Combination; Female; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Inpatients; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Outcome Assessment, Health Care; Outpatients; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin

2011
Pitavastatin enhances antiviral efficacy of standard pegylated interferon plus ribavirin in patients with chronic hepatitis C: a prospective randomized pilot study.
    Journal of hepatology, 2012, Volume: 56, Issue:1

    Topics: Antiviral Agents; Drug Synergism; Hepatitis C, Chronic; Humans; Interferon-alpha; Pilot Projects; Prospective Studies; Quinolines; Random Allocation; Ribavirin; Viral Load

2012
Genetic polymorphism of low-density lipoprotein receptor did not affect treatment outcome of chronic hepatitis C genotype 3.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2011, Volume: 94 Suppl 1

    Topics: Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Chronic Disease; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Receptors, LDL; Ribavirin; RNA, Viral; Treatment Outcome

2011
Predicting response to therapy in chronic hepatitis C: an approach combining interleukin-28B gene polymorphisms and clinical data.
    Journal of gastroenterology and hepatology, 2012, Volume: 27, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Biomarkers; Chi-Square Distribution; Drug Therapy, Combination; Female; Gene Frequency; Haplotypes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Patient Selection; Phenotype; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Spain; Time Factors; Treatment Outcome; Viral Load; Young Adult

2012
[Gene expression profiling in the first twelve weeks of treatment in chronic hepatitis C patients].
    Enfermedades infecciosas y microbiologia clinica, 2011, Volume: 29, Issue:8

    Topics: Adult; Alcohol Drinking; Antiviral Agents; Drug Therapy, Combination; Female; Gene Expression Profiling; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Time Factors; Viremia

2011
The assessment of serum hepatitis C virus RNA 12 weeks after the end of treatment using TaqMan polymerase chain reaction is less relevant than after 24 weeks for predicting sustained virological response.
    Hepatology (Baltimore, Md.), 2011, Volume: 54, Issue:4

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin

2011
[Therapy of hepatitis C: individualized approach to treatment].
    Przeglad epidemiologiczny, 2011, Volume: 65, Issue:1

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Precision Medicine; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2011
Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene.
    Journal of medical virology, 2011, Volume: 83, Issue:9

    Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Core Proteins

2011
Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state.
    Journal of medical virology, 2011, Volume: 83, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Liver; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Ribavirin; RNA, Messenger; Suppressor of Cytokine Signaling Proteins; Treatment Failure

2011
Pre-treatment prediction of response to pegylated-interferon plus ribavarin for chronic hepatitis C using RVR.
    Journal of hepatology, 2011, Volume: 55, Issue:5

    Topics: Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Interleukins; Male; Polymorphism, Single Nucleotide; Ribavirin

2011
Reversal of hypolipidemia in chronic hepatitis C patients after successful antiviral therapy.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2011, Volume: 110, Issue:6

    Topics: Antiviral Agents; Body Mass Index; Cholesterol; Drug Monitoring; Female; Genotype; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Lipid Metabolism; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Research Design; Ribavirin; Risk Factors; Treatment Outcome; Triglycerides

2011
IL28B genotype effects during early treatment with peginterferon and ribavirin in difficult-to-treat hepatitis C virus infection.
    The Journal of infectious diseases, 2011, Aug-01, Volume: 204, Issue:3

    Topics: Adult; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Models, Theoretical; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral

2011
Pegylated interferon plus ribavirin therapy improves pancreatic β-cell function in chronic hepatitis C patients.
    Liver international : official journal of the International Association for the Study of the Liver, 2011, Volume: 31, Issue:8

    Topics: Adult; Antiviral Agents; Biomarkers; Blood Glucose; Chi-Square Distribution; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin; Insulin Resistance; Insulin-Secreting Cells; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Taiwan; Time Factors; Treatment Outcome; Viral Load

2011
Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy.
    Liver international : official journal of the International Association for the Study of the Liver, 2011, Volume: 31, Issue:9

    Topics: Aged; Amino Acid Substitution; Antiviral Agents; Biopsy; Chi-Square Distribution; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Japan; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Mutation; Patient Selection; Phenotype; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Core Proteins; Viral Load; Viral Nonstructural Proteins

2011
[Reasons for not initating HCV treatment in prison: a subanalysis of the EPIBAND study].
    Revista espanola de sanidad penitenciaria, 2011, Volume: 13, Issue:2

    Topics: Adult; Antiviral Agents; Comorbidity; Contraindications; Cross-Sectional Studies; Female; Health Knowledge, Attitudes, Practice; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prisoners; Prisons; Prospective Studies; Recombinant Proteins; Refusal to Treat; Ribavirin; Spain; Treatment Refusal

2011
Boceprevir for chronic HCV genotype 1 infection.
    The New England journal of medicine, 2011, 07-14, Volume: 365, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Genetic; Proline; Recombinant Proteins; Ribavirin

2011
Boceprevir for chronic HCV genotype 1 infection.
    The New England journal of medicine, 2011, 07-14, Volume: 365, Issue:2

    Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Viral Load

2011
Case 10-2011: Fever, confusion, and liver failure.
    The New England journal of medicine, 2011, 07-14, Volume: 365, Issue:2

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Hepatitis, Autoimmune; Humans; Interferon-alpha; Liver Failure; Lymphohistiocytosis, Hemophagocytic; Middle Aged; Ribavirin

2011
Liver stiffness diminishes with antiviral response in chronic hepatitis C.
    Alimentary pharmacology & therapeutics, 2011, Volume: 34, Issue:6

    Topics: Adult; Antiviral Agents; Elasticity Imaging Techniques; Female; France; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin

2011
A multi-disciplinary approach to treating hepatitis C with interferon and ribavirin in alcohol-dependent patients with ongoing abuse.
    Journal of hepatology, 2012, Volume: 56, Issue:2

    Topics: Adult; Alcoholism; Antiviral Agents; Behavior, Addictive; Case-Control Studies; Cohort Studies; Female; France; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Ribavirin; Temperance; Time Factors; Treatment Outcome; Viral Load

2012
Gaps in the achievement of effectiveness of HCV treatment in national VA practice.
    Journal of hepatology, 2012, Volume: 56, Issue:2

    Topics: Adult; Antiviral Agents; Cohort Studies; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Treatment Outcome; United States; United States Department of Veterans Affairs; Viremia

2012
Polymorphism of tumor necrosis factor-α and interleukin-10 gene promoter region in chronic hepatitis C virus patients and their effect on pegylated interferon-α therapy response.
    Human immunology, 2011, Volume: 72, Issue:10

    Topics: Adult; Antiviral Agents; Biomarkers, Pharmacological; Case-Control Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; India; Interferon alpha-2; Interferon-alpha; Interleukin-10; Middle Aged; Outpatients; Polyethylene Glycols; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Prospective Studies; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Tumor Necrosis Factor-alpha

2011
Anemia is not predictive of sustained virological response in liver transplant recipients with hepatitis C virus who are treated with pegylated interferon and ribavirin.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2011, Volume: 17, Issue:11

    Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Prevalence; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Severity of Illness Index; Treatment Outcome

2011
Diagnosing and treating hepatitis C virus infection.
    The American journal of managed care, 2011, Volume: 17 Suppl 4

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; United States; Viral Load

2011
[Pegylated interferon and ribavirin associated retinopathy in patients with hepatitis C].
    Archivos de la Sociedad Espanola de Oftalmologia, 2011, Volume: 86, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Exudates and Transudates; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retinal Diseases; Retinal Hemorrhage; Ribavirin

2011
Long-term cohort study of chronic hepatitis C according to interferon efficacy.
    Journal of gastroenterology and hepatology, 2012, Volume: 27, Issue:2

    Topics: Adult; Antiviral Agents; Biomarkers; Biopsy; Carcinoma, Hepatocellular; Cause of Death; Chi-Square Distribution; Combined Modality Therapy; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Japan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2012
[Retreatment with peginterferon alpha-2a plus ribavirin for chronic hepatitis C: a case report].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2011, Volume: 19, Issue:4

    Topics: Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2011
A longitudinal cohort study of mucocutaneous drug eruptions during interferon and ribavirin treatment of hepatitis C.
    Journal of clinical gastroenterology, 2012, Volume: 46, Issue:2

    Topics: Antiviral Agents; Cohort Studies; Drug Eruptions; Drug Therapy, Combination; Eczema; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Ribavirin; Treatment Outcome

2012
Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin.
    Antiviral therapy, 2011, Volume: 16, Issue:5

    Topics: Adult; Aged; Anemia, Hemolytic; Antiviral Agents; Creatinine; Drug Administration Schedule; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Interferon-alpha; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome

2011
Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
    Antiviral therapy, 2011, Volume: 16, Issue:5

    Topics: Antiviral Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Models, Theoretical; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Replicon; Ribavirin; RNA, Viral; Time Factors; Viral Load

2011
Discordance between HCV RNA assays for week 24 HCV RNA determination during pegylated interferon-α/ribavirin treatment for chronic hepatitis C.
    Antiviral therapy, 2011, Volume: 16, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult

2011
Education by a nurse increases the adherence to therapy in chronic hepatitis C patients.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2012, Volume: 10, Issue:2

    Topics: Antiviral Agents; Education, Medical; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Medication Adherence; Polyethylene Glycols; Ribavirin

2012
[Coinfection with HIV and HCV: abacavir and ribavirine, why not?].
    Revista clinica espanola, 2012, Volume: 212, Issue:1

    Topics: Anti-HIV Agents; Antiviral Agents; Coinfection; Dideoxynucleosides; Drug Combinations; Drug Interactions; Hepatitis C, Chronic; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Ribavirin; Zidovudine

2012
Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: a matched case-control study.
    Journal of gastroenterology, 2011, Volume: 46, Issue:11

    Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Propensity Score; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2011
Gene expression patterns in livers of Hispanic patients infected with hepatitis C virus.
    Autoimmunity, 2011, Volume: 44, Issue:7

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Biopsy; Female; Gene Expression Regulation, Viral; Hepacivirus; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon alpha-2; Interferon-alpha; Male; Mexico; Middle Aged; Oligonucleotide Array Sequence Analysis; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Messenger; Young Adult

2011
Ribavirin downmodulates inducible costimulator on CD4+ T cells and their interleukin-10 secretion to assist in hepatitis C virus clearance.
    Journal of gastroenterology and hepatology, 2012, Volume: 27, Issue:4

    Topics: Adult; Aged; Antiviral Agents; CD4-Positive T-Lymphocytes; Cells, Cultured; Dendritic Cells; Down-Regulation; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Inducible T-Cell Co-Stimulator Ligand; Inducible T-Cell Co-Stimulator Protein; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Interleukin-10; Interleukin-4; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Signal Transduction; Viral Load

2012
The use of real-time PCR to detect hepatitis C virus RNA in dried blood spots from Brazilian patients infected chronically.
    Journal of virological methods, 2012, Volume: 179, Issue:1

    Topics: Antiviral Agents; Blood; Brazil; Desiccation; Diagnostic Errors; Drug Monitoring; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Molecular Diagnostic Techniques; Polyethylene Glycols; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Sensitivity and Specificity; Specimen Handling; Virology

2012
Interleukin-28B genetic variations and response to interferon-based therapy: Asian perspectives.
    Journal of gastroenterology and hepatology, 2011, Volume: 26, Issue:9

    Topics: Antiviral Agents; Asian People; Female; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; White People

2011
Complete early virological response was highly achieved by double filtration plasmapheresis plus IFN-beta induction therapy for HCV-1b patients with relapse or no response after previous IFN therapy.
    Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2011, Volume: 15, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Combined Modality Therapy; Drug Therapy, Combination; Female; Filtration; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Plasmapheresis; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2011
Coffee consumption and reduced self-reported side effects in HIV-HCV co-infected patients during PEG-IFN and ribavirin treatment: results from ANRS CO13 HEPAVIH.
    Journal of hepatology, 2012, Volume: 56, Issue:3

    Topics: Adult; Antiviral Agents; Coffee; Coinfection; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Surveys and Questionnaires

2012
The effect of cytokine profiles on the viral response to re-treatment in antiviral-experienced patients with chronic hepatitis C virus infection.
    Antiviral research, 2011, Volume: 92, Issue:2

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Cytokines; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Th1 Cells; Treatment Outcome; Young Adult

2011
Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:1

    Topics: Adaptor Proteins, Signal Transducing; Aged; Antiviral Agents; DEAD Box Protein 58; DEAD-box RNA Helicases; Drug Resistance, Viral; Female; Gene Expression; Gene Expression Profiling; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Innate; Interferon-alpha; Interferons; Interleukins; Liver; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Receptors, Immunologic; Ribavirin; ROC Curve; Sensitivity and Specificity

2012
Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:1

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Hepatitis C, Chronic; Humans; Injections, Intravenous; Interferon-alpha; Needles; Polyethylene Glycols; Prevalence; Ribavirin; Risk Factors; Secondary Prevention; Substance-Related Disorders; Syringes; United Kingdom

2012
Retinopathy associated with pegylated interferon and ribavirin causing permanent visual impairment in a patient with chronic hepatitis C.
    Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye, 2011, Sep-08, Volume: 42 Online

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Male; Retinal Diseases; Ribavirin; Vision Disorders; Visual Acuity

2011
A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus.
    European journal of gastroenterology & hepatology, 2011, Volume: 23, Issue:10

    Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Ribavirin; Treatment Outcome; Viral Load

2011
Outcomes of chronic hepatitis C therapy in patients treated in community versus academic centres in Canada: final results of APPROACH (a prospective study of peginterferon alfa-2a and ribavirin at academic and community centres in Canada).
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2011, Volume: 25, Issue:9

    Topics: Academic Medical Centers; Adult; Antiviral Agents; Canada; Efficiency; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hospitals, Community; Humans; Interferon-alpha; Male; Middle Aged; Office Visits; Polyethylene Glycols; Prospective Studies; Quality of Life; Recombinant Proteins; Ribavirin; Viral Load; Work

2011
The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection.
    Journal of gastroenterology, 2011, Volume: 46, Issue:12

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; gamma-Glutamyltransferase; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Reproducibility of Results; Retrospective Studies; Ribavirin; Treatment Outcome; Young Adult

2011
[Minimization of endogenous intoxication syndrome by individual choice of drugs for therapy of chronic hepatitis].
    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2011, Volume: 56, Issue:3-4

    Topics: Acridines; Adolescent; Antiviral Agents; Asymptomatic Infections; Biomarkers; Child; Child, Preschool; Cost-Benefit Analysis; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon Inducers; Interferon-alpha; Ribavirin; Treatment Outcome

2011
[Comparison of 5'UTR and HVR1 of hepatitis c virus (HCV) in serum and peripheral blood mononuclear cells in the early phase of interferon and ribavirin treatment].
    Przeglad epidemiologiczny, 2011, Volume: 65, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Poland; Polymorphism, Single-Stranded Conformational; Recombinant Proteins; Ribavirin; Sequence Alignment; Viral Envelope Proteins

2011
HIV/HCV-coinfected natural viral suppressors have better virologic responses to PEG-IFN and ribavirin than ARV-treated HIV/HCV patients.
    Journal of acquired immune deficiency syndromes (1999), 2011, Oct-01, Volume: 58, Issue:2

    Topics: Adult; Anti-HIV Agents; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Virus Replication

2011
Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis.
    Gut, 2012, Volume: 61, Issue:2

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Computer Simulation; Disease Progression; Drug Costs; Drug Therapy, Combination; Drug Utilization; France; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Markov Chains; Middle Aged; Models, Economic; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Young Adult

2012
IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study.
    PLoS medicine, 2011, Volume: 8, Issue:9

    Topics: Adult; Alleles; Antiviral Agents; Case-Control Studies; Cohort Studies; Cross-Sectional Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HLA-C Antigens; Humans; Interferon-alpha; Interferons; Interleukins; Killer Cells, Natural; Male; Middle Aged; Odds Ratio; Pharmacogenetics; Polymorphism, Single Nucleotide; Predictive Value of Tests; Receptors, KIR; Receptors, KIR2DL3; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; White People

2011
Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:2

    Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral

2012
Treatment of chronic hepatitis C in a patient with Fanconi anaemia.
    Advances in medical sciences, 2011, Volume: 56, Issue:2

    Topics: Adult; Fanconi Anemia; Female; Genotype; Granulocyte Colony-Stimulating Factor; Hepatitis C, Chronic; Humans; Interferon-alpha; Phenotype; Ribavirin; Risk; Time Factors; Treatment Outcome; Viral Load

2011
Side effects of the therapy with peginterferon and ribavirin in chronic hepatitis C: a small audit.
    Journal of pharmacy practice, 2012, Volume: 25, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Patient Compliance; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Retrospective Studies; Ribavirin; Young Adult

2012
Dynamics of regulatory T cells and plasmacytoid dendritic cells as immune markers for virological response in pegylated interferon-α and ribavirin therapy for chronic hepatitis C patients.
    Journal of gastroenterology, 2012, Volume: 47, Issue:2

    Topics: Adult; Antibodies, Monoclonal; Antiviral Agents; Dendritic Cells; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Killer Cells, Natural; Male; Middle Aged; Multivariate Analysis; Platelet Count; Ribavirin; T-Lymphocytes, Regulatory; Treatment Outcome; Viral Load

2012
Tongue hyperpigmentation resulting from peginterferon alfa-2b and ribavirin treatment in a patient with chronic hepatitis C.
    Digestive diseases and sciences, 2012, Volume: 57, Issue:3

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Hyperpigmentation; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tongue; Tongue Diseases

2012
IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C.
    Journal of hepatology, 2012, Volume: 56, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Precision Medicine; Retrospective Studies; Ribavirin; Severity of Illness Index; Viral Load; Young Adult

2012
Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients.
    Internal medicine (Tokyo, Japan), 2011, Volume: 50, Issue:19

    Topics: Aged; Antiviral Agents; Cohort Studies; Depression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-beta; Male; Middle Aged; Prospective Studies; Ribavirin; RNA, Viral; Treatment Outcome

2011
Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus.
    The Journal of antimicrobial chemotherapy, 2011, Volume: 66, Issue:12

    Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Interactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Retrospective Studies; Ribavirin; Spain; Treatment Failure; Viral Load

2011
The study of relationship between neutropenia and infection during treatment with peginterferon α and ribavirin for chronic hepatitis C.
    European journal of gastroenterology & hepatology, 2011, Volume: 23, Issue:12

    Topics: Adult; Age Factors; Antiviral Agents; Diabetes Complications; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Immunocompromised Host; Interferon-alpha; Leukocyte Count; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Opportunistic Infections; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors

2011
Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2012, Volume: 31, Issue:6

    Topics: Adult; Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Methadone; Middle Aged; Opiate Substitution Treatment; Opioid-Related Disorders; Prospective Studies; Ribavirin; Treatment Outcome; Viral Load

2012
Association between IL28B polymorphisms and first-phase viral load decrease in chronic hepatitis C virus-infected patients treated with peginterferon alfa-2b/ribavirin.
    International journal of antimicrobial agents, 2011, Volume: 38, Issue:6

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2011
Peginterferon alfa-2b and ribavirin therapy in Kuwaiti patients with chronic hepatitis C virus infection.
    Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit, 2011, Volume: 17, Issue:8

    Topics: Adult; Antiviral Agents; Biomarkers; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kuwait; Logistic Models; Male; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Viral Load

2011
Unilateral hearing loss due to pegylated interferon-α2b and ribavirin therapy.
    Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2011, Volume: 30, Issue:5

    Topics: Adult; Antiviral Agents; Audiometry, Pure-Tone; Drug Therapy, Combination; Earache; Hearing Loss, Unilateral; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2011
IL28B polymorphisms associated with therapy response in Chilean chronic hepatitis C patients.
    World journal of gastroenterology, 2011, Aug-21, Volume: 17, Issue:31

    Topics: Antiviral Agents; Chile; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome

2011
[New triple therapy in chronic hepatitis C. Increased patient chances].
    MMW Fortschritte der Medizin, 2011, Sep-29, Volume: 153, Issue:39

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Proline; Protease Inhibitors; Ribavirin; RNA, Viral

2011
Genetic variants of interferon-stimulated genes and IL-28B as host prognostic factors of response to combination treatment for chronic hepatitis C.
    Clinical pharmacology and therapeutics, 2011, Volume: 90, Issue:5

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genetic Variation; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prognosis; Recombinant Proteins; Retrospective Studies; Ribavirin; Signal Transduction; Treatment Outcome

2011
Ultra-rapid virological response, young age, low γ-GT/ALT-ratio, and absence of steatosis identify a subgroup of HCV Genotype 3 patients who achieve SVR with IFN-α(2a) monotherapy.
    Digestive diseases and sciences, 2011, Volume: 56, Issue:11

    Topics: Adult; Age Factors; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Fatty Liver; Female; gamma-Glutamyltransferase; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; Young Adult

2011
Social support and clinical outcomes during antiviral therapy for chronic hepatitis C.
    Journal of psychosomatic research, 2011, Volume: 71, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Social Support; Treatment Outcome

2011
Decreased anti-hepatitis C virus titer and associated factors in chronic hepatitis C patients after sustained virological response: a prospective study.
    Journal of gastroenterology and hepatology, 2012, Volume: 27, Issue:6

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-beta; Male; Middle Aged; Platelet Count; Prospective Studies; Ribavirin; Treatment Outcome

2012
Penile paraffinoma developing during treatment with pegylated interferon alfa-2a for chronic hepatitis C virus infection.
    Archives of dermatology, 2011, Volume: 147, Issue:10

    Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Antiviral Agents; Clavulanic Acid; Drug Therapy, Combination; Granuloma, Foreign-Body; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Mineral Oil; Penile Diseases; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2011
Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin.
    Hepatology (Baltimore, Md.), 2011, Volume: 54, Issue:5

    Topics: Adult; Antiviral Agents; Drug Monitoring; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Multicenter Studies as Topic; Polyethylene Glycols; Predictive Value of Tests; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome

2011
Thyroid hormonal disturbances related to treatment of hepatitis C with interferon-alpha and ribavirin.
    Clinics (Sao Paulo, Brazil), 2011, Volume: 66, Issue:10

    Topics: Adult; Analysis of Variance; Antiviral Agents; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Ribavirin; Statistics, Nonparametric; Thyroid Function Tests; Thyroid Hormones; Thyroiditis; Thyroiditis, Autoimmune; Time Factors; Treatment Outcome; Ultrasonography

2011
One step forward in understanding the differences in antiviral response to interferon a2a and a2b in chronic hepatitis C patients with advanced fibrosis.
    Journal of hepatology, 2012, Volume: 56, Issue:2

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2012
Viral decline over 48h and HCV amino acid mutations are related to efficacy of PEG-IFN/ribavirin.
    Hepato-gastroenterology, 2012, Volume: 59, Issue:115

    Topics: Adolescent; Adult; Aged; Amino Acid Substitution; Antiviral Agents; Biomarkers; Chi-Square Distribution; DNA Mutational Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Japan; Logistic Models; Male; Middle Aged; Mutation; Patient Selection; Phenotype; Polyethylene Glycols; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Virus Replication; Young Adult

2012
Importance of minimal residual viremia for relapse prediction in patients with chronic hepatitis C genotype 1 infection.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011, Volume: 53, Issue:11

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Risk Assessment; Viral Load; Viremia

2011
Toll like receptor 3 expression as a novel predictor of response to treatment in chronic hepatitis C virus patients.
    Scandinavian journal of clinical and laboratory investigation, 2011, Volume: 71, Issue:8

    Topics: Adult; Antiviral Agents; Biomarkers; Biopsy; Dendritic Cells; Drug Therapy, Combination; Female; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; ROC Curve; Toll-Like Receptor 3; Treatment Outcome; Viral Load

2011
Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
    Antiviral therapy, 2011, Volume: 16, Issue:7

    Topics: Adult; Aged; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis B; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome

2011
Serum interleukin (IL)-10 and IL-12 levels and IL28B gene polymorphisms: pretreatment prediction of treatment failure in chronic hepatitis C.
    Antiviral therapy, 2011, Volume: 16, Issue:7

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukin-10; Interleukin-12 Subunit p40; Interleukin-18; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Failure; Viral Load

2011
Serum interleukin-6 levels correlate with resistance to treatment of chronic hepatitis C infection with pegylated-interferon-α2b plus ribavirin.
    Antiviral therapy, 2011, Volume: 16, Issue:7

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-6; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2011
Data mining model using simple and readily available factors could identify patients at high risk for hepatocellular carcinoma in chronic hepatitis C.
    Journal of hepatology, 2012, Volume: 56, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Data Mining; Decision Trees; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Neoplasms; Male; Middle Aged; Models, Statistical; Polyethylene Glycols; Ribavirin; Risk Assessment; Risk Factors

2012
Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1.
    Journal of hepatology, 2012, Volume: 56, Issue:3

    Topics: Adult; Antiviral Agents; Black or African American; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral; White People

2012
Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/hepatitis C virus-coinfected patients treated for chronic hepatitis C.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011, Volume: 53, Issue:12

    Topics: Adult; Anemia; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Incidence; Inosine Triphosphatase; Male; Middle Aged; Polymorphism, Genetic; Pyrophosphatases; Ribavirin; Risk Assessment

2011
Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:4

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Substance Abuse, Intravenous; Superinfection; Treatment Outcome

2012
Interferon-free treatment regimens for hepatitis C: are we there yet?
    Gastroenterology, 2011, Volume: 141, Issue:6

    Topics: Aminoisobutyric Acids; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Leucine; Male; Oligopeptides; Proline; Quinolines; Ribavirin; RNA-Dependent RNA Polymerase; Thiazoles

2011
Rapid, early and sustained virological responses in a cohort of Irish patients treated with pegylated interferon and ribavirin for chronic hepatitis C virus infection.
    Irish journal of medical science, 2012, Volume: 181, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Ireland; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load

2012
Genetic variation of the IL-28B promoter affecting gene expression.
    PloS one, 2011, Volume: 6, Issue:10

    Topics: Dinucleotide Repeats; Gene Expression; Genetic Variation; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Molecular Sequence Data; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Ribavirin

2011
[Results of treatment with peginterferon plus ribavirin in patients with chronic hepatitis C].
    Revista medica de Chile, 2011, Volume: 139, Issue:6

    Topics: Adult; Aged; Analysis of Variance; Antiviral Agents; Chile; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult

2011
Polymorphism of the inosine triphosphate pyrophosphatase gene predicts ribavirin-induced anemia in chronic hepatitis C patients.
    Molecular medicine reports, 2012, Volume: 5, Issue:2

    Topics: Adult; Aged; Alleles; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Ribavirin; Serotyping

2012
[Peginterferon alpha combined with ribavirin for the treatment of chronic hepatitis C].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2011, Volume: 19, Issue:6

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Ribavirin

2011
The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.
    Annals of internal medicine, 2012, Feb-21, Volume: 156, Issue:4

    Topics: Aged; Antiviral Agents; Cohort Studies; Computer Simulation; Contraindications; Cost-Benefit Analysis; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon-alpha; Markov Chains; Mass Screening; Middle Aged; Primary Health Care; Quality-Adjusted Life Years; Ribavirin; Sensitivity and Specificity; United States

2012
Implications of rapid virological response in hepatitis C therapy in the US veteran population.
    Alimentary pharmacology & therapeutics, 2012, Volume: 35, Issue:1

    Topics: Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; United States; Veterans; Viral Load

2012
Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus.
    Nature biotechnology, 2011, Nov-08, Volume: 29, Issue:11

    Topics: Animals; Clinical Trials as Topic; Drug Discovery; Genotype; Hepacivirus; Hepatitis C, Chronic; History, 20th Century; History, 21st Century; Humans; Interferon-alpha; Mice; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins

2011
Treatment of hepatitis C virus infection in patients on maintenance hemodialysis: a single United Arab Emirates center experience.
    European journal of internal medicine, 2011, Volume: 22, Issue:6

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Retrospective Studies; Ribavirin; Treatment Outcome; United Arab Emirates

2011
Depressive symptoms in patients with hepatitis C treated with pegylated interferon alpha therapy: a 24-week prospective study.
    Psychiatria Danubina, 2011, Volume: 23, Issue:4

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Comorbidity; Depressive Disorder; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Personality Inventory; Psychometrics; Ribavirin; Risk Factors; Young Adult

2011
Successful treatment of activated occult hepatitis B in a non-responder chronic hepatitis C patient.
    Virology journal, 2011, Nov-14, Volume: 8

    Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load; Virus Activation; Young Adult

2011
Partial splenic embolization facilitates the adherence to peginterferon in chronic hepatitis C with thrombocytopenia.
    Internal medicine (Tokyo, Japan), 2011, Volume: 50, Issue:22

    Topics: Adult; Aged; Antiviral Agents; Embolization, Therapeutic; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Splenic Artery; Thrombocytopenia; Treatment Outcome

2011
Viral kinetics during the first weeks of pegylated interferon and ribavirin treatment can identify patients at risk of relapse after its discontinuation: new strategies for such patients?
    Infection, 2012, Volume: 40, Issue:2

    Topics: Adult; Analysis of Variance; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Secondary Prevention; Time Factors; Viral Load

2012
Predictive value of early viral dynamics during peginterferon and ribavirin combination therapy based on genetic polymorphisms near the IL28B gene in patients infected with HCV genotype 1b.
    Journal of medical virology, 2012, Volume: 84, Issue:1

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Middle Aged; Molecular Diagnostic Techniques; Polymorphism, Genetic; Predictive Value of Tests; Prognosis; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2012
Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:4

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Fatty Liver; Female; Ferritins; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Phenotype; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Treatment Outcome; Young Adult

2012
[Virus removal and eradication by double filtration plasmapheresis (DFPP)].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 4

    Topics: Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Plasmapheresis; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2011
[Treatment of elderly patients with chronic hepatitis C].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 4

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2011
[Response to interferon therapy using mutations in the HCV-NS5A].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 4

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Interferon alpha-2; Interferon-alpha; Mutation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins

2011
[Prediction of response to peginterferon and ribavirin therapy for chronic hepatitis C analyzed by data mining method].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 4

    Topics: Data Mining; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2011
[Efficacy of the NS3-4A protease inhibitor telaprevir in patients with chronic hepatitis C].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 4

    Topics: Adult; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin

2011
Hepatitis C virus nonstructural protein specific T cells are associated with virological responses to combination therapy in chronic HCV patients.
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32, Issue:1

    Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Host-Parasite Interactions; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; T-Lymphocytes; Viral Load; Viral Nonstructural Proteins; Young Adult

2012
IL28B polymorphisms are markers of therapy response and are influenced by genetic ancestry in chronic hepatitis C patients from an admixed population.
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32, Issue:3

    Topics: Case-Control Studies; Female; Gene Frequency; Genetic Markers; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Polyethylene Glycols; Polymorphism, Single Nucleotide; Racial Groups; Recombinant Proteins; Ribavirin; Statistics, Nonparametric; Treatment Outcome; Viral Load

2012
Liver protein profiling in chronic hepatitis C: identification of potential predictive markers for interferon therapy outcome.
    Journal of proteome research, 2012, Feb-03, Volume: 11, Issue:2

    Topics: Antiviral Agents; Area Under Curve; Biomarkers; Biopsy; Cluster Analysis; Electrophoresis, Gel, Two-Dimensional; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Polyethylene Glycols; Principal Component Analysis; Prognosis; Proteome; Proteomics; Recombinant Proteins; Reproducibility of Results; Retrospective Studies; Ribavirin; Treatment Outcome

2012
Clinical impact of HFE mutations in Japanese patients with chronic hepatitis C.
    Journal of gastroenterology and hepatology, 2012, Volume: 27, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hemochromatosis Protein; Hepatitis C, Chronic; Histocompatibility Antigens Class I; Humans; Interferon alpha-2; Interferon-alpha; Iron Overload; Male; Membrane Proteins; Middle Aged; Mutation; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load

2012
Role of hepatic HCV-RNA level on the severity of chronic hepatitis C and response to antiviral therapy.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2012, Volume: 53, Issue:1

    Topics: Adult; Biopsy; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Ribavirin; RNA, Viral; Severity of Illness Index; Treatment Outcome

2012
Durability of antiviral therapy for chronic hepatitis C after achieving sustained virological response.
    The Korean journal of hepatology, 2011, Volume: 17, Issue:3

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2011
Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin.
    The Korean journal of hepatology, 2011, Volume: 17, Issue:3

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2011
Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus.
    The Korean journal of hepatology, 2011, Volume: 17, Issue:3

    Topics: Adult; Antiviral Agents; Cross-Sectional Studies; DNA, Viral; Drug Therapy, Combination; Female; Genotype; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2011
Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis.
    The Korean journal of hepatology, 2011, Volume: 17, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Viral Load

2011
Plasma ribavirin trough concentrations during treatment of chronic hepatitis C in genotype-1 patients.
    Journal of clinical gastroenterology, 2012, Volume: 46, Issue:4

    Topics: Adult; Antiviral Agents; Cohort Studies; Drug Monitoring; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Time Factors

2012
Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study.
    Journal of gastroenterology, 2012, Volume: 47, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Incidence; Interferons; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Ribavirin; Risk Factors; Treatment Outcome; Young Adult

2012
Reducing Peg-IFN doses causes later virologic response or no response in HCV genotype 1 patients treated with Peg-IFN alfa-2b plus ribavirin.
    Journal of gastroenterology, 2012, Volume: 47, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Propensity Score; Recombinant Proteins; Retrospective Studies; Ribavirin; Time Factors; Treatment Failure; Treatment Outcome

2012
Early quantification of HCV core antigen may help to determine the duration of therapy for chronic genotype 2 or 3 HCV infection.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2012, Volume: 31, Issue:7

    Topics: Adult; Antiviral Agents; Genotype; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Core Proteins; Viral Load

2012
Incidence and risk factors of retinopathy in Egyptian patients with chronic hepatitis C virus treated with pegylated interferon plus ribavirin.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2012, Volume: 16, Issue:1

    Topics: Adult; Antiviral Agents; Egypt; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Retinal Diseases; Retrospective Studies; Ribavirin; Risk Factors; Young Adult

2012
IL28B and interferon-gamma inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV-HCV-coinfected patients.
    European journal of clinical investigation, 2012, Volume: 42, Issue:6

    Topics: Adult; Antiviral Agents; Chemokine CXCL10; Coinfection; Female; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Models, Biological; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Ribavirin; Treatment Outcome; Viral Load; Young Adult

2012
The treatment response of chronically hepatitis C virus-infected patients depends on interferon concentration but not on interferon gene expression in peripheral blood mononuclear cells.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:2

    Topics: Adult; Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Gene Expression Regulation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2012
Toward the establishment of a prediction system for the personalized treatment of chronic hepatitis C.
    The Journal of infectious diseases, 2012, Jan-15, Volume: 205, Issue:2

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Area Under Curve; Aspartate Aminotransferases; Child; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Precision Medicine; Predictive Value of Tests; Recombinant Proteins; Retrospective Studies; Ribavirin; ROC Curve; Viral Load; Young Adult

2012
Improved hepatitis C treatment response in younger patients: findings from the UK HCV National Register cohort study.
    Epidemiology and infection, 2012, Volume: 140, Issue:10

    Topics: Adult; Antiviral Agents; Cohort Studies; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin; Treatment Outcome; United Kingdom

2012
Early dynamics of viremia in patients with genotype 1b chronic hepatitis C: Peg-IFNalpha2a shows earlier viral decline than peg-IFNalpha2b in combination therapy with ribavirin.
    Medical science monitor : international medical journal of experimental and clinical research, 2011, Volume: 17, Issue:12

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Male; Middle Aged; Models, Biological; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viremia

2011
Risk score based PEG Interferon alpha 2b and Ribavirin treatment response estimation model for genotype 1 chronic hepatitis C patients.
    Advances in medical sciences, 2011, Volume: 56, Issue:2

    Topics: Adult; Aged; Body Mass Index; Female; Genotype; Hepatitis C, Chronic; Humans; Infectious Disease Medicine; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk; Risk Factors; Treatment Outcome

2011
Very low viral load (VLVL) relapse following treatment of naïve patients with chronic hepatitis C.
    Digestive diseases and sciences, 2012, Volume: 57, Issue:1

    Topics: Adult; Antiviral Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2012
Association between IL28B gene polymorphisms and sustained virological response in patients coinfected with HCV and HIV in Brazil.
    The Journal of antimicrobial chemotherapy, 2012, Volume: 67, Issue:2

    Topics: Adult; Antiviral Agents; Brazil; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Interleukins; Male; Polymorphism, Single Nucleotide; Ribavirin; Viral Load

2012
[Pegasys and ribavirin therapy in an elderly patient with chronic hepatitis C].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2011, Volume: 19, Issue:8

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Recombinant Proteins; Ribavirin; Treatment Outcome

2011
Pegylated interferon-α2b and ribavirin combination therapy induces Hashitoxicosis followed by type 1 diabetes mellitus.
    Diabetes research and clinical practice, 2012, Volume: 95, Issue:3

    Topics: Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Hashimoto Disease; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thyrotoxicosis

2012
Ribavirin and interferon alter MMP-9 abundance in vitro and in HIV-HCV-coinfected patients.
    Antiviral therapy, 2011, Volume: 16, Issue:8

    Topics: Adult; Antiviral Agents; Cell Line; Cohort Studies; Coinfection; Female; Hepacivirus; Hepatic Stellate Cells; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Ireland; Lopinavir; Male; Monocytes; Recombinant Proteins; Ribavirin; RNA, Viral; Saquinavir; Tissue Inhibitor of Metalloproteinase-2; United Kingdom; Viral Load

2011
Relative impact of ribavirin monitoring and HIV coinfection on sustained virological response in patients with chronic hepatitis C.
    Antiviral therapy, 2011, Volume: 16, Issue:8

    Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Coinfection; Drug Monitoring; Drug Therapy, Combination; Female; France; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Virus Replication

2011
Intravenous silibinin as 'rescue treatment' for on-treatment non-responders to pegylated interferon/ribavirin combination therapy.
    Antiviral therapy, 2011, Volume: 16, Issue:8

    Topics: Adult; Antioxidants; Antiviral Agents; Austria; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Intravenous; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Silybin; Silymarin; Treatment Outcome; Viral Load; Virus Replication

2011
Correlation between insulin resistance and outcome of pegylated interferon and ribavirin therapy, hepatic steatosis, hepatic fibrosis in chronic hepatitis C-1b and high viral load.
    Digestion, 2011, Volume: 84 Suppl 1

    Topics: Aged; Antiviral Agents; Body Mass Index; Drug Therapy, Combination; Fatty Liver; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2011
Double-Filtration Plasmapheresis plus Interferon-β for HCV-1b Patients with Non-Sustained Virological Response to Previous Combination Therapy.
    Digestion, 2011, Volume: 84 Suppl 1

    Topics: Adult; Aged; Antiviral Agents; Combined Modality Therapy; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-beta; Interferons; Interleukins; Male; Middle Aged; Plasmapheresis; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2011
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes.
    The Journal of infectious diseases, 2012, Feb-01, Volume: 205, Issue:3

    Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Cohort Studies; Female; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin

2012
Neutrophil function and apoptosis in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin.
    Archivum immunologiae et therapiae experimentalis, 2012, Volume: 60, Issue:1

    Topics: Adult; Antigens, CD; Antiviral Agents; Apoptosis; Cell Adhesion Molecules; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Neutrophils; Polyethylene Glycols; Reactive Oxygen Species; Recombinant Proteins; Ribavirin; Young Adult

2012
[Experience with ronkoleukin and alfaferon combination in complex chronic hepatitis C treatment].
    Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, 2011, Issue:6

    Topics: Adult; Antigens, CD; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Cellular; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Viral Load

2011
Assessment of hepatitis C virus protein sequences with regard to interferon/ribavirin combination therapy response in patients with HCV genotype 1b.
    The protein journal, 2012, Volume: 31, Issue:2

    Topics: Amino Acid Sequence; Antiviral Agents; Computational Biology; Databases, Protein; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Expert Systems; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Protein Structure, Tertiary; Recombinant Proteins; Ribavirin; Serbia; Viral Proteins

2012
Hepatitis C virus genotyping in Greece: unexpected high prevalence of genotype 5a in a Greek island.
    Journal of medical virology, 2012, Volume: 84, Issue:2

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Greece; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load; Young Adult

2012
Branch retinal artery occlusion and central retinal vein occlusion associated with pegylated interferon plus ribavirin combination therapy for chronic hepatitis C.
    Cutaneous and ocular toxicology, 2012, Volume: 31, Issue:3

    Topics: Adult; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Retinal Artery Occlusion; Retinal Vein Occlusion; Ribavirin; Visual Acuity

2012
[Treatment of chronic hepatitis C virus infection. A study of best predictors for response].
    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2011, Volume: 24, Issue:4

    Topics: Adolescent; Adult; Age Factors; Aged; Analysis of Variance; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Intention to Treat Analysis; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Predictive Value of Tests; Prognosis; Recombinant Proteins; Retrospective Studies; Ribavirin; Sex Factors; Treatment Outcome; Young Adult

2011
Hepatic STAT1-nuclear translocation and interleukin 28B polymorphisms predict treatment outcomes in hepatitis C virus genotype 1-infected patients.
    PloS one, 2011, Volume: 6, Issue:12

    Topics: Asian People; Cell Nucleus; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Immunohistochemistry; Interferon-alpha; Interferons; Interleukins; Japan; Liver; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Protein Transport; Recombinant Proteins; Ribavirin; STAT1 Transcription Factor; Treatment Outcome

2011
Development and specificities of anti-interferon neutralizing antibodies in patients with chronic hepatitis C treated with pegylated interferon-α.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2012, Volume: 18, Issue:10

    Topics: Adult; Aged; Antibodies, Neutralizing; Antiviral Agents; Chi-Square Distribution; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2012
Weight loss and resting energy expenditure in patients with chronic hepatitis C before and during standard treatment.
    Nutrition (Burbank, Los Angeles County, Calif.), 2012, Volume: 28, Issue:6

    Topics: Adipose Tissue; Adult; Antiviral Agents; Basal Metabolism; Body Fluid Compartments; Body Mass Index; Diet Records; Energy Intake; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Standard of Care; Statistics, Nonparametric; Weight Loss

2012
Menopause, and not age, is a critical factor associated with a worse response to antiviral therapy in women affected by chronic hepatitis C.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2012, Volume: 16, Issue:2

    Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin

2012
Pretreatment serum microRNA-122 is not predictive for treatment response in chronic hepatitis C virus infection.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2012, Volume: 44, Issue:5

    Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; MicroRNAs; Middle Aged; Polyethylene Glycols; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin

2012
Effect of interleukin-28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with pegylated interferon alpha-2a/ribavirin.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:5

    Topics: Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukins; Male; Polyethylene Glycols; Ribavirin

2012
Prioritizing treatment experienced patients with hepatitis C infection for treatment with telaprevir: a number needed to treat approach.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:5

    Topics: Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Ribavirin

2012
Short communication: impact of hepatitis C viral clearance on CD4+ T-lymphocyte course in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.
    AIDS research and human retroviruses, 2012, Volume: 28, Issue:9

    Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2012
Treatment with pegylated interferon (PegIFN) combined with ribavirin (Rbv) is the only option for preventing HCV-related end stage liver disease.
    Journal of viral hepatitis, 2012, Volume: 19 Suppl 1

    Topics: Drug Therapy, Combination; End Stage Liver Disease; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Polyethylene Glycols; Ribavirin

2012
Clinical drivers in naïve patient eligibility for treatment of chronic hepatitis C.
    Journal of viral hepatitis, 2012, Volume: 19 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Eligibility Determination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Practice Guidelines as Topic; Ribavirin; Treatment Outcome

2012
Optimal treatment duration for patients with HCV genotype 1 infection.
    Journal of viral hepatitis, 2012, Volume: 19 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome

2012
Severe anaemia related to oseltamivir during treatment of chronic hepatitis C: a new drug interaction?
    Journal of viral hepatitis, 2012, Volume: 19 Suppl 1

    Topics: Adult; Anemia; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Interferon alpha-2; Interferon-alpha; Oseltamivir; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2012
Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin.
    Journal of viral hepatitis, 2012, Volume: 19, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Models, Statistical; Polyethylene Glycols; Prognosis; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Assessment; Sensitivity and Specificity; Treatment Outcome; Viral Load

2012
CCL5 mRNA is a marker for early fibrosis in chronic hepatitis C and is regulated by interferon-α therapy and toll-like receptor 3 signalling.
    Journal of viral hepatitis, 2012, Volume: 19, Issue:2

    Topics: Antiviral Agents; Biomarkers; Biopsy; Chemokine CCL5; Gene Expression Profiling; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Leukocytes; Liver; Liver Cirrhosis; Microarray Analysis; Real-Time Polymerase Chain Reaction; Ribavirin; RNA, Messenger; Signal Transduction; Toll-Like Receptor 3

2012
Serum PAI-1 is a novel predictor for response to pegylated interferon-α-2b plus ribavirin therapy in chronic hepatitis C virus infection.
    Journal of viral hepatitis, 2012, Volume: 19, Issue:2

    Topics: Aged; Antiviral Agents; Biomarkers; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Serum; Treatment Outcome; Viral Load

2012
Hepatic expression of MxA and OAS1 in an ex vivo liver slice assay independently predicts treatment outcomes in chronic hepatitis C.
    Journal of viral hepatitis, 2012, Volume: 19, Issue:2

    Topics: 2',5'-Oligoadenylate Synthetase; Adult; Antiviral Agents; Biopsy; Cells, Cultured; Female; Gene Expression; GTP-Binding Proteins; Hepatitis C, Chronic; Humans; Immunohistochemistry; Immunologic Factors; Interferons; Liver; Male; Middle Aged; Myxovirus Resistance Proteins; Ribavirin; Treatment Outcome

2012
Treatment and follow up of children with chronic hepatitis C in Albania.
    Virology journal, 2012, Jan-13, Volume: 9

    Topics: Administration, Oral; Adolescent; Albania; Antiviral Agents; Child; Child, Preschool; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome

2012
Response rates of standard interferon therapy in chronic HCV patients of Khyber Pakhtunkhwa (KPK).
    Virology journal, 2012, Jan-14, Volume: 9

    Topics: Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Pakistan; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Young Adult

2012
Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin.
    Journal of medical virology, 2012, Volume: 84, Issue:3

    Topics: Adolescent; Adult; Aged; Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Molecular Sequence Data; Mutation; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prevalence; Prognosis; Recombinant Proteins; Ribavirin; Sequence Alignment; Treatment Outcome; Viral Nonstructural Proteins; Young Adult

2012
Current treatment options and response rates in children with chronic hepatitis C.
    World journal of gastroenterology, 2012, Jan-14, Volume: 18, Issue:2

    Topics: Adolescent; Antiviral Agents; Child; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Infectious Disease Transmission, Vertical; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load

2012
Factors linked to severe thrombocytopenia during antiviral therapy in patients with chronic hepatitis c and pretreatment low platelet counts.
    BMC gastroenterology, 2012, Jan-18, Volume: 12

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Severity of Illness Index; Thrombocytopenia

2012
Twelve-week posttreatment follow-up to predict sustained virologic response for recurrent hepatitis C infection in liver recipients.
    Transplantation, 2012, Feb-27, Volume: 93, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Quality of Life; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome

2012
Predictors of changes in hemoglobin levels in patients with chronic hepatitis C treated with ribavirin plus pegylated interferon-α.
    Renal failure, 2012, Volume: 34, Issue:4

    Topics: Administration, Oral; Anemia; Antiviral Agents; Biomarkers; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Taiwan

2012
Pegylated interferon-α2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003-2007).
    Antiviral therapy, 2012, Volume: 17, Issue:1

    Topics: Adult; Age Factors; Antiviral Agents; Biomarkers, Pharmacological; Cohort Studies; Female; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Observation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2012
Liver follicular helper T-cells predict the achievement of virological response following interferon-based treatment in HCV-infected patients.
    Antiviral therapy, 2012, Volume: 17, Issue:1

    Topics: Adult; Antiviral Agents; Biomarkers, Pharmacological; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon-alpha; Interferons; Interleukins; Liver; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; T-Lymphocytes, Helper-Inducer; Viral Load

2012
Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment.
    Archives of virology, 2012, Volume: 157, Issue:4

    Topics: Adult; Amino Acid Sequence; Antiviral Agents; Cluster Analysis; Conserved Sequence; eIF-2 Kinase; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Molecular Sequence Data; Phosphorylation; Phylogeny; Ribavirin; Sequence Alignment; Sequence Analysis, DNA; Serum; Viral Envelope Proteins

2012
Post-load insulin resistance does not predict virological response to treatment of chronic hepatitis C patients without the metabolic syndrome.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2012, Volume: 44, Issue:5

    Topics: Antiviral Agents; Blood Glucose; Female; Ferritins; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA

2012
Influence of HLA alleles in response to treatment with pegylated interferon-alpha and ribavirin in patients with chronic hepatitis C.
    International journal of immunogenetics, 2012, Volume: 39, Issue:4

    Topics: Adult; Alleles; Drug Therapy, Combination; Female; Follow-Up Studies; Genes, MHC Class I; Genes, MHC Class II; Genotype; Hepacivirus; Hepatitis C, Chronic; Histocompatibility Testing; HLA-DRB1 Chains; Humans; Interferon-alpha; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome

2012
Hepatic Methionine-enkephalin may interfere with response to antiviral therapy in chronic hepatitis C.
    European journal of gastroenterology & hepatology, 2012, Volume: 24, Issue:4

    Topics: Adult; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Enkephalin, Methionine; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Receptors, Opioid, delta; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Treatment Failure

2012
Cytoplasmic rods and rings autoantibodies developed during pegylated interferon and ribavirin therapy in patients with chronic hepatitis C.
    Antiviral therapy, 2012, Volume: 17, Issue:5

    Topics: Adult; Animals; Antiviral Agents; Autoantibodies; Cell Line; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Organelles; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2012
Plasma IL-6 and IL-9 predict the failure of interferon-α plus ribavirin therapy in HIV/HCV-coinfected patients.
    The Journal of antimicrobial chemotherapy, 2012, Volume: 67, Issue:5

    Topics: Adult; Antiviral Agents; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Interleukin-6; Interleukin-9; Male; Middle Aged; Prognosis; Retrospective Studies; Ribavirin; Treatment Failure; Viral Load

2012
Impact of IL28B gene polymorphisms on interferon-λ3 plasma levels during pegylated interferon-α/ribavirin therapy for chronic hepatitis C in patients coinfected with HIV.
    The Journal of antimicrobial chemotherapy, 2012, Volume: 67, Issue:5

    Topics: Adult; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Immunoenzyme Techniques; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Ribavirin

2012
UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.
    Alimentary pharmacology & therapeutics, 2012, Volume: 35, Issue:6

    Topics: Algorithms; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Patient Selection; Polyethylene Glycols; Proline; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; United Kingdom; Viral Load

2012
The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C patients.
    Antiviral therapy, 2012, Volume: 17, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Haplotypes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Receptors, Calcitriol; Ribavirin; Treatment Outcome; Vitamin D

2012
Early virological response in 1220 patients with HCV (genotype lb) chronic hepatitis and cirrhosis treated with PegInterferon plus Ribavirin.
    Romanian journal of internal medicine = Revue roumaine de medecine interne, 2011, Volume: 49, Issue:2

    Topics: Adult; Antiviral Agents; Biopsy; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Romania; Time Factors; Treatment Failure; Treatment Outcome; Viral Load

2011
Functional reconstitution of defective myeloid dendritic cells in chronic hepatitis C infection on successful antiviral treatment.
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32, Issue:7

    Topics: Adult; Antigens, CD; Antiviral Agents; B7-1 Antigen; B7-2 Antigen; CD83 Antigen; Dendritic Cells; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Immunoglobulins; Interferon-alpha; Male; Membrane Glycoproteins; Middle Aged; Myeloid Cells; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Up-Regulation; Young Adult

2012
The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin.
    Journal of translational medicine, 2012, Feb-07, Volume: 10

    Topics: Antiviral Agents; Cohort Studies; Down-Regulation; Female; Gene Expression Profiling; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Regulatory Factor-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Signal Transduction; Suppressor of Cytokine Signaling 1 Protein; Suppressor of Cytokine Signaling Proteins; Time Factors; Up-Regulation

2012
Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy.
    PloS one, 2012, Volume: 7, Issue:2

    Topics: Antiviral Agents; Base Sequence; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Nonstructural Proteins

2012
Reversible sudden sensorineural hearing loss during chronic hepatitis C treatment with pegylated interferon/ribavirin.
    Acta gastro-enterologica Belgica, 2011, Volume: 74, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hearing Loss, Sensorineural; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2011
Detection of specific antibodies to HCV-ARF/CORE+1 protein in patients treated with pegylated interferon plus ribavirin.
    Journal of viral hepatitis, 2012, Volume: 19, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Escherichia coli; Female; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Core Proteins; Young Adult

2012
Pegylated interferon-associated retinopathy is frequent in hepatitis C virus patients with hypertension and justifies ophthalmologic screening.
    Hepatology (Baltimore, Md.), 2012, Volume: 56, Issue:2

    Topics: Adult; Antiviral Agents; Diabetic Retinopathy; Diagnostic Techniques, Ophthalmological; Drug Monitoring; Female; Health Care Costs; Hepatitis C, Chronic; Humans; Hypertension; Hypertensive Retinopathy; Interferon alpha-2; Interferon-alpha; Longitudinal Studies; Male; Mass Screening; Metabolic Syndrome; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors

2012
[Impact of age and sex on virologic responses of peginterferon alfa-2a and ribavirin treatment in chronic hepatitis C].
    Zhonghua nei ke za zhi, 2011, Volume: 50, Issue:12

    Topics: Adult; Age Factors; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Sex Factors; Treatment Outcome

2011
Lack of full CD8 functional restoration after antiviral treatment for acute and chronic hepatitis C virus infection.
    Gut, 2012, Volume: 61, Issue:7

    Topics: Antiviral Agents; Apoptosis Regulatory Proteins; CD8-Positive T-Lymphocytes; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Programmed Cell Death 1 Receptor; Ribavirin; Viral Load

2012
HCV genotype-3a T cell immunity: specificity, function and impact of therapy.
    Gut, 2012, Volume: 61, Issue:11

    Topics: Antiviral Agents; Case-Control Studies; CD4-Positive T-Lymphocytes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Cellular; Interferon-gamma; Longitudinal Studies; Lymphocyte Activation; Male; Reference Values; Ribavirin; Sensitivity and Specificity; T-Cell Antigen Receptor Specificity

2012
[Use of boceprevir and telaprevir in patients with hepatitis C virus infection (practical considerations)].
    Gastroenterologia y hepatologia, 2012, Volume: 35, Issue:5

    Topics: Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin

2012
Lateral rectus muscle paralysis induced by ribavirin and pegylated interferon-α2a in a patient with HIV/HCV co-infection.
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2012, Volume: 18, Issue:6

    Topics: Abducens Nerve Diseases; Adult; Antiviral Agents; Eye; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Muscle, Skeletal; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2012
IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients.
    Journal of gastroenterology, 2012, Volume: 47, Issue:7

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Fatty Liver; Female; Genotype; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Liver; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Ribavirin; Young Adult

2012
New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis.
    Annals of internal medicine, 2012, Feb-21, Volume: 156, Issue:4

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Decision Support Techniques; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Liver Neoplasms; Male; Markov Chains; Medication Adherence; Protease Inhibitors; Quality-Adjusted Life Years; Ribavirin; Risk Factors; Treatment Outcome

2012
Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients.
    Transplant international : official journal of the European Society for Organ Transplantation, 2012, Volume: 25, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Patient Compliance; Polyethylene Glycols; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Sex Factors; Treatment Outcome; Viral Load

2012
Study for frequency and aetiology of lymphadenopathy during combination therapy for chronic hepatitis C (pegylated interferon alpha plus ribavirin) at a tertiary care hospital in Hyderabad.
    JPMA. The Journal of the Pakistan Medical Association, 2011, Volume: 61, Issue:10

    Topics: Adult; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Hospitals, University; Humans; Interferon alpha-2; Interferon-alpha; Lymphatic Diseases; Male; Middle Aged; Pakistan; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin

2011
The outcomes of glucose abnormalities in pre-diabetic chronic hepatitis C patients receiving peginterferon plus ribavirin therapy.
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Biomarkers; Blood Glucose; Chi-Square Distribution; Drug Therapy, Combination; Female; Glycated Hemoglobin; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prediabetic State; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Taiwan; Treatment Outcome; Viral Load

2012
Differences in virological response to peginterferon-α plus ribavirin in HIV-positive patients coinfected with HCV subtypes 1a or 1b.
    Journal of acquired immune deficiency syndromes (1999), 2012, Jun-01, Volume: 60, Issue:2

    Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load

2012
Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients.
    PloS one, 2012, Volume: 7, Issue:2

    Topics: Adult; Bacteria; Biomarkers; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Coinfection; Demography; Female; Fibrosis; Hepatitis C, Chronic; HIV Infections; HLA-DR Antigens; Humans; Interferon-alpha; Lipopolysaccharide Receptors; Lipopolysaccharides; Lymphocyte Activation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Solubility; Treatment Outcome

2012
Agranulocytosis during treatment of chronic hepatitis C complicated by hyperthyreosis. Case reports.
    Endokrynologia Polska, 2012, Volume: 63, Issue:1

    Topics: Adult; Agranulocytosis; Antithyroid Agents; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Hyperthyroidism; Interferon alpha-2; Interferon-alpha; Methimazole; Middle Aged; Polyethylene Glycols; Propylthiouracil; Recombinant Proteins; Ribavirin; Time Factors; Viral Load

2012
Interferon-induced thyroiditis during treatment of chronic hepatitis C.
    Endokrynologia Polska, 2012, Volume: 63, Issue:1

    Topics: Age Factors; Algorithms; Antithyroid Agents; Antiviral Agents; Autoantibodies; Diagnosis, Differential; Drug Interactions; Female; Graves Disease; Hashimoto Disease; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Ribavirin; Risk Factors; Sex Factors; Thyroid Gland; Thyroiditis

2012
HCV infection, HOMA index and sustained virological response: the step we need to take before moving forward.
    Journal of hepatology, 2012, Volume: 57, Issue:2

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon-alpha; Ribavirin

2012
The "pegylated" story continues--perhaps because both ends (α2a and α2b) are true?
    Journal of hepatology, 2012, Volume: 57, Issue:1

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Ribavirin

2012
Durability of sustained response shown in paediatric patients with chronic hepatitis C who were treated with interferon alfa-2b plus ribavirin.
    Journal of viral hepatitis, 2012, Volume: 19, Issue:4

    Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Clinical Trials as Topic; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult

2012
The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients.
    BMC research notes, 2012, Mar-10, Volume: 5

    Topics: Aged; Antiviral Agents; Blood Platelets; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Typing; Multivariate Analysis; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sex Factors; Treatment Outcome; Viral Load; Virus Replication

2012
[The effect of cryoglobulinemia on the antiviral therapy in patients with chronic hepatitis C].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2011, Volume: 19, Issue:10

    Topics: Adult; Aged; Antiviral Agents; Cryoglobulinemia; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2011
The risk of infections in HIV-HCV coinfected patients during antiviral therapy with pegIFN+RBV.
    The Journal of infection, 2012, Volume: 65, Issue:2

    Topics: Adult; Anti-Retroviral Agents; Antiviral Agents; Bacterial Infections; CD4-Positive T-Lymphocytes; Female; Hepatitis C, Chronic; HIV Infections; Humans; Incidence; Interferons; Leukocyte Count; Male; Middle Aged; Neutrophils; Opportunistic Infections; Ribavirin

2012
[Current indications for triple therapy in hepatitis C virus infection].
    Gastroenterologia y hepatologia, 2012, Volume: 35, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin

2012
The expression kinetics of CD137 in chronic hepatitis C patients treated with pegylated-interferon and ribavirin.
    Scandinavian journal of gastroenterology, 2012, Volume: 47, Issue:5

    Topics: Adult; Aged; Antiviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Confidence Intervals; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Statistics, Nonparametric; Time Factors; Treatment Outcome; Tumor Necrosis Factor Receptor Superfamily, Member 9; Viral Load; Young Adult

2012
Insulin resistance and diabetes mellitus in patients with chronic hepatitis C: spectators or actors?
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2012, Volume: 44, Issue:5

    Topics: Antiviral Agents; Diabetes Mellitus, Type 2; Female; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2012
Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:6

    Topics: Adult; Anemia; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Polymorphism, Genetic; Pyrophosphatases; Ribavirin; Risk Factors

2012
Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation.
    Journal of gastroenterology and hepatology, 2012, Volume: 27, Issue:9

    Topics: Adult; Aged; Antiviral Agents; Chi-Square Distribution; Confidence Intervals; Donor Selection; End Stage Liver Disease; Female; Genetic Testing; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Transplantation; Logistic Models; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome

2012
Suppression of ribosomal protein synthesis and protein translation factors by Peg-interferon alpha/ribavirin in HCV patients blood mononuclear cells (PBMC).
    Journal of translational medicine, 2012, Mar-22, Volume: 10

    Topics: Down-Regulation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocytes, Mononuclear; Peptide Elongation Factors; Peptide Initiation Factors; Polyethylene Glycols; Protein Biosynthesis; Recombinant Proteins; Ribavirin; Ribosomal Proteins; Ribosomes

2012
Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus.
    Journal of gastroenterology, 2012, Volume: 47, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Genome-Wide Association Study; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Linkage Disequilibrium; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult

2012
Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load.
    Journal of gastroenterology, 2012, Volume: 47, Issue:10

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Mutation; Polymorphism, Genetic; Ribavirin; Sequence Analysis; Treatment Outcome; Viral Load; Viral Nonstructural Proteins

2012
NK cells from HCV-infected patients effectively induce apoptosis of activated primary human hepatic stellate cells in a TRAIL-, FasL- and NKG2D-dependent manner.
    Laboratory investigation; a journal of technical methods and pathology, 2012, Volume: 92, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Apoptosis; Case-Control Studies; Fas Ligand Protein; Female; Hepatic Stellate Cells; Hepatitis C, Chronic; Humans; In Vitro Techniques; Interferon-alpha; Interferon-gamma; Killer Cells, Natural; Male; Middle Aged; NK Cell Lectin-Like Receptor Subfamily K; Polyethylene Glycols; Recombinant Proteins; Ribavirin; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha

2012
An inadequate dose of ribavirin is related to virological relapse by chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin.
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2012, Volume: 18, Issue:5

    Topics: Aged; Analysis of Variance; Antiviral Agents; Dose-Response Relationship, Drug; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; ROC Curve; Treatment Outcome; Viral Load

2012
Acquired haemophilia complicated with gastrointestinal bleeding and spontaneous iliopsoas muscle haematoma in a woman with chronic C hepatitis under treatment with pegylated IFN alpha 2a and ribavirin.
    Journal of gastrointestinal and liver diseases : JGLD, 2012, Volume: 21, Issue:1

    Topics: Antiviral Agents; Female; Gastrointestinal Hemorrhage; Hematoma; Hemophilia A; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Polyethylene Glycols; Psoas Muscles; Recombinant Proteins; Ribavirin

2012
[Virological sustained response to former young intravenous drug abusers with chronic hepatitis C treated by pegylated interferon-α plus ribavirin].
    Vnitrni lekarstvi, 2012, Volume: 58, Issue:2

    Topics: Adolescent; Adult; Antibodies, Viral; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Substance Abuse, Intravenous; Young Adult

2012
The pharmacokinetics of peginterferon alfa-2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C.
    Alimentary pharmacology & therapeutics, 2012, Volume: 35, Issue:10

    Topics: Adult; Antiviral Agents; Area Under Curve; Black or African American; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Genotype; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; White People

2012
Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy.
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32, Issue:7

    Topics: Adolescent; Adult; Age Factors; Aged; Anemia; Antiviral Agents; Contraindications; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Practice Guidelines as Topic; Prevalence; Retrospective Studies; Ribavirin; Thrombocytopenia; Young Adult

2012
Single centre experience with pegylated interferon and ribavirin for hepatitis C: looking back before moving forward.
    Internal medicine journal, 2012, Volume: 42, Issue:7

    Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome

2012
[Analysis of thyroid dysfunction and influencing factors in chronic hepatitis C patients treated with peg-IFNa-2a and ribavirin].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2012, Volume: 20, Issue:3

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Thyroid Diseases; Thyroid Gland; Treatment Outcome

2012
Liver biopsy in chronic hepatitis C: the experience of 15 Italian wards of infectious diseases.
    Le infezioni in medicina, 2012, Volume: 20, Issue:1

    Topics: Adult; Antiviral Agents; Biopsy, Needle; Drug Therapy, Combination; Female; Health Surveys; Hepatitis C, Chronic; Hospital Units; Hospitals, Isolation; Humans; Inpatients; Interferon alpha-2; Interferon-alpha; Italy; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Surveys and Questionnaires; Treatment Outcome

2012
B-cell-activating factor affects the occurrence of thyroid autoimmunity in chronic hepatitis C patients treated with interferon alpha.
    Clinical & developmental immunology, 2012, Volume: 2012

    Topics: Age Factors; Antiviral Agents; Autoantibodies; Autoimmunity; B-Cell Activating Factor; Biomarkers; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Peroxidase; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Sex Factors; Thyroid Gland

2012
Efficacy and factors influencing treatment with peginterferon alpha-2a and ribavirin in elderly patients with chronic hepatitis C.
    Hepatobiliary & pancreatic diseases international : HBPD INT, 2012, Volume: 11, Issue:2

    Topics: Age Factors; Aged; Antiviral Agents; Biopsy; Dose-Response Relationship, Drug; Drug Therapy; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load

2012
Response-guided telaprevir therapy in prior relapsers? The role of bridging data from treatment-naïve and experienced subjects.
    Hepatology (Baltimore, Md.), 2013, Volume: 57, Issue:3

    Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Approval; Drug Monitoring; Drug Resistance, Viral; Drug Therapy, Combination; Evidence-Based Medicine; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Ribavirin; Secondary Prevention; United States

2013
[Dysacusia associated with pegylated-interferon and ribavirin combination therapy during chronic hepatitis C treatment: a report of two cases].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2012, Volume: 20, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hearing Disorders; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Recombinant Proteins; Ribavirin

2012
[A study of the relationship between neutropenia and clinical infection risk during treatment with peginterferon alfa-2a and ribavirin for chronic hepatitis C].
    Zhonghua nei ke za zhi, 2012, Volume: 51, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Infections; Interferon-alpha; Leukocyte Count; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors

2012
Hepatitis C treatment highlights from the 2011 American Association for the Study of Liver Disease meeting.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Volume: 55, Issue:3

    Topics: Administration, Oral; Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Protease Inhibitors; Ribavirin

2012
Protein-tyrosine phosphatases are involved in interferon resistance associated with insulin resistance in HepG2 cells and obese mice.
    The Journal of biological chemistry, 2012, Jun-01, Volume: 287, Issue:23

    Topics: Animals; Antiviral Agents; Enzyme Inhibitors; Gene Knockdown Techniques; Gene Silencing; Hep G2 Cells; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Insulin Receptor Substrate Proteins; Insulin Resistance; Interferon-alpha; Male; Metformin; Mice; Mice, Obese; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Proto-Oncogene Proteins c-akt; Ribavirin; STAT1 Transcription Factor; Tumor Necrosis Factor-alpha; Vanadates

2012
Chronic hepatitis C: treat or wait? Medical decision making in clinical practice.
    World journal of gastroenterology, 2012, Mar-28, Volume: 18, Issue:12

    Topics: Adult; Antiviral Agents; Cohort Studies; Decision Making; Female; Germany; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Practice Patterns, Physicians'; Prospective Studies; Recombinant Proteins; Refusal to Treat; Ribavirin; Surveys and Questionnaires; Treatment Refusal

2012
Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response.
    Journal of viral hepatitis, 2012, Volume: 19, Issue:5

    Topics: Adult; Antiviral Agents; Cholesterol, LDL; Female; Genetic Association Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Genetic; Ribavirin; Treatment Outcome; Viral Load

2012
Should routine screening for celiac disease be considered before starting interferon/ribavirin treatment in patients affected by chronic hepatitis C or not?
    Bratislavske lekarske listy, 2012, Volume: 113, Issue:4

    Topics: Celiac Disease; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin

2012
Comparison of hepatitis C virus treatment between incarcerated and community patients.
    Hepatology (Baltimore, Md.), 2012, Volume: 56, Issue:4

    Topics: Adult; Age Factors; Aged; Analysis of Variance; Antiviral Agents; Confidence Intervals; Databases, Factual; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Incidence; Interferon-alpha; Logistic Models; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Predictive Value of Tests; Prisoners; Recombinant Proteins; Residence Characteristics; Retrospective Studies; Ribavirin; Risk Assessment; Severity of Illness Index; Sex Factors; Substance Abuse, Intravenous; Treatment Outcome; Young Adult

2012
Frequency of IL28B rs12979860 single-nucleotide polymorphism alleles in newborn infants and in patients with chronic hepatitis C in Morocco.
    Genetic testing and molecular biomarkers, 2012, Volume: 16, Issue:8

    Topics: Adult; Alleles; Base Sequence; Cohort Studies; DNA Primers; Hepatitis C, Chronic; Humans; Infant, Newborn; Interferons; Interleukins; Morocco; Polymorphism, Single Nucleotide; Real-Time Polymerase Chain Reaction; Ribavirin

2012
Which is the real efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in HCV infected patients with advanced fibrosis?
    Journal of hepatology, 2012, Volume: 57, Issue:3

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Ribavirin

2012
The effect of alanine aminotransferase dynamics on predicting sustained virological response in chronic hepatitis C virus infection.
    The Korean journal of hepatology, 2012, Volume: 18, Issue:1

    Topics: Alanine Transaminase; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2012
Rapid normalization of alanine aminotransferase predicts viral response during combined peginterferon and ribavirin treatment in chronic hepatitis C patients.
    The Korean journal of hepatology, 2012, Volume: 18, Issue:1

    Topics: Adult; Age Factors; Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral

2012
Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials.
    PloS one, 2012, Volume: 7, Issue:4

    Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Evolution, Molecular; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2012
Hepatitis C infection in childhood.
    Clinics and research in hepatology and gastroenterology, 2012, Volume: 36, Issue:3

    Topics: Antiviral Agents; Biopsy; Child; Female; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver; Mass Screening; Polyethylene Glycols; Pregnancy; Recombinant Proteins; Ribavirin

2012
Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office.
    The American journal of gastroenterology, 2012, Volume: 107, Issue:5

    Topics: Antiviral Agents; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Proline; Recombinant Proteins; Ribavirin; Risk Factors

2012
Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin.
    Alimentary pharmacology & therapeutics, 2012, Volume: 35, Issue:12

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Lipase; Liver Cirrhosis; Logistic Models; Male; Membrane Proteins; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2012
Development of new IL28B genotyping method using Invader Plus assay.
    Microbiology and immunology, 2012, Volume: 56, Issue:5

    Topics: Adult; Aged; Asian People; Female; Genetic Techniques; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Reagent Kits, Diagnostic; Ribavirin

2012
Genetic factors and hepatitis C virus infection.
    Gastroenterology, 2012, Volume: 142, Issue:6

    Topics: Antiviral Agents; Gene Frequency; Genetic Predisposition to Disease; Genome-Wide Association Study; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Proline; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome

2012
Is there a role for ribavirin in the era of hepatitis C virus direct-acting antivirals?
    Gastroenterology, 2012, Volume: 142, Issue:6

    Topics: Antiviral Agents; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Time Factors; Treatment Outcome

2012
[Position paper of the Catalan Society of Gastroenterology: treatment of Genotype 1 Chronic Hepatitis C Virus with Triple Therapy].
    Gastroenterologia y hepatologia, 2012, Volume: 35, Issue:9

    Topics: Antiviral Agents; Biopsy; Contraindications; Diagnostic Imaging; Drug Therapy, Combination; Genotype; Health Services Accessibility; Hepacivirus; Hepatitis C, Chronic; Humans; Informed Consent; Interferon Type I; Interferons; Interleukins; Liver Cirrhosis; Oligopeptides; Patient Care Team; Polyethylene Glycols; Proline; Protease Inhibitors; Recurrence; Ribavirin; Viral Load

2012
IL28B favorable genotype and ultrarapid viral response as the earliest treatment predictors of a sustained viral response in a Georgian cohort infected with the hepatitis C genotype 1.
    European journal of gastroenterology & hepatology, 2012, Volume: 24, Issue:7

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prognosis; Prospective Studies; Real-Time Polymerase Chain Reaction; Ribavirin; Treatment Outcome; Viral Load

2012
New genetic discoveries and treatment for hepatitis C.
    JAMA, 2012, May-09, Volume: 307, Issue:18

    Topics: Antiviral Agents; DNA, Viral; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Pharmacogenetics; Polyethylene Glycols; Polymorphism, Single Nucleotide; Precision Medicine; Proline; Recombinant Proteins; Ribavirin

2012
Gene expression profiles associated with anaemia and ITPA genotypes in patients with chronic hepatitis C (CH-C).
    Journal of viral hepatitis, 2012, Volume: 19, Issue:6

    Topics: Adult; Aged; Anemia; Cohort Studies; Female; Gene Expression Profiling; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Polymorphism, Genetic; Pyrophosphatases; Ribavirin

2012
Response-guided therapy for patients with hepatitis C virus genotype 6 infection: a pilot study.
    Journal of viral hepatitis, 2012, Volume: 19, Issue:6

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Monitoring; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult

2012
Severe transaminitis after interferon-ribavirin therapy in HIV/HCV-coinfected patients: influence of a sustained HCV response.
    Journal of viral hepatitis, 2012, Volume: 19, Issue:6

    Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aspartate Aminotransferases; Cohort Studies; Coinfection; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver; Male; Middle Aged; Prospective Studies; Ribavirin

2012
Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to pegylated interferon plus ribavirin therapy in hepatitis C virus 1B infection.
    Hepatology (Baltimore, Md.), 2012, Volume: 56, Issue:5

    Topics: Adolescent; Adult; Aged; Alleles; Antiviral Agents; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Japan; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Open Reading Frames; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recurrence; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Nonstructural Proteins

2012
Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort.
    European journal of gastroenterology & hepatology, 2012, Volume: 24, Issue:8

    Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Clinical Trials as Topic; Cohort Studies; Drug Therapy, Combination; Female; Genetic Variation; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Ribavirin; Scandinavian and Nordic Countries; Treatment Outcome

2012
Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1.
    Journal of medical virology, 2012, Volume: 84, Issue:7

    Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Japan; Male; Middle Aged; Oligopeptides; Predictive Value of Tests; Ribavirin; Sensitivity and Specificity; Treatment Outcome; Virology

2012
ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV.
    Journal of medical virology, 2012, Volume: 84, Issue:7

    Topics: Adult; Anemia; Antiviral Agents; Coinfection; Female; Genotype; Hemoglobins; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Pilot Projects; Polymorphism, Single Nucleotide; Prospective Studies; Pyrophosphatases; Ribavirin; Treatment Outcome

2012
Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy.
    Journal of gastroenterology, 2012, Volume: 47, Issue:12

    Topics: Adult; Amino Acid Sequence; Antiviral Agents; Case-Control Studies; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cells, Cultured; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Immunity, Cellular; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Lymphocyte Activation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2012
Boceprevir dosing for late responders and null responders: the role of bridging data between treatment-naïve and -experienced subjects.
    Hepatology (Baltimore, Md.), 2013, Volume: 57, Issue:3

    Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Approval; Drug Monitoring; Drug Resistance, Viral; Drug Therapy, Combination; Evidence-Based Medicine; Hepatitis C, Chronic; Humans; Interferon-alpha; Proline; Ribavirin; United States

2013
Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2012, Volume: 56, Issue:5

    Topics: Adolescent; Adult; Aged; Alleles; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Vitamin D; Vitamin D-Binding Protein; Young Adult

2012
Sustained virological response after 14-day treatment with danoprevir and 48-week treatment with pegylated interferon-α2a (40 KD) plus ribavirin.
    Antiviral therapy, 2012, Volume: 17, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Retrospective Studies; Ribavirin; Sulfonamides; Time Factors; Treatment Outcome; Viral Load

2012
Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1.
    Journal of hepatology, 2012, Volume: 57, Issue:3

    Topics: Aged; Antiviral Agents; Area Under Curve; Cohort Studies; Confidence Intervals; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Homeostasis; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Models, Biological; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; ROC Curve; Treatment Outcome

2012
Comparison of three different methods for the evaluation of IL28 and ITPA polymorphisms in patients infected with HCV.
    Journal of virological methods, 2012, Volume: 184, Issue:1-2

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Leukocytes, Mononuclear; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Treatment Outcome; Virology

2012
Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin.
    Hepatology (Baltimore, Md.), 2012, Volume: 56, Issue:2

    Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Databases, Factual; Drug Monitoring; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Proline; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Failure

2012
Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection.
    The AAPS journal, 2012, Volume: 14, Issue:3

    Topics: Adult; Antiviral Agents; Area Under Curve; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin

2012
Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2012, Volume: 16, Issue:8

    Topics: Adult; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Young Adult

2012
Negative HCV-RNA 2 weeks after initiation of treatment predicts sustained virological response to pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C.
    Scandinavian journal of gastroenterology, 2012, Volume: 47, Issue:8-9

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2012
Methylenetetrahydrofolate reductase homozygosis and low-density lipoproteins in patients with genotype 1 chronic hepatitis C.
    Journal of viral hepatitis, 2012, Volume: 19, Issue:7

    Topics: Adult; Biopsy; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Homozygote; Humans; Interferon-alpha; Lipoproteins, LDL; Liver Cirrhosis; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load

2012
The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin.
    Journal of viral hepatitis, 2012, Volume: 19, Issue:7

    Topics: Adult; Antiviral Agents; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2012
Is the end of chronic hepatitis C virus infection in sight?
    The Medical journal of Australia, 2012, Jun-04, Volume: 196, Issue:10

    Topics: Antiviral Agents; Drug Users; Hepatitis C, Chronic; Humans; Interferon-alpha; Models, Biological; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Substance Abuse, Intravenous

2012
Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia.
    The Medical journal of Australia, 2012, Jun-04, Volume: 196, Issue:10

    Topics: Antiviral Agents; Drug Therapy, Combination; Drug Users; Hepatitis C, Chronic; Humans; Interferon-alpha; Models, Biological; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Substance Abuse, Intravenous; Victoria

2012
Interferon-γ-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C.
    Gastroenterology, 2012, Volume: 143, Issue:3

    Topics: Acute Disease; Adolescent; Adult; Antiviral Agents; Biopsy; Blotting, Western; CD8-Positive T-Lymphocytes; Cells, Cultured; Drug Resistance, Viral; Drug Therapy, Combination; Endopeptidases; Female; Gene Expression Profiling; Gene Expression Regulation; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Immunohistochemistry; Interferon-alpha; Interferon-gamma; Liver; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Phosphorylation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; STAT1 Transcription Factor; Switzerland; Time Factors; Transcription, Genetic; Treatment Outcome; Ubiquitin Thiolesterase

2012
Serum ferritin levels in chronic hepatitis C patients during antiviral therapy and prediction of treatment response.
    Scandinavian journal of infectious diseases, 2012, Volume: 44, Issue:10

    Topics: Adult; Aged; Antiviral Agents; Biomarkers; Female; Ferritins; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Prognosis; Ribavirin; Serum; Treatment Outcome

2012
Longitudinal analysis of the 5'UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients.
    Antiviral research, 2012, Volume: 95, Issue:2

    Topics: 5' Untranslated Regions; Adult; Amino Acid Sequence; Antiviral Agents; Base Sequence; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Molecular Sequence Data; Ribavirin; Sequence Alignment; Treatment Failure; Viral Envelope Proteins; Viral Nonstructural Proteins

2012
Interferon-induced sarcoidosis.
    BMJ case reports, 2011, Apr-19, Volume: 2011

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sarcoidosis

2011
Extent of liver inflammation in predicting response to interferon α & Ribavirin in chronic hepatitis C patients: a cohort study.
    BMC gastroenterology, 2012, Jun-14, Volume: 12

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin; Severity of Illness Index; Treatment Outcome

2012
Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2012, Volume: 55, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Drug Monitoring; Female; Genotype; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Immunoassay; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Core Proteins

2012
Results of antiviral treatment of patients with chronic hepatitis C: experience of Poznan centre.
    Postepy higieny i medycyny doswiadczalnej (Online), 2012, Jun-14, Volume: 66

    Topics: Adolescent; Adult; Age Factors; Aged; Alanine Transaminase; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viremia; Young Adult

2012
Early anemia and rapid virological response improve the predictive efficiency of IL28B-genotype for treatment outcome to antiviral combination therapy in patients infected with chronic HCV genotype 1.
    Journal of medical virology, 2012, Volume: 84, Issue:8

    Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome

2012
Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: does ethnicity matter?
    Journal of medical virology, 2012, Volume: 84, Issue:8

    Topics: Adult; Antiviral Agents; Black People; Drug Therapy, Combination; Egypt; Female; Genotype; Greece; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Outcome; White People

2012
Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype.
    Virology journal, 2012, Jun-19, Volume: 9

    Topics: Adult; Antiviral Agents; Asian People; China; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Predictive Value of Tests; Ribavirin; Treatment Outcome

2012
The interaction between insulin resistance, liver fibrosis and early virological response in Egyptian patients with chronic hepatitis C.
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2012, Volume: 26, Issue:6

    Topics: Adult; Age Factors; Antiviral Agents; Biopsy; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Egypt; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Viral Load

2012
New approaches to the management of hepatitis C in haemophilia in 2012.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2012, Volume: 18 Suppl 4

    Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Hemophilia A; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2012
Different impact of IL28B polymorphisms on response to peginterferon-α plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2012, Volume: 55, Issue:1

    Topics: Adult; Antiviral Agents; Cohort Studies; Coinfection; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin

2012
Gene expression profiles predict emergence of psychiatric adverse events in HIV/HCV-coinfected patients on interferon-based HCV therapy.
    Journal of acquired immune deficiency syndromes (1999), 2012, Jul-01, Volume: 60, Issue:3

    Topics: Adult; Antiviral Agents; Computational Biology; Down-Regulation; Female; Gene Expression Profiling; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Mental Disorders; Middle Aged; Molecular Diagnostic Techniques; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Up-Regulation

2012
[Efficacy of peg interferon alpha-2a in combination with ribavirin in treatment of with hepatitis C cirrhosis patients].
    Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology, 2011, Volume: 25, Issue:6

    Topics: Adult; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2011
Impact of ribavirin dose on retreatment of chronic hepatitis C patients.
    World journal of gastroenterology, 2012, Jun-21, Volume: 18, Issue:23

    Topics: Adult; Age Factors; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Viral Load

2012
Effect of discounting on estimation of benefits determined by hepatitis C treatment.
    World journal of gastroenterology, 2012, Jun-21, Volume: 18, Issue:23

    Topics: Antiviral Agents; Computer Simulation; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Markov Chains; Oligopeptides; Proline; Quality-Adjusted Life Years; Ribavirin

2012
Changes in fasting plasma glucose levels with ribavirin and pegylated interferon treatment in normal and impaired glucose tolerant patients with chronic hepatitis C.
    Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health, 2012, Volume: 71, Issue:5

    Topics: Antiviral Agents; Blood Glucose; Female; Glucose Intolerance; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin

2012
Successful desensitization to ribavirin in a patient with chronic hepatitis C.
    Journal of clinical gastroenterology, 2012, Volume: 46, Issue:8

    Topics: Aged; Antiviral Agents; Desensitization, Immunologic; Drug Hypersensitivity; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2012
The effect of increased oxidative stress and ferritin in reducing the effectiveness of therapy in chronic hepatitis C patients.
    Clinical biochemistry, 2012, Volume: 45, Issue:16-17

    Topics: Adult; Aged; Alanine Transaminase; Antioxidants; Antiviral Agents; Aspartate Aminotransferases; Drug Therapy, Combination; Female; Ferritins; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Oxidation-Reduction; Oxidative Stress; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thiobarbituric Acid Reactive Substances; Treatment Outcome

2012
Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study.
    Journal of hepatology, 2012, Volume: 57, Issue:5

    Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatigue; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Longitudinal Studies; Male; Polyethylene Glycols; Prevalence; Recombinant Proteins; Retrospective Studies; Ribavirin; Severity of Illness Index

2012
High-dose silibinin rescue treatment for HCV-infected patients showing suboptimal virologic response to standard combination therapy.
    Journal of viral hepatitis, 2012, Volume: 19, Issue:8

    Topics: Adult; Aged; Antioxidants; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Infusions, Intravenous; Interferon-alpha; Male; Middle Aged; Ribavirin; Silybin; Silymarin; Treatment Outcome; Viremia

2012
Reversible sudden hearing loss in a chronic hepatitis C patient who achieved a sustained response to antiviral re-treatment.
    Le infezioni in medicina, 2012, Volume: 20, Issue:2

    Topics: Alanine Transaminase; Anemia; Antiviral Agents; Biomarkers; Drug Monitoring; Drug Substitution; Drug Therapy, Combination; Hearing Loss, Sudden; Hearing Loss, Unilateral; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2012
Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction?
    AIDS (London, England), 2012, Nov-13, Volume: 26, Issue:17

    Topics: Adult; Anti-HIV Agents; Antiviral Agents; Coinfection; Dideoxynucleosides; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Seropositivity; HIV-1; Humans; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Ribavirin; RNA, Viral; Surveys and Questionnaires; Treatment Outcome; Viral Load

2012
[Clinical evaluation of peginterferon α plus ribavirin for patients co-infected with HIV and HCV at Nagoya Medical Center].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2012, Volume: 109, Issue:7

    Topics: Adult; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Ribavirin

2012
Chemokine CXCL10 at week 4 of treatment predicts sustained virological response in patients with chronic hepatitis C.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2012, Volume: 32, Issue:8

    Topics: Adult; Antiviral Agents; Biomarkers; Chemokine CXCL10; Chemokine CXCL11; Chemokine CXCL9; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Load

2012
A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C.
    PloS one, 2012, Volume: 7, Issue:7

    Topics: 25-Hydroxyvitamin D3 1-alpha-Hydroxylase; Adult; Aged; Calcifediol; Demography; Female; Gene Frequency; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Reproducibility of Results; Ribavirin; Seasons; Treatment Outcome; Vitamin D; Young Adult

2012
A formula to estimate the optimal dosage of ribavirin for the treatment of chronic hepatitis C: influence of ITPA polymorphisms.
    Antiviral therapy, 2012, Volume: 17, Issue:8

    Topics: Algorithms; Anemia; Antiviral Agents; Hemoglobins; Hepatitis C, Chronic; Humans; Models, Biological; Polymorphism, Genetic; Pyrophosphatases; Reproducibility of Results; Ribavirin

2012
Eukaryotic initiation factor 5B: a new player for the anti-hepatitis C virus effect of ribavirin?
    Medical hypotheses, 2012, Volume: 79, Issue:4

    Topics: Antiviral Agents; Drug Synergism; Eukaryotic Initiation Factor-2; Eukaryotic Initiation Factors; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Models, Biological; Peptide Chain Initiation, Translational; Ribavirin

2012
Single-nucleotide polymorphism in the promoter region of the osteopontin gene at nucleotide -443 as a marker predicting the efficacy of pegylated interferon/ribavirin-therapy in Egyptians patients with chronic hepatitis C.
    Human immunology, 2012, Volume: 73, Issue:10

    Topics: Adult; Antiviral Agents; Egypt; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Osteopontin; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Promoter Regions, Genetic; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult

2012
Ribavirin exerts differential effects on functions of Cd4+ Th1, Th2, and regulatory T cell clones in hepatitis C.
    PloS one, 2012, Volume: 7, Issue:7

    Topics: Adult; Aged; Antiviral Agents; Cell Proliferation; Clone Cells; Female; Hepatitis C, Chronic; Humans; Interleukin-2; Male; Middle Aged; Ribavirin; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Th1 Cells; Th2 Cells

2012
Interleukin-28B (IL-28B) single-nucleotide polymorphisms and interferon plus ribavirin treatment outcome in Italian chronically HCV-infected patients.
    Journal of viral hepatitis, 2012, Volume: 19, Issue:9

    Topics: Antiviral Agents; Cohort Studies; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Italy; Male; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome; Viral Load

2012
Predicted effects of treatment for HCV infection vary among European countries.
    Gastroenterology, 2012, Volume: 143, Issue:4

    Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Therapy, Combination; Europe; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Markov Chains; Mass Screening; Middle Aged; Polyethylene Glycols; Protease Inhibitors; Ribavirin

2012
Telaprevir and boceprevir in African Americans with genotype 1 chronic hepatitis C: implications for patients and providers.
    Southern medical journal, 2012, Volume: 105, Issue:8

    Topics: Antiviral Agents; Black or African American; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Proline; Research Subjects; Ribavirin; Serine Proteinase Inhibitors; Time Factors; Treatment Failure

2012
A case of chronic hepatitis C with nephrotic diabetic nephropathy who achieved sustained viral remission by double-filtration plasmapheresis and interferon combination therapy.
    Internal medicine (Tokyo, Japan), 2012, Volume: 51, Issue:15

    Topics: Aged; Antiviral Agents; Combined Modality Therapy; Diabetic Nephropathies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Plasmapheresis; Polyethylene Glycols; Recombinant Proteins; Remission Induction; Ribavirin; Viral Load

2012
Expression of IFNAR2 mRNA in peripheral blood mononuclear cells of patients with HCV infection.
    Acta gastro-enterologica Belgica, 2012, Volume: 75, Issue:2

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Liver Cirrhosis; Male; Middle Aged; Receptor, Interferon alpha-beta; Recombinant Proteins; Ribavirin; RNA, Messenger

2012
Relationship between the genetic variation in interleukin 28B and response to antiviral therapy in patients with chronic hepatitis C.
    Chinese medical journal, 2012, Volume: 125, Issue:13

    Topics: Adult; Antiviral Agents; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Middle Aged; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Ribavirin

2012
Efficacy of pegylated interferon-alpha-2a plus ribavirin for patients aged at least 60 years with chronic hepatitis C.
    Chinese medical journal, 2012, Volume: 125, Issue:11

    Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Young Adult

2012
Successful antiviral therapy for hepatitis C virus-induced cirrhosis after an increase in the platelet count with romiplostim: two case reports.
    European journal of gastroenterology & hepatology, 2012, Volume: 24, Issue:12

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Middle Aged; Platelet Count; Receptors, Fc; Recombinant Fusion Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Thrombocytopenia; Thrombopoietin; Time Factors; Treatment Outcome

2012
Mutations in non-structural 5A and rapid viral response to pegylated interferon-α-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C.
    International journal of molecular medicine, 2012, Volume: 30, Issue:5

    Topics: Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Mutation; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Treatment Outcome; Viral Nonstructural Proteins

2012
A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy.
    The Journal of antimicrobial chemotherapy, 2012, Volume: 67, Issue:11

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Decision Support Techniques; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Liver Neoplasms; Prognosis; Ribavirin; Treatment Outcome

2012
Despite poor interferon response in advanced hepatitis C virus infection, models of protease inhibitor treatment predict maximum treatment benefit.
    Alimentary pharmacology & therapeutics, 2012, Volume: 36, Issue:7

    Topics: Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Models, Theoretical; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome

2012
Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:11

    Topics: Aged; Antiviral Agents; Cyclosporine; Disease Management; Drug Therapy, Combination; Everolimus; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Sirolimus; Tacrolimus; Viral Load

2012
Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.
    Acta biochimica Polonica, 2012, Volume: 59, Issue:3

    Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Genotype; Genotyping Techniques; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prognosis; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Young Adult

2012
Study of the effect of antiviral therapy on homocysteinemia in hepatitis C virus- infected patients.
    BMC gastroenterology, 2012, Aug-28, Volume: 12

    Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Cholesterol; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Homocysteine; Humans; Hyperhomocysteinemia; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Triglycerides; Young Adult

2012
IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin.
    Journal of medical virology, 2012, Volume: 84, Issue:10

    Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Interleukins; Male; Middle Aged; Pilot Projects; Polymorphism, Genetic; Prospective Studies; Ribavirin; Treatment Outcome; Viral Nonstructural Proteins

2012
Association of IL28B genotype and viral response of hepatitis C virus genotype 2 to interferon plus ribavirin combination therapy.
    Journal of medical virology, 2012, Volume: 84, Issue:10

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Japan; Male; Middle Aged; Ribavirin; Treatment Outcome; Young Adult

2012
HLA-B*15:02 is associated with anemia in patients with chronic hepatitis C treated with pegylated interferon-α and ribavirin.
    Tissue antigens, 2012, Volume: 80, Issue:5

    Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Histocompatibility Antigens Class I; Histocompatibility Antigens Class II; Histocompatibility Testing; HLA-B15 Antigen; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA

2012
New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye.
    Gut, 2012, Volume: 61, Issue:12

    Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Failure

2012
Utility of high-resolution accurate MS to eliminate interferences in the bioanalysis of ribavirin and its phosphate metabolites.
    Bioanalysis, 2012, Volume: 4, Issue:15

    Topics: Adenosine Monophosphate; Antiviral Agents; Chromatography, High Pressure Liquid; Chromatography, Ion Exchange; Glucuronosyltransferase; Hepatitis C, Chronic; Humans; Nucleotides; Ribavirin; Spectrometry, Mass, Electrospray Ionization; Uridine; Uridine Diphosphate; Uridine Monophosphate

2012
A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin.
    Antiviral therapy, 2012, Volume: 17, Issue:7

    Topics: Adult; Anti-Retroviral Agents; Cardiac Output; CD4 Lymphocyte Count; Coinfection; Familial Primary Pulmonary Hypertension; Female; Hemodynamics; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Hypertension, Portal; Hypertension, Pulmonary; Interferon-alpha; Liver; Liver Cirrhosis; Lung; Male; Middle Aged; Polyethylene Glycols; Prevalence; Prospective Studies; Ribavirin; Risk Factors; RNA, Viral; Severity of Illness Index; Treatment Outcome; Viremia

2012
A new tool to study ribavirin-induced haemolysis.
    Antiviral therapy, 2012, Volume: 17, Issue:7

    Topics: Adenosine Triphosphate; Adult; Anemia, Hemolytic; Dipyridamole; Drug Evaluation, Preclinical; Drug Therapy, Combination; Erythrocytes; Glutathione; Hematologic Tests; Hemolysis; Hepacivirus; Hepatitis C, Chronic; Humans; Inhibitory Concentration 50; Interferon alpha-2; Interferon-alpha; Poliovirus; Polyethylene Glycols; Prodrugs; Recombinant Proteins; Ribavirin; RNA, Viral

2012
Hepatitis B virus and hepatitis C virus co-infection: a therapeutic challenge.
    Clinics and research in hepatology and gastroenterology, 2013, Volume: 37, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin

2013
Restoration of innate and adaptive immune responses by HCV viral inhibition with an induction approach using natural interferon-beta in chronic hepatitis C.
    Clinical & developmental immunology, 2012, Volume: 2012

    Topics: Adaptive Immunity; Adult; Aged; Antiviral Agents; Chemokines; Cytokines; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Innate; Interferon-alpha; Interferon-beta; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2012
Anti-interferon-α neutralizing antibody is associated with nonresponse to pegylated interferon-α plus ribavirin in chronic hepatitis C.
    Journal of viral hepatitis, 2012, Volume: 19, Issue:10

    Topics: Adult; Aged; Antibodies, Neutralizing; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Neutralization Tests; Ribavirin; Treatment Outcome

2012
Variability of hepatitis C virus hypervariable region 1 (HVR-1) during the early phase of pegylated interferon and ribavirin therapy.
    Advances in medical sciences, 2012, Volume: 57, Issue:2

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single-Stranded Conformational; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Proteins

2012
[Long-term assessment of relapse and associated risk factors in chronic hepatitis C patients treated with interferon and ribavirin].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2012, Volume: 20, Issue:5

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult

2012
Incidence of hepatocellular carcinoma in HCV-infected patients with normal alanine aminotransferase levels categorized by Japanese treatment guidelines.
    Journal of gastroenterology, 2013, Volume: 48, Issue:4

    Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Clinical Enzyme Tests; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Japan; Liver Neoplasms; Male; Middle Aged; Patient Selection; Platelet Count; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Retrospective Studies; Ribavirin; Severity of Illness Index; Treatment Outcome

2013
Correlation between HCV viraemia and splenic volume in chronic HCV infected patients: an Egyptian study.
    Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology, 2012, Volume: 13, Issue:2

    Topics: Adult; Antiviral Agents; Chi-Square Distribution; Cross-Sectional Studies; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Organ Size; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Spleen; Statistics, Nonparametric; Ultrasonography; Viral Load; Viremia

2012
High serum palmitic acid is associated with low antiviral effects of interferon-based therapy for hepatitis C virus.
    Lipids, 2012, Volume: 47, Issue:11

    Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Middle Aged; Palmitic Acid; Polymorphism, Single Nucleotide; Ribavirin; Virus Replication; Young Adult

2012
[Changes of the serum adiponectin during treatment with peginterferon α-2a and ribavirin for chronic hepatitis C].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2012, Volume: 20, Issue:5

    Topics: Adiponectin; Adolescent; Adult; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Young Adult

2012
ACE inhibitors and ribavirin-associated cough: a common undefined predisposing factor?
    European journal of clinical pharmacology, 2013, Volume: 69, Issue:3

    Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Antiviral Agents; Cough; Drug Substitution; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Hypertension; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors

2013
Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2013, Volume: 57, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Incidence; Interferons; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Ribavirin; Risk Factors

2013
Alleles at rs4273729 in the chromosome 6 do not predict response to peg-interferon-α and ribavirin therapy in hepatitis C virus/HIV-1-coinfected patients.
    AIDS (London, England), 2012, Sep-24, Volume: 26, Issue:15

    Topics: Acquired Immunodeficiency Syndrome; Alleles; Anti-HIV Agents; Antiviral Agents; Chromosomes, Human, Pair 6; Coinfection; Female; Genotype; Hepatitis C, Chronic; HIV-1; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure

2012
NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients.
    Journal of clinical microbiology, 2012, Volume: 50, Issue:12

    Topics: Antiviral Agents; Egypt; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Molecular Sequence Data; Predictive Value of Tests; Prognosis; Ribavirin; Sequence Analysis, DNA; Treatment Outcome; Viral Nonstructural Proteins

2012
Infectious disease. Despite setbacks, optimism on drugs for hepatitis C.
    Science (New York, N.Y.), 2012, Sep-21, Volume: 337, Issue:6101

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Ribavirin

2012
IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C.
    World journal of gastroenterology, 2012, Sep-21, Volume: 18, Issue:35

    Topics: Adult; Antiviral Agents; Biopsy; Chi-Square Distribution; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Odds Ratio; Phenotype; Platelet Count; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Severity of Illness Index; Treatment Outcome; Viral Load

2012
SASLT practice guidelines: management of hepatitis C virus infection.
    Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association, 2012, Volume: 18 Suppl

    Topics: Antiviral Agents; Blood Transfusion; Drug Therapy, Combination; Evidence-Based Medicine; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Patient Care Team; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin; Risk Factors; Saudi Arabia

2012
Adverse effects of peg-Interferon and Ribavirin combined antiviral treatment in a Romanian hepatitis C virus infected cohort.
    Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie, 2012, Volume: 53, Issue:3

    Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Ribavirin; Romania; Treatment Outcome

2012
Treatment with Peg-IFNα2a/ribavirin and low-dose NSAID for patients with chronic hepatitis C and rheumatoid syndrome.
    European journal of gastroenterology & hepatology, 2013, Volume: 25, Issue:1

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Biomarkers; Case-Control Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Inflammation Mediators; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Rheumatic Diseases; Ribavirin; Time Factors; Treatment Outcome; Viral Load

2013
Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin.
    Viruses, 2012, Volume: 4, Issue:8

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Ribavirin; Treatment Outcome

2012
Vitamin D and the racial difference in the genotype 1 chronic hepatitis C treatment response.
    The American journal of clinical nutrition, 2012, Volume: 96, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Black or African American; Cross-Sectional Studies; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Vitamin D; Young Adult

2012
Polymorphisms in interleukin-10 and interleukin-28B genes in Egyptian patients with chronic hepatitis C virus genotype 4 and their effect on the response to pegylated interferon/ribavirin-therapy.
    Journal of gastroenterology and hepatology, 2012, Volume: 27, Issue:12

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Forecasting; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukin-10; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; ROC Curve; Treatment Outcome

2012
[Treatment of chronic hepatitis viral C: new associations].
    Presse medicale (Paris, France : 1983), 2013, Volume: 42, Issue:6 Pt 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin

2013
Longitudinal study of a human drug-induced model of autoantibody to cytoplasmic rods/rings following HCV therapy with ribavirin and interferon-α.
    PloS one, 2012, Volume: 7, Issue:9

    Topics: Antiviral Agents; Autoantibodies; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Ribavirin

2012
Single-nucleotide polymorphisms in GALNT8 are associated with the response to interferon therapy for chronic hepatitis C.
    The Journal of general virology, 2013, Volume: 94, Issue:Pt 1

    Topics: Alleles; Antiviral Agents; Asian People; Case-Control Studies; Chromosomes, Human, Pair 12; Female; Genotype; Hepatitis C, Chronic; Humans; Interferons; Introns; Male; Middle Aged; N-Acetylgalactosaminyltransferases; Polymorphism, Single Nucleotide; Polypeptide N-acetylgalactosaminyltransferase; Ribavirin; Transcription, Genetic; Treatment Outcome; Virus Replication

2013
Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program.
    Journal of substance abuse treatment, 2012, Volume: 43, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heroin Dependence; Humans; Interferon-alpha; Male; Medication Adherence; Methadone; Middle Aged; Opiate Substitution Treatment; Polyethylene Glycols; Psychotherapy, Group; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load

2012
Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection.
    Internal medicine (Tokyo, Japan), 2012, Volume: 51, Issue:19

    Topics: Antiviral Agents; Hepatitis C, Chronic; Hodgkin Disease; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Remission Induction; Ribavirin; Tomography, X-Ray Computed

2012
Occult hepatitis B infection in Portuguese patients with chronic hepatitis C liver disease: prevalence and clinical significance.
    European journal of gastroenterology & hepatology, 2013, Volume: 25, Issue:2

    Topics: Adult; Antiviral Agents; Biomarkers; Carrier State; Coinfection; DNA, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C, Chronic; Humans; Interferons; Liver; Male; Middle Aged; Portugal; Prospective Studies; Ribavirin; Viral Load

2013
Double filtration plasmapheresis could induce a favorable immune response for chronic hepatitis C therapy.
    Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2012, Volume: 16, Issue:5

    Topics: Antiviral Agents; Combined Modality Therapy; Drug Therapy, Combination; Filtration; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Plasmapheresis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2012
Pegylated interferon treatment in HCV genotype 2 and 3 patients refractory to conventional interferon.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2012, Volume: 22, Issue:10

    Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Pakistan; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2012
Mutations in different regions of the genome of hepatitis C virus genotype 1b and association with response to interferon therapy.
    International journal of molecular medicine, 2012, Volume: 30, Issue:6

    Topics: Adult; Amino Acid Sequence; Antiviral Agents; Drug Therapy, Combination; Female; Genetic Association Studies; Genetic Variation; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Viral Envelope Proteins; Viral Nonstructural Proteins; Young Adult

2012
A single nucleotide polymorphism in IL28B affects viral evolution of hepatitis C quasispecies after pegylated interferon and ribavirin therapy.
    Journal of medical virology, 2012, Volume: 84, Issue:12

    Topics: Adolescent; Adult; Aged; Amino Acid Substitution; Antiviral Agents; Black People; Drug Therapy, Combination; Evolution, Molecular; Female; Genome, Human; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Phylogeny; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Viral Load; Viral Nonstructural Proteins; White People; Young Adult

2012
Approach to the treatment-experienced patient with hepatitis C virus genotype 1 infection.
    Infectious disease clinics of North America, 2012, Volume: 26, Issue:4

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Recurrence; Ribavirin; RNA, Viral; Viral Load

2012
Combination effect of ribavirin and erythropoietin treatment on hemoglobin A1c in a diabetic patient with chronic hepatitis C.
    Journal of the Chinese Medical Association : JCMA, 2012, Volume: 75, Issue:10

    Topics: Diabetes Complications; Diabetes Mellitus, Type 2; Drug Synergism; Drug Therapy, Combination; Erythropoietin; Female; Glycated Hemoglobin; Hepatitis C, Chronic; Humans; Middle Aged; Ribavirin

2012
Optimum ribavirin exposure overcomes racial disparity in efficacy of peginterferon and ribavirin treatment for hepatitis C genotype 1.
    The American journal of gastroenterology, 2012, Volume: 107, Issue:11

    Topics: Antiviral Agents; Area Under Curve; Black or African American; Body Weight; Chi-Square Distribution; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome; White People

2012
A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C.
    Clinical and molecular hepatology, 2012, Volume: 18, Issue:3

    Topics: Antiviral Agents; Body Mass Index; Body Weight; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Sex Factors; Treatment Outcome

2012
Impact of ribavirin dose reduction during treatment in chronic hepatitis C genotype 1 patients.
    Clinical and molecular hepatology, 2012, Volume: 18, Issue:3

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2012
The kinetics of virological and biochemical responses in the treatment of chronic hepatitis C by dual antiviral therapy.
    Medical archives (Sarajevo, Bosnia and Herzegovina), 2012, Volume: 66, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Young Adult

2012
Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study.
    Journal of hepatology, 2013, Volume: 58, Issue:3

    Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin

2013
Treatment of chronic hepatitis C with pegylated interferon-α in a patient with recurrent autoimmune thrombotic thrombocytopenic purpura.
    Transfusion medicine (Oxford, England), 2013, Volume: 23, Issue:1

    Topics: ADAM Proteins; ADAMTS13 Protein; Antiviral Agents; Autoantibodies; Autoimmune Diseases; Biopsy; Female; Hepatitis C, Chronic; Hepatomegaly; Humans; Interferon-alpha; Middle Aged; Polyethylene Glycols; Purpura, Thrombotic Thrombocytopenic; Recombinant Proteins; Recurrence; Ribavirin; Splenomegaly; von Willebrand Factor

2013
Is combination therapy interferon and ribavirin in patients with chronic hepatitis C infection toxic for eyes?
    Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2013, Volume: 29, Issue:3

    Topics: Adult; Antiviral Agents; Diabetes Mellitus; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Hypertension; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retinal Diseases; Ribavirin; Risk Factors

2013
Chronic hepatitis C virus hepatitis and psoriasis: no longer a contraindication to interferon use in the era of biological agents?
    Scandinavian journal of infectious diseases, 2013, Volume: 45, Issue:4

    Topics: Antiviral Agents; Contraindications; Etanercept; Hepatitis C, Chronic; Humans; Immunoglobulin G; Interferon-alpha; Male; Middle Aged; Psoriasis; Receptors, Tumor Necrosis Factor; Ribavirin

2013
Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C.
    Alimentary pharmacology & therapeutics, 2013, Volume: 37, Issue:1

    Topics: Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2013
Insulin resistance predicts sustained virological response to treatment of chronic hepatitis C independently of the IL28b rs12979860 polymorphism.
    Alimentary pharmacology & therapeutics, 2013, Volume: 37, Issue:1

    Topics: Adult; Antiviral Agents; Blood Glucose; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Genotyping Techniques; Hepatitis C, Chronic; Humans; Insulin; Insulin Resistance; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Regression Analysis; Ribavirin; Treatment Outcome; Viral Load

2013
Candidiasis and other oral mucosal lesions during and after interferon therapy for HCV-related chronic liver diseases.
    BMC gastroenterology, 2012, Nov-02, Volume: 12

    Topics: Adult; Aged; Antiviral Agents; Candidiasis, Oral; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Lichen Planus, Oral; Male; Middle Aged; Polyethylene Glycols; Prevalence; Ribavirin; Salivary Glands; Serum Albumin; Steroids; Stomatitis; Treatment Outcome; Weight Loss

2012
Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients.
    AIDS (London, England), 2013, Jan-14, Volume: 27, Issue:2

    Topics: Adult; Alleles; Antiviral Agents; Coinfection; Cytokines; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; Viral Load

2013
Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene.
    Gut, 2013, Volume: 62, Issue:9

    Topics: Animals; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Cellular; Interferon-alpha; Interferons; Interleukins; Male; Mice; Mice, SCID; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2013
Genetic polymorphisms of ICAM 1 and IL28 as predictors of liver fibrosis severity and viral clearance in hepatitis C genotype 4.
    Clinics and research in hepatology and gastroenterology, 2013, Volume: 37, Issue:3

    Topics: Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Gene Frequency; Genetic Markers; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Intercellular Adhesion Molecule-1; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Severity of Illness Index

2013
The assessment of data mining for the prediction of therapeutic outcome in 3719 Egyptian patients with chronic hepatitis C.
    Clinics and research in hepatology and gastroenterology, 2013, Volume: 37, Issue:3

    Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; alpha-Fetoproteins; Antiviral Agents; Decision Trees; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Sex Factors

2013
Negative regulation of hepatitis C virus specific immunity is highly heterogeneous and modulated by pegylated interferon-alpha/ribavirin therapy.
    PloS one, 2012, Volume: 7, Issue:11

    Topics: Adult; Antiviral Agents; Cell Proliferation; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Cellular; Interferon-alpha; Interleukin-10; Male; Middle Aged; Ribavirin; RNA, Viral; T-Lymphocytes, Regulatory; Transforming Growth Factor beta; Virus Replication

2012
Effect of laparoscopic splenectomy in patients with Hepatitis C and cirrhosis carrying IL28B minor genotype.
    BMC gastroenterology, 2012, Nov-12, Volume: 12

    Topics: Antiviral Agents; Cytokines; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Laparoscopy; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Ribavirin; Severity of Illness Index; Spleen; Splenectomy; Treatment Outcome; Ubiquitins

2012
Interferon-induced central retinal vein thrombosis.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2012, Volume: 22, Issue:11

    Topics: Anticholesteremic Agents; Anticoagulants; Antiviral Agents; Dyslipidemias; Female; Hepatitis C, Chronic; Humans; Interferons; Middle Aged; Retinal Vein Occlusion; Ribavirin; Treatment Outcome; Visual Acuity

2012
A single nucleotide polymorphism, rs129679860, in the IL28B locus is associated with the viral kinetics and a sustained virological response in a chronic, monoinfected hepatitis C virus genotype-1 Brazilian population treated with pegylated interferon-rib
    Memorias do Instituto Oswaldo Cruz, 2012, Volume: 107, Issue:7

    Topics: Antiviral Agents; Brazil; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2012
Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: is it feasible?
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2013, Volume: 56, Issue:2

    Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Kidney Failure, Chronic; Male; Middle Aged; Oligopeptides; Renal Dialysis; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2013
Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: a multicenter study.
    Journal of medical virology, 2013, Volume: 85, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Predictive Value of Tests; Prognosis; Ribavirin; RNA, Viral; Sensitivity and Specificity; Time Factors; Treatment Outcome; Viral Load; Young Adult

2013
Sarcoidosis and chronic hepatitis C: a case report.
    World journal of gastroenterology, 2012, Oct-28, Volume: 18, Issue:40

    Topics: Adrenal Cortex Hormones; Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Diseases; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sarcoidosis; Sarcoidosis, Pulmonary; Time Factors; Tomography, X-Ray Computed; Treatment Outcome

2012
Cryoglobulinemia is an independent factor negatively associated with sustained virological response in chronic hepatitis C patients.
    Chinese medical journal, 2012, Volume: 125, Issue:22

    Topics: Adolescent; Adult; Aged; Cryoglobulinemia; Cryoglobulins; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Young Adult

2012
Futility rules for telaprevir combination treatment for patients with hepatitis C virus infection.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2013, Volume: 11, Issue:2

    Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Medical Futility; Oligopeptides; Retrospective Studies; Ribavirin; RNA, Viral; Viral Load

2013
Comparison of the efficacy of ribavirin plus peginterferon alfa-2b for chronic hepatitis C infection in patients with and without coagulation disorders.
    Journal of medical virology, 2013, Volume: 85, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Blood Coagulation Disorders; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult

2013
Add-on therapy of pitavastatin and eicosapentaenoic acid improves outcome of peginterferon plus ribavirin treatment for chronic hepatitis C.
    Journal of medical virology, 2013, Volume: 85, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Eicosapentaenoic Acid; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Quinolines; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2013
Intrahepatic mRNA levels of SOCS1 and SOCS3 are associated with cirrhosis but do not predict virological response to therapy in chronic hepatitis C.
    Liver international : official journal of the International Association for the Study of the Liver, 2013, Volume: 33, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Linear Models; Liver; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Nuclear Proteins; Odds Ratio; Retrospective Studies; Ribavirin; RNA, Messenger; Suppressor of Cytokine Signaling 1 Protein; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Treatment Outcome; Young Adult

2013
Recurrence of hepatitis C virus infection during pityriasis rosea.
    Acta dermato-venereologica, 2013, Jul-06, Volume: 93, Issue:4

    Topics: Adult; Antiviral Agents; Biopsy; DNA, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Herpesvirus 6, Human; Herpesvirus 7, Human; Humans; Interferon-alpha; Pityriasis Rosea; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Virus Activation

2013
Association of genetic variations in GNB1 with response to peginterferon plus ribavirin therapy for chronic hepatitis C in a Chinese population in Taiwan.
    BMC gastroenterology, 2012, Nov-22, Volume: 12

    Topics: Adult; Antiviral Agents; Asian People; Chi-Square Distribution; Confidence Intervals; Drug Therapy, Combination; Female; Gene Frequency; GTP-Binding Protein beta Subunits; Haplotypes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral; Taiwan; Treatment Outcome

2012
None of the six SNPs of IL28B could predict treatment responses in genotype 2 chronic HCV infected patients by propensity score matching analysis.
    PloS one, 2012, Volume: 7, Issue:11

    Topics: Data Interpretation, Statistical; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome

2012
Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia.
    Journal of gastroenterology and hepatology, 2013, Volume: 28, Issue:4

    Topics: Adult; Antiviral Agents; Australia; Cohort Studies; Cost-Benefit Analysis; Drug Therapy, Combination; Early Medical Intervention; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Markov Chains; Models, Statistical; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Substance Abuse, Intravenous; Victoria

2013
Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection.
    Journal of hepatology, 2013, Volume: 58, Issue:3

    Topics: Adult; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Vitamin D

2013
[Genetic variation of IL-28B is associated with treatment response of patients with chronic hepatitis C].
    Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology, 2012, Volume: 26, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome

2012
Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection.
    Journal of hepatology, 2013, Volume: 58, Issue:4

    Topics: Anemia; Antiviral Agents; Cohort Studies; Female; Genetic Association Studies; Hemoglobins; Hepatitis C, Chronic; Humans; Male; Membrane Transport Proteins; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Treatment Outcome

2013
Interferon-stimulated genes are associated with peginterferon/ribavirin treatment response regardless of IL28B alleles in hepatitis C virus/HIV-coinfected patients.
    AIDS (London, England), 2013, Mar-13, Volume: 27, Issue:5

    Topics: Adult; Alleles; Antiviral Agents; Cohort Studies; Coinfection; Drug Therapy, Combination; Female; Gene Expression Regulation; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Spain; Treatment Outcome; Viral Load

2013
Triple therapy with boceprevir or telaprevir for prior HCV non-responders.
    Best practice & research. Clinical gastroenterology, 2012, Volume: 26, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Proline; Protease Inhibitors; Recombinant Proteins; Recurrence; Retreatment; Ribavirin

2012
Allelic inhibition of displacement activity: a simplified one tube allele-specific PCR for evaluation of ITPA polymorphisms.
    Journal of virological methods, 2013, Volume: 187, Issue:2

    Topics: Alleles; Anemia, Hemolytic; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Polymerase Chain Reaction; Polymorphism, Genetic; Pyrophosphatases; Ribavirin; Sensitivity and Specificity

2013
Lower incidence of hepatocellular carcinoma in patients with transient virologic response to peginterferon and ribavirin combination therapy: is it really the effect of the therapy?
    Journal of hepatology, 2013, Volume: 58, Issue:4

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Neoplasms; Male; Polyethylene Glycols; Ribavirin

2013
Reply to: "Lower incidence of hepatocellular carcinoma in patients with transient virologic response to peginterferon and ribavirin combination therapy: is it really the effect of the therapy?".
    Journal of hepatology, 2013, Volume: 58, Issue:4

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Neoplasms; Male; Polyethylene Glycols; Ribavirin

2013
Diagnosis of inflammatory bowel disease in chronic hepatitis C patients treated with pegylated interferon and ribavirin: coincidence or consequence?
    Journal of Crohn's & colitis, 2013, Volume: 7, Issue:5

    Topics: Adult; Antiviral Agents; Colitis, Ulcerative; Crohn Disease; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Ribavirin

2013
[Triple therapy with direct acting antiviral agent, peginterferon and ribavirin for chronic hepatitis C].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2012, Volume: 109, Issue:12

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-beta; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2012
Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers.
    Transplant international : official journal of the European Society for Organ Transplantation, 2013, Volume: 26, Issue:3

    Topics: Antiviral Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Genotype; Graft Rejection; Graft Survival; Hepatitis C, Chronic; Humans; Interferon-alpha; Italy; Kaplan-Meier Estimate; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Regression Analysis; Retreatment; Retrospective Studies; Ribavirin; Risk Assessment; Survival Analysis; Treatment Outcome

2013
IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4.
    Journal of viral hepatitis, 2013, Volume: 20, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral; Syria; Treatment Outcome; Viral Load

2013
Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfected patients.
    AIDS (London, England), 2013, Jan-14, Volume: 27, Issue:2

    Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Risk Factors; Vitamin D; Vitamin D Deficiency

2013
A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients.
    The Journal of antimicrobial chemotherapy, 2013, Volume: 68, Issue:4

    Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Models, Statistical; Prognosis; Prospective Studies; Ribavirin; Treatment Outcome

2013
Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2013, Volume: 56, Issue:4

    Topics: Adult; Age Factors; Aged; Antiviral Agents; Aspartate Aminotransferases; Body Mass Index; Drug Therapy, Combination; Female; Genetic Testing; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Heterozygote; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sex Factors; Time Factors; Treatment Outcome

2013
Acoustic radiation force impulse imaging for evaluation of antiviral treatment response in chronic hepatitis C.
    Journal of gastrointestinal and liver diseases : JGLD, 2012, Volume: 21, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Treatment Outcome

2012
Retreatment with peginterferon α-2a + ribavirin in patients who failed previous peginterferon α-2b + ribavirin combination therapy.
    Digestive diseases (Basel, Switzerland), 2012, Volume: 30, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Chi-Square Distribution; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Statistics, Nonparametric; Time Factors; Treatment Failure

2012
[Lingual hyperpigmentation in a patient with chronic infection].
    Enfermedades infecciosas y microbiologia clinica, 2013, Volume: 31, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Hyperpigmentation; Interferons; Polyethylene Glycols; Pregnancy; Pregnancy Complications; Pregnancy Complications, Infectious; Ribavirin; Tongue Diseases

2013
From genetic association studies to the biology of interleukin-28B in hepatitis C virus infection and beyond.
    Gut, 2013, Volume: 62, Issue:9

    Topics: Animals; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2013
Assessment and utilization of rapid virologic response in US veterans with chronic hepatitis C: evaluating provider adherence to practice guidelines.
    Journal of clinical gastroenterology, 2013, Volume: 47, Issue:3

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Guideline Adherence; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Practice Guidelines as Topic; Practice Patterns, Physicians'; Recombinant Proteins; Retrospective Studies; Ribavirin; United States; United States Department of Veterans Affairs; Veterans

2013
The effectiveness of retreatment with peginterferon alfa and ribavirin in patients with chronic viral hepatitis C genotype 2 and 3: a prospective cohort study in Brazil.
    BMC infectious diseases, 2012, Dec-27, Volume: 12

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome

2012
Liver transplantation for HCV cirrhosis; cautious optimism after 10 years of experience.
    Annals of transplantation, 2012, Dec-31, Volume: 17, Issue:4

    Topics: Adult; Combined Modality Therapy; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Recurrence; Reoperation; Ribavirin; Survival Rate; Treatment Outcome

2012
Predictors of psychopathological outcome during peg-interferon and ribavirin therapy in patients with chronic HCV-correlated hepatitis.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2013, Volume: 33, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Interferons; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Prognosis; Psychopathology; Ribavirin; Surveys and Questionnaires; Treatment Outcome

2013
Hepatitis C virus load and expression of a unique subset of cellular genes in circulating lymphoid cells differentiate non-responders from responders to pegylated interferon alpha-ribavirin treatment.
    Journal of medical virology, 2013, Volume: 85, Issue:3

    Topics: 2',5'-Oligoadenylate Synthetase; Adolescent; Adult; Aged; Antiviral Agents; Child; Cytokines; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Lymphocytes; Male; Middle Aged; Prognosis; Ribavirin; RNA, Viral; Toll-Like Receptors; Treatment Outcome; Ubiquitins; Viral Load; Young Adult

2013
Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients.
    Alimentary pharmacology & therapeutics, 2013, Volume: 37, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Contraindications; Databases, Factual; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Infant; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; United States; Young Adult

2013
[The effects of individualized therapeutic programs on chronic hepatitis C and the influential factors of virological response].
    Zhonghua nei ke za zhi, 2012, Volume: 51, Issue:10

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Precision Medicine; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Young Adult

2012
Natural killer cell activity and function in chronic HCV-infected patients during peg interferon and ribavirin: early effects of active substance use.
    Antiviral research, 2013, Volume: 97, Issue:3

    Topics: Adult; Drug Users; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Killer Cells, Natural; Male; Middle Aged; Ribavirin; Substance-Related Disorders

2013
Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C.
    Journal of medical virology, 2013, Volume: 85, Issue:3

    Topics: Aged; Anemia; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Prognosis; Pyrophosphatases; Ribavirin; Treatment Failure

2013
Improvement of neurocognitive function in responders to an antiviral therapy for chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:2

    Topics: Adult; Antiviral Agents; Attention; Cognition; Cognition Disorders; Drug Therapy, Combination; Female; Follow-Up Studies; Germany; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Psychological Tests; Psychometrics; Recombinant Proteins; Reproducibility of Results; Ribavirin; Treatment Outcome

2013
Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices.
    Journal of viral hepatitis, 2013, Volume: 20, Issue:2

    Topics: Aged; Anemia, Hemolytic; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Esophageal and Gastric Varices; Female; Genetic Association Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Pyrophosphatases; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Treatment Outcome

2013
[Comparison of efficacy of peginterferon and ribavirin combination therapy for chronic hepatitis C among Korean, Caucasian and other Asians].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2012, Volume: 60, Issue:5

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2012
Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2013, Volume: 32, Issue:6

    Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2013
Pegylated interferon and ribavirin: A therapeutic option in patients who fail to respond to telaprevir-based triple therapy?
    Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:2

    Topics: Adult; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome

2013
A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis.
    Scientific reports, 2013, Volume: 3

    Topics: Antibodies; Antigens, Neoplasm; Antiviral Agents; Hepatitis C, Chronic; Humans; Immunoassay; Interferon-alpha; Lectins; Liver Cirrhosis; Membrane Glycoproteins; Polyethylene Glycols; Reagent Kits, Diagnostic; Recombinant Proteins; Ribavirin

2013
Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C.
    Clinical and molecular hepatology, 2012, Volume: 18, Issue:4

    Topics: Adult; Antiviral Agents; Asian People; Cohort Studies; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Republic of Korea; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome

2012
Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model.
    Applied health economics and health policy, 2013, Volume: 11, Issue:1

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Markov Chains; Middle Aged; Models, Economic; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; United Kingdom

2013
Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C.
    Alimentary pharmacology & therapeutics, 2013, Volume: 37, Issue:4

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2013
Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C - authors' reply.
    Alimentary pharmacology & therapeutics, 2013, Volume: 37, Issue:4

    Topics: Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2013
IL28B polymorphism and cytomegalovirus predict response to treatment in Egyptian HCV type 4 patients.
    World journal of gastroenterology, 2013, Jan-14, Volume: 19, Issue:2

    Topics: Adult; Alleles; Antiviral Agents; Case-Control Studies; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Predictive Value of Tests; Ribavirin; Treatment Outcome

2013
Clinical significance and functional studies of myeloid-derived suppressor cells in chronic hepatitis C patients.
    Journal of clinical immunology, 2013, Volume: 33, Issue:4

    Topics: Adult; Antiviral Agents; Arginase; Cell Count; Disease Progression; Female; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Interferon-alpha; Lymphocyte Activation; Male; Middle Aged; Myeloid Cells; Ribavirin; RNA, Viral; T-Lymphocytes; Young Adult

2013
Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal.
    Applied health economics and health policy, 2013, Volume: 11, Issue:1

    Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Markov Chains; Middle Aged; Polyethylene Glycols; Portugal; Proline; Recombinant Proteins; Ribavirin

2013
Human leukocyte antigen class I alleles can predict response to pegylated interferon/ribavirin therapy in chronic hepatitis C Egyptian patients.
    Archives of Iranian medicine, 2013, Volume: 16, Issue:2

    Topics: Adult; Alleles; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Genes, MHC Class I; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin; Treatment Outcome

2013
High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C.
    Journal of viral hepatitis, 2013, Volume: 20, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Biomarkers; Biopsy; CD36 Antigens; Enzyme-Linked Immunosorbent Assay; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Male; Middle Aged; Plasma; Ribavirin; Severity of Illness Index

2013
HCV RNA decline in chronic HCV genotype 2 and 3 during standard of care treatment according to IL28B polymorphism.
    Journal of viral hepatitis, 2013, Volume: 20, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Coinfection; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Genetic; Ribavirin; RNA, Viral; Standard of Care; Treatment Outcome; Viral Load; Young Adult

2013
[Association of interleukin 28B polymorphisms with response to pegylatedinterferon plus ribavirin therapy for chronic hepatitis C].
    Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2012, Volume: 43, Issue:6

    Topics: Adult; Antiviral Agents; Base Sequence; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Molecular Sequence Data; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA

2012
Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus.
    Journal of hepatology, 2013, Volume: 58, Issue:6

    Topics: Adult; Alanine Transaminase; Cohort Studies; Coinfection; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver; Male; Proportional Hazards Models; Ribavirin

2013
Efficacy of interferon-based antiviral therapy on the risk of hepatocellular carcinoma of patients with chronic hepatitis C: further evidence in decompensation cirrhosis.
    Journal of hepatology, 2013, Volume: 58, Issue:6

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Neoplasms; Male; Polyethylene Glycols; Ribavirin

2013
[What is expected from the novel triple combination antiviral treatment of patients infected with hepatitis C virus genotype 1?].
    Orvosi hetilap, 2013, Feb-17, Volume: 154, Issue:7

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hungary; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Recurrence; Retreatment; Retrospective Studies; Ribavirin; Treatment Outcome; Waiting Lists

2013
Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
    European journal of gastroenterology & hepatology, 2013, Volume: 25, Issue:7

    Topics: Adult; Antiviral Agents; Aspartate Aminotransferases; Biomarkers; Carcinoma, Hepatocellular; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Female; Greece; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2013
Osteopontin gene polymorphisms as predictors for the efficacy of interferon therapy in chronic hepatitis C Egyptian patients with genotype 4.
    Cell biochemistry and function, 2013, Volume: 31, Issue:7

    Topics: Adult; Antiviral Agents; Case-Control Studies; Egypt; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Osteopontin; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin

2013
Fatal lactic acidosis in a HIV-positive patient treated with interferon and ribavirin for chronic hepatitis C.
    Journal of hepatology, 2002, Volume: 37, Issue:2

    Topics: Acidosis, Lactic; Adult; Antiviral Agents; Fatal Outcome; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Ribavirin

2002
[Pegylated interferon sets a new standard. Better prognosis for hepatitis C infected patients].
    MMW Fortschritte der Medizin, 2002, May-23, Volume: 144, Issue:21

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2002
Role of cytokines in the assessment of the severity of chronic hepatitis C and the prediction of response to therapy.
    Romanian journal of gastroenterology, 2002, Volume: 11, Issue:2

    Topics: Antineoplastic Agents; Antiviral Agents; Enzyme-Linked Immunosorbent Assay; Forecasting; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Predictive Value of Tests; Ribavirin; Severity of Illness Index; Tumor Necrosis Factor-alpha

2002
Manifestation of sarcoidosis during interferon and ribavirin therapy for chronic hepatitis C: a report of two cases.
    European journal of gastroenterology & hepatology, 2002, Volume: 14, Issue:8

    Topics: Biopsy, Needle; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Risk Assessment; Sarcoidosis; Skin Diseases

2002
Effect of induction therapy on Hepatitis C.
    Saudi medical journal, 2002, Volume: 23, Issue:7

    Topics: Adult; Antiviral Agents; Case-Control Studies; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin

2002
Non-transferrin-bound iron in untreated and ribavirin-treated chronic hepatitis C patients.
    Alimentary pharmacology & therapeutics, 2002, Volume: 16, Issue:8

    Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Hemochromatosis Protein; Hepatitis C, Chronic; Hepatocytes; Histocompatibility Antigens Class I; Humans; Interferon-alpha; Iron; Male; Membrane Proteins; Middle Aged; Mutation, Missense; Ribavirin; Transferrin

2002
Difficulties in conducting large-scale studies on rare diseases: the case for pediatric hepatitis C infection.
    Journal of pediatric gastroenterology and nutrition, 2002, Volume: 35, Issue:2

    Topics: Antiviral Agents; Child; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Sample Size; Treatment Outcome

2002
Urticarial vasculitis with asymptomatic chronic hepatitis C infection: response to doxepin, interferon-alfa, and ribavirin.
    Journal of clinical gastroenterology, 2002, Volume: 35, Issue:3

    Topics: Adolescent; Antiviral Agents; Doxepin; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Histamine Antagonists; Humans; Interferon-alpha; Ribavirin; Urticaria; Vasculitis

2002
Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C.
    Alimentary pharmacology & therapeutics, 2002, Volume: 16, Issue:9

    Topics: Adult; Analysis of Variance; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Ribavirin; Risk Factors

2002
Intrahepatic MxA and PKR protein expression in chronic hepatitis C virus infection.
    Journal of medical virology, 2002, Volume: 68, Issue:2

    Topics: Adult; Antiviral Agents; Case-Control Studies; Cohort Studies; eIF-2 Kinase; GTP-Binding Proteins; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Liver; Liver Diseases; Myxovirus Resistance Proteins; Proteins; Recombinant Proteins; Ribavirin

2002
Dynamics of HCV replication in patients with chronic hepatitis C during interferon and ribavirin combined therapy.
    Medical science monitor : international medical journal of experimental and clinical research, 2001, Volume: 7 Suppl 1

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Polymerase Chain Reaction; Ribavirin; Time Factors; Virus Replication

2001
[Chronic hepatitis C virus infection: always treat!--Pro].
    Deutsche medizinische Wochenschrift (1946), 2002, Sep-06, Volume: 127, Issue:36

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Ribavirin

2002
[Chronic hepatitis C virus infection: always treat!--Contra].
    Deutsche medizinische Wochenschrift (1946), 2002, Sep-06, Volume: 127, Issue:36

    Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Contraindications; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Prognosis; Ribavirin

2002
Interstitial pneumonitis during combination therapy with interferon-alpha and ribavirin in a patient with chronic Hepatitis C.
    Zeitschrift fur Gastroenterologie, 2002, Volume: 40, Issue:9

    Topics: Antiviral Agents; Blood Sedimentation; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lung Diseases, Interstitial; Middle Aged; Recombinant Proteins; Ribavirin; Tomography, X-Ray Computed

2002
Role of ribavirin in membranoproliferative glomerulonephritis associated with hepatitis C virus infection refractory to alpha-interferon.
    Nephron, 2002, Volume: 92, Issue:2

    Topics: Antiviral Agents; Cyclophosphamide; Drug Resistance; Female; Glomerulonephritis, Membranoproliferative; Hepatitis C, Chronic; Humans; Interferon Type I; Middle Aged; Nephrotic Syndrome; Recombinant Proteins; Ribavirin

2002
A case study in hepatitis C disease progression: reaching out while searching for new clues.
    American clinical laboratory, 2002, Volume: 21, Issue:6

    Topics: Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thyroid Gland

2002
Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C.
    Journal of viral hepatitis, 2002, Volume: 9, Issue:5

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Remission Induction; Ribavirin; Treatment Outcome; Viral Load

2002
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.
    Gastroenterology, 2002, Volume: 123, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome

2002
I favor therapy for hepatitis C virus recurrence after transplantation.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2002, Volume: 8, Issue:10 Suppl 1

    Topics: Acute Disease; Antiviral Agents; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Postoperative Complications; Recurrence; Ribavirin; RNA, Viral

2002
Is the IFN-alpha-related thyroid autoimmunity an immunologically heterogeneous disease?
    Journal of internal medicine, 2002, Volume: 252, Issue:4

    Topics: Antiviral Agents; Autoimmune Diseases; Autoimmunity; Drug Therapy, Combination; Genetic Predisposition to Disease; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Thyroid Diseases; Thyroid Gland

2002
Pilot study of interferon alpha high-dose induction therapy in combination with ribavirin for chronic hepatitis C in HIV-co-infected patients.
    AIDS (London, England), 2002, Oct-18, Volume: 16, Issue:15

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Pilot Projects; Ribavirin; Treatment Outcome

2002
Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models.
    Clinical pharmacology and therapeutics, 2002, Volume: 72, Issue:4

    Topics: Adult; Aged; Confidence Intervals; Dose-Response Relationship, Drug; Female; Hepatitis C, Chronic; Humans; Logistic Models; Male; Models, Biological; Ribavirin

2002
Weight loss in HIV-infected patients.
    The New England journal of medicine, 2002, Oct-17, Volume: 347, Issue:16

    Topics: Adult; Anti-HIV Agents; Antiviral Agents; Dideoxynucleosides; Drug Synergism; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Mitochondria; Ribavirin; Weight Loss

2002
Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome.
    Hepatology (Baltimore, Md.), 2002, Volume: 36, Issue:5

    Topics: Adult; Antiviral Agents; Asia, Southeastern; Asian People; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Core Proteins

2002
Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2002, Volume: 36, Issue:5

    Topics: Adult; Antiviral Agents; Black People; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Infections; Interferon-alpha; Leukocyte Count; Male; Middle Aged; Neutropenia; Neutrophils; Prevalence; Retrospective Studies; Ribavirin; United States; White People

2002
Porphyria cutanea tarda during interferon/ribavirin therapy for chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2002, Volume: 36, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Middle Aged; Porphyria Cutanea Tarda; Ribavirin

2002
[Pegylated interferon alfa-2a. Improved prognosis in hepatitis C].
    MMW Fortschritte der Medizin, 2002, Sep-19, Volume: 144, Issue:38

    Topics: Antiviral Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2002
Alopecia areata during interferon alpha-2b/ribavirin therapy.
    Dermatology (Basel, Switzerland), 2002, Volume: 205, Issue:3

    Topics: Alopecia Areata; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Ribavirin

2002
C-C chemokine receptor 2 and C-C chemokine receptor 5 genotypes in patients treated for chronic hepatitis C virus infection.
    Immunologic research, 2002, Volume: 26, Issue:1-3

    Topics: Adult; Aged; Antiviral Agents; Female; Genetic Variation; Genotype; Haplotypes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Promoter Regions, Genetic; Receptors, CCR2; Receptors, CCR5; Receptors, Chemokine; Recombinant Proteins; Ribavirin; RNA, Viral; Viremia

2002
Is delayed normalization of alanine aminotransferase a poor prognostic predictor in chronic hepatitis C patients treated with a combined interferon and ribavirin therapy?
    Journal of gastroenterology and hepatology, 2002, Volume: 17, Issue:12

    Topics: Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prognosis; Recombinant Proteins; Ribavirin; Time Factors

2002
Interferon alpha and ribavirin for membranoproliferative glomerulonephritis and hepatitis C infection.
    The American journal of medicine, 2002, Oct-15, Volume: 113, Issue:6

    Topics: Adult; Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Female; Glomerulonephritis, Membranoproliferative; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Ribavirin

2002
Ribavirin inhibits DNA, RNA, and protein synthesis in PHA-stimulated human peripheral blood mononuclear cells: possible explanation for therapeutic efficacy in patients with chronic HCV infection.
    Journal of medical virology, 2003, Volume: 69, Issue:1

    Topics: Antimetabolites; Antiviral Agents; Apoptosis; Cell Division; Cells, Cultured; Cytokines; DNA; Hepacivirus; Hepatitis C, Chronic; Humans; Leukocytes, Mononuclear; Phytohemagglutinins; Protein Biosynthesis; Proteins; Ribavirin; RNA; RNA, Viral

2003
Treatment of chronic hepatitis C virus infection with interferon alfa and ribavirin: sustained response in two patients with transfusion dependent thalassaemia.
    The Medical journal of Malaysia, 2002, Volume: 57, Issue:3

    Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Ribavirin; Thalassemia; Time Factors

2002
Diffuse inflammatory lesions in patients treated with interferon alfa and ribavirin for hepatitis C: a series of 20 patients.
    The British journal of dermatology, 2002, Volume: 147, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Ribavirin

2002
[What therapy is meaningful in chronic hepatitis C and resection of hepatocellular carcinoma for recurrence prophylaxis?].
    Deutsche medizinische Wochenschrift (1946), 2002, Nov-29, Volume: 127, Issue:48

    Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Recurrence; Ribavirin

2002
Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
    Arthritis and rheumatism, 2002, Volume: 46, Issue:12

    Topics: Adult; Aged; Antiviral Agents; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Vasculitis; Viremia

2002
Normalization of markedly elevated alpha-fetoprotein in a virologic nonresponder with HCV-related cirrhosis.
    Digestive diseases and sciences, 2002, Volume: 47, Issue:12

    Topics: Alanine Transaminase; alpha-Fetoproteins; Antiviral Agents; Aspartate Aminotransferases; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Failure

2002
Ribavirin quantification in combination treatment of chronic hepatitis C.
    Antimicrobial agents and chemotherapy, 2003, Volume: 47, Issue:1

    Topics: Adult; Aged; Biological Availability; Chromatography, High Pressure Liquid; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Ribavirin; Treatment Outcome

2003
Regression of splenic lymphoma after treatment of hepatitis C virus infection.
    The New England journal of medicine, 2002, Dec-26, Volume: 347, Issue:26

    Topics: Antiviral Agents; Cryoglobulinemia; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Lymphoma, B-Cell; Ribavirin; RNA, Viral; Splenic Neoplasms

2002
Listeria monocytogenes meningitis in a patient with chronic hepatitis C infection, treated by interferon alfa and ribavirin.
    The Journal of infection, 2003, Volume: 46, Issue:1

    Topics: Adult; Anti-Bacterial Agents; Antiviral Agents; Disease Susceptibility; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Listeria monocytogenes; Listeriosis; Meningitis; Ribavirin

2003
Successfull response to alpha 2b interferon plus ribavirin associated with venesectomies in a patient with chronic hepatitis C and genetic hemochromatosis.
    Journal of gastroenterology and hepatology, 2003, Volume: 18, Issue:1

    Topics: Antiviral Agents; Hemochromatosis; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Phlebotomy; Recombinant Proteins; Ribavirin

2003
[Prospective study of combination of interferon-alpha with ribavirin for treatment of chronic hepatitis C in children].
    Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology, 2001, Volume: 15, Issue:1

    Topics: Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Infant; Interferon alpha-2; Interferon-alpha; Male; Prospective Studies; Recombinant Proteins; Ribavirin

2001
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C.
    The New England journal of medicine, 2003, Jan-16, Volume: 348, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2003
Treatment for chronic hepatitis C.
    Current gastroenterology reports, 2003, Volume: 5, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2003
[Pegylated interferon alpha-2a. Quality of life improves significantly during successful therapy].
    MMW Fortschritte der Medizin, 2002, Nov-28, Volume: 144, Issue:48

    Topics: Administration, Oral; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Patient Compliance; Quality of Life; Recombinant Proteins; Ribavirin; Time Factors

2002
[Chronic hepatitis C. A new chance with Consensus Interferon for patients with handicaps].
    MMW Fortschritte der Medizin, 2002, Nov-07, Volume: 144, Issue:45

    Topics: Antiviral Agents; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Meta-Analysis as Topic; Multicenter Studies as Topic; Prognosis; Randomized Controlled Trials as Topic; Ribavirin; Risk Factors; Time Factors; Viral Load

2002
Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.
    Hepatology (Baltimore, Md.), 2003, Volume: 37, Issue:2

    Topics: Adult; Alcohol Drinking; Antidepressive Agents; Antiviral Agents; Depression; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Medical Records; Mental Disorders; Methadone; Middle Aged; Patient Compliance; Patient Dropouts; Prospective Studies; Ribavirin; Risk Factors; Substance-Related Disorders

2003
SEN virus infection in patients with chronic hepatitis C: preferential coinfection with hepatitis C genotype 2a and no effect on response to therapy with interferon plus ribavirin.
    The Journal of infectious diseases, 2003, Jan-15, Volume: 187, Issue:2

    Topics: Adult; Antiviral Agents; DNA Viruses; DNA, Single-Stranded; DNA, Viral; Female; Genes, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Virus Diseases

2003
Treatment of chronic hepatitis C in a state correctional facility.
    Annals of internal medicine, 2003, Feb-04, Volume: 138, Issue:3

    Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Patient Compliance; Prisons; Retrospective Studies; Rhode Island; Ribavirin; RNA, Viral; Treatment Outcome

2003
Summaries for patients. Treatment for hepatitis C virus infection among inmates.
    Annals of internal medicine, 2003, Feb-04, Volume: 138, Issue:3

    Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Patient Compliance; Prisons; Retrospective Studies; Rhode Island; Ribavirin; RNA, Viral; Treatment Outcome

2003
Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection.
    Journal of viral hepatitis, 2003, Volume: 10, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2003
Assessment of depression in patients with chronic hepatitis: effect of interferon treatment.
    Digestive diseases (Basel, Switzerland), 2002, Volume: 20, Issue:3-4

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Depression; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; Surveys and Questionnaires

2002
Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin.
    Ophthalmology, 2003, Volume: 110, Issue:2

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Fluorescein Angiography; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Retina; Retinal Diseases; Ribavirin; Vision Disorders; Visual Fields

2003
Characteristics of and current treatment options for hepatitis B and hepatitis C.
    Journal (Canadian Dental Association), 2000, Volume: 66, Issue:10

    Topics: Adult; Antiviral Agents; Drug Combinations; Hepatitis B; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Lamivudine; Reverse Transcriptase Inhibitors; Ribavirin

2000
[ROC curve analysis of factors predictive of response to treatment with interferon plus ribavirin in patients with chronic hepatitis C relapse after previous interferon treatment].
    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2002, Volume: 15, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Predictive Value of Tests; Recurrence; Ribavirin; ROC Curve

2002
Erythematous maculopapular eruption due to ribavirin administration in a patient with chronic hepatitis C.
    Journal of clinical gastroenterology, 2003, Volume: 36, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon Type I; Interferon-alpha; Male; Middle Aged; Parapsoriasis; Recombinant Proteins; Ribavirin

2003
Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy.
    Hepatology (Baltimore, Md.), 2003, Volume: 37, Issue:3

    Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Female; gamma-Glutamyltransferase; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Regression Analysis; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2003
Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2003, Volume: 37, Issue:3

    Topics: Aged; Antiviral Agents; Gene Expression Profiling; Gene Expression Regulation; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Leukocytes, Mononuclear; Middle Aged; Oligonucleotide Array Sequence Analysis; Recombinant Proteins; Ribavirin; RNA, Messenger

2003
Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin.
    Journal of viral hepatitis, 2003, Volume: 10, Issue:2

    Topics: Amino Acid Sequence; Antiviral Agents; Base Sequence; Drug Therapy, Combination; Eukaryotic Initiation Factor-2; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Point Mutation; Recombinant Proteins; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Sequence Alignment; Viral Envelope Proteins; Viral Nonstructural Proteins

2003
The impact of prior hepatitis B virus infection on liver histology and the response to interferon therapy in chronic hepatitis C.
    Journal of viral hepatitis, 2003, Volume: 10, Issue:2

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis B Antibodies; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Ribavirin; RNA, Viral

2003
Effectiveness of interferon alfa-2b/ribavirin combination therapy for chronic hepatitis C in a clinic setting.
    The Medical journal of Australia, 2003, Mar-17, Volume: 178, Issue:6

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome

2003
[Only 1 injection per week brings a 60% chance of healing. New therapy recommendations in chronic hepatitis C].
    MMW Fortschritte der Medizin, 2003, Jan-16, Volume: 145, Issue:1-2

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load

2003
Cost-effectiveness analysis of therapeutic strategies for patients with chronic hepatitis C previously not responding to interferon.
    Alimentary pharmacology & therapeutics, 2003, Mar-15, Volume: 17, Issue:6

    Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Decision Support Systems, Clinical; Drug Combinations; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Quality of Life; Ribavirin; Sensitivity and Specificity

2003
A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C.
    Alimentary pharmacology & therapeutics, 2003, Mar-01, Volume: 17, Issue:5

    Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Treatment Outcome

2003
Hemoglobinuria with ribavirin treatment.
    Journal of clinical gastroenterology, 2003, Volume: 36, Issue:4

    Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Hemoglobinuria; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Maximum Tolerated Dose; Middle Aged; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index

2003
Effect of ribavirin and amantadine on early hepatitis C virus RNA rebound and clearance in serum during daily high-dose interferon.
    Digestive diseases and sciences, 2003, Volume: 48, Issue:1

    Topics: Adult; Alanine Transaminase; Amantadine; Antiviral Agents; Drug Administration Schedule; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Viral Load

2003
[Anterior uveitis in a patient treated with pegylated interferon and ribavirin].
    Medicina clinica, 2003, Mar-15, Volume: 120, Issue:9

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Uveitis

2003
[Clinical response to etiotropic therapy of chronic viral hepatitis C].
    Klinicheskaia meditsina, 2003, Volume: 81, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2003
Mannan-binding lectin and hepatitis C infection.
    Clinical and experimental immunology, 2003, Volume: 132, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Case-Control Studies; Disease Progression; Disease Susceptibility; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Mannose-Binding Lectin; Middle Aged; Ribavirin

2003
Sustained response to combination therapy in patients with chronic hepatitis C who failed to respond to interferon.
    Journal of hepatology, 2003, Volume: 38, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin

2003
[Use of peg-intron in combined treatment of chronic liver disease caused by HIV infection].
    Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, 2003, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load

2003
Immunological predictors of different responses to combination therapy with interferon alpha and ribavirin in patients with chronic hepatitis C.
    Journal of gastroenterology, 2003, Volume: 38, Issue:3

    Topics: Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Drug Therapy, Combination; Female; Flow Cytometry; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Ribavirin

2003
Concomitant augmentation of type 1 CD4+ and CD8+ T-cell responses during successful interferon-alpha and ribavirin treatment for chronic hepatitis C virus infection.
    Human immunology, 2003, Volume: 64, Issue:5

    Topics: Antiviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Epitopes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Ribavirin; Time Factors; Treatment Outcome; Viral Load

2003
Combination therapy with interferon-alpha and ribavirin as immunomodulators in patients with chronic hepatitis C.
    Journal of gastroenterology, 2003, Volume: 38, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Th1 Cells

2003
Upregulation of endogenous intrahepatic interferon stimulated genes during chronic hepatitis C virus infection.
    Journal of medical virology, 2003, Volume: 70, Issue:2

    Topics: 2',5'-Oligoadenylate Synthetase; Adult; Cytokines; Drug Therapy, Combination; eIF-2 Kinase; Female; GTP-Binding Proteins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukin-8; Liver; Liver Diseases; Male; Myxovirus Resistance Proteins; Proteins; Recombinant Proteins; Ribavirin; RNA, Messenger; Ubiquitins; Up-Regulation

2003
Normal erythropoietin response in chronic hepatitis C patients with ribavirin-induced anaemia.
    Antiviral therapy, 2003, Volume: 8, Issue:1

    Topics: Adult; Aged; Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Biological; Recombinant Proteins; Ribavirin

2003
Paternal exposure to ribavirin: pregnancy and neonatal outcome.
    Antiviral therapy, 2003, Volume: 8, Issue:1

    Topics: Abnormalities, Drug-Induced; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Fetus; Hepatitis C, Chronic; Humans; Infant, Newborn; Interferons; Male; Paternal Exposure; Pregnancy; Pregnancy Outcome; Ribavirin

2003
[Antiviral treatment in liver cirrhosis due to hepatitis C virus].
    Gastroenterologia y hepatologia, 2003, Volume: 26, Issue:5

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Liver Transplantation; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Waiting Lists

2003
A pilot study of eicosapentaenoic acid therapy for ribavirin-related anemia in patients with chronic hepatitis C.
    International journal of molecular medicine, 2003, Volume: 11, Issue:6

    Topics: Adult; Anemia; Antiviral Agents; Eicosapentaenoic Acid; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Reticulocyte Count; Ribavirin

2003
[Chronic viral hepatitis].
    Vestnik Rossiiskoi akademii meditsinskikh nauk, 2003, Issue:4

    Topics: Adult; Age Factors; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Clinical Enzyme Tests; Diagnosis, Differential; Drug Therapy, Combination; Female; Glucocorticoids; Hepatitis B e Antigens; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Prognosis; Retrospective Studies; Ribavirin; Risk Factors; Sex Factors; Time Factors

2003
Nonresponse to interferon monotherapy in HCV-related chronic hepatitis: results of retreatment and prognostic factors.
    Digestive diseases and sciences, 2003, Volume: 48, Issue:4

    Topics: Adult; Antiviral Agents; Biopsy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Intercellular Adhesion Molecule-1; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2003
[Hepatitis C and tricholeukocyte leukemia: a fortuitous association? A case report].
    Annales de medecine interne, 2003, Volume: 154, Issue:2

    Topics: Adult; Antineoplastic Agents; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukemia, Hairy Cell; Male; Ribavirin

2003
Male periconceptional ribavir-ininterferon alpha-2b exposure with no adverse fetal effects.
    Birth defects research. Part A, Clinical and molecular teratology, 2003, Volume: 67, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Paternal Exposure; Pregnancy; Pregnancy Outcome; Recombinant Proteins; Ribavirin

2003
High sustained virological response in chronic hepatitis C by combining induction and prolonged maintenance therapy.
    Journal of viral hepatitis, 2003, Volume: 10, Issue:3

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2003
An heteroduplex mobility analysis assay based on capillary electrophoresis for the study of HCV quasispecies.
    Journal of virological methods, 2003, Jun-09, Volume: 110, Issue:1

    Topics: Adult; Amino Acid Sequence; Antiviral Agents; Base Sequence; Electrophoresis, Capillary; Female; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Heteroduplex Analysis; Humans; Interferons; Liver Transplantation; Male; Middle Aged; Molecular Sequence Data; Ribavirin; Sensitivity and Specificity; Sequence Analysis, DNA; Viral Proteins

2003
[Similar poor response in genotype 4 chronic Hepatitis C treatment with interferon and ribavirin compared with genotype 1 treatment].
    Revista espanola de enfermedades digestivas, 2003, Volume: 95, Issue:3

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Outcome

2003
Severe migraine headaches are caused by ribavirin but not by interferon alpha-2B in combination therapy for chronic hepatitis C.
    Journal of hepatology, 2003, Volume: 38, Issue:6

    Topics: Adult; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Migraine Disorders; Recombinant Proteins; Ribavirin; Severity of Illness Index

2003
[Treatment of chronic hepatitis C with PEG-interferon alpha-2b and ribavirin: 24 weeks of therapy are sufficient for HCV genotype 2 and 3].
    Zeitschrift fur Gastroenterologie, 2003, Volume: 41, Issue:6

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multicenter Studies as Topic; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors

2003
Weight-based ribavirin with pegylated interferon alfa 2b: benefits, risks, and the origin of the evidence.
    Gastroenterology, 2003, Volume: 124, Issue:7

    Topics: Adult; Antiviral Agents; Body Weight; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2003
Interleukin-2 has no additional therapeutic efficacy in the retreatment of patients with chronic hepatitis C that had not responded to interferon-alpha plus ribavirin.
    European journal of clinical investigation, 2003, Volume: 33, Issue:7

    Topics: Analgesics, Non-Narcotic; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interleukin-2; Retreatment; Ribavirin; Treatment Outcome

2003
Effect of antiviral therapy on markers of fibrogenesis in patients with chronic hepatitis C.
    Scandinavian journal of gastroenterology, 2003, Volume: 38, Issue:6

    Topics: Adipokines; Adult; Antiviral Agents; Biomarkers; Chitinase-3-Like Protein 1; Female; Glycoproteins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Lectins; Liver Cirrhosis; Male; Matrix Metalloproteinase 2; Middle Aged; Peptide Fragments; Predictive Value of Tests; Procollagen; Ribavirin; RNA, Viral; Severity of Illness Index; Tissue Inhibitor of Metalloproteinase-1; Treatment Outcome

2003
Mortality rate during interferon alfa-ribavirin combination therapy of chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2003, Volume: 38, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin

2003
Management of hepatitis C.
    Minnesota medicine, 2003, Volume: 86, Issue:6

    Topics: Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Minnesota; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2003
Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and amplicor monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy.
    Journal of clinical microbiology, 2003, Volume: 41, Issue:7

    Topics: Antiviral Agents; Branched DNA Signal Amplification Assay; Drug Therapy, Combination; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Immunoenzyme Techniques; Interferons; Reagent Kits, Diagnostic; Reproducibility of Results; Ribavirin; RNA, Viral; Sensitivity and Specificity; Viral Core Proteins; Viral Load; Viremia

2003
Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
    JAMA, 2003, Jul-09, Volume: 290, Issue:2

    Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Costs; Female; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Life Expectancy; Liver Cirrhosis; Male; Markov Chains; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; United States

2003
Correlation of sICAM-1 and sVCAM-1 level with biochemical, histological and viral findings in chronic hepatitis C after interferon-alpha + ribavirin therapy.
    Romanian journal of gastroenterology, 2003, Volume: 12, Issue:2

    Topics: Adult; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C, Chronic; Humans; Intercellular Adhesion Molecule-1; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Ribavirin; Treatment Outcome; Vascular Cell Adhesion Molecule-1

2003
The Delta 32 mutation of the chemokine-receptor 5 gene neither is correlated with chronic hepatitis C nor does it predict response to therapy with interferon-alpha and ribavirin.
    Clinical immunology (Orlando, Fla.), 2003, Volume: 108, Issue:1

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Mutation; Receptors, CCR5; Ribavirin

2003
[Place of consensus type interferon alpha in the management of chronic type C hepatitis].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2003, Volume: 14, Issue:82

    Topics: Antiviral Agents; Consensus; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin

2003
HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C.
    The American journal of gastroenterology, 2003, Volume: 98, Issue:7

    Topics: Adult; Aging; Alleles; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Histocompatibility Antigens Class II; HLA-B Antigens; HLA-B44 Antigen; Humans; Interferons; Middle Aged; Multivariate Analysis; Ribavirin; Treatment Outcome; Tumor Necrosis Factor-alpha

2003
Effects of the CCR5-Delta32 mutation on antiviral treatment in chronic hepatitis C.
    Journal of hepatology, 2003, Volume: 39, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Multivariate Analysis; Point Mutation; Receptors, CCR5; Ribavirin

2003
Reversal of cirrhosis: evidence-based medicine?
    Gastroenterology, 2003, Volume: 125, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Evidence-Based Medicine; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2003
Hepatitis C infections. From diagnosis to treatment.
    Saudi medical journal, 2003, Volume: 24 Suppl 2

    Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Practice Guidelines as Topic; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Saudi Arabia; Severity of Illness Index; Treatment Outcome

2003
Hematologic disorders associated with hepatitis C virus infection and their management.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003, Aug-15, Volume: 37, Issue:4

    Topics: Antiviral Agents; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukin-11; Recombinant Proteins; Ribavirin; United States

2003
Response of interferon alone and with ribavirin in patients of chronic hepatitis C.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2003, Volume: 13, Issue:8

    Topics: Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Prospective Studies; Ribavirin

2003
Hyperlipasemia associated with hepatitis C virus.
    Digestive diseases and sciences, 2003, Volume: 48, Issue:8

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Lipase; Liver Function Tests; Male; Middle Aged; Pancreatitis; Retrospective Studies; Ribavirin; Viral Load

2003
Hepatitis C: a review of diagnosis, management, and ocular complications from treatment.
    Optometry (St. Louis, Mo.), 2003, Volume: 74, Issue:8

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retinal Diseases; Ribavirin

2003
Peginterferons in hepatitis C virus: virological, pharmacokinetic, and clinical implications. Introduction.
    Seminars in liver disease, 2003, Volume: 23 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2003
High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2003, Volume: 38, Issue:3

    Topics: Adult; Antiviral Agents; Body Mass Index; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Obesity; Retrospective Studies; Ribavirin; Risk Factors; Treatment Failure

2003
Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2003, Volume: 38, Issue:3

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load

2003
High dose consensus interferon in nonresponders to interferon alpha-2b and ribavirin with chronic hepatitis C.
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2003, Volume: 17, Issue:8

    Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2003
Early prediction of nonresponders to treatment with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2003, Volume: 17, Issue:8

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Failure; Viral Load

2003
Response to combination therapy with interferon alfa-2a and ribavirin in chronic hepatitis C according to a TNF-alpha promoter polymorphism.
    Digestion, 2003, Volume: 68, Issue:1

    Topics: Adult; Alleles; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polymorphism, Genetic; Promoter Regions, Genetic; Recombinant Proteins; Ribavirin; Tumor Necrosis Factor-alpha

2003
The effect of early treatment in children with chronic hepatitis.
    Journal of pediatric gastroenterology and nutrition, 2003, Volume: 37, Issue:3

    Topics: Antiviral Agents; Child; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viremia

2003
Slow viral dynamics of hepatitis C virus genotype 4.
    Journal of viral hepatitis, 2003, Volume: 10, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Load

2003
Cost effectiveness of pegylated interferon alpha 2b and ribavirin combination in chronic hepatitis C.
    Gut, 2003, Volume: 52, Issue:10

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2003
Antiviral treatment down-regulates peripheral B-cell CD81 expression and CD5 expansion in chronic hepatitis C virus infection.
    Journal of virology, 2003, Volume: 77, Issue:19

    Topics: Adult; Aged; Antigens, CD; Antiviral Agents; B-Lymphocytes; CD5 Antigens; Down-Regulation; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Membrane Proteins; Middle Aged; Ribavirin; RNA, Viral; Tetraspanin 28

2003
Sustained virological response after a short course of treatment with interferon and ribavirin in two chronic hepatitis C patients.
    Journal of hepatology, 2003, Volume: 39, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; Treatment Outcome

2003
Hepatitis C virus-specific cytolytic T cell responses after antiviral therapy.
    Clinical immunology (Orlando, Fla.), 2003, Volume: 108, Issue:3

    Topics: Adult; Antiviral Agents; Cell Division; Cells, Cultured; Cross-Sectional Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Lymphocyte Count; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Species Specificity; T-Lymphocytes, Cytotoxic; Viremia

2003
Hepatitis C virus RNA load in relapsed patients: week two of treatment is the best time to predict the complete response.
    European journal of gastroenterology & hepatology, 2003, Volume: 15, Issue:10

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Predictive Value of Tests; Remission Induction; Ribavirin; RNA, Viral; Sensitivity and Specificity; Treatment Outcome; Viral Load

2003
A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with alpha-interferon and ribavirin.
    Journal of gastroenterology, 2003, Volume: 38, Issue:8

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Recurrence; Ribavirin; Virus Activation

2003
The treatment of viral hepatitis, present and future.
    Journal of hepato-biliary-pancreatic surgery, 2003, Volume: 10, Issue:2

    Topics: Amantadine; Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2003
Cutaneous side-effects of treatment of chronic hepatitis C by interferon alfa and ribavirin.
    The British journal of dermatology, 2003, Volume: 149, Issue:3

    Topics: Antiviral Agents; Drug Eruptions; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin

2003
Pretreatment laparoscopic appearance of the liver can predict response to combination therapy with interferon alpha 2B and ribavirin in chronic hepatitis C.
    Gastrointestinal endoscopy, 2003, Volume: 58, Issue:3

    Topics: Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Laparoscopy; Liver; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin

2003
Daily interferon alpha-2B and ribavirin combination therapy for liver transplant patients with chronic hepatitis C infection.
    Transplantation proceedings, 2003, Volume: 35, Issue:6

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Polymerase Chain Reaction; Postoperative Complications; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2003
Therapy with interferon-alpha plus ribavirin for membranoproliferative glomerulonephritis induced by hepatitis C virus.
    The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2003, Volume: 7, Issue:5

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Glomerulonephritis, Membranoproliferative; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Ribavirin; Treatment Outcome

2003
Multiple fixed drug eruption with interferon/ribavirin combination therapy for hepatitis C virus infection.
    Journal of drugs in dermatology : JDD, 2003, Volume: 2, Issue:5

    Topics: Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin

2003
[Chronic C virus infection management].
    Revista clinica espanola, 2003, Volume: 203, Issue:9

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2003
Outcomes of interferon alpha and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases.
    Gut, 2003, Volume: 52, Issue:11

    Topics: Administration, Oral; Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome

2003
[Effects of HCV genotypes and HLA-DRB alleles on the response of chronic hepatitis C patients to interferon alpha and libavilin].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2003, Volume: 11, Issue:10

    Topics: Adult; Alleles; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HLA-DR Antigens; HLA-DRB1 Chains; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin

2003
Chronic viral hepatitis, interferon, diabetes mellitus, and celiac disease.
    The American journal of gastroenterology, 2003, Volume: 98, Issue:10

    Topics: Adult; Celiac Disease; Diabetes Mellitus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Function Tests; Male; Prognosis; Ribavirin; Risk Assessment

2003
The role of specific CD4+ T helper cell response in the course of hepatitis C virus infection.
    Sbornik lekarsky, 2003, Volume: 104, Issue:1

    Topics: Adult; Antiviral Agents; CD4 Antigens; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; T-Lymphocytes, Helper-Inducer

2003
Anemia in the treatment of hepatitis C virus infection.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003, Volume: 37 Suppl 4

    Topics: Anemia; Antiviral Agents; Epoetin Alfa; Erythropoietin; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Recombinant Proteins; Ribavirin

2003
[Therapy with interferon alfa and ribavirin in patients with chronic hepatitis C and normal levels of alanine aminotransferase].
    Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti, 2003, Volume: 57, Issue:3

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Retrospective Studies; Ribavirin

2003
Antiviral therapy for chronic hepatitis C.
    Australian family physician, 2003, Volume: 32, Issue:10

    Topics: Antiviral Agents; Australia; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Family Practice; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Prognosis; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome

2003
Vertebral osteopenia due to bone marrow hyperplasia during interferon-alpha and ribavirin therapy for chronic hepatitis C.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2003, Volume: 35, Issue:10

    Topics: Antiviral Agents; Bone Diseases, Metabolic; Bone Marrow; Hepatitis C, Chronic; Humans; Hyperplasia; Interferon alpha-2; Interferon-alpha; Lumbar Vertebrae; Magnetic Resonance Imaging; Male; Middle Aged; Recombinant Proteins; Ribavirin

2003
Pretreatment intrahepatic CD8+ cell count correlates with virological response to antiviral therapy in chronic hepatitis C virus infection.
    The Journal of infectious diseases, 2003, Nov-15, Volume: 188, Issue:10

    Topics: Adult; Antiviral Agents; Biopsy; CD8-Positive T-Lymphocytes; Cell Count; Cytokines; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral

2003
Predictive value of early HCV RNA quantitation for sustained response in nonresponders receiving daily interferon and ribavirin therapy.
    Journal of medical virology, 2004, Volume: 72, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Sensitivity and Specificity; Treatment Outcome; Viral Load

2004
Erythropoietin for ribavirin-induced anemia in hepatitis C: more answers but many more questions.
    The American journal of gastroenterology, 2003, Volume: 98, Issue:11

    Topics: Anemia, Hemolytic; Erythropoietin; Female; Hepatitis C, Chronic; Humans; Male; Prognosis; Ribavirin; Treatment Outcome

2003
Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis.
    Annals of the rheumatic diseases, 2003, Volume: 62, Issue:12

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antiviral Agents; Cryoglobulinemia; Drug Resistance, Neoplasm; Drug Resistance, Viral; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lymphoma, Non-Hodgkin; Middle Aged; Recombinant Proteins; Remission Induction; Ribavirin; Rituximab; Vasculitis

2003
Peginterferon-based therapy for chronic hepatitis C virus infection in patients with normal alanine aminotransferase levels.
    Annals of internal medicine, 2003, Dec-02, Volume: 139, Issue:11

    Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2003
Tyranny of algorithms in the treatment of patients with hepatitis C.
    Hepatology (Baltimore, Md.), 2003, Volume: 38, Issue:6

    Topics: Algorithms; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2003
Use of incomplete post-treatment data in the analysis of viral eradication studies.
    Statistics in medicine, 2003, Dec-15, Volume: 22, Issue:23

    Topics: Antiviral Agents; Clinical Trials as Topic; Data Interpretation, Statistical; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Models, Statistical; Ribavirin; Viral Load

2003
[Chronic hepatitis C. Chances of healing good as never before].
    MMW Fortschritte der Medizin, 2003, Oct-16, Volume: 145, Issue:42

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Recombinant Proteins; Ribavirin; Time Factors

2003
[Patient, 50, with chronic hepatitis C genotype 1 infection. Therapeutic success despite poor prognosis].
    MMW Fortschritte der Medizin, 2003, Oct-09, Volume: 145, Issue:41

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin

2003
Outcome, tolerability and compliance of compassionate use interferon and ribavirin for hepatitis C infection in a shared care hospital clinic.
    Internal medicine journal, 2003, Volume: 33, Issue:11

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Compliance; Recombinant Proteins; Ribavirin; RNA, Viral

2003
Progress on the treatment of hepatitis C.
    The Lancet. Infectious diseases, 2003, Volume: 3, Issue:12

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2003
Possible autoimmune thrombocytopenia associated with pegylated interferon-alpha2a plus ribavarin treatment for hepatitis C.
    Journal of clinical gastroenterology, 2004, Volume: 38, Issue:1

    Topics: Adult; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Purpura, Thrombocytopenic, Idiopathic; Ribavirin

2004
[Treatment of hepatitis C in nonresponders to ribavirin and/or interferon].
    Gastroenterologia y hepatologia, 2004, Volume: 27, Issue:1

    Topics: Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Failure

2004
[Pegylated-interferon-induced diabetes mellitus type 1 in two patients with chronic hepatitis C].
    Gastroenterologia y hepatologia, 2004, Volume: 27, Issue:2

    Topics: Adult; Antiviral Agents; Autoantibodies; Autoantigens; Autoimmune Diseases; Diabetes Mellitus, Type 1; Glutamate Decarboxylase; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Islets of Langerhans; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2004
Treatment of chronic hepatitis C in a state correctional facility.
    Annals of internal medicine, 2004, Jan-20, Volume: 140, Issue:2

    Topics: Data Interpretation, Statistical; Hepatitis C, Chronic; Humans; Interferon-alpha; Prisons; Rhode Island; Ribavirin

2004
Lack of clinical significance of variability in the internal ribosome entry site of hepatitis C virus.
    Journal of medical virology, 2004, Volume: 72, Issue:3

    Topics: 5' Untranslated Regions; Adult; Antiviral Agents; Base Sequence; Codon, Initiator; Drug Resistance, Viral; Female; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Nucleic Acid Conformation; Point Mutation; Polymorphism, Genetic; Protein Biosynthesis; Recombinant Proteins; Regulatory Sequences, Nucleic Acid; Ribavirin; RNA, Viral

2004
[Combined interferon-alfa-2b and ribavirin therapy in patients with recurrent chronic hepatitis c after liver transplantation].
    Orvosi hetilap, 2003, Nov-30, Volume: 144, Issue:48

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Bilirubin; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Severity of Illness Index; Treatment Outcome

2003
Treatment of interferon non-responsive chronic hepatitis C with triple therapy with interferon, ribavirin, and amantidine can be encouraging.
    Gut, 2004, Volume: 53, Issue:3

    Topics: Adult; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin

2004
Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2004, Volume: 29, Issue:3

    Topics: Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Recombinant Proteins; Ribavirin; Severity of Illness Index; Substance Abuse, Intravenous; Treatment Outcome

2004
[Hemosiderosis in Chronic Hepatitis C: Should Venesection Precede Treatment with Interferon-alpha and Ribavirin?].
    Zeitschrift fur Gastroenterologie, 2004, Volume: 42, Issue:2

    Topics: Antiviral Agents; Bloodletting; Combined Modality Therapy; Female; Hemochromatosis Protein; Hemosiderosis; Hepatitis B; Hepatitis C, Chronic; Histocompatibility Antigens Class I; Humans; Interferon-alpha; Male; Membrane Proteins; Mutation; Randomized Controlled Trials as Topic; Ribavirin

2004
Severe, generalized nummular eczema secondary to interferon alfa-2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection.
    Archives of dermatology, 2004, Volume: 140, Issue:2

    Topics: Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Eczema; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin

2004
Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
    PharmacoEconomics, 2004, Volume: 22, Issue:4

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Markov Chains; Models, Economic; Polyethylene Glycols; Quality of Life; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Treatment Outcome

2004
Pegylated interferon: new preparation. Chronic hepatitis C: advantageous for some patients, but more data needed.
    Prescrire international, 2003, Volume: 12, Issue:68

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Approval; Drug Therapy, Combination; France; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2003
Efficacy of hepatitis C treatment may be enhanced by a longer interferon administration.
    Liver international : official journal of the International Association for the Study of the Liver, 2003, Volume: 23, Issue:6

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Treatment Outcome

2003
Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin.
    Liver international : official journal of the International Association for the Study of the Liver, 2003, Volume: 23, Issue:6

    Topics: Adult; Amino Acid Substitution; Antiviral Agents; Drug Therapy, Combination; eIF-2 Kinase; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Male; Middle Aged; Phosphorylation; Point Mutation; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Treatment Outcome; Viral Envelope Proteins; Viral Nonstructural Proteins

2003
Increased circulating and intrahepatic T-cell-specific chemokines in chronic hepatitis C: relationship with the type of virological response to peginterferon plus ribavirin combination therapy.
    Alimentary pharmacology & therapeutics, 2004, Mar-01, Volume: 19, Issue:5

    Topics: Adult; Antiviral Agents; Cytokines; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; T-Lymphocytes; Viral Load

2004
Viral hepatitis C.
    Lancet (London, England), 2004, Feb-21, Volume: 363, Issue:9409

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Ribavirin

2004
Antiviral action of ribavirin in chronic hepatitis C.
    Gastroenterology, 2004, Volume: 126, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Case-Control Studies; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Osmolar Concentration; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2004
Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin.
    The American journal of psychiatry, 2004, Volume: 161, Issue:3

    Topics: Adult; Antimanic Agents; Antipsychotic Agents; Antiviral Agents; Bipolar Disorder; Dose-Response Relationship, Drug; Drug Therapy, Combination; Follow-Up Studies; Haloperidol; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lithium Carbonate; Long-Term Care; Male; Polyethylene Glycols; Psychoses, Substance-Induced; Recombinant Proteins; Ribavirin

2004
Summaries for patients. Duration and dose of antiviral treatment for chronic hepatitis C.
    Annals of internal medicine, 2004, Mar-02, Volume: 140, Issue:5

    Topics: Adult; Antiviral Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2004
Urinary nitrite/nitrate concentrations and total antioxidant capacity in patients with chronic hepatitis C in therapy with interferon and ribavirin.
    Journal of chemotherapy (Florence, Italy), 2003, Volume: 15, Issue:6

    Topics: Adult; Antioxidants; Antiviral Agents; Biomarkers; Case-Control Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Injections, Intramuscular; Interferon alpha-2; Interferon-alpha; Linear Models; Liver Function Tests; Male; Middle Aged; Nitric Oxide; Probability; Recombinant Proteins; Ribavirin; Sampling Studies; Sensitivity and Specificity; Severity of Illness Index; Treatment Outcome

2003
Late relapse in chronic hepatitis C after sustained viral response to interferon and ribavirin.
    Journal of gastroenterology and hepatology, 2004, Volume: 19, Issue:4

    Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Recurrence; Ribavirin; Time Factors

2004
[Successful treatment of chronic hepatitis C in hemophiliacs based on historical development of therapeutic protocols].
    Vnitrni lekarstvi, 2004, Volume: 50, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hemophilia A; Hepatitis C, Chronic; Humans; Interferon Type I; Recombinant Proteins; Ribavirin

2004
Ribavirin-induced pure red-cell aplasia during treatment of chronic hepatitis C.
    The New England journal of medicine, 2004, Mar-18, Volume: 350, Issue:12

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Red-Cell Aplasia, Pure; Ribavirin

2004
Should routine screening for coeliac disease be considered before starting interferon/ribavirin treatment in patients affected by chronic hepatitis C?
    European journal of gastroenterology & hepatology, 2004, Volume: 16, Issue:4

    Topics: Antiviral Agents; Celiac Disease; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin

2004
Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination.
    Journal of hepatology, 2004, Volume: 40, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Drug Tolerance; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin

2004
Cutaneous sarcoidosis associated with pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C.
    Journal of the American Academy of Dermatology, 2004, Volume: 50, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sarcoidosis; Skin Diseases

2004
The presence of non-organ-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C.
    BMC infectious diseases, 2004, Feb-13, Volume: 4

    Topics: Antibody Specificity; Antiviral Agents; Autoantibodies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin

2004
[Onset of type 1 diabetes mellitus during combination therapy of chronic hepatitis C with interferon-alpha and ribavirin].
    Ugeskrift for laeger, 2004, Mar-08, Volume: 166, Issue:11

    Topics: Antiviral Agents; Autoimmunity; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin

2004
Soluble CD26/30 levels before and after treatment with interferon-alpha and ribavirin combination therapy in a pediatric hepatitis C patient.
    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2004, Volume: 37, Issue:1

    Topics: Child; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ki-1 Antigen; Male; Ribavirin; Solubility; Treatment Outcome

2004
Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2004, Volume: 2, Issue:4

    Topics: Anemia; Biological Availability; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythrocytes; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Assessment; Sampling Studies; Severity of Illness Index

2004
Does sequencing the PKRBD of hepatitis C virus NS5A predict therapeutic response to combination therapy in an Australian population?
    Journal of gastroenterology and hepatology, 2004, Volume: 19, Issue:5

    Topics: Adult; Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Australia; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polymerase Chain Reaction; Predictive Value of Tests; Ribavirin; RNA, Viral; Statistics, Nonparametric; Viral Nonstructural Proteins

2004
Ribavirin upregulates interleukin-12 receptor and induces T cell differentiation towards type 1 in chronic hepatitis C.
    Journal of gastroenterology and hepatology, 2004, Volume: 19, Issue:5

    Topics: Antiviral Agents; Cell Differentiation; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C, Chronic; Humans; Immunity, Cellular; Male; Middle Aged; Phenotype; Receptors, Interleukin; Receptors, Interleukin-12; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Messenger; Statistics, Nonparametric; Th1 Cells; Th2 Cells; Up-Regulation

2004
Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
    AIDS (London, England), 2004, Jan-02, Volume: 18, Issue:1

    Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Pilot Projects; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Virus Replication

2004
Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.
    AIDS (London, England), 2004, Jan-02, Volume: 18, Issue:1

    Topics: Adult; Anti-Retroviral Agents; Antiviral Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Virus Replication

2004
Decreased frequencies of virus-specific T helper type 1 cells during interferon alpha plus ribavirin treatment in HIV-hepatitis C virus co-infection.
    AIDS (London, England), 2004, Jan-02, Volume: 18, Issue:1

    Topics: Antiviral Agents; CD4 Lymphocyte Count; Cytomegalovirus Infections; Enzyme-Linked Immunosorbent Assay; Hepatitis C, Chronic; HIV Infections; Humans; Immunity, Cellular; Interferon-alpha; Lymphocyte Activation; Ribavirin; Th1 Cells

2004
Pegylated interferon alpha-2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients.
    AIDS (London, England), 2004, Jan-02, Volume: 18, Issue:1

    Topics: Antiviral Agents; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load

2004
HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin.
    Journal of hepatology, 2004, Volume: 40, Issue:5

    Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Evolution, Molecular; Female; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Phylogeny; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Viral Proteins

2004
Onset of dermatitis herpetiformis after treatment by interferon and ribavirin for chronic hepatitis C.
    Journal of hepatology, 2004, Volume: 40, Issue:5

    Topics: Antiviral Agents; Dermatitis Herpetiformis; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Recombinant Proteins; Ribavirin

2004
[Therapeutic behaviour for a HCV+ patient].
    Presse medicale (Paris, France : 1983), 2004, Apr-10, Volume: 33, Issue:7

    Topics: Antiviral Agents; Biopsy; Contraindications; Critical Pathways; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferons; Liver; Ribavirin; Risk Factors

2004
Effects of interferon and ribavirin combination therapy on CD4+ proliferation, lymphocyte activation, and Th1 and Th2 cytokine profiles in chronic hepatitis C.
    Journal of viral hepatitis, 2004, Volume: 11, Issue:3

    Topics: Adult; Antiviral Agents; Case-Control Studies; CD4-Positive T-Lymphocytes; Cell Division; Cytokines; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; In Vitro Techniques; Interferon alpha-2; Interferon-alpha; Lymphocyte Activation; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; Th1 Cells; Th2 Cells; Viremia

2004
Polymorphisms of NS5B protein relates to early clearance of hepatitis C virus by interferon plus ribavirin: a pilot study.
    Journal of viral hepatitis, 2004, Volume: 11, Issue:3

    Topics: Aged; Amino Acid Sequence; Antiviral Agents; Base Sequence; DNA, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Molecular; Molecular Sequence Data; Pilot Projects; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Sequence Homology, Amino Acid; Viral Nonstructural Proteins

2004
Effectiveness of interferon alpha-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2004, Volume: 2, Issue:5

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome

2004
Differential efficacy of corticosteroids and interferon in a patient with chronic hepatitis C-autoimmune hepatitis overlap syndrome.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2004, Volume: 2, Issue:5

    Topics: Adult; Antiviral Agents; Azathioprine; Drug Therapy, Combination; Female; Glucocorticoids; Haplotypes; Hepacivirus; Hepatitis C, Chronic; Hepatitis, Autoimmune; Humans; Interferon alpha-2; Interferon-alpha; Prednisone; Recombinant Proteins; Remission Induction; Ribavirin; Syndrome

2004
Ribavirin may be an important factor in IFN-induced neuropsychiatric effects.
    The Journal of clinical psychiatry, 2004, Volume: 65, Issue:4

    Topics: Antiviral Agents; Depressive Disorder; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Mental Disorders; Research Design; Ribavirin

2004
Hepatitis C virus Core Antigen as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon alpha-2b plus ribavirin.
    Journal of hepatology, 2004, Volume: 40, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Osmolar Concentration; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Core Proteins

2004
Soluble interleukin 2 receptor plasma levels in non-responders with chronic hepatitis C treated with pegylated interferon-alpha 2b and ribavirin.
    Journal of clinical gastroenterology, 2004, Volume: 38, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Receptors, Interleukin-2; Recombinant Proteins; Ribavirin; Treatment Failure

2004
Treatment of chronic hepatitis C virus in the virginia department of corrections: can compliance overcome racial differences to response?
    The American journal of gastroenterology, 2004, Volume: 99, Issue:5

    Topics: Administration, Oral; Adult; Black or African American; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prisons; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Assessment; Sampling Studies; Severity of Illness Index; Telemedicine; Treatment Outcome; Virginia; White People

2004
Acute west nile virus in two patients receiving interferon and ribavirin for chronic hepatitis C.
    The American journal of gastroenterology, 2004, Volume: 99, Issue:5

    Topics: Acute Disease; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Risk Assessment; West Nile Fever; West Nile virus

2004
Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
    PharmacoEconomics, 2004, Volume: 22, Issue:7

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin

2004
Kinetics of soluble tumour necrosis factor (TNF)-alpha receptors and cytokines in the early phase of treatment for chronic hepatitis C: comparison between interferon (IFN)-alpha alone, IFN-alpha plus amantadine or plus ribavirin.
    Clinical and experimental immunology, 2004, Volume: 136, Issue:3

    Topics: Adult; Amantadine; Antiviral Agents; Biomarkers; Combined Modality Therapy; Cytokines; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C, Chronic; Humans; Immunotherapy, Active; Interferon-alpha; Interferon-gamma; Interleukin-10; Interleukin-12; Male; Middle Aged; Receptors, Tumor Necrosis Factor; Ribavirin; Statistics, Nonparametric; Tumor Necrosis Factor-alpha; Viral Load

2004
Eczema-like lesions and disruption of therapy in patients treated with interferon-alfa and ribavirin for chronic hepatitis C: the value of an interdisciplinary assessment.
    The British journal of dermatology, 2004, Volume: 150, Issue:5

    Topics: Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Psychotherapy; Recombinant Proteins; Ribavirin

2004
Presence of HCV RNA in hepatic tissue and effectiveness of treatment with interferon and ribavirin.
    Medical science monitor : international medical journal of experimental and clinical research, 2003, Volume: 9 Suppl 3

    Topics: Adolescent; Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral; Viral Load

2003
Assessment of selected clinical factors as predictors of response to combined interferon-alpha plus ribavirin therapy among patients with chronic hepatitis C.
    Medical science monitor : international medical journal of experimental and clinical research, 2003, Volume: 9 Suppl 3

    Topics: Adult; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin

2003
Blood serum glutathione alpha s-transferase (alpha GST) activity during antiviral therapy in patients with chronic hepatitis C.
    Medical science monitor : international medical journal of experimental and clinical research, 2003, Volume: 9 Suppl 3

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Glutathione Transferase; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral

2003
Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients.
    AIDS research and human retroviruses, 2004, Volume: 20, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Viremia

2004
High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection.
    Journal of medical virology, 2004, Volume: 73, Issue:3

    Topics: Adolescent; Adult; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferons; Male; Prisoners; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; Risk Factors; RNA, Viral; Serotyping; Substance Abuse, Intravenous

2004
Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response.
    Infection, 2004, Volume: 32, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C Antibodies; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral; Viral Envelope Proteins; Viral Nonstructural Proteins

2004
Determination of ribavirin in human serum and plasma by capillary electrophoresis.
    Electrophoresis, 2004, Volume: 25, Issue:10-11

    Topics: Acetonitriles; Chromatography, High Pressure Liquid; Cytidine; Electrophoresis, Capillary; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin

2004
Interferon induced glomerular disease in a patient with chronic hepatitis C.
    The Medical journal of Malaysia, 2003, Volume: 58, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Liver Function Tests; Male; Nephrotic Syndrome; Ribavirin

2003
Interferon alpha-2b in combination with ribavirin for the treatment of chronic hepatitis C: assessment of virological, biochemical and histological treatment response.
    Medicina (Kaunas, Lithuania), 2004, Volume: 40, Issue:6

    Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Biopsy; Data Interpretation, Statistical; Drug Therapy, Combination; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Middle Aged; Polymerase Chain Reaction; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome

2004
[Hepatitis C infection. Overweight virus carriers are more difficult to cure].
    MMW Fortschritte der Medizin, 2004, Mar-25, Volume: 146, Issue:13

    Topics: Antiviral Agents; Biological Availability; Body Weight; Carrier State; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Metabolic Clearance Rate; Obesity; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2004
Perihepatic lymph nodes and antiviral response in chronic HCV-associated hepatitis.
    Ultrasound in medicine & biology, 2004, Volume: 30, Issue:6

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Lymphatic Diseases; Male; Middle Aged; Prognosis; Prospective Studies; Ribavirin; Treatment Outcome; Ultrasonography

2004
Tomato-based functional food as interferon adjuvant in HCV eradication therapy.
    Journal of clinical gastroenterology, 2004, Volume: 38, Issue:6 Suppl

    Topics: Antioxidants; Antiviral Agents; Biological Availability; Carotenoids; Drug Therapy, Combination; Female; Flavonoids; Hepatitis C, Chronic; Humans; Interferons; Male; Oxidative Stress; Ribavirin; Treatment Outcome; Vitamin E

2004
SEN virus does not affect treatment response in hepatitis C virus coinfected patients but SEN virus response depends on SEN virus DNA concentration.
    World journal of gastroenterology, 2004, Jul-01, Volume: 10, Issue:13

    Topics: Adult; Antiviral Agents; DNA Virus Infections; DNA Viruses; DNA, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; RNA, Viral

2004
Pegylated interferon-alpha 2b monotherapy for haemodialysis patients with chronic hepatitis C.
    Alimentary pharmacology & therapeutics, 2004, Jul-01, Volume: 20, Issue:1

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin

2004
[Observation on the efficacy and safety of Infergen combined with capsule ribavirin in treatment of hepatitis C patients].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2004, Volume: 12, Issue:6

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon Type I; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Safety; Treatment Outcome; Viral Load

2004
Treatment of chronic hepatitis C in hemophilic patients.
    Acta virologica, 2004, Volume: 48, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hemophilia A; Hepatitis C, Chronic; Humans; Interferon Type I; Recombinant Proteins; Ribavirin

2004
Monitoring intrahepatic CD8+ T cells by fine-needle aspiration cytology in chronic hepatitis C infection.
    Journal of viral hepatitis, 2004, Volume: 11, Issue:4

    Topics: Biopsy, Fine-Needle; Blood Cells; CD3 Complex; CD8 Antigens; CD8-Positive T-Lymphocytes; Cell Count; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Immunohistochemistry; Immunophenotyping; Interferon alpha-2; Interferon-alpha; Liver; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2004
Use of PEG-interferon alfa-2a plus ribavirin as treatment for chronic HCV hepatitis in a child cured of ALL.
    Pediatric blood & cancer, 2004, Volume: 43, Issue:2

    Topics: Antiviral Agents; Child, Preschool; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins; Ribavirin

2004
Liver fibrosis stage predicts early treatment outcomes with peginterferon plus ribavirin in HIV/hepatitis C virus co-infected patients.
    AIDS (London, England), 2004, Jul-23, Volume: 18, Issue:11

    Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome

2004
HIV Infection, hepatitis C infection, and HAART: hard clinical choices.
    JAMA, 2004, Jul-14, Volume: 292, Issue:2

    Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load

2004
Improvement of a CIDP associated with hepatitis C virus infection using antiviral therapy.
    Neurology, 2004, Jul-13, Volume: 63, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Recombinant Proteins; Remission Induction; Ribavirin

2004
Combination pegylated interferon and ribavirin therapy precipitating acute renal failure and exacerbating IgA nephropathy.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2004, Volume: 19, Issue:8

    Topics: Acute Kidney Injury; Antiviral Agents; Drug Therapy, Combination; Glomerulonephritis, IGA; Hematuria; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2004
Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy.
    Journal of medical virology, 2004, Volume: 74, Issue:1

    Topics: Adult; Amino Acid Substitution; Antiviral Agents; Capsid Proteins; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genetic Variation; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Mutation; Phylogeny; Polymorphism, Single-Stranded Conformational; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Selection, Genetic; Sequence Analysis, DNA; Viral Envelope Proteins; Viral Load; Viral Nonstructural Proteins

2004
Determination of glycated hemoglobin in patients with advanced liver disease.
    World journal of gastroenterology, 2004, Aug-01, Volume: 10, Issue:15

    Topics: Antiviral Agents; Fructosamine; Glycated Hemoglobin; Hepatitis C, Chronic; Hepatitis, Chronic; Humans; Liver Cirrhosis; Ribavirin

2004
Isolation and functional analysis of circulating dendritic cells from hepatitis C virus (HCV) RNA-positive and HCV RNA-negative patients with chronic hepatitis C: role of antiviral therapy.
    Clinical and experimental immunology, 2004, Volume: 137, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Dendritic Cells; Female; Hepacivirus; Hepatitis C, Chronic; HLA Antigens; Humans; Interferon-alpha; Interleukin-12; Lymphocyte Activation; Male; Middle Aged; Ribavirin; RNA, Viral

2004
FDA approves Hep C drugs.
    AIDS alert, 2004, Volume: 19, Issue:6

    Topics: Antiviral Agents; Drug Approval; Hepatitis C, Chronic; Humans; Ribavirin; United States; United States Food and Drug Administration

2004
Artificial neural networks for the prediction of response to interferon plus ribavirin treatment in patients with chronic hepatitis C.
    Current pharmaceutical design, 2004, Volume: 10, Issue:17

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Databases, Factual; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neural Networks, Computer; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Treatment Outcome

2004
Treating hepatitis C in "difficult-to-treat" patients.
    The New England journal of medicine, 2004, Jul-29, Volume: 351, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2004
Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C.
    Journal of gastroenterology, 2004, Volume: 39, Issue:7

    Topics: Adult; Aged; Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin

2004
Ribavirin-induced hemolytic anemia in chronic hepatitis C patients.
    Journal of gastroenterology, 2004, Volume: 39, Issue:7

    Topics: Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin

2004
Treatment of hepatitis C virus infection in patients of northern India.
    Journal of gastroenterology and hepatology, 2004, Volume: 19, Issue:9

    Topics: Adult; Aged; Analysis of Variance; Antiviral Agents; Chi-Square Distribution; Female; Genotype; Hepatitis C, Chronic; Humans; India; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2004
Platelet sparing effect of COX II inhibition used with pegylated interferon alfa-2a for the treatment of chronic hepatitis C: a short term pilot study.
    Cytokine, 2004, Sep-21, Volume: 27, Issue:6

    Topics: Antiviral Agents; Biomarkers; Blood Platelets; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Carriers; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-13; Interleukin-8; Membrane Proteins; Middle Aged; P-Selectin; Polyethylene Glycols; Prostaglandin-Endoperoxide Synthases; Recombinant Proteins; Ribavirin; Viral Load

2004
Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
    The American journal of gastroenterology, 2004, Volume: 99, Issue:8

    Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Genotype; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; United States; Viral Load

2004
Acute pancreatitis associated with interferon and ribavirin therapy in patients with chronic hepatitis C.
    Digestive diseases and sciences, 2004, Volume: 49, Issue:6

    Topics: Acute Disease; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pancreatitis; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome

2004
Serious ophthalmic pathology compromising vision in HCV/HIV co-infected patients treated with peginterferon alpha-2b and ribavirin.
    AIDS (London, England), 2004, Sep-03, Volume: 18, Issue:13

    Topics: Adult; Cataract; Color Vision Defects; Eye Diseases; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Vision Disorders

2004
Cutaneous reactions to interferon and ribavirin.
    Internal medicine journal, 2004, Volume: 34, Issue:8

    Topics: Antiviral Agents; Dermatologic Agents; Drug Eruptions; Drug Therapy, Combination; Hepatitis C, Chronic; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin

2004
Treatment of chronic hepatitis C in blacks and non-Hispanic whites.
    The New England journal of medicine, 2004, Aug-19, Volume: 351, Issue:8

    Topics: Antiviral Agents; Black or African American; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Metabolic Syndrome; Polyethylene Glycols; Recombinant Proteins; Ribavirin; White People

2004
Treatment of chronic hepatitis C in blacks and non-Hispanic whites.
    The New England journal of medicine, 2004, Aug-19, Volume: 351, Issue:8

    Topics: Antiviral Agents; Black or African American; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins; White People

2004
Treatment response in HCV related chronic hepatitis.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2004, Volume: 14, Issue:8

    Topics: Adolescent; Adult; Antiviral Agents; Child; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin; RNA, Viral; Treatment Outcome

2004
Chronic hepatitis C and normal ALT: considerations for treatment.
    The American journal of gastroenterology, 2004, Volume: 99, Issue:9

    Topics: Adult; Alanine Transaminase; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Multicenter Studies as Topic; Prognosis; Randomized Controlled Trials as Topic; Recombinant Proteins; Reference Values; Ribavirin; Severity of Illness Index; Treatment Outcome

2004
Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4.
    The American journal of gastroenterology, 2004, Volume: 99, Issue:9

    Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Probability; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Assessment; Sampling Studies; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome

2004
Serum levels of hepatitis C virus core antigen as a marker of infection and response to therapy.
    The American journal of gastroenterology, 2004, Volume: 99, Issue:9

    Topics: Adult; Biomarkers; Cohort Studies; Confidence Intervals; Drug Therapy, Combination; Female; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Predictive Value of Tests; Probability; Prognosis; Recombinant Proteins; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; Risk Assessment; Sensitivity and Specificity; Severity of Illness Index; Treatment Outcome; Viral Core Proteins

2004
Hepatitis C infection associated with renal disease and chronic renal failure.
    Seminars in liver disease, 2004, Volume: 24 Suppl 2

    Topics: Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Diseases; Kidney Failure, Chronic; Kidney Transplantation; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2004
Oxidative status in chronic hepatitis C: the influence of antiviral therapy and prognostic value of serum hydroperoxide assay.
    Free radical research, 2004, Volume: 38, Issue:6

    Topics: Adult; Antiviral Agents; Cross-Sectional Studies; Female; Follow-Up Studies; Free Radical Scavengers; Hepatitis C, Chronic; Humans; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Oxidation-Reduction; Peroxides; Predictive Value of Tests; Prognosis; Ribavirin; Time Factors

2004
Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.
    Hepatology (Baltimore, Md.), 2004, Volume: 40, Issue:3

    Topics: Antiviral Agents; Black or African American; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2004
[Due to normal transaminase values, no further treatment. Hepatitis C patient "suddenly" has liver cirrhosis].
    MMW Fortschritte der Medizin, 2004, May-06, Volume: 146, Issue:19

    Topics: Antiviral Agents; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; False Negative Reactions; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Polyethylene Glycols; Recombinant Proteins; Reference Values; Ribavirin; Transaminases

2004
Effects of ribavirin combined with interferon-alpha 2b on viral kinetics during first 12 weeks of treatment in patients with hepatitis C virus genotype 1 and high baseline viral loads.
    Journal of viral hepatitis, 2004, Volume: 11, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2004
Carriage of the apolipoprotein E-epsilon4 allele and histologic outcome of recurrent hepatitis C after antiviral treatment.
    American journal of clinical pathology, 2004, Volume: 122, Issue:3

    Topics: Alleles; Antiviral Agents; Apolipoproteins E; Disease Progression; Female; Hepacivirus; Hepatitis C, Chronic; History, 16th Century; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Genetic; Recurrence; Ribavirin

2004
Interferon-alpha-associated sarcoidosis responsive to infliximab therapy.
    The American journal of the medical sciences, 2004, Volume: 328, Issue:3

    Topics: Antibodies, Monoclonal; Gastrointestinal Agents; Hepatitis C, Chronic; Humans; Infliximab; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Sarcoidosis

2004
[Progress in the treatment of hepatitis B and C co-infection in HIV patients].
    MMW Fortschritte der Medizin, 2004, Apr-26, Volume: 146 Spec No 1

    Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Survival Rate

2004
[APRICOT Study evaluated. Surprisingly high virologic response in HIV-HCV coinfection].
    MMW Fortschritte der Medizin, 2004, Apr-26, Volume: 146 Spec No 1

    Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Multicenter Studies as Topic; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Viral Load

2004
[Eliminating the gray zone. What can be done in normal ALT values?].
    MMW Fortschritte der Medizin, 2004, Apr-26, Volume: 146 Spec No 1

    Topics: AIDS-Related Opportunistic Infections; Alanine Transaminase; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Multicenter Studies as Topic; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome

2004
Cutaneous vasculitis with undetectable cryoglobulinemia in chronic hepatitis C.
    Journal of gastroenterology and hepatology, 2004, Volume: 19, Issue:10

    Topics: Antiviral Agents; Cryoglobulinemia; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Ribavirin; Skin Diseases; Vasculitis

2004
[Chronic hepatitis and cirrhosis caused by C virus before and after liver transplantation. Report of one case].
    Revista medica de Chile, 2004, Volume: 132, Issue:4

    Topics: Antiviral Agents; Child; Drug Therapy, Combination; Fatal Outcome; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Ribavirin; Viral Load

2004
Histopathologic efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C.
    Transplantation, 2004, Sep-27, Volume: 78, Issue:6

    Topics: Antiviral Agents; Aspartate Aminotransferases; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Transplantation; Liver; Liver Function Tests; Male; Middle Aged; Ribavirin; RNA, Viral; Statistics, Nonparametric; Treatment Outcome; Viral Load

2004
The prevalence and clinical characteristics of coinfection of SENV-H among Taiwanese chronic hepatitis C patients with combination therapy of high-dose interferon-alfa and ribavirin.
    Antiviral research, 2004, Volume: 64, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Base Sequence; Circoviridae; Circoviridae Infections; DNA, Viral; Female; Hepatitis C, Chronic; Humans; Interferon Type I; Male; Middle Aged; Recombinant Proteins; Ribavirin; Taiwan; Viremia

2004
Lanreotide treatment in a patient with interferon-associated Graves' ophthalmopathy.
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2005, Volume: 243, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Graves Disease; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Peptides, Cyclic; Ribavirin; Somatostatin; Tomography, X-Ray Computed; Treatment Outcome

2005
Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation?
    Antiviral therapy, 2004, Volume: 9, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Infections; Interferon alpha-2; Interferon Type I; Interferon-alpha; Italy; Longitudinal Studies; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Respiratory Tract Infections; Retrospective Studies; Ribavirin

2004
[Bilateral AION after the combined therapy of hepatitis C with PEG-interferon alpha2B and ribavirin].
    Klinische Monatsblatter fur Augenheilkunde, 2004, Volume: 221, Issue:9

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Optic Atrophy; Optic Neuropathy, Ischemic; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Visual Acuity; Visual Fields

2004
Treatment of chronic hepatitis C patients not responding to combination therapy with ribavirin and interferon alpha--hype or hope?
    Wiener klinische Wochenschrift, 2004, Aug-31, Volume: 116, Issue:15-16

    Topics: Amantadine; Antiviral Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Combinations; Drug Tolerance; Evidence-Based Medicine; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Treatment Failure; Treatment Outcome

2004
Lymphocyte T helper-specific reactivity in sustained responders to interferon and ribavirin with negativation (seroreversion) of anti-hepatitis C virus.
    Liver international : official journal of the International Association for the Study of the Liver, 2004, Volume: 24, Issue:5

    Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lymphocyte Activation; Male; Middle Aged; Recombinant Proteins; Ribavirin; T-Lymphocytes, Helper-Inducer

2004
Factors contributing to ribavirin-induced anemia.
    Journal of gastroenterology and hepatology, 2004, Volume: 19, Issue:11

    Topics: Adult; Aged; Anemia, Hemolytic; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Risk Factors

2004
[Necrotic lesion in a patient with hepatitis C virus liver disease under treatment with pegylated interferon].
    Enfermedades infecciosas y microbiologia clinica, 2004, Volume: 22, Issue:8

    Topics: Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Necrosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2004
S-adenosylhomocysteine hydrolase, S-adenosylmethionine, S-adenosylhomocysteine: correlations with ribavirin induced anemia.
    Medical hypotheses, 2004, Volume: 63, Issue:5

    Topics: Adenosylhomocysteinase; Anemia; Animals; Antiviral Agents; Erythrocytes; Hepatitis C, Chronic; Humans; Models, Biological; Ribavirin; S-Adenosylhomocysteine; S-Adenosylmethionine; Statistics as Topic

2004
Recurrent hepatitis C genotype 1b following liver transplantation: treatment with combination interferon-ribavirin therapy.
    European journal of gastroenterology & hepatology, 2004, Volume: 16, Issue:11

    Topics: Acute Disease; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recurrence; Ribavirin; Treatment Outcome

2004
Virological response in post-partum treated chronic hepatitis C women with pegylated interferon-alpha plus ribavirin. A case-control study.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2004, Volume: 31, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Postpartum Period; Recombinant Proteins; Ribavirin; Treatment Outcome

2004
Improvement of liver histopathology in patients with hepatitis C after interferon and ribavirin combination therapy.
    Medicina (Kaunas, Lithuania), 2004, Volume: 40, Issue:10

    Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Male; Middle Aged; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome

2004
Generalized exfoliative dermatitis induced by interferon alfa.
    The Annals of pharmacotherapy, 2004, Volume: 38, Issue:12

    Topics: Adult; Antiviral Agents; Dermatitis, Exfoliative; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Pruritus; Recombinant Proteins; Ribavirin

2004
PKR gene expression and response to pegylated interferon plus ribavirin therapy in chronic hepatitis C.
    Antiviral therapy, 2004, Volume: 9, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; eIF-2 Kinase; Female; Gene Expression Regulation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2004
Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study.
    Archives of internal medicine, 2004, Nov-22, Volume: 164, Issue:21

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; Sex Factors; Thyroid Diseases; Treatment Outcome

2004
Peginterferon plus ribavirin for hepatitis C in HIV-infected patients.
    The New England journal of medicine, 2004, Nov-25, Volume: 351, Issue:22

    Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2004
Interferon for hepatitis C patients with psychiatric disorders.
    The American journal of psychiatry, 2004, Volume: 161, Issue:12

    Topics: Antiviral Agents; Bipolar Disorder; Comorbidity; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Mental Disorders; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Viral Load

2004
Interferon for hepatitis C patients with psychiatric disorders.
    The American journal of psychiatry, 2004, Volume: 161, Issue:12

    Topics: Antiviral Agents; Bipolar Disorder; Comorbidity; Drug Therapy, Combination; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Mental Disorders; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Substance Withdrawal Syndrome

2004
Interferon for hepatitis C patients with psychiatric disorders.
    The American journal of psychiatry, 2004, Volume: 161, Issue:12

    Topics: Amines; Antimanic Agents; Antiviral Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminobutyric Acid; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Treatment Outcome

2004
Peginterferon plus ribavirin for hepatitis C in HIV-infected patients.
    The New England journal of medicine, 2004, Nov-25, Volume: 351, Issue:22

    Topics: Antiviral Agents; Body Mass Index; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2004
Possible herbal treatment for C4HCV patients who are not suitable for interferon based treatment.
    Saudi medical journal, 2004, Volume: 25, Issue:11

    Topics: Antiviral Agents; Complementary Therapies; Genotype; Hepacivirus; Hepatitis C, Chronic; Herbal Medicine; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure

2004
Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.
    Journal of gastroenterology, 2004, Volume: 39, Issue:11

    Topics: Anemia, Hemolytic; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin

2004
How to avoid discontinuation of ribavirin in combination with interferon to maintain efficacy of treatment for chronic hepatitis C patients.
    Journal of gastroenterology, 2004, Volume: 39, Issue:11

    Topics: Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin

2004
Hepatitis C, depressive symptoms, viral load, and therapy: interactions and reactions.
    Brain, behavior, and immunity, 2005, Volume: 19, Issue:1

    Topics: Antiviral Agents; Comorbidity; Depressive Disorder; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Failure; Viral Load

2005
Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C.
    Brain, behavior, and immunity, 2005, Volume: 19, Issue:1

    Topics: Adult; Antiviral Agents; Comorbidity; Depressive Disorder; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Statistics, Nonparametric; Substance-Related Disorders; Treatment Failure; Treatment Outcome; Viral Load

2005
Hematologic side effects of PEG interferon and ribavirin. Management with growth factors.
    Journal of clinical gastroenterology, 2005, Volume: 39, Issue:1 Suppl

    Topics: Antiviral Agents; Drug Therapy, Combination; Growth Substances; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; United States

2005
[Chronic hepatitis C with normal level of alanine-aminotransferase].
    Recenti progressi in medicina, 2004, Volume: 95, Issue:11

    Topics: Alanine Transaminase; Antiviral Agents; Biopsy; Body Mass Index; Clinical Enzyme Tests; Female; Hepatitis C, Chronic; Humans; Interferons; Liver; Male; Ribavirin; Time Factors

2004
Treatment of chronic hepatitis C in children.
    Pediatric transplantation, 2004, Volume: 8, Issue:6

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Diseases; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2004
Treatment of hepatitis C in HIV-infected patients: significant progress but not the final step.
    JAMA, 2004, Dec-15, Volume: 292, Issue:23

    Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load

2004
Analysis of quasispecies in the viral 5' untranslated region of hepatitis C virus to evaluate ribavirin mutagenic effect in patients receiving ribavirin and interferon-alfa.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2004, Volume: 23, Issue:12

    Topics: 5' Untranslated Regions; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome

2004
Development of reversible diabetes mellitus after cessation of interferon-alpha therapy for chronic hepatitis C infection.
    The New Zealand medical journal, 2004, Dec-17, Volume: 117, Issue:1207

    Topics: Adult; Antiviral Agents; Autoimmune Diseases; Diabetes Mellitus; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin

2004
A particular hepatitis C virus protease NS3 gene pattern in a patient not responding to interferon-ribavirin therapy.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2005, Volume: 24, Issue:1

    Topics: Biopsy, Needle; DNA, Viral; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Polymerase Chain Reaction; Ribavirin; Severity of Illness Index; Treatment Failure; Viral Load; Viral Nonstructural Proteins

2005
Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2005, Volume: 41, Issue:1

    Topics: Adult; Antiviral Agents; Cells, Cultured; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Lymphocytes; Macrophages; Male; Middle Aged; Monocytes; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Time Factors; Virus Replication

2005
Orally administered Kampo medicine, Juzen-taiho-to, ameliorates anemia during interferon plus ribavirin therapy in patients with chronic hepatitis C.
    Journal of gastroenterology, 2004, Volume: 39, Issue:12

    Topics: Administration, Oral; Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Medicine, Kampo; Middle Aged; Retrospective Studies; Ribavirin

2004
Thymosin alpha 1 in combination with interferon alpha and ribavirin in chronic hepatitis C patients who are non-responders or relapsers to interferon alpha plus ribavirin.
    JPMA. The Journal of the Pakistan Medical Association, 2004, Volume: 54, Issue:11

    Topics: Adjuvants, Immunologic; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Retreatment; Ribavirin; Thymalfasin; Thymosin

2004
Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirin.
    Clinical pharmacology and therapeutics, 2005, Volume: 77, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Cognition Disorders; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Memory; Middle Aged; Prospective Studies; Psychomotor Disorders; Psychomotor Performance; Reaction Time; Recombinant Proteins; Ribavirin; Severity of Illness Index

2005
Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-week interim results of a pilot study.
    Journal of gastroenterology and hepatology, 2004, Volume: 19, Issue:12

    Topics: Adjuvants, Immunologic; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thymalfasin; Thymosin; Time Factors; Treatment Failure

2004
Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis C.
    Antiviral therapy, 2004, Volume: 9, Issue:6

    Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Depression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Ribavirin

2004
Polyarteritis nodosa after interferon treatment for chronic hepatitis C.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2005, Volume: 32, Issue:2

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyarteritis Nodosa; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2005
The effect of adherence to therapy on sustained response in daily or three times a week interferon alpha-2b plus ribavirin treatment of naive and nonresponder chronic hepatitis C patients.
    Journal of viral hepatitis, 2005, Volume: 12, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Compliance; Recombinant Proteins; Ribavirin

2005
Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression.
    Journal of viral hepatitis, 2005, Volume: 12, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Depression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Ribavirin; Selective Serotonin Reuptake Inhibitors

2005
Generalized nummular eczema secondary to peginterferon Alfa-2b and ribavirin combination therapy for hepatitis C infection.
    Archives of dermatology, 2005, Volume: 141, Issue:1

    Topics: Adult; Antiviral Agents; Eczema; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2005
Meyerson's phenomenon induced by interferon-alfa plus ribavirin in hepatitis C infection.
    The British journal of dermatology, 2005, Volume: 152, Issue:1

    Topics: Adult; Antiviral Agents; Drug Eruptions; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin

2005
Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin.
    The American journal of gastroenterology, 2005, Volume: 100, Issue:2

    Topics: Anemia; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythropoietin; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2005
Relationships between hepatic iron content and virologic response in chronic hepatitis C patients treated with interferon and ribavirin.
    The American journal of gastroenterology, 2005, Volume: 100, Issue:2

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Iron; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2005
Successful treatment of resistant chronic hepatitis C virus infection with high dose pegylated interferon.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2005, Volume: 15, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2005
Chronic hepatitis C in HIV-infected patients: low eligibility and applicability of therapy with pegylated interferon-alpha plus ribavirin.
    Journal of acquired immune deficiency syndromes (1999), 2005, Feb-01, Volume: 38, Issue:2

    Topics: Adult; Antiviral Agents; Cohort Studies; Eligibility Determination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon Type I; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin

2005
Treatment of chronic hepatitis C in a patient with systemic lupus erythematosus.
    Gastroenterologie clinique et biologique, 2004, Volume: 28, Issue:12

    Topics: Aged; Anemia; Antiviral Agents; Asthenia; Drug Therapy, Combination; Female; Headache; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Lupus Erythematosus, Systemic; Ribavirin

2004
Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C.
    European journal of gastroenterology & hepatology, 2005, Volume: 17, Issue:2

    Topics: Adolescent; Adult; Age Factors; Aged; Antiviral Agents; Body Mass Index; Drug Therapy, Combination; Fatty Liver; Female; Genotype; Hepatitis C, Chronic; Humans; Interferons; Logistic Models; Male; Middle Aged; Retrospective Studies; Ribavirin; Risk Factors; Treatment Failure

2005
Ribavirin monotherapy for hepatitis C virus-associated membranous nephropathy.
    Clinical nephrology, 2005, Volume: 63, Issue:1

    Topics: Adult; Antiviral Agents; Female; Glomerulonephritis, Membranous; Hepatitis C, Chronic; Humans; Ribavirin

2005
[Evolution of Sjögren syndrome associated with hepatitis C virus when chronic hepatitis C is treated by interferon or the association of interferon and ribavirin].
    La Revue de medecine interne, 2005, Volume: 26, Issue:2

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Prospective Studies; Ribavirin; Sjogren's Syndrome; Viral Load

2005
Acute ulcerative colitis during successful interferon/ribavirin treatment for chronic hepatitis.
    Gut, 2005, Volume: 54, Issue:3

    Topics: Acute Disease; Antiviral Agents; Colitis, Ulcerative; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2005
Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2005, Feb-15, Volume: 40, Issue:4

    Topics: Adult; Aged; Antibodies, Antinuclear; Antibody Specificity; Antiviral Agents; Autoantibodies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Muscle, Smooth; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2005
Non-organ-specific autoantibodies in hepatitis C virus infection: do they matter?
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2005, Feb-15, Volume: 40, Issue:4

    Topics: Adult; Antibody Specificity; Antiviral Agents; Autoantibodies; Child; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Transaminases; Treatment Outcome

2005
Intrahepatic and peripheral blood virus-specific cytotoxic T lymphocyte activity is associated with a response to combination IFN-alpha and ribavirin treatment among patients with chronic hepatitis C virus infection.
    Journal of viral hepatitis, 2005, Volume: 12, Issue:2

    Topics: Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Lymphocyte Activation; Male; Probability; Prognosis; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; T-Lymphocytes, Cytotoxic; Treatment Outcome; Viral Load

2005
Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels.
    Hepatology (Baltimore, Md.), 2005, Volume: 41, Issue:3

    Topics: Alanine Transaminase; Antiviral Agents; gamma-Glutamyltransferase; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2005
Hepatitis C virus genotypes, HLA-DRB alleles and their response to interferon-alpha and ribavirin in patients with chronic hepatitis C.
    Hepatobiliary & pancreatic diseases international : HBPD INT, 2005, Volume: 4, Issue:1

    Topics: Adult; Aged; Alleles; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Genetic Markers; Genotype; Hepacivirus; Hepatitis C, Chronic; HLA-DR Antigens; HLA-DRB1 Chains; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome

2005
Interferon-induced depression: prevalence and management.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2005, Volume: 37, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Depression; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Prevalence; Prognosis; Review Literature as Topic; Ribavirin; Selective Serotonin Reuptake Inhibitors; Treatment Outcome

2005
Interferon alpha-2b and ribavirin for patients with chronic hepatitis C and normal ALT.
    The American journal of gastroenterology, 2005, Volume: 100, Issue:3

    Topics: Alanine Transaminase; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis, Alcoholic; Recombinant Proteins; Ribavirin

2005
[Hepatitis C and HIV in Spanish prisons].
    Enfermedades infecciosas y microbiologia clinica, 2005, Volume: 23, Issue:2

    Topics: Adult; Antiviral Agents; Comorbidity; Female; Hepatitis C, Chronic; HIV Infections; HIV Seroprevalence; Hospitalization; Hospitals, Public; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prisoners; Prisons; Recombinant Proteins; Ribavirin; Seroepidemiologic Studies; Spain; Substance Abuse, Intravenous

2005
Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
    Antiviral therapy, 2005, Volume: 10, Issue:1

    Topics: Adult; Antiviral Agents; Case-Control Studies; DNA, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon Type I; Male; Middle Aged; Recombinant Proteins; Ribavirin; Viral Interference

2005
News in hepatitis C: Report from the 39th annual meeting of the European Association for the Study of the Liver.
    Antiviral therapy, 2005, Volume: 10, Issue:1

    Topics: Antiviral Agents; Europe; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Societies, Scientific

2005
[Incidence of haemolytic anaemia during combination therapy of chronic hepatitis C with interferon alpha-2b and ribavirin].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2004, Volume: 17, Issue:101

    Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Poland; Recombinant Proteins; Ribavirin; Time Factors

2004
Ribavirin and use of clotting factors in patients with hemophilia and chronic hepatitis C.
    JAMA, 2005, Mar-09, Volume: 293, Issue:10

    Topics: Adult; Antiviral Agents; Blood Coagulation Factors; Hemophilia A; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin

2005
Non-responders to previous treatment for hepatitis C.
    Minerva gastroenterologica e dietologica, 2005, Volume: 51, Issue:1

    Topics: Antiviral Agents; Controlled Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Multicenter Studies as Topic; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Load

2005
Occurrence of porphyria cutanea tarda during peginterferon/ribavirin therapy for chronic viral hepatitis C.
    Journal of hepatology, 2005, Volume: 42, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Porphyria Cutanea Tarda; Recombinant Proteins; Ribavirin

2005
Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.
    Gastroenterology, 2005, Volume: 128, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Viremia

2005
Bell's palsy associated with IFN-alpha and ribavirin therapy for hepatitis C virus infection.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2005, Volume: 25, Issue:3

    Topics: Adult; Antiviral Agents; Bell Palsy; Hepatitis C, Chronic; Humans; Interferon Type I; Male; Middle Aged; Myelin Sheath; Recombinant Proteins; Ribavirin; Schwann Cells; Self Tolerance; Substance Abuse, Intravenous

2005
Retinal toxicity during pegylated alpha-interferon therapy for chronic hepatitis C: a multifocal electroretinogram investigation.
    Alimentary pharmacology & therapeutics, 2005, Mar-15, Volume: 21, Issue:6

    Topics: Adult; Antiviral Agents; Delayed-Action Preparations; Electroretinography; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Ischemia; Male; Middle Aged; Photic Stimulation; Polyethylene Glycols; Reaction Time; Recombinant Proteins; Retinal Hemorrhage; Retinal Vessels; Retrospective Studies; Ribavirin; Vision Disorders; Visual Fields

2005
Monitoring treatment response by the hepatitis C virus core antigen assay.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2005, Volume: 24, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon-alpha; Reagent Kits, Diagnostic; Regression Analysis; Ribavirin; RNA, Viral; Viral Core Proteins

2005
Treatment of chronic hepatitis C in Canadian prison inmates.
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2005, Volume: 19, Issue:3

    Topics: Adult; Antiviral Agents; Canada; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Prisoners; Recombinant Proteins; Retrospective Studies; Ribavirin

2005
Factors accelerating liver fibrosis progression in renal transplant patients receiving ribavirin monotherapy for chronic hepatitis C.
    Journal of medical virology, 2005, Volume: 76, Issue:1

    Topics: Adult; Aged; Anemia, Hemolytic; Antiviral Agents; Cytokines; Female; Hepatitis C, Chronic; Humans; Iron; Iron Overload; Kidney Transplantation; Liver; Liver Cirrhosis; Male; Middle Aged; Postoperative Complications; Ribavirin; Transferrin

2005
Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C.
    The Journal of general virology, 2005, Volume: 86, Issue:Pt 4

    Topics: Amino Acid Sequence; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Molecular Sequence Data; Mutation; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Treatment Outcome; Viral Nonstructural Proteins

2005
Development of hepatocellular carcinoma after interferon therapy in chronic hepatitis C. Is it possible to reduce the incidence by ribanirin and IFN combination therapy?
    Intervirology, 2005, Volume: 48, Issue:1

    Topics: Age Factors; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin; Risk Factors; Sex Factors; Treatment Outcome

2005
Ribavirin monotherapy increases sustained response rate in relapsers of end treatment virologic responders.
    World journal of gastroenterology, 2005, Mar-21, Volume: 11, Issue:11

    Topics: Adult; Antiviral Agents; Cost Savings; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Recurrence; Ribavirin; Treatment Outcome; Viral Load

2005
Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C.
    Intervirology, 2005, Volume: 48, Issue:2-3

    Topics: Adult; Aged; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral

2005
HCV clearance patterns in saliva and serum of patients with chronic HCV infection under interferon plus ribavirin therapy.
    Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2005, Volume: 34, Issue:5

    Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Saliva; Viral Load

2005
Pharmacokinetic/pharmacodynamic and time-to-event models of ribavirin-induced anaemia in chronic hepatitis C.
    Clinical pharmacokinetics, 2005, Volume: 44, Issue:4

    Topics: Adult; Aged; Anemia; Antiviral Agents; Bayes Theorem; Creatinine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythrocyte Count; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Models, Biological; Retrospective Studies; Ribavirin

2005
Antiviral therapy in advanced chronic liver disease due to hepatitis C virus infection: pilot study.
    Journal of gastroenterology and hepatology, 2005, Volume: 20, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Pilot Projects; Ribavirin; Statistics, Nonparametric; Survival Rate; Treatment Outcome

2005
Usefulness of combined measurement of serum bile acids and ferritin as additional prognostic markers to predict failure to reach sustained response to antiviral treatment in chronic hepatitis C.
    Journal of gastroenterology and hepatology, 2005, Volume: 20, Issue:4

    Topics: Adult; Antiviral Agents; Bile Acids and Salts; Chi-Square Distribution; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Ferritins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Linear Models; Male; Predictive Value of Tests; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome

2005
Ribavirin treatment in patients with chronic hepatitis C infection who had renal transplantation.
    Digestive surgery, 2005, Volume: 22, Issue:1-2

    Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Ribavirin; Treatment Failure

2005
Impact of liver steatosis on virological response in [corrected] Italian patients with chronic hepatitis C treated with peg-interferon alpha-2b plus ribavarin.
    Alimentary pharmacology & therapeutics, 2005, May-01, Volume: 21, Issue:9

    Topics: Adult; Antiviral Agents; Drug Evaluation; Drug Therapy, Combination; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome

2005
Diffuse cutaneous eruption due to interferon alfa and ribavirin treatment of chronic hepatitis C.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2005, Volume: 19, Issue:3

    Topics: Antiviral Agents; Drug Eruptions; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin

2005
[Severe autoimmune neutropenia and thrombopenia associated with chronic C hepatitis: effect of antiviral therapy].
    Gastroenterologie clinique et biologique, 2005, Volume: 29, Issue:3

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Purpura, Thrombocytopenic, Idiopathic; Recombinant Proteins; Ribavirin; RNA, Viral

2005
SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C.
    Journal of gastroenterology, 2005, Volume: 40, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Biomarkers; DNA; Drug Administration Routes; Drug Therapy, Combination; Female; Follow-Up Studies; GTP-Binding Proteins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Linkage Disequilibrium; Male; Mannose-Binding Lectin; Middle Aged; Multienzyme Complexes; Myxovirus Resistance Proteins; Osteopontin; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Predictive Value of Tests; Promoter Regions, Genetic; Proteasome Endopeptidase Complex; Retrospective Studies; Ribavirin; RNA, Viral; Sialoglycoproteins; Treatment Outcome

2005
Hemolytic anemia during pegylated IFN-alpha2b plus ribavirin treatment for chronic hepatitis C: ribavirin is not always the culprit.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2005, Volume: 25, Issue:5

    Topics: Anemia, Hemolytic, Autoimmune; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2005
The influence of occult infection with hepatitis B virus on liver histology and response to interferon treatment in chronic hepatitis C patients.
    The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2004, Volume: 8, Issue:6

    Topics: Adult; Antiviral Agents; Biopsy, Needle; Case-Control Studies; DNA, Viral; Drug Therapy, Combination; Female; Genotype; Hepatitis B; Hepatitis B virus; Hepatitis C, Chronic; Humans; Interferons; Liver; Male; Middle Aged; Polymerase Chain Reaction; Ribavirin; Risk Factors

2004
The uncertain natural history of thyrotoxic patients treated with combination interferon alfa-2beta and ribavirin.
    Archives of internal medicine, 2005, May-09, Volume: 165, Issue:9

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; Thyroid Function Tests; Thyrotoxicosis

2005
Exacerbation of psoriasis due to peginterferon alpha-2b plus ribavirin treatment of chronic active hepatitis C.
    Chemotherapy, 2005, Volume: 51, Issue:2-3

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Psoriasis; Recombinant Proteins; Ribavirin

2005
Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection.
    Gastroenterology, 2005, Volume: 128, Issue:5

    Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2005
TGF-beta1 mRNA expression in liver biopsy specimens and TGF-beta1 serum levels in patients with chronic hepatitis C before and after antiviral therapy.
    Journal of clinical pharmacy and therapeutics, 2005, Volume: 30, Issue:3

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Messenger; Transforming Growth Factor beta; Transforming Growth Factor beta1

2005
Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon alpha-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany.
    The European journal of health economics : HEPAC : health economics in prevention and care, 2005, Volume: 6, Issue:2

    Topics: Adult; Cooperative Behavior; Cost-Benefit Analysis; Decision Making; Drug Therapy, Combination; Germany; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Life Expectancy; Models, Theoretical; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin

2005
Expression of bcl-2 protein in chronic hepatitis C: effect of interferon alpha 2b with ribavirin therapy.
    World journal of gastroenterology, 2005, May-21, Volume: 11, Issue:19

    Topics: Adult; Antiviral Agents; Apoptosis; Biopsy; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Recombinant Proteins; Ribavirin

2005
Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2005, Volume: 33, Issue:2

    Topics: Adult; Amantadine; Amino Acid Sequence; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; France; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Alignment; Sequence Analysis, DNA; Viral Load

2005
Pilot study of interferon gamma for chronic hepatitis C.
    Journal of hepatology, 2005, Volume: 43, Issue:1

    Topics: Antiviral Agents; Blood Cell Count; Dose-Response Relationship, Drug; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-gamma; Male; Middle Aged; Pilot Projects; Recurrence; Ribavirin; RNA, Viral; Transaminases; Treatment Failure

2005
T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2005, Volume: 41, Issue:6

    Topics: Antiviral Agents; Black People; CD4 Lymphocyte Count; Cell Proliferation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Phytohemagglutinins; Prospective Studies; Ribavirin; T-Lymphocytes; Viral Load; White People

2005
Reversible alopecia universalis during treatment with PEG-interferon and ribavirin for chronic hepatitis C.
    Journal of chemotherapy (Florence, Italy), 2005, Volume: 17, Issue:2

    Topics: Adult; Alopecia; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index

2005
The association between viral clearance and depression in patients with hepatitis C receiving interferon-alpha and ribavirin.
    Brain, behavior, and immunity, 2005, Volume: 19, Issue:4

    Topics: Comorbidity; Depressive Disorder, Major; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome; Viral Load

2005
Vogt-Koyanagi-Harada disease associated with interferon-A and ribavirin therapy for chronic hepatitis C infection.
    The Journal of infection, 2006, Volume: 52, Issue:2

    Topics: Adrenal Cortex Hormones; Adult; Antiviral Agents; Female; Fluorescein Angiography; Hepatitis C, Chronic; Humans; Interferon-alpha; Retinal Detachment; Ribavirin; Treatment Outcome; Uveomeningoencephalitic Syndrome

2006
Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens.
    Gut, 2005, Volume: 54, Issue:7

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Erythropoiesis; Female; Hematopoiesis; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; Thrombopoiesis

2005
Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2005, Volume: 3, Issue:6

    Topics: Antiviral Agents; Biopsy; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Odds Ratio; Retrospective Studies; Ribavirin; RNA, Viral; Severity of Illness Index; Treatment Outcome; Virulence

2005
Tear function changes during interferon and ribavirin treatment in patients with chronic hepatitis C.
    Cornea, 2005, Volume: 24, Issue:5

    Topics: Adult; Antiviral Agents; Conjunctiva; Drug Therapy, Combination; Dry Eye Syndromes; Epithelial Cells; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lacrimal Apparatus; Male; Metaplasia; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; Surveys and Questionnaires; Tears

2005
Selective granulocyte and monocyte apheresis as a new adjunct to enhance the efficacy of interferon-alpha + ribavirin in patients with high plasma hepatitis C virus.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2005, Volume: 37, Issue:7

    Topics: Adjuvants, Immunologic; Adult; Aged; Alanine Transaminase; Combined Modality Therapy; Drug Therapy, Combination; Female; Granulocytes; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukapheresis; Male; Middle Aged; Monocytes; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load

2005
Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy.
    The American journal of gastroenterology, 2005, Volume: 100, Issue:7

    Topics: Adult; Antiviral Agents; Asian People; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Homeostasis; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; White People

2005
Interstitial pneumonia recurrence during chronic hepatitis C treatment.
    The American journal of gastroenterology, 2005, Volume: 100, Issue:7

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lung Diseases, Interstitial; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Tomography, X-Ray Computed

2005
Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2005, Volume: 5, Issue:8

    Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Graft Survival; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2005
Treatment with pegylated interferon alpha-2b and ribavirin in patients unresponsive to previous treatments with standard interferon as monotherapy or combined with ribavirin.
    Revista espanola de enfermedades digestivas, 2005, Volume: 97, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure

2005
Unilateral oculomotor nerve palsy induced by combination therapy of interferon-alpha2b and ribavirin.
    Internal medicine (Tokyo, Japan), 2005, Volume: 44, Issue:6

    Topics: Adult; Antiviral Agents; Diagnosis, Differential; Diplopia; Drug Therapy, Combination; Eye Movements; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Magnetic Resonance Imaging; Oculomotor Nerve Diseases; Recombinant Proteins; Ribavirin; Tomography, X-Ray Computed

2005
[Hypothyroid myopathy caused by interferon-alpha therapy for chronic hepatitis C].
    Rinsho shinkeigaku = Clinical neurology, 2005, Volume: 45, Issue:6

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Hypothyroidism; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Muscular Diseases; Recombinant Proteins; Ribavirin

2005
Thyroid dysfunction during interferon alpha therapy for chronic hepatitis C.
    Clinical nuclear medicine, 2005, Volume: 30, Issue:8

    Topics: Adult; Antiviral Agents; Female; Graves Disease; Hepatitis C, Chronic; Humans; Interferon-alpha; Radionuclide Imaging; Radiopharmaceuticals; Ribavirin; Sodium Pertechnetate Tc 99m; Thyroiditis

2005
Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy.
    Hepatology (Baltimore, Md.), 2005, Volume: 42, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral

2005
[Curative short term treatment of chronic viral C hepatitis].
    Presse medicale (Paris, France : 1983), 2005, Jun-04, Volume: 34, Issue:10

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2005
The clinical utility of using Catrimox-14-treated whole blood in detecting hepatitis C virus RNA.
    Antiviral therapy, 2005, Volume: 10, Issue:4

    Topics: Adult; Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Quaternary Ammonium Compounds; Recombinant Proteins; Ribavirin; RNA, Viral; Surface-Active Agents; Trimethyl Ammonium Compounds

2005
Mitochondrial DNA depletion in HIV-infected patients is more pronounced with chronic hepatitis C and enhanced following treatment with pegylated interferon plus ribavirin.
    Antiviral therapy, 2005, Volume: 10, Issue:4

    Topics: Adult; Antiviral Agents; DNA, Mitochondrial; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Polyethylene Glycols; Ribavirin

2005
A case report of pityriasis lichenoides in a patient with chronic hepatitis C.
    The Journal of infection, 2005, Volume: 51, Issue:2

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferons; Middle Aged; Pityriasis Lichenoides; Ribavirin; Skin; Treatment Outcome

2005
Polymorphisms in the interferon-gamma gene at position +874 in patients with chronic hepatitis C treated with high-dose interferon-alpha and ribavirin.
    Antiviral research, 2005, Volume: 67, Issue:2

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-gamma; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Genetic; Ribavirin

2005
Interferon-beta induction/interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C.
    International journal of clinical pharmacology research, 2005, Volume: 25, Issue:2

    Topics: Adult; Aged; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-beta; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral

2005
Gamma-glutamyl transferase (GGT) as an independent predictive factor of sustained virologic response in patients with hepatitis C treated with interferon-alpha and ribavirin.
    Journal of clinical gastroenterology, 2005, Volume: 39, Issue:8

    Topics: Adult; Antiviral Agents; Biomarkers; Biopsy; Drug Therapy, Combination; Female; Follow-Up Studies; gamma-Glutamyltransferase; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Polymerase Chain Reaction; Prognosis; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome

2005
Incidence and severity of infections according to the development of neutropenia during combined therapy with pegylated interferon-alpha2a plus ribavirin in chronic hepatitis C infection.
    Methods and findings in experimental and clinical pharmacology, 2005, Volume: 27, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Logistic Models; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2005
HCV clearance and treatment outcome in genotype 1 HCV-monoinfected, HIV-coinfected and liver transplanted patients on peg-IFN-alpha-2b/ribavirin.
    Journal of hepatology, 2005, Volume: 43, Issue:5

    Topics: Adult; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV Seropositivity; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia

2005
Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection.
    The American journal of gastroenterology, 2005, Volume: 100, Issue:8

    Topics: Antiviral Agents; Contraindications; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Mental Disorders; Middle Aged; Patient Acceptance of Health Care; Patient Selection; Ribavirin; Substance-Related Disorders; Treatment Outcome; United States; Veterans

2005
Hair repigmentation in a hepatitis C patient treated with interferon and ribavirin.
    Dermatology (Basel, Switzerland), 2005, Volume: 211, Issue:2

    Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Hair; Hepatitis C, Chronic; Humans; Hyperpigmentation; Interferons; Male; Middle Aged; Ribavirin; Risk Assessment; Severity of Illness Index

2005
Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C.
    Journal of hepatology, 2005, Volume: 43, Issue:4

    Topics: Amino Acid Sequence; Antiviral Agents; Base Sequence; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Molecular Sequence Data; Mutagens; Mutation; Ribavirin; Viral Load; Viral Nonstructural Proteins

2005
Mutagenic effects of ribavirin in vivo.
    Journal of hepatology, 2005, Volume: 43, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Mutagens; Ribavirin; Viral Load

2005
Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy.
    Journal of viral hepatitis, 2005, Volume: 12, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Predictive Value of Tests; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia

2005
Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response.
    Journal of viral hepatitis, 2005, Volume: 12, Issue:5

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viremia

2005
Clinical usefulness of total hepatitis C virus core antigen quantification to monitor the response to treatment with peginterferon alpha-2a plus ribavirin*.
    Journal of viral hepatitis, 2005, Volume: 12, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Core Proteins; Viremia

2005
Weight loss during pegylated interferon and ribavirin treatment of chronic hepatitis C*.
    Journal of viral hepatitis, 2005, Volume: 12, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Health Status; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Polyethylene Glycols; Ribavirin; Weight Loss

2005
Treatment with Peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia.
    Journal of hepatology, 2005, Volume: 43, Issue:4

    Topics: Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2005
The preliminary efficacy of interferon-alpha and ribavirin combination treatment of chronic hepatitis C in HIV-infected patients.
    Chinese medical journal, 2005, Jul-20, Volume: 118, Issue:14

    Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral

2005
[Type 2 diabetes mellitus with histological finding of nonalcoholic steatohepatitis following combination therapy with interferon and ribavirin for chronic hepatitis C].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2005, Volume: 102, Issue:8

    Topics: Adult; Antiviral Agents; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Fatty Liver; Hepatitis C, Chronic; Humans; Interferons; Male; Ribavirin

2005
Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapy.
    Journal of hepatology, 2005, Volume: 43, Issue:5

    Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Interferon alpha-2; Interferon-alpha; Lymphocyte Activation; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; T-Lymphocytes; Treatment Outcome; Viral Core Proteins; Viral Load; Viremia

2005
Acute sensorineural hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment: outcome after resumption of therapy.
    World journal of gastroenterology, 2005, Sep-14, Volume: 11, Issue:34

    Topics: Acute Disease; Antiviral Agents; Drug Therapy, Combination; Female; Hearing Loss, Sensorineural; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2005
Hashimoto encephalopathy with pegylated interferon alfa-2b and ribavirin.
    The Annals of pharmacotherapy, 2005, Volume: 39, Issue:10

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hashimoto Disease; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Neurotoxicity Syndromes; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2005
Peginterferon Alfa-2b and ribavirin for 12 versus 24 weeks in HCV infection.
    The New England journal of medicine, 2005, Sep-15, Volume: 353, Issue:11

    Topics: Antiviral Agents; Body Mass Index; Drug Administration Schedule; Drug Therapy, Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; United States

2005
Patient education and treatment strategies implemented at a pharmacist-managed hepatitis C virus clinic.
    Pharmacotherapy, 2005, Volume: 25, Issue:9

    Topics: Ambulatory Care Facilities; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Patient Compliance; Patient Education as Topic; Pharmacy Service, Hospital; Polyethylene Glycols; Professional Role; Recombinant Proteins; Ribavirin

2005
Treatment of chronic hepatitis C with interferon alone or combined with ribavirin in Japan.
    Intervirology, 2006, Volume: 49, Issue:1-2

    Topics: Aged; Antiviral Agents; Body Mass Index; Clinical Trials as Topic; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Japan; Male; Middle Aged; Multicenter Studies as Topic; Patient Compliance; Ribavirin; RNA, Viral; Species Specificity; Treatment Outcome; Treatment Refusal

2006
Peginterferon Alfa-2b and ribavirin for 12 versus 24 weeks in HCV infection.
    The New England journal of medicine, 2005, Sep-15, Volume: 353, Issue:11

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2005
Ischaemic jejunal vasculitis during treatment with pegylated interferon-alpha 2b and ribavirin for hepatitis C virus related cirrhosis.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2006, Volume: 38, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Infarction; Interferon alpha-2; Interferon-alpha; Ischemia; Jejunum; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Vasculitis

2006
Chronic hepatitis C in Latinos: natural history, treatment eligibility, acceptance, and outcomes.
    The American journal of gastroenterology, 2005, Volume: 100, Issue:10

    Topics: Adult; Antiviral Agents; Eligibility Determination; Female; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Acceptance of Health Care; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Veterans; White People

2005
[Pulmonary sarcoidosis associated with pegylated interferon in the treatment of chronic hepatitis C].
    Gastroenterologia y hepatologia, 2005, Volume: 28, Issue:8

    Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Ribavirin; Sarcoidosis, Pulmonary; Th1 Cells; Tomography, X-Ray Computed

2005
Intra-host evolutionary dynamics of hepatitis C virus E2 in treated patients.
    The Journal of general virology, 2005, Volume: 86, Issue:Pt 10

    Topics: Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Evolution, Molecular; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Molecular Sequence Data; Phylogeny; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Envelope Proteins

2005
Peginterferon and dose-titrated ribavirin for hepatitis C-associated nephrotic membranoproliferative glomerulonephritis type 1.
    Digestive diseases and sciences, 2005, Volume: 50, Issue:10

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glomerulonephritis, Membranoproliferative; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Nephrotic Syndrome; Polyethylene Glycols; Recombinant Proteins; Renal Insufficiency; Ribavirin

2005
[The apoptosis of hepatic tissues in hepatitis C].
    Przeglad epidemiologiczny, 2005, Volume: 59, Issue:2

    Topics: Adult; Antiviral Agents; Apoptosis; Biopsy, Needle; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Hepatocytes; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Poland; Recombinant Proteins; Ribavirin; Severity of Illness Index; Tumor Suppressor Protein p53

2005
[Neuropsychiatric disorders in HCV-infected people--own observations].
    Przeglad epidemiologiczny, 2005, Volume: 59, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Depression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mood Disorders; Poland; Psychiatric Status Rating Scales; Quality of Life; Recombinant Proteins; Ribavirin; Severity of Illness Index; Time Factors; Treatment Outcome

2005
[The influence of HCV infection and immunomodulating therapy (interferon-alpha and ribavirin) on the condition of minor salivary glands and oral mucosa].
    Przeglad epidemiologiczny, 2005, Volume: 59, Issue:2

    Topics: Adolescent; Adult; Antiviral Agents; Case-Control Studies; Child; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Lichen Planus, Oral; Male; Middle Aged; Ribavirin; Risk Factors; Salivary Gland Diseases; Time Factors

2005
[Alterations within white blood cell subsets in children with chronic viral hepatitis C before treatment with pegylated interferon and ribavirin].
    Przeglad epidemiologiczny, 2005, Volume: 59, Issue:2

    Topics: Adolescent; Antiviral Agents; B-Lymphocytes; Biomarkers; Case-Control Studies; Child; Child Welfare; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Killer Cells, Natural; Leukocytes; Lymphocyte Subsets; Male; Monocytes; Poland; Polyethylene Glycols; Recombinant Proteins; Ribavirin; T-Lymphocytes; Time Factors

2005
[Effects of treatment with pegylated interferon and ribavirin in children with chronic hepatitis C].
    Przeglad epidemiologiczny, 2005, Volume: 59, Issue:2

    Topics: Adolescent; Alanine Transaminase; Antiviral Agents; Case-Control Studies; Child; Child Welfare; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Poland; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Viral Load; Viremia

2005
[Complications in a patient with liver cirrhosis and HCV coinfection during treatment with peginterferon and ribavirin].
    Przeglad epidemiologiczny, 2005, Volume: 59, Issue:2

    Topics: Adolescent; Antiviral Agents; Biliary Atresia; Child; Female; Hepatitis C, Chronic; Humans; Hypertension, Portal; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Failure; Liver Transplantation; Polyethylene Glycols; Portasystemic Shunt, Transjugular Intrahepatic; Recombinant Proteins; Ribavirin; Treatment Outcome

2005
Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C.
    Journal of managed care pharmacy : JMCP, 2005, Volume: 11, Issue:8

    Topics: Administration, Oral; Adult; Antiviral Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Multicenter Studies as Topic; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome

2005
The impact of past alcohol use on treatment response rates in patients with chronic hepatitis C.
    Alimentary pharmacology & therapeutics, 2005, Oct-15, Volume: 22, Issue:8

    Topics: Adult; Alcohol Drinking; Antiviral Agents; Black People; Drug Therapy, Combination; Ethanol; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome

2005
Safe use of pegylated interferon/ribavirin in hepatitis C virus cirrhotic patients with hypersplenism after partial splenic embolization.
    European journal of gastroenterology & hepatology, 2005, Volume: 17, Issue:11

    Topics: Antiviral Agents; Combined Modality Therapy; Drug Therapy, Combination; Embolization, Therapeutic; Female; Hepatitis C, Chronic; Humans; Hypersplenism; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Thrombocytopenia; Treatment Outcome

2005
Onset of inflammatory bowel diseases during combined alpha-interferon and ribavirin therapy for chronic hepatitis C: report of two cases.
    European journal of gastroenterology & hepatology, 2005, Volume: 17, Issue:11

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Inflammatory Bowel Diseases; Interferon-alpha; Male; Middle Aged; Ribavirin

2005
The impact of haematopoietic growth factors on the management and efficacy of antiviral treatment in patients with hepatitis C virus.
    Antiviral therapy, 2005, Volume: 10, Issue:6

    Topics: Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2005
Improvement of quantitative testing of liver function in patients with chronic hepatitis C after installment of antiviral therapy.
    World journal of gastroenterology, 2005, Sep-21, Volume: 11, Issue:35

    Topics: Adult; Antiviral Agents; Case-Control Studies; Female; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Function Tests; Male; Middle Aged; Ribavirin

2005
Meyerson's naevi induced by interferon alfa plus ribavirin combination therapy in hepatitis C infection.
    The British journal of dermatology, 2005, Volume: 153, Issue:5

    Topics: Adult; Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Nevus; Recombinant Proteins; Ribavirin; Skin Neoplasms

2005
No role of the -2518 promoter polymorphism of monocyte chemotactic protein-1 in chronic hepatitis C.
    Gastroenterology, 2005, Volume: 129, Issue:4

    Topics: Antiviral Agents; Chemokine CCL2; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Sequence Deletion

2005
Erythropoietic growth factors for treatment-induced anemia in hepatitis C: a cost-effectiveness analysis.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2005, Volume: 3, Issue:10

    Topics: Anemia; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Darbepoetin alfa; Erythropoietin; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Transaminases; Treatment Outcome

2005
Interleukin 6 and 12, alanine aminotransferase activity, and HCV viral load in children with chronic hepatitis C treated with interferon and ribavirin.
    Inflammation, 2004, Volume: 28, Issue:6

    Topics: Alanine Transaminase; Antiviral Agents; Child; Cohort Studies; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-12; Interleukin-6; Male; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Viral Load

2004
[Interferon-alpha and ribavirin combination therapy for co-infection of hepatitis C virus and human immunodeficiency virus].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2005, Volume: 13, Issue:10

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Ribavirin

2005
The effect of ribavirin on bone density in patients with chronic hepatitis C treated with interferon-ribavirin therapy.
    Journal of pediatric gastroenterology and nutrition, 2005, Volume: 41, Issue:5

    Topics: Adolescent; Biomarkers; Bone and Bones; Bone Density; Child; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lumbar Vertebrae; Male; Recombinant Proteins; Ribavirin

2005
Maintenance of T1 response as induced during PEG-IFNalpha plus ribavirin therapy controls viral replication in genotype-1 patients with chronic hepatitis C.
    Revista espanola de enfermedades digestivas, 2005, Volume: 97, Issue:7

    Topics: Adult; Analysis of Variance; Antiviral Agents; Chi-Square Distribution; Cytokines; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Flow Cytometry; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; T-Lymphocytes; Time Factors; Treatment Outcome

2005
[Treatment for hepatitis C virus associated cryoglobulinemia with interferon alpha and ribavirin].
    Revista espanola de enfermedades digestivas, 2005, Volume: 97, Issue:7

    Topics: Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Treatment Outcome

2005
Hepatic steatosis in chronic hepatitis C: impact on response to anti-viral treatment with peg-interferon and ribavirin.
    Alimentary pharmacology & therapeutics, 2005, Nov-15, Volume: 22, Issue:10

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2005
Does depression symptomatology affect medication compliance during the first weeks of anti-HCV therapy in intravenous drug users?
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2006, Volume: 38, Issue:2

    Topics: Adult; Antiviral Agents; Comorbidity; Depression; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Patient Compliance; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Substance Abuse, Intravenous

2006
Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1.
    Gut, 2006, Volume: 55, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunohistochemistry; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Obesity; Phosphoenolpyruvate Carboxykinase (GTP); Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Signal Transduction; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Treatment Outcome

2006
Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy.
    The Journal of antimicrobial chemotherapy, 2005, Volume: 56, Issue:6

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin

2005
Vogt-Koyanagi-Harada disease in patients with chronic hepatitis C.
    American journal of ophthalmology, 2005, Volume: 140, Issue:5

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Fluorescein Angiography; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Uveomeningoencephalitic Syndrome

2005
Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naïve and non-responder patients on a stable immunosuppressive regimen.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2006, Volume: 38, Issue:1

    Topics: Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral

2006
[Efficacy of peginterferon plus ribavirin for HIV-HCV co-infection. Results of the APRICOT study].
    Presse medicale (Paris, France : 1983), 2005, Nov-19, Volume: 34, Issue:20 Pt 2

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Multicenter Studies as Topic; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Viral Load

2005
Tumor necrosis factor- alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection.
    The Journal of infectious diseases, 2006, Jan-01, Volume: 193, Issue:1

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polymorphism, Genetic; Predictive Value of Tests; Promoter Regions, Genetic; Ribavirin; Treatment Outcome; Tumor Necrosis Factor-alpha

2006
Hepatitis C treatment in an HIV-HCV-coinfected patient with drug addiction and psychiatric illness: a case report.
    The AIDS reader, 2005, Volume: 15, Issue:11

    Topics: Adult; Antiviral Agents; Depression; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Substance-Related Disorders; Treatment Outcome

2005
Studies on the variation in clinical laboratory data and safety evaluation of pharmaceuticals.
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2005, Volume: 125, Issue:12

    Topics: Antiviral Agents; Clinical Laboratory Information Systems; Clinical Laboratory Techniques; Clinical Trials as Topic; Data Interpretation, Statistical; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Patient Selection; Pharmaceutical Preparations; Reference Values; Ribavirin; Sensitivity and Specificity

2005
Treatment of hepatitis C virus infection in thalassemia.
    Annals of the New York Academy of Sciences, 2005, Volume: 1054

    Topics: Adolescent; Adult; Antiviral Agents; Biopsy, Needle; Bone Marrow Transplantation; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Iron; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Mass Spectrometry; Polyethylene Glycols; Ribavirin; Thalassemia; Transfusion Reaction; Treatment Outcome; Viremia

2005
Hemolytic anemia during 24 weeks of ribavirin and interferon-alpha2b combination therapy does not influence the cardiac function of patients with viral hepatitis C.
    Journal of clinical gastroenterology, 2006, Volume: 40, Issue:1

    Topics: Anemia, Hemolytic; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Natriuretic Peptide, Brain; Recombinant Proteins; Ribavirin

2006
Changes in serum and red blood cell membrane lipids in patients treated with interferon ribavirin for chronic hepatitis C.
    Clinical and experimental medicine, 2005, Volume: 5, Issue:4

    Topics: Adult; Antiviral Agents; Erythrocyte Membrane; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Lipids; Male; Membrane Lipids; Middle Aged; Ribavirin; Thiobarbituric Acid Reactive Substances

2005
[Retinopathy during interferon treatment in combination with ribavirin for chronic hepatitis C].
    Nippon Ganka Gakkai zasshi, 2005, Volume: 109, Issue:11

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Retinal Diseases; Retinal Hemorrhage; Ribavirin

2005
Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2006, Volume: 43, Issue:1

    Topics: Adult; Age Factors; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Patient Compliance; Prospective Studies; Recombinant Proteins; Ribavirin

2006
Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2006, Volume: 43, Issue:1

    Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Cohort Studies; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2006
What do patients consider when making decisions about treatment for hepatitis C?
    The American journal of medicine, 2005, Volume: 118, Issue:12

    Topics: Adult; Antiviral Agents; Cross-Sectional Studies; Decision Making; Female; Focus Groups; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Participation; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Refusal

2005
[Retreatment of patients with chronic hepatitis C].
    Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti, 2005, Volume: 59, Issue:5

    Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Retreatment; Ribavirin; Treatment Failure

2005
[Treatment of viral hepatitis in children].
    Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti, 2005, Volume: 59, Issue:5

    Topics: Child; Drug Therapy, Combination; Hepatitis B; Hepatitis B, Chronic; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin

2005
[Treatment of chronic hepatitis C in patients with HIV infection].
    Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti, 2005, Volume: 59, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Ribavirin

2005
A success story with chronic hepatitis C.
    The Journal of the Arkansas Medical Society, 2005, Volume: 102, Issue:6

    Topics: Antiviral Agents; Drug Carriers; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2005
Sustained virological response rate to pegylated interferon plus ribavirin for chronic hepatitis C in African Americans: results in treatment-naïve patients in a university liver clinic.
    Journal of the National Medical Association, 2005, Volume: 97, Issue:12

    Topics: Adult; Alleles; Antiviral Agents; Black or African American; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Hispanic or Latino; Hospitals, University; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors; Time Factors; White People

2005
[Effectiveness of antiviral therapy in patients with chronic hepatitis C treated by private practice gastroenterologists].
    Zeitschrift fur Gastroenterologie, 2006, Volume: 44, Issue:1

    Topics: Adult; Antiviral Agents; Drug Combinations; Female; Gastroenterology; Germany; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Outcome Assessment, Health Care; Private Practice; Prognosis; Remote Consultation; Ribavirin; Treatment Outcome

2006
Effect of iron overload on the severity of liver histologic alterations and on the response to interferon and ribavirin therapy of patients with hepatitis C infection.
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2006, Volume: 39, Issue:1

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Iron Overload; Male; Middle Aged; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Severity of Illness Index

2006
Tongue and skin hyperpigmentation during PEG-interferon-alpha/ribavirin therapy in dark-skinned non-Caucasian patients with chronic hepatitis C.
    The American journal of gastroenterology, 2006, Volume: 101, Issue:1

    Topics: Adult; Black People; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Hyperpigmentation; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Sampling Studies; Severity of Illness Index; Skin; Tongue

2006
Ribavirin levels and haemoglobin decline in early virological responders and non-responders to hepatitis C virus combination therapy.
    Pharmacology, 2006, Volume: 76, Issue:3

    Topics: Alanine Transaminase; Antiviral Agents; Blood Preservation; Chromatography, High Pressure Liquid; Disease Progression; Drug Monitoring; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Half-Life; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome

2006
Effects of combined antiviral therapy on asymptomatic mixed cryoglobulinemia in naive patients with chronic hepatitis C virus infection: a preliminary study.
    Digestive diseases and sciences, 2005, Volume: 50, Issue:12

    Topics: Adult; Aged; Antiviral Agents; Cryoglobulinemia; Cryoglobulins; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Prospective Studies; Ribavirin; Risk Assessment; Severity of Illness Index; Treatment Outcome; Viral Load

2005
Hepatitis C virus genotype 5 in southern belgium: epidemiological characteristics and response to therapy.
    Digestive diseases and sciences, 2005, Volume: 50, Issue:12

    Topics: Adult; Age Distribution; Antiviral Agents; Belgium; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Risk Assessment; RNA, Viral; Severity of Illness Index; Sex Distribution; Treatment Outcome

2005
Anti-HCV agent, ribavirin, elevates the activity of clotting factor VII in patients with hemophilia: a possible mechanism of decreased events of bleeding in patients with hemophilia by ribavirin.
    Journal of thrombosis and haemostasis : JTH, 2006, Volume: 4, Issue:2

    Topics: Adult; Antiviral Agents; Cells, Cultured; Factor VII; Gene Expression; Hemophilia A; Hemophilia B; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Male; Middle Aged; Ribavirin; RNA, Messenger

2006
Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice.
    Alimentary pharmacology & therapeutics, 2006, Feb-01, Volume: 23, Issue:3

    Topics: Adult; Antiviral Agents; Canada; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome

2006
Effect of cytokine gene polymorphism on histological activity index, viral load and response to treatment in patients with chronic hepatitis C genotype 3.
    World journal of gastroenterology, 2005, Nov-14, Volume: 11, Issue:42

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Cytokines; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome; Viral Load

2005
Effect of pegylated interferon alpha 2b plus ribavirin treatment on plasma transforming growth factor-beta1, metalloproteinase-1, and tissue metalloproteinase inhibitor-1 in patients with chronic hepatitis C.
    World journal of gastroenterology, 2005, Nov-21, Volume: 11, Issue:43

    Topics: Adult; Antiviral Agents; Drug Carriers; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Matrix Metalloproteinase 1; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Statistics as Topic; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta; Transforming Growth Factor beta1

2005
Depression, anemia and health-related quality of life in chronic hepatitis C.
    Journal of hepatology, 2006, Volume: 44, Issue:3

    Topics: Adult; Aged; Anemia; Antiviral Agents; Depression; Female; Follow-Up Studies; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Prospective Studies; Quality of Life; Recombinant Proteins; Ribavirin; Risk Factors; Surveys and Questionnaires

2006
[Perspectives in hepatology in the next 2-3 years: what will be clinically relevant? Viral hepatitis].
    Deutsche medizinische Wochenschrift (1946), 2005, Dec-16, Volume: 130 Suppl 5

    Topics: Amantadine; Antiviral Agents; Genotype; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatovirus; Humans; Interferons; Nucleic Acid Synthesis Inhibitors; Protease Inhibitors; Ribavirin; Viral Load

2005
Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy.
    Alimentary pharmacology & therapeutics, 2006, Feb-15, Volume: 23, Issue:4

    Topics: Adult; Alanine Transaminase; alpha-Fetoproteins; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome

2006
Thalidomide in the treatment of chronic hepatitis C unresponsive to alfa-interferon and ribavirin.
    The American journal of gastroenterology, 2006, Volume: 101, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Male; Middle Aged; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Thalidomide; Treatment Outcome

2006
Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: incidence, associated factors and prognosis.
    Journal of gastroenterology and hepatology, 2006, Volume: 21, Issue:1 Pt 2

    Topics: Antiviral Agents; Autoantibodies; Case-Control Studies; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Thyroid Diseases; Thyrotropin; Thyroxine

2006
Treatment of HCV infection with interferon alpha-2b and ribavirin in a patient with X-linked lymphoproliferative syndrome.
    European journal of pediatrics, 2006, Volume: 165, Issue:5

    Topics: Antiviral Agents; Child; DNA, Viral; Drug Therapy, Combination; Epstein-Barr Virus Infections; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lymphoproliferative Disorders; Recombinant Proteins; Ribavirin; RNA, Viral

2006
[Generalized eczema secondary to combined treatment with peginterferon alfa-2a and ribavirin in a patient with chronic hepatitis from the hepatitis C virus].
    Actas dermo-sifiliograficas, 2005, Volume: 96, Issue:2

    Topics: Adult; Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Eczema; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2005
Treatment outcomes in a centralized specialty clinic for hepatitis C virus are comparable with those from clinical trials.
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2006, Volume: 20, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Clinical Trials as Topic; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Manitoba; Outcome Assessment, Health Care; Outpatient Clinics, Hospital; Recombinant Proteins; Ribavirin

2006
Soluble tumor necrosis factor-related ligand (sTRAIL) levels and kinetics during antiviral treatment in chronic hepatitis C.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2006, Volume: 26, Issue:2

    Topics: Adult; Aged; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin; TNF-Related Apoptosis-Inducing Ligand

2006
Reactivation of severe, acute pulmonary tuberculosis during treatment with pegylated interferon-alpha and ribavirin for chronic HCV hepatitis.
    Scandinavian journal of infectious diseases, 2006, Volume: 38, Issue:3

    Topics: Acute Disease; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Radiography; Ribavirin; Severity of Illness Index; Tomography Scanners, X-Ray Computed; Tuberculosis, Pulmonary

2006
[Psychological side effects during interferon-alpha therapy -- a case study].
    Psychiatrische Praxis, 2006, Volume: 33, Issue:2

    Topics: Adult; Antiviral Agents; Asthenia; Combined Modality Therapy; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Psychoanalytic Therapy; Psychophysiologic Disorders; Recombinant Proteins; Retreatment; Ribavirin; Sick Role; Substance Withdrawal Syndrome

2006
[Treatment of chronic hepatitis C in haemophilia patients].
    Orvosi hetilap, 2006, Jan-15, Volume: 147, Issue:2

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Drug Therapy, Combination; Female; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome

2006
Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy.
    AIDS (London, England), 2006, Jan-09, Volume: 20, Issue:2

    Topics: Acute Disease; Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; HIV-1; Homosexuality, Male; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Phylogeny; Recombinant Proteins; Retrospective Studies; Ribavirin; Sexual Behavior; Sexually Transmitted Diseases, Viral; Treatment Outcome

2006
The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.
    Journal of hepatology, 2006, Volume: 44, Issue:4

    Topics: Dose-Response Relationship, Drug; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Viremia

2006
Pegylated interferon and ribavirin in haemodialysis patients.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2006, Volume: 21, Issue:5

    Topics: Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Polymerase Chain Reaction; Recombinant Proteins; Renal Dialysis; Ribavirin; Risk Assessment; RNA, Viral; Treatment Outcome

2006
Hepatic interferon receptor mRNA expression: clinical relevance and its relationship with effectiveness of interferon plus ribavirin therapy in patients with genotype 1b hepatitis C virus infection.
    Antiviral therapy, 2006, Volume: 11, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Receptors, Interferon; Recombinant Proteins; Ribavirin; RNA, Messenger; Treatment Outcome

2006
Effect of interferon alpha and ribavirin treatment on serum levels of transforming growth factor-beta1, vascular endothelial growth factor, and basic fibroblast growth factor in patients with chronic hepatitis C.
    World journal of gastroenterology, 2006, Feb-14, Volume: 12, Issue:6

    Topics: Adult; Antiviral Agents; Biomarkers; Female; Fibroblast Growth Factor 2; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prognosis; Ribavirin; Transforming Growth Factor beta; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A

2006
[Patient with HCV chronic hepatitis who has subcutaneous nodules after finishing treatment with pegylated interferon].
    Revista clinica espanola, 2005, Volume: 205, Issue:12

    Topics: Antiviral Agents; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Hypertension; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sarcoidosis

2005
Does a lower insulin resistance affect antiviral therapy response in patients suffering from HCV related chronic hepatitis?
    Gut, 2006, Volume: 55, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Diet; Drug Therapy, Combination; Energy Intake; Female; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2006
Sustained virologic response with short-course ribavirin and peginterferon treatment in 2 patients coinfected with HIV and HCV genotype 1.
    The AIDS reader, 2006, Volume: 16, Issue:3

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2006
Hepatitis C treatment of veterans with psychiatric illness.
    The American journal of gastroenterology, 2006, Volume: 101, Issue:3

    Topics: Antiviral Agents; Cohort Studies; Comorbidity; Contraindications; Dementia; Hepatitis C, Chronic; Humans; Interferon-alpha; Mental Disorders; Prejudice; Ribavirin; Risk Factors; Substance-Related Disorders; Veterans

2006
Significance of occult HBV infection in patients with chronic hepatitis C.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2006, Volume: 16, Issue:3

    Topics: Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Follow-Up Studies; Hepatitis B; Hepatitis B virus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Polymerase Chain Reaction; Ribavirin; Time Factors; Treatment Outcome

2006
[Clinical benefit of HCV core antigen assay in patients receiving interferon and ribavirin combination therapy].
    Rinsho byori. The Japanese journal of clinical pathology, 2006, Volume: 54, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Nucleic Acid Amplification Techniques; Ribavirin; RNA, Viral; Viral Core Proteins; Viral Load

2006
Are elderly patients poor candidates for pegylated interferon plus ribavirin in the treatment of chronic hepatitis C?
    Journal of the American Geriatrics Society, 2006, Volume: 54, Issue:3

    Topics: Age Factors; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome

2006
[Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea].
    The Korean journal of hepatology, 2006, Volume: 12, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Korea; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2006
Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2006, May-01, Volume: 835, Issue:1-2

    Topics: Chemical Fractionation; Chromatography, High Pressure Liquid; Drug Monitoring; Hepatitis C, Chronic; Humans; Reproducibility of Results; Ribavirin; Sensitivity and Specificity; Ultraviolet Rays

2006
Treatment of chronic hepatitis C in patients with glucose-6-phosphate dehydrogenase deficiency: is ribavirin harmful?
    Blood, 2006, Apr-15, Volume: 107, Issue:8

    Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Drug Combinations; Female; Glucosephosphate Dehydrogenase Deficiency; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin

2006
[Thyroid alterations following treatment with pegylated interferon and ribavirin: differences between HIV-coinfected and non-coinfected patients].
    Enfermedades infecciosas y microbiologia clinica, 2006, Volume: 24, Issue:3

    Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Seropositivity; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thyroid Gland; Thyroid Hormones

2006
Modulation of the anti-inflammatory interleukin 10 and of proapoptotic IL-18 in patients with chronic hepatitis C treated with interferon alpha and ribavirin.
    Journal of viral hepatitis, 2006, Volume: 13, Issue:4

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Apoptosis; Aspartate Aminotransferases; Case-Control Studies; Drug Therapy, Combination; fas Receptor; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-10; Interleukin-18; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Statistics, Nonparametric

2006
Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin*.
    Journal of viral hepatitis, 2006, Volume: 13, Issue:4

    Topics: Alanine Transaminase; Antiviral Agents; Biopsy; Black People; Dose-Response Relationship, Drug; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Ribavirin; RNA, Viral; White People

2006
[Acute pancreatitis in a hepatitis C positive patient following treatment with peginterferon alfa-2b and ribavirin].
    Nederlands tijdschrift voor geneeskunde, 2006, Mar-25, Volume: 150, Issue:12

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pancreatitis, Acute Necrotizing; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2006
De novo hepatocellular carcinoma in a patient with chronic hepatitis C 5 years after sustained virologic response to interferon/ribavirin therapy.
    Digestive diseases and sciences, 2006, Volume: 51, Issue:3

    Topics: Antiviral Agents; Biopsy, Needle; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Drug Therapy, Combination; Follow-Up Studies; Hepatectomy; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferons; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Ribavirin; Risk Assessment; Severity of Illness Index

2006
[The meaning of viral kinetics in the beginning of the pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C].
    Vnitrni lekarstvi, 2006, Volume: 52, Issue:2

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viremia

2006
[The role of STAT proteins in the regulation of the response to the interferone alpha therapy in chronic hepatitis C].
    Vnitrni lekarstvi, 2006, Volume: 52, Issue:2

    Topics: Antiviral Agents; Biopsy; Hepatitis C, Chronic; Humans; Interferon-alpha; Janus Kinase 1; Liver; Mitogen-Activated Protein Kinase 3; Protein Inhibitors of Activated STAT; Protein-Tyrosine Kinases; Ribavirin; Signal Transduction; Small Ubiquitin-Related Modifier Proteins; STAT Transcription Factors; Suppressor of Cytokine Signaling Proteins; Viral Load

2006
Efficacy and safety of pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
    AIDS research and human retroviruses, 2006, Volume: 22, Issue:4

    Topics: Adult; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Virus Replication

2006
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy.
    Hepatology (Baltimore, Md.), 2006, Volume: 43, Issue:5

    Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA; Time Factors

2006
Mutations within protein kinase R-binding domain of NS5A protein of hepatitis C virus (HCV) and specificity of HCV antibodies in pretreatment sera of HCV-chronically infected patients and their effect on the result of treatment.
    Japanese journal of infectious diseases, 2006, Volume: 59, Issue:2

    Topics: Adult; Amino Acid Sequence; Antiviral Agents; Biomarkers; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Immunoenzyme Techniques; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Mutation; Pilot Projects; Polyethylene Glycols; Prognosis; Protein Kinases; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Nonstructural Proteins

2006
Autoimmune disorders during interferon therapy in a patient with chronic hepatitis C infection: how many of them can be observed in a single patient?
    Journal of clinical gastroenterology, 2006, Volume: 40, Issue:4

    Topics: Anemia, Hemolytic, Autoimmune; Antiviral Agents; Disease Progression; Hashimoto Disease; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin

2006
Mild hepatitis C: treat or monitor.
    Journal of viral hepatitis, 2006, Volume: 13, Issue:5

    Topics: Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin

2006
Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting.
    Journal of viral hepatitis, 2006, Volume: 13, Issue:5

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Intercellular Signaling Peptides and Proteins; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Organometallic Compounds; Peptides; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral

2006
Pegylated interferon for treatment in hemodialysis patients with chronic hepatitis C.
    Journal of gastroenterology and hepatology, 2006, Volume: 21, Issue:3

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin; Risk Factors

2006
Late onset autoimmune thrombocytopenia associated with pegylated interferon-alpha-2b plus ribavirin treatment for chronic hepatitis C.
    Journal of gastroenterology and hepatology, 2006, Volume: 21, Issue:3

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia; Treatment Outcome

2006
Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C.
    Scandinavian journal of gastroenterology, 2006, Volume: 41, Issue:5

    Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Health Status; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Quality of Life; Recombinant Proteins; Ribavirin; Sweden

2006
[Therapy with peginterferon alfa in a patient with polyneuropathy caused by hepatitis C-associated vasculitis].
    Medizinische Klinik (Munich, Germany : 1983), 2006, Mar-15, Volume: 101, Issue:3

    Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Inflammation Mediators; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Neuritis; Neurologic Examination; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Vasculitis

2006
Intracerebral hemorrhage in a patient receiving combination therapy of pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.
    Internal medicine (Tokyo, Japan), 2006, Volume: 45, Issue:7

    Topics: Antiviral Agents; Cerebral Hemorrhage; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2006
The effect of interferon alpha plus ribavirin on health-related quality of life in chronic C hepatitis. The Romanian experience.
    Journal of gastrointestinal and liver diseases : JGLD, 2006, Volume: 15, Issue:1

    Topics: Adult; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Health Status; Hepatitis C, Chronic; Humans; Interferon-alpha; Longitudinal Studies; Male; Matched-Pair Analysis; Quality of Life; Ribavirin

2006
[Association of chronic hepatitis C and lichen planus--in two patients].
    Orvosi hetilap, 2006, Mar-26, Volume: 147, Issue:12

    Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon-alpha; Lichen Planus; Male; Middle Aged; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Skin

2006
Alcohol use and treatment of hepatitis C virus: results of a national multicenter study.
    Gastroenterology, 2006, Volume: 130, Issue:6

    Topics: Aged; Alcohol Drinking; Antiviral Agents; Case-Control Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Patient Selection; Probability; Prospective Studies; Recombinant Proteins; Reference Values; Ribavirin; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Survival Rate; Treatment Outcome

2006
Effects of interferon plus ribavirin treatment on NF-kappaB, TGF-beta1, and metalloproteinase activity in chronic hepatitis C.
    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2006, Volume: 19, Issue:8

    Topics: Adult; Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Fibrosis; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Metalloproteases; Middle Aged; NF-kappa B; Retrospective Studies; Ribavirin; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta; Transforming Growth Factor beta1; Treatment Outcome

2006
[Concomitant nodular goiter during IFN and ribavirin treatment of HCV: a case report].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2006, Volume: 14, Issue:3

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Goiter, Nodular; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin

2006
Onset of type 1 diabetes mellitus during peginterferon alpha-2b plus ribavirin treatment for chronic hepatitis C.
    European journal of gastroenterology & hepatology, 2006, Volume: 18, Issue:6

    Topics: Antiviral Agents; Autoimmunity; Chronic Disease; Combined Modality Therapy; Diabetes Mellitus, Type 1; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2006
Central hypothyroidism and hypophysitis during treatment of chronic hepatitis C with pegylated interferon alpha and ribavirin.
    European journal of gastroenterology & hepatology, 2006, Volume: 18, Issue:6

    Topics: Antiviral Agents; Autoimmune Diseases; Combined Modality Therapy; Female; Hepatitis C, Chronic; Humans; Hypothyroidism; Interferon alpha-2; Interferon-alpha; Magnetic Resonance Imaging; Middle Aged; Pituitary Diseases; Recombinant Proteins; Ribavirin; Thyroid Hormones

2006
[Development of porphyria cutanea tarda in a chronic hepatitis C patient with indetectable viremia under treatment with peg-interferon plus ribavirin].
    Acta gastroenterologica Latinoamericana, 2006, Volume: 36, Issue:1

    Topics: Antiviral Agents; Hemochromatosis; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Porphyria Cutanea Tarda; Recombinant Proteins; Ribavirin

2006
[How to use viral genomic analysis in clinical practice: chronic hepatitis B and C].
    Rinsho byori. The Japanese journal of clinical pathology, 2006, Volume: 54, Issue:4

    Topics: Adult; Genome, Viral; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2006
[Severe thrombocytopenia with probable autoimmune mechanism associated with interferon therapy in a patient with chronic hepatitis C].
    Gastroenterologia y hepatologia, 2006, Volume: 29, Issue:5

    Topics: Adult; Antiviral Agents; Combined Modality Therapy; Drug Therapy, Combination; Hemorrhagic Disorders; Hepatitis C, Chronic; Humans; Immunoglobulins, Intravenous; Interferons; Male; Methylprednisolone; Platelet Transfusion; Polyethylene Glycols; Purpura, Thrombocytopenic, Idiopathic; Ribavirin

2006
Cost-effectiveness of chronic hepatitis C treatment with thymosin alpha-1.
    Archives of medical research, 2006, Volume: 37, Issue:5

    Topics: Adjuvants, Immunologic; Antiviral Agents; Costs and Cost Analysis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Mexico; Polyethylene Glycols; Prospective Studies; Quality of Life; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Thymalfasin; Thymosin

2006
Treatment of cryoglobulinemia associated peripheral neuropathy with rituximab.
    The Journal of rheumatology, 2006, Volume: 33, Issue:6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Cryoglobulinemia; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Male; Middle Aged; Peripheral Nervous System Diseases; Prednisolone; Remission Induction; Ribavirin; Rituximab

2006
Quasispecies as predictive response factors for antiviral treatment in patients with chronic hepatitis C.
    Digestive diseases and sciences, 2006, Volume: 51, Issue:5

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Prognosis; Ribavirin; Viral Load

2006
Serum proteome to predict virologic response in patients with hepatitis C treated by pegylated interferon plus ribavirin.
    Gastroenterology, 2006, Volume: 130, Issue:7

    Topics: Adult; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genetic Markers; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Predictive Value of Tests; Proteome; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Assessment; Severity of Illness Index; Treatment Outcome; Viral Load

2006
Peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy.
    The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2006, Volume: 10, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2006
Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?
    The American journal of gastroenterology, 2006, Volume: 101, Issue:6

    Topics: Aged; Aged, 80 and over; Alanine Transaminase; Analysis of Variance; Antiviral Agents; Biopsy; Chi-Square Distribution; Female; France; Hepatitis C, Chronic; Humans; Interferons; Liver Function Tests; Logistic Models; Male; Retrospective Studies; Ribavirin; Severity of Illness Index

2006
Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with peginterferon alfa-2a and ribavirin.
    Haematologica, 2006, Volume: 91, Issue:6 Suppl

    Topics: Anemia, Hemolytic, Autoimmune; Antiviral Agents; Drug Therapy, Combination; Hematocrit; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2006
Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden.
    Scandinavian journal of infectious diseases, 2006, Volume: 38, Issue:6-7

    Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Markov Chains; Monte Carlo Method; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Sweden

2006
Immunomodulatory activities of IFN-gamma1b in combination with type I IFN: implications for the use of IFN-gamma1b in the treatment of chronic HCV infections.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2006, Volume: 26, Issue:7

    Topics: Antigen Presentation; Antiviral Agents; Cells, Cultured; Dendritic Cells; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Killer Cells, Natural; Lymphocyte Activation; Plasma Cells; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Th1 Cells

2006
Sustained virological response to peginterferon plus ribavirin in chronic hepatitis C genotype 1 patients is associated with a persistent Th1 immune response.
    Alimentary pharmacology & therapeutics, 2006, Jul-01, Volume: 24, Issue:1

    Topics: Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cytokines; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Immunity, Cellular; Interferon alpha-2; Interferon-alpha; Longitudinal Studies; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Th1 Cells; Treatment Outcome; Viral Load

2006
Blood transaminase elevation with pegylated interferon alfa 2b plus ribavirin in an HIV/HCV coinfected haemophilic patient.
    Infection, 2006, Volume: 34, Issue:3

    Topics: Adult; Drug Therapy, Combination; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Transaminases; Treatment Outcome

2006
Increased hepatic expression of insulin-like growth factor-I receptor in chronic hepatitis C.
    World journal of gastroenterology, 2006, Jun-28, Volume: 12, Issue:24

    Topics: Antiviral Agents; Gene Expression Profiling; Hepatitis C, Chronic; Hepatocytes; Humans; Immunohistochemistry; Insulin-Like Growth Factor I; Interferon-alpha; Liver Regeneration; Receptor, IGF Type 1; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Messenger; Up-Regulation

2006
Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.
    Journal of gastroenterology and hepatology, 2006, Volume: 21, Issue:7

    Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Intramuscular; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2006
Serum alanine aminotransferase level and response to interferon-ribavirin combination therapy in patients with chronic hepatitis C.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2006, Volume: 16, Issue:7

    Topics: Adult; Alanine Transaminase; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin

2006
Clinical and therapeutic implications of hepatitis C virus compartmentalization.
    Gastroenterology, 2006, Volume: 131, Issue:1

    Topics: Adult; Antiviral Agents; Cell Compartmentation; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Polymorphism, Single-Stranded Conformational; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Viral Load

2006
The role of thyroid autoantibodies in the development of thyroid dysfunction in Taiwanese chronic hepatitis C patients with interferon-alpha and ribavirin combination therapy.
    Journal of viral hepatitis, 2006, Volume: 13, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Autoantibodies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Taiwan; Thyroid Diseases; Thyroid Gland

2006
[Primer treatment of acute and chronic hepatitis C].
    Acta gastroenterologica Latinoamericana, 2006, Volume: 36 Suppl 1

    Topics: Acute Disease; Antiretroviral Therapy, Highly Active; Antiviral Agents; Clinical Trials as Topic; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2006
Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment.
    Hepatology (Baltimore, Md.), 2006, Volume: 44, Issue:2

    Topics: Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Lipoproteins, LDL; Male; Middle Aged; Retrospective Studies; Ribavirin; Treatment Outcome

2006
[The effect of patient's body weight, gender and baseline viral load on the efficacy of hepatitis C therapy].
    Vnitrni lekarstvi, 2006, Volume: 52, Issue:6

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sex Factors; Treatment Outcome; Viral Load

2006
Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis.
    Journal of gastroenterology and hepatology, 2006, Volume: 21, Issue:8

    Topics: Antiviral Agents; Biopsy; Body Mass Index; Case-Control Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Obesity; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Failure

2006
Branch retinal vein thrombosis and visual loss probably associated with pegylated interferon therapy of chronic hepatitis C.
    World journal of gastroenterology, 2006, Jul-28, Volume: 12, Issue:28

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retinal Vein Occlusion; Ribavirin; Vision, Low; Visual Acuity

2006
Relapse to opioid use after treatment of chronic hepatitis C with pegylated interferon and ribavirin.
    The American journal of psychiatry, 2006, Volume: 163, Issue:8

    Topics: Antiviral Agents; Behavior, Addictive; Cocaine-Related Disorders; Comorbidity; Drug Administration Schedule; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Male; Methadone; Middle Aged; Opioid-Related Disorders; Patient Care Planning; Recurrence; Ribavirin; Risk Assessment; Substance Abuse, Intravenous; Treatment Outcome

2006
Response to treatment with interferon-alpha and ribavirin in patients with chronic Hepatitis C virus genotypes 2 and 3 depends on the degree of hepatic fibrosis.
    The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2006, Volume: 10, Issue:2

    Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Polymerase Chain Reaction; Retrospective Studies; Ribavirin; RNA, Viral; Severity of Illness Index; Treatment Outcome; Viral Load

2006
Chronic hepatitis C and Crohn's disease: nosocomial infection treatment with PEG-interferon plus ribavirin.
    Digestion, 2006, Volume: 73, Issue:4

    Topics: Adult; Antiviral Agents; Biopsy; Crohn Disease; Cross Infection; DNA, Viral; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2006
Genetic predisposition of responsiveness to therapy for chronic hepatitis C.
    Pharmacogenomics, 2006, Volume: 7, Issue:5

    Topics: Adult; Aged; Female; Genetic Predisposition to Disease; Haplotypes; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polymorphism, Genetic; Retrospective Studies; Ribavirin

2006
Identification of novel defective HCV clones in liver transplant recipients with recurrent HCV infection.
    Journal of viral hepatitis, 2006, Volume: 13, Issue:8

    Topics: Adult; Aged; Antiviral Agents; Base Sequence; Clone Cells; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Molecular Sequence Data; Recombinant Proteins; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Viral Load

2006
Plasma ribavirin concentrations during treatment of recurrent hepatitis C with peginterferon alpha-2b and ribavirin combination after liver transplantation.
    Journal of viral hepatitis, 2006, Volume: 13, Issue:8

    Topics: Alanine Transaminase; Antiviral Agents; Biopsy; Cohort Studies; Combined Modality Therapy; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral

2006
Sensitivity to antiviral therapy may change after liver transplantation in patients with chronic hepatitis C virus infection.
    Journal of viral hepatitis, 2006, Volume: 13, Issue:8

    Topics: Adult; Aged; Amino Acid Sequence; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Molecular Sequence Data; Mutation; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Alignment; Viral Load

2006
Disappointing results of combination therapy for HCV?
    Gut, 2006, Volume: 55, Issue:9

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure

2006
Decline in haemoglobin A1c values in diabetic patients receiving interferon-alpha and ribavirin for chronic hepatitis C.
    Journal of viral hepatitis, 2006, Volume: 13, Issue:9

    Topics: Antiviral Agents; Blood Glucose; Body Weight; Diabetes Complications; Diabetes Mellitus; Erythrocyte Indices; Female; Glycated Hemoglobin; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon-alpha; L-Lactate Dehydrogenase; Male; Middle Aged; Reticulocyte Count; Retrospective Studies; Ribavirin

2006
Ribavirin enhances osteoclast formation through osteoblasts via up-regulation of TRANCE/RANKL.
    Molecular and cellular biochemistry, 2007, Volume: 296, Issue:1-2

    Topics: Alkaline Phosphatase; Animals; Antiviral Agents; Cell Differentiation; Cell Line; Gene Expression Regulation; Hepatitis C, Chronic; Humans; Interferon-alpha; Mice; Osteoblasts; Osteoclasts; Osteogenesis; RANK Ligand; Ribavirin

2007
Potential role of hepatic progenitor cells expression in cases of chronic hepatitis C and their relation to response to therapy: a clinicopathologic study.
    Liver international : official journal of the International Association for the Study of the Liver, 2006, Volume: 26, Issue:7

    Topics: Adult; alpha-Fetoproteins; Antiviral Agents; Biomarkers; Biopsy; Cell Differentiation; Cell Proliferation; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Keratin-19; Keratin-7; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Stem Cells

2006
Tuberculosis complicating treatment of hepatitis C in an HIV-infected haemophilia A patient.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2006, Volume: 12, Issue:5

    Topics: Adult; Antiviral Agents; Hemophilia A; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Lymphadenitis; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Tuberculosis, Lymph Node

2006
Variations in the viral NS5B region in Japanese patients with chronic hepatitis C virus genotype 1b infection. No specific amino acid substitution was identified as determinants of treatment response to interferon/ribavirin combination therapy.
    Intervirology, 2006, Volume: 49, Issue:6

    Topics: Adult; Aged; Amino Acid Sequence; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Molecular Sequence Data; Mutation; Polymorphism, Genetic; Ribavirin; Sequence Alignment; Viral Nonstructural Proteins

2006
Evolution of hepatitis C virus quasispecies during ribavirin and interferon-alpha-2b combination therapy and interferon-alpha-2b monotherapy.
    Intervirology, 2006, Volume: 49, Issue:6

    Topics: 5' Untranslated Regions; Antiviral Agents; Drug Therapy, Combination; Evolution, Molecular; Genetic Drift; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Mutation; Phylogeny; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Sequence Homology; Viral Envelope Proteins; Viral Nonstructural Proteins

2006
From trials to a real hospital setting: effectiveness of pegylated interferon-alpha-2b/ribavirin combination therapy for naïve chronic hepatitis C patients.
    Digestive diseases and sciences, 2006, Volume: 51, Issue:9

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Severity of Illness Index; Treatment Outcome; Viral Load

2006
Autoimmune thrombocytopenia induced by PEG-IFN-alpha plus ribavirin in hepatitis C.
    Platelets, 2006, Volume: 17, Issue:5

    Topics: Adult; Antiviral Agents; Danazol; Drug Carriers; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Immunoglobulins, Intravenous; Interferon-alpha; Purpura, Thrombocytopenic, Idiopathic; Ribavirin

2006
A government sponsored clinic for the evaluation and treatment of chronic hepatitis C in an underinsured population in Puerto Rico.
    Puerto Rico health sciences journal, 2004, Volume: 23, Issue:2 Suppl

    Topics: Adult; Algorithms; Antiviral Agents; Female; Health Facilities; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Medically Uninsured; Middle Aged; Polyethylene Glycols; Public Assistance; Puerto Rico; Recombinant Proteins; Ribavirin

2004
Steatosis as a predictive factor for treatment response in patients with chronic hepatitis C.
    Puerto Rico health sciences journal, 2004, Volume: 23, Issue:2 Suppl

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Prognosis; Retrospective Studies; Ribavirin; Risk Factors; Treatment Outcome

2004
CCR5Delta32 mutation does not influence the susceptibility to HCV infection, severity of liver disease and response to therapy in patients with chronic hepatitis C.
    World journal of gastroenterology, 2006, Aug-07, Volume: 12, Issue:29

    Topics: Adult; Alanine Transaminase; Alleles; Antiviral Agents; Case-Control Studies; Disease Progression; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mutation; Polyethylene Glycols; Receptors, CCR5; Recombinant Proteins; Ribavirin; Severity of Illness Index

2006
Retinal vein thrombosis associated with pegylated-interferon and ribavirin combination therapy for chronic hepatitis C.
    World journal of gastroenterology, 2006, Aug-14, Volume: 12, Issue:30

    Topics: Antiviral Agents; Drug Therapy, Combination; Fibrosis; Hepatitis C, Chronic; Humans; Indians, North American; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retinal Vein Occlusion; Ribavirin

2006
Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
    Translational research : the journal of laboratory and clinical medicine, 2006, Volume: 148, Issue:3

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Kinetics; Male; Middle Aged; Predictive Value of Tests; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2006
Pegylated interferon (PEG-IFN) alfa-2b and ribavirin for recurrent hepatitis C (genotype 1) after liver transplantation: relationship with steatosis.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2006, Volume: 38, Issue:11

    Topics: Adult; Antiviral Agents; Body Mass Index; Cholesterol; Drug Therapy, Combination; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Triglycerides

2006
Syncytial giant cell hepatitis in human immunodeficiency virus-infected patients with chronic hepatitis C: 2 cases and review of the literature.
    Human pathology, 2006, Volume: 37, Issue:10

    Topics: Adult; Antiviral Agents; Biopsy; Comorbidity; Drug Therapy, Combination; Fatal Outcome; Giant Cells; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Hospitals, Special; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Remission Induction; Retrospective Studies; Ribavirin; RNA, Viral; Spain

2006
[A case of exacerbation of ulcerative colitis induced by combination therapy with PEG-interferon alpha-2b and ribavirin for chronic hepatitis C].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2006, Volume: 103, Issue:9

    Topics: Antiviral Agents; Catheter Ablation; Colitis, Ulcerative; Drug Therapy, Combination; Hepatectomy; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2006
The hepatitis C virus NS5A protein and response to interferon alpha: mutational analyses in patients with chronic HCV genotype 3a infection from India.
    Medical microbiology and immunology, 2007, Volume: 196, Issue:1

    Topics: Adult; Amino Acid Sequence; Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; India; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Mutation; Protein Structure, Secondary; Ribavirin; Sequence Alignment; Viral Nonstructural Proteins

2007
2'-,5'-Oligoadenylate synthetase response ratio predicting virological response to PEG-interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C.
    Journal of clinical pharmacy and therapeutics, 2006, Volume: 31, Issue:5

    Topics: 2',5'-Oligoadenylate Synthetase; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral

2006
Long term suppressive therapy with pegylated interferon for chronic hepatitis C associated membranoproliferative glomerulonephritis.
    Gut, 2006, Volume: 55, Issue:10

    Topics: Antiviral Agents; Drug Therapy, Combination; Glomerulonephritis, Membranoproliferative; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2006
Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin.
    Journal of viral hepatitis, 2006, Volume: 13, Issue:10

    Topics: Adult; Antiviral Agents; Biomarkers; Biopsy; Contraindications; Female; Hepatitis C, Chronic; Humans; Hyaluronic Acid; Interferon-alpha; Liver Cirrhosis; Longitudinal Studies; Male; Matrix Metalloproteinase 1; Matrix Metalloproteinase 9; Middle Aged; Peptide Fragments; Procollagen; Retrospective Studies; Ribavirin; Tissue Inhibitor of Metalloproteinase-1

2006
Accurate model predicting sustained response at week 4 of therapy with pegylated interferon with ribavirin in patients with chronic hepatitis C.
    Journal of viral hepatitis, 2006, Volume: 13, Issue:10

    Topics: Adult; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Statistical; Multivariate Analysis; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome

2006
Dynamics of immature subsets of dendritic cells during antiviral therapy in HLA-A24-positive chronic hepatitis C patients.
    Journal of gastroenterology, 2006, Volume: 41, Issue:8

    Topics: Adult; Aged; Antiviral Agents; Dendritic Cells; Female; Flow Cytometry; Hepacivirus; Hepatitis C, Chronic; HLA-A Antigens; HLA-A24 Antigen; Humans; Immunity, Cellular; Interferon-alpha; Male; Middle Aged; Ribavirin; T-Lymphocyte Subsets; T-Lymphocytes, Cytotoxic

2006
Do DCs influence the antiviral effect of interferon/ribavirin by changing their profile during the therapy?
    Journal of gastroenterology, 2006, Volume: 41, Issue:8

    Topics: Antiviral Agents; Dendritic Cells; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; T-Lymphocyte Subsets; T-Lymphocytes, Cytotoxic

2006
Serum procalcitonin levels in chronic hepatitis C patients under pegylated interferon-alpha plus ribavirin treatment.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2006, Volume: 37, Issue:4

    Topics: Adult; Antiviral Agents; Calcitonin; Calcitonin Gene-Related Peptide; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Protein Precursors; Recombinant Proteins; Ribavirin

2006
[A case of Bell's palsy associated with peginterferon Alfa-2a and ribavirin therapy for chronic hepatitis C virus infection].
    The Korean journal of hepatology, 2006, Volume: 12, Issue:3

    Topics: Adult; Antiviral Agents; Bell Palsy; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2006
Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C.
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2006, Volume: 20, Issue:9

    Topics: Adult; Age Factors; Aged; Anemia; Antiviral Agents; Biomarkers; Blood Cell Count; Blood Platelets; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Middle Aged; Neutropenia; Neutrophils; Polyethylene Glycols; Quebec; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Thrombocytopenia; Treatment Outcome

2006
Prevalence of autoantibodies and the risk of autoimmune thyroid disease in children with chronic hepatitis C virus infection treated with interferon-alpha.
    World journal of gastroenterology, 2006, Sep-28, Volume: 12, Issue:36

    Topics: Adolescent; Antiviral Agents; Autoantibodies; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hypothyroidism; Interferon-alpha; Male; Ribavirin; Thyroid Gland; Thyroiditis, Autoimmune

2006
Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C.
    Alimentary pharmacology & therapeutics, 2006, Oct-15, Volume: 24, Issue:8

    Topics: Antiviral Agents; Depressive Disorder, Major; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mood Disorders; Patient Compliance; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Failure

2006
Use of ribavirin in patients with chronic HCV genotype 1: when enough is really enough.
    Gastroenterology, 2006, Volume: 131, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2006
Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response.
    Liver international : official journal of the International Association for the Study of the Liver, 2006, Volume: 26, Issue:9

    Topics: Age Factors; Anemia; Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Sex Factors; Treatment Outcome

2006
Differential expression of toll-like receptor mRNA in treatment non-responders and sustained virologic responders at baseline in patients with chronic hepatitis C.
    Liver international : official journal of the International Association for the Study of the Liver, 2006, Volume: 26, Issue:9

    Topics: Antiviral Agents; Cytokines; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Male; Middle Aged; NFATC Transcription Factors; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Messenger; Th1 Cells; Th2 Cells; Toll-Like Receptors; Treatment Outcome

2006
Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.
    Liver international : official journal of the International Association for the Study of the Liver, 2006, Volume: 26, Issue:9

    Topics: Adult; Aging; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Body Mass Index; Drug Therapy, Combination; Fatty Liver; Female; gamma-Glutamyltransferase; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome

2006
T cell receptor excision circles (TRECs), CD4+, CD8+, and their CD45RO+, and CD45RA+, subpopulations in hepatitis C virus (HCV)-HIV-co-infected patients during treatment with interferon alpha plus ribavirin: analysis in a population on effective antiretro
    Clinical and experimental immunology, 2006, Volume: 146, Issue:2

    Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Follow-Up Studies; Gene Rearrangement, T-Lymphocyte; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Leukocyte Common Antigens; Male; Polyethylene Glycols; Prospective Studies; Receptors, Antigen, T-Cell; Recombinant Proteins; Ribavirin; T-Lymphocyte Subsets; Thymus Gland; Treatment Outcome

2006
A case of exacerbation of ulcerative colitis induced by combination therapy with PEG-interferon alpha-2b and ribavirin.
    Gut, 2006, Volume: 55, Issue:11

    Topics: Antiviral Agents; Colitis, Ulcerative; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2006
Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C.
    Journal of gastroenterology, 2006, Volume: 41, Issue:9

    Topics: Adult; Aged; Anemia, Hemolytic; Antiviral Agents; Disease Progression; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome

2006
Treatment rates in patients with chronic hepatitis C after liver biopsy.
    Journal of viral hepatitis, 2006, Volume: 13, Issue:11

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Biopsy; Female; Hepatitis C, Chronic; Humans; Insurance, Health; Interferon alpha-2; Interferon-alpha; Liver; Male; Medicaid; Medicare; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin

2006
An artificial neural network approach to the drug efficacy of interferon treatments.
    Pharmacogenomics, 2006, Volume: 7, Issue:7

    Topics: Aging; Algorithms; Antiviral Agents; Drug Therapy, Combination; Forecasting; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferons; Neural Networks, Computer; Polymorphism, Single Nucleotide; Reproducibility of Results; Ribavirin; Sex Characteristics; Signal Transduction; Viral Load

2006
Ischemic colitis during pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2006, Volume: 20, Issue:10

    Topics: Adult; Antiviral Agents; Colitis, Ischemic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2006
Effects of iron and HFE mutations on response to therapy in chronic hepatitis C: an ironic interaction?
    Gastroenterology, 2006, Volume: 131, Issue:5

    Topics: Hemochromatosis Protein; Hepatitis C, Chronic; Histocompatibility Antigens Class I; Humans; Interferons; Iron; Membrane Proteins; Mutation; Ribavirin

2006
Referral for chronic hepatitis C treatment from a drug dependency treatment setting.
    Drug and alcohol dependence, 2007, Apr-17, Volume: 88, Issue:1

    Topics: Analgesics, Opioid; Antiviral Agents; Australia; Hepatitis C, Chronic; Humans; Interferon-alpha; Methadone; Referral and Consultation; Ribavirin; Substance Abuse Treatment Centers; Substance Abuse, Intravenous

2007
Acute exacerbation of hepatitis in a boy with chronic HCV genotype-2 infection after a 9-year period of normal transaminases levels.
    European journal of pediatrics, 2007, Volume: 166, Issue:5

    Topics: Acute Disease; Antiviral Agents; Child; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Recombinant Proteins; Ribavirin; Transaminases

2007
Changes of soluble CD26 and CD30 levels correlate with response to interferon plus ribavirin therapy in patients with chronic hepatitis C.
    Journal of gastroenterology and hepatology, 2006, Volume: 21, Issue:12

    Topics: Adult; Antiviral Agents; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Immunity, Cellular; Interferon alpha-2; Interferon-alpha; Ki-1 Antigen; Male; Middle Aged; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Th1 Cells; Th2 Cells; Treatment Outcome

2006
Cost-utility analysis of different peg-interferon alpha-2b plus ribavirin treatment strategies as initial therapy for naïve Chinese patients with chronic hepatitis C.
    Alimentary pharmacology & therapeutics, 2006, Nov-15, Volume: 24, Issue:10

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Markov Chains; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Taiwan

2006
Regression of liver fibrosis in hepatitis C virus/HIV-co-infected patients after treatment with pegylated interferon plus ribavirin.
    AIDS (London, England), 2006, Nov-14, Volume: 20, Issue:17

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2006
Development of hepatocellular carcinoma (HCC) in peginterferon and ribavirin HCV-infected cirrhotic treated patients.
    Revista espanola de enfermedades digestivas, 2006, Volume: 98, Issue:10

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2006
Clinical significance of organ- and non-organ-specific autoantibodies on the response to anti-viral treatment of patients with chronic hepatitis C.
    Alimentary pharmacology & therapeutics, 2006, Volume: 24, Issue:11-12

    Topics: Adult; Aged; Antiviral Agents; Autoantibodies; Autoimmunity; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Treatment Outcome

2006
A 24-week course of high-dose interferon-alpha plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels.
    Liver international : official journal of the International Association for the Study of the Liver, 2006, Volume: 26, Issue:10

    Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Case-Control Studies; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin

2006
Life-threatening thrombocytopenia and nephrotic syndrome due to focal segmental glomerulosclerosis associated with pegylated interferon alpha-2b and ribavirin treatment for hepatitis C.
    Liver international : official journal of the International Association for the Study of the Liver, 2006, Volume: 26, Issue:10

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Glomerulosclerosis, Focal Segmental; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Nephrotic Syndrome; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia

2006
Tolerability of Peg interferon-alpha2b and Ribavirin therapy in patients with chronic hepatitis C and glucose-6-phosphate dehydrogenase deficiency.
    Journal of hepatology, 2007, Volume: 46, Issue:1

    Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Drug Tolerance; Female; Glucosephosphate Dehydrogenase Deficiency; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2007
The faster the better?
    Internal and emergency medicine, 2006, Volume: 1, Issue:2

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Forecasting; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver Cirrhosis; Liver Neoplasms; Male; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2006
[Virological response of chronic hepatitis C management with peg-interferon alpha-2b and ribavirin].
    Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, 2006, Volume: 28, Issue:5

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome

2006
[Expert recommendations for the diagnosis and treatment of chronic hepatitis C infection in the prison setting].
    Enfermedades infecciosas y microbiologia clinica, 2006, Volume: 24, Issue:9

    Topics: Anti-HIV Agents; Antiviral Agents; Biopsy; Comorbidity; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Function Tests; Patient Compliance; Polyethylene Glycols; Practice Guidelines as Topic; Prevalence; Prisoners; Prisons; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Spain; Substance Abuse, Intravenous; Treatment Outcome

2006
Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfected patients.
    AIDS care, 2007, Volume: 19, Issue:1

    Topics: Adult; Antidepressive Agents; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Mental Disorders; Polyethylene Glycols; Prospective Studies; Quality of Life; Recombinant Proteins; Recurrence; Ribavirin; Treatment Refusal

2007
Insulin resistance and hepatitis C.
    World journal of gastroenterology, 2006, Nov-28, Volume: 12, Issue:44

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Insulin; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2006
Growth factors during HCV therapy may be "cost-effective", but are they "effective"?
    Hepatology (Baltimore, Md.), 2006, Volume: 44, Issue:6

    Topics: Algorithms; Antiviral Agents; Cost-Benefit Analysis; Erythropoietin; Hepatitis C, Chronic; Humans; Intercellular Signaling Peptides and Proteins; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome

2006
Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy.
    Hepatology (Baltimore, Md.), 2006, Volume: 44, Issue:6

    Topics: Anemia; Cost-Benefit Analysis; Darbepoetin alfa; Decision Trees; Drug Therapy, Combination; Erythropoietin; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Markov Chains; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin

2006
A mutation in the interferon sensitivity-determining region is associated with responsiveness to interferon-ribavirin combination therapy in chronic hepatitis patients infected with a Japan-specific subtype of hepatitis C virus genotype 1B.
    Journal of medical virology, 2007, Volume: 79, Issue:1

    Topics: Drug Resistance, Viral; Drug Therapy, Combination; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Mutation; Phylogeny; Ribavirin

2007
Standard interferon-alpha in combination with ribavirin for hepatitis C patients with advanced liver disease and thrombocytopenia.
    Wiener klinische Wochenschrift, 2006, Volume: 118, Issue:19-20

    Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Thrombocytopenia

2006
Differences in viral kinetics between genotypes 1 and 3 of hepatitis C virus and between cirrhotic and non-cirrhotic patients during antiviral therapy.
    World journal of gastroenterology, 2006, Dec-07, Volume: 12, Issue:45

    Topics: Antiviral Agents; Brazil; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Kinetics; Liver Cirrhosis; Ribavirin; RNA, Viral; Viral Load

2006
[Early virologic response value as predictive factor of sustained virologic response to treatment with interferon alpha-2b plus ribavirin in chronic hepatitis C patients with or without HIV coinfection].
    Medicina clinica, 2006, Oct-21, Volume: 127, Issue:15

    Topics: Adult; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prognosis; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2006
[Applicability of hepatitis C virus kinetics in patients co-infected with HIV].
    Medicina clinica, 2006, Oct-21, Volume: 127, Issue:15

    Topics: Antiviral Agents; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Treatment Outcome

2006
[Treatment of chronic hepatitis C within a heroine-assisted treatment program].
    Deutsche medizinische Wochenschrift (1946), 2006, Dec-15, Volume: 131, Issue:50

    Topics: Administration, Oral; Adult; Antiviral Agents; Buprenorphine; Cocaine-Related Disorders; Combined Modality Therapy; Comorbidity; Drug Therapy, Combination; Hepatitis C, Chronic; Heroin; Heroin Dependence; Humans; Injections, Intravenous; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Rehabilitation, Vocational; Ribavirin; Social Adjustment; Social Welfare; Substance Abuse, Intravenous

2006
Race, insulin resistance and hepatic steatosis in chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2007, Volume: 45, Issue:1

    Topics: Adult; Antiviral Agents; Black or African American; Drug Therapy, Combination; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Prevalence; Prospective Studies; Recombinant Proteins; Ribavirin; Severity of Illness Index; Signal Transduction; White People

2007
Efficacy and long-term follow up of combination therapy with interferon alpha and ribavirin for chronic hepatitis C in Korea.
    Yonsei medical journal, 2006, Dec-31, Volume: 47, Issue:6

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Korea; Male; Middle Aged; Retrospective Studies; Ribavirin

2006
[Changes of immunocytes in livers of chronic hepatitis C patients treated with IFN alpha-2b and ribavirin].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2006, Volume: 14, Issue:12

    Topics: Adult; Aged; Antigens, CD; Antiviral Agents; CTLA-4 Antigen; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Killer Cells, Natural; Liver; Male; Middle Aged; Recombinant Proteins; Ribavirin

2006
[The importance of using ribavirin in treating chronic hepatitis C].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2006, Volume: 14, Issue:12

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Ribavirin

2006
Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2007, Volume: 5, Issue:1

    Topics: Adult; Antiviral Agents; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome

2007
Response to pegylated interferon alpha-2b and ribavirin in children with chronic hepatitis C.
    Journal of clinical gastroenterology, 2007, Volume: 41, Issue:1

    Topics: Adolescent; Antiviral Agents; Biopsy; Child; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2007
Immune response in addicts with chronic hepatitis C treated with interferon and ribavirin.
    Journal of gastroenterology and hepatology, 2007, Volume: 22, Issue:1

    Topics: Adult; Antiviral Agents; Case-Control Studies; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Methadone; Opioid-Related Disorders; Recombinant Proteins; Ribavirin; Statistics, Nonparametric; Viral Load

2007
Treatment of hepatitis C virus-associated inflammatory polyneuropathy with pegylated interferon-alpha and ribavirin.
    European journal of gastroenterology & hepatology, 2007, Volume: 19, Issue:1

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Peripheral Nervous System Diseases; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2007
Direct evidence for immunomodulatory properties of ribavirin on T-cell reactivity to hepatitis C virus.
    Antiviral research, 2007, Volume: 75, Issue:1

    Topics: Antiviral Agents; CD4-Positive T-Lymphocytes; Cell Division; Cells, Cultured; Cytokines; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Gene Expression; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon-gamma; Interleukin-10; Peptide Fragments; Ribavirin; RNA, Messenger; RNA, Viral; T-Lymphocytes; Viral Core Proteins; Viral Nonstructural Proteins

2007
Hepatic oxidative DNA damage correlates with iron overload in chronic hepatitis C patients.
    Free radical biology & medicine, 2007, Feb-01, Volume: 42, Issue:3

    Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Aged; Alanine Transaminase; Antimicrobial Cationic Peptides; Antiviral Agents; Aspartate Aminotransferases; Deoxyguanosine; DNA Adducts; DNA Damage; Drug Therapy, Combination; Female; Ferritins; Hepatitis C, Chronic; Hepcidins; Humans; Interferons; Iron Overload; Liver; Male; Middle Aged; Oxidative Stress; Ribavirin

2007
Pegylated interferon and ribavirin combination therapy for chronic hepatitis C in patients with congenital bleeding disorders: a single-centre experience.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2007, Volume: 13, Issue:1

    Topics: Adolescent; Adult; Antiviral Agents; Blood Coagulation Disorders; Combined Modality Therapy; Depression; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Mental Disorders; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load

2007
High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy.
    Journal of hepatology, 2007, Volume: 46, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; Time Factors; Treatment Failure; Treatment Outcome; Viral Load

2007
Lichen aureus induced by interferon-alpha plus ribavirin.
    Acta dermato-venereologica, 2007, Volume: 87, Issue:1

    Topics: Adult; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Lichenoid Eruptions; Male; Ribavirin

2007
Treatment with pegylated interferon and ribavirin for hepatitis C virus-associated severe cryoglobulinemia in a liver/kidney transplant recipient.
    Journal of clinical gastroenterology, 2007, Volume: 41, Issue:2

    Topics: Antiviral Agents; Creatinine; Cryoglobulinemia; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney; Kidney Transplantation; Leg Ulcer; Liver; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2007
Pegylated interferon and ribavirin failures: is retreatment an option?
    Digestive diseases and sciences, 2007, Volume: 52, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retreatment; Retrospective Studies; Ribavirin; Treatment Failure

2007
Reactivation of hepatitis B virus replication during peginterferon-ribavirin therapy in an HIV/hepatitis C virus-co-infected patient with isolated anti-hepatitis B core antibodies.
    AIDS (London, England), 2007, Jan-30, Volume: 21, Issue:3

    Topics: Adult; Antiviral Agents; Female; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Virus Activation

2007
Natural history of anemia associated with interferon/ribavirin therapy for patients with HIV/HCV coinfection.
    AIDS research and human retroviruses, 2007, Volume: 23, Issue:1

    Topics: Adolescent; Adult; Aged; Anemia; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Black People; Cell Count; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythropoietin; Female; Hemoglobins; Hepatitis C, Chronic; Hispanic or Latino; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Protease Inhibitors; Recombinant Proteins; Reticulocytes; Retrospective Studies; Reverse Transcriptase Inhibitors; Ribavirin; Time Factors; Treatment Outcome; White People; Zidovudine

2007
Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy.
    Journal of virology, 2007, Volume: 81, Issue:7

    Topics: Antiviral Agents; Biomarkers; Down-Regulation; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Oligonucleotide Array Sequence Analysis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Messenger; Up-Regulation

2007
Recent i.v.-drug users with chronic hepatitis C can be efficiently treated with daily high dose induction therapy using consensus interferon: an open-label pilot study.
    World journal of gastroenterology, 2007, Jan-28, Volume: 13, Issue:4

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Interferon-alpha; Male; Middle Aged; Pilot Projects; Quality of Life; Recombinant Proteins; Ribavirin; Substance Abuse, Intravenous

2007
A case of deep venous thrombosis associated with pegylated interferon alpha2b plus ribavirin treatment of chronic hepatitis C.
    Journal of gastroenterology, 2006, Volume: 41, Issue:12

    Topics: Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Partial Thromboplastin Time; Polyethylene Glycols; Prothrombin Time; Recombinant Proteins; Ribavirin; RNA, Viral; Venous Thrombosis

2006
Combined pegylated interferon and ribavirin for the management of chronic hepatitis C in a prison setting.
    The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2006, Volume: 10, Issue:4

    Topics: Adult; Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Italy; Male; Polyethylene Glycols; Prisons; Recombinant Proteins; Ribavirin; Treatment Outcome

2006
Weight-based combination therapy with peginterferon alpha-2b and ribavirin for naïve, relapser and non-responder patients with chronic hepatitis C.
    The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2006, Volume: 10, Issue:5

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Body Weight; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2006
Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy).
    Transplantation, 2007, Feb-15, Volume: 83, Issue:3

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Disease Progression; Female; Fibrosis; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Secondary Prevention

2007
Effectiveness of a multi-disciplinary standardized management model in the treatment of chronic hepatitis C in drug addicts engaged in detoxification programmes.
    Addiction (Abingdon, England), 2007, Volume: 102, Issue:3

    Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome

2007
Genetic distance and heterogenecity between quasispecies is a critical predictor to IFN response in Egyptian patients with HCV genotype-4.
    Virology journal, 2007, Feb-14, Volume: 4

    Topics: 5' Untranslated Regions; Adolescent; Adult; Antiviral Agents; Egypt; Female; Genetic Heterogeneity; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Mutation; Phylogeny; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Statistics as Topic; Treatment Outcome

2007
A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
    Antiviral therapy, 2006, Volume: 11, Issue:8

    Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin; Survival Rate; Taiwan; Time Factors

2006
Cutaneous sarcoidosis limited to scars following pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2007, Volume: 21, Issue:3

    Topics: Cicatrix; Diagnosis, Differential; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Recombinant Proteins; Ribavirin; Sarcoidosis; Skin Diseases

2007
Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection.
    Antiviral therapy, 2006, Volume: 11, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver Cirrhosis; Male; Middle Aged; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome

2006
Presence of hepatitis C virus (HCV)-RNA in peripheral blood mononuclear cells in HCV serum negative patients during interferon and ribavirin therapy.
    Japanese journal of infectious diseases, 2007, Volume: 60, Issue:1

    Topics: Adolescent; Antibodies, Viral; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; In Situ Hybridization, Fluorescence; Interferons; Leukocytes, Mononuclear; Male; Polymerase Chain Reaction; Ribavirin; RNA, Viral

2007
Mitochondrial DNA depletion in HIV-infected patients with chronic hepatitis C and effect of pegylated interferon plus ribavirin therapy.
    AIDS (London, England), 2007, Mar-12, Volume: 21, Issue:5

    Topics: Adult; Antiviral Agents; DNA, Mitochondrial; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Viral Load

2007
Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3.
    The American journal of gastroenterology, 2007, Volume: 102, Issue:4

    Topics: Antiviral Agents; Black or African American; Chi-Square Distribution; Female; Genotype; Hepatitis C, Chronic; Humans; Interferons; Liver Function Tests; Male; Middle Aged; Ribavirin; Statistics, Nonparametric; Treatment Outcome

2007
Adult systemic cat scratch disease associated with therapy for hepatitis C.
    BMC infectious diseases, 2007, Feb-23, Volume: 7

    Topics: Bartonella henselae; Cat-Scratch Disease; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2007
Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV.
    The American journal of medicine, 2007, Volume: 120, Issue:3

    Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antiviral Agents; Cohort Studies; Cost of Illness; Cost-Benefit Analysis; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Markov Chains; Middle Aged; Recombinant Proteins; Ribavirin; Survival Analysis; Treatment Outcome; United States; Urban Health

2007
Evaluation of a pharmacist-managed hepatitis C care clinic.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2007, Mar-15, Volume: 64, Issue:6

    Topics: Adult; Ambulatory Care Facilities; Disease Management; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Hospitals, Veterans; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pharmaceutical Services; Pharmacists; Polyethylene Glycols; Practice Guidelines as Topic; Professional Role; Quality of Health Care; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; United States; United States Department of Veterans Affairs

2007
Treatment and retreatment in patients with chronic hepatitis C: 10 years clinical practice in a single centre.
    Liver international : official journal of the International Association for the Study of the Liver, 2007, Volume: 27, Issue:3

    Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin

2007
Severe hepatitis C virus-related cryoglobulinaemic sensory-motor polyneuropathy treated with pegylated interferon-a2b and ribavirin: clinical, laboratory and neurophysiological study.
    Liver international : official journal of the International Association for the Study of the Liver, 2007, Volume: 27, Issue:3

    Topics: Adult; Antiviral Agents; Central Nervous System Diseases; Cryoglobulinemia; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polyneuropathies; Recombinant Proteins; Ribavirin

2007
Replicative homeostasis III: implications for antiviral therapy and mechanisms of response and non-response.
    Virology journal, 2007, Mar-13, Volume: 4

    Topics: Adaptation, Biological; Drug Synergism; Genetic Variation; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Homeostasis; Humans; Interferon-alpha; Ribavirin; Treatment Outcome; Viral Load; Viral Proteins; Virus Replication

2007
Rapid and early virological response to chronic hepatitis C treatment with IFN alpha2b or PEG-IFN alpha2b plus ribavirin in HIV/HCV co-infected patients.
    Gut, 2007, Volume: 56, Issue:8

    Topics: Algorithms; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; ROC Curve; Treatment Outcome

2007
[Cutaneous sarcoidosis during pegylated interferon alpha and ribavirin treatment of chronic hepatitis C--a case report].
    Ceskoslovenska patologie, 2007, Volume: 43, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sarcoidosis; Skin Diseases

2007
Peginterferon and ribavirin for hepatitis C.
    The New England journal of medicine, 2007, Mar-22, Volume: 356, Issue:12

    Topics: Alcohol Drinking; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2007
Peginterferon and ribavirin for hepatitis C.
    The New England journal of medicine, 2007, Mar-22, Volume: 356, Issue:12

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load

2007
[Protocol for the treatment of chronic viral hepatitis].
    Orvosi hetilap, 2006, Dec-24, Volume: 147, Issue:51

    Topics: Algorithms; Antiviral Agents; Hepatitis C, Chronic; Hepatitis, Chronic; Hepatitis, Viral, Human; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2006
[Pulmonary toxicity by pegylated interferon alpha-2a in a patient with chronic hepatitis C].
    The Korean journal of hepatology, 2007, Volume: 13, Issue:1

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lung Diseases; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2007
Peginterferon and ribavirin for hepatitis C.
    The New England journal of medicine, 2007, Mar-22, Volume: 356, Issue:12

    Topics: Adult; Antiviral Agents; Autoimmune Diseases; Contraindications; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Myasthenia Gravis; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2007
Peginterferon and ribavirin for hepatitis C.
    The New England journal of medicine, 2007, Mar-22, Volume: 356, Issue:12

    Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors

2007
Peginterferon and ribavirin for hepatitis C.
    The New England journal of medicine, 2007, Mar-22, Volume: 356, Issue:12

    Topics: Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2007
Peginterferon and ribavirin for hepatitis C.
    The New England journal of medicine, 2007, Mar-22, Volume: 356, Issue:12

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Pancreatitis; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2007
Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy.
    Gastroenterology, 2007, Volume: 132, Issue:3

    Topics: Adult; Antiviral Agents; Cell Line, Tumor; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Monosaccharides; Mutagens; Mutation; Replicon; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Triazoles; Viral Nonstructural Proteins

2007
[Cutaneous necrosis in patient with chronic hepatitis].
    Revista clinica espanola, 2007, Volume: 207, Issue:2

    Topics: Adult; Antiviral Agents; Biopsy; Hepatitis C, Chronic; Humans; Injections; Interferon alpha-2; Interferon-alpha; Male; Necrosis; Recombinant Proteins; Ribavirin; Skin

2007
Long-term treatment with the combination of amantadine and ribavirin in hepatitis C nonresponders. A case series.
    Digestive diseases and sciences, 2007, Volume: 52, Issue:12

    Topics: Amantadine; Antiviral Agents; Biopsy; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug Tolerance; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Time Factors; Viral Load

2007
The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr.
    The American journal of gastroenterology, 2007, Volume: 102, Issue:7

    Topics: Adult; Age Factors; Aged; Antiviral Agents; Biopsy; Drug Carriers; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome

2007
Prognostic significance of hepatitis C virus RNA detection by transcription-mediated amplification with negative polymerase chain reaction during therapy with peginterferon alpha and ribavirin.
    Digestive diseases and sciences, 2007, Volume: 52, Issue:10

    Topics: Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Nucleic Acid Amplification Techniques; Polyethylene Glycols; Polymerase Chain Reaction; Predictive Value of Tests; Prognosis; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Transcription, Genetic; Viremia

2007
Factors influencing treatment efficacy of 24-week combination therapy with interferon alpha-2b plus ribavirin for chronic hepatitis C.
    Digestive diseases and sciences, 2007, Volume: 52, Issue:9

    Topics: Antiviral Agents; Biopsy; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunoenzyme Techniques; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome

2007
Case report of 3 patients with severe mental illness and chronic hepatitis C virus infection treated with interferon-alpha.
    International journal of psychiatry in medicine, 2006, Volume: 36, Issue:4

    Topics: Adult; Alcoholics Anonymous; Alcoholism; Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Antiviral Agents; Bipolar Disorder; Combined Modality Therapy; Comorbidity; Drug Therapy, Combination; Female; Fluoxetine; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamotrigine; Male; Middle Aged; Patient Care Team; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Triazines; Viral Load

2006
[Exceptional pancytopenia secondary to treatment with pegylated interferon and ribavirin].
    Gastroenterologia y hepatologia, 2007, Volume: 30, Issue:4

    Topics: Adult; Antiviral Agents; Darbepoetin alfa; Drug Therapy, Combination; Erythropoietin; Filgrastim; Granulocyte Colony-Stimulating Factor; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Iron; Male; Pancytopenia; Polyethylene Glycols; Receptor, Interferon alpha-beta; Recombinant Proteins; Ribavirin; Signal Transduction

2007
Severe allergic eczema due to pegylated alpha-interferon may abate after switching to daily conventional alpha-interferon.
    Journal of clinical gastroenterology, 2007, Volume: 41, Issue:4

    Topics: Adult; Antiviral Agents; Drug Eruptions; Eczema; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2007
[The peculiarities of the clinical picture and the effectiveness of antiviral therapy of chronic hepatitis related to alcohol consumption plus hepatitis C virus effect].
    Klinicheskaia meditsina, 2007, Volume: 85, Issue:1

    Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Hepatitis, Alcoholic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Severity of Illness Index; Ultrasonography

2007
Psychosis during peginterferon-alpha 2a and ribavirin therapy: case report.
    The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2006, Volume: 10, Issue:6

    Topics: Antipsychotic Agents; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Psychoses, Substance-Induced; Recombinant Proteins; Ribavirin; Risperidone

2006
Vitiligo improvement in a hepatitis C patient after treatment with PEG-interferon alpha-2a and ribavirin: a case report.
    Digestive diseases and sciences, 2007, Volume: 52, Issue:12

    Topics: Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Failure; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load; Vitiligo

2007
Preventing relapse of major depression during interferon-alpha therapy for hepatitis C--A pilot study.
    Digestive diseases and sciences, 2007, Volume: 52, Issue:10

    Topics: Adolescent; Adult; Antidepressive Agents; Antiviral Agents; Citalopram; Depression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Pilot Projects; Quality of Life; Ribavirin; Secondary Prevention; Severity of Illness Index; Treatment Outcome

2007
Development of specific antibodies to an ARF protein in treated patients with chronic HCV infection.
    Digestive diseases and sciences, 2007, Volume: 52, Issue:9

    Topics: Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Core Proteins

2007
Cosmetic permanent fillers for soft tissue augmentation: a new contraindication for interferon therapies.
    Archives of dermatology, 2007, Volume: 143, Issue:4

    Topics: Adjuvants, Immunologic; Antiviral Agents; Collagen; Cosmetic Techniques; Face; Female; Granuloma, Foreign-Body; Hepatitis C, Chronic; Humans; Injections; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Polymethyl Methacrylate; Recombinant Proteins; Ribavirin

2007
A 5-year prospective study of the late resolution of chronic hepatitis C after antiviral therapy.
    Alimentary pharmacology & therapeutics, 2007, May-01, Volume: 25, Issue:9

    Topics: Adult; Aged; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-gamma; Male; Middle Aged; Prospective Studies; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome

2007
Clinical responders to antiviral therapy of chronic HCV infection show elevated antiviral CD4+ and CD8+ T-cell responses.
    Journal of viral hepatitis, 2007, Volume: 14, Issue:5

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Black or African American; Case-Control Studies; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Division; Cohort Studies; Cross-Sectional Studies; Drug Therapy, Combination; Epitopes; Female; Flow Cytometry; Genotype; Hepacivirus; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; T-Lymphocytes; Time Factors; Treatment Outcome; Viral Core Proteins; Viral Nonstructural Proteins; White People

2007
Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Journal of gastroenterology and hepatology, 2007, Volume: 22, Issue:5

    Topics: Adult; Age Factors; Aged; alpha-Fetoproteins; Antiviral Agents; Aspartate Aminotransferases; Biomarkers; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Male; Middle Aged; Odds Ratio; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Severity of Illness Index; Time Factors; Treatment Outcome; Up-Regulation; Viral Load

2007
Prediction of efficient virological response to pegylated interferon/ribavirin combination therapy by NS5A sequences of hepatitis C virus and anti-NS5A antibodies in pre-treatment sera.
    Microbiology and immunology, 2007, Volume: 51, Issue:4

    Topics: Antibodies, Viral; Combined Modality Therapy; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Outcome and Process Assessment, Health Care; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Nonstructural Proteins; Viremia

2007
Acute pancreatitis associated with the use of peginterferon.
    Pancreas, 2007, Volume: 34, Issue:4

    Topics: Acute Disease; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Pancreatitis; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2007
Hepatitis C in pregnancy.
    American journal of perinatology, 2007, Volume: 24, Issue:4

    Topics: Female; Hepatitis C, Chronic; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Interferon-alpha; Pregnancy; Pregnancy Complications, Infectious; Ribavirin

2007
Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b during interferon or combined interferon-ribavirin therapy.
    World journal of gastroenterology, 2007, Feb-28, Volume: 13, Issue:8

    Topics: Adult; Aged; Antiviral Agents; Biological Evolution; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mutation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Sequence Homology, Amino Acid; Sequence Homology, Nucleic Acid; Viral Nonstructural Proteins

2007
The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C.
    Alimentary pharmacology & therapeutics, 2007, May-15, Volume: 25, Issue:10

    Topics: Adipocytes; Adult; Antiviral Agents; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Intra-Abdominal Fat; Liver Cirrhosis; Male; Middle Aged; Obesity; Recombinant Proteins; Ribavirin

2007
The role of genomic and antigenomic HCV-RNA strands as predictive factors of response to pegylated interferon plus ribavirin therapy.
    Alimentary pharmacology & therapeutics, 2007, May-15, Volume: 25, Issue:10

    Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Genome, Viral; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2007
Serum levels of anti-NS4a and anti-NS5a predict treatment response of patients with chronic hepatitis C.
    Journal of medical virology, 2007, Volume: 79, Issue:6

    Topics: Algorithms; Antiviral Agents; Biomarkers; Carrier Proteins; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Intracellular Signaling Peptides and Proteins; Predictive Value of Tests; Ribavirin; RNA, Viral; Treatment Outcome; Viral Core Proteins; Viral Nonstructural Proteins; Viral Proteins

2007
Impact of disease severity on outcome of antiviral therapy in treatment-naïve patients with chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2007, Volume: 45, Issue:5

    Topics: Antiviral Agents; Cohort Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2007
[Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)].
    Orvosi hetilap, 2007, May-06, Volume: 148, Issue:18

    Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Hungary; Interferon alpha-2; Interferon-alpha; Interferons; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Treatment Outcome

2007
Effective treatment of hepatitis C-associated immune-complex nephritis with cryoprecipitate apheresis and antiviral therapy.
    Clinical nephrology, 2007, Volume: 67, Issue:4

    Topics: Adult; Antiviral Agents; Biopsy; Blood Component Removal; Diagnosis, Differential; Drug Therapy, Combination; Female; Glomerulonephritis, Membranoproliferative; Hepatitis C, Chronic; Humans; Interferon-alpha; Pregnancy; Pregnancy Complications, Infectious; Ribavirin

2007
[Side effect of pegylated-interferon treatment in chronic C hepatitis: agranulocytosis].
    Orvosi hetilap, 2006, Feb-19, Volume: 147, Issue:7

    Topics: Agranulocytosis; Antiviral Agents; Bacteremia; Bone Marrow; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2006
[Mesenteric vein thrombosis and protein C and S deficiency in a patient with chronic hepatitis C on treatment with interferon and ribavirin].
    Gastroenterologia y hepatologia, 2007, Volume: 30, Issue:5

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Fatal Outcome; Gram-Negative Bacterial Infections; Hemoperitoneum; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Mesenteric Vascular Occlusion; Mesenteric Veins; Pneumonia, Bacterial; Polyethylene Glycols; Protein C Deficiency; Protein S Deficiency; Recurrence; Respiration, Artificial; Ribavirin; Stenotrophomonas maltophilia; Thrombectomy; Thrombophilia; Venous Thrombosis

2007
Sustained virological response in the antiviral therapy of chronic hepatitis C: is there a predictive value of interferon-induced depression?
    Chemotherapy, 2007, Volume: 53, Issue:4

    Topics: Adolescent; Adult; Antiviral Agents; Depression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2007
Impaired ability of interferon-alpha-primed dendritic cells to stimulate Th1-type CD4 T-cell response in chronic hepatitis C virus infection.
    Journal of viral hepatitis, 2007, Volume: 14, Issue:6

    Topics: Adult; Antiviral Agents; B7-2 Antigen; CD4-Positive T-Lymphocytes; Cells, Cultured; Dendritic Cells; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-gamma; Interleukin-10; Interleukin-2; Male; Middle Aged; Ribavirin; Viral Load

2007
Antiviral therapy effects upon hepatitis C cholestatic syndrome.
    Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie, 2007, Volume: 48, Issue:1

    Topics: Alkaline Phosphatase; Antiviral Agents; Bilirubin; Cholestasis; Cholesterol; Drug Therapy, Combination; gamma-Glutamyltransferase; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leucyl Aminopeptidase; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Syndrome

2007
Incidence and characterization of serum transaminases elevations in pegylated interferon and ribavirin treated patients with chronic hepatitis C.
    Alimentary pharmacology & therapeutics, 2007, Jun-01, Volume: 25, Issue:11

    Topics: Administration, Cutaneous; Administration, Oral; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Retrospective Studies; Ribavirin; Transaminases; Treatment Outcome

2007
Ribavirin in combination therapy for HCV chronic infection in HIV patients: how to win the war after winning the first battle?
    Journal of hepatology, 2007, Volume: 47, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2007
An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.
    World journal of gastroenterology, 2007, Apr-28, Volume: 13, Issue:16

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Parasitic Diseases; Recombinant Proteins; Ribavirin; Schizophrenia, Paranoid; Treatment Outcome

2007
Association of polymorphisms in the first exon of mannose binding lectin gene (MBL2) in Brazilian patients with HCV infection.
    Clinical immunology (Orlando, Fla.), 2007, Volume: 124, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Brazil; Case-Control Studies; Disease Progression; Exons; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Mannose-Binding Lectin; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome

2007
Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in a patient with Crohn's disease.
    The American journal of gastroenterology, 2007, Volume: 102, Issue:6

    Topics: Antibodies, Monoclonal; Antiviral Agents; Crohn Disease; Drug Therapy, Combination; Gastrointestinal Agents; Hepatitis C, Chronic; Humans; Infliximab; Interferons; Male; Middle Aged; Ribavirin

2007
Tongue hyperpigmentation in a caucasian patient coinfected with HIV and hepatitis C during peginterferon alfa-2b and ribavirin therapy.
    The American journal of gastroenterology, 2007, Volume: 102, Issue:6

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Hyperpigmentation; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tongue Diseases; White People

2007
Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System.
    Pharmacotherapy, 2007, Volume: 27, Issue:6

    Topics: Age Factors; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Fibrosis; Genotype; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Markov Chains; Middle Aged; Models, Economic; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; United States; United States Department of Veterans Affairs

2007
Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2007, Volume: 5, Issue:8

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Biopsy; DNA, Viral; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Hypertension, Portal; Interferon alpha-2; Interferon-alpha; Liver Circulation; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Venous Pressure; Viral Load; Virulence

2007
Antiviral therapy for hepatitis C virus recurrence after liver transplantation in HIV-infected patients: outcome in the Bonn cohort.
    AIDS (London, England), 2007, Jun-19, Volume: 21, Issue:10

    Topics: Administration, Oral; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome

2007
[A case of peripheral facial nerve palsy with cryoglobulinemia and chronic thyroiditis occurring during interferon plus ribavirin therapy for chronic hepatitis C].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2007, Volume: 104, Issue:6

    Topics: Adult; Antiviral Agents; Chronic Disease; Cryoglobulinemia; Facial Paralysis; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Thyroiditis

2007
Productivity improvements in hepatitis C treatment: impact on efficacy, cost, cost-effectiveness and quality of life.
    Scandinavian journal of gastroenterology, 2007, Volume: 42, Issue:7

    Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Administration Schedule; Efficiency; Female; Genotype; Health Care Costs; Hepatitis C, Chronic; Humans; Interferons; Male; Markov Chains; Models, Economic; Quality of Life; Ribavirin; Treatment Outcome

2007
Pharmacokinetic evaluation of the effects of ribavirin on zidovudine triphosphate formation: ACTG 5092s Study Team.
    HIV medicine, 2007, Volume: 8, Issue:5

    Topics: Adult; Antiviral Agents; Area Under Curve; Drug Interactions; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Middle Aged; Phosphorylation; Reverse Transcriptase Inhibitors; Ribavirin; Zidovudine

2007
Chronic hepatitis C: viral clearance several months after discontinuation of therapy in two non-responders.
    Infection, 2007, Volume: 35, Issue:3

    Topics: Adult; Alanine Transaminase; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load

2007
Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Journal of gastroenterology and hepatology, 2007, Volume: 22, Issue:6

    Topics: Adult; Antiviral Agents; Chi-Square Distribution; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Logistic Models; Male; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2007
Neutralizing antibodies in patients with chronic hepatitis C infection treated with (Peg)-interferon/ribavirin.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2007, Volume: 39, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferons; Neutralization Tests; Polyethylene Glycols; Polymorphism, Single-Stranded Conformational; Ribavirin; Viral Envelope Proteins

2007
Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection.
    Journal of viral hepatitis, 2007, Volume: 14, Issue:7

    Topics: Adult; Africa South of the Sahara; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2007
Response prediction and treatment tailoring for chronic hepatitis C virus genotype 1 infection.
    Journal of clinical microbiology, 2007, Volume: 45, Issue:8

    Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia

2007
Intraocular complications of IFN-alpha and ribavirin therapy in patients with chronic viral hepatitis C.
    World journal of gastroenterology, 2007, Jun-14, Volume: 13, Issue:22

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Eye Diseases; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Optic Neuropathy, Ischemic; Retinal Vein Occlusion; Ribavirin; Uveomeningoencephalitic Syndrome

2007
The magnitude of week 4 HCV RNA decay on pegylated interferon/ribavirin accurately predicts virological failure in patients with genotype 1.
    Antiviral therapy, 2007, Volume: 12, Issue:3

    Topics: Aspartate Aminotransferases; Cohort Studies; Drug Therapy, Combination; Endpoint Determination; Female; Genetic Markers; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Spain; Species Specificity; Time Factors; Treatment Failure; Urban Population; Viral Load

2007
Occult HBV infection may represent a major risk factor of non-response to antiviral therapy of chronic hepatitis C.
    Journal of medical virology, 2007, Volume: 79, Issue:8

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Failure; Viral Load

2007
Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C.
    Journal of medical virology, 2007, Volume: 79, Issue:8

    Topics: Aged; Antiviral Agents; Drug Administration Schedule; Hepatitis C, Chronic; Humans; Interferons; Liver Neoplasms; Middle Aged; Ribavirin; Risk Factors

2007
Studies of therapy with thymosin alpha1 in combination with pegylated interferon alpha2a and ribavirin in nonresponder patients with chronic hepatitis C.
    Annals of the New York Academy of Sciences, 2007, Volume: 1112

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thymalfasin; Thymosin

2007
Thymalfasin for the treatment of chronic hepatitis C infection.
    Annals of the New York Academy of Sciences, 2007, Volume: 1112

    Topics: Adjuvants, Immunologic; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thymalfasin; Thymosin

2007
Qualitative application of COBAS AMPLICOR HCV test version 2.0 assays in patients with chronic hepatitis C virus infection and comparison of clinical performance with version 1.0.
    The Kaohsiung journal of medical sciences, 2007, Volume: 23, Issue:7

    Topics: Hepatitis C, Chronic; Humans; Interferons; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Sensitivity and Specificity

2007
Efficacy of ribavirin plus interferon-alpha in patients aged >or=60 years with chronic hepatitis C.
    Journal of gastroenterology and hepatology, 2007, Volume: 22, Issue:7

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin

2007
Bile acids promote the expression of hepatitis C virus in replicon-harboring cells.
    Journal of virology, 2007, Volume: 81, Issue:18

    Topics: Animals; Antiviral Agents; Bile Acids and Salts; Cell Line; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; Drug Antagonism; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Interferon-alpha; Interferon-gamma; Pregnenediones; Receptors, Cytoplasmic and Nuclear; Replicon; Ribavirin; Swine; Transcription Factors; Vesicular Exanthema of Swine; Vesicular exanthema of swine virus; Virus Replication

2007
[Chronic hepatitis C and B. What can be accomplished with antiviral therapy].
    MMW Fortschritte der Medizin, 2007, Feb-15, Volume: 149, Issue:7

    Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferons; Prognosis; Ribavirin

2007
Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C.
    The American journal of gastroenterology, 2007, Volume: 102, Issue:10

    Topics: Adult; Antiviral Agents; Asian People; Body Mass Index; Canada; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load

2007
A health economic model to assess the cost-effectiveness of PEG IFN alpha-2a and ribavirin in patients with mild chronic hepatitis C.
    Journal of viral hepatitis, 2007, Volume: 14, Issue:8

    Topics: Antiviral Agents; Belgium; Computer Simulation; Cost-Benefit Analysis; Drug Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Markov Chains; Middle Aged; Models, Econometric; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin

2007
Staphylococcus aureus bacteremia in patients receiving pegylated interferon-alpha and ribavirin for chronic hepatitis C virus infection.
    Journal of viral hepatitis, 2007, Volume: 14, Issue:8

    Topics: Adult; Alberta; Antiviral Agents; DNA, Bacterial; Drug Therapy, Combination; Electrophoresis, Gel, Pulsed-Field; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Recombinant Proteins; Ribavirin; Staphylococcal Infections; Staphylococcus aureus

2007
Hepatitis-C patients have reduced growth hormone (GH) secretion which improves during long-term therapy with pegylated interferon-alpha.
    The American journal of gastroenterology, 2007, Volume: 102, Issue:12

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Growth Hormone; Hepatitis C, Chronic; Humans; Insulin-Like Growth Factor Binding Protein 1; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Monosaccharides; Pituitary Function Tests; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Statistics, Nonparametric; Treatment Outcome; Triazoles

2007
Antiviral therapy for chronic hepatitis C in patients with inherited bleeding disorders: an international, multicenter cohort study.
    Journal of thrombosis and haemostasis : JTH, 2007, Volume: 5, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Cohort Studies; Female; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferons; International Cooperation; Male; Middle Aged; Ribavirin; Treatment Outcome

2007
Antiviral therapy for cryoglobulinemic neuropathy: comment on the article by Saadoun et al.
    Arthritis and rheumatism, 2007, Volume: 56, Issue:8

    Topics: Antiviral Agents; Cryoglobulinemia; Drug Carriers; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Peripheral Nervous System Diseases; Polyethylene Glycols; Recombinant Proteins; Remission Induction; Ribavirin

2007
Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin.
    Transplantation, 2007, Jul-27, Volume: 84, Issue:2

    Topics: Adult; Antiviral Agents; Biopsy; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Prognosis; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Survival Rate

2007
Evolution of T-cell responses to hepatitis C virus (HCV) during pegylated interferon plus ribavirin treatment in HCV-monoinfected and in HCV/HIV-coinfected patients.
    Antiviral therapy, 2007, Volume: 12, Issue:4

    Topics: Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; T-Lymphocytes

2007
Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients.
    Antiviral therapy, 2007, Volume: 12, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome

2007
Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy.
    Hepatology (Baltimore, Md.), 2007, Volume: 46, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Biopsy; Cell Line; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Liver; Male; Metabolic Syndrome; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Treatment Outcome

2007
Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients.
    The Journal of infectious diseases, 2007, Sep-01, Volume: 196, Issue:5

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injury; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2007
Serum KL-6 level is elevated in chronic hepatitis C patients with combination therapy of pegylated interferon and ribavirin.
    Internal medicine (Tokyo, Japan), 2007, Volume: 46, Issue:15

    Topics: Adolescent; Adult; Aged; Antigens, Neoplasm; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Lung Diseases, Interstitial; Male; Middle Aged; Mucin-1; Mucins; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Retrospective Studies; Ribavirin

2007
Sudden hearing loss in chronic hepatitis C patient suffering from Turner syndrome, treated with pegylated interferon and ribavirin.
    International journal of audiology, 2007, Volume: 46, Issue:7

    Topics: Adult; Antiviral Agents; Audiometry, Pure-Tone; Disease Progression; Drug Therapy, Combination; Female; Hearing Loss, Sensorineural; Hearing Loss, Sudden; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index; Turner Syndrome

2007
[Expression of toll-like receptors on blood leucocytes of children with chronic viral hepatitis C].
    Przeglad epidemiologiczny, 2006, Volume: 60, Issue:4

    Topics: Adolescent; Antiviral Agents; Child; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocytes; Male; Ribavirin; Toll-Like Receptor 2; Toll-Like Receptor 4; Toll-Like Receptors

2006
[Comparison of early virologic response among patients with chronic hepatitis C infected with genotype non 2/3 treated with pegylated interferon alfa-2B and ribavirin in dependence with hepatic fibrosis stages].
    Przeglad epidemiologiczny, 2006, Volume: 60, Issue:4

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Biopsy, Needle; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Viremia

2006
Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus.
    The Journal of dermatology, 2007, Volume: 34, Issue:8

    Topics: Adult; Aged; Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2007
Impact of hepatitis B core antibody (anti HBc) seropositivity on interferon/ribavirin treatment response in patients with chronic hepatitis C.
    Bratislavske lekarske listy, 2007, Volume: 108, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin

2007
HCV-related cryoglobulinemic glomerulonephritis: implications of antiviral and immunosuppressive therapies.
    Acta bio-medica : Atenei Parmensis, 2007, Volume: 78, Issue:1

    Topics: Adrenal Cortex Hormones; Adult; Aged; Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Female; Glomerulonephritis; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Male; Middle Aged; Ribavirin

2007
Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection.
    Liver international : official journal of the International Association for the Study of the Liver, 2007, Volume: 27, Issue:7

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Failure; Viral Load

2007
Evaluating the cost of sustained virologic response in naïve chronic hepatitis C patients treated à la carte.
    Alimentary pharmacology & therapeutics, 2007, Sep-01, Volume: 26, Issue:5

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Cost Control; Decision Trees; Drug Therapy, Combination; Economics, Pharmaceutical; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sensitivity and Specificity

2007
The cost-effectiveness of the new protocol reflecting rapid virologic response to peginterferon alpha-2b and ribavirin for chronic hepatitis C.
    European journal of gastroenterology & hepatology, 2007, Volume: 19, Issue:9

    Topics: Antiviral Agents; Cost of Illness; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Markov Chains; Models, Econometric; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; RNA, Viral; Sensitivity and Specificity; Treatment Outcome; Viral Load

2007
Pyoderma gangrenosum and exacerbation of psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic hepatitis C.
    European journal of gastroenterology & hepatology, 2007, Volume: 19, Issue:9

    Topics: Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Psoriasis; Pyoderma Gangrenosum; Recombinant Proteins; Ribavirin

2007
Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection.
    European journal of gastroenterology & hepatology, 2007, Volume: 19, Issue:9

    Topics: Adult; Alopecia Areata; Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2007
[Treatment with natural interferon (alfaferone) in clinical practice--our experience].
    Przeglad epidemiologiczny, 2007, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B, Chronic; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Treatment Outcome

2007
Adverse effects during the treatment with pegylated interferon and ribavirin in children with chronic hepatitis C.
    Pharmacoepidemiology and drug safety, 2007, Volume: 16, Issue:10

    Topics: Adolescent; Adult; Alanine Transaminase; Antiviral Agents; Bilirubin; Child; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2007
[Serum levels of vascular endothelial growth factor in chronic hepatitis C patients treated with interferon alpha and ribavirin].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 2007, Volume: 60, Issue:3-4

    Topics: Adult; Antiviral Agents; Case-Control Studies; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Poland; Ribavirin; Vascular Endothelial Growth Factor A

2007
Polymorphisms in the IFNAR1 gene in patients with chronic hepatitis C: outcome of combined IFN-alpha therapy.
    European cytokine network, 2007, Volume: 18, Issue:3

    Topics: Adult; Age Factors; Antiviral Agents; Brazil; DNA; Drug Therapy, Combination; Female; Genome, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Male; Middle Aged; Polymorphism, Genetic; Receptor, Interferon alpha-beta; Recombinant Proteins; Remission Induction; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome

2007
Hepatitis C virus with normal transaminase levels.
    Digestive diseases (Basel, Switzerland), 2007, Volume: 25, Issue:3

    Topics: Alanine Transaminase; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2007
Sustained HCV-RNA response and hepatitis Bs seroconversion after individualized antiviral therapy with pegylated interferon alpha plus ribavirin and active vaccination in a hepatitis C virus/hepatitis B virus-coinfected patient.
    European journal of gastroenterology & hepatology, 2007, Volume: 19, Issue:10

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2007
Haematological support during peg-interferon therapy for HCV-infected haemophiliacs improves virological outcomes.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2007, Volume: 13, Issue:5

    Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hemophilia A; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Viral Load

2007
Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C.
    Gut, 2008, Volume: 57, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Biomarkers; Cell Line, Transformed; Drug Therapy, Combination; Female; Gene Expression Profiling; Genetic Markers; Haplotypes; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Ribavirin; RNA, Messenger; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Treatment Failure; Treatment Outcome

2008
Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C.
    Gut, 2008, Volume: 57, Issue:4

    Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Gene Expression; Gene Expression Profiling; Genetic Markers; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Messenger; Treatment Outcome

2008
[Treatment of chronic hepatitis C: shorter treatment duration for genotype 2 or 3 infection].
    The Korean journal of hepatology, 2007, Volume: 13, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome

2007
[Short-term therapy with pegylated interferon plus ribavirin for the chronic hepatitis C genotype 2 patients].
    The Korean journal of hepatology, 2007, Volume: 13, Issue:3

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome

2007
[A case of vasculitis in chronic hepatitis C patient treated with pegylated interferon alpha-2a and ribavirin].
    The Korean journal of hepatology, 2007, Volume: 13, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Skin; Vasculitis

2007
Hepatocellular carcinoma appearance in patients with hepatitis C virus-related chronic liver disease 90 and 70 months after sustained virological response to interferon and ribavirin.
    Liver international : official journal of the International Association for the Study of the Liver, 2008, Volume: 28, Issue:3

    Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Time Factors

2008
Recommendations for the treatment of chronic hepatitis C infection in children.
    JPMA. The Journal of the Pakistan Medical Association, 2007, Volume: 57, Issue:8

    Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Infant; Infant, Newborn; Interferon-alpha; Ribavirin

2007
Recurrent myocardial ischaemia during combination antiviral therapy in a patient with chronic hepatitis C and normal aminotransferase levels.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2008, Volume: 40, Issue:9

    Topics: Alanine Transaminase; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Monitoring, Physiologic; Myocardial Ischemia; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Risk Assessment; Severity of Illness Index

2008
Iron and hepatitis C: beginning to make sense.
    Journal of gastroenterology and hepatology, 2007, Volume: 22, Issue:11

    Topics: Alcohol Drinking; Antiviral Agents; Disease Progression; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Iron; Iron Overload; Liver; Phlebotomy; Platelet Count; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Sex Factors; Transaminases; Treatment Failure; Treatment Outcome

2007
[Two cases of pyogenic spondylitis with chronic hepatitis C during combination therapy of interferon alfa and ribavirin].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2007, Volume: 104, Issue:10

    Topics: Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Spondylitis; Staphylococcal Infections; Streptococcal Infections; Suppuration; Treatment Outcome; Viridans Streptococci

2007
Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy.
    Journal of viral hepatitis, 2007, Volume: 14, Issue:11

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Logistic Models; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome

2007
Development of Myasthenia gravis due to treatment of chronic hepatitis C with a combination of interferon-alpha and ribavirin.
    Digestion, 2007, Volume: 75, Issue:4

    Topics: Antiviral Agents; Diagnosis, Differential; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Myasthenia Gravis; Ribavirin

2007
Response of combination therapy on viral load and disease severity in chronic hepatitis C.
    Digestive diseases and sciences, 2008, Volume: 53, Issue:4

    Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome; Viral Load

2008
Etiologic treatment of hepatitis C virus-associated mixed cryoglobulinemia.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2007, Volume: 39 Suppl 1

    Topics: Cryoglobulinemia; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2007
HCV patients, psychopathology and tryptophan metabolism: analysis of the effects of pegylated interferon plus ribavirin treatment.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2007, Volume: 39 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Interferon alpha-2; Interferon-alpha; Kynurenine; Macrophages; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tryptophan

2007
B-cell depletion in the treatment of mixed cryoglobulinemia.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2007, Volume: 39 Suppl 1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; B-Lymphocytes; Cryoglobulinemia; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Lymphocyte Depletion; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Rituximab; Treatment Outcome

2007
Pegylated interferon therapy in chronic hepatitis C: lights and shadows of an innovative treatment.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2007, Volume: 39 Suppl 1

    Topics: Antiviral Agents; Black or African American; Drug Tolerance; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2007
Antiviral treatment of HCV-related cirrhosis.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2007, Volume: 39 Suppl 1

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2007
Improved cognitive function as a consequence of hepatitis C virus treatment.
    HIV medicine, 2007, Volume: 8, Issue:8

    Topics: Adult; Antiviral Agents; Cognition Disorders; Cognitive Behavioral Therapy; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Neuropsychological Tests; Predictive Value of Tests; Prospective Studies; Quality of Life; Ribavirin; Treatment Outcome

2007
PEG-IFN, RBV dosing during chronic HCV re-treatment.
    IAPAC monthly, 2007, Volume: 13, Issue:2

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2007
Intrahepatic interferon-stimulated gene responses: can they predict treatment responses in chronic hepatitis C infection?
    Hepatology (Baltimore, Md.), 2007, Volume: 46, Issue:5

    Topics: Antiviral Agents; Gene Expression; Gene Expression Profiling; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2007
[Cutaneous reactions induced by pegylated-interferon plus ribavirin combination therapy in a patient with chronic hepatitis C].
    Fukuoka igaku zasshi = Hukuoka acta medica, 2007, Volume: 98, Issue:9

    Topics: Aged; Anti-Allergic Agents; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Skin Diseases

2007
Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3.
    Journal of hepatology, 2008, Volume: 48, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Blood Glucose; Body Mass Index; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin; Insulin Resistance; Interferons; Liver; Liver Cirrhosis; Liver Function Tests; Logistic Models; Male; Middle Aged; Obesity; Ribavirin; Treatment Failure; Treatment Outcome

2008
[A periappendiceal abscess during combination interferon and ribavirin treatment for chronic hepatitis C].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2007, Volume: 104, Issue:11

    Topics: Abscess; Antiviral Agents; Appendix; Cecal Diseases; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Recombinant Proteins; Ribavirin

2007
De novo nephrotic syndrome following pegylated interferon alfa 2b/ribavirin therapy for chronic hepatitis C infection.
    International urology and nephrology, 2008, Volume: 40, Issue:2

    Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Nephrotic Syndrome; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2008
De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C.
    Alimentary pharmacology & therapeutics, 2008, Feb-01, Volume: 27, Issue:3

    Topics: Adult; Antiviral Agents; Anxiety Disorders; Chi-Square Distribution; Depression; Diagnostic and Statistical Manual of Mental Disorders; Drug Therapy, Combination; Educational Status; Emigrants and Immigrants; Employment; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Compliance; Polyethylene Glycols; Prospective Studies; Psychiatric Status Rating Scales; Recombinant Proteins; Ribavirin; Treatment Outcome

2008
Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study.
    Antiviral therapy, 2007, Volume: 12, Issue:7

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Failure; Viral Load

2007
Summaries for patients. Sustained virologic response in hepatitis C.
    Annals of internal medicine, 2007, Nov-20, Volume: 147, Issue:10

    Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Failure; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome

2007
Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.
    Annals of internal medicine, 2007, Nov-20, Volume: 147, Issue:10

    Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Failure; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome

2007
High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon alpha for chronic hepatitis C virus infection.
    Liver international : official journal of the International Association for the Study of the Liver, 2008, Volume: 28, Issue:1

    Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 1; DNA Probes, HLA; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2008
Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2008, Volume: 23, Issue:2

    Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin

2008
Measurement of ribavirin plasma concentrations by high-performance liquid chromatography using a novel solid-phase extraction method in patients treated for chronic hepatitis C.
    Therapeutic drug monitoring, 2007, Volume: 29, Issue:6

    Topics: Adult; Antiviral Agents; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Monitoring; Hepatitis C, Chronic; Humans; Ribavirin; Sensitivity and Specificity; Solid Phase Extraction

2007
Response to antiviral therapy and hepatic expression of cyclooxygenases in chronic hepatitis C.
    European journal of gastroenterology & hepatology, 2007, Volume: 19, Issue:11

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Cyclooxygenase 1; Cyclooxygenase 2; Female; Gene Expression; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Prostaglandin-Endoperoxide Synthases; Recombinant Proteins; Ribavirin; RNA, Viral; Staining and Labeling; Treatment Outcome

2007
[Chronic fatigue. IV--Assessment of a 40-year-old patient].
    Praxis, 2007, Nov-07, Volume: 96, Issue:45

    Topics: Adult; Anemia, Iron-Deficiency; Antiviral Agents; Diagnosis, Differential; Drug Therapy, Combination; Fatigue Syndrome, Chronic; Hashimoto Disease; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Methadone; Narcotics; Opioid-Related Disorders; Ribavirin; Thyroid Function Tests

2007
Introduction. Necroinflammation and the course of chronic hepatitis.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2007, Volume: 39 Suppl 3

    Topics: Antiviral Agents; Congresses as Topic; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Inflammation; Interferon alpha-2; Interferon-alpha; Liver; Necrosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2007
Ribavirin posology, observance, and sustained virologic response.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2008, Volume: 6, Issue:3

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2008
Predictive factors for interferon and ribavirin combination therapy in patients with chronic hepatitis C.
    World journal of gastroenterology, 2007, Dec-14, Volume: 13, Issue:46

    Topics: Adult; Age Factors; Alanine Transaminase; Amino Acid Sequence; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Mutation; Predictive Value of Tests; Ribavirin; RNA, Viral; Treatment Outcome

2007
Response rates to combination therapy for chronic HCV infection in a clinical setting and derivation of probability tables for individual patient management.
    Journal of viral hepatitis, 2008, Volume: 15, Issue:4

    Topics: Adult; Age Factors; Antiviral Agents; Drug Therapy, Combination; Female; Forecasting; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; United Kingdom; Viremia

2008
Assessment of hepatitis C virus-RNA clearance under combination therapy for hepatitis C virus genotype 1: performance of the transcription-mediated amplification assay.
    Journal of viral hepatitis, 2008, Volume: 15, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Nucleic Acid Amplification Techniques; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Sensitivity and Specificity; Transcription, Genetic; Treatment Outcome

2008
Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults.
    AIDS (London, England), 2007, Oct-18, Volume: 21, Issue:16

    Topics: Adult; Alanine Transaminase; Anti-Retroviral Agents; Antiviral Agents; Aspartate Aminotransferases; Biomarkers; Biopsy; Disease Progression; Female; Fibrosis; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Incidence; Interferons; Liver; Logistic Models; Male; Middle Aged; Platelet Count; Predictive Value of Tests; Prospective Studies; Ribavirin

2007
Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    AIDS (London, England), 2008, Jan-02, Volume: 22, Issue:1

    Topics: Administration, Oral; Antiviral Agents; Biomarkers; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Endpoint Determination; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Hospitals; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Multicenter Studies as Topic; Polyethylene Glycols; Polymerase Chain Reaction; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Spain; Treatment Outcome; Viral Load

2008
Treating children with chronic hepatitis C after malignancy in a single center.
    Pediatric hematology and oncology, 2007, Volume: 24, Issue:8

    Topics: Adolescent; Adult; Antiviral Agents; Blood Component Transfusion; Child; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Infant; Interferons; Male; Neoplasms; Ribavirin

2007
Impaired anger control as an underappreciated side effect of treatments for chronic HCV infection in HIV-HCV coinfected patients.
    Journal of clinical gastroenterology, 2008, Volume: 42, Issue:1

    Topics: Adult; Anger; Anti-Retroviral Agents; Antiviral Agents; Anxiety Disorders; Cross-Sectional Studies; Female; France; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Medical Records; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Surveys and Questionnaires; Treatment Outcome

2008
Thyrotoxic periodic paralysis induced by pegylated interferon alpha plus ribavirin for chronic hepatitis C.
    Journal of clinical gastroenterology, 2008, Volume: 42, Issue:1

    Topics: Adrenergic beta-Antagonists; Adult; Antithyroid Agents; Antiviral Agents; Carbimazole; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Propranolol; Quadriplegia; Recombinant Proteins; Ribavirin; Thyroid Diseases; Time Factors; Treatment Outcome

2008
[Predicting sustained virological response in chronic hepatitis C patients treated with pegylated interferon and ribavirin using a novel highly sensitive Real-time detection PCR assay].
    Rinsho byori. The Japanese journal of clinical pathology, 2007, Volume: 55, Issue:11

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Forecasting; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Sensitivity and Specificity

2007
[Clinical outcome after living donor liver transplantation in patients with hepatitis C virus-associated cirrhosis].
    The Korean journal of hepatology, 2007, Volume: 13, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Combined Modality Therapy; Female; Graft Survival; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Severity of Illness Index; Treatment Outcome

2007
Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop.
    Hepatology (Baltimore, Md.), 2008, Volume: 47, Issue:1

    Topics: Antiviral Agents; Gene Expression; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Outcome

2008
Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2008, Volume: 14, Issue:1

    Topics: Antiviral Agents; Biopsy; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Failure; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Treatment Outcome

2008
[Effectiveness and complications of combination therapy with interferon alpha and ribavirin in patients with chronic hepatitis C].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2007, Volume: 49, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin

2007
Severe stomatitis complicating treatment with pegylated-interferon alpha-2a and ribavirin in an HCV-infected patient.
    Southern medical journal, 2008, Volume: 101, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Stomatitis

2008
[Development of a myasthenia crisis during interferon treatment for chronic C hepatitis].
    Gastroenterologie clinique et biologique, 2007, Volume: 31, Issue:12

    Topics: Aged; Antiviral Agents; Cholinesterase Inhibitors; Follow-Up Studies; Glucocorticoids; Hepatitis C, Chronic; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Interferon-alpha; Male; Myasthenia Gravis; Mycophenolic Acid; Prednisone; Pyridostigmine Bromide; Ribavirin

2007
Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin.
    Journal of viral hepatitis, 2008, Volume: 15, Issue:2

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Combinations; Fatty Liver; Genotype; Hepacivirus; Hepatitis C, Chronic; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Ribavirin

2008
[Changes in socio-economics, quality of life and knowledge of patients with chronic hepatitis C during the Hepatitis Competence Net Project].
    Zeitschrift fur Gastroenterologie, 2008, Volume: 46, Issue:1

    Topics: Antiviral Agents; Biopsy; Female; Follow-Up Studies; Health Knowledge, Attitudes, Practice; Health Status; Hepatitis C, Chronic; Humans; Insurance, Health; Interferons; Liver; Liver Cirrhosis; Male; Middle Aged; Patient Education as Topic; Prospective Studies; Quality of Life; Ribavirin; Self-Help Groups; Socioeconomic Factors; Surveys and Questionnaires; Time Factors

2008
Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
    The American journal of gastroenterology, 2008, Volume: 103, Issue:3

    Topics: Adiponectin; Adult; Antiviral Agents; Biomarkers; Body Mass Index; Drug Therapy, Combination; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral; Tumor Necrosis Factor-alpha

2008
[Protocol for the treatment of chronic viral hepatitis].
    Orvosi hetilap, 2008, Jan-20, Volume: 149, Issue:3

    Topics: Adenine; Algorithms; Antiviral Agents; Clinical Protocols; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Lamivudine; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2008
[Acute portal thrombosis in patients with hepatitis C treated with pegylated interferon and ribavirin].
    Gastroenterologia y hepatologia, 2008, Volume: 31, Issue:1

    Topics: Acute Disease; Adult; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Portal Vein; Recombinant Proteins; Ribavirin; Thrombosis

2008
Consensus interferon and ribavirin in patients with chronic hepatitis C who were nonresponders to pegylated interferon alfa-2b and ribavirin.
    Digestive diseases and sciences, 2008, Volume: 53, Issue:7

    Topics: Administration, Oral; Antiviral Agents; Chi-Square Distribution; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Injections; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retreatment; Retrospective Studies; Ribavirin; Treatment Outcome

2008
[Chronic hepatitis C treatment with pegilated interferon alpha2a and ribavirin in patients with HIV-infection].
    Terapevticheskii arkhiv, 2007, Volume: 79, Issue:11

    Topics: Adult; Antiviral Agents; Biomarkers; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Retrospective Studies; Ribavirin

2007
Quasispecies as predictive factor of rapid, early and sustained virological responses in chronic hepatitis C, genotype 1, treated with peginterferon-ribavirin.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2008, Volume: 41, Issue:4

    Topics: Adult; Age Factors; Aged; Antiviral Agents; gamma-Glutamyltransferase; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2008
Interferon-ribavirin-associated ischemic colitis.
    Journal of clinical gastroenterology, 2008, Volume: 42, Issue:3

    Topics: Antiviral Agents; Biopsy; Colitis, Ischemic; Colon; Colonoscopy; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin

2008
Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2008, Volume: 6, Issue:2

    Topics: Ethnicity; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukopenia; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Thrombocytopenia; Treatment Outcome; Viral Load; Weight Loss

2008
Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response.
    Arthritis and rheumatism, 2008, Volume: 58, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Lymphoma, B-Cell; Male; Middle Aged; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Vasculitis; Virus Replication

2008
Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients.
    Antiviral therapy, 2007, Volume: 12, Issue:8

    Topics: Adult; Anemia; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Fibrosis; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Male; Neutropenia; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Spain; Thrombocytopenia; Zidovudine

2007
Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, Mar-01, Volume: 46, Issue:5

    Topics: Adult; Anti-HIV Agents; Disease Progression; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver; Liver Cirrhosis; Male; Middle Aged; Mitochondria; Prevalence; Ribavirin; Risk Factors

2008
Changes in the Th1/Th2 ratio during a 24-week course of an interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.
    Journal of gastroenterology and hepatology, 2008, Volume: 23, Issue:8 Pt 2

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Th1 Cells; Th2 Cells

2008
Investigation of hyperuricemia during pegylated-interferon-alpha2b plus ribavirin combination therapy in patients with chronic hepatitis C.
    Journal of digestive diseases, 2008, Volume: 9, Issue:1

    Topics: Aged; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Hyperuricemia; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Uric Acid

2008
IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C.
    Brain, behavior, and immunity, 2008, Volume: 22, Issue:6

    Topics: Adult; Antiviral Agents; Basal Ganglia; Depression; Fatigue; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Neuropsychological Tests; Prospective Studies; Psychiatric Status Rating Scales; Reaction Time; Regression Analysis; Ribavirin

2008
Psychiatric symptoms during interferon treatment for hepatitis C: experiences from a tertiary care hepatology centre.
    Alimentary pharmacology & therapeutics, 2008, Jun-01, Volume: 27, Issue:11

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Mental Disorders; Middle Aged; Polyethylene Glycols; Psychotropic Drugs; Recombinant Proteins; Retrospective Studies; Ribavirin

2008
The genetic differences with whole genome linkage disequilibrium mapping between responder and non-responder in interferon-alpha and ribavirin combined therapy for chronic hepatitis C patients.
    International journal of immunogenetics, 2008, Volume: 35, Issue:2

    Topics: Antigens, CD; Antiviral Agents; Asian People; Drug Resistance, Viral; Female; Genetic Markers; Genome, Human; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukin-15; Linkage Disequilibrium; Male; Microsatellite Repeats; Polymorphism, Single Nucleotide; Ribavirin; Taiwan; Tetraspanin 28

2008
[Healing of chronic hepatitis C following 12 weeks of therapy with peginterferon-alpha and ribavirin].
    Revista espanola de enfermedades digestivas, 2007, Volume: 99, Issue:12

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors

2007
PEG-IFN and ribavirin re-treatment of HCV-1b cirrhosis non responder to conventional combination therapy.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2008, Volume: 40, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome

2008
Is serum uric acid a predictive factor of response to IFN-treatment in patients with chronic hepatitis C infection?
    Journal of medical virology, 2008, Volume: 80, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Prognosis; Prospective Studies; Ribavirin; Severity of Illness Index; Treatment Outcome; Uric Acid; Viral Load

2008
Possible molecular mechanism of the relationship between NS5B polymorphisms and early clearance of hepatitis C virus during interferon plus ribavirin treatment.
    Journal of medical virology, 2008, Volume: 80, Issue:4

    Topics: Amino Acid Substitution; Antiviral Agents; Cell Line; Genes, Reporter; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Luciferases; Mutation, Missense; Polymorphism, Genetic; Ribavirin; Transfection; Viral Nonstructural Proteins

2008
[Evaluation of hepatitis C virus genotype and its influence on therapeutical respond on combined therapy with pegilated interferon A 2a (40)kD and ribavirin].
    Medicinski arhiv, 2007, Volume: 61, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2007
Effectiveness of pegylated interferon/ribavirin combination in 'real world' patients with chronic hepatitis C virus infection.
    Alimentary pharmacology & therapeutics, 2008, Volume: 27, Issue:9

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Epidemiologic Methods; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome; United States

2008
Does a rapid decline in the hematological and biochemical parameters induced by interferon and ribavirin combination therapy for the hepatitis C virus predict a sustained viral response?
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2008, Volume: 22, Issue:2

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Blood Cell Count; Cohort Studies; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Predictive Value of Tests; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome; Viral Load

2008
Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C.
    Journal of hepatology, 2008, Volume: 48, Issue:5

    Topics: Adult; Alanine Transaminase; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin; Viral Load

2008
Artificially low HbA1c associated with treatment with ribavirin.
    BMJ (Clinical research ed.), 2008, Mar-01, Volume: 336, Issue:7642

    Topics: Antiviral Agents; Diabetes Mellitus; Glycated Hemoglobin; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Ribavirin

2008
Eicosapentaenoic acid supplementation for chronic hepatitis C patients during combination therapy of pegylated interferon alpha-2b and ribavirin.
    Lipids, 2008, Volume: 43, Issue:4

    Topics: Alanine Transaminase; Antiviral Agents; Ascorbic Acid; Dietary Supplements; Drug Therapy, Combination; Eicosapentaenoic Acid; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Vitamin E

2008
Using pegylated interferon alfa-2b and ribavirin to treat chronic hepatitis patients infected with hepatitis c virus genotype 1: are nonresponders and relapsers different populations?
    The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2007, Volume: 11, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2007
Depression in chronic hepatitis: the virus, the drug, or the ethnic background?
    Liver international : official journal of the International Association for the Study of the Liver, 2008, Volume: 28, Issue:4

    Topics: Antiviral Agents; Depressive Disorder; Female; Follow-Up Studies; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis, Chronic; Humans; Interferons; Liver Function Tests; Male; Ribavirin; Risk Assessment; Severity of Illness Index

2008
[Diabetes mellitus during interferon therapy].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26, Issue:2

    Topics: Adult; Anti-HIV Agents; Antiviral Agents; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2008
[Bacterial endocarditis in the course of sepsis in 7th month of treatment with peginterferon alfa and ribavirin in patient with chronic hepatitis C].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 2007, Volume: 60, Issue:9-10

    Topics: Antiviral Agents; Endocarditis, Bacterial; Escherichia coli; Escherichia coli Infections; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sepsis; Time Factors; Treatment Outcome

2007
Tongue hyperpigmentation resulting from peginterferon alpha-2a and ribavirin treatment in a Caucasian patient with chronic hepatitis C.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2008, Volume: 22, Issue:11

    Topics: Adult; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Pigmentation Disorders; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tongue; White People

2008
Rapid viral response and treatment outcome in genotype 2 and 3 chronic hepatitis C: comparison between two HCV RNA quantitation methods.
    Journal of medical virology, 2008, Volume: 80, Issue:5

    Topics: Adult; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sensitivity and Specificity; Time Factors; Treatment Outcome; Viral Load

2008
Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase.
    Journal of viral hepatitis, 2008, Volume: 15, Issue:8

    Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Mutation; Ribavirin; RNA-Dependent RNA Polymerase; Selection, Genetic; Viral Nonstructural Proteins

2008
[Clinical outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C].
    The Korean journal of hepatology, 2008, Volume: 14, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; Treatment Outcome

2008
[Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha-2b plus ribavirin according to treatment duration in patients with chronic hepatitis C].
    The Korean journal of hepatology, 2008, Volume: 14, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome

2008
[Acute pancreatitis during treatment for chronic viral hepatitis C].
    Gastroenterologie clinique et biologique, 2008, Volume: 32, Issue:3

    Topics: Acute Disease; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Pancreatitis; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2008
Early and accurate prediction of Peg-IFNs/ribavirin therapy outcome in the individual patient with chronic hepatitis C by modeling the dynamics of the infected cells.
    Clinical pharmacology and therapeutics, 2008, Volume: 84, Issue:2

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Drug Carriers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interleukin-2; Kinetics; Male; Middle Aged; Models, Biological; Models, Theoretical; Polyethylene Glycols; Predictive Value of Tests; Ribavirin; RNA, Viral; ROC Curve; Treatment Outcome; Viral Load

2008
Chronic genotype 4 hepatitis C.
    Hepatology (Baltimore, Md.), 2008, Volume: 47, Issue:5

    Topics: Antiviral Agents; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load

2008
Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C.
    Liver international : official journal of the International Association for the Study of the Liver, 2008, Volume: 28, Issue:8

    Topics: Adult; alpha-Fetoproteins; Antiviral Agents; Fatty Liver; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2008
Fulminant autoimmune hepatitis after successful interferon treatment in an HIV-HCV co-infected patient.
    International journal of STD & AIDS, 2008, Volume: 19, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Hepatitis, Autoimmune; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome

2008
Treatment of chronic hepatitis C in haemodialysis patients requires more ribavirin.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2008, Volume: 23, Issue:7

    Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Male; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin; Treatment Outcome

2008
Increased soluble IL-2 receptor levels during interferon and ribavirin treatment are associated with a good response in genotype 2a/2b patients with chronic hepatitis C.
    European journal of gastroenterology & hepatology, 2008, Volume: 20, Issue:5

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lymphocyte Activation; Male; Middle Aged; Receptors, Interleukin-2; Recombinant Proteins; Ribavirin; RNA, Viral; T-Lymphocytes; Treatment Outcome

2008
Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2008, Volume: 6, Issue:5

    Topics: Adolescent; Adult; Aged; Area Under Curve; Black or African American; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome; Viral Load; White People

2008
[Antiviral therapy of patients with chronic hepatitis C with normal level of aminotransferases].
    Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, 2007, Issue:4

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Transaminases; Treatment Outcome; Viral Load

2007
Associations between the human MHC and sustained virologic response in the treatment of chronic hepatitis C virus infection.
    Genes and immunity, 2008, Volume: 9, Issue:4

    Topics: Alleles; Antiviral Agents; Black or African American; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Genes, MHC Class I; Genes, MHC Class II; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterozygote; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; United States; Viral Load; White People

2008
Adverse skin reactions associated with hepatitis C treatment: comment.
    The Journal of dermatology, 2008, Volume: 35, Issue:4

    Topics: Antiviral Agents; Drug Eruptions; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin

2008
Type 1 diabetes mellitus provoked by peginterferon alpha-2b plus ribavirin treatment for chronic hepatitis C.
    Internal medicine (Tokyo, Japan), 2008, Volume: 47, Issue:8

    Topics: Antiviral Agents; Blood Glucose; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Glutamate Decarboxylase; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Insulin; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2008
ADVANCE study begins enrollment.
    AIDS patient care and STDs, 2008, Volume: 22, Issue:4

    Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral

2008
[Peginterferon alpha-2a and ribavirin for treating chronic hepatitis C patients with persistent normal aminotransferase levels].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2008, Volume: 16, Issue:4

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Transaminases; Young Adult

2008
Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a.
    AIDS (London, England), 2008, Apr-23, Volume: 22, Issue:7

    Topics: Adult; Antiviral Agents; Blood Glucose; Drug Administration Schedule; Fasting; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Homeostasis; Humans; Insulin; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2008
Similar hepatitis C virus RNA kinetics in HIV/hepatitis C virus monoinfected genotype 2 or 3 matched controls during hepatitis C virus combination therapy.
    AIDS (London, England), 2008, Apr-23, Volume: 22, Issue:7

    Topics: Adult; Antiviral Agents; Case-Control Studies; Combined Modality Therapy; Drug Administration Schedule; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Messenger; Statistics, Nonparametric; Viral Load

2008
Response-guided therapy: optimizing treatment now and in the future.
    Antiviral therapy, 2008, Volume: 13 Suppl 1

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Load

2008
Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: Some issues.
    Hepatology (Baltimore, Md.), 2008, Volume: 47, Issue:5

    Topics: Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin

2008
Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2008, Volume: 47, Issue:5

    Topics: Adult; Antiviral Agents; Area Under Curve; Body Mass Index; Dose-Response Relationship, Drug; Hepatitis C, Chronic; Humans; Middle Aged; Prothrombin Time; Ribavirin; RNA, Viral; Viral Load

2008
Chronic hepatitis C genotype 2 or 3 short treatment.
    Hepatology (Baltimore, Md.), 2008, Volume: 47, Issue:5

    Topics: Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2008
[Results of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in clinical practice: a 5-year experience].
    Gastroenterologia y hepatologia, 2008, Volume: 31, Issue:5

    Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors

2008
Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients.
    AIDS (London, England), 2008, May-11, Volume: 22, Issue:8

    Topics: Adult; Anti-HIV Agents; Antiviral Agents; Biomarkers; Cholesterol, LDL; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Lipids; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome

2008
Refined analysis of genetic variability parameters in hepatitis C virus and the ability to predict antiviral treatment response.
    Journal of viral hepatitis, 2008, Volume: 15, Issue:8

    Topics: Antiviral Agents; Drug Resistance, Viral; Genetic Variation; Haplotypes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Mutation, Missense; Ribavirin; Treatment Outcome; Viral Envelope Proteins; Viral Nonstructural Proteins

2008
Potential relevance of cytoplasmic viral sensors and related regulators involving innate immunity in antiviral response.
    Gastroenterology, 2008, Volume: 134, Issue:5

    Topics: Antiviral Agents; Biomarkers; Blotting, Western; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Gene Expression Regulation; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Innate; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; ROC Curve

2008
Patient's age modifies the impact of the proposed predictors of sustained virological response in chronic hepatitis C patients treated with PEG-interferon plus ribavirin.
    European journal of internal medicine, 2008, Volume: 19, Issue:4

    Topics: Adult; Age Factors; Aged; Antiviral Agents; Biopsy, Needle; Female; Forecasting; Genotype; Greece; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load

2008
Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin.
    The American journal of gastroenterology, 2008, Volume: 103, Issue:5

    Topics: Adult; Aged; Antiviral Agents; California; Cohort Studies; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2008
Differences in hepatitis C virus (HCV)-specific CD8 T-cell phenotype during pegylated alpha interferon and ribavirin treatment are related to response to antiviral therapy in patients chronically infected with HCV.
    Journal of virology, 2008, Volume: 82, Issue:15

    Topics: Adult; Antiviral Agents; CD8-Positive T-Lymphocytes; Epitopes; Female; Granzymes; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Perforin; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Core Proteins; Viral Nonstructural Proteins

2008
Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.
    Journal of viral hepatitis, 2008, Volume: 15, Issue:8

    Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2008
[Treatment of hepatitis C: therapeutic management].
    Gastroenterologie clinique et biologique, 2008, Volume: 32, Issue:5 Pt 2

    Topics: Anemia; Antiviral Agents; Erythropoietin; Female; Hepatitis C, Chronic; Humans; Interferons; Middle Aged; Ribavirin

2008
Efficacy of interferon in immunocompromised HCV patients after liver transplantation or with HIV co-infection.
    European journal of clinical investigation, 2008, Volume: 38, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Calcineurin Inhibitors; CD4 Lymphocyte Count; Cyclosporine; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Immunocompromised Host; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Retrospective Studies; Ribavirin; Statistics, Nonparametric; Tacrolimus; Treatment Outcome; Viral Load

2008
Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.
    The Netherlands journal of medicine, 2008, Volume: 66, Issue:5

    Topics: Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral

2008
Expansion of CD56- NK cells in chronic HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNalpha and ribavirin.
    Clinical immunology (Orlando, Fla.), 2008, Volume: 128, Issue:1

    Topics: Adult; Aged; Antiviral Agents; CD56 Antigen; Female; Flow Cytometry; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Killer Cells, Natural; Lymphocyte Subsets; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viremia

2008
Virological pattern in plasma, peripheral blood mononuclear cells and liver tissue and clinical outcome in chronic hepatitis B and C virus coinfection.
    Antiviral therapy, 2008, Volume: 13, Issue:2

    Topics: Adult; Antiviral Agents; DNA, Viral; Female; Hepacivirus; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Liver; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral

2008
Efficacy of combined interferon and ribavirin for treatment of hepatitis C.
    Lancet (London, England), 1998, Jan-10, Volume: 351, Issue:9096

    Topics: Adult; Antiviral Agents; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Recombinant Proteins; Ribavirin; Time Factors

1998
Ribavirin and immune thrombocytopenic purpura.
    Lancet (London, England), 1998, May-30, Volume: 351, Issue:9116

    Topics: Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Purpura, Thrombocytopenic, Idiopathic; Ribavirin

1998
Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients.
    Journal of viral hepatitis, 1998, Volume: 5, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Liver; Male; Middle Aged; Retrospective Studies; Ribavirin; Treatment Outcome

1998
Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus.
    Journal of hepatology, 1998, Volume: 29, Issue:1

    Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; Ribavirin; RNA, Viral; Viral Load

1998
From the Food and Drug Administration.
    JAMA, 1998, Aug-05, Volume: 280, Issue:5

    Topics: Allergens; Antiviral Agents; Cisapride; Contraindications; Desensitization, Immunologic; Drug Labeling; Drug Therapy, Combination; Gastrointestinal Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Mammography; Piperidines; Poaceae; Pollen; Recombinant Proteins; Ribavirin; United States; United States Food and Drug Administration

1998
Effects of the ribavirin-interferon alpha combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients.
    Cytokine, 1998, Volume: 10, Issue:8

    Topics: 2',5'-Oligoadenylate Synthetase; Adult; Aged; Antiviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Division; Cells, Cultured; Cytokines; Drug Interactions; Enzyme Activation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral

1998
Interferon alpha with ribavirin for the treatment of chronic hepatitis C in non-responders or relapsers to interferon monotherapy.
    Alimentary pharmacology & therapeutics, 1998, Volume: 12, Issue:8

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Combined Modality Therapy; Drug Resistance; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome

1998
Interferon and ribavirin combination therapy in patients with chronic hepatitis C and mixed cryoglobulinemia.
    Blood, 1998, Oct-15, Volume: 92, Issue:8

    Topics: Adult; Antiviral Agents; Cryoglobulinemia; Drug Evaluation; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin

1998
[Indications for combination interferon-ribavirin therapy in chronic hepatitis C].
    Der Internist, 1998, Volume: 39, Issue:9

    Topics: Adult; Antiviral Agents; Combined Modality Therapy; Hepatitis C, Chronic; Humans; Interferons; Middle Aged; Ribavirin; Treatment Outcome

1998
Combination therapy for hepatitis C infection.
    The New England journal of medicine, 1998, Nov-19, Volume: 339, Issue:21

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Viral Load

1998
Combination therapy of chronic hepatitis C: an important step but not the final goal!
    Journal of hepatology, 1998, Volume: 29, Issue:6

    Topics: Antiviral Agents; Combined Modality Therapy; Hepatitis C, Chronic; Humans; Liver Transplantation; Recurrence; Ribavirin; Treatment Outcome

1998
Severe anemia following combined alpha-interferon/ribavirin therapy of chronic hepatitis C.
    Journal of hepatology, 1998, Volume: 29, Issue:6

    Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin

1998
Efficacy of ribavirin plus interferon alpha on viraemia of GB virus-C/hepatitis G virus: comparison with interferon alpha alone.
    Journal of gastroenterology and hepatology, 1998, Volume: 13, Issue:12

    Topics: Adult; Alanine Transaminase; Drug Therapy, Combination; Female; Flaviviridae; Hepatitis C, Chronic; Hepatitis, Viral, Human; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Treatment Outcome; Viremia

1998
Comparison of 3 quantitative HCV RNA assays--accuracy of baseline viral load to predict treatment outcome in chronic hepatitis C.
    Scandinavian journal of infectious diseases, 1998, Volume: 30, Issue:5

    Topics: Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Randomized Controlled Trials as Topic; Ribavirin; RNA, Viral; Viral Load

1998
Amantadine in the treatment of patients with chronic hepatitis C.
    Italian journal of gastroenterology and hepatology, 1998, Volume: 30, Issue:6

    Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; RNA, Viral

1998
Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile.
    Journal of hepatology, 1999, Volume: 30, Issue:3

    Topics: Antiviral Agents; Carcinogens; Cells, Cultured; Cytokines; Cytotoxicity, Immunologic; Enterotoxins; Hepatitis C, Chronic; Humans; Lymphocyte Activation; Ribavirin; T-Lymphocytes; Tetradecanoylphorbol Acetate

1999
Making end points meet.
    Gastroenterology, 1999, Volume: 116, Issue:5

    Topics: Biomarkers; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Failure; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Survival Rate; Transaminases; Treatment Outcome; Viral Load

1999
Combination therapy for chronic hepatitis C.
    Italian journal of gastroenterology and hepatology, 1999, Volume: 31, Issue:2

    Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin

1999
Photoallergic skin reaction to ribavirin.
    The American journal of gastroenterology, 1999, Volume: 94, Issue:6

    Topics: Aged; Antiviral Agents; Dermatitis, Photoallergic; Female; Hepatitis C, Chronic; Humans; Ribavirin; Skin; Ultraviolet Rays

1999
Interferon plus ribavirin for chronic hepatitis C.
    The Medical letter on drugs and therapeutics, 1999, Jun-04, Volume: 41, Issue:1054

    Topics: Administration, Oral; Clinical Trials as Topic; Costs and Cost Analysis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Injections, Intravenous; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin

1999
Hemolytic anemia and the treatment of chronic hepatitis C.
    Journal of clinical gastroenterology, 1999, Volume: 28, Issue:4

    Topics: Anemia, Hemolytic; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin

1999
Interferon + ribavirin combination therapy. Open new approach to treatment of patients with hepatitis C virus.
    Italian journal of gastroenterology and hepatology, 1999, Volume: 31, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome

1999
Enhancing the response to interferon-alpha.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 1999, Volume: 13, Issue:1-2

    Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Models, Biological; Recombinant Proteins; Ribavirin; Sarcoma, Kaposi

1999
Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy.
    Journal of hepatology, 1999, Volume: 30, Issue:6

    Topics: Adult; Aged; Amino Acid Sequence; Antiviral Agents; Combined Modality Therapy; Europe; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Ribavirin; RNA-Dependent RNA Polymerase; RNA, Viral; Viral Nonstructural Proteins

1999
[Treatment of chronic hepatitis C: interferon alpha-2b alone or in combination with ribavirin].
    Gastroenterologie clinique et biologique, 1999, Volume: 23, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin

1999
The scientific challenge of hepatitis C.
    Science (New York, N.Y.), 1999, Jul-02, Volume: 285, Issue:5424

    Topics: Animals; Antiviral Agents; Drug Therapy, Combination; Egypt; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Patents as Topic; Recombinant Proteins; Replicon; Ribavirin; Viral Hepatitis Vaccines; Virus Cultivation

1999
Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C.
    Journal of virology, 1999, Volume: 73, Issue:9

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Treatment Outcome; Viral Envelope Proteins; Viral Load; Viral Nonstructural Proteins

1999
Oral thymic extract to treat hepatitis C.
    Annals of internal medicine, 1999, Aug-17, Volume: 131, Issue:4

    Topics: Antiviral Agents; Complementary Therapies; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Thymus Extracts

1999
Response to retreatment with interferon-alpha plus ribavirin in chronic hepatitis C patients is independent of the NS5A gene nucleotide sequence.
    The American journal of gastroenterology, 1999, Volume: 94, Issue:9

    Topics: Adult; Antiviral Agents; Base Sequence; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA-Dependent RNA Polymerase; Treatment Outcome; Viral Nonstructural Proteins

1999
Interferon plus ribavirin: a cautionary note.
    The American journal of gastroenterology, 1999, Volume: 94, Issue:10

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Myocardial Infarction; Ribavirin

1999
Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C.
    Hepatology (Baltimore, Md.), 1999, Volume: 30, Issue:5

    Topics: Antiviral Agents; Cost-Benefit Analysis; Decision Trees; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Markov Chains; Middle Aged; Models, Statistical; Probability; Quality of Life; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Time Factors; United States

1999
[Recommendations from a Swedish meeting of experts. Hepatitis C is to be treated with the combination of interferon and ribavirin].
    Lakartidningen, 1999, Nov-03, Volume: 96, Issue:44

    Topics: Adult; Antiviral Agents; Child; Contraindications; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon Type I; Recombinant Proteins; Ribavirin

1999
Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group.
    Hepatology (Baltimore, Md.), 2000, Volume: 31, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Polymerase Chain Reaction; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; ROC Curve; Treatment Outcome

2000
Utilizing daily interferon (alpha 2b) and ribavirin combination therapy in chronic hepatitis C: a preliminary report.
    The Journal of the Oklahoma State Medical Association, 1999, Volume: 92, Issue:12

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin

1999
Long-term outcome of chronic hepatitis C virus infection in primary hypogammaglobulinaemia.
    QJM : monthly journal of the Association of Physicians, 1999, Volume: 92, Issue:8

    Topics: Adolescent; Adult; Agammaglobulinemia; Antiviral Agents; Common Variable Immunodeficiency; Disease Progression; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Ribavirin

1999
Hepatitis C therapy in treatment-naïve patients.
    The American journal of medicine, 1999, Dec-27, Volume: 107, Issue:6B

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Randomized Controlled Trials as Topic; Ribavirin; RNA, Viral

1999
Management of interferon relapsers.
    The American journal of medicine, 1999, Dec-27, Volume: 107, Issue:6B

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Recurrence; Ribavirin; RNA, Viral; Viral Load

1999
Available options for treatment of interferon nonresponders.
    The American journal of medicine, 1999, Dec-27, Volume: 107, Issue:6B

    Topics: Antiviral Agents; Combined Modality Therapy; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Phlebotomy; Ribavirin; Treatment Failure

1999
Hepatitis C virus and human immunodeficiency virus: clinical issues in coinfection.
    The American journal of medicine, 1999, Dec-27, Volume: 107, Issue:6B

    Topics: Anti-HIV Agents; Antiviral Agents; Biopsy, Needle; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Liver; Ribavirin

1999
Mutations in the protein kinase-binding domain of the NS5A protein in patients infected with hepatitis C virus type 1a are associated with treatment response.
    The Journal of infectious diseases, 2000, Volume: 181, Issue:2

    Topics: Adult; Amino Acid Sequence; Antiviral Agents; Binding Sites; Drug Therapy, Combination; eIF-2 Kinase; Female; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon Type I; Male; Middle Aged; Molecular Sequence Data; Mutation; Phylogeny; Protein Structure, Secondary; Protein Structure, Tertiary; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Viral Nonstructural Proteins

2000
Combination treatment for hepatitis C can be hazardous in patients co-infected with HIV.
    Antiviral therapy, 1998, Volume: 3, Issue:4

    Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Ribavirin

1998
Doing battle with HCV.
    The American journal of gastroenterology, 2000, Volume: 95, Issue:3

    Topics: Antiviral Agents; Cross-Sectional Studies; Drug Costs; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; United States; Veterans

2000
[Does combination therapy of chronic viral hepatitis C with interferon-alpha and ribavirin approach financial limits?].
    Versicherungsmedizin, 2000, Mar-01, Volume: 52, Issue:1

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Germany; Hepatitis C, Chronic; Humans; Interferon-alpha; National Health Programs; Ribavirin

2000
Cost-effectiveness of interferon alfa 2b and ribavirin in the treatment of chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2000, Volume: 31, Issue:3

    Topics: Antiviral Agents; Cost-Benefit Analysis; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin

2000
[Horton's disease in the course of chronic hepatitis C].
    Presse medicale (Paris, France : 1983), 2000, Feb-26, Volume: 29, Issue:7

    Topics: Adrenal Cortex Hormones; Antiviral Agents; Arterial Occlusive Diseases; Drug Therapy, Combination; Female; Giant Cell Arteritis; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Radiography; Ribavirin; Temporal Arteries

2000
Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage.
    Hepatology (Baltimore, Md.), 2000, Volume: 31, Issue:4

    Topics: Adenosine Triphosphate; Adult; Anemia, Hemolytic; Anion Exchange Protein 1, Erythrocyte; Antiviral Agents; Carrier Proteins; Complement C3; Erythrocyte Membrane; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Immunoglobulin G; Interferons; K Cl- Cotransporters; Male; Middle Aged; Oxidative Stress; Reticulocyte Count; Ribavirin; Sodium-Potassium-Exchanging ATPase; Symporters

2000
Severe strongyloidiasis during interferon plus ribavirin therapy for chronic HCV infection.
    European journal of gastroenterology & hepatology, 2000, Volume: 12, Issue:2

    Topics: Adult; Animals; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Interferons; Middle Aged; Ribavirin; Severity of Illness Index; Strongyloides stercoralis; Strongyloidiasis

2000
Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C.
    Digestive diseases and sciences, 2000, Volume: 45, Issue:4

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2000
Interferon alfa-2b plus ribavirin for chronic hepatitis C patients who have not responded to interferon monotherapy.
    Alimentary pharmacology & therapeutics, 2000, Volume: 14, Issue:4

    Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral

2000
[Hepatitis C. Saving the liver].
    MMW Fortschritte der Medizin, 1999, Nov-18, Volume: 141, Issue:46

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Ribavirin

1999
Extensive psoriasis induced by interferon alfa treatment for chronic hepatitis C.
    Postgraduate medical journal, 2000, Volume: 76, Issue:896

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Male; Middle Aged; Psoriasis; Recurrence; Ribavirin

2000
Decisions, decisions, decisions.
    Gastroenterology, 2000, Volume: 118, Issue:6

    Topics: Antiviral Agents; Gastroenterology; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin

2000
Sustained response to combination therapy in a patient with chronic hepatitis C and thrombocytopenia secondary to alpha-interferon.
    Journal of gastroenterology and hepatology, 2000, Volume: 15, Issue:5

    Topics: Antiviral Agents; Combined Modality Therapy; Hepatitis C, Chronic; Humans; Immunoglobulin G; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prednisone; Recombinant Proteins; Ribavirin; Thrombocytopenia

2000
Needle-stick exposure in the health care setting: do not forget hepatitis C!
    The Netherlands journal of medicine, 2000, Volume: 57, Issue:1

    Topics: Acute Disease; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Health Personnel; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Needlestick Injuries; Netherlands; Primary Prevention; Ribavirin; Time Factors

2000
[Early prediction of lack of response to treatment with interferon and interferon plus ribavirin using biochemical and virological criteria in patients with chronic hepatitis C].
    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 1999, Volume: 12, Issue:3

    Topics: Adolescent; Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Predictive Value of Tests; Ribavirin; RNA, Viral; Time Factors; Treatment Failure

1999
Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
    The American journal of gastroenterology, 2000, Volume: 95, Issue:6

    Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Life Expectancy; Male; Middle Aged; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Time Factors

2000
[Treatment and prevention of hepatitis C].
    La Revue du praticien, 2000, May-15, Volume: 50, Issue:10

    Topics: Antiviral Agents; Clinical Protocols; Delayed-Action Preparations; Disease Progression; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Incidence; Interferon-alpha; Liver Cirrhosis; Prospective Studies; Ribavirin

2000
Clinical utility of early viral load quantification.
    Hepatology (Baltimore, Md.), 2000, Volume: 32, Issue:1

    Topics: Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; RNA, Viral

2000
The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2000, Volume: 32, Issue:2

    Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Recombinant Proteins; Ribavirin

2000
Firstline treatment for hepatitis C: combination interferon/ribavirin versus interferon monotherapy.
    Journal of gastroenterology and hepatology, 2000, Volume: 15 Suppl

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin

2000
Subacute thyroiditis during treatment with combination therapy (interferon plus ribavirin) for hepatitis C virus.
    Journal of viral hepatitis, 2000, Volume: 7, Issue:5

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Ribavirin; Thyroiditis, Subacute

2000
Ribavirin therapy for chronic hepatitis C does not modify HIV viral load in HIV-1 positive patients under antiretroviral treatment.
    AIDS (London, England), 2000, Jul-28, Volume: 14, Issue:11

    Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Seropositivity; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load

2000
Interferon-alpha and ribavirin in treating children and young adults with chronic hepatitis C after malignancy.
    Pediatrics, 2000, Volume: 106, Issue:4

    Topics: Adolescent; Adult; Antiviral Agents; Child; Drug Therapy, Combination; Female; Hematologic Neoplasms; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Pilot Projects; Recombinant Proteins; Ribavirin; RNA, Viral; Transaminases

2000
Combination treatment for hepatitis C is not being given.
    BMJ (Clinical research ed.), 2000, Oct-07, Volume: 321, Issue:7265

    Topics: Antiviral Agents; Drug Costs; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; United Kingdom

2000
Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C.
    Therapeutic drug monitoring, 2000, Volume: 22, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2000
Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report.
    Gut, 2000, Volume: 47, Issue:5

    Topics: Adult; Anemia; Antiviral Agents; CD4 Lymphocyte Count; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Polymerase Chain Reaction; Recurrence; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load

2000
Chronic hepatitis C--Swedish experts' meeting recommends combination treatment.
    Scandinavian journal of infectious diseases, 2000, Volume: 32, Issue:5

    Topics: Adult; Antiviral Agents; Child; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; RNA, Viral; Sweden; Viral Load

2000
[Chronic viral hepatitis: guidelines for diagnosis and therapy. When to treat--when wait?].
    MMW Fortschritte der Medizin, 2000, Oct-19, Volume: 142, Issue:42

    Topics: Drug Monitoring; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Prognosis; Ribavirin

2000
Interferon plus ribavirin for chronic hepatitis C in HIV-infected patients.
    AIDS (London, England), 2000, Oct-20, Volume: 14, Issue:15

    Topics: Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Ribavirin

2000
Adding low-dose antidepressants to interferon alpha treatment for chronic hepatitis C improved psychiatric tolerability in a patient with schizoaffective psychosis.
    Neuropsychobiology, 2000, Volume: 42 Suppl 1

    Topics: Adult; Antidepressive Agents; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon Type I; Psychiatric Status Rating Scales; Psychotic Disorders; Recombinant Proteins; Ribavirin

2000
Re: Khalili et al.--chronic Hepatitis C treatment in interferon nonresponders.
    The American journal of gastroenterology, 2000, Volume: 95, Issue:11

    Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin

2000
Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C.
    Journal of hepatology, 2000, Volume: 33, Issue:5

    Topics: Bone Density; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Osteoporosis; Ribavirin

2000
[Hepatitis C in Egypt, a iatrogenic epidemic].
    Nederlands tijdschrift voor geneeskunde, 2000, Dec-02, Volume: 144, Issue:49

    Topics: Antiviral Agents; Drug Therapy, Combination; Egypt; Glycyrrhetinic Acid; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Plant Extracts; Recombinant Proteins; Ribavirin

2000
The response to interferon + ribavirin re-treatment for chronic hepatitis C in interferon non-responders is not influenced by race.
    Journal of hepatology, 2000, Volume: 33, Issue:6

    Topics: Adult; Antiviral Agents; Black People; Drug Combinations; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Retreatment; Ribavirin; White People

2000
Combination therapy with ribavirin and alpha interferon for the treatment of chronic hepatitis C refractory to interferon.
    Alimentary pharmacology & therapeutics, 2001, Volume: 15, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral

2001
Time course of serum hepatitis C virus-RNA during chronic hepatitis C treatment accurately predicts the type of response.
    Alimentary pharmacology & therapeutics, 2001, Volume: 15, Issue:2

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Outcome Assessment, Health Care; Predictive Value of Tests; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome

2001
Early decrease of interferon-gamma+ and interleukin-2+ T cells during combination treatment with interferon-alpha and ribavirin in patients with chronic hepatitis C.
    The American journal of gastroenterology, 2000, Volume: 95, Issue:12

    Topics: Antiviral Agents; Case-Control Studies; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Interleukin-2; Male; Middle Aged; Recombinant Proteins; Ribavirin; T-Lymphocyte Subsets; Time Factors

2000
Dynamics of serum hepatitis C virus load and quasispecies complexity during antiviral therapy in patients with chronic hepatitis C.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2001, Volume: 20, Issue:1-2

    Topics: Adult; Amantadine; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Phylogeny; Polymorphism, Single-Stranded Conformational; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; Viral Load

2001
Nonresponse to interferon in chronic hepatitis C: re-treatment redux.
    JAMA, 2001, Jan-10, Volume: 285, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Failure; Viral Load

2001
[Efficacy and safety of combination therapy with interferon-alpha and ribavirin in patients with chronic hepatitis C coinfected with human immunodeficiency virus].
    Gastroenterologie clinique et biologique, 2000, Volume: 24, Issue:10

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin

2000
[Pulmonal sarcoidosis: A rare side effect of interferon-alpha treatment for chronic hepatitis C infection].
    Zeitschrift fur Gastroenterologie, 2000, Volume: 38, Issue:12

    Topics: Adult; Biopsy; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Lung; Ribavirin; Risk Factors; Sarcoidosis, Pulmonary; Tomography, X-Ray Computed

2000
Treating chronic Hepatitis C patients with psychiatric disorders: an uphill battle.
    The American journal of gastroenterology, 2001, Volume: 96, Issue:1

    Topics: Clinical Trials as Topic; Depressive Disorder; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Prognosis; Ribavirin; Risk Assessment

2001
Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2001, Volume: 16, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Renal Dialysis; Ribavirin; RNA, Viral; Safety

2001
[When standard therapy fails. New therapy options in chronic hepatitis C].
    MMW Fortschritte der Medizin, 2001, Jan-18, Volume: 143, Issue:3

    Topics: Drug Administration Schedule; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Ribavirin; Treatment Failure

2001
Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection.
    Hepatology (Baltimore, Md.), 2001, Volume: 33, Issue:3

    Topics: Alleles; Antiviral Agents; Drug Therapy, Combination; Gene Frequency; Genetic Variation; Haplotypes; Hepatitis C, Chronic; Heterozygote; Homozygote; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-10; Polymorphism, Genetic; Prognosis; Recombinant Proteins; Ribavirin

2001
Diabetic ketoacidosis induced by alpha interferon and ribavirin treatment in a patient with hepatitis C.
    The American journal of gastroenterology, 2001, Volume: 96, Issue:2

    Topics: Antiviral Agents; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Recombinant Proteins; Ribavirin

2001
Interferon and ribavirin treatment for chronic hepatitis C may activate celiac disease.
    The American journal of gastroenterology, 2001, Volume: 96, Issue:2

    Topics: Adult; Antiviral Agents; Celiac Disease; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin

2001
Monitoring virological responses to interferon-ribavirin and interferon monotherapy of chronic hepatitis C re-treated due to relapse or non-response.
    Scandinavian journal of infectious diseases, 2001, Volume: 33, Issue:2

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Treatment Failure; Viral Load; Viremia

2001
The effect of antiviral therapy on t(14;18) translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection.
    Blood, 2001, Mar-15, Volume: 97, Issue:6

    Topics: Adult; Aged; Antiviral Agents; B-Lymphocytes; Cell Division; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 18; Drug Therapy, Combination; Female; Gene Rearrangement; Genes, bcl-2; Hepatitis C, Chronic; Humans; Immunoglobulin Heavy Chains; Interferon-alpha; Lymphoma, B-Cell; Male; Middle Aged; Ribavirin; Translocation, Genetic

2001
Chronic hepatitis C in HIV-coinfected patients: feasibility and efficacy of interferon-alpha2b and ribavirin combination therapy.
    Journal of acquired immune deficiency syndromes (1999), 2001, Mar-01, Volume: 26, Issue:3

    Topics: Adult; Anti-HIV Agents; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin; RNA, Viral

2001
Pilot study of interferon-alpha high-dose induction therapy in combination with ribavirin plus amantadine for nonresponder patients with chronic hepatitis C.
    Zeitschrift fur Gastroenterologie, 2001, Volume: 39, Issue:2

    Topics: Adult; Aged; Amantadine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Retreatment; Ribavirin; Treatment Outcome

2001
Managing chronic hepatitis C acquired through intravenous drug use.
    QJM : monthly journal of the Association of Physicians, 2001, Volume: 94, Issue:3

    Topics: Adolescent; Adult; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Cirrhosis; Male; Middle Aged; Patient Acceptance of Health Care; Patient Compliance; Recombinant Proteins; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Severity of Illness Index; Substance Abuse, Intravenous; Treatment Outcome

2001
[Ribavirin in combination with interferon alpha-2b in the treatment of chronic hepatitis C].
    Presse medicale (Paris, France : 1983), 2001, Feb-24, Volume: 30, Issue:7

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin

2001
Evolution of hepatitis C virus genome in chronically infected patients receiving ribavirin monotherapy.
    Journal of viral hepatitis, 2001, Volume: 8, Issue:2

    Topics: Amino Acid Sequence; Antiviral Agents; Evolution, Molecular; Female; Genome, Viral; Genotype; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Molecular Sequence Data; Ribavirin; Sequence Alignment; Viral Nonstructural Proteins; Viral Proteins; Viral Structural Proteins

2001
Development of insulin-dependent diabetes mellitus in a patient with chronic hepatitis C during therapy with interferon-alpha.
    European journal of gastroenterology & hepatology, 2001, Volume: 13, Issue:3

    Topics: Adult; Antibodies; Antiviral Agents; Autoimmunity; Diabetes Mellitus, Type 1; Glutamate Decarboxylase; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; Risk

2001
Treatment with ribavirin and interferon-alpha reduces interferon-gamma expression in patients with chronic hepatitis C.
    Clinical and experimental immunology, 2001, Volume: 123, Issue:3

    Topics: Adjuvants, Immunologic; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-gamma; Interleukin-10; Interleukin-2; Interleukin-4; Lymphocyte Activation; Male; Middle Aged; Ribavirin; Viral Load

2001
Combination therapy with interferon-alpha 2b and ribavirin for the treatment of relapse patients and non-responders with chronic HCV infection.
    Zeitschrift fur Gastroenterologie, 2001, Volume: 39, Issue:3

    Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome

2001
Uric acid nephrolithiasis associated with interferon and ribavirin treatment of hepatitis C.
    Digestive diseases and sciences, 2001, Volume: 46, Issue:4

    Topics: Adult; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Calculi; Male; Recombinant Proteins; Ribavirin; Uric Acid

2001
Combined therapy with interferon and ribavirin in chronic hepatitis C does not affect serum quasispecies diversity.
    Digestive diseases and sciences, 2001, Volume: 46, Issue:5

    Topics: Adult; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polymorphism, Single-Stranded Conformational; Ribavirin; RNA, Viral; Treatment Outcome

2001
Ribavirin approved for hepatitis C combination treatment.
    AIDS treatment news, 1998, Jun-19, Issue:No 297

    Topics: Antiviral Agents; Drug Approval; Drug Combinations; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; United States; United States Food and Drug Administration

1998
Can science meet the challenges of the HCV pandemic: new treatment options for chronic hepatitis C.
    Journal of the International Association of Physicians in AIDS Care, 1998, Volume: 4, Issue:7

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon Type I; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

1998
Hepatitis C virus and HIV co-infection: a sleeping giant wakes.
    The Hopkins HIV report : a bimonthly newsletter for healthcare providers, 1999, Volume: 11, Issue:1

    Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Drugs, Investigational; Hepatitis C, Chronic; HIV Infections; Humans; Interferon Type I; Polyethylene Glycols; Recombinant Proteins; Ribavirin

1999
Interferon alfa down-regulates CD81 in patients with chronic hepatitis C.
    Hepatology (Baltimore, Md.), 2001, Volume: 33, Issue:6

    Topics: Antigens, CD; Antiviral Agents; Cells, Cultured; Dose-Response Relationship, Drug; Down-Regulation; Drug Combinations; Hepatitis C, Chronic; Hepatocytes; Humans; Interferon-alpha; Lymphocytes; Membrane Proteins; Ribavirin; RNA, Messenger; Tetraspanin 28

2001
Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis C.
    Clinical biochemistry, 2001, Volume: 34, Issue:3

    Topics: Adult; Alanine Transaminase; Biomarkers; Case-Control Studies; Enzyme-Linked Immunosorbent Assay; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Middle Aged; Ribavirin; RNA, Viral; Tumor Necrosis Factor-alpha; Viral Load

2001
Treatment of chronic hepatitis C in hereditary spherocytosis.
    The American journal of gastroenterology, 2001, Volume: 96, Issue:6

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hemoglobins; Hepatitis C, Chronic; Humans; Interferons; Male; Ribavirin; Spherocytosis, Hereditary

2001
Pegylated interferon (PEG-Intron) for chronic hepatitis C.
    The Medical letter on drugs and therapeutics, 2001, Jun-25, Volume: 43, Issue:1107

    Topics: Antimetabolites; Antiviral Agents; Area Under Curve; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Multicenter Studies as Topic; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tablets

2001
Effective antiviral treatment for hepatitis C virus-related chronic active hepatitis in haemophiliac patients.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2001, Volume: 33, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hemophilia A; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin

2001
[Management of chronic hepatitis C infection in patients infected with the human immunodeficiency virus: from what we know to what we ignore].
    Medicina clinica, 2001, Jun-02, Volume: 116, Issue:20

    Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Prognosis; Ribavirin

2001
Development of lupic anticoagulant during combination therapy in a patient with chronic hepatitis C.
    Journal of hepatology, 2001, Volume: 34, Issue:6

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lupus Coagulation Inhibitor; Middle Aged; Partial Thromboplastin Time; Recombinant Proteins; Ribavirin

2001
Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection--a pilot study.
    Journal of viral hepatitis, 2001, Volume: 8, Issue:4

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Biopsy; Drug Therapy, Combination; Erythropoiesis; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Pilot Projects; Polymerase Chain Reaction; Renal Dialysis; Ribavirin; RNA, Viral

2001
Conception soon after discontinuing interferon/ribavirin therapy: a successful outcome.
    The American journal of gastroenterology, 2001, Volume: 96, Issue:7

    Topics: Adult; Female; Fertilization; Fetus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Pregnancy; Pregnancy Outcome; Recombinant Proteins; Ribavirin

2001
No evidence for mutagenic effects of ribavirin: report of two normal pregnancies.
    The American journal of gastroenterology, 2001, Volume: 96, Issue:7

    Topics: Adult; Antimetabolites; Female; Fertilization; Fetus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Mutagenesis; Paternal Exposure; Pregnancy; Pregnancy Outcome; Recombinant Proteins; Ribavirin

2001
Interferon and ribavirin therapy in dialysis patients with chronic hepatitis C.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2001, Volume: 16, Issue:8

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Pilot Projects; Recombinant Proteins; Renal Dialysis; Ribavirin

2001
Long-term response to interferon plus ribavirin in patients with chronic hepatitis C refractory to interferon.
    Revista espanola de enfermedades digestivas, 2001, Volume: 93, Issue:6

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Longitudinal Studies; Male; Prospective Studies; Ribavirin; Time Factors; Treatment Failure

2001
Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden.
    Scandinavian journal of gastroenterology, 2001, Volume: 36, Issue:8

    Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Markov Chains; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Sweden

2001
Patterns of response during therapy with interferon and outcome of retreatment with interferon plus ribavirin for chronic hepatitis C.
    Journal of clinical gastroenterology, 2001, Volume: 33, Issue:3

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Retreatment; Ribavirin

2001
Impairment of metabolic function in chronic hepatitis C is related to factors associated with resistance to therapy.
    The American journal of gastroenterology, 2001, Volume: 96, Issue:8

    Topics: Adult; Alanine Transaminase; Antipyrine; Antiviral Agents; Chi-Square Distribution; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2001
Changes in serum lipoprotein profile during interferon therapy in chronic hepatitis C.
    The American journal of gastroenterology, 2001, Volume: 96, Issue:8

    Topics: Adult; Aged; Antiviral Agents; Chi-Square Distribution; Cholesterol; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Randomized Controlled Trials as Topic; Ribavirin; Triglycerides

2001
Combination therapy for hepatitis C virus reinfection after orthoptic liver transplantation.
    Transplantation proceedings, 2001, Volume: 33, Issue:6

    Topics: Antiviral Agents; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Postoperative Complications; Retrospective Studies; Ribavirin; Time Factors

2001
Erythema dyschromicum perstans and hepatitis C virus infection.
    International journal of dermatology, 2001, Volume: 40, Issue:5

    Topics: Antiviral Agents; Erythema; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Pigmentation Disorders; Recombinant Proteins; Ribavirin

2001
Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin.
    The British journal of ophthalmology, 2001, Volume: 85, Issue:10

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Remission, Spontaneous; Retinal Diseases; Retinal Hemorrhage; Ribavirin; Treatment Outcome

2001
Costs of hepatitis C.
    Archives of internal medicine, 2001, Oct-08, Volume: 161, Issue:18

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Costs and Cost Analysis; Cross-Sectional Studies; Female; Health Expenditures; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Ribavirin; Survival Rate; United States

2001
Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study.
    Lancet (London, England), 2001, Oct-13, Volume: 358, Issue:9289

    Topics: Adult; Aged; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Prospective Studies; Ribavirin; Viral Load

2001
Interstitial pneumonitis in a patient treated with alpha-interferon and ribavirin for hepatitis C infection.
    The American journal of the medical sciences, 2001, Volume: 322, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon Type I; Lung Diseases, Interstitial; Male; Middle Aged; Recombinant Proteins; Ribavirin; Tomography, X-Ray Computed

2001
Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: a pragmatic study.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2001, Volume: 7, Issue:10

    Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recurrence; Ribavirin; Statistics, Nonparametric; Treatment Outcome

2001
Compliance with therapy in patients with chronic hepatitis C: associations with psychiatric symptoms, interpersonal problems, and mode of acquisition.
    Digestive diseases and sciences, 2001, Volume: 46, Issue:10

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Emotions; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interpersonal Relations; Male; Middle Aged; Patient Compliance; Personality; Psychometrics; Recombinant Proteins; Ribavirin; Sensitivity and Specificity

2001
Development of myasthenia gravis during treatment of chronic hepatitis C with interferon-alpha and ribavirin.
    Journal of gastroenterology, 2001, Volume: 36, Issue:10

    Topics: Adult; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Myasthenia Gravis; Ribavirin

2001
Treatment of chronic hepatitis C.
    BMJ (Clinical research ed.), 2001, Nov-17, Volume: 323, Issue:7322

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin

2001
High-Dose interferon-alpha2b plus ribavirin for retreatment of interferon-nonresponsive patients infected with genotype 1 hepatitis C virus.
    Digestive diseases and sciences, 2001, Volume: 46, Issue:11

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Time Factors

2001
Influence of three successive antiviral treatments on viral heterogeneity in nonresponder chronic hepatitis C patients.
    Journal of medical virology, 2001, Volume: 65, Issue:4

    Topics: Amino Acid Sequence; Antiviral Agents; Cloning, Molecular; Drug Therapy, Combination; Female; Genes, Viral; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Molecular Sequence Data; Recombinant Proteins; Ribavirin; Sequence Alignment; Treatment Outcome; Viral Proteins

2001
SEN and sensibility: interactions between newly discovered and other hepatitis viruses?
    Lancet (London, England), 2001, Dec-08, Volume: 358, Issue:9297

    Topics: Antiviral Agents; DNA Virus Infections; DNA Viruses; Hepatitis C, Chronic; Hepatitis, Viral, Human; Humans; Interferon alpha-2; Interferon-alpha; Liver Diseases; Recombinant Proteins; Ribavirin; Treatment Outcome

2001
Effect on treatment outcome of coinfection with SEN viruses in patients with hepatitis C.
    Lancet (London, England), 2001, Dec-08, Volume: 358, Issue:9297

    Topics: Alanine Transaminase; Antiviral Agents; DNA Primers; DNA Virus Infections; DNA Viruses; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Diseases; Male; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome

2001
Cost effectiveness of combination therapy for hepatitis C: a decision analytic model.
    Gut, 2002, Volume: 50, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Decision Support Techniques; Drug Combinations; Female; Health Resources; Health Status; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Male; Markov Chains; Middle Aged; Quality-Adjusted Life Years; Ribavirin; Sensitivity and Specificity

2002
Hepatitis C virus infection.
    The New England journal of medicine, 2001, Nov-08, Volume: 345, Issue:19

    Topics: Antiviral Agents; Consensus Development Conferences as Topic; Contraindications; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Psychotic Disorders; Ribavirin

2001
[Sarcoidosis during the treatment of hepatitis C by interferon-alpha and ribavirin: 2 cases].
    La Revue de medecine interne, 2001, Volume: 22, Issue:12

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Lung Diseases; Male; Middle Aged; Ribavirin; Sarcoidosis; Time Factors

2001
Probable reinfection with hepatitis C virus in a chronic hepatitis C patient with a sustained response to combination therapy.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2001, Volume: 100, Issue:12

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Viremia

2001
Peginterferon alfa-2b plus ribavirin for chronic hepatitis.
    Lancet (London, England), 2002, Jan-19, Volume: 359, Issue:9302

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2002
Peginterferon alfa-2b plus ribavirin for chronic hepatitis.
    Lancet (London, England), 2002, Jan-19, Volume: 359, Issue:9302

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2002
Peginterferon alfa-2b plus ribavirin for chronic hepatitis.
    Lancet (London, England), 2002, Jan-19, Volume: 359, Issue:9302

    Topics: Antiviral Agents; Body Weight; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2002
Combination of "low-dose" ribavirin and interferon alfa-2a therapy followed by interferon alfa-2a monotherapy in chronic HCV-infected non-responders and relapsers after interferon alfa-2a monotherapy.
    World journal of gastroenterology, 2001, Volume: 7, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin

2001
[Chronic liver diseases. The nihilism has gone].
    MMW Fortschritte der Medizin, 2001, Dec-13, Volume: 143, Issue:51-52

    Topics: Amantadine; Antioxidants; Antiviral Agents; Chronic Disease; Dipeptides; Drug Therapy, Combination; Flumazenil; GABA Modulators; Hepatic Encephalopathy; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Diseases; Pentoxifylline; Phosphodiesterase Inhibitors; Prospective Studies; Protective Agents; Ribavirin; Silymarin

2001
Interferon-alpha in treatment of chronic hepatitis C in co-infected HIV-patients in combination with ribavirin and as a pre-load therapy in treatment-naive HIV-positive patients. 8th European Conference on Clinical Aspects and Treatment of HIV Infection (
    European journal of medical research, 2002, Jan-29, Volume: 7, Issue:1

    Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Clinical Trials as Topic; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2002
Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin.
    Journal of hepatology, 2002, Volume: 36, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Immunity, Innate; Interferons; Interleukin-10; Male; Middle Aged; Polymorphism, Genetic; Promoter Regions, Genetic; Ribavirin; Transforming Growth Factor beta; Transforming Growth Factor beta1; Treatment Outcome; Tumor Necrosis Factor-alpha

2002
Virological characteristics of hepatitis C virus infection in HIV-infected individuals with chronic hepatitis C: implications for treatment.
    AIDS (London, England), 2002, Feb-15, Volume: 16, Issue:3

    Topics: Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon Type I; Male; Recombinant Proteins; Ribavirin; RNA, Viral; Viremia

2002
[Eradication of hepatitis C virus after 3 months of interferon and ribavirin treatment in an a interferon non-responder patient with chronic hepatitis C].
    Gastroenterologie clinique et biologique, 2001, Volume: 25, Issue:11

    Topics: Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Viremia

2001
Prevalence of hepatitis C genotypes in Indian patients and their clinical significance.
    The Journal of the Association of Physicians of India, 2001, Volume: 49

    Topics: Adolescent; Adult; Age Factors; Aged; Antiviral Agents; Chi-Square Distribution; Child; Data Interpretation, Statistical; Female; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; India; Interferons; Male; Middle Aged; Prevalence; Ribavirin; Sex Factors

2001
[Serious side-effects of interferon alfa and ribavirin combination therapy in patients with chronic hepatitis C].
    Vnitrni lekarstvi, 2002, Volume: 48, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Jaundice; Male; Psychoses, Substance-Induced; Recombinant Proteins; Ribavirin

2002
24 weeks of interferon-ribavirin therapy should not routinely be given to all hepatitis C patients.
    The American journal of gastroenterology, 2002, Volume: 97, Issue:2

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Prospective Studies; Ribavirin; Risk Assessment; Sensitivity and Specificity; Time Factors; Treatment Outcome; Viral Load

2002
Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin.
    Hepatology (Baltimore, Md.), 2002, Volume: 35, Issue:3

    Topics: Antiviral Agents; Clinical Trials as Topic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral

2002
Risk of HAART therapy in hepatitis C.
    Hepatology (Baltimore, Md.), 2002, Volume: 35, Issue:3

    Topics: Antiretroviral Therapy, Highly Active; Drug Interactions; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Risk

2002
Management of chronic hepatitis C--time for a change?
    Journal of viral hepatitis, 2002, Volume: 9, Issue:2

    Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors

2002
Complement C4 monitoring in the follow-up of chronic hepatitis C treatment.
    Clinical and experimental immunology, 2002, Volume: 127, Issue:1

    Topics: Adult; Antiviral Agents; Biomarkers; Complement Activation; Complement C4; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin

2002
Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases.
    The British journal of dermatology, 2002, Volume: 146, Issue:2

    Topics: Adult; Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Sarcoidosis

2002
[Pegylated interferon plus ribavirin in chronic hepatitis C. More than half of patients show a lasting response].
    MMW Fortschritte der Medizin, 2002, Feb-21, Volume: 144, Issue:8

    Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Immunocompromised Host; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors

2002
Autoimmune thrombocytopenia induced by PEG-IFN-alpha2b plus ribavirin in hepatitis C.
    Digestive diseases and sciences, 2002, Volume: 47, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Purpura, Thrombocytopenic, Idiopathic; Recombinant Proteins; Ribavirin

2002
Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C.
    The American journal of gastroenterology, 2002, Volume: 97, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferons; Lymphotoxin-alpha; Male; Middle Aged; Polymorphism, Genetic; Predictive Value of Tests; Ribavirin; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha

2002
[Hepatitis C treatment without liver biopsy].
    Ugeskrift for laeger, 2002, Mar-11, Volume: 164, Issue:11

    Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Ribavirin; RNA, Viral

2002
Management of chronic hepatitis C.
    Journal of the American Academy of Nurse Practitioners, 2001, Volume: 13, Issue:10

    Topics: Algorithms; Antiviral Agents; Disease Management; Hepatitis C, Chronic; Humans; Interferon-alpha; National Institutes of Health (U.S.); Practice Guidelines as Topic; Ribavirin; United States

2001
Liver biopsy in hepatitis C: reassessing its role in 2001.
    The Medical journal of Australia, 2002, Jan-21, Volume: 176, Issue:2

    Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin

2002
Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load.
    Intervirology, 2002, Volume: 45, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load

2002
[Living donor liver transplantation in a patient with HIV].
    Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60, Issue:4

    Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Therapy, Combination; Hemophilia B; Hepatitis C, Chronic; HIV Seropositivity; HIV-1; Humans; Interferon-alpha; Liver Transplantation; Living Donors; Male; Middle Aged; Ribavirin; Treatment Outcome

2002
Consensus interferon for chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, interferon alpha-2b and ribavirin in combination: an Italian pilot study.
    European journal of gastroenterology & hepatology, 2002, Volume: 14, Issue:5

    Topics: Adult; Antiviral Agents; Drug Administration Schedule; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Logistic Models; Male; Pilot Projects; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors

2002
Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.
    Gastroenterology, 2002, Volume: 122, Issue:5

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin

2002
Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C.
    Gastroenterology, 2002, Volume: 122, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Recombinant Proteins; Ribavirin

2002
Early detection of nonresponse to interferon plus ribavirin combination treatment of chronic hepatitis C.
    Journal of viral hepatitis, 2002, Volume: 9, Issue:3

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Predictive Value of Tests; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Sensitivity and Specificity; Time Factors; Treatment Outcome; Viral Load

2002
Triple antiviral re-therapy for chronic hepatitis C with interferon-alpha, ribavirin and amantadine in nonresponders to interferon-alpha and ribavirin.
    European journal of medical research, 2002, Apr-30, Volume: 7, Issue:4

    Topics: Adult; Aged; Amantadine; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; Safety

2002
Approach to the patient with chronic hepatitis C virus infection.
    Annals of internal medicine, 2002, May-21, Volume: 136, Issue:10

    Topics: Antiviral Agents; Biopsy; Complementary Therapies; Contraindications; Diet; Disease Transmission, Infectious; Female; Health Behavior; Hepatitis C, Chronic; Humans; Infectious Disease Transmission, Vertical; Insurance, Life; Interferons; Middle Aged; Prognosis; Ribavirin; Risk Factors; Spouses

2002
The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism.
    European journal of endocrinology, 2002, Volume: 146, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Autoantibodies; Case-Control Studies; Cross-Sectional Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Hypothyroidism; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; Ribavirin; Risk; Thyroid Gland; Thyroid Hormones

2002
SEN viruses and treatment response in chronic hepatitis C virus.
    Lancet (London, England), 2002, May-18, Volume: 359, Issue:9319

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Respirovirus Infections; Ribavirin; Sendai virus

2002
SEN viruses and treatment response in chronic hepatitis C virus.
    Lancet (London, England), 2002, May-18, Volume: 359, Issue:9319

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Respirovirus Infections; Ribavirin; Sendai virus; Treatment Outcome

2002
Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection.
    Digestive diseases and sciences, 2002, Volume: 47, Issue:6

    Topics: Adult; Amino Acid Sequence; Antiviral Agents; Codon; Drug Resistance, Viral; Drug Therapy, Combination; eIF-2 Kinase; Eukaryotic Initiation Factor-2; Female; Genotype; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Phosphorylation; Ribavirin; RNA, Viral; Sequence Homology, Amino Acid; Treatment Outcome; Viral Envelope Proteins

2002
Treatment of hepatitis C virus genotype 4-related cirrhosis: ribavirin and interferon combination compared with interferon alone.
    Journal of clinical gastroenterology, 2002, Volume: 35, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Cirrhosis; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome

2002
Antiviral treatment responses in patients with chronic hepatitis C virus infection evaluated by a third generation anti-hepatitis C virus assay.
    Journal of viral hepatitis, 2002, Volume: 9, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Drug Combinations; Female; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Immunoenzyme Techniques; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Reagent Kits, Diagnostic; Recombinant Proteins; Ribavirin; Sensitivity and Specificity

2002
[Treatment of chronic hepatitis C].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2002, Apr-10, Volume: 122, Issue:9

    Topics: Antiviral Agents; Contraindications; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin

2002
High sustained response to daily dosing of interferon with ribavirin in chronic hepatitis C patients naïve to therapy.
    Journal of gastroenterology and hepatology, 2002, Volume: 17, Issue:5

    Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Reference Values; Ribavirin; RNA, Viral; Treatment Outcome

2002
Lack of evidence for ribavirin-induced bone loss.
    Hepatology (Baltimore, Md.), 2002, Volume: 36, Issue:1

    Topics: Bone Density; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Osteoporosis; Ribavirin

2002
Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2002, Volume: 8, Issue:7

    Topics: Adult; Aged; Anemia; Antiviral Agents; Clinical Protocols; Drug Therapy, Combination; Erythrocyte Transfusion; Erythropoietin; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polymerase Chain Reaction; Postoperative Complications; Recombinant Proteins; Recurrence; Ribavirin

2002
HFE gene mutations prevent sustained virological response to interferon plus ribavirin in chronic hepatitis C patients with serum markers of iron overload.
    The American journal of gastroenterology, 2002, Volume: 97, Issue:6

    Topics: Adult; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Hemochromatosis Protein; Hepacivirus; Hepatitis C, Chronic; Histocompatibility Antigens Class I; HLA Antigens; Humans; Interferons; Iron Overload; Male; Membrane Proteins; Middle Aged; Mutation; Ribavirin

2002
Production of interleukins 10 and 12 by activated peripheral blood monocytes/macrophages in patients suffering from chronic hepatitis C virus infection with respect to the response to interferon and ribavirin treatment.
    Immunology letters, 2002, Oct-01, Volume: 83, Issue:3

    Topics: Adult; Antiviral Agents; B7-1 Antigen; Carrier State; Drug Therapy, Combination; Female; Flow Cytometry; Hepatitis C, Chronic; Humans; Interferons; Interleukin-10; Interleukin-12; Macrophages; Male; Monocytes; Ribavirin

2002
[Why is there a poor response to combined therapy with interferon alfa 2b and ribavirin in patients with chronic hepatitis C?].
    Casopis lekaru ceskych, 2002, Jun-07, Volume: 141, Issue:11

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin

2002
Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection.
    Liver, 2002, Volume: 22, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Ferritins; Genotype; Hemochromatosis Protein; Hepacivirus; Hepatitis C, Chronic; Histocompatibility Antigens Class I; Humans; Interferon-alpha; Iron; Liver; Male; Membrane Proteins; Middle Aged; Mutation; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load

2002